- preprint:
    doi: 10.1101/2021.04.07.438649
  tweets:
    - id: 1392209505039970300
      id_str: "1392209505039970304"
      created_at: Tue May 11 20:06:26 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.04.07.438649v1
- preprint:
    doi: 10.1101/2020.12.08.415836
  tweets:
    - id: 1391847033548513300
      id_str: "1391847033548513280"
      created_at: Mon May 10 20:06:06 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.08.415836v1
- preprint:
    doi: 10.1101/2020.12.12.422516
  tweets:
    - id: 1391836736234430500
      id_str: "1391836736234430466"
      created_at: Mon May 10 19:25:11 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.12.422516v1
- preprint:
    doi: 10.1101/703801
  tweets:
    - id: 1391484653425541000
      id_str: "1391484653425541120"
      created_at: Sun May 09 20:06:08 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/703801v4
- preprint:
    doi: 10.1101/2021.04.23.441101
  tweets:
    - id: 1391122233016397800
      id_str: "1391122233016397824"
      created_at: Sat May 08 20:06:00 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.04.23.441101v1
- preprint:
    doi: 10.1101/2021.03.12.435194
  tweets:
    - id: 1390759866919264300
      id_str: "1390759866919264257"
      created_at: Fri May 07 20:06:05 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.12.435194v1
- preprint:
    doi: 10.1101/2021.03.24.436620
  tweets:
    - id: 1390397507335774200
      id_str: "1390397507335774211"
      created_at: Thu May 06 20:06:12 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.24.436620v1
- preprint:
    doi: 10.1101/2020.12.04.409144
  tweets:
    - id: 1390035038566338600
      id_str: "1390035038566338569"
      created_at: Wed May 05 20:05:53 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.04.409144v1
- preprint:
    doi: 10.1101/2021.01.27.427998
  tweets:
    - id: 1387497218853294000
      id_str: "1387497218853294081"
      created_at: Wed Apr 28 20:01:30 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.27.427998v1
- preprint:
    doi: 10.1101/2021.04.11.439311
  tweets:
    - id: 1387134724020207600
      id_str: "1387134724020207617"
      created_at: Tue Apr 27 20:01:04 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.04.11.439311v1
- preprint:
    doi: 10.1101/2021.02.27.433180
  tweets:
    - id: 1386772363019268000
      id_str: "1386772363019268101"
      created_at: Mon Apr 26 20:01:10 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.27.433180v1
- preprint:
    doi: 10.1101/2020.12.12.422516
  tweets:
    - id: 1386409953213042700
      id_str: "1386409953213042697"
      created_at: Sun Apr 25 20:01:05 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.12.422516v1
- preprint:
    doi: 10.1101/2021.03.10.432967
  tweets:
    - id: 1386047590752477200
      id_str: "1386047590752477184"
      created_at: Sat Apr 24 20:01:11 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.10.432967v1
- preprint:
    doi: 10.1101/2021.02.14.431043
  tweets:
    - id: 1385685210021441500
      id_str: "1385685210021441541"
      created_at: Fri Apr 23 20:01:13 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.14.431043v1
- preprint:
    doi: 10.1101/2021.01.15.426911
  tweets:
    - id: 1385322787099775000
      id_str: "1385322787099774976"
      created_at: Thu Apr 22 20:01:05 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.15.426911v1
- preprint:
    doi: 10.1101/2021.02.14.431043
  tweets:
    - id: 1384960464875032600
      id_str: "1384960464875032577"
      created_at: Wed Apr 21 20:01:20 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.14.431043v1
- preprint:
    doi: 10.1101/2020.12.31.425021
  tweets:
    - id: 1384598026065485800
      id_str: "1384598026065485827"
      created_at: Tue Apr 20 20:01:08 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.31.425021v1
- preprint:
    doi: 10.1101/2021.03.29.437450
  tweets:
    - id: 1384235613415559200
      id_str: "1384235613415559175"
      created_at: Mon Apr 19 20:01:02 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.29.437450v1
- preprint:
    doi: 10.1101/2021.03.06.434193
  tweets:
    - id: 1383873288414191600
      id_str: "1383873288414191624"
      created_at: Sun Apr 18 20:01:17 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.06.434193v1
- preprint:
    doi: 10.1101/2020.06.29.174888
  tweets:
    - id: 1383510866650222600
      id_str: "1383510866650222594"
      created_at: Sat Apr 17 20:01:09 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.06.29.174888v1
- preprint:
    doi: 10.1101/2021.03.10.434840
  tweets:
    - id: 1383148442663411700
      id_str: "1383148442663411714"
      created_at: Fri Apr 16 20:01:01 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.10.434840v1
- preprint:
    doi: 10.1101/2020.09.08.280818
  tweets:
    - id: 1382786153011642400
      id_str: "1382786153011642374"
      created_at: Thu Apr 15 20:01:24 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.09.08.280818v1
- preprint:
    doi: 10.1101/2020.01.30.927871
  tweets:
    - id: 1382423695801647000
      id_str: "1382423695801647118"
      created_at: Wed Apr 14 20:01:07 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.01.30.927871v2
- preprint:
    doi: 10.1101/2021.01.26.426986
  tweets:
    - id: 1382061355453255700
      id_str: "1382061355453255687"
      created_at: Tue Apr 13 20:01:19 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.26.426986v1
- preprint:
    doi: 10.1101/2021.01.25.428137
  tweets:
    - id: 1381698970569822200
      id_str: "1381698970569822209"
      created_at: Mon Apr 12 20:01:19 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.25.428137v1
- preprint:
    doi: 10.1101/2021.03.18.435945
  tweets:
    - id: 1381336552777912300
      id_str: "1381336552777912320"
      created_at: Sun Apr 11 20:01:12 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.18.435945v1
- preprint:
    doi: 10.1101/2021.03.12.435194
  tweets:
    - id: 1380974162383151000
      id_str: "1380974162383151110"
      created_at: Sat Apr 10 20:01:12 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.12.435194v1
- preprint:
    doi: 10.1101/2021.03.18.436013
  tweets:
    - id: 1380611776392409000
      id_str: "1380611776392409092"
      created_at: Fri Apr 09 20:01:12 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.18.436013v1
- preprint:
    doi: 10.1101/2021.03.24.436752
  tweets:
    - id: 1380249365672034300
      id_str: "1380249365672034306"
      created_at: Thu Apr 08 20:01:07 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.24.436752v1
- preprint:
    doi: 10.1101/2021.01.27.427998
  tweets:
    - id: 1379886938673537000
      id_str: "1379886938673537026"
      created_at: Wed Apr 07 20:00:57 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.27.427998v1
- preprint:
    doi: 10.1101/2021.03.10.434756
  tweets:
    - id: 1379524605304582100
      id_str: "1379524605304582150"
      created_at: Tue Apr 06 20:01:10 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.10.434756v1
- preprint:
    doi: 10.1101/2021.02.27.433180
  tweets:
    - id: 1379162184828215300
      id_str: "1379162184828215300"
      created_at: Mon Apr 05 20:01:03 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.27.433180v1
- preprint:
    doi: 10.1101/2020.12.12.422516
  tweets:
    - id: 1378799859306741800
      id_str: "1378799859306741760"
      created_at: Sun Apr 04 20:01:17 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.12.422516v1
- preprint:
    doi: 10.1101/2021.03.10.432967
  tweets:
    - id: 1378437352503320600
      id_str: "1378437352503320579"
      created_at: Sat Apr 03 20:00:49 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.10.432967v1
- preprint:
    doi: 10.1101/2021.01.18.427166
  tweets:
    - id: 1378074936477106200
      id_str: "1378074936477106180"
      created_at: Fri Apr 02 20:00:42 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.18.427166v1
- preprint:
    doi: 10.1101/2021.01.15.426911
  tweets:
    - id: 1377712631981744000
      id_str: "1377712631981744128"
      created_at: Thu Apr 01 20:01:02 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.15.426911v1
- preprint:
    doi: 10.1101/2021.02.14.431043
  tweets:
    - id: 1377350254303965200
      id_str: "1377350254303965185"
      created_at: Wed Mar 31 20:01:05 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.14.431043v1
- preprint:
    doi: 10.1101/2021.01.07.425740
  tweets:
    - id: 1376987865071095800
      id_str: "1376987865071095813"
      created_at: Tue Mar 30 20:01:04 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.07.425740v1
- preprint:
    doi: 10.1101/2021.02.23.432474
  tweets:
    - id: 1376625515310817300
      id_str: "1376625515310817280"
      created_at: Mon Mar 29 20:01:13 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.23.432474v1
- preprint:
    doi: 10.1101/2020.11.15.383323
  tweets:
    - id: 1375900686488064000
      id_str: "1375900686488064003"
      created_at: Sat Mar 27 20:01:01 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.11.15.383323v1
- preprint:
    doi: 10.1101/2020.12.28.424451
  tweets:
    - id: 1375538433821704200
      id_str: "1375538433821704198"
      created_at: Fri Mar 26 20:01:33 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.28.424451v1
- preprint:
    doi: 10.1101/2021.03.10.434840
  tweets:
    - id: 1375175997637623800
      id_str: "1375175997637623810"
      created_at: Thu Mar 25 20:01:22 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.10.434840v1
- preprint:
    doi: 10.1101/2021.01.06.425392
  tweets:
    - id: 1374813580890140700
      id_str: "1374813580890140678"
      created_at: Wed Mar 24 20:01:15 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.06.425392v1
- preprint:
    doi: 10.1101/2020.12.14.422737
  tweets:
    - id: 1374451411874812000
      id_str: "1374451411874811906"
      created_at: Tue Mar 23 20:02:07 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.14.422737v1
- preprint:
    doi: 10.1101/2021.01.26.426986
  tweets:
    - id: 1374088948184707000
      id_str: "1374088948184707076"
      created_at: Mon Mar 22 20:01:49 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.26.426986v1
- preprint:
    doi: 10.1101/2020.09.08.280818
  tweets:
    - id: 1373726589113020400
      id_str: "1373726589113020419"
      created_at: Sun Mar 21 20:01:56 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.09.08.280818v1
- preprint:
    doi: 10.1101/2021.02.02.429430
  tweets:
    - id: 1373364157131722800
      id_str: "1373364157131722755"
      created_at: Sat Mar 20 20:01:45 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.02.429430v1
- preprint:
    doi: 10.1101/2020.01.30.927871
  tweets:
    - id: 1373001859355525000
      id_str: "1373001859355525123"
      created_at: Fri Mar 19 20:02:07 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.01.30.927871v2
- preprint:
    doi: 10.1101/2021.02.01.429069
  tweets:
    - id: 1372639402132922400
      id_str: "1372639402132922374"
      created_at: Thu Mar 18 20:01:50 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.01.429069v1
- preprint:
    doi: 10.1101/2021.01.25.428137
  tweets:
    - id: 1372277012283465700
      id_str: "1372277012283465734"
      created_at: Wed Mar 17 20:01:50 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.25.428137v1
- preprint:
    doi: 10.1101/2021.01.27.427998
  tweets:
    - id: 1371914700393435100
      id_str: "1371914700393435139"
      created_at: Tue Mar 16 20:02:08 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.27.427998v1
- preprint:
    doi: 10.1101/2021.01.18.426984
  tweets:
    - id: 1371573211175981000
      id_str: "1371573211175981057"
      created_at: Mon Mar 15 21:25:10 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.18.426984v1
- preprint:
    doi: 10.1101/2021.02.27.433180
  tweets:
    - id: 1371189849928130600
      id_str: "1371189849928130561"
      created_at: Sun Mar 14 20:01:50 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.27.433180v1
- preprint:
    doi: 10.1101/2020.12.12.422516
  tweets:
    - id: 1370827464495206400
      id_str: "1370827464495206409"
      created_at: Sat Mar 13 20:01:50 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.12.422516v1
- preprint:
    doi: 10.1101/2020.12.31.425021
  tweets:
    - id: 1370465117482188800
      id_str: "1370465117482188800"
      created_at: Fri Mar 12 20:02:00 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.31.425021v1
- preprint:
    doi: 10.1101/2021.01.18.427166
  tweets:
    - id: 1370102650881069000
      id_str: "1370102650881069065"
      created_at: Thu Mar 11 20:01:41 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.18.427166v1
- preprint:
    doi: 10.1101/2021.01.15.426911
  tweets:
    - id: 1369741629448413200
      id_str: "1369741629448413185"
      created_at: Wed Mar 10 20:07:07 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.15.426911v1
- preprint:
    doi: 10.1101/2021.02.14.431043
  tweets:
    - id: 1369377905013371000
      id_str: "1369377905013370894"
      created_at: Tue Mar 09 20:01:49 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.14.431043v1
- preprint:
    doi: 10.1101/2021.01.07.425740
  tweets:
    - id: 1369015510231302100
      id_str: "1369015510231302146"
      created_at: Mon Mar 08 20:01:47 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.07.425740v1
- preprint:
    doi: 10.1101/2021.02.05.430003
  tweets:
    - id: 1368653129072394200
      id_str: "1368653129072394245"
      created_at: Sun Mar 07 20:01:48 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.05.430003v1
- preprint:
    doi: 10.1101/2020.10.14.338996
  tweets:
    - id: 1368290789562998800
      id_str: "1368290789562998787"
      created_at: Sat Mar 06 20:02:00 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.10.14.338996v2
- preprint:
    doi: 10.1101/2020.12.14.422555
  tweets:
    - id: 1367929833443975200
      id_str: "1367929833443975175"
      created_at: Fri Mar 05 20:07:41 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.14.422555v1
- preprint:
    doi: 10.1101/782557
  tweets:
    - id: 1367567159413637000
      id_str: "1367567159413637121"
      created_at: Thu Mar 04 20:06:33 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/782557v1
- preprint:
    doi: 10.1101/2021.02.02.428884
  tweets:
    - id: 1367204793136140300
      id_str: "1367204793136140295"
      created_at: Wed Mar 03 20:06:38 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.02.428884v1
- preprint:
    doi: 10.1101/2020.12.14.422737
  tweets:
    - id: 1366842507267506200
      id_str: "1366842507267506177"
      created_at: Tue Mar 02 20:07:03 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.14.422737v1
- preprint:
    doi: 10.1101/2021.01.26.426986
  tweets:
    - id: 1366478811521577000
      id_str: "1366478811521576966"
      created_at: Mon Mar 01 20:01:51 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.26.426986v1
- preprint:
    doi: 10.1101/2020.11.15.383323
  tweets:
    - id: 1366116431893573600
      id_str: "1366116431893573639"
      created_at: Sun Feb 28 20:01:53 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.11.15.383323v1
- preprint:
    doi: 10.1101/2020.09.08.280818
  tweets:
    - id: 1365753983973875700
      id_str: "1365753983973875713"
      created_at: Sat Feb 27 20:01:38 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.09.08.280818v1
- preprint:
    doi: 10.1101/2021.01.06.425392
  tweets:
    - id: 1365633169492443100
      id_str: "1365633169492443139"
      created_at: Sat Feb 27 12:01:34 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.06.425392v1
- preprint:
    doi: 10.1101/2020.01.30.927871
  tweets:
    - id: 1365391554253316000
      id_str: "1365391554253316098"
      created_at: Fri Feb 26 20:01:28 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.01.30.927871v2
- preprint:
    doi: 10.1101/2021.01.25.428137
  tweets:
    - id: 1365029290052567000
      id_str: "1365029290052567040"
      created_at: Thu Feb 25 20:01:58 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.25.428137v1
- preprint:
    doi: 10.1101/2021.01.27.427998
  tweets:
    - id: 1364666801188200400
      id_str: "1364666801188200451"
      created_at: Wed Feb 24 20:01:34 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.27.427998v1
- preprint:
    doi: 10.1101/2020.06.01.128728
  tweets:
    - id: 1364304475507335200
      id_str: "1364304475507335170"
      created_at: Tue Feb 23 20:01:49 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.06.01.128728v1
- preprint:
    doi: 10.1101/2020.12.28.424451
  tweets:
    - id: 1363942004208636000
      id_str: "1363942004208635906"
      created_at: Mon Feb 22 20:01:29 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.28.424451v1
- preprint:
    doi: 10.1101/2020.12.12.422516
  tweets:
    - id: 1363579651197706200
      id_str: "1363579651197706241"
      created_at: Sun Feb 21 20:01:37 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.12.422516v1
- preprint:
    doi: 10.1101/2021.01.18.426984
  tweets:
    - id: 1363217219421888500
      id_str: "1363217219421888516"
      created_at: Sat Feb 20 20:01:27 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.18.426984v1
- preprint:
    doi: 10.1101/2020.12.31.425021
  tweets:
    - id: 1362854888024256500
      id_str: "1362854888024256512"
      created_at: Fri Feb 19 20:01:40 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.31.425021v1
- preprint:
    doi: 10.1101/2021.01.15.426911
  tweets:
    - id: 1362492537626374100
      id_str: "1362492537626374159"
      created_at: Thu Feb 18 20:01:49 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.15.426911v1
- preprint:
    doi: 10.1101/2021.01.18.427166
  tweets:
    - id: 1361405346942750700
      id_str: "1361405346942750721"
      created_at: Mon Feb 15 20:01:43 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.18.427166v1
- preprint:
    doi: 10.1101/2021.01.07.425740
  tweets:
    - id: 1361376954625233000
      id_str: "1361376954625232900"
      created_at: Mon Feb 15 18:08:53 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.07.425740v1
- preprint:
    id: "141169"
    doi: 10.1101/2021.05.07.21256539
    first_posted: 2021-05-10
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.07.21256539v1
    url: https://api.rxivist.org/v1/papers/141169
    title: Immune profile of children with post-acute sequelae of SARS-CoV-2
      infection (Long Covid)
    category: pediatrics
    abstract: There is increasing reporting by patients organization and researchers
      of long covid (or post-acute sequelae of SARS-CoV-2 - PASC), characterized
      by symptoms such as fatigue, dyspnea, chest pain, cognitive and sleeping
      disturbances, arthralgia and decline in quality of life. Immune system
      dysregulation with a hyperinflammatory state, direct viral toxicity,
      endothelial damage and microvascular injury have been proposed as
      pathologenic mechanisms. Recently, cohorts of children with PASC have been
      reported in Italy, Sweden and Russia. However, immunological studies of
      children with PASC have never been performed. In this study, we documented
      significant immunologic differences between children that completely
      recovered from acute infection and those with PASC, providing the first
      objective laboratory sign of the existence of PASC in children.
    authors:
      - name: Gabriele Di Sante
        orcid: null
      - name: Danilo Buonsenso
        orcid: http://orcid.org/0000-0001-8567-2639
      - name: Cristina De Rose
        orcid: null
      - name: Piero Valentini
        orcid: null
      - name: Francesco Ria
        orcid: null
      - name: Maurizio Sanguinetti
        orcid: http://orcid.org/0000-0002-9780-7059
      - name: Michela Sali
        orcid: null
  comment:
    dislikes: 0
    thread: "8514441850"
    numReports: 0
    likes: 1
    id: "5379558205"
    createdAt: 2021-05-12T01:30:10
    author:
      username: heidiconnahs
      about: ""
      name: Heidi Connahs
      isPowerContributor: false
      profileUrl: https://disqus.com/by/heidiconnahs/
      url: ""
      location: ""
      id: "369226202"
    isApproved: true
    raw_message: Interesting paper! I have one comment though. I am noticing an
      increasing number of papers using the term post-exertional malaise (PEM)
      without providing any definition of what this condition represents. This
      is important because PEM is not a term widely known in the medical
      community and it has a distinct presentation. PEM is the worsening of a
      variety of symptoms following even minor physical or mental exertion and
      moreover, the severity of the impact is often delayed by hours or days and
      can take days, weeks or months to recover from. The reason why PEM is not
      widely known is because it is the cardinal symptom of the disease ME/CFS
      which has been significantly ignored and underfunded. PEM is unique to
      ME/CFS and any mention of PEM should really provide appropriate references
      to ME/CFS literature.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.07.21256539v1
  tweets:
    - created_at: Sat May 15 20:12:20 +0000 2021
      id: 1393660540510212000
      id_str: "1393660540510212096"
      text: >-
        üí¨ medRxiv comment on "Immune profile of children wit..."


        "Interesting paper! I have one comment though. I am notic‚Ä¶ https://t.co/DbZ2yzqMk2
      truncated: true
      entities:
        urls:
          - url: https://t.co/DbZ2yzqMk2
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 15 20:12:20 +0000 2021
      id: 1393660541340631000
      id_str: "1393660541340631040"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/PMDM2HKZfz
      truncated: false
      entities:
        urls:
          - url: https://t.co/PMDM2HKZfz
      in_reply_to_status_id: 1393660540510212000
      in_reply_to_status_id_str: "1393660540510212096"
- preprint:
    id: 136561
    metric: 4079
    title: An emerging SARS-CoV-2 mutant evading cellular immunity and increasing
      viral infectivity
    url: https://api.rxivist.org/v1/papers/136561
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.02.438288v1
    doi: 10.1101/2021.04.02.438288
    category: microbiology
    first_posted: 2021-04-05
    abstract: During the current SARS-CoV-2 pandemic that is devastating the modern
      societies worldwide, many variants that naturally acquire multiple
      mutations have emerged. Emerging mutations can affect viral properties
      such as infectivity and immune resistance. Although the sensitivity of
      naturally occurring SARS-CoV-2 variants to humoral immunity has recently
      been investigated, that to human leukocyte antigen (HLA)-restricted
      cellular immunity remains unaddressed. Here we demonstrate that two
      recently emerging mutants in the receptor binding domain of the SARS-CoV-2
      spike protein, L452R (in B.1.427/429) and Y453F (in B.1.298), can escape
      from the HLA-24-restricted cellular immunity. These mutations reinforce
      the affinity to viral receptor ACE2, and notably, the L452R mutation
      increases protein stability, viral infectivity, and potentially promotes
      viral replication. Our data suggest that the HLA-restricted cellular
      immunity potentially affects the evolution of viral phenotypes, and the
      escape from cellular immunity can be a further threat of the SARS-CoV-2
      pandemic.
    authors:
      - name: Chihiro Motozono
      - name: Mako Toyoda
      - name: Jiri Zahradnik
      - name: Terumasa Ikeda
      - name: Akatsuki Saito
      - name: Toong Seng Tan
      - name: Isaac Ngare
      - name: Hesham Nasser
      - name: Izumi Kimura
      - name: Keiya Uriu
      - name: Yusuke Kosugi
      - name: Shiho Torii
      - name: Akiko Yonekawa
      - name: Nobuyuki Shimono
      - name: Yoji Nagasaki
      - name: Rumi Minami
      - name: Takashi Toya
      - name: Noritaka Sekiya
      - name: Takasuke Fukuhara
      - name: Yoshiharu Matsuura
      - name: Gideon Schreiber
      - name: The Genotype to Phenotype Japan (G2P-Japan) consortium
      - name: So Nakagawa
      - name: Takamasa Ueno
      - name: Kei Sato
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sat May 15 20:20:00 +0000 2021
      id: 1393662469558743000
      id_str: "1393662469558743048"
      text: >-
        üî• bioRxiv Microbiology preprint by C. Motozono et al:


        "An emerging SARS-CoV-2 mutant evading cellular immunity and‚Ä¶ https://t.co/rcjDkdXgxY
      truncated: true
      entities:
        urls:
          - url: https://t.co/rcjDkdXgxY
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "108636"
    doi: 10.1101/2020.04.10.20057869
    first_posted: 2020-04-14
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.04.10.20057869v1
    url: https://api.rxivist.org/v1/papers/108636
    title: Multi-centre derivation and validation of a colitis-associated cancer
      risk prediction web-tool
    category: gastroenterology
    abstract: >-
      ObjectiveUlcerative colitis (UC) patients diagnosed with low-grade
      dysplasia (LGD) have increased risk of developing advanced neoplasia (AN;
      high-grade dysplasia or colorectal cancer). We aimed to develop and
      validate a predictor of AN risk in UC patients with LGD and create a
      visual web-tool to effectively communicate the risk.


      DesignIn our retrospective multi-centre validated cohort study, adult UC patients with an index diagnosis of LGD, identified from four UK centres between 2001-2019, were followed until progression to AN. In the discovery cohort (n=246), a multivariate risk prediction model was derived from clinicopathological features using Cox regression. Validation used data from 3 external centres (n=198). The validated model was embedded in a web-tool to calculate patient-specific risk.


      ResultsFour clinicopathological variables were significantly associated with AN progression in the discovery cohort: endoscopically visible LGD > 1 cm (HR = 2.7; 95% CI 1.2-5.9), unresectable or incomplete endoscopic resection (HR = 3.4; 95% CI 1.6-7.4), moderate/severe histological inflammation within 5 years of LGD diagnosis (HR = 3.1; 95% CI 1.5-6.7), and multifocality (HR = 2.9; 95% CI 1.3-6.2). In the validation cohort, this 4-variable model accurately predicted future AN cases with overall calibration Observed/Expected = 1 (95% CI 0.63-1.5), and achieved 100% specificity for the lowest risk group over 13 years of available follow-up.


      ConclusionMulti-cohort validation confirms that patients with large, unresected, multifocal LGD and recent moderate/severe inflammation are at highest risk of developing AN. Personalised risk prediction provided via the Ulcerative Colitis-Cancer Risk Estimator (www.UC-CaRE.uk) can support treatment decision-making.


      SUMMARY BOXO_ST_ABSWhat is already known about this subject?C_ST_ABSO_LIThe risk of ulcerative colitis-associated low-grade dysplasia (LGD) progression to more advanced neoplasia is currently not clearly defined. The literature consists of historical data from small heterogenous observational studies with limited follow-up or lack of information on endoscopic resection status.

      C_LI


      What are the new findings?O_LIWe present the results from the largest multi-centre cohort study to evaluate LGD long-term prognosis based on clinicopathological factors that are reflective of modern surveillance techniques.

      C_LIO_LIRecent moderate or severe active inflammation or LGD that is large, not fully resectable or is multifocal remain independent predictors of advanced neoplasia progression, even when stratified to reflect the most modern era of high definition endoscopic imaging, chromoendoscopy and advanced polypectomy techniques.

      C_LIO_LIColorectal cancer incidence after endoscopic resection of unifocal polypoid and non-polypoid dysplasia is 0.6 per 100 patient-years.

      C_LIO_LILong-term incidence of advanced neoplasia is similar if LGD is invisible or if LGD is visible but not completely endoscopically resected.

      C_LIO_LIUsing these data, we have designed and externally validated a cancer risk prediction tool for ulcerative colitis patients with LGD.

      C_LI


      How might it impact on clinical practice in the foreseeable future?O_LIThe UC-CaRE (Ulcerative Colitis-Cancer Risk Estimator) tool can be used to calculate and communicate individualised numerical cancer risk estimates to colitis patients with LGD.

      C_LIO_LIIt facilitates the risk stratification of the lowest-risk patients, who can be reassured by undergoing continued surveillance, and those at the highest-risk who may benefit from a prophylactic colectomy.

      C_LIO_LIThis visual aid presents the calculated risk in a graphical and pictorial form to optimise risk comprehension and informed treatment choices.

      C_LI
    authors:
      - name: Kit Curtius
        orcid: http://orcid.org/0000-0002-2678-0960
      - name: Misha Kabir
        orcid: http://orcid.org/0000-0003-3991-1015
      - name: Ibrahim Al Bakir
        orcid: null
      - name: Chang-Ho Ryan Choi
        orcid: null
      - name: Juanda L Hartono
        orcid: null
      - name: Michael Johnson
        orcid: null
      - name: James E. East
        orcid: http://orcid.org/0000-0001-8035-3700
      - name: Oxford IBD Cohort Study Investigators
        orcid: null
      - name: James O Lindsay
        orcid: http://orcid.org/0000-0003-3353-9590
      - name: Roser Vega
        orcid: http://orcid.org/0000-0002-0116-7211
      - name: Siwan Thomas-Gibson
        orcid: null
      - name: Janindra Warusavitarne
        orcid: null
      - name: Ana Wilson
        orcid: null
      - name: Trevor A Graham
        orcid: http://orcid.org/0000-0001-9582-1597
      - name: Ailsa Hart
        orcid: null
  comment:
    dislikes: 0
    thread: "8264437163"
    numReports: 0
    likes: 0
    id: "5383811963"
    createdAt: 2021-05-14T21:23:13
    author:
      username: kitcurtius
      about: ""
      name: Kit Curtius
      isPowerContributor: false
      profileUrl: https://disqus.com/by/kitcurtius/
      url: ""
      location: ""
      id: "361053116"
    isApproved: true
    raw_message: We acknowledge Dr. Adam Brentnall (QMUL) for helpful discussions on
      statistical prediction modeling!
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.04.10.20057869v2
  tweets:
    - created_at: Sun May 16 00:41:42 +0000 2021
      id: 1393728330281758700
      id_str: "1393728330281758724"
      text: >-
        üí¨ medRxiv comment on "Multi-centre derivation and va..."


        "We acknowledge Dr. Adam Brentnall (QMUL) for helpful dis‚Ä¶ https://t.co/FZrfdoeSUQ
      truncated: true
      entities:
        urls:
          - url: https://t.co/FZrfdoeSUQ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 16 00:41:43 +0000 2021
      id: 1393728331120525300
      id_str: "1393728331120525317"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/RAK59UjbvN
      truncated: false
      entities:
        urls:
          - url: https://t.co/RAK59UjbvN
      in_reply_to_status_id: 1393728330281758700
      in_reply_to_status_id_str: "1393728330281758724"
- preprint:
    id: 139187
    metric: 3346
    title: Rapid induction of antigen-specific CD4+ T cells guides coordinated
      humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination
    url: https://api.rxivist.org/v1/papers/139187
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.21.440862v1
    doi: 10.1101/2021.04.21.440862
    category: immunology
    first_posted: 2021-04-22
    abstract: The SARS-CoV-2 mRNA vaccines have shown remarkable clinical efficacy,
      but questions remain about the nature and kinetics of T cell priming. We
      performed longitudinal antigen-specific T cell analyses in healthy
      individuals following mRNA vaccination. Vaccination induced rapid
      near-maximal antigen-specific CD4+ T cell responses in all subjects after
      the first vaccine dose. CD8+ T cell responses developed gradually after
      the first and second dose and were variable. Vaccine-induced T cells had
      central memory characteristics and included both Tfh and Th1 subsets,
      similar to natural infection. Th1 and Tfh responses following the first
      dose predicted post-boost CD8+ T cell and neutralizing antibody levels,
      respectively. Integrated analysis of 26 antigen-specific T cell and
      humoral responses revealed coordinated features of the immune response to
      vaccination. Lastly, whereas booster vaccination improved CD4+ and CD8+ T
      cell responses in SARS-CoV-2 naive subjects, the second vaccine dose had
      little effect on T cell responses in SARS-CoV-2 recovered individuals.
      Thus, longitudinal analysis revealed robust T cell responses to mRNA
      vaccination and highlighted early induction of antigen-specific CD4+ T
      cells.
    authors:
      - name: Mark M. Painter
      - name: Divij Mathew
      - name: Rishi R. Goel
      - name: Sokratis A. Apostolidis
      - name: Ajinkya Pattekar
      - name: Oliva Kuthuru
      - name: Amy E. Baxter
      - name: Ramin Herati
      - name: Derek A. Oldridge
      - name: Sigrid Gouma
      - name: Philip Hicks
      - name: Sarah Dysinger
      - name: Kendall A Lundgreen
      - name: Leticia Kuri-Cervantes
      - name: Sharon Adamski
      - name: Amanda Hicks
      - name: Scott Korte
      - name: Josephine R. Giles
      - name: Madison E. Weirick
      - name: Christopher M. McAllister
      - name: Jeanette Dougherty
      - name: Sherea Long
      - name: Kurt D'Andrea
      - name: Jacob T. Hamilton
      - name: Michael R. Betts
      - name: Paul Bates
      - name: Scott E Hensley
      - name: Alba Grifoni
      - name: Daniela Weiskopf
      - name: Alessandro Sette
      - name: Allison R. Greenplate
      - name: E John Wherry
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sun May 16 20:19:55 +0000 2021
      id: 1394024838294122500
      id_str: "1394024838294122498"
      text: >-
        üî• bioRxiv Immunology preprint by M. M. Painter et al:


        "Rapid induction of antigen-specific CD4+ T cells guides coo‚Ä¶ https://t.co/eKwFidTTnt
      truncated: true
      entities:
        urls:
          - url: https://t.co/eKwFidTTnt
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "127169"
    doi: 10.1101/2021.01.27.21250604
    first_posted: 2021-01-29
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.01.27.21250604v1
    url: https://api.rxivist.org/v1/papers/127169
    title: "The World Mortality Dataset: Tracking excess mortality across countries
      during the COVID-19 pandemic"
    category: epidemiology
    abstract: Comparing the impact of the COVID-19 pandemic between countries or
      across time is difficult because the reported numbers of cases and deaths
      can be strongly affected by testing capacity and reporting policy. Excess
      mortality, defined as the increase in all-cause mortality relative to the
      recent average, is widely considered as a more objective indicator of the
      COVID-19 death toll. However, there has been no central,
      frequently-updated repository of the all-cause mortality data across
      countries. To fill this gap, we have collected weekly, monthly, or
      quarterly all-cause mortality data from 77 countries, openly available as
      the regularly-updated World Mortality Dataset. We used this dataset to
      compute the excess mortality in each country during the COVID-19 pandemic.
      We found that in the worst-affected countries the annual mortality
      increased by over 50%, while in several other countries it decreased by
      over 5%, presumably due to lockdown measures decreasing the non-COVID
      mortality. Moreover, we found that while some countries have been
      reporting the COVID-19 deaths very accurately, many countries have been
      underreporting their COVID-19 deaths by an order of magnitude or more.
      Averaging across the entire dataset suggests that the world's COVID-19
      death toll may be at least 1.6 times higher than the reported number of
      confirmed deaths.
    authors:
      - name: Ariel Karlinsky
        orcid: null
      - name: Dmitry Kobak
        orcid: http://orcid.org/0000-0002-5639-7209
  comment:
    dislikes: 0
    thread: "8375844078"
    numReports: 0
    likes: 1
    id: "5383665582"
    createdAt: 2021-05-14T19:13:52
    author:
      username: disqus_rQjDV4hy9h
      about: ""
      name: John Smith
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_rQjDV4hy9h/
      url: ""
      location: ""
      id: "289967088"
    isApproved: true
    raw_message: Interesting report, I wonder if they will come back with a response.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.01.27.21250604v1
  tweets:
    - created_at: Mon May 17 00:37:37 +0000 2021
      id: 1394089690882461700
      id_str: "1394089690882461703"
      text: >-
        üí¨ medRxiv comment on "The World Mortality Dataset: T..."


        "Interesting report, I wonder if they will come back with‚Ä¶ https://t.co/c40ufjz4rJ
      truncated: true
      entities:
        urls:
          - url: https://t.co/c40ufjz4rJ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 17 00:37:38 +0000 2021
      id: 1394089691738083300
      id_str: "1394089691738083328"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/SYOosLErcL
      truncated: false
      entities:
        urls:
          - url: https://t.co/SYOosLErcL
      in_reply_to_status_id: 1394089690882461700
      in_reply_to_status_id_str: "1394089690882461703"
- preprint:
    id: "91759"
    doi: 10.1101/2020.07.21.212639
    first_posted: 2020-07-21
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.07.21.212639v1
    url: https://api.rxivist.org/v1/papers/91759
    title: SARS-CoV-2 infection induces a pro-inflammatory cytokine response through
      cGAS-STING and NF-Œ∫B
    category: microbiology
    abstract: >-
      SARS-CoV-2 is a novel virus that has rapidly spread, causing a global
      pandemic. In the majority of infected patients, SARS-CoV-2 leads to mild
      disease; however, in a significant proportion of infections, individuals
      develop severe symptoms that can lead to permanent lung damage or death.
      These severe cases are often associated with high levels of
      pro-inflammatory cytokines and low antiviral responses which can lead to
      systemic complications. We have evaluated transcriptional and cytokine
      secretion profiles from infected cell cultures and detected a distinct
      upregulation of inflammatory cytokines that parallels samples taken from
      infected patients. Building on these observations, we found a specific
      activation of NF-Œ∫B and a block of IRF3 nuclear translocation in
      SARS-CoV-2 infected cells. This NF-Œ∫B response is mediated by cGAS-STING
      activation and could be attenuated through STING targeting drugs. Our
      results show that SARS-CoV-2 curates a cGAS-STING mediated NF-Œ∫B driven
      inflammatory immune response in epithelial cells that likely contributes
      to inflammatory responses seen in patients and might be a target to
      suppress severe disease symptoms.


      ### Competing Interest Statement


      The authors have declared no competing interest.
    authors:
      - name: Christopher J. Neufeldt
        orcid: http://orcid.org/0000-0002-4551-1811
      - name: Berati Cerikan
        orcid: null
      - name: Mirko Cortese
        orcid: http://orcid.org/0000-0003-1786-4211
      - name: Jamie Frankish
        orcid: http://orcid.org/0000-0003-2200-4320
      - name: Ji-Young Lee
        orcid: http://orcid.org/0000-0002-7631-5127
      - name: Agnieszka Plociennikowska
        orcid: null
      - name: Florian Heigwer
        orcid: http://orcid.org/0000-0002-8230-1485
      - name: Sebastian Joecks
        orcid: null
      - name: Sandy S Burkart
        orcid: http://orcid.org/0000-0003-1096-0550
      - name: David Y Zander
        orcid: null
      - name: Mathieu Gendarme
        orcid: null
      - name: Bachir El Debs
        orcid: null
      - name: Niels Halama
        orcid: null
      - name: Uta Merle
        orcid: null
      - name: Michael Boutros
        orcid: http://orcid.org/0000-0003-1077-2031
      - name: Marco Binder
        orcid: http://orcid.org/0000-0002-5805-6109
      - name: Ralf Bartenschlager
        orcid: http://orcid.org/0000-0001-5601-9307
  comment:
    dislikes: 0
    thread: "8135625357"
    numReports: 0
    likes: 0
    id: "5385282156"
    createdAt: 2021-05-16T07:18:06
    author:
      username: ralfstephan
      about: ""
      name: Ralf Stephan
      isPowerContributor: false
      profileUrl: https://disqus.com/by/ralfstephan/
      url: ""
      location: ""
      id: "63331807"
    isApproved: true
    raw_message: Has this been published? It would contradict results about STING
      binding by SARS-CoV-2 proteins 3CLpro and ORF3a (Rui et al, 2021; PMID
      33723219).
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.07.21.212639v1
  tweets:
    - created_at: Mon May 17 12:17:21 +0000 2021
      id: 1394265781341356000
      id_str: "1394265781341356034"
      text: >-
        üí¨ bioRxiv comment on "SARS-CoV-2 infection induces a..."


        "Has this been published? It would contradict results abo‚Ä¶ https://t.co/E5Yk0m9dlz
      truncated: true
      entities:
        urls:
          - url: https://t.co/E5Yk0m9dlz
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 17 12:17:21 +0000 2021
      id: 1394265782238937000
      id_str: "1394265782238937091"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/hk06nOveos
      truncated: false
      entities:
        urls:
          - url: https://t.co/hk06nOveos
      in_reply_to_status_id: 1394265781341356000
      in_reply_to_status_id_str: "1394265781341356034"
- preprint:
    id: "129659"
    doi: 10.1101/2021.02.16.431518
    first_posted: 2021-02-17
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.02.16.431518v1
    url: https://api.rxivist.org/v1/papers/129659
    title: Leptin regulates glucose homeostasis via the canonical WNT pathway.
    category: physiology
    abstract: Leptin is a body weight regulatory hormone, but it is arguably even
      more potent at regulating blood glucose levels. To further our
      understanding of the molecular mechanisms by which leptin controls glucose
      homeostasis, we have used transgenic zebrafish models and conditional
      deletion of beta catenin in the mediobasal hypothalamus of adult mice to
      show that Wnt signalling in the brain mediates glucoregulatory effects of
      leptin. In zebrafish, under normal feeding conditions, leptin regulates
      glucose homeostasis but not adipostasis. In times of nutrient excess, we
      found that leptin also regulates body weight and size in this species.
      Using a Wnt signalling reporter fish, we show that leptin directly
      activates the canonical Wnt pathway in vivo. Pharmacological inhibition of
      this pathway prevented the leptin-induced improvement in glucose
      tolerance. In adult mice, conditional deletion of the key Wnt effector
      molecule, {beta}-catenin, in the mediobasal hypothalamus of male mice
      confirmed the essential role of the Wnt pathway in mediating leptin action
      and the neuroendocrine regulation of glucose homeostasis. Adult-onset
      {beta}-catenin deletion in the mediobasal hypothalamus led to glucose
      intolerance, exacerbation of caloric intake and body weight gain under
      high fat diet, as well as resistance to exogenous leptin.
    authors:
      - name: Kaj Kamstra
        orcid: null
      - name: Mohammed Rizwan
        orcid: null
      - name: Julia A Horsfield
        orcid: http://orcid.org/0000-0002-9536-7790
      - name: Dominik Pretz
        orcid: null
      - name: Peter R Shepherd
        orcid: null
      - name: David R Grattan
        orcid: null
      - name: Alexander Tups
        orcid: null
  comment:
    dislikes: 0
    thread: "8402405180"
    numReports: 0
    likes: 0
    id: "5385017408"
    createdAt: 2021-05-16T00:09:26
    author:
      username: pouriarostamiasrabadi
      about: ""
      name: POURIA ROSTAMIASRABADI
      isPowerContributor: false
      profileUrl: https://disqus.com/by/pouriarostamiasrabadi/
      url: ""
      location: ""
      id: "369427255"
    isApproved: true
    raw_message: >-
      Hello,


      Thanks so much for an amazing paper on leptin and the canonical WNT pathway. Overall, the paper was a very interesting read, and I learned a lot about the subject area. Here are some suggestions/comments regarding the figures and experiments you performed:


      - Figure 1 does not show how pyrvinium pamoate affects the canonical WNT pathway through fluorescence intensity. Although the paper mentions that pyrvinium pamoate inhibits the pathway, it would be more effective to show this effect through the transgenic zebrafish.

      - It would be best to move Figure 1E and 1F to supplementary to create more space for the fluorescent images.

      - Figure 2 should be broken into two separate figures. This also allows you to display the results on leptin-a and leptin-b deficient zebrafish for the glucose immersion experiment. This will also give you a chance to increase the size of the graphs for better visualization.  

      - For figure 4J, explicitly mention what pre and post-treatment refer to. I know that the figure legend explains it, but it would be best to have it directly on the figure.

      - Overall, the experiments were very well conducted. I am convinced that leptin regulates glucose homeostasis through the canonical WNT pathway. Nonetheless, for the glucose immersion and overfeeding experiments, adipose tissue level should have also been measured to show that leptin does not regulate adipostasis in zebrafish.  


      Thanks so much for taking the time to read this. I hope these comments can be of some help to your paper!
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.02.16.431518v1
  tweets:
    - created_at: Mon May 17 16:25:09 +0000 2021
      id: 1394328145566867500
      id_str: "1394328145566867456"
      text: >-
        üí¨ bioRxiv comment on "Leptin regulates glucose homeo..."


        "Hello,


        Thanks so much for an amazing paper on leptin an‚Ä¶ https://t.co/NmnDb2FdkL
      truncated: true
      entities:
        urls:
          - url: https://t.co/NmnDb2FdkL
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 17 16:25:10 +0000 2021
      id: 1394328146497974300
      id_str: "1394328146497974274"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/AhKlXFjF1A
      truncated: false
      entities:
        urls:
          - url: https://t.co/AhKlXFjF1A
      in_reply_to_status_id: 1394328145566867500
      in_reply_to_status_id_str: "1394328145566867456"
- preprint:
    id: "141782"
    doi: 10.1101/2021.05.13.444086
    first_posted: 2021-05-15
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.13.444086v1
    url: https://api.rxivist.org/v1/papers/141782
    title: Site-specific epigenetic marks in Trypanosoma brucei transcription
      termination, antigenic variation, and proliferation
    category: genetics
    abstract: In Trypanosoma brucei, genes assemble into polycistronic transcription
      units (PTUs). Transcription termination sites (TTSs) hold deposition sites
      for three non-essential chromatin factors, histone variants (H3v and H4v)
      and a DNA modification (base J, a hydroxyl-glucosyl dT). Here, I found
      that H4v is a major sign for transcription termination at TTSs and
      readthrough transcription machineries progress until they encounter the
      next bidirectional transcription start site. While having a secondary
      function at TTSs, H3v is important for monoallelic transcription of
      telomeric antigen genes. The simultaneous absence of both histone variants
      leads to proliferation and replication defects, which are exacerbated by
      the J deficiency, accompanied by accumulation of sub-G1 population. Base J
      likely contributes to DNA replication and cell-cycle control. I propose
      that the coordinated actions of H3v, H4v and J function in concert for
      cellular fate determination and provide compensatory mechanisms for each
      other in chromatin organization, transcription, and replication.
    authors:
      - name: Hee-Sook Kim
        orcid: http://orcid.org/0000-0003-2289-7827
  comment:
    dislikes: 0
    thread: "8521497228"
    numReports: 0
    likes: 0
    id: "5386427954"
    createdAt: 2021-05-17T08:46:33
    author:
      name: Nicolai Siegel
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    raw_message: >-
      Excellent work!


      I am very curious about the VSG expression patterns in your DKO and TKO cells. In Figure 6D, did you account for differences in read mappability? Since some genes have more 'unique sequence' than others, mappability may affect your RPKM.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.05.13.444086v1
  tweets:
    - created_at: Mon May 17 20:13:03 +0000 2021
      id: 1394385498647392300
      id_str: "1394385498647392256"
      text: |-
        üí¨ bioRxiv comment on "Site-specific epigenetic marks..."

        "Excellent work!

        I am very curious about the VSG express‚Ä¶ https://t.co/vVZV9SMluC
      truncated: true
      entities:
        urls:
          - url: https://t.co/vVZV9SMluC
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 17 20:13:04 +0000 2021
      id: 1394385499742109700
      id_str: "1394385499742109702"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/JHrcdxB0FQ
      truncated: false
      entities:
        urls:
          - url: https://t.co/JHrcdxB0FQ
      in_reply_to_status_id: 1394385498647392300
      in_reply_to_status_id_str: "1394385498647392256"
- preprint:
    id: 139398
    metric: 5704
    title: Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and
      P681R, in the second wave of COVID-19 in Maharashtra, India
    url: https://api.rxivist.org/v1/papers/139398
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.22.440932v1
    doi: 10.1101/2021.04.22.440932
    category: molecular-biology
    first_posted: 2021-04-24
    abstract: As the global severe acute respiratory syndrome coronavirus 2
      (SARS-CoV-2) pandemic expands, genomic epidemiology and whole genome
      sequencing are being constantly used to investigate its transmissions and
      evolution. In the backdrop of the global emergence of variants of concern
      (VOCs) during December 2020 and an upsurge in a state in the western part
      of India since January 2021, whole genome sequencing and analysis of spike
      protein mutations using sequence and structural approaches was undertaken
      to identify possible new variants and gauge the fitness of current
      circulating strains. Phylogenetic analysis revealed that the predominant
      clade in circulation was a distinct newly identified lineage B.1.617
      possessing common signature mutations D111D, G142D, L452R, E484Q, D614G
      and P681R, in the spike protein including within the receptor binding
      domain (RBD). Of these, the mutations at residue positions 452, 484 and
      681 have been reported in other globally circulating lineages. The
      structural analysis of RBD mutations L452R and E484Q along with P681R in
      the furin cleavage site, revealed that these may possibly result in
      increased ACE2 binding and rate of S1-S2 cleavage resulting in better
      transmissibility. The same two RBD mutations indicated decreased binding
      to select monoclonal antibodies (mAbs) and may affect their neutralization
      potential. Experimental validation against a wider panel of mAbs, sera
      from vaccinees and those that recovered from natural infection needs to be
      studied. The emergence of such local variants through the accumulation of
      convergent mutations during the COVID-19 second wave needs to be further
      investigated for their public health impact in the rest of the country and
      its possibility of becoming a VOC.
    authors:
      - name: Sarah Cherian
      - name: Varsha Potdar
      - name: Santosh Jadhav
      - name: Pragya Yadav
      - name: Nivedita Gupta
      - name: Mousmi Das
      - name: Partha Rakshit
      - name: Sujeet Singh
      - name: Priya Abraham
      - name: Samiran Panda
      - name: NIC team
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Mon May 17 20:20:49 +0000 2021
      id: 1394387449552547800
      id_str: "1394387449552547846"
      text: >-
        üî• bioRxiv Molecular-biology preprint by S. Cherian et al:


        "Convergent evolution of SARS-CoV-2 spike mutations, L45‚Ä¶ https://t.co/ovG85u4GJo
      truncated: true
      entities:
        urls:
          - url: https://t.co/ovG85u4GJo
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "141849"
    doi: 10.1101/2021.05.13.21257109
    first_posted: 2021-05-16
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.13.21257109v1
    url: https://api.rxivist.org/v1/papers/141849
    title: Opioid Prescribing Mediating State Policy Intervention Effects on Drug
      Overdose Mortality
    category: health-policy
    abstract: The Centers for Disease Control and Prevention reported 70 630 drug
      overdose deaths for 2019 in the United States, 70.5% of which were
      opioid-related. Preliminary estimates now warn that drug overdose deaths
      likely surpassed 86 000 during 2020. Despite a 57.4% decrease in opioid
      prescribing since a peak in 2012, the opioid death rate has increased
      105.8% through 2019, as the share of those deaths involving fentanyl
      increased from 16.4% to 72.9%. This letter seeks to determine whether the
      opioid prescribing and mortality paradox is robust to accepted methods of
      causal policy analysis and if prescribing rates mediate the effects of
      policy interventions on overdose deaths. Using loge-loge ordinary least
      squares with three different specifications as sensitivity analyses for
      all 50 states and Washington, DC for the period 2001-2019, the
      elasticities from the regressions with all control variables report
      operational prescription drug monitoring programs (PDMPs) reduce
      prescribing rates 8.7%, while mandatory PDMPs increase death rates from
      opioids 16.6%, heroin and fentanyl 19.0%, cocaine 17.3% and all drugs
      10.5%. There is also weak evidence that recreational marijuana laws reduce
      prescribing, increases in prescribing increase pain reliever deaths, pill
      mill laws increase cocaine deaths, and medical marijuana laws increase
      total overdose deaths, with demographic variables suggesting states with
      more male, less non-Hispanic white, and older citizens experience more
      overdoses. Weak mediation effects were observed for pain reliever,
      cocaine, and illicit opioid deaths, while broad reductions in prescribing
      have failed to reduce opioid overdoses.
    authors:
      - name: Jacob James Rich
        orcid: http://orcid.org/0000-0002-2272-5446
      - name: Robert Capodilupo
        orcid: null
  comment:
    dislikes: 0
    thread: "8522891427"
    numReports: 0
    likes: 0
    id: "5387217982"
    createdAt: 2021-05-17T21:44:07
    author:
      username: redlawhern
      about: Advocate and web author for chronic neurological facepain patients.
        Formerly webmaster for the US Trigeminal Neuralgia Association.
      name: Red Lawhern
      isPowerContributor: false
      profileUrl: https://disqus.com/by/redlawhern/
      url: http://www.face-facts.org/Lawhern
      location: Fort Mill, SC
      id: "99089704"
    isApproved: true
    raw_message: >-
      In your paper you write 



      "drug monitoring programs (PDMPs) reduce prescribing rates 8.7%, while 

      mandatory PDMPs increase death rates from opioids 16.6%, heroin and 

      fentanyl 19.0%, cocaine 17.3% and all drugs 10.5%" 


      This phrasing seems to assert demonstrated cause and effect.  It is not at all clear to me that the techniques you are applying have the capability to establish that. 


      Likewise, there is an important question in this process that you do not address and I would hope you may be willing to attempt:  recognizing that predominant modes of overdose mortality involve multiple legal and illegal opioids in the great majority of deaths, is the contribution of opioids prescribed by doctors to their patients (not diverted) statistically significant  in the overall mortality rate due to all opioids, legal and illegal? Based on the relative rarity of addiction to medically managed prescription opioids,  I would suggest that it is not.  


      Your comments are invited.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.13.21257109v1
  tweets:
    - created_at: Tue May 18 00:41:53 +0000 2021
      id: 1394453151135137800
      id_str: "1394453151135137797"
      text: |-
        üí¨ medRxiv comment on "Opioid Prescribing Mediating S..."

        "In your paper you write 

        "drug monitoring programs (PDM‚Ä¶ https://t.co/3TZYvBaiel
      truncated: true
      entities:
        urls:
          - url: https://t.co/3TZYvBaiel
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue May 18 00:41:53 +0000 2021
      id: 1394453152129110000
      id_str: "1394453152129110016"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/csjma3h5nC
      truncated: false
      entities:
        urls:
          - url: https://t.co/csjma3h5nC
      in_reply_to_status_id: 1394453151135137800
      in_reply_to_status_id_str: "1394453151135137797"
- preprint:
    id: "122704"
    doi: 10.1101/2020.12.23.423904
    first_posted: 2020-12-23
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.12.23.423904v1
    url: https://api.rxivist.org/v1/papers/122704
    title: Cytosolic localization and in vitro assembly of human de novo thymidylate
      synthesis complex
    category: biochemistry
    abstract: "De novo thymidylate synthesis is a crucial pathway for normal and
      cancer cells. Deoxythymidine monophosphate (dTMP) is synthesized by the
      combined action of three enzymes: serine hydroxymethyltransferase (SHMT),
      dihydrofolate reductase (DHFR) and thymidylate synthase (TYMS), the latter
      two targets of widely used chemotherapeutics such as antifolates and
      5-fluorouracil. These proteins translocate to the nucleus after
      SUMOylation and are suggested to assemble in this compartment into the
      thymidylate synthesis complex (dTMP-SC). We report the intracellular
      dynamics of the complex in lung cancer cells by in situ proximity ligation
      assay, showing that it is also detected in the cytoplasm. This result
      strongly indicates that the role of the dTMP-SC assembly may go beyond
      dTMP synthesis. We have successfully assembled the dTMP synthesis complex
      in vitro, employing tetrameric SHMT1 and a bifunctional chimeric enzyme
      comprising human TYMS and DHFR. We show that the SHMT1 tetrameric state is
      required for efficient complex assembly, indicating that this aggregation
      state is evolutionary selected in eukaryotes to optimize protein-protein
      interactions. Lastly, our results on the activity of the complete
      thymidylate cycle in vitro, may provide a useful tool to develop drugs
      targeting the entire complex instead of the individual components."
    authors:
      - name: Sharon Spizzichino
        orcid: null
      - name: Dalila Boi
        orcid: null
      - name: Giovanna Boumis
        orcid: http://orcid.org/0000-0001-5323-7288
      - name: Roberta Lucchi
        orcid: null
      - name: Francesca Romana Liberati
        orcid: null
      - name: Davide Capelli
        orcid: http://orcid.org/0000-0002-6716-3854
      - name: Roberta Montanari
        orcid: http://orcid.org/0000-0002-7533-5425
      - name: Giorgio Pochetti
        orcid: http://orcid.org/0000-0002-3980-3180
      - name: Alessio Paone
        orcid: http://orcid.org/0000-0001-9406-3982
      - name: Serena Rinaldo
        orcid: http://orcid.org/0000-0003-0682-023X
      - name: Roberto Contestabile
        orcid: http://orcid.org/0000-0002-5235-9993
      - name: Alessandro Paiardini
        orcid: http://orcid.org/0000-0001-9078-7545
      - name: Angela Tramonti
        orcid: http://orcid.org/0000-0002-5625-1170
      - name: Giorgio Giardina
        orcid: http://orcid.org/0000-0002-0802-1370
      - name: Francesca Cutruzzol√°
        orcid: http://orcid.org/0000-0002-4621-2135
  comment:
    dislikes: 0
    thread: "8378755337"
    numReports: 0
    likes: 0
    id: "5387170427"
    createdAt: 2021-05-17T20:59:10
    author:
      username: virginia_bain
      about: ""
      name: Virginia Bain
      isPowerContributor: false
      profileUrl: https://disqus.com/by/virginia_bain/
      url: ""
      location: ""
      id: "369529985"
    isApproved: true
    raw_message: Hello~ I have a question for the authors. It looks like there is
      nuclear DHFR by immunofluorescence in A549 cells in figure 2C but in 2F
      you nicely show that  DHFR is only in the cytoplasm. What do you make of
      the nuclear DHFR in figure 2C? Thanks!
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.12.23.423904v2
  tweets:
    - created_at: Tue May 18 13:01:59 +0000 2021
      id: 1394639401880363000
      id_str: "1394639401880363017"
      text: >-
        üí¨ bioRxiv comment on "Cytosolic localization and in ..."


        "Hello~ I have a question for the authors. It looks like‚Ä¶ https://t.co/htIrFvsQaN
      truncated: true
      entities:
        urls:
          - url: https://t.co/htIrFvsQaN
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue May 18 13:01:59 +0000 2021
      id: 1394639403071455200
      id_str: "1394639403071455235"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/QFqflcwef6
      truncated: false
      entities:
        urls:
          - url: https://t.co/QFqflcwef6
      in_reply_to_status_id: 1394639401880363000
      in_reply_to_status_id_str: "1394639401880363017"
- preprint:
    id: "80107"
    doi: 10.1101/2020.04.16.044255
    first_posted: 2020-04-17
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.04.16.044255v1
    url: https://api.rxivist.org/v1/papers/80107
    title: Stability of the vaginal microbiota during pregnancy and its importance
      for early infant colonization
    category: bioinformatics
    abstract: Early life microbiota has been linked to the development of chronic
      inflammatory diseases. It has been hypothesized that maternal vaginal
      microbiota is an important initial seeding source and therefore can have
      lifelong effects on disease risk. To understand maternal vaginal
      microbiota's role in seeding the child's microbiota and the extent of
      delivery mode-dependent transmission, we studied 700 mother-child dyads
      from the COPSAC2010 cohort. The maternal vaginal microbiota was evaluated
      in the third trimester and compared with the children's fecal and airway
      microbiota. The vaginal samples displayed known stable community state
      types and only 1:6 changed over time. Only one OTU were significantly
      transferred to children's fecal compartment, but an inflated number had
      positive transfer odds. A few taxonomic families showed early transfer
      enrichment to vaginally-born children, indicating vertical transfer, while
      half of the observed transfer effects were delivery mode independent
      enrichment with attenuating strength over time, indicating a common
      reservoir.
    authors:
      - name: Martin S. Mortensen
        orcid: http://orcid.org/0000-0001-5483-7533
      - name: Morten A. Rasmussen
        orcid: null
      - name: Jakob Stokholm
        orcid: http://orcid.org/0000-0003-4989-9769
      - name: Asker D. Brejnrod
        orcid: null
      - name: Christina Balle
        orcid: null
      - name: Jonathan Thorsen
        orcid: null
      - name: Karen A. Krogfelt
        orcid: http://orcid.org/0000-0001-7536-3453
      - name: Hans Bisgaard
        orcid: http://orcid.org/0000-0003-4131-7592
      - name: S√∏ren J. S√∏rensen
        orcid: http://orcid.org/0000-0001-6227-9906
  comment:
    dislikes: 0
    thread: "7975653931"
    numReports: 0
    likes: 0
    id: "5387820233"
    createdAt: 2021-05-18T12:28:19
    author:
      username: martinsteenmortensen
      about: ""
      name: Martin Steen Mortensen
      isPowerContributor: false
      profileUrl: https://disqus.com/by/martinsteenmortensen/
      url: ""
      location: ""
      id: "105193295"
    isApproved: true
    raw_message: We had this article printed in eLife (10.7554/eLife.57051), but due
      to an updated title it does not seem to have been registered here.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.04.16.044255v1
  tweets:
    - created_at: Tue May 18 20:17:23 +0000 2021
      id: 1394748974083436500
      id_str: "1394748974083436544"
      text: >-
        üí¨ bioRxiv comment on "Stability of the vaginal micro..."


        "We had this article printed in eLife (10.7554/eLife.5705‚Ä¶ https://t.co/UH3K9yglqy
      truncated: true
      entities:
        urls:
          - url: https://t.co/UH3K9yglqy
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue May 18 20:17:23 +0000 2021
      id: 1394748974976757800
      id_str: "1394748974976757761"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/ojArj6Z8J7
      truncated: false
      entities:
        urls:
          - url: https://t.co/ojArj6Z8J7
      in_reply_to_status_id: 1394748974083436500
      in_reply_to_status_id_str: "1394748974083436544"
- preprint:
    id: 127224
    metric: 4264
    title: Heterologous vaccination regimens with self-amplifying RNA and Adenoviral
      COVID vaccines induce robust immune responses in mice
    url: https://api.rxivist.org/v1/papers/127224
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.01.28.428665v1
    doi: 10.1101/2021.01.28.428665
    category: immunology
    first_posted: 2021-01-29
    abstract: Several vaccines have demonstrated efficacy against SARS-CoV-2
      mediated disease, yet there is limited data on the immune response induced
      by heterologous vaccination regimens using alternate vaccine modalities.
      Here, we present a detailed description of the immune response, in mice,
      following vaccination with a self-amplifying RNA (saRNA) vaccine and an
      adenoviral vectored vaccine (ChAdOx1 nCoV-19/AZD1222) against SARS-CoV-2.
      We demonstrate that antibody responses are higher in two dose heterologous
      vaccination regimens than single dose regimens. Neutralising titres after
      heterologous prime-boost were at least comparable or higher than the
      titres measured after homologous prime boost vaccination with viral
      vectors. Importantly, the cellular immune response after a heterologous
      regimen is dominated by cytotoxic T cells and Th1+ CD4 T cells which is
      superior to the response induced in homologous vaccination regimens in
      mice. These results underpin the need for clinical trials to investigate
      the immunogenicity of heterologous regimens with alternate vaccine
      technologies.
    authors:
      - name: Alexandra J Spencer
      - name: Paul F McKay
      - name: Sandra Belij-Rammerstorfer
      - name: Marta Ulaszewska
      - name: Cameron D Bissett
      - name: Kai Hu
      - name: Karnyart Samnuan
      - name: Anna K. Blakney
      - name: Hannah R Sharpe
      - name: Daniel Wright
      - name: Ciaran Gilbride
      - name: Adam Truby
      - name: Elizabeth R Allen
      - name: Sarah C Gilbert
      - name: Robin J Shattock
      - name: Teresa Lambe
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Tue May 18 20:25:30 +0000 2021
      id: 1394751018022359000
      id_str: "1394751018022359044"
      text: >-
        üî• bioRxiv Immunology preprint by A. J. Spencer et al:


        "Heterologous vaccination regimens with self-amplifying RNA‚Ä¶ https://t.co/CqHl2SBkG3
      truncated: true
      entities:
        urls:
          - url: https://t.co/CqHl2SBkG3
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "130515"
    doi: 10.1101/2021.02.23.432421
    first_posted: 2021-02-23
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.02.23.432421v1
    url: https://api.rxivist.org/v1/papers/130515
    title: A more accurate method for colocalisation analysis allowing for multiple
      causal variants
    category: genetics
    abstract: In genome-wide association studies (GWAS) it is now common to search
      for, and find, multiple causal variants located in close proximity. It has
      also become standard to ask whether different traits share the same causal
      variants, but one of the popular methods to answer this question, coloc,
      makes the simplifying assumption that only a single causal variant exists
      for any given trait in any genomic region. Here, we examine the potential
      of the recently proposed Sum of Single Effects (SuSiE) regression
      framework, which can be used for fine-mapping genetic signals, for use
      with coloc. SuSiE is a novel approach that allows evidence for association
      at multiple causal variants to be evaluated simultaneously, whilst
      separating the statistical support for each variant conditional on the
      causal signal being considered. We show this results in more accurate
      coloc inference than other proposals to adapt coloc for multiple causal
      variants based on conditioning or masking. We therefore recommend that
      coloc be used in combination with SuSiE to optimise accuracy of
      colocalisation analyses when multiple causal variants exist.
    authors:
      - name: Chris Wallace
        orcid: http://orcid.org/0000-0001-9755-1703
  comment:
    dislikes: 0
    thread: "8410450800"
    numReports: 0
    likes: 0
    id: "5387656036"
    createdAt: 2021-05-18T08:18:43
    author:
      username: disqus_SKjVenadaX
      about: ""
      name: Chris Wallace üè≥Ô∏è‚Äçüåà  üá™üá∫
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_SKjVenadaX/
      url: ""
      location: ""
      id: "325883660"
    isApproved: true
    raw_message: >-
      Thank you for taking the time to review.  I haven't had a public review
      before to my knowledge, but they seem a thoroughly good thing.  I am not
      sure of the conventions, but hope it is in the right spirit to post a
      summary of my responses to each of your main points, which I think have
      improved the manuscript.  The changes I describe may be seen in version 2
      on biorxiv.


      1. I have adjusted coloc to use the Bayes factors that are now returned by susie_rss (thank you), so the back-calculation is no longer needed and I have removed that equation. I have also updated the relevant text to give more details on how susie_rss is called, and the number of colocalisation comparisons returned and how the pairwise probabilities of colocalisation may be interpreted.





      2. I completely agree it would be cheating to tell any method how many causal variants were simulated! I have updated the legend to figure 3, which hopefully clarifies what AA, BB etc signals are. 





      In the setting where each trait has 2 causal variants A and B, there should ideally be 4 comparisons: AA, AB, BA, BB.  Very occasionally there are more (a handful of times susie_rss reports > 2 signals).  Often there are fewer (due to power), and even when there are 4, they may not all be assignable to labelled groups and some will fall in ‚Äú?‚Äù. This is why the bar height, which is proportional to the number of comparisons performed in a given category divided by the number of simulations, doesn‚Äôt reach 1.





      3. Figure 1 has now been changed to show both the change in PIP at the causal variants and at the non-causal variants. Specifically, following the approach of coloc to consider comparisons between vectors of Bayes factors corresponding to detected credible sets, I took the colSums of obj$alpha[ obj$sets$cs_index, ] as a measure of the total PIP after a run of susie_rss(). Thus the total PIP can increase/decrease by 1 if a credible set is ‚Äúdiscovered‚Äù or ‚Äúlost‚Äù after trimming.  This view of the data shows false positives are indeed introduced after trimming. This is now described at the beginning of the Results section





      Fig 3 shows, however, that despite these false positives coloc with SuSiE outperforms the alternatives, and appears to do at least as well when trimming as not. Therefore, I expanded the Discussion on trimming to give a clearer warning that while trimming is possible for coloc, these results do not support its use in fine-mapping. 





      4. Thank you for these detailed explanations. I agree it would be preferable to never trim data. I have extended the discussion to cover these points, and acknowledged your comments in helping me to do that.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.02.23.432421v1
  tweets:
    - created_at: Wed May 19 00:38:04 +0000 2021
      id: 1394814579050418200
      id_str: "1394814579050418177"
      text: >-
        üí¨ bioRxiv comment on "A more accurate method for col..."


        "Thank you for taking the time to review.  I haven't had‚Ä¶ https://t.co/0t8vLXlLjk
      truncated: true
      entities:
        urls:
          - url: https://t.co/0t8vLXlLjk
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed May 19 00:38:04 +0000 2021
      id: 1394814579805507600
      id_str: "1394814579805507588"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/mThs3YVlCp
      truncated: false
      entities:
        urls:
          - url: https://t.co/mThs3YVlCp
      in_reply_to_status_id: 1394814579050418200
      in_reply_to_status_id_str: "1394814579050418177"
- preprint:
    id: "124483"
    doi: 10.1101/2020.12.21.20248121
    first_posted: 2020-12-24
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.12.21.20248121v1
    url: https://api.rxivist.org/v1/papers/124483
    title: HLA-C* 04:01 is a Genetic Risk Allele for Severe Course of COVID-19
    category: genetic-and-genomic-medicine
    abstract: >-
      BackgroundSince the beginning of the coronavirus disease 2019 (COVID-19)
      pandemic, there has been increasing demand to identify predictors of
      severe clinical course in patients infected with severe acute respiratory
      syndrome coronavirus 2 (SARS-CoV-2). Human leukocyte antigen alleles (HLA)
      have been suggested as potential genetic host factors. We sought to
      evaluate this hypothesis by conducting an international multicenter study
      using HLA sequencing with subsequent independent validation.


      MethodsWe analyzed a total of 332 samples. First, we enrolled 233 patients in Germany, Spain, and Switzerland for HLA and whole exome sequencing. Furthermore, we validated our results in a public data set (United States, n=99). Patients older than 18 years presenting with COVID-19 were included, representing the full spectrum of the disease. HLA candidate alleles were identified in the derivation cohort (n=92) and tested in two independent validation cohorts (n=240).


      ResultsWe identified HLA-C* 04:01 as a novel genetic predictor for severe clinical course in COVID-19. Carriers of HLA-C* 04:01 had twice the risk of intubation when infected with SARS-CoV-2 (hazard ratio 2.1, adjusted p-value=0.0036). Importantly, these findings were successfully replicated in an independent data set. Furthermore, our findings are biologically plausible, as HLA-C* 04:01 has fewer predicted bindings sites with relevant SARS-CoV-2 peptides as compared to other HLA alleles. Exome sequencing confirmed findings from HLA analysis.


      ConclusionsHLA-C* 04:01 carriage is associated with a twofold increased risk of intubation in patients infected with SARS-CoV-2. Testing for HLA-C* 04:01 could have clinical implications to identify high-risk patients and individualize management.
    authors:
      - name: Weiner January
        orcid: null
      - name: Suwalski Phillip
        orcid: null
      - name: Holtgrewe Manuel
        orcid: null
      - name: Thibeault Charlotte
        orcid: http://orcid.org/0000-0002-8979-9386
      - name: Melina M√ºller
        orcid: null
      - name: Patriki Dimitri
        orcid: null
      - name: Quedenau Claudia
        orcid: null
      - name: Ulrike Kr√ºger
        orcid: null
      - name: T. Helbig Elisa
        orcid: null
      - name: Lippert Lena
        orcid: null
      - name: Stubbemann Paula
        orcid: null
      - name: Real Luis Miguel
        orcid: null
      - name: Sanchez Juan Macias
        orcid: null
      - name: A. Pineda Juan
        orcid: null
      - name: Fernandez-Fuertes Marta
        orcid: null
      - name: Wang Xiaomin
        orcid: null
      - name: Karadeniz Zehra
        orcid: null
      - name: Saccomanno Jacopo
        orcid: null
      - name: Doehn Jan-Moritz
        orcid: null
      - name: H√ºbner Ralf-Harto
        orcid: null
      - name: Hinzmann Bernd
        orcid: null
      - name: Salvo Mauricio
        orcid: null
      - name: Blueher Anja
        orcid: null
      - name: Siemann Sandra
        orcid: null
      - name: Jurisic Stjepan
        orcid: null
      - name: Beer Hansjuerg
        orcid: null
      - name: Rutishauser Jonas
        orcid: null
      - name: Wiggli Benedikt
        orcid: null
      - name: Schmid Hansruedi
        orcid: null
      - name: Danninger Kathrin
        orcid: null
      - name: Binder Ronald
        orcid: null
      - name: M. Victor Corman
        orcid: null
      - name: M√ºhlemann Barbara
        orcid: null
      - name: Braun Alice
        orcid: null
      - name: Ripke Stephan
        orcid: null
      - name: C. Jones Terry
        orcid: null
      - name: Suttorp Norbert
        orcid: null
      - name: Witzenrath Martin
        orcid: null
      - name: Hippenstiel Stefan
        orcid: null
      - name: Zemojtel Tomasz
        orcid: null
      - name: Skurk Carsten
        orcid: null
      - name: Poller Wolfgang
        orcid: null
      - name: Borodina Tatiana
        orcid: null
      - name: Pa-COVID Study Group
        orcid: null
      - name: E. Sander Leif
        orcid: null
      - name: Beule Dieter
        orcid: null
      - name: Landmesser Ulf
        orcid: null
      - name: Guettouche Toumy
        orcid: null
      - name: Kurth Florian
        orcid: null
      - name: Heidecker Bettina
        orcid: null
  comment:
    dislikes: 0
    thread: "8328945006"
    numReports: 0
    likes: 0
    id: "5388394685"
    createdAt: 2021-05-18T20:33:29
    author:
      username: disqus_WaA83XvM0B
      about: ""
      name: Rene Warren
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_WaA83XvM0B/
      url: ""
      location: ""
      id: "157460079"
    isApproved: true
    raw_message: "We have done that in our work using the Overmyer (New York) cohort
      and reported our findings on November 2nd, 2020:
      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605564/"
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.12.21.20248121v1
  tweets:
    - created_at: Wed May 19 12:17:09 +0000 2021
      id: 1394990509026914300
      id_str: "1394990509026914309"
      text: >-
        üí¨ medRxiv comment on "HLA-C* 04:01 is a Genetic Risk..."


        "We have done that in our work using the Overmyer (New Yo‚Ä¶ https://t.co/IYWHjQPThj
      truncated: true
      entities:
        urls:
          - url: https://t.co/IYWHjQPThj
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed May 19 12:17:09 +0000 2021
      id: 1394990509823828000
      id_str: "1394990509823827973"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/hPghHHcQqX
      truncated: false
      entities:
        urls:
          - url: https://t.co/hPghHHcQqX
      in_reply_to_status_id: 1394990509026914300
      in_reply_to_status_id_str: "1394990509026914309"
- preprint:
    id: "120813"
    doi: 10.1101/2020.12.01.20241919
    first_posted: 2020-12-09
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.12.01.20241919v1
    url: https://api.rxivist.org/v1/papers/120813
    title: bootComb - An R Package to Derive Confidence Intervals for Combinations
      of Independent Parameter Estimates
    category: epidemiology
    abstract: "Motivation. The epidemiologist sometimes needs to combine several
      independent parameter estimates: e.g. (i) adjust an incidence rate for
      healthcare utilisation, (ii) derive a disease prevalence from the
      conditional prevalence on another condition and the prevalence of that
      condition, (iii) adjust a seroprevalence for test sensitivity and
      specificity. While obtaining the combined parameter estimate is usually
      straightforward, deriving a corresponding confidence interval often is
      not. bootComb is an R package using parametric bootstrap sampling to
      derive such confidence intervals. Implementation. bootComb is a package
      for the statistical computation environment R. General features. As well
      as a function that returns confidence intervals for parameters combined
      from several independent estimates, bootComb provides auxiliary functions
      for 6 common distributions (beta, normal, exponential, gamma, Poisson and
      negative binomial) to derive best-fit distributions (and their sampling
      functions) for parameters given their reported confidence intervals.
      Availability. bootComb is available from the Comprehensive R Archive
      Network (https://CRAN.R-project.org/package=bootComb)."
    authors:
      - name: Marc YR Henrion
        orcid: http://orcid.org/0000-0003-1242-839X
  comment:
    dislikes: 0
    thread: "8306836802"
    numReports: 0
    likes: 0
    id: "5389485884"
    createdAt: 2021-05-19T17:50:25
    author:
      username: marchenrion
      about: ""
      name: marchenrion
      isPowerContributor: false
      profileUrl: https://disqus.com/by/marchenrion/
      url: ""
      location: ""
      id: "369633532"
    isApproved: true
    raw_message: >-
      This article has been accepted for publication in the International
      Journal of Epidemiology published by Oxford University Press.



      The DOI for the version of record is https://doi.org/10.1093/ije/dyab049.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.12.01.20241919v1
  tweets:
    - created_at: Wed May 19 20:12:34 +0000 2021
      id: 1395110151296794600
      id_str: "1395110151296794633"
      text: >-
        üí¨ medRxiv comment on "bootComb - An R Package to Der..."


        "This article has been accepted for publication in the In‚Ä¶ https://t.co/h1mkrF0BX1
      truncated: true
      entities:
        urls:
          - url: https://t.co/h1mkrF0BX1
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed May 19 20:12:34 +0000 2021
      id: 1395110152177606700
      id_str: "1395110152177606658"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/zHk5Ao17H8
      truncated: false
      entities:
        urls:
          - url: https://t.co/zHk5Ao17H8
      in_reply_to_status_id: 1395110151296794600
      in_reply_to_status_id_str: "1395110151296794633"
- preprint:
    id: 104150
    metric: 4184
    title: Analysis of SARS-CoV-2 spike glycosylation reveals shedding of a vaccine
      candidate
    url: https://api.rxivist.org/v1/papers/104150
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.11.16.384594v1
    doi: 10.1101/2020.11.16.384594
    category: biochemistry
    first_posted: 2020-11-16
    abstract: >-
      Severe acute respiratory syndrome coronavirus 2 is the causative pathogen
      of the COVID-19 pandemic which as of Nov 15, 2020 has claimed 1,319,946
      lives worldwide. Vaccine development focuses on the viral trimeric spike
      glycoprotein as the main target of the humoral immune response. Viral
      spikes carry glycans that facilitate immune evasion by shielding specific
      protein epitopes from antibody neutralisation. Immunogen integrity is
      therefore important for glycoprotein-based vaccine candidates. Here we
      show how site-specific glycosylation differs between virus-derived spikes
      and spike proteins derived from a viral vectored SARS-CoV-2 vaccine
      candidate. We show that their cellular secretion pathways are unique,
      resulting in different protein glycosylation and secretion, which may have
      implications for the resulting immune response and future vaccine design.


      ### Competing Interest Statement


      W.B.S. is a shareholder and consultant to Refeyn Ltd. All other authors declare no conflict of interest.
    authors:
      - name: Juliane Brun
      - name: Snezana Vasiljevic
      - name: Bevin Gangadharan
      - name: Mario Hensen
      - name: Anu V. Chandran
      - name: Michelle L. Hill
      - name: J.L. Kiappes
      - name: Raymond A. Dwek
      - name: Dominic S. Alonzi
      - name: Weston B. Struwe
      - name: Nicole Zitzmann
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Wed May 19 20:20:31 +0000 2021
      id: 1395112150230839300
      id_str: "1395112150230839303"
      text: >-
        üî• bioRxiv Biochemistry preprint by J. Brun et al:


        "Analysis of SARS-CoV-2 spike glycosylation reveals shedding of‚Ä¶ https://t.co/pUILp7mqvt
      truncated: true
      entities:
        urls:
          - url: https://t.co/pUILp7mqvt
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "123354"
    doi: 10.1101/2020.12.31.425005
    first_posted: 2021-01-02
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.12.31.425005v1
    url: https://api.rxivist.org/v1/papers/123354
    title: YhcB (DUF1043), a novel cell division protein conserved across
      gamma-proteobacteria
    category: microbiology
    abstract: >-
      YhcB, an uncharacterized protein conserved across gamma-proteobacteria, is
      composed predominantly of a single Domain of Unknown Function (DUF 1043)
      with an N-terminal transmembrane -helix. Here, we show that E. coli YhcB
      is a conditionally essential protein that interacts with the proteins of
      the cell divisome (e.g., FtsI, FtsQ) and elongasome (e.g., RodZ, RodA). We
      found 7 interactions of YhcB that are conserved in Yersinia pestis and/or
      Vibrio cholerae. Furthermore, we identified several point mutations that
      abolished interactions of YhcB with FtsI and RodZ. The yhcB knock-out
      strain does not grow at 45{degrees}C and is hypersensitive to cell-wall
      acting antibiotics even in stationary phase. The deletion of yhcB leads to
      filamentation, abnormal FtsZ ring formation, and aberrant septa
      development. The 2.8 [A] crystal structure for the cytosolic domain from
      Haemophilus ducreyi YhcB shows a unique tetrameric -helical coiled-coil
      structure that combines parallel and anti-parallel coiled-coil
      intersubunit interactions. This structure is likely to organize
      interprotein oligomeric interactions on the inner surface of the
      cytoplasmic membrane, possibly involved in regulation of cell division
      and/or envelope biogenesis/integrity in proteobacteria. In summary, YhcB
      is a conserved and conditionally essential protein that is predicted to
      play a role in cell division and consequently or in addition affects
      envelope biogenesis.


      ImportanceOnly 0.8 % of the protein annotations in the UniProt are based on experimental evidence and thus, functional characterization of unknown proteins remains a rate-limiting step in molecular biology. Herein, the functional properties of YhcB (DUF1043) were investigated using an integrated approach combining X-ray crystallography with genetics and molecular biology. YhcB is a conserved protein that appears to be needed for the transition from exponential to stationary growth and is involved in cell division and/or envelope biogenesis/integrity. This study will serve as a starting point for future studies on this protein family and on how cells transit from exponential to stationary survival.
    authors:
      - name: Jitender Mehla
        orcid: http://orcid.org/0000-0002-7829-557X
      - name: George Liechti
        orcid: http://orcid.org/0000-0003-3028-8474
      - name: Randy Morgenstein
        orcid: http://orcid.org/0000-0003-0749-6830
      - name: J. Harry Caufield
        orcid: http://orcid.org/0000-0001-5705-7831
      - name: Ali Hosseinnia
        orcid: http://orcid.org/0000-0002-6499-0758
      - name: Alla Gagarinova
        orcid: http://orcid.org/0000-0002-6521-6406
      - name: Sadhna Phanse
        orcid: http://orcid.org/0000-0001-6306-0551
      - name: Mary Brockett
        orcid: http://orcid.org/0000-0002-5167-9231
      - name: Neha Sakhawalkar
        orcid: null
      - name: Mohan Babu
        orcid: null
      - name: Rong Xiao
        orcid: null
      - name: Gaetano T. Montelione
        orcid: http://orcid.org/0000-0002-9440-3059
      - name: Sergey Vorobiev
        orcid: http://orcid.org/0000-0001-8537-3671
      - name: Tanneke den Blaauwen
        orcid: http://orcid.org/0000-0002-5403-5597
      - name: John F. Hunt
        orcid: http://orcid.org/0000-0003-0034-5167
      - name: Peter Uetz
        orcid: http://orcid.org/0000-0001-6194-4927
  comment:
    dislikes: 0
    thread: "8346695005"
    numReports: 0
    likes: 0
    id: "5389262434"
    createdAt: 2021-05-19T15:03:33
    author:
      username: disqus_vbFUJ0jUw9
      about: ""
      name: Peter Uetz
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_vbFUJ0jUw9/
      url: https://www.facebook.com/app_scoped_user_id/YXNpZADpBWEV4UERQSHR4OTV5T1ZAiM0NaUXJoS3VfU1FHOW5uOUpOcjM1WDhvdU16WVkySmxSLVhEQzVEaVNoaVNzY1BRN1JmYTNwME56YWtwUU5XajdsREl6dml1WWZAuVGhKVmpEcDdC/
      location: ""
      id: "191120429"
    isApproved: true
    raw_message: "A revision of this paper has now been published in the Journal of
      Biological Chemistry: https://pubmed.ncbi.nlm.nih.gov/33895137/"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.12.31.425005v2
  tweets:
    - created_at: Thu May 20 00:35:52 +0000 2021
      id: 1395176410558472200
      id_str: "1395176410558472198"
      text: >-
        üí¨ bioRxiv comment on "YhcB (DUF1043), a novel cell d..."


        "A revision of this paper has now been published in the J‚Ä¶ https://t.co/m20d9V3ByV
      truncated: true
      entities:
        urls:
          - url: https://t.co/m20d9V3ByV
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 20 00:35:52 +0000 2021
      id: 1395176411476922400
      id_str: "1395176411476922368"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/vcWIH7J1wX
      truncated: false
      entities:
        urls:
          - url: https://t.co/vcWIH7J1wX
      in_reply_to_status_id: 1395176410558472200
      in_reply_to_status_id_str: "1395176410558472198"
- preprint:
    id: "109282"
    doi: 10.1101/2020.04.20.20073437
    first_posted: 2020-04-24
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.04.20.20073437v1
    url: https://api.rxivist.org/v1/papers/109282
    title: Estimated inequities in COVID-19 infection fatality rates by ethnicity
      for Aotearoa New Zealand
    category: epidemiology
    abstract: There is limited evidence as to how COVID-19 infection fatality rates
      (IFR) may vary by ethnicity. We combine demographic and health data for
      ethnic groupings in Aotearoa New Zealand with international data on IFR
      for different age groups to estimate inequities in IFR by ethnicity. We
      find that, if age is the dominant factor determining IFR, estimated IFR
      for M[a]ori is around 50% higher than non-M[a]ori. If underlying health
      conditions are more important than age per se, then estimated IFR for
      M[a]ori is more than 2.5 times that of New Zealand European, and estimated
      IFR for Pasifika is almost double that of New Zealand European. IFRs for
      M[a]ori and Pasifika are likely to be increased above these estimates by
      racism within the healthcare system and other inequities not reflected in
      official data. IFR does not account for differences among ethnicities in
      COVID-19 incidence, which could be higher in M[a]ori and Pasifika as a
      result of crowded housing and higher inter-generational contact rates.
      These factors should be included in future disease incidence modelling.
      The communities at the highest risk will be those with elderly
      populations, and M[a]ori and Pasifika communities, where the compounded
      effects of underlying health conditions, socioeconomic disadvantage, and
      structural racism result in imbricated risk of contracting COVID-19,
      becoming unwell, and death.
    authors:
      - name: Nicholas Steyn
        orcid: null
      - name: Rachelle N Binny
        orcid: http://orcid.org/0000-0002-3433-0417
      - name: Kate Hannah
        orcid: http://orcid.org/0000-0002-4934-7377
      - name: Shaun C Hendy
        orcid: http://orcid.org/0000-0003-3468-6517
      - name: Alex James
        orcid: http://orcid.org/0000-0002-1543-7139
      - name: Tahu Kukutai
        orcid: http://orcid.org/0000-0001-5080-2296
      - name: Audrey Lustig
        orcid: http://orcid.org/0000-0002-0869-3847
      - name: Melissa McLeod
        orcid: http://orcid.org/0000-0002-5834-7846
      - name: Michael J Plank
        orcid: http://orcid.org/0000-0002-7539-3465
      - name: Kannan Ridings
        orcid: null
      - name: Andrew Sporle
        orcid: null
  comment:
    dislikes: 0
    thread: "7990193862"
    numReports: 0
    likes: 0
    id: "5389829779"
    createdAt: 2021-05-19T22:26:18
    author:
      username: disqus_Pc9ZQufNd1
      about: ""
      name: Michael Plank
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_Pc9ZQufNd1/
      url: ""
      location: ""
      id: "369642137"
    isApproved: true
    raw_message: "This paper has now been published in the New Zealand Medical
      Journal and is available open access at:
      https://www.nzma.org.nz/journal-articles/estimated-inequities-in-covid-19\
      -infection-fatality-rates-by-ethnicity-for-aotearoa-new-zealand"
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.04.20.20073437v1
  tweets:
    - created_at: Thu May 20 12:17:37 +0000 2021
      id: 1395353011673829400
      id_str: "1395353011673829376"
      text: >-
        üí¨ medRxiv comment on "Estimated inequities in COVID-..."


        "This paper has now been published in the New Zealand Med‚Ä¶ https://t.co/fcKfJUZwaQ
      truncated: true
      entities:
        urls:
          - url: https://t.co/fcKfJUZwaQ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 20 12:17:37 +0000 2021
      id: 1395353012579836000
      id_str: "1395353012579835910"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/1WFsniCwvc
      truncated: false
      entities:
        urls:
          - url: https://t.co/1WFsniCwvc
      in_reply_to_status_id: 1395353011673829400
      in_reply_to_status_id_str: "1395353011673829376"
- preprint:
    id: "141912"
    doi: 10.1101/2021.05.15.21257017
    first_posted: 2021-05-17
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.15.21257017v1
    url: https://api.rxivist.org/v1/papers/141912
    title: Extended interval BNT162b2 vaccination enhances peak antibody generation
      in older people
    category: infectious-diseases
    abstract: "Abstract Objectives: To assess the relative immunogenicity of
      standard or extended interval BNT162b2 vaccination. Design: Population
      based cohort study comparing immune responses 2 weeks after the second
      vaccine, with appropriate time-matched samples in participants who
      received standard or extended interval double vaccination. Setting:
      Primary care networks, Birmingham, UK. December 2020 to April 2021.
      Participants: 175 people aged over 80 years of age. All donors received
      the BNT162b2 Pfizer/BioNTech vaccination and were vaccinated with either a
      standard 3 week interval between doses or an extended interval schedule.
      Main outcome measures: Peak quantitative spike-specific antibody and
      cellular immune responses. Results: In donors without evidence of previous
      infection the peak antibody response was 3.5-fold higher in donors who had
      undergone delayed interval vaccination. Cellular immune responses were
      3.6-fold lower. Conclusion: Peak antibody responses after the second
      BNT162b2 vaccine are markedly enhanced in older people when this is
      delayed to 12 weeks although cellular responses are lower. Extended
      interval vaccination may therefore offer the potential to enhance and
      extend humoral immunity. Further follow up is now required to assess long
      term immunity and clinical protection."
    authors:
      - name: Helen M Parry
        orcid: http://orcid.org/0000-0002-9707-8167
      - name: Rachel Bruton
        orcid: null
      - name: Christine Stephens
        orcid: null
      - name: Kevin Brown
        orcid: null
      - name: Gayatri Amirthalingam
        orcid: http://orcid.org/0000-0003-2078-0975
      - name: Bassam Hallis
        orcid: http://orcid.org/0000-0002-8461-0038
      - name: Ashley Otter
        orcid: null
      - name: Jianmin Zuo
        orcid: http://orcid.org/0000-0002-8341-465X
      - name: Paul Moss
        orcid: null
  comment:
    dislikes: 0
    thread: "8524358522"
    numReports: 0
    likes: 0
    id: "5389554172"
    createdAt: 2021-05-19T18:42:43
    author:
      username: FredBass
      about: Preventive medicine physician concerned with our suicidal, massive
        ecological destruction.
      name: Fred Bass
      isPowerContributor: false
      profileUrl: https://disqus.com/by/FredBass/
      url: ""
      location: Vancouver BC Canada
      id: "215341"
    isApproved: true
    raw_message: Were the patients randomized into those getting usual and those
      getting 12 week delay?  Having 99 in one group and 73 in the other does
      not seem like a random split of 172 people!  A bias toward giving
      healthier seniors the longer interval might account for some or even all
      of the results.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.15.21257017v1
  tweets:
    - created_at: Thu May 20 16:30:44 +0000 2021
      id: 1395416713546584000
      id_str: "1395416713546584075"
      text: >-
        üí¨ medRxiv comment on "Extended interval BNT162b2 vac..."


        "Were the patients randomized into those getting usual an‚Ä¶ https://t.co/zKIlho8gD9
      truncated: true
      entities:
        urls:
          - url: https://t.co/zKIlho8gD9
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 20 16:30:44 +0000 2021
      id: 1395416714431565800
      id_str: "1395416714431565828"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/x0AIV3f5Lu
      truncated: false
      entities:
        urls:
          - url: https://t.co/x0AIV3f5Lu
      in_reply_to_status_id: 1395416713546584000
      in_reply_to_status_id_str: "1395416713546584075"
- preprint:
    id: "142319"
    doi: 10.1101/2021.05.18.443629
    first_posted: 2021-05-18
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.18.443629v1
    url: https://api.rxivist.org/v1/papers/142319
    title: "Whole-ExM: Expansion microscopy imaging of all anatomical structures of
      whole larval zebrafish"
    category: developmental-biology
    abstract: Nanoscale imaging of all anatomical structures over whole vertebrates
      is needed for a systematic understanding of human diseases, but this has
      not yet been achieved. Here, we demonstrate whole-ExM, which enables
      nanoscale imaging of all anatomical structures of whole zebrafish larvae
      by labeling the proteins of the larvae with fluorophores and expanding
      them four-fold. We first optimize the fluorophore selection and labeling
      procedure to visualize a broader range of anatomical structures. We then
      develop an expansion protocol for zebrafish larvae having calcified body
      parts. Through this process, we visualize the nanoscale details of diverse
      larvae organs, which have corresponding organ counterparts in humans, over
      the intact larvae. We show that whole-ExM retains the fluorescence signals
      of fluorescent proteins, and its resolution is high enough to visualize
      various structures that can be imaged only with electron microscopy.
      Whole-ExM would enable the nanoscale study of the molecular mechanisms of
      human diseases.
    authors:
      - name: Jueun Sim
        orcid: null
      - name: Chan E Park
        orcid: null
      - name: In Cho
        orcid: null
      - name: Kyeongbae Min
        orcid: null
      - name: Jeong-Soo Lee
        orcid: null
      - name: Yosep Chong
        orcid: null
      - name: Jeewon Kim
        orcid: null
      - name: Jeong Seuk Kang
        orcid: null
      - name: Kiryl D Piatkevich
        orcid: http://orcid.org/0000-0002-7777-9468
      - name: Erica E. Jung
        orcid: null
      - name: Seok-Kyu Kwon
        orcid: http://orcid.org/0000-0002-7280-9867
      - name: Young-Gyu Yoon
        orcid: null
      - name: Edward S. Boyden
        orcid: http://orcid.org/0000-0002-0419-3351
      - name: Jae-Byum Chang
        orcid: null
  comment:
    dislikes: 0
    thread: "8530175268"
    numReports: 0
    likes: 0
    id: "5390733799"
    createdAt: 2021-05-20T17:14:04
    author:
      name: Tanya Whitfield
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    raw_message: >-
      Congratulations on this beautiful work.


      The ‚Äòunknown structures' that you have imaged in the olfactory epithelium and skin in Suppl. Fig. 32 are rodlet cells, which have been described in several previous papers, including in the zebrafish.  See: 

      Hansen and Zeiske (1998) The Peripheral Olfactory Organ of the Zebrafish, Danio rerio: an Ultrastructural Study.  Chem. Senses 23: 39-48

      DePasquale, J. A. (2020). Tropomyosin and alpha-actinin in teleost rodlet cells. Acta Zool. 00, 1‚Äì10. doi: 10.1111/azo.12344


      We included some discussion on rodlet cells in our recent paper on a different cell type, olfactory rod cells, which have a single actin-rich projection (and are also visible in your Suppl. Video 14).  See Cheung et al. (2021).  Olfactory Rod Cells: A Rare Cell Type in the Larval Zebrafish Olfactory Epithelium With a Large Actin-Rich Apical Projection. Front Physiol. 12:626080. doi: 10.3389/fphys.2021.626080

      PMID: 33716772
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.05.18.443629v1
  tweets:
    - created_at: Thu May 20 20:10:46 +0000 2021
      id: 1395472085175050200
      id_str: "1395472085175050240"
      text: |-
        üí¨ bioRxiv comment on "Whole-ExM: Expansion microscop..."

        "Congratulations on this beautiful work.

        The ‚Äòunknown st‚Ä¶ https://t.co/fFnrcv4BP8
      truncated: true
      entities:
        urls:
          - url: https://t.co/fFnrcv4BP8
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 20 20:10:46 +0000 2021
      id: 1395472086018130000
      id_str: "1395472086018129923"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/IDj4DEiLfL
      truncated: false
      entities:
        urls:
          - url: https://t.co/IDj4DEiLfL
      in_reply_to_status_id: 1395472085175050200
      in_reply_to_status_id_str: "1395472085175050240"
- preprint:
    id: 140989
    metric: 7077
    title: SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades
      antibodies induced by infection and vaccination
    url: https://api.rxivist.org/v1/papers/140989
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.04.442663v1
    doi: 10.1101/2021.05.04.442663
    category: molecular-biology
    first_posted: 2021-05-05
    abstract: The emergence of SARS-CoV-2 variants threatens efforts to contain the
      COVID-19 pandemic. The number of COVID-19 cases and deaths in India has
      risen steeply in recent weeks and a novel SARS-CoV-2 variant, B.1.617, is
      believed to be responsible for many of these cases. The spike protein of
      B.1.617 harbors two mutations in the receptor binding domain, which
      interacts with the ACE2 receptor and constitutes the main target of
      neutralizing antibodies. Therefore, we analyzed whether B.1.617 is more
      adept in entering cells and/or evades antibody responses. B.1.617 entered
      two out of eight cell lines tested with slightly increased efficiency and
      was blocked by entry inhibitors. In contrast, B.1.617 was resistant
      against Bamlanivimab, an antibody used for COVID-19 treatment. Finally,
      B.1.617 evaded antibodies induced by infection or vaccination, although
      with moderate efficiency. Collectively, our study reveals that antibody
      evasion of B.1.617 may contribute to the rapid spread of this variant.
    authors:
      - name: Markus Hoffmann
      - name: Heike Hofmann-Winkler
      - name: Nadine Krueger
      - name: Amy Kempf
      - name: Inga Nehlmeier
      - name: Luise Graichen
      - name: Anzhalika Sidarovich
      - name: Anna-Sophie Moldenhauer
      - name: Martin S Winkler
      - name: Sebastian Schulz
      - name: Hans-Martin Jaeck
      - name: Metodi V Stankov
      - name: Georg M. N. Behrens
      - name: Stefan Poehlmann
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Thu May 20 20:18:31 +0000 2021
      id: 1395474037866905600
      id_str: "1395474037866905606"
      text: >-
        üî• bioRxiv Molecular-biology preprint by M. Hoffmann et al:


        "SARS-CoV-2 variant B.1.617 is resistant to Bamlanivima‚Ä¶ https://t.co/uOoc6GFu46
      truncated: true
      entities:
        urls:
          - url: https://t.co/uOoc6GFu46
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "109399"
    doi: 10.1101/2020.04.23.20074575
    first_posted: 2020-04-28
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.04.23.20074575v1
    url: https://api.rxivist.org/v1/papers/109399
    title: Wisconsin April 2020 Election Not Associated with Increase in COVID-19
      Infection Rates
    category: public-and-global-health
    abstract: "Background: Wisconsin (WI) held a primary election in the midst of
      the COVID-19 pandemic. Live voting at polls was allowed despite concern
      over increasing the spread of COVID-19. In addition to 1.1 million
      absentee ballots cast, 453,222 persons voted live. The purpose of our
      study was to determine if an increase in COVID-19 activity was associated
      with the election. Methods: Using the voting age population for the United
      States (US), WI, and its 3 largest counties, and daily new COVID-19 case
      reports from various COVID-19 web-based dashboards, daily new case rates
      were calculated. With election day April 7, the incubation period included
      April 12-21. The new case activity in the rest of the US was compared with
      the Wisconsin activity during the incubation period. Results: WI daily new
      case rates were lower than those of the rest of the US for the 10-day
      period before the election and remained lower during the post exposure
      incubation period. The ratio of Wisconsin new case rates to US new case
      rates was 0.34 WI: 1 US for the 10 days leading up to the election and
      declined to 0.28 WI: 1 US for the 10-day post-incubation period after the
      election. Similar analysis for Milwaukee county showed a pre-election
      ratio of 1.02 Milwaukee: 1 US and after the election the ratio was 0.63
      Milwaukee: 1 US. Dane county had a pre-election ratio of 0.21 Dane: 1 US
      case, and it fell to 0.13 Dane: 1 US after the election. Waukesha county
      had a pre-election ratio of 0.27 Waukesha: 1 US case and that fell to 0.19
      Waukesha: 1 US after the election. Conclusions: There was no increase in
      COVID-19 new case daily rates observed for Wisconsin or its 3 largest
      counties following the election on April 7, 2020, as compared to the US,
      during the post-incubation interval period."
    authors:
      - name: Andrew C Berry
        orcid: http://orcid.org/0000-0001-8952-6559
      - name: Madhuri S Mulekar
        orcid: null
      - name: Bruce B Berry
        orcid: null
  comment:
    dislikes: 0
    thread: "7996288688"
    numReports: 0
    likes: 0
    id: "5390833960"
    createdAt: 2021-05-20T18:34:22
    author:
      username: disqus_MR50o7ZtSH
      about: ""
      name: Andrew
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_MR50o7ZtSH/
      url: ""
      location: ""
      id: "369691865"
    isApproved: true
    raw_message: >-
      PEER REVIEWED UPDATED PAPER:

      https://clinmedjournals.org/articles/jide/journal-of-infectious-diseases-and-epidemiology-jide-6-148.php?jid=jide.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.04.23.20074575v1
  tweets:
    - created_at: Fri May 21 12:17:41 +0000 2021
      id: 1395715419080740900
      id_str: "1395715419080740868"
      text: |-
        üí¨ medRxiv comment on "Wisconsin April 2020 Election ..."

        "PEER REVIEWED UPDATED PAPER:
        https://t.co/q7jN7jWcNU."

        https://t.co/yHwXoYBGaD
      truncated: false
      entities:
        urls:
          - url: https://t.co/q7jN7jWcNU
          - url: https://t.co/yHwXoYBGaD
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 21 12:17:41 +0000 2021
      id: 1395715419764314000
      id_str: "1395715419764314113"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/96w1lfgg2e
      truncated: false
      entities:
        urls:
          - url: https://t.co/96w1lfgg2e
      in_reply_to_status_id: 1395715419080740900
      in_reply_to_status_id_str: "1395715419080740868"
- preprint:
    id: "83104"
    doi: 10.1101/2020.05.11.084202
    first_posted: 2020-05-12
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.05.11.084202v1
    url: https://api.rxivist.org/v1/papers/83104
    title: Metric and chronological time in human episodic memory
    category: neuroscience
    abstract: >-
      The relative contributions of metric and chronological time in the
      encoding of episodic memories are unknown. One hundred one healthy young
      adults viewed 48 unique episodes of visual events and were later tested on
      recall of the order of events (chronological time) and the precise timing
      of events (metric time). The behavioral results show that metric recall
      accuracy correlates with chronological accuracy for events within
      episodes, but does not play a role on larger time-scales across episodes.
      Functional magnetic resonance imaging during encoding and recall showed
      that metric time was represented in the posterior medial entorhinal
      cortex, as well as the temporal pole and the cerebellum, whereas
      chronological time was represented in a widespread brain network including
      the anterior lateral entorhinal cortex, hippocampus, parahippocampal
      cortex and the prefrontal cortex. We conclude that metric time has a role
      in episodic memory on short time-scales and is mainly subserved by medial
      temporal lobe structures.


      ### Competing Interest Statement


      The authors have declared no competing interest.
    authors:
      - name: Hallvard R√∏e Evensmoen
        orcid: http://orcid.org/0000-0002-2926-7476
      - name: Lars M. Rimol
        orcid: http://orcid.org/0000-0002-1243-0396
      - name: Henning Hoel Rise
        orcid: http://orcid.org/0000-0002-0954-4018
      - name: Tor Ivar Hansen
        orcid: null
      - name: Hamed Nili
        orcid: http://orcid.org/0000-0002-6629-7957
      - name: Anderson Winkler
        orcid: http://orcid.org/0000-0002-4169-9781
      - name: Asta H√•berg
        orcid: null
  comment:
    dislikes: 0
    thread: "8021687075"
    numReports: 0
    likes: 0
    id: "5390831307"
    createdAt: 2021-05-20T18:32:15
    author:
      username: hallvardreevensmoen
      about: ""
      name: Hallvard R√∏e Evensmoen
      isPowerContributor: false
      profileUrl: https://disqus.com/by/hallvardreevensmoen/
      url: ""
      location: ""
      id: "369691697"
    isApproved: true
    raw_message: Thank you so much, and thank you for creating such an excellent
      R-package. I`ll definitively include the citation.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.05.11.084202v1
  tweets:
    - created_at: Fri May 21 16:25:21 +0000 2021
      id: 1395777747054731300
      id_str: "1395777747054731264"
      text: >-
        üí¨ bioRxiv comment on "Metric and chronological time ..."


        "Thank you so much, and thank you for creating such an ex‚Ä¶ https://t.co/pe2ZeaogRt
      truncated: true
      entities:
        urls:
          - url: https://t.co/pe2ZeaogRt
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 21 16:25:22 +0000 2021
      id: 1395777747830591500
      id_str: "1395777747830591489"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/muz2C2wvuV
      truncated: false
      entities:
        urls:
          - url: https://t.co/muz2C2wvuV
      in_reply_to_status_id: 1395777747054731300
      in_reply_to_status_id_str: "1395777747054731264"
- preprint:
    id: "122406"
    doi: 10.1101/2020.12.19.423561
    first_posted: 2020-12-21
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.12.19.423561v1
    url: https://api.rxivist.org/v1/papers/122406
    title: Invasive garlic mustard demonstrates stronger relationships with
      pathotrophic than mycorrhizal fungi
    category: ecology
    abstract: Garlic mustard (Alliaria petiolata) has long been known to degrade
      mycorrhizal mutualisms in soils it invades and may also promote the
      abundance of microbial pathogens harmful to native plants or alter
      saprotrophic communities to disrupt nutrient cycling. Phenology of other
      invasive species, like Lepidium latifolium and Lonicera maackii, plays a
      role in their interactions with soil microbial communities, and so we may
      expect garlic mustard phenology to influence its effects on native soil
      microbiomes as well. Here, we investigate differences in fungal,
      bacterial, and archaeal community structure, as well as the abundance of
      key functional groups, between garlic mustard present, absent, and removed
      treatments in central-Illinois forest soils across different stages of the
      garlic mustard life cycle. Across its phenology, garlic mustard present
      soils had different overall fungal community structure and greater
      abundance of pathotrophic fungi than soils where garlic mustard was absent
      or removed. However, abundance of ectomycorrhizal and saprotrophic fungi
      as well as bacterial and archaeal community structure were similar between
      treatments and did not interact with garlic mustard phenology. The most
      abundant overall fungal taxon was a plant pathogen, Entorrhiza
      aschersoniana, that was greatest in garlic mustard present soils,
      particularly while the plants were flowering. These results support the
      hypothesis that invasive plants form active relationships with microbial
      pathogens that could contribute to their overall success in invading
      ecosystems.
    authors:
      - name: Joseph D. Edwards
        orcid: null
      - name: Wendy H Yang
        orcid: null
      - name: Anthony C. Yannarell
        orcid: null
  comment:
    dislikes: 0
    thread: "8325281704"
    numReports: 0
    likes: 0
    id: "5391745614"
    createdAt: 2021-05-21T14:14:59
    author:
      username: rgregthorn
      about: ""
      name: R Greg Thorn
      isPowerContributor: false
      profileUrl: https://disqus.com/by/rgregthorn/
      url: ""
      location: ""
      id: "369732656"
    isApproved: true
    raw_message: Nice work and potentially an important concept in invasion biology,
      but please clarify the identification step of your bioinformatics
      pipeline. An approximate match in QIIME/UNITE is not an identification.
      Talaromyces marneffei is (we hope!) unlikely to be a common fungus in
      Illinois soils. It is a serious human pathogen that is, so far as we know,
      restricted to southeast Asia, centered on Laos, Cambodia and Vietnam. Some
      other IDs are equally suspect. Please don't let this get into print.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.12.19.423561v1
  tweets:
    - created_at: Fri May 21 20:12:54 +0000 2021
      id: 1395835011580969000
      id_str: "1395835011580968960"
      text: >-
        üí¨ bioRxiv comment on "Invasive garlic mustard demons..."


        "Nice work and potentially an important concept in invasi‚Ä¶ https://t.co/tovratjq84
      truncated: true
      entities:
        urls:
          - url: https://t.co/tovratjq84
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 21 20:12:54 +0000 2021
      id: 1395835012436594700
      id_str: "1395835012436594692"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/IAxBtJFaSp
      truncated: false
      entities:
        urls:
          - url: https://t.co/IAxBtJFaSp
      in_reply_to_status_id: 1395835011580969000
      in_reply_to_status_id_str: "1395835011580968960"
- preprint:
    id: 140997
    metric: 5984
    title: Combination Respiratory Vaccine Containing Recombinant SARS-CoV-2 Spike
      and QuadrivalentSeasonal Influenza Hemagglutinin Nanoparticles with
      Matrix-M Adjuvant
    url: https://api.rxivist.org/v1/papers/140997
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.05.442782v1
    doi: 10.1101/2021.05.05.442782
    category: immunology
    first_posted: 2021-05-05
    abstract: The 2019 outbreak of a severe respiratory disease caused by an
      emerging coronavirus, SARS-CoV-2, has spread globally with high morbidity
      and mortality. Co-circulating seasonal influenza has greatly diminished
      recently, but expected to return with novel strains emerging, thus
      requiring annual strain adjustments. We have developed a recombinant
      hemagglutinin (HA) quadrivalent nanoparticle influenza vaccine (qNIV)
      produced using an established recombinant insect cell expression system to
      produce nanoparticles. Influenza qNIV adjuvanted with Matrix-M was
      well-tolerated and induced robust antibody and cellular responses, notably
      against both homologous and drifted A/H3N2 viruses in Phase 1, 2, and 3
      trials. We also developed a full-length SARS-CoV-2 spike protein vaccine
      stable in the prefusion conformation (NVX-CoV2373) using the same platform
      technology. In phase 3 clinical trials, NVX-CoV2373 is highly immunogenic
      and protective against the prototype strain and B.1.1.7 variant. Here we
      describe the immunogenicity and efficacy of a combination quadrivalent
      seasonal flu and COVID-19 vaccine (qNIV/CoV2373). In ferret and hamster
      models, qNIV/CoV2373 vaccine produces high titer influenza
      hemagglutination inhibiting (HAI) and neutralizing antibodies against
      influenza A and B strains. The combination vaccine also elicited
      antibodies that block SARS-CoV-2 spike protein binding to the human
      angiotensin converting enzyme-2 (hACE2) receptor. Significantly, hamsters
      immunized with qNIV/CoV2373 vaccine and challenged with SARS-CoV-2 were
      protected against weight loss and were free of replicating SARS-CoV-2 in
      the upper and lower respiratory tract with no evidence of viral pneumonia.
      This study supports evaluation of qNIV/CoV2373 combination vaccine as a
      preventive measure for seasonal influenza and CoVID-19.
    authors:
      - name: Micheal J Massare
      - name: Nita Patel
      - name: Bin Zhou
      - name: Sonia Maciejewski
      - name: Rhonda Flores
      - name: Mimi Guebre-Xabier
      - name: Jing-Hui Tian
      - name: Alyse D Portnoff
      - name: Louis Fries
      - name: Vivek Shinde
      - name: Larry R Ellingsworth
      - name: Greg Glenn
      - name: Gale Smith
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Fri May 21 20:20:50 +0000 2021
      id: 1395837005880246300
      id_str: "1395837005880246276"
      text: >-
        üî• bioRxiv Immunology preprint by M. J. Massare et al:


        "Combination Respiratory Vaccine Containing Recombinant SARS‚Ä¶ https://t.co/JDSzZdP5dZ
      truncated: true
      entities:
        urls:
          - url: https://t.co/JDSzZdP5dZ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "40679"
    doi: 10.1101/507590
    first_posted: 2018-12-28
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/507590v4
    url: https://api.rxivist.org/v1/papers/40679
    title: Plants emit informative airborne sounds under stress
    category: plant-biology
    abstract: Stressed plants show altered phenotypes, including changes in color,
      smell, and shape. Yet, the possibility that plants emit airborne sounds
      when stressed ‚Äì similarly to many animals ‚Äì has not been investigated.
      Here we show, to our knowledge for the first time, that stressed plants
      emit airborne sounds that can be recorded remotely, both in acoustic
      chambers and in greenhouses. We recorded ‚àº65 dBSPL ultrasonic sounds 10 cm
      from tomato and tobacco plants, implying that these sounds could be
      detected by some organisms from up to several meters away. We developed
      machine learning models that were capable of distinguishing between plant
      sounds and general noises, and identifying the condition of the plants ‚Äì
      dry, cut, or intact ‚Äì based solely on the emitted sounds. Our results
      suggest that animals, humans, and possibly even other plants, could use
      sounds emitted by a plant to gain information about the plant‚Äôs condition.
      More investigation on plant bioacoustics in general and on sound emission
      in plants in particular may open new avenues for understanding plants and
      their interactions with the environment, and it may also have a
      significant impact on agriculture.
    authors:
      - name: I. Khait
        orcid: null
      - name: Ohad Lewin-Epstein
        orcid: http://orcid.org/0000-0002-8636-9006
      - name: R. Sharon
        orcid: null
      - name: K. Saban
        orcid: null
      - name: R. Perelman
        orcid: null
      - name: A. Boonman
        orcid: null
      - name: Y. Yovel
        orcid: null
      - name: L. Hadany
        orcid: null
  comment:
    dislikes: 0
    thread: "7743645557"
    numReports: 0
    likes: 0
    id: "5392045414"
    createdAt: 2021-05-21T18:32:43
    author:
      username: disqus_TTEjfexw3K
      about: ""
      name: Hoya
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_TTEjfexw3K/
      url: ""
      location: ""
      id: "327716968"
    isApproved: true
    raw_message: Its caused by cavitations that plants create within their cells
      when under stress. Like bubbles underwater carrying sound.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/507590v4
  tweets:
    - created_at: Sat May 22 00:38:55 +0000 2021
      id: 1395901953939497000
      id_str: "1395901953939496960"
      text: >-
        üí¨ bioRxiv comment on "Plants emit informative airbor..."


        "Its caused by cavitations that plants create within thei‚Ä¶ https://t.co/QqqYwscFw8
      truncated: true
      entities:
        urls:
          - url: https://t.co/QqqYwscFw8
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 22 00:38:55 +0000 2021
      id: 1395901954744856600
      id_str: "1395901954744856576"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/j5uJLr3XOS
      truncated: false
      entities:
        urls:
          - url: https://t.co/j5uJLr3XOS
      in_reply_to_status_id: 1395901953939497000
      in_reply_to_status_id_str: "1395901953939496960"
- preprint:
    id: "142319"
    doi: 10.1101/2021.05.18.443629
    first_posted: 2021-05-18
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.18.443629v1
    url: https://api.rxivist.org/v1/papers/142319
    title: "Whole-ExM: Expansion microscopy imaging of all anatomical structures of
      whole larval zebrafish"
    category: developmental-biology
    abstract: Nanoscale imaging of all anatomical structures over whole vertebrates
      is needed for a systematic understanding of human diseases, but this has
      not yet been achieved. Here, we demonstrate whole-ExM, which enables
      nanoscale imaging of all anatomical structures of whole zebrafish larvae
      by labeling the proteins of the larvae with fluorophores and expanding
      them four-fold. We first optimize the fluorophore selection and labeling
      procedure to visualize a broader range of anatomical structures. We then
      develop an expansion protocol for zebrafish larvae having calcified body
      parts. Through this process, we visualize the nanoscale details of diverse
      larvae organs, which have corresponding organ counterparts in humans, over
      the intact larvae. We show that whole-ExM retains the fluorescence signals
      of fluorescent proteins, and its resolution is high enough to visualize
      various structures that can be imaged only with electron microscopy.
      Whole-ExM would enable the nanoscale study of the molecular mechanisms of
      human diseases.
    authors:
      - name: Jueun Sim
        orcid: null
      - name: Chan E Park
        orcid: null
      - name: In Cho
        orcid: null
      - name: Kyeongbae Min
        orcid: null
      - name: Jeong-Soo Lee
        orcid: null
      - name: Yosep Chong
        orcid: null
      - name: Jeewon Kim
        orcid: null
      - name: Jeong Seuk Kang
        orcid: null
      - name: Kiryl D Piatkevich
        orcid: http://orcid.org/0000-0002-7777-9468
      - name: Erica E. Jung
        orcid: null
      - name: Seok-Kyu Kwon
        orcid: http://orcid.org/0000-0002-7280-9867
      - name: Young-Gyu Yoon
        orcid: null
      - name: Edward S. Boyden
        orcid: http://orcid.org/0000-0002-0419-3351
      - name: Jae-Byum Chang
        orcid: null
  comment:
    dislikes: 0
    thread: "8530175268"
    numReports: 0
    likes: 1
    id: "5391279863"
    createdAt: 2021-05-21T02:22:22
    author:
      username: jaebyumchang
      about: ""
      name: jaebyumchang
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jaebyumchang/
      url: ""
      location: ""
      id: "369710841"
    isApproved: true
    raw_message: >-
      Hi Dr. Whitfield, 


      Thank you so much for letting us know the identity of the unknown structures. Also, thank you for letting us know the details on olfactory rod cells! We will add those information to the manuscript when we submit a revised version!
    forum: biorxivstage
    points: 1
    link: https://www.biorxiv.org/content/10.1101/2021.05.18.443629v1
  tweets:
    - created_at: Sat May 22 12:16:36 +0000 2021
      id: 1396077534270288000
      id_str: "1396077534270287874"
      text: |-
        üí¨ bioRxiv comment on "Whole-ExM: Expansion microscop..."

        "Hi Dr. Whitfield, 

        Thank you so much for letting us kno‚Ä¶ https://t.co/UWYBUOEONU
      truncated: true
      entities:
        urls:
          - url: https://t.co/UWYBUOEONU
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 22 12:16:36 +0000 2021
      id: 1396077535255941000
      id_str: "1396077535255941120"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/IDj4DEiLfL
      truncated: false
      entities:
        urls:
          - url: https://t.co/IDj4DEiLfL
      in_reply_to_status_id: 1396077534270288000
      in_reply_to_status_id_str: "1396077534270287874"
- preprint:
    id: "108561"
    doi: 10.1101/2020.04.08.20058743
    first_posted: 2020-04-11
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.04.08.20058743v1
    url: https://api.rxivist.org/v1/papers/108561
    title: A stochastic model for COVID-19 spread and the effects of Alert Level 4
      in Aotearoa New Zealand
    category: epidemiology
    abstract: While case numbers remain low, population-wide control methods
      combined with efficient tracing, testing, and case isolation, offer the
      opportunity for New Zealand to contain and eliminate COVID-19. We use a
      stochastic model to investigate containment and elimination scenarios for
      COVID-19 in New Zealand, as the country considers the exit from its four
      week period of strong Level 4 population-wide control measures. In
      particular we consider how the effectiveness of its case isolation
      operations influence the outcome of lifting these strong population-wide
      controls. The model is parameterised for New Zealand and is initialised
      using current case data, although we do not make use of information
      concerning the geographic dispersion of cases and the model is not
      stratified for age or co-morbidities. We find that fast tracing and case
      isolation (i.e. operations that are sustained at rates comparable to that
      at the early stages of New Zealand's response) can lead to containment or
      elimination, as long as strong population-wide controls remain in place.
      Slow case isolation can lead to containment (but not elimination) as long
      as strong Level 4 population-wide controls remain in place. However, we
      find that relaxing strong population-wide controls after four weeks will
      most likely lead to a further outbreak, although the speed of growth of
      this outbreak can be reduced by fast case isolation, by tracing, testing,
      or otherwise. We find that elimination is only likely if case isolation is
      combined with strong population-wide controls that are maintained for
      longer than four weeks. Further versions of this model will include an
      age-structured population as well as considering the effects of geographic
      dispersion and contact network structure, the possibility of regional
      containment combined with inter-regional travel restrictions, and the
      potential for harm to at risk communities and essential workers.
    authors:
      - name: Michael J Plank
        orcid: http://orcid.org/0000-0002-7539-3465
      - name: Rachelle N Binny
        orcid: http://orcid.org/0000-0002-3433-0417
      - name: Shaun C Hendy
        orcid: http://orcid.org/0000-0003-3468-6517
      - name: Audrey Lustig
        orcid: http://orcid.org/0000-0002-0869-3847
      - name: Alex James
        orcid: http://orcid.org/0000-0002-1543-7139
      - name: Nicholas Steyn
        orcid: null
  comment:
    dislikes: 0
    thread: "7964122231"
    numReports: 0
    likes: 0
    id: "5392404304"
    createdAt: 2021-05-22T00:45:46
    author:
      username: disqus_Pc9ZQufNd1
      about: ""
      name: Michael Plank
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_Pc9ZQufNd1/
      url: ""
      location: ""
      id: "369642137"
    isApproved: true
    raw_message: "The model and results in this pre-print are now part of an article
      published in the Journal of the Royal Society of New Zealand, available
      open access at: https://doi.org/10.1080/03036758.2021.1876111"
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.04.08.20058743v1
  tweets:
    - created_at: Sat May 22 16:23:52 +0000 2021
      id: 1396139760490528800
      id_str: "1396139760490528768"
      text: >-
        üí¨ medRxiv comment on "A stochastic model for COVID-1..."


        "The model and results in this pre-print are now part of‚Ä¶ https://t.co/D1dj1ptVum
      truncated: true
      entities:
        urls:
          - url: https://t.co/D1dj1ptVum
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 22 16:23:52 +0000 2021
      id: 1396139761279115300
      id_str: "1396139761279115271"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/2qx6zHwlI9
      truncated: false
      entities:
        urls:
          - url: https://t.co/2qx6zHwlI9
      in_reply_to_status_id: 1396139760490528800
      in_reply_to_status_id_str: "1396139760490528768"
- preprint:
    id: "142725"
    doi: 10.1101/2021.05.19.21257429
    first_posted: 2021-05-21
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.19.21257429v1
    url: https://api.rxivist.org/v1/papers/142725
    title: "Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with
      COVID-19 compared to standard treatment: Randomized controlled trial"
    category: epidemiology
    abstract: "Background: COVID-19 is a pandemic disease caused by SARS-CoV-2,
      which is an RNA virus similar to HCV in the replication process.
      Sofosbuvir/ledipasvir is an approved drug by the FDA to treat HCV
      infection. This study investigates the efficacy of Sofosbuvir/ledipasvir
      as a treatment for patients with moderate COVID-19 infection.. Methods:
      This is a single-blinded parallel-randomized controlled trial. The
      participants were randomized equally into the intervention group received
      Sofosbuvir/ledipasvir (S.L. group), and the control group received
      Oseltamivir, Hydroxychloroquine, and Azithromycin (OCH group). The primary
      outcomes were the cure rate over time and the incidence of serious adverse
      events. The secondary outcomes included the laboratory findings. Results:
      Two hundred and fifty patients were divided equally into each group. Both
      groups were similar regarding gender, but age was higher in the S.L. group
      (p=0.001). In the S.L. group, 89 (71.2%) patients were cured, while only
      51 (40.8%) patients were cured in the OCH group. The cure rate was
      significantly higher in the S.L. group (RR=1.75, p<0.001). Kaplan-Meir
      plot showed a considerably higher cure over time in the S.L. group
      (Log-rank test, p=0.032). There were no deaths in the S.L. group, but
      there were six deaths (4.8%) in the OCH group (RR=0.08, p=0.013). Seven
      patients (5.6%) in the S.L. group and six patients (4.8%) in the OCH group
      were admitted to ICU (RR=1.17, P=0.776). There was no significant
      difference between treatment groups regarding Total Leukocyte Count,
      Neutrophils count, Lymph, Alanine transaminase, and Urea. Conclusion:
      Sofosbuvir/ledipasvir is suggestive of being effective in treating
      patients with moderate COVID-19 infection. Further studies are needed to
      compare Sofosbuvir/ledipasvir with the new treatment protocols."
    authors:
      - name: Mohamed Abdel-Salam Elgohary
        orcid: null
      - name: Eman Medhat Hasan
        orcid: null
      - name: Amany Ahmad Ibrahim
        orcid: null
      - name: Mohamed Farouk Ahmed
        orcid: null
      - name: Raafat Zaher Abdel-Rahman
        orcid: null
      - name: Ashraf Ibrahim Zaki
        orcid: null
      - name: Mohamed Bakr Elaatar
        orcid: null
      - name: Mohamed Thabet Elnagar
        orcid: null
      - name: Mohamed Emam Emam
        orcid: null
      - name: Mahmoud Moustafa Hamada
        orcid: null
      - name: Taimour Mohamed Abdel-Hamid
        orcid: null
      - name: Ahmad Samir Abdel-Hafez
        orcid: null
      - name: Mohamed G. Seadawy
        orcid: null
      - name: Ahmad Rashad Fatoh
        orcid: null
      - name: Mohamed Ali Elsaied
        orcid: null
      - name: Marwa Abdel-Rahman Sakr
        orcid: null
      - name: Ahmed Omar Elkady
        orcid: null
      - name: Mohamed Muawad Shehata
        orcid: null
      - name: Osama Mohamed Nawar
        orcid: null
      - name: Mohamed Abu-elnaga Selem
        orcid: null
      - name: Mohamed Saeed Abd-aal
        orcid: null
      - name: Hany Hafez Lotfy
        orcid: null
      - name: Tarek Refaat Elnagdy
        orcid: null
      - name: Sherine Helmy
        orcid: null
      - name: Magdy Amin Mubark
        orcid: null
  comment:
    dislikes: 0
    thread: "8539627995"
    numReports: 0
    likes: 0
    id: "5392315732"
    createdAt: 2021-05-21T22:52:28
    author:
      username: ilmarihaavisto
      about: ""
      name: Ilmari Haavisto
      isPowerContributor: false
      profileUrl: https://disqus.com/by/ilmarihaavisto/
      url: ""
      location: ""
      id: "296100347"
    isApproved: true
    raw_message: The beginning state of medication of disease is very important. Was
      it equal to both groups?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.19.21257429v1
  tweets:
    - created_at: Sat May 22 20:12:23 +0000 2021
      id: 1396197267585917000
      id_str: "1396197267585916930"
      text: >-
        üí¨ medRxiv comment on "Efficacy of Sofosbuvir plus Le..."


        "The beginning state of medication of disease is very imp‚Ä¶ https://t.co/cXiiRrQtyz
      truncated: true
      entities:
        urls:
          - url: https://t.co/cXiiRrQtyz
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 22 20:12:23 +0000 2021
      id: 1396197268554846200
      id_str: "1396197268554846209"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/xi29SUZYMS
      truncated: false
      entities:
        urls:
          - url: https://t.co/xi29SUZYMS
      in_reply_to_status_id: 1396197267585917000
      in_reply_to_status_id_str: "1396197267585916930"
- preprint:
    id: "132578"
    doi: 10.1101/2021.03.07.21253098
    first_posted: 2021-03-09
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.03.07.21253098v1
    url: https://api.rxivist.org/v1/papers/132578
    title: The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by
      non-neutralizing antibodies that target both the NTD and the RBD
    category: infectious-diseases
    abstract: In this study we profiled vaccine-induced polyclonal antibodies as
      well as plasmablast derived mAbs from subjects who received SARS-CoV-2
      spike mRNA vaccine. Polyclonal antibody responses in vaccinees were robust
      and comparable to or exceeded those seen after natural infection. However,
      that the ratio of binding to neutralizing antibodies after vaccination was
      greater than that after natural infection and, at the monoclonal level, we
      found that the majority of vaccine-induced antibodies did not have
      neutralizing activity. We also found a co-dominance of mAbs targeting the
      NTD and RBD of SARS-CoV-2 spike and an original antigenic-sin like
      backboost to seasonal human coronaviruses OC43 and HKU1 spike proteins.
      Neutralizing activity of NTD mAbs but not RBD mAbs against a clinical
      viral isolate carrying E484K as well as extensive changes in the NTD was
      abolished, suggesting that a proportion of vaccine induced RBD binding
      antibodies may provide substantial protection against viral variants
      carrying E484K.
    authors:
      - name: Fatima Amanat
        orcid: http://orcid.org/0000-0002-8029-8227
      - name: Mahima Thapa
        orcid: null
      - name: Tingting Lei
        orcid: null
      - name: Shaza M. Sayed Ahmed
        orcid: null
      - name: Daniel C. Adelsberg
        orcid: null
      - name: Juan Manuel Carreno
        orcid: null
      - name: Shirin Strohmeier
        orcid: null
      - name: Aaron J Schmitz
        orcid: null
      - name: Sarah Zafar
        orcid: null
      - name: Julian Q Zhou
        orcid: http://orcid.org/0000-0001-9602-2092
      - name: Willemijn Rijnink
        orcid: null
      - name: Hala Alshammary
        orcid: null
      - name: Nicholas Borcherding
        orcid: http://orcid.org/0000-0003-1427-6342
      - name: Ana Gonzalez Reiche
        orcid: null
      - name: Komal Srivastava
        orcid: null
      - name: Emilia M Sordillo
        orcid: http://orcid.org/0000-0001-7787-3051
      - name: Harm van Bakel
        orcid: http://orcid.org/0000-0002-1376-6916
      - name: Jackson S Turner
        orcid: http://orcid.org/0000-0002-4396-6265
      - name: Goran Bajic
        orcid: http://orcid.org/0000-0003-0480-4324
      - name: Viviana M Simon
        orcid: null
      - name: Ali H. Ellebedy
        orcid: http://orcid.org/0000-0002-6129-2532
      - name: Florian Krammer
        orcid: http://orcid.org/0000-0003-4121-776X
  comment:
    dislikes: 0
    thread: "8501801389"
    numReports: 0
    likes: 0
    id: "5392249349"
    createdAt: 2021-05-21T21:38:46
    author:
      username: lbaustin
      about: ""
      name: lbaustin
      isPowerContributor: false
      profileUrl: https://disqus.com/by/lbaustin/
      url: ""
      location: Austin, TX
      id: "7360516"
    isApproved: true
    raw_message: Has this been submitted to a MEDLINE indexed journal?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.03.07.21253098v2
  tweets:
    - created_at: Sun May 23 00:44:16 +0000 2021
      id: 1396265688575119400
      id_str: "1396265688575119365"
      text: |-
        üí¨ medRxiv comment on "The plasmablast response to SA..."

        "Has this been submitted to a MEDLINE indexed journal?"

        https://t.co/uVjMN8D3Ce
      truncated: false
      entities:
        urls:
          - url: https://t.co/uVjMN8D3Ce
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 23 00:44:16 +0000 2021
      id: 1396265689401499600
      id_str: "1396265689401499651"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/lNgUKY3gxH
      truncated: false
      entities:
        urls:
          - url: https://t.co/lNgUKY3gxH
      in_reply_to_status_id: 1396265688575119400
      in_reply_to_status_id_str: "1396265688575119365"
- preprint:
    id: "139760"
    doi: 10.1101/2021.04.21.21255898
    first_posted: 2021-04-27
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.04.21.21255898v1
    url: https://api.rxivist.org/v1/papers/139760
    title: Practical Indicators for Risk of Airborne Transmission in Shared Indoor
      Environments and their application to COVID-19 Outbreaks
    category: infectious-diseases
    abstract: "Some infectious diseases, including COVID-19, can be transmitted via
      aerosols that are emitted by an infectious person and inhaled by
      susceptible individuals. Although physical distancing effectively reduces
      short-range airborne transmission, many infections have occurred when
      sharing room air despite maintaining distancing. We propose two simple
      parameters as indicators of infection risk for this situation. They
      combine the key factors that control airborne disease transmission
      indoors: virus-containing aerosol generation rate, breathing flow rate,
      masking and its quality, ventilation and air cleaning rates, number of
      occupants, and duration of exposure. COVID-19 outbreaks show a clear trend
      in relation to these parameters that is consistent with an airborne
      infection model, supporting the importance of airborne transmission for
      these outbreaks. The observed trends of outbreak size vs. risk parameters
      allow us to recommend values of the parameters to minimize COVID-19 indoor
      infection risk. All of the pre-pandemic spaces are in a regime where they
      are highly sensitive to mitigation efforts. Measles outbreaks occur at
      much lower risk parameter values than COVID-19, while tuberculosis
      outbreaks are observed at much higher risk parameter values. Since both
      diseases are accepted as airborne, the fact that COVID-19 is less
      contagious than measles does not rule out airborne transmission. It is
      important that future outbreak reports include ventilation information, to
      allow expanding our knowledge of the circumstances conducive to airborne
      transmission of different diseases."
    authors:
      - name: Zhe Peng
        orcid: http://orcid.org/0000-0002-6823-452X
      - name: William Bahnfleth
        orcid: null
      - name: Giorgio Buonanno
        orcid: null
      - name: Stephanie J. Dancer
        orcid: null
      - name: Jarek Kurnitski
        orcid: null
      - name: Yuguo Li
        orcid: http://orcid.org/0000-0002-2281-4529
      - name: Marcel G.L.C. Loomans
        orcid: null
      - name: Linsey C. Marr
        orcid: http://orcid.org/0000-0003-3628-6891
      - name: Lidia Morawska
        orcid: null
      - name: William Nazaroff
        orcid: null
      - name: Catherine Noakes
        orcid: null
      - name: Xavier Querol
        orcid: null
      - name: Chandra Sekhar
        orcid: null
      - name: Raymond Tellier
        orcid: null
      - name: Trisha Greenhalgh
        orcid: http://orcid.org/0000-0003-2369-8088
      - name: Lydia Bourouiba
        orcid: null
      - name: Atze Boerstra
        orcid: null
      - name: Julian Tang
        orcid: null
      - name: Shelly Miller
        orcid: http://orcid.org/0000-0002-1967-7551
      - name: Jose L Jimenez
        orcid: http://orcid.org/0000-0001-6203-1847
  comment:
    dislikes: 0
    thread: "8509938572"
    numReports: 0
    likes: 0
    id: "5392210208"
    createdAt: 2021-05-21T20:59:55
    author:
      username: haroldthimbleby
      about: ""
      name: Harold Thimbleby
      isPowerContributor: false
      profileUrl: https://disqus.com/by/haroldthimbleby/
      url: ""
      location: ""
      id: "369749286"
    isApproved: true
    raw_message: >-
      From harold@thimbleby.net


      I mailed the author for correspondence constructively two weeks ago but I have had no reply. 


      I am a professor of computer science. The Excel spreadsheet is, sadly, appalling and needs a lot of professional work to be believable. There is no useful documentation about how it is intended to work. It is obscure and impossible to check. I doubt it is correct, unless evidence can be provided. In short, the results described in this paper cannot be relied on or used for any public health purposes.


      Have any of the authors carefully reviewed the spreadsheet? Any independent parties? If so I think the paper should say so.


      Best wishes, though, with this important work.


      -Harold
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.04.21.21255898v2
  tweets:
    - created_at: Sun May 23 12:16:57 +0000 2021
      id: 1396440010526691300
      id_str: "1396440010526691328"
      text: |-
        üí¨ medRxiv comment on "Practical Indicators for Risk ..."

        "From harold@thimbleby.net

        I mailed the author for corre‚Ä¶ https://t.co/T2EYF5Er7Y
      truncated: true
      entities:
        urls:
          - url: https://t.co/T2EYF5Er7Y
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 23 12:16:58 +0000 2021
      id: 1396440011516567600
      id_str: "1396440011516567557"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/t6Sw09nOAz
      truncated: false
      entities:
        urls:
          - url: https://t.co/t6Sw09nOAz
      in_reply_to_status_id: 1396440010526691300
      in_reply_to_status_id_str: "1396440010526691328"
- preprint:
    id: "141912"
    doi: 10.1101/2021.05.15.21257017
    first_posted: 2021-05-17
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.15.21257017v1
    url: https://api.rxivist.org/v1/papers/141912
    title: Extended interval BNT162b2 vaccination enhances peak antibody generation
      in older people
    category: infectious-diseases
    abstract: "Abstract Objectives: To assess the relative immunogenicity of
      standard or extended interval BNT162b2 vaccination. Design: Population
      based cohort study comparing immune responses 2 weeks after the second
      vaccine, with appropriate time-matched samples in participants who
      received standard or extended interval double vaccination. Setting:
      Primary care networks, Birmingham, UK. December 2020 to April 2021.
      Participants: 175 people aged over 80 years of age. All donors received
      the BNT162b2 Pfizer/BioNTech vaccination and were vaccinated with either a
      standard 3 week interval between doses or an extended interval schedule.
      Main outcome measures: Peak quantitative spike-specific antibody and
      cellular immune responses. Results: In donors without evidence of previous
      infection the peak antibody response was 3.5-fold higher in donors who had
      undergone delayed interval vaccination. Cellular immune responses were
      3.6-fold lower. Conclusion: Peak antibody responses after the second
      BNT162b2 vaccine are markedly enhanced in older people when this is
      delayed to 12 weeks although cellular responses are lower. Extended
      interval vaccination may therefore offer the potential to enhance and
      extend humoral immunity. Further follow up is now required to assess long
      term immunity and clinical protection."
    authors:
      - name: Helen M Parry
        orcid: http://orcid.org/0000-0002-9707-8167
      - name: Rachel Bruton
        orcid: null
      - name: Christine Stephens
        orcid: null
      - name: Kevin Brown
        orcid: null
      - name: Gayatri Amirthalingam
        orcid: http://orcid.org/0000-0003-2078-0975
      - name: Bassam Hallis
        orcid: http://orcid.org/0000-0002-8461-0038
      - name: Ashley Otter
        orcid: null
      - name: Jianmin Zuo
        orcid: http://orcid.org/0000-0002-8341-465X
      - name: Paul Moss
        orcid: null
  comment:
    dislikes: 0
    thread: "8524358522"
    numReports: 0
    likes: 0
    id: "5392137838"
    createdAt: 2021-05-21T19:55:16
    author:
      username: honourary
      about: ""
      name: Honourary
      isPowerContributor: false
      profileUrl: https://disqus.com/by/honourary/
      url: ""
      location: ""
      id: "345738756"
    isApproved: true
    raw_message: All of your concerns about potential sample bias are covered in the
      section titled ‚ÄòStatistical Analysis‚Äô. It wasn‚Äôt a random split because
      they couldn‚Äôt assume a normal distribution.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.15.21257017v1
  tweets:
    - created_at: Sun May 23 16:23:59 +0000 2021
      id: 1396502175510003700
      id_str: "1396502175510003715"
      text: >-
        üí¨ medRxiv comment on "Extended interval BNT162b2 vac..."


        "All of your concerns about potential sample bias are cov‚Ä¶ https://t.co/xoGuOMEqzI
      truncated: true
      entities:
        urls:
          - url: https://t.co/xoGuOMEqzI
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 23 16:23:59 +0000 2021
      id: 1396502176499835000
      id_str: "1396502176499834883"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/x0AIV2XumU
      truncated: false
      entities:
        urls:
          - url: https://t.co/x0AIV2XumU
      in_reply_to_status_id: 1396502175510003700
      in_reply_to_status_id_str: "1396502175510003715"
- preprint:
    id: 140428
    metric: 4531
    title: N440K variant of SARS-CoV-2 has Higher Infectious Fitness
    url: https://api.rxivist.org/v1/papers/140428
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.30.441434v1
    doi: 10.1101/2021.04.30.441434
    category: microbiology
    first_posted: 2021-04-30
    abstract: Several variants of SARS-CoV-2 have been emerging across the globe,
      continuing to threaten the efforts to end COVID-19 pandemic. Recent data
      indicate the prevalence of variants with N440K Spike substitution in
      several parts of India, which is under the second wave of the pandemic.
      Here, we first analyze the prevalence of N440K variants within the
      sequences submitted from India and identify a rising trend of its spread
      across various clusters. We then compare the replicative fitness and
      infectivity of a prototype of this variant with two other previously
      prevalent strains. The N440K variant produced ten times higher infectious
      viral titers than a prevalent A2a strain, and over 1000 folds higher
      titers than a much less prevalent A3i strain prototype in Caco2 cells.
      Similar results were detected in Calu-3 cells as well, confirming the
      increased potency of the N440K variant. Interestingly, A3i strain showed
      the highest viral RNA levels, but the lowest infectious titers in the
      culture supernatants, indicating the absence of correlation between the
      RNA content and the infectivity of the sample. N440K mutation has been
      reported in several viral sequences across India and based on our results,
      we predict that the higher infectious titers achieved by this strain could
      possibly lead to its higher rate of transmission. Availability of more
      sequencing data in the immediate future would help understand the
      potential spread of this variant in more detail.
    authors:
      - name: Dixit Tandel
      - name: Divya Gupta
      - name: Vishal Sah
      - name: Krishnan Harinivas Harshan
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Mon May 24 20:21:27 +0000 2021
      id: 1396924323974295600
      id_str: "1396924323974295556"
      text: >-
        üî• bioRxiv Microbiology preprint by D. Tandel et al:


        "N440K variant of SARS-CoV-2 has Higher Infectious Fitness"‚Ä¶ https://t.co/RaV0xfhP8O
      truncated: true
      entities:
        urls:
          - url: https://t.co/RaV0xfhP8O
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "119116"
    doi: 10.1101/2020.11.26.384925
    first_posted: 2020-11-27
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.11.26.384925v1
    url: https://api.rxivist.org/v1/papers/119116
    title: Muscle Van Gogh-like 2 shapes the neuromuscular synapse by regulating
      MuSK signaling activity
    category: neuroscience
    abstract: The development of the neuromuscular junction (NMJ) requires dynamic
      trans-synaptic coordination orchestrated by secreted factors, including
      the morphogens of the Wnt family. Yet, how the signal of these synaptic
      cues is transduced, and particularly during the regulation of
      acetylcholine receptor (AChR) accumulation in the postsynaptic membrane
      remains unclear. We explored the function of Van Gogh-Like protein 2
      (Vangl2), a core component of Wnt planar cell polarity signaling. We
      showed that the conditional genetic ablation of Vangl2 in muscle
      reproduces the NMJ differentiation defects in mice with constitutive
      Vangl2 deletion. These alterations persisted into adulthood with NMJs
      disassembly leading to an impairment of neurotransmission and motor
      function deficits. Mechanistically, we found that Vangl2 and the
      muscle-specific kinase MuSK acted in the same genetic pathway and that
      Vangl2 binds MuSK, thus controlling its signaling activity. Our results
      identify Vangl2 as a key player of the core complex of molecules shaping
      neuromuscular synapses and shed light on the molecular mechanisms
      underlying NMJ assembly.
    authors:
      - name: Myriam Bo√´x
        orcid: null
      - name: Julien Mess√©ant
        orcid: null
      - name: Steve Cottin
        orcid: null
      - name: Marius Halliez
        orcid: null
      - name: St√©phanie Bauch√©
        orcid: null
      - name: C√©line Buon
        orcid: null
      - name: Nathalie Sans
        orcid: http://orcid.org/0000-0001-7658-2471
      - name: M Montcouquiol
        orcid: http://orcid.org/0000-0001-8739-6519
      - name: Jordi Molg√≥
        orcid: null
      - name: Muriel Amar
        orcid: null
      - name: Arnaud Ferry
        orcid: null
      - name: M√©gane Lemaitre
        orcid: null
      - name: Andr√©e Rouche
        orcid: null
      - name: Dominique Langui
        orcid: null
      - name: Asha Baskaran
        orcid: null
      - name: Bertrand Fontaine
        orcid: null
      - name: Laure Strochlic
        orcid: http://orcid.org/0000-0001-5373-4284
  comment:
    dislikes: 0
    thread: "8319683835"
    numReports: 0
    likes: 0
    id: "5395644447"
    createdAt: 2021-05-24T22:53:30
    author:
      username: disqus_Dfdg8RCumO
      about: ""
      name: ESHA CHAWLA
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_Dfdg8RCumO/
      url: ""
      location: ""
      id: "369904596"
    isApproved: true
    raw_message: >-
      Recently, my biomedical research seminar had the opportunity to read and
      discuss your paper. Detailed below are some of the comments we had on your
      work. 


      Strengths: We appreciated your figures also diagrammed your methods ‚Äì for example, Figure 1A made it extremely clear what you were knocking out and how you were doing so. We also really appreciated that your figures were not all graphs/quantitative data, but also the IHC stains that were eventually used for data analysis (i.e. Figures 1D, 2C, 3A, 6C, 7A). 


      Weaknesses/Suggestions: While we did appreciate the IHC images, the quantitative graphs were too small and need to be enlarged to allow for easier data analysis. Additionally, certain figures were redundant ‚Äì for example, both 4A and 4B show absolute force; similarly, both 4E and 4D show stimulation frequency and CMAP amplitude. Such redundancies convoluted the conversation, as students were confused what new information (if any) they were being presented with. Finally, the images need to be made more accessible to all readers ‚Äì consider using magenta/blue stains to make data readable to colorblind readers, and include arrows in IHC stains so readers know what they are looking for. 


      Overall, we really appreciated your scientific writing and the significance of your work ‚Äì finding the mechanism by which Vangl2 interacts with MuSK to affect neuromuscular activity. We believe that with these small revisions, you can improve your data presentation and make the science more accessible to the readers.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.11.26.384925v2
  tweets:
    - created_at: Tue May 25 00:41:03 +0000 2021
      id: 1396989657552855000
      id_str: "1396989657552855042"
      text: >-
        üí¨ bioRxiv comment on "Muscle Van Gogh-like 2 shapes ..."


        "Recently, my biomedical research seminar had the opportu‚Ä¶ https://t.co/tMlUNXAwM5
      truncated: true
      entities:
        urls:
          - url: https://t.co/tMlUNXAwM5
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue May 25 00:41:04 +0000 2021
      id: 1396989658685329400
      id_str: "1396989658685329408"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/WW8Eaz1Ksz
      truncated: false
      entities:
        urls:
          - url: https://t.co/WW8Eaz1Ksz
      in_reply_to_status_id: 1396989657552855000
      in_reply_to_status_id_str: "1396989657552855042"
- preprint:
    id: "143059"
    doi: 10.1101/2021.05.24.445329
    first_posted: 2021-05-24
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.24.445329v1
    url: https://api.rxivist.org/v1/papers/143059
    title: Principles of gene regulation quantitatively connect DNA to RNA and
      proteins in bacteria
    category: systems-biology
    abstract: "Bacteria allocate their proteome to cellular functions differently in
      different growth conditions. It is largely unknown how such allocation
      arises from known mechanisms of gene regulation while constrained by
      limited translation capacity and fixed protein density. Here, we performed
      absolute transcriptomic and proteomic analysis for E. coli across many
      conditions, obtaining a plethora of results on promoters and mRNAs
      characteristics that clash with conventional expectations: the majority of
      mRNAs exhibit similar translational efficiencies, while the promoter
      strengths are vastly different across genes. These characteristics
      prescribe two principles of gene regulation guiding bacteria to attain the
      desired protein allocation under global constraints: Total transcriptional
      output is tightly coordinated with ribosomal activity, and the
      concentrations of individual proteins are largely set by transcription.
      These two principles lead to a quantitative formulation of Central Dogma
      which unravels the complex relationship between gene regulatory activities
      and mRNA/protein concentrations across conditions. The knowledge obtained
      will be invaluable for accurately inferring gene regulatory interactions
      from 'omics data, as well as for guiding the design of genetic circuits
      for synthetic biology applications in E. coli and other organisms."
    authors:
      - name: Rohan Balakrishnan
        orcid: http://orcid.org/0000-0002-7547-8565
      - name: Matteo Mori
        orcid: http://orcid.org/0000-0002-6263-8021
      - name: Igor Segota
        orcid: null
      - name: Zhongge Zhang
        orcid: http://orcid.org/0000-0002-6474-7045
      - name: Ruedi Aebersold
        orcid: http://orcid.org/0000-0002-9576-3267
      - name: Christina Ludwig
        orcid: http://orcid.org/0000-0002-6131-7322
      - name: Terence Hwa
        orcid: http://orcid.org/0000-0003-1837-6842
  comment:
    dislikes: 0
    thread: "8547788914"
    numReports: 0
    likes: 0
    id: "5395629598"
    createdAt: 2021-05-24T22:36:53
    author:
      username: disqus_QL326OaLB9
      about: ""
      name: Howard Salis
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_QL326OaLB9/
      url: https://plus.google.com/107639019335100166999
      location: ""
      id: "242280388"
    isApproved: true
    raw_message: >-
      Readers note: The authors make the following assumptions in all their
      analysis, which critically undermines several of their most important (and
      controversial) conclusions:


      1.   The authors are treating their ribosome profiling experiments as a measurement of translation rate. That's incorrect. Ribosome profiling measures the relative density of ribosomes bound to mRNAs. It is not a direct measurement of translation rate nor is it a direct measurement of translational efficiency.  


      Let me be clear with these terms: Translation rate is the number of proteins produced per mRNA per time. Translational efficiency is the number of proteins produced by a single transcript before it is degraded. Ribosome density is the translation initiation rate divided by the mRNA's translation elongation rate. 


      2.  The authors assume that all mRNAs have the same translation elongation rate in order to convert ribosome densities into translation rates. For example, in their Equation 5, epsilon (translation elongation rate) is just a single constant, used throughout to relate translation rates to protein synthesis rates and protein concentrations. This is incorrect. mRNAs do not all have the same translation elongation rate. There is a whole genre of literature on synonymous codon usage, the effects of synonymous codons on ribosome translocation speeds, and the use of codon optimization to increase heterologous protein expression levels. Epsilon is not a single constant. At the very least, if we only care about protein concentrations, one must consider the CDS-averaged translation elongation rate for each mRNA transcript in the transcriptome. 


      The authors' conclusion "Translation initiation rates are similar across mRNAs and growth conditions" needs to be revisited without assuming that all translation elongation rates are the same. Likewise, the conclusion that "Total mRNA abundance matches the translational capacity" depends on the veracity of this conclusion. The conclusion that "Constancy of ribosome spacing across mRNA and nutrient conditions" is more accurately viewed as "Constancy of *ribosome density* across mRNA and nutrient conditions".  Finally, the conclusion that "Total mRNA synthesis flux is adjusted to match translational capacity" is again dependent on the veracity of the first conclusion. 


      Concluding that all mRNAs have the same translation rate is bold. But it's not supported by data. If you see someone using ribosome profiling to make this claim, be skeptical!
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.05.24.445329v1
  tweets:
    - created_at: Tue May 25 12:19:40 +0000 2021
      id: 1397165467492667400
      id_str: "1397165467492667398"
      text: >-
        üí¨ bioRxiv comment on "Principles of gene regulation ..."


        "Readers note: The authors make the following assumptions‚Ä¶ https://t.co/MaP8DWp5Ry
      truncated: true
      entities:
        urls:
          - url: https://t.co/MaP8DWp5Ry
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue May 25 12:19:40 +0000 2021
      id: 1397165468411179000
      id_str: "1397165468411179016"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/Q8gYXIKA8R
      truncated: false
      entities:
        urls:
          - url: https://t.co/Q8gYXIKA8R
      in_reply_to_status_id: 1397165467492667400
      in_reply_to_status_id_str: "1397165467492667398"
- preprint:
    id: "134118"
    doi: 10.1101/2021.03.19.436082
    first_posted: 2021-03-19
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.03.19.436082v1
    url: https://api.rxivist.org/v1/papers/134118
    title: Pronounced genetic separation among varieties of the Primula cusickiana
      species complex, a Great Basin endemic
    category: evolutionary-biology
    abstract: Distinguishing between unique species and populations with strong
      genetic structure is a common challenge in population genetics, especially
      in fragmented habitats where allopatric speciation may be widespread and
      distinct groups may be morphologically similar. Such is often the case
      with species complexes across sky island environments. In these scenarios,
      biogeography may help to explain the relations between species complex
      members, and RADseq methods are commonly used to compare closely related
      species across thousands of genetic loci. Here we use RADseq to clarify
      the relations between geographically distinct but morphologically similar
      varieties of the Primula cusickiana species complex, and to contextualize
      past findings of strong genetic structure among populations within
      varieties. Our genomic analyses demonstrate pronounced separation between
      isolated populations of this Great Basin endemic, indicating that the
      current varietal classification of complex members is inaccurate and
      emphasizing their conservation importance. We discuss how these results
      correspond to recent biogeographical models used to describe the
      distribution of other sky island taxa in western North America. Our
      findings also fit into a wider trend observed for alpine Primula species
      complexes, and we consider how heterostylous breeding systems may be
      contributing to frequent diversification via allopatric speciation in this
      genus.
    authors:
      - name: Austin Koontz
        orcid: http://orcid.org/0000-0002-6103-5894
      - name: William D. Pearse
        orcid: http://orcid.org/0000-0002-6241-3164
      - name: Paul Wolf
        orcid: http://orcid.org/0000-0002-4317-6976
  comment:
    dislikes: 0
    thread: "8444467131"
    numReports: 0
    likes: 0
    id: "5396630337"
    createdAt: 2021-05-25T18:52:04
    author:
      username: disqus_wmUv5Zir8n
      about: ""
      name: KW
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_wmUv5Zir8n/
      url: ""
      location: ""
      id: "369275119"
    isApproved: true
    raw_message: Best of luck!
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.03.19.436082v1
  tweets:
    - created_at: Wed May 26 00:49:36 +0000 2021
      id: 1397354197306196000
      id_str: "1397354197306195970"
      text: |-
        üí¨ bioRxiv comment on "Pronounced genetic separation ..."

        "Best of luck!"

        https://t.co/7GhuBK9Fmx
      truncated: false
      entities:
        urls:
          - url: https://t.co/7GhuBK9Fmx
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed May 26 00:49:37 +0000 2021
      id: 1397354198006653000
      id_str: "1397354198006652929"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/uqranEVcds
      truncated: false
      entities:
        urls:
          - url: https://t.co/uqranEVcds
      in_reply_to_status_id: 1397354197306196000
      in_reply_to_status_id_str: "1397354197306195970"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8549959681"
    numReports: 0
    likes: 2
    id: "5397065865"
    createdAt: 2021-05-26T02:24:19
    author:
      username: disqus_WhklNKQ0tI
      about: ""
      name: ŸÖÿ±ÿ™ÿ∂€å ŸÜ€åÿß€å€å
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_WhklNKQ0tI/
      url: ""
      location: ""
      id: "369965509"
    isApproved: true
    raw_message: Hi, I'm Dr.Niaee and I was surprised that even basic data from our
      RCT is completely mispresented and is WRONG. We had 60 indivisuals in
      control groups and 120 in intervention groups and even this simple thing
      is mispresrntated.
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v1
  tweets:
    - created_at: Wed May 26 12:22:00 +0000 2021
      id: 1397528445459091500
      id_str: "1397528445459091458"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "Hi, I'm Dr.Niaee and I was surprised that even basic dat‚Ä¶ https://t.co/w47gys9bo0
      truncated: true
      entities:
        urls:
          - url: https://t.co/w47gys9bo0
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed May 26 12:22:01 +0000 2021
      id: 1397528446302138400
      id_str: "1397528446302138368"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1397528445459091500
      in_reply_to_status_id_str: "1397528445459091458"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8549959681"
    numReports: 0
    likes: 2
    id: "5397127949"
    createdAt: 2021-05-26T03:59:44
    author:
      username: stevekirsch
      about: ""
      name: Steve Kirsch
      isPowerContributor: false
      profileUrl: https://disqus.com/by/stevekirsch/
      url: ""
      location: ""
      id: "56290616"
    isApproved: true
    raw_message: >-
      Why hasn't this paper been retracted yet?


      They reversed the numbers for the Niaee study which was pivotal to their conclusion. See <a href="https://twitter.com/Covid19Crusher/status/1397214174766325765">this tweet from CovidAnalysis</a> for details on the switch. There is also a video from Niaee himself attesting to the fact ivermectin works. 


      When you use the correct data, it shows ivermectin works. No surprise.
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v1
  tweets:
    - created_at: Wed May 26 17:04:50 +0000 2021
      id: 1397599621183119400
      id_str: "1397599621183119360"
      text: |-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."

        "Why hasn't this paper been retracted yet?

        They reversed‚Ä¶ https://t.co/kAlMrYY2gp
      truncated: true
      entities:
        urls:
          - url: https://t.co/kAlMrYY2gp
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed May 26 17:04:50 +0000 2021
      id: 1397599621908729900
      id_str: "1397599621908729857"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1397599621183119400
      in_reply_to_status_id_str: "1397599621183119360"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 2
    id: "5397292434"
    createdAt: 2021-05-26T09:30:26
    author:
      username: norbertszolnoky
      about: ""
      name: Norbert Szolnoky
      isPowerContributor: false
      profileUrl: https://disqus.com/by/norbertszolnoky/
      url: https://www.expertenglish.jp
      location: Toyama, Japan
      id: "105834632"
    isApproved: true
    raw_message: >-
      "...a yet-proven truth, that all the wearing of masks was futile..."

      Man, you are waaaay behind on real evidence. There's plenty of real research and data to show that no type of mask stops the SARS-CoV-2 virus and make no difference in COVID-19 infections, because the virus spreads through aerosol. 


      If you just wanna look at one place to see the list of evidence then look here: 

      1. https://swprs.org/face-masks-evidence/

      2. Or perhaps this section as well: 

      https://swprs.org/covid-update-may-2021/#virus-transmission
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Wed May 26 20:37:37 +0000 2021
      id: 1397653170063659000
      id_str: "1397653170063659010"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        ""...a yet-proven truth, that all the wearing of masks wa‚Ä¶ https://t.co/zF8gDOnd5L
      truncated: true
      entities:
        urls:
          - url: https://t.co/zF8gDOnd5L
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed May 26 20:37:37 +0000 2021
      id: 1397653171007328300
      id_str: "1397653171007328260"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1397653170063659000
      in_reply_to_status_id_str: "1397653170063659010"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8549959681"
    numReports: 0
    likes: 2
    id: "5396809572"
    createdAt: 2021-05-25T21:27:31
    author:
      username: disqus_0dfmguf04M
      about: ""
      name: Alex
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_0dfmguf04M/
      url: ""
      location: ""
      id: "366966096"
    isApproved: true
    raw_message: >-
      Can you please double check? 


      It is mentioned <a href=https://twitter.com/Covid19Crusher/status/1397214174766325765"#"><b>here</b></a> that arm data from the key Niaee study appears to have been swapped, and that when put back in the right order ivermectin worked much better than reported (66% lower risk of death, p=.031).
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v1
  tweets:
    - created_at: Wed May 26 22:30:36 +0000 2021
      id: 1397681601409077200
      id_str: "1397681601409077252"
      text: |-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."

        "Can you please double check? 

        It is mentioned &lt;a href=‚Ä¶ https://t.co/nYKQIsLQXM
      truncated: true
      entities:
        urls:
          - url: https://t.co/nYKQIsLQXM
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed May 26 22:30:36 +0000 2021
      id: 1397681602247995400
      id_str: "1397681602247995392"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1397681601409077200
      in_reply_to_status_id_str: "1397681601409077252"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8549959681"
    numReports: 0
    likes: 2
    id: "5396747902"
    createdAt: 2021-05-25T20:30:08
    author:
      username: disqus_haqbHtjpTs
      about: ""
      name: Marek J
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_haqbHtjpTs/
      url: ""
      location: ""
      id: "246931175"
    isApproved: true
    raw_message: >-
      You have wrong data in the mortality analysis for Niaee study. You swaped
      IVM for Control. According to the study, 4 deaths from 116 occured in IVM
      and 11/49 occured in Control.


      Looking forward to your recalculation.
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v1
  tweets:
    - created_at: Thu May 27 01:44:53 +0000 2021
      id: 1397730495778234400
      id_str: "1397730495778234373"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "You have wrong data in the mortality analysis for Niaee‚Ä¶ https://t.co/XwOJDZoO7X
      truncated: true
      entities:
        urls:
          - url: https://t.co/XwOJDZoO7X
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 27 01:44:53 +0000 2021
      id: 1397730496461918200
      id_str: "1397730496461918212"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1397730495778234400
      in_reply_to_status_id_str: "1397730495778234373"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 5
    id: "5397814595"
    createdAt: 2021-05-26T17:57:17
    author:
      username: disqus_4sBBARIHtf
      about: ""
      name: Jeremy
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_4sBBARIHtf/
      url: ""
      location: ""
      id: "249175760"
    isApproved: true
    raw_message: The study literally states that mask usage didn't slow the spread
      of the virus. Whether it helped the wearer or not is a moot point, since
      the data clearly showed it helped no one.
    forum: medrxiv
    points: 5
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Thu May 27 12:53:26 +0000 2021
      id: 1397898740149543000
      id_str: "1397898740149542912"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "The study literally states that mask usage didn't slow t‚Ä¶ https://t.co/TkFV17lJMf
      truncated: true
      entities:
        urls:
          - url: https://t.co/TkFV17lJMf
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 27 12:53:26 +0000 2021
      id: 1397898741118509000
      id_str: "1397898741118509058"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU30MFJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU30MFJ
      in_reply_to_status_id: 1397898740149543000
      in_reply_to_status_id_str: "1397898740149542912"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 4
    thread: "8550177462"
    numReports: 0
    likes: 3
    id: "5397842480"
    createdAt: 2021-05-26T18:19:28
    author:
      username: rusbowden
      about: ""
      name: rusbowden
      isPowerContributor: false
      profileUrl: https://disqus.com/by/rusbowden/
      url: ""
      location: ""
      id: "10245173"
    isApproved: true
    raw_message: Keep looking, Norbert-man. Seems you cherry pick, which is what I
      suspect these researchers of doing too. That's politics, not science.
      Aerosol can get through, which means the effectiveness is not 100%. Unless
      there is  smart steering on board the tiny particles, or the mask material
      actually repels them, the mask will stop some. (It would be interesint for
      someone to find a smart mask material that draws the aerosol.) Note too,
      how vapor saturation of masks from the wearer's breath increases mask
      effectiveness. This is out there as well.
    forum: medrxiv
    points: -1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Thu May 27 14:40:58 +0000 2021
      id: 1397925802327502800
      id_str: "1397925802327502862"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Keep looking, Norbert-man. Seems you cherry pick, which‚Ä¶ https://t.co/7wuETvvZis
      truncated: true
      entities:
        urls:
          - url: https://t.co/7wuETvvZis
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 27 14:40:58 +0000 2021
      id: 1397925803409567700
      id_str: "1397925803409567744"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU30MFJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU30MFJ
      in_reply_to_status_id: 1397925802327502800
      in_reply_to_status_id_str: "1397925802327502862"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8549959681"
    numReports: 0
    likes: 3
    id: "5396741277"
    createdAt: 2021-05-25T20:24:16
    author:
      username: disqus_NW5PxcfXXi
      about: Synchronicity & Spiritus Mundi
      name: Green Ranger
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_NW5PxcfXXi/
      url: ""
      location: Earth
      id: "207417544"
    isApproved: true
    raw_message: >-
      The results and conclusions of this study are wrong.  The authors mistook
      the ivermectin and control arms of one of the RCTs that they
      included.  Look at figure 2.  The results from Niaee 2020 are dramatically
      misreported.  The actual results for that study are as follows:


      Control groups: 11 deaths out of 60 patients.

      Ivermectin groups: 4 deaths out of 90 patients.


      When this is corrected, the results of this meta-analysis confirm what other meta-analyses have found.  Ivermectin use is associated with approximately 66% reduction in Covid fatalities.  And this result is statistically significant.  


      <a href="https://twitter.com/julienpotet/status/1397234802617630725">A source for this.</a>
    forum: medrxiv
    points: 3
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v1
  tweets:
    - created_at: Thu May 27 17:16:53 +0000 2021
      id: 1397965039865368600
      id_str: "1397965039865368587"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "The results and conclusions of this study are wrong.  Th‚Ä¶ https://t.co/MToLOVpeLx
      truncated: true
      entities:
        urls:
          - url: https://t.co/MToLOVpeLx
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 27 17:16:53 +0000 2021
      id: 1397965040695791600
      id_str: "1397965040695791617"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1397965039865368600
      in_reply_to_status_id_str: "1397965039865368587"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8549959681"
    numReports: 0
    likes: 3
    id: "5396630537"
    createdAt: 2021-05-25T18:52:14
    author:
      username: stephenjcollings
      about: ""
      name: Stephen J. Collings
      isPowerContributor: false
      profileUrl: https://disqus.com/by/stephenjcollings/
      url: ""
      location: ""
      id: "113031321"
    isApproved: true
    raw_message: Looks like an error in the extraction of data from Niaee 2020 has
      led to an incorrect mortality conclusion. Please correct as a matter of
      urgency.
    forum: medrxiv
    points: 3
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v1
  tweets:
    - created_at: Thu May 27 19:04:27 +0000 2021
      id: 1397992109655875600
      id_str: "1397992109655875588"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "Looks like an error in the extraction of data from Niaee‚Ä¶ https://t.co/1ojKMGhQJ2
      truncated: true
      entities:
        urls:
          - url: https://t.co/1ojKMGhQJ2
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 27 19:04:27 +0000 2021
      id: 1397992110448652300
      id_str: "1397992110448652288"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1397992109655875600
      in_reply_to_status_id_str: "1397992109655875588"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8549959681"
    numReports: 0
    likes: 2
    id: "5398389706"
    createdAt: 2021-05-27T04:05:21
    author:
      username: andrewdavidshillermd
      about: ""
      name: Andrew David Shiller MD
      isPowerContributor: false
      profileUrl: https://disqus.com/by/andrewdavidshillermd/
      url: ""
      location: ""
      id: "147885763"
    isApproved: true
    raw_message: Interesting.   I see all the comments reporting that the authors
      mixed up the data.  Very disturbing, but exactly why we have peer
      review.  What's odd is that those comments show up here in version 1 of
      the medrxiv publication.  And there is also a "version 2" of the
      publication
      (https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v2) which
      appears to have the same abstract, but no comments pointing toward the
      mixed up data and conclusions.  What's up with that?
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v1
  tweets:
    - created_at: Thu May 27 20:34:34 +0000 2021
      id: 1398014791050989600
      id_str: "1398014791050989571"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "Interesting.   I see all the comments reporting that the‚Ä¶ https://t.co/zV7SC1FxLY
      truncated: true
      entities:
        urls:
          - url: https://t.co/zV7SC1FxLY
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 27 20:34:34 +0000 2021
      id: 1398014791734681600
      id_str: "1398014791734681602"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1398014791050989600
      in_reply_to_status_id_str: "1398014791050989571"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 17
    thread: "8550177462"
    numReports: 0
    likes: 2
    id: "5398246952"
    createdAt: 2021-05-27T00:37:03
    author:
      username: danielansari
      about: ""
      name: Daniel Ansari
      isPowerContributor: false
      profileUrl: https://disqus.com/by/danielansari/
      url: ""
      location: ""
      id: "254725529"
    isApproved: true
    raw_message: >-
      From your first link (1) - point (4) is misinformation and discredits the
      entire article and thus the site.


      The technical report in point is https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-face-masks-community-first-update.pdf, which states:


      "The evidence regarding the effectiveness of medical face masks for the prevention of COVID-19 in the community is compatible with a small to moderate protective effect, but there are still significant uncertainties about the size of this effect.", and


      "Although the evidence for the use of medical face masks in the community to prevent COVID-19 is limited, face masks should be considered as a non-pharmaceutical intervention in combination with other measures as part of efforts to control the COVID-19 pandemic."


      I'm not even going to bother going over the other cherry-picked/misrepresented studies/reports.
    forum: medrxiv
    points: -15
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Thu May 27 22:31:23 +0000 2021
      id: 1398044187900141600
      id_str: "1398044187900141572"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "From your first link (1) - point (4) is misinformation a‚Ä¶ https://t.co/MZqfknv7rp
      truncated: true
      entities:
        urls:
          - url: https://t.co/MZqfknv7rp
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 27 22:31:23 +0000 2021
      id: 1398044188751679500
      id_str: "1398044188751679488"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398044187900141600
      in_reply_to_status_id_str: "1398044187900141572"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 37
    thread: "8550177462"
    numReports: 0
    likes: 2
    id: "5396692581"
    createdAt: 2021-05-25T19:41:53
    author:
      username: rusbowden
      about: ""
      name: rusbowden
      isPowerContributor: false
      profileUrl: https://disqus.com/by/rusbowden/
      url: ""
      location: ""
      id: "10245173"
    isApproved: true
    raw_message: >-
      A further point needs to be made, before we throw away our masks -- that
      masks do not help the individual wearer. This research barely touches on
      that, thus is open to be used politically to cause virus spread.  And if
      an individual thought that this research showed that a mask does not help
      the wearer, it could cause many to shed their masks when it would be
      dangerous. 


      Here in my city, we just dropped off the "high risk" or "red" category last week, which means too many spreaders were walking around town, many willy nilly. Should I still be wearing a mask, can it stop the virus from getting to me? This study does not answer that question. If masks help as many studies shown or at least indicated, then public health officials need help now in getting the message out.


      Let's backtrack and attempt the assumptive leap for a moment and try to affirm that this study points to a yet-proven truth, that all the wearing of masks was futile, because of the ineffectiveness of the mask only, which even causes problems for wearers. Let's try to affirm that with a thought experiment. Imagine with me that what got invented is the dream 100% mask back in April 2020, that (1) when worn, causes no discomfort or infection in the wearer and (2) completely prevents any wearer from being able to catch the covid virus. What if any difference would this have made to the results of this study? The hypotheses this leads to have to do with how human behavior and politics help viruses spread -- even in the face of mask-wearing. 


      For instance, consider the work of Ngaire Woods, founding dean of the Blavatnik School of Government and professor of Global Economic Governance at the University of Oxford. In his article, "What factors have determined how well countries have done in responding to the pandemic?," Richard Smith, a fellow of the Royal College of Physicians of Edinburgh, writes that "Woods identified three factors that had a strong influence on how well countries did," and, "The single most important factor, she argued, was effective collaboration between national and subnational governments." 


      Could this be translated for our purposes here, to be that there was little "subversion" by the populace too, that more successful countries had fewer parties or funerals where masks were shed, events which I witnessed and attended. It only takes one bullet to hit a target, so catch the target when the mask is off or down under the nose. In other words, if you were a virus, how would you enlist "subversive grandmother soldiers," say, to unmask around their grandchildren, allowing a snaking trail of the virus to spread from household to household. How many people broke their social bubbles?
    forum: medrxiv
    points: -35
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri May 28 01:53:57 +0000 2021
      id: 1398095167597551600
      id_str: "1398095167597551617"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "A further point needs to be made, before we throw away o‚Ä¶ https://t.co/9apo2ZMVDZ
      truncated: true
      entities:
        urls:
          - url: https://t.co/9apo2ZMVDZ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 28 01:53:58 +0000 2021
      id: 1398095168318980000
      id_str: "1398095168318980103"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398095167597551600
      in_reply_to_status_id_str: "1398095167597551617"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 3
    id: "5398809648"
    createdAt: 2021-05-27T14:27:10
    author:
      username: michaelwperry
      about: ""
      name: Michael W. Perry
      isPowerContributor: false
      profileUrl: https://disqus.com/by/michaelwperry/
      url: ""
      location: ""
      id: "57866673"
    isApproved: true
    raw_message: >-
      This study reinforces an earlier Danish one published in the <i>Annals of
      Internal Medicine</i> which found that the result of mask wearing had so
      little statistical significance it could be "compatible with a 46%
      reduction to a 23% increase in infection."


      <blockquote>Results:

      A total of 3030 participants were randomly assigned to the recommendation to wear masks, and 2994 were assigned to control; 4862 completed the study. Infection with SARS-CoV-2 occurred in 42 participants recommended masks (1.8%) and 53 control participants (2.1%). The between-group difference was ‚àí0.3 percentage point (95% CI, ‚àí1.2 to 0.4 percentage point; P‚Äâ= 0.38) (odds ratio, 0.82 [CI, 0.54 to 1.23]; P‚Äâ= 0.33). Multiple imputation accounting for loss to follow-up yielded similar results. Although the difference observed was not statistically significant, the 95% CIs are compatible with a 46% reduction to a 23% increase in infection.

      https://www.acpjournals.org/doi/10.7326/M20-6817</blockquote>
    forum: medrxiv
    points: 3
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri May 28 12:56:48 +0000 2021
      id: 1398261976795656200
      id_str: "1398261976795656194"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "This study reinforces an earlier Danish one published in‚Ä¶ https://t.co/2DCfROClsI
      truncated: true
      entities:
        urls:
          - url: https://t.co/2DCfROClsI
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 28 12:56:48 +0000 2021
      id: 1398261977517113300
      id_str: "1398261977517113346"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398261976795656200
      in_reply_to_status_id_str: "1398261976795656194"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 6
    thread: "8550177462"
    numReports: 0
    likes: 3
    id: "5398455261"
    createdAt: 2021-05-27T06:20:33
    author:
      username: disqus_0bT5QNRHDf
      about: ""
      name: Mike Stevens
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_0bT5QNRHDf/
      url: ""
      location: ""
      id: "68437046"
    isApproved: true
    raw_message: >-
      Well, it‚Äôs not whether there is a mandate in place, is it?

      <b>It‚Äôs whether the mandate is adhered to.

      And when people actually comply, and wear the masks, Covid spread declines.</b>

      <code>https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0249891</code>


      Funny how a disease spread primarily through droplet spread can be halted by methods that stop droplet spread, isn‚Äôt it?

      ...Who would have thought it?
    forum: medrxiv
    points: -3
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri May 28 14:37:16 +0000 2021
      id: 1398287260101976000
      id_str: "1398287260101976066"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Well, it‚Äôs not whether there is a mandate in place, is i‚Ä¶ https://t.co/E8yWGubU0J
      truncated: true
      entities:
        urls:
          - url: https://t.co/E8yWGubU0J
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 28 14:37:16 +0000 2021
      id: 1398287261020541000
      id_str: "1398287261020540939"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU30MFJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU30MFJ
      in_reply_to_status_id: 1398287260101976000
      in_reply_to_status_id_str: "1398287260101976066"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 1
    thread: "8550177462"
    numReports: 0
    likes: 5
    id: "5399193302"
    createdAt: 2021-05-27T19:49:37
    author:
      username: Kaliix
      about: ""
      name: Kaliix
      isPowerContributor: false
      profileUrl: https://disqus.com/by/Kaliix/
      url: ""
      location: ""
      id: "31779148"
    isApproved: true
    raw_message: It is not possible for masks to work. The virus size is akin to
      that of smoke of vaporizer particles. Cloth masks can't filter that sized
      particle. This has been know for years. Masks, like an N-95, must be
      fitted to be at all effective. Otherwise, you create strong side vent
      outgasings that just disperse the exhaled breath around the mask.
    forum: medrxiv
    points: 4
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri May 28 17:15:30 +0000 2021
      id: 1398327079465259000
      id_str: "1398327079465259013"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "It is not possible for masks to work. The virus size is‚Ä¶ https://t.co/IGKVjEP99N
      truncated: true
      entities:
        urls:
          - url: https://t.co/IGKVjEP99N
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 28 17:15:30 +0000 2021
      id: 1398327080312610800
      id_str: "1398327080312610816"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398327079465259000
      in_reply_to_status_id_str: "1398327079465259013"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 7
    thread: "8550177462"
    numReports: 0
    likes: 3
    id: "5399211411"
    createdAt: 2021-05-27T20:05:21
    author:
      username: NC91
      about: ""
      name: NC91
      isPowerContributor: false
      profileUrl: https://disqus.com/by/NC91/
      url: ""
      location: ""
      id: "18641112"
    isApproved: true
    raw_message: No one mentions the caution at the top of the article.
    forum: medrxiv
    points: -4
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri May 28 19:15:33 +0000 2021
      id: 1398357292546879500
      id_str: "1398357292546879489"
      text: |-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."

        "No one mentions the caution at the top of the article."

        https://t.co/UxDCA6r4Ij
      truncated: false
      entities:
        urls:
          - url: https://t.co/UxDCA6r4Ij
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 28 19:15:33 +0000 2021
      id: 1398357293356372000
      id_str: "1398357293356371969"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU30MFJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU30MFJ
      in_reply_to_status_id: 1398357292546879500
      in_reply_to_status_id_str: "1398357292546879489"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 4
    thread: "8550177462"
    numReports: 0
    likes: 3
    id: "5399049181"
    createdAt: 2021-05-27T17:47:20
    author:
      username: disqus_EKGoKRJzoO
      about: ""
      name: Right Warrior
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_EKGoKRJzoO/
      url: ""
      location: ""
      id: "353159389"
    isApproved: true
    raw_message: This hasn't been subject to peer review yet.  Why are we supposed
      to take this at face value?
    forum: medrxiv
    points: -1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri May 28 20:43:07 +0000 2021
      id: 1398379331139915800
      id_str: "1398379331139915778"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "This hasn't been subject to peer review yet.  Why are we‚Ä¶ https://t.co/dwnyQ3juSb
      truncated: true
      entities:
        urls:
          - url: https://t.co/dwnyQ3juSb
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 28 20:43:08 +0000 2021
      id: 1398379331865415700
      id_str: "1398379331865415682"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398379331139915800
      in_reply_to_status_id_str: "1398379331139915778"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 3
    id: "5398871329"
    createdAt: 2021-05-27T15:20:16
    author:
      username: disqus_5aza9C29Vf
      about: wear the uniform; live life
      name: J√§ger
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_5aza9C29Vf/
      url: ""
      location: Flathead County
      id: "116324005"
    isApproved: true
    raw_message: >-
      01 Dec 2020

            A large randomized community-based trial in which 4862 healthy
              participants were divided into a group wearing medical/surgical
              masks and a control group found no difference in infection with
              SARS-CoV-2. A recent systematic review found nine trials (of
              which eight were cluster-randomized controlled trials in which
              clusters of people, versus individuals, were randomized)
              comparing medical/surgical masks versus no masks to prevent the
              spread of viral respiratory illness. Two trials were with
              healthcare workers and seven in the community. The review
              concluded that wearing a mask may make little or no difference
              to the prevention of influenza-like illness.https://www.who.int/publications/i/item/advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak
    forum: medrxiv
    points: 3
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri May 28 22:35:12 +0000 2021
      id: 1398407535388942300
      id_str: "1398407535388942337"
      text: |-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."

        "01 Dec 2020

              A large randomized community-based tr‚Ä¶ https://t.co/4bfUtNbYPK
      truncated: true
      entities:
        urls:
          - url: https://t.co/4bfUtNbYPK
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 28 22:35:12 +0000 2021
      id: 1398407536122990600
      id_str: "1398407536122990592"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398407535388942300
      in_reply_to_status_id_str: "1398407535388942337"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 10
    thread: "8550177462"
    numReports: 0
    likes: 2
    id: "5398406513"
    createdAt: 2021-05-27T04:38:06
    author:
      username: rusbowden
      about: ""
      name: rusbowden
      isPowerContributor: false
      profileUrl: https://disqus.com/by/rusbowden/
      url: ""
      location: ""
      id: "10245173"
    isApproved: true
    raw_message: The study does not show what you say it does, and from your
      response, my fear that people will use it to think that unmasking is as
      safe as masking, means we have study here that puts people in peril.
    forum: medrxiv
    points: -8
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sat May 29 02:10:21 +0000 2021
      id: 1398461681068560400
      id_str: "1398461681068560386"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "The study does not show what you say it does, and from y‚Ä¶ https://t.co/vKU6j1rpqF
      truncated: true
      entities:
        urls:
          - url: https://t.co/vKU6j1rpqF
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 29 02:10:21 +0000 2021
      id: 1398461681844605000
      id_str: "1398461681844604931"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398461681068560400
      in_reply_to_status_id_str: "1398461681068560386"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 3
    id: "5398864745"
    createdAt: 2021-05-27T15:14:45
    author:
      username: notanotherskippy
      about: ""
      name: notanotherskippy
      isPowerContributor: false
      profileUrl: https://disqus.com/by/notanotherskippy/
      url: ""
      location: ""
      id: "24425828"
    isApproved: true
    raw_message: >-
      Read your own reference:


      <blockquote>However, this effect was not statistically significant in several studies, and the quality of the evidence was

      assessed as low in several studies, so the results should be interpreted with caution.

      Looking at the evidence from studies in healthcare settings or other diseases than COVID-19 (i.e. influenza

      and other respiratory viral infections) did not improve the certainty of the evidence.</blockquote>
    forum: medrxiv
    points: 3
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sat May 29 12:58:52 +0000 2021
      id: 1398624883735679000
      id_str: "1398624883735678980"
      text: |-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."

        "Read your own reference:

        &lt;blockquote&gt;However, this effe‚Ä¶ https://t.co/95uCa95KtG
      truncated: true
      entities:
        urls:
          - url: https://t.co/95uCa95KtG
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 29 12:58:52 +0000 2021
      id: 1398624884452962300
      id_str: "1398624884452962307"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398624883735679000
      in_reply_to_status_id_str: "1398624883735678980"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 2
    id: "5399187781"
    createdAt: 2021-05-27T19:44:53
    author:
      username: rolandwalkenhorst
      about: ""
      name: Roland
      isPowerContributor: false
      profileUrl: https://disqus.com/by/rolandwalkenhorst/
      url: ""
      location: ""
      id: "59375167"
    isApproved: true
    raw_message: >-
      <blockquote>Note too, how vapor saturation of masks from the wearer's
      breath increases mask effectiveness. This is out there as
      well.</blockquote>

      I would like to read about that if you can provide a link. It makes more sense to me that as your mask gets coated with spit, it begins to act as a mesh nebulizer to convert the previously harmless big drops into aerosol droplets every time you exhale through the mask's tiny pores. Those can float around for hours and be inhaled by other people. In other words, if you are infected, putting on a mask turns you into a walking covid mosquito fogger.

      If masks worked as well as the faithful claim they do, we would see overwhelming correlation between mask use and reduced cases, deaths and hospitalizations. We don't. <a href="https://twitter.com/ianmsc">Ian Miller</a> tweets the non-proof every day.
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sat May 29 14:38:53 +0000 2021
      id: 1398650055855415300
      id_str: "1398650055855415301"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "&lt;blockquote&gt;Note too, how vapor saturation of masks from‚Ä¶ https://t.co/IzJD1m4R6F
      truncated: true
      entities:
        urls:
          - url: https://t.co/IzJD1m4R6F
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 29 14:38:53 +0000 2021
      id: 1398650056694173700
      id_str: "1398650056694173699"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398650055855415300
      in_reply_to_status_id_str: "1398650055855415301"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 2
    id: "5398869493"
    createdAt: 2021-05-27T15:18:44
    author:
      username: disqus_5aza9C29Vf
      about: wear the uniform; live life
      name: J√§ger
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_5aza9C29Vf/
      url: ""
      location: Flathead County
      id: "116324005"
    isApproved: true
    raw_message: >-
      And what you're continuing is cherrypicking fear mongering - not
      science.  With word salad cherrypicking, hoping to get away with calling
      it "science".



      Jan 2021 U.S. Department of Health and Human Services

            According to the current knowledge, the virus SARS-CoV-2 has a
              diameter of 60 nm to 140 nm [nanometers (billionth of a meter)],
              while medical and non-medical facemasks‚Äô thread diameter ranges
              from 55 ¬µm to 440 ¬µm [micrometers (one millionth of a meter),
              which is more than 1000 times larger.  Due to the difference in
              sizes between SARS-CoV-2 diameter and facemasks thread diameter,
              SARS-CoV-2 can easily pass through any facemask.

            

            A meta-analysis among health care workers
              found that compared to no masks, surgical mask and N95
              respirators were not effective against transmission of viral
              infections or influenza-like illness based on six RCTs. Using
              separate analysis of 23 observational studies, this meta-analysis
              found no protective effect of medical mask or N95 respirators
              against SARS virus. A recent systematic review of 39 studies
              including 33,867 participants in community settings (self-report
              illness), found no difference between N95 respirators versus
              surgical masks and surgical mask versus no masks in the risk for
              developing influenza or influenza-like illness, suggesting their
              ineffectiveness of blocking viral transmissions in community
              settings.

            https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680614/
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sat May 29 17:21:27 +0000 2021
      id: 1398690965871804400
      id_str: "1398690965871804416"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "And what you're continuing is cherrypicking fear mongeri‚Ä¶ https://t.co/fK7xK36NTS
      truncated: true
      entities:
        urls:
          - url: https://t.co/fK7xK36NTS
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 29 17:21:27 +0000 2021
      id: 1398690966614249500
      id_str: "1398690966614249474"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398690965871804400
      in_reply_to_status_id_str: "1398690965871804416"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5400767226"
    createdAt: 2021-05-29T04:09:06
    author:
      username: sailcat_the_banned
      about: ""
      name: sailcat_the_stranger
      isPowerContributor: false
      profileUrl: https://disqus.com/by/sailcat_the_banned/
      url: ""
      location: ""
      id: "92926218"
    isApproved: true
    raw_message: |-
      No one wears a mask correctly.
      Surgical masks are meant to be one use, not hung from the rear view.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sat May 29 19:24:22 +0000 2021
      id: 1398721900222861300
      id_str: "1398721900222861315"
      text: |-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."

        "No one wears a mask correctly.
        Surgical masks are meant‚Ä¶ https://t.co/UkdWSE1S6O
      truncated: true
      entities:
        urls:
          - url: https://t.co/UkdWSE1S6O
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 29 19:24:22 +0000 2021
      id: 1398721900960944000
      id_str: "1398721900960944135"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398721900222861300
      in_reply_to_status_id_str: "1398721900222861315"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8552957443"
    numReports: 0
    likes: 1
    id: "5399735000"
    createdAt: 2021-05-28T08:48:55
    author:
      username: disqus_DK5eeDLz0I
      about: ""
      name: Enzo
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_DK5eeDLz0I/
      url: ""
      location: ""
      id: "354888269"
    isApproved: true
    raw_message: >-
      Yet another huge double mistake :

      In Fig.6 (viral clearance) for Karamat study, the number of events are WRONG, and they're represented on the WRONG SIDE. 

      Karamat counts nb of viral clearance at day 3 (17 IVM vs 2 control), then the *additional* number at day 7 (20 more in IVM group vs 18 more in control group). Fig.6 only counts the additional count between day 3 and day 7, and forgets what happened till day 3. 

      Hence the figures in Fig.6 for Karamat should be either "17 for Ivermectin and 2 for Control" or "37 for Ivermectin and 20 for Control". 

      And these figures are IN FAVOR of ivermectin. Even the wrong "20" and "18" should have been represented on the "favors IVM " side.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v2
  tweets:
    - created_at: Sat May 29 20:47:30 +0000 2021
      id: 1398742821763354600
      id_str: "1398742821763354625"
      text: |-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."

        "Yet another huge double mistake :
        In Fig.6 (viral cleara‚Ä¶ https://t.co/wx7vIf9LLH
      truncated: true
      entities:
        urls:
          - url: https://t.co/wx7vIf9LLH
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 29 20:47:30 +0000 2021
      id: 1398742822778376200
      id_str: "1398742822778376192"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx56p3x
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx56p3x
      in_reply_to_status_id: 1398742821763354600
      in_reply_to_status_id_str: "1398742821763354625"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5400753754"
    createdAt: 2021-05-29T03:44:48
    author:
      username: Ispythegov
      about: ""
      name: You Know you thought the same.
      isPowerContributor: false
      profileUrl: https://disqus.com/by/Ispythegov/
      url: ""
      location: Some Where in the Once Free USA
      id: "22553928"
    isApproved: true
    raw_message: |-
      But the CDC has known this for years.
      https://wwwnc.cdc.gov/eid/article/26/5/19-0994_article
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sat May 29 22:37:07 +0000 2021
      id: 1398770404685144000
      id_str: "1398770404685144066"
      text: |-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."

        "But the CDC has known this for years.
        "

        https://t.co/UxDCA69tQL
      truncated: false
      entities:
        urls:
          - url: https://t.co/UxDCA69tQL
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 29 22:37:07 +0000 2021
      id: 1398770405243068400
      id_str: "1398770405243068417"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398770404685144000
      in_reply_to_status_id_str: "1398770404685144066"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8552957443"
    numReports: 0
    likes: 1
    id: "5399650102"
    createdAt: 2021-05-28T05:59:35
    author:
      username: disqus_WhklNKQ0tI
      about: ""
      name: ŸÖÿ±ÿ™ÿ∂€å ŸÜ€åÿß€å€å
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_WhklNKQ0tI/
      url: ""
      location: ""
      id: "369965509"
    isApproved: true
    raw_message: Hi, I'm Dr.Niaee and I was surprised that even basic data from our
      RCT is completely mispresented and is WRONG. We had 60 indivisuals in
      control groups and 120 in intervention groups and even this simple thing
      is mispresented.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v2
  tweets:
    - created_at: Sun May 30 02:24:45 +0000 2021
      id: 1398827692993224700
      id_str: "1398827692993224712"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "Hi, I'm Dr.Niaee and I was surprised that even basic dat‚Ä¶ https://t.co/SK7UgbHgH3
      truncated: true
      entities:
        urls:
          - url: https://t.co/SK7UgbHgH3
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 30 02:24:45 +0000 2021
      id: 1398827693702008800
      id_str: "1398827693702008834"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1398827692993224700
      in_reply_to_status_id_str: "1398827692993224712"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8552957443"
    numReports: 0
    likes: 1
    id: "5399634852"
    createdAt: 2021-05-28T05:26:03
    author:
      username: disqus_DK5eeDLz0I
      about: ""
      name: Enzo
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_DK5eeDLz0I/
      url: ""
      location: ""
      id: "354888269"
    isApproved: true
    raw_message: >-
      Other mistakes seem to weigh on the results and on the conclusions.
      Examples :

      In Figure 3, how could the mean length of stay in Niaee's control group be smaller than the one in ivermectin group, when Niaee finds a significant reduction of stay with IVM ?

      In Figure 2 (Mortality), how can RR for Chaccour be 1 when there's no event ? (Shouldn't it be "not calculatable" ?)

      In Figure 5, (severe adverse events), one is included despite Krolewiecki mentions the one reported "has not been reported in association to IVM"
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v2
  tweets:
    - created_at: Sun May 30 12:58:45 +0000 2021
      id: 1398987242631278600
      id_str: "1398987242631278592"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "Other mistakes seem to weigh on the results and on the c‚Ä¶ https://t.co/aq1sMbhbAZ
      truncated: true
      entities:
        urls:
          - url: https://t.co/aq1sMbhbAZ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 30 12:58:45 +0000 2021
      id: 1398987243658809300
      id_str: "1398987243658809349"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1398987242631278600
      in_reply_to_status_id_str: "1398987242631278592"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5399577042"
    createdAt: 2021-05-28T03:32:40
    author:
      username: joshuagibbons
      about: ""
      name: Joshua Gibbons
      isPowerContributor: false
      profileUrl: https://disqus.com/by/joshuagibbons/
      url: ""
      location: ""
      id: "81913636"
    isApproved: true
    raw_message: You're not, feel free to rebuke it, that's why it's been presented
      to the public, so peer review can happen. Pretty hard to get peer review
      without presenting your study, no? Pretty obvious stuff here.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sun May 30 14:40:51 +0000 2021
      id: 1399012937331843000
      id_str: "1399012937331843073"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "You're not, feel free to rebuke it, that's why it's been‚Ä¶ https://t.co/mZs84AneGc
      truncated: true
      entities:
        urls:
          - url: https://t.co/mZs84AneGc
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 30 14:40:51 +0000 2021
      id: 1399012938049073200
      id_str: "1399012938049073162"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399012937331843000
      in_reply_to_status_id_str: "1399012937331843073"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5400593481"
    createdAt: 2021-05-28T23:54:05
    author:
      username: beamansurchit
      about: ""
      name: beamansurchit
      isPowerContributor: false
      profileUrl: https://disqus.com/by/beamansurchit/
      url: ""
      location: ""
      id: "125228403"
    isApproved: true
    raw_message: >-
      A legitimate question.  Will you take it at face value after it has been
      peer reviewed?

      I've been looking into the science behind mask mandates for a while now and there is literally NOT ONE RCT study which has found masks (or respirators for that matter) to be effective to reduce the transmission of viral illness.  Other things like droplets, sure, but not viral illness.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sun May 30 17:19:04 +0000 2021
      id: 1399052754669219800
      id_str: "1399052754669219848"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "A legitimate question.  Will you take it at face value a‚Ä¶ https://t.co/aN07LQRhD8
      truncated: true
      entities:
        urls:
          - url: https://t.co/aN07LQRhD8
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 30 17:19:04 +0000 2021
      id: 1399052755537383400
      id_str: "1399052755537383425"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399052754669219800
      in_reply_to_status_id_str: "1399052754669219848"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8552957443"
    numReports: 0
    likes: 0
    id: "5402311185"
    createdAt: 2021-05-30T17:55:22
    author:
      username: fatlas
      about: ""
      name: fatlas
      isPowerContributor: false
      profileUrl: https://disqus.com/by/fatlas/
      url: ""
      location: ""
      id: "370182889"
    isApproved: true
    raw_message: >-
      When the data for Niaee study was corrected for version 2 the weights
      given to the studies were also changed. The weights in figure 2 changed in
      a way that is hard to explain by the Niaee data fix alone.


      Was any other parameter adjusted for version 2 than data for Niaee study? If so, on what basis was the other parameters changed?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v2
  tweets:
    - created_at: Sun May 30 19:20:58 +0000 2021
      id: 1399083430458052600
      id_str: "1399083430458052612"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "When the data for Niaee study was corrected for version‚Ä¶ https://t.co/fzlxBR2MM0
      truncated: true
      entities:
        urls:
          - url: https://t.co/fzlxBR2MM0
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 30 19:20:58 +0000 2021
      id: 1399083431330463700
      id_str: "1399083431330463745"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1399083430458052600
      in_reply_to_status_id_str: "1399083430458052612"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5401827647"
    createdAt: 2021-05-30T05:39:10
    author:
      username: fatboyjddiesel
      about: ""
      name: FatBoy ‚ÄúJD‚Äù Diesel
      isPowerContributor: false
      profileUrl: https://disqus.com/by/fatboyjddiesel/
      url: ""
      location: ""
      id: "295719846"
    isApproved: true
    raw_message: >-
      Seeing people going back and forth here, but I'll just point this out:


      If wearing masks are really that effective, as some claim, how are medical staff getting infected <i>on the job</i> despite the extra medical gear, protection, and protocols? The overwhelming majority of you can only provide conjecture <i>at best.</i> If medical staff adhering to strict sanitation protocols still get infected by a respiratory illness </I>on site,</I> what makes anyone believe that less effective equipment, or less physical coverage provided by said equipment, would be effective for a general population less equipped to adhere to stricter sanitation protocols?
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sun May 30 20:48:27 +0000 2021
      id: 1399105448054345700
      id_str: "1399105448054345737"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Seeing people going back and forth here, but I'll just p‚Ä¶ https://t.co/d7sSHuysxO
      truncated: true
      entities:
        urls:
          - url: https://t.co/d7sSHuysxO
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 30 20:48:27 +0000 2021
      id: 1399105448825999400
      id_str: "1399105448825999368"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399105448054345700
      in_reply_to_status_id_str: "1399105448054345737"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8552957443"
    numReports: 0
    likes: 1
    id: "5401473605"
    createdAt: 2021-05-29T20:55:44
    author:
      username: RGregoryClark
      about: I teach math at an east coast U.S. university.
      name: Robert Clark
      isPowerContributor: false
      profileUrl: https://disqus.com/by/RGregoryClark/
      url: http://exoscientist.blogspot.com
      location: Philadelphia, PA
      id: "41262611"
    isApproved: true
    raw_message: >-
      Seriously, it‚Äôs like some researchers opposed to the concept of EARLY
      treatment of COVID will go to any lengths to provide evidence against it,
      even if it crosses the line of scientific ethics.


      Sorry, to have to say this but the authors no longer have any credibility on this issue.

       Extremely important to recognize the importance of this: to provide evidence against IVM researchers have had to change data to fit their conclusion.

       What does that tell you about the effectiveness of IVM?

        Robert Clark
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v2
  tweets:
    - created_at: Sun May 30 22:39:14 +0000 2021
      id: 1399133326473056300
      id_str: "1399133326473056259"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "Seriously, it‚Äôs like some researchers opposed to the con‚Ä¶ https://t.co/kcOLJgHSNE
      truncated: true
      entities:
        urls:
          - url: https://t.co/kcOLJgHSNE
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 30 22:39:14 +0000 2021
      id: 1399133328469540900
      id_str: "1399133328469540865"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1399133326473056300
      in_reply_to_status_id_str: "1399133326473056259"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5401226162"
    createdAt: 2021-05-29T16:36:40
    author:
      username: disqus_xTMdo65OVv
      about: ""
      name: BajaRon
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_xTMdo65OVv/
      url: ""
      location: ""
      id: "39358479"
    isApproved: true
    raw_message: If you follow real science (of which there is a great deal on this
      subject). There has never been any that can show any advantage of mask
      wearing for a viral issue. Theories on water droplet dispersion rates,
      etc., abound. But the hard evidence clearly and repeatedly shows that the
      spread of any virus is not affected in the least by wearing a mask. It's
      like trying to keep flies out with a chain link fence.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon May 31 02:35:48 +0000 2021
      id: 1399192862936416300
      id_str: "1399192862936416259"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "If you follow real science (of which there is a great de‚Ä¶ https://t.co/GBErMbE0bo
      truncated: true
      entities:
        urls:
          - url: https://t.co/GBErMbE0bo
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 31 02:35:49 +0000 2021
      id: 1399192863737516000
      id_str: "1399192863737516034"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399192862936416300
      in_reply_to_status_id_str: "1399192862936416259"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 2
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5402275797"
    createdAt: 2021-05-30T17:20:05
    author:
      username: badger_vanamburgh
      about: ""
      name: Badger Vanamburgh
      isPowerContributor: false
      profileUrl: https://disqus.com/by/badger_vanamburgh/
      url: ""
      location: ""
      id: "360872283"
    isApproved: true
    raw_message: It‚Äôs astonishing that anyone thinks that this study is in any way
      scientific, controlled, with conclusions based on anything but bias. It‚Äôs
      alarming that such nonsense writings like these are even taken seriously
      enough for someone to decide to publish it, spread it around the internet.
      The times of truth, fact and reality ruling the day, are behind us. They
      are destroying science and destroying our democracy. That is very sad
      indeed.
    forum: medrxiv
    points: -1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon May 31 13:01:14 +0000 2021
      id: 1399350254609342500
      id_str: "1399350254609342470"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "It‚Äôs astonishing that anyone thinks that this study is i‚Ä¶ https://t.co/ZvgHr037jq
      truncated: true
      entities:
        urls:
          - url: https://t.co/ZvgHr037jq
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 31 13:01:14 +0000 2021
      id: 1399350255435530200
      id_str: "1399350255435530240"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399350254609342500
      in_reply_to_status_id_str: "1399350254609342470"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5401702515"
    createdAt: 2021-05-30T01:48:50
    author:
      username: DeanAnniballi
      about: ""
      name: Dean Anniballi
      isPowerContributor: false
      profileUrl: https://disqus.com/by/DeanAnniballi/
      url: ""
      location: ""
      id: "81416142"
    isApproved: true
    raw_message: The disease is spread primarily by aerosolized particles, not
      droplets.  That's why the masks are pretty much useless.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon May 31 14:39:29 +0000 2021
      id: 1399374981314850800
      id_str: "1399374981314850823"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "The disease is spread primarily by aerosolized particles‚Ä¶ https://t.co/swp4mPxQIw
      truncated: true
      entities:
        urls:
          - url: https://t.co/swp4mPxQIw
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 31 14:39:29 +0000 2021
      id: 1399374982124347400
      id_str: "1399374982124347398"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399374981314850800
      in_reply_to_status_id_str: "1399374981314850823"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 2
    id: "5401706081"
    createdAt: 2021-05-30T01:54:15
    author:
      username: DeanAnniballi
      about: ""
      name: Dean Anniballi
      isPowerContributor: false
      profileUrl: https://disqus.com/by/DeanAnniballi/
      url: ""
      location: ""
      id: "81416142"
    isApproved: true
    raw_message: I find it interesting that those states that implemented early mask
      mandates have slightly high death rates than states that never implemented
      masking.  In addition, when new case rates were at the highest we also had
      >93% mask compliance in those states that required masks.  The real world
      data seems to refute your position.
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon May 31 17:41:07 +0000 2021
      id: 1399420690223317000
      id_str: "1399420690223317000"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "I find it interesting that those states that implemented‚Ä¶ https://t.co/6AbayYTUfV
      truncated: true
      entities:
        urls:
          - url: https://t.co/6AbayYTUfV
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 31 17:41:07 +0000 2021
      id: 1399420691016032300
      id_str: "1399420691016032268"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399420690223317000
      in_reply_to_status_id_str: "1399420690223317000"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 2
    id: "5400974494"
    createdAt: 2021-05-29T11:28:54
    author:
      username: lunararmor
      about: ""
      name: LunarArmor
      isPowerContributor: false
      profileUrl: https://disqus.com/by/lunararmor/
      url: ""
      location: ""
      id: "281578529"
    isApproved: true
    raw_message: You obviously don't grasp what they are saying.  Mandates
      absolutely increased the amount of people wearing masks.  Even though
      those mandates were in place, the data shows that it did not slow the
      spread of Covid during times of Covid surges.  Ergo, the mandate and
      wearing masks do decrease the rate of transmission.
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon May 31 19:50:46 +0000 2021
      id: 1399453318896832500
      id_str: "1399453318896832513"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "You obviously don't grasp what they are saying.  Mandate‚Ä¶ https://t.co/UbrlXCrpL5
      truncated: true
      entities:
        urls:
          - url: https://t.co/UbrlXCrpL5
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 31 19:50:46 +0000 2021
      id: 1399453319719002000
      id_str: "1399453319719002115"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399453318896832500
      in_reply_to_status_id_str: "1399453318896832513"
- preprint:
    id: 141863
    metric: 16417
    title: The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified
      in India Provide Partial Resistance to Vaccine-elicited and Therapeutic
      Monoclonal Antibodies.
    url: https://api.rxivist.org/v1/papers/141863
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.14.444076v1
    doi: 10.1101/2021.05.14.444076
    category: immunology
    first_posted: 2021-05-16
    abstract: Highly transmissible SARS-CoV-2 variants recently identified in India
      designated B.1.617 and B.1.618 have mutations within the spike protein
      that may contribute to their increased transmissibility and that could
      potentially result in re-infection or resistance to vaccine-elicited
      antibody. B.1.617 encodes a spike protein with mutations L452R, E484Q,
      D614G and P681R while the B.1.618 spike has mutations {Delta}145-146,
      E484K and D614G. We generated lentiviruses pseudotyped by the variant
      proteins and determined their resistance to neutralization by convalescent
      sera, vaccine-elicited antibodies and therapeutic monoclonal antibodies.
      Viruses with B.1.617 and B.1.618 spike were neutralized with a 2-5-fold
      decrease in titer by convalescent sera and vaccine-elicited antibodies.
      The E484Q and E484K versions were neutralized with a 2-4-fold decrease in
      titer. Virus with the B.1.617 spike protein was neutralized with a
      4.7-fold decrease in titer by the Regeneron monoclonal antibody cocktail
      as a result of the L452R mutation. The modest neutralization resistance of
      the variant spike proteins to vaccine elicited antibody suggests that
      current vaccines will remain protective against the B.1.617 and B.1.618
      variants.
    authors:
      - name: Takuya Tada
      - name: Hao Zhou
      - name: Belinda M Dcosta
      - name: Marie I. Samanovic
      - name: Mark J Mulligan
      - name: Nathaniel R Landau
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Mon May 31 21:13:12 +0000 2021
      id: 1399474064666906600
      id_str: "1399474064666906624"
      text: >-
        üî• bioRxiv Immunology preprint by T. Tada et al:


        "The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Ide‚Ä¶ https://t.co/RkZe4QYK56
      truncated: true
      entities:
        urls:
          - url: https://t.co/RkZe4QYK56
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5401161627"
    createdAt: 2021-05-29T15:27:58
    author:
      username: thomaseddlem
      about: History Teacher, Freelance Writer, Father, Constitutionalist
      name: Thomas Eddlem
      isPowerContributor: false
      profileUrl: https://disqus.com/by/thomaseddlem/
      url: ""
      location: Taunton. Massachusetts
      id: "61626577"
    isApproved: true
    raw_message: >-
      I'm skeptical of both studies. The one you linked to has a small sample
      size, and I don't like that it reported a coefficient (140 cases/100,000),
      which is small, and doesn't note that there were wide overlapping
      confidence intervals in its conclusions. Really wide. Did you check the
      chart? 


      This study on this page seems anti-mask agenda-driven, and its conclusions in the summary are over-generalized. There probably is not a statistically significant difference between mask-mandate states and non-mask mandate states, but that doesn't mean masks never work. 


      A mandate to wear a mask walking down a city street is not the same as a mandate to wear one when visiting someone in a hospital or a brief visit in some other close-up situation. But both studies tend to treat these as roughly the same. 


      There's clearly a lot more research needed on this. Most of the studies done in 2020 are junk, proven inaccurate by the historical data.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon May 31 21:18:45 +0000 2021
      id: 1399475460988452900
      id_str: "1399475460988452870"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "I'm skeptical of both studies. The one you linked to has‚Ä¶ https://t.co/AsGf2mxbBD
      truncated: true
      entities:
        urls:
          - url: https://t.co/AsGf2mxbBD
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 31 21:18:45 +0000 2021
      id: 1399475461860823000
      id_str: "1399475461860823041"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399475460988452900
      in_reply_to_status_id_str: "1399475460988452870"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 5
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5400794931"
    createdAt: 2021-05-29T05:06:51
    author:
      username: disqus_0bT5QNRHDf
      about: ""
      name: Mike Stevens
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_0bT5QNRHDf/
      url: ""
      location: ""
      id: "68437046"
    isApproved: true
    raw_message: >-
      The study states the mandate didn‚Äôt slow spread.

      But we know that the mandate is irrelevant, it‚Äôs whether it is properly adhered to and whether people are compliant with a range of measures that is important.
    forum: medrxiv
    points: -4
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon May 31 22:51:25 +0000 2021
      id: 1399498783063433200
      id_str: "1399498783063433219"
      text: |-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."

        "The study states the mandate didn‚Äôt slow spread.
        But we‚Ä¶ https://t.co/TwkizeeP4s
      truncated: true
      entities:
        urls:
          - url: https://t.co/TwkizeeP4s
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 31 22:51:26 +0000 2021
      id: 1399498783956910000
      id_str: "1399498783956910080"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399498783063433200
      in_reply_to_status_id_str: "1399498783063433219"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 8
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5400793613"
    createdAt: 2021-05-29T05:03:42
    author:
      username: disqus_0bT5QNRHDf
      about: ""
      name: Mike Stevens
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_0bT5QNRHDf/
      url: ""
      location: ""
      id: "68437046"
    isApproved: true
    raw_message: >-
      Well, your argument would just verify my point...it‚Äôs the wearing of masks
      that cuts Covid transmission, not whether there is some advice in place to
      do so.

      But of course one needs to wear them properly, or they may not work. 


      An suitable analogy might be as follows:

      ‚ÄúInstallation of clean water and sewage facilities does not cut dysentery risk‚Äù

      If one finds that a significant number of the population are refusing to practice basic hygiene and are still defecating in the wells used for drinking, do you think the study conclusion should be ‚ÄúPublic health interventions do not stop the spread of dysentery‚Äù, and for governments to cease to provide tap water and toilets for their citizens?


      PS: The reuse of surgical masks depends upon their contamination. They are used for 4-6 hours continuously in hospital settings. It‚Äôs advised that you wear a new mask if as a member of the public you are taking one off and then need to remask. There is an elements of common sense here... if I am going into say Tesco‚Äôs for a few minutes, then into Boots 5 minutes later, I might for the sake of convenience just put on the mask again, assuming I have kept it clean in the interim. I notice some people ‚Äúwearing their mask‚Äù in open air spaces in towns, usually because they are going from one shop to the next a few doors down. Taking the mask off between those times seems more trouble than it‚Äôs worth, so they leave it on. This week I was dropping in at the petrol station attached to my local Tesco superstore, so I didn‚Äôt bother to take off my mask, drove 300 yds in the car while wearing my mask, then got petrol. No big deal. I didn‚Äôt die from hypoxia, but no doubt some antimasker laughed when they saw me wearing the mask in the car.

      Just use your common sense, I say. There‚Äôs not much of that about these days.
    forum: medrxiv
    points: -7
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Tue Jun 01 03:03:23 +0000 2021
      id: 1399562190080798700
      id_str: "1399562190080798720"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Well, your argument would just verify my point...it‚Äôs th‚Ä¶ https://t.co/K3UxMeN3Px
      truncated: true
      entities:
        urls:
          - url: https://t.co/K3UxMeN3Px
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 01 03:03:23 +0000 2021
      id: 1399562191028686800
      id_str: "1399562191028686853"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU30MFJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU30MFJ
      in_reply_to_status_id: 1399562190080798700
      in_reply_to_status_id_str: "1399562190080798720"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8552957443"
    numReports: 0
    likes: 1
    id: "5402212445"
    createdAt: 2021-05-30T16:14:37
    author:
      username: docj1
      about: ""
      name: wj
      isPowerContributor: false
      profileUrl: https://disqus.com/by/docj1/
      url: ""
      location: ""
      id: "368482963"
    isApproved: true
    raw_message: The amount of misrepresentation of data in this meta-analysis as
      outlined in below comments reaches the level of <i>scientific
      misconduct</i>, given that the Niaee RR was corrected but the associated
      conclusion was not. I have faith that peer reviewers will reject based on
      this glaring falsity if the authors do not retract beforehand.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v2
  tweets:
    - created_at: Tue Jun 01 13:16:45 +0000 2021
      id: 1399716549850718200
      id_str: "1399716549850718213"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "The amount of misrepresentation of data in this meta-ana‚Ä¶ https://t.co/0JqyussVTw
      truncated: true
      entities:
        urls:
          - url: https://t.co/0JqyussVTw
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 01 13:16:45 +0000 2021
      id: 1399716550605742000
      id_str: "1399716550605742087"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1399716549850718200
      in_reply_to_status_id_str: "1399716549850718213"
- preprint:
    id: "129733"
    doi: 10.1101/2021.02.17.431604
    first_posted: 2021-02-17
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.02.17.431604v1
    url: https://api.rxivist.org/v1/papers/129733
    title: The IL-10GFP (VeRT-X) mouse strain is not suitable for the detection of
      IL-10 production by granulocytes during lung inflammation
    category: immunology
    abstract: The clear and unequivocal identification of immune effector functions
      is essential to understand immune responses. The cytokine IL-10 is a
      critical immune regulator and was shown, for example, to limit pathology
      during various lung diseases. However, the clear identification of
      IL-10-producing cells is challenging and, therefore, reporter mouse lines
      were developed to facilitate their detection. Several such reporter lines
      utilize GFP, including the IL-10 GFP (VeRT-X) reporter strain studied
      here. In line with previous reports, we found that this IL-10 GFP line
      faithfully reports on the IL-10 production of lymphoid cells. However, we
      show that the IL-10 GFP reporter is not suitable to analyse IL-10
      production of myeloid cells during inflammations. During inflammation, the
      autofluorescence of myeloid cells increased to an extent that entirely
      masked the IL-10-specific GFP-signal. Our data illustrate a general and
      important technical caveat using GFP-reporter lines for the analysis of
      myeloid cells and suggest that previous reports on effector functions of
      myeloid cells using such GFP-based reporters might require re-evaluation.
    authors:
      - name: M√ºge √ñzkan
        orcid: http://orcid.org/0000-0002-3927-1882
      - name: Yusuf  Cem Eskiocak
        orcid: null
      - name: Gerhard Wingender
        orcid: http://orcid.org/0000-0002-7115-298X
  comment:
    dislikes: 0
    thread: "8402814496"
    numReports: 0
    likes: 0
    id: "5403029660"
    createdAt: 2021-05-31T11:32:09
    author:
      username: gerhardwingender
      about: ""
      name: Gerhard WINGENDER
      isPowerContributor: false
      profileUrl: https://disqus.com/by/gerhardwingender/
      url: ""
      location: ""
      id: "370218532"
    isApproved: true
    raw_message: "This study has been published:
      https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0247895"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.02.17.431604v1
  tweets:
    - created_at: Tue Jun 01 14:50:52 +0000 2021
      id: 1399740233244098600
      id_str: "1399740233244098562"
      text: |-
        üí¨ bioRxiv comment on "The IL-10GFP (VeRT-X) mouse st..."

        "This study has been published: "

        https://t.co/SbhjbOgAGN
      truncated: false
      entities:
        urls:
          - url: https://t.co/SbhjbOgAGN
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 01 14:50:52 +0000 2021
      id: 1399740233952989200
      id_str: "1399740233952989184"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/H4MbuXXBbD
      truncated: false
      entities:
        urls:
          - url: https://t.co/H4MbuXXBbD
      in_reply_to_status_id: 1399740233244098600
      in_reply_to_status_id_str: "1399740233244098562"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5403947977"
    createdAt: 2021-06-01T04:43:20
    author:
      username: ARMSTROB
      about: ""
      name: ARMSTROB
      isPowerContributor: false
      profileUrl: https://disqus.com/by/ARMSTROB/
      url: ""
      location: ""
      id: "21380356"
    isApproved: true
    raw_message: I agree.  Also, why don't the surges disappear or get smaller as
      time goes by if the masks are working?
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Tue Jun 01 18:08:21 +0000 2021
      id: 1399789931816538000
      id_str: "1399789931816538114"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "I agree.  Also, why don't the surges disappear or get sm‚Ä¶ https://t.co/WzZMuLuVA4
      truncated: true
      entities:
        urls:
          - url: https://t.co/WzZMuLuVA4
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 01 18:08:21 +0000 2021
      id: 1399789932613341200
      id_str: "1399789932613341191"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399789931816538000
      in_reply_to_status_id_str: "1399789931816538114"
- preprint:
    id: 86387
    metric: 34
    title: "ANANSE: An enhancer network-based computational approach for predicting
      key transcription factors in cell fate determination"
    url: https://api.rxivist.org/v1/papers/86387
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.06.05.135798v2
    doi: 10.1101/2020.06.05.135798
    category: systems-biology
    first_posted: 2020-06-06
    abstract: Proper cell fate determination is largely orchestrated by complex gene
      regulatory networks centered around transcription factors. However,
      experimental elucidation of key transcription factors that drive cellular
      identity is currently often intractable. Here, we present ANANSE (ANalysis
      Algorithm for Networks Specified by Enhancers), a network-based method
      that exploits enhancerencoded regulatory information to identify the key
      transcription factors in cell fate determination. As cell type-specific
      transcription factors predominantly bind to enhancers, we use regulatory
      networks based on enhancer properties to prioritize transcription factors.
      First, we predict genome-wide binding profiles of transcription factors in
      various cell types using enhancer activity and transcription factor
      binding motifs. Subsequently, applying these inferred binding profiles, we
      construct cell type-specific gene regulatory networks, and then predict
      key transcription factors controlling cell fate conversions using
      differential gene networks between cell types. This method outperforms
      existing approaches in correctly predicting major transcription factors
      previously identified to be sufficient for trans-differentiation. Finally,
      we apply ANANSE to define an atlas of key transcription factors in 18
      normal human tissues. In conclusion, we present a ready-to-implement
      computational tool for efficient prediction of transcription factors in
      cell fate determination and to study transcription factor-mediated
      regulatory mechanisms. ANANSE is freely available at
      https://github.com/vanheeringen-lab/ANANSE.
    authors:
      - name: Quan Xu
      - name: Georgios Georgiou
      - name: Siebren Froelich
      - name: Maarten van der Sande
      - name: Gert Jan C Veenstra
      - name: Huiqing Zhou
      - name: Simon J. van Heeringen
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Tue Jun 01 21:28:42 +0000 2021
      id: 1399840351549075500
      id_str: "1399840351549075462"
      text: >-
        üî• bioRxiv Systems-biology preprint by Q. Xu et al:


        "ANANSE: An enhancer network-based computational approach for p‚Ä¶ https://t.co/ThM8jx6qKz
      truncated: true
      entities:
        urls:
          - url: https://t.co/ThM8jx6qKz
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 0
    id: "5404468009"
    createdAt: 2021-06-01T16:02:48
    author:
      username: justinlovern
      about: ""
      name: Justin Lovern
      isPowerContributor: false
      profileUrl: https://disqus.com/by/justinlovern/
      url: ""
      location: ""
      id: "284782035"
    isApproved: true
    raw_message: The burden of proof is on the entity wanting to enforce mask
      mandates that mask mandates actually work. There is no burden to prove
      that masks don't work. This study (and many others) set out to determine
      if mask mandates work (reduce transmission rates) and was not able to
      establish any correlation between mandates and reduced transmission rates.
      Hence, the burden of proof is still on the maskers to prove that masks
      work - not on anti-maskers to prove they don't.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Tue Jun 01 21:31:58 +0000 2021
      id: 1399841174060515300
      id_str: "1399841174060515328"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "The burden of proof is on the entity wanting to enforce‚Ä¶ https://t.co/eC8lF2nYft
      truncated: true
      entities:
        urls:
          - url: https://t.co/eC8lF2nYft
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 01 21:31:58 +0000 2021
      id: 1399841175029309400
      id_str: "1399841175029309454"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399841174060515300
      in_reply_to_status_id_str: "1399841174060515328"
- preprint:
    id: "141492"
    doi: 10.1101/2021.05.12.21256975
    first_posted: 2021-05-13
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.12.21256975v1
    url: https://api.rxivist.org/v1/papers/141492
    title: Inferring the COVID-19 IFR with a simple Bayesian evidence synthesis of
      seroprevalence study data and imprecise mortality data
    category: epidemiology
    abstract: Estimating the COVID-19 infection fatality rate (IFR) has proven to be
      particularly challenging --and rather controversial-- due to the fact that
      both the data on deaths and the data on the number of individuals infected
      are subject to many different biases. We consider a Bayesian evidence
      synthesis approach which, while simple enough for researchers to
      understand and use, accounts for many important sources of uncertainty
      inherent in both the seroprevalence and mortality data. We estimate the
      COVID-19 IFR to be 0.40% (95% credible interval of (0.20%, 0.63%)) for a
      typical population where the proportion of those aged over 65 years old is
      9% and where the GDP (at purchasing-power parity (ppp)) per capita is
      $17.8K (the approximate worldwide values). Our results suggest that, as
      one might expect, lower IFRs are associated with younger and with
      wealthier populations.
    authors:
      - name: Harlan Campbell
        orcid: http://orcid.org/0000-0002-0959-1594
      - name: Paul Gustafson
        orcid: http://orcid.org/0000-0002-2375-5006
  comment:
    dislikes: 0
    thread: "8519217784"
    numReports: 0
    likes: 0
    id: "5404391858"
    createdAt: 2021-06-01T14:57:57
    author:
      username: disqus_Tt0mr386bH
      about: ""
      name: happydog
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_Tt0mr386bH/
      url: ""
      location: ""
      id: "59198730"
    isApproved: true
    raw_message: In version 2 of the manuscript, the Brazil data is not included.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.12.21256975v1
  tweets:
    - created_at: Tue Jun 01 22:58:39 +0000 2021
      id: 1399862988513837000
      id_str: "1399862988513837059"
      text: >-
        üí¨ medRxiv comment on "Inferring the COVID-19 IFR wit..."


        "In version 2 of the manuscript, the Brazil data is not i‚Ä¶ https://t.co/rCfqbxRaOo
      truncated: true
      entities:
        urls:
          - url: https://t.co/rCfqbxRaOo
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 01 22:58:39 +0000 2021
      id: 1399862989495308300
      id_str: "1399862989495308290"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/QUuq9FzzpV
      truncated: false
      entities:
        urls:
          - url: https://t.co/QUuq9FzzpV
      in_reply_to_status_id: 1399862988513837000
      in_reply_to_status_id_str: "1399862988513837059"
- preprint:
    id: "134592"
    doi: 10.1101/2021.03.22.436484
    first_posted: 2021-03-23
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.03.22.436484v1
    url: https://api.rxivist.org/v1/papers/134592
    title: "scTenifoldKnk: a machine learning workflow performing virtual knockout
      experiments on single-cell gene regulatory networks"
    category: bioinformatics
    abstract: Gene knockout (KO) experiments are a proven approach for studying gene
      function. A typical KO experiment usually involves the phenotypic
      characterization of KO organisms. The recent advent of single-cell
      technology has greatly boosted the resolution of cellular phenotyping,
      providing unprecedented insights into cell-type-specific gene function.
      However, the use of single-cell technology in large-scale, systematic KO
      experiments is prohibitive due to the vast resources required. Here we
      present scTenifoldKnk, a machine learning workflow that performs virtual
      KO experiments using single-cell RNA sequencing (scRNA-seq) data.
      scTenifoldKnk first uses data from wild-type (WT) samples to construct a
      single-cell gene regulatory network (scGRN). Then, a gene is knocked out
      from the constructed scGRN by setting weights of the gene's outward edges
      to zeros. ScTenifoldKnk then compares this "pseudo-KO" scGRN with the
      original scGRN to identify differentially regulated (DR) genes. These DR
      genes, also called virtual-KO perturbed genes, are used to assess the
      impact of the gene KO and reveal the gene's function in analyzed cells.
      Using existing data sets, we demonstrate that the scTenifoldKnk analysis
      recapitulates the main findings of three real-animal KO experiments and
      confirms the functions of genes underlying three Mendelian diseases. We
      show the power of scTenifoldKnk as a predictive method to successfully
      predict the outcomes of two KO experiments that involve intestinal
      enterocytes in Ahr-/- mice and pancreatic islet cells in Malat1-/- mice,
      respectively. Finally, we demonstrate the use of scTenifoldKnk to perform
      systematic KO analyses, in which a large number of genes are virtually
      deleted, allowing gene functions to be revealed in a cell type-specific
      manner.
    authors:
      - name: Daniel Osorio
        orcid: http://orcid.org/0000-0003-4424-8422
      - name: Yan Zhong
        orcid: null
      - name: Guanxun Li
        orcid: null
      - name: Qian Xu
        orcid: http://orcid.org/0000-0002-9267-906X
      - name: Andrew E. Hillhouse
        orcid: null
      - name: Jingshu Chen
        orcid: null
      - name: Laurie A. Davidson
        orcid: null
      - name: Yanan Tian
        orcid: null
      - name: Robert S Chapkin
        orcid: null
      - name: Jianhua Z Huang
        orcid: null
      - name: James J. Cai
        orcid: http://orcid.org/0000-0002-8081-6725
  comment:
    dislikes: 0
    thread: "8449125883"
    numReports: 0
    likes: 0
    id: "5404831186"
    createdAt: 2021-06-01T21:20:00
    author:
      username: disqus_DD69BrY3Kn
      about: ""
      name: disqus_DD69BrY3Kn
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_DD69BrY3Kn/
      url: ""
      location: ""
      id: "370292693"
    isApproved: true
    raw_message: >-
      Dear Samuel,


      Thank you very much for your interest in our work, as well as for your thorough review and comments. We will try our best to solve your questions below:


      1.	We agree with your point of view about the effect of a gene knockout on cellular homeostasis. In fact, in metabolic models where this kind of analysis is usually done using optimization approaches, the propagation effect of the gene knockout across several parts of the metabolism is evident. Nevertheless, Santolini and Barabasi (DOI: 10.1073/pnas.1720589115) compared the performance of the topology to predict the perturbation patterns caused by a gene knockout against the result of the optimization methods. They found a good overlap in the prediction, and based on those findings; we decided to use the topological approach. We did not try multi-knockout experiments since, as you mention single-cell RNA-seq characterization for those experiments is not yet available. However, we did try a double knockout and found a good overlap with the findings reported by the paper describing the dataset (Figure 3, Panel C). We yet do not have any other evidence to support or reject your hypothesis about the decrease of the precision of the predictions with an increasing number of knocked-out genes at the same time. 


      2.	Since the regulatory link between two genes is assessed using principal components regression (PCR), the result after evaluating all the associations is a fully connected asymmetric weighted network. You may consider PCR as a partial correlation analysis (pcorr). When C1 and C2 are the same, pcorr(A,B|C1) equals pcorr(B,A|C2). However, in PCR, C1 is not equal to C2‚ÄîC1 is all genes excluding B, while C2 is all genes excluding A. This asymmetry makes the result of PCR an asymmetric matrix. To further set the directionality of the resultant matrix, first, we removed the weaker link between two genes, and then, we filtered the links below the 95th percentile to reduce the false-positive rate. We provided evidence supporting that the true directionality of the regulation is favored by the regression method with a larger weight value (Figure S1, Panel C) when the directionality is tested using the transcription factors and their target genes reported by the ENCODE database. We also provided evidence of the accuracy of principal components regression to detect the association between genes in single-cell RNA-seq without imputation compared with other methods during the benchmark of scTenifoldNet (Figure 2, Panel A in DOI:10.1016/j.patter.2020.100139).


      3.	We are afraid we have to disagree with you on this. We did our best to perform an unbiased comparison of the gene knockout phenotypic effect reported by the authors of the datasets and the results provided by scTenifoldKnk. In fact, the characterizations made for the authors are not only based on data-driven approaches using the generated single-cell RNA-seq datasets but also include other experimental techniques. We used several gene-set databases to evaluate the extent of the overlap that we can predict, as it is recognized that a single gene or pathway often cannot fully explain a particular cellular state. Instead, biological processes are better characterized by gene regulatory networks, whose structures are altered as the phenotype changes (DOI: 10.1038/s41540-018-0052-5). We thought about reporting the result of scTenifoldNet and compare them with the results predicted by scTenifoldKnk. Still, since we are the developers of both methods, we decided to better compare our findings with the results reported by the original authors of the datasets. Please note that the original authors did not report all the changes or perturbed gene sets found after the gene knockout. We believe your experimental design is correct and feasible. However, also have in mind that not all the regulatory changes induced by a gene are detectable as changes in the expression level since a given gene may be under the regulation of more of one gene at the same time.


      4.	To evaluate the stability and robustness of the results provided by scTenifoldKnk, we used two approaches. First, we compared the results obtained by running independently scTenifoldKnk over two biological replicates in the Mecp2 example (Figure S2, Panel D) and found that the overlapping results agree with what is known about the Rett Syndrome pathology that is caused by the malfunctioning of the Mecp2 gene. Second, we resampled the cells used as input for scTenifoldKnk 10 times and compared the rank of the perturbed genes in the predicted in-silico knockout for each one of them. Since single-cell RNA-seq allows to uncover hidden subpopulations of cells with specialized phenotypes, and for that reason, by random subsampling the cells, we expect each of the constructed gene regulatory networks to be unique and provide a unique result. Because the approach is the same and the expected biological effect is the same (randomly sampling cells), we only performed the analysis over the Trem2 dataset. We expect the results to be similar in the other datasets.  


      Please let us know if you have any other questions or concerns,


      Best wishes,


      Daniel and James
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.03.22.436484v1
  tweets:
    - created_at: Wed Jun 02 03:02:59 +0000 2021
      id: 1399924475894902800
      id_str: "1399924475894902785"
      text: |-
        üí¨ bioRxiv comment on "scTenifoldKnk: a machine learn..."

        "Dear Samuel,

        Thank you very much for your interest in o‚Ä¶ https://t.co/q9Dl9HfXxy
      truncated: true
      entities:
        urls:
          - url: https://t.co/q9Dl9HfXxy
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 02 03:02:59 +0000 2021
      id: 1399924476603736000
      id_str: "1399924476603736064"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/vhC6P5scn7
      truncated: false
      entities:
        urls:
          - url: https://t.co/vhC6P5scn7
      in_reply_to_status_id: 1399924475894902800
      in_reply_to_status_id_str: "1399924475894902785"
- preprint:
    id: "144122"
    doi: 10.1101/2021.05.31.446345
    first_posted: 2021-05-31
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.31.446345v1
    url: https://api.rxivist.org/v1/papers/144122
    title: Balanced mitochondrial and cytosolic translatomes underlie the biogenesis
      of human respiratory complexes
    category: cell-biology
    abstract: Oxidative phosphorylation (OXPHOS) complexes consist of nuclear and
      mitochondrial DNA- encoded subunits. Their biogenesis requires
      cross-compartment gene regulation to mitigate the accumulation of
      disproportionate subunits. To determine how human cells coordinate
      mitochondrial and nuclear gene expression processes, we established an
      optimized ribosome profiling approach tailored for the unique features of
      the human mitoribosome. Analysis of ribosome footprints in five cell types
      revealed that average mitochondrial synthesis rates corresponded precisely
      to cytosolic rates across OXPHOS complexes. Balanced mitochondrial and
      cytosolic synthesis did not rely on rapid feedback between the two
      translation systems. Rather, LRPPRC, a gene associated with Leigh's
      syndrome, is required for the reciprocal translatomes and maintains
      cellular proteostasis. Based on our findings, we propose that human
      mitonuclear balance is enabled by matching OXPHOS subunit synthesis rates
      across cellular compartments, which may represent a vulnerability for
      cellular proteostasis.
    authors:
      - name: Iliana C Soto
        orcid: null
      - name: Mary Couvillion
        orcid: null
      - name: Erik McShane
        orcid: null
      - name: Katja G Hansen
        orcid: http://orcid.org/0000-0002-9006-984X
      - name: J. Conor Moran
        orcid: null
      - name: Antoni Barrientos
        orcid: http://orcid.org/0000-0001-9018-3231
      - name: L. Stirling Churchman
        orcid: http://orcid.org/0000-0003-3888-2574
  comment:
    dislikes: 0
    thread: "8565056594"
    numReports: 0
    likes: 0
    id: "5404696578"
    createdAt: 2021-06-01T19:17:24
    author:
      username: eleonoraleucci
      about: ""
      name: Eleonora Leucci
      isPowerContributor: false
      profileUrl: https://disqus.com/by/eleonoraleucci/
      url: ""
      location: ""
      id: "352095537"
    isApproved: true
    raw_message: >-
      Coordination between the two translational machineries and its role in
      proteostasis was already shown in mouse and human cells and their
      desynchronisation for therapeutic purposes proposed. Here a few readings
      in case you want to acknowledge the authors...

      -https://www.cell.com/cell-reports/pdf/S2211-1247(17)31875-2.pdf

      -Nature. 2016 Mar 24;531(7595):518-22. doi: 10.1038/nature17161.

      -Nat Struct Mol Biol. 2018 Nov;25(11):1035-1046. doi: 10.1038/s41594-018-0143-4. Epub 2018 Oct 29.

      -bioRxiv 2020.06.26.173492; doi: https://doi.org/10.1101/2020.06.26.173492
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.05.31.446345v1
  tweets:
    - created_at: Wed Jun 02 13:21:44 +0000 2021
      id: 1400080193046282200
      id_str: "1400080193046282241"
      text: >-
        üí¨ bioRxiv comment on "Balanced mitochondrial and cyt..."


        "Coordination between the two translational machineries a‚Ä¶ https://t.co/mInpd1iq3P
      truncated: true
      entities:
        urls:
          - url: https://t.co/mInpd1iq3P
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 02 13:21:45 +0000 2021
      id: 1400080194090659800
      id_str: "1400080194090659841"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/1MSxR76y5s
      truncated: false
      entities:
        urls:
          - url: https://t.co/1MSxR76y5s
      in_reply_to_status_id: 1400080193046282200
      in_reply_to_status_id_str: "1400080193046282241"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5404243620"
    createdAt: 2021-06-01T12:34:57
    author:
      username: The_European1000
      about: ""
      name: The_European1000
      isPowerContributor: false
      profileUrl: https://disqus.com/by/The_European1000/
      url: ""
      location: ""
      id: "221279842"
    isApproved: true
    raw_message: >-
      This is not good information, and the research is not well done. 


      They used a two-tailed t test with Holm Sidak correction, as if that is suffient to compensate for the complex interplay of factors that produce the same result (infection/non infection). Hell, they even made a simple linear regression to add insult to injury. 


      Essentially, to explain it more simply, using those tests rests on the assumption that there are 2 categories that correlate to other to categories perfectly- mask/not mask and infected/not infected. 


      This is not the case. Masks wearers that social distance will have lesses infection rates than mask wearers who do not. Ventialtion of enclosed areas is also an issue. 


      These "researchers" did not account for the confounding variables that affect infection rates- everything from other measures to testing rate differences among states. 


      Overall, there are many flaws with this research. Not good.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Wed Jun 02 15:03:15 +0000 2021
      id: 1400105740099068000
      id_str: "1400105740099067913"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "This is not good information, and the research is not we‚Ä¶ https://t.co/L1Ep58NWej
      truncated: true
      entities:
        urls:
          - url: https://t.co/L1Ep58NWej
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 02 15:03:15 +0000 2021
      id: 1400105740858187800
      id_str: "1400105740858187776"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1400105740099068000
      in_reply_to_status_id_str: "1400105740099067913"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5404010397"
    createdAt: 2021-06-01T06:55:31
    author:
      username: disqus_JpMFCTX7AP
      about: ""
      name: Darren Zhao
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_JpMFCTX7AP/
      url: ""
      location: ""
      id: "370259886"
    isApproved: true
    raw_message: >-
      I think you do have a couple fair points and I myself am a bit critical of
      the paper and agree that concluding masks wearing is not helpful is rash
      on this paper alone. However, Some of the factors that you mention should
      be held constant are, practically, infeasible in my opinion. How do you
      measure amount of enforcement objectively and their effect on mask
      wearing?

      Mask use potentially causing breaches of social distancing, while maybe true, are out of scope of the paper. Even under the assumption that that's true, that event would technically be encouraged under mandated states due to increased mask wearing and I think is fair to say is an unintended effect of mask wearing mandates.


      More research definitely does need to be done on this because, as you point out, a lot of factors could be compounding to mitigate any effectiveness mandates by themselves would bring but discrediting the paper because they do not explore all possible factors is not helpful either. If all papers were to explore all possible factors every time, publications would be few and far between.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Wed Jun 02 18:20:57 +0000 2021
      id: 1400155491410624500
      id_str: "1400155491410624513"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "I think you do have a couple fair points and I myself am‚Ä¶ https://t.co/388hTB7jGy
      truncated: true
      entities:
        urls:
          - url: https://t.co/388hTB7jGy
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 02 18:20:57 +0000 2021
      id: 1400155492165562400
      id_str: "1400155492165562377"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1400155491410624500
      in_reply_to_status_id_str: "1400155491410624513"
- preprint:
    id: 143783
    metric: 236
    title: The SARS-CoV-2 variants associated with infections in India, B.1.617,
      show enhanced spike cleavage by furin
    url: https://api.rxivist.org/v1/papers/143783
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.28.446163v1
    doi: 10.1101/2021.05.28.446163
    category: microbiology
    first_posted: 2021-05-28
    abstract: The SARS-CoV-2 spike (S) glycoprotein contains a suboptimal furin
      cleavage site at the S1/S2 junction with the sequence 681PRRAR/S686. This
      cleavage site is required for efficient airway replication, transmission,
      and pathogenicity of the virus. The B.1.617 lineage has recently emerged
      in India, coinciding with substantial disease burden across the country.
      Early evidence suggests that B.1.617.2 (a sublineage of B.1.617) is more
      highly transmissible than contemporary lineages. B.1.617 and its
      sublineages contain a constellation of S mutations including the
      substitution P681R predicted to further optimise this furin cleavage site.
      In this short report we provide experimental evidence that virus of the
      B.1.617 lineage has enhanced S cleavage, that enhanced processing of an
      expressed B.1.617 S protein in cells is due to P681R, and that this
      mutation enables more efficient cleavage of a peptide mimetic of the
      B.1.617 S1/S2 cleavage site by recombinant furin. Together, these data
      demonstrate viruses in this emerging lineage have enhanced S cleavage by
      furin which we hypothesise could be enhancing transmissibility and
      pathogenicity.
    authors:
      - name: Thomas P. Peacock
      - name: Carol M. Sheppard
      - name: Jonathan C. Brown
      - name: Niluka Goonawardane
      - name: Jie Zhou
      - name: Max Whiteley
      - name: PHE Virology Consortium
      - name: Thushan de Silva
      - name: Wendy S. Barclay
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Wed Jun 02 21:25:48 +0000 2021
      id: 1400202011233165300
      id_str: "1400202011233165320"
      text: >-
        üî• bioRxiv Microbiology preprint by T. P. Peacock et al:


        "The SARS-CoV-2 variants associated with infections in Ind‚Ä¶ https://t.co/0zYRW0mqjm
      truncated: true
      entities:
        urls:
          - url: https://t.co/0zYRW0mqjm
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5404967191"
    createdAt: 2021-06-01T23:55:02
    author:
      username: justinlovern
      about: ""
      name: Justin Lovern
      isPowerContributor: false
      profileUrl: https://disqus.com/by/justinlovern/
      url: ""
      location: ""
      id: "284782035"
    isApproved: true
    raw_message: Could your refer to any good research purporting to show that
      masking reduces transmission rates? The burden of proof is on the maskers
      if they want to impose masking, not on those who don't want to wear masks
      to prove they don't work.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Wed Jun 02 21:28:30 +0000 2021
      id: 1400202688906866700
      id_str: "1400202688906866690"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Could your refer to any good research purporting to show‚Ä¶ https://t.co/nMhNTVx0r1
      truncated: true
      entities:
        urls:
          - url: https://t.co/nMhNTVx0r1
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 02 21:28:30 +0000 2021
      id: 1400202689653489700
      id_str: "1400202689653489671"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1400202688906866700
      in_reply_to_status_id_str: "1400202688906866690"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5405653767"
    createdAt: 2021-06-02T15:17:27
    author:
      username: miglet32
      about: ""
      name: Miglet32
      isPowerContributor: false
      profileUrl: https://disqus.com/by/miglet32/
      url: ""
      location: Chicago, IL
      id: "95808427"
    isApproved: true
    raw_message: Something that could be accounted for by other measures such as
      distancing or increased handwashing protocols.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Wed Jun 02 22:54:55 +0000 2021
      id: 1400224438780633000
      id_str: "1400224438780633093"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Something that could be accounted for by other measures‚Ä¶ https://t.co/VmwRptsvfY
      truncated: true
      entities:
        urls:
          - url: https://t.co/VmwRptsvfY
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 02 22:54:55 +0000 2021
      id: 1400224439539802000
      id_str: "1400224439539802112"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1400224438780633000
      in_reply_to_status_id_str: "1400224438780633093"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5405929190"
    createdAt: 2021-06-02T18:51:12
    author:
      username: georgerapko
      about: ""
      name: George Rapko
      isPowerContributor: false
      profileUrl: https://disqus.com/by/georgerapko/
      url: ""
      location: ""
      id: "51917517"
    isApproved: true
    raw_message: What?  Sidak adjusts alpha to control type 1 error for multiple
      comparisons.  It has nothing to do with confounding factors. In their
      test, they tested early mandates vs late mandates and early mandates
      versus no mandates and therefore needed to use a correction.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Thu Jun 03 02:38:29 +0000 2021
      id: 1400280698792067000
      id_str: "1400280698792067075"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "What?  Sidak adjusts alpha to control type 1 error for m‚Ä¶ https://t.co/fGuT7uQxjk
      truncated: true
      entities:
        urls:
          - url: https://t.co/fGuT7uQxjk
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 03 02:38:29 +0000 2021
      id: 1400280699626741800
      id_str: "1400280699626741766"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1400280698792067000
      in_reply_to_status_id_str: "1400280698792067075"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 1
    id: "5405282971"
    createdAt: 2021-06-02T08:09:56
    author:
      username: disqus_z3JbLWlo5D
      about: ""
      name: Le Bon
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_z3JbLWlo5D/
      url: ""
      location: ""
      id: "54104695"
    isApproved: true
    raw_message: >-
      The idea of looking at patients who had at least a substantial cumulated
      dose is great, but there is an important immortal time bias, since the
      patients can't die the first 10 days in the HCQ group, as seen on the
      Kaplan-Me√Øer


      I suggest to calculate again the results with excluding the first 10 days death in the control group.


      Due to the small group size, you will probably loose significance, but it still will be usefull for pooled analysis.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Thu Jun 03 12:57:57 +0000 2021
      id: 1400436595317166000
      id_str: "1400436595317166081"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "The idea of looking at patients who had at least a subst‚Ä¶ https://t.co/ypthFQaWXC
      truncated: true
      entities:
        urls:
          - url: https://t.co/ypthFQaWXC
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 03 12:57:58 +0000 2021
      id: 1400436596256743400
      id_str: "1400436596256743424"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1400436595317166000
      in_reply_to_status_id_str: "1400436595317166081"
- preprint:
    id: "144165"
    doi: 10.1101/2021.05.31.21258081
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.31.21258081v1
    url: https://api.rxivist.org/v1/papers/144165
    title: Favorable outcome on viral load and culture viability using Ivermectin in
      early treatment of non-hospitalized patients with mild COVID-19, A
      double-blind, randomized placebo-controlled trial.
    category: infectious-diseases
    abstract: "Background: Ivermectin, an antiparasitic agent, also has antiviral
      properties. Our aim was to assess whether ivermectin can shorten the viral
      shedding in patients at an early stage of COVID19 infection. Methods: The
      double blinded trial compared patients receiving ivermectin 0.2 mg/kg for
      3 days vs. placebo in non-hospitalized COVID19 patients. RT-PCR from a
      nasopharyngeal swab was obtained at recruitment and then every two days.
      Primary endpoint was reduction of viral-load on the 6th day (third day
      after termination of treatment) as reflected by Ct level>30
      (non-infectious level). The primary outcome was supported by determination
      of viral culture viability. Results: Eighty nine patients were eligible
      (47 in ivermectin and 42 in placebo arm). Their median age was 35 years.
      Females accounted for 21.6%, and 16.8% were asymptomatic at recruitment.
      Median time from symptom onset was 4 days. There were no statistical
      differences in these parameters between the two groups. On day 6, 34 out
      of 47 (72%) patients in the ivermectin arm reached the endpoint, compared
      to 21/ 42 (50%) in the placebo arm (OR 2.62; 95% CI: 1.09 to 6.31). In a
      multivariable logistic regression model, the odds of a negative test at
      day 6 was 2.62 time higher in the ivermectin group (95% CI: 1.06 to 6.45).
      Cultures at days 2 to 6 were positive in 3/23 (13.0%) of ivermectin
      samples vs. 14/29 (48.2%) in the placebo group (p=0.008). Conclusions:
      There were significantly lower viral loads and viable cultures in the
      ivermectin group, which could lead to shortening isolation time in these
      patients."
    authors:
      - name: Asaf Biber
        orcid: http://orcid.org/0000-0001-6007-0383
      - name: Michal Mandelboim
        orcid: http://orcid.org/0000-0002-5997-7241
      - name: Geva Harmelin
        orcid: null
      - name: Dana Lev
        orcid: null
      - name: Li Ram
        orcid: null
      - name: Amit Shaham
        orcid: null
      - name: Ital Nemet
        orcid: null
      - name: Limor Kliker
        orcid: null
      - name: Oran Erster
        orcid: http://orcid.org/0000-0003-4839-8997
      - name: Eli Schwartz
        orcid: null
  comment:
    dislikes: 0
    thread: "8565279083"
    numReports: 0
    likes: 1
    id: "5404874525"
    createdAt: 2021-06-01T22:05:39
    author:
      username: st_publichealth
      about: ""
      name: st_publichealth
      isPowerContributor: false
      profileUrl: https://disqus.com/by/st_publichealth/
      url: ""
      location: ""
      id: "370294261"
    isApproved: true
    raw_message: >-
      The article is interesting. A few questions to the authors. Did you
      pre-specify the definition of negative PCR?

      Did you compare changes in viral loads from the baseline? Since the median viral load was higher in the placebo arm, this might have affected the likelihood of viral clearance at day 6 and it should be accounted for.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.31.21258081v1
  tweets:
    - created_at: Thu Jun 03 14:40:25 +0000 2021
      id: 1400462378844627000
      id_str: "1400462378844626951"
      text: >-
        üí¨ medRxiv comment on "Favorable outcome on viral loa..."


        "The article is interesting. A few questions to the autho‚Ä¶ https://t.co/cGNZ7rtpoO
      truncated: true
      entities:
        urls:
          - url: https://t.co/cGNZ7rtpoO
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 03 14:40:25 +0000 2021
      id: 1400462379960336400
      id_str: "1400462379960336399"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/fIgXlfChaW
      truncated: false
      entities:
        urls:
          - url: https://t.co/fIgXlfChaW
      in_reply_to_status_id: 1400462378844627000
      in_reply_to_status_id_str: "1400462378844626951"
- preprint:
    id: "144165"
    doi: 10.1101/2021.05.31.21258081
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.31.21258081v1
    url: https://api.rxivist.org/v1/papers/144165
    title: Favorable outcome on viral load and culture viability using Ivermectin in
      early treatment of non-hospitalized patients with mild COVID-19, A
      double-blind, randomized placebo-controlled trial.
    category: infectious-diseases
    abstract: "Background: Ivermectin, an antiparasitic agent, also has antiviral
      properties. Our aim was to assess whether ivermectin can shorten the viral
      shedding in patients at an early stage of COVID19 infection. Methods: The
      double blinded trial compared patients receiving ivermectin 0.2 mg/kg for
      3 days vs. placebo in non-hospitalized COVID19 patients. RT-PCR from a
      nasopharyngeal swab was obtained at recruitment and then every two days.
      Primary endpoint was reduction of viral-load on the 6th day (third day
      after termination of treatment) as reflected by Ct level>30
      (non-infectious level). The primary outcome was supported by determination
      of viral culture viability. Results: Eighty nine patients were eligible
      (47 in ivermectin and 42 in placebo arm). Their median age was 35 years.
      Females accounted for 21.6%, and 16.8% were asymptomatic at recruitment.
      Median time from symptom onset was 4 days. There were no statistical
      differences in these parameters between the two groups. On day 6, 34 out
      of 47 (72%) patients in the ivermectin arm reached the endpoint, compared
      to 21/ 42 (50%) in the placebo arm (OR 2.62; 95% CI: 1.09 to 6.31). In a
      multivariable logistic regression model, the odds of a negative test at
      day 6 was 2.62 time higher in the ivermectin group (95% CI: 1.06 to 6.45).
      Cultures at days 2 to 6 were positive in 3/23 (13.0%) of ivermectin
      samples vs. 14/29 (48.2%) in the placebo group (p=0.008). Conclusions:
      There were significantly lower viral loads and viable cultures in the
      ivermectin group, which could lead to shortening isolation time in these
      patients."
    authors:
      - name: Asaf Biber
        orcid: http://orcid.org/0000-0001-6007-0383
      - name: Michal Mandelboim
        orcid: http://orcid.org/0000-0002-5997-7241
      - name: Geva Harmelin
        orcid: null
      - name: Dana Lev
        orcid: null
      - name: Li Ram
        orcid: null
      - name: Amit Shaham
        orcid: null
      - name: Ital Nemet
        orcid: null
      - name: Limor Kliker
        orcid: null
      - name: Oran Erster
        orcid: http://orcid.org/0000-0003-4839-8997
      - name: Eli Schwartz
        orcid: null
  comment:
    dislikes: 1
    thread: "8565279083"
    numReports: 0
    likes: 1
    id: "5404617686"
    createdAt: 2021-06-01T18:07:54
    author:
      username: japhetk
      about: ""
      name: japhetk
      isPowerContributor: false
      profileUrl: https://disqus.com/by/japhetk/
      url: ""
      location: ""
      id: "346900262"
    isApproved: true
    raw_message: >-
      This research is problematic. 

      First, this clinical trial's primary outcome measures were as attached below. And authors did not mention 2 out of 3 primary outcome measures. These are not good omissions apparently. 


      Second even the primary outcome measure they used was not specified before the study. Authors used ct cut value of 30, which was arbitrary. Authors explain why they did not use 40, but they must have used 40 if that leads to the good results. And that is not a clinical trial. 


      They did not correct for multiple comparisons across three primary endpoints, either, which they should have done as there are three primary endpoints. 




      Second as the figure 2 and the table shows the ct values of two groups before the intervention are close to statistically significant differences (p = 0.10).

      And as the figure 2 shows this group difference did not show even a hint of change at day 6! The two groups were almost statistically different from the beginning and that did not change visually at day 6 apparently. I can't see any hints of effects of IVM from this study. 




      Lay persons are watching this study, and they say they love IVM and hate vaccine and let's use IVM instead of vaccine based on this study's result. We hope authors do the proper research. They should provide three primary endpoints, correct the preexisting differences, and correct multiple comparisons, and should provide apparent conclusions. 






      Primary Outcome Measures  :
            


      Viral clearance at day 6 [ Time Frame: Outcome will be determined till 6 days post intervention ]



      The primary outcome will be the viral clearance at day 6 in the intervention group compared to placebo.


                  	


      Viral shedding duration [ Time Frame: Outcome will be determined till 14 days post intervention ]



      Secondary outcomes: viral shedding duration (time between first positive PCR to last of two consecutive negative tests)


                  	


      Symptoms clearance time [ Time Frame: Outcome will be determined till 14 days post intervention ]



      Time between drug treatment and symptoms resolution
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.31.21258081v1
  tweets:
    - created_at: Thu Jun 03 17:51:55 +0000 2021
      id: 1400510574094606300
      id_str: "1400510574094606338"
      text: |-
        üí¨ medRxiv comment on "Favorable outcome on viral loa..."

        "This research is problematic. 
        First, this clinical tria‚Ä¶ https://t.co/qgoP8cvgjZ
      truncated: true
      entities:
        urls:
          - url: https://t.co/qgoP8cvgjZ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 03 17:51:55 +0000 2021
      id: 1400510575046692900
      id_str: "1400510575046692867"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/fIgXlfTSzw
      truncated: false
      entities:
        urls:
          - url: https://t.co/fIgXlfTSzw
      in_reply_to_status_id: 1400510574094606300
      in_reply_to_status_id_str: "1400510574094606338"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 2
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5404241223"
    createdAt: 2021-06-01T12:32:06
    author:
      username: The_European1000
      about: ""
      name: The_European1000
      isPowerContributor: false
      profileUrl: https://disqus.com/by/The_European1000/
      url: ""
      location: ""
      id: "221279842"
    isApproved: true
    raw_message: >-
      That is not a good point. 


      Medical personel are more exposed to the virus than the general population. Errors in use of protective equipment will produce greater infections than the equivalent errors in the general population. 


      Also, the use of masks as source control (controlling the spread instead of just preventing infection) has been demonstrated as effective thorlugh research and practice for more than a 100 years.
    forum: medrxiv
    points: -1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Thu Jun 03 19:58:40 +0000 2021
      id: 1400542471789088800
      id_str: "1400542471789088781"
      text: |-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."

        "That is not a good point. 

        Medical personel are more ex‚Ä¶ https://t.co/5kvAV7kF5n
      truncated: true
      entities:
        urls:
          - url: https://t.co/5kvAV7kF5n
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 03 19:58:40 +0000 2021
      id: 1400542472686682000
      id_str: "1400542472686682116"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1400542471789088800
      in_reply_to_status_id_str: "1400542471789088781"
- preprint:
    id: 138498
    metric: 9335
    title: Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural
      infection and mRNA Vaccination
    url: https://api.rxivist.org/v1/papers/138498
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.15.440089v1
    doi: 10.1101/2021.04.15.440089
    category: immunology
    first_posted: 2021-04-19
    abstract: We analyzed data from two ongoing COVID-19 longitudinal serological
      surveys in Orange County, CA., between April 2020 and March 2021. A total
      of 8,476 finger stick blood specimens were collected before and after an
      aggressive mRNA vaccination campaign. IgG levels were determined using a
      multiplex antigen microarray containing 10 SARS-CoV-2 antigens, 4 SARS, 3
      MERS, 12 Common CoV, and 8 Influenza antigens. Twenty-six percent of 3,347
      specimens from unvaccinated Orange County residents in December 2020 were
      SARS-CoV-2 seropositive. The Ab response was predominantly against
      nucleocapsid (NP), full length spike and the spike S2 domain.
      Anti-receptor binding domain (RBD) reactivity was low and there was no
      cross-reactivity against SARS S1 or SARS RBD. An aggressive mRNA
      vaccination campaign at the UCI Medical Center started on December 16,
      2020 and 6,724 healthcare workers were vaccinated within 3 weeks.
      Seroprevalence increased from 13% in December to 79% in January, 93% in
      February and 99% in March. mRNA vaccination induced much higher Ab levels
      especially against the RBD domain and significant cross-reactivity against
      SARS RBD and S1 was also observed. Nucleocapsid protein Abs can be used to
      distinguish individuals in a population of vaccinees to classify those who
      have been previously infected and those who have not, because nucleocapsid
      is not in the vaccine. Previously infected individuals developed higher Ab
      titers to the vaccine than those who have not been previously exposed.
      These results indicate that mRNA vaccination rapidly induces a much
      stronger and broader Ab response than SARS-CoV-2 infection.
    authors:
      - name: Rafael Ramiro de Assis
      - name: Aarti Jain
      - name: Rie Nakajima
      - name: Algis Jasinskas
      - name: Saahir Khan
      - name: Anton Palma
      - name: Daniel M. Parker
      - name: Anthony Chau
      - name: Amanda Leung
      - name: Christina Grabar
      - name: Fjolla Muqolli
      - name: Ghali Khalil
      - name: Jessica Colin Escobar
      - name: Jenny Ventura
      - name: Huw Davies
      - name: Bruce Albala
      - name: Bernadette Boden-Albala
      - name: Sebastian Schubl
      - name: Philip L Felgner
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Thu Jun 03 21:17:13 +0000 2021
      id: 1400562236565950500
      id_str: "1400562236565950469"
      text: >-
        üî• bioRxiv Immunology preprint by R. R. d. Assis et al:


        "Distinct SARS-CoV-2 antibody reactivity patterns elicited‚Ä¶ https://t.co/irMcCVOqLB
      truncated: true
      entities:
        urls:
          - url: https://t.co/irMcCVOqLB
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5403997539"
    createdAt: 2021-06-01T06:28:18
    author:
      username: disqus_JpMFCTX7AP
      about: ""
      name: Darren Zhao
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_JpMFCTX7AP/
      url: ""
      location: ""
      id: "370259886"
    isApproved: true
    raw_message: >-
      I've only attempted to fact check your second source, the Denmark one, and
      your quotes really show your bias here. I could not find the first one cuz
      your reference kinda sucks. I attempted to ctrl f both quotes, and the
      first one "The researchers found no statistically significant difference
      between mask wearers and bare-faced participants." does not exist. 


      The second one while partially true, is cut off from what is actually said. The real quote is:


      "The recommendation to wear surgical masks to supplement other public health measures did not reduce the SARS-CoV-2 infection rate among wearers by more than 50% in a community with modest infection rates, some degree of social distancing, and uncommon general mask use. The data were compatible with lesser degrees of self-protection". 


      Note here where they specify the limitations of their study. Their conclusion is less general than, "does not reduce infection rate", but rather that when everyone else does not where masks, mask wearing does not appear to help. Their study, if you did actually read it, is only relevant to the specific scenario in the quote and by the authors notes while responding to comments ‚Äúthe findings, however, should not be used to conclude that a recommendation for everyone to wear masks in the community would not be effective in reducing SARS-CoV-2 infections, because the trial did not test the role of masks in source control of SARS-CoV-2 infection.‚Äù


      If you are going to cite papers, please read them instead of skimming for anything that you believe.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Thu Jun 03 21:23:06 +0000 2021
      id: 1400563719009046500
      id_str: "1400563719009046529"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "I've only attempted to fact check your second source, th‚Ä¶ https://t.co/Wu09rotThb
      truncated: true
      entities:
        urls:
          - url: https://t.co/Wu09rotThb
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 03 21:23:06 +0000 2021
      id: 1400563720003096600
      id_str: "1400563720003096576"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU30MFJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU30MFJ
      in_reply_to_status_id: 1400563719009046500
      in_reply_to_status_id_str: "1400563719009046529"
- preprint:
    id: "132435"
    doi: 10.1101/2021.03.05.21252998
    first_posted: 2021-03-08
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.03.05.21252998v1
    url: https://api.rxivist.org/v1/papers/132435
    title: COVID-19 mRNA vaccine is not detected in human milk
    category: pediatrics
    abstract: Several countries have recently approved the use of mRNA vaccines
      against COVID-19 under an emergency use authorization. However, no
      pregnant or lactating individuals were included in the Phase 3 clinical
      trials of these vaccines despite belonging to a group at high risk for
      severe complications of COVID-19 infection. We show here that the mRNA
      from anti-COVID vaccines is not detected in human breast milk samples
      collected 4-48 hours post-vaccine. These results strengthen the
      recommendation of ABM and WHO that lactating individuals who receive the
      anti-COVID-19 mRNA-based vaccine should continue to breastfeed their
      infants uninterrupted.
    authors:
      - name: Yarden Golan
        orcid: http://orcid.org/0000-0002-3043-3638
      - name: Mary Prahl
        orcid: null
      - name: Arianna Cassidy
        orcid: null
      - name: Christine Y Lin
        orcid: null
      - name: Nadav Ahituv
        orcid: http://orcid.org/0000-0002-7434-8144
      - name: Valerie J Flaherman
        orcid: null
      - name: Stephanie L. Gaw
        orcid: null
  comment:
    dislikes: 0
    thread: "8428869045"
    numReports: 0
    likes: 1
    id: "5403771013"
    createdAt: 2021-06-01T00:21:43
    author:
      username: patfrank
      about: ""
      name: Pat Frank
      isPowerContributor: false
      profileUrl: https://disqus.com/by/patfrank/
      url: ""
      location: ""
      id: "39488002"
    isApproved: true
    raw_message: >-
      "<i>We show here that the mRNA from anti-COVID BNT162b2 (Pfizer) and 

      mRNA-1273 (Moderna) vaccines is not detected in human breast milk 

      samples collected 4-48 hours post-vaccine</i>"



      Nice, but irrelevant. The worry has been that the mRNA encoded <i><b>spike protein</b></i> gets into breast milk (and other tissues). 




      There does not appear to be any concern that the mRNA itself appears in breast milk. So the paper of Golan, et al., is irrelevant to the concern.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.03.05.21252998v1
  tweets:
    - created_at: Thu Jun 03 22:56:59 +0000 2021
      id: 1400587344634433500
      id_str: "1400587344634433536"
      text: >-
        üí¨ medRxiv comment on "COVID-19 mRNA vaccine is not d..."


        ""&lt;i&gt;We show here that the mRNA from anti-COVID BNT162b2‚Ä¶ https://t.co/aCVm0KXnwm
      truncated: true
      entities:
        urls:
          - url: https://t.co/aCVm0KXnwm
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 03 22:56:59 +0000 2021
      id: 1400587345456504800
      id_str: "1400587345456504836"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/Dml5mNFcAW
      truncated: false
      entities:
        urls:
          - url: https://t.co/Dml5mNFcAW
      in_reply_to_status_id: 1400587344634433500
      in_reply_to_status_id_str: "1400587344634433536"
- preprint:
    id: "144560"
    doi: 10.1101/2021.06.03.21258293
    first_posted: 2021-06-03
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.03.21258293v1
    url: https://api.rxivist.org/v1/papers/144560
    title: Interim estimates of increased transmissibility, growth rate, and
      reproduction number of the Covid-19 B.1.617.2 variant of concern in the
      United Kingdom
    category: infectious-diseases
    abstract: This paper relates to data from the Wellcome Sanger Institute, UK,
      regarding Covid-19 genomic surveillance. We use a simple model to give
      point estimates of the effective reproduction numbers of the B.1.617.2 and
      B.1.1.7 lineages in England, from sequenced data as at 15 May 2021.
      Comparison with the estimated reproduction number of B.1.1.7 enables an
      estimate of the increased transmissibility of B.1.617.2. We conclude that
      it is almost certain that there is increased transmissibility that will
      rapidly lead to B.1.617.2 becoming the prevailing variant in the UK. The
      derived estimates of increased transmissibility have uncertainty relating
      to the actual distribution of the generation interval, but they do point,
      under present conditions of vaccination coverage and NPIs, to exponential
      growth of positive cases.
    authors:
      - name: John S Dagpunar
        orcid: http://orcid.org/0000-0001-7197-8231
  comment:
    dislikes: 0
    thread: "8571083762"
    numReports: 0
    likes: 0
    id: "5407102395"
    createdAt: 2021-06-03T18:02:57
    author:
      username: disqus_wtPyWa2JzO
      about: Father. Scientist. Singer.
      name: Peter Ellis
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_wtPyWa2JzO/
      url: ""
      location: ""
      id: "52268877"
    isApproved: true
    raw_message: >-
      "We conclude that it is almost certain that there is increased
      transmissibility that will rapidly lead to B.1.617.2 becoming the
      prevailing variant in the UK."


      This was posted on the day Public Health England released a report showing that the Delta variant (B.1.617.2) is currently 73% of sequenced cases - i.e. it was 73% of new cases a couple of weeks ago. S gene proxy data is only a week out of date and has the prevalence of Delta at 85.4%


      Forget journals not being able to keep up, even preprints can't keep up with this.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.03.21258293v1
  tweets:
    - created_at: Fri Jun 04 02:01:41 +0000 2021
      id: 1400633825768755200
      id_str: "1400633825768755204"
      text: >-
        üí¨ medRxiv comment on "Interim estimates of increased..."


        ""We conclude that it is almost certain that there is inc‚Ä¶ https://t.co/o2hHrSkL8a
      truncated: true
      entities:
        urls:
          - url: https://t.co/o2hHrSkL8a
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 04 02:01:41 +0000 2021
      id: 1400633826674622500
      id_str: "1400633826674622465"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/PfElOztpGA
      truncated: false
      entities:
        urls:
          - url: https://t.co/PfElOztpGA
      in_reply_to_status_id: 1400633825768755200
      in_reply_to_status_id_str: "1400633825768755204"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5406165268"
    createdAt: 2021-06-02T22:17:50
    author:
      username: georgerapko
      about: ""
      name: George Rapko
      isPowerContributor: false
      profileUrl: https://disqus.com/by/georgerapko/
      url: ""
      location: ""
      id: "51917517"
    isApproved: true
    raw_message: What's really interesting is the people that believe masks work now
      point to the reduction in recorded flu cases.  It doesn't come mind that
      the travel restrictions are a likely culprit in the reduction of seasonal
      flu.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri Jun 04 13:09:06 +0000 2021
      id: 1400801786290708500
      id_str: "1400801786290708481"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "What's really interesting is the people that believe mas‚Ä¶ https://t.co/wTGl51VE2U
      truncated: true
      entities:
        urls:
          - url: https://t.co/wTGl51VE2U
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 04 13:09:06 +0000 2021
      id: 1400801787062464500
      id_str: "1400801787062464518"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1400801786290708500
      in_reply_to_status_id_str: "1400801786290708481"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5406160873"
    createdAt: 2021-06-02T22:13:03
    author:
      username: karl_elshoff
      about: ""
      name: Karl Elshoff
      isPowerContributor: false
      profileUrl: https://disqus.com/by/karl_elshoff/
      url: ""
      location: ""
      id: "327040158"
    isApproved: true
    raw_message: Lol.  Blaylock was using researched material.  You didn't even read
      his article.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri Jun 04 14:54:11 +0000 2021
      id: 1400828234695053300
      id_str: "1400828234695053317"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Lol.  Blaylock was using researched material.  You didn'‚Ä¶ https://t.co/u4QrkO4hs0
      truncated: true
      entities:
        urls:
          - url: https://t.co/u4QrkO4hs0
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 04 14:54:12 +0000 2021
      id: 1400828235324272600
      id_str: "1400828235324272643"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1400828234695053300
      in_reply_to_status_id_str: "1400828234695053317"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5404294629"
    createdAt: 2021-06-01T13:28:56
    author:
      username: disqus_suDe0WWfKq
      about: ""
      name: Publius
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_suDe0WWfKq/
      url: ""
      location: ""
      id: "75251292"
    isApproved: true
    raw_message: Then how do you explain Sweden which had one of the lowest excess
      death rates with no mask mandates and no lockdowns?
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri Jun 04 17:48:17 +0000 2021
      id: 1400872047417434000
      id_str: "1400872047417434119"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Then how do you explain Sweden which had one of the lowe‚Ä¶ https://t.co/MbPlqZ6cxS
      truncated: true
      entities:
        urls:
          - url: https://t.co/MbPlqZ6cxS
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 04 17:48:17 +0000 2021
      id: 1400872048054915000
      id_str: "1400872048054915078"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1400872047417434000
      in_reply_to_status_id_str: "1400872047417434119"
- preprint:
    id: "68453"
    doi: 10.1101/871194
    first_posted: 2019-12-11
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/871194v1
    url: https://api.rxivist.org/v1/papers/68453
    title: Insights into the ligand-free structure of cyclic diguanosine
      monophosphate I riboswitch of Vibrio cholerae using molecular dynamics
      simulation
    category: bioinformatics
    abstract: Riboswitches are key cis regulatory elements present at 5' UTRs of
      mRNAs. They play a critical role in gene expression regulation at
      transcriptional and translational level by binding selectively to specific
      ligands followed by conformational changes. Ligands bind to the aptamer of
      riboswitches and their complex structures have been solved, but
      ligand-free riboswitches structures are not available which is important
      to understand specific ligand binding mechanism. In this paper, an all
      atom 150 nano-second (ns) molecular dynamics (MD) simulations of cyclic
      diguanosine monophosphate (c-di-GMP I) riboswitch aptamer domain from
      Vibrio cholerae were carried out to study ligand-free c-di-GMP I
      riboswitch aptamer structure and the binding mechanism. The Principle
      component analysis, cross correlation dynamics analysis and trajectory
      analyses revealed that the ligand-free structure has stable conformation
      with folded P2, P3 and an open P1 helix which opens the ligand binding
      helix-join-helix while the ligand-bound structure shows less deviation and
      remains as closed structure compared to the ligand-free structure. The
      junction residues significantly showed anti-correlated motions with each
      other elucidating the open conformation of the ligand-free aptamer of
      riboswitch. The identified key residues involved in binding are A18, G20,
      C46, A47 and C92.
    authors:
      - name: Priyanka Kumari
        orcid: null
      - name: Anup Som
        orcid: http://orcid.org/0000-0003-1857-2368
  comment:
    dislikes: 0
    thread: "7758680208"
    numReports: 0
    likes: 1
    id: "5406484599"
    createdAt: 2021-06-03T05:36:41
    author:
      username: dranupsom
      about: ""
      name: Dr. Anup Som
      isPowerContributor: false
      profileUrl: https://disqus.com/by/dranupsom/
      url: ""
      location: ""
      id: "370362590"
    isApproved: true
    raw_message: >-
      This preprint has been published in Indian Journal of Biochemistry and
      Biophysics.  

      <b>Paper Link:</b>

      http://op.niscair.res.in/index.php/IJBB/article/view/37679
    forum: biorxivstage
    points: 1
    link: https://www.biorxiv.org/content/10.1101/871194v1
  tweets:
    - created_at: Fri Jun 04 19:48:29 +0000 2021
      id: 1400902294380630000
      id_str: "1400902294380630019"
      text: >-
        üí¨ bioRxiv comment on "Insights into the ligand-free ..."


        "This preprint has been published in Indian Journal of Bi‚Ä¶ https://t.co/4eUtpiI7nP
      truncated: true
      entities:
        urls:
          - url: https://t.co/4eUtpiI7nP
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 04 19:48:29 +0000 2021
      id: 1400902295185985500
      id_str: "1400902295185985543"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/D1nwcPMwOs
      truncated: false
      entities:
        urls:
          - url: https://t.co/D1nwcPMwOs
      in_reply_to_status_id: 1400902294380630000
      in_reply_to_status_id_str: "1400902294380630019"
- preprint:
    id: 140810
    metric: 3763
    title: Highly functional Cellular Immunity in SARS-CoV-2 Non-Seroconvertors is
      associated with immune protection
    url: https://api.rxivist.org/v1/papers/140810
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.04.438781v1
    doi: 10.1101/2021.05.04.438781
    category: immunology
    first_posted: 2021-05-04
    abstract: The role of T cells in the control of SARS-CoV-2 infection has been
      underestimated in favor of neutralizing antibodies. However, cellular
      immunity is essential for long-term viral control and protection from
      disease severity. To understand T-cell immunity in the absence of antibody
      generation we focused on a group of SARS-CoV-2 Non-Seroconvertors (NSC)
      recovered from infection. We performed an immune comparative analysis of
      SARS-CoV-2 infected individuals stratified by the absence or presence of
      seroconversion and disease severity. We report high levels of total naive
      and low effector CD8+ T cells in NSC. Moreover, polyfunctional
      Nucleocapsid (NP)-specific CD8+ T-cell responses, as well as reduced
      levels of T-cell activation monitored by PD-1 and activation-induced
      markers, were distinctive immunological traits in NSC. Longitudinal data
      support the stability of the NSC phenotype over three months. Our results
      implicate highly functional SARS-CoV-2 Spike and NP T-cell responses with
      low immune activation in protection from disease severity in the absence
      of seroconversion.
    authors:
      - name: Athina Kilpelainen
      - name: Esther Jimenez-Moyano
      - name: Oscar Blanch-Lombarte
      - name: Dan Ouchi
      - name: Ruth Penya
      - name: Bibiana Quirant-Sanchez
      - name: Anna Chamorro
      - name: Ignacio Blanco
      - name: Eva Martinez-Caceres
      - name: Roger Paredes
      - name: Lourdes Mateu
      - name: Jorge Carrillo
      - name: Julia Blanco
      - name: Christian Brander
      - name: Marta Massanella
      - name: Bonaventura Clotet
      - name: Julia G Prado
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Fri Jun 04 21:10:01 +0000 2021
      id: 1400922812886433800
      id_str: "1400922812886433798"
      text: >-
        üî• bioRxiv Immunology preprint by A. Kilpelainen et al:


        "Highly functional Cellular Immunity in SARS-CoV-2 Non-Sero‚Ä¶ https://t.co/IiQmmGbBoo
      truncated: true
      entities:
        urls:
          - url: https://t.co/IiQmmGbBoo
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "104133"
    doi: 10.1101/2020.11.15.383596
    first_posted: 2020-11-15
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.11.15.383596v1
    url: https://api.rxivist.org/v1/papers/104133
    title: Mayaro Virus Infection Elicits an Innate Immune Response and Represses
      Autophagy in Anopheles stephensi
    category: microbiology
    abstract: Mayaro virus (MAYV) is an arboviral pathogen in the genus Alphavirus
      that is circulating in South America with potential to spread to naive
      regions. MAYV is also one of the few viruses with the ability to be
      transmitted by mosquitoes in the genus Anopheles in addition to the
      typical arbovirus transmitting mosquitoes in the genus Aedes. Few studies
      have investigated the infection response of Anopheles mosquitoes to
      arboviruses. In this study we detail the transcriptomic and small RNA
      responses of An. stephensi to infection with MAYV via infectious bloodmeal
      at 2, 7, and 14 days post infection (dpi). 487 unique transcripts were
      significantly regulated and 79 novel miRNAs were identified. Gene ontology
      analysis of transcripts regulated at each timepoint suggested activation
      of the Toll pathway at 7 dpi and repression of pathways related to
      autophagy at 14 dpi. These findings provide a basic understanding of the
      infection response of An. stephensi to MAYV and help to identify host
      factors which might be useful to target to inhibit viral replication in
      Anopheles mosquitoes.
    authors:
      - name: Cory A Henderson
        orcid: null
      - name: Marco Brustolin
        orcid: http://orcid.org/0000-0002-3594-4488
      - name: Shivanand Hegde
        orcid: http://orcid.org/0000-0001-7249-6795
      - name: Grant Hughes
        orcid: http://orcid.org/0000-0002-7567-7185
      - name: Christina Bergey
        orcid: null
      - name: Jason L Rasgon
        orcid: http://orcid.org/0000-0002-4050-8429
  comment:
    dislikes: 0
    thread: "8365660728"
    numReports: 0
    likes: 0
    id: "5408362728"
    createdAt: 2021-06-04T18:54:07
    author:
      username: jasonrasgon
      about: ""
      name: jasonrasgon
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jasonrasgon/
      url: ""
      location: ""
      id: "370445078"
    isApproved: true
    raw_message: We are aware of an error in this manuscript regarding the small RNA
      analysis, the data have been reanalyzed and a corrected version will be
      uploaded shortly.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.11.15.383596v2
  tweets:
    - created_at: Fri Jun 04 21:14:35 +0000 2021
      id: 1400923964579455000
      id_str: "1400923964579454982"
      text: >-
        üí¨ bioRxiv comment on "Mayaro Virus Infection Elicits..."


        "We are aware of an error in this manuscript regarding th‚Ä¶ https://t.co/oAHeBDsgA5
      truncated: true
      entities:
        urls:
          - url: https://t.co/oAHeBDsgA5
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 04 21:14:35 +0000 2021
      id: 1400923965464498200
      id_str: "1400923965464498176"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/shcGK2eXZf
      truncated: false
      entities:
        urls:
          - url: https://t.co/shcGK2eXZf
      in_reply_to_status_id: 1400923964579455000
      in_reply_to_status_id_str: "1400923964579454982"
- preprint:
    id: "138543"
    doi: 10.1101/2021.04.19.440383
    first_posted: 2021-04-19
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.19.440383v1
    url: https://api.rxivist.org/v1/papers/138543
    title: A biosensor to gauge protein homeostasis resilience differences in the
      nucleus compared to cytosol of mammalian cells
    category: biochemistry
    abstract: An extensive network of chaperones and other proteins maintain protein
      homeostasis and guard against inappropriate protein aggregation that is a
      hallmark of neurodegenerative diseases. Using a fluorescence resonance
      energy-based biosensor that simultaneously reports on intact cellular
      chaperone holdase activity and detrimental aggregation propensity, we
      investigated the buffering capacity of the systems managing protein
      homeostasis in the nucleus of the human cell line HEK293 compared to the
      cytosol. We found that the nucleus showed lower net holdase activity and
      reduced capacity to suppress protein aggregation, suggesting that the
      nuclear quality control resources are less effective compared to those in
      the cytosol. Aggregation of mutant huntingtin exon 1 protein (Httex1) in
      the cytosol appeared to deplete cytosolic chaperone supply by depleting
      holdase activity. Unexpectedly, the same stress increased holdase activity
      in the nucleus suggesting that proteostasis stress can trigger a rebalance
      of chaperone supply in different subcellular compartments. Collectively
      the findings suggest the cytosol has more capacity to manage imbalances in
      proteome foldedness than the nucleus, but chaperone supply can be
      redirected into the nucleus under conditions of proteostasis stress caused
      by cytosolic protein aggregation.
    authors:
      - name: Candice B. Raeburn
        orcid: null
      - name: Angelique Royale Ormsby
        orcid: null
      - name: Nagaraj S. Moily
        orcid: null
      - name: Dezerae Cox
        orcid: http://orcid.org/0000-0002-5345-8360
      - name: Simon Ebbinghaus
        orcid: null
      - name: Alex Dickson
        orcid: http://orcid.org/0000-0002-9640-1380
      - name: Gawain McColl
        orcid: null
      - name: Danny M Hatters
        orcid: http://orcid.org/0000-0002-9965-2847
  comment:
    dislikes: 0
    thread: "8484479046"
    numReports: 0
    likes: 0
    id: "5408166220"
    createdAt: 2021-06-04T16:07:21
    author:
      name: Andrew Alamban
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    raw_message: >-
      ‚ÄúA biosensor to gauge protein homeostasis resilience differences in the
      nucleus compared to cytosol of mammalian cells‚Äù. Raeburn et al.

      doi: https://doi.org/10.1101/2021.04.19.440383

      Reviewed by Andrew Alamban* and Linh Tram*

      *University of California San Francisco 


      <b>Summary:</b>

      In the cell, there is an extensive network of protein quality control machinery that maintains protein homeostasis. A disruption in this network may lead to protein aggregation, which is a hallmark for many neurodegenerative diseases. This has prompted a need to develop a biosensor that can measure chaperone activity in the cell, which the authors have done in their previous work (Wood, R. et al. 2018. Nat. Comm.). One way to gauge chaperone activity is to measure their ability to bind unfolded proteins, also known as ‚Äúholdase‚Äù activity, to prevent aggregation. We found that the authors give a helpful explanation of how their previously-designed biosensor works, reducing the need for the reader to reference the previous publication.


      In this manuscript, the authors improve upon this tool to include nuclear localization or export sequences (NLS or NES, respectively) to probe protein homeostasis in the nucleus or cytosol, respectively. This control of biosensor localization is very impressive. Using this new capability, they show that 1) holdase activity in the cytosol is more abundant than in the nucleus and 2) imbalance in protein homeostasis - by co-expressing the huntingtin exon 1 mutant -  can reallocate chaperone supply in different areas of the cell. 


      A long-standing view in the proteostasis field is that the quality control machinery is more abundant in the cytosol. Their new biosensor supports this view by showing that there is more holdase activity detected in the cytosol than in the nucleus.


      The authors show that Huntingtin (Htt) inclusions can affect the fluorescence analysis of cells via flow cytometry. We appreciate that they addressed this limitation of their biosensor. They propose a workaround by measuring FRET using microscopy instead of their flow cytometry method. Using this workaround, the authors find evidence that the cell can reallocate quality control machinery between the cytosol and the nucleus.


      By adding the NLS or NES, the authors have extended the biosensor‚Äôs capability to answer more questions about proteostasis. While the constructed biosensor only used barnase, which binds to Hsp70 and Hsp40 family chaperones, as the model protein, the scheme suggests a potential to expand the scope of the biosensor by using different model proteins that bind other quality control proteins beyond Hsp70 and Hsp40 families.


      <b>Major Points: </b>


      The authors modify their previously-developed biosensor to restrict its localization to either the cytosol or nucleus using an NES or NLS, respectively. Because protein folding is essential to the biosensor‚Äôs function, the authors validate these new modifications by measuring protein stability via urea denaturation of the wild type* (WT*) barnase. The authors only perform the validation for the WT* but not for the mutants. Could the differences in the lower slope gradient observed in Figure 2B for the mutants be due to the NES or NLS affecting the mutant barnase stability differently than WT*? 


      There seems to be a discrepancy between data from Fig 2B and Fig 3B. Fig 2B shows that there is a lower slope gradient in the cytosol than in the nucleus. Looking more closely at Fig 3B, it almost looks like the nucleus has a lower slope gradient than the cytosol. This contradicts the conclusion from Fig 2B that the cytosol has more holdase activity when in Fig 3B, it looks like the nucleus has more. How could these differences be reconciled? 


      <b>Minor Points:</b>


      <u>Introduction:</u>

      In page 1 line 57, the abundance of unfolded-like barnase is not detected by FRET but rather by the absence of FRET


      Duplicate citations on refs. 5 and 6


      In the paragraph that starts on page 1/line 59, I was able to understand the motivation for creating the biosensor. However, the authors go on to explain that they added localization sequences without motivating a reason for why the comparison between the nucleus and the cytosol is important. The authors have this information in their discussion (line 226-227) and a brief mention of this in the introduction would help motivate the study.


      <u>Methods:</u>

      In line 270, it was unclear to me what it means to ‚Äúdecouple the expression of the two plasmids‚Äù. More detail in this section would also help in the ease of reproducibility of the work. 


      Catalog numbers should be included for all materials


      In line 280, there‚Äôs a typo. ‚ÄúOvine‚Äù should be ‚Äúbovine‚Äù


      We like that the authors provide scripts alongside the example datasets for their image analysis. This aids in reproducibility


      <u>Figure 1:</u>

      Labeling style for Fig 1A could benefit from the cartoon in the style of the (Wood, R. et al. 2018. Nat. Comm. Fig. 1), where the conformations of the bait, as well as the other proteins, were explicitly shown


      We are curious about how the linker control was designed since the linker control was not introduced in the initial biosensor paper (Wood, R. et al. 2018. Nat. Comm.) Which factors determine the linker control‚Äôs length and its amino acid sequence? 


      It looks like both localization sequences (NLS and NES) are appended to the biosensor in Fig 1A, which contrasts with what described in the Results.


      Fig 1D, unclear that they didn‚Äôt label ‚ÄúD‚Äù and ‚ÄúA‚Äù


      Mentioning that urea acts as a denaturing agent would be helpful, especially to newcomers unfamiliar with the assay


      <u>Figure 2:</u>

      Figure 2C: How was the percentage of cells with aggregates calculated? Legend of the figure suggest that the percentage is derived from the ratio (upper slope)/(lower slope)


      In Line 113-114, the authors observed that the I25A I96G mutant was potentially outside of the detected dynamic range of the biosensor. However, the I25A,I96G mutant was still used in subsequent experiments without providing further explanations.


      <u>Figure 3:</u>

      Fig 1 and 3, using the same color for the Hoechst dye would help better with continuity across figures


      What drove the choice for using the Y66L Emerald as the transfection control rather than an empty vector? 


      <u>Figure 4:</u>

      It would be useful to see a color map for the FRET map on the side to get a better idea of the range


      What does white or red arrow mean in figure 4? We think that the white arrow indicates inclusion-targeted and the red arrow indicates diffuse-targeted


      The signal that the white arrow is referring to in Figure 4A for the nucleus is barely visible


      In Figure 4, would it be possible to use different line styles for the WT* and the mutants?


      In Figure 4, WT should be labeled as WT*
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.04.19.440383v1
  tweets:
    - created_at: Fri Jun 04 22:47:03 +0000 2021
      id: 1400947231885197300
      id_str: "1400947231885197315"
      text: >-
        üí¨ bioRxiv comment on "A biosensor to gauge protein h..."


        "‚ÄúA biosensor to gauge protein homeostasis resilience dif‚Ä¶ https://t.co/Rt5OC2cBEJ
      truncated: true
      entities:
        urls:
          - url: https://t.co/Rt5OC2cBEJ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 04 22:47:03 +0000 2021
      id: 1400947232870781000
      id_str: "1400947232870780929"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/DjsC6LUmyP
      truncated: false
      entities:
        urls:
          - url: https://t.co/DjsC6LUmyP
      in_reply_to_status_id: 1400947231885197300
      in_reply_to_status_id_str: "1400947231885197315"
- preprint:
    id: "61533"
    doi: 10.1101/779215
    first_posted: 2019-09-23
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/779215v1
    url: https://api.rxivist.org/v1/papers/61533
    title: "Hackflex: low cost Illumina Nextera Flex sequencing library construction"
    category: genomics
    abstract: We developed a low-cost method for the production of
      Illumina-compatible sequencing libraries that allows up to 14 times more
      libraries for high-throughput Illumina sequencing to be generated for the
      same cost. We call this new method Hackflex. Quality of library
      preparation was tested by constructing libraries from E. coli MG1655
      genomic DNA using either Hackflex, standard Nextera Flex or a variation of
      standard Nextera Flex in which the bead-linked transposase is diluted
      prior to use. In order to test the library quality for genomes with a
      higher and a lower GC content, library construction methods were also
      tested on P. aeruginosa PAO1 and S. aureus ATCC25923, respectively. We
      demonstrated that Hackflex can produce high quality libraries and yields a
      highly uniform coverage, equivalent to the standard Nextera Flex kit. We
      show that strongly size selected libraries produce sufficient yield and
      complexity to support de novo microbial genome assembly, and that
      assemblies of the large insert libraries can be much more contiguous than
      standard libraries without strong size selection. We introduce a new set
      of sample barcodes that are distinct from standard Illumina barcodes,
      enabling Hackflex samples to be multiplexed with samples barcoded using
      standard Illumina kits. Using Hackflex, we were able to achieve a per
      sample reagent cost for library prep of A$7.22 (USD$5.60), which is 9.87
      times lower than the Standard Nextera Flex protocol at advertised retail
      price. An additional simple modification and further simplification of the
      protocol by omitting the wash step enables a further price reduction to
      reach an overall 14-fold cost saving. This method will allow researchers
      to construct more libraries within a given budget, thereby yielding more
      data and facilitating research programs where sequencing large numbers of
      libraries is beneficial.
    authors:
      - name: Daniela Gaio
        orcid: http://orcid.org/0000-0002-7695-3145
      - name: Kay Anantanawat
        orcid: http://orcid.org/0000-0002-7862-0969
      - name: Joyce To
        orcid: http://orcid.org/0000-0003-3482-4369
      - name: Michael Liu
        orcid: http://orcid.org/0000-0002-8467-3215
      - name: Leigh Monahan
        orcid: http://orcid.org/0000-0003-2933-9000
      - name: Aaron E Darling
        orcid: http://orcid.org/0000-0003-2397-7925
  comment:
    dislikes: 0
    thread: "8557230117"
    numReports: 0
    likes: 0
    id: "5407872580"
    createdAt: 2021-06-04T11:22:19
    author:
      username: mickwatson
      about: ""
      name: Mick Watson
      isPowerContributor: false
      profileUrl: https://disqus.com/by/mickwatson/
      url: ""
      location: ""
      id: "58943289"
    isApproved: true
    raw_message: Have you tried this with metagenomics?
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/779215v2
  tweets:
    - created_at: Sat Jun 05 01:45:11 +0000 2021
      id: 1400992061113909200
      id_str: "1400992061113909255"
      text: |-
        üí¨ bioRxiv comment on "Hackflex: low cost Illumina Ne..."

        "Have you tried this with metagenomics?"

        https://t.co/iteyEEhWcL
      truncated: false
      entities:
        urls:
          - url: https://t.co/iteyEEhWcL
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 05 01:45:11 +0000 2021
      id: 1400992061965361200
      id_str: "1400992061965361153"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/qUJ6GcrBq3
      truncated: false
      entities:
        urls:
          - url: https://t.co/qUJ6GcrBq3
      in_reply_to_status_id: 1400992061113909200
      in_reply_to_status_id_str: "1400992061113909255"
- preprint:
    id: "122413"
    doi: 10.1101/2020.12.19.423618
    first_posted: 2020-12-21
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.12.19.423618v1
    url: https://api.rxivist.org/v1/papers/122413
    title: A scale-dependent measure of system dimensionality
    category: neuroscience
    abstract: A fundamental problem in science is uncovering the effective number of
      dynamical degrees of freedom in a complex system, a quantity that depends
      on the spatio-temporal scale at which the system is observed. Here, we
      propose a scale-dependent generalization of a classic enumeration of
      latent variables, the Participation Ratio. We show how this measure
      relates to conventional quantities such as the Correlation dimension and
      Principal Component Analysis, and demonstrate its properties in dynamical
      systems such as the Lorentz attractor. We apply the method to neural
      population recordings in multiple brain areas and brain states, and
      demonstrate fundamental differences in the effective dimensionality of
      neural activity in behaviorally engaged states versus spontaneous
      activity. Our method applies broadly to multi-variate data across fields
      of science.
    authors:
      - name: Stefano Recanatesi
        orcid: http://orcid.org/0000-0002-3576-9261
      - name: Serena Bradde
        orcid: http://orcid.org/0000-0001-8410-2992
      - name: Vijay Balasubramanian
        orcid: http://orcid.org/0000-0001-7552-1992
      - name: Nicholas A Steinmetz
        orcid: http://orcid.org/0000-0001-7029-2908
      - name: Eric Shea-Brown
        orcid: http://orcid.org/0000-0002-9012-1396
  comment:
    dislikes: 0
    thread: "8327046125"
    numReports: 0
    likes: 0
    id: "5407622046"
    createdAt: 2021-06-04T03:38:02
    author:
      username: disqus_O8DO352efZ
      about: ""
      name: Jingwen Li
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_O8DO352efZ/
      url: ""
      location: ""
      id: "364152235"
    isApproved: true
    raw_message: >-
      This review was done as part of the SfN Reviewer Mentor Program (Mentor:
      Mike X Cohen, Mentee: Jingwen Li).


      The authors generalized a method of measuring dimensionality, Participation Ratio dimension, to a scale-dependent quantity that captures the dimension at different scales. They verified the quantity on two examples and Gaussian distributions in comparison with the scale-dependent Correlation dimension. They further applied the quantity to different brain regions under different states. I found the methods and results interesting and important, as many complex systems could have dimensionality varying upon the scales. However, my main concern arises when the authors applied the quantity to neural systems. There seems lacking a bridge between the examples and the neural systems analyzed in the study, as well as a clear interpretation of the results. I hope that my comments below will help the authors improve their manuscript.

      1) The definition of distance r is important since the aim of the generalized DPR is to measure dimensionality at different scales. While r used in the examples is spatial distance, the r used in neural system is functional ‚Äúdistance.‚Äù It is not clear how these two concepts of distance relate, or whether it is trivial to exchange one for the other. In particular, for the cases where the dimensionality changes with scales (visual cortex, frontal cortex, and midbrain), it‚Äôs not clear to me what it means to vary scales in this functional space. Perhaps the authors could include an additional example that validates using spatial, topological, and functional distance measures. This might help the readers smoothly transfer to applications in neural system later in the manuscript. It would also be nice if these examples show different dimensionalities at different scales, as mentioned in discussion.

      2) Relatedly, the interpretation of ‚Äúdimensionality‚Äù in functional space could be more clearly defined. How is this dimensionality related to more commonly used functional metrics like synchronization/noise correlation? For example, as the scale r increases, neurons with a larger functional distance are included, so presumably synchrony of those neurons will decrease. Linking their proposed DPR measure to existing neural synchrony measures (in the four brain regions across two behavioral states) will facilitate a physiological interpretation, and may also help clarify the benefits of DPR. For instance, recent studies found that noise correlation (calculating pairwise correlations of spike counts among neurons) in visual cortex decreases due to locomotion/arousal (Dadarlat & Stryker 2017 J of Neuroscience; Vinck et al 2015 Neuron; Erisken et al 2014 Current Biology). However, the state-dependent decrease of noise correlation is not found in thalamus although firing rate changes with behavioral state (Erisken et al 2014 Current Biology). It would be interesting to compare these findings with the authors‚Äô results in visual cortex and thalamus. This is also interesting because the authors observed lower dimensionality in task-driven states, but active neural processing has been associated with increased synchronization at spatial scales captured by LFP and EEG. Thus, the relationship between dimensionality and synchronization does not seem trivial, and could be very insightful.


      A few minor suggestions:

      1) When using the scale-free Gaussian example, the statement of ‚Äúsystems with such properties are often deemed to be near criticality and are studied in a number of contexts‚Äù should be followed by a few citations. Furthermore, it would be helpful if the authors explain how the power law exponent affects the dimensionality in such a system, i.e., the relation of the original Gaussian dimension d and the exponent alpha. This would intuitively explain why DPR saturates at a finite value despite the Gaussian dimension d, although it is derived later by Eq. 5.

      2) In Fig. 1, one of the indices e) is supposed to be d).

      3) In Fig. 3, is data used for b) the same for bottom panels in a), and just rearranged for better presentation? If yes, the authors should indicate in captions of b) for clarification.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.12.19.423618v3
  tweets:
    - created_at: Sat Jun 05 12:58:21 +0000 2021
      id: 1401161471313199000
      id_str: "1401161471313199110"
      text: >-
        üí¨ bioRxiv comment on "A scale-dependent measure of s..."


        "This review was done as part of the SfN Reviewer Mentor‚Ä¶ https://t.co/setT9X4fNL
      truncated: true
      entities:
        urls:
          - url: https://t.co/setT9X4fNL
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 05 12:58:21 +0000 2021
      id: 1401161472214978600
      id_str: "1401161472214978563"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/ZWxoQKfTSI
      truncated: false
      entities:
        urls:
          - url: https://t.co/ZWxoQKfTSI
      in_reply_to_status_id: 1401161471313199000
      in_reply_to_status_id_str: "1401161471313199110"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 3
    thread: "8550177462"
    numReports: 1
    likes: 0
    id: "5407054115"
    createdAt: 2021-06-03T17:21:18
    author:
      username: rusbowden
      about: ""
      name: rusbowden
      isPowerContributor: false
      profileUrl: https://disqus.com/by/rusbowden/
      url: ""
      location: ""
      id: "10245173"
    isApproved: true
    raw_message: The insanity is in thinking that the earth is suddenly flat, and
      that this research paper, done by people outside their specialties with no
      epidemiologists or virologists involved, can overturn all the knowledge we
      have been amassing for over a year. We know, for instance that within
      states, city ordinances change transmission -- and that's all we can
      really talk about when looking at this study. It tries to ask the question
      whether state mandates work to change the mask-wearing and
      distance-keeping behavior of the population, in such a way that the virus
      can be combatted -- or are there enough anti-maskers who refuse to abide,
      who will sabotage public health efforts. So, we know that mask wearing and
      distance-keeping mandates, and more, work at the municipal level to combat
      the virus. We also know, from looking outside the box of just the USA,
      that mandates work when comparing countries to other countries. Let's take
      the case of the phenomen of a couple walking in public, one wearing a
      mask, the other not. The one not masked up has a greater chance of
      contracting the virus, and thus spreading it to the other (and the rest of
      their families), thus negating much of what the masked individual was
      trying to accomplish. We can call this the sabotage factor. In the face of
      the massive amount of information that supports mask wearing, we have to
      really rip this study open to see if it holds the water it pretends to,
      and also, for whatever truth it may hold, what are the social
      implications. The paper simply does not show what many readers would like
      it to show, that the world is flat.
    forum: medrxiv
    points: -3
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sat Jun 05 14:37:40 +0000 2021
      id: 1401186463820091400
      id_str: "1401186463820091396"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "The insanity is in thinking that the earth is suddenly f‚Ä¶ https://t.co/rzmcONfM6q
      truncated: true
      entities:
        urls:
          - url: https://t.co/rzmcONfM6q
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 05 14:37:40 +0000 2021
      id: 1401186464646393900
      id_str: "1401186464646393867"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU30MFJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU30MFJ
      in_reply_to_status_id: 1401186463820091400
      in_reply_to_status_id_str: "1401186463820091396"
- preprint:
    id: 21370
    metric: 2810
    title: "Report of Partial findings from the National Toxicology Program
      Carcinogenesis Studies of Cell Phone Radiofrequency Radiation in Hsd:
      Sprague Dawley¬Æ SD rats (Whole Body Exposure)"
    url: https://api.rxivist.org/v1/papers/21370
    biorxiv_url: https://www.biorxiv.org/content/10.1101/055699v3
    doi: 10.1101/055699
    category: cancer-biology
    first_posted: 2016-05-26
    abstract: The U.S. National Toxicology Program (NTP) has carried out extensive
      rodent toxicology and carcinogenesis studies of radiofrequency radiation
      (RFR) at frequencies and modulations used in the U.S. telecommunications
      industry. This report presents partial findings from these studies. The
      occurrences of two tumor types in male Harlan Sprague Dawley rats exposed
      to RFR, malignant gliomas in the brain and schwannomas of the heart, were
      considered of particular interest and are the subject of this report. The
      findings in this report were reviewed by expert peer reviewers selected by
      the NTP and National Institutes of Health (NIH). These reviews and
      responses to comments are included as appendices to this report, and
      revisions to the current document have incorporated and addressed these
      comments. When the studies are completed, they will undergo additional
      peer review before publication in full as part of the NTP's Toxicology and
      Carcinogenesis Technical Reports Series. No portion of this work has been
      submitted for publication in a scientific journal. Supplemental
      information in the form of four additional manuscripts has or will soon be
      submitted for publication. These manuscripts describe in detail the
      designs and performance of the RFR exposure system, the dosimetry of RFR
      exposures in rats and mice, the results to a series of pilot studies
      establishing the ability of the animals to thermoregulate during RFR
      exposures, and studies of DNA damage. (1) Capstick M, Kuster N, Kuhn S,
      Berdinas-Torres V, Wilson P, Ladbury J, Koepke G, McCormick D, Gauger J,
      and Melnick R. A radio frequency radiation reverberation chamber exposure
      system for rodents; (2) Yijian G, Capstick M, McCormick D, Gauger J, Horn
      T, Wilson P, Melnick RL, and Kuster N. Life time dosimetric assessment for
      mice and rats exposed to cell phone radiation; (3) Wyde ME, Horn TL,
      Capstick M, Ladbury J, Koepke G, Wilson P, Stout MD, Kuster N, Melnick R,
      Bucher JR, and McCormick D. Pilot studies of the National Toxicology
      Program's cell phone radiofrequency radiation reverberation chamber
      exposure system; (4) Smith-Roe SL, Wyde ME, Stout MD, Winters J, Hobbs CA,
      Shepard KG, Green A, Kissling GE, Tice RR, Bucher JR, and Witt KL.
      Evaluation of the genotoxicity of cell phone radiofrequency radiation in
      male and female rats and mice following subchronic exposure.
    authors:
      - name: Michael Wyde
      - name: Mark Cesta
      - name: Chad Blystone
      - name: Susan Elmore
      - name: Paul Foster
      - name: Michelle Hooth
      - name: Grace Kissling
      - name: David Malarkey
      - name: Robert Sills
      - name: Matthew Stout
      - name: Nigel Walker
      - name: Kristine Witt
      - name: Mary Wolfe
      - name: John Bucher
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sat Jun 05 20:30:50 +0000 2021
      id: 1401275341289709600
      id_str: "1401275341289709576"
      text: >-
        üî• bioRxiv Cancer-biology preprint by M. Wyde et al:


        "Report of Partial findings from the National Toxicology Progr‚Ä¶ https://t.co/PXpCm8oDYk
      truncated: true
      entities:
        urls:
          - url: https://t.co/PXpCm8oDYk
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "112460"
    doi: 10.1101/2020.06.13.20129627
    first_posted: 2020-06-13
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.06.13.20129627v1
    url: https://api.rxivist.org/v1/papers/112460
    title: Sentinel surveillance of SARS-CoV-2 in wastewater anticipates the
      occurrence of COVID-19 cases
    category: epidemiology
    abstract: SARS-CoV-2 was detected in Barcelona sewage long before the
      declaration of the first COVID-19 case, indicating that the infection was
      present in the population before the first imported case was reported.
      Sentinel surveillance of SARS-CoV-2 in wastewater would enable adoption of
      immediate measures in the event of future COVID-19 waves.
    authors:
      - name: Gemma Chavarria-Mir√≥
        orcid: null
      - name: Eduard Anfruns-Estrada
        orcid: null
      - name: Susana Guix
        orcid: http://orcid.org/0000-0002-1588-3198
      - name: Miquel Paraira
        orcid: null
      - name: Bel√©n Galofr√©
        orcid: null
      - name: Gloria S√°anchez
        orcid: null
      - name: Rosa Pinto
        orcid: http://orcid.org/0000-0003-1382-6648
      - name: Albert Bosch
        orcid: http://orcid.org/0000-0002-8111-9059
  comment:
    dislikes: 0
    thread: "8075166583"
    numReports: 0
    likes: 1
    id: "5405399598"
    createdAt: 2021-06-02T11:15:56
    author:
      username: disqus_gVV0Ir3gpV
      about: ""
      name: Philip Ward
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_gVV0Ir3gpV/
      url: ""
      location: ""
      id: "214031581"
    isApproved: true
    raw_message: >-
      The authors of the paper have now published a second study that states
      their earliest positive sewage sample is from January 15th 2020 and does
      not make any reference to this preprint:


      https://journals.asm.org/doi/10.1128/AEM.02750-20
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2020.06.13.20129627v1
  tweets:
    - created_at: Sat Jun 05 22:33:10 +0000 2021
      id: 1401306128491827200
      id_str: "1401306128491827203"
      text: >-
        üí¨ medRxiv comment on "Sentinel surveillance of SARS-..."


        "The authors of the paper have now published a second stu‚Ä¶ https://t.co/xjhHDjvym2
      truncated: true
      entities:
        urls:
          - url: https://t.co/xjhHDjvym2
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 05 22:33:10 +0000 2021
      id: 1401306129481695200
      id_str: "1401306129481695234"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/bjIFJg763C
      truncated: false
      entities:
        urls:
          - url: https://t.co/bjIFJg763C
      in_reply_to_status_id: 1401306128491827200
      in_reply_to_status_id_str: "1401306128491827203"
- preprint:
    id: "106432"
    doi: 10.1101/2019.12.13.19014902
    first_posted: 2019-12-15
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2019.12.13.19014902v1
    url: https://api.rxivist.org/v1/papers/106432
    title: "OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for
      Normal Aging and Alzheimer Disease"
    category: radiology-and-imaging
    abstract: OASIS-3 is a compilation of MRI and PET imaging and related clinical
      data for 1098 participants who were collected across several ongoing
      studies in the Washington University Knight Alzheimer Disease Research
      Center over the course of 15 years. Participants include 605 cognitively
      normal adults and 493 individuals at various stages of cognitive decline
      ranging in age from 42 to 95 years. The OASIS-3 dataset contains over 2000
      MR sessions, including multiple structural and functional sequences. PET
      metabolic and amyloid imaging includes over 1500 raw imaging scans and the
      accompanying post-processed files from the PET Unified Pipeline (PUP) are
      also available in OASIS-3. OASIS-3 also contains post-processed imaging
      data such as volumetric segmentations and PET analyses. Imaging data is
      accompanied by dementia and APOE status and longitudinal clinical and
      cognitive outcomes. OASIS-3 is available as an open access data set to the
      scientific community to answer questions related to healthy aging and
      dementia.
    authors:
      - name: Pamela J. LaMontagne
        orcid: http://orcid.org/0000-0002-6752-8518
      - name: Tammie LS. Benzinger
        orcid: http://orcid.org/0000-0002-8114-0552
      - name: John C Morris
        orcid: null
      - name: Sarah Keefe
        orcid: null
      - name: Russ Hornbeck
        orcid: null
      - name: Chengjie Xiong
        orcid: http://orcid.org/0000-0003-0044-4499
      - name: Elizabeth Grant
        orcid: null
      - name: Jason Hassenstab
        orcid: http://orcid.org/0000-0002-7802-3371
      - name: Krista Moulder
        orcid: null
      - name: Andrei G. Vlassenko
        orcid: null
      - name: Marcus E. Raichle
        orcid: http://orcid.org/0000-0002-1847-9588
      - name: Carlos Cruchaga
        orcid: http://orcid.org/0000-0002-0276-2899
      - name: Daniel Marcus
        orcid: null
  comment:
    dislikes: 0
    thread: "7765276129"
    numReports: 0
    likes: 1
    id: "5409147752"
    createdAt: 2021-06-05T13:34:28
    author:
      username: disqus_wiwZ9GIjro
      about: ""
      name: Gowtham Kumar
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_wiwZ9GIjro/
      url: ""
      location: ""
      id: "370481766"
    isApproved: true
    raw_message: We were trying to access the scans available in Oasis-1 dataset but
      we were unable to open the scans because the extensions of the files are
      .nifti.img , if you have any idea to open this please help us.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2019.12.13.19014902v1
  tweets:
    - created_at: Sun Jun 06 19:03:06 +0000 2021
      id: 1401615651773550600
      id_str: "1401615651773550592"
      text: >-
        üí¨ medRxiv comment on "OASIS-3: Longitudinal Neuroima..."


        "We were trying to access the scans available in Oasis-1‚Ä¶ https://t.co/u0hBzHTkUi
      truncated: true
      entities:
        urls:
          - url: https://t.co/u0hBzHTkUi
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 06 19:03:06 +0000 2021
      id: 1401615652495016000
      id_str: "1401615652495015936"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/g0h3LeTied
      truncated: false
      entities:
        urls:
          - url: https://t.co/g0h3LeTied
      in_reply_to_status_id: 1401615651773550600
      in_reply_to_status_id_str: "1401615651773550592"
- preprint:
    id: 141745
    metric: 2525
    title: Archival influenza virus genomes from Europe reveal genomic and
      phenotypic variability during the 1918 pandemic
    url: https://api.rxivist.org/v1/papers/141745
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.14.444134v1
    doi: 10.1101/2021.05.14.444134
    category: microbiology
    first_posted: 2021-05-14
    abstract: The 1918 influenza pandemic was the deadliest respiratory pandemic of
      the 20th century and determined the genomic make-up of subsequent human
      influenza A viruses (IAV). Here, we analyze the first 1918 IAV genomes
      from Europe and from the first, milder wave of the pandemic. 1918 IAV
      genomic diversity is consistent with local transmission and frequent
      long-distance dispersal events and in vitro polymerase characterization
      suggests potential phenotypic variability. Comparison of first and second
      wave genomes shows variation at two sites in the nucleoprotein gene
      associated with resistance to host antiviral response, pointing at a
      possible adaptation of 1918 IAV to humans. Finally, phylogenetic estimates
      based on extended molecular clock modelling suggests a pure pandemic
      descent of seasonal H1N1 IAV as an alternative to the hypothesis of an
      intrasubtype reassortment origin.
    authors:
      - name: Livia V Patrono
      - name: Bram Vrancken
      - name: Matthias Budt
      - name: Ariane Duex
      - name: Sebastian Lequime
      - name: Senguel Boral
      - name: M. Thomas P. Gilbert
      - name: Jan F. Gogarten
      - name: Luisa Hoffmann
      - name: David Horst
      - name: Kevin Merkel
      - name: David Morens
      - name: Baptiste Prepoint
      - name: Jasmin Schlotterbeck
      - name: Verena Schuenemann
      - name: Marc A Suchard
      - name: Jeffery K Taubenberger
      - name: Luisa Tenkhoff
      - name: Christian Urban
      - name: Navena Widulin
      - name: Eduard Winter
      - name: Michael Worobey
      - name: Fabian H Leendertz
      - name: Thomas Schnalke
      - name: Thorsten Wolff
      - name: Philippe Lemey
      - name: Sebastien Calvignac-Spencer
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sun Jun 06 20:31:32 +0000 2021
      id: 1401637904233992200
      id_str: "1401637904233992204"
      text: >-
        üî• bioRxiv Microbiology preprint by L. V. Patrono et al:


        "Archival influenza virus genomes from Europe reveal genom‚Ä¶ https://t.co/A9iPw8226m
      truncated: true
      entities:
        urls:
          - url: https://t.co/A9iPw8226m
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "139172"
    doi: 10.1101/2021.04.19.21255701
    first_posted: 2021-04-22
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.04.19.21255701v1
    url: https://api.rxivist.org/v1/papers/139172
    title: Public Perception of COVID-19 Vaccines through Analysis of Twitter
      Content and Users
    category: public-and-global-health
    abstract: Twitter is a robust medium to understand wide-scale, organic public
      perception about the COVID-19 vaccine. In this cross-sectional
      observational study, we evaluated 2.4 million English tweets from nearly 1
      million user accounts matching keywords (('covid*' OR 'coronavirus') AND
      'vaccine') during vaccine development from Feb 1st through Dec 11th, 2020.
      We applied topic modeling, sentiment and emotion analysis, and demographic
      inference of users on the COVID-19 vaccine related tweets to provide
      insight into the evolution of public attitudes. Individuals generated
      87.9% (n=834,224) of tweets. Of individuals, men (n=560,824) outnumbered
      women (n=273,400) by 2:1 and 39.5% (n=329,776) of individuals were
      [&ge;]40 years old. Daily mean sentiment fluctuated congruent with news
      events, but overall trended positively. Trust, anticipation, and fear were
      the three most predominant emotions; while fear was the most predominant
      emotion early in the study period, trust outpaced fear from April 2020
      onward. Fear was more prevalent in tweets by individuals (26.3% vs.
      organizations 19.4%; p<0.001), specifically among women (28.4% vs. males
      25.4%; p <0.001). Multiple topics had a monthly trend towards more
      positive sentiment. Tweets comparing COVID-19 to the influenza vaccine had
      strongly negative early sentiment but improved over time. Our findings are
      concerning for COVID-19 vaccine hesitancy, but also identify targets for
      educational interventions.
    authors:
      - name: Sameh Nagui Saleh
        orcid: http://orcid.org/0000-0001-5959-1659
      - name: Samuel A McDonald
        orcid: http://orcid.org/0000-0002-8383-3854
      - name: Mujeeb A Basit
        orcid: http://orcid.org/0000-0002-4948-6158
      - name: Sanat Kumar
        orcid: null
      - name: Reuben J Arasaratnam
        orcid: null
      - name: Trish M Perl
        orcid: http://orcid.org/0000-0001-9539-2358
      - name: Christoph U Lehmann
        orcid: http://orcid.org/0000-0001-9559-4646
      - name: Richard J Medford
        orcid: http://orcid.org/0000-0001-9814-8043
  comment:
    dislikes: 0
    thread: "8488550733"
    numReports: 0
    likes: 0
    id: "5410195486"
    createdAt: 2021-06-06T13:42:01
    author:
      username: maryampahlavan
      about: ""
      name: Maryam Pahlavan
      isPowerContributor: false
      profileUrl: https://disqus.com/by/maryampahlavan/
      url: ""
      location: ""
      id: "370530555"
    isApproved: true
    raw_message: Hej, How I canrequest for dataset?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.04.19.21255701v1
  tweets:
    - created_at: Sun Jun 06 20:35:06 +0000 2021
      id: 1401638804860059600
      id_str: "1401638804860059656"
      text: |-
        üí¨ medRxiv comment on "Public Perception of COVID-19 ..."

        "Hej, How I canrequest for dataset?"

        https://t.co/QTuzwoBGa2
      truncated: false
      entities:
        urls:
          - url: https://t.co/QTuzwoBGa2
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 06 20:35:07 +0000 2021
      id: 1401638805581488000
      id_str: "1401638805581488130"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/7USKP0uobf
      truncated: false
      entities:
        urls:
          - url: https://t.co/7USKP0uobf
      in_reply_to_status_id: 1401638804860059600
      in_reply_to_status_id_str: "1401638804860059656"
- preprint:
    id: "138913"
    doi: 10.1101/2021.04.20.21254636
    first_posted: 2021-04-21
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.04.20.21254636v1
    url: https://api.rxivist.org/v1/papers/138913
    title: Effectiveness of the BNT162b2 vaccine in preventing COVID-19 in the
      working age population - first results from a cohort study in Southern
      Sweden
    category: infectious-diseases
    abstract: Background Vaccine effectiveness against COVID-19 needs to be assessed
      in diverse real-world population settings. Methods A cohort study of 805
      741 residents in Scania county, Southern Sweden, aged 18-64 years, of whom
      26 587 received at least one dose of the BNT162b2 vaccine. Incidence rates
      of COVID-19 were estimated in sex- and age-adjusted analysis and
      stratified in two-week periods with substantial community spread of the
      disease. Results The estimated vaccine effectiveness in preventing
      infection >7 days after second dose was 86% (95% CI 72-94%) but only 42%
      (95% CI 14-63%) >14 days after a single dose. No difference in vaccine
      effectiveness was observed between females and males. Having a prior
      positive test was associated with 91% (95% CI 85 to 94%) effectiveness
      against new infection among the unvaccinated. Conclusion A satisfactory
      effectiveness of BNT162b2 after the second dose was suggested, but with
      possibly substantially lower effect before the second dose.
    authors:
      - name: Jonas Bjork
        orcid: http://orcid.org/0000-0003-1883-2000
      - name: Malin Inghammar
        orcid: null
      - name: Mahnaz Moghaddassi
        orcid: null
      - name: Magnus Rasmussen
        orcid: null
      - name: Ulf Malmqvist
        orcid: null
      - name: Fredrik Kahn
        orcid: http://orcid.org/0000-0001-5566-6350
  comment:
    dislikes: 0
    thread: "8486875630"
    numReports: 0
    likes: 0
    id: "5410034045"
    createdAt: 2021-06-06T09:28:02
    author:
      username: Ulltand
      about: ""
      name: Ulltand
      isPowerContributor: false
      profileUrl: https://disqus.com/by/Ulltand/
      url: ""
      location: ""
      id: "29192773"
    isApproved: true
    raw_message: 4 days after one dose. What does it say? We know from other studies
      that 21 days after one dose protection is about 90 %. 14 days is a to
      short period.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.04.20.21254636v1
  tweets:
    - created_at: Sun Jun 06 22:31:56 +0000 2021
      id: 1401668206029332500
      id_str: "1401668206029332489"
      text: >-
        üí¨ medRxiv comment on "Effectiveness of the BNT162b2 ..."


        "4 days after one dose. What does it say? We know from ot‚Ä¶ https://t.co/068uzCDeS2
      truncated: true
      entities:
        urls:
          - url: https://t.co/068uzCDeS2
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 06 22:31:56 +0000 2021
      id: 1401668206838829000
      id_str: "1401668206838829057"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/Fw2Nxn9pb7
      truncated: false
      entities:
        urls:
          - url: https://t.co/Fw2Nxn9pb7
      in_reply_to_status_id: 1401668206029332500
      in_reply_to_status_id_str: "1401668206029332489"
- preprint:
    id: "109294"
    doi: 10.1101/2020.04.22.20076091
    first_posted: 2020-04-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.04.22.20076091v1
    url: https://api.rxivist.org/v1/papers/109294
    title: Gut microbiota may underlie the predisposition of healthy individuals to
      COVID-19
    category: public-and-global-health
    abstract: The COVID-19 pandemic is spreading globally with high disparity in the
      susceptibility of the disease severity. Identification of the key
      underlying factors for this disparity is highly warranted. Here we
      describe constructing a proteomic risk score based on 20 blood proteomic
      biomarkers which predict the progression to severe COVID-19. We
      demonstrate that in our own cohort of 990 individuals without infection,
      this proteomic risk score is positively associated with proinflammatory
      cytokines mainly among older, but not younger, individuals. We further
      discovered that a core set of gut microbiota could accurately predict the
      above proteomic biomarkers among 301 individuals using a machine learning
      model, and that these gut microbiota features are highly correlated with
      proinflammatory cytokines in another set of 366 individuals. Fecal
      metabolomic analysis suggested potential amino acid-related pathways
      linking gut microbiota to inflammation. This study suggests that gut
      microbiota may underlie the predisposition of normal individuals to severe
      COVID-19.
    authors:
      - name: Wanglong Gou
        orcid: null
      - name: Yuanqing Fu
        orcid: http://orcid.org/0000-0002-3955-9376
      - name: Liang Yue
        orcid: null
      - name: Geng-dong Chen
        orcid: null
      - name: Xue Cai
        orcid: http://orcid.org/0000-0002-7427-2100
      - name: Menglei Shuai
        orcid: null
      - name: Fengzhe Xu
        orcid: null
      - name: Xiao Yi
        orcid: http://orcid.org/0000-0002-6288-5233
      - name: Hao Chen
        orcid: http://orcid.org/0000-0001-8319-8101
      - name: Yi Zhu
        orcid: http://orcid.org/0000-0002-1778-8880
      - name: Mian-li Xiao
        orcid: null
      - name: Zengliang Jiang
        orcid: null
      - name: Zelei Miao
        orcid: null
      - name: Congmei Xiao
        orcid: null
      - name: Bo Shen
        orcid: http://orcid.org/0000-0002-1662-3558
      - name: Xiaomai Wu
        orcid: null
      - name: Haihong Zhao
        orcid: null
      - name: Wenhua Ling
        orcid: null
      - name: Jun Wang
        orcid: http://orcid.org/0000-0003-0801-9796
      - name: Yu-ming Chen
        orcid: http://orcid.org/0000-0003-1658-5528
      - name: Tiannan Guo
        orcid: http://orcid.org/0000-0003-3869-7651
      - name: Ju-Sheng Zheng
        orcid: http://orcid.org/0000-0001-6560-4890
  comment:
    dislikes: 0
    thread: "7991899793"
    numReports: 0
    likes: 0
    id: "5409966791"
    createdAt: 2021-06-06T07:02:22
    author:
      username: jushengzheng
      about: ""
      name: Ju-Sheng Zheng
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jushengzheng/
      url: ""
      location: ""
      id: "370518531"
    isApproved: true
    raw_message: "This work is now published in the Journal of Genetics and
      Genomics. 2021. doi: 10.1016/j.jgg.2021.04.002"
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.04.22.20076091v1
  tweets:
    - created_at: Mon Jun 07 01:38:57 +0000 2021
      id: 1401715271350558700
      id_str: "1401715271350558721"
      text: >-
        üí¨ medRxiv comment on "Gut microbiota may underlie th..."


        "This work is now published in the Journal of Genetics an‚Ä¶ https://t.co/Fu0M2J9Cpz
      truncated: true
      entities:
        urls:
          - url: https://t.co/Fu0M2J9Cpz
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 07 01:38:58 +0000 2021
      id: 1401715272071983000
      id_str: "1401715272071983110"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/kGDqjheLLD
      truncated: false
      entities:
        urls:
          - url: https://t.co/kGDqjheLLD
      in_reply_to_status_id: 1401715271350558700
      in_reply_to_status_id_str: "1401715271350558721"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 0
    id: "5409793354"
    createdAt: 2021-06-06T01:39:01
    author:
      username: xpofoncxpawd
      about: ""
      name: Florin
      isPowerContributor: false
      profileUrl: https://disqus.com/by/xpofoncxpawd/
      url: ""
      location: ""
      id: "229571034"
    isApproved: true
    raw_message: Why didn't those restrictions work for covid?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon Jun 07 13:16:32 +0000 2021
      id: 1401890821461450800
      id_str: "1401890821461450755"
      text: |-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."

        "Why didn't those restrictions work for covid?"

        https://t.co/UxDCA69tQL
      truncated: false
      entities:
        urls:
          - url: https://t.co/UxDCA69tQL
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 07 13:16:32 +0000 2021
      id: 1401890822220664800
      id_str: "1401890822220664845"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1401890821461450800
      in_reply_to_status_id_str: "1401890821461450755"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 0
    id: "5409792147"
    createdAt: 2021-06-06T01:37:20
    author:
      username: xpofoncxpawd
      about: ""
      name: Florin
      isPowerContributor: false
      profileUrl: https://disqus.com/by/xpofoncxpawd/
      url: ""
      location: ""
      id: "229571034"
    isApproved: true
    raw_message: Not really, because the flu probably spreads primarily via aerosols
      just like covid. The only difference is that covid is more contagious.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon Jun 07 14:51:24 +0000 2021
      id: 1401914697042038800
      id_str: "1401914697042038785"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Not really, because the flu probably spreads primarily v‚Ä¶ https://t.co/VU514s9Sjg
      truncated: true
      entities:
        urls:
          - url: https://t.co/VU514s9Sjg
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 07 14:51:25 +0000 2021
      id: 1401914698245750800
      id_str: "1401914698245750792"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1401914697042038800
      in_reply_to_status_id_str: "1401914697042038785"
- preprint:
    id: "144702"
    doi: 10.1101/2021.06.03.446998
    first_posted: 2021-06-04
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.03.446998v1
    url: https://api.rxivist.org/v1/papers/144702
    title: Accelerating RepeatClassifier Based on Spark and Greedy Algorithm with
      Dynamic Upper Boundary
    category: bioinformatics
    abstract: Transposable elements (TEs) represent quantitatively important
      components of genome sequences (e.g. 90% of the wheat genome), and play
      important roles in genome organization and evolution. The promotion of
      unsupervised annotation of transposable elements is of great significance.
      Classification is an important step in TE annotation, which summarize the
      information about the type or mechanism for the raw repetitive sequences.
      RepeatClassifier is a basic homology-based classification tool which
      compares the TE families to both the Repeat Protein Database (DB) and
      libraries of RepeatMasker. Unfortunately, RepeatClassifier is inefficient
      and takes a few days to classify the repetitive sequences of large
      genomes. Hence, we proposed Spark-based RepeatClassifier (SRC) which uses
      Greedy Algorithm with Dynamic Upper Boundary (GDUB) for data division and
      load balancing, and Spark to improve the parallelism of RepeatClassifier.
      Experimental results show that SRC can not only ensure the same level of
      accuracy as that of RepeatClassifier, but also achieve 42-88 times of
      acceleration compared to RepeatClassifier. At the same time, SRC shows
      excellent parallel performance when dealing with input datasets with
      unbalanced length distribution.
    authors:
      - name: Kang Hu
        orcid: null
      - name: Xingyu Liao
        orcid: null
      - name: You Zou
        orcid: null
      - name: Jianxin Wang
        orcid: null
  comment:
    dislikes: 0
    thread: "8572964724"
    numReports: 0
    likes: 1
    id: "5410319835"
    createdAt: 2021-06-06T15:55:16
    author:
      username: xingyuliao
      about: King Abdullah University of Science and Technology (KAUST),  Thuwal,
        23955, Saudi Arabia.
      name: Xingyu Liao
      isPowerContributor: false
      profileUrl: https://disqus.com/by/xingyuliao/
      url: https://cemse.kaust.edu.sa/sfb
      location: King Abdullah University of Science and Technology (KAUST), Saudi Arabia.
      id: "370535601"
    isApproved: true
    raw_message: SRC is publicly available at <a
      href="#">https://github.com/BioinformaticsCSU/SRC</a>
    forum: biorxivstage
    points: 1
    link: https://www.biorxiv.org/content/10.1101/2021.06.03.446998v1
  tweets:
    - created_at: Mon Jun 07 17:40:58 +0000 2021
      id: 1401957370222329900
      id_str: "1401957370222329860"
      text: |-
        üí¨ bioRxiv comment on "Accelerating RepeatClassifier ..."

        "SRC is publicly available at &lt;a href="#"&gt;"

        https://t.co/ejI2tGgGSh
      truncated: false
      entities:
        urls:
          - url: https://t.co/ejI2tGgGSh
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 07 17:40:59 +0000 2021
      id: 1401957371107229700
      id_str: "1401957371107229697"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/gGduX0OQNN
      truncated: false
      entities:
        urls:
          - url: https://t.co/gGduX0OQNN
      in_reply_to_status_id: 1401957370222329900
      in_reply_to_status_id_str: "1401957370222329860"
- preprint:
    id: "144836"
    doi: 10.1101/2021.06.04.447051
    first_posted: 2021-06-05
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.04.447051v1
    url: https://api.rxivist.org/v1/papers/144836
    title: "Patterning on the move: the effects of Hh morphogen source movement on
      signaling dynamics"
    category: developmental-biology
    abstract: Morphogens of the Hh-family trigger gene expression changes of
      receiving cells in a concentration-dependent manner. The outputs of the
      pathway include regulation of cell identity, proliferation, death or
      metabolism, depending on the tissue or organ. This variety of responses
      relies on a conserved signaling pathway. Its internal logic includes a
      negative feedback loop involving the Hh receptor Ptc. In this paper, we
      use experiments and computational models to study and compare the
      different spatial signaling profiles downstream of Hh in several
      developing Drosophila organs. We show that the spatial distribution of Ptc
      and the activator form of the Gli transcription factor, CiA, in wing,
      antenna and ocellus show similar features, but markedly different from
      that in the compound eye (CE). We show that these two profile types
      represent two time points along the signaling dynamics, and that the
      interplay between the spatial displacement of the Hh source in the CE and
      the negative feedback loop maintains the receiving cells effectively in an
      earlier stage of signaling. These results indicate that the dynamics of
      the Hh source strongly influences the signaling profile Hh elicits in
      receiving cells, and show how the interaction between spatial and temporal
      dynamics of signaling and differentiation processes can contribute to the
      informational versatility of the conserved Hh signaling pathway.
    authors:
      - name: david G Miguez
        orcid: http://orcid.org/0000-0001-8065-1142
      - name: Antonella G Iannini
        orcid: null
      - name: diana garcia-morales
        orcid: null
      - name: Fernando Casares
        orcid: http://orcid.org/0000-0002-2181-3858
  comment:
    dislikes: 0
    thread: "8575513360"
    numReports: 0
    likes: 0
    id: "5409919618"
    createdAt: 2021-06-06T05:13:39
    author:
      username: disqus_t6H9fs1Wrl
      about: ""
      name: Stuart Newman
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_t6H9fs1Wrl/
      url: ""
      location: ""
      id: "370515184"
    isApproved: true
    raw_message: What is described here is a "morphodynamic" mechanism, as defined
      in this paper https://pubmed.ncbi.nlm.nih.gov/12668618/
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.04.447051v1
  tweets:
    - created_at: Mon Jun 07 19:56:36 +0000 2021
      id: 1401991500775428000
      id_str: "1401991500775428096"
      text: >-
        üí¨ bioRxiv comment on "Patterning on the move: the ef..."


        "What is described here is a "morphodynamic" mechanism, a‚Ä¶ https://t.co/0sVpXmRhZP
      truncated: true
      entities:
        urls:
          - url: https://t.co/0sVpXmRhZP
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 07 19:56:36 +0000 2021
      id: 1401991501568225300
      id_str: "1401991501568225281"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/WfvSKyxFqY
      truncated: false
      entities:
        urls:
          - url: https://t.co/WfvSKyxFqY
      in_reply_to_status_id: 1401991500775428000
      in_reply_to_status_id_str: "1401991500775428096"
- preprint:
    id: 131874
    metric: 5
    title: The mRNA-LNP platform's lipid nanoparticle component used in preclinical
      vaccine studies is highly inflammatory
    url: https://api.rxivist.org/v1/papers/131874
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.03.04.430128v1
    doi: 10.1101/2021.03.04.430128
    category: immunology
    first_posted: 2021-03-04
    abstract: >-
      Vaccines based on mRNA-containing lipid nanoparticles (LNPs) are a
      promising new platform used by two leading vaccines against coronavirus
      disease in 2019 (COVID-19). Clinical trials and ongoing vaccinations
      present with very high protection levels and varying degrees of side
      effects. However, the nature of the reported side effects remains poorly
      defined. Here we present evidence that LNPs used in many preclinical
      studies are highly inflammatory in mice. Intradermal injection of these
      LNPs led to rapid and robust inflammatory responses, characterized by
      massive neutrophil infiltration, activation of diverse inflammatory
      pathways, and production of various inflammatory cytokines and chemokines.
      The same dose of LNP delivered intranasally led to similar inflammatory
      responses in the lung and resulted in a high mortality rate.


      In summary, here we show that the LNPs used for many preclinical studies are highly inflammatory. Thus, their potent adjuvant activity and reported superiority comparing to other adjuvants in supporting the induction of adaptive immune responses could stem from their inflammatory nature. Furthermore, the preclinical LNPs are similar to the ones used for human vaccines, which could also explain the observed side effects in humans using this platform.
    authors:
      - name: Sonia Ndeupen
      - name: Zhen Qin
      - name: Sonya Jacobsen
      - name: Henri Estanbouli
      - name: Aur√©lie Bouteau
      - name: Botond Z. Igy√°rt√≥
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Mon Jun 07 21:15:49 +0000 2021
      id: 1402011437749395500
      id_str: "1402011437749395458"
      text: >-
        üî• bioRxiv Immunology preprint by S. Ndeupen et al:


        "The mRNA-LNP platform's lipid nanoparticle component used in p‚Ä¶ https://t.co/NFFgZN3ZQb
      truncated: true
      entities:
        urls:
          - url: https://t.co/NFFgZN3ZQb
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "144165"
    doi: 10.1101/2021.05.31.21258081
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.31.21258081v1
    url: https://api.rxivist.org/v1/papers/144165
    title: Favorable outcome on viral load and culture viability using Ivermectin in
      early treatment of non-hospitalized patients with mild COVID-19, A
      double-blind, randomized placebo-controlled trial.
    category: infectious-diseases
    abstract: "Background: Ivermectin, an antiparasitic agent, also has antiviral
      properties. Our aim was to assess whether ivermectin can shorten the viral
      shedding in patients at an early stage of COVID19 infection. Methods: The
      double blinded trial compared patients receiving ivermectin 0.2 mg/kg for
      3 days vs. placebo in non-hospitalized COVID19 patients. RT-PCR from a
      nasopharyngeal swab was obtained at recruitment and then every two days.
      Primary endpoint was reduction of viral-load on the 6th day (third day
      after termination of treatment) as reflected by Ct level>30
      (non-infectious level). The primary outcome was supported by determination
      of viral culture viability. Results: Eighty nine patients were eligible
      (47 in ivermectin and 42 in placebo arm). Their median age was 35 years.
      Females accounted for 21.6%, and 16.8% were asymptomatic at recruitment.
      Median time from symptom onset was 4 days. There were no statistical
      differences in these parameters between the two groups. On day 6, 34 out
      of 47 (72%) patients in the ivermectin arm reached the endpoint, compared
      to 21/ 42 (50%) in the placebo arm (OR 2.62; 95% CI: 1.09 to 6.31). In a
      multivariable logistic regression model, the odds of a negative test at
      day 6 was 2.62 time higher in the ivermectin group (95% CI: 1.06 to 6.45).
      Cultures at days 2 to 6 were positive in 3/23 (13.0%) of ivermectin
      samples vs. 14/29 (48.2%) in the placebo group (p=0.008). Conclusions:
      There were significantly lower viral loads and viable cultures in the
      ivermectin group, which could lead to shortening isolation time in these
      patients."
    authors:
      - name: Asaf Biber
        orcid: http://orcid.org/0000-0001-6007-0383
      - name: Michal Mandelboim
        orcid: http://orcid.org/0000-0002-5997-7241
      - name: Geva Harmelin
        orcid: null
      - name: Dana Lev
        orcid: null
      - name: Li Ram
        orcid: null
      - name: Amit Shaham
        orcid: null
      - name: Ital Nemet
        orcid: null
      - name: Limor Kliker
        orcid: null
      - name: Oran Erster
        orcid: http://orcid.org/0000-0003-4839-8997
      - name: Eli Schwartz
        orcid: null
  comment:
    dislikes: 0
    thread: "8565279083"
    numReports: 0
    likes: 0
    id: "5409257116"
    createdAt: 2021-06-05T15:33:22
    author:
      username: nordic_spectator
      about: ""
      name: Scandinavian Journal
      isPowerContributor: false
      profileUrl: https://disqus.com/by/nordic_spectator/
      url: ""
      location: Stockholm, Sweden
      id: "62710197"
    isApproved: true
    raw_message: Imo the twelve (13¬∑5%) patients that had comorbidities associated
      with risk for severe disease [17] made a courageous contribution by
      accepting the possibility of ending up receiving placebo in the trial.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.31.21258081v1
  tweets:
    - created_at: Mon Jun 07 21:21:10 +0000 2021
      id: 1402012785945550800
      id_str: "1402012785945550852"
      text: >-
        üí¨ medRxiv comment on "Favorable outcome on viral loa..."


        "Imo the twelve (13¬∑5%) patients that had comorbidities a‚Ä¶ https://t.co/Jsy5L8UO40
      truncated: true
      entities:
        urls:
          - url: https://t.co/Jsy5L8UO40
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 07 21:21:11 +0000 2021
      id: 1402012786763485200
      id_str: "1402012786763485184"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/fIgXlfTSzw
      truncated: false
      entities:
        urls:
          - url: https://t.co/fIgXlfTSzw
      in_reply_to_status_id: 1402012785945550800
      in_reply_to_status_id_str: "1402012785945550852"
- preprint:
    id: "111834"
    doi: 10.1101/2020.05.30.20117556
    first_posted: 2020-06-03
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.05.30.20117556v1
    url: https://api.rxivist.org/v1/papers/111834
    title: "SIR-PID: A Proportional-Integral-Derivative Controller for COVID-19
      Outbreak Containment"
    category: epidemiology
    abstract: Ongoing social restrictions, as distancing and lockdown, adopted by
      many countries for contrasting the COVID-19 epidemic spread, try to find a
      trade-off between induced economic crisis, healthcare system collapse and
      costs in terms of human lives. Applying and removing restrictions on a
      system with uncontrollable inertia, as represented by an epidemic
      outbreak, may create critical instabilities, overshoots and strong
      oscillations of infected people around the desirable set-point, defined as
      the maximum number of hospitalizations acceptable by a given healthcare
      system. A good understanding of the system reaction to a change of the
      input control variable can be reasonably achieved using a
      proportional-integral-derivative controller, widely used in technological
      applications. In this paper we make use of this basic control theory for
      understanding the reaction of COVID-19 propagation to social restrictions
      and for exploiting a very known technology to reduce the epidemic damages
      through the correct tuning of the containment policy.
    authors:
      - name: Nicola Rossi
        orcid: http://orcid.org/0000-0002-7046-528X
      - name: Aldo Ianni
        orcid: http://orcid.org/0000-0002-6962-3682
  comment:
    dislikes: 0
    thread: "8057297405"
    numReports: 0
    likes: 0
    id: "5409165813"
    createdAt: 2021-06-05T13:55:27
    author:
      username: disqus_BSvFLJa2NJ
      about: ""
      name: Tim Winton
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_BSvFLJa2NJ/
      url: ""
      location: ""
      id: "370340367"
    isApproved: true
    raw_message: Would it be possible to see the code for this?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.05.30.20117556v1
  tweets:
    - created_at: Mon Jun 07 22:48:18 +0000 2021
      id: 1402034712479154200
      id_str: "1402034712479154179"
      text: |-
        üí¨ medRxiv comment on "SIR-PID: A Proportional-Integr..."

        "Would it be possible to see the code for this?"

        https://t.co/W5FsPbjFfD
      truncated: false
      entities:
        urls:
          - url: https://t.co/W5FsPbjFfD
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 07 22:48:18 +0000 2021
      id: 1402034713183854600
      id_str: "1402034713183854592"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/xbcm7ufJwN
      truncated: false
      entities:
        urls:
          - url: https://t.co/xbcm7ufJwN
      in_reply_to_status_id: 1402034712479154200
      in_reply_to_status_id_str: "1402034712479154179"
- preprint:
    id: "144820"
    doi: 10.1101/2021.06.04.447073
    first_posted: 2021-06-05
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.04.447073v1
    url: https://api.rxivist.org/v1/papers/144820
    title: Modeling sequence-space exploration and emergence of epistatic signals in
      protein evolution
    category: evolutionary-biology
    abstract: During their evolution, proteins explore sequence space via an
      interplay between random mutations and phenotypic selection. Here we build
      upon recent progress in reconstructing data-driven fitness landscapes for
      families of homologous proteins, to propose stochastic models of
      experimental protein evolution. These models predict quantitatively
      important features of experimentally evolved sequence libraries, like
      fitness distributions and position-specific mutational spectra. They also
      allow us to efficiently simulate sequence libraries for a vast array of
      combinations of experimental parameters like sequence divergence,
      selection strength and library size. We showcase the potential of the
      approach in re-analyzing two recent experiments to determine protein
      structure from signals of epistasis emerging in experimental sequence
      libraries. To be detectable, these signals require sufficiently large and
      sufficiently diverged libraries. Our modeling framework offers a
      quantitative explanation for the variable success of recently published
      experiments. Furthermore, we can forecast the outcome of time- and
      resource-intensive evolution experiments, opening thereby a way to
      computationally optimize experimental protocols.
    authors:
      - name: Matteo Bisardi
        orcid: null
      - name: Juan Rodriguez-Rivas
        orcid: null
      - name: Francesco Zamponi
        orcid: http://orcid.org/0000-0001-9260-1951
      - name: Martin Weigt
        orcid: http://orcid.org/0000-0002-0492-3684
  comment:
    dislikes: 0
    thread: "8574576439"
    numReports: 0
    likes: 0
    id: "5409014907"
    createdAt: 2021-06-05T10:20:07
    author:
      name: Marc Robinson-Rechavi
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    raw_message: >-
      Under <b>Data and code availability</b>, the authors write:


      <blockquote>The code for evolutionary simulations together with sample notoebooks and data used in the article will be made available on GitHub along with the publication of the manuscript.</blockquote>


      This is a publication, i.e. it is made public as part of the scientific record and is citable, thus I strongly invite the authors to make the corresponding GitHub available without delay.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.04.447073v1
  tweets:
    - created_at: Tue Jun 08 01:35:44 +0000 2021
      id: 1402076849358966800
      id_str: "1402076849358966789"
      text: >-
        üí¨ bioRxiv comment on "Modeling sequence-space explor..."


        "Under &lt;b&gt;Data and code availability&lt;/b&gt;, the authors wri‚Ä¶ https://t.co/4SoUC5l5ye
      truncated: true
      entities:
        urls:
          - url: https://t.co/4SoUC5l5ye
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 08 01:35:45 +0000 2021
      id: 1402076850130755600
      id_str: "1402076850130755595"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/TqknsPTeBM
      truncated: false
      entities:
        urls:
          - url: https://t.co/TqknsPTeBM
      in_reply_to_status_id: 1402076849358966800
      in_reply_to_status_id_str: "1402076849358966789"
- preprint:
    id: "144205"
    doi: 10.1101/2021.06.01.446425
    first_posted: 2021-06-01
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.01.446425v1
    url: https://api.rxivist.org/v1/papers/144205
    title: Brief exposure of neuronal cells to levels of short chain fatty acids
      observed in human systemic circulation impair the cell lipid metabolism
      resulting in associated cell death by apoptosis
    category: neuroscience
    abstract: Communication between gut microbiota and the brain is an enigma.
      Alterations in the gut microbial community affects enteric metabolite
      levels, such as SCFAs. SCFAs have been proposed as a possible mechanism
      through which the gut microbiome modulate brain health and function. This
      study analyzed for the first time the effects of SCFAs at levels reported
      in human systemic circulation on human neuronal cell energy metabolism,
      viability, survival and the brain lipidome. Cell and rat brain lipidomics
      was done using UHPLC-HESI-HRAMS/MS. Neuronal cells viability, survival and
      energy metabolism were analyzed via flow cytometer, immunofluorescence,
      and SeahorseXF platform. Lipidomics analysis demonstrated that SCFAs
      significantly remodeled the brain lipidome in vivo and in vitro. The most
      notable remodulation was observed in the metabolism of
      phosphatidylethanolamine plasmalogens, and mitochondrial lipids carnitine
      and cardiolipin. Increased mitochondrial mass, fragmentation, and
      hyperfusion occurred concomitant with the altered mitochondrial lipid
      metabolism resulting in decreased neuronal cell respiration, ATP
      production, and increased cell death. This suggests SCFAs at levels
      observed in human systemic circulation can adversely alter the brain
      lipidome and neuronal cell function potentially negatively impacting brain
      health outcomes.
    authors:
      - name: Tiffany A Fillier
        orcid: http://orcid.org/0000-0002-9663-351X
      - name: Shrushti Shah
        orcid: null
      - name: Karen M Doody
        orcid: null
      - name: Thu H Pham
        orcid: null
      - name: Isabelle Aubry
        orcid: null
      - name: Michel L Tremblay
        orcid: http://orcid.org/0000-0002-0281-541X
      - name: Sukhinder K Cheema
        orcid: null
      - name: Jacqueline Blundell
        orcid: null
      - name: Raymond H Thomas
        orcid: null
  comment:
    dislikes: 0
    thread: "8567118713"
    numReports: 0
    likes: 0
    id: "5409003303"
    createdAt: 2021-06-05T09:58:50
    author:
      name: Dr Raymond Thomas
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    raw_message: Gut microbial metabolites (acetate, propionate and butyrate) at
      levels measure in human blood circulation can adversely alter the brain
      lipidome and brain energetics. I encourage my colleagues to look at the
      work in this paper and consider this an area of further research. There is
      alot of information in the literature on the  health benefits of short
      chain fatty acids  but more attention should be placed on effects on brain
      health.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.01.446425v1
  tweets:
    - created_at: Tue Jun 08 12:34:48 +0000 2021
      id: 1402242708547293200
      id_str: "1402242708547293185"
      text: >-
        üí¨ bioRxiv comment on "Brief exposure of neuronal cel..."


        "Gut microbial metabolites (acetate, propionate and butyr‚Ä¶ https://t.co/7OLIdJKV14
      truncated: true
      entities:
        urls:
          - url: https://t.co/7OLIdJKV14
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 08 12:34:48 +0000 2021
      id: 1402242709335720000
      id_str: "1402242709335719937"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/GZNbr4J41i
      truncated: false
      entities:
        urls:
          - url: https://t.co/GZNbr4J41i
      in_reply_to_status_id: 1402242708547293200
      in_reply_to_status_id_str: "1402242708547293185"
- preprint:
    id: "144165"
    doi: 10.1101/2021.05.31.21258081
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.31.21258081v1
    url: https://api.rxivist.org/v1/papers/144165
    title: Favorable outcome on viral load and culture viability using Ivermectin in
      early treatment of non-hospitalized patients with mild COVID-19, A
      double-blind, randomized placebo-controlled trial.
    category: infectious-diseases
    abstract: "Background: Ivermectin, an antiparasitic agent, also has antiviral
      properties. Our aim was to assess whether ivermectin can shorten the viral
      shedding in patients at an early stage of COVID19 infection. Methods: The
      double blinded trial compared patients receiving ivermectin 0.2 mg/kg for
      3 days vs. placebo in non-hospitalized COVID19 patients. RT-PCR from a
      nasopharyngeal swab was obtained at recruitment and then every two days.
      Primary endpoint was reduction of viral-load on the 6th day (third day
      after termination of treatment) as reflected by Ct level>30
      (non-infectious level). The primary outcome was supported by determination
      of viral culture viability. Results: Eighty nine patients were eligible
      (47 in ivermectin and 42 in placebo arm). Their median age was 35 years.
      Females accounted for 21.6%, and 16.8% were asymptomatic at recruitment.
      Median time from symptom onset was 4 days. There were no statistical
      differences in these parameters between the two groups. On day 6, 34 out
      of 47 (72%) patients in the ivermectin arm reached the endpoint, compared
      to 21/ 42 (50%) in the placebo arm (OR 2.62; 95% CI: 1.09 to 6.31). In a
      multivariable logistic regression model, the odds of a negative test at
      day 6 was 2.62 time higher in the ivermectin group (95% CI: 1.06 to 6.45).
      Cultures at days 2 to 6 were positive in 3/23 (13.0%) of ivermectin
      samples vs. 14/29 (48.2%) in the placebo group (p=0.008). Conclusions:
      There were significantly lower viral loads and viable cultures in the
      ivermectin group, which could lead to shortening isolation time in these
      patients."
    authors:
      - name: Asaf Biber
        orcid: http://orcid.org/0000-0001-6007-0383
      - name: Michal Mandelboim
        orcid: http://orcid.org/0000-0002-5997-7241
      - name: Geva Harmelin
        orcid: null
      - name: Dana Lev
        orcid: null
      - name: Li Ram
        orcid: null
      - name: Amit Shaham
        orcid: null
      - name: Ital Nemet
        orcid: null
      - name: Limor Kliker
        orcid: null
      - name: Oran Erster
        orcid: http://orcid.org/0000-0003-4839-8997
      - name: Eli Schwartz
        orcid: null
  comment:
    dislikes: 0
    thread: "8565279083"
    numReports: 0
    likes: 0
    id: "5408619497"
    createdAt: 2021-06-04T23:07:32
    author:
      username: artpatronforever
      about: ""
      name: artpatronforever
      isPowerContributor: false
      profileUrl: https://disqus.com/by/artpatronforever/
      url: ""
      location: ""
      id: "370453372"
    isApproved: true
    raw_message: |-
      Why has the ages established and rational dogma of medicine advocating 
      early treatment to blunt the severity or to halt the progression of 
      disease been a fundamental principle of medicine abandoned as an 
      unprecedented exception for COVID-19 ?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.31.21258081v1
  tweets:
    - created_at: Tue Jun 08 14:28:21 +0000 2021
      id: 1402271281064693800
      id_str: "1402271281064693764"
      text: >-
        üí¨ medRxiv comment on "Favorable outcome on viral loa..."


        "Why has the ages established and rational dogma of medic‚Ä¶ https://t.co/wKgvR2xxES
      truncated: true
      entities:
        urls:
          - url: https://t.co/wKgvR2xxES
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 08 14:28:21 +0000 2021
      id: 1402271281840537600
      id_str: "1402271281840537601"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/fIgXlfTSzw
      truncated: false
      entities:
        urls:
          - url: https://t.co/fIgXlfTSzw
      in_reply_to_status_id: 1402271281064693800
      in_reply_to_status_id_str: "1402271281064693764"
- preprint:
    id: "87572"
    doi: 10.1101/2020.06.15.153056
    first_posted: 2020-06-16
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.06.15.153056v2
    url: https://api.rxivist.org/v1/papers/87572
    title: Enhancing Mask Activity in Dopaminergic Neurons Extends Lifespan in Flies
    category: neuroscience
    abstract: Dopaminergic neurons (DANs) are essential modulators for brain
      functions involving memory formation, reward processing, and decision
      making. Here I demonstrate a novel and important function of the DANs in
      regulating aging and longevity. Overexpressing the putative scaffolding
      protein Mask in two small groups of DANs in flies can significantly extend
      the lifespan in flies and sustain adult locomotor and fecundity at old
      ages. Such a Mask-induced beneficial effect requires dopaminergic
      transmission but cannot be recapitulated by elevating dopamine production
      in the DANs. Independent activation of Gs in the same two groups of DANs
      via the drug-inducible DREADD system also extends fly lifespan, further
      indicating the connection of specific DANs to aging control. The
      Mask-induced lifespan extension appears to depend on the function of Mask
      to regulate microtubule (MT) stability. A structure-function analysis
      demonstrated that the ankyrin repeats domain in the Mask protein is both
      necessary for regulating MT stability (when expressed in muscles and motor
      neurons) and sufficient to prolong longevity (when expressed in the two
      groups of DANs). Furthermore, DAN-specific overexpression of Unc-104 or
      knockdown of p150Glued, two independent interventions previously shown to
      impact MTs dynamics, also extend lifespan in flies. Together these data
      demonstrated a novel DANs-dependent mechanism that, upon neuronal
      cell-type specific tuning of MT dynamics, modulates systemic aging and
      longevity in flies.
    authors:
      - name: Xiaolin Tian
        orcid: http://orcid.org/0000-0001-8898-1664
  comment:
    dislikes: 0
    thread: "8486628525"
    numReports: 0
    likes: 0
    id: "5408432537"
    createdAt: 2021-06-04T19:55:41
    author:
      username: layalsuboh
      about: ""
      name: LAYAL SUBOH
      isPowerContributor: false
      profileUrl: https://disqus.com/by/layalsuboh/
      url: ""
      location: ""
      id: "370447791"
    isApproved: true
    raw_message: >-
      This was a great and very interesting paper to read. The figures were easy
      to read and use of the color was really helpful to visualize the results.
      However, I think that in figure 1D, including a table or figure legend to
      explain what the various colors are in the diagram would be very helpful.
      Also, the paper and figures switch between referring to PAM dopaminergic
      neurons as 0273, which can be a little confusing, so keeping the notation
      consistent would be great. 


      I understand that you overexpress Mask from birth, but would it be possible to let the flies grow up and then induce Mask overexpression to see whether the same phenotype is observed? This could avoid any complications with Mask‚Äôs potential role in development and other signaling pathways. Also, exploring what the flies are dying of that Mask overexpression avoids would make your argument of Mask‚Äôs role in increasing survivorship stronger. I found it very interesting that increasing microtubule dynamics increased lifespan, but I think that more clearly showing how/why Mask increases microtubule dynamics would strengthen the association between microtubules, Mask, and lifespan. Perhaps including a coimmunoprecipitation to show Mask‚Äôs interacting partners or showing how Unc-104 or P150 glued are affected due to Mask overexpression would make this association clearer. 


      It is truly commendable you were able to generate these results on your own, so please keep up the great work! I look forward to reading your future research
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.06.15.153056v3
  tweets:
    - created_at: Tue Jun 08 16:48:57 +0000 2021
      id: 1402306666687774700
      id_str: "1402306666687774724"
      text: >-
        üí¨ bioRxiv comment on "Enhancing Mask Activity in Dop..."


        "This was a great and very interesting paper to read. The‚Ä¶ https://t.co/mAM8xLk6GT
      truncated: true
      entities:
        urls:
          - url: https://t.co/mAM8xLk6GT
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 08 16:48:57 +0000 2021
      id: 1402306667577057300
      id_str: "1402306667577057286"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/MC2P104ipf
      truncated: false
      entities:
        urls:
          - url: https://t.co/MC2P104ipf
      in_reply_to_status_id: 1402306666687774700
      in_reply_to_status_id_str: "1402306666687774724"
- preprint:
    id: "105266"
    doi: 10.1101/2020.10.19.20215392
    first_posted: 2020-10-21
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.10.19.20215392v2
    url: https://api.rxivist.org/v1/papers/105266
    title: "ANTsX: A dynamic ecosystem for quantitative biological and medical
      imaging"
    category: radiology-and-imaging
    abstract: The Advanced Normalizations Tools ecosystem, known as ANTsX, consists
      of multiple open-source software libraries which house top-performing
      algorithms used worldwide by scientific and research communities for
      processing and analyzing biological and medical imaging data. The base
      software library, ANTs, is built upon, and contributes to, the
      NIH-sponsored Insight Toolkit. Founded in 2008 with the highly regarded
      Symmetric Normalization image registration framework, the ANTs library has
      since grown to include additional functionality. Recent enhancements
      include statistical, visualization, and deep learning capabilities through
      interfacing with both the R statistical project (ANTsR) and Python
      (ANTsPy). Additionally, the corresponding deep learning extensions
      ANTsRNet and ANTsPyNet (built on the popular TensorFlow/Keras libraries)
      contain several popular network architectures and trained models for
      specific applications. One such comprehensive application is a deep
      learning analog for generating cortical thickness data from structural
      T1-weighted brain MRI. Not only does this significantly improve
      computational efficiency and provide comparable-to-superior accuracy over
      multiple criteria relative to the existing ANTs pipelines but it also
      illustrates the importance of the comprehensive ANTsX approach as a
      framework for medical image analysis.
    authors:
      - name: Nicholas J. Tustison
        orcid: http://orcid.org/0000-0001-9418-5103
      - name: Philip A. Cook
        orcid: http://orcid.org/0000-0002-1985-8475
      - name: Andrew J. Holbrook
        orcid: http://orcid.org/0000-0002-3558-200X
      - name: Hans J. Johnson
        orcid: http://orcid.org/0000-0001-9513-2660
      - name: John Muschelli
        orcid: http://orcid.org/0000-0001-6469-1750
      - name: Gabriel A Devenyi
        orcid: http://orcid.org/0000-0002-7766-1187
      - name: Jeffrey T. Duda
        orcid: http://orcid.org/0000-0002-5031-5735
      - name: Sandhitsu R. Das
        orcid: http://orcid.org/0000-0003-0530-2887
      - name: Nicholas C. Cullen
        orcid: null
      - name: Daniel L. Gillen
        orcid: http://orcid.org/0000-0003-0200-1771
      - name: Michael A. Yassa
        orcid: http://orcid.org/0000-0002-8635-1498
      - name: James R. Stone
        orcid: null
      - name: James Gee
        orcid: http://orcid.org/0000-0002-2258-0187
      - name: Brian B. Avants
        orcid: http://orcid.org/0000-0002-4212-3362
  comment:
    dislikes: 0
    thread: "8424573660"
    numReports: 0
    likes: 0
    id: "5408431583"
    createdAt: 2021-06-04T19:54:51
    author:
      username: nicktustison
      about: ""
      name: Nick Tustison
      isPowerContributor: false
      profileUrl: https://disqus.com/by/nicktustison/
      url: ""
      location: ""
      id: "370447806"
    isApproved: true
    raw_message: https://www.nature.com/articles/s41598-021-87564-6
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.10.19.20215392v7
  tweets:
    - created_at: Tue Jun 08 18:48:33 +0000 2021
      id: 1402336762987528200
      id_str: "1402336762987528196"
      text: |-
        üí¨ medRxiv comment on "ANTsX: A dynamic ecosystem for..."

        ""

        https://t.co/Dic9usX95e
      truncated: false
      entities:
        urls:
          - url: https://t.co/Dic9usX95e
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 08 18:48:33 +0000 2021
      id: 1402336763813695500
      id_str: "1402336763813695503"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/L3zeAcu6y9
      truncated: false
      entities:
        urls:
          - url: https://t.co/L3zeAcu6y9
      in_reply_to_status_id: 1402336762987528200
      in_reply_to_status_id_str: "1402336762987528196"
- preprint:
    id: 143752
    metric: 10
    title: Multi-dimensional analyses identify genes of high priority for pancreatic
      cancer research
    url: https://api.rxivist.org/v1/papers/143752
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.28.446056v1
    doi: 10.1101/2021.05.28.446056
    category: cancer-biology
    first_posted: 2021-05-28
    abstract: Genomic profiling has unveiled the molecular subtypes and mutational
      landscape of pancreatic ductal adenocarcinoma (PDAC). However, there is a
      knowledge gap on the consistency of gene expression across PDAC tumors
      profiled in independent studies and this limits follow up research. To
      facilitate novel drug target prioritization and biomarker discovery, we
      investigated the most consistently expressed genes in human PDAC. We
      identified ~4,000 genes highly or lowly expressed in at least 4 of 5
      microarrays (adjusted P<0.05) and validated their expression pattern in
      additional datasets, bulk tumor and single-cell RNA sequencing samples.
      Over 50% of the genes were previously uncharacterized in PDAC; many
      correlated with proliferation, metastasis, mutation, tumor grade, and ~41%
      predicted overall survival. We identified 185 high-priority targets
      (notably in cell cycle and glycolysis) whose inhibition suppressed PDAC
      cell viability in multiple RNA interference datasets and these genes
      predicted treatment in mouse models. Our results represent important
      milestone in the quest for mechanisms, drug targets and biomarkers in
      PDAC, and originate from an adaptable analytical concept that can aid
      discovery in other cancers.
    authors:
      - name: Zeribe C. Nwosu
      - name: Heather Giza
      - name: Maya Nassif
      - name: Verodia Charlestin
      - name: Rosa E. Menjivar
      - name: Daeho Kim
      - name: Samantha Kemp
      - name: Nina Steele
      - name: Jiantao Hu
      - name: Biao Hu
      - name: Shaomeng Wang
      - name: Marina Pasca di Magliano
      - name: Costas A Lyssiotis
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Tue Jun 08 20:22:59 +0000 2021
      id: 1402360527720894500
      id_str: "1402360527720894465"
      text: >-
        üî• bioRxiv Cancer-biology preprint by Z. C. Nwosu et al:


        "Multi-dimensional analyses identify genes of high priorit‚Ä¶ https://t.co/qdUzKJAvBH
      truncated: true
      entities:
        urls:
          - url: https://t.co/qdUzKJAvBH
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "114844"
    doi: 10.1101/2020.07.30.20068114
    first_posted: 2020-08-02
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.07.30.20068114v1
    url: https://api.rxivist.org/v1/papers/114844
    title: A multicentric, randomized, controlled phase III study of centhaquine
      (Lyfaquin(R)) as a resuscitative agent in hypovolemic shock patients
    category: intensive-care-and-critical-care-medicine
    abstract: "INTRODUCTION: Centhaquine (Lyfaquin(R)) showed significant safety and
      efficacy in preclinical and clinical phase I and II studies. METHODS: A
      prospective, multicentric, randomized phase III study was conducted in
      patients with hypovolemic shock having systolic blood pressure (SBP) of
      [&le;]90 mm Hg and blood lactate levels of [&ge;]2 mmol/L. Patients were
      randomized in a 2:1 ratio, 71 patients to the centhaquine group and 34
      patients to the control (saline) group. Every patient received standard of
      care (SOC) and was followed for 28 days. The study drug (normal saline or
      centhaquine (0.01 mg/kg)) was administered in 100 mL of normal saline
      infusion over 1 hour. The primary objectives were to determine changes
      (mean through 48 hours) in SBP, diastolic blood pressure (DBP), blood
      lactate levels, and base deficit. The secondary objectives included the
      amount of fluids, blood products, vasopressors administered in the first
      48 hours, duration of hospital stay, time in ICU, time on the ventilator
      support, change in patient's Acute Respiratory Distress Syndrome (ARDS),
      Multiple Organ Dysfunction Syndrome (MODS) scores, and the proportion of
      patients with 28-day all-cause mortality. RESULTS: The demographics of
      patients and baseline vitals in both groups were comparable. Trauma was
      the cause of hypovolemic shock in 29.41% of control and 47.06% of
      centhaquine, gastroenteritis in 44.12% of control, and 29.41% of
      centhaquine patients. An equal amount of fluids and blood products were
      administered in both groups during the first 48 hours of resuscitation. A
      lesser amount of vasopressors was needed in the first 48 hours of
      resuscitation in the centhaquine group. An increase in SBP from the
      baseline was consistently higher in the centhaquine group than in the
      control. A significant increase in pulse pressure in the centhaquine group
      than the control group suggests improved stroke volume due to centhaquine.
      The shock index was significantly lower in the centhaquine group than
      control from 1 hour (p=0.0320) till 4 hours (p=0.0494) of resuscitation.
      Resuscitation with centhaquine had a significantly greater number of
      patients with improved blood lactate and the base deficit than the control
      group. ARDS and MODS improved with centhaquine, and an 8.8% absolute
      reduction in 28-day all-cause mortality was observed in the centhaquine
      group. CONCLUSION: Centhaquine is a highly efficacious resuscitative agent
      for treating hypovolemic shock. The efficacy of centhaquine in
      distributive shock due to sepsis and COVID-19 is being explored. The study
      protocol (PMZ-2010/CT-3.1/2018) was approved by the Drug Controller
      General of India (DCGI), Ministry of Health and Family Welfare, Government
      of India, and Institutional Ethics Committee of all the 14 Institutions."
    authors:
      - name: Anil Gulati
        orcid: http://orcid.org/0000-0002-7420-4554
      - name: Rajat Choudhuri
        orcid: null
      - name: Ajay Gupta
        orcid: null
      - name: Saurabh Singh
        orcid: http://orcid.org/0000-0001-8038-1808
      - name: S. K. Noushad Ali
        orcid: null
      - name: Gursaran Kaur Sidhu
        orcid: null
      - name: Parvez David Haque
        orcid: null
      - name: Prashant Rahate
        orcid: null
      - name: Aditya R Bothra
        orcid: null
      - name: G P Singh
        orcid: null
      - name: Sanjeev Maheshwari
        orcid: null
      - name: Deepak Jeswani
        orcid: null
      - name: Sameer Haveri
        orcid: null
      - name: Apurva Agarwal
        orcid: null
      - name: Nilesh Radheshyam Agrawal
        orcid: null
  comment:
    dislikes: 0
    thread: "8513625128"
    numReports: 0
    likes: 0
    id: "5408406213"
    createdAt: 2021-06-04T19:32:52
    author:
      username: disqus_RkUV3iytSn
      about: ""
      name: Anil Gulati
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_RkUV3iytSn/
      url: ""
      location: ""
      id: "370446934"
    isApproved: true
    raw_message: This article is published in DRUGS. DOI
      https://doi.org/10.1007/s40265-021-01547-5
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.07.30.20068114v4
  tweets:
    - created_at: Tue Jun 08 20:26:53 +0000 2021
      id: 1402361511184679000
      id_str: "1402361511184678915"
      text: |-
        üí¨ medRxiv comment on "A multicentric, randomized, co..."

        "This article is published in DRUGS. DOI "

        https://t.co/3joH9eCSO9
      truncated: false
      entities:
        urls:
          - url: https://t.co/3joH9eCSO9
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 08 20:26:53 +0000 2021
      id: 1402361511885017000
      id_str: "1402361511885017088"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/vkjuniyTA1
      truncated: false
      entities:
        urls:
          - url: https://t.co/vkjuniyTA1
      in_reply_to_status_id: 1402361511184679000
      in_reply_to_status_id_str: "1402361511184678915"
- preprint:
    id: "140951"
    doi: 10.1101/2021.05.05.442755
    first_posted: 2021-05-05
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.05.442755v1
    url: https://api.rxivist.org/v1/papers/140951
    title: "STARsolo: accurate, fast and versatile mapping/quantification of
      single-cell and single-nucleus RNA-seq data"
    category: bioinformatics
    abstract: We present STARsolo, a comprehensive turnkey solution for quantifying
      gene expression in single-cell/nucleus RNA-seq data, built into RNA-seq
      aligner STAR. Using simulated data that closely resembles realistic
      scRNA-seq, we demonstrate that STARsolo is highly accurate and
      significantly outperforms pseudoalignment-to-transcriptome tools. STARsolo
      can replicate the results of, but is considerably faster than CellRanger,
      currently the most widely used tool for pre-processing scRNA-seq data. In
      addition to uniquely mapped reads, STARsolo takes account of multi-gene
      reads, necessary to detect certain classes of biologically important
      genes. It has a flexible cell barcode processing scheme, compatible with
      many established scRNA-seq protocols, and extendable to emerging
      technologies. STARsolo can quantify transcriptomic features beyond gene
      expression, which we illustrate by analyzing cell-type-specific
      alternative splicing in the Tabula Muris project.
    authors:
      - name: Benjamin Kaminow
        orcid: http://orcid.org/0000-0002-2266-3353
      - name: Dinar Yunusov
        orcid: http://orcid.org/0000-0003-3478-7203
      - name: Alexander Dobin
        orcid: http://orcid.org/0000-0002-4115-9128
  comment:
    dislikes: 0
    thread: "8507723355"
    numReports: 0
    likes: 0
    id: "5413004491"
    createdAt: 2021-06-08T21:04:01
    author:
      username: charleswarden
      about: I am a Bioinformatics Specialist at City of Hope, but comments represent
        my own opinions.
      name: Charles Warden
      isPowerContributor: false
      profileUrl: https://disqus.com/by/charleswarden/
      url: https://sites.google.com/site/cwarden45/about-me
      location: Monrovia, CA
      id: "84464988"
    isApproved: true
    raw_message: >-
      Also, I am waiting for my other comment to be approved, but I think the
      template for <b>Figure 5C-G</b> was used for <b>Supplemental Figures
      S6-S13</b> (without shifting the letters to begin with "A," for each
      separate cell type)?


      Thank you again for developing this tool!
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.05.05.442755v1
  tweets:
    - created_at: Tue Jun 08 22:21:38 +0000 2021
      id: 1402390388904657000
      id_str: "1402390388904656896"
      text: >-
        üí¨ bioRxiv comment on "STARsolo: accurate, fast and v..."


        "Also, I am waiting for my other comment to be approved,‚Ä¶ https://t.co/BAeTalhdOh
      truncated: true
      entities:
        urls:
          - url: https://t.co/BAeTalhdOh
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 08 22:21:38 +0000 2021
      id: 1402390389823185000
      id_str: "1402390389823184897"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/xasDNX5GvU
      truncated: false
      entities:
        urls:
          - url: https://t.co/xasDNX5GvU
      in_reply_to_status_id: 1402390388904657000
      in_reply_to_status_id_str: "1402390388904656896"
- preprint:
    id: "140951"
    doi: 10.1101/2021.05.05.442755
    first_posted: 2021-05-05
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.05.442755v1
    url: https://api.rxivist.org/v1/papers/140951
    title: "STARsolo: accurate, fast and versatile mapping/quantification of
      single-cell and single-nucleus RNA-seq data"
    category: bioinformatics
    abstract: We present STARsolo, a comprehensive turnkey solution for quantifying
      gene expression in single-cell/nucleus RNA-seq data, built into RNA-seq
      aligner STAR. Using simulated data that closely resembles realistic
      scRNA-seq, we demonstrate that STARsolo is highly accurate and
      significantly outperforms pseudoalignment-to-transcriptome tools. STARsolo
      can replicate the results of, but is considerably faster than CellRanger,
      currently the most widely used tool for pre-processing scRNA-seq data. In
      addition to uniquely mapped reads, STARsolo takes account of multi-gene
      reads, necessary to detect certain classes of biologically important
      genes. It has a flexible cell barcode processing scheme, compatible with
      many established scRNA-seq protocols, and extendable to emerging
      technologies. STARsolo can quantify transcriptomic features beyond gene
      expression, which we illustrate by analyzing cell-type-specific
      alternative splicing in the Tabula Muris project.
    authors:
      - name: Benjamin Kaminow
        orcid: http://orcid.org/0000-0002-2266-3353
      - name: Dinar Yunusov
        orcid: http://orcid.org/0000-0003-3478-7203
      - name: Alexander Dobin
        orcid: http://orcid.org/0000-0002-4115-9128
  comment:
    dislikes: 0
    thread: "8507723355"
    numReports: 0
    likes: 0
    id: "5412792816"
    createdAt: 2021-06-08T18:04:03
    author:
      username: charleswarden
      about: I am a Bioinformatics Specialist at City of Hope, but comments represent
        my own opinions.
      name: Charles Warden
      isPowerContributor: false
      profileUrl: https://disqus.com/by/charleswarden/
      url: https://sites.google.com/site/cwarden45/about-me
      location: Monrovia, CA
      id: "84464988"
    isApproved: true
    raw_message: >-
      Hi,


      Thank you very much for posting this preprint.


      I am working on trying to read through the manuscript more carefully, which I hope can improve my understanding of <i>STARsolo</i> as well the regular <i>STAR</i> alignment.  I also thought the different results with varying settings of <i>Alevin</i> was interesting and important.


      However, in the meantime, I believe that you have a minor error in one of your references:


      [30]. R. S. Br√ºning et al. Comparative Analysis of Common Alignment Tools for Single Cell RNA Sequencing. <u><b>preprint. Bioinformatics</b></u>, 2021. doi: 10.1101/2021.02.15.430948.


      I think this should be a bioRxiv preprint (not a Bioinformatics preprint)?


      For example, the DOI leads to this reference:


      https://www.biorxiv.org/content/10.1101/2021.02.15.430948v2


      Thanks Again,

      Charles
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.05.05.442755v1
  tweets:
    - created_at: Wed Jun 09 01:10:59 +0000 2021
      id: 1402433006300713000
      id_str: "1402433006300712960"
      text: |-
        üí¨ bioRxiv comment on "STARsolo: accurate, fast and v..."

        "Hi,

        Thank you very much for posting this preprint.

        I a‚Ä¶ https://t.co/ZH7HHMwgYq
      truncated: true
      entities:
        urls:
          - url: https://t.co/ZH7HHMwgYq
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 09 01:10:59 +0000 2021
      id: 1402433007164838000
      id_str: "1402433007164837891"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/xasDNWO5Em
      truncated: false
      entities:
        urls:
          - url: https://t.co/xasDNWO5Em
      in_reply_to_status_id: 1402433006300713000
      in_reply_to_status_id_str: "1402433006300712960"
- preprint:
    id: "143606"
    doi: 10.1101/2021.05.26.445837
    first_posted: 2021-05-27
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.26.445837v1
    url: https://api.rxivist.org/v1/papers/143606
    title: Loose ends in cancer genome structure
    category: genomics
    abstract: Recent pan-cancer studies have delineated patterns of structural
      genomic variation across thousands of tumor whole genome sequences. It is
      not known to what extent the shortcomings of short read ([&le;] 150 bp)
      whole genome sequencing (WGS) used for structural variant analysis has
      limited our understanding of cancer genome structure. To formally address
      this, we introduce the concept of "loose ends" - copy number alterations
      that cannot be mapped to a rearrangement by WGS but can be indirectly
      detected through the analysis of junction-balanced genome graphs.
      Analyzing 2,319 pan-cancer WGS cases across 31 tumor types, we found loose
      ends were enriched in reference repeats and fusions of the mappable genome
      to repetitive or foreign sequences. Among these we found genomic
      footprints of neotelomeres, which were surprisingly enriched in cancers
      with low telomerase expression and alternate lengthening of telomeres
      phenotype. Our results also provide a rigorous upper bound on the role of
      non-allelic homologous recombination (NAHR) in large-scale cancer
      structural variation, while nominating INO80, FANCA, and ARID1A as
      positive modulators of somatic NAHR. Taken together, we estimate that
      short read WGS maps >97% of all large-scale (>10 kbp) cancer structural
      variation; the rest represent loose ends that require long molecule
      profiling to unambiguously resolve. Our results have broad relevance for
      future research and clinical applications of short read WGS and delineate
      precise directions where long molecule studies might provide
      transformative insight into cancer genome structure.
    authors:
      - name: Julie M Behr
        orcid: http://orcid.org/0000-0001-8601-4902
      - name: Xiaotong Yao
        orcid: http://orcid.org/0000-0002-5140-6639
      - name: Kevin Hadi
        orcid: http://orcid.org/0000-0003-4271-6261
      - name: Huasong Tian
        orcid: http://orcid.org/0000-0002-0079-538X
      - name: Aditya Deshpande
        orcid: http://orcid.org/0000-0002-4463-2697
      - name: Joel Rosiene
        orcid: http://orcid.org/0000-0002-8610-370X
      - name: Titia de Lange
        orcid: http://orcid.org/0000-0002-9267-367X
      - name: Marcin Imielinski
        orcid: http://orcid.org/0000-0002-2211-4741
  comment:
    dislikes: 0
    thread: "8556410171"
    numReports: 0
    likes: 0
    id: "5413275186"
    createdAt: 2021-06-09T02:14:15
    author:
      username: disqus_yrjh6NA1Ln
      about: ""
      name: Daniel Cameron
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_yrjh6NA1Ln/
      url: ""
      location: ""
      id: "370661701"
    isApproved: true
    raw_message: >-
      Very catchy title and some quite interesting results. Xiaotong Yao
      suggested I raise my terminology concerns as a biorxiv comment:

      ‚ÄòLoose ends‚Äô is a catchy title but I am concerned that the use of new terminology for existing concepts has the potential to confuse readers. The definition you are using for ‚Äòloose ends‚Äô is equivalent to concept of a single breakend variant defined in the VCFv4.1 specifications about a decade ago.
       
      Whilst it is only recently that variant callers have actually explicitly reported VCF single breakends (GRIDSS2 from SR/OEA/breakend assemblies, PURPLE from unexplained CN transitions), the loose end/single breakend concept has a long history of implicit usage. For example, NovelSeq (Sahinalp, 2010) uses an orientation-constrained assembly approach (OEA+/OEA-) very similar to that of jabba to produce what this paper calls loose end assemblies (although what NovelSeq does afterwards is different). The assembly similarity can also be seen in GRIDSS1 which uses the terms ‚Äòbreakend assembly‚Äô and ‚Äòanchoring reads‚Äô when discussing it‚Äôs separate assemblies of forward/- and backward/+ orientation reads/breaks. Viral integration detection software has a similar history of implicit usage of loose ends/single breakends without explicitly using either terminology (only the recently published VIRUSBreakend uses the term).
       
      In summary, this paper would benefit from briefing mentioning the long history of the loose end concept, and how it has been incorporated into existing tools.
       
      ---

      Some additional thoughts to consider:
       
      One interesting benchmarking comparison you could incorporate is against WEAVER. It also generates junction-balanced breakpoint graphs using integer programming, but its conceptual model does not appear to include single breakends. In my benchmarking (https://doi.org/10.1101/781013, Figure 3), I found that weaver failed badly on some samples and I suspect this was due to missing high copy SVs causing all junction balancing solutions to be terrible (thus reporting unbelievable ASCNs). Comparing to WEAVER (or comparing jabba MIP results with/without single breakend support) would be a good demonstration of how essential single breakend support is to the junction balancing process itself.
       
      > we found that almost half (48%, 12,068 of 25,271) of loose ends arose from Type 0 junctions that were missed during genome-wide analysis‚Äù
       
      Is this a consequence of waiting till after SV and CN calling is done before looking for single breakends or due to the choice of caller? Would another SV caller (e.g. manta) reduce this? How many of the single breakends found by jabba can be found by stand-alone single breakend SV calling (e.g. GRIDSS2)? I notice jabba allows a BND style VCF input. Does it support single breakend BND calls?


      Single breakend from SV calling and single breakends unbalanced CN junctions seems very much like they are complementary approaches so combining them should improve the final jabba results. I suspect this will be especially true for complex events as they frequently containing many clustered SVs and accurate copy number determination becomes more difficult the shorter the CN segments become.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.05.26.445837v1
  tweets:
    - created_at: Wed Jun 09 12:32:46 +0000 2021
      id: 1402604585164763100
      id_str: "1402604585164763138"
      text: >-
        üí¨ bioRxiv comment on "Loose ends in cancer genome st..."


        "Very catchy title and some quite interesting results. Xi‚Ä¶ https://t.co/XvH1pfMG3Q
      truncated: true
      entities:
        urls:
          - url: https://t.co/XvH1pfMG3Q
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 09 12:32:47 +0000 2021
      id: 1402604586213384200
      id_str: "1402604586213384202"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/ra9kWBN9C4
      truncated: false
      entities:
        urls:
          - url: https://t.co/ra9kWBN9C4
      in_reply_to_status_id: 1402604585164763100
      in_reply_to_status_id_str: "1402604585164763138"
- preprint:
    id: "139933"
    doi: 10.1101/2021.04.27.441590
    first_posted: 2021-04-28
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.27.441590v1
    url: https://api.rxivist.org/v1/papers/139933
    title: A massively parallel reporter assay reveals focused and broadly encoded
      RNA localization signals in neurons
    category: genomics
    abstract: "Asymmetric subcellular localization of mRNA is a common cellular
      phenomenon that is thought to contribute to spatial gene regulation. In
      highly polar neurons, subcellular transcript localization and translation
      are thought to enhance cellular efficiency and timely responses to
      external cues. Although mRNA localization has been observed in many
      tissues and numerous examples of the functional importance of this process
      exist, we still lack a systematic understanding of how the transcript
      sorting machinery works in a sequence-specific manner. Here, we addressed
      these gaps by combining subcellular transcriptomics and rationally
      designed sequence libraries. We developed a massively parallel reporter
      assay (MPRA) for mRNA localization and tested ~50,000 sequences for their
      ability to drive RNA localization to neurites of neuronal cell lines. By
      scanning the 3'UTR of >300 genes we identified many previously unknown
      localization regions and mapped the localization potential of endogenous
      sequences. Our data suggest two ways the localization potential can be
      encoded in the 3'UTR: focused localization motifs and broadly encoded
      localization potential based on small contributions. We identified
      sequence motifs enriched in dendritically localized transcripts and tested
      the potential of these motifs to affect the localization behavior of an
      mRNA. This assay revealed sequence elements with the ability to bias
      localization towards neurite as well as soma. Depletion of RNA binding
      proteins predicted or experimentally shown to bind these motifs abolished
      the effect on localization, suggesting that these motifs act by recruiting
      specific RNA-binding proteins. Based on our dataset we developed machine
      learning models that accurately predict the localization behavior of novel
      sequences. Testing this predictor on native mRNA sequencing data showed
      good agreement between predicted and observed localization potential,
      suggesting that the rules uncovered by our MPRA also apply to the
      localization of native transcripts. Applying similar systematic
      high-throughput approaches to other cell types will open the door for a
      comparative perspective on RNA localization across tissues and reveal the
      commonalities and differences of this crucial regulatory mechanism."
    authors:
      - name: Martin Mikl
        orcid: http://orcid.org/0000-0001-8913-7158
      - name: Davide Eletto
        orcid: http://orcid.org/0000-0002-2650-1968
      - name: Minkyoung Lee
        orcid: http://orcid.org/0000-0002-3956-7288
      - name: Atefeh Lafzi
        orcid: http://orcid.org/0000-0003-4237-4847
      - name: Farah Mhamedi
        orcid: null
      - name: Simona Baghai Sain
        orcid: http://orcid.org/0000-0002-2357-7027
      - name: Kristina Handler
        orcid: http://orcid.org/0000-0001-8952-6487
      - name: Andreas E. Moor
        orcid: http://orcid.org/0000-0001-8715-8449
  comment:
    dislikes: 0
    thread: "8497125718"
    numReports: 0
    likes: 0
    id: "5412912512"
    createdAt: 2021-06-08T19:43:21
    author:
      username: sethvigneron
      about: ""
      name: Seth Vigneron
      isPowerContributor: false
      profileUrl: https://disqus.com/by/sethvigneron/
      url: ""
      location: ""
      id: "370643658"
    isApproved: true
    raw_message: >-
      Summary:

      This manuscript by Mikl, M., et al, aims to understand how RNA transcript subcellular localization signals are encoded in 3‚Äô UTR sequences. To this end, the authors designed an MPRA to test thousands of 3‚Äô UTR sequences in parallel. The authors transfect the library to neural cells grown in microporous membranes which allows them to separate the soma from the neurites and subsequently sequence the transcripts in each. The results from the MPRA demonstrate that only a subset of transcripts are enriched in the soma or neurites fractions and localization signals encoded in the 3‚Äô UTR are sufficient to drive transcript localization. The authors then validate a subset of their enriched transcripts via smFISH demonstrating their MPRA mimics endogenous transcript localization. The authors proceed to analyze the sequence of enriched transcripts via mutagenesis and insertions which elucidates that RNA binding proteins (RBPs) largely prevent localization of transcripts to neurites. The authors then follow up their investigations with the creation and validation of longer, novel synthetic 3‚ÄôUTR sequences capable of neurite enrichment, with subsequent biochemical pulldowns of cell lysates identifying RBP‚Äôs necessary for localization. Utilizing their vast dataset of 3‚ÄôUTR localizing motifs, the authors generated two computational models, one trained on known RBP binding sites and the other assessing all possible sets of 4mers within the sequence, that could successfully predict the localization behavior of unseen 3‚ÄôUTRs through the estimation of the combined contributions of multiple individual directing sequence elements.


      The major success of this manuscript is in the development of a high-throughput assay to elucidate 3‚Äô UTR encoded transcript localization signals and generation of machine learning models that predict subcellular transcript localization. Overall, we think this manuscript is of high impact and relevance to understand the mechanisms underlying mRNA transcript localization. 


      Below are the major and minor points that should be addressed before the manuscript is published to aid interpretation. 


      Major Points:

      A major concern we have is that the authors mention previous transcript localization studies have very little overlap on enriched dendritically localized transcripts. The authors attributed the lack of overlap to different experimental set ups and cell-types used.  Therefore, the manuscript would be improved by adding a brief explanation as to how their experimental set up and cell types used contrast with previous methods and why their approach might be a better method to identify localization signals encoded in the RNA transcripts. Is there any agreement with previous studies that shed light on biases of the different approaches? Comments on these points will assure readers of the broader significance of their findings and not just the cell type used in the study. 


      Reasoning for the cell type used (CAD and Neuro2a cells) is not explained until the discussion and when mentioned it is not very clear. The manuscript would benefit from a brief explanation of cell type choice when authors explain the final library is transfected into CAD and Neuro2a cells in the results section. 
       
      Regarding the differentiation protocol of Neuro2a and CAD cells, the authors mention in the methods section that they induced differentiation via serum starvation to differentiate cells into a ‚Äúmore neuron-like phenotype‚Äù. However, they do not specify at what day post-differentiation the MPRA experiment is done. Consider adding the day of differentiation assays are done. Also,  the manuscript would greatly benefit from IF, qPCR, or WB for neuronal markers to know the cell-type population used in this study, as transcriptional control is largely cell-type dependent. 


      Minor Points:

      Not clear if or how the author's account for the effects differential expression of transcripts and transfection of constructs might have on their output library. 


      Figure 1A: The experimental outline can be improved to aid the reader understand the library design. The construct used in the library could be edited to include what promoter is upstream of GFP, GFP, the 12 nucleotide barcode, the 150 nucleotide sequence, and the pA-site.



      When the authors test the hypothesis that localization potential in RNA is broadly encoded in the 3‚Äô UTR they refer to the experimental setup from Taliaferro et al., 2016 (second line on page 7). To make the experiments clearer for researchers across fields, we suggest adding a brief explanation of the experimental set up. 


      Figure 2: This figure could be improved by re-organizing the order of the panels such that it is easier for the redear to follow the panels from A to F. 
       
      Figure 2D: Not entirely clear why they include St6gal1 on figure 2D without mentioning in the text. We suggest adding a sentence explanation in the main text. 


      Figure 2D and 2E: For smFISH images and quantification, was there a control construct with just GFP? If data is available, the authors should show the image of the ‚Äònormal‚Äô distribution of GFP and then use it as a normalization control for their quantification on 2E. 
       
      Figure 2: No example graph of a broadly encoded transcript is included. Since this is a major conclusion from the paper we suggest the graph to be moved from the supplementary figures to figure 2.  


      In the main text when authors explain the broadly encoded signals might have ‚Äúmany small contributions making up the net localization behavior‚Äù it is not clear what they mean by that. A brief explanation of what ‚Äúsmall contributions‚Äù could be will help make their results more clear to the reader. 


      For RNAi experiments, it is not clear the extent of knockdown for targets as qRT-PCR data mentioned in the methods section is not presented. The qRT-PCR data should be included in the supplementary figures.


      When AGGUA is inserted 1 to 4 times (5th line on page 9) Where is the sequence inserted (at what position(s), throughout the transcript, one after another, etc.)?


      After the knockdown experiments the authors state that ‚ÄúDazap1 is one mechanism underlying soma enrichment‚Äù. To ascertain this is the mechanism responsible for retention of transcripts in the soma, the knockdown experiments could benefit by the addition of rescuing DAzap1 and see if that rescues the negative effect. 


      It is unclear as to how the MEME Suite generates the de novo synthetic sequences, how many were generated, and what was the range in sequence lengths. A brief, yet more explicit description in the main text of how these synthetic sequences were generated and then ‚Äòintroduced in native contexts‚Äô, e.g. were they added to the end/beginning/within existing 3‚ÄôUTRs, would help the reader better understand your experimentation.


      Figure 4B and 4C: The vast majority of the synthetic motifs appear to be shifted towards more negative logFC‚Äôs indicating increased soma localization. While the success of SU1 is impressive, the low replicability should be mentioned as a caveat in the main text and it‚Äôs potential causes speculated upon in the discussion.


      The analysis of the proteomics data should be better explained either within the text or figure captions. Figures 5B, 5D, and 5E are very difficult to understand without any explanation as to how to interpret them in the text. 


      Figure 5: It appears that the plots in Figure 5D and 5E have been switched based on their references in the main text.


      The font size of Figure 5C, 5D, and 5E is much too small to be legible and easily understood.


      Figure 5F: It would greatly help with clarity for the meaning of the red vertical line to be indicated within the plot itself and not solely within the figure caption as it is vital for data interpretation.


      Consider adding more background into why Celf1 and Celf6 were chosen for validation over the other 23 identified proteins. It would be valuable to state the known, or utilize experimentation to determine, the pathway by which these proteins binding to the 3‚ÄôUTR shuttles them to the neurite. In other words, what is the entire mechanism for neurite localization, not just the identity of the RBP. 


      There is an inconsistency in the spelling of ‚Äò4mer‚Äô (as spelled in the main text and caption) and ‚Äòfourmer‚Äô as it appears in Figure 6A. There is also never a direct definition of what the 4mers are and what information they convey to the computational model. 


      Some speculation into the power of your computational model would be helpful in the determination of its use in future projects. How might further iterations and optimizations be done to improve the auROC?


      Reviewed by Seth Vigneron (UCSF) and Dianne Laboy Cintron (UCSF)
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.04.27.441590v1
  tweets:
    - created_at: Wed Jun 09 14:23:40 +0000 2021
      id: 1402632491249328000
      id_str: "1402632491249328128"
      text: |-
        üí¨ bioRxiv comment on "A massively parallel reporter ..."

        "Summary:
        This manuscript by Mikl, M., et al, aims to und‚Ä¶ https://t.co/QXjhNc1c6s
      truncated: true
      entities:
        urls:
          - url: https://t.co/QXjhNc1c6s
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 09 14:23:40 +0000 2021
      id: 1402632492226646000
      id_str: "1402632492226646019"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/FtlDs4ZIQW
      truncated: false
      entities:
        urls:
          - url: https://t.co/FtlDs4ZIQW
      in_reply_to_status_id: 1402632491249328000
      in_reply_to_status_id_str: "1402632491249328128"
- preprint:
    id: "144743"
    doi: 10.1101/2021.06.03.21258228
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.03.21258228v1
    url: https://api.rxivist.org/v1/papers/144743
    title: Persistent SARS-CoV-2 infection and intra-host evolution in association
      with advanced HIV infection
    category: infectious-diseases
    abstract: While most people effectively clear SARS-CoV-2, there are several
      reports of prolonged infection in immunosuppressed individuals. Here we
      present a case of prolonged infection of greater than 6 months with the
      shedding of high titter SARS-CoV-2 in an individual with advanced HIV and
      antiretroviral treatment failure. Through whole-genome sequencing at
      multiple time points, we demonstrate the early emergence of the E484K
      substitution associated with escape from neutralizing antibodies, followed
      by other escape mutations and the N501Y substitution found in most
      variants of concern. This provides support to the hypothesis of intra-host
      evolution as one mechanism for the emergence of SARS-CoV-2 variants with
      immune evasion properties.
    authors:
      - name: Farina Karim
        orcid: null
      - name: Mohamed YS Moosa
        orcid: null
      - name: Bernadett Gosnell
        orcid: null
      - name: Cele Sandile
        orcid: null
      - name: Jennifer Giandhari
        orcid: null
      - name: Sureshnee Pillay
        orcid: null
      - name: Houriiyah Tegally
        orcid: null
      - name: Eduan Wilkinson
        orcid: http://orcid.org/0000-0002-2503-9441
      - name: Emmanuel James San
        orcid: null
      - name: Nokukhanya Msomi
        orcid: null
      - name: Koleka Mlisana
        orcid: null
      - name: Khadija Khan
        orcid: null
      - name: Mallory Bernstein
        orcid: null
      - name: Nithendra Manickchund Nithendra
        orcid: null
      - name: Lavanya Singh
        orcid: null
      - name: Upasana Ramphal
        orcid: null
      - name: Willem Hanekom
        orcid: http://orcid.org/0000-0003-3070-6154
      - name: Richard J. Lessells
        orcid: null
      - name: Alex Sigal
        orcid: http://orcid.org/0000-0001-8571-2004
      - name: Tulio de Oliveira
        orcid: http://orcid.org/0000-0002-3027-5254
  comment:
    dislikes: 0
    thread: "8573294551"
    numReports: 0
    likes: 0
    id: "5412838137"
    createdAt: 2021-06-08T18:41:47
    author:
      username: keithflippen
      about: ""
      name: Keith Flippen
      isPowerContributor: false
      profileUrl: https://disqus.com/by/keithflippen/
      url: ""
      location: ""
      id: "73788638"
    isApproved: true
    raw_message: Was there tracking of HIV viral load and T cell count during the
      infection and are numbers known prior to COVID?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.03.21258228v1
  tweets:
    - created_at: Wed Jun 09 16:41:13 +0000 2021
      id: 1402667108455039000
      id_str: "1402667108455038978"
      text: >-
        üí¨ medRxiv comment on "Persistent SARS-CoV-2 infectio..."


        "Was there tracking of HIV viral load and T cell count du‚Ä¶ https://t.co/OsnI5B9EoL
      truncated: true
      entities:
        urls:
          - url: https://t.co/OsnI5B9EoL
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 09 16:41:13 +0000 2021
      id: 1402667109289709600
      id_str: "1402667109289709574"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/SqCeSJAv1Y
      truncated: false
      entities:
        urls:
          - url: https://t.co/SqCeSJAv1Y
      in_reply_to_status_id: 1402667108455039000
      in_reply_to_status_id_str: "1402667108455038978"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5413963308"
    createdAt: 2021-06-09T17:03:22
    author:
      username: disqus_7MxpsSnj56
      about: ""
      name: Frank A.
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_7MxpsSnj56/
      url: ""
      location: ""
      id: "370695709"
    isApproved: true
    raw_message: Were all participants exposed to the live virus to ensure infection
      would have happened?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Wed Jun 09 18:41:09 +0000 2021
      id: 1402697290683400200
      id_str: "1402697290683400198"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "Were all participants exposed to the live virus to ensur‚Ä¶ https://t.co/d8vyQ6feuI
      truncated: true
      entities:
        urls:
          - url: https://t.co/d8vyQ6feuI
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 09 18:41:09 +0000 2021
      id: 1402697291471982600
      id_str: "1402697291471982595"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1402697290683400200
      in_reply_to_status_id_str: "1402697290683400198"
- preprint:
    id: 120002
    metric: 65
    title: "Thinking ahead: prediction in context as a keystone of language in
      humans and machines"
    url: https://api.rxivist.org/v1/papers/120002
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.12.02.403477v1
    doi: 10.1101/2020.12.02.403477
    category: neuroscience
    first_posted: 2020-12-03
    abstract: Departing from classical rule-based linguistic models, advances in
      deep learning have led to the development of a new family of
      self-supervised deep language models (DLMs). These models are trained
      using a simple self-supervised autoregressive objective, which aims to
      predict the next word in the context of preceding words in real-life
      corpora. After training, autoregressive DLMs are able to generate new
      'context-aware' sentences with appropriate syntax and convincing semantics
      and pragmatics. Here we provide empirical evidence for the deep connection
      between autoregressive DLMs and the human language faculty using a 30-min
      spoken narrative and electrocorticographic (ECoG) recordings.
      Behaviorally, we demonstrate that humans have a remarkable capacity for
      word prediction in natural contexts, and that, given a sufficient context
      window, DLMs can attain human-level prediction performance. Next, we
      leverage DLM embeddings to demonstrate that many electrodes spontaneously
      predict the meaning of upcoming words, even hundreds of milliseconds
      before they are perceived. Finally, we demonstrate that contextual
      embeddings derived from autoregressive DLMs capture neural representations
      of the unique, context-specific meaning of words in the narrative. Our
      findings suggest that deep language models provide an important step
      toward creating a biologically feasible computational framework for
      generative language.
    authors:
      - name: Ariel Goldstein
      - name: Zaid Zada
      - name: Eliav Buchnik
      - name: Mariano Schain
      - name: Amy Price
      - name: Bobbi Aubrey
      - name: Christopher A Baldassano
      - name: Amir Feder
      - name: Dotan Emanuel
      - name: Alon Cohen
      - name: Aren Jansen
      - name: Harshvardhan Gazula
      - name: Gina Choe
      - name: Aditi Rao
      - name: Catherine Kim
      - name: Colton Casto
      - name: Fanda Lora
      - name: Adeen Flinker
      - name: Sasha Devore
      - name: Werner Doyle
      - name: Patricia Dugan
      - name: Daniel Friedman
      - name: Avinatan Hassidim
      - name: Michael Brenner
      - name: Yossi Matias
      - name: Ken A. Norman
      - name: Orrin Devinsky
      - name: Uri Hasson
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Wed Jun 09 20:15:42 +0000 2021
      id: 1402721085469212700
      id_str: "1402721085469212673"
      text: >-
        üî• bioRxiv Neuroscience preprint by A. Goldstein et al:


        "Thinking ahead: prediction in context as a keystone of lan‚Ä¶ https://t.co/69OzBsWyUm
      truncated: true
      entities:
        urls:
          - url: https://t.co/69OzBsWyUm
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 1
    id: "5413914815"
    createdAt: 2021-06-09T16:25:49
    author:
      username: disqus_ZoTkgnnndJ
      about: ""
      name: livefreeinTX
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_ZoTkgnnndJ/
      url: ""
      location: TX
      id: "35440054"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: It's heartbreaking to me that all those hundreds, perhaps
      thousands, of NYC patients in the spring of 2020 were left to sit around
      at home until they could barely breath and were then hospitalized and put
      on ventilators, and were denied HCQ, which may have saved hundreds of
      lives.  Truly sickening, imo.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Wed Jun 09 20:19:55 +0000 2021
      id: 1402722145797562400
      id_str: "1402722145797562375"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "It's heartbreaking to me that all those hundreds, perhap‚Ä¶ https://t.co/HIJveeyVK7
      truncated: true
      entities:
        urls:
          - url: https://t.co/HIJveeyVK7
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 09 20:19:55 +0000 2021
      id: 1402722146573598700
      id_str: "1402722146573598727"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1402722145797562400
      in_reply_to_status_id_str: "1402722145797562375"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 2
    thread: "8574386276"
    numReports: 0
    likes: 1
    id: "5413667506"
    createdAt: 2021-06-09T12:56:25
    author:
      username: tracii_kunkel
      about: ""
      name: Tracii Kunkel
      isPowerContributor: false
      profileUrl: https://disqus.com/by/tracii_kunkel/
      url: ""
      location: ""
      id: "133823091"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: The key here - NOT PEER REVIEWED.  It's been demonstrated that
      people who have been invfected have often changed their health-risk
      behaviors after recovery. How could the researchers have not assessed this
      factor? It's possible that the low rate of re-infection by those without
      the vaccine was heavily influenced by them taking precuautions much more
      seriously.
    forum: medrxiv
    points: -1
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Wed Jun 09 22:21:34 +0000 2021
      id: 1402752760458760200
      id_str: "1402752760458760195"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "The key here - NOT PEER REVIEWED.  It's been demonstrate‚Ä¶ https://t.co/dwHRcZ0KRX
      truncated: true
      entities:
        urls:
          - url: https://t.co/dwHRcZ0KRX
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 09 22:21:34 +0000 2021
      id: 1402752761259868200
      id_str: "1402752761259868164"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1402752760458760200
      in_reply_to_status_id_str: "1402752760458760195"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5414321846"
    createdAt: 2021-06-09T22:00:05
    author:
      username: disqus_ZRn0tkqspY
      about: ""
      name: Dr Chad
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_ZRn0tkqspY/
      url: ""
      location: ""
      id: "142629142"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: This would coincide with virtually all other RNA respiratory
      viruses studied.  I am surprised that the initial instinct seems to be
      resistant to recognizing that natural immunity would be inferior to
      induced immunity when we have no precedent to suggest that would be the
      case.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Thu Jun 10 01:08:09 +0000 2021
      id: 1402794681839272000
      id_str: "1402794681839271936"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "This would coincide with virtually all other RNA respira‚Ä¶ https://t.co/edpjINiLvf
      truncated: true
      entities:
        urls:
          - url: https://t.co/edpjINiLvf
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 10 01:08:09 +0000 2021
      id: 1402794682632056800
      id_str: "1402794682632056834"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1402794681839272000
      in_reply_to_status_id_str: "1402794681839271936"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 2
    thread: "8574386276"
    numReports: 0
    likes: 5
    id: "5414158263"
    createdAt: 2021-06-09T19:40:05
    author:
      username: disqus_kHXf1vQnjg
      about: The savior son of Zenn La, Herald to Mighty Galactus, The Sentinel of the
        Spaceway.
      name: Norrin Radd
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_kHXf1vQnjg/
      url: ""
      location: In your black hole.
      id: "144774837"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      6 months post covid and I refuse to get vaccinated when my antibody test
      came in at over 300--I never wear a mask and I don't social distance.

      That's just me.  And everyone I know.
    forum: medrxiv
    points: 3
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Thu Jun 10 12:38:29 +0000 2021
      id: 1402968409944514600
      id_str: "1402968409944514570"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "6 months post covid and I refuse to get vaccinated when‚Ä¶ https://t.co/jww3pRpnOa
      truncated: true
      entities:
        urls:
          - url: https://t.co/jww3pRpnOa
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 10 12:38:29 +0000 2021
      id: 1402968410628280300
      id_str: "1402968410628280326"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1402968409944514600
      in_reply_to_status_id_str: "1402968409944514570"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 1
    thread: "8574386276"
    numReports: 0
    likes: 2
    id: "5414281812"
    createdAt: 2021-06-09T21:22:25
    author:
      username: disqus_koXpYYhDtS
      about: ""
      name: Al Smith
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_koXpYYhDtS/
      url: ""
      location: ""
      id: "370707180"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: The study indicated zero re-infection. Unless they never left the
      house again that would be nearly impossible to avoid.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Thu Jun 10 14:21:13 +0000 2021
      id: 1402994265131675600
      id_str: "1402994265131675655"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "The study indicated zero re-infection. Unless they never‚Ä¶ https://t.co/hNfVRjwUuK
      truncated: true
      entities:
        urls:
          - url: https://t.co/hNfVRjwUuK
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 10 14:21:14 +0000 2021
      id: 1402994266280849400
      id_str: "1402994266280849408"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmfcNF6
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmfcNF6
      in_reply_to_status_id: 1402994265131675600
      in_reply_to_status_id_str: "1402994265131675655"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 1
    thread: "8574386276"
    numReports: 0
    likes: 1
    id: "5414320055"
    createdAt: 2021-06-09T21:58:19
    author:
      username: disqus_G1IerTO75P
      about: ""
      name: Everett Miller
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_G1IerTO75P/
      url: ""
      location: ""
      id: "365305925"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      it's possible, but not relevant.  Control for behavior of the subjects
      would be true of all--yes or no previously infected, yes or no vaccinated,
      yes or no both; maybe they all changed their behavior, maybe some a
      little, maybe some no change, it matters not the the point of the
      study.  Furthermore your characterization of "the low rate of
      re-infection" shows your unexplained bias.  It wasn't "low" IT WAS ZERO.

      NOT ONE SUBJECT, PREVIOUSLY INFECTED, HAD A RE-INFECTION.

      This is consistent with all history of coronavirus infections, and viral infections in general.  Even after antibodies have subsided, they will re-surge when presented with the virus at a later date--even many decades.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Thu Jun 10 16:41:10 +0000 2021
      id: 1403029485058920400
      id_str: "1403029485058920455"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "it's possible, but not relevant.  Control for behavior o‚Ä¶ https://t.co/EuGbX1EO5w
      truncated: true
      entities:
        urls:
          - url: https://t.co/EuGbX1EO5w
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 10 16:41:11 +0000 2021
      id: 1403029486061359000
      id_str: "1403029486061359107"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1403029485058920400
      in_reply_to_status_id_str: "1403029485058920455"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 1
    id: "5414236752"
    createdAt: 2021-06-09T20:43:58
    author:
      username: bobleon
      about: ""
      name: Bob Leon
      isPowerContributor: false
      profileUrl: https://disqus.com/by/bobleon/
      url: ""
      location: ""
      id: "78987827"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Where has it been "demonstrated that people who have been invfected
      have often changed their health-risk behaviors after recovery."?
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Thu Jun 10 18:39:42 +0000 2021
      id: 1403059311203418000
      id_str: "1403059311203418115"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "Where has it been "demonstrated that people who have bee‚Ä¶ https://t.co/WlLrJhYYkp
      truncated: true
      entities:
        urls:
          - url: https://t.co/WlLrJhYYkp
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 10 18:39:42 +0000 2021
      id: 1403059312222638000
      id_str: "1403059312222638080"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmfcNF6
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmfcNF6
      in_reply_to_status_id: 1403059311203418000
      in_reply_to_status_id_str: "1403059311203418115"
- preprint:
    id: 133869
    metric: 6
    title: Design of anti-SARS-CoV-2 molecules from hydroxychloroquine (HCQ)for
      better binding SARS-CoV-2 N protein
    url: https://api.rxivist.org/v1/papers/133869
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.03.16.435741v1
    doi: 10.1101/2021.03.16.435741
    category: biophysics
    first_posted: 2021-03-17
    abstract: SARS-CoV-2 is the coronavirus causing the ongoing pandemic which
      already led to >129 millions of infections and >2.8 millions of deaths.
      Hydroxychloroquine (HCQ) has been shown to own promising potential in
      clinically combating SARS-CoV-2 but the underlying mechanisms remain
      highly elusive and its action sites were proposed all on the host cells.
      Very recently, by NMR spectroscopy, for the first time we have decoded
      that HCQ specifically binds both N-terminal domain (NTD) and C-terminal
      domain (CTD) of SARS-CoV-2 nucleocapsid (N) protein to inhibit their
      interactions with nucleic acids (NAs), as well as to disrupt its
      NA-induced liquid-liquid phase separation (LLPS) essential for the viral
      life cycle including the final package of gRNA and N protein into new
      virions. Here with NMR-derived constraints, we constructed the structure
      of the HCQ-CTD complex in which HCQ binds two pockets on the dimeric CTD.
      This unexpected finding thus allowed us to formulate a design strategy by
      linking two HCQ together to generate a bivalent/multivalent binder for
      CTD. The linked molecule is anticipated to have significantly enhanced
      affinity and specificity in binding CTD. We are willing to collaborate
      with synthetic chemists on this strategy by experimentally charactering
      the synthetic molecules on their binding and effects on LLPS of SARS-CoV-2
      N protein.
    authors:
      - name: Mei Dang
      - name: Jianxing Song
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Thu Jun 10 20:15:55 +0000 2021
      id: 1403083527965524000
      id_str: "1403083527965523968"
      text: >-
        üî• bioRxiv Biophysics preprint by M. Dang et al:


        "Design of anti-SARS-CoV-2 molecules from hydroxychloroquine (HCQ)‚Ä¶ https://t.co/oBnrWjCHMk
      truncated: true
      entities:
        urls:
          - url: https://t.co/oBnrWjCHMk
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 2
    id: "5414170568"
    createdAt: 2021-06-09T19:49:55
    author:
      username: disqus_EiMPcdqxbR
      about: ""
      name: Emily Russell
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_EiMPcdqxbR/
      url: ""
      location: ""
      id: "370703746"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: It's important to note that a null statistical finding does not
      indicate that there is no evidence of association. With only 1,359
      individuals who were previously infected and unvaccinated, I question that
      this study has enough statistical power to support the bold claims in the
      discussion. I would like to see a power analysis as part of the final
      published work.
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Thu Jun 10 20:19:40 +0000 2021
      id: 1403084472183107600
      id_str: "1403084472183107590"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "It's important to note that a null statistical finding d‚Ä¶ https://t.co/Oot5fgTuWS
      truncated: true
      entities:
        urls:
          - url: https://t.co/Oot5fgTuWS
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 10 20:19:41 +0000 2021
      id: 1403084472929693700
      id_str: "1403084472929693697"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1403084472183107600
      in_reply_to_status_id_str: "1403084472183107590"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 1
    thread: "8574386276"
    numReports: 0
    likes: 1
    id: "5414190650"
    createdAt: 2021-06-09T20:06:14
    author:
      username: dan_deyoung
      about: ""
      name: Dan D
      isPowerContributor: false
      profileUrl: https://disqus.com/by/dan_deyoung/
      url: ""
      location: ""
      id: "370704240"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: But, ZERO infections. Not slightly fewer or even far fewer‚Ä¶ZERO.
      More at play than precautions. It shouldn‚Äôt be a surprise that natural
      antibodies protect against the disease‚Ä¶they are antibodies after all. The
      question will be, ‚Äúhow long do natural antibodies last vs those generated
      by the vaccine?‚Äù
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Thu Jun 10 22:18:42 +0000 2021
      id: 1403114425863839700
      id_str: "1403114425863839748"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "But, ZERO infections. Not slightly fewer or even far few‚Ä¶ https://t.co/P97904q6OL
      truncated: true
      entities:
        urls:
          - url: https://t.co/P97904q6OL
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 10 22:18:42 +0000 2021
      id: 1403114426648207400
      id_str: "1403114426648207375"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1403114425863839700
      in_reply_to_status_id_str: "1403114425863839748"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 1
    id: "5414045383"
    createdAt: 2021-06-09T18:09:15
    author:
      username: Paul_F_Cwik
      about: Professor of Economics and Finance
      name: Paul Cwik
      isPowerContributor: false
      profileUrl: https://disqus.com/by/Paul_F_Cwik/
      url: ""
      location: North Carolina
      id: "60666715"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Peer Review in this case does not mean that peers reconduct the
      experiments.  It simply means that others (with suitable credentials) have
      read and accepted the paper as having correctly followed the scientific
      methods.  In other words, they are simply looking for errors in the paper,
      not re-doing and confirming the results.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Fri Jun 11 01:02:18 +0000 2021
      id: 1403155597244211200
      id_str: "1403155597244211209"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "Peer Review in this case does not mean that peers recond‚Ä¶ https://t.co/wgV9n2X5Rz
      truncated: true
      entities:
        urls:
          - url: https://t.co/wgV9n2X5Rz
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 11 01:02:18 +0000 2021
      id: 1403155598087229400
      id_str: "1403155598087229440"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1403155597244211200
      in_reply_to_status_id_str: "1403155597244211209"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5413327367"
    createdAt: 2021-06-09T03:28:09
    author:
      username: disqus_6WhGFDNxSa
      about: ""
      name: Damian
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_6WhGFDNxSa/
      url: ""
      location: ""
      id: "370665743"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: So you agree mask mandates don‚Äôt work? You‚Äôre only disagreement is
      that you feel they would be effective if everyone adhered to them
      completely and always wore a proper mask and wore it properly?
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri Jun 11 12:29:26 +0000 2021
      id: 1403328519262855200
      id_str: "1403328519262855183"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "So you agree mask mandates don‚Äôt work? You‚Äôre only disag‚Ä¶ https://t.co/rAyozzjjMg
      truncated: true
      entities:
        urls:
          - url: https://t.co/rAyozzjjMg
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 11 12:29:26 +0000 2021
      id: 1403328520009490400
      id_str: "1403328520009490435"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1403328519262855200
      in_reply_to_status_id_str: "1403328519262855183"
- preprint:
    id: "136233"
    doi: 10.1101/2021.04.01.437990
    first_posted: 2021-04-02
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.01.437990v1
    url: https://api.rxivist.org/v1/papers/136233
    title: Novel zebrafish mutants reveal new roles for Apolipoprotein B during
      embryonic development and pathological conditions
    category: developmental-biology
    abstract: "Apolipoprotein B (ApoB) is the primary protein of chylomicrons, VLDLs
      and LDLs and is essential for their assembly. Defects in ApoB synthesis
      and secretion result in several human diseases, including
      abetalipoproteinemia and familial hypobetalipoproteinemia. Conversely,
      high levels of APOB in plasma are associated with increased risk for
      coronary heart disease and atherosclerosis. The involvement of APOB in
      lipid metabolism and atherogenesis prompted the generation of several
      mutant mice. However, as APOB is required for supplying nutrients to the
      developing embryo, ApoB null mice are embryonic lethal, thereby precluding
      the study of the roles of this protein during development. Here, we
      established novel zebrafish mutants for two apoB genes: apoBa and apoBb.1.
      Double-mutant embryos display hepatic steatosis, a common hallmark of
      FHBL1 and NAFLD. In addition, we detect early developmental defects in
      double apoB mutants, including abnormal liver laterality, decreased
      numbers of goblet cells in the gut and impaired angiogenesis. We further
      use these models to identify the domains within ApoB responsible for its
      functions. By assessing the ability of different truncated forms of human
      APOB to rescue the mutant phenotypes, we demonstrate the benefits of this
      model for prospective therapeutic screens. Overall, our novel zebrafish
      models uncover new functions of ApoB in organ development and
      morphogenesis and shed new light on the mechanisms underlying
      hypolipidemia-related diseases."
    authors:
      - name: Hanoch Tempelhof
        orcid: null
      - name: Noga Moshe
        orcid: null
      - name: Inbal Avraham-Davidi
        orcid: http://orcid.org/0000-0001-7118-9179
      - name: Karina Yaniv
        orcid: http://orcid.org/0000-0001-5638-7150
  comment:
    dislikes: 0
    thread: "8462585861"
    numReports: 0
    likes: 0
    id: "5415695726"
    createdAt: 2021-06-11T01:06:47
    author:
      username: sriharshatalapaneni
      about: ""
      name: Sriharsha Talapaneni
      isPowerContributor: false
      profileUrl: https://disqus.com/by/sriharshatalapaneni/
      url: ""
      location: ""
      id: "370768226"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      For Figure 2, no WT shown which would be good for a reference. In 2C, it
      is unclear what is happening. A suggestion is to zoom out for a better
      image or do a zoomed out pic with a zoomed in figure beside it.
      Additionally, are both prox1a and tfa necessary? One subfigure could
      potentially be put in supplemental. Labels for arrows would also be
      helpful for 2D, F, and H. There also appears to be an inconsistency with
      dpf in the figure. Is the prox1a expression gone by 4 dpf? The reasoning
      for only showing 2 dpf might be needed. Concerning Figure 2F, a suggestion
      is to have a graph show foxa2 expression over time (1.5 dpf to 2.5 dpf).
      There also seems to be a resolution issue throughout the figure. A
      potential fix would be for 2F, to possibly trace it. To support claim and
      significance, we would also like to see more animals and different time
      points.


      A potential future experiment could be the use of an organoid.


      Moreover, I understand that the main idea of the paper is prove that zebrafish can be used as model system by conducting the experiments in various organ systems. But I believe that this point is kind of understand and people would normally get lost in the details of the figure and forget why you conducted experiments in different organ systems. Therefore, for this it would be better to mention and repeat it so that we understand the reason for the transition.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.04.01.437990v1
  tweets:
    - created_at: Fri Jun 11 14:18:53 +0000 2021
      id: 1403356065354420200
      id_str: "1403356065354420227"
      text: >-
        üí¨ bioRxiv comment on "Novel zebrafish mutants reveal..."


        "For Figure 2, no WT shown which would be good for a refe‚Ä¶ https://t.co/8YNBGtIRmg
      truncated: true
      entities:
        urls:
          - url: https://t.co/8YNBGtIRmg
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 11 14:18:53 +0000 2021
      id: 1403356066151342000
      id_str: "1403356066151342081"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/W75JLGEHQv
      truncated: false
      entities:
        urls:
          - url: https://t.co/W75JLGEHQv
      in_reply_to_status_id: 1403356065354420200
      in_reply_to_status_id_str: "1403356065354420227"
- preprint:
    id: "91613"
    doi: 10.1101/2020.07.18.207258
    first_posted: 2020-07-19
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.07.18.207258v1
    url: https://api.rxivist.org/v1/papers/91613
    title: The structure and spontaneous curvature of clathrin lattices at the
      plasma membrane.
    category: cell-biology
    abstract: >-
      Clathrin mediated endocytosis is the primary pathway for receptor and
      cargo internalization in eukaryotic cells. It is characterized by a
      polyhedral clathrin lattice that coats budding membranes. The mechanism
      and control of lattice assembly, curvature, and vesicle formation at the
      plasma membrane has been a matter of longstanding debate. Here, we use
      platinum replica and cryo electron microscopy and tomography to present a
      global structural framework of the pathway. We determine the shape and
      size parameters common to clathrin-mediated endocytosis. We show that
      clathrin sites maintain a constant surface area during curvature across
      multiple cell lines. Flat clathrin is present in all cells and
      spontaneously curves into coated pits without additional energy sources or
      recruited bending factors. Finally, we attribute curvature generation to
      loosely connected and pentagon-containing flat lattices that can rapidly
      curve when a flattening force is released. Together, these data present a
      new universal mechanistic model of clathrin mediated endocytosis.


      ### Competing Interest Statement


      The authors have declared no competing interest.
    authors:
      - name: Kem A Sochacki
        orcid: null
      - name: Bridgette L. Heine
        orcid: null
      - name: Gideon J. Haber
        orcid: null
      - name: John R Jimah
        orcid: null
      - name: Bijeta Prasai
        orcid: null
      - name: Marco A. Alfonzo-Mendez
        orcid: null
      - name: Aleah D Roberts
        orcid: null
      - name: Agila Somasundaram
        orcid: null
      - name: Jenny E Hinshaw
        orcid: null
      - name: Justin W Taraska
        orcid: http://orcid.org/0000-0001-5355-9535
  comment:
    dislikes: 0
    thread: "8132961499"
    numReports: 0
    likes: 0
    id: "5415423412"
    createdAt: 2021-06-10T20:03:55
    author:
      username: jgalaz
      about: ""
      name: jgalaz
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jgalaz/
      url: ""
      location: ""
      id: "47197520"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: In your cryoET observations, how would you distinguish true,
      biologically-driven deviations from the hexagonal pattern vs disruptions
      due to mechanical forces during cryo preservation and/or artifacts from
      the missing wedge and/or errors in tilt series alignment during
      tomographic reconstruction?
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.07.18.207258v1
  tweets:
    - created_at: Fri Jun 11 16:35:17 +0000 2021
      id: 1403390390401736700
      id_str: "1403390390401736713"
      text: >-
        üí¨ bioRxiv comment on "The structure and spontaneous ..."


        "In your cryoET observations, how would you distinguish t‚Ä¶ https://t.co/yFewt9Go05
      truncated: true
      entities:
        urls:
          - url: https://t.co/yFewt9Go05
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 11 16:35:17 +0000 2021
      id: 1403390391089610800
      id_str: "1403390391089610763"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/oBOGvB1Cw3
      truncated: false
      entities:
        urls:
          - url: https://t.co/oBOGvB1Cw3
      in_reply_to_status_id: 1403390390401736700
      in_reply_to_status_id_str: "1403390390401736713"
- preprint:
    id: "145105"
    doi: 10.1101/2021.06.05.447177
    first_posted: 2021-06-07
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.05.447177v1
    url: https://api.rxivist.org/v1/papers/145105
    title: Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19
      recovered cases and vaccinees of BBV152
    category: microbiology
    abstract: Recently, multiple SARS-CoV-2 variants have been detected across the
      globe.The recent emergence of B.1.617 lineage has created serious public
      health problem in India. The high transmissibility was observed with this
      lineage which has led to daily increase in the number of SARS-CoV-2
      infections. Apparently, the sub-lineage B.1.617.2 has slowly dominated the
      other variants including B1617.1, B.617.3 and B.1.1.7. With this, World
      Health Organization has described B.1.617.2 as variant of concern. Besides
      this, variant of concern B.1.351 has been also reported from India, known
      to showreducedefficacyfor many approved vaccines. With the increasing
      threat of the SARS-CoV-2 variants, it is imperative to assess the efficacy
      of the currently available vaccines against these variants. Here, we have
      evaluated the neutralization potential of sera collected from COVID-19
      recovered cases (n=20) and vaccinees with two doses of BBV152 (n=17)
      against B.1.351 and B.1.617.2 compared to the prototype B.1 (D614G)
      variant.The finding of the study demonstrated a reduction in
      neutralization titers with sera of COVID-19 recovered cases(3.3-fold and
      4.6-fold) and BBV152 vaccinees (3. 0 and 2.7 fold) against B.1.351 and
      B.1.617.2 respectively. Although, there is reduction in neutralization
      titer, the whole-virion inactivated SARS-CoV-2 vaccine (BBV152)
      demonstrates protective response against VOC B.1351 and B.1.617.2.
    authors:
      - name: Pragya D Yadav
        orcid: null
      - name: Gajanan Sapkal
        orcid: null
      - name: Raches Ella
        orcid: http://orcid.org/0000-0002-4646-4471
      - name: Rima R Sahay
        orcid: null
      - name: Dimpal A Nyayanit
        orcid: null
      - name: Deepak Y Patil
        orcid: null
      - name: Gururaj Deshpande
        orcid: null
      - name: Anita M Shete
        orcid: null
      - name: Nivedita Gupta
        orcid: null
      - name: V Krishna Mohan
        orcid: null
      - name: Priya Abraham
        orcid: null
      - name: Samiran Panda
        orcid: http://orcid.org/0000-0002-5077-6275
      - name: Balram Bhargava
        orcid: null
  comment:
    dislikes: 0
    thread: "8579640106"
    numReports: 0
    likes: 0
    id: "5415899223"
    createdAt: 2021-06-11T06:48:20
    author:
      name: Shahid Jameel
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: The study is encouraging. However, every author has a conflict of
      interest and the competing interest statement is a misrepresentation of
      facts.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.05.447177v1
  tweets:
    - created_at: Fri Jun 11 18:24:58 +0000 2021
      id: 1403417994663977000
      id_str: "1403417994663976963"
      text: >-
        üí¨ bioRxiv comment on "Neutralization against B.1.351..."


        "The study is encouraging. However, every author has a co‚Ä¶ https://t.co/WfXqXMzlWT
      truncated: true
      entities:
        urls:
          - url: https://t.co/WfXqXMzlWT
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 11 18:24:59 +0000 2021
      id: 1403417995431616500
      id_str: "1403417995431616517"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/zYi1VqMUON
      truncated: false
      entities:
        urls:
          - url: https://t.co/zYi1VqMUON
      in_reply_to_status_id: 1403417994663977000
      in_reply_to_status_id_str: "1403417994663976963"
- preprint:
    id: 128579
    metric: 12
    title: Spatial transcriptomics reveals unique molecular fingerprints of human
      nociceptors
    url: https://api.rxivist.org/v1/papers/128579
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.02.06.430065v1
    doi: 10.1101/2021.02.06.430065
    category: neuroscience
    first_posted: 2021-02-08
    abstract: Nociceptors are specialized sensory neurons that detect damaging or
      potentially damaging stimuli and are found in the dorsal root (DRG) and
      trigeminal ganglia. These neurons are critical for the generation of
      neuronal signals that ultimately create the perception of pain. These
      neurons are also primary targets for acute and chronic pain therapeutics.
      Single-cell transcriptomics on mouse nociceptors has transformed our
      understanding of pain mechanisms. We sought to generate equivalent
      information for human nociceptors with the goal of identifying
      transcriptomic signatures of nociceptors, identifying species differences
      and elucidating new drug targets. We used spatial transcriptomics to
      molecularly characterize transcriptomes of single dorsal root ganglion
      (DRG) neurons from 8 organ donors. We identified 12 clusters of human
      sensory neurons, 5 of which are C nociceptors; as well as 1 Abeta;
      nociceptor, 2 Adelta;, 2 Abeta; and 1 proprioceptor subtypes. By focusing
      on expression profiles for ion channels, G-protein coupled receptors
      (GPCRs) and other pharmacological targets, we provide a rich map of drug
      targets in the human DRG with direct comparison to mouse sensory neuron
      transcriptomes. We also compare human DRG neuronal subtypes to non-human
      primates showing conserved patterns of gene expression among many cell
      types, but divergence among specific nociceptor subsets. Finally, we
      identify sex differences in human DRG subpopulation transcriptomes,
      including a marked increase in CALCA expression in female pruritogen
      receptor enriched nociceptors. Our data open the door to development of
      drug discovery programs for new pain targets and unparalleled molecular
      characterization of clinical sensory disorders.
    authors:
      - name: Diana Tavares-Ferreira
      - name: Stephanie Shiers
      - name: Pradipta Ray
      - name: Andi Wangzhou
      - name: Vivekanand Jeevakumar
      - name: Ishwarya Sankaranarayanan
      - name: Anna Cervantes
      - name: Jeffrey C. Reese
      - name: Alexander Chamessian
      - name: Bryan Copits
      - name: Patrick M. Dougherty
      - name: Robert Gereau
      - name: Michael D Burton
      - name: Gregory Dussor
      - name: Theodore J Price
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Fri Jun 11 20:15:32 +0000 2021
      id: 1403445818179391500
      id_str: "1403445818179391494"
      text: >-
        üî• bioRxiv Neuroscience preprint by D. Tavares-Ferreira et al:


        "Spatial transcriptomics reveals unique molecular fi‚Ä¶ https://t.co/FpdZDMU5gk
      truncated: true
      entities:
        urls:
          - url: https://t.co/FpdZDMU5gk
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "145457"
    doi: 10.1101/2021.06.08.447489
    first_posted: 2021-06-10
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.08.447489v1
    url: https://api.rxivist.org/v1/papers/145457
    title: Brain charts for the human lifespan
    category: neuroscience
    abstract: Over the past 25 years, neuroimaging has become a ubiquitous tool in
      basic research and clinical studies of the human brain. However, there are
      no reference standards against which to anchor measures of individual
      differences in brain morphology, in contrast to growth charts for traits
      such as height and weight. Here, we built an interactive online resource
      (www.brainchart.io) to quantify individual differences in brain structure
      from any current or future magnetic resonance imaging (MRI) study, against
      models of expected age-related trends. With the goal of basing these on
      the largest and most inclusive dataset, we aggregated MRI data spanning
      115 days post-conception through 100 postnatal years, totaling 122,123
      scans from 100,071 individuals in over 100 studies across 6 continents.
      When quantified as centile scores relative to the reference models,
      individual differences show high validity with non-MRI brain growth
      estimates and high stability across longitudinal assessment. Centile
      scores helped identify previously unreported brain developmental
      milestones and demonstrated increased genetic heritability compared to
      non-centiled MRI phenotypes. Crucially for the study of brain disorders,
      centile scores provide a standardised and interpretable measure of
      deviation that reveals new patterns of neuroanatomical differences across
      neurological and psychiatric disorders emerging during development and
      ageing. In sum, brain charts for the human lifespan are an essential first
      step towards robust, standardised quantification of individual variation
      and for characterizing deviation from age-related trends. Our global
      collaborative study provides such an anchorpoint for basic neuroimaging
      research and will facilitate implementation of research-based standards in
      clinical studies.
    authors:
      - name: Richard A.I. Bethlehem
        orcid: http://orcid.org/0000-0002-0714-0685
      - name: Jakob Seidlitz
        orcid: http://orcid.org/0000-0002-8164-7476
      - name: Simon R White
        orcid: http://orcid.org/0000-0002-7047-9876
      - name: Jacob W Vogel
        orcid: http://orcid.org/0000-0001-6394-9940
      - name: Kevin M Anderson
        orcid: http://orcid.org/0000-0002-1176-6605
      - name: Chris Adamson
        orcid: http://orcid.org/0000-0002-8084-8305
      - name: Sophie Adler
        orcid: http://orcid.org/0000-0002-3978-7424
      - name: George S. Alexopoulos
        orcid: http://orcid.org/0000-0001-5677-7001
      - name: Evdokia Anagnostou
        orcid: http://orcid.org/0000-0002-3455-9887
      - name: Ariosky Areces-Gonzalez
        orcid: null
      - name: Duncan E. Astle
        orcid: http://orcid.org/0000-0002-7042-5392
      - name: Bonnie Auyeung
        orcid: http://orcid.org/0000-0003-1741-0949
      - name: Muhammad Ayub
        orcid: http://orcid.org/0000-0001-9757-2467
      - name: Gareth Ball
        orcid: http://orcid.org/0000-0003-3509-1435
      - name: Simon Baron-Cohen
        orcid: http://orcid.org/0000-0001-9217-2544
      - name: Richard Beare
        orcid: http://orcid.org/0000-0002-7530-5664
      - name: Saashi A. Bedford
        orcid: http://orcid.org/0000-0002-0491-5342
      - name: Vivek Benegal
        orcid: http://orcid.org/0000-0002-8896-9689
      - name: Frauke Beyer
        orcid: http://orcid.org/0000-0001-5401-852X
      - name: Jong Bin Bae
        orcid: null
      - name: John Blangero
        orcid: http://orcid.org/0000-0001-6250-5723
      - name: Manuel Blesa Cabez
        orcid: http://orcid.org/0000-0002-5665-4105
      - name: James P. Boardman
        orcid: http://orcid.org/0000-0003-3904-8960
      - name: Matthew Borzage
        orcid: http://orcid.org/0000-0001-7010-2318
      - name: Jorge F. Bosch-Bayard
        orcid: http://orcid.org/0000-0003-4193-8268
      - name: Niall Bourke
        orcid: http://orcid.org/0000-0001-6478-1430
      - name: Vince Calhoun
        orcid: http://orcid.org/0000-0001-9058-0747
      - name: Mallar M. Chakravarty
        orcid: http://orcid.org/0000-0002-0759-5508
      - name: Christina Chen
        orcid: null
      - name: Casey Chertavian
        orcid: null
      - name: Gael Chetelat
        orcid: null
      - name: Yap S. Chong
        orcid: null
      - name: James H Cole
        orcid: http://orcid.org/0000-0003-1178-5846
      - name: Aiden Corvin
        orcid: http://orcid.org/0000-0001-6717-4089
      - name: Eric Courchesne
        orcid: http://orcid.org/0000-0002-3772-5799
      - name: Fabrice Crivello
        orcid: http://orcid.org/0000-0001-6950-984X
      - name: Vanessa L. Cropley
        orcid: http://orcid.org/0000-0003-0029-1525
      - name: Jennifer Crosbie
        orcid: http://orcid.org/0000-0002-8710-3322
      - name: Nicolas Crossley
        orcid: null
      - name: Marion Delarue
        orcid: null
      - name: Sylvane Desrivieres
        orcid: http://orcid.org/0000-0002-9120-7060
      - name: Gabriel Devenyi
        orcid: null
      - name: Maria A. Di Biase
        orcid: http://orcid.org/0000-0002-8038-9217
      - name: Ray Dolan
        orcid: http://orcid.org/0000-0001-9356-761X
      - name: Kirsten A. Donald
        orcid: http://orcid.org/0000-0002-0276-9660
      - name: Gary Donohoe
        orcid: null
      - name: Katharine Dunlop
        orcid: http://orcid.org/0000-0003-4366-7692
      - name: Anthony D Edwards
        orcid: http://orcid.org/0000-0003-4801-7066
      - name: Jed T. Elison
        orcid: null
      - name: Cameron T. Ellis
        orcid: http://orcid.org/0000-0002-3254-5940
      - name: Jeremy A. Elman
        orcid: http://orcid.org/0000-0002-5840-1769
      - name: Lisa Eyler
        orcid: http://orcid.org/0000-0002-7783-8798
      - name: Damien A. Fair
        orcid: http://orcid.org/0000-0001-8602-393X
      - name: Paul C. Fletcher
        orcid: http://orcid.org/0000-0001-8906-2280
      - name: Peter Fonagy
        orcid: http://orcid.org/0000-0003-0229-0091
      - name: Carol E. Franz
        orcid: http://orcid.org/0000-0002-8987-1755
      - name: Lidice Galan-Garcia
        orcid: http://orcid.org/0000-0003-2636-5588
      - name: Ali Gholipour
        orcid: http://orcid.org/0000-0002-2469-7952
      - name: Jay Giedd
        orcid: http://orcid.org/0000-0003-2002-8978
      - name: John H. Gilmore
        orcid: null
      - name: David C. Glahn
        orcid: http://orcid.org/0000-0002-4749-6977
      - name: Ian Goodyer
        orcid: http://orcid.org/0000-0002-0947-9906
      - name: P. E. Grant
        orcid: http://orcid.org/0000-0002-2039-1964
      - name: Nynke A. Groenewold
        orcid: http://orcid.org/0000-0002-0865-8427
      - name: Faith M. Gunning
        orcid: http://orcid.org/0000-0003-1854-9969
      - name: Raquel E Gur
        orcid: http://orcid.org/0000-0002-4082-8502
      - name: Ruben C Gur
        orcid: http://orcid.org/0000-0002-9657-1996
      - name: Christopher F. Hammill
        orcid: null
      - name: Oskar Hansson
        orcid: http://orcid.org/0000-0001-8467-7286
      - name: Trey Hedden
        orcid: null
      - name: Andreas Heinz
        orcid: http://orcid.org/0000-0001-5405-9065
      - name: Richard Henson
        orcid: http://orcid.org/0000-0002-0712-2639
      - name: Katja Heuer
        orcid: http://orcid.org/0000-0002-7237-0196
      - name: Jacqueline Hoare
        orcid: null
      - name: Bharath Holla
        orcid: http://orcid.org/0000-0003-0999-1237
      - name: Avram J. Holmes
        orcid: http://orcid.org/0000-0001-6583-803X
      - name: Rosie Holt
        orcid: null
      - name: Hao Huang
        orcid: http://orcid.org/0000-0002-0774-4374
      - name: Kiho Im
        orcid: http://orcid.org/0000-0002-9239-8970
      - name: Jonathan Ipser
        orcid: http://orcid.org/0000-0003-1272-0032
      - name: Clifford R. Jack
        orcid: http://orcid.org/0000-0001-7916-622X
      - name: Andrea P Jackowski
        orcid: http://orcid.org/0000-0001-8842-5406
      - name: Tianye Jia
        orcid: http://orcid.org/0000-0001-5399-2953
      - name: Keith A Johnson
        orcid: http://orcid.org/0000-0002-8578-5921
      - name: David T Jones
        orcid: http://orcid.org/0000-0002-8362-7698
      - name: Peter B Jones
        orcid: http://orcid.org/0000-0003-1445-4081
      - name: Rene Kahn
        orcid: null
      - name: Hasse Karlsson
        orcid: http://orcid.org/0000-0002-4992-1893
      - name: Linnea Karlsson
        orcid: http://orcid.org/0000-0002-9201-8560
      - name: Ryuta Kawashima
        orcid: http://orcid.org/0000-0002-6132-3861
      - name: Elizabeth A. Kelley
        orcid: http://orcid.org/0000-0003-2990-3636
      - name: Silke Kern
        orcid: http://orcid.org/0000-0001-7617-7214
      - name: K.W. Kim
        orcid: null
      - name: Manfred G. Kitzbichler
        orcid: http://orcid.org/0000-0002-4494-0753
      - name: William S. Kremen
        orcid: http://orcid.org/0000-0002-8629-5609
      - name: Francois Lalonde
        orcid: null
      - name: Brigitte Landeau
        orcid: http://orcid.org/0000-0002-0814-3714
      - name: Subin Lee
        orcid: null
      - name: Jason Lerch
        orcid: null
      - name: John D. Lewis
        orcid: http://orcid.org/0000-0002-0832-7396
      - name: Jiao Li
        orcid: http://orcid.org/0000-0002-9079-6772
      - name: Wei Liao
        orcid: http://orcid.org/0000-0001-9987-3546
      - name: Deirel P. Linares
        orcid: http://orcid.org/0000-0002-2144-8184
      - name: Conor Liston
        orcid: http://orcid.org/0000-0002-1639-5401
      - name: Michael V. Lombardo
        orcid: http://orcid.org/0000-0001-6780-8619
      - name: Jinglei Lv
        orcid: http://orcid.org/0000-0002-4906-2646
      - name: Charles Lynch
        orcid: http://orcid.org/0000-0003-1936-9740
      - name: Travis T. Mallard
        orcid: http://orcid.org/0000-0002-3265-3001
      - name: Machteld Marcelis
        orcid: http://orcid.org/0000-0003-0045-9244
      - name: Ross D. Markello
        orcid: http://orcid.org/0000-0003-1057-1336
      - name: Bernard Mazoyer
        orcid: http://orcid.org/0000-0003-0970-2837
      - name: Philip McGuire
        orcid: http://orcid.org/0000-0003-4381-0532
      - name: Michael J. Meaney
        orcid: null
      - name: Andrea Mechelli
        orcid: http://orcid.org/0000-0002-6770-2934
      - name: Nenad Medic
        orcid: http://orcid.org/0000-0002-4633-9515
      - name: Bratislav Misic
        orcid: http://orcid.org/0000-0003-0307-2862
      - name: Sarah E Morgan
        orcid: http://orcid.org/0000-0002-1261-5884
      - name: David Mothersill
        orcid: null
      - name: Joel Nigg
        orcid: null
      - name: Marcus Q.W. Ong
        orcid: http://orcid.org/0000-0003-1799-7671
      - name: Cynthia Ortinau
        orcid: http://orcid.org/0000-0003-0851-0796
      - name: Rik Ossenkoppele
        orcid: http://orcid.org/0000-0003-1584-7477
      - name: Minhui Ouyang
        orcid: null
      - name: Lena Palaniyappan
        orcid: http://orcid.org/0000-0003-1640-7182
      - name: Leo Paly
        orcid: null
      - name: Pedro M. Pan
        orcid: http://orcid.org/0000-0002-1943-6520
      - name: Christos Pantelis
        orcid: http://orcid.org/0000-0002-9565-0238
      - name: Min Tae M. Park
        orcid: http://orcid.org/0000-0002-4268-7432
      - name: Tomas Paus
        orcid: http://orcid.org/0000-0003-1495-9338
      - name: Zdenka Pausova
        orcid: http://orcid.org/0000-0002-7784-1380
      - name: Alexa Pichet Binette
        orcid: http://orcid.org/0000-0001-5218-3337
      - name: Karen Pierce
        orcid: http://orcid.org/0000-0001-7690-1030
      - name: Xing Qian
        orcid: http://orcid.org/0000-0002-7784-4688
      - name: Anqi Qiu
        orcid: http://orcid.org/0000-0002-0215-6338
      - name: Jiang Qiu
        orcid: http://orcid.org/0000-0003-3839-4167
      - name: Armin Raznahan
        orcid: http://orcid.org/0000-0002-5622-1190
      - name: Timothy Rittman
        orcid: http://orcid.org/0000-0003-1063-6937
      - name: Caitlin K. Rollins
        orcid: http://orcid.org/0000-0002-0500-0056
      - name: Rafael Romero-Garcia
        orcid: http://orcid.org/0000-0002-5199-4573
      - name: Lisa Ronan
        orcid: http://orcid.org/0000-0001-8580-921X
      - name: Monica D. Rosenberg
        orcid: http://orcid.org/0000-0001-6179-4025
      - name: David H. Rowitch
        orcid: http://orcid.org/0000-0002-0079-0060
      - name: Giovanni A. Salum
        orcid: http://orcid.org/0000-0002-7537-7289
      - name: Theodore D. Satterthwaite
        orcid: http://orcid.org/0000-0001-7072-9399
      - name: H. L. Schaare
        orcid: null
      - name: Russell J Schachar
        orcid: null
      - name: Michael Scholl
        orcid: http://orcid.org/0000-0001-7800-1781
      - name: Aaron P. Schultz
        orcid: http://orcid.org/0000-0002-0418-0999
      - name: Gunter Schumann
        orcid: http://orcid.org/0000-0002-7740-6469
      - name: David Sharp
        orcid: http://orcid.org/0000-0002-6915-1283
      - name: Russell T. Shinohara
        orcid: http://orcid.org/0000-0001-8627-8203
      - name: Ingmar Skoog
        orcid: http://orcid.org/0000-0002-9803-3438
      - name: Christopher D. Smyser
        orcid: null
      - name: Reisa A. Sperling
        orcid: http://orcid.org/0000-0003-1535-6133
      - name: Dan J. Stein
        orcid: http://orcid.org/0000-0002-0186-6872
      - name: Aleks Stolicyn
        orcid: null
      - name: John Suckling
        orcid: http://orcid.org/0000-0002-5098-1527
      - name: Gemma Sullivan
        orcid: http://orcid.org/0000-0003-1499-3536
      - name: Yasuyuki Taki
        orcid: http://orcid.org/0000-0003-3691-1159
      - name: Benjamin Thyreau
        orcid: http://orcid.org/0000-0001-6748-8192
      - name: Roberto Toro
        orcid: http://orcid.org/0000-0002-6671-858X
      - name: Kamen A. Tsvetanov
        orcid: http://orcid.org/0000-0002-3178-6363
      - name: Nicholas B. Turk-Browne
        orcid: http://orcid.org/0000-0001-7519-3001
      - name: Jetro J Tuulari
        orcid: http://orcid.org/0000-0002-1797-8000
      - name: Christophe Tzourio
        orcid: http://orcid.org/0000-0002-6517-2984
      - name: Etienne Vachon-Presseau
        orcid: null
      - name: Mitchell J. Valdes-Sosa
        orcid: http://orcid.org/0000-0002-1580-8374
      - name: Pedro A. Valdes-Sosa
        orcid: http://orcid.org/0000-0001-5485-2661
      - name: Sofie L. Valk
        orcid: null
      - name: Therese van Amelsvoort
        orcid: null
      - name: Simon N. Vandekar
        orcid: http://orcid.org/0000-0002-7457-9073
      - name: Lana Vasung
        orcid: null
      - name: Petra E Vertes
        orcid: null
      - name: Lindsay W. Victoria
        orcid: http://orcid.org/0000-0001-7693-5839
      - name: Sylvia Villeneuve
        orcid: http://orcid.org/0000-0003-2338-0467
      - name: Arno Villringer
        orcid: http://orcid.org/0000-0003-2604-2404
      - name: Konrad Wagstyl
        orcid: http://orcid.org/0000-0003-3439-5808
      - name: Yin-Shan S. Wang
        orcid: null
      - name: Simon K Warfield
        orcid: http://orcid.org/0000-0002-7659-3880
      - name: Varun Warrier
        orcid: http://orcid.org/0000-0003-4532-8571
      - name: Eric Westman
        orcid: http://orcid.org/0000-0002-3115-2977
      - name: Margaret L. Westwater
        orcid: http://orcid.org/0000-0002-2918-0979
      - name: Heather C. Whalley
        orcid: http://orcid.org/0000-0002-4505-8869
      - name: A. V. Witte
        orcid: http://orcid.org/0000-0001-9054-6688
      - name: Ning Yang
        orcid: http://orcid.org/0000-0002-6354-3534
      - name: B. T.T. Yeo
        orcid: http://orcid.org/0000-0002-9649-8311
      - name: H. J. Yun
        orcid: null
      - name: Andrew Zalesky
        orcid: http://orcid.org/0000-0003-2298-9908
      - name: Heather J. Zar
        orcid: null
      - name: Anna Zettergren
        orcid: http://orcid.org/0000-0002-9145-9444
      - name: Juan H. Zhou
        orcid: http://orcid.org/0000-0002-0180-8648
      - name: Hisham Ziauddeen
        orcid: http://orcid.org/0000-0003-4044-1719
      - name: Andre Zugman
        orcid: http://orcid.org/0000-0002-6126-7759
      - name: Xi-Nian Zuo
        orcid: http://orcid.org/0000-0001-9110-585X
      - name: AIBL
        orcid: null
      - name: Alzheimer's Disease Neuroimaging Initiative
        orcid: null
      - name: Alzheimer's Disease Repository Without Borders Investigators
        orcid: null
      - name: ASRB
        orcid: null
      - name: CALM Team
        orcid: null
      - name: Cam-CAN
        orcid: null
      - name: CCNP, 3R-BRAIN
        orcid: null
      - name: COBRE
        orcid: null
      - name: ENIGMA Developmental Brain Age working group
        orcid: null
      - name: FinnBrain
        orcid: null
      - name: Harvard Aging Brain Study
        orcid: null
      - name: IMAGEN
        orcid: null
      - name: KNE96
        orcid: null
      - name: NSPN
        orcid: null
      - name: OASIS-3
        orcid: null
      - name: OpenPain Project
        orcid: null
      - name: POND
        orcid: null
      - name: The PREVENT-AD Research Group
        orcid: null
      - name: VETSA
        orcid: null
      - name: Edward T. Bullmore
        orcid: http://orcid.org/0000-0002-8955-8283
      - name: Aaron F. Alexander-Bloch
        orcid: http://orcid.org/0000-0001-6554-1893
  comment:
    dislikes: 0
    thread: "8584753014"
    numReports: 0
    likes: 0
    id: "5415091636"
    createdAt: 2021-06-10T15:24:54
    author:
      username: muratbilgel
      about: ""
      name: Murat Bilgel
      isPowerContributor: false
      profileUrl: https://disqus.com/by/muratbilgel/
      url: ""
      location: ""
      id: "69406908"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: 'Very impressive sample size and a monumental study! I think you
      will find this recent paper "The Brain Chart of Aging" by Habes et al.
      relevant:
      https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12178'
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.08.447489v1
  tweets:
    - created_at: Fri Jun 11 20:19:19 +0000 2021
      id: 1403446769158078500
      id_str: "1403446769158078465"
      text: >-
        üí¨ bioRxiv comment on "Brain charts for the human lif..."


        "Very impressive sample size and a monumental study! I th‚Ä¶ https://t.co/kw7bfFj62h
      truncated: true
      entities:
        urls:
          - url: https://t.co/kw7bfFj62h
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 11 20:19:19 +0000 2021
      id: 1403446770777079800
      id_str: "1403446770777079811"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/SUapionEUQ
      truncated: false
      entities:
        urls:
          - url: https://t.co/SUapionEUQ
      in_reply_to_status_id: 1403446769158078500
      in_reply_to_status_id_str: "1403446769158078465"
- preprint:
    id: "145290"
    doi: 10.1101/2021.06.08.447603
    first_posted: 2021-06-09
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.08.447603v1
    url: https://api.rxivist.org/v1/papers/145290
    title: PRDM9 losses in vertebrates are coupled to the loss of at least three
      other meiotic genes
    category: evolutionary-biology
    abstract: "In most mammals and likely throughout vertebrates, the gene PRDM9
      specifies the locations of meiotic double strand breaks; in mice and
      humans at least, it also aids in their repair. For both roles, many of the
      molecular partners remain unknown. Here, we take a phylogenetic approach
      to identify genes that may be interacting with PRDM9, by leveraging the
      fact that PRDM9 arose before the origin of vertebrates, but was lost many
      times, either partially or entirely--and with it, its role in
      recombination. As a first step, we characterize PRDM9 domain composition
      across 379 vertebrate species, inferring at least eight independent
      losses. We then use the interdigitation of PRDM9 orthologs across
      vertebrates to test whether it co-evolved with any of 241 candidate genes
      co-expressed with PRDM9 in mice or associated with recombination
      phenotypes in mammals. Accounting for the phylogenetic relationship among
      species, we identify three genes whose presence and absence is
      unexpectedly coincident with that of PRDM9: ZCWPW1, which was recently
      shown to be recruited to sites of PRDM9 binding and to facilitate double
      strand break repair; TEX15, which has also been suggested to play a role
      in repair; and ZCWPW2, the paralog of ZCWPW1. ZCWPW2 is expected to be
      recruited to sites of PRDM9 binding as well; its tight coevolution with
      PRDM9 across vertebrates suggests that it is a key interactor, with a role
      either in recruiting the recombination machinery or in double strand break
      repair."
    authors:
      - name: Maria Izabel Alves Cavassim
        orcid: http://orcid.org/0000-0001-9726-1431
      - name: Zachary Baker
        orcid: http://orcid.org/0000-0002-1540-0731
      - name: Carla Hoge
        orcid: http://orcid.org/0000-0001-9798-9684
      - name: Mikkel Schierup
        orcid: http://orcid.org/0000-0002-5028-1790
      - name: Molly Schumer
        orcid: http://orcid.org/0000-0002-2075-5668
      - name: Molly Przeworski
        orcid: http://orcid.org/0000-0002-5369-9009
  comment:
    dislikes: 0
    thread: "8582336970"
    numReports: 0
    likes: 0
    id: "5416676121"
    createdAt: 2021-06-11T20:51:51
    author:
      name: Maria Izabel Cavassim Alves
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "Thanks to Dr. Todd Jackman (Villanova), who emailed us a comment
      on our preprint, we have realized that there is an error in the
      distribution of TEX15 orthologs that we reconstructed: whereas we
      initially only detected the presence of a partial PRDM9 ortholog in Anolis
      carolinensis, there is in fact a complete TEX15 ortholog. As a result, the
      evidence for co-evolution of TEX15 and PRDM9 is less compelling (p-value =
      0.058 in Table 1). We will be updating the preprint shortly to reflect
      this change."
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.08.447603v1
  tweets:
    - created_at: Fri Jun 11 22:20:14 +0000 2021
      id: 1403477201358569500
      id_str: "1403477201358569481"
      text: >-
        üí¨ bioRxiv comment on "PRDM9 losses in vertebrates ar..."


        "Thanks to Dr. Todd Jackman (Villanova), who emailed us a‚Ä¶ https://t.co/gwwvBqEra0
      truncated: true
      entities:
        urls:
          - url: https://t.co/gwwvBqEra0
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 11 22:20:15 +0000 2021
      id: 1403477202272931800
      id_str: "1403477202272931848"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/W0XMPA4V1Y
      truncated: false
      entities:
        urls:
          - url: https://t.co/W0XMPA4V1Y
      in_reply_to_status_id: 1403477201358569500
      in_reply_to_status_id_str: "1403477201358569481"
- preprint:
    id: "130341"
    doi: 10.1101/2021.02.20.432090
    first_posted: 2021-02-20
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.02.20.432090v1
    url: https://api.rxivist.org/v1/papers/130341
    title: "Preprints in motion: tracking changes between posting and journal
      publication"
    category: scientific-communication-and-education
    abstract: Amidst the COVID-19 pandemic, preprints in the biomedical sciences are
      being posted and accessed at unprecedented rates, drawing widespread
      attention from the general public, press and policymakers for the first
      time. This phenomenon has sharpened longstanding questions about the
      reliability of information shared prior to journal peer review. Does the
      information shared in preprints typically withstand the scrutiny of peer
      review, or are conclusions likely to change in the version of record? We
      assessed preprints that had been posted and subsequently published in a
      journal between 1st January and 30th April 2020, representing the initial
      phase of the pandemic response. We utilised a combination of automatic and
      manual annotations to quantify how an article changed between the
      preprinted and published version. We found that the total number of figure
      panels and tables changed little between preprint and published articles.
      Moreover, the conclusions of 6% of non-COVID-19-related and 15% of
      COVID-19-related abstracts undergo a discrete change by the time of
      publication, but the majority of these changes do not reverse the main
      message of the paper.
    authors:
      - name: Jessica K Polka
        orcid: http://orcid.org/0000-0001-6610-9293
      - name: Gautam Dey
        orcid: http://orcid.org/0000-0003-1416-6223
      - name: Mate Palfy
        orcid: http://orcid.org/0000-0003-2532-9438
      - name: Federico Nanni
        orcid: http://orcid.org/0000-0003-2484-4331
      - name: Liam Brierley
        orcid: http://orcid.org/0000-0002-3026-4723
      - name: Nicholas Fraser
        orcid: http://orcid.org/0000-0002-7582-6339
      - name: Jonathon Alexis Coates
        orcid: http://orcid.org/0000-0001-9039-9219
  comment:
    dislikes: 0
    thread: "8465389038"
    numReports: 0
    likes: 0
    id: "5416670758"
    createdAt: 2021-06-11T20:46:55
    author:
      username: jessicapolka
      about: Director, ASAPbio
      name: Jessica Polka
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jessicapolka/
      url: http://jessicapolka.com
      location: Boston, MA
      id: "63061838"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "My co-authors and I welcome additional public comments on this
      work, ideally by the end of June, 2021! #FeedbackASAP"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.02.20.432090v2
  tweets:
    - created_at: Sat Jun 12 00:57:16 +0000 2021
      id: 1403516717054279700
      id_str: "1403516717054279689"
      text: >-
        üí¨ bioRxiv comment on "Preprints in motion: tracking ..."


        "My co-authors and I welcome additional public comments o‚Ä¶ https://t.co/4iBsjg6e0H
      truncated: true
      entities:
        urls:
          - url: https://t.co/4iBsjg6e0H
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 12 00:57:16 +0000 2021
      id: 1403516717909909500
      id_str: "1403516717909909507"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/jC8jwWp8Ph
      truncated: false
      entities:
        urls:
          - url: https://t.co/jC8jwWp8Ph
      in_reply_to_status_id: 1403516717054279700
      in_reply_to_status_id_str: "1403516717054279689"
- preprint:
    id: "145628"
    doi: 10.1101/2021.06.10.447951
    first_posted: 2021-06-10
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.10.447951v1
    url: https://api.rxivist.org/v1/papers/145628
    title: "Safety and Potency of COVIran Barekat Inactivated Vaccine Candidate for
      SARS-CoV-2: A Preclinical Study"
    category: immunology
    abstract: There is an urgent demand to manufacture an effective and safe vaccine
      to prevent SARS-CoV2 infection, which resulted in a global pandemic. In
      this study, we developed an inactivated whole-virus SARS-CoV-2 candidate
      vaccine named COVIran Barekat. Immunization at two different doses (3
      microgram or 5 microgram per dose) elicited a high level of SARS-CoV-2
      specific neutralizing antibodies in mice, rabbits, and non-human primates.
      The results show the safety profile in studied animals (include guinea
      pig, rabbit, mice, and monkeys). Rhesus macaques were immunized with the
      two-dose of 5 microgram and microgram of the COVIran Barekat vaccine and
      showed highly efficient protection against 104 TCID50 of SARS-CoV-2
      intratracheal challenge compared with the control group. These results
      highlight the COVIran Barekat vaccine as a potential candidate to induce a
      strong and potent immune response which may be a promising and feasible
      vaccine to protect against SARS-CoV2 infection.
    authors:
      - name: Asghar Abdoli
        orcid: null
      - name: Reza Aalizadeh
        orcid: null
      - name: Hossein Aminianfar
        orcid: null
  comment:
    dislikes: 0
    thread: "8586047747"
    numReports: 0
    likes: 0
    id: "5416670070"
    createdAt: 2021-06-11T20:46:22
    author:
      username: seyyedmmiri
      about: ""
      name: Seyyed M Miri
      isPowerContributor: false
      profileUrl: https://disqus.com/by/seyyedmmiri/
      url: http://www.drmiri.com
      location: ""
      id: "347657184"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      No Conflict of interest.

      although some of the authors are working in private companies, there is no coflict of interest in this article. We recomment authors to declare it.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.10.447951v1
  tweets:
    - created_at: Sat Jun 12 12:29:50 +0000 2021
      id: 1403691009486344200
      id_str: "1403691009486344192"
      text: |-
        üí¨ bioRxiv comment on "Safety and Potency of COVIran ..."

        "No Conflict of interest.
        although some of the authors ar‚Ä¶ https://t.co/6ywO70xisM
      truncated: true
      entities:
        urls:
          - url: https://t.co/6ywO70xisM
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 12 12:29:50 +0000 2021
      id: 1403691010312507400
      id_str: "1403691010312507395"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/AMwMzS6zrj
      truncated: false
      entities:
        urls:
          - url: https://t.co/AMwMzS6zrj
      in_reply_to_status_id: 1403691009486344200
      in_reply_to_status_id_str: "1403691009486344192"
- preprint:
    id: "145454"
    doi: 10.1101/2021.06.09.447681
    first_posted: 2021-06-10
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.09.447681v1
    url: https://api.rxivist.org/v1/papers/145454
    title: Heightened condition dependent expression of structural colouration in
      the faces, but not wings, of male and female flies
    category: evolutionary-biology
    abstract: Structurally coloured sexual signals are a conspicuous and widespread
      class of ornament used in mate choice, though the extent to which they
      encode information on the quality of their bearers is not fully resolved.
      Theory predicts that signalling traits under strong sexual selection as
      honest indicators should evolve to be more developmentally integrated and
      exaggerated than nonsexual traits, thereby leading to heightened condition
      dependence. Here we test this prediction through examination of the
      sexually dimorphic faces and wings of the cursorial fly Lispe cana. Males
      and females possess structural UV-white and golden faces, respectively,
      and males present their faces and wings to females during close-range,
      ground-based courtship displays, thereby creating the opportunity for
      mutual inspection. Across a field-collected sample of individuals, we
      found that the appearance of the faces of both sexes scaled positively
      with individual condition, though along separate axes. Males in better
      condition expressed brighter faces as modelled according to conspecific
      flies, whereas condition scaled with facial saturation in females. We
      found no such relationships for their wing interference pattern nor
      abdomens, with the latter included as a nonsexual control. Our results
      suggest that the structurally coloured faces, but not the iridescent
      wings, of male and female Lispe cana are reliable guides to individual
      quality and support the broader potential for structural colours as honest
      signals. They also highlight the potential for mutual mate choice in this
      system, while arguing for one of several alternate signalling roles for
      wing interferences patterns among the myriad taxa which bear them.
    authors:
      - name: Thomas E. White
        orcid: http://orcid.org/0000-0002-3976-1734
      - name: Amy Locke
        orcid: null
      - name: Tanya Latty
        orcid: http://orcid.org/0000-0002-7469-8590
  comment:
    dislikes: 0
    thread: "8584512567"
    numReports: 0
    likes: 0
    id: "5414775544"
    createdAt: 2021-06-10T09:34:35
    author:
      username: marcrobinsonrechavi
      about: ""
      name: Marc RobinsonRechavi
      isPowerContributor: false
      profileUrl: https://disqus.com/by/marcrobinsonrechavi/
      url: ""
      location: ""
      id: "67492738"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Under Data availability, the authors write:



      <blockquote>All underlying data and code will be persistently archived upon acceptance</blockquote>



      This is a publication, i.e. it is made public as part of the scientific record and is citable, thus I strongly invite the authors to make the corresponding data and code available without delay.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.09.447681v1
  tweets:
    - created_at: Sat Jun 12 14:17:29 +0000 2021
      id: 1403718101401747500
      id_str: "1403718101401747456"
      text: |-
        üí¨ bioRxiv comment on "Heightened condition dependent..."

        "Under Data availability, the authors write:

        &lt;blockquote‚Ä¶ https://t.co/RbcxTsoa1u
      truncated: true
      entities:
        urls:
          - url: https://t.co/RbcxTsoa1u
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 12 14:17:30 +0000 2021
      id: 1403718102312001500
      id_str: "1403718102312001545"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/jSRgf2dinT
      truncated: false
      entities:
        urls:
          - url: https://t.co/jSRgf2dinT
      in_reply_to_status_id: 1403718101401747500
      in_reply_to_status_id_str: "1403718101401747456"
- preprint:
    id: "145322"
    doi: 10.1101/2021.06.07.21258447
    first_posted: 2021-06-09
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.07.21258447v1
    url: https://api.rxivist.org/v1/papers/145322
    title: Breakthrough infection with SARS-CoV-2 and its predictors among
      healthcare workers in a medical college and hospital complex in Delhi,
      India
    category: public-and-global-health
    abstract: >-
      IntroductionThe study objective was to determine the breakthrough
      infection rate of Covid-19 (SARS-CoV-2) infection in those vaccinated with
      either BBV152 or AZD1222 (ChAdOx1-S) vaccine among healthcare workers
      (HCWs).


      MethodsA cross-sectional analysis was conducted a medical college and hospital complex in Delhi, India through telephonic interviews among HCWs who had received at-least one dose of a Covid-19 vaccine during January to March 2021. Breakthrough infections were operationally defined as occurrence of Covid-19 infection [&ge;]14 days after administration of two doses of either Covid-19 vaccine.


      ResultsWe enrolled 326 HCWs with mean (SD) age of 29.1 (85.9) years including 212 (65%) males. Two hundred eighty (90.9%) HCWs were fully vaccinated while 46 (14.1%) were partially vaccinated. There were 168 (51.5%) BBV152 and 158 (48.5%) AZD1222 (ChAdOx1-S) recipients.


      A total of 36 (11%, 95% C.I. 8.1, 14.9) breakthrough infections were reported in the HCWs. The median (IQR) time until incidence of Covid-19 infection since receiving second dose of either Covid-19 vaccine was 46 (28.2, 54.7) days. Furthermore, Covid-19 infections occurred in 65 (19.9%, 95% C.I 15.9, 24.6) HCWs vaccinated with at-least one dose of vaccine but prior to receiving their second dose or <14 days post second dose. Most breakthrough infection cases (94.4%) were mild and did not require supplemental oxygen therapy. HCWs with past history of natural Covid-19 infection with recovery were 4.5 times less likely to experience a Covid-19 infection after partial vaccination.


      ConclusionNearly one in nine HCWs experienced a Covid-19 breakthrough infection in the present study.
    authors:
      - name: Pragya Sharma
        orcid: http://orcid.org/0000-0003-4492-2720
      - name: Suruchi Mishra
        orcid: http://orcid.org/0000-0001-8693-0273
      - name: Saurav Basu
        orcid: http://orcid.org/0000-0003-1336-8720
      - name: Neha Tanwar
        orcid: null
      - name: Rajesh Kumar
        orcid: null
  comment:
    dislikes: 0
    thread: "8583178511"
    numReports: 0
    likes: 0
    id: "5415782982"
    createdAt: 2021-06-11T03:08:36
    author:
      username: kelsigmund
      about: ""
      name: Kel Sigmund
      isPowerContributor: false
      profileUrl: https://disqus.com/by/kelsigmund/
      url: ""
      location: ""
      id: "370765100"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      1. Do you know if the relative lack of severe manifestations among the
      vaccinees with breakthrough covid 19 was associated with the occurrence of
      prior Covid 19 infection before undergoing vaccination?

      2. Do you have data  on the demographics of the vaccinee recipients, especially risk factors for severe disease and age because it would be interesting to know if the vaccine truly mitigated the severity of disease or the vaccinated population is younger and healthier than most being health care workers.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.07.21258447v1
  tweets:
    - created_at: Sat Jun 12 16:32:26 +0000 2021
      id: 1403752062454796300
      id_str: "1403752062454796289"
      text: >-
        üí¨ medRxiv comment on "Breakthrough infection with SA..."


        "1. Do you know if the relative lack of severe manifestat‚Ä¶ https://t.co/YVuntPuV2h
      truncated: true
      entities:
        urls:
          - url: https://t.co/YVuntPuV2h
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 12 16:32:26 +0000 2021
      id: 1403752063172022300
      id_str: "1403752063172022272"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/moFyyu9wkW
      truncated: false
      entities:
        urls:
          - url: https://t.co/moFyyu9wkW
      in_reply_to_status_id: 1403752062454796300
      in_reply_to_status_id_str: "1403752062454796289"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 1
    id: "5415319121"
    createdAt: 2021-06-10T18:36:47
    author:
      username: patrickmeredith
      about: ""
      name: Patrick Meredith
      isPowerContributor: false
      profileUrl: https://disqus.com/by/patrickmeredith/
      url: ""
      location: ""
      id: "82921577"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Need zinc too. Otherwise you are just hoping that your patients
      have enough serum zinc naturally.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Sat Jun 12 18:25:10 +0000 2021
      id: 1403780430256611300
      id_str: "1403780430256611328"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "Need zinc too. Otherwise you are just hoping that your p‚Ä¶ https://t.co/YLilV6Z4dm
      truncated: true
      entities:
        urls:
          - url: https://t.co/YLilV6Z4dm
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 12 18:25:10 +0000 2021
      id: 1403780431107997700
      id_str: "1403780431107997697"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1403780430256611300
      in_reply_to_status_id_str: "1403780430256611328"
- preprint:
    id: 93510
    metric: 15
    title: FDR control in GWAS with population structure
    url: https://api.rxivist.org/v1/papers/93510
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.08.04.236703v1
    doi: 10.1101/2020.08.04.236703
    category: genomics
    first_posted: 2020-08-04
    abstract: We present a comprehensive statistical framework to analyze data from
      genome-wide association studies of polygenic traits, producing distinct
      and interpretable discoveries while controlling the false discovery rate.
      This approach leverages sophisticated multivariate models, correcting for
      linkage disequilibrium, and accounts for population structure and
      relatedness, adapting to the characteristics of the samples at hand. A key
      element is the recognition that the observed genotypes can be considered
      as a random sample from an appropriate model, encapsulating our knowledge
      of genetic inheritance and human populations. This allows us to generate
      imperfect copies (knockoffs) of these variables which serve as ideal
      negative controls; knockoffs are indistinguishable from the original
      genotypes in distribution, and independent from the phenotype. In sharp
      contrast with state-of-the-art methods, the validity of our inference in
      no way depends on assumptions about the unknown relation between genotypes
      and phenotype. We develop and leverage a model for the genotypes that
      accounts for arbitrary and unknown population structure, which may be due
      to diverse ancestries or familial relatedness. We build a pipeline that is
      robust to the most prominent possible confounders, facilitating the
      discovery of causal variants. Validity and effectiveness are demonstrated
      by extensive simulations with real data, as well as by the analysis of
      several phenotypes in the UK Biobank. Finally, fast software is made
      available for researchers to apply the proposed methodology to
      Biobank-scale data sets.
    authors:
      - name: Matteo Sesia
      - name: Stephen Bates
      - name: Emmanuel Cand√®s
      - name: Jonathan Marchini
      - name: Chiara Sabatti
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sat Jun 12 20:16:24 +0000 2021
      id: 1403808424450740200
      id_str: "1403808424450740232"
      text: |-
        üî• bioRxiv Genomics preprint by M. Sesia et al:

        "FDR control in GWAS with population structure"‚Ä¶ https://t.co/eLAlcZOa5l
      truncated: true
      entities:
        urls:
          - url: https://t.co/eLAlcZOa5l
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 1
    id: "5415027531"
    createdAt: 2021-06-10T14:31:53
    author:
      username: disqus_uRsnQErmiW
      about: ""
      name: Jeff Krantz
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_uRsnQErmiW/
      url: ""
      location: ""
      id: "271051582"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: I would really like to know the lab you went to.  Quest Diagnostics
      doesn't have a quantitative test for C19.  Thank you
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Sat Jun 12 20:20:10 +0000 2021
      id: 1403809373911191600
      id_str: "1403809373911191555"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "I would really like to know the lab you went to.  Quest‚Ä¶ https://t.co/xr3hJmHPSL
      truncated: true
      entities:
        urls:
          - url: https://t.co/xr3hJmHPSL
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 12 20:20:11 +0000 2021
      id: 1403809374687084500
      id_str: "1403809374687084547"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1403809373911191600
      in_reply_to_status_id_str: "1403809373911191555"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 1
    id: "5415631423"
    createdAt: 2021-06-10T23:42:05
    author:
      username: disqus_hU6Dp6Ib7R
      about: ""
      name: Wayne B
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_hU6Dp6Ib7R/
      url: ""
      location: ""
      id: "370765093"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Have to reread more carefully, but it seems that if you make it to
      10 days regardless, chances of survival go up, and most of the treatments
      were inititated at 10 days?  That's a big confound.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Sat Jun 12 22:19:11 +0000 2021
      id: 1403839324068757500
      id_str: "1403839324068757510"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "Have to reread more carefully, but it seems that if you‚Ä¶ https://t.co/ktFJ8s3qNh
      truncated: true
      entities:
        urls:
          - url: https://t.co/ktFJ8s3qNh
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 12 22:19:11 +0000 2021
      id: 1403839324781699000
      id_str: "1403839324781699075"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1403839324068757500
      in_reply_to_status_id_str: "1403839324068757510"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 1
    id: "5415059353"
    createdAt: 2021-06-10T14:58:00
    author:
      username: johnartuli
      about: ""
      name: John Artuli
      isPowerContributor: false
      profileUrl: https://disqus.com/by/johnartuli/
      url: ""
      location: ""
      id: "369312159"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Figure 2 is reporting 80mg/kg cumulative HCQ dose, which is approx.
      10 days of HCQ dosing.  A Cox regression with a time dependent covariate
      (of HCQ use) would be a better analysis.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Sun Jun 13 01:03:39 +0000 2021
      id: 1403880714492317700
      id_str: "1403880714492317696"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "Figure 2 is reporting 80mg/kg cumulative HCQ dose, which‚Ä¶ https://t.co/MNyBqJJjJP
      truncated: true
      entities:
        urls:
          - url: https://t.co/MNyBqJJjJP
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 13 01:03:40 +0000 2021
      id: 1403880715217932300
      id_str: "1403880715217932289"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1403880714492317700
      in_reply_to_status_id_str: "1403880714492317696"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 1
    thread: "8564791155"
    numReports: 1
    likes: 4
    id: "5415056113"
    createdAt: 2021-06-10T14:55:18
    author:
      username: johnartuli
      about: ""
      name: John Artuli
      isPowerContributor: false
      profileUrl: https://disqus.com/by/johnartuli/
      url: ""
      location: ""
      id: "369312159"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      The statistical analysis is invalid suffering from an very clear immortal
      time bias. This is really basic stats 101.  There is a reason this
      pre-print has not been accepted in a peer-reviewed journal.  


      For a Kaplan-Meier survival analysis, groups need to be defined at baseline.  For persons to have received >80 mg/kg cumulative HCQ dosing (where a standard 600mg dose could is ~8mg/kg/day), persons need to survive for 10 days.  So Figure 2, compares those who survive to receive 10 days of HCQ versus all others  This is an immortal time bias. 


      As 88% of people overall received HCQ, likely a large proportion of those 40% who died before day 10 received HCQ (at max only ~12% could not have received HCQ).
       
      The authors should re-do their analysis using a Cox-regression with a time-dependent covariate for receiving HCQ.
    forum: medrxiv
    points: 3
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Sun Jun 13 12:30:24 +0000 2021
      id: 1404053540616683500
      id_str: "1404053540616683529"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "The statistical analysis is invalid suffering from an ve‚Ä¶ https://t.co/VkEyeG9tYp
      truncated: true
      entities:
        urls:
          - url: https://t.co/VkEyeG9tYp
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 13 12:30:24 +0000 2021
      id: 1404053541363269600
      id_str: "1404053541363269635"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1404053540616683500
      in_reply_to_status_id_str: "1404053540616683529"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 4
    id: "5414774986"
    createdAt: 2021-06-10T09:33:28
    author:
      username: marcelomazocco
      about: Algu√©m perdido em algum lugar
      name: Marcelo Mazocco
      isPowerContributor: false
      profileUrl: https://disqus.com/by/marcelomazocco/
      url: ""
      location: Mundo, estranho mundo.
      id: "154637687"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Stephen, can you assure that not even around 7 out of the 224 patients to
      whom were given HCQ did get included in the "success" group by cumulative
      dosages (the 18 survivors that took >3g HCQ + >1g AZM) JUST BECAUSE they
      survived and therefore had more time to consolidate those dosages, and not
      the other way around?


      Because if that is the case, I believe you got a problem of statistical significance. That would leave us with just 3 survivors above general average. And by 7 out of 224, that might be the case.


      Another issue: 87% of all patients received HCQ in some form but what was the percentage of those in the survivors group? I couldn't find the number but I suspect this result is something to look at. It should be higher than 87% if any form of it works in any way. As is also something to look at the randomized double blinded studies that compare those who took HCQ+AZM to those who didn't, in a more broad way, so that we can compare the effects. I suspect that this study not being blinded or double blinded could have also skewed the results by some amount, and that is another issue.


      One more issue: I find it quite weird that you had 78% death rate when the average north american death rate for intubated patients of covid is around 46% for what I've seen. Even using a few medications that supposedly work. There must be something else at play here, probably also skewing the results.
    forum: medrxiv
    points: 4
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Sun Jun 13 14:17:35 +0000 2021
      id: 1404080512478634000
      id_str: "1404080512478633986"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "Stephen, can you assure that not even around 7 out of th‚Ä¶ https://t.co/naT7enVoJI
      truncated: true
      entities:
        urls:
          - url: https://t.co/naT7enVoJI
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 13 14:17:35 +0000 2021
      id: 1404080513321681000
      id_str: "1404080513321680899"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1404080512478634000
      in_reply_to_status_id_str: "1404080512478633986"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 1
    id: "5415754630"
    createdAt: 2021-06-11T02:27:08
    author:
      username: pepa65
      about: ""
      name: pepa65
      isPowerContributor: false
      profileUrl: https://disqus.com/by/pepa65/
      url: ""
      location: ""
      id: "741284"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "This factor has indeed not been controlled for. But the conclusion
      still stands: re-infection rates are zero, so no urgency to vaccinate."
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Sun Jun 13 16:32:34 +0000 2021
      id: 1404114484499783700
      id_str: "1404114484499783683"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "This factor has indeed not been controlled for. But the‚Ä¶ https://t.co/rcYnxTZlkx
      truncated: true
      entities:
        urls:
          - url: https://t.co/rcYnxTZlkx
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 13 16:32:35 +0000 2021
      id: 1404114485183459300
      id_str: "1404114485183459331"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1404114484499783700
      in_reply_to_status_id_str: "1404114484499783683"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 1
    thread: "8564791155"
    numReports: 0
    likes: 1
    id: "5415445667"
    createdAt: 2021-06-10T20:23:12
    author:
      username: disqus_Gk8O4AglB4
      about: ""
      name: John Jay
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_Gk8O4AglB4/
      url: ""
      location: ""
      id: "370721963"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Sorry if this was already mentioned, but is there a discussion of
      how the demographics (ie age, co-morbidities, status before care, etc.)
      varied between the group given 3,000mg HCQ + 1,000mg AZM and all other
      patients in the study?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Sun Jun 13 18:25:38 +0000 2021
      id: 1404142936086954000
      id_str: "1404142936086953991"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "Sorry if this was already mentioned, but is there a disc‚Ä¶ https://t.co/EklcmmlpLC
      truncated: true
      entities:
        urls:
          - url: https://t.co/EklcmmlpLC
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 13 18:25:38 +0000 2021
      id: 1404142936774881300
      id_str: "1404142936774881283"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1404142936086954000
      in_reply_to_status_id_str: "1404142936086953991"
- preprint:
    id: 145879
    metric: 32
    title: Harnessing methylotrophs as a bacterial platform to reduce adverse
      effects of the use of the heavy lanthanide gadolinium in magnetic
      resonance imaging
    url: https://api.rxivist.org/v1/papers/145879
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.12.448192v1
    doi: 10.1101/2021.06.12.448192
    category: microbiology
    first_posted: 2021-06-12
    abstract: Gadolinium is a key component of magnetic resonance imaging contrast
      agents that are critical tools for enhanced detection and diagnosis of
      tissue and vascular abnormalities. Untargeted post-injection deposition of
      gadolinium in vivo, and association with diseases like nephrogenic
      systemic fibrosis, has alerted regulatory agencies to re-evaluate their
      widespread use and generated calls for safer gadolinium-based contrast
      agents (GBCAs). Increasing anthropogenic gadolinium in surface water has
      also raised concerns of potential bioaccumulation in plants and animals.
      Methylotrophic bacteria can acquire, transport, store and use light
      lanthanides as part of a cofactor complex with pyrroloquinoline quinone
      (PQQ), an essential component of XoxF-type methanol dehydrogenases (MDHs),
      a critical enzyme for methylotrophic growth with methanol. We report
      robust gadolinium-dependent methanol growth of a genetic variant of
      Methylorubrum extorquens AM1, named evo-HLn, for evolved for heavy
      lanthanides. Genetic adaptation of evo-HLn resulted in increased xox1
      promoter and XoxF MDH activities, transport and storage of Gd3+, and
      augmented biosynthesis of PQQ. Gadolinium-grown cells exhibited a shorter
      T1 relaxation time compared to cells with lanthanum or no lanthanide when
      analyzed by MRI. In addition, evo-HLn was able to grow on methanol using
      the GBCA Gd-DTPA as the sole gadolinium source, showing the potential of
      this strain for the development of novel GBCAs and gadolinium recovery
      from medical waste and/or wastewater.
    authors:
      - name: Nathan Michael Good
      - name: Harvey Lee
      - name: Emily R Hawker
      - name: Assaf Gilad
      - name: Norma Cecilia Martinez-Gomez
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sun Jun 13 20:15:39 +0000 2021
      id: 1404170622666559500
      id_str: "1404170622666559493"
      text: >-
        üî• bioRxiv Microbiology preprint by N. M. Good et al:


        "Harnessing methylotrophs as a bacterial platform to reduce a‚Ä¶ https://t.co/bwlfhZQRQ8
      truncated: true
      entities:
        urls:
          - url: https://t.co/bwlfhZQRQ8
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5415540956"
    createdAt: 2021-06-10T21:54:34
    author:
      username: Tweeter83
      about: ""
      name: Tweeter83
      isPowerContributor: false
      profileUrl: https://disqus.com/by/Tweeter83/
      url: ""
      location: Georgia
      id: "53595572"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      So far some experts are looking at no significant signs of decrease after
      a solid 10 months, meanwhile there are still some talks about vax boosters
      possibly being needed due to noted drops in antibodies from the vaccine
      after 6-8 months.


      If I can find the link to that article again I'll post it back here for you.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Sun Jun 13 20:19:26 +0000 2021
      id: 1404171574756921300
      id_str: "1404171574756921345"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "So far some experts are looking at no significant signs‚Ä¶ https://t.co/hMSadbknAn
      truncated: true
      entities:
        urls:
          - url: https://t.co/hMSadbknAn
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 13 20:19:26 +0000 2021
      id: 1404171575570710500
      id_str: "1404171575570710528"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1404171574756921300
      in_reply_to_status_id_str: "1404171574756921345"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5415472260"
    createdAt: 2021-06-10T20:47:05
    author:
      username: tracii_kunkel
      about: ""
      name: Tracii Kunkel
      isPowerContributor: false
      profileUrl: https://disqus.com/by/tracii_kunkel/
      url: ""
      location: ""
      id: "133823091"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: zero infections in a sample of 1,359 over less than half a year
      isn't that surprising. It's a very very small sample size.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Sun Jun 13 22:19:15 +0000 2021
      id: 1404201729642610700
      id_str: "1404201729642610696"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "zero infections in a sample of 1,359 over less than half‚Ä¶ https://t.co/A0i1fHy48N
      truncated: true
      entities:
        urls:
          - url: https://t.co/A0i1fHy48N
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 13 22:19:15 +0000 2021
      id: 1404201730364129300
      id_str: "1404201730364129281"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1404201729642610700
      in_reply_to_status_id_str: "1404201729642610696"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5415438009"
    createdAt: 2021-06-10T20:16:24
    author:
      username: tracii_kunkel
      about: ""
      name: Tracii Kunkel
      isPowerContributor: false
      profileUrl: https://disqus.com/by/tracii_kunkel/
      url: ""
      location: ""
      id: "133823091"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Great to hear Norrin. I'm not trying to tell anyone to wear a mask,
      or saying that vaccination is necessary. I'm just commenting on the
      research paper itself. This will never pass peer review as is. There are
      just some important variables that MAY have had an impact that the
      researchers did not address. It happens in all research.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Mon Jun 14 01:00:02 +0000 2021
      id: 1404242191770427400
      id_str: "1404242191770427396"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "Great to hear Norrin. I'm not trying to tell anyone to w‚Ä¶ https://t.co/vrU66sCHgV
      truncated: true
      entities:
        urls:
          - url: https://t.co/vrU66sCHgV
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 14 01:00:02 +0000 2021
      id: 1404242192445628400
      id_str: "1404242192445628422"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1404242191770427400
      in_reply_to_status_id_str: "1404242191770427396"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 3
    id: "5416539078"
    createdAt: 2021-06-11T18:53:43
    author:
      username: SemperCogitens
      about: ""
      name: SemperCogitens
      isPowerContributor: false
      profileUrl: https://disqus.com/by/SemperCogitens/
      url: ""
      location: Third planet from the sun, Milky Way galaxy, Laniakea Supercluster
      id: "14179515"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      A couple of things people really need to note here:

      1) This is PRE-publication. It hasn't been peer-reviewed. Everything on this website is such. It cannot be regarded the same as something which has gone through the full process with a respected journal.

      2) This is an observational study (retrospective cohort). It is NOT a randomized, placebo-controlled clinical trial. Only the RCT can prove causation. This is hypothesis-generating research only. It does not PROVE HCQ works, merely suggests that. 


      3) If you dig in a bit, they define "treatment" to include only 37 of the advertised 250ish patients in the cohort, specifically those receiving >3,000mg HCQ and >1g azithromycin. Small sample sizes should always be viewed with extreme skepticism. Less than 30ish and your p-value is essentially meaningless. 


      4) The overall mortality rate of the total group was ~80%! These people were old, unhealthy to begin with, admitted to the hospital after nearly a week of progressing symptoms, required ICU care, intubation, and mechanical ventilation. These were very sick patients.


      5) Clinically, we see a pattern for the treatment of ARDS and secondary pneumonia, not COVID. High dose corticosteroids work (we know this for ARDS), tocilizumab, a potent anti-inflammatory works (we have some data for this in ARDS as well). And azithromycin is a very common drug to treat bacterial pneumonias that often pop up secondary to lung disease like this.



      So, please avoid jumping to unsupported conclusions. If we want real answers, we have to keep our skepticism, and be very careful in our analysis. The key here is we need corroborating studies. An April 2020 study at the VA showed exactly the opposite effect of HCQ in a similar patient population (though the VA obviously serves more males).
    forum: medrxiv
    points: 3
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Mon Jun 14 12:30:47 +0000 2021
      id: 1404416021658734600
      id_str: "1404416021658734593"
      text: |-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."

        "A couple of things people really need to note here:
        1) T‚Ä¶ https://t.co/OQamnWxBKV
      truncated: true
      entities:
        urls:
          - url: https://t.co/OQamnWxBKV
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 14 12:30:47 +0000 2021
      id: 1404416022367588400
      id_str: "1404416022367588357"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1404416021658734600
      in_reply_to_status_id_str: "1404416021658734593"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 2
    id: "5416969243"
    createdAt: 2021-06-12T02:45:53
    author:
      username: disqus_eYODYVGYgJ
      about: ""
      name: Evidence
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_eYODYVGYgJ/
      url: ""
      location: ""
      id: "367467666"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "Why wouldn't you say the same think about the vaccinated people?
      Why should you consider that the low rate of re-infection by those with
      the vaccine was not heavily influenced by them taking precautions much
      more seriously, either??Its on the two sides, my friend, don't look only
      at one side of the wall..But there is one crucial difference: the natural
      infection is with the real virus and not a synthetic one in the vaccine,
      so the immune response would be much more robust than the vaccine."
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Mon Jun 14 14:23:32 +0000 2021
      id: 1404444398449053700
      id_str: "1404444398449053697"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "Why wouldn't you say the same think about the vaccinated‚Ä¶ https://t.co/yKT7wPMgzq
      truncated: true
      entities:
        urls:
          - url: https://t.co/yKT7wPMgzq
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 14 14:23:32 +0000 2021
      id: 1404444399107510300
      id_str: "1404444399107510275"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1404444398449053700
      in_reply_to_status_id_str: "1404444398449053697"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 2
    id: "5416174245"
    createdAt: 2021-06-11T13:44:12
    author:
      username: jayalanerdman
      about: ""
      name: Jay Alan Erdman
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jayalanerdman/
      url: ""
      location: ""
      id: "370790190"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Where to begin? 1) This is an abstract; not yet peer reviewed; so
      it's just four guys saying this.  2)They don't say how they got their
      population.  3) They provide no data.  4) There is no control group either
      randomized, case control, or cohort. 5) They really do not specify their
      methods.  6) There is no treatment protocol so we don't know what
      additional treatment they may have received.   Overall this doesn't meet
      any scientific standard.  But even if it had been well done;  these
      patients presented in the Spring of 2020 when treatment protocols were
      very different and outcomes much worse.  This study says nothing about
      whether HCQ would be of any benefit to patients receiving treatment in
      Spring 2021.
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Mon Jun 14 16:33:58 +0000 2021
      id: 1404477221578973200
      id_str: "1404477221578973187"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "Where to begin? 1) This is an abstract; not yet peer rev‚Ä¶ https://t.co/lo6LcoaCwp
      truncated: true
      entities:
        urls:
          - url: https://t.co/lo6LcoaCwp
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 14 16:33:58 +0000 2021
      id: 1404477222359027700
      id_str: "1404477222359027712"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1404477221578973200
      in_reply_to_status_id_str: "1404477221578973187"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 1
    id: "5416509134"
    createdAt: 2021-06-11T18:28:35
    author:
      username: lee_r
      about: ""
      name: lee_r
      isPowerContributor: false
      profileUrl: https://disqus.com/by/lee_r/
      url: ""
      location: ""
      id: "2453481"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: I see no indication of how many patients received the high doses of
      hydroxychloroquine and zinc, so it is impossible to tell how meaningful
      the results are.  If 78.2% of the 255 patients died, that leaves only 55
      or 56 who survived.  Is the increased survival rate a function of the
      small number phenomenon, the drug regimen, both, neither?
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Mon Jun 14 18:24:11 +0000 2021
      id: 1404504957840199700
      id_str: "1404504957840199682"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "I see no indication of how many patients received the hi‚Ä¶ https://t.co/8jK2XP0QZ1
      truncated: true
      entities:
        urls:
          - url: https://t.co/8jK2XP0QZ1
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 14 18:24:11 +0000 2021
      id: 1404504958481977300
      id_str: "1404504958481977348"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1404504957840199700
      in_reply_to_status_id_str: "1404504957840199682"
- preprint:
    id: 136557
    metric: 21
    title: Driving potent neutralization of a SARS-CoV-2 Variant of Concern with a
      heterotypic boost
    url: https://api.rxivist.org/v1/papers/136557
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.03.438330v1
    doi: 10.1101/2021.04.03.438330
    category: immunology
    first_posted: 2021-04-05
    abstract: The emergence of SARS-CoV-2 Variants of Concern (VOCs) with mutations
      in key neutralizing antibody epitopes threatens to undermine vaccines
      developed against the pandemic founder variant (Wu-Hu-1). Widespread
      vaccine rollout and continued transmission are creating a population that
      has antibody responses of varying potency to Wu-Hu-1. Against this
      background, it is critical to assess the outcomes of subsequent
      immunization with variant antigens. It is not yet known whether
      heterotypic vaccine boosts would be compromised by original antigenic sin,
      where pre-existing responses to a prior variant dampen responses to a new
      one, or whether the primed memory B cell repertoire would bridge the gap
      between Wu-Hu-1 and VOCs. Here, we show that a single adjuvanted dose of
      receptor binding domain (RBD) protein from VOC 501Y.V2 (B.1.351) drives an
      extremely potent neutralizing antibody response capable of
      cross-neutralizing both Wu-Hu-1 and 501Y.V2 in rhesus macaques previously
      immunized with Wu-Hu-1 spike protein. Passive immunization with plasma
      sampled following this boost protected K18-hACE2 mice from lethal
      challenge with a 501Y.V2 clinical isolate, whereas only partial protection
      was afforded by plasma sampled after two Wu-Hu-1 spike immunizations.
    authors:
      - name: Daniel J Sheward
      - name: Marco Mandolesi
      - name: Egon Urgard
      - name: Changil Kim
      - name: Leo Hanke
      - name: Laura Perez Vidakovics
      - name: Alec Pankow
      - name: Natalie L. Smith
      - name: Xaquin Castro Dopico
      - name: Gerald M McInerney
      - name: Jonathan M Coquet
      - name: Gunilla Karlsson Hedestam
      - name: Ben Murrell
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Mon Jun 14 20:15:59 +0000 2021
      id: 1404533094288433200
      id_str: "1404533094288433155"
      text: >-
        üî• bioRxiv Immunology preprint by D. J. Sheward et al:


        "Driving potent neutralization of a SARS-CoV-2 Variant of Co‚Ä¶ https://t.co/55F89xssBq
      truncated: true
      entities:
        urls:
          - url: https://t.co/55F89xssBq
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 1
    id: "5416181053"
    createdAt: 2021-06-11T13:50:33
    author:
      username: jayalanerdman
      about: ""
      name: Jay Alan Erdman
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jayalanerdman/
      url: ""
      location: ""
      id: "370790190"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: My apologies, I didn't see the full text so some of my criticism
      can be refuted.  Nonetheless it is a chart review with not a very large
      N.  And again, most importantly, it says nothing about  current treatment.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Mon Jun 14 20:19:44 +0000 2021
      id: 1404534040770797600
      id_str: "1404534040770797569"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "My apologies, I didn't see the full text so some of my c‚Ä¶ https://t.co/tr7cUTHC34
      truncated: true
      entities:
        urls:
          - url: https://t.co/tr7cUTHC34
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 14 20:19:45 +0000 2021
      id: 1404534041597157400
      id_str: "1404534041597157385"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1404534040770797600
      in_reply_to_status_id_str: "1404534040770797569"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 1
    id: "5416301508"
    createdAt: 2021-06-11T15:37:05
    author:
      username: bobleon
      about: ""
      name: Bob Leon
      isPowerContributor: false
      profileUrl: https://disqus.com/by/bobleon/
      url: ""
      location: ""
      id: "78987827"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Below is an excerpt from the full text stating that the purpose of the
      study was to prove that it was beneficial for the previously infected to
      still receive the vaccine.  Thankfully the researchers had the ethics to
      report that they found the opposite of what they purposed to find.


      "A strong case for vaccinating previously infected persons can be made if it can be shown that previously infected persons who are vaccinated have a lower incidence of COVID-19 than previously infected persons who did not receive the vaccine.


      The purpose of this study was to attempt to do just that,"
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Mon Jun 14 22:20:57 +0000 2021
      id: 1404564545901797400
      id_str: "1404564545901797377"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "Below is an excerpt from the full text stating that the‚Ä¶ https://t.co/ndnMI0snlH
      truncated: true
      entities:
        urls:
          - url: https://t.co/ndnMI0snlH
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 14 22:20:58 +0000 2021
      id: 1404564546925187000
      id_str: "1404564546925187079"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmfcNF6
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmfcNF6
      in_reply_to_status_id: 1404564545901797400
      in_reply_to_status_id_str: "1404564545901797377"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 1
    id: "5415993489"
    createdAt: 2021-06-11T09:54:15
    author:
      username: patrikdhaeseleer
      about: ""
      name: Patrik D'haeseleer
      isPowerContributor: false
      profileUrl: https://disqus.com/by/patrikdhaeseleer/
      url: ""
      location: ""
      id: "50845151"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: How did you deal with correcting for multiple hypothesis testing in
      this study? It sounds like you focused on one sub-population of 255 out of
      >1200 patients. How many different sub-populations did you wind up
      testing, how many different medications, and how many different tests per
      medication?
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Tue Jun 15 01:05:19 +0000 2021
      id: 1404605908165042200
      id_str: "1404605908165042176"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "How did you deal with correcting for multiple hypothesis‚Ä¶ https://t.co/kdBZcwSzlM
      truncated: true
      entities:
        urls:
          - url: https://t.co/kdBZcwSzlM
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 15 01:05:19 +0000 2021
      id: 1404605908961869800
      id_str: "1404605908961869827"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1404605908165042200
      in_reply_to_status_id_str: "1404605908165042176"
- preprint:
    id: "134064"
    doi: 10.1101/2021.03.18.436038
    first_posted: 2021-03-19
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.03.18.436038v1
    url: https://api.rxivist.org/v1/papers/134064
    title: Transcriptomic analysis of temporal shifts in berry development between
      two grapevine cultivars of the Pinot family reveals potential genes
      controlling ripening time
    category: developmental-biology
    abstract: "Background: Grapevine cultivars of the Pinot family represent
      clonally propagated mutants with major phenotypic and physiological
      differences, such as different colour or shifted ripening time, as well as
      changes in important viticultural traits. Specifically, the cultivars
      'Pinot Noir' (PN) and 'Pinot Noir Precoce' (PNP, early ripening) flower at
      the same time, but vary in the beginning of berry ripening (veraison) and,
      consequently, harvest time. In addition to genotype, seasonal climatic
      conditions (i.e. high temperatures) also affect ripening times. To reveal
      possible regulatory genes that affect the timing of veraison onset, we
      investigated differences in gene expression profiles between PN and PNP
      throughout berry development with a closely meshed time series and over
      two separate years. Results: The difference in the duration of berry
      formation between PN and PNP was quantified to be approximately two weeks
      under the growth conditions applied, using plant material with a proven PN
      and PNP clonal relationship. Clusters of co-expressed genes and
      differentially expressed genes (DEGs) were detected which reflect the
      shift in the timing of veraison onset. Functional annotation of these DEGs
      fit to observed phenotypic and physiological changes during berry
      development. In total, we observed 3,342 DEGs in 2014 and 2,745 DEGs in
      2017 between PN and PNP, with 1,923 DEGs across both years. Among these,
      388 DEGs were identified as veraison-specific and 12 were considered as
      berry ripening time regulatory candidates. The expression profiles
      revealed two candidate genes for ripening time control which we designated
      VviRTIC1 and VviRTIC2 (VIT_210s0071g01145 and VIT_200s0366g00020,
      respectively). These genes likely contribute the phenotypic differences
      observed between PN and PNP. Conclusions: Many of the 1,923 DEGs show
      highly similar expression profiles in both cultivars if the patterns are
      aligned according to developmental stage. In our work, putative genes
      differentially expressed between PNP and PN which could control ripening
      time as well as veraison-specific genes were identified. We point out
      connections of these genes to molecular events during berry development
      and discuss potential candidate genes which may control ripening time. Two
      of these candidates were observed to be differentially expressed in the
      early berry development phase. Several down-regulated genes during berry
      ripening are annotated as auxin response factors / ARFs. Conceivably,
      general changes in auxin signaling may cause the earlier ripening
      phenotype of PNP."
    authors:
      - name: Jens Theine
        orcid: http://orcid.org/0000-0002-6042-373X
      - name: Daniela Holtgr√§we
        orcid: http://orcid.org/0000-0002-1062-4576
      - name: Katja Herzog
        orcid: null
      - name: Florian Schwander
        orcid: null
      - name: Anna Kicherer
        orcid: null
      - name: Ludger Hausmann
        orcid: http://orcid.org/0000-0002-4046-9626
      - name: Prisca Vieh√∂ver
        orcid: http://orcid.org/0000-0003-3286-4121
      - name: Reinhard T√∂pfer
        orcid: http://orcid.org/0000-0003-1569-2495
      - name: Bernd Weisshaar
        orcid: http://orcid.org/0000-0002-7635-3473
  comment:
    dislikes: 0
    thread: "8500231074"
    numReports: 0
    likes: 0
    id: "5420435524"
    createdAt: 2021-06-15T09:18:58
    author:
      name: Jens Theine
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Dear Adaobi Okafor,

      thanks for your interest and your question!

      We revised our manuscript, and in the new version, we tried to make it clearer which kind of reads were used in each analysis (see material and methods). Tank you for your input! Greets, Jens
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.03.18.436038v2
  tweets:
    - created_at: Tue Jun 15 12:35:30 +0000 2021
      id: 1404779597422530600
      id_str: "1404779597422530565"
      text: |-
        üí¨ bioRxiv comment on "Transcriptomic analysis of tem..."

        "Dear Adaobi Okafor,
        thanks for your interest and your qu‚Ä¶ https://t.co/d7QezCQSCt
      truncated: true
      entities:
        urls:
          - url: https://t.co/d7QezCQSCt
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 15 12:35:30 +0000 2021
      id: 1404779598324408300
      id_str: "1404779598324408327"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/X1vn2rwJ4z
      truncated: false
      entities:
        urls:
          - url: https://t.co/X1vn2rwJ4z
      in_reply_to_status_id: 1404779597422530600
      in_reply_to_status_id_str: "1404779597422530565"
- preprint:
    id: "142286"
    doi: 10.1101/2021.05.17.444558
    first_posted: 2021-05-18
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.17.444558v1
    url: https://api.rxivist.org/v1/papers/142286
    title: Polarized Dishevelled dissolution and condensation drives embryonic axis
      specification in oocytes
    category: cell-biology
    abstract: The organismal body axes that are formed during embryogenesis are
      intimately linked to intrinsic asymmetries established at the cellular
      scale in oocytes. Here, we report an axis-defining event in meiotic
      oocytes of the sea star Patiria miniata. Dishevelled is a cytoplasmic Wnt
      pathway effector required for axis development in diverse species, but the
      mechanisms governing its function and distribution remain poorly defined.
      Using time-lapse imaging, we find that Dishevelled localizes uniformly to
      puncta throughout the cell cortex in Prophase I-arrested oocytes, but
      becomes enriched at the vegetal pole following meiotic resumption through
      a dissolution-condensation mechanism. This process is driven by an initial
      disassembly phase of Dvl puncta, followed by selective reformation of Dvl
      assemblies at the vegetal pole. Rather than being driven by Wnt signaling,
      this localization behavior is coupled to meiotic cell cycle progression
      and influenced by Lamp1+ endosome association and Frizzled receptors
      pre-localized within the oocyte cortex. Our results reveal a cell
      cycle-linked mechanism by which maternal cellular polarity is transduced
      to the embryo through spatially-regulated Dishevelled dynamics.
    authors:
      - name: Zak Swartz
        orcid: null
      - name: Tzer Han Tan
        orcid: null
      - name: Margherita Perillo
        orcid: null
      - name: Nikta Fakhri
        orcid: null
      - name: Gary M. Wessel
        orcid: http://orcid.org/0000-0002-1210-9279
      - name: Athula Wikramanayake
        orcid: null
      - name: Iain M Cheeseman
        orcid: http://orcid.org/0000-0002-3829-5612
  comment:
    dislikes: 0
    thread: "8529219331"
    numReports: 0
    likes: 0
    id: "5420500019"
    createdAt: 2021-06-15T11:04:54
    author:
      username: iaincheeseman
      about: ""
      name: Iain Cheeseman
      isPowerContributor: false
      profileUrl: https://disqus.com/by/iaincheeseman/
      url: ""
      location: ""
      id: "370970146"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "My co-authors and I welcome additional public comments on this
      work. Thanks! #FeedbackASAP"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.05.17.444558v1
  tweets:
    - created_at: Tue Jun 15 14:18:32 +0000 2021
      id: 1404805525741650000
      id_str: "1404805525741649921"
      text: >-
        üí¨ bioRxiv comment on "Polarized Dishevelled dissolut..."


        "My co-authors and I welcome additional public comments o‚Ä¶ https://t.co/CNFKSZbNKB
      truncated: true
      entities:
        urls:
          - url: https://t.co/CNFKSZbNKB
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 15 14:18:32 +0000 2021
      id: 1404805526609858600
      id_str: "1404805526609858568"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/8jyX0H819K
      truncated: false
      entities:
        urls:
          - url: https://t.co/8jyX0H819K
      in_reply_to_status_id: 1404805525741650000
      in_reply_to_status_id_str: "1404805525741649921"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5420730834"
    createdAt: 2021-06-15T14:59:14
    author:
      username: disqus_4XHtZdDj7W
      about: ""
      name: Billy Budapest
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_4XHtZdDj7W/
      url: ""
      location: ""
      id: "283163756"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: First, you did not answer my question.  Second, I don't know why
      you get a flu shot every year, maybe you could tell me.  If you're asking
      me if you need to get it every year, my answer is the published science
      says "no".
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Tue Jun 15 16:35:34 +0000 2021
      id: 1404840013838241800
      id_str: "1404840013838241799"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "First, you did not answer my question.  Second, I don't‚Ä¶ https://t.co/OYL5tMMiX5
      truncated: true
      entities:
        urls:
          - url: https://t.co/OYL5tMMiX5
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 15 16:35:34 +0000 2021
      id: 1404840014794481700
      id_str: "1404840014794481667"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmfcNF6
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmfcNF6
      in_reply_to_status_id: 1404840013838241800
      in_reply_to_status_id_str: "1404840013838241799"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5418847111"
    createdAt: 2021-06-13T22:52:58
    author:
      username: derekgard
      about: ""
      name: Deplorable D
      isPowerContributor: false
      profileUrl: https://disqus.com/by/derekgard/
      url: ""
      location: ""
      id: "125999308"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: The flu is interesting.  Either, many COVID cases were counted as
      the flu, or SARS-CoV-2 was the dominant virus this year and thus the flu
      was not able to infect many people.  I suspect we will learn it is a
      combination of both.  Many, many people were declared COVID positive based
      only on symptoms.  My doctor declared I likely had covid and I did not
      even go to the office or take a test.  I had a headache, fever, and a
      cough... Viola!  Covid!!
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Tue Jun 15 18:26:21 +0000 2021
      id: 1404867894781964300
      id_str: "1404867894781964289"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "The flu is interesting.  Either, many COVID cases were c‚Ä¶ https://t.co/wQxNnbXdu7
      truncated: true
      entities:
        urls:
          - url: https://t.co/wQxNnbXdu7
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 15 18:26:22 +0000 2021
      id: 1404867895620890600
      id_str: "1404867895620890624"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU30MFJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU30MFJ
      in_reply_to_status_id: 1404867894781964300
      in_reply_to_status_id_str: "1404867894781964289"
- preprint:
    id: 146065
    metric: 34
    title: Mapping the Genetic Landscape of DNA Double-strand Break Repair
    url: https://api.rxivist.org/v1/papers/146065
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.14.448344v1
    doi: 10.1101/2021.06.14.448344
    category: genomics
    first_posted: 2021-06-14
    abstract: Cells repair DNA double-strand breaks (DSBs) through a complex set of
      pathways that are critical for maintaining genomic integrity. Here we
      present Repair-seq, a high-throughput screening approach that measures the
      effects of thousands of genetic perturbations on the distribution of
      mutations introduced at targeted DNA lesions. Using Repair-seq, we
      profiled DSB repair outcomes induced by two programmable nucleases (Cas9
      and Cas12a) after knockdown of 476 genes involved in DSB repair or
      associated processes in the presence or absence of oligonucleotides for
      homology-directed repair (HDR). The resulting data enabled principled,
      data-driven inference of DSB end joining and HDR pathways and demonstrated
      that repair outcomes with superficially similar sequence architectures can
      have markedly different genetic dependencies. Systematic interrogation of
      these dependencies then uncovered unexpected relationships among DSB
      repair genes and isolated incompletely characterized repair mechanisms.
      This work provides a foundation for understanding the complex pathways of
      DSB repair and for optimizing genome editing across modalities.
    authors:
      - name: Jeffrey A Hussmann
      - name: Jia Ling
      - name: Purnima Ravisankar
      - name: Jun Yan
      - name: Ann Cirincione
      - name: Albert Xu
      - name: Danny Simpson
      - name: Dian Yang
      - name: Anne Bothmer
      - name: Cecilia Cotta-Ramusino
      - name: Jonathan S Weissman
      - name: Britt Adamson
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Tue Jun 15 20:15:54 +0000 2021
      id: 1404895460456870000
      id_str: "1404895460456869890"
      text: >-
        üî• bioRxiv Genomics preprint by J. A. Hussmann et al:


        "Mapping the Genetic Landscape of DNA Double-strand Break Rep‚Ä¶ https://t.co/nNv1SfPslO
      truncated: true
      entities:
        urls:
          - url: https://t.co/nNv1SfPslO
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5418844859"
    createdAt: 2021-06-13T22:49:57
    author:
      username: derekgard
      about: ""
      name: Deplorable D
      isPowerContributor: false
      profileUrl: https://disqus.com/by/derekgard/
      url: ""
      location: ""
      id: "125999308"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Cite the research.  I can cite dozens of studies that argue the
      opposite.  What you are saying is just not backed by the majority of
      studies.  And real world examples do not bear out what you are
      saying.  Despite nearly 100% masking compliance, countries, states,
      cities, counties with strict mask adherence have not done better than
      their counterparts with no mask mandates and low compliance.  We can see
      real world results after 15 months of masks.  It is really not a debate
      anymore.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Tue Jun 15 20:19:42 +0000 2021
      id: 1404896417181753300
      id_str: "1404896417181753350"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Cite the research.  I can cite dozens of studies that ar‚Ä¶ https://t.co/PZ4JcCyvxu
      truncated: true
      entities:
        urls:
          - url: https://t.co/PZ4JcCyvxu
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 15 20:19:42 +0000 2021
      id: 1404896418041581600
      id_str: "1404896418041581572"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1404896417181753300
      in_reply_to_status_id_str: "1404896417181753350"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5421028168"
    createdAt: 2021-06-15T18:52:28
    author:
      username: quixander
      about: ""
      name: Quixander
      isPowerContributor: false
      profileUrl: https://disqus.com/by/quixander/
      url: ""
      location: ""
      id: "356173685"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: That‚Äôs not necessarily the case re real vs contrived. The immune
      system may be ‚Äúkeyed‚Äù to only the real and original virus, and may not
      recognize significant variants the more different from the original they
      become. The neat thing about mRNA vaccine is that a specific protein was
      strategically chosen as the ‚Äúkey‚Äù that, based on many years of research
      and analysis, was believed to be most likely preserved across many future
      mutations. In this way, the mRNA vaccine is very likely to provide better
      immunity to a changing virus.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Tue Jun 15 22:19:56 +0000 2021
      id: 1404926677478776800
      id_str: "1404926677478776834"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "That‚Äôs not necessarily the case re real vs contrived. Th‚Ä¶ https://t.co/W6IUG7uKTg
      truncated: true
      entities:
        urls:
          - url: https://t.co/W6IUG7uKTg
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 15 22:19:57 +0000 2021
      id: 1404926678237917200
      id_str: "1404926678237917187"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1404926677478776800
      in_reply_to_status_id_str: "1404926677478776834"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5421021894"
    createdAt: 2021-06-15T18:47:23
    author:
      username: quixander
      about: ""
      name: Quixander
      isPowerContributor: false
      profileUrl: https://disqus.com/by/quixander/
      url: ""
      location: ""
      id: "356173685"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Good point, and doubly so if they had faith in what President Trump
      was telling the public for months, that having had COVID-19 guaranteed
      immunity. Also there are a lot of people who think they had COVID-19 way
      back in late 2019/early 2020, but never confirmed it with testing and
      probably had some other respiratory illness.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Wed Jun 16 01:01:49 +0000 2021
      id: 1404967417214902300
      id_str: "1404967417214902275"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "Good point, and doubly so if they had faith in what Pres‚Ä¶ https://t.co/iGcBx6oVXY
      truncated: true
      entities:
        urls:
          - url: https://t.co/iGcBx6oVXY
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 16 01:01:50 +0000 2021
      id: 1404967418045374500
      id_str: "1404967418045374471"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1404967417214902300
      in_reply_to_status_id_str: "1404967417214902275"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 1
    id: "5421303282"
    createdAt: 2021-06-15T22:59:25
    author:
      username: disqus_eYODYVGYgJ
      about: ""
      name: Evidence
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_eYODYVGYgJ/
      url: ""
      location: ""
      id: "367467666"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      That's wrong. Please inform yourself better. There are studies confirming
      that natural immunity has the ability to recognize all variants and adapt
      to it, people with natural immunity are just as protected or even more
      that the ones than are vaccinated, with a plus, unvaccinated do not have
      to take serious risks that come after getting this experimental vaccine.
      And by the way the "many years" you refer were done in rats and ferrets,
      not in humans... 


      https://www.dailymail.co.uk/news/article-9419591/Coronavirus-study-Immune-recognise-virtually-types-Covid-vaccine.html


      https://www.scientificamerican.com/article/your-immune-system-evolves-to-fight-coronavirus-variants/
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Wed Jun 16 12:31:12 +0000 2021
      id: 1405140903543533600
      id_str: "1405140903543533571"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "That's wrong. Please inform yourself better. There are s‚Ä¶ https://t.co/q7oXEex9UI
      truncated: true
      entities:
        urls:
          - url: https://t.co/q7oXEex9UI
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 16 12:31:12 +0000 2021
      id: 1405140904579534800
      id_str: "1405140904579534852"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmfcNF6
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmfcNF6
      in_reply_to_status_id: 1405140903543533600
      in_reply_to_status_id_str: "1405140903543533571"
- preprint:
    id: "145889"
    doi: 10.1101/2021.06.10.21258647
    first_posted: 2021-06-13
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.10.21258647v1
    url: https://api.rxivist.org/v1/papers/145889
    title: Seasonal variation in SARS-CoV-2 transmission in temperate climates
    category: epidemiology
    abstract: "While seasonal variation has a known influence on the transmission of
      several respiratory viral infections, its role in SARS-CoV-2 transmission
      remains unclear. As previous analyses have not accounted for the
      implementation of non-pharmaceutical interventions (NPIs) in the first
      year of the pandemic, they may yield biased estimates of seasonal effects.
      Building on two state-of-the-art observational models and datasets, we
      adapt a fully Bayesian method for estimating the association between
      seasonality and transmission in 143 temperate European regions. We find
      strong seasonal patterns, consistent with a reduction in the time-variable
      Rt of 42.1% (95% CI: 24.7% - 53.4%) from the peak of winter to the peak of
      summer. These results imply that the seasonality of SARS-CoV-2
      transmission is comparable in magnitude to the most effective individual
      NPIs but less than the combined effect of multiple interventions."
    authors:
      - name: Tomas Gavenciak
        orcid: http://orcid.org/0000-0003-1119-2426
      - name: Joshua Teperowski Monrad
        orcid: http://orcid.org/0000-0002-7377-2074
      - name: Gavin Leech
        orcid: http://orcid.org/0000-0002-9298-1488
      - name: Mrinank Sharma
        orcid: http://orcid.org/0000-0002-4304-7963
      - name: Soren Mindermann
        orcid: http://orcid.org/0000-0002-0315-9821
      - name: Jan Markus Brauner
        orcid: http://orcid.org/0000-0002-1588-5724
      - name: Samir Bhatt
        orcid: http://orcid.org/0000-0002-0891-4611
      - name: Jan Kulveit
        orcid: http://orcid.org/0000-0002-3791-8355
  comment:
    dislikes: 0
    thread: "8590472452"
    numReports: 0
    likes: 0
    id: "5421702437"
    createdAt: 2021-06-16T09:11:37
    author:
      username: jankulveit
      about: ""
      name: Jan Kulveit
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jankulveit/
      url: ""
      location: ""
      id: "104437483"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      1. While what exact interventions are tracked and what are the results is
      not  not part of this investigation - however, please note the underlying
      studies are in fact "compatible", only estimating different effects. Eg.
      in case of schools, the 1st wave study is estimating the difference
      between "schools open without any precautions in pre-pandemic state" and
      "schools closed". The 2nd wave study is estimating the difference between
      "schools open will all the safety measures implemented in autumn, which
      often included cohorts, improved ventilation, testing, screening for
      symptoms, changes in class layout etc." and "schools closed". If we expect
      the safety measures have some effect, the estimated effect sizes must be
      different, which is indeed the case.


      2. Effect of vaccination was negligible in the study period. The most vaccinated country in the dataset, UK, had about 5% of the population vaccinated mid-Jan (and most UK regions excluded from the study due to VOC)


      3. cos(t) seasonality is a common functional form used for modelling seasonality. Note that e.g. average daily insolation could be well approximated by the first and second term in the Fourier series, leading also to the cos(t) form.

      As mentioned in the preprint, school calendars are included in the school NPI (given the irregularity of school calendars in 2020, I would argue this is the correct choice)
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.10.21258647v1
  tweets:
    - created_at: Wed Jun 16 14:18:39 +0000 2021
      id: 1405167946092191700
      id_str: "1405167946092191750"
      text: >-
        üí¨ medRxiv comment on "Seasonal variation in SARS-CoV..."


        "1. While what exact interventions are tracked and what a‚Ä¶ https://t.co/44sxFdEZVm
      truncated: true
      entities:
        urls:
          - url: https://t.co/44sxFdEZVm
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 16 14:18:39 +0000 2021
      id: 1405167946989772800
      id_str: "1405167946989772803"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/Bv6GzFFKho
      truncated: false
      entities:
        urls:
          - url: https://t.co/Bv6GzFFKho
      in_reply_to_status_id: 1405167946092191700
      in_reply_to_status_id_str: "1405167946092191750"
- preprint:
    id: "146269"
    doi: 10.1101/2021.06.15.448399
    first_posted: 2021-06-16
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.15.448399v1
    url: https://api.rxivist.org/v1/papers/146269
    title: "15 years of introgression studies: quantifying gene flow across
      Eukaryotes"
    category: evolutionary-biology
    abstract: With the rise of affordable next generation sequencing technology,
      introgression - or the exchange of genetic materials between taxa - is
      widely perceived to be a ubiquitous phenomenon in nature. Although this
      claim is supported by several keystone studies, no thorough assessment on
      the frequency of introgression in nature has been performed to date. In
      this manuscript, we aim to address this knowledge gap by providing a
      meta-analysis of the most comprehensive survey of introgression studies in
      Eukaryotes to date (724 papers with claims of introgression). We first
      examined the evidence given to support introgression, and if/how the lines
      of evidence have changed across time. We then collated a single statistic,
      Patterson's D, that quantifies the strength of introgression across 123
      studies to further assess how taxonomic group, divergence time, and
      aspects of life history influence introgression. We find three main
      results. Studies on introgression are much more frequent in plants and
      mammals than any other taxonomic group. The study of introgression has
      shifted from a largely qualitative assessment of whether introgression
      happens, to a focus on when and how much introgression has occurred across
      taxa. The most-often used introgression statistic, Patterson's D, shows
      several intriguing patterns suggesting introgression reports may be biased
      by both differences in reporting criteria and sequencing technology, but
      may also differ across taxonomic systems and throughout the process of
      speciation. Together, these results suggest the need for a unified
      approach to quantifying introgression in natural communities, and
      highlight important areas of future research that can be better assessed
      once this unified approach is met.
    authors:
      - name: Andrius J Dagilis
        orcid: http://orcid.org/0000-0003-2013-0825
      - name: David Peede
        orcid: http://orcid.org/0000-0002-4826-0464
      - name: Jenn M. Coughlan
        orcid: null
      - name: Gaston I Jofre
        orcid: null
      - name: Emmanuel R R D'Agostino
        orcid: http://orcid.org/0000-0003-0829-6435
      - name: Heidi Mavengere
        orcid: http://orcid.org/0000-0002-6207-1088
      - name: Alexander D Tate
        orcid: null
      - name: Daniel R Matute
        orcid: http://orcid.org/0000-0002-8494-8012
  comment:
    dislikes: 0
    thread: "8596763671"
    numReports: 0
    likes: 0
    id: "5421934363"
    createdAt: 2021-06-16T14:01:01
    author:
      username: marcrobinsonrechavi
      about: ""
      name: Marc RobinsonRechavi
      isPowerContributor: false
      profileUrl: https://disqus.com/by/marcrobinsonrechavi/
      url: ""
      location: ""
      id: "67492738"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Under Data Availability, the authors write:



      <blockquote>All scripts/data used for analyses and to generate plots are available on request, and will be made available on Dryad prior to publication.</blockquote>



      This is a publication, i.e. it is made public as part of the scientific record and is citable, thus I strongly invite the authors to make the corresponding scripts and data available without delay.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.15.448399v1
  tweets:
    - created_at: Wed Jun 16 16:34:00 +0000 2021
      id: 1405202008949334000
      id_str: "1405202008949334018"
      text: |-
        üí¨ bioRxiv comment on "15 years of introgression stud..."

        "Under Data Availability, the authors write:

        &lt;blockquote‚Ä¶ https://t.co/d75pTE7M4B
      truncated: true
      entities:
        urls:
          - url: https://t.co/d75pTE7M4B
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 16 16:34:01 +0000 2021
      id: 1405202009708449800
      id_str: "1405202009708449803"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/jgg5psObr4
      truncated: false
      entities:
        urls:
          - url: https://t.co/jgg5psObr4
      in_reply_to_status_id: 1405202008949334000
      in_reply_to_status_id_str: "1405202008949334018"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5421669799"
    createdAt: 2021-06-16T08:08:46
    author:
      username: disqus_CDUZwoWjil
      about: ""
      name: Johannes
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_CDUZwoWjil/
      url: ""
      location: ""
      id: "159169073"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      "multiple confounding variables"- such as what ?

      and would this problem of confounding variables also apply to vaccine trials ?



      Thanks
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Wed Jun 16 18:25:17 +0000 2021
      id: 1405230010399694800
      id_str: "1405230010399694854"
      text: |-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."

        ""multiple confounding variables"- such as what ?
        and wou‚Ä¶ https://t.co/IWHiMy5bfx
      truncated: true
      entities:
        urls:
          - url: https://t.co/IWHiMy5bfx
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 16 18:25:17 +0000 2021
      id: 1405230011339219000
      id_str: "1405230011339218944"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1405230010399694800
      in_reply_to_status_id_str: "1405230010399694854"
- preprint:
    id: 146175
    metric: 14
    title: Zinc2+ ion inhibits SARS-CoV-2 main protease and viral replication in
      vitro.
    url: https://api.rxivist.org/v1/papers/146175
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.15.448551v1
    doi: 10.1101/2021.06.15.448551
    category: biochemistry
    first_posted: 2021-06-15
    abstract: Zinc deficiency is linked to poor prognosis in COVID-19 patients while
      clinical trials with Zinc demonstrate better clinical outcome. The
      molecular target and mechanistic details of anti-coronaviral (SARS-CoV2)
      activity of Zinc remain obscure. We show that ionic Zinc not only inhibits
      SARS-CoV-2 main protease (Mpro) with nanomolar affinity, but also viral
      replication. We present the first crystal structure of Mpro-Zinc2+ complex
      at 1.9 [A] and provide the structural basis of viral replication
      inhibition.
    authors:
      - name: Love Panchariya
      - name: Wajahat Ali Khan
      - name: Shobhan Kuila
      - name: Kirtishila Sonkar
      - name: Sibasis Sahoo
      - name: Archita Ghoshal
      - name: Ankit Kumar
      - name: Dileep Kumar Verma
      - name: Abdul Hasan
      - name: Shubhashis Das
      - name: Jitendra K. Thakur
      - name: Rajkumar Halder
      - name: Sujatha Sunil
      - name: Arockiasamy Arulandu
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Wed Jun 16 20:16:13 +0000 2021
      id: 1405257928777535500
      id_str: "1405257928777535493"
      text: >-
        üî• bioRxiv Biochemistry preprint by L. Panchariya et al:


        "Zinc2+ ion inhibits SARS-CoV-2 main protease and viral re‚Ä¶ https://t.co/1PVkVSvKQa
      truncated: true
      entities:
        urls:
          - url: https://t.co/1PVkVSvKQa
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5421596579"
    createdAt: 2021-06-16T05:46:24
    author:
      username: Rosey1980
      about: ""
      name: Rosey1980
      isPowerContributor: false
      profileUrl: https://disqus.com/by/Rosey1980/
      url: ""
      location: ""
      id: "5813094"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      I'll answer your first question. Where did you get the idea that people
      who have recovered from Covid don't have immunity? Studies have shown that
      yes, recovered individuals do have immunity to Covid.


      https://www.sciencedirect.com/science/article/pii/S0092867420310084


      The point of this study is to show that vaccines should be given to those who have not been infected with Covid since the people who have recovered have developed an immunity to it.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Wed Jun 16 20:19:42 +0000 2021
      id: 1405258807740178400
      id_str: "1405258807740178436"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "I'll answer your first question. Where did you get the i‚Ä¶ https://t.co/3iKA85II4D
      truncated: true
      entities:
        urls:
          - url: https://t.co/3iKA85II4D
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 16 20:19:43 +0000 2021
      id: 1405258808545493000
      id_str: "1405258808545492992"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1405258807740178400
      in_reply_to_status_id_str: "1405258807740178436"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 1
    id: "5421590186"
    createdAt: 2021-06-16T05:33:28
    author:
      username: Rosey1980
      about: ""
      name: Rosey1980
      isPowerContributor: false
      profileUrl: https://disqus.com/by/Rosey1980/
      url: ""
      location: ""
      id: "5813094"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Covid 19 is in the same group of Coronaviruses as SARS and MERS
      which are not classified as the common cold.  People who have recovered
      from SARS still show a strong immune response to SARS 17 years later.
      Other studies have come out showing that people who recovered from Covid
      have immunity(T cells) for at least 10 months but it could very well be
      longer.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Wed Jun 16 22:19:44 +0000 2021
      id: 1405289014601470000
      id_str: "1405289014601469952"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "Covid 19 is in the same group of Coronaviruses as SARS a‚Ä¶ https://t.co/KGvlvJTYiX
      truncated: true
      entities:
        urls:
          - url: https://t.co/KGvlvJTYiX
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 16 22:19:44 +0000 2021
      id: 1405289015633322000
      id_str: "1405289015633321990"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmfcNF6
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmfcNF6
      in_reply_to_status_id: 1405289014601470000
      in_reply_to_status_id_str: "1405289014601469952"
- preprint:
    id: "141624"
    doi: 10.1101/2021.05.13.21256805
    first_posted: 2021-05-14
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.13.21256805v1
    url: https://api.rxivist.org/v1/papers/141624
    title: "Impact of the COVID-19 pandemic on the mental health and wellbeing of
      parents with young children: a qualitative interview study"
    category: psychiatry-and-clinical-psychology
    abstract: "Background Parents have faced unique challenges during the
      coronavirus disease 2019 (COVID-19) pandemic, including mobility
      constraints, isolation measures, working from home, and the closure of
      schools and childcare facilities. There is presently a lack of in-depth
      qualitative research exploring how these changes have affected parents
      mental health and wellbeing. Methods Semi-structured qualitative
      interviews with 29 parents of young children. Interviews were analysed
      using reflexive thematic analysis. Results We identified five
      superordinate themes affecting participant mental health and wellbeing: 1)
      navigation of multiple responsibilities and change inside the home; 2)
      disruption to home life; 3) changes to usual support networks; 4) changes
      in personal relationships; and 5) use of coping strategies. Participants
      described stress and exhaustion from navigating multiple pressures and
      conflicting responsibilities with home, schooling, and work, without their
      usual support networks and in the context of disrupted routines. Family
      roles and relationships were sometimes tested, however, many parents
      identified coping strategies that protected their wellbeing including
      access to outdoor space, spending time away from family, and avoiding
      conflict and pandemic-related media coverage. Conclusions Employers must
      be cognisant of the challenges that the pandemic has placed on parents,
      particularly women and lone parents. Flexible working arrangements and
      support might therefore relieve stress and increase productivity. Coping
      strategies identified by parents in this study could be harnessed and
      encouraged by employers and policymakers to promote positive wellbeing
      during times of stress throughout the pandemic and beyond."
    authors:
      - name: Jo Dawes
        orcid: http://orcid.org/0000-0003-0248-4160
      - name: Tom May
        orcid: http://orcid.org/0000-0003-3077-523X
      - name: Alison Ruth McKinlay
        orcid: http://orcid.org/0000-0002-3271-3502
      - name: Daisy Fancourt
        orcid: http://orcid.org/0000-0002-6952-334X
      - name: Alexandra Burton
        orcid: http://orcid.org/0000-0002-4433-3902
  comment:
    dislikes: 0
    thread: "8520660691"
    numReports: 0
    likes: 0
    id: "5421532684"
    createdAt: 2021-06-16T03:43:19
    author:
      username: mariumamir
      about: ""
      name: Marium Amir
      isPowerContributor: false
      profileUrl: https://disqus.com/by/mariumamir/
      url: ""
      location: ""
      id: "371005558"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: please can you help me find additional file 1 for complete
      interview guide questions and subquestions
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.13.21256805v1
  tweets:
    - created_at: Thu Jun 17 00:59:54 +0000 2021
      id: 1405329319719747600
      id_str: "1405329319719747588"
      text: >-
        üí¨ medRxiv comment on "Impact of the COVID-19 pandemi..."


        "please can you help me find additional file 1 for comple‚Ä¶ https://t.co/bQb8vp0IlU
      truncated: true
      entities:
        urls:
          - url: https://t.co/bQb8vp0IlU
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 17 00:59:54 +0000 2021
      id: 1405329320512532500
      id_str: "1405329320512532481"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/VMNRCEvTvr
      truncated: false
      entities:
        urls:
          - url: https://t.co/VMNRCEvTvr
      in_reply_to_status_id: 1405329319719747600
      in_reply_to_status_id_str: "1405329319719747588"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 1
    id: "5421162600"
    createdAt: 2021-06-15T20:42:31
    author:
      username: joegrane
      about: ""
      name: Joe Grane
      isPowerContributor: false
      profileUrl: https://disqus.com/by/joegrane/
      url: ""
      location: ""
      id: "229597815"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Wasn't the "VA" study just a review of health records without the all of
      the dosing analysis in this, Smith, et al. study. 


      Some of the main points in Smith, et al are that you have so many obese patients.  Doses of HCQ and AZT need to be weight dependent.  


      "no Covid study has examined the effects of these differences in weight on response to HCQ therapy or HCQ adverse effects."


      Furthermore they noticed that the cumulative dose had a big effect on the outcome.   They explain that HCQ has a long half-life but it also takes a long time to get optimal amounts into the lungs. 


      "We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients...HCQ cumulative dose > 80 mg/kg works substantially better. "


      "Patients receiving >3g HCQ/>1g AZM had 3.26 times lower risk of mortality  than those who did not receive these <b>doses</b> [HR = .307,95% CI = 0.183 ‚Äì 0.516, p < .001]. Patients receiving TOZ had 2.00 times lower risk of death than patients who did not receive the <b>medicine</b> [HR = .50, 95% CI = 0.36 ‚Äì 0.69, p < .001]. 


      Their statements about patient EKGs were striking.  They were particularly critical of the FDA's April 2020 warning on the issue. 


      "there was no correlation between HCQ cumulative dose and QTc delta (r = -0.170).... No patient experienced  torsades de pointes...given the data presented here, the studies reporting HCQ‚Äôs effect of QTc intervals need to be reevaluated."


      Apparently Smith, et al were looking for ways to make HCQ helpful to Covid patients--a seemingly unusual interest. 


      In contrast Boulware, et al concluded HCQ was not beneficial for post exposure prophylaxis when started within 4 days.   However several other groups reanalyzed the data and concluded HCQ <b>was</b> beneficial when started within 3 days. 

      https://www.medrxiv.org/content/10.1101/2020.11.29.20235218v1

      https://arxiv.org/ftp/arxiv/papers/2007/2007.09477.pdf

      https://www.longdom.org/open-access/hydroxychloroquine-and-interferons-for-the-prophylaxis-and-early-treatment-of-covid19current-clinical-advances.pdf
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Thu Jun 17 12:35:28 +0000 2021
      id: 1405504365847273500
      id_str: "1405504365847273474"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "Wasn't the "VA" study just a review of health records wi‚Ä¶ https://t.co/GfPmX413NC
      truncated: true
      entities:
        urls:
          - url: https://t.co/GfPmX413NC
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 17 12:35:28 +0000 2021
      id: 1405504366661021700
      id_str: "1405504366661021704"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1405504365847273500
      in_reply_to_status_id_str: "1405504365847273474"
- preprint:
    id: "127819"
    doi: 10.1101/2021.02.02.429376
    first_posted: 2021-02-02
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.02.02.429376v1
    url: https://api.rxivist.org/v1/papers/127819
    title: Spc1 regulates substrate selection for signal peptidase
    category: biochemistry
    abstract: Signal peptidase (SPase) cleaves the signal sequences (SSs) of
      secretory precursors. It contains an evolutionarily conserved membrane
      protein subunit, Spc1 that is dispensable for the catalytic activity of
      SPase, and its role remains elusive. In the present study, we investigated
      the function of yeast Spc1. First, we set up an in vivo SPase cleavage
      assay using secretory protein CPY variants with SSs modified in the n and
      h regions. When comparing the SS cleavage efficiencies of these variants
      in cells with or without Spc1, we found that signal-anchored sequences
      become more susceptible to cleavage by SPase without Spc1. Further,
      SPase-mediated processing of transmembrane (TM) segments in model membrane
      proteins was reduced upon overexpression of Spc1. Spc1 was
      co-immunoprecipitated with membrane proteins carrying uncleaved
      signal-anchored or TM segments. These results suggest a role of Spc1 in
      shielding TM segments from SPase action, thereby contributing to accurate
      substrate selection for SPase.
    authors:
      - name: Chewon Yim
        orcid: null
      - name: Yeonji Chung
        orcid: null
      - name: Jeesoo Kim
        orcid: null
      - name: IngMarie Nilsson
        orcid: http://orcid.org/0000-0002-7981-3201
      - name: Jong-Seo Kim
        orcid: http://orcid.org/0000-0002-8909-8440
      - name: Hyun (Joy) Kim
        orcid: http://orcid.org/0000-0003-2076-9020
  comment:
    dislikes: 0
    thread: "8381891088"
    numReports: 0
    likes: 0
    id: "5421511068"
    createdAt: 2021-06-16T03:10:21
    author:
      username: disqus_nio721O19c
      about: ""
      name: Joy Kim
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_nio721O19c/
      url: ""
      location: ""
      id: "371004584"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: This manuscript is now accepted for publication in  Journal of Cell
      Science, under the revised title of "Spc1 regulates the signal
      peptidase-mediated processing of membrane proteins".
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.02.02.429376v1
  tweets:
    - created_at: Thu Jun 17 14:18:38 +0000 2021
      id: 1405530328588906500
      id_str: "1405530328588906508"
      text: >-
        üí¨ bioRxiv comment on "Spc1 regulates substrate selec..."


        "This manuscript is now accepted for publication in  Jour‚Ä¶ https://t.co/NcA0IfxpsM
      truncated: true
      entities:
        urls:
          - url: https://t.co/NcA0IfxpsM
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 17 14:18:38 +0000 2021
      id: 1405530329910186000
      id_str: "1405530329910185997"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/f3KTDOqWtS
      truncated: false
      entities:
        urls:
          - url: https://t.co/f3KTDOqWtS
      in_reply_to_status_id: 1405530328588906500
      in_reply_to_status_id_str: "1405530328588906508"
- preprint:
    id: "134759"
    doi: 10.1101/2021.03.12.21253115
    first_posted: 2021-03-24
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.03.12.21253115v1
    url: https://api.rxivist.org/v1/papers/134759
    title: Genome-wide study of DNA methylation in Amyotrophic Lateral Sclerosis
      identifies differentially methylated loci and implicates metabolic,
      inflammatory and cholesterol pathways
    category: neurology
    abstract: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
      disease with an estimated heritability of around 50%. DNA methylation
      patterns can serve as biomarkers of (past) exposures and disease
      progression, as well as providing a potential mechanism that mediates
      genetic or environmental risk. Here, we present a blood-based
      epigenome-wide association study (EWAS) meta-analysis in 10,462 samples
      (7,344 ALS patients and 3,118 controls), representing the largest
      case-control study of DNA methylation for any disease to date. We
      identified a total of 45 differentially methylated positions (DMPs)
      annotated to 42 genes, which are enriched for pathways and traits related
      to metabolism, cholesterol biosynthesis, and immunity. We show that
      DNA-methylation-based proxies for HDL-cholesterol, BMI, white blood cell
      (WBC) proportions and alcohol intake were independently associated with
      ALS. Integration of these results with our latest GWAS showed that
      cholesterol biosynthesis was causally related to ALS. Finally, we found
      that DNA methylation levels at several DMPs and blood cell proportion
      estimates derived from DNA methylation data, are associated with survival
      rate in patients, and could represent indicators of underlying disease
      processes.
    authors:
      - name: Paul J. Hop
        orcid: http://orcid.org/0000-0002-9007-7436
      - name: Ramona A.J. Zwamborn
        orcid: http://orcid.org/0000-0003-3952-5042
      - name: Eilis Hannon
        orcid: http://orcid.org/0000-0001-6840-072X
      - name: Gemma L Shireby
        orcid: null
      - name: Marta F Nabais
        orcid: http://orcid.org/0000-0002-9545-5889
      - name: Emma M Walker
        orcid: null
      - name: Wouter van Rheenen
        orcid: http://orcid.org/0000-0002-5860-1533
      - name: Joke J.F.A. van Vugt
        orcid: http://orcid.org/0000-0002-4161-4004
      - name: Annelot M. Dekker
        orcid: null
      - name: Henk-Jan Westeneng
        orcid: null
      - name: Gijs H. Tazelaar
        orcid: null
      - name: Kristel R. van Eijk
        orcid: null
      - name: Matthieu Moisse
        orcid: http://orcid.org/0000-0001-8880-9311
      - name: Denis Baird
        orcid: null
      - name: Ahmad Al Khleifat
        orcid: http://orcid.org/0000-0002-7406-9831
      - name: Alfredo Iacoangeli
        orcid: null
      - name: Nicola Ticozzi
        orcid: null
      - name: Antonia Ratti
        orcid: http://orcid.org/0000-0002-4264-6614
      - name: Jonathan Cooper-Knock
        orcid: null
      - name: Karen E. Morrison
        orcid: http://orcid.org/0000-0003-0216-5717
      - name: Pamela J. Shaw
        orcid: null
      - name: A. Nazli Basak
        orcid: http://orcid.org/0000-0001-6977-2517
      - name: Adriano Chi√≤
        orcid: http://orcid.org/0000-0001-9579-5341
      - name: Andrea Calvo
        orcid: http://orcid.org/0000-0002-5122-7243
      - name: Cristina Moglia
        orcid: http://orcid.org/0000-0001-7377-7222
      - name: Antonio Canosa
        orcid: null
      - name: Maura Brunetti
        orcid: http://orcid.org/0000-0001-9547-904X
      - name: Maurizio Grassano
        orcid: http://orcid.org/0000-0001-6714-6897
      - name: Marc Gotkine
        orcid: http://orcid.org/0000-0003-2541-6232
      - name: Yossef Lerner
        orcid: null
      - name: Michal Zabari
        orcid: null
      - name: Patrick Vourc'h
        orcid: null
      - name: Philippe Corcia
        orcid: null
      - name: Philippe Couratier
        orcid: null
      - name: Jesus S. Mora Pardina
        orcid: http://orcid.org/0000-0001-6633-5354
      - name: Teresa Salas
        orcid: null
      - name: Patrick Dion
        orcid: null
      - name: Jay P. Ross
        orcid: http://orcid.org/0000-0002-8183-2524
      - name: Robert D. Henderson
        orcid: http://orcid.org/0000-0002-2820-8183
      - name: Susan Mathers
        orcid: http://orcid.org/0000-0001-8445-1594
      - name: Pamela A. McCombe
        orcid: http://orcid.org/0000-0003-2704-8517
      - name: Merrilee Needham
        orcid: http://orcid.org/0000-0001-6591-1444
      - name: Garth Nicholson
        orcid: http://orcid.org/0000-0001-9694-066X
      - name: Dominic B. Rowe
        orcid: http://orcid.org/0000-0003-0912-2146
      - name: Roger Pamphlett
        orcid: http://orcid.org/0000-0003-3326-7273
      - name: Karen A. Mather
        orcid: http://orcid.org/0000-0003-4143-8941
      - name: Perminder S. Sachdev
        orcid: http://orcid.org/0000-0002-9595-3220
      - name: Sarah Furlong
        orcid: http://orcid.org/0000-0001-5914-500X
      - name: Fleur C. Garton
        orcid: http://orcid.org/0000-0002-1490-5930
      - name: Anjali K. Henders
        orcid: http://orcid.org/0000-0003-3672-1451
      - name: Tian Lin
        orcid: http://orcid.org/0000-0002-5981-1911
      - name: Shyuan T. Ngo
        orcid: http://orcid.org/0000-0002-1388-2108
      - name: Frederik J. Steyn
        orcid: http://orcid.org/0000-0002-4782-3608
      - name: Leanne Wallace
        orcid: http://orcid.org/0000-0003-4310-7572
      - name: Kelly L. Williams
        orcid: http://orcid.org/0000-0001-6319-9473
      - name: BIOS Consortium
        orcid: null
      - name: Brain MEND Consortium
        orcid: null
      - name: Miguel Mitne Neto
        orcid: http://orcid.org/0000-0001-8252-3531
      - name: Ruben J. Cauchi
        orcid: null
      - name: Ian P. Blair
        orcid: http://orcid.org/0000-0003-3083-0075
      - name: Matthew C. Kiernan
        orcid: http://orcid.org/0000-0001-9054-026X
      - name: Vivian Drory
        orcid: null
      - name: Monica Povedano
        orcid: null
      - name: Mamede de Carvalho
        orcid: http://orcid.org/0000-0001-7556-0158
      - name: Susana Pinto
        orcid: http://orcid.org/0000-0002-0727-5897
      - name: Markus Weber
        orcid: http://orcid.org/0000-0002-5538-9274
      - name: Guy Rouleau
        orcid: null
      - name: Vincenzo Silani
        orcid: http://orcid.org/0000-0002-7698-3854
      - name: John E. Landers
        orcid: null
      - name: Christopher E. Shaw
        orcid: null
      - name: Peter M. Andersen
        orcid: http://orcid.org/0000-0003-0094-5429
      - name: Allan F McRae
        orcid: http://orcid.org/0000-0001-5286-5485
      - name: Michael A. van Es
        orcid: null
      - name: R. J. Pasterkamp
        orcid: http://orcid.org/0000-0003-1631-6440
      - name: Naomi R. Wray
        orcid: http://orcid.org/0000-0001-7421-3357
      - name: Russell L. McLaughlin
        orcid: http://orcid.org/0000-0003-3915-2135
      - name: Orla Hardiman
        orcid: http://orcid.org/0000-0003-2610-1291
      - name: Kevin P. Kenna
        orcid: null
      - name: Ellen Tsai
        orcid: null
      - name: Heiko Runz
        orcid: http://orcid.org/0000-0002-2133-7345
      - name: Ammar Al-Chalabi
        orcid: http://orcid.org/0000-0002-4924-7712
      - name: Leonard H. van den Berg
        orcid: http://orcid.org/0000-0002-6559-3965
      - name: Philip Van Damme
        orcid: http://orcid.org/0000-0002-4010-2357
      - name: Jonathan Mill
        orcid: http://orcid.org/0000-0003-1115-3224
      - name: Jan H. Veldink
        orcid: http://orcid.org/0000-0001-5572-9657
  comment:
    dislikes: 0
    thread: "8450211689"
    numReports: 0
    likes: 0
    id: "5421384561"
    createdAt: 2021-06-16T00:33:08
    author:
      username: debrakumar
      about: ""
      name: Debra Kumar
      isPowerContributor: false
      profileUrl: https://disqus.com/by/debrakumar/
      url: ""
      location: ""
      id: "370999365"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      I am c9 positive and recently had my dna age calculated. To my utter
      disappointment my biological age 63 is higher than my chronological age
      59. 


      In January I did a comprehensive blood test through Boston Heath Diagnostics. My LDL came back higher than normal but other lipids normal, or rather high. HDL was 103, total cholesterol 248. I‚Äôve always been proud of my optimal cholesterol numbers but now I‚Äôm thinking egads am I barreling toward symptom onset? Inflammation, Oxidation and Metabolic all optimal. Interestingly my WBC came in low at 3.48. 


      I am a dog walker and walk on average 6 miles daily. I don‚Äôt smoke, and drink moderately. I‚Äôm living what I consider an ideal healthy lifestyle only to find it will kill me üò©
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.03.12.21253115v1
  tweets:
    - created_at: Thu Jun 17 16:34:33 +0000 2021
      id: 1405564531527630800
      id_str: "1405564531527630852"
      text: >-
        üí¨ medRxiv comment on "Genome-wide study of DNA methy..."


        "I am c9 positive and recently had my dna age calculated.‚Ä¶ https://t.co/wnLB8KABrN
      truncated: true
      entities:
        urls:
          - url: https://t.co/wnLB8KABrN
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 17 16:34:33 +0000 2021
      id: 1405564532328652800
      id_str: "1405564532328652802"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/JHd0DpyAbZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/JHd0DpyAbZ
      in_reply_to_status_id: 1405564531527630800
      in_reply_to_status_id_str: "1405564531527630852"
- preprint:
    id: "80333"
    doi: 10.1101/2020.04.16.044461
    first_posted: 2020-04-18
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.04.16.044461v2
    url: https://api.rxivist.org/v1/papers/80333
    title: "RootPainter: Deep Learning Segmentation of Biological Images with
      Corrective Annotation"
    category: plant-biology
    abstract: >-
      We present RootPainter, a GUI-based software tool for the rapid training
      of deep neural networks for use in biological image analysis. RootPainter
      facilitates both fully-automatic and semi-automatic image segmentation. We
      investigate the effectiveness of RootPainter using three plant image
      datasets, evaluating its potential for root length extraction from chicory
      roots in soil, biopore counting and root nodule counting from scanned
      roots. We also use RootPainter to compare dense annotations to corrective
      ones which are added during the training based on the weaknesses of the
      current model.


      ### Competing Interest Statement


      The authors have declared no competing interest.
    authors:
      - name: Abraham George Smith
        orcid: http://orcid.org/0000-0001-9782-2825
      - name: Eusun Han
        orcid: http://orcid.org/0000-0001-6338-2454
      - name: Jens Petersen
        orcid: null
      - name: Niels Alvin Faircloth Olsen
        orcid: null
      - name: Christian Giese
        orcid: null
      - name: Miriam Athmann
        orcid: http://orcid.org/0000-0001-7294-5976
      - name: Dorte Bodin Dresboell
        orcid: http://orcid.org/0000-0001-6374-7257
      - name: Kristian Thorup-Kristensen
        orcid: null
  comment:
    dislikes: 0
    thread: "8022160861"
    numReports: 0
    likes: 0
    id: "5423322062"
    createdAt: 2021-06-17T15:57:46
    author:
      username: disqus_n8cbT9ldjl
      about: ""
      name: Abraham Smith
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_n8cbT9ldjl/
      url: ""
      location: ""
      id: "371075591"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      For users without a suitable GPU, a tutorial is now available for
      installing and running the RootPainter server with Google Colab:


      https://colab.research.google.com/drive/104narYAvTBt-X4QEDrBSOZm_DRaAKHtA


      The tutorial also includes extra instructions on how to get started with annotation and using the client software.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.04.16.044461v2
  tweets:
    - created_at: Thu Jun 17 18:25:11 +0000 2021
      id: 1405592374097678300
      id_str: "1405592374097678338"
      text: >-
        üí¨ bioRxiv comment on "RootPainter: Deep Learning Seg..."


        "For users without a suitable GPU, a tutorial is now avai‚Ä¶ https://t.co/xnPqOznWl7
      truncated: true
      entities:
        urls:
          - url: https://t.co/xnPqOznWl7
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 17 18:25:11 +0000 2021
      id: 1405592375016231000
      id_str: "1405592375016230914"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/y7vrYUchJL
      truncated: false
      entities:
        urls:
          - url: https://t.co/y7vrYUchJL
      in_reply_to_status_id: 1405592374097678300
      in_reply_to_status_id_str: "1405592374097678338"
- preprint:
    id: 146371
    metric: 14
    title: Visualizing looping of two endogenous genomic loci using synthetic
      zinc-finger proteins with anti-FLAG and anti-HA frankenbodies in living
      cells
    url: https://api.rxivist.org/v1/papers/146371
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.16.448697v1
    doi: 10.1101/2021.06.16.448697
    category: cell-biology
    first_posted: 2021-06-16
    abstract: In eukaryotic nuclei, chromatin loops mediated through cohesin are
      critical structures that regulate gene expression and DNA replication.
      Here we demonstrate a new method to visualize endogenous genomic loci
      using synthetic zinc-finger proteins harboring repeat epitope tags (ZF
      probes) for signal amplification via binding of tag-specific intracellular
      antibodies, or frankenbodies, fused with fluorescent proteins. We achieve
      this in two steps. First, we develop an anti-FLAG frankenbody that can
      bind FLAG-tagged proteins in diverse live-cell environments. The anti-FLAG
      frankenbody complements the anti-HA frankenbody, enabling two-color signal
      amplification from FLAG and HA-tagged proteins. Second, we develop a pair
      of cell-permeable ZF probes that specifically bind two endogenous
      chromatin loci predicted to be involved in chromatin looping. By coupling
      our anti-FLAG and anti-HA frankenbodies with FLAG- and HA-tagged ZF
      probes, we simultaneously visualize the dynamics of the two loci in single
      living cells. This reveals close association between the two loci in the
      majority of cells, but the loci markedly separate upon the triggered
      degradation of the cohesin subunit RAD21. Our ability to image two
      endogenous genomic loci simultaneously in single living cells provides a
      proof-of-principle that ZF probes coupled with frankenbodies are useful
      new tools for exploring genome dynamics in multiple colors.
    authors:
      - name: Yang Liu
      - name: Ning Zhao
      - name: Masato T Kanemaki
      - name: Yotaro Yamamoto
      - name: Yoshifusa Sadamura
      - name: Timothy J Stasevich
      - name: Hiroshi Kimura
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Thu Jun 17 20:16:23 +0000 2021
      id: 1405620357667725300
      id_str: "1405620357667725313"
      text: >-
        üî• bioRxiv Cell-biology preprint by Y. Liu et al:


        "Visualizing looping of two endogenous genomic loci using synthet‚Ä¶ https://t.co/rl5xLjQGxD
      truncated: true
      entities:
        urls:
          - url: https://t.co/rl5xLjQGxD
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "143641"
    doi: 10.1101/2021.05.27.445799
    first_posted: 2021-05-27
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.27.445799v1
    url: https://api.rxivist.org/v1/papers/143641
    title: The type 3 secretion system requires actin polymerization to open
      translocon pores
    category: microbiology
    abstract: Many bacterial pathogens require a type 3 secretion system (T3SS) to
      establish a niche. Host contact activates bacterial T3SS assembly of a
      translocon pore in the host plasma membrane. Following pore formation, the
      T3SS docks onto the translocon pore. Docking establishes a continuous
      passage that enables the translocation of virulence proteins, effectors,
      into the host cytosol. Here we investigate the contribution of actin
      polymerization to T3SS-mediated translocation. Using the T3SS model
      organism Shigella flexneri, we show that actin polymerization is required
      for assembling the translocon pore in an open conformation, thereby
      enabling effector translocation. Opening of the pore channel is associated
      with a conformational change to the pore, which is dependent upon actin
      polymerization and a coiled-coil domain in the pore protein IpaC. An IpaC
      mutant is identified that shows actin polymerization-dependent pore
      opening is distinct from the previously described actin
      polymerization-dependent ruffles that are required for bacterial
      internalization. Moreover, actin polymerization is not required for other
      pore functions, including docking or pore protein insertion into the
      plasma membrane. Thus, activation of the T3SS is a multilayered process in
      which host signals are sensed by the translocon pore leading to the
      activation of effector translocation.
    authors:
      - name: Brian C Russo
        orcid: http://orcid.org/0000-0001-6433-5617
      - name: Jeffrey K. Duncan-Lowey
        orcid: http://orcid.org/0000-0002-3615-9596
      - name: Poyin Chen
        orcid: null
      - name: Marcia B. Goldberg
        orcid: http://orcid.org/0000-0003-4266-9733
  comment:
    dislikes: 0
    thread: "8556745945"
    numReports: 0
    likes: 0
    id: "5421353339"
    createdAt: 2021-06-15T23:57:01
    author:
      username: alejandroheuck
      about: ""
      name: Alejandro Heuck
      isPowerContributor: false
      profileUrl: https://disqus.com/by/alejandroheuck/
      url: ""
      location: ""
      id: "337114827"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Some comments that may help the authors 



      1) Fig. 2b, what cells are shown in this figure? The legend mentioned MEFs Vim+/+ and Vim-/-, but it is not indicated in the panel,



      2) Fig. 5g. The authors claim that based on the reduced hemoglobin release observed for Q308P (40%) the ‚Äúpore formed by IpaC Q308P is partially closed‚Äù . If the mechanism of RBC lysis is osmotic lysis, a pore large enough to allow water to go through will trigger RBC lysis. The overall hemoglobin release reflect the number of RBC with at least one pore, it would not be directly related to the size of the formed pores as suggested. 



      3) Interaction of IpaC with intermediate filaments (IFs) was tested in solution (yeast cytosol) (Nat. Microb. 2016), where IpaC does not adopt its native membrane-inserted conformation (as in translocon pores). While those experiments suggested a potential interaction between IpaC and IFs, there are not data showing a direct interaction between IpaC and the IFs in functional translocons. While This is very difficult to show, but one should be careful when using this assumption (or model) to interpret new experiments.



      4) The authors claim that "actin polymerization induces conformational changes to the T3SS translocon pore" . However, it is the inhibition of actin polymerization by CytD that affects the proper assembly of the translocon in the target cell membrane. In the absence of CytD, the translocon assembles properly and actin is polymerized.



      5) check lines 251-252 for number of mutants and repeated ones



      6) line 382 was E. coli induced with IPTG?



      7) line 387, what was the ratio RBC/bacteria used during the hemolysis assay?



      8) line 415, did the authors consider the possibility of separating detergent resistant membranes containing translocators in the pellet under this experimental conditions?



      9) line 430, labeling should be insertion



      10) line 436 define F buffer
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.05.27.445799v1
  tweets:
    - created_at: Thu Jun 17 20:21:04 +0000 2021
      id: 1405621537701572600
      id_str: "1405621537701572613"
      text: |-
        üí¨ bioRxiv comment on "The type 3 secretion system re..."

        "Some comments that may help the authors 

        1) Fig. 2b, wh‚Ä¶ https://t.co/eyUsDTtuFK
      truncated: true
      entities:
        urls:
          - url: https://t.co/eyUsDTtuFK
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 17 20:21:04 +0000 2021
      id: 1405621538741801000
      id_str: "1405621538741800966"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/kMhj6aHKoB
      truncated: false
      entities:
        urls:
          - url: https://t.co/kMhj6aHKoB
      in_reply_to_status_id: 1405621537701572600
      in_reply_to_status_id_str: "1405621537701572613"
- preprint:
    id: "129669"
    doi: 10.1101/2021.02.16.431537
    first_posted: 2021-02-17
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.02.16.431537v1
    url: https://api.rxivist.org/v1/papers/129669
    title: "Simons Collaborative Marine Atlas Project (Simons CMAP): an open-source
      portal to share, visualize and analyze ocean data"
    category: ecology
    abstract: Simons Collaborative Marine Atlas Project (Simons CMAP) is an
      open-source data portal that interconnects large, complex, and diverse
      public data sets currently dispersed in different formats across different
      Oceanography discipline-specific databases. Simons CMAP is designed to
      streamline the retrieval of custom subsets of data, the generation of data
      visualizations, and the analyses of diverse data, thus expanding the power
      of these potentially underutilized data sets for cross-disciplinary
      studies of ocean processes. We describe a unified architecture that allows
      numerical model outputs, satellite products, and field observations to be
      readily shared, mined, and integrated regardless of data set size or
      resolution. A current focus of Simons CMAP is integration of physical,
      chemical, and biological data sets essential for characterizing the
      biogeography of key marine microbes across ocean basins and seasonal
      cycles. Using a practical example, we demonstrate how our unifying data
      harmonization plans significantly simplifies and allows for systematic
      data integration across all Simons CMAP data sets.
    authors:
      - name: Mohammad Dehghani Ashkezari
        orcid: null
      - name: Norland Raphael Hagen
        orcid: null
      - name: Michael Denholtz
        orcid: null
      - name: Andrew Neang
        orcid: null
      - name: Tansy Clay Burns
        orcid: null
      - name: Rhonda Lynn Morales
        orcid: null
      - name: Charlotte Lee
        orcid: null
      - name: Christopher Hill
        orcid: null
      - name: E Virginia Armbrust
        orcid: http://orcid.org/0000-0001-7865-5101
  comment:
    dislikes: 0
    thread: "8402443966"
    numReports: 0
    likes: 0
    id: "5421351237"
    createdAt: 2021-06-15T23:54:35
    author:
      name: Mohammad Dehghani Ashkezari
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: |-
      This article is now published on Limnology and Oceanography Methods: 

      https://doi.org/10.1002/lom3.10439
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.02.16.431537v1
  tweets:
    - created_at: Thu Jun 17 22:20:10 +0000 2021
      id: 1405651511057735700
      id_str: "1405651511057735680"
      text: >-
        üí¨ bioRxiv comment on "Simons Collaborative Marine At..."


        "This article is now published on Limnology and Oceanogra‚Ä¶ https://t.co/dEzzI7MNYY
      truncated: true
      entities:
        urls:
          - url: https://t.co/dEzzI7MNYY
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 17 22:20:10 +0000 2021
      id: 1405651511783329800
      id_str: "1405651511783329795"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/Z1Eyrg4LhJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/Z1Eyrg4LhJ
      in_reply_to_status_id: 1405651511057735700
      in_reply_to_status_id_str: "1405651511057735680"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5421348366"
    createdAt: 2021-06-15T23:51:09
    author:
      username: disqus_BPulZT7zlg
      about: ""
      name: Drew
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_BPulZT7zlg/
      url: ""
      location: ""
      id: "370992328"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Anyone know an estimate as to when the article will be
      peer-reviewed? Thanks in advance!
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Fri Jun 18 01:03:28 +0000 2021
      id: 1405692607636787200
      id_str: "1405692607636787201"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "Anyone know an estimate as to when the article will be p‚Ä¶ https://t.co/ihsIisl4rr
      truncated: true
      entities:
        urls:
          - url: https://t.co/ihsIisl4rr
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 18 01:03:29 +0000 2021
      id: 1405692608521719800
      id_str: "1405692608521719808"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmfcNF6
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmfcNF6
      in_reply_to_status_id: 1405692607636787200
      in_reply_to_status_id_str: "1405692607636787201"
- preprint:
    id: "131218"
    doi: 10.1101/2021.02.17.21251905
    first_posted: 2021-02-22
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.02.17.21251905v1
    url: https://api.rxivist.org/v1/papers/131218
    title: Methodological Approach for Wastewater Based Epidemiological Studies for
      SARS-CoV-2
    category: epidemiology
    abstract: Post COVID-19 outbreak, wastewater-based epidemiology (WBE) studies as
      surveillance system is becoming an emerging interest due to its functional
      advantage as tool for early warning signal and to catalyze effective
      disease management strategies based on the community diagnosis. A
      comprehensive attempt was made in this study to define a methodological
      approach for conducting WBE studies in the framework of
      identifying/selection of surveillance sites, standardizing sampling
      policy, designing sampling protocols to improve sensitivity, adopting
      safety protocol, and interpreting the data. The methodology was applied to
      a community and studied its epidemiological status with reference to
      occurrence, persistence, and variation of SARS-CoV-2 genome load in
      wastewater system to understand the prevalence of infection. Hourly and
      daily grab samples were analyzed and compared with the composite samples
      over a surveillance window of 7 days. Based on the SARS-CoV-2 RNA
      copies/L, faeces shedding, and volume of sewage generated the infected
      individuals and the population who are in active phase in the studied
      community was estimated.
    authors:
      - name: Harishankar Kopperi
        orcid: null
      - name: Athmakuri Tharak
        orcid: null
      - name: Manupati Hemalatha
        orcid: null
      - name: Uday Kiran
        orcid: null
      - name: C. G. Gokulan
        orcid: null
      - name: Rakesh K Mishra
        orcid: http://orcid.org/0000-0001-6636-7380
      - name: S Venkata Mohan
        orcid: http://orcid.org/0000-0001-5564-4135
  comment:
    dislikes: 0
    thread: "8409440100"
    numReports: 0
    likes: 0
    id: "5423376051"
    createdAt: 2021-06-17T16:40:52
    author:
      username: svenkatamohan
      about: ""
      name: S Venkata Mohan
      isPowerContributor: false
      profileUrl: https://disqus.com/by/svenkatamohan/
      url: ""
      location: ""
      id: "370434512"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: This pre-print has been peer-reviewed and published in
      ‚ÄòEnvironmental Technology & Innovation‚Äô,
      doi.org/10.1016/j.eti.2021.101696.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.02.17.21251905v1
  tweets:
    - created_at: Fri Jun 18 12:31:31 +0000 2021
      id: 1405865761168580600
      id_str: "1405865761168580612"
      text: >-
        üí¨ medRxiv comment on "Methodological Approach for Wa..."


        "This pre-print has been peer-reviewed and published in ‚Äò‚Ä¶ https://t.co/lUb3CHi1Ld
      truncated: true
      entities:
        urls:
          - url: https://t.co/lUb3CHi1Ld
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 18 12:31:32 +0000 2021
      id: 1405865762003247000
      id_str: "1405865762003247106"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/Ket5qTJtX1
      truncated: false
      entities:
        urls:
          - url: https://t.co/Ket5qTJtX1
      in_reply_to_status_id: 1405865761168580600
      in_reply_to_status_id_str: "1405865761168580612"
- preprint:
    id: "146269"
    doi: 10.1101/2021.06.15.448399
    first_posted: 2021-06-16
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.15.448399v1
    url: https://api.rxivist.org/v1/papers/146269
    title: "15 years of introgression studies: quantifying gene flow across
      Eukaryotes"
    category: evolutionary-biology
    abstract: With the rise of affordable next generation sequencing technology,
      introgression - or the exchange of genetic materials between taxa - is
      widely perceived to be a ubiquitous phenomenon in nature. Although this
      claim is supported by several keystone studies, no thorough assessment on
      the frequency of introgression in nature has been performed to date. In
      this manuscript, we aim to address this knowledge gap by providing a
      meta-analysis of the most comprehensive survey of introgression studies in
      Eukaryotes to date (724 papers with claims of introgression). We first
      examined the evidence given to support introgression, and if/how the lines
      of evidence have changed across time. We then collated a single statistic,
      Patterson's D, that quantifies the strength of introgression across 123
      studies to further assess how taxonomic group, divergence time, and
      aspects of life history influence introgression. We find three main
      results. Studies on introgression are much more frequent in plants and
      mammals than any other taxonomic group. The study of introgression has
      shifted from a largely qualitative assessment of whether introgression
      happens, to a focus on when and how much introgression has occurred across
      taxa. The most-often used introgression statistic, Patterson's D, shows
      several intriguing patterns suggesting introgression reports may be biased
      by both differences in reporting criteria and sequencing technology, but
      may also differ across taxonomic systems and throughout the process of
      speciation. Together, these results suggest the need for a unified
      approach to quantifying introgression in natural communities, and
      highlight important areas of future research that can be better assessed
      once this unified approach is met.
    authors:
      - name: Andrius J Dagilis
        orcid: http://orcid.org/0000-0003-2013-0825
      - name: David Peede
        orcid: http://orcid.org/0000-0002-4826-0464
      - name: Jenn M. Coughlan
        orcid: null
      - name: Gaston I Jofre
        orcid: null
      - name: Emmanuel R R D'Agostino
        orcid: http://orcid.org/0000-0003-0829-6435
      - name: Heidi Mavengere
        orcid: http://orcid.org/0000-0002-6207-1088
      - name: Alexander D Tate
        orcid: null
      - name: Daniel R Matute
        orcid: http://orcid.org/0000-0002-8494-8012
  comment:
    dislikes: 0
    thread: "8596763671"
    numReports: 0
    likes: 0
    id: "5423877722"
    createdAt: 2021-06-18T00:21:09
    author:
      username: disqus_wB6yZCthij
      about: ""
      name: Daniel Ricardo Matute
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_wB6yZCthij/
      url: ""
      location: ""
      id: "32322521"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "Data and scripts: https://github.com/adagilis/introgression_meta_biorxiv"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.15.448399v1
  tweets:
    - created_at: Fri Jun 18 14:23:30 +0000 2021
      id: 1405893943347368000
      id_str: "1405893943347367938"
      text: |-
        üí¨ bioRxiv comment on "15 years of introgression stud..."

        "Data and scripts: "

        https://t.co/ecr2gSrWeb
      truncated: false
      entities:
        urls:
          - url: https://t.co/ecr2gSrWeb
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 18 14:23:31 +0000 2021
      id: 1405893943963889700
      id_str: "1405893943963889667"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/jgg5psObr4
      truncated: false
      entities:
        urls:
          - url: https://t.co/jgg5psObr4
      in_reply_to_status_id: 1405893943347368000
      in_reply_to_status_id_str: "1405893943347367938"
- preprint:
    id: "135104"
    doi: 10.1101/2021.03.25.437032
    first_posted: 2021-03-26
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.03.25.437032v1
    url: https://api.rxivist.org/v1/papers/135104
    title: Dynamic distortion of the orientation representational space after
      learning in the mouse primary visual cortex
    category: neuroscience
    abstract: Learning is an essential cognitive mechanism that supports behavioral
      adaptation through neural processing adjustments. Learning was shown to
      modify sensory integration, yet the nature of those modifications and the
      computational advantages they confer remain unclear. By comparing the
      responses of primary visual cortex (V1) neurons evoked by oriented stimuli
      in naive mice and mice performing an orientation discrimination task, we
      found that the representations of rewarded and non-rewarded cues were
      sparser, more accurate and more stable in trained mice. This improved
      representation was associated with a distortion of the V1 orientation
      space such that stimuli close to the task cues were represented as the
      task stimuli themselves. This distortion was context-dependent, as it was
      absent in trained mice passively viewing the cues. Hence, visual
      processing in V1 was dynamically adapted to enhance the reliability of the
      representation of the learned cues and favor stimulus generalization in
      the task-relevant computational space.
    authors:
      - name: Julien Corbo
        orcid: http://orcid.org/0000-0002-1251-0572
      - name: John P McClure
        orcid: http://orcid.org/0000-0002-9261-4995
      - name: Orhan Batuhan Erkat
        orcid: null
      - name: Pierre-Olivier Polack
        orcid: http://orcid.org/0000-0003-1716-6595
  comment:
    dislikes: 0
    thread: "8452938327"
    numReports: 0
    likes: 0
    id: "5423784127"
    createdAt: 2021-06-17T22:30:54
    author:
      username: sashaburckhardt
      about: ""
      name: Sasha Burckhardt
      isPowerContributor: false
      profileUrl: https://disqus.com/by/sashaburckhardt/
      url: ""
      location: ""
      id: "371090525"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: 'Typo? "We found a lower amount of APrE per neuron and per trial in
      the na√Øve than in the trained group (mean ¬± standard deviation; na√Øve:
      0.93¬±0.16; trained: 0.86¬±0.15; effect size: Hedge‚Äôs g = 0.48)." Based on
      the numbers and the subsequent conclusions, APrE should be greater in
      naive mice, no?'
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.03.25.437032v1
  tweets:
    - created_at: Fri Jun 18 16:33:39 +0000 2021
      id: 1405926695966814200
      id_str: "1405926695966814215"
      text: >-
        üí¨ bioRxiv comment on "Dynamic distortion of the orie..."


        "Typo? "We found a lower amount of APrE per neuron and pe‚Ä¶ https://t.co/N5Psembs4C
      truncated: true
      entities:
        urls:
          - url: https://t.co/N5Psembs4C
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 18 16:33:40 +0000 2021
      id: 1405926697095110700
      id_str: "1405926697095110656"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/yCphlKhVWI
      truncated: false
      entities:
        urls:
          - url: https://t.co/yCphlKhVWI
      in_reply_to_status_id: 1405926695966814200
      in_reply_to_status_id_str: "1405926695966814215"
- preprint:
    id: "136905"
    doi: 10.1101/2021.04.06.21254949
    first_posted: 2021-04-07
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.04.06.21254949v1
    url: https://api.rxivist.org/v1/papers/136905
    title: Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies
      patients
    category: infectious-diseases
    abstract: Studies describing SARS-CoV-2 immune responses following mRNA
      vaccination in hematology malignancy (HM) patients are virtually
      non-existent. We measured SARS-CoV-2 IgG production in 67 HM patients who
      received 2 mRNA vaccine doses. We found that 46% of HM patients did not
      produce antibodies and were therefore vaccine non-responders. Patients
      with B-cell CLL were at a particularly high risk, as only 23% had
      detectable antibodies despite the fact that nearly 70% of these patients
      were not undergoing cancer therapy. HM patients should be counseled about
      the ongoing risk of COVID-19 despite vaccination. Routine measurement of
      post-vaccine antibodies in HM patients should be considered. Novel
      strategies are needed to prevent COVID-19 in these individuals.
    authors:
      - name: Mounzer Agha
        orcid: null
      - name: Maggie Blake
        orcid: null
      - name: Charles Chilleo
        orcid: null
      - name: Alan H. Wells
        orcid: http://orcid.org/0000-0002-1637-8150
      - name: Ghady Haidar
        orcid: null
  comment:
    dislikes: 0
    thread: "8469418204"
    numReports: 0
    likes: 0
    id: "5424567845"
    createdAt: 2021-06-18T16:19:49
    author:
      username: disqus_hSMGlNb5cU
      about: ""
      name: Jim D
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_hSMGlNb5cU/
      url: ""
      location: ""
      id: "39549736"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Hi, I have CLL, asymptomatic and very low count. I had the Pfizer vaccine,
      both doses.  My arm was sore for 3 weeks after the first shot even tho I
      moved it around alot.  On the third day after my second shot, it seemed
      that my shingles was reactivated, big pain, couldn't sleep. My PCP sent me
      to emergency for CT scan. Other than spike in white cell count, nothing
      showed from the scan. I shared the info about this study with PCP and
      Hemotology oncologist to try to get a quantitative antibody test.  I have
      not heard back, other than those tests are extremely difficult to
      get.  Also then with further reading, I learned that even with a
      quantitative test, I would not learn much since there is no standard for
      determining what number is safe.

      My question is:  has there been any new info since this study was posted.  Thanks. J
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.04.06.21254949v1
  tweets:
    - created_at: Fri Jun 18 18:23:57 +0000 2021
      id: 1405954452910133200
      id_str: "1405954452910133262"
      text: >-
        üí¨ medRxiv comment on "Suboptimal response to COVID-1..."


        "Hi, I have CLL, asymptomatic and very low count. I had t‚Ä¶ https://t.co/9BZML0pymg
      truncated: true
      entities:
        urls:
          - url: https://t.co/9BZML0pymg
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 18 18:23:57 +0000 2021
      id: 1405954453640040400
      id_str: "1405954453640040450"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/pP8N7PQ9pn
      truncated: false
      entities:
        urls:
          - url: https://t.co/pP8N7PQ9pn
      in_reply_to_status_id: 1405954452910133200
      in_reply_to_status_id_str: "1405954452910133262"
- preprint:
    id: 28610
    metric: 253
    title: Gender balance in time-keeping at life science conferences
    url: https://api.rxivist.org/v1/papers/28610
    biorxiv_url: https://www.biorxiv.org/content/10.1101/267120v2
    doi: 10.1101/267120
    category: scientific-communication-and-education
    first_posted: 2018-02-19
    abstract: Scientific conferences are biased against women when selecting
      speakers, but recent studies showed a positive trend where the ratio of
      invited female speakers had increased. We have recorded speaking times at
      11 different conferences during 2016-2017 to analyze which factors
      influenced a speaker's time keeping. Men and women went over time 47% and
      41% of the talks, respectively. In a regression analysis, it was found
      that the most important factors that influences how long a presenter spoke
      was 1) their allocated time, 2) their career stage and 3) the level of
      time keeping enforcement. It was also found that gender and the size of
      the conference contributed significantly towards the speaker's timing.
      Male speakers exceeded their allocated time more frequently than female
      speakers, especially at large conferences (60% vs 49%). Since conferences
      are an important arena for science dissemination this might have a
      negative impact on female scientist's careers.
    authors:
      - name: Petra Edlund
      - name: Erin M. Tranfield
      - name: Vera van Noort
      - name: Karen Siu Ting
      - name: Sofia Tapani
      - name: Johanna L. Hoog
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Fri Jun 18 20:16:19 +0000 2021
      id: 1405982730270261200
      id_str: "1405982730270261251"
      text: >-
        üî• bioRxiv Scientific-communication-and-education preprint by P. Edlund
        et al:


        "Gender balance in time-keeping at l‚Ä¶ https://t.co/MAOks59bJb
      truncated: true
      entities:
        urls:
          - url: https://t.co/MAOks59bJb
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5424506849"
    createdAt: 2021-06-18T15:27:12
    author:
      username: mattjolley
      about: ""
      name: Matt Jolley
      isPowerContributor: false
      profileUrl: https://disqus.com/by/mattjolley/
      url: ""
      location: ""
      id: "88523447"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      The study reports no reinfections.  This recent UK PHE data shows 15,983 

      "possible reinfections".   https://www.gov.uk/government/news/new-national-surveillance-of-possible-covid-19-reinfection-published-by-phe
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Fri Jun 18 20:20:08 +0000 2021
      id: 1405983691034271700
      id_str: "1405983691034271744"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "The study reports no reinfections.  This recent UK PHE d‚Ä¶ https://t.co/t6C4hSLT45
      truncated: true
      entities:
        urls:
          - url: https://t.co/t6C4hSLT45
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 18 20:20:08 +0000 2021
      id: 1405983691768320000
      id_str: "1405983691768320000"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1405983691034271700
      in_reply_to_status_id_str: "1405983691034271744"
- preprint:
    id: "141057"
    doi: 10.1101/2021.05.03.21256520
    first_posted: 2021-05-06
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.03.21256520v1
    url: https://api.rxivist.org/v1/papers/141057
    title: The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and
      innate immune responses
    category: infectious-diseases
    abstract: The mRNA-based BNT162b2 vaccine from Pfizer/BioNTech was the first
      registered COVID-19 vaccine and has been shown to be up to 95% effective
      in preventing SARS-CoV-2 infections. Little is known about the broad
      effects of the new class of mRNA vaccines, especially whether they have
      combined effects on innate and adaptive immune responses. Here we
      confirmed that BNT162b2 vaccination of healthy individuals induced
      effective humoral and cellular immunity against several SARS-CoV-2
      variants. Interestingly, however, the BNT162b2 vaccine also modulated the
      production of inflammatory cytokines by innate immune cells upon
      stimulation with both specific (SARS-CoV-2) and non-specific (viral,
      fungal and bacterial) stimuli. The response of innate immune cells to TLR4
      and TLR7/8 ligands was lower after BNT162b2 vaccination, while
      fungi-induced cytokine responses were stronger. In conclusion, the mRNA
      BNT162b2 vaccine induces complex functional reprogramming of innate immune
      responses, which should be considered in the development and use of this
      new class of vaccines.
    authors:
      - name: F. Konstantin F√∂hse
        orcid: http://orcid.org/0000-0002-4708-6943
      - name: B√ºsranur Geckin
        orcid: http://orcid.org/0000-0002-4751-4960
      - name: Gijs J. Overheul
        orcid: http://orcid.org/0000-0002-8356-8165
      - name: Josephine van de Maat
        orcid: http://orcid.org/0000-0001-7351-4596
      - name: Gizem Kilic
        orcid: http://orcid.org/0000-0002-8251-1909
      - name: Ozlem Bulut
        orcid: http://orcid.org/0000-0001-7077-6216
      - name: Helga Dijkstra
        orcid: null
      - name: Heidi Lemmers
        orcid: null
      - name: S. Andrei Sarlea
        orcid: null
      - name: Maartje Reijnders
        orcid: null
      - name: Jacobien Hoogerwerf
        orcid: http://orcid.org/0000-0001-9957-3703
      - name: Jaap ten Oever
        orcid: http://orcid.org/0000-0003-2397-0125
      - name: Elles Simonetti
        orcid: null
      - name: Frank L van de Veerdonk
        orcid: http://orcid.org/0000-0002-1121-4894
      - name: Leo A.B. Joosten
        orcid: http://orcid.org/0000-0001-6166-9830
      - name: Bart L. Haagmans
        orcid: http://orcid.org/0000-0001-6221-2015
      - name: Reinout van Crevel
        orcid: null
      - name: Yang Li
        orcid: http://orcid.org/0000-0003-4022-7341
      - name: Ronald P. van Rij
        orcid: http://orcid.org/0000-0003-0221-4689
      - name: Corine GeurtsvanKessel
        orcid: http://orcid.org/0000-0002-7678-314X
      - name: Marien I. de Jonge
        orcid: http://orcid.org/0000-0003-2812-5895
      - name: Jorge Dom√≠nguez-Andr√©s
        orcid: http://orcid.org/0000-0002-9091-1961
      - name: Mihai G. Netea
        orcid: http://orcid.org/0000-0003-2421-6052
  comment:
    dislikes: 0
    thread: "8508876244"
    numReports: 0
    likes: 0
    id: "5424145467"
    createdAt: 2021-06-18T07:48:44
    author:
      username: disqus_Yqv71uDqvw
      about: ""
      name: Tobi
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_Yqv71uDqvw/
      url: ""
      location: ""
      id: "371107628"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      This is really interesting and needs to be considered further.


      However, such fine tuning effects upon natural infection of artificial eliciting events are - at least from my experience - not unusual, since induced reactions to a specific PAMP always lead to physiological readjustments of "the whole system" and, thus, also affect reactions to certain other immunological stimuli (no upregulations without downregulations).


      Therefore, it's a shame that this preprint is already misused by YouTubers to generate fear of COVID vaccines due to long term effects.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.03.21256520v1
  tweets:
    - created_at: Fri Jun 18 22:19:43 +0000 2021
      id: 1406013786331488300
      id_str: "1406013786331488265"
      text: >-
        üí¨ medRxiv comment on "The BNT162b2 mRNA vaccine agai..."


        "This is really interesting and needs to be considered fu‚Ä¶ https://t.co/dTHJZ9CUUz
      truncated: true
      entities:
        urls:
          - url: https://t.co/dTHJZ9CUUz
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 18 22:19:44 +0000 2021
      id: 1406013787249983500
      id_str: "1406013787249983489"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/dJAkyRxqBb
      truncated: false
      entities:
        urls:
          - url: https://t.co/dJAkyRxqBb
      in_reply_to_status_id: 1406013786331488300
      in_reply_to_status_id_str: "1406013786331488265"
- preprint:
    id: "118473"
    doi: 10.1101/2020.10.30.20217364
    first_posted: 2020-11-03
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.10.30.20217364v1
    url: https://api.rxivist.org/v1/papers/118473
    title: "Honey and Nigella sativa against COVID-19 in Pakistan (HNS-COVID-PK): A
      multi-center placebo-controlled randomized clinical trial"
    category: infectious-diseases
    abstract: "BACKGROUND: No definitive treatment exists for Coronavirus Disease
      2019 (COVID-19). Honey and Nigella sativa (HNS) have established antiviral
      properties. Hence, we investigated the efficacy of HNS against COVID-19.
      METHODS: We conducted a multicenter, placebo-controlled, randomized
      clinical trial at 4 centers in Pakistan. RT-PCR confirmed COVID-19 adults
      showing moderate or severe disease were enrolled in the study. Patients
      presenting with multi-organ failure, ventilator support, and chronic
      diseases (except diabetes mellitus and hypertension) were excluded.
      Patients were randomly assigned in 1:1 ratio to receive either honey (1
      gm/Kg/day) and Nigella sativa seeds (80 mg/Kg/day) or placebo up-to 13
      days along with standard care. The outcomes included symptom alleviation,
      viral clearance, and 30-day mortality in the intention-to-treat
      population. This trial was registered with ClinicalTrials.gov,
      NCT04347382. FINDINGS Three hundred and thirteen patients - 210 moderate
      and 103 severe - underwent randomization from April 30 to July 29, 2020.
      Among these, 107 were assigned to HNS whereas 103 to placebo for moderate
      cases. For severe cases, 50 were given HNS, and 53 were given placebos.
      HNS resulted in ~50% reduction in time taken to alleviate symptoms as
      compared to placebo (Moderate (4 versus 7 days), Hazard Ratio [HR]: 6.11;
      95% Confidence Interval [CI]: 4.23-8.84, P<0.0001 and severe (6 versus 13
      days) HR: 4.04; 95% CI, 2.46-6.64, P<0.0001). HNS also cleared the virus 4
      days earlier than the placebo group in moderate (6 versus 10 days, HR:
      5.53; 95% CI: 3.76-8.14, P<0.0001) and severe cases (8.5 versus 12 days,
      HR: 4.32; 95% CI: 2.62-7.13, P<0.0001). HNS further led to a better
      clinical score on day 6 with normal activity resumption in 63.6% versus
      10.9% among moderate cases (OR: 0.07; 95% CI: 0.03-0.13, P<0.0001) and
      hospital discharge in 50% versus 2.8% in severe cases (OR: 0.03; 95% CI:
      0.01-0.09, P<0.0001). In severe cases, mortality rate was four-fold lower
      in HNS group than placebo (4% versus 18.87%, OR: 0.18; 95% CI: 0.02-0.92,
      P=0.029). No HNS-related adverse effects were observed. INTERPRETATION HNS
      significantly improved symptoms, viral clearance, and mortality in
      COVID-19 patients. Thus, HNS represents an affordable over the counter
      therapy and can either be used alone or in combination with other
      treatments to achieve potentiating effects against COVID-19. FUNDING:
      Funded by Smile Welfare Organization, Shaikh Zayed Medical Complex, and
      Services Institute of Medical Sciences."
    authors:
      - name: Sohaib Ashraf
        orcid: http://orcid.org/0000-0003-3127-3557
      - name: Shoaib Ashraf
        orcid: http://orcid.org/0000-0002-1218-4877
      - name: Moneeb Ashraf
        orcid: http://orcid.org/0000-0002-5769-9524
      - name: Muhammad Ahmad Imran
        orcid: http://orcid.org/0000-0003-3358-229X
      - name: Larab Kalsoom
        orcid: http://orcid.org/0000-0003-1075-6285
      - name: Uzma Nasim Siddiqui
        orcid: null
      - name: Iqra Farooq
        orcid: null
      - name: Zaigham Habib
        orcid: null
      - name: Sidra Ashraf
        orcid: http://orcid.org/0000-0002-4254-2583
      - name: Muhammad Ghufran
        orcid: null
      - name: Muhammad Kiwan Akram
        orcid: http://orcid.org/0000-0002-8415-9363
      - name: Nighat Majeed
        orcid: http://orcid.org/0000-0003-0238-7520
      - name: Zain ul Abdin
        orcid: null
      - name: Rutaba Akmal
        orcid: null
      - name: Sundas Rafique
        orcid: null
      - name: Khawar Nawaz
        orcid: null
      - name: Muhammad Ismail Khalid Yousaf
        orcid: null
      - name: Sohail Ahmad
        orcid: null
      - name: Muhammad Sarmad Shahab
        orcid: null
      - name: Muhammad Faisal Nadeem
        orcid: http://orcid.org/0000-0002-1356-103X
      - name: Abubakar Hilal
        orcid: null
      - name: Arz Muhammad
        orcid: null
      - name: Zeeshan Shoukat
        orcid: null
      - name: Ayesha Khaqan
        orcid: null
      - name: Kanwal Hayat
        orcid: null
      - name: Shahroz Arshad
        orcid: null
      - name: Muhammad Hassan
        orcid: null
      - name: Abeer bin Awais
        orcid: null
      - name: Abdur Rehman Virk
        orcid: null
      - name: Ammara Ahmad
        orcid: null
      - name: Tayyab Mughal
        orcid: null
      - name: Muhammad Umer
        orcid: null
      - name: Muhammad Suhail
        orcid: null
      - name: Sibgha Zulfiqar
        orcid: null
      - name: Saulat Sarfraz
        orcid: null
      - name: Imran Anwar
        orcid: http://orcid.org/0000-0002-8540-0139
      - name: Ayesha Humayun
        orcid: null
      - name: Muhammad Azam
        orcid: null
      - name: Hui Zheng
        orcid: null
      - name: Amber Malik
        orcid: null
      - name: Mahmood Ayyaz
        orcid: http://orcid.org/0000-0003-1957-383X
      - name: Ali Ahmad
        orcid: http://orcid.org/0000-0001-7689-7115
      - name: Talha Mahmud
        orcid: http://orcid.org/0000-0003-4585-0765
      - name: Qazi Abdul Saboor
        orcid: null
      - name: Muhammad Ashraf
        orcid: null
      - name: Mateen Izhar
        orcid: null
  comment:
    dislikes: 0
    thread: "8296231249"
    numReports: 0
    likes: 0
    id: "5424035373"
    createdAt: 2021-06-18T04:01:15
    author:
      username: nimaarabani
      about: ""
      name: NA
      isPowerContributor: false
      profileUrl: https://disqus.com/by/nimaarabani/
      url: ""
      location: ""
      id: "367790418"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: What is the status currently (two months later) for publishing?
      Have lower impact journals been approached? Thank you,
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.10.30.20217364v4
  tweets:
    - created_at: Sat Jun 19 01:01:44 +0000 2021
      id: 1406054557030006800
      id_str: "1406054557030006784"
      text: >-
        üí¨ medRxiv comment on "Honey and Nigella sativa again..."


        "What is the status currently (two months later) for publ‚Ä¶ https://t.co/B0kRRYx70L
      truncated: true
      entities:
        urls:
          - url: https://t.co/B0kRRYx70L
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 19 01:01:44 +0000 2021
      id: 1406054557889749000
      id_str: "1406054557889748996"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/4lT0fD4fj5
      truncated: false
      entities:
        urls:
          - url: https://t.co/4lT0fD4fj5
      in_reply_to_status_id: 1406054557030006800
      in_reply_to_status_id_str: "1406054557030006784"
- preprint:
    id: "122874"
    doi: 10.1101/2020.12.24.424328
    first_posted: 2020-12-24
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.12.24.424328v1
    url: https://api.rxivist.org/v1/papers/122874
    title: Development of a continuous fluorescence-based assay for N-terminal
      acetyltransferase D
    category: biochemistry
    abstract: N-terminal acetylation catalyzed by N-terminal acetyltransferases
      (NATs) has various biological functions in protein regulation. N-terminal
      acetyltransferase D (NatD) is one of the most specific NAT with only
      histone H4 and H2A proteins as the known substrates. Dysregulation of NatD
      has been implicated in colorectal and lung cancer progression, implying
      its therapeutic potential in cancers. However, there is no reported
      inhibitor for NatD yet. To facilitate the discovery of small-molecule NatD
      inhibitors, we report the development of a fluorescence-based
      acetyltransferase assay in 384-well high-throughput screening (HTS) format
      through monitoring the formation of coenzyme A. The fluorescent signal is
      generated from the adduct in the reaction between coenzyme A and
      fluorescent probe ThioGlo4. The assay exhibited a Z-factor of 0.77 and a
      coefficient of variation of 6%, indicating it is a robust assay for HTS. A
      pilot screen of 1280 pharmacologically active compounds and subsequent
      validation identified two hits, confirming the application of this
      fluorescence assay in HTS.
    authors:
      - name: Yi-Hsun Ho
        orcid: null
      - name: Lan Chen
        orcid: http://orcid.org/0000-0003-4520-5109
      - name: Rong Huang
        orcid: http://orcid.org/0000-0002-1477-3165
  comment:
    dislikes: 0
    thread: "8329212395"
    numReports: 0
    likes: 0
    id: "5423698241"
    createdAt: 2021-06-17T21:05:43
    author:
      username: disqus_GHKotnPlDZ
      about: ""
      name: Huanglab
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_GHKotnPlDZ/
      url: ""
      location: ""
      id: "352654011"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Final version has been published https://www.mdpi.com/1422-0067/22/2/594
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.12.24.424328v1
  tweets:
    - created_at: Sat Jun 19 12:29:48 +0000 2021
      id: 1406227716546891800
      id_str: "1406227716546891776"
      text: |-
        üí¨ bioRxiv comment on "Development of a continuous fl..."

        "Final version has been published "

        https://t.co/cSSC6iQRjq
      truncated: false
      entities:
        urls:
          - url: https://t.co/cSSC6iQRjq
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 19 12:29:48 +0000 2021
      id: 1406227717247410200
      id_str: "1406227717247410177"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/siLHUqeQpV
      truncated: false
      entities:
        urls:
          - url: https://t.co/siLHUqeQpV
      in_reply_to_status_id: 1406227716546891800
      in_reply_to_status_id_str: "1406227716546891776"
- preprint:
    id: "126574"
    doi: 10.1101/2021.01.24.427995
    first_posted: 2021-01-26
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.01.24.427995v1
    url: https://api.rxivist.org/v1/papers/126574
    title: Novel bisubstrate inhibitors for protein N-terminal acetyltransferase D
    category: biochemistry
    abstract: Protein N-terminal acetyltransferase D (NatD, NAA40) that specifically
      acetylates the alpha-N-terminus of histone H4 and H2A has been implicated
      in various diseases, but no inhibitor has been reported for this important
      enzyme. Based on the acetyl transfer mechanism of NatD, we designed and
      prepared a series of highly potent NatD bisubstrate inhibitors by
      covalently linking coenzyme A to different peptide substrates via an
      acetyl or propionyl spacer. The most potent bisubstrate inhibitor
      displayed an apparent Ki value of 1.0 nM. Biochemical studies indicated
      that bisubstrate inhibitor is competitive to the peptide substrate and
      noncompetitive to the cofactor, suggesting NatD undergoes an ordered Bi-Bi
      mechanism. We also demonstrated that these inhibitors are highly specific
      towards NatD, displaying about 1,000-fold selectivity over other closely
      related acetyltransferases. High-resolution crystal structures of NatD
      bound to two of these inhibitors revealed the molecular basis for their
      selectivity and inhibition mechanism, providing a rational path for future
      inhibitor development.
    authors:
      - name: Youchao Deng
        orcid: null
      - name: Sunbin Deng
        orcid: http://orcid.org/0000-0001-7798-4317
      - name: Yi-Hsun Ho
        orcid: null
      - name: Sarah M Gardner
        orcid: null
      - name: Zhi Huang
        orcid: http://orcid.org/0000-0001-6982-8285
      - name: Ronen Marmorstein
        orcid: http://orcid.org/0000-0003-4373-4752
      - name: Rong Huang
        orcid: http://orcid.org/0000-0002-1477-3165
  comment:
    dislikes: 0
    thread: "8371985004"
    numReports: 0
    likes: 0
    id: "5423697135"
    createdAt: 2021-06-17T21:04:42
    author:
      username: disqus_GHKotnPlDZ
      about: ""
      name: Huanglab
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_GHKotnPlDZ/
      url: ""
      location: ""
      id: "352654011"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Final version has been published on J Med Chem.
      https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00141
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.01.24.427995v1
  tweets:
    - created_at: Sat Jun 19 14:17:13 +0000 2021
      id: 1406254746302705700
      id_str: "1406254746302705667"
      text: |-
        üí¨ bioRxiv comment on "Novel bisubstrate inhibitors f..."

        "Final version has been published on J Med Chem. "

        https://t.co/DWqqo3H00Z
      truncated: false
      entities:
        urls:
          - url: https://t.co/DWqqo3H00Z
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 19 14:17:13 +0000 2021
      id: 1406254747179384800
      id_str: "1406254747179384837"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/Q7XlNqcPHh
      truncated: false
      entities:
        urls:
          - url: https://t.co/Q7XlNqcPHh
      in_reply_to_status_id: 1406254746302705700
      in_reply_to_status_id_str: "1406254746302705667"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5424853150"
    createdAt: 2021-06-18T20:22:26
    author:
      username: disqus_JAjOOZQCOY
      about: ""
      name: Dennis Cooper
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_JAjOOZQCOY/
      url: ""
      location: ""
      id: "358319583"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: A hypothesis with a 30 person study and a hope seems like light
      evidence to justify running run around telling people to "please inform
      themselves better"
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Sat Jun 19 16:31:30 +0000 2021
      id: 1406288541018099700
      id_str: "1406288541018099716"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "A hypothesis with a 30 person study and a hope seems lik‚Ä¶ https://t.co/6BTmJvRY1Y
      truncated: true
      entities:
        urls:
          - url: https://t.co/6BTmJvRY1Y
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 19 16:31:30 +0000 2021
      id: 1406288541882200000
      id_str: "1406288541882200066"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1406288541018099700
      in_reply_to_status_id_str: "1406288541018099716"
- preprint:
    id: "137204"
    doi: 10.1101/2021.04.06.21254993
    first_posted: 2021-04-09
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.04.06.21254993v1
    url: https://api.rxivist.org/v1/papers/137204
    title: "Reopening Italy's Schools in September 2020: A Bayesian Estimation of
      the Change in the Growth Rate of New SARS-CoV-2 Cases"
    category: public-and-global-health
    abstract: "Abstract Objectives: CoViD-19's second wave started a debate on the
      potential role of schools as a primary factor in the contagion resurgence.
      Two opposite positions appeared: those convinced that schools played a
      major role in spreading SARS-CoV-2 infections and those who were not. We
      studied the growth rate of the total number of SARS-CoV-2 infections in
      all the Italian regions, before and after the school reopening (September
      - October 2020), investigating the hypothesis of an association between
      schools and the resurgence of the virus in Italy. Methods: Using Bayesian
      piecewise linear regression to scrutinize the number of daily SARS-CoV-2
      infections in each Italian, we looked for an estimate of a changepoint in
      the growth rate of those confirmed cases. We compared the changepoints
      with the school opening dates, for each Italian region. The regression
      allows to discuss the change in steepness of the infection curve, before
      and after the changepoint. Results: In 15 out of 21 Italian regions (71%),
      an estimated change in the rate of growth of the total number of daily
      SARS-CoV-2 infection cases occurred after an average of 16.66 days (CI 95%
      14.47 to 18.73) since the school reopening. The number of days required
      for the SARS-CoV-2 daily cases to double went from an average of 47.50
      days (CI 95% 37.18 to 57.61) before the changepoint to an average of 7.72
      days (CI 95% 7.00 to 8.48) after it. Conclusion: Studying the rate of
      growth of daily SARS-CoV-2 cases in all the Italian regions provides some
      evidence in favor of a link between school reopening and the resurgence of
      the virus in Italy. The number of factors that could have played a role
      are too many to give a definitive answer. Still, the temporal
      correspondence warrants for a controlled experiment to clarify how much
      reopening schools mattered."
    authors:
      - name: Luca Casini
        orcid: http://orcid.org/0000-0002-3468-6974
      - name: Marco Roccetti
        orcid: http://orcid.org/0000-0003-1264-8595
  comment:
    dislikes: 0
    thread: "8471585559"
    numReports: 0
    likes: 0
    id: "5423619227"
    createdAt: 2021-06-17T19:58:09
    author:
      username: marcoroccetti
      about: ""
      name: Marco Roccetti
      isPowerContributor: false
      profileUrl: https://disqus.com/by/marcoroccetti/
      url: ""
      location: ""
      id: "371081903"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      We thank Maurizio for the careful reading of our paper and his interesting
      comment.


      We do agree that elections and workers are two factors of a certain relevance that, besides school reopenings, deserve attention and further investigations. We have already maintained this in our paper (abstract, limitations, discussion, conclusion).


      Nonetheless, Maurizio should give more credit to the following facts:

      - elections were held on two different days (sun 20 and mon 21), hence the number of participants should be distributed over two different days

      - Italian students and school personell (11 million people on a national basis) go to school each and every day (mon-fri/sat)

      - Mobility reports by Google tag workplaces (Google News. https://news.google.com/covid19/map?hl=it&gl=IT&ceid=IT%3Ait&mid=%2Fm%2F03rjj)

      The revised version of our paper, which is going to appear on a renowned International medical journal, discusses all those points above.


      Sincerely,

      The Authors
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.04.06.21254993v1
  tweets:
    - created_at: Sat Jun 19 18:23:18 +0000 2021
      id: 1406316678598873000
      id_str: "1406316678598873088"
      text: >-
        üí¨ medRxiv comment on "Reopening Italy's Schools in S..."


        "We thank Maurizio for the careful reading of our paper a‚Ä¶ https://t.co/tjifDZkyVj
      truncated: true
      entities:
        urls:
          - url: https://t.co/tjifDZkyVj
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 19 18:23:19 +0000 2021
      id: 1406316679576105000
      id_str: "1406316679576104962"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/cIRnxwxLG0
      truncated: false
      entities:
        urls:
          - url: https://t.co/cIRnxwxLG0
      in_reply_to_status_id: 1406316678598873000
      in_reply_to_status_id_str: "1406316678598873088"
- preprint:
    id: 125045
    metric: 109
    title: "An insight into neurotoxic and toxicity of spike fragments SARS-CoV-2 by
      exposure environment: A threat to aquatic health?"
    url: https://api.rxivist.org/v1/papers/125045
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.01.11.425914v1
    doi: 10.1101/2021.01.11.425914
    category: molecular-biology
    first_posted: 2021-01-13
    abstract: The Spike protein (S protein) is a critical component in the infection
      of the new coronavirus (SARS-CoV-2). The objective of this work was to
      evaluate whether peptides from S protein could cause negative impact in
      the aquatic animals. The aquatic toxicity of SARS-CoV-2 spike protein
      peptides derivatives has been evaluated in tadpoles (n = 50 tadpoles / 5
      replicates of 10 animals) from species Physalaemus cuvieri
      (Leptodactylidae). After synthesis, purification, and characterization of
      peptides (PSDP2001, PSDP2002, PSDP2003) an aquatic contamination has been
      simulatedwith these peptides during 24 hours of exposure in two
      concentrations (100 and 500 ng/mL). The control group (C) was composed of
      tadpoles kept in polyethylene containers containing de-chlorinated water.
      Oxidative stress, antioxidant biomarkers and neurotoxicity activity were
      assessed. In both concentrations, PSPD2002 and PSPD2003 increased catalase
      and superoxide dismutase antioxidants enzymes activities, as well as
      oxidative stress (nitrite levels, hydrogen peroxide and reactive oxygen
      species). All three peptides also increased acetylcholinesterase activity
      in the highest concentration. These peptides showed molecular interactions
      in silico with acetylcholinesterase and antioxidant enzymes. Aquatic
      particle contamination of SARS-CoV-2 has neurotoxics effects in P. cuvieri
      tadpoles. These findings indicate that the COVID-19 can constitute
      environmental impact or biological damage potential.
    authors:
      - name: Ives Charlie-Silva
      - name: Amanda Araujo
      - name: Abraao Guimaraes
      - name: Flavio Veras
      - name: Helyson Braz
      - name: Leticia Pontes
      - name: Roberta Jorge
      - name: Marco Belo
      - name: Bianca Fernandes
      - name: Rafael H. N√≥brega
      - name: Giovane Galdino
      - name: Antonio Condino-Neto
      - name: Jorge Galindo-Villegas
      - name: Glaucia Machodo-Santelli
      - name: Paulo Sanches
      - name: Rafael Rezende
      - name: Eduardo Cilli
      - name: Guilherme Malafaia
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sat Jun 19 20:15:46 +0000 2021
      id: 1406344978708807700
      id_str: "1406344978708807680"
      text: >-
        üî• bioRxiv Molecular-biology preprint by I. Charlie-Silva et al:


        "An insight into neurotoxic and toxicity of spike‚Ä¶ https://t.co/wIzVNG3Vdl
      truncated: true
      entities:
        urls:
          - url: https://t.co/wIzVNG3Vdl
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "109817"
    doi: 10.1101/2020.04.28.20083576
    first_posted: 2020-05-05
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.04.28.20083576v1
    url: https://api.rxivist.org/v1/papers/109817
    title: "Global Economic Cost of Deaths Attributable to Ambient Air Pollution:
      Disproportionate Burden on the Ageing Population"
    category: health-economics
    abstract: "Summary Background The health impacts of ambient air pollution impose
      large costs on society. While all people are exposed to air pollution,
      older individuals tend to be disproportionally affected. As a result,
      there is growing concern about the public health impacts of air pollution
      as many countries undergo rapid population ageing. We investigated the
      spatial and temporal variation in the health economic cost of deaths
      attributable to ambient air pollution, and its interaction with population
      ageing from 2000 to 2016 at global and regional levels. Methods We
      developed an age-adjusted measure of the value of a statistical life year
      (VSLY) to estimate the health economic cost attributable to ambient PM2.5
      pollution using the Global Burden of Disease 2017 data and country-level
      socioeconomic information. First, we estimated the global age- and
      cause-specific mortality and years of life lost (YLL) attributable to
      PM2.5 pollution using the global exposure mortality model (GEMM) and
      global estimates of exposure derived from ground monitoring, satellite
      retrievals and chemical transport model simulations at 0.1 by 0.1 degree
      (~11 km at the equator) resolution. Second, for each year between 2000 and
      2016, we translated the YLL within each age-group into a health-related
      economic cost using a country-specific, age-adjusted measure of VSLY.
      Third, we decomposed the major driving factors that contributed to the
      temporal change in health costs related to PM2.5. Finally, we conducted a
      sensitivity test to analyze the variability of the estimated health costs
      to four alternative valuation measures. We identified the uncertainty
      intervals (UIs) from 1000 draws of the parameters and exposure-response
      functions by age, cause, country and year. All economic values are
      reported in 2011 purchasing-power-parity-adjusted US dollars. Findings
      Globally, 8.42 million (95% UI: 6.50, 10.52) deaths and 163.68 million
      (116.03, 219.44) YLL were attributable to ambient PM2.5 in 2016. The
      average attributable mortality for the older population was 12 times
      higher than for those younger than 60 years old. In 2016, the global
      health economic cost of ambient PM2.5 pollution for the older population
      was US$2.40 trillion (1.89, 2.93) accounting for 59% of the cost for the
      total population. The health cost for the older population alone was
      equivalent to 2.1% (1.7%, 2.6%) of global gross domestic product (GDP) in
      2016. While the economic cost per capita for the older population was
      US$2739 (2160, 3345) in 2016, the cost per capita for the younger
      population was only US$268 (205, 335). From 2000 to 2016, the annual
      global health economic cost for the total population increased from
      US$2.37 trillion (1.88, 2.87) to US$4.09 trillion (3.19, 5.05).
      Decomposing the factors that contributed to the rise in health economic
      costs, we found that increases in GDP per capita, population ageing,
      population growth, age-specific mortality reduction, and PM2.5 exposure
      changed the total health economic cost by 77%, 21.2%, 15.6%, -41.1% and
      -0.2%, respectively. Compared to using an age-invariant VSLY or an
      age-invariant value of a statistical life (VSL), the estimates of the
      older population share of the total health economic cost using an
      age-adjusted VSLY was 2 and 18 percentage points lower, respectively.
      Interpretation The health economic cost borne by the older population
      almost doubled between 2000 and 2016, driven primarily by GDP growth,
      population ageing and population growth. Compared to younger individuals,
      air pollution leads to disproportionately higher health costs amongst the
      older population, even after accounting for their relatively shorter
      remaining life expectancy and increased disability. The age-specific
      estimates of health economic cost inform the optimal design of air
      pollution reduction strategies and allocation of healthcare resources. The
      positive relationship between age and economic costs suggests that
      countries with severe air pollution and rapid aging rates would
      particularly benefit from improving their air quality. In addition,
      strategies aimed at enhancing healthcare services, especially for the
      older population, may be beneficial for reducing the costs of ambient air
      pollution."
    authors:
      - name: Hao Yin
        orcid: http://orcid.org/0000-0002-8382-1239
      - name: Michael Brauer
        orcid: http://orcid.org/0000-0002-9103-9343
      - name: Junfeng (Jim) Zhang
        orcid: null
      - name: Wenjia Cai
        orcid: null
      - name: Stale Navrud
        orcid: http://orcid.org/0000-0002-6627-4595
      - name: Richard Burnett
        orcid: http://orcid.org/0000-0001-6772-4239
      - name: Courtney Howard
        orcid: null
      - name: Zhu Deng
        orcid: null
      - name: Daniel M. Kammen
        orcid: http://orcid.org/0000-0003-2984-7777
      - name: Hans Joachim Schellnhuber
        orcid: http://orcid.org/0000-0001-7453-4935
      - name: Kai Chen
        orcid: null
      - name: Haidong Kan
        orcid: http://orcid.org/0000-0002-1871-8999
      - name: Zhanming Chen
        orcid: null
      - name: Bin Chen
        orcid: null
      - name: Ning Zhang
        orcid: http://orcid.org/0000-0003-2775-1755
      - name: Zhifu Mi
        orcid: null
      - name: DMaris Coffman
        orcid: null
      - name: Yiming Wei
        orcid: null
      - name: Aaron Cohen
        orcid: http://orcid.org/0000-0002-4610-9912
      - name: Dabo Guan
        orcid: null
      - name: Qiang Zhang
        orcid: http://orcid.org/0000-0002-8359-3715
      - name: Peng Gong
        orcid: null
      - name: Zhu Liu
        orcid: http://orcid.org/0000-0002-1266-6059
  comment:
    dislikes: 0
    thread: "8008482879"
    numReports: 0
    likes: 0
    id: "5423342628"
    createdAt: 2021-06-17T16:13:50
    author:
      username: hao_yin
      about: ""
      name: Hao Yin
      isPowerContributor: false
      profileUrl: https://disqus.com/by/hao_yin/
      url: ""
      location: ""
      id: "371076485"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "Note: Contents in this draft are our preliminary results. The
      final results of this study are published on the journal, Lancet Planetary
      Health, please check out our online peer reviewed paper:
      https://doi.org/10.1016/S2542-5196(21)00131-5"
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.04.28.20083576v1
  tweets:
    - created_at: Sat Jun 19 20:19:36 +0000 2021
      id: 1406345944153604000
      id_str: "1406345944153604096"
      text: >-
        üí¨ medRxiv comment on "Global Economic Cost of Deaths..."


        "Note: Contents in this draft are our preliminary results‚Ä¶ https://t.co/s5yEwoG8rS
      truncated: true
      entities:
        urls:
          - url: https://t.co/s5yEwoG8rS
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 19 20:19:36 +0000 2021
      id: 1406345944963104800
      id_str: "1406345944963104770"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/kI6wKRNfJE
      truncated: false
      entities:
        urls:
          - url: https://t.co/kI6wKRNfJE
      in_reply_to_status_id: 1406345944153604000
      in_reply_to_status_id_str: "1406345944153604096"
- preprint:
    id: "136868"
    doi: 10.1101/2021.04.05.21254656
    first_posted: 2021-04-07
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.04.05.21254656v1
    url: https://api.rxivist.org/v1/papers/136868
    title: Glucocorticoids and B Cell Depleting Agents Substantially Impair
      Immunogenicity of mRNA Vaccines to SARS-CoV-2
    category: infectious-diseases
    abstract: >-
      BackgroundIndividuals with chronic inflammatory diseases (CID) are
      frequently treated with immunosuppressive medications that can increase
      their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2
      vaccination platforms provide robust protection in immunocompetent
      individuals, the immunogenicity in CID patients on immunosuppression is
      not well established. Therefore, determining the effectiveness of
      SARS-CoV-2 vaccines in the setting of immunosuppression is essential to
      risk-stratify CID patients with impaired protection and provide clinical
      guidance regarding medication management.


      MethodsWe conducted a prospective assessment of mRNA-based vaccine immunogenicity in 133 adults with CIDs and 53 immunocompetent controls. Blood from participants over 18 years of age was collected before initial immunization and 1-2 weeks after the second immunization. Serum anti-SARS-CoV-2 spike (S) IgG+ binding, neutralizing antibody titers, and circulating S-specific plasmablasts were quantified to assess the magnitude and quality of the humoral response following vaccination.


      ResultsCompared to immunocompetent controls, a three-fold reduction in anti-S IgG titers (P=0.009) and SARS-CoV-2 neutralization (p<0.0001) were observed in CID patients. B cell depletion and glucocorticoids exerted the strongest effect with a 36- and 10-fold reduction in humoral responses, respectively (p<0.0001). Janus kinase inhibitors and antimetabolites, including methotrexate, also blunted antibody titers in multivariate regression analysis (P<0.0001, P=0.0023, respectively). Other targeted therapies, such as TNF inhibitors, IL-12/23 inhibitors, and integrin inhibitors, had only modest impacts on antibody formation and neutralization.


      ConclusionsCID patients treated with immunosuppressive therapies exhibit impaired SARS-CoV-2 vaccine-induced immunity, with glucocorticoids and B cell depletion therapy more severely impeding optimal responses.
    authors:
      - name: Parakkal Deepak
        orcid: http://orcid.org/0000-0002-3436-9784
      - name: Wooseob Kim
        orcid: http://orcid.org/0000-0002-9199-1000
      - name: Michael A Paley
        orcid: http://orcid.org/0000-0001-8724-3176
      - name: Monica Yang
        orcid: http://orcid.org/0000-0002-2693-3648
      - name: Alexander B Carvidi
        orcid: null
      - name: Alia A El-Qunni
        orcid: http://orcid.org/0000-0003-0212-8094
      - name: Alem Haile
        orcid: null
      - name: Katherine Huang
        orcid: http://orcid.org/0000-0002-5013-4790
      - name: Baylee Kinnett
        orcid: null
      - name: Mariel J. Liebeskind
        orcid: http://orcid.org/0000-0003-4595-0651
      - name: Zhuoming Liu
        orcid: http://orcid.org/0000-0001-8198-0976
      - name: Lily E McMorrow
        orcid: http://orcid.org/0000-0003-2823-5859
      - name: Diane Paez
        orcid: null
      - name: Dana C Perantie
        orcid: http://orcid.org/0000-0002-6380-8133
      - name: Rebecca E Schriefer
        orcid: http://orcid.org/0000-0002-7430-0626
      - name: Shannon Sides
        orcid: null
      - name: Mahima Thapa
        orcid: null
      - name: Mate Gergely
        orcid: null
      - name: Suha Abushamma
        orcid: null
      - name: Micahel Kelbert
        orcid: null
      - name: Lynne Mitchell
        orcid: null
      - name: Billy Nix
        orcid: null
      - name: Jonathan D Graf
        orcid: null
      - name: Kimberly E Taylor
        orcid: http://orcid.org/0000-0001-6848-9074
      - name: Salim Chahin
        orcid: http://orcid.org/0000-0002-4115-4300
      - name: Matthew A Ciorba
        orcid: http://orcid.org/0000-0002-7656-0982
      - name: Patricia A Katz
        orcid: http://orcid.org/0000-0002-8146-2519
      - name: Mehrdad Matloubian
        orcid: http://orcid.org/0000-0001-6233-985X
      - name: Jane A O'Halloran
        orcid: http://orcid.org/0000-0001-8265-9471
      - name: Rachel M Presti
        orcid: http://orcid.org/0000-0002-5469-0727
      - name: Gregory F Wu
        orcid: http://orcid.org/0000-0003-3588-0637
      - name: Sean P. J. Whelan
        orcid: http://orcid.org/0000-0003-1564-8590
      - name: William J Buchser
        orcid: http://orcid.org/0000-0002-6675-6359
      - name: Lianne S Gensler
        orcid: http://orcid.org/0000-0001-6314-5336
      - name: Mary C Nakamura
        orcid: http://orcid.org/0000-0001-8127-9426
      - name: Ali H. Ellebedy
        orcid: http://orcid.org/0000-0002-6129-2532
      - name: Alfred HJ Kim
        orcid: http://orcid.org/0000-0003-4074-0516
  comment:
    dislikes: 0
    thread: "8468746386"
    numReports: 0
    likes: 0
    id: "5423049484"
    createdAt: 2021-06-17T11:47:05
    author:
      username: disqus_oK7rXbxiph
      about: ""
      name: Jay
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_oK7rXbxiph/
      url: ""
      location: ""
      id: "371065969"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: |-
      What are the doses or the duration of the treatment with glucocorticoids
       of this study? I'm in a middle of a prednisona treatment I will get the
       Pfizer vaccine in a few days. I have a cycle of 50mg x3days, 30mg 
      x3days, 15mgx3 days and 5mg x2months and I want to know if it's better 
      now (15mg) or next week with 5mg but more time with the treatment.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.04.05.21254656v1
  tweets:
    - created_at: Sat Jun 19 22:18:47 +0000 2021
      id: 1406375939160871000
      id_str: "1406375939160870918"
      text: >-
        üí¨ medRxiv comment on "Glucocorticoids and B Cell Dep..."


        "What are the doses or the duration of the treatment with‚Ä¶ https://t.co/PdbdBZzcaH
      truncated: true
      entities:
        urls:
          - url: https://t.co/PdbdBZzcaH
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 19 22:18:47 +0000 2021
      id: 1406375940003971000
      id_str: "1406375940003971077"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/zdork41vHy
      truncated: false
      entities:
        urls:
          - url: https://t.co/zdork41vHy
      in_reply_to_status_id: 1406375939160871000
      in_reply_to_status_id_str: "1406375939160870918"
- preprint:
    id: "113637"
    doi: 10.1101/2020.07.03.20145797
    first_posted: 2020-07-06
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.07.03.20145797v1
    url: https://api.rxivist.org/v1/papers/113637
    title: Dengue antibodies can cross-react with SARS-CoV-2 and vice versa-Antibody
      detection kits can give false-positive results for both viruses in regions
      where both COVID-19 and Dengue co-exist
    category: infectious-diseases
    abstract: Five of thirteen Dengue antibody- positive serum samples, dated 2017
      (pre-dating the COVID-19 outbreak) produced false-positive results in
      SARS-CoV-2 IgG/IgM rapid strip tests. Our results emphasize the importance
      of NAT and/or virus antigen tests to complement sero-surveillance for
      definitive diagnosis of COVID-19/Dengue in regions where both viruses are
      co-endemic.
    authors:
      - name: Himadri Nath
        orcid: http://orcid.org/0000-0003-2213-6278
      - name: Abinash Mallick
        orcid: http://orcid.org/0000-0002-3837-4935
      - name: Subrata Roy
        orcid: http://orcid.org/0000-0002-3031-6116
      - name: Soumi Sukla
        orcid: http://orcid.org/0000-0003-2267-8595
      - name: Keya Basu
        orcid: http://orcid.org/0000-0002-3960-2469
      - name: Abhishek De
        orcid: http://orcid.org/0000-0001-5998-2430
      - name: Subhajit Biswas
        orcid: http://orcid.org/0000-0002-9001-7150
  comment:
    dislikes: 0
    thread: "8112723131"
    numReports: 0
    likes: 0
    id: "5422971348"
    createdAt: 2021-06-17T09:47:55
    author:
      username: disqus_boDeDSYRlm
      about: ""
      name: Subhajit Biswas
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_boDeDSYRlm/
      url: https://iicb.res.in/faculty/subhajit-biswas
      location: Kolkata, India
      id: "353187409"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Dear Readers,


      I am pleased to inform you that the above preprint posted in <b>medRxiv</b> has now been accepted and published by the "<b>Journal of Medical Microbiology</b>". Please see link below:


      Title: <b>Archived dengue serum samples produced false-positive results in SARS-CoV-2 lateral flow-based rapid antibody tests</b>


      Link: https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.001369


      Best wishes to all; stay safe.


      Yours sincerely,

      Subhajit Biswas (Corresponding Author).
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.07.03.20145797v1
  tweets:
    - created_at: Sun Jun 20 01:04:23 +0000 2021
      id: 1406417613031366700
      id_str: "1406417613031366657"
      text: |-
        üí¨ medRxiv comment on "Dengue antibodies can cross-re..."

        "Dear Readers,

        I am pleased to inform you that the above‚Ä¶ https://t.co/WaZJULiKq3
      truncated: true
      entities:
        urls:
          - url: https://t.co/WaZJULiKq3
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 20 01:04:23 +0000 2021
      id: 1406417613874413600
      id_str: "1406417613874413569"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/SGdsWjiVuU
      truncated: false
      entities:
        urls:
          - url: https://t.co/SGdsWjiVuU
      in_reply_to_status_id: 1406417613031366700
      in_reply_to_status_id_str: "1406417613031366657"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 0
    id: "5422545038"
    createdAt: 2021-06-16T22:39:24
    author:
      username: johnartuli
      about: ""
      name: John Artuli
      isPowerContributor: false
      profileUrl: https://disqus.com/by/johnartuli/
      url: ""
      location: ""
      id: "369312159"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: There are two other large post-exposure prophylaxis trials which
      showed no benefit of HCQ (Mitja NEJM; Barnabas CID).   The post-hoc
      analyses of the Boulware NEJM seems a likely over interpretation of small
      subgroups -- which are not able to be replicated in the other
      trials.  This is common in post-hoc analyses.   In large datasets, one can
      find a subgroup who do better, but is it true?  If true, one should be
      able to replicate in other trials.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Sun Jun 20 12:30:01 +0000 2021
      id: 1406590159336976400
      id_str: "1406590159336976386"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "There are two other large post-exposure prophylaxis tria‚Ä¶ https://t.co/75DELYCUXC
      truncated: true
      entities:
        urls:
          - url: https://t.co/75DELYCUXC
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 20 12:30:02 +0000 2021
      id: 1406590160192606200
      id_str: "1406590160192606208"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1406590159336976400
      in_reply_to_status_id_str: "1406590159336976386"
- preprint:
    id: "146219"
    doi: 10.1101/2021.06.15.21258346
    first_posted: 2021-06-15
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.15.21258346v1
    url: https://api.rxivist.org/v1/papers/146219
    title: "Antibody response after a single dose of ChAdOx1-nCOV (Covishield)
      vaccine in subjects with prior SARS-CoV2 infection: Is a single dose
      sufficient?"
    category: infectious-diseases
    abstract: "It is crucial to know whether a single dose of vaccine against
      SARS-CoV-2 is sufficient to elicit immune response in previously infected
      people in India. A total of 121 participants (baseline seropositive 46 and
      seronegative 75) were included to study the immune response to
      ChAdOx1-nCOV (Covishield) vaccine in previously infected or uninfected
      people. IgG antibodies were estimated at three different time intervals,
      i.e. pre-vaccination, 25-35 days post 1st vaccination and 25-35 days post
      2nd vaccination. The IgG antibody titre was significantly high among
      previous seropositive subjects with single dose of vaccine compared to
      seronegative group with both doses of vaccine respectively
      (Mean:4.59,SD:1.04 vs Mean:3.08 SD:1.22, p-value: <0.0001). In conclusion,
      a single dose of Covishield vaccine might be sufficient to induce an
      effective immune response n subjects with prior SARS-CoV2 infection.
      Stratifying vacinees based on their SARS-CoV2 IgG antibody titre before
      vaccination would help in meeting the increasing vaccine demand and could
      be effective to circumvent further wave of the pandemic in India."
    authors:
      - name: Biswajyoti Borkakoty
        orcid: null
      - name: Mandakini Das Sarmah
        orcid: null
      - name: Chandra Kanta Bhattacharjee
        orcid: null
      - name: Nargis Bali
        orcid: null
      - name: Gayatri Gogoi
        orcid: null
  comment:
    dislikes: 0
    thread: "8595892758"
    numReports: 0
    likes: 0
    id: "5422519244"
    createdAt: 2021-06-16T22:10:09
    author:
      username: disqus_Mhs4dqSRaR
      about: ""
      name: Alberto
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_Mhs4dqSRaR/
      url: ""
      location: ""
      id: "291576185"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      What the figures show is not well explained in the abstract or the text
      itself. Basically they show that people who were previously infected had a
      level of antibodies at baseline (prior to vaccination) which is roughly
      equal to those not previously infected after two doses. After one dose,
      they exceed that level.



      Furthermore it also shows that most of the persons not previously infected don't benefit from a second dose, since the average is roughly the same after one and two doses. Only a small subset of the subjects seem to get some benefit from a second dose.



      Therefor, it seems a more logical conclusion that persons previously infected should not need to take the vaccine and that people previously infected should take just one dose (with a few exceptions).



      Always remember that in medicine, when you need to take something you should take it. But when you don't need to take it, you shouldn't take it.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.15.21258346v1
  tweets:
    - created_at: Sun Jun 20 14:17:23 +0000 2021
      id: 1406617177906684000
      id_str: "1406617177906683914"
      text: >-
        üí¨ medRxiv comment on "Antibody response after a sing..."


        "What the figures show is not well explained in the abstr‚Ä¶ https://t.co/QGYsoVkJGg
      truncated: true
      entities:
        urls:
          - url: https://t.co/QGYsoVkJGg
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 20 14:17:23 +0000 2021
      id: 1406617178904928300
      id_str: "1406617178904928256"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/2POKShETLv
      truncated: false
      entities:
        urls:
          - url: https://t.co/2POKShETLv
      in_reply_to_status_id: 1406617177906684000
      in_reply_to_status_id_str: "1406617177906683914"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5422515740"
    createdAt: 2021-06-16T22:06:17
    author:
      username: disqus_ZS1wI1aZfw
      about: ""
      name: thomas
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_ZS1wI1aZfw/
      url: ""
      location: ""
      id: "173366461"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: I got the idea from people in the comments. They are suggesting
      that the recommendations from this study are wrong, and people who have
      had COVID need to get the vax. That would imply that people aren't getting
      immunity naturally, or that natural immunity is inferior. That's all my
      first question was about.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Sun Jun 20 16:31:08 +0000 2021
      id: 1406650838873825300
      id_str: "1406650838873825285"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "I got the idea from people in the comments. They are sug‚Ä¶ https://t.co/9YlaO6Pglo
      truncated: true
      entities:
        urls:
          - url: https://t.co/9YlaO6Pglo
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 20 16:31:09 +0000 2021
      id: 1406650839897280500
      id_str: "1406650839897280514"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmfcNF6
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmfcNF6
      in_reply_to_status_id: 1406650838873825300
      in_reply_to_status_id_str: "1406650838873825285"
- preprint:
    id: "144531"
    doi: 10.1101/2021.05.28.21257602
    first_posted: 2021-06-02
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21257602v1
    url: https://api.rxivist.org/v1/papers/144531
    title: "Prevalence of persistent symptoms in children during the COVID-19
      pandemic: evidence from a household cohort study in England and Wales"
    category: pediatrics
    abstract: Using data from 4678 children participating in VirusWatch, a UK
      household cohort study, we estimated the prevalence of persistent symptoms
      as 1.7%, and 4.6% in children with a history of SARS-CoV-2 infection.
      Persistent symptoms prevalence was higher in girls, teenagers and children
      with long-term conditions.
    authors:
      - name: Faith Miller
        orcid: null
      - name: Vincent Nguyen
        orcid: null
      - name: Annalan MD Navaratnam
        orcid: null
      - name: Madhumita Shrotri
        orcid: http://orcid.org/0000-0001-9791-122X
      - name: Jana Kovar
        orcid: null
      - name: Andrew C Hayward
        orcid: null
      - name: Ellen Benard Fragaszy
        orcid: http://orcid.org/0000-0002-0178-6098
      - name: Robert William Aldridge
        orcid: http://orcid.org/0000-0003-0542-0816
      - name: Virus Watch Collaborative
        orcid: null
      - name: Pia Hardelid
        orcid: http://orcid.org/0000-0002-0154-1306
  comment:
    dislikes: 0
    thread: "8569851205"
    numReports: 0
    likes: 0
    id: "5422463379"
    createdAt: 2021-06-16T21:14:35
    author:
      username: disqus_rVRQnS9tHX
      about: ""
      name: Amanda
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_rVRQnS9tHX/
      url: ""
      location: ""
      id: "63796687"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      hi -  i think there is a typo!  This says 8/174 -- yet earlier it said
      175.


      The overall prevalence of persistent symptoms was 1.7% (80/4678 children; 95% CI 1.4%, 2.1%), and 4.6% (8/174 children; 95% CI 2.0%, 8.9%) in children who had a history of SARS-CoV-2 infection before persistent symptom onset.


      Also ages 2-11 were overrepresented versus 12-17
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21257602v1
  tweets:
    - created_at: Sun Jun 20 18:23:15 +0000 2021
      id: 1406679050798743600
      id_str: "1406679050798743552"
      text: >-
        üí¨ medRxiv comment on "Prevalence of persistent sympt..."


        "hi -  i think there is a typo!  This says 8/174 -- yet e‚Ä¶ https://t.co/oXdqVDqmU6
      truncated: true
      entities:
        urls:
          - url: https://t.co/oXdqVDqmU6
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 20 18:23:15 +0000 2021
      id: 1406679051616542700
      id_str: "1406679051616542729"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/aTbggLf7Td
      truncated: false
      entities:
        urls:
          - url: https://t.co/aTbggLf7Td
      in_reply_to_status_id: 1406679050798743600
      in_reply_to_status_id_str: "1406679050798743552"
- preprint:
    id: 146647
    metric: 11
    title: Multiplexed bioluminescence microscopy via phasor analysis
    url: https://api.rxivist.org/v1/papers/146647
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.18.448905v1
    doi: 10.1101/2021.06.18.448905
    category: bioengineering
    first_posted: 2021-06-18
    abstract: Microscopic bioluminescence imaging has been historically challenging
      due to a lack of detection methods and easily resolved probes. Here we
      combine bioluminescence with phasor analysis, an optical method commonly
      used to distinguish spectrally similar fluorophores. Bioluminescent phasor
      enabled rapid differentiation of multiple luciferase reporters and
      resonance energy transfer processes. The merger of bioluminescence and
      phasor analysis provides a platform for routine, time-lapse imaging of
      collections of cellular features.
    authors:
      - name: Zi Yao
      - name: Caroline K. Brennan
      - name: Lorenzo Scipioni
      - name: Hongtao Chen
      - name: Kevin Ng
      - name: Michelle Digman
      - name: Jennifer A. Prescher
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sun Jun 20 20:15:36 +0000 2021
      id: 1406707325776371700
      id_str: "1406707325776371714"
      text: >-
        üî• bioRxiv Bioengineering preprint by Z. Yao et al:


        "Multiplexed bioluminescence microscopy via phasor analysis"‚Ä¶ https://t.co/tc3QcsSZJ3
      truncated: true
      entities:
        urls:
          - url: https://t.co/tc3QcsSZJ3
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "145889"
    doi: 10.1101/2021.06.10.21258647
    first_posted: 2021-06-13
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.10.21258647v1
    url: https://api.rxivist.org/v1/papers/145889
    title: Seasonal variation in SARS-CoV-2 transmission in temperate climates
    category: epidemiology
    abstract: "While seasonal variation has a known influence on the transmission of
      several respiratory viral infections, its role in SARS-CoV-2 transmission
      remains unclear. As previous analyses have not accounted for the
      implementation of non-pharmaceutical interventions (NPIs) in the first
      year of the pandemic, they may yield biased estimates of seasonal effects.
      Building on two state-of-the-art observational models and datasets, we
      adapt a fully Bayesian method for estimating the association between
      seasonality and transmission in 143 temperate European regions. We find
      strong seasonal patterns, consistent with a reduction in the time-variable
      Rt of 42.1% (95% CI: 24.7% - 53.4%) from the peak of winter to the peak of
      summer. These results imply that the seasonality of SARS-CoV-2
      transmission is comparable in magnitude to the most effective individual
      NPIs but less than the combined effect of multiple interventions."
    authors:
      - name: Tomas Gavenciak
        orcid: http://orcid.org/0000-0003-1119-2426
      - name: Joshua Teperowski Monrad
        orcid: http://orcid.org/0000-0002-7377-2074
      - name: Gavin Leech
        orcid: http://orcid.org/0000-0002-9298-1488
      - name: Mrinank Sharma
        orcid: http://orcid.org/0000-0002-4304-7963
      - name: S√∂ren Mindermann
        orcid: http://orcid.org/0000-0002-0315-9821
      - name: Jan Markus Brauner
        orcid: http://orcid.org/0000-0002-1588-5724
      - name: Samir Bhatt
        orcid: http://orcid.org/0000-0002-0891-4611
      - name: Jan Kulveit
        orcid: http://orcid.org/0000-0002-3791-8355
  comment:
    dislikes: 0
    thread: "8590472452"
    numReports: 0
    likes: 0
    id: "5422312410"
    createdAt: 2021-06-16T19:10:44
    author:
      username: jindrichweiss
      about: ""
      name: J W
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jindrichweiss/
      url: ""
      location: ""
      id: "338108045"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      ad 1, I am not sure how compatible the studies are. I understand Your
      explanation of the differencies, still they can work as underlying set
      only if done with exact same interventions, same countries etc

      ad 2 My mistake, did not realise the early end of the second study, it just shows how pure data are on the whole year, taking into account the gradual spread and chaotic treatment of the first year and the variants evolved later

      ad 3 Sure, if You do not have any other idea and no supporting data how to incorporate a would be periodic behaviour, cos(t) may be the first choice. However, with the multicountry studies You indeed have a reasonable data not only on seasonality, but also on the differences between each of them.  You can use the daily temperatures and percentage of local sunshine hours. It is just a pitty not to use them and not to see the fundamental driving force.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.10.21258647v1
  tweets:
    - created_at: Sun Jun 20 20:19:21 +0000 2021
      id: 1406708270673404000
      id_str: "1406708270673403907"
      text: >-
        üí¨ medRxiv comment on "Seasonal variation in SARS-CoV..."


        "ad 1, I am not sure how compatible the studies are. I un‚Ä¶ https://t.co/wTJTBtgfRS
      truncated: true
      entities:
        urls:
          - url: https://t.co/wTJTBtgfRS
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 20 20:19:21 +0000 2021
      id: 1406708271386402800
      id_str: "1406708271386402824"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/Bv6GzFFKho
      truncated: false
      entities:
        urls:
          - url: https://t.co/Bv6GzFFKho
      in_reply_to_status_id: 1406708270673404000
      in_reply_to_status_id_str: "1406708270673403907"
- preprint:
    id: "137532"
    doi: 10.1101/2021.04.10.21254672
    first_posted: 2021-04-12
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.04.10.21254672v1
    url: https://api.rxivist.org/v1/papers/137532
    title: "Inhaled budesonide for COVID-19 in people at higher risk of adverse
      outcomes in the community: interim analyses from the PRINCIPLE trial"
    category: primary-care-research
    abstract: BACKGROUND Inhaled budesonide has shown efficacy for treating COVID-19
      in the community but has not yet been tested in effectiveness trials.
      METHODS We performed a multicenter, open-label, multi-arm, adaptive
      platform randomized controlled trial involving people aged [&ge;]65 years,
      or [&ge;]50 years with comorbidities, and unwell [&le;]14 days with
      suspected COVID-19 in the community (PRINCIPLE). Participants were
      randomized to usual care, usual care plus inhaled budesonide (800g twice
      daily for 14 days), or usual care plus other interventions. The co-primary
      endpoints are time to first self-reported recovery, and
      hospitalization/death related to COVID-19, both measured over 28 days from
      randomisation and analysed using Bayesian models. RESULTS The trial opened
      on April 2, 2020. Randomization to inhaled budesonide began on November
      27, 2020 and was stopped on March 31, 2021 based on an interim analysis
      using data from March 4, 2021. Here, we report updated interim analysis
      data from March 25, 2021, at which point the trial had randomized 4663
      participants with suspected COVID-19. Of these, 2617 (56.1%) tested
      SARS-CoV-2 positive and contributed data to this interim budesonide
      primary analysis; 751 budesonide, 1028 usual care and 643 to other
      interventions. Time to first self-reported recovery was shorter in the
      budesonide group compared to usual care (hazard ratio 1.208 [95% BCI 1.076
      - 1.356], probability of superiority 0.999, estimated benefit [95% BCI] of
      3.011 [1.134 - 5.41] days). Among those in the interim budesonide primary
      analysis who had the opportunity to contribute data for 28 days follow up,
      there were 59/692 (8.5%) COVID-19 related hospitalizations/deaths in the
      budesonide group vs 100/968 (10.3%) in the usual care group (estimated
      percentage benefit, 2.1% [95% BCI -0.7% - 4.8%], probability of
      superiority 0.928). CONCLUSIONS In this updated interim analysis, inhaled
      budesonide reduced time to recovery by a median of 3 days in people with
      COVID-19 with risk factors for adverse outcomes. Once 28 day follow up is
      complete for all participants randomized to budesonide, final analyses of
      time to recovery and hospitalization/death will be published. (Funded by
      the National Institute of Health Research/ United Kingdom Research
      Innovation [MC_PC_19079]; PRINCIPLE ISRCTN number, ISRCTN86534580.)
    authors:
      - name: The PRINCIPLE Trial Collaborative Group
        orcid: null
      - name: Ly-Mee Yu
        orcid: http://orcid.org/0000-0003-0331-7364
      - name: Mona Bafadhel
        orcid: http://orcid.org/0000-0002-9993-2478
      - name: Jienchi Dorward
        orcid: http://orcid.org/0000-0001-6072-1430
      - name: Gail Hayward
        orcid: http://orcid.org/0000-0003-0852-627X
      - name: Benjamin R Saville
        orcid: null
      - name: Oghenekome Gbinigie
        orcid: http://orcid.org/0000-0002-2963-4491
      - name: Oliver van Hecke
        orcid: http://orcid.org/0000-0002-6229-5057
      - name: Emma Ogburn
        orcid: http://orcid.org/0000-0001-7643-572X
      - name: Philip H Evans
        orcid: http://orcid.org/0000-0002-5277-3545
      - name: Nicholas PB Thomas
        orcid: http://orcid.org/0000-0003-0460-6870
      - name: Mahendra G Patel
        orcid: http://orcid.org/0000-0001-6703-3542
      - name: Nicholas Berry
        orcid: http://orcid.org/0000-0001-8701-3258
      - name: Michelle A. Detry
        orcid: http://orcid.org/0000-0002-2794-1439
      - name: Christina T. Saunders
        orcid: http://orcid.org/0000-0003-4325-9568
      - name: Mark Fitzgerald
        orcid: http://orcid.org/0000-0002-8912-1663
      - name: Victoria Harris
        orcid: http://orcid.org/0000-0002-3345-2826
      - name: Simon de Lusignan
        orcid: http://orcid.org/0000-0002-8553-2641
      - name: Monique I Andersson
        orcid: http://orcid.org/0000-0003-0619-1074
      - name: Peter J Barnes
        orcid: null
      - name: Richard EK Russell
        orcid: http://orcid.org/0000-0002-3890-7201
      - name: Dan V Nicolau
        orcid: http://orcid.org/0000-0002-7758-226X
      - name: Sanjay Ramakrishnan
        orcid: http://orcid.org/0000-0002-3003-7918
      - name: FD Richard Hobbs
        orcid: http://orcid.org/0000-0001-7976-7172
      - name: Christopher C Butler
        orcid: http://orcid.org/0000-0002-0102-3453
  comment:
    dislikes: 0
    thread: "8474798347"
    numReports: 0
    likes: 0
    id: "5422254081"
    createdAt: 2021-06-16T18:24:27
    author:
      username: disqus_xQiC0jt6OF
      about: ""
      name: David McAllister
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_xQiC0jt6OF/
      url: ""
      location: ""
      id: "249320956"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Given that randomisation to budesonide was stopped in March, are we
      expecting the updated findings soon?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.04.10.21254672v1
  tweets:
    - created_at: Sun Jun 20 22:19:04 +0000 2021
      id: 1406738395444007000
      id_str: "1406738395444006921"
      text: >-
        üí¨ medRxiv comment on "Inhaled budesonide for COVID-1..."


        "Given that randomisation to budesonide was stopped in Ma‚Ä¶ https://t.co/46Kl3RIVxr
      truncated: true
      entities:
        urls:
          - url: https://t.co/46Kl3RIVxr
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 20 22:19:04 +0000 2021
      id: 1406738396303741000
      id_str: "1406738396303740930"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/JvKM41Z00e
      truncated: false
      entities:
        urls:
          - url: https://t.co/JvKM41Z00e
      in_reply_to_status_id: 1406738395444007000
      in_reply_to_status_id_str: "1406738395444006921"
- preprint:
    id: "137196"
    doi: 10.1101/2021.04.06.21254882
    first_posted: 2021-04-09
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.04.06.21254882v1
    url: https://api.rxivist.org/v1/papers/137196
    title: Evidence for increased breakthrough rates of SARS-CoV-2 variants of
      concern in BNT162b2 mRNA vaccinated individuals
    category: epidemiology
    abstract: The SARS-CoV-2 pandemic has been raging for over a year, creating
      global detrimental impact. The BNT162b2 mRNA vaccine has demonstrated high
      protection levels, yet apprehension exists that several variants of
      concerns (VOCs) can surmount the immune defenses generated by the
      vaccines. Neutralization assays have revealed some reduction in
      neutralization of VOCs B.1.1.7 and B.1.351, but the relevance of these
      assays in real life remains unclear. Here, we performed a case-control
      study that examined whether BNT162b2 vaccinees with documented SARS-CoV-2
      infection were more likely to become infected with B.1.1.7 or B.1.351
      compared with unvaccinated individuals. Vaccinees infected at least a week
      after the second dose were disproportionally infected with B.1.351 (odds
      ratio of 8:1). Those infected between two weeks after the first dose and
      one week after the second dose, were disproportionally infected by B.1.1.7
      (odds ratio of 26:10), suggesting reduced vaccine effectiveness against
      both VOCs under different dosage/timing conditions. Nevertheless, the
      B.1.351 incidence in Israel to-date remains low and vaccine effectiveness
      remains high against B.1.1.7, among those fully vaccinated. These results
      overall suggest that vaccine breakthrough infection is more frequent with
      both VOCs, yet a combination of mass-vaccination with two doses coupled
      with non-pharmaceutical interventions control and contain their spread.
    authors:
      - name: Talia Kustin
        orcid: http://orcid.org/0000-0001-5677-4150
      - name: Noam Harel
        orcid: http://orcid.org/0000-0002-6034-3801
      - name: Uriah Finkel
        orcid: null
      - name: Shay Perchik
        orcid: null
      - name: Sheri Harari
        orcid: null
      - name: Maayan Tahor
        orcid: null
      - name: Itamar Caspi
        orcid: null
      - name: Rachel Levy
        orcid: null
      - name: Michael Leschinsky
        orcid: null
      - name: Shifra Ken Dror
        orcid: null
      - name: Galit Bergerzon
        orcid: null
      - name: Hala Gadban
        orcid: null
      - name: Faten Gadban
        orcid: null
      - name: Eti Eliassian
        orcid: null
      - name: Orit Shimron
        orcid: null
      - name: Loulou Saleh
        orcid: null
      - name: Haim Ben-Zvi
        orcid: null
      - name: Doron Amichay
        orcid: null
      - name: Anat Ben-Dor
        orcid: null
      - name: Dana Sagas
        orcid: null
      - name: Merav Strauss
        orcid: null
      - name: Yonat Shemer Avni
        orcid: null
      - name: Amit Huppert
        orcid: http://orcid.org/0000-0002-3306-185X
      - name: Eldad Kepten
        orcid: null
      - name: Ran D. Balicer
        orcid: http://orcid.org/0000-0002-7783-6362
      - name: Doron Nezer
        orcid: null
      - name: Shay Ben-Shachar
        orcid: null
      - name: Adi Stern
        orcid: http://orcid.org/0000-0002-2919-3542
  comment:
    dislikes: 1
    thread: "8480741529"
    numReports: 0
    likes: 0
    id: "5422220621"
    createdAt: 2021-06-16T17:57:15
    author:
      username: disqus_NWAizRoMaq
      about: ""
      name: Harley Cole
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_NWAizRoMaq/
      url: ""
      location: ""
      id: "371033008"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Did you miss this part?? P.S Fauci has NEVER been right from the
      beginning. " We performed a case-control study that examined the
      distribution of SARS-CoV-2 variants observed in infections of vaccinated
      individuals (‚Äúbreakthrough cases‚Äù) and matched infections of unvaccinated
      individuals. We hypothesized that if there is lower vaccine effectiveness
      against one of the VOCs, its proportion among the breakthrough cases
      should be higher than among unvaccinated cases."
    forum: medrxiv
    points: -1
    link: https://www.medrxiv.org/content/10.1101/2021.04.06.21254882v2
  tweets:
    - created_at: Mon Jun 21 01:06:26 +0000 2021
      id: 1406780518256029700
      id_str: "1406780518256029702"
      text: >-
        üí¨ medRxiv comment on "Evidence for increased breakth..."


        "Did you miss this part?? P.S Fauci has NEVER been right‚Ä¶ https://t.co/CxatHBuIWQ
      truncated: true
      entities:
        urls:
          - url: https://t.co/CxatHBuIWQ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 21 01:06:27 +0000 2021
      id: 1406780519149408300
      id_str: "1406780519149408256"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/c9MZWrtLby
      truncated: false
      entities:
        urls:
          - url: https://t.co/c9MZWrtLby
      in_reply_to_status_id: 1406780518256029700
      in_reply_to_status_id_str: "1406780518256029702"
- preprint:
    id: "120702"
    doi: 10.1101/2020.12.07.414144
    first_posted: 2020-12-08
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.12.07.414144v1
    url: https://api.rxivist.org/v1/papers/120702
    title: Cortical depth-dependent human fMRI of resting-state networks using EPIK
    category: neuroscience
    abstract: Recent laminar-fMRI studies have provided substantial understanding of
      the evoked cortical responses in multiple sub-systems; in contrast, the
      laminar component of resting-state networks spread over the whole brain
      remains largely unknown. Here, we used EPIK, which offers unprecedented
      coverage at sub-millimetre resolution, to investigate cortical broad
      resting-state dynamics with depth specificity. After verifying laminar
      activation profiles in response to a motor task, we observed that the
      amplitude of the resting state fluctuations was larger in the superficial
      layers of the cortical ribbon, and that these superficial layers had a
      stronger local functional connectivity (regional homogeneity) in sulci but
      not in gyri. Cortical-depth dependent correlation and coherence analysis
      revealed that resting-state connections involved mostly the supragranular
      layers of the cortex, although the preferred laminae through which
      networks communicated was variable. Using a second resting-state scan as
      control data and comparing the results obtained during task performance
      with the resting-state condition, we identified a modified distribution of
      layer-specific responses that seemed dependent on brain state, both in the
      ROIs presumably involved in the motor task, and in those supporting
      resting-state networks. Whole-brain evaluation of laminar-fMRI encompasses
      unprecedented computational challenges; nonetheless, it enables a new
      dimension of the human cerebral cortex to be investigated from a global
      view, which may be key in the characterization of neurological disorders
      from a novel perspective.
    authors:
      - name: Patricia Pais-Roldan
        orcid: http://orcid.org/0000-0002-9381-3048
      - name: Seong Dae Yun
        orcid: http://orcid.org/0000-0001-7398-1899
      - name: Nicola Palomero-Gallagher
        orcid: http://orcid.org/0000-0003-4463-8578
      - name: Jon N Shah
        orcid: http://orcid.org/0000-0002-8151-6169
  comment:
    dislikes: 0
    thread: "8390205801"
    numReports: 0
    likes: 0
    id: "5427400589"
    createdAt: 2021-06-21T07:56:54
    author:
      username: patriciapaisroldan
      about: ""
      name: Patricia Pais-Roldan
      isPowerContributor: false
      profileUrl: https://disqus.com/by/patriciapaisroldan/
      url: ""
      location: ""
      id: "371242288"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Dear Sebastian Dresbach, Lonike Faes, Johannes Franz, Omer Faruk Gulban, 

      Renzo Huber, Miriam Heynckes, Alessandra Pizzuti and Till Steinbach,



      Thank you very much for your detailed revision of our article and the kind words of appreciation. We highly appreciate the constructive criticism, which will definitely improve the quality of the manuscript.



      With best regards,



      Partricia Pais-Rold√°n, Seong Dae Yun, Nicola Palomero-Gallagher, and Jon Shah
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.12.07.414144v2
  tweets:
    - created_at: Mon Jun 21 12:31:55 +0000 2021
      id: 1406953023943889000
      id_str: "1406953023943888900"
      text: >-
        üí¨ bioRxiv comment on "Cortical depth-dependent human..."


        "Dear Sebastian Dresbach, Lonike Faes, Johannes Franz, Om‚Ä¶ https://t.co/CH4rbB8Oon
      truncated: true
      entities:
        urls:
          - url: https://t.co/CH4rbB8Oon
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 21 12:31:55 +0000 2021
      id: 1406953024631738400
      id_str: "1406953024631738378"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/SUng8fEx6Z
      truncated: false
      entities:
        urls:
          - url: https://t.co/SUng8fEx6Z
      in_reply_to_status_id: 1406953023943889000
      in_reply_to_status_id_str: "1406953023943888900"
- preprint:
    id: "146667"
    doi: 10.1101/2021.06.18.449005
    first_posted: 2021-06-18
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.18.449005v1
    url: https://api.rxivist.org/v1/papers/146667
    title: Extensive protein dosage compensation in aneuploid human cancers
    category: genomics
    abstract: Aneuploidy is a hallmark of human cancers, but the effects of
      aneuploidy on protein expression remain poorly understood. To uncover how
      chromosome copy number changes influence the cancer proteome, we have
      conducted an analysis of hundreds of human cancer cell lines with matched
      copy number, RNA expression, and protein expression data. We found that a
      majority of proteins exhibit dosage compensation and fail to change by the
      degree expected based on chromosome copy number alone. We uncovered a
      variety of gene groups that were recurrently buffered upon both chromosome
      gain and loss, including protein complex subunits and cell cycle genes.
      Several genetic and biophysical factors were predictive of protein
      buffering, highlighting complex post-translational regulatory mechanisms
      that maintain appropriate gene product dosage. Finally, we established
      that chromosomal aneuploidy has an unexpectedly moderate effect on the
      expression of oncogenes and tumor suppressors, demonstrating that these
      key cancer drivers can be subject to dosage compensation as well. In
      total, our comprehensive analysis of aneuploidy and dosage compensation
      across cancers will help identify the key driver genes encoded on altered
      chromosomes and will shed light on the overall consequences of aneuploidy
      during tumor development.
    authors:
      - name: Klaske Marijke Schukken
        orcid: http://orcid.org/0000-0002-7311-2164
      - name: Jason Meyer Sheltzer
        orcid: null
  comment:
    dislikes: 0
    thread: "8601596298"
    numReports: 0
    likes: 0
    id: "5427418306"
    createdAt: 2021-06-21T08:33:48
    author:
      username: benjaminssimpson
      about: ""
      name: Benjamin S. Simpson
      isPowerContributor: false
      profileUrl: https://disqus.com/by/benjaminssimpson/
      url: ""
      location: ""
      id: "371243767"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Fascinating stuff, a great paper. May I ask, in the full paper do
      you plan on releasing the full list of scaling and non-scaling genes as
      supplementary? I have a few areas I would love to check. I am sure there
      are many who would do the same.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.18.449005v1
  tweets:
    - created_at: Mon Jun 21 14:22:29 +0000 2021
      id: 1406980850055626800
      id_str: "1406980850055626760"
      text: >-
        üí¨ bioRxiv comment on "Extensive protein dosage compe..."


        "Fascinating stuff, a great paper. May I ask, in the full‚Ä¶ https://t.co/zBHyGBdX2A
      truncated: true
      entities:
        urls:
          - url: https://t.co/zBHyGBdX2A
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 21 14:22:29 +0000 2021
      id: 1406980850902839300
      id_str: "1406980850902839302"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/ry977eRqjw
      truncated: false
      entities:
        urls:
          - url: https://t.co/ry977eRqjw
      in_reply_to_status_id: 1406980850055626800
      in_reply_to_status_id_str: "1406980850055626760"
- preprint:
    id: "131375"
    doi: 10.1101/2021.02.23.21252259
    first_posted: 2021-02-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.02.23.21252259v1
    url: https://api.rxivist.org/v1/papers/131375
    title: A Novel and Expanding SARS-CoV-2 Variant, B.1.526, Identified in New York
    category: epidemiology
    abstract: Recent months have seen surges of SARS-CoV-2 infection across the
      globe along with considerable viral evolution1-3. Extensive mutations in
      the spike protein may threaten efficacy of vaccines and therapeutic
      monoclonal antibodies4. Two signature mutations of concern are E484K,
      which plays a crucial role in the loss of neutralizing activity of
      antibodies, and N501Y, a driver of rapid worldwide transmission of the
      B.1.1.7 lineage. Here, we report the emergence of a novel variant lineage
      B.1.526 that contains E484K and its alarming rise to dominance in New York
      City in recent months. This variant is partially or completely resistant
      to two therapeutic monoclonal antibodies in clinical use. It is also less
      susceptible to neutralization by convalescent plasma or vaccinee sera by
      4.1-fold or 3.3-3.6-fold, respectively. The B.1.526 lineage has now been
      reported from at least 32 states in the US and numerous other countries.
      B.1526 has been outpacing B.1.1.7 in Northern Manhattan, and both variants
      have been spreading throughout New York with comparable estimated doubling
      times. Such transmission dynamics, together with its resistance to
      therapeutic antibodies, would warrant B.1.526 as a SARS-CoV-2 variant of
      concern.
    authors:
      - name: Medini K Annavajhala
        orcid: http://orcid.org/0000-0002-9229-8849
      - name: Hiroshi Mohri
        orcid: http://orcid.org/0000-0003-1850-5165
      - name: Pengfei Wang
        orcid: http://orcid.org/0000-0003-2454-7652
      - name: Jason E. Zucker
        orcid: null
      - name: Zizhang Sheng
        orcid: http://orcid.org/0000-0002-3253-3309
      - name: Angela Gomez-Simmonds
        orcid: http://orcid.org/0000-0001-5078-7137
      - name: Trevor Bedford
        orcid: http://orcid.org/0000-0002-4039-5794
      - name: David D Ho
        orcid: http://orcid.org/0000-0003-1627-149X
      - name: Anne-Catrin Uhlemann
        orcid: http://orcid.org/0000-0002-9798-4768
  comment:
    dislikes: 0
    thread: "8589278250"
    numReports: 0
    likes: 0
    id: "5427198993"
    createdAt: 2021-06-21T01:41:23
    author:
      username: downtownpete
      about: ""
      name: Downtown-Pete
      isPowerContributor: false
      profileUrl: https://disqus.com/by/downtownpete/
      url: ""
      location: ""
      id: "334120123"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Just one question about this statement in your"Materials&Methods":
      .."between November 1, 2020 and March 5, 2020.." : I assume you mean March
      2021? 

      It would make a difference, if the statement as currently written (March 2020)

      is indeed correct.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.02.23.21252259v3
  tweets:
    - created_at: Mon Jun 21 16:32:54 +0000 2021
      id: 1407013669213401000
      id_str: "1407013669213401088"
      text: >-
        üí¨ medRxiv comment on "A Novel and Expanding SARS-CoV..."


        "Just one question about this statement in your"Materials‚Ä¶ https://t.co/g3ztAOok0w
      truncated: true
      entities:
        urls:
          - url: https://t.co/g3ztAOok0w
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 21 16:32:54 +0000 2021
      id: 1407013670190665700
      id_str: "1407013670190665729"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/0HBOQ8pBh5
      truncated: false
      entities:
        urls:
          - url: https://t.co/0HBOQ8pBh5
      in_reply_to_status_id: 1407013669213401000
      in_reply_to_status_id_str: "1407013669213401088"
- preprint:
    id: "146667"
    doi: 10.1101/2021.06.18.449005
    first_posted: 2021-06-18
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.18.449005v1
    url: https://api.rxivist.org/v1/papers/146667
    title: Extensive protein dosage compensation in aneuploid human cancers
    category: genomics
    abstract: Aneuploidy is a hallmark of human cancers, but the effects of
      aneuploidy on protein expression remain poorly understood. To uncover how
      chromosome copy number changes influence the cancer proteome, we have
      conducted an analysis of hundreds of human cancer cell lines with matched
      copy number, RNA expression, and protein expression data. We found that a
      majority of proteins exhibit dosage compensation and fail to change by the
      degree expected based on chromosome copy number alone. We uncovered a
      variety of gene groups that were recurrently buffered upon both chromosome
      gain and loss, including protein complex subunits and cell cycle genes.
      Several genetic and biophysical factors were predictive of protein
      buffering, highlighting complex post-translational regulatory mechanisms
      that maintain appropriate gene product dosage. Finally, we established
      that chromosomal aneuploidy has an unexpectedly moderate effect on the
      expression of oncogenes and tumor suppressors, demonstrating that these
      key cancer drivers can be subject to dosage compensation as well. In
      total, our comprehensive analysis of aneuploidy and dosage compensation
      across cancers will help identify the key driver genes encoded on altered
      chromosomes and will shed light on the overall consequences of aneuploidy
      during tumor development.
    authors:
      - name: Klaske Marijke Schukken
        orcid: http://orcid.org/0000-0002-7311-2164
      - name: Jason Meyer Sheltzer
        orcid: null
  comment:
    dislikes: 0
    thread: "8601596298"
    numReports: 0
    likes: 0
    id: "5427686938"
    createdAt: 2021-06-21T14:33:58
    author:
      username: disqus_V6NB7lVn00
      about: Postdoctoral fellow at CSHL, studying aneuploidy in cancer
      name: Klaske M. Schukken
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_V6NB7lVn00/
      url: ""
      location: ""
      id: "371253369"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Thank you for your interest! In Supplementary Data 2, there is a list of
      genes with their expression difference upon chromosome gain and loss, as
      well as the classification as either "Scaling", "Buffered", or
      "Anti-Scaling". 


      Not all genes are included in the analysis, as I only took genes with a minimum of 10 datapoints per gain/neutral/loss chromosome category. Hopefully, your proteins of interest are in the list. 


      This data should already be available (link: https://www.biorxiv.org/content/biorxiv/early/2021/06/18/2021.06.18.449005/DC6/embed/media-6.xlsx?download=true), if you have any trouble accessing it, please get in contact with us, and we will send it to you directly.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.18.449005v1
  tweets:
    - created_at: Mon Jun 21 18:24:07 +0000 2021
      id: 1407041659049758700
      id_str: "1407041659049758720"
      text: >-
        üí¨ bioRxiv comment on "Extensive protein dosage compe..."


        "Thank you for your interest! In Supplementary Data 2, th‚Ä¶ https://t.co/imir20b2qN
      truncated: true
      entities:
        urls:
          - url: https://t.co/imir20b2qN
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 21 18:24:07 +0000 2021
      id: 1407041659829985300
      id_str: "1407041659829985283"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/ry977eRqjw
      truncated: false
      entities:
        urls:
          - url: https://t.co/ry977eRqjw
      in_reply_to_status_id: 1407041659049758700
      in_reply_to_status_id_str: "1407041659049758720"
- preprint:
    id: 145508
    metric: 232
    title: A rat model of pregnancy in the male parabiont
    url: https://api.rxivist.org/v1/papers/145508
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.09.447686v1
    doi: 10.1101/2021.06.09.447686
    category: developmental-biology
    first_posted: 2021-06-10
    abstract: >-
      Male pregnancy is a unique phenomenon in syngnathidae which refers to the
      incubation of embryos or fetuses by males. However, whether male mammalian
      animals have the potential to conceive and maintain pregnancy remains
      unclear. Here, we constructed a rat model of male pregnancy by a four-step
      strategy: a heterosexual parabiotic pair was firstly produced by
      surgically joining a castrated male rat and a female rat. Uterus
      transplantation (UTx) was then performed on the male parabiont 8 weeks
      later. After recovery, blastocyst-stage embryos were transplanted to the
      grafted uterus of male parabiont and the native uterus of female
      parabiont. Caesarean section was performed at embryonic day (ED) 21.5. The
      success rate of modeling was only 3.68%, but 10 pups could still be
      delivered from male parabionts and developed. Our experiment reveals the
      possibility of normal embryonic development in male mammalian animals, and
      it may have a profound impact on reproductive biology.


      One-sentence summaryA rat model of male pregnancy can be constructed in four steps.


      Graphical abstract


      O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=152 SRC="FIGDIR/small/447686v1_ufig1.gif" ALT="Figure 1">

      View larger version (44K):

      org.highwire.dtl.DTLVardef@1a0146aorg.highwire.dtl.DTLVardef@9c4329org.highwire.dtl.DTLVardef@fd652borg.highwire.dtl.DTLVardef@1fd0120_HPS_FORMAT_FIGEXP  M_FIG C_FIG
    authors:
      - name: Rongjia Zhang
      - name: Yuhuan Liu
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Mon Jun 21 20:15:55 +0000 2021
      id: 1407069792264241200
      id_str: "1407069792264241156"
      text: >-
        üî• bioRxiv Developmental-biology preprint by R. Zhang et al:


        "A rat model of pregnancy in the male parabiont"‚Ä¶ https://t.co/a6nsYElqE7
      truncated: true
      entities:
        urls:
          - url: https://t.co/a6nsYElqE7
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5427114372"
    createdAt: 2021-06-20T23:38:30
    author:
      username: rantalbott
      about: Software engineer, debater, debunker of myths
      name: Ran Talbott
      isPowerContributor: false
      profileUrl: https://disqus.com/by/rantalbott/
      url: ""
      location: Rural Arizona
      id: "59100570"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      It's confusing and uncertain.


      <b>All </b>of the studies show that antibody levels decline somewhat over time, so there's some concern that immunity <b>might </b>eventually wear off, as it does with some diseases. But the studies have only lasted for 4-6 months, so it's too soon to tell. It does look like the doctor's advice that "you definitely don't need a vaccine until at least 6 months" is sound. It'll <b>probably </b>turn out that immunity lasts longer, maybe even for life, but we don't know yet. 


      A word about "immunity": vaccines or survival don't mean that you won't get infected (again). What they do is "educate" your immune system so it <b>immediately </b>springs into action, instead of waiting to recognize that "Hey! This thing is hurting me!". Notice that nearly all the cases reported in the vaccine trials are asymptomatic, only a small number are "mild", and <b>none </b>have been severe or fatal.


      To allay your concerns, the fact that your parents were only recently infected means that there are <b>tens of millions</b> of people who are <b>way </b>ahead of them on whatever curve there might be. So, if it does turn out that resistance declines too much, they'll get lots of warning.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Mon Jun 21 20:19:35 +0000 2021
      id: 1407070717070426000
      id_str: "1407070717070426121"
      text: |-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."

        "It's confusing and uncertain.

        &lt;b&gt;All &lt;/b&gt;of the studies‚Ä¶ https://t.co/9SG2GzFdom
      truncated: true
      entities:
        urls:
          - url: https://t.co/9SG2GzFdom
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 21 20:19:35 +0000 2021
      id: 1407070717791948800
      id_str: "1407070717791948804"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1407070717070426000
      in_reply_to_status_id_str: "1407070717070426121"
- preprint:
    id: "146209"
    doi: 10.1101/2021.06.11.21258690
    first_posted: 2021-06-15
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.11.21258690v1
    url: https://api.rxivist.org/v1/papers/146209
    title: Brain imaging before and after COVID-19 in UK Biobank
    category: neurology
    abstract: There is strong evidence for brain-related pathologies in COVID-19,
      some of which could be a consequence of viral neurotropism. The vast
      majority of brain imaging studies so far have focused on qualitative,
      gross pathology of moderate to severe cases, often carried out on
      hospitalised patients. It remains unknown however whether the impact of
      COVID-19 can be detected in milder cases, in a quantitative and automated
      manner, and whether this can reveal a possible mechanism for the spread of
      the disease. UK Biobank scanned over 40,000 participants before the start
      of the COVID-19 pandemic, making it possible to invite back in 2021
      hundreds of previously-imaged participants for a second imaging visit.
      Here, we studied the effects of the disease in the brain using multimodal
      data from 782 participants from the UK Biobank COVID-19 re-imaging study,
      with 394 participants having tested positive for SARS-CoV-2 infection
      between their two scans. We used structural and functional brain scans
      from before and after infection, to compare longitudinal brain changes
      between these 394 COVID-19 patients and 388 controls who were matched for
      age, sex, ethnicity and interval between scans. We identified significant
      effects of COVID-19 in the brain with a loss of grey matter in the left
      parahippocampal gyrus, the left lateral orbitofrontal cortex and the left
      insula. When looking over the entire cortical surface, these results
      extended to the anterior cingulate cortex, supramarginal gyrus and
      temporal pole. We further compared COVID-19 patients who had been
      hospitalised (n=15) with those who had not (n=379), and while results were
      not significant, we found comparatively similar findings to the COVID-19
      vs control group comparison, with, in addition, a greater loss of grey
      matter in the cingulate cortex, central nucleus of the amygdala and
      hippocampal cornu ammonis (all |Z|>3). Our findings thus consistently
      relate to loss of grey matter in limbic cortical areas directly linked to
      the primary olfactory and gustatory system. Unlike in post hoc disease
      studies, the availability of pre-infection imaging data helps avoid the
      danger of pre-existing risk factors or clinical conditions being
      mis-interpreted as disease effects. Since a possible entry point of the
      virus to the central nervous system might be via the olfactory mucosa and
      the olfactory bulb, these brain imaging results might be the in vivo
      hallmark of the spread of the disease (or the virus itself) via olfactory
      and gustatory pathways.
    authors:
      - name: Gwena√´lle Douaud
        orcid: http://orcid.org/0000-0003-1981-391X
      - name: Soojin Lee
        orcid: http://orcid.org/0000-0002-6258-1280
      - name: Fidel Alfaro-Almagro
        orcid: http://orcid.org/0000-0002-9133-5951
      - name: Christoph Arthofer
        orcid: null
      - name: Chaoyue Wang
        orcid: null
      - name: Frederik Lange
        orcid: http://orcid.org/0000-0002-1736-7162
      - name: Jesper L.R. Andersson
        orcid: null
      - name: Ludovica Griffanti
        orcid: http://orcid.org/0000-0002-0540-9353
      - name: Eugene Duff
        orcid: null
      - name: Saad Jbabdi
        orcid: http://orcid.org/0000-0003-3234-5639
      - name: Bernd Taschler
        orcid: null
      - name: Anderson Winkler
        orcid: http://orcid.org/0000-0002-4169-9781
      - name: Thomas E. Nichols
        orcid: http://orcid.org/0000-0002-4516-5103
      - name: Rory Collins
        orcid: null
      - name: Paul M. Matthews
        orcid: null
      - name: Naomi Allen
        orcid: http://orcid.org/0000-0003-1938-5038
      - name: Karla L Miller
        orcid: http://orcid.org/0000-0002-2511-3189
      - name: Stephen M Smith
        orcid: http://orcid.org/0000-0001-8166-069X
  comment:
    dislikes: 0
    thread: "8595911767"
    numReports: 0
    likes: 0
    id: "5426612311"
    createdAt: 2021-06-20T14:25:52
    author:
      username: soares_reis
      about: ""
      name: Ricardo S R
      isPowerContributor: false
      profileUrl: https://disqus.com/by/soares_reis/
      url: ""
      location: ""
      id: "165347462"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Do you have data on which patients had anosmia? Since the primary
      olfactory cortex is involved, would be interesting to know if this volume
      loss is related to plasticity/wallerian degeneration-like phenomena.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.11.21258690v1
  tweets:
    - created_at: Mon Jun 21 22:19:28 +0000 2021
      id: 1407100887743467500
      id_str: "1407100887743467521"
      text: >-
        üí¨ medRxiv comment on "Brain imaging before and after..."


        "Do you have data on which patients had anosmia? Since th‚Ä¶ https://t.co/MXLGAHNPDG
      truncated: true
      entities:
        urls:
          - url: https://t.co/MXLGAHNPDG
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 21 22:19:29 +0000 2021
      id: 1407100888574054400
      id_str: "1407100888574054404"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/yeuDlfEN1V
      truncated: false
      entities:
        urls:
          - url: https://t.co/yeuDlfEN1V
      in_reply_to_status_id: 1407100887743467500
      in_reply_to_status_id_str: "1407100887743467521"
- preprint:
    id: "144165"
    doi: 10.1101/2021.05.31.21258081
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.31.21258081v1
    url: https://api.rxivist.org/v1/papers/144165
    title: Favorable outcome on viral load and culture viability using Ivermectin in
      early treatment of non-hospitalized patients with mild COVID-19, A
      double-blind, randomized placebo-controlled trial.
    category: infectious-diseases
    abstract: "Background: Ivermectin, an antiparasitic agent, also has antiviral
      properties. Our aim was to assess whether ivermectin can shorten the viral
      shedding in patients at an early stage of COVID19 infection. Methods: The
      double blinded trial compared patients receiving ivermectin 0.2 mg/kg for
      3 days vs. placebo in non-hospitalized COVID19 patients. RT-PCR from a
      nasopharyngeal swab was obtained at recruitment and then every two days.
      Primary endpoint was reduction of viral-load on the 6th day (third day
      after termination of treatment) as reflected by Ct level>30
      (non-infectious level). The primary outcome was supported by determination
      of viral culture viability. Results: Eighty nine patients were eligible
      (47 in ivermectin and 42 in placebo arm). Their median age was 35 years.
      Females accounted for 21.6%, and 16.8% were asymptomatic at recruitment.
      Median time from symptom onset was 4 days. There were no statistical
      differences in these parameters between the two groups. On day 6, 34 out
      of 47 (72%) patients in the ivermectin arm reached the endpoint, compared
      to 21/ 42 (50%) in the placebo arm (OR 2.62; 95% CI: 1.09 to 6.31). In a
      multivariable logistic regression model, the odds of a negative test at
      day 6 was 2.62 time higher in the ivermectin group (95% CI: 1.06 to 6.45).
      Cultures at days 2 to 6 were positive in 3/23 (13.0%) of ivermectin
      samples vs. 14/29 (48.2%) in the placebo group (p=0.008). Conclusions:
      There were significantly lower viral loads and viable cultures in the
      ivermectin group, which could lead to shortening isolation time in these
      patients."
    authors:
      - name: Asaf Biber
        orcid: http://orcid.org/0000-0001-6007-0383
      - name: Michal Mandelboim
        orcid: http://orcid.org/0000-0002-5997-7241
      - name: Geva Harmelin
        orcid: null
      - name: Dana Lev
        orcid: null
      - name: Li Ram
        orcid: null
      - name: Amit Shaham
        orcid: null
      - name: Ital Nemet
        orcid: null
      - name: Limor Kliker
        orcid: null
      - name: Oran Erster
        orcid: http://orcid.org/0000-0003-4839-8997
      - name: Eli Schwartz
        orcid: null
  comment:
    dislikes: 0
    thread: "8565279083"
    numReports: 0
    likes: 0
    id: "5426516065"
    createdAt: 2021-06-20T12:22:57
    author:
      username: hlodovic
      about: ""
      name: Hlodovic
      isPowerContributor: false
      profileUrl: https://disqus.com/by/hlodovic/
      url: ""
      location: ""
      id: "207733789"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Has anyone given consideration to the fact that Ivermectin is
      administered to animals for intestinal parasites (worms, mainly)?  Could
      it be that the ivermectin used in this study killed some kind of parasite
      common to most humans, thereby relieving the natural defense system from
      that fight and allowing it to attack the virus full force.  Being already
      exercised by the battle of the parasites, the defense system would be
      strong.  Suddenly relieving it of that battle could be like when you go in
      your car, but it seems to require that you give it a lot of extra
      gas.  You realize the parking brake is on and release it.  So the car
      suddenly takes off, throwing you back in the seat.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.31.21258081v1
  tweets:
    - created_at: Tue Jun 22 00:59:04 +0000 2021
      id: 1407141051685539800
      id_str: "1407141051685539849"
      text: >-
        üí¨ medRxiv comment on "Favorable outcome on viral loa..."


        "Has anyone given consideration to the fact that Ivermect‚Ä¶ https://t.co/UmssLmhUeX
      truncated: true
      entities:
        urls:
          - url: https://t.co/UmssLmhUeX
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 22 00:59:05 +0000 2021
      id: 1407141052776173600
      id_str: "1407141052776173568"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/fIgXlfTSzw
      truncated: false
      entities:
        urls:
          - url: https://t.co/fIgXlfTSzw
      in_reply_to_status_id: 1407141051685539800
      in_reply_to_status_id_str: "1407141051685539849"
- preprint:
    id: "144731"
    doi: 10.1101/2021.05.25.21257256
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.25.21257256v1
    url: https://api.rxivist.org/v1/papers/144731
    title: Identification of ultra-rare genetic variants in Pediatric Acute Onset
      Neuropsychiatric Syndrome (PANS) by exome and whole genome sequencing
    category: genetic-and-genomic-medicine
    abstract: "Pediatric acute onset neuropsychiatric syndrome (PANS) is viewed as
      an autoimmune/autoinflammatory condition characterized by the abrupt onset
      of severe neurological and psychiatric symptoms, in particular
      obsessive-compulsive disorder (OCD), tics, anxiety, mood swings,
      irritability, and restricted eating, often triggered by infections.
      However, direct evidence of autoimmunity, infections, or a proinflammatory
      state is often lacking, and there is no unifying pathogenic pathway. This
      could be due to underlying genetic heterogeneity, which could lead to the
      development of PANS through different cellular and molecular pathways.
      Unfortunately, little is known about the genetic basis of PANS.
      Consequently, we carried out whole exome sequencing (WES) on a U.S. cohort
      of 386 cases who met diagnostic criteria for PANS, including 133 family
      triads, and whole genome sequencing (WGS) on ten cases from the European
      Union, who were selected for WGS because of severe PANS symptoms. We
      focused on identifying potentially deleterious genetic variants that were
      either de novo or ultra-rare with a minor allele frequency (MAF) < 0.001.
      Candidate mutations were found in 11 genes: PPM1D, SGCE, PLCG2, NLRC4,
      CACNA1B, SHANK3, CHK2, GRIN2A, RAG1, GABRG2, and SYNGAP1 in a total of 20
      cases, which included two sets of siblings, and two or more unrelated
      subjects with ultra-rare variants in SGCE, NLRC4, RAG1, and SHANK3. The
      PANS candidate genes we identified separate into two broad functional
      categories. One group regulates peripheral innate and adaptive immune
      responses (e.g., PPM1D, CHK2, NLRC4, RAG1, PLCG2), some of which also
      influence microglia function. Another is expressed primarily at neuronal
      synapses or directly modulates synaptic function (SHANK3, SYNGAP1, GRIN2A,
      GABRG2, CACNA1B, SGCE). These neuronal PANS candidate genes are often
      mutated in autism spectrum disorder, developmental disorders, and
      myoclonus-dystonia. In fact, eight out of 20 cases in this study developed
      PANS superimposed on a preexisting neurodevelopmental disorder. There is,
      however, clinical overlap between these two groups and some crossover
      expression (e.g., some neuronal genes are expressed in immune cells and
      vice versa) that diminishes the neuronal/immune dichotomy. Genes in both
      categories are also highly expressed in the enteric nervous system, and in
      the choroid plexus and brain vasculature, suggesting they might contribute
      to a breach in the blood-CSF barrier and blood-brain barrier (BBB) that
      would permit the entry of autoantibodies, inflammatory cytokines,
      chemokines, prostaglandins, and autoantibodies into the brain. Thus, PANS
      is a genetically heterogeneous condition that can occur as a stand-alone
      neuropsychiatric condition or co-morbid with neurodevelopmental disorders,
      with candidate genes functioning at several levels of the
      neuroinflammatory axis."
    authors:
      - name: herbert lachman
        orcid: null
      - name: Rosario Trifiletti
        orcid: null
      - name: Olivia Manusama
        orcid: null
      - name: Deyou Zheng
        orcid: http://orcid.org/0000-0003-4354-5337
      - name: Alberto Spalice
        orcid: null
      - name: Pietro Chiurazzi
        orcid: null
      - name: Allan Schornagel
        orcid: null
      - name: Andreea Serban
        orcid: null
      - name: Rogier van Wijck
        orcid: null
      - name: Sigrid Swagemakers
        orcid: null
      - name: Peter van der Spek
        orcid: null
  comment:
    dislikes: 0
    thread: "8573239421"
    numReports: 0
    likes: 0
    id: "5428488558"
    createdAt: 2021-06-22T03:53:16
    author:
      username: disqus_m7AaRv6WrC
      about: ""
      name: Bob Horvath
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_m7AaRv6WrC/
      url: ""
      location: ""
      id: "200934392"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Thank you for this paper - parents of PANS patients are grateful to see
      this kind of genetics work being done on PANS.  May I ask:


      1) What was the total number of variants meeting the criteria described (at lines 141-144 of the document for the European samples, and lines 154-158 for the U.S samples)?


      2) Presumably, the list of candidate genes (described at lines 161-162) were all the genes that encompassed the variant lists in 1) above, with the possible exception of MTHC2 and BID that are mentioned as additions.  What was the total number of  candidate genes considered, before the list was narrowed to the 11 listed?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.25.21257256v1
  tweets:
    - created_at: Tue Jun 22 12:35:31 +0000 2021
      id: 1407316318534123500
      id_str: "1407316318534123521"
      text: >-
        üí¨ medRxiv comment on "Identification of ultra-rare g..."


        "Thank you for this paper - parents of PANS patients are‚Ä¶ https://t.co/FG0Xpwqumd
      truncated: true
      entities:
        urls:
          - url: https://t.co/FG0Xpwqumd
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 22 12:35:31 +0000 2021
      id: 1407316319486320600
      id_str: "1407316319486320640"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/aTfASqZ9E1
      truncated: false
      entities:
        urls:
          - url: https://t.co/aTfASqZ9E1
      in_reply_to_status_id: 1407316318534123500
      in_reply_to_status_id_str: "1407316318534123521"
- preprint:
    id: "146945"
    doi: 10.1101/2021.06.21.449268
    first_posted: 2021-06-21
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.21.449268v1
    url: https://api.rxivist.org/v1/papers/146945
    title: Artemisinin-based hybrids produce intracellular proteasome inhibitors
      that overcome resistance in Plasmodium falciparum
    category: microbiology
    abstract: Artemisinin resistant Plasmodium falciparum (Pf) is spreading despite
      combination chemotherapy (ACT). Here we report the design of artezomibs,
      single-molecule hybrids of an artemisinin and a Pf-selective proteasome
      inhibitor. Artezomibs exert a novel mode of action inside the malaria
      parasites. The artemisinin component covalently modifies parasite
      proteins, which become substrates of the Pf proteasome. The proteasomal
      degradation products that bear the proteasome inhibitor component of the
      hybrid then inhibit Pf proteasomes, including those with mutations that
      reduce binding affinity of the proteasome inhibitor component on its own.
      We demonstrated that artezomibs circumvent both artemisinin resistance
      conferred by Kelch13 polymorphism and resistance to the proteasome
      inhibitor associated with mutations in Pf proteasomes. This mode of action
      may enable the use of a single molecule with one pharmacokinetic profile
      to prevent the emergence of resistance.
    authors:
      - name: Wenhu Zhan
        orcid: null
      - name: Yi Jing Liu
        orcid: null
      - name: Changmei Yang
        orcid: null
      - name: Hao Zhang
        orcid: http://orcid.org/0000-0001-7043-5438
      - name: Jacob C Harris
        orcid: null
      - name: Rong Wang
        orcid: null
      - name: Songbiao Zhu
        orcid: null
      - name: Julian Sherman
        orcid: null
      - name: George Sukenick
        orcid: null
      - name: Ana Rodriguez
        orcid: http://orcid.org/0000-0002-0060-3405
      - name: Haiteng Deng
        orcid: http://orcid.org/0000-0001-9496-1280
      - name: Carl F Nathan
        orcid: null
      - name: Laura A Kirkman
        orcid: null
      - name: Gang Lin
        orcid: http://orcid.org/0000-0003-4797-7073
  comment:
    dislikes: 0
    thread: "8607647676"
    numReports: 0
    likes: 0
    id: "5428849431"
    createdAt: 2021-06-22T13:41:59
    author:
      username: disqus_ecOFDFI5gZ
      about: ""
      name: Wenhu
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_ecOFDFI5gZ/
      url: ""
      location: ""
      id: "371301397"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Hope a drug based on this concept could eradicate malaria one day!!!
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.21.449268v1
  tweets:
    - created_at: Tue Jun 22 14:18:50 +0000 2021
      id: 1407342318135517200
      id_str: "1407342318135517190"
      text: >-
        üí¨ bioRxiv comment on "Artemisinin-based hybrids prod..."


        "Hope a drug based on this concept could eradicate malari‚Ä¶ https://t.co/ifQlPfnRJC
      truncated: true
      entities:
        urls:
          - url: https://t.co/ifQlPfnRJC
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 22 14:18:50 +0000 2021
      id: 1407342319049838600
      id_str: "1407342319049838602"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/knqqWKm1xW
      truncated: false
      entities:
        urls:
          - url: https://t.co/knqqWKm1xW
      in_reply_to_status_id: 1407342318135517200
      in_reply_to_status_id_str: "1407342318135517190"
- preprint:
    id: "127738"
    doi: 10.1101/2021.02.01.429253
    first_posted: 2021-02-02
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.02.01.429253v1
    url: https://api.rxivist.org/v1/papers/127738
    title: Combining chemogenomic and gene-dose assays to investigate drug synergy
    category: genomics
    abstract: From the earliest days of using natural remedies to modern
      applications of clinically tested medications, combining therapies for
      disease treatment has been standard practice. Combination treatments can
      exhibit synergistic effects, broadly defined as a greater-than-additive
      effect of two or more therapeutic agents. Indeed, clinicians often use
      their experience and expertise to tailor such combinations in the hopes of
      maximizing the therapeutic effect. Alongside these efforts, computational
      studies into understanding and predicting the biophysical underpinnings of
      how synergy is achieved have benefitted from high-throughput screening and
      computational biology. One challenge is how to best design and analyze the
      results of synergy studies performed at scale, especially because the
      number of possible combinations to test quickly becomes unmanageable, and
      the tools to analyze the resulting data are quite new. Nevertheless, the
      benefits of such studies are clear -- by combining multiple drugs in the
      treatment of infectious disease and cancer, for instance, one can lessen
      host toxicity and simultaneously reduce the likelihood of resistance to
      treatment. In this study, we extend the widely validated chemogenomic
      HIPHOP assay to drug combinations. We identify a class of
      ''combination-specific sensitive strains'' that suggest mechanisms for the
      synergies we observe and further suggest focused follow-up studies.
    authors:
      - name: Hamid Gaikani
        orcid: http://orcid.org/0000-0002-1795-2927
      - name: Andrew M Smith
        orcid: http://orcid.org/0000-0003-1141-2978
      - name: Anna Y. Lee
        orcid: null
      - name: Guri Giaever
        orcid: null
      - name: Corey Nislow
        orcid: http://orcid.org/0000-0002-4016-8874
  comment:
    dislikes: 0
    thread: "8381452007"
    numReports: 0
    likes: 0
    id: "5428514394"
    createdAt: 2021-06-22T04:41:27
    author:
      username: hamidgaikani
      about: ""
      name: Hamid Gaikani
      isPowerContributor: false
      profileUrl: https://disqus.com/by/hamidgaikani/
      url: ""
      location: ""
      id: "363818919"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      This preprint was peer-reviewed in "Frontiers in Fungal Biology" and is
      currently available under the title of "<b>Systematic prediction of
      antifungal drug synergy by chemogenomic screening in Saccharomyces
      cerevisiae</b>"

      doi: 10.3389/ffunb.2021.683414
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.02.01.429253v1
  tweets:
    - created_at: Tue Jun 22 16:35:19 +0000 2021
      id: 1407376663843909600
      id_str: "1407376663843909632"
      text: >-
        üí¨ bioRxiv comment on "Combining chemogenomic and gen..."


        "This preprint was peer-reviewed in "Frontiers in Fungal‚Ä¶ https://t.co/1aC63cUavr
      truncated: true
      entities:
        urls:
          - url: https://t.co/1aC63cUavr
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 22 16:35:19 +0000 2021
      id: 1407376664670134300
      id_str: "1407376664670134279"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/98lMvrkDuI
      truncated: false
      entities:
        urls:
          - url: https://t.co/98lMvrkDuI
      in_reply_to_status_id: 1407376663843909600
      in_reply_to_status_id_str: "1407376663843909632"
- preprint:
    id: "137502"
    doi: 10.1101/2021.04.11.439338
    first_posted: 2021-04-11
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.11.439338v1
    url: https://api.rxivist.org/v1/papers/137502
    title: Emergent RNA-RNA interactions can promote stability in a nascent
      phototrophic endosymbiosis
    category: evolutionary-biology
    abstract: "Eukaryote-eukaryote endosymbiosis was responsible for the spread of
      chloroplast (plastid) organelles. Stability is required for the metabolic
      and genetic integration that drives the establishment of new organelles,
      yet the mechanisms which act to stabilise nascent endosymbioses - between
      two fundamentally selfish biological organisms - are unclear. Theory
      suggests that enforcement mechanisms, which punish misbehaviour, may act
      to stabilise such interactions by resolving conflict. However, how such
      mechanisms can emerge in a nascent endosymbiosis has yet to be explored.
      Here, we propose that endosymbiont-host RNA-RNA interactions, arising from
      digestion of the endosymbiont population, can result in a cost to host
      growth for breakdown of the endosymbiosis. Using the model nascent
      endosymbiosis, Paramecium bursaria - Chlorella spp., we demonstrate that
      this mechanism is dependent on the host RNA-interference (RNAi) system. We
      reveal through small RNA (sRNA) sequencing that endosymbiont-derived mRNA
      released upon endosymbiont digestion can be processed by the host RNAi
      system into 23-nt sRNA. We predict multiple regions of shared sequence
      identity between endosymbiont and host mRNA, and demonstrate through
      delivery of synthetic endosymbiont sRNA that exposure to these regions can
      knock-down expression of complementary host genes, resulting in a cost to
      host growth. This process of host gene knock-down in response to
      endosymbiont-derived RNA processing by host RNAi factors, which we term
      'RNAi-collisions', represents a mechanism which can promote stability in a
      nascent eukaryote-eukaryote endosymbiosis. By imposing a cost for
      breakdown of the endosymbiosis, endosymbiont-host RNA-RNA interactions may
      drive maintenance of the symbiosis across fluctuating ecological
      conditions and symbiotic status. SIGNIFICANCE STATEMENT: Stable
      endosymbiosis between eukaryotic microbes has driven the evolution of
      further cellular complexity. Yet the mechanisms which can act to stabilise
      a nascent eukaryote-eukaryote endosymbiosis are unclear. Using the model
      nascent endosymbiotic system, Paramecium bursaria-Chlorella, we
      demonstrate that endosymbiont-host RNA-RNA interactions can drive a cost
      to host growth upon endosymbiont digestion, punishing the host for
      misbehaviour. These RNA-RNA interactions are facilitated by the host
      RNA-interference system. For endosymbiont mRNA sharing a high-level of
      sequence identity with host transcripts, this process can result in host
      gene knock-down. We propose that these endosymbiont-host RNA-RNA
      interactions-'RNAi collisions'-represent a viable enforcement mechanism to
      sanction the host for breakdown of the endosymbiosis, promoting the
      stability of a nascent endosymbiotic interaction."
    authors:
      - name: Benjamin H Jenkins
        orcid: http://orcid.org/0000-0002-3803-6418
      - name: Finlay Maguire
        orcid: http://orcid.org/0000-0002-1203-9514
      - name: Guy Leonard
        orcid: null
      - name: Joshua D Eaton
        orcid: null
      - name: Steven West
        orcid: null
      - name: Benjamin E. Housden
        orcid: http://orcid.org/0000-0001-9134-4279
      - name: David S Milner
        orcid: null
      - name: Thomas A Richards
        orcid: null
  comment:
    dislikes: 0
    thread: "8519819237"
    numReports: 0
    likes: 0
    id: "5428472904"
    createdAt: 2021-06-22T03:26:06
    author:
      username: senjie_lin
      about: Marine ecology, genomics, CRISPR/Cas9, dinoflagellates, microbes, HABs,
        symbioses (coral-dinoflagellate, dinoflagellate-alga, protist-alga,
        alga-microbe)
      name: Senjie Lin
      isPowerContributor: false
      profileUrl: https://disqus.com/by/senjie_lin/
      url: https://marinesciences.uconn.edu/person/senjie-lin
      location: ""
      id: "351459876"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "That is exciting finding, offering support for the postulation
      that Symbiodiniaceae might use its  miRNA to influence coral host's gene
      expression (DOI: 10.1126/science.aad0408). Looks like a perfect example of
      adaptive co-evolution."
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.04.11.439338v2
  tweets:
    - created_at: Tue Jun 22 18:23:51 +0000 2021
      id: 1407403979890376700
      id_str: "1407403979890376710"
      text: >-
        üí¨ bioRxiv comment on "Emergent RNA-RNA interactions ..."


        "That is exciting finding, offering support for the postu‚Ä¶ https://t.co/hMBqdSU4d3
      truncated: true
      entities:
        urls:
          - url: https://t.co/hMBqdSU4d3
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 22 18:23:51 +0000 2021
      id: 1407403980632756200
      id_str: "1407403980632756228"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/xTWVd0gmHw
      truncated: false
      entities:
        urls:
          - url: https://t.co/xTWVd0gmHw
      in_reply_to_status_id: 1407403979890376700
      in_reply_to_status_id_str: "1407403979890376710"
- preprint:
    id: 146837
    metric: 18
    title: Large-scale neural recordings with single-cell resolution in human cortex
      using high-density Neuropixels probes
    url: https://api.rxivist.org/v1/papers/146837
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.20.449152v1
    doi: 10.1101/2021.06.20.449152
    category: neuroscience
    first_posted: 2021-06-21
    abstract: Recent advances in multi-electrode array technology have made it
      possible to monitor large neuronal ensembles at high resolution. In
      humans, however, current approaches either restrict recordings to only a
      few neurons per penetrating electrode or combine the signals of thousands
      of neurons in local field potential (LFP) recordings. Here, we describe a
      set of techniques which enable simultaneous recording from over 200
      well-isolated cortical single units in human participants during
      intraoperative neurosurgical procedures using Neuropixels silicon probes.
      We characterized a diversity of extracellular waveforms with eight
      separable single unit classes, with differing firing rates, positions
      along the length of the linear electrode array, spatial spread of the
      waveform, and modulation by LFP events such as inter-ictal discharges and
      burst suppression. While some additional challenges remain in creating a
      turn-key system capable of recording, Neuropixels technology could pave
      the way to studying human-specific cognitive processes and their
      dysfunction at unprecedented spatiotemporal resolution.
    authors:
      - name: Angelique C Paulk
      - name: Yoav Kfir
      - name: Arjun Khanna
      - name: Martina Mustroph
      - name: Eric M. Trautmann
      - name: Dan J Soper
      - name: Sergey D. Stavisky
      - name: Marleen Welkenhuysen
      - name: Barundeb Dutta
      - name: Krishna V. Shenoy
      - name: Leigh R. Hochberg
      - name: Mark Richardson
      - name: Ziv M Williams
      - name: Sydney S Cash
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Tue Jun 22 20:16:06 +0000 2021
      id: 1407432227437355000
      id_str: "1407432227437355009"
      text: >-
        üî• bioRxiv Neuroscience preprint by A. C. Paulk et al:


        "Large-scale neural recordings with single-cell resolution i‚Ä¶ https://t.co/GyUUWHm4l5
      truncated: true
      entities:
        urls:
          - url: https://t.co/GyUUWHm4l5
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "82342"
    doi: 10.1101/2020.05.04.077545
    first_posted: 2020-05-05
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.05.04.077545v1
    url: https://api.rxivist.org/v1/papers/82342
    title: Heritable functional architecture in human visual cortex
    category: neuroscience
    abstract: How much of the functional organization of our visual system is
      inherited? Here we tested the heritability of retinotopic maps in human
      visual cortex using functional magnetic resonance imaging. We demonstrate
      that retinotopic organization shows a closer correspondence in monozygotic
      (MZ) compared to dizygotic (DZ) twin pairs, suggesting a partial genetic
      determination. Using population receptive field (pRF) analysis to examine
      the preferred spatial location and selectivity of these neuronal
      populations, we estimate a heritability around 30% for polar angle
      preferences and spatial selectivity, as quantified by pRF size, in
      extrastriate areas V2 and V3. Our findings are consistent with
      heritability in both the macroscopic arrangement of visual regions and
      stimulus tuning properties of visual cortex. This could constitute a
      neural substrate for variations in a range of perceptual effects, which
      themselves have been found to be at least partially genetically
      determined. These findings also add convergent evidence for the hypothesis
      that functional map topology is linked with cortical morphology.
    authors:
      - name: Ivan Alvarez
        orcid: http://orcid.org/0000-0003-2815-2666
      - name: Nonie J Finlayson
        orcid: null
      - name: Shwe Ei
        orcid: null
      - name: Benjamin de Haas
        orcid: http://orcid.org/0000-0003-1722-7757
      - name: John A. Greenwood
        orcid: http://orcid.org/0000-0002-6184-0818
      - name: D. Samuel Schwarzkopf
        orcid: http://orcid.org/0000-0003-3686-1622
  comment:
    dislikes: 0
    thread: "8486196868"
    numReports: 0
    likes: 0
    id: "5428448923"
    createdAt: 2021-06-22T02:49:46
    author:
      username: dsamuelschwarzkopf
      about: ""
      name: D Samuel Schwarzkopf
      isPowerContributor: false
      profileUrl: https://disqus.com/by/dsamuelschwarzkopf/
      url: ""
      location: ""
      id: "118608058"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: |-
      Now published in Neuroimage:

      https://doi.org/10.1016/j.neuroimage.2021.118286
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.05.04.077545v4
  tweets:
    - created_at: Tue Jun 22 20:19:58 +0000 2021
      id: 1407433198481588200
      id_str: "1407433198481588234"
      text: |-
        üí¨ bioRxiv comment on "Heritable functional architect..."

        "Now published in Neuroimage:

        "

        https://t.co/iR4BLmGvvj
      truncated: false
      entities:
        urls:
          - url: https://t.co/iR4BLmGvvj
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 22 20:19:58 +0000 2021
      id: 1407433199253344300
      id_str: "1407433199253344257"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/PAszAlbALv
      truncated: false
      entities:
        urls:
          - url: https://t.co/PAszAlbALv
      in_reply_to_status_id: 1407433198481588200
      in_reply_to_status_id_str: "1407433198481588234"
- preprint:
    id: "122819"
    doi: 10.1101/2020.12.23.424196
    first_posted: 2020-12-24
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.12.23.424196v1
    url: https://api.rxivist.org/v1/papers/122819
    title: Evidence that pain sensitivity is rhythmic in humans, mainly driven by
      the endogenous circadian system and little by sleep
    category: neuroscience
    abstract: >-
      Pain intensity has been reported to fluctuate during the day in some
      experimental and clinical conditions, but the mechanisms underlying these
      fluctuations are unknown. Although the circadian timing system is known to
      regulate a wide range of physiological functions, its implication in pain
      regulation is unknown. We show here, using highly controlled laboratory
      constant routine conditions, that pain sensitivity is rhythmic over the
      24-hours and strongly controlled by the endogenous circadian timing
      system. We find that pain sensitivity follows a sinusoidal circadian
      rhythmicity, with a maximum in the middle of the night and a minimum in
      the afternoon. We also find a weak homeostatic control of pain
      sensitivity, with a linear increase over the 34 hours of prolonged
      wakefulness, which parallels that of sleep pressure. Using mathematical
      modelling, we describe that the circadian system accounts for 80% of the
      full magnitude of pain sensitivity over the 24 hours, and that
      sleep-related processes account for only 20%. This result reveals that
      nocturnal analgesia is predominantly induced by the circadian system and
      has been wrongly attributed only to sleep. Our findings highlight the need
      to consider the time of day in pain assessment, and suggest that
      personalized circadian medicine may be a promising approach to pain
      management.


      Significance statementWe discovered that sensitivity to pain is rhythmic in healthy humans, that sensitivity is maximal at night and minimal in the afternoon. Contrarily to the current thinking that sleep is the best painkiller, we find that the 24-h rhythmicity of sensitivity to pain is mainly controlled by a biological circadian clock in our body, and very little by our sleep. Our article reveals the neurobiological mechanisms involved in driving the rhythmicity of pain perception in humans, with the main time-piece located in the brain (the suprachiasmatic nuclei in the hypothalamus). Our findings challenge the current vision of pain physiology, and reveal the need to consider time-of-day and internal biological time for pain evaluation and pain management.
    authors:
      - name: I Daguet
        orcid: null
      - name: V Raverot
        orcid: null
      - name: D Bouhassira
        orcid: null
      - name: C Gronfier
        orcid: http://orcid.org/0000-0002-6549-799X
  comment:
    dislikes: 0
    thread: "8329136468"
    numReports: 0
    likes: 0
    id: "5429152365"
    createdAt: 2021-06-22T17:53:40
    author:
      name: Anon_Reader
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      I think an argument could be made for both a similar and different
      profile, but I would predict that the profiles would be the same between
      hot/cold pain modalities. I'm not sure if the same would stand for
      mechnical/electric/chemical pain, however.


      Another question I have for you is why you chose to only examine males in this study?
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.12.23.424196v1
  tweets:
    - created_at: Tue Jun 22 22:19:36 +0000 2021
      id: 1407463309159305200
      id_str: "1407463309159305216"
      text: >-
        üí¨ bioRxiv comment on "Evidence that pain sensitivity..."


        "I think an argument could be made for both a similar and‚Ä¶ https://t.co/X6mnzIQO6i
      truncated: true
      entities:
        urls:
          - url: https://t.co/X6mnzIQO6i
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 22 22:19:37 +0000 2021
      id: 1407463309935251500
      id_str: "1407463309935251456"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/GRwb8n4s0B
      truncated: false
      entities:
        urls:
          - url: https://t.co/GRwb8n4s0B
      in_reply_to_status_id: 1407463309159305200
      in_reply_to_status_id_str: "1407463309159305216"
- preprint:
    id: "60393"
    doi: 10.1101/763888
    first_posted: 2019-09-10
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/763888v2
    url: https://api.rxivist.org/v1/papers/60393
    title: MRI of Capn15 knockout mice and analysis of Capn15 distribution reveal
      possible roles in brain development and plasticity
    category: neuroscience
    abstract: The Small Optic Lobe (SOL) family of calpains are intracellular
      cysteine proteases that are expressed in the nervous system and play an
      important role in neuronal development in both Drosophila, where loss of
      this calpain leads to the eponymous small optic lobes, and in mouse and
      human, where loss of this calpain leads to eye anomalies. Some human
      individuals with biallelic variants in CAPN15 also have developmental
      delay and autism. However, neither the specific effect of the loss of the
      Capn15 protein on brain development nor the brain regions where this
      calpain is expressed in the adult is known. Here we show using small
      animal MRI that mice with the complete loss of Capn15 have smaller brains
      overall with larger decreases in the thalamus and subregions of the
      hippocampus. These losses are not seen in Capn15 conditional KO mice where
      Capn15 is knocked out only in excitatory neurons in the adult. Based on
      {beta}-galactosidase expression in an insert strain where lacZ is
      expressed under the control of the Capn15 promoter, we show that Capn15 is
      expressed in adult mice, particularly in neurons involved in plasticity
      such as the hippocampus, lateral amygdala and Purkinje neurons, and
      partially in other non-characterized cell types. The regions of the brain
      in the adult where Capn15 is expressed do not correspond well to the
      regions of the brain most affected by the complete knockout suggesting
      distinct roles of Capn15 in brain development and adult brain function.
    authors:
      - name: Congyao Zha
        orcid: null
      - name: Carole Abi Farah
        orcid: null
      - name: Vladimir Fonov
        orcid: http://orcid.org/0000-0003-3402-7749
      - name: David Rudko
        orcid: null
      - name: Wayne S Sossin
        orcid: http://orcid.org/0000-0003-1927-9315
  comment:
    dislikes: 0
    thread: "8431565903"
    numReports: 0
    likes: 0
    id: "5429119368"
    createdAt: 2021-06-22T17:28:05
    author:
      username: wsossin
      about: ""
      name: wsossin
      isPowerContributor: false
      profileUrl: https://disqus.com/by/wsossin/
      url: ""
      location: ""
      id: "371310614"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      This paper is now published.

      Neuroscience. 2021 Jun 15;465:128-141. doi: 10.1016/j.neuroscience.2021.04.023. Epub 2021 May 2.

      PMID: 33951504
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/763888v3
  tweets:
    - created_at: Wed Jun 23 00:54:30 +0000 2021
      id: 1407502290311815200
      id_str: "1407502290311815171"
      text: |-
        üí¨ bioRxiv comment on "MRI of Capn15 knockout mice an..."

        "This paper is now published.
        Neuroscience. 2021 Jun 15;4‚Ä¶ https://t.co/JOO8gWh6cy
      truncated: true
      entities:
        urls:
          - url: https://t.co/JOO8gWh6cy
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 23 00:54:31 +0000 2021
      id: 1407502291322609700
      id_str: "1407502291322609665"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/KWGBph5caF
      truncated: false
      entities:
        urls:
          - url: https://t.co/KWGBph5caF
      in_reply_to_status_id: 1407502290311815200
      in_reply_to_status_id_str: "1407502290311815171"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 0
    id: "5429562192"
    createdAt: 2021-06-23T00:12:20
    author:
      username: disqus_pnXxBPirjv
      about: ""
      name: Sock Dollager
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_pnXxBPirjv/
      url: ""
      location: USA
      id: "158918419"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Thx for explaining.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Wed Jun 23 12:24:07 +0000 2021
      id: 1407675835461611500
      id_str: "1407675835461611520"
      text: |-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."

        "Thx for explaining."

        https://t.co/pwOlr48mC5
      truncated: false
      entities:
        urls:
          - url: https://t.co/pwOlr48mC5
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 23 12:24:07 +0000 2021
      id: 1407675836065538000
      id_str: "1407675836065538048"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1407675835461611500
      in_reply_to_status_id_str: "1407675835461611520"
- preprint:
    id: "147105"
    doi: 10.1101/2021.06.22.449331
    first_posted: 2021-06-22
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.22.449331v1
    url: https://api.rxivist.org/v1/papers/147105
    title: Homolog of ELAC2 is a central regulator of the mitochondrial unfolded
      protein response
    category: cell-biology
    abstract: The mitochondrial unfolded protein response (UPRmt) has emerged as a
      predominant mechanism that preserves mitochondrial function. Consequently,
      multiple pathways likely exist to modulate UPRmt. We unexpectedly
      discovered that the tRNA processing enzyme, homolog of ELAC2 (HOE-1), is
      central to UPRmt regulation in Caenorhabditis elegans. We find that
      nuclear HOE-1 is necessary and sufficient to robustly activate UPRmt. We
      show that HOE-1 acts via transcription factors ATFS-1 and DVE-1 that are
      crucial for UPRmt. Mechanistically, we show that HOE-1 likely mediates its
      effects via tRNAs, as blocking tRNA export prevents HOE-1-induced UPRmt.
      Interestingly, we find that HOE-1 does not act via the integrated stress
      response, which can be activated by uncharged tRNAs, pointing towards its
      reliance on a new mechanism. Finally, we show that the subcellular
      localization of HOE-1 is responsive to mitochondrial stress and is subject
      to negative regulation via ATFS-1. Together, we have discovered a novel
      RNA-based cellular pathway that modulates UPRmt.
    authors:
      - name: James P Held
        orcid: null
      - name: Benjamin R Saunders
        orcid: null
      - name: Claudia V Pereria
        orcid: null
      - name: Maulik R Patel
        orcid: http://orcid.org/0000-0003-3749-0122
  comment:
    dislikes: 0
    thread: "8609234875"
    numReports: 0
    likes: 0
    id: "5429546036"
    createdAt: 2021-06-22T23:53:26
    author:
      username: disqus_ZRJca2PSPz
      about: ""
      name: Maulik Patel
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_ZRJca2PSPz/
      url: ""
      location: ""
      id: "371324261"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: I am very proud to post this manuscript from my lab. It represents
      more than 3 years of work on a project initiated and executed by an
      extremely talented graduate student James Held in the lab. We would love
      to receive helpful feedback on the manuscript! Thank you.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.22.449331v1
  tweets:
    - created_at: Wed Jun 23 14:16:37 +0000 2021
      id: 1407704147974033400
      id_str: "1407704147974033414"
      text: >-
        üí¨ bioRxiv comment on "Homolog of ELAC2 is a central ..."


        "I am very proud to post this manuscript from my lab. It‚Ä¶ https://t.co/dQBgmbl0R0
      truncated: true
      entities:
        urls:
          - url: https://t.co/dQBgmbl0R0
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 23 14:16:37 +0000 2021
      id: 1407704148733276200
      id_str: "1407704148733276170"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/WAHRMSQ9BD
      truncated: false
      entities:
        urls:
          - url: https://t.co/WAHRMSQ9BD
      in_reply_to_status_id: 1407704147974033400
      in_reply_to_status_id_str: "1407704147974033414"
- preprint:
    id: "146973"
    doi: 10.1101/2021.06.21.449261
    first_posted: 2021-06-22
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.21.449261v1
    url: https://api.rxivist.org/v1/papers/146973
    title: Analysis of scientific journalism in Nature reveals gender and regional
      disparities in coverage
    category: scientific-communication-and-education
    abstract: "Scientific journalism is a critical way in which the public can
      remain informed and benefit from new scientific findings. Such journalism
      also shapes the public's view of the current state of scientific findings
      and legitimizes experts. Those covering science can only cite and quote a
      limited number of sources. Sources may be identified by the journalist's
      research or by recommendations by other scientists. In both cases, biases
      may influence who is identified and ultimately included as an expert. We
      analyzed 22,001 non-research articles published by Nature to quantify
      possible disparities. Our analysis considered three possible sources of
      disparity: gender, name origin, and country affiliation. To explore these
      sources of disparity, we extracted cited authors' names and affiliations,
      as well as extracted names of quoted speakers. While citations and
      quotations within a piece do not reflect the entire information-gathering
      process, they can provide insight into the demographics of visible
      sources. We then used the extracted names to predict gender and name
      origin of the cited authors and speakers. In order to appropriately
      quantify the level of difference, we must identify a suitable reference
      set for comparison. We chose first and last authors within primary
      research articles in Nature and a subset of Springer Nature articles in
      the same time period as our comparator. In our analysis, we found a skew
      towards male quotation in Nature journalism-related articles, but
      quotation is trending toward equal representation at a faster rate than
      first and last authorship in academic publishing. Interestingly, we found
      that the gender disparity in quotes was column-dependent, with the
      \"Career Features\" column reaching gender parity. Our name origin
      analysis found a significant over-representation of names with predicted
      Celtic/English origin and under-representation of names with a predicted
      East Asian origin. This finding was observed both in extracted quotes and
      journal citations, but dampened in citations. Finally, we performed an
      analysis to identify how countries vary in the way that they're described
      in scientific journalism. We focused on two groups of countries: countries
      that are often mentioned in articles, but do not often have affiliated
      authors cited, and countries that have affiliated authors that are often
      cited, but the country is not typically mentioned. We found that the
      articles in which the less cited countries occur tend to have more
      agricultural, extraction-related, and political terms, whereas articles
      including highly cited countries have broader scientific terms. This
      discrepancy indicates a possible lack of regional diversity in the
      reporting of scientific output."
    authors:
      - name: Natalie R Davidson
        orcid: http://orcid.org/0000-0002-1745-8072
      - name: Casey S Greene
        orcid: http://orcid.org/0000-0001-8713-9213
  comment:
    dislikes: 0
    thread: "8608088225"
    numReports: 0
    likes: 0
    id: "5430219818"
    createdAt: 2021-06-23T15:01:58
    author:
      name: Stefano
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Really interesting preprint! May I ask for a clarification point?
      If I understood correctly, you are checking for divergence from  the
      "demographic makeup of  the scientists who publish their primary research
      in Nature" (and specifically, last authors). Yet it has been shown that
      this demographic (i.e. scientists that are published by Nature) is itself
      biased. E.g. Abdill 2020 10.7554/eLife.58496 showing that several Nature
      titles disproportionately publish research from the united states. It is
      also possible to imagine bias towards Western authors given Nature's
      publishing model/fees etc.. Doesn't this suggest that the biases in Nature
      journalism, with respect to global science, are likely even stronger than
      what measured? I.e. Nature journalism over-represents English/men authors
      compared to a reference that already over-represents them, and
      underrepresents East-Asian/women authors compared to a reference that
      already under-represents them? I would be really interested in hearing
      your thoughts on this point.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.21.449261v1
  tweets:
    - created_at: Wed Jun 23 16:25:53 +0000 2021
      id: 1407736679511715800
      id_str: "1407736679511715844"
      text: >-
        üí¨ bioRxiv comment on "Analysis of scientific journal..."


        "Really interesting preprint! May I ask for a clarificati‚Ä¶ https://t.co/7TDuTijVjL
      truncated: true
      entities:
        urls:
          - url: https://t.co/7TDuTijVjL
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 23 16:25:53 +0000 2021
      id: 1407736680505774000
      id_str: "1407736680505774083"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/D3rVy5WLz0
      truncated: false
      entities:
        urls:
          - url: https://t.co/D3rVy5WLz0
      in_reply_to_status_id: 1407736679511715800
      in_reply_to_status_id_str: "1407736679511715844"
- preprint:
    id: "114848"
    doi: 10.1101/2020.07.30.20165365
    first_posted: 2020-08-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.07.30.20165365v1
    url: https://api.rxivist.org/v1/papers/114848
    title: "Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A
      randomized controlled trial"
    category: infectious-diseases
    abstract: >-
      BackgroundHydroxychloroquine (HCQ) has been considered to treat
      Coronavirus disease 2019 (COVID-19) but data on efficacy is conflicting.
      we analyzed the efficacy of HCQ) in addition to standard of care (SOC)
      compared with SOC alone in reducing disease progression in Mild COVID-19


      MethodsA single centre open label randomized controlled trial during 10th April to 31st May 2020 was conducted at Pak emirates Military Hospital (PEMH) Five hundred patients of both genders having age between 18-80 years with Mild COVID-19 were enrolled. Patients assigned to standard dose of HCQ plus SOC were 349 while 151 patients received SOC (control group). Primary outcome was progression of disease while secondary outcome was PCR negativity on day 7 and 14. The results were analyzed on SPSS version 23. P value <0.05 was considered significant.


      ResultsMedian age of intervention group (34 {+/-} 11.778 years) and control group (34 {+/-} 9.813 years). Disease progressed in 16 patients, 11 (3.15%) were in intervention group as compared to 5 (3.35%) in control group, (P value = 0.865). PCR negativity in intervention and control groups were (day 7, 182 (52.1%) vs. 54 (35.7%) (P value = 0.001), (day 14, 244 (69.9%) vs. 110 (72.8%) (P value = 0.508). Consecutive PCR negativity at day 7 and 14 was observed in 240 (68.8%) in intervention group compared to 108 (71.5%) in control group. (P value = 0.231).


      ConclusionAddition of HCQ to SOC in Mild COVID-19 neither stops disease progression nor help in early and sustained viral clearance.


      Clinical Trial numberNCT04491994 available at ClinicalTrials.gov
    authors:
      - name: Sultan Mehmood Kamran
        orcid: http://orcid.org/0000-0002-0048-6675
      - name: Zill-e-Humayun Mirza
        orcid: http://orcid.org/0000-0002-9121-4981
      - name: Arshad Naseem
        orcid: http://orcid.org/0000-0002-3985-4631
      - name: Rizwan Azam
        orcid: null
      - name: Naqeeb Ullah
        orcid: null
      - name: Farrukh Saeed
        orcid: null
      - name: Wasim Alamgir
        orcid: null
      - name: Salman Saleem
        orcid: null
      - name: Shazia Nisar
        orcid: http://orcid.org/0000-0002-0996-7029
      - name: Mehmood Hussain
        orcid: null
  comment:
    dislikes: 0
    thread: "8235429737"
    numReports: 0
    likes: 0
    id: "5430144180"
    createdAt: 2021-06-23T14:04:38
    author:
      username: david_sbabo
      about: ""
      name: David Sbabo
      isPowerContributor: false
      profileUrl: https://disqus.com/by/david_sbabo/
      url: ""
      location: ""
      id: "78439348"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: |-
      The name of this is
      p-hacking.

      If you want to test at day 7, do it from the start.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.07.30.20165365v2
  tweets:
    - created_at: Wed Jun 23 18:22:36 +0000 2021
      id: 1407766050603741200
      id_str: "1407766050603741184"
      text: |-
        üí¨ medRxiv comment on "Clearing the fog: Is HCQ effec..."

        "The name of this is
        p-hacking.

        If you want to test at d‚Ä¶ https://t.co/5RwaedpW50
      truncated: true
      entities:
        urls:
          - url: https://t.co/5RwaedpW50
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 23 18:22:36 +0000 2021
      id: 1407766051476193300
      id_str: "1407766051476193281"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/kSowXAJLPp
      truncated: false
      entities:
        urls:
          - url: https://t.co/kSowXAJLPp
      in_reply_to_status_id: 1407766050603741200
      in_reply_to_status_id_str: "1407766050603741184"
- preprint:
    id: 146736
    metric: 24
    title: SARS-CoV-2 mRNA Vaccine Induces Robust Specific and Cross-reactive IgG
      and Unequal Strain-specific Neutralizing Antibodies in NaiÃàve and
      Previously Infected Recipients
    url: https://api.rxivist.org/v1/papers/146736
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.19.449100v1
    doi: 10.1101/2021.06.19.449100
    category: immunology
    first_posted: 2021-06-19
    abstract: With the advance of SARS-CoV-2 vaccines, the outlook for overcoming
      the global COVID-19 pandemic has improved. However, understanding of
      immunity and protection offered by the SARS-CoV-2 vaccines against
      circulating variants of concern (VOC) is rapidly evolving. We investigated
      the mRNA vaccine-induced antibody responses against the referent WIV04
      (Wuhan) strain, circulating variants, and human endemic coronaviruses in
      168 naive and previously infected people at three-time points. Samples
      were collected prior to vaccination, after the first and after the second
      doses of one of the two available mRNA-based vaccines. After full
      vaccination, both naive and previously infected participants developed
      comparable robust SARS-CoV-2 specific spike IgG levels, modest IgM and IgA
      binding antibodies, and varying degrees of HCoV cross-reactive antibodies.
      However, the strength and frequency of neutralizing antibodies produced in
      naive people were significantly lower than in the previously infected
      group. We also found that 1/3rd of previously infected people had
      undetectable neutralizing antibodies after the first vaccine dose; 40% of
      this group developed neutralizing antibodies after the second dose. In all
      subjects neutralizing antibodies produced against the B.1.351 and P.1
      variants were weaker than those produced against the reference and B.1.1.7
      strains. Our findings provide support for future booster vaccinations
      modified to be active against the circulating variants.
    authors:
      - name: Tara M Narowski
      - name: Kristin Raphel
      - name: Lily E Adams
      - name: Jenny Huang
      - name: Nadja A. Vielot
      - name: Ramesh Jadi
      - name: Aravinda M de Silva
      - name: Ralph S. Baric
      - name: John E Lafleur
      - name: Lakshmanane Premkumar
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Wed Jun 23 20:14:50 +0000 2021
      id: 1407794297890652200
      id_str: "1407794297890652170"
      text: >-
        üî• bioRxiv Immunology preprint by T. M. Narowski et al:


        "SARS-CoV-2 mRNA Vaccine Induces Robust Specific and Cross-‚Ä¶ https://t.co/K8Q1WI0eSk
      truncated: true
      entities:
        urls:
          - url: https://t.co/K8Q1WI0eSk
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "146973"
    doi: 10.1101/2021.06.21.449261
    first_posted: 2021-06-22
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.21.449261v1
    url: https://api.rxivist.org/v1/papers/146973
    title: Analysis of scientific journalism in Nature reveals gender and regional
      disparities in coverage
    category: scientific-communication-and-education
    abstract: "Scientific journalism is a critical way in which the public can
      remain informed and benefit from new scientific findings. Such journalism
      also shapes the public's view of the current state of scientific findings
      and legitimizes experts. Those covering science can only cite and quote a
      limited number of sources. Sources may be identified by the journalist's
      research or by recommendations by other scientists. In both cases, biases
      may influence who is identified and ultimately included as an expert. We
      analyzed 22,001 non-research articles published by Nature to quantify
      possible disparities. Our analysis considered three possible sources of
      disparity: gender, name origin, and country affiliation. To explore these
      sources of disparity, we extracted cited authors' names and affiliations,
      as well as extracted names of quoted speakers. While citations and
      quotations within a piece do not reflect the entire information-gathering
      process, they can provide insight into the demographics of visible
      sources. We then used the extracted names to predict gender and name
      origin of the cited authors and speakers. In order to appropriately
      quantify the level of difference, we must identify a suitable reference
      set for comparison. We chose first and last authors within primary
      research articles in Nature and a subset of Springer Nature articles in
      the same time period as our comparator. In our analysis, we found a skew
      towards male quotation in Nature journalism-related articles, but
      quotation is trending toward equal representation at a faster rate than
      first and last authorship in academic publishing. Interestingly, we found
      that the gender disparity in quotes was column-dependent, with the
      \"Career Features\" column reaching gender parity. Our name origin
      analysis found a significant over-representation of names with predicted
      Celtic/English origin and under-representation of names with a predicted
      East Asian origin. This finding was observed both in extracted quotes and
      journal citations, but dampened in citations. Finally, we performed an
      analysis to identify how countries vary in the way that they're described
      in scientific journalism. We focused on two groups of countries: countries
      that are often mentioned in articles, but do not often have affiliated
      authors cited, and countries that have affiliated authors that are often
      cited, but the country is not typically mentioned. We found that the
      articles in which the less cited countries occur tend to have more
      agricultural, extraction-related, and political terms, whereas articles
      including highly cited countries have broader scientific terms. This
      discrepancy indicates a possible lack of regional diversity in the
      reporting of scientific output."
    authors:
      - name: Natalie R Davidson
        orcid: http://orcid.org/0000-0002-1745-8072
      - name: Casey S Greene
        orcid: http://orcid.org/0000-0001-8713-9213
  comment:
    dislikes: 0
    thread: "8608088225"
    numReports: 0
    likes: 0
    id: "5430478900"
    createdAt: 2021-06-23T17:51:51
    author:
      username: natalierdavidson
      about: ""
      name: Natalie R Davidson
      isPowerContributor: false
      profileUrl: https://disqus.com/by/natalierdavidson/
      url: ""
      location: ""
      id: "371356687"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Hi Stefano! Thanks for your interest in our work! You bring up an
      excellent point that <i>Nature</i> publications are likely a biased sample
      of the scientific community. We partially address this in some of our
      supplementary analyses, mainly supplementary figures 2A and 4. We took an
      additional comparative dataset of a random subset of papers published by
      <i>Springer Nature</i>. In these analyses, we observe what you suspected
      in your comment -- the disparity may be more significant when comparing
      against other journals. 


      For our predicted gender analysis, we find that authorship in <i>Springer Nature</i> is closer to parity than <i>Nature</i>, but still far from parity. We also found that the proportion of predicted male quotes has a larger disparity than first authors in <i>Springer Nature</i>.


      Regarding our predicted name origin analysis, let's look at supplementary figures 4 C and D. Here, when we compare springer last author vs. nature last author, we find springer last authors to be much more diverse. Specifically looking at the "East Asian" last author name origins, we see that <i>Springer Nature</i> last authors make up between 10-40%, whereas Nature last authors only make up between 15-25%.


      An additional experiment would be to take multiple journals based in various countries, have multiple estimated impact factors, any other parameters that may be important, and perform the comparisons. The biggest problem with this, is that not all journals make this information readily available. If I were to do this, I would try to additionally pick journals published within <i>Springer Nature</i>, since their API is easy to use.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.21.449261v1
  tweets:
    - created_at: Wed Jun 23 20:18:16 +0000 2021
      id: 1407795159257870300
      id_str: "1407795159257870336"
      text: >-
        üí¨ bioRxiv comment on "Analysis of scientific journal..."


        "Hi Stefano! Thanks for your interest in our work! You br‚Ä¶ https://t.co/dXtb1gh1x8
      truncated: true
      entities:
        urls:
          - url: https://t.co/dXtb1gh1x8
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 23 20:18:16 +0000 2021
      id: 1407795160138731500
      id_str: "1407795160138731527"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/D3rVy5WLz0
      truncated: false
      entities:
        urls:
          - url: https://t.co/D3rVy5WLz0
      in_reply_to_status_id: 1407795159257870300
      in_reply_to_status_id_str: "1407795159257870336"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 0
    id: "5430372430"
    createdAt: 2021-06-23T16:41:14
    author:
      username: disqus_pnXxBPirjv
      about: ""
      name: Sock Dollager
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_pnXxBPirjv/
      url: https://townhall.com/columnists/wayneallynroot/2021/05/09/heres-how-you-know-democrats-rigged-and-stole-the-2020-election-n2589148
      location: USA
      id: "158918419"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Thank you for the explanation.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Wed Jun 23 22:17:53 +0000 2021
      id: 1407825262356713500
      id_str: "1407825262356713474"
      text: |-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."

        "Thank you for the explanation."

        https://t.co/pwOlr48mC5
      truncated: false
      entities:
        urls:
          - url: https://t.co/pwOlr48mC5
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 23 22:17:53 +0000 2021
      id: 1407825262985744400
      id_str: "1407825262985744384"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1407825262356713500
      in_reply_to_status_id_str: "1407825262356713474"
- preprint:
    id: "146297"
    doi: 10.1101/2021.06.15.21258542
    first_posted: 2021-06-16
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.15.21258542v1
    url: https://api.rxivist.org/v1/papers/146297
    title: "Casirivimab and imdevimab in patients admitted to hospital with COVID-19
      (RECOVERY): a randomised, controlled, open-label, platform trial"
    category: infectious-diseases
    abstract: "Background: REGEN-COV is a combination of 2 monoclonal antibodies
      (casirivimab and imdevimab) that bind to two different sites on the
      receptor binding domain of the SARS-CoV-2 spike protein. We aimed to
      evaluate the efficacy and safety of REGEN-COV in patients admitted to
      hospital with COVID-19. Methods: In this randomised, controlled,
      open-label platform trial, several possible treatments were compared with
      usual care in patients hospitalised with COVID-19. Eligible and consenting
      patients were randomly allocated (1:1) to either usual standard of care
      alone (usual care group) or usual care plus a single dose of REGEN-COV 8g
      (casirivimab 4g and imdevimab 4g) by intravenous infusion (REGEN-COV
      group). The primary outcome was 28-day mortality assessed first among
      patients without detectable antibodies to SARS-CoV-2 at randomisation
      (seronegative) and then in the overall population. Findings: Between 18
      September 2020 and 22 May 2021, 9785 patients were randomly allocated to
      receive usual care plus REGEN-COV or usual care alone, including 3153
      (32%) seronegative patients, 5272 (54%) seropositive patients and 1360
      (14%) patients with unknown baseline antibody status. In the primary
      efficacy population of seronegative patients, 396 (24%) of 1633 patients
      allocated to REGEN-COV and 451 (30%) of 1520 patients allocated to usual
      care died within 28 days (rate ratio 0.80; 95% CI 0.70-0.91; p=0.0010). In
      an analysis involving all randomised patients (regardless of baseline
      antibody status), 944 (20%) of 4839 patients allocated to REGEN-COV and
      1026 (21%) of 4946 patients allocated to usual care died within 28 days
      (rate ratio 0.94; 95% CI 0.86-1.03; p=0.17). The proportional effect of
      REGEN-COV on mortality differed significantly between seropositive and
      seronegative patients (p value for heterogeneity = 0.001). Interpretation:
      In patients hospitalised with COVID-19, the monoclonal antibody
      combination of casirivimab and imdevimab (REGEN-COV) reduced 28-day
      mortality among patients who were seronegative at baseline."
    authors:
      - name: Peter W Horby
        orcid: http://orcid.org/0000-0002-9822-1586
      - name: Marion Mafham
        orcid: http://orcid.org/0000-0003-0562-3963
      - name: Leon Peto
        orcid: http://orcid.org/0000-0002-4100-2163
      - name: Mark Campbell
        orcid: http://orcid.org/0000-0002-9759-0232
      - name: Guilherme Pessoa-Amorim
        orcid: http://orcid.org/0000-0002-4050-6191
      - name: Enti Spata
        orcid: http://orcid.org/0000-0002-7207-2076
      - name: Natalie Staplin
        orcid: http://orcid.org/0000-0003-4482-4418
      - name: Jonathan R Emberson
        orcid: http://orcid.org/0000-0001-7792-9422
      - name: Benjamin Prudon
        orcid: null
      - name: Paul Hine
        orcid: null
      - name: Thomas Brown
        orcid: null
      - name: Christopher A Green
        orcid: http://orcid.org/0000-0002-1984-4014
      - name: Rahuldeb Sarkar
        orcid: http://orcid.org/0000-0002-4343-8526
      - name: Purav Desai
        orcid: null
      - name: Bryan Yates
        orcid: null
      - name: Tom Bewick
        orcid: null
      - name: Simon Tiberi
        orcid: null
      - name: Tim Felton
        orcid: null
      - name: J Kenneth Baillie
        orcid: http://orcid.org/0000-0001-5258-793X
      - name: Maya H Buch
        orcid: http://orcid.org/0000-0002-8962-5642
      - name: Lucy C Chappell
        orcid: http://orcid.org/0000-0001-6219-3379
      - name: Jeremy N Day
        orcid: http://orcid.org/0000-0002-7843-6280
      - name: Saul N Faust
        orcid: http://orcid.org/0000-0003-3410-7642
      - name: Thomas Jaki
        orcid: http://orcid.org/0000-0002-1096-188X
      - name: Katie Jeffery
        orcid: http://orcid.org/0000-0002-6506-2689
      - name: Edmund Juszczak
        orcid: http://orcid.org/0000-0001-5500-2247
      - name: Wei Shen Lim
        orcid: http://orcid.org/0000-0002-7694-3051
      - name: Alan Montgomery
        orcid: http://orcid.org/0000-0003-0450-1606
      - name: Andrew Mumford
        orcid: http://orcid.org/0000-0002-5523-511X
      - name: Kathryn Rowan
        orcid: http://orcid.org/0000-0001-8217-5602
      - name: Guy Thwaites
        orcid: http://orcid.org/0000-0002-2858-2087
      - name: David M Weinreich
        orcid: null
      - name: Richard Haynes
        orcid: http://orcid.org/0000-0002-1179-0023
      - name: Martin J Landray
        orcid: http://orcid.org/0000-0001-6646-827X
  comment:
    dislikes: 0
    thread: "8596736056"
    numReports: 0
    likes: 0
    id: "5430307669"
    createdAt: 2021-06-23T15:59:54
    author:
      username: disqus_vNPXLcKZbq
      about: ""
      name: Alain Tremblay
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_vNPXLcKZbq/
      url: ""
      location: ""
      id: "371354809"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Do the authors have more information regarding the seropositive
      cases. Are these believed to be seropositive due to late phase of acute
      illness, prior SARS-Cov-2 infection, or prior vaccination? Since the trial
      recruited well into the vaccination effort in the UK, vaccination status
      of participants should be reported as well. Thanks for this great effort!
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.15.21258542v1
  tweets:
    - created_at: Thu Jun 24 00:49:17 +0000 2021
      id: 1407863363401625600
      id_str: "1407863363401625601"
      text: >-
        üí¨ medRxiv comment on "Casirivimab and imdevimab in p..."


        "Do the authors have more information regarding the serop‚Ä¶ https://t.co/WhbLEew5KB
      truncated: true
      entities:
        urls:
          - url: https://t.co/WhbLEew5KB
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 24 00:49:17 +0000 2021
      id: 1407863364169224200
      id_str: "1407863364169224192"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/pcSi9pXLpS
      truncated: false
      entities:
        urls:
          - url: https://t.co/pcSi9pXLpS
      in_reply_to_status_id: 1407863363401625600
      in_reply_to_status_id_str: "1407863363401625601"
- preprint:
    id: "147028"
    doi: 10.1101/2021.06.18.449051
    first_posted: 2021-06-22
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.18.449051v1
    url: https://api.rxivist.org/v1/papers/147028
    title: Recovery of deleted deep sequencing data sheds more light on the early
      Wuhan SARS-CoV-2 epidemic
    category: evolutionary-biology
    abstract: The origin and early spread of SARS-CoV-2 remains shrouded in mystery.
      Here I identify a data set containing SARS-CoV-2 sequences from early in
      the Wuhan epidemic that has been deleted from the NIH's Sequence Read
      Archive. I recover the deleted files from the Google Cloud, and
      reconstruct partial sequences of 13 early epidemic viruses. Phylogenetic
      analysis of these sequences in the context of carefully annotated existing
      data suggests that the Huanan Seafood Market sequences that are the focus
      of the joint WHO-China report are not fully representative of the viruses
      in Wuhan early in the epidemic. Instead, the progenitor of known
      SARS-CoV-2 sequences likely contained three mutations relative to the
      market viruses that made it more similar to SARS-CoV-2's bat coronavirus
      relatives.
    authors:
      - name: Jesse D Bloom
        orcid: http://orcid.org/0000-0003-1267-3408
  comment:
    dislikes: 1
    thread: "8609030409"
    numReports: 0
    likes: 5
    id: "5429850002"
    createdAt: 2021-06-23T07:38:24
    author:
      username: acc_account
      about: ""
      name: ACC
      isPowerContributor: false
      profileUrl: https://disqus.com/by/acc_account/
      url: ""
      location: ""
      id: "263854694"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      This work by Professor Jesse Bloom details a phylogenetic analysis of a
      set of SARS-CoV-2 genomic sequences originally submitted to the Sequence
      Read Archive, likely by the authors of Wang et al. 2020, in February -
      March, 2020. Both a preprint, and a later paper (by Wang et al.), were
      publicly available describing these sequences, including key aspects of
      their genomic features. However, independently of the preprint or paper,
      which make no direct reference to an NCBI submission, the sequences  been
      marked for deletion on NCBI, but were re-obtained by Bloom via internet
      backups of the data. While sharing more genomic data from the early
      epidemic can be valuable, I believe the current version of this work makes
      several errors that are important to address in both scientific content
      and critically, in scientific communication.



      In general, the work is vague or remiss about extremely important context and details about the sequences in question. To begin, the genomes obtained are consistently referred throughout the title and abstract (and indeed most of the text) as being from the "early" epidemic. This terminology is too vague, as it may invite the reader to assume that the genomes include  the earliest cases known - in fact, they are not, and were originally reported by Wang et al. 2020 to be from January 2020. Over 25 genomes had previously been obtained during 2019 for SARS-CoV-2. To properly interpret the context of this work, an emphasis on the timing is critical and should not be avoided in the abstract or title. 



      Secondly, the abstract and title both strongly give the inaccurate impression that the re-obtained sequences alone newly demonstrate that the known and reported genetic diversity of viruses in the Huanan market was not representative of all circulating SARS-CoV-2 variants at the time. This is alluded to in the title, which says they "shed more light" on the early epidemic. Yet, this is not supported by the data in the manuscript: it was already known that the genetic diversity of viruses obtained from Huanan market cases was not representative of all genetic variants circulating at that time.  As can be seen most clearly in Figs 3 and 5, the new sequences obtained were not completely unique in sequence or unusual in case timing. There were already several reported publicly available similar genomes with for the most part identical sequences from the early epidemic. The author is certainly aware of this, as it is evident from the data presented and from the works cited (both Garry 2021 and Kumar et al. 2021 discuss this at length), but this key point is not emphasized in the title or abstract, and indeed is a  weakness of the importance of the work itself. 



      Thirdly, in the introduction the work makes several key omissions about the timing of cases. The introduction directly suggests that the Huanan market is unlikely to be a site of zoonosis because a number of early cases could not be confirmed to be connected to the market; However, this was true of SARS-CoV-1 in Fushan as well. The author also neglects to mention that a significant fraction of cases were connected to *other* markets in the city, including the earliest cases (as described in the WHO report). And indeed, if there were multiple spillover events, e.g. from a shared wildlife supply chain that connected multiple markets throughout the city, even with perfect contact tracing data one would not expect all cases to be connected to one market.



      Fourthly, I believe the inclusion of Figure 2 in this paper is highly unprofessional and misleading. This is a screenshot of an email from a scientist who is not associated with the papers or data described in the data; indeed, the only relevance between them seems to be a shared nationality of the author(s). Additionally, as of June 2021 the data described as 'deleted' in this screenshot is publicly available again on NCBI. While I understand that Bloom likely did not realize this mistake, it is difficult to justify the inclusion of this figure in a scientific work. 




      Fifthly, and perhaps most importantly, I think the previous point happens to provide a fortuitous lesson about a key error that Bloom makes in assuming misconduct on the part of the Wang et al. 2020 authors. He writes "It therefore seems the sequences were deleted to obscure their existence". It is implicitly assumed that Bloom believed that to also be true of the data described in Figure 2 - hence its inclusion - but its recent re-publication on NCBI makes it abundantly clear that was not the case. To be honest, this is not surprising. Claims of scientific misconduct made from a distance, without knowledge of the details and circumstance surrounding the issue, have the potential to appear convincing despite having perfectly ordinary (or perhaps slightly less than ideal, but not nefarious) scientific rationale. 




      Similarly, there is also evidence that scientific misconduct is also highly unlikely to be the case with the dataset that is described in this paper. Primarily, this is because the paper describing these sequences  was published in a journal several months later. If the authors were indeed trying to obscure their data, they would simply also not publish their paper in a public journal, or request it to not be published after submitting for review. If these sequences were removed for the purpose of obscurity, it is also worth noting that such an effort clearly flopped - because as described above, these sequences do not immediately provide any completely new knowledge about the genetic diversity of SARS-CoV-2 in the early pandemic. In both the preprint and the paper (the first submitted before data removal; the second published likely after), no mention of a BioProject accession is made, and instead it is said that the data is available upon reasonable request from the authors. If the writers initially intended for the data to be made public, standard practice would have included the BioProject reference (or even a placeholder) in the text. The fact that there was never such a reference makes it quite evident that there likely was a miscommunication between co-authors about whether the data was intended to be released to NCBI. 




      The reality is that minor scientific missteps and less-than-ideal circumstances surround the sharing of scientific data all of the time. The process of publishing on scientific data is fraught with tiny details and hard work, the trainees responsible for it are often overworked, and there are often unfortunate but relatively ordinary scientific incentives to avoid making as much data public as should be. The rationale behind what data is and is not shared for scientific works are often nuanced, and sometimes quite personal. The scientific process would be better if it were not the case, but these forces are almost universal, and everyone encounters them in scientific work. In this circumstance, like in the circumstance outlined in Figure 2 of this work, these ordinary forces of scientific circumstance are almost certainly more likely the case than direct censorship or misconduct. It is unfortunate and alarming that this work as it currently stands baselessly contributes to an environment where many readers assume the latter depending on the country of origin of the original authors.




      Minor point: 


      At the bottom of page 5: "But although there are unusual aspects of RatG13's primary sequencing data". This statement is vague, the language is unscientific, and many interpretations of it would not be supported by the citations provided. I would recommend that Bloom change this sentence to present a coherent scientific statement if indeed there is a point about genome quality to be made there that is relevant to the text.
    forum: biorxivstage
    points: 4
    link: https://www.biorxiv.org/content/10.1101/2021.06.18.449051v1
  tweets:
    - created_at: Thu Jun 24 12:31:19 +0000 2021
      id: 1408040038386966500
      id_str: "1408040038386966544"
      text: >-
        üí¨ bioRxiv comment on "Recovery of deleted deep seque..."


        "This work by Professor Jesse Bloom details a phylogeneti‚Ä¶ https://t.co/h0xRuaoOdm
      truncated: true
      entities:
        urls:
          - url: https://t.co/h0xRuaoOdm
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 24 12:31:20 +0000 2021
      id: 1408040039464853500
      id_str: "1408040039464853514"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/BSMtowYvFU
      truncated: false
      entities:
        urls:
          - url: https://t.co/BSMtowYvFU
      in_reply_to_status_id: 1408040038386966500
      in_reply_to_status_id_str: "1408040038386966544"
- preprint:
    id: "146209"
    doi: 10.1101/2021.06.11.21258690
    first_posted: 2021-06-15
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.11.21258690v1
    url: https://api.rxivist.org/v1/papers/146209
    title: Brain imaging before and after COVID-19 in UK Biobank
    category: neurology
    abstract: There is strong evidence for brain-related pathologies in COVID-19,
      some of which could be a consequence of viral neurotropism. The vast
      majority of brain imaging studies so far have focused on qualitative,
      gross pathology of moderate to severe cases, often carried out on
      hospitalised patients. It remains unknown however whether the impact of
      COVID-19 can be detected in milder cases, in a quantitative and automated
      manner, and whether this can reveal a possible mechanism for the spread of
      the disease. UK Biobank scanned over 40,000 participants before the start
      of the COVID-19 pandemic, making it possible to invite back in 2021
      hundreds of previously-imaged participants for a second imaging visit.
      Here, we studied the effects of the disease in the brain using multimodal
      data from 782 participants from the UK Biobank COVID-19 re-imaging study,
      with 394 participants having tested positive for SARS-CoV-2 infection
      between their two scans. We used structural and functional brain scans
      from before and after infection, to compare longitudinal brain changes
      between these 394 COVID-19 patients and 388 controls who were matched for
      age, sex, ethnicity and interval between scans. We identified significant
      effects of COVID-19 in the brain with a loss of grey matter in the left
      parahippocampal gyrus, the left lateral orbitofrontal cortex and the left
      insula. When looking over the entire cortical surface, these results
      extended to the anterior cingulate cortex, supramarginal gyrus and
      temporal pole. We further compared COVID-19 patients who had been
      hospitalised (n=15) with those who had not (n=379), and while results were
      not significant, we found comparatively similar findings to the COVID-19
      vs control group comparison, with, in addition, a greater loss of grey
      matter in the cingulate cortex, central nucleus of the amygdala and
      hippocampal cornu ammonis (all |Z|>3). Our findings thus consistently
      relate to loss of grey matter in limbic cortical areas directly linked to
      the primary olfactory and gustatory system. Unlike in post hoc disease
      studies, the availability of pre-infection imaging data helps avoid the
      danger of pre-existing risk factors or clinical conditions being
      mis-interpreted as disease effects. Since a possible entry point of the
      virus to the central nervous system might be via the olfactory mucosa and
      the olfactory bulb, these brain imaging results might be the in vivo
      hallmark of the spread of the disease (or the virus itself) via olfactory
      and gustatory pathways.
    authors:
      - name: Gwena√´lle Douaud
        orcid: http://orcid.org/0000-0003-1981-391X
      - name: Soojin Lee
        orcid: http://orcid.org/0000-0002-6258-1280
      - name: Fidel Alfaro-Almagro
        orcid: http://orcid.org/0000-0002-9133-5951
      - name: Christoph Arthofer
        orcid: null
      - name: Chaoyue Wang
        orcid: null
      - name: Frederik Lange
        orcid: http://orcid.org/0000-0002-1736-7162
      - name: Jesper L.R. Andersson
        orcid: null
      - name: Ludovica Griffanti
        orcid: http://orcid.org/0000-0002-0540-9353
      - name: Eugene Duff
        orcid: null
      - name: Saad Jbabdi
        orcid: http://orcid.org/0000-0003-3234-5639
      - name: Bernd Taschler
        orcid: null
      - name: Anderson Winkler
        orcid: http://orcid.org/0000-0002-4169-9781
      - name: Thomas E. Nichols
        orcid: http://orcid.org/0000-0002-4516-5103
      - name: Rory Collins
        orcid: null
      - name: Paul M. Matthews
        orcid: null
      - name: Naomi Allen
        orcid: http://orcid.org/0000-0003-1938-5038
      - name: Karla L Miller
        orcid: http://orcid.org/0000-0002-2511-3189
      - name: Stephen M Smith
        orcid: http://orcid.org/0000-0001-8166-069X
  comment:
    dislikes: 0
    thread: "8595911767"
    numReports: 0
    likes: 0
    id: "5430928310"
    createdAt: 2021-06-23T23:58:28
    author:
      username: id9192
      about: ""
      name: ID9192
      isPowerContributor: false
      profileUrl: https://disqus.com/by/id9192/
      url: ""
      location: ""
      id: "224049202"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Psychological stress is known to bring about several changes in the
      brain, and it is possible that people who contracted covid-19 were really
      stressed out and this may explain the changes in the brain.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.11.21258690v1
  tweets:
    - created_at: Thu Jun 24 14:18:39 +0000 2021
      id: 1408067046508617700
      id_str: "1408067046508617729"
      text: >-
        üí¨ medRxiv comment on "Brain imaging before and after..."


        "Psychological stress is known to bring about several cha‚Ä¶ https://t.co/ecHJE9eGyx
      truncated: true
      entities:
        urls:
          - url: https://t.co/ecHJE9eGyx
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 24 14:18:39 +0000 2021
      id: 1408067047729221600
      id_str: "1408067047729221641"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/yeuDlfWnTt
      truncated: false
      entities:
        urls:
          - url: https://t.co/yeuDlfWnTt
      in_reply_to_status_id: 1408067046508617700
      in_reply_to_status_id_str: "1408067046508617729"
- preprint:
    id: "142591"
    doi: 10.1101/2021.05.20.445036
    first_posted: 2021-05-20
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.20.445036v1
    url: https://api.rxivist.org/v1/papers/142591
    title: RNA silencing by CRISPR in plants does not require Cas13
    category: plant-biology
    abstract: RNA-targeting CRISPR-Cas can provide potential advantages over DNA
      editing, such as avoiding pleiotropic effects of genome editing, providing
      precise spatiotemporal regulation and expanded function including
      anti-viral immunity. Here, we report the use of CRISPR-Cas13 in plants to
      reduce both viral and endogenous RNA. Unexpectedly, we discovered that
      crRNA designed to guide Cas13 could, in the absence of the Cas13 protein,
      cause substantial reduction in RNA levels as well. We demonstrate
      Cas13-independent guide-induced gene silencing (GIGS) in three plant
      species, including stable transgenic Arabidopsis. We determined that GIGS
      utilizes endogenous RNAi machinery despite the fact that crRNA are unlike
      canonical triggers of RNAi such as miRNA, hairpins or long double-stranded
      RNA. These results suggest that GIGS offers a novel and flexible approach
      to RNA reduction with potential benefits over existing technologies for
      crop improvement. Our results demonstrate that GIGS is active across a
      range of plant species, evidence similar to recent findings in an insect
      system, which suggests that GIGS is potentially active across many
      eukaryotes.
    authors:
      - name: Veerendra Sharma
        orcid: null
      - name: Sandeep R. Marla
        orcid: http://orcid.org/0000-0001-5778-7850
      - name: Wenguang Zheng
        orcid: null
      - name: Divya Mishra
        orcid: http://orcid.org/0000-0003-1562-1718
      - name: Jun Huang
        orcid: null
      - name: WEI ZHANG
        orcid: null
      - name: Geoffrey P Morris
        orcid: http://orcid.org/0000-0002-3067-3359
      - name: David Cook
        orcid: http://orcid.org/0000-0002-2719-4701
  comment:
    dislikes: 0
    thread: "8537385894"
    numReports: 0
    likes: 0
    id: "5430016155"
    createdAt: 2021-06-23T11:58:40
    author:
      username: disqus_8CxiYFjgeh
      about: ""
      name: Tom Jacobs
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_8CxiYFjgeh/
      url: ""
      location: ""
      id: "198759940"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Interesting. I like the work. Just as you write, folks generally do not
      include the Cas- or gRNA/crRNA-only controls anymore. This was done back
      when CRISPR took off but it has largely been dropped. 


      I wonder about the sRNA sequencing. Did you observe the intact DR + spacer in the reads, or only the processed forms? It looks like your library prep protocol would have excluded larger fragments. You mention the reads are 21-24 nt in length, but which part of the DR+spacer does that contain? Is it a single species? Or spread out across the 28-nt spacer? 


      sRNAs should be produced along the entire length of your TRV vectors. Maybe what you are observing with the viral work is just the production of a functional siRNA from the viral RNA (standard VIGS) and not from a crRNA? Unless I missed it, all the results show that the presence of the crRNA vector is sufficient, but is there evidence that expression of the crRNA is required? I'm curious what would happen if you removed the U6 promoter and/or the DR. Or change the initiating nucleotide. That could establish that GIGS requires crRNA expression and not just presence.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.05.20.445036v1
  tweets:
    - created_at: Thu Jun 24 16:31:49 +0000 2021
      id: 1408100558494445600
      id_str: "1408100558494445568"
      text: >-
        üí¨ bioRxiv comment on "RNA silencing by CRISPR in pla..."


        "Interesting. I like the work. Just as you write, folks g‚Ä¶ https://t.co/taeuMPrz6K
      truncated: true
      entities:
        urls:
          - url: https://t.co/taeuMPrz6K
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 24 16:31:49 +0000 2021
      id: 1408100559467565000
      id_str: "1408100559467565057"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/cEfkKjZhu6
      truncated: false
      entities:
        urls:
          - url: https://t.co/cEfkKjZhu6
      in_reply_to_status_id: 1408100558494445600
      in_reply_to_status_id_str: "1408100558494445568"
- preprint:
    id: "125874"
    doi: 10.1101/2021.01.16.21249924
    first_posted: 2021-01-20
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.01.16.21249924v1
    url: https://api.rxivist.org/v1/papers/125874
    title: Sword of Damocles or choosing well. Population genetics sheds light into
      the future of the COVID-19 pandemic and SARS-CoV-2 new mutant strains.
    category: epidemiology
    abstract: Abstract An immense scientific effort has been made worldwide due to
      Covid-19s pandemic magnitude. It has made possible to identify almost
      300,000 SARS-CoV-2 different genetic variants, connecting them with
      clinical and epidemiological findings. Among this immense data collection,
      that constitutes the biggest evolutionary experiment in history, is buried
      the answer to what will happen in the future. Will new strains, more
      contagious than the current ones or resistant to the vaccines, arise by
      mutation? Although theoretic population genetics is, by far, the most
      powerful tool we have to do an accurate prediction, it has been barely
      used for the study of SARS-CoV-2 due to its conceptual difficulty. Having
      in mind that the size of the SARS-CoV-2 population is astronomical we can
      apply a discrete treatment, based on the branching process method,
      Fokker-Plank equations and Kolmogoroffs forward equations, to calculate
      the survival likelihood through time, to elucidate the likelihood to
      become dominant genotypes and how long will this take, for new SARS-CoV-2
      mutants depending on their selective advantage. Results show that most of
      the new mutants that will arise in the SARS-CoV-2 meta-population will
      stay at very low frequencies. However, some few new mutants, significantly
      more infectious than current ones, will still emerge and become dominant
      in the population favoured by a great selective advantage. Far from
      showing a mutational meltdown, SARS-CoV-2 meta-population will increase
      its fitness becoming more infective. There is a probability, small but
      finite, that new mutants arise resistant to some vaccines. High infected
      numbers and slow vaccination programs will significantly increase this
      likelihood.
    authors:
      - name: Javier Garcia Garcia de Alca√±iz
        orcid: null
      - name: Victoria Lopez-Rodas
        orcid: null
      - name: Eduardo Costas
        orcid: null
  comment:
    dislikes: 0
    thread: "8363456675"
    numReports: 0
    likes: 0
    id: "5429950731"
    createdAt: 2021-06-23T10:31:57
    author:
      username: avantduel
      about: I am the Master of the Unheard Of
      name: Otto von Ruggins
      isPowerContributor: false
      profileUrl: https://disqus.com/by/avantduel/
      url: http://www.ottovr.com
      location: Brooklyn, NY
      id: "28194417"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: As a retired High School English Teacher, my concern with this
      Pre-print release is that at times it reads very poorly for a would be
      scientific paper. There are numerous errors in syntax and sentences that
      are not properly formatted. As much as I appreciate the findings of the
      researchers, I am disappointed in the lack of editing prior to the
      pre-print. I am willing to go through this paper and make corrections, but
      I can also imagine a simple Word document Spelling and Grammer check would
      also be a place to start. As an example, just try reading the paragraphs
      prior to the endnotes from "4. Muller‚Äôs ratchet, 'mutational meltdown' and
      fundamental principle of natural selection" on. You will encounter 'led'
      which should be spelled 'lead', two non-sentences in a row, the word
      'where' which was probably supposed to be 'were', which would have made
      one of those phrases an actual sentence and more. Sadly, as I read this
      informative document, every time I came across these errors, I cringed at
      how it ever reached this stage with so many stumbling blocks to a proper
      English read!
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.01.16.21249924v1
  tweets:
    - created_at: Thu Jun 24 18:24:47 +0000 2021
      id: 1408128988099264500
      id_str: "1408128988099264522"
      text: >-
        üí¨ medRxiv comment on "Sword of Damocles or choosing ..."


        "As a retired High School English Teacher, my concern wit‚Ä¶ https://t.co/E1NrBcETP8
      truncated: true
      entities:
        urls:
          - url: https://t.co/E1NrBcETP8
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 24 18:24:47 +0000 2021
      id: 1408128988917207000
      id_str: "1408128988917207046"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/6G3GiVeipg
      truncated: false
      entities:
        urls:
          - url: https://t.co/6G3GiVeipg
      in_reply_to_status_id: 1408128988099264500
      in_reply_to_status_id_str: "1408128988099264522"
- preprint:
    id: 94129
    metric: 9
    title: Structural basis for VIPP1 oligomerization and maintenance of thylakoid
      membrane integrity
    url: https://api.rxivist.org/v1/papers/94129
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.08.11.243204v1
    doi: 10.1101/2020.08.11.243204
    category: plant-biology
    first_posted: 2020-08-11
    abstract: >-
      Vesicle-inducing protein in plastids (VIPP1) is essential for the
      biogenesis and maintenance of thylakoid membranes, which transform light
      into life. However, it is unknown how VIPP1 performs its vital
      membrane-shaping function. Here, we use cryo-electron microscopy to
      determine structures of cyanobacterial VIPP1 rings, revealing how VIPP1
      monomers flex and interweave to form basket-like assemblies of different
      symmetries. Three VIPP1 monomers together coordinate a non-canonical
      nucleotide binding pocket that is required for VIPP1 oligomerization.
      Inside the ring's lumen, amphipathic helices from each monomer align to
      form large hydrophobic columns, enabling VIPP1 to bind and curve
      membranes. In vivo point mutations in these hydrophobic surfaces cause
      extreme thylakoid swelling under high light, indicating an essential role
      of VIPP1 lipid binding in resisting stress-induced damage. Our study
      provides a structural basis for understanding how the oligomerization of
      VIPP1 drives the biogenesis of thylakoid membranes and protects these
      life-giving membranes from environmental stress.


      ### Competing Interest Statement


      The authors have declared no competing interest.
    authors:
      - name: Tilak Kumar Gupta
      - name: Sven Klumpe
      - name: Karin Gries
      - name: Steffen Heinz
      - name: Wojciech Wietrzynski
      - name: Norikazu Ohnishi
      - name: Justus Niemeyer
      - name: Miroslava Schaffer
      - name: Anna Rast
      - name: Mike Strauss
      - name: Juergen M Plitzko
      - name: Wolfgang Baumeister
      - name: Till Rudack
      - name: Wataru Sakamoto
      - name: J√∂rg Nickelsen
      - name: Jan M. Schuller
      - name: Michael Schroda
      - name: Benjamin D. Engel
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Thu Jun 24 20:08:08 +0000 2021
      id: 1408154998614204400
      id_str: "1408154998614204418"
      text: >-
        üî• bioRxiv Plant-biology preprint by T. K. Gupta et al:


        "Structural basis for VIPP1 oligomerization and maintenance‚Ä¶ https://t.co/0pufELD3ya
      truncated: true
      entities:
        urls:
          - url: https://t.co/0pufELD3ya
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "143071"
    doi: 10.1101/2021.05.22.21257658
    first_posted: 2021-05-24
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.22.21257658v1
    url: https://api.rxivist.org/v1/papers/143071
    title: Effectiveness of COVID-19 vaccines against the B.1.617.2 variant
    category: epidemiology
    abstract: "Background: The B.1.617.2 COVID-19 variant has contributed to the
      surge in cases in India and has now been detected across the globe,
      including a notable increase in cases in the UK. We estimate the
      effectiveness of the BNT162b2 and ChAdOx1 COVID-19 vaccines against this
      variant. Methods: A test negative case control design was used to estimate
      the effectiveness of vaccination against symptomatic disease with both
      variants over the period that B.1.617.2 began circulating with cases
      identified based on sequencing and S-gene target status. Data on all
      symptomatic sequenced cases of COVID-19 in England was used to estimate
      the proportion of cases with B.1.617.2 compared to the predominant strain
      (B.1.1.7) by vaccination status. Results: Effectiveness was notably lower
      after 1 dose of vaccine with B.1.617.2 cases 33.5% (95%CI: 20.6 to 44.3)
      compared to B.1.1.7 cases 51.1% (95%CI: 47.3 to 54.7) with similar results
      for both vaccines. With BNT162b2 2 dose effectiveness reduced from 93.4%
      (95%CI: 90.4 to 95.5) with B.1.1.7 to 87.9% (95%CI: 78.2 to 93.2) with
      B.1.617.2. With ChAdOx1 2 dose effectiveness reduced from 66.1% (95% CI:
      54.0 to 75.0) with B.1.1.7 to 59.8% (95%CI: 28.9 to 77.3) with B.1.617.2.
      Sequenced cases detected after 1 or 2 doses of vaccination had a higher
      odds of infection with B.1.617.2 compared to unvaccinated cases (OR 1.40;
      95%CI: 1.13-1.75). Conclusions: After 2 doses of either vaccine there were
      only modest differences in vaccine effectiveness with the B.1.617.2
      variant. Absolute differences in vaccine effectiveness were more marked
      with dose 1. This would support maximising vaccine uptake with two doses
      among vulnerable groups."
    authors:
      - name: Jamie Lopez Bernal
        orcid: http://orcid.org/0000-0002-1301-5653
      - name: Nick Andrews
        orcid: null
      - name: Charlotte Gower
        orcid: null
      - name: Eileen Gallagher
        orcid: null
      - name: Ruth Simmons
        orcid: http://orcid.org/0000-0001-8156-0146
      - name: Simon Thelwall
        orcid: http://orcid.org/0000-0002-0434-2724
      - name: Elise Tessier
        orcid: null
      - name: Natalie Groves
        orcid: null
      - name: Gavin Dabrera
        orcid: http://orcid.org/0000-0003-4606-5945
      - name: Richard Myers
        orcid: null
      - name: Colin Campbell
        orcid: null
      - name: Gayatri Amirthalingam
        orcid: http://orcid.org/0000-0003-2078-0975
      - name: Matt Edmunds
        orcid: null
      - name: Maria Zambon
        orcid: http://orcid.org/0000-0002-8897-7881
      - name: Kevin Brown
        orcid: null
      - name: Susan Hopkins
        orcid: http://orcid.org/0000-0001-5179-5702
      - name: Meera Chand
        orcid: http://orcid.org/0000-0001-9697-0340
      - name: Mary Ramsay
        orcid: null
  comment:
    dislikes: 0
    thread: "8547961204"
    numReports: 0
    likes: 0
    id: "5431573994"
    createdAt: 2021-06-24T15:13:53
    author:
      username: damionifade
      about: ""
      name: dami Onifade
      isPowerContributor: false
      profileUrl: https://disqus.com/by/damionifade/
      url: ""
      location: ""
      id: "371402412"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: In paragraph describing table 3. "these results would indicate
      effectiveness of 45% and 76% respectively for B.1.617.2" How have you
      derived these estimates?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.22.21257658v1
  tweets:
    - created_at: Thu Jun 24 20:16:12 +0000 2021
      id: 1408157028246339600
      id_str: "1408157028246339590"
      text: >-
        üí¨ medRxiv comment on "Effectiveness of COVID-19 vacc..."


        "In paragraph describing table 3. "these results would in‚Ä¶ https://t.co/dGT5d7bVq7
      truncated: true
      entities:
        urls:
          - url: https://t.co/dGT5d7bVq7
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 24 20:16:12 +0000 2021
      id: 1408157029085204500
      id_str: "1408157029085204482"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/eQVSQuTGsy
      truncated: false
      entities:
        urls:
          - url: https://t.co/eQVSQuTGsy
      in_reply_to_status_id: 1408157028246339600
      in_reply_to_status_id_str: "1408157028246339590"
- preprint:
    id: "114898"
    doi: 10.1101/2020.07.31.20166116
    first_posted: 2020-08-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.07.31.20166116v1
    url: https://api.rxivist.org/v1/papers/114898
    title: "Face masks to prevent transmission of respiratory diseases: Systematic
      review and meta-analysis of randomized controlled trials"
    category: epidemiology
    abstract: Objectives. To examine the effect of face mask intervention in
      respiratory infections across different exposure settings and age groups.
      Design. Systematic review and meta-analysis. Data sources. PubMed,
      Cochrane Central Register of Controlled Trials, and Web of Science were
      searched for randomized controlled trials investigating the effect of face
      masks on respiratory infections published by November 18th 2020. We
      followed PRISMA guidelines. Eligibility criteria for selecting studies.
      Randomized controlled trials investigating face masks in respiratory
      infections across different exposure settings. Two reviewers performed the
      search, extracted data, and assessed the risk of bias. Random effects
      meta-analysis with risk ratio, adjusted odds ratios, and number needed to
      treat were performed. Findings by source control or wearer protection, age
      groups, exposure settings, and role of non-compliance were evaluated.
      Results. Seventeen studies were included, (N=11,601 cases and N=10,286
      controls, follow-up from 4 days to 19 months). Fourteen trials included
      adults and children and three trials included children only. Twelve
      studies showed non-compliance in treatment and eleven in control group.
      Four studies supported the use of face masks. Meta-analysis across all
      studies with risk ratios found no association with number of infections
      (RR=0.957 [0.810 - 1.131], p=0.608). Meta-analysis using odds ratios
      adjusted for age, sex, and vaccination (when available) showed protective
      effect of face masks (OR=0.850 [0.736 - 0.982], p=0.027). Subgroup
      meta-analysis with adjusted odds ratios found a decrease in respiratory
      infections among adults (14 studies, OR = 0.829 [0.709-0.969], p=0.019) in
      source control setting (OR = 0.845 [0.7375 - 0.969], p=0.0159) and when
      face masks were used together with hand hygiene OR = 0.690 [0.568 -
      0.838], p=0.0002). Overall between-study heterogeneity was large also in
      the subgroup analyses. Conclusion. Despite the large between study
      heterogeneity, compliance bias and differences by environmental settings,
      the findings support the use of face masks to prevent respiratory
      infections. PROSPERO registration number CRD42020205523.
    authors:
      - name: Hanna M Ollila
        orcid: http://orcid.org/0000-0002-5302-6429
      - name: Markku Partinen
        orcid: null
      - name: Jukka T Koskela
        orcid: http://orcid.org/0000-0002-0154-7222
      - name: Riikka Savolainen
        orcid: null
      - name: Anna Rotkirch
        orcid: null
      - name: Liisa T Laine
        orcid: null
  comment:
    dislikes: 0
    thread: "8480829581"
    numReports: 0
    likes: 0
    id: "5432007679"
    createdAt: 2021-06-24T20:22:50
    author:
      username: disqus_rKdn7akaLf
      about: ""
      name: Mikko Heikkil√§
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_rKdn7akaLf/
      url: ""
      location: ""
      id: "363263236"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      It seems that the Adjusted Odds Ratios are not all adjusted for covariates
      but are Crude Odds Ratios. This is for at least Macintyre 2015 and 2016
      and Aiello 2010 and 2012 papers.


      It is worth noting that even some of these are erroneous as for example Aiello et al. 2010 subtracted individuals with previous respiratory infections and therefore the intervention groups for mask and hand hygiene were actually 316 (367 in Ollila et al.) and for the mask only 347 (378 in Ollila et al.). As previously reported to Ollila et al for their first version (published 8/2020) if the aim is to define the effect of the mask as intervention using the results from both intervention groups does not render robust results.


      Also, for the Abdin et al. 2005 paper the original intervention groups were 257 (mask and Health Education booklet), 292 (HE booklet only) and 446 (control). It is apparent that Ollila et al. used the compliance within the groups as redefining the groups: mask+HE booklet compliance 81.3% (209), HE booklet group compliance 51.7% (151) and control group using masks 33.6% (150). New intervention group 150+151+209=510 and control 995-510=485. Abdin et al. only reported the adjusted OR with these compliance based groups and no RR or OR based on the original Randomised Control Trial protocol. As Ollila et al. is by the authors a systematic review and meta-analysis of Randomised Control Trials these results should not be used as they have.


      More, from the Simmerman et al. 2011 Ollila et al. chose only the Influenza Like Illness (ILI) results for their meta-analysis even though Simmerman et al. also reported PCR confirmed infections. For the sub-analysis with Adjusted Odds Ratios Ollila et al. preferred to use the PCR confirmed results from the same paper with OR 1.16 (95% CI 0.74-1.82) instead of the ILI results that were OR 2.15 (95% CI 1.27-3.62). The latter would push the pooled result much more towards the null hypothesis.


      The same goes for the Cowling et al. 2009 where the authors reported respiratory infections based on three criteria: RT-PCR confirmed, Clinical definition 1 (2 symptoms) and Clinical definition 2 (3 symptoms). Ollila et al. only used the Clinical definition 2 results for their meta-analysis.


      With these and all previously reported research flaws one can only conclude that the conclusions of Ollila et al. are not supported by the results if calculated correctly.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.07.31.20166116v3
  tweets:
    - created_at: Thu Jun 24 22:19:46 +0000 2021
      id: 1408188123901800400
      id_str: "1408188123901800456"
      text: >-
        üí¨ medRxiv comment on "Face masks to prevent transmis..."


        "It seems that the Adjusted Odds Ratios are not all adjus‚Ä¶ https://t.co/XgdZYwXL3E
      truncated: true
      entities:
        urls:
          - url: https://t.co/XgdZYwXL3E
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 24 22:19:46 +0000 2021
      id: 1408188124816105500
      id_str: "1408188124816105476"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/fKpRLo8sEB
      truncated: false
      entities:
        urls:
          - url: https://t.co/fKpRLo8sEB
      in_reply_to_status_id: 1408188123901800400
      in_reply_to_status_id_str: "1408188123901800456"
- preprint:
    id: "141246"
    doi: 10.1101/2021.05.10.21256982
    first_posted: 2021-05-11
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.10.21256982v1
    url: https://api.rxivist.org/v1/papers/141246
    title: "Precision Medicine Approach to Alzheimer's Disease: Successful
      Proof-of-Concept Trial"
    category: neurology
    abstract: "Abstract Importance: Effective therapeutics for Alzheimer's disease
      and mild cognitive impairment are needed. Objective: To determine whether
      a precision medicine approach to Alzheimer's disease and mild cognitive
      impairment, in which potential contributors to cognitive decline are
      identified and targeted therapeutically, is effective enough in a
      proof-of-concept trial to warrant a larger, randomized, controlled
      clinical trial. Rationale: Previous clinical trials for Alzheimer's
      disease have pre-determined a single treatment modality, such as a drug
      candidate or therapeutic procedure, that may be unrelated to the primary
      drivers of the neurodegenerative process. Therefore, increasing data set
      size to include the potential contributors to cognitive decline for each
      patient, and addressing the identified potential contributors, may
      represent a more effective therapeutic strategy. Hypothesis: Alzheimer's
      disease is a multi-factorial network dysfunction that results from a
      chronic or repeated insufficiency of support for a neuroplasticity
      network; thus factors that increase demand -- such as infections or toxin
      exposure -- or reduce support -- such as reduced energetics or trophic
      support -- may contribute to the neurodegenerative process. Rectifying
      this hypothesized network dysfunction represents a rational approach to
      the treatment of the cognitive decline associated with Alzheimer's disease
      and mild cognitive impairment. Design: Twenty-five patients with
      Alzheimer's disease or mild cognitive impairment, with Montreal Cognitive
      Assessment (MoCA) scores of 19 or higher, were evaluated for markers of
      inflammation, chronic infection, dysbiosis, insulin resistance, protein
      glycation, vascular disease, nocturnal hypoxemia, hormone insufficiency or
      dysregulation, nutrient deficiency, toxin or toxicant exposure (metals,
      organic toxicants, and biotoxins), genetic predisposition to cognitive
      decline, and other biochemical parameters associated with cognitive
      decline. Brain magnetic resonance imaging with volumetrics was performed
      at baseline and study conclusion. Patients were treated for nine months
      with a personalized, precision medicine protocol that addressed each
      patient's identified potentially contributory factors, and cognition was
      assessed at t = 0, 3, 6, and 9 months. Trial registration and IRB
      approval: The clinical trial was registered at clinicaltrials.gov
      (NCT03883633), 1 and approved by the Advarra IRB. Support for the trial:
      The trial was supported by a grant from the Four Winds Foundation via
      Evanthea, LLC, and we are grateful to Diana Merriam and Gayle Brown for
      their interest, discussions, and support. Main Outcome Measures: Trained
      external raters evaluated the study subjects with the Montreal Cognitive
      Assessment (MoCA), CNS Vital Signs (a computerized cognitive assessment
      battery), AQ-21 (a subjective scale completed by the significant other or
      study partner), and AQ-C change scale (a subjective scale of cognitive
      improvement or decline, completed by the significant other or study
      partner). Follow-up brain MRI with volumetrics was carried out at the
      completion of the trial. Results: All outcome measures revealed
      improvement: statistically highly significant improvement in MoCA scores,
      CNS Vital Signs Neurocognitive Index, and AQ-C were documented. No serious
      adverse events were recorded. Conclusions and Relevance: Based on the
      cognitive improvements observed in this study of patients with Alzheimer's
      disease or mild cognitive impairment, a larger, randomized, controlled
      trial of the precision medicine therapeutic approach described herein is
      warranted."
    authors:
      - name: Kat Toups
        orcid: null
      - name: Ann Hathaway
        orcid: null
      - name: Deborah Gordon
        orcid: null
      - name: Henrianna Chung
        orcid: null
      - name: Cyrus Raji
        orcid: null
      - name: Alan Boyd
        orcid: null
      - name: Benjamin D. Hill
        orcid: null
      - name: Sharon Hausman-Cohen
        orcid: null
      - name: Mouna Attarha
        orcid: null
      - name: Won Jong Chwa
        orcid: null
      - name: Michael Jarrett
        orcid: null
      - name: Dale E. Bredesen
        orcid: null
  comment:
    dislikes: 0
    thread: "8516300633"
    numReports: 0
    likes: 0
    id: "5431523415"
    createdAt: 2021-06-24T14:30:44
    author:
      username: dog_cat_rescuer
      about: ""
      name: dog_cat_rescuer
      isPowerContributor: false
      profileUrl: https://disqus.com/by/dog_cat_rescuer/
      url: ""
      location: ""
      id: "21203031"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Misha, what is the protocol at GWCIM?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.10.21256982v1
  tweets:
    - created_at: Fri Jun 25 01:07:22 +0000 2021
      id: 1408230301570982000
      id_str: "1408230301570981889"
      text: |-
        üí¨ medRxiv comment on "Precision Medicine Approach to..."

        "Misha, what is the protocol at GWCIM?"

        https://t.co/SMRBLZHYIc
      truncated: false
      entities:
        urls:
          - url: https://t.co/SMRBLZHYIc
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 25 01:07:22 +0000 2021
      id: 1408230302464450600
      id_str: "1408230302464450563"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/evATf0snn0
      truncated: false
      entities:
        urls:
          - url: https://t.co/evATf0snn0
      in_reply_to_status_id: 1408230301570982000
      in_reply_to_status_id_str: "1408230301570981889"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 0
    id: "5431267181"
    createdAt: 2021-06-24T09:15:57
    author:
      username: KKRay
      about: ""
      name: KKRay
      isPowerContributor: false
      profileUrl: https://disqus.com/by/KKRay/
      url: ""
      location: ""
      id: "570329"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Why no data from April?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Fri Jun 25 12:31:02 +0000 2021
      id: 1408402353133400000
      id_str: "1408402353133400071"
      text: |-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."

        "Why no data from April?"

        https://t.co/pwOlr48mC5
      truncated: false
      entities:
        urls:
          - url: https://t.co/pwOlr48mC5
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 25 12:31:02 +0000 2021
      id: 1408402353808625700
      id_str: "1408402353808625665"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1408402353133400000
      in_reply_to_status_id_str: "1408402353133400071"
- preprint:
    id: "121407"
    doi: 10.1101/2020.12.13.422570
    first_posted: 2020-12-13
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.12.13.422570v1
    url: https://api.rxivist.org/v1/papers/121407
    title: Uncovering novel mutational signatures by de novo extraction with
      SigProfilerExtractor
    category: bioinformatics
    abstract: Mutational signature analysis is commonly performed in genomic studies
      surveying cancer and normal somatic tissues. Here we present
      SigProfilerExtractor, an automated tool for accurate de novo extraction of
      mutational signatures for all types of somatic mutations. Benchmarking
      with a total of 33 distinct scenarios encompassing 1,900 simulated
      signatures operative in more than 60,000 unique synthetic genomes
      demonstrates that SigProfilerExtractor outperforms thirteen other tools
      across all datasets with and without noise. For simulations with 5% noise,
      reflecting high-quality genomic datasets, SigProfilerExtractor outperforms
      other approaches by elucidating between 20% and 50% more true positive
      signatures while yielding more than 5-fold less false positive signatures.
      Applying SigProfilerExtractor to 2,778 whole-genome sequenced cancers
      reveals three previously missed mutational signatures. Two of the
      signatures are confirmed in independent cohorts with one of these
      signatures associating with tobacco smoking. In summary, this report
      provides a reference tool for analysis of mutational signatures, a
      comprehensive benchmarking of bioinformatics tools for extracting
      mutational signatures, and several novel mutational signatures including a
      signature putatively attributed to direct tobacco smoking mutagenesis in
      bladder cancer and in normal bladder epithelium.
    authors:
      - name: S M Ashiqul Islam
        orcid: http://orcid.org/0000-0002-5686-6474
      - name: Yang Wu
        orcid: http://orcid.org/0000-0002-1837-8330
      - name: Marcos Diaz-Gay
        orcid: null
      - name: Erik N. Bergstrom
        orcid: http://orcid.org/0000-0001-7740-022X
      - name: Yudou He
        orcid: null
      - name: Mark Barnes
        orcid: null
      - name: Mike Vella
        orcid: null
      - name: Jingwei Wang
        orcid: http://orcid.org/0000-0002-7408-8362
      - name: Jon W Teague
        orcid: null
      - name: Peter Clapham
        orcid: null
      - name: Sarah Moody
        orcid: http://orcid.org/0000-0003-4904-1041
      - name: Sergey Senkin
        orcid: http://orcid.org/0000-0001-5848-005X
      - name: Yun Rose Li
        orcid: null
      - name: Laura Riva
        orcid: null
      - name: Tongwu Zhang
        orcid: null
      - name: Andreas J. Gruber
        orcid: http://orcid.org/0000-0001-7664-4257
      - name: Raviteja Vangara
        orcid: null
      - name: Christopher D Steele
        orcid: http://orcid.org/0000-0002-6110-0086
      - name: Burcak Otlu
        orcid: null
      - name: Azhar Khandekar
        orcid: http://orcid.org/0000-0002-0521-1195
      - name: Ammal Abbasi
        orcid: http://orcid.org/0000-0003-0623-2243
      - name: Laura Humphreys
        orcid: null
      - name: Natalia Syulyukina
        orcid: null
      - name: Samuel W Brady
        orcid: null
      - name: Boian Stoianov Alexandrov
        orcid: null
      - name: Nischalan Pillay
        orcid: http://orcid.org/0000-0003-0579-4105
      - name: Jinghui Zhang
        orcid: http://orcid.org/0000-0003-3350-9682
      - name: David J. Adams
        orcid: http://orcid.org/0000-0002-7030-2288
      - name: Inigo Marticorena
        orcid: null
      - name: David C Wedge
        orcid: http://orcid.org/0000-0002-7572-3196
      - name: Maria Teresa Landi
        orcid: null
      - name: Paul Brennan
        orcid: http://orcid.org/0000-0002-0518-8714
      - name: Michael R. Stratton
        orcid: http://orcid.org/0000-0001-6035-153X
      - name: Steven G Rozen
        orcid: http://orcid.org/0000-0002-4288-0056
      - name: Ludmil B Alexandrov
        orcid: http://orcid.org/0000-0003-3596-4515
  comment:
    dislikes: 0
    thread: "8523939620"
    numReports: 0
    likes: 0
    id: "5429941058"
    createdAt: 2021-06-23T10:16:32
    author:
      username: disqus_vcWkbrUPaz
      about: Research Associate at MRC CU, University of Cambridge, UK
      name: Andrea Degasperi
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_vcWkbrUPaz/
      url: http://andreadegasperi.x10.mx
      location: Cambridge, UK
      id: "370968235"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Congratulations for this wonderful work! May I just make sure that
      our approach implemented in the signature.tools.lib package is used
      correctly? From the supplementary notes you provide it seems that the
      guidance for using our method is not followed. We advise using at least 20
      bootstraps with 200 repeats and filter of best runs with RTOL=0.001 (see
      ‚Äúwhat parameters should I use for signature extraction‚Äù,
      https://github.com/Nik-Zainal-Group/signature.tools.lib#faq). However, in
      the supplementary notes it is stated that 100 bootstraps with no filter is
      used. Also, the default parameters shown in our package, in particular
      repeats=10 is only meant for testing, not for practical purposes, as at
      least 100 repeats are in general necessary for small medium problems.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.12.13.422570v2
  tweets:
    - created_at: Fri Jun 25 14:19:42 +0000 2021
      id: 1408429700381282300
      id_str: "1408429700381282305"
      text: >-
        üí¨ bioRxiv comment on "Uncovering novel mutational si..."


        "Congratulations for this wonderful work! May I just make‚Ä¶ https://t.co/oLL5iZWhyq
      truncated: true
      entities:
        urls:
          - url: https://t.co/oLL5iZWhyq
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 25 14:19:42 +0000 2021
      id: 1408429701174108200
      id_str: "1408429701174108160"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/eP3Zz0ALNn
      truncated: false
      entities:
        urls:
          - url: https://t.co/eP3Zz0ALNn
      in_reply_to_status_id: 1408429700381282300
      in_reply_to_status_id_str: "1408429700381282305"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 0
    id: "5432777880"
    createdAt: 2021-06-25T13:49:58
    author:
      username: disqus_w8LdLejsM2
      about: ""
      name: Stephen Smith
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_w8LdLejsM2/
      url: ""
      location: ""
      id: "371160113"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Yes, we looked high and low at different subgroups with different headers
      or covariates. We couldn't find anything. That statisticians then used a
      causal model, called Rubin, to determine what percent of the difference in
      survival was "caused" by higher doses of HCQ and AZM. 

      I understand the skepticism. I, at a minimum, hope people will rethink how they analyze HCQ/AZM data. As for pts in the ICU currently, I feel strongly HCQ/AZM at these higher doses should be used. You don't have much to lose. 

      I haven't run the numbers over the past 6-8 months. It appears fewer hospitalized Covid pts get intubated, but the survival rate for those intubated appears even worse than before. This is just an observation or guess, which is from talking with the ICU staff, who told me their opinion, and our own observations.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Fri Jun 25 16:31:38 +0000 2021
      id: 1408462900746985500
      id_str: "1408462900746985479"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "Yes, we looked high and low at different subgroups with‚Ä¶ https://t.co/97D5DkqGr5
      truncated: true
      entities:
        urls:
          - url: https://t.co/97D5DkqGr5
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 25 16:31:38 +0000 2021
      id: 1408462901577453600
      id_str: "1408462901577453569"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1408462900746985500
      in_reply_to_status_id_str: "1408462900746985479"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 0
    id: "5432770317"
    createdAt: 2021-06-25T13:43:06
    author:
      username: disqus_w8LdLejsM2
      about: ""
      name: Stephen Smith
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_w8LdLejsM2/
      url: ""
      location: ""
      id: "371160113"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      I wish. I am a private practitioner and I "own" the Smith Center for
      Infectious Diseases and Urban Health. I worked hundreds of hours on this
      study. My hourly rate = $0,000.00 for Smith Center work. In other words,
      before Covid, my work at the Smith Center was not reimbursed.  

      So, I can't afford to spend much more time on this study. 

      Further, I don't have access to another set of data. 

      But clearly these data beg for others to look at their data similarly. 


      Thanks,

      SMS
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Fri Jun 25 18:24:48 +0000 2021
      id: 1408491380633124900
      id_str: "1408491380633124864"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "I wish. I am a private practitioner and I "own" the Smit‚Ä¶ https://t.co/JRLRaXgohl
      truncated: true
      entities:
        urls:
          - url: https://t.co/JRLRaXgohl
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 25 18:24:48 +0000 2021
      id: 1408491381396549600
      id_str: "1408491381396549633"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1408491380633124900
      in_reply_to_status_id_str: "1408491380633124864"
- preprint:
    id: 147291
    metric: 10
    title: Increased lung cell entry of B.1.617.2 and evasion of antibodies induced
      by infection and BNT162b2 vaccination
    url: https://api.rxivist.org/v1/papers/147291
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.23.449568v1
    doi: 10.1101/2021.06.23.449568
    category: molecular-biology
    first_posted: 2021-06-23
    abstract: The delta variant of SARS-CoV-2, B.1.617.2, emerged in India and has
      subsequently spread to over 80 countries. B.1.617.2 rapidly replaced
      B.1.1.7 as the dominant virus in the United Kingdom, resulting in a steep
      increase in new infections, and a similar development is expected for
      other countries. Effective countermeasures require information on
      susceptibility of B.1.617.2 to control by antibodies elicited by vaccines
      and used for COVID-19 therapy. We show, using pseudotyping, that B.1.617.2
      evades control by antibodies induced upon infection and BNT162b2
      vaccination, although with lower efficiency as compared to B.1.351.
      Further, we found that B.1.617.2 is resistant against Bamlanivimab, a
      monoclonal antibody with emergency use authorization for COVID-19 therapy.
      Finally, we show increased Calu-3 lung cell entry and enhanced
      cell-to-cell fusion of B.1.617.2, which may contribute to augmented
      transmissibility and pathogenicity of this variant. These results identify
      B.1.617.2 as an immune evasion variant with increased capacity to enter
      and fuse lung cells.
    authors:
      - name: Prerna Arora
      - name: Nadine Krueger
      - name: Amy Kempf
      - name: Inga Nehlmeier
      - name: Anzhalika Sidarovich
      - name: Luise Graichen
      - name: Anna-Sophie Moldenhauer
      - name: Martin S Winkler
      - name: Sebastian Schulz
      - name: Hans-Martin Jaeck
      - name: Metodi V Stankov
      - name: Georg MN Behrens
      - name: Stefan Poehlmann
      - name: Markus Hoffmann
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Fri Jun 25 20:16:04 +0000 2021
      id: 1408519384059068400
      id_str: "1408519384059068434"
      text: >-
        üî• bioRxiv Molecular-biology preprint by P. Arora et al:


        "Increased lung cell entry of B.1.617.2 and evasion of ant‚Ä¶ https://t.co/QQio8B75mz
      truncated: true
      entities:
        urls:
          - url: https://t.co/QQio8B75mz
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 0
    id: "5433097238"
    createdAt: 2021-06-25T18:19:47
    author:
      username: disqus_IUF4sSzSSg
      about: ""
      name: Xolo
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_IUF4sSzSSg/
      url: ""
      location: ""
      id: "338966033"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Very good point about the masks.  And why weren't all the previous
      outbreaks contained this way - shutting down everything?  Probably the
      prior viruses weren't as contagious?  Interesting to see how climate
      change, economic system reset all intersecting at the same time.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri Jun 25 20:20:04 +0000 2021
      id: 1408520391346229200
      id_str: "1408520391346229249"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Very good point about the masks.  And why weren't all th‚Ä¶ https://t.co/4XeG3qN0uJ
      truncated: true
      entities:
        urls:
          - url: https://t.co/4XeG3qN0uJ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 25 20:20:05 +0000 2021
      id: 1408520392097120300
      id_str: "1408520392097120265"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1408520391346229200
      in_reply_to_status_id_str: "1408520391346229249"
- preprint:
    id: "141246"
    doi: 10.1101/2021.05.10.21256982
    first_posted: 2021-05-11
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.10.21256982v1
    url: https://api.rxivist.org/v1/papers/141246
    title: "Precision Medicine Approach to Alzheimer's Disease: Successful
      Proof-of-Concept Trial"
    category: neurology
    abstract: "Abstract Importance: Effective therapeutics for Alzheimer's disease
      and mild cognitive impairment are needed. Objective: To determine whether
      a precision medicine approach to Alzheimer's disease and mild cognitive
      impairment, in which potential contributors to cognitive decline are
      identified and targeted therapeutically, is effective enough in a
      proof-of-concept trial to warrant a larger, randomized, controlled
      clinical trial. Rationale: Previous clinical trials for Alzheimer's
      disease have pre-determined a single treatment modality, such as a drug
      candidate or therapeutic procedure, that may be unrelated to the primary
      drivers of the neurodegenerative process. Therefore, increasing data set
      size to include the potential contributors to cognitive decline for each
      patient, and addressing the identified potential contributors, may
      represent a more effective therapeutic strategy. Hypothesis: Alzheimer's
      disease is a multi-factorial network dysfunction that results from a
      chronic or repeated insufficiency of support for a neuroplasticity
      network; thus factors that increase demand -- such as infections or toxin
      exposure -- or reduce support -- such as reduced energetics or trophic
      support -- may contribute to the neurodegenerative process. Rectifying
      this hypothesized network dysfunction represents a rational approach to
      the treatment of the cognitive decline associated with Alzheimer's disease
      and mild cognitive impairment. Design: Twenty-five patients with
      Alzheimer's disease or mild cognitive impairment, with Montreal Cognitive
      Assessment (MoCA) scores of 19 or higher, were evaluated for markers of
      inflammation, chronic infection, dysbiosis, insulin resistance, protein
      glycation, vascular disease, nocturnal hypoxemia, hormone insufficiency or
      dysregulation, nutrient deficiency, toxin or toxicant exposure (metals,
      organic toxicants, and biotoxins), genetic predisposition to cognitive
      decline, and other biochemical parameters associated with cognitive
      decline. Brain magnetic resonance imaging with volumetrics was performed
      at baseline and study conclusion. Patients were treated for nine months
      with a personalized, precision medicine protocol that addressed each
      patient's identified potentially contributory factors, and cognition was
      assessed at t = 0, 3, 6, and 9 months. Trial registration and IRB
      approval: The clinical trial was registered at clinicaltrials.gov
      (NCT03883633), 1 and approved by the Advarra IRB. Support for the trial:
      The trial was supported by a grant from the Four Winds Foundation via
      Evanthea, LLC, and we are grateful to Diana Merriam and Gayle Brown for
      their interest, discussions, and support. Main Outcome Measures: Trained
      external raters evaluated the study subjects with the Montreal Cognitive
      Assessment (MoCA), CNS Vital Signs (a computerized cognitive assessment
      battery), AQ-21 (a subjective scale completed by the significant other or
      study partner), and AQ-C change scale (a subjective scale of cognitive
      improvement or decline, completed by the significant other or study
      partner). Follow-up brain MRI with volumetrics was carried out at the
      completion of the trial. Results: All outcome measures revealed
      improvement: statistically highly significant improvement in MoCA scores,
      CNS Vital Signs Neurocognitive Index, and AQ-C were documented. No serious
      adverse events were recorded. Conclusions and Relevance: Based on the
      cognitive improvements observed in this study of patients with Alzheimer's
      disease or mild cognitive impairment, a larger, randomized, controlled
      trial of the precision medicine therapeutic approach described herein is
      warranted."
    authors:
      - name: Kat Toups
        orcid: null
      - name: Ann Hathaway
        orcid: null
      - name: Deborah Gordon
        orcid: null
      - name: Henrianna Chung
        orcid: null
      - name: Cyrus Raji
        orcid: null
      - name: Alan Boyd
        orcid: null
      - name: Benjamin D. Hill
        orcid: null
      - name: Sharon Hausman-Cohen
        orcid: null
      - name: Mouna Attarha
        orcid: null
      - name: Won Jong Chwa
        orcid: null
      - name: Michael Jarrett
        orcid: null
      - name: Dale E. Bredesen
        orcid: null
  comment:
    dislikes: 0
    thread: "8516300633"
    numReports: 0
    likes: 0
    id: "5432884371"
    createdAt: 2021-06-25T15:21:28
    author:
      username: mishakogan
      about: ""
      name: Misha Kogan
      isPowerContributor: false
      profileUrl: https://disqus.com/by/mishakogan/
      url: ""
      location: ""
      id: "369361615"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: This exact protocol, except that we do much lower cost genetic analysis.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.10.21256982v1
  tweets:
    - created_at: Fri Jun 25 22:19:45 +0000 2021
      id: 1408550510433554400
      id_str: "1408550510433554437"
      text: >-
        üí¨ medRxiv comment on "Precision Medicine Approach to..."


        "This exact protocol, except that we do much lower cost g‚Ä¶ https://t.co/YJo1ISX1s2
      truncated: true
      entities:
        urls:
          - url: https://t.co/YJo1ISX1s2
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 25 22:19:46 +0000 2021
      id: 1408550511251538000
      id_str: "1408550511251537923"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/evATf0JYLA
      truncated: false
      entities:
        urls:
          - url: https://t.co/evATf0JYLA
      in_reply_to_status_id: 1408550510433554400
      in_reply_to_status_id_str: "1408550510433554437"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 0
    id: "5432766411"
    createdAt: 2021-06-25T13:39:36
    author:
      username: disqus_w8LdLejsM2
      about: ""
      name: Stephen Smith
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_w8LdLejsM2/
      url: ""
      location: ""
      id: "371160113"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      I won't get into the strengths and weaknesses of those studies. I will
      point a few things in general. You can't show a drug or therapy improves
      mortality when 98% of the control patients survive. 

      There is no RCT that looked at HCQ/AZM by cumulative dose or HCQ/AZM in critically ill pts. 

      I can get into the Brazil RCT with HCQ/AZM on mildly ill Covid pts, but that study has many, many problems, including a very high survival rate in all groups.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Sat Jun 26 00:59:23 +0000 2021
      id: 1408590680490791000
      id_str: "1408590680490790917"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "I won't get into the strengths and weaknesses of those s‚Ä¶ https://t.co/6AGXTxgGgq
      truncated: true
      entities:
        urls:
          - url: https://t.co/6AGXTxgGgq
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 26 00:59:23 +0000 2021
      id: 1408590681426120700
      id_str: "1408590681426120705"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7ajlT5
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7ajlT5
      in_reply_to_status_id: 1408590680490791000
      in_reply_to_status_id_str: "1408590680490790917"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 0
    id: "5432763196"
    createdAt: 2021-06-25T13:36:37
    author:
      username: disqus_w8LdLejsM2
      about: ""
      name: Stephen Smith
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_w8LdLejsM2/
      url: ""
      location: ""
      id: "371160113"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Data from April? The study period was from March 12th - May 1st, 2020.

      This is the date of admission time period. 

      One pt was admitted in February and acquired nosocomial Covid. She too is included.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Sat Jun 26 12:29:54 +0000 2021
      id: 1408764455324897300
      id_str: "1408764455324897285"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "Data from April? The study period was from March 12th -‚Ä¶ https://t.co/kS17hxe07E
      truncated: true
      entities:
        urls:
          - url: https://t.co/kS17hxe07E
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 26 12:29:54 +0000 2021
      id: 1408764456058998800
      id_str: "1408764456058998784"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1408764455324897300
      in_reply_to_status_id_str: "1408764455324897285"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 0
    id: "5432613125"
    createdAt: 2021-06-25T10:48:30
    author:
      username: scottkorba
      about: Entrepreneur
      name: ScottK
      isPowerContributor: false
      profileUrl: https://disqus.com/by/scottkorba/
      url: ""
      location: Newport Beach mostly
      id: "131137860"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Since this was an observational study with a small number of survivors,
      the fear is that you draw conclusions that are tied to survival and not to
      treatments.  Simply put...

      MDs won't prescribe HCQ/Zithro to certain risk pools.

      Cumulative dose may rise with survival, not the other way around.

      You've got 15% of the total population in the study on this regimen and 20% of the population survived.  If the MDs picked 10-15 of the 'least contraindicated' patients to do anything with, chances are that you'd see higher survival.


      Double blind, controlled or explain the heck out of the pooling and selection criteria.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Sat Jun 26 14:17:13 +0000 2021
      id: 1408791461202698200
      id_str: "1408791461202698243"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "Since this was an observational study with a small numbe‚Ä¶ https://t.co/trDHcH56Sr
      truncated: true
      entities:
        urls:
          - url: https://t.co/trDHcH56Sr
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 26 14:17:13 +0000 2021
      id: 1408791461915680800
      id_str: "1408791461915680777"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1408791461202698200
      in_reply_to_status_id_str: "1408791461202698243"
- preprint:
    id: "146990"
    doi: 10.1101/2021.06.21.21259286
    first_posted: 2021-06-22
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.21.21259286v1
    url: https://api.rxivist.org/v1/papers/146990
    title: Predicting the mutational drivers of future SARS-CoV-2 variants of concern
    category: infectious-diseases
    abstract: SARS-CoV-2 evolution threatens vaccine- and natural infection-derived
      immunity, and the efficacy of therapeutic antibodies. Herein we sought to
      predict Spike amino acid changes that could contribute to future variants
      of concern. We tested the importance of features comprising epidemiology,
      evolution, immunology, and neural network-based protein sequence modeling.
      This resulted in identification of the primary biological drivers of
      SARS-CoV-2 intra-pandemic evolution. We found evidence that resistance to
      population-level host immunity has increasingly shaped SARS-CoV-2
      evolution over time. We identified with high accuracy mutations that will
      spread, at up to four months in advance, across different phases of the
      pandemic. Behavior of the model was consistent with a plausible causal
      structure wherein epidemiological variables integrate the effects of
      diverse and shifting drivers of viral fitness. We applied our model to
      forecast mutations that will spread in the future, and characterize how
      these mutations affect the binding of therapeutic antibodies. These
      findings demonstrate that it is possible to forecast the driver mutations
      that could appear in emerging SARS-CoV-2 variants of concern. This
      modeling approach may be applied to any pathogen with genomic surveillance
      data, and so may address other rapidly evolving pathogens such as
      influenza, and unknown future pandemic viruses.
    authors:
      - name: M. Cyrus Maher
        orcid: http://orcid.org/0000-0002-6666-3574
      - name: Istvan Bartha
        orcid: http://orcid.org/0000-0003-3360-1999
      - name: Steven Weaver
        orcid: http://orcid.org/0000-0002-6931-7191
      - name: Julia Di Iulio
        orcid: http://orcid.org/0000-0001-9343-127X
      - name: Elena Ferri
        orcid: http://orcid.org/0000-0002-8672-4733
      - name: Leah Soriaga
        orcid: http://orcid.org/0000-0001-5852-741X
      - name: Florian A Lempp
        orcid: http://orcid.org/0000-0001-6103-8078
      - name: Brian L Hie
        orcid: http://orcid.org/0000-0003-3224-8142
      - name: Bryan Bryson
        orcid: http://orcid.org/0000-0003-1716-6712
      - name: Bonnie Berger
        orcid: http://orcid.org/0000-0002-2724-7228
      - name: David L Robertson
        orcid: http://orcid.org/0000-0001-6338-0221
      - name: Gyorgy Snell
        orcid: null
      - name: Davide Corti
        orcid: http://orcid.org/0000-0002-5797-1364
      - name: Herbert W Virgin
        orcid: http://orcid.org/0000-0001-8580-7628
      - name: Sergei Kosakovsky Pond
        orcid: http://orcid.org/0000-0003-4817-4029
      - name: Amalio Telenti
        orcid: http://orcid.org/0000-0001-6290-7677
  comment:
    dislikes: 0
    thread: "8608476295"
    numReports: 0
    likes: 0
    id: "5432608508"
    createdAt: 2021-06-25T10:42:32
    author:
      username: helene_banoun
      about: ""
      name: helene banoun
      isPowerContributor: false
      profileUrl: https://disqus.com/by/helene_banoun/
      url: ""
      location: ""
      id: "359126512"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Congratulations for your work!


      It would be interesting to study also the mutations related to the immune system not located on the spike like those on orf3 and orf8


      https://www.karger.com/Article/Abstract/515417 

      Evolution of SARS-CoV-2: review of mutations, role of the host immune system ‚Ä®

      Banoun H, Nephron (2021 Apr 28:1-12)
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.21.21259286v1
  tweets:
    - created_at: Sat Jun 26 16:30:10 +0000 2021
      id: 1408824921984098300
      id_str: "1408824921984098311"
      text: |-
        üí¨ medRxiv comment on "Predicting the mutational driv..."

        "Congratulations for your work!

        It would be interesting‚Ä¶ https://t.co/EdDxuVz6sx
      truncated: true
      entities:
        urls:
          - url: https://t.co/EdDxuVz6sx
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 26 16:30:11 +0000 2021
      id: 1408824923095662600
      id_str: "1408824923095662595"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/5OTgDfjo0Q
      truncated: false
      entities:
        urls:
          - url: https://t.co/5OTgDfjo0Q
      in_reply_to_status_id: 1408824921984098300
      in_reply_to_status_id_str: "1408824921984098311"
- preprint:
    id: "141912"
    doi: 10.1101/2021.05.15.21257017
    first_posted: 2021-05-17
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.15.21257017v1
    url: https://api.rxivist.org/v1/papers/141912
    title: Extended interval BNT162b2 vaccination enhances peak antibody generation
      in older people
    category: infectious-diseases
    abstract: "Abstract Objectives: To assess the relative immunogenicity of
      standard or extended interval BNT162b2 vaccination. Design: Population
      based cohort study comparing immune responses 2 weeks after the second
      vaccine, with appropriate time-matched samples in participants who
      received standard or extended interval double vaccination. Setting:
      Primary care networks, Birmingham, UK. December 2020 to April 2021.
      Participants: 175 people aged over 80 years of age. All donors received
      the BNT162b2 Pfizer/BioNTech vaccination and were vaccinated with either a
      standard 3 week interval between doses or an extended interval schedule.
      Main outcome measures: Peak quantitative spike-specific antibody and
      cellular immune responses. Results: In donors without evidence of previous
      infection the peak antibody response was 3.5-fold higher in donors who had
      undergone delayed interval vaccination. Cellular immune responses were
      3.6-fold lower. Conclusion: Peak antibody responses after the second
      BNT162b2 vaccine are markedly enhanced in older people when this is
      delayed to 12 weeks although cellular responses are lower. Extended
      interval vaccination may therefore offer the potential to enhance and
      extend humoral immunity. Further follow up is now required to assess long
      term immunity and clinical protection."
    authors:
      - name: Helen M Parry
        orcid: http://orcid.org/0000-0002-9707-8167
      - name: Rachel Bruton
        orcid: null
      - name: Christine Stephens
        orcid: null
      - name: Kevin Brown
        orcid: null
      - name: Gayatri Amirthalingam
        orcid: http://orcid.org/0000-0003-2078-0975
      - name: Bassam Hallis
        orcid: http://orcid.org/0000-0002-8461-0038
      - name: Ashley Otter
        orcid: null
      - name: Jianmin Zuo
        orcid: http://orcid.org/0000-0002-8341-465X
      - name: Paul Moss
        orcid: null
  comment:
    dislikes: 0
    thread: "8524358522"
    numReports: 0
    likes: 0
    id: "5434068991"
    createdAt: 2021-06-26T16:12:33
    author:
      username: disqus_S8W7k6Gyjj
      about: ""
      name: Daisy
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_S8W7k6Gyjj/
      url: ""
      location: ""
      id: "64410198"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Why on earth wouldn‚Äôt they include all age groups?  Or at least
      those 60 and up, who have lower immune response.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.15.21257017v1
  tweets:
    - created_at: Sat Jun 26 18:24:11 +0000 2021
      id: 1408853616169980000
      id_str: "1408853616169979911"
      text: >-
        üí¨ medRxiv comment on "Extended interval BNT162b2 vac..."


        "Why on earth wouldn‚Äôt they include all age groups?  Or a‚Ä¶ https://t.co/8cu4zjmGnM
      truncated: true
      entities:
        urls:
          - url: https://t.co/8cu4zjmGnM
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 26 18:24:12 +0000 2021
      id: 1408853616895611000
      id_str: "1408853616895610880"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/x0AIV3f5Lu
      truncated: false
      entities:
        urls:
          - url: https://t.co/x0AIV3f5Lu
      in_reply_to_status_id: 1408853616169980000
      in_reply_to_status_id_str: "1408853616169979911"
- preprint:
    id: 141398
    metric: 73
    title: mRNA vaccine-induced SARS-CoV-2-specific T cells recognize B.1.1.7 and
      B.1.351 variants but differ in longevity and homing properties depending
      on prior infection status
    url: https://api.rxivist.org/v1/papers/141398
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.12.443888v1
    doi: 10.1101/2021.05.12.443888
    category: immunology
    first_posted: 2021-05-12
    abstract: While mRNA vaccines are proving highly efficacious against SARS-CoV-2,
      it is important to determine how booster doses and prior infection
      influence the immune defense they elicit, and whether they protect against
      variants. Focusing on the T cell response, we conducted a longitudinal
      study of infection-naive and COVID-19 convalescent donors before
      vaccination and after their first and second vaccine doses, using a
      high-parameter CyTOF analysis to phenotype their SARS-CoV-2-specific T
      cells. Vaccine-elicited spike-specific T cells responded similarly to
      stimulation by spike epitopes from the ancestral, B.1.1.7 and B.1.351
      variant strains, both in terms of cell numbers and phenotypes. In
      infection-naive individuals, the second dose boosted the quantity but not
      quality of the T cell response, while in convalescents the second dose
      helped neither. Spike-specific T cells from convalescent vaccinees
      differed strikingly from those of infection-naive vaccinees, with
      phenotypic features suggesting superior long-term persistence and ability
      to home to the respiratory tract including the nasopharynx. These results
      provide reassurance that vaccine-elicited T cells respond robustly to the
      B.1.1.7 and B.1.351 variants, confirm that convalescents may not need a
      second vaccine dose, and suggest that vaccinated convalescents may have
      more persistent nasopharynx-homing SARS-CoV-2-specific T cells compared to
      their infection-naive counterparts.
    authors:
      - name: Jason Neidleman
      - name: Xiaoyu Luo
      - name: Matthew McGregor
      - name: Guorui Xie
      - name: Victoria Murray
      - name: Warner C. Greene
      - name: Sulggi A. Lee
      - name: Nadia R. Roan
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sat Jun 26 20:15:25 +0000 2021
      id: 1408881605561700400
      id_str: "1408881605561700357"
      text: >-
        üî• bioRxiv Immunology preprint by J. Neidleman et al:


        "mRNA vaccine-induced SARS-CoV-2-specific T cells recognize B‚Ä¶ https://t.co/7dB0eDHMAn
      truncated: true
      entities:
        urls:
          - url: https://t.co/7dB0eDHMAn
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "144192"
    doi: 10.1101/2021.05.27.21257908
    first_posted: 2021-06-01
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.27.21257908v1
    url: https://api.rxivist.org/v1/papers/144192
    title: Policy and Effectiveness of Covid-19 Response
    category: epidemiology
    abstract: A comparative analysis of selected national jurisdictions with respect
      to Covid-19 policy response indicated that factors such as effective
      communications and effective targeted intervention in the environments of
      higher epidemiological risk can be the key factors in the overall
      effectiveness of the epidemiological response minimizing both the impact
      of the epidemics and disruptions in the life of the society.
    authors:
      - name: Serge Dolgikh
        orcid: http://orcid.org/0000-0001-5929-8954
  comment:
    dislikes: 0
    thread: "8566413973"
    numReports: 0
    likes: 0
    id: "5434045473"
    createdAt: 2021-06-26T15:55:06
    author:
      username: disqus_CLis2YV8Sy
      about: Uppity Injun
      name: Prospector
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_CLis2YV8Sy/
      url: ""
      location: Coldfoot, Alaska
      id: "66780930"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Hindsight is 20/20. It was a naturally panicked reaction to the
      quickly spreading virus, but I believe history will show us that those
      nations and states that did not use draconian lockdown mandates will lag
      in recovery as compared to those jurisdictions where leadership made
      available the best information at the time to the public and allowed the
      public to choose for themselves what is best. Within the U.S., this is
      exactly what is playing out between the red and blue states.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.27.21257908v1
  tweets:
    - created_at: Sat Jun 26 20:18:45 +0000 2021
      id: 1408882444187676700
      id_str: "1408882444187676675"
      text: >-
        üí¨ medRxiv comment on "Policy and Effectiveness of Co..."


        "Hindsight is 20/20. It was a naturally panicked reaction‚Ä¶ https://t.co/o9Q31ZsutG
      truncated: true
      entities:
        urls:
          - url: https://t.co/o9Q31ZsutG
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 26 20:18:45 +0000 2021
      id: 1408882445089448000
      id_str: "1408882445089447945"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/lZgfiv6EmY
      truncated: false
      entities:
        urls:
          - url: https://t.co/lZgfiv6EmY
      in_reply_to_status_id: 1408882444187676700
      in_reply_to_status_id_str: "1408882444187676675"
- preprint:
    id: "146209"
    doi: 10.1101/2021.06.11.21258690
    first_posted: 2021-06-15
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.11.21258690v1
    url: https://api.rxivist.org/v1/papers/146209
    title: Brain imaging before and after COVID-19 in UK Biobank
    category: neurology
    abstract: There is strong evidence for brain-related pathologies in COVID-19,
      some of which could be a consequence of viral neurotropism. The vast
      majority of brain imaging studies so far have focused on qualitative,
      gross pathology of moderate to severe cases, often carried out on
      hospitalised patients. It remains unknown however whether the impact of
      COVID-19 can be detected in milder cases, in a quantitative and automated
      manner, and whether this can reveal a possible mechanism for the spread of
      the disease. UK Biobank scanned over 40,000 participants before the start
      of the COVID-19 pandemic, making it possible to invite back in 2021
      hundreds of previously-imaged participants for a second imaging visit.
      Here, we studied the effects of the disease in the brain using multimodal
      data from 782 participants from the UK Biobank COVID-19 re-imaging study,
      with 394 participants having tested positive for SARS-CoV-2 infection
      between their two scans. We used structural and functional brain scans
      from before and after infection, to compare longitudinal brain changes
      between these 394 COVID-19 patients and 388 controls who were matched for
      age, sex, ethnicity and interval between scans. We identified significant
      effects of COVID-19 in the brain with a loss of grey matter in the left
      parahippocampal gyrus, the left lateral orbitofrontal cortex and the left
      insula. When looking over the entire cortical surface, these results
      extended to the anterior cingulate cortex, supramarginal gyrus and
      temporal pole. We further compared COVID-19 patients who had been
      hospitalised (n=15) with those who had not (n=379), and while results were
      not significant, we found comparatively similar findings to the COVID-19
      vs control group comparison, with, in addition, a greater loss of grey
      matter in the cingulate cortex, central nucleus of the amygdala and
      hippocampal cornu ammonis (all |Z|>3). Our findings thus consistently
      relate to loss of grey matter in limbic cortical areas directly linked to
      the primary olfactory and gustatory system. Unlike in post hoc disease
      studies, the availability of pre-infection imaging data helps avoid the
      danger of pre-existing risk factors or clinical conditions being
      mis-interpreted as disease effects. Since a possible entry point of the
      virus to the central nervous system might be via the olfactory mucosa and
      the olfactory bulb, these brain imaging results might be the in vivo
      hallmark of the spread of the disease (or the virus itself) via olfactory
      and gustatory pathways.
    authors:
      - name: Gwena√´lle Douaud
        orcid: http://orcid.org/0000-0003-1981-391X
      - name: Soojin Lee
        orcid: http://orcid.org/0000-0002-6258-1280
      - name: Fidel Alfaro-Almagro
        orcid: http://orcid.org/0000-0002-9133-5951
      - name: Christoph Arthofer
        orcid: null
      - name: Chaoyue Wang
        orcid: null
      - name: Frederik Lange
        orcid: http://orcid.org/0000-0002-1736-7162
      - name: Jesper L.R. Andersson
        orcid: null
      - name: Ludovica Griffanti
        orcid: http://orcid.org/0000-0002-0540-9353
      - name: Eugene Duff
        orcid: null
      - name: Saad Jbabdi
        orcid: http://orcid.org/0000-0003-3234-5639
      - name: Bernd Taschler
        orcid: null
      - name: Anderson Winkler
        orcid: http://orcid.org/0000-0002-4169-9781
      - name: Thomas E Nichols
        orcid: http://orcid.org/0000-0002-4516-5103
      - name: Rory Collins
        orcid: null
      - name: Paul M. Matthews
        orcid: null
      - name: Naomi Allen
        orcid: http://orcid.org/0000-0003-1938-5038
      - name: Karla L Miller
        orcid: http://orcid.org/0000-0002-2511-3189
      - name: Stephen M Smith
        orcid: http://orcid.org/0000-0001-8166-069X
  comment:
    dislikes: 0
    thread: "8595911767"
    numReports: 0
    likes: 0
    id: "5434025885"
    createdAt: 2021-06-26T15:33:38
    author:
      username: disqus_0gLdIZ7FlY
      about: ""
      name: Mari
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_0gLdIZ7FlY/
      url: ""
      location: ""
      id: "204662037"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Stress does not cause these specific patterns of brain damage. We know a
      lot about stress, and these do not look like the brain effects of stress
      even from more traumatic incidents.



      It's important not to have a panicked or credulous reaction to these results, but it's also important not to be overly skeptical when the evidence is clear and overwhelming that even mild cases of COVID cause specific patterns of brain damage.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.11.21258690v1
  tweets:
    - created_at: Sat Jun 26 22:19:05 +0000 2021
      id: 1408912730283823000
      id_str: "1408912730283823112"
      text: >-
        üí¨ medRxiv comment on "Brain imaging before and after..."


        "Stress does not cause these specific patterns of brain d‚Ä¶ https://t.co/SgccntEmFm
      truncated: true
      entities:
        urls:
          - url: https://t.co/SgccntEmFm
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jun 26 22:19:06 +0000 2021
      id: 1408912731097505800
      id_str: "1408912731097505793"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/yeuDlfEN1V
      truncated: false
      entities:
        urls:
          - url: https://t.co/yeuDlfEN1V
      in_reply_to_status_id: 1408912730283823000
      in_reply_to_status_id_str: "1408912730283823112"
- preprint:
    id: "147536"
    doi: 10.1101/2021.06.22.21259342
    first_posted: 2021-06-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.22.21259342v1
    url: https://api.rxivist.org/v1/papers/147536
    title: MONITORING SARS-COV-2 TRANSMISSION AND PREVALENCE IN POPULATIONS UNDER
      REPEATED TESTING
    category: epidemiology
    abstract: We describe a repeat SARS-CoV-2 testing model for monitoring and
      containing outbreaks in a residential community. The analysis is motivated
      by the Ohio State University (OSU) approach to monitoring disease at its
      Columbus, Ohio campus during the COVID-19 epidemic in autumn 2020. The
      model is simple, yet flexible enough to accommodate changes in be- havior
      over time and to eliminate bias due to a nonrandom testing scheme. Model
      parameters are estimated from individual results of weekly SARS- CoV-2
      testing of residents. Model output serves several purposes, including
      estimating the effective reproduction number and monitoring prevalence to
      help inform isolation and quarantine bed capacity. An extended version of
      the model is also considered where the residential population (on-campus
      students) is assumed to interact with another population for whom the
      testing regime is more relaxed and possibly less frequent (off-campus
      students or in- structional faculty and staff). To illustrate the model
      application, we analyze both the synthetic data as well as the actual
      student SARS-CoV-2 testing data collected at OSU Columbus campus.
    authors:
      - name: Matthew Wascher
        orcid: null
      - name: Patrick M Schnell
        orcid: null
      - name: Wasiur R Khudabukhsh
        orcid: http://orcid.org/0000-0003-1803-0470
      - name: Mikkel Quam
        orcid: null
      - name: Joseph H Tien
        orcid: null
      - name: Grzegorz A Rempala
        orcid: http://orcid.org/0000-0002-6307-4555
  comment:
    dislikes: 0
    thread: "8614658873"
    numReports: 0
    likes: 0
    id: "5433889178"
    createdAt: 2021-06-26T12:51:39
    author:
      username: grzegorzarempala
      about: ""
      name: Grzegorz A Rempala
      isPowerContributor: false
      profileUrl: https://disqus.com/by/grzegorzarempala/
      url: ""
      location: ""
      id: "371491279"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: A paper from our group on modeling repeated testing on OSU campus.
      We hope that the methodology can be used in other situations when
      vaccination is not an option and repeated testing is requited.   Thanks to
      all who contributed to data collection for this project !
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.22.21259342v1
  tweets:
    - created_at: Sun Jun 27 01:09:14 +0000 2021
      id: 1408955547412484000
      id_str: "1408955547412484102"
      text: >-
        üí¨ medRxiv comment on "MONITORING SARS-COV-2 TRANSMIS..."


        "A paper from our group on modeling repeated testing on O‚Ä¶ https://t.co/dyhrECbeCd
      truncated: true
      entities:
        urls:
          - url: https://t.co/dyhrECbeCd
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 27 01:09:14 +0000 2021
      id: 1408955548263981000
      id_str: "1408955548263981058"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/vA34s4XncY
      truncated: false
      entities:
        urls:
          - url: https://t.co/vA34s4XncY
      in_reply_to_status_id: 1408955547412484000
      in_reply_to_status_id_str: "1408955547412484102"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 1
    id: "5432079844"
    createdAt: 2021-06-24T21:27:14
    author:
      username: johnartuli
      about: ""
      name: John Artuli
      isPowerContributor: false
      profileUrl: https://disqus.com/by/johnartuli/
      url: ""
      location: ""
      id: "369312159"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Adjusting for weight does not solve an immortal time bias.   You can say
      it, but it's not correct.  When one has to survive long enough to receive
      5 days (Table 4) or 10 days of medicine (Figure 2), then you have created
      an immortal time bias.   


      Table 4 presents a Cox regression model.   As above, I stated that the correct analysis is a Cox-regression with a time-dependent covariate for HCQ use.  That is a different statistical model than just a "Cox model."   In using a time-dependent variable for HCQ use, that would minimize the immortal time bias. (There may be other biases, such as a selection bias where people on hospice did not receive aggressive therapy. That is an inherent problem with observational data).
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Sun Jun 27 12:30:26 +0000 2021
      id: 1409126976623988700
      id_str: "1409126976623988737"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "Adjusting for weight does not solve an immortal time bia‚Ä¶ https://t.co/WlMJX3aujb
      truncated: true
      entities:
        urls:
          - url: https://t.co/WlMJX3aujb
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 27 12:30:26 +0000 2021
      id: 1409126977395728400
      id_str: "1409126977395728386"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1409126976623988700
      in_reply_to_status_id_str: "1409126976623988737"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 1
    id: "5432064748"
    createdAt: 2021-06-24T21:12:53
    author:
      username: johnartuli
      about: ""
      name: John Artuli
      isPowerContributor: false
      profileUrl: https://disqus.com/by/johnartuli/
      url: ""
      location: ""
      id: "369312159"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Cumulative dosing = immortal time bias.  

      1) To get to 3g of HCQ, one needs to survive 5 days at the max FDA-approved dose of 600mg/day.  

      2) For >80mg/kg of HCQ and >1g AZ), with an average weight of 89 kg and daily dose of 600mg/day that is ~6.7 mg/kg of HCQ per day on average. Thus to get to 80 mg/kg of HCQ, one needs to survive approx 12 days  (6.7*12 = 80).  Weights will be variable so maybe it's surviving 10-12 days.  Thus this comparison is comparing people who received a medicine for 10-12 days versus those who did not survive 10-12 days. That is why no one died before 10 days in the >80mg/kg HCQ group.  That is an immortal time bias.    


      As 88% of people received hydroxychloroquine and 80% overall died, this does not seem that impressive of a therapy.   You have presented an immortal time bias.  The correct statistical analysis is a time-dependent Cox Regression which would eliminate the immortal time bias problem.   I assume you know this, but if you do the correct analysis, it does not show what you want it to show. 


      Is Hydroxychloroquine + Azithromycin still used at your hospital at standard of care?
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Sun Jun 27 14:17:18 +0000 2021
      id: 1409153872417931300
      id_str: "1409153872417931265"
      text: |-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."

        "Cumulative dosing = immortal time bias.  
        1) To get to 3‚Ä¶ https://t.co/7yxg4b1fAq
      truncated: true
      entities:
        urls:
          - url: https://t.co/7yxg4b1fAq
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 27 14:17:18 +0000 2021
      id: 1409153873214902300
      id_str: "1409153873214902274"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1409153872417931300
      in_reply_to_status_id_str: "1409153872417931265"
- preprint:
    id: "146616"
    doi: 10.1101/2021.06.11.21258733
    first_posted: 2021-06-18
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.11.21258733v1
    url: https://api.rxivist.org/v1/papers/146616
    title: Impact estimation on COVID-19 infections following school reopening in
      September 2020 in Italy
    category: epidemiology
    abstract: Background Since its outbreak, CoViD-19 (formally known as 2019-nCoV)
      has been triggering many questions among public authorities, social
      organisms and school officials, as to when students should be allowed to
      return to school. Such a decision is critical and must take into account,
      other than its beneficial effects, also those associated with an increased
      exposition of the students to the virus, which, as a result, might spread
      at a faster rate. To date, in Italy, a few studies have rigorously
      investigated the correlation between school reopening and number of people
      tested positive to CoViD-19. Therefore, this paper aims to provide an
      assessment of such an impact as well as to illustrate the methodology
      followed. Methods Official daily data on the cumulative number of people
      tested positive to CoViD-19, in conjunction with external information
      accounting for the different points in time schools reopened in the
      various Italian regions, have been employed to build a stochastic model of
      the type Seasonal Autoregressive Moving Average embodying external
      information. Results There was a statistically significant increase in the
      number of positive cases in all the Italian regions related to schools
      reopening. Such an increase occurred, in average, about 18.9 days after
      the schools have been reopened. Schools reopening have been significantly
      contributed to the diffusion of the pandemic, with an overall estimated
      impact of about 228,724 positive cases. Conclusions The results suggest
      the need for strict control of all in-school activities. This could be
      done by using, to a variable extent, all the non-pharmaceutical
      interventions available, such as limited access to school spaces, no
      overlapping practices between different sports in the same space,
      universal masking, bubble-size classroom. However, in many cases, such
      measures might not be a viable option, at least in the short run, nor be
      reasonably applicable. Therefore, whenever the established safety criteria
      could not be met, school buildings should remain closed.
    authors:
      - name: Livio Fenga
        orcid: http://orcid.org/0000-0002-8185-2680
      - name: Massimo Galli
        orcid: http://orcid.org/0000-0001-8887-6215
  comment:
    dislikes: 0
    thread: "8601010467"
    numReports: 0
    likes: 0
    id: "5433784167"
    createdAt: 2021-06-26T09:53:47
    author:
      username: mauriziorainisio
      about: ""
      name: Maurizio Rainisio
      isPowerContributor: false
      profileUrl: https://disqus.com/by/mauriziorainisio/
      url: ""
      location: ""
      id: "346137793"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Once more a paper on the effect of school closure aimed at supporting the
      strong belief that schools are one of the major causes of the CoViD-19
      epidemic, trying to prove hypotheses that are set post hoc in a framework
      where the very concept of hypothesis testing is meaningless.


      The way how inferential statistics is used is embarrassing; the misuse of the word "significant" while no null hypothesis is predefined (nor could be), and, if any were implicit, it would be adapted to the situation post hoc (the parameter k is selected to maximize Student's t).


      Causality is inferred, while just coincidence is measured, without any consideration for other possible concomitant events. E.g.: The national referendum involving 25 millions of voters on September 20-21, would prove a better predictor of the increase of the epidemic curve using exactly the same method.


      Wording like "The estimated overall impact of schools reopening is quantified in around 227,724 positives" and the header "school related positives" without the benefit of doubt is not a scientifically sound way to approach the issue; statements of this kind should not be accepted by any scientific papers reviewer.


      A more careful analysis of the data looking at the changes the Rt parameter (or growth rate) that is the trigger to any increase in absolute number of infections, would show that in most of the regions the school openings happened after clear signals of trend changes provided by a properly computed Rt.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.11.21258733v1
  tweets:
    - created_at: Sun Jun 27 16:30:15 +0000 2021
      id: 1409187329554751500
      id_str: "1409187329554751492"
      text: >-
        üí¨ medRxiv comment on "Impact estimation on COVID-19 ..."


        "Once more a paper on the effect of school closure aimed‚Ä¶ https://t.co/xYzsoJTCEJ
      truncated: true
      entities:
        urls:
          - url: https://t.co/xYzsoJTCEJ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 27 16:30:15 +0000 2021
      id: 1409187330334859300
      id_str: "1409187330334859271"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/G8ZDRQog2r
      truncated: false
      entities:
        urls:
          - url: https://t.co/G8ZDRQog2r
      in_reply_to_status_id: 1409187329554751500
      in_reply_to_status_id_str: "1409187329554751492"
- preprint:
    id: "146990"
    doi: 10.1101/2021.06.21.21259286
    first_posted: 2021-06-22
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.21.21259286v1
    url: https://api.rxivist.org/v1/papers/146990
    title: Predicting the mutational drivers of future SARS-CoV-2 variants of concern
    category: infectious-diseases
    abstract: SARS-CoV-2 evolution threatens vaccine- and natural infection-derived
      immunity, and the efficacy of therapeutic antibodies. Herein we sought to
      predict Spike amino acid changes that could contribute to future variants
      of concern. We tested the importance of features comprising epidemiology,
      evolution, immunology, and neural network-based protein sequence modeling.
      This resulted in identification of the primary biological drivers of
      SARS-CoV-2 intra-pandemic evolution. We found evidence that resistance to
      population-level host immunity has increasingly shaped SARS-CoV-2
      evolution over time. We identified with high accuracy mutations that will
      spread, at up to four months in advance, across different phases of the
      pandemic. Behavior of the model was consistent with a plausible causal
      structure wherein epidemiological variables integrate the effects of
      diverse and shifting drivers of viral fitness. We applied our model to
      forecast mutations that will spread in the future, and characterize how
      these mutations affect the binding of therapeutic antibodies. These
      findings demonstrate that it is possible to forecast the driver mutations
      that could appear in emerging SARS-CoV-2 variants of concern. This
      modeling approach may be applied to any pathogen with genomic surveillance
      data, and so may address other rapidly evolving pathogens such as
      influenza, and unknown future pandemic viruses.
    authors:
      - name: M. Cyrus Maher
        orcid: http://orcid.org/0000-0002-6666-3574
      - name: Istvan Bartha
        orcid: http://orcid.org/0000-0003-3360-1999
      - name: Steven Weaver
        orcid: http://orcid.org/0000-0002-6931-7191
      - name: Julia Di Iulio
        orcid: http://orcid.org/0000-0001-9343-127X
      - name: Elena Ferri
        orcid: http://orcid.org/0000-0002-8672-4733
      - name: Leah Soriaga
        orcid: http://orcid.org/0000-0001-5852-741X
      - name: Florian A Lempp
        orcid: http://orcid.org/0000-0001-6103-8078
      - name: Brian L Hie
        orcid: http://orcid.org/0000-0003-3224-8142
      - name: Bryan Bryson
        orcid: http://orcid.org/0000-0003-1716-6712
      - name: Bonnie Berger
        orcid: http://orcid.org/0000-0002-2724-7228
      - name: David L Robertson
        orcid: http://orcid.org/0000-0001-6338-0221
      - name: Gyorgy Snell
        orcid: null
      - name: Davide Corti
        orcid: http://orcid.org/0000-0002-5797-1364
      - name: Herbert W Virgin
        orcid: http://orcid.org/0000-0001-8580-7628
      - name: Sergei Kosakovsky Pond
        orcid: http://orcid.org/0000-0003-4817-4029
      - name: Amalio Telenti
        orcid: http://orcid.org/0000-0001-6290-7677
  comment:
    dislikes: 0
    thread: "8608476295"
    numReports: 0
    likes: 0
    id: "5433281234"
    createdAt: 2021-06-25T20:59:11
    author:
      username: amaliotelenti
      about: ""
      name: amalio telenti
      isPowerContributor: false
      profileUrl: https://disqus.com/by/amaliotelenti/
      url: ""
      location: ""
      id: "213667029"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: You are right - these studies are planned. We expect the approach
      to be generalizable across the viral genomes and hopefully to other
      pathogens provided sufficient data
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.21.21259286v1
  tweets:
    - created_at: Sun Jun 27 18:24:11 +0000 2021
      id: 1409216001611337700
      id_str: "1409216001611337733"
      text: >-
        üí¨ medRxiv comment on "Predicting the mutational driv..."


        "You are right - these studies are planned. We expect the‚Ä¶ https://t.co/OWXhmQWZ5Z
      truncated: true
      entities:
        urls:
          - url: https://t.co/OWXhmQWZ5Z
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 27 18:24:11 +0000 2021
      id: 1409216002420785200
      id_str: "1409216002420785164"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/5OTgDf1N9i
      truncated: false
      entities:
        urls:
          - url: https://t.co/5OTgDf1N9i
      in_reply_to_status_id: 1409216001611337700
      in_reply_to_status_id_str: "1409216001611337733"
- preprint:
    id: 144340
    metric: 62
    title: The human language system does not support music processing
    url: https://api.rxivist.org/v1/papers/144340
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.01.446439v1
    doi: 10.1101/2021.06.01.446439
    category: neuroscience
    first_posted: 2021-06-01
    abstract: "Language and music are two human-unique capacities whose relationship
      remains debated. Some argue for overlap in processing mechanisms,
      especially for structure processing, but others fail to find overlap.
      Using fMRI, we examined the responses of language brain regions to diverse
      music stimuli, and also probed the musical abilities of individuals with
      severe aphasia. Across four experiments, we obtained a clear answer: music
      does not recruit nor requires the language system. The language regions'
      responses to music are generally low and never exceed responses elicited
      by non-music auditory conditions, like animal sounds. Further, the
      language regions are not sensitive to music structure: they show low
      responses to both intact and scrambled music, and to melodies with vs.
      without structural violations. Finally, individuals with aphasia who
      cannot judge sentence grammaticality perform well on melody
      well-formedness judgments. Thus the mechanisms that process structure in
      language do not appear to support music processing."
    authors:
      - name: Xuanyi Chen
      - name: Josef Affourtit
      - name: Rachel Ryskin
      - name: Tamar I Regev
      - name: Samuel Norman-Haignere
      - name: Olessia Jouravlev
      - name: Saima Malik-Moraleda
      - name: Hope Kean
      - name: Rosemary Varley
      - name: Evelina Fedorenko
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sun Jun 27 20:15:28 +0000 2021
      id: 1409244006270345200
      id_str: "1409244006270345221"
      text: >-
        üî• bioRxiv Neuroscience preprint by X. Chen et al:


        "The human language system does not support music processing"‚Ä¶ https://t.co/CcZrMGqPoL
      truncated: true
      entities:
        urls:
          - url: https://t.co/CcZrMGqPoL
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 0
    id: "5433215045"
    createdAt: 2021-06-25T20:02:29
    author:
      username: lolberttrollbertson
      about: ""
      name: das-pikle
      isPowerContributor: false
      profileUrl: https://disqus.com/by/lolberttrollbertson/
      url: ""
      location: ""
      id: "197239597"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: They did, and COVID is many, many times more infectious than the
      flu. Comparing mask mandates is useless, comparing mask compliance with
      adjustments for individual daily travel, individual daily interactions,
      population density, etc. would be a more thorough study - but a bajillion
      well-designed studies showing masks worked didn't convince you before, I
      doubt another one would convince you now.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sun Jun 27 20:18:52 +0000 2021
      id: 1409244863770595300
      id_str: "1409244863770595332"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "They did, and COVID is many, many times more infectious‚Ä¶ https://t.co/IbpzU0w4jb
      truncated: true
      entities:
        urls:
          - url: https://t.co/IbpzU0w4jb
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 27 20:18:52 +0000 2021
      id: 1409244864512938000
      id_str: "1409244864512937984"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1409244863770595300
      in_reply_to_status_id_str: "1409244863770595332"
- preprint:
    id: "146973"
    doi: 10.1101/2021.06.21.449261
    first_posted: 2021-06-22
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.21.449261v1
    url: https://api.rxivist.org/v1/papers/146973
    title: Analysis of scientific journalism in Nature reveals gender and regional
      disparities in coverage
    category: scientific-communication-and-education
    abstract: "Scientific journalism is a critical way in which the public can
      remain informed and benefit from new scientific findings. Such journalism
      also shapes the public's view of the current state of scientific findings
      and legitimizes experts. Those covering science can only cite and quote a
      limited number of sources. Sources may be identified by the journalist's
      research or by recommendations by other scientists. In both cases, biases
      may influence who is identified and ultimately included as an expert. We
      analyzed 22,001 non-research articles published by Nature to quantify
      possible disparities. Our analysis considered three possible sources of
      disparity: gender, name origin, and country affiliation. To explore these
      sources of disparity, we extracted cited authors' names and affiliations,
      as well as extracted names of quoted speakers. While citations and
      quotations within a piece do not reflect the entire information-gathering
      process, they can provide insight into the demographics of visible
      sources. We then used the extracted names to predict gender and name
      origin of the cited authors and speakers. In order to appropriately
      quantify the level of difference, we must identify a suitable reference
      set for comparison. We chose first and last authors within primary
      research articles in Nature and a subset of Springer Nature articles in
      the same time period as our comparator. In our analysis, we found a skew
      towards male quotation in Nature journalism-related articles, but
      quotation is trending toward equal representation at a faster rate than
      first and last authorship in academic publishing. Interestingly, we found
      that the gender disparity in quotes was column-dependent, with the
      \"Career Features\" column reaching gender parity. Our name origin
      analysis found a significant over-representation of names with predicted
      Celtic/English origin and under-representation of names with a predicted
      East Asian origin. This finding was observed both in extracted quotes and
      journal citations, but dampened in citations. Finally, we performed an
      analysis to identify how countries vary in the way that they're described
      in scientific journalism. We focused on two groups of countries: countries
      that are often mentioned in articles, but do not often have affiliated
      authors cited, and countries that have affiliated authors that are often
      cited, but the country is not typically mentioned. We found that the
      articles in which the less cited countries occur tend to have more
      agricultural, extraction-related, and political terms, whereas articles
      including highly cited countries have broader scientific terms. This
      discrepancy indicates a possible lack of regional diversity in the
      reporting of scientific output."
    authors:
      - name: Natalie R Davidson
        orcid: http://orcid.org/0000-0002-1745-8072
      - name: Casey S Greene
        orcid: http://orcid.org/0000-0001-8713-9213
  comment:
    dislikes: 0
    thread: "8608088225"
    numReports: 0
    likes: 0
    id: "5432542439"
    createdAt: 2021-06-25T09:03:07
    author:
      name: S
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: I see! thank you so much!
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.21.449261v1
  tweets:
    - created_at: Sun Jun 27 22:19:03 +0000 2021
      id: 1409275108863139800
      id_str: "1409275108863139842"
      text: |-
        üí¨ bioRxiv comment on "Analysis of scientific journal..."

        "I see! thank you so much!"

        https://t.co/6yjpGD4Qjo
      truncated: false
      entities:
        urls:
          - url: https://t.co/6yjpGD4Qjo
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jun 27 22:19:03 +0000 2021
      id: 1409275109647519700
      id_str: "1409275109647519749"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/D3rVy5FaHs
      truncated: false
      entities:
        urls:
          - url: https://t.co/D3rVy5FaHs
      in_reply_to_status_id: 1409275108863139800
      in_reply_to_status_id_str: "1409275108863139842"
- preprint:
    id: "132435"
    doi: 10.1101/2021.03.05.21252998
    first_posted: 2021-03-08
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.03.05.21252998v1
    url: https://api.rxivist.org/v1/papers/132435
    title: COVID-19 mRNA vaccine is not detected in human milk
    category: pediatrics
    abstract: Several countries have recently approved the use of mRNA vaccines
      against COVID-19 under an emergency use authorization. However, no
      pregnant or lactating individuals were included in the Phase 3 clinical
      trials of these vaccines despite belonging to a group at high risk for
      severe complications of COVID-19 infection. We show here that the mRNA
      from anti-COVID vaccines is not detected in human breast milk samples
      collected 4-48 hours post-vaccine. These results strengthen the
      recommendation of ABM and WHO that lactating individuals who receive the
      anti-COVID-19 mRNA-based vaccine should continue to breastfeed their
      infants uninterrupted.
    authors:
      - name: Yarden Golan
        orcid: http://orcid.org/0000-0002-3043-3638
      - name: Mary Prahl
        orcid: null
      - name: Arianna Cassidy
        orcid: null
      - name: Christine Y Lin
        orcid: null
      - name: Nadav Ahituv
        orcid: http://orcid.org/0000-0002-7434-8144
      - name: Valerie J Flaherman
        orcid: null
      - name: Stephanie L. Gaw
        orcid: null
  comment:
    dislikes: 0
    thread: "8428869045"
    numReports: 0
    likes: 0
    id: "5435542960"
    createdAt: 2021-06-27T22:42:22
    author:
      username: drtanjaninkovic
      about: ""
      name: Dr Tanja Ninkovic
      isPowerContributor: false
      profileUrl: https://disqus.com/by/drtanjaninkovic/
      url: ""
      location: ""
      id: "371556403"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: it is actually very relevant. spike protein is a transmembrane
      protein. a human cell which gets the mRNA vaccine in it starts producing
      the protein and gets killed by the immune system, and fully diggested.
      spike will not float around. the mRNA in lipid particles can float around
      and should be detected using the test they present here, if it goes into
      the breastmilk. but i cannot judge if the timeframe is correct. the mRNA
      vaccines are stable only for 8-10h in a body, some papers say, so i guess
      the timeframe is correct, but i don't understand than why is this paper
      not yet published. i can not getting a vaccine until i am sure that it is
      not going into the milk, and i would love to see what is going on with
      this research.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.03.05.21252998v1
  tweets:
    - created_at: Mon Jun 28 01:03:20 +0000 2021
      id: 1409316450087567400
      id_str: "1409316450087567363"
      text: >-
        üí¨ medRxiv comment on "COVID-19 mRNA vaccine is not d..."


        "it is actually very relevant. spike protein is a transme‚Ä¶ https://t.co/BTEKanooOx
      truncated: true
      entities:
        urls:
          - url: https://t.co/BTEKanooOx
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 28 01:03:20 +0000 2021
      id: 1409316451119362000
      id_str: "1409316451119362049"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/Dml5mNWNsu
      truncated: false
      entities:
        urls:
          - url: https://t.co/Dml5mNWNsu
      in_reply_to_status_id: 1409316450087567400
      in_reply_to_status_id_str: "1409316450087567363"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8603406700"
    numReports: 0
    likes: 0
    id: "5435690522"
    createdAt: 2021-06-28T02:07:33
    author:
      username: disqus_CiMr2RjsDS
      about: ""
      name: Matt
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_CiMr2RjsDS/
      url: ""
      location: Loomis
      id: "137706225"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: The study seems to have a fatal flaw, which is that it was based on
      healthcare workers.  Hospitals and other healthcare offices would have
      very strict mask enforcement and many other mitigation measures not found
      outside of healthcare settings.  Therefore, I don't see how one  can
      extrapolate the results to the general population.  In other words, maybe
      it was the mitigation measures and not the vaccine or prior infection that
      was the primary driver in limiting the spread in this particular scenario.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v3
  tweets:
    - created_at: Mon Jun 28 12:34:59 +0000 2021
      id: 1409490511384223700
      id_str: "1409490511384223747"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "The study seems to have a fatal flaw, which is that it w‚Ä¶ https://t.co/i3BBMQYKo4
      truncated: true
      entities:
        urls:
          - url: https://t.co/i3BBMQYKo4
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 28 12:34:59 +0000 2021
      id: 1409490512139145200
      id_str: "1409490512139145220"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1409490511384223700
      in_reply_to_status_id_str: "1409490511384223747"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 0
    id: "5435365847"
    createdAt: 2021-06-27T19:34:48
    author:
      username: rusbowden
      about: ""
      name: rusbowden
      isPowerContributor: false
      profileUrl: https://disqus.com/by/rusbowden/
      url: ""
      location: ""
      id: "10245173"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      There is no question that they work. They work to keep much of the virus
      from spreading. Below, I have already listed several of the studies that
      show this -- including a global study with very different results. The WHO
      is also ignoring this study as it calls for mask wearing just this week. 


      Social distancing does not work 100% either. Neither do vaccines. Neither does good ventilation. The better the mask, the better the protection, the longer the social distancing, the better the protection. The better the ventilation or the more the rain and wind gusts, the better the protection. The consistency of taking precautions, the less the spread. If you wear a mask and then go home to a family with members who do not, you're in trouble. If you all wear masks all the time, and then attend a funeral and mask down, the virus has an in and will take it. People die from such carelessness by the hundreds of thousands. 


      The only reason the virus has been spreading, is that people have not been taking precautions. That's pretty much what this study showed, the sabotage and inconsistency prevailed, such that a brainless virus outsmarted humans causing millions to suffer and get all sorts of organ damage, and millions in the world to die. Viruses work. That's what this study showed, nothing else. 


      For the present strain, as need for better masks and not letting guards down is ever more important, a study such as this requires a virologist or epidemiologist on board to guide both how the study is performed, and what the results of the study actually can show -- how the study can help scientists, and beyond that, how the study can inform people while a deadly pandemic is killing them, their friends and relatives. It's not about appealing to people who would rather not wear a mask for whatever uninformed personal or political opinion they have been exposed to -- and that's who is using this study, the otherwsie uninformed. Science is not about news stories. 


      Onefault of this study is too obvious, that the mandates in sister cities, such as Lowell versus the stricter Cambridge Massachusetts with more compliant citizenry, show incredibly different results. Still today, go to Cambridge, which is a denser city with the same population, and you will see far more people masked up than in Lowell, where the rebel factor has been extreme -- and its citizens paid for it, with their organs, and with their lives. We saw all this happen across the country, as communities in the same state stayed in the "red" or dangerous-to-go-out category, long after similar cities with stricter mandates or better compliance, did not. 


      The study fails at the world level, where so many countries stayed far away from the extraordinarily deadly results that the USA got. We are a beacon of Covid-19 swill. Ultimately, in countries where people got together and governing was caring and effective, the pandemic was kept to a minimum. Every US state could have learned from New Zealand. This week, one person with Covid entered Australia, and the effected communities snapped into action, while in the US, we have just by count alone, 4000 cases of vaccinated people having caught contracted the virus, or need I mention the hundreds still dying each day, testament to the irresponsibility of reporting simething like this.


      The study should have been looking for why they got the results they did. What did it really show? What was wrong with the study, as we already know masks work, and whatever was right with the study, what did it really show? Was it the extent to which sabotaging mask-wearing works? Was it that mask wearing was not as consistently performed as it could have been (a no brainer)? In other words, did people find funerals a good place to finally take masks off and spread the virus around? What good was all the hours of mask wearing? I saw couples (plural) under the cover of night, where the man was unmasked and his woman was not. What good was her mask?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon Jun 28 14:22:45 +0000 2021
      id: 1409517631003054000
      id_str: "1409517631003054081"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "There is no question that they work. They work to keep m‚Ä¶ https://t.co/wqNlDrFUIf
      truncated: true
      entities:
        urls:
          - url: https://t.co/wqNlDrFUIf
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 28 14:22:45 +0000 2021
      id: 1409517631737143300
      id_str: "1409517631737143296"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1409517631003054000
      in_reply_to_status_id_str: "1409517631003054081"
- preprint:
    id: "86557"
    doi: 10.1101/2020.06.08.140210
    first_posted: 2020-06-08
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.06.08.140210v1
    url: https://api.rxivist.org/v1/papers/86557
    title: Neuromodulation Exerts Feedback and Feedforward Control of Action Selection
    category: neuroscience
    abstract: >-
      To be effective, behavioral choices must result in actions that are
      appropriate to an animal's needs and environmental circumstances. In
      addition, the actions must be ones the animal can sustain until its needs
      are met. This aligning of goals, action, and motivation requires the
      coordinated activity of multiple brain circuits, but how such coordination
      is achieved is poorly understood. Here, we show how the insect hormone
      Bursicon coordinates the selection and sustains execution of a behavior in
      newly emerged adult Drosophila. Such flies must expand and harden their
      wings after metamorphosis, but they choose to delay expansion in confined
      conditions. We show that the decision to expand is mediated by an
      environmentally-sensitive, positive feedback loop in which Bursicon
      promotes its own sustained release. Released Bursicon then modulates motor
      neurons to promote wing expansion behavior. Bursicon thus exerts
      feedforward and feedback control to coordinately select and motivate a
      goal-directed action.


      ### Competing Interest Statement


      The authors have declared no competing interest.
    authors:
      - name: Fengqiu Diao
        orcid: null
      - name: Nathan Peabody
        orcid: null
      - name: Benjamin H. White
        orcid: http://orcid.org/0000-0003-0612-8075
  comment:
    dislikes: 0
    thread: "8066727689"
    numReports: 0
    likes: 0
    id: "5436158572"
    createdAt: 2021-06-28T14:28:04
    author:
      username: laurentseroude
      about: ""
      name: Laurent Seroude
      isPowerContributor: false
      profileUrl: https://disqus.com/by/laurentseroude/
      url: ""
      location: ""
      id: "167235240"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Where one can find the Videos for this article?
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.06.08.140210v1
  tweets:
    - created_at: Mon Jun 28 16:39:23 +0000 2021
      id: 1409552017174024200
      id_str: "1409552017174024201"
      text: |-
        üí¨ bioRxiv comment on "Neuromodulation Exerts Feedbac..."

        "Where one can find the Videos for this article?"

        https://t.co/8sF4ovZC1l
      truncated: false
      entities:
        urls:
          - url: https://t.co/8sF4ovZC1l
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 28 16:39:23 +0000 2021
      id: 1409552017865982000
      id_str: "1409552017865981960"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/mGlWLJDADc
      truncated: false
      entities:
        urls:
          - url: https://t.co/mGlWLJDADc
      in_reply_to_status_id: 1409552017174024200
      in_reply_to_status_id_str: "1409552017174024201"
- preprint:
    id: "147698"
    doi: 10.1101/2021.06.25.450004
    first_posted: 2021-06-26
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.25.450004v1
    url: https://api.rxivist.org/v1/papers/147698
    title: Dynamic rewiring of biological activity across genotype and lineage
      revealed by context-dependent functional interactions
    category: systems-biology
    abstract: Coessentiality networks derived from CRISPR screens in cell lines
      provide a powerful framework for identifying functional modules in the
      cell and for inferring the role of uncharacterized genes. However, these
      networks integrate signal across all underlying data, and can mask strong
      interactions that occur in only a subset of the cell lines analyzed. Here
      we decipher dynamic functional interactions by identifying significant
      cellular contexts, primarily by oncogenic mutation, lineage, and tumor
      type, and discovering coessentiality relationships that depend on these
      contexts. We recapitulate well-known gene-context interactions such as
      oncogene-mutation, paralog buffering, and tissue-specific essential genes,
      show how mutation rewires known signal transduction pathways, including
      RAS/RAF and IGF1R-PIK3CA, and illustrate the implications for drug
      targeting. We further demonstrate how context-dependent functional
      interactions can elucidate lineage-specific gene function, as illustrated
      by the maturation of proreceptors IGF1R and MET by proteases FURIN and
      CPD. This approach advances our understanding of context-dependent
      interactions and how they can be gleaned from these data.
    authors:
      - name: Eiru Kim
        orcid: http://orcid.org/0000-0002-1901-5670
      - name: Veronica Gheorghe
        orcid: null
      - name: Traver Hart
        orcid: http://orcid.org/0000-0002-1880-3341
  comment:
    dislikes: 0
    thread: "8616679379"
    numReports: 0
    likes: 0
    id: "5435984864"
    createdAt: 2021-06-28T11:16:05
    author:
      username: hebasailem
      about: ""
      name: Heba Sailem
      isPowerContributor: false
      profileUrl: https://disqus.com/by/hebasailem/
      url: ""
      location: ""
      id: "371577392"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Interesting work! KCML is a highly relevant work and discusses
      similar ideas with a focus on gene function
      (https://www.embopress.org/doi/full/10.15252/msb.20199083). KCML is a
      machine learning approach for inferring context-dependent gene functions
      based on siRNA and CRISPR screens (measuring viability or multi-parametric
      phenotypes).
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.25.450004v1
  tweets:
    - created_at: Mon Jun 28 18:33:04 +0000 2021
      id: 1409580623916941300
      id_str: "1409580623916941314"
      text: >-
        üí¨ bioRxiv comment on "Dynamic rewiring of biological..."


        "Interesting work! KCML is a highly relevant work and dis‚Ä¶ https://t.co/uPKiVp93HO
      truncated: true
      entities:
        urls:
          - url: https://t.co/uPKiVp93HO
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 28 18:33:04 +0000 2021
      id: 1409580624831258600
      id_str: "1409580624831258625"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/ojG5FT3RCZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/ojG5FT3RCZ
      in_reply_to_status_id: 1409580623916941300
      in_reply_to_status_id_str: "1409580623916941314"
- preprint:
    id: 123031
    metric: 44
    title: Attentionally modulated subjective images reconstructed from brain activity
    url: https://api.rxivist.org/v1/papers/123031
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.12.27.424510v1
    doi: 10.1101/2020.12.27.424510
    category: neuroscience
    first_posted: 2020-12-28
    abstract: Visual image reconstruction from brain activity produces images whose
      features are consistent with the neural representations in the visual
      cortex given arbitrary visual instances [1-3], presumably reflecting the
      persons visual experience. Previous reconstruction studies have been
      concerned either with how stimulus images are faithfully reconstructed or
      with whether mentally imagined contents can be reconstructed in the
      absence of external stimuli. However, many lines of vision research have
      demonstrated that even stimulus perception is shaped both by
      stimulus-induced processes and top-down processes. In particular,
      attention (or the lack of it) is known to profoundly affect visual
      experience [4-8] and brain activity [9-21]. Here, to investigate how
      top-down attention impacts the neural representation of visual images and
      the reconstructions, we use a state-of-the-art method (deep image
      reconstruction [3]) to reconstruct visual images from fMRI activity
      measured while subjects attend to one of two images superimposed with
      equally weighted contrasts. Deep image reconstruction exploits the
      hierarchical correspondence between the brain and a deep neural network
      (DNN) to translate (decode) brain activity into DNN features of multiple
      layers, and then create images that are consistent with the decoded DNN
      features [3, 22, 23]. Using the deep image reconstruction model trained on
      fMRI responses to single natural images, we decode brain activity during
      the attention trials. Behavioral evaluations show that the reconstructions
      resemble the attended rather than the unattended images. The
      reconstructions can be modeled by superimposed images with contrasts
      biased to the attended one, which are comparable to the appearance of the
      stimuli under attention measured in a separate session. Attentional
      modulations are found in a broad range of hierarchical visual
      representations and mirror the brain-DNN correspondence. Our results
      demonstrate that top-down attention counters stimulus-induced responses
      and modulate neural representations to render reconstructions in
      accordance with subjective appearance. The reconstructions appear to
      reflect the content of visual experience and volitional control, opening a
      new possibility of brain-based communication and creation.
    authors:
      - name: Tomoyasu Horikawa
      - name: Yukiyasu Kamitani
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Mon Jun 28 20:15:33 +0000 2021
      id: 1409606415652622300
      id_str: "1409606415652622339"
      text: >-
        üî• bioRxiv Neuroscience preprint by T. Horikawa et al:


        "Attentionally modulated subjective images reconstructed fro‚Ä¶ https://t.co/B2zfrD4rv4
      truncated: true
      entities:
        urls:
          - url: https://t.co/B2zfrD4rv4
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "147485"
    doi: 10.1101/2021.06.24.449756
    first_posted: 2021-06-25
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.24.449756v1
    url: https://api.rxivist.org/v1/papers/147485
    title: "The Clade Displacement Index: how to detect hotizontal gene transfers in
      unrooted gene trees"
    category: bioinformatics
    abstract: "While most genes of any organism are inherited vertically - i.e. from
      its parent organisms - sometimes they can be exchanged between unrelated
      species in a process known as the horizontal gene transfer (HGT). Studies
      of HGT contribute to our knowledge about the mechanisms of evolution,
      including the emergence of new pathogens, and a great deal of effort has
      been put into different methods of finding transferred genes. The golden
      standard of HGT detection is the analysis of the incongruence between the
      gene and the species trees. Those methods typically require rooted trees,
      in which the direction of evolution is known. Gene trees are typically
      unrooted, and rooting them is yet another step in HGT analysis, prone to
      errors which may lead to wrong conclusions. A natural question arises: can
      HGTs be detected in gene trees without rooting them at all? It turns out
      that, for a particular, yet broad, class of transfers, the answer to this
      question is: yes. It also turns out that the same methodology can be
      applied to complement the bootstrap support in assessing the stability of
      gene tree topology. In this article, we present the Clade Displacement
      Index, a measure of shift of a given clade's location between two trees.
      We derive algorithms to compute it and give several examples of its
      applications to HGT detection and gene tree stability analysis. We finish
      by pointing out directions for further studies and an example that shows
      that not all HGTs are detectable without knowing the location of the root
      of the gene tree. A Jupyter Notebook with the implementation and
      applications of CDI described in this paper is available at
      \\url{https://github.com/mciach/CDI}"
    authors:
      - name: Micha≈Ç Aleksander Ciach
        orcid: http://orcid.org/0000-0003-4961-7071
  comment:
    dislikes: 0
    thread: "8614532600"
    numReports: 0
    likes: 0
    id: "5435914043"
    createdAt: 2021-06-28T09:17:42
    author:
      username: PalaeoSmith
      about: Assistant Professor in Palaeontology
      name: Martin R. Smith
      isPowerContributor: false
      profileUrl: https://disqus.com/by/PalaeoSmith/
      url: https://community.dur.ac.uk/martin.smith
      location: Durham University
      id: "325420274"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "This looks like an interesting approach; I wonder whether you've
      considered an incorporating an information theoretic approaches for
      comparing two splits?  I found that the use of Shannon information led to
      an improvement on generalized RF distances based on split comparisons
      (Smith (2020, Bioinformatics:
      https://doi.org/10.1093/bioinformatics/btaa614 ), and wonder whether the
      same might be true in this context?"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.24.449756v1
  tweets:
    - created_at: Mon Jun 28 20:19:15 +0000 2021
      id: 1409607348667125800
      id_str: "1409607348667125760"
      text: >-
        üí¨ bioRxiv comment on "The Clade Displacement Index: ..."


        "This looks like an interesting approach; I wonder whethe‚Ä¶ https://t.co/g06DgPaU9N
      truncated: true
      entities:
        urls:
          - url: https://t.co/g06DgPaU9N
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 28 20:19:16 +0000 2021
      id: 1409607349782814700
      id_str: "1409607349782814726"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/01kxRhsDCW
      truncated: false
      entities:
        urls:
          - url: https://t.co/01kxRhsDCW
      in_reply_to_status_id: 1409607348667125800
      in_reply_to_status_id_str: "1409607348667125760"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5435243016"
    createdAt: 2021-06-27T17:38:27
    author:
      username: Notbuyingit3337
      about: ""
      name: Notbuyingit3337
      isPowerContributor: false
      profileUrl: https://disqus.com/by/Notbuyingit3337/
      url: ""
      location: ""
      id: "25889044"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: All SE Asian, Oceanic, and African countries had significantly
      lower deaths per capita no matter what their restrictions were.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon Jun 28 22:18:57 +0000 2021
      id: 1409637472615551000
      id_str: "1409637472615550979"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "All SE Asian, Oceanic, and African countries had signifi‚Ä¶ https://t.co/1OKuJOV2zS
      truncated: true
      entities:
        urls:
          - url: https://t.co/1OKuJOV2zS
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jun 28 22:18:58 +0000 2021
      id: 1409637473672581000
      id_str: "1409637473672581126"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU30MFJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU30MFJ
      in_reply_to_status_id: 1409637472615551000
      in_reply_to_status_id_str: "1409637472615550979"
- preprint:
    id: "90273"
    doi: 10.1101/2020.07.07.191742
    first_posted: 2020-07-07
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.07.07.191742v1
    url: https://api.rxivist.org/v1/papers/90273
    title: The Connexin 43 Carboxyl Terminal Mimetic Peptide alphaCT1 Prompts
      Differentiation of a Collagen Scar Matrix Resembling Unwounded Skin
    category: cell-biology
    abstract: >-
      Phase II clinical trials have reported that acute treatment of surgical
      skin wounds with the therapeutic peptide alphaCT1 improves cutaneous scar
      appearance by 47% 9-months post-surgery - though mode-of-action remains
      unknown. Scar matrix structure in biopsies 2 to 6 weeks post-wounding
      treated topically with alphaCT1 or control treatments from human subjects,
      Sprague-Dawley rats, and IAF hairless guinea pigs were compared. The sole
      effect on scar structure was that alphaCT1-treated scars had less
      alignment of collagen fibers relative to control wounds, a state that
      resembles unwounded skin. This more random alignment was recapitulated in
      both animal models, together with transient increases in collagen density,
      although the guinea pig was found to more closely replicate the pattern of
      response to alphaCT1 in human scars, compared to rat. Fibroblasts treated
      with alphaCT1 in vitro showed decreased directionality and an agent-based
      computational model parameterized with fibroblast motility data predicted
      collagen alignments in simulated scars consistent with that observed
      experimentally in human and the animal models. In conclusion, alphaCT1
      prompts decreased directionality of fibroblast movement and the generation
      of a 3D collagen matrix post-wounding that is similar to unwounded skin -
      changes that correlate with long-term improvement in scar appearance.


      ### Competing Interest Statement


      GSG is CEO and President of FirstString Research Inc. CLG is Senior Director of Research and Development at FirstString Research Inc. RGG is a non-remunerated member of the Scientific Advisory Board of FirstString Research, which licensed Œ± carboxyl terminus 1 peptide. GSG, RGG, LJJ, and CLG have ownership interests in FirstString Research Inc. The remaining authors have no disclosures to report.
    authors:
      - name: Jade Montgomery
        orcid: null
      - name: William J. Richardson
        orcid: http://orcid.org/0000-0001-8678-9716
      - name: J. Matthew Rhett
        orcid: http://orcid.org/0000-0003-2608-3767
      - name: Francis Bustos
        orcid: null
      - name: Katherine Degen
        orcid: null
      - name: Gautam S. Ghatnekar
        orcid: http://orcid.org/0000-0003-2578-9039
      - name: Christina L. Grek
        orcid: null
      - name: Spencer Marsh
        orcid: null
      - name: L. Jane Jourdan
        orcid: null
      - name: Jeffrey W. Holmes
        orcid: http://orcid.org/0000-0001-9125-7220
      - name: Robert G. Gourdie
        orcid: http://orcid.org/0000-0001-6021-0796
  comment:
    dislikes: 0
    thread: "8114731662"
    numReports: 0
    likes: 0
    id: "5436699980"
    createdAt: 2021-06-28T21:36:15
    author:
      username: robertgourdie
      about: ""
      name: Robert Gourdie
      isPowerContributor: false
      profileUrl: https://disqus.com/by/robertgourdie/
      url: ""
      location: ""
      id: "156948610"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: A revised manuscript has been accepted for publications at the
      FASEB Journal -  Montgomery J, Richardson WJ, Rhett JM, Bustos F, Degen K,
      Ghatnekar GS, Grek CL, Jourdan LJ, Holmes JW, and RG Gourdie. The Cx43
      Carboxyl Terminal Mimetic alpaCT1 Prompts Collagen Organization in Human
      Scar Granulation Tissue Resembling Unwounded Dermis. FASEB Journal, in
      press, 2021. doi:10.1096/fj.202001881R
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.07.07.191742v1
  tweets:
    - created_at: Tue Jun 29 00:59:02 +0000 2021
      id: 1409677757638799400
      id_str: "1409677757638799360"
      text: >-
        üí¨ bioRxiv comment on "The Connexin 43 Carboxyl Termi..."


        "A revised manuscript has been accepted for publications‚Ä¶ https://t.co/89z0Ih7erv
      truncated: true
      entities:
        urls:
          - url: https://t.co/89z0Ih7erv
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 29 00:59:02 +0000 2021
      id: 1409677758666469400
      id_str: "1409677758666469389"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/R4yTqSBt4A
      truncated: false
      entities:
        urls:
          - url: https://t.co/R4yTqSBt4A
      in_reply_to_status_id: 1409677757638799400
      in_reply_to_status_id_str: "1409677757638799360"
- preprint:
    id: "146930"
    doi: 10.1101/2021.06.20.21259195
    first_posted: 2021-06-21
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.20.21259195v1
    url: https://api.rxivist.org/v1/papers/146930
    title: Rapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in
      the United States
    category: infectious-diseases
    abstract: The SARS-CoV-2 variant of concern B.1.617.2 displaced B.1.1.7 as the
      dominant variant in England and other countries. This study aimed to
      determine whether B.1.617.2 was also displacing B.1.1.7 in the United
      States. We analyzed PCR testing results and viral sequencing results of
      samples collected across the United States, and showed that B.1.1.7 was
      rapidly being displaced and is no longer responsible for the majority of
      new cases. The percentage of SARS-CoV-2 positive cases that are B.1.1.7
      dropped from 70% in April 2021 to 42% in just 6 weeks. Our analysis showed
      rapid growth of variants B.1.617.2 and P.1 as the primary drivers for this
      displacement. Currently, the growth rate of B.1.617.2 was higher than P.1
      in the US (0.61 vs. 0.22), which is consistent with reports from other
      countries. Lastly, we showed that B.1.617.2 was growing faster in counties
      with a lower vaccination rate.
    authors:
      - name: Alexandre Bolze
        orcid: http://orcid.org/0000-0001-7399-2766
      - name: Elizabeth T. Cirulli
        orcid: null
      - name: Shishi Luo
        orcid: null
      - name: Simon White
        orcid: http://orcid.org/0000-0001-6375-2363
      - name: Tyler Cassens
        orcid: null
      - name: Sharoni Jacobs
        orcid: null
      - name: Jason Nguyen
        orcid: http://orcid.org/0000-0002-6812-9017
      - name: Jimmy M Ramirez
        orcid: null
      - name: Efren Sandoval
        orcid: null
      - name: Xueqing Wang
        orcid: http://orcid.org/0000-0002-2049-8403
      - name: David Wong
        orcid: null
      - name: David Becker
        orcid: null
      - name: Marc Laurent
        orcid: null
      - name: James Lu
        orcid: http://orcid.org/0000-0002-1873-7049
      - name: Magnus Isaksson
        orcid: null
      - name: Nicole L. Washington
        orcid: http://orcid.org/0000-0001-8936-9143
      - name: William Lee
        orcid: null
  comment:
    dislikes: 0
    thread: "8607080142"
    numReports: 0
    likes: 0
    id: "5436962928"
    createdAt: 2021-06-29T02:14:48
    author:
      username: disqus_3RfpD2OJtg
      about: ""
      name: JM V
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_3RfpD2OJtg/
      url: ""
      location: ""
      id: "233198323"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: I presume growth rates are in units of "per week" ?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.20.21259195v1
  tweets:
    - created_at: Tue Jun 29 12:34:10 +0000 2021
      id: 1409852694085312500
      id_str: "1409852694085312515"
      text: |-
        üí¨ medRxiv comment on "Rapid displacement of SARS-CoV..."

        "I presume growth rates are in units of "per week" ?"

        https://t.co/y6PABKRDxf
      truncated: false
      entities:
        urls:
          - url: https://t.co/y6PABKRDxf
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 29 12:34:10 +0000 2021
      id: 1409852694982848500
      id_str: "1409852694982848515"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/M9ds9DVYq7
      truncated: false
      entities:
        urls:
          - url: https://t.co/M9ds9DVYq7
      in_reply_to_status_id: 1409852694085312500
      in_reply_to_status_id_str: "1409852694085312515"
- preprint:
    id: "93054"
    doi: 10.1101/2020.07.31.230987
    first_posted: 2020-07-31
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.07.31.230987v3
    url: https://api.rxivist.org/v1/papers/93054
    title: Global variation in the SARS-CoV-2 proteome reveals the mutational
      hotspots in the drug and vaccine candidates
    category: bioinformatics
    abstract: >-
      To accelerate the drug and vaccine development against the severe acute
      respiratory syndrome virus 2 (SARS-CoV-2), a comparative analysis of
      SARS-CoV-2 proteome has been performed in two phases by considering
      manually curated 31389 whole genome sequences from 84 countries. Among the
      9 mutations that occur at a high significance (T85I-NPS2, L37F-NSP6,
      P323L-NSP12, D614G-spike, Q57H-ORF3a, G251V-ORF3a, L84S-ORF8,
      R203K-nucleocapsid and G204R-nucleocapsid), R203K-nucleocapsid and
      G204R-nucleocapsid are co-occurring (dependent) mutations and P323L-NSP12
      and D614G-spike often appear simultaneously. Other notable variations that
      appear with a moderate to low significance are, M85-NSP1 deletion,
      D268-NSP2 deletion, 112 amino acids deletion in ORF8, a phenylalanine
      insertion amidst F34-F36 (NSP6) and several co-existing (dependent)
      substitution/deletion (I559V & P585S in NSP2, P504L & Y541C in NSP13, G82
      & H83 deletions in NSP1 and K141, S142 & F143 deletions in NSP2)
      mutations. P323L-NSP12, D614G-spike, L37F-NSP6, L84S-ORF8 and the
      sequences deficient of the high significant mutations have led to 4 major
      SARS-CoV-2 clades. The top 5 countries bearing all the high significant
      and majority of the moderate significant mutations are: USA, England,
      Wales, Australia and Scotland. Further, the majority of the significant
      mutations have evolved in the first phase and have already transmitted
      around the globe indicating the positive selection pressure. Among the 26
      SARS-CoV-2 proteins, nucleocapsid protein, ORF3a, ORF8, RNA dependent RNA
      polymerase and spike exhibit a higher heterogeneity compared with the rest
      of the proteins. However, NSP9, NSP10, NSP8, the envelope protein and NSP4
      are highly resistant to mutations and can be exploited for drug/vaccine
      development.


      ### Competing Interest Statement


      The authors have declared no competing interest.
    authors:
      - name: L Ponoop Prasad Patro
        orcid: null
      - name: Chakkarai Sathyaseelan
        orcid: null
      - name: Patil Pranita Uttamrao
        orcid: null
      - name: Thenmalarchelvi Rathinavelan
        orcid: http://orcid.org/0000-0002-1142-0583
  comment:
    dislikes: 0
    thread: "8154742983"
    numReports: 0
    likes: 0
    id: "5437076523"
    createdAt: 2021-06-29T05:06:44
    author:
      username: lponoopprasadpatro
      about: ""
      name: L PONOOP PRASAD Patro
      isPowerContributor: false
      profileUrl: https://disqus.com/by/lponoopprasadpatro/
      url: ""
      location: ""
      id: "371617814"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: The preprint has been now published with doi
      https://doi.org/10.1016/j.meegid.2021.104973 and a link will be
      forthcoming in the current page.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.07.31.230987v3
  tweets:
    - created_at: Tue Jun 29 14:22:31 +0000 2021
      id: 1409879959489978400
      id_str: "1409879959489978375"
      text: >-
        üí¨ bioRxiv comment on "Global variation in the SARS-C..."


        "The preprint has been now published with doi  and a link‚Ä¶ https://t.co/nTElwFpobR
      truncated: true
      entities:
        urls:
          - url: https://t.co/nTElwFpobR
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 29 14:22:31 +0000 2021
      id: 1409879960513302500
      id_str: "1409879960513302541"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/XH0ArtpodZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/XH0ArtpodZ
      in_reply_to_status_id: 1409879959489978400
      in_reply_to_status_id_str: "1409879959489978375"
- preprint:
    id: "147318"
    doi: 10.1101/2021.06.19.21259117
    first_posted: 2021-06-23
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.19.21259117v1
    url: https://api.rxivist.org/v1/papers/147318
    title: Systematic single-variant and gene-based association testing of 3,700
      phenotypes in 281,850 UK Biobank exomes
    category: genetic-and-genomic-medicine
    abstract: Genome-wide association studies have successfully discovered thousands
      of common variants associated with human diseases and traits, but the
      landscape of rare variation in human disease has not been explored at
      scale. Exome sequencing studies of population biobanks provide an
      opportunity to systematically evaluate the impact of rare coding variation
      across a wide range of phenotypes to discover genes and allelic series
      relevant to human health and disease. Here, we present results from
      systematic association analyses of 3,700 phenotypes using single-variant
      and gene tests of 281,850 individuals in the UK Biobank with exome
      sequence data. We find that the discovery of genetic associations is
      tightly linked to frequency as well as correlated with metrics of
      deleteriousness and natural selection. We highlight biological findings
      elucidated by these data and release the dataset as a public resource
      alongside a browser framework for rapidly exploring rare variant
      association results.
    authors:
      - name: Konrad Karczewski
        orcid: http://orcid.org/0000-0003-2878-4671
      - name: Matthew Solomonson
        orcid: http://orcid.org/0000-0002-5344-9026
      - name: Katherine R Chao
        orcid: http://orcid.org/0000-0003-2897-2410
      - name: Julia K Goodrich
        orcid: http://orcid.org/0000-0003-0480-1924
      - name: Grace Tiao
        orcid: http://orcid.org/0000-0001-9864-8275
      - name: Wenhan Lu
        orcid: null
      - name: Bridget Riley-Gillis
        orcid: null
      - name: Ellen Tsai
        orcid: http://orcid.org/0000-0002-5625-1189
      - name: Hye In Kim
        orcid: null
      - name: Xiuwen Zheng
        orcid: http://orcid.org/0000-0002-1390-0708
      - name: Fedik Rahimov
        orcid: null
      - name: Sahar Esmaeeli
        orcid: null
      - name: A Jason Grundstad
        orcid: null
      - name: Mark Reppell
        orcid: null
      - name: Jeff Waring
        orcid: null
      - name: Howard Jacob
        orcid: null
      - name: David Sexton
        orcid: null
      - name: Paola G. Bronson
        orcid: http://orcid.org/0000-0001-9996-9812
      - name: Xing Chen
        orcid: http://orcid.org/0000-0002-6740-9535
      - name: Xinli Hu
        orcid: null
      - name: Jacqueline I Goldstein
        orcid: http://orcid.org/0000-0003-1902-6916
      - name: Daniel King
        orcid: null
      - name: Chris Vittal
        orcid: null
      - name: Timothy Poterba
        orcid: http://orcid.org/0000-0003-1287-3434
      - name: Duncan S Palmer
        orcid: http://orcid.org/0000-0002-0824-0047
      - name: Claire Churchhouse
        orcid: http://orcid.org/0000-0003-3140-6452
      - name: Daniel P Howrigan
        orcid: http://orcid.org/0000-0002-7721-4838
      - name: Wei Zhou
        orcid: http://orcid.org/0000-0001-7719-0859
      - name: Nicholas A Watts
        orcid: null
      - name: Kevin Nguyen
        orcid: null
      - name: Huy Nguyen
        orcid: null
      - name: Cara Mason
        orcid: null
      - name: Christopher Farnham
        orcid: null
      - name: Charlotte Tolonen
        orcid: null
      - name: Laura D Gauthier
        orcid: null
      - name: Namrata Gupta
        orcid: null
      - name: Daniel G MacArthur
        orcid: http://orcid.org/0000-0002-5771-2290
      - name: Heidi L Rehm
        orcid: http://orcid.org/0000-0002-6025-0015
      - name: Cotton Seed
        orcid: null
      - name: Anthony Philippakis
        orcid: null
      - name: Mark Daly
        orcid: http://orcid.org/0000-0002-0949-8752
      - name: J Wade Davis
        orcid: null
      - name: Heiko Runz
        orcid: http://orcid.org/0000-0002-2133-7345
      - name: Melissa R. Miller
        orcid: null
      - name: Benjamin M Neale
        orcid: http://orcid.org/0000-0003-1513-6077
  comment:
    dislikes: 0
    thread: "8611420055"
    numReports: 0
    likes: 0
    id: "5436827730"
    createdAt: 2021-06-28T23:40:06
    author:
      username: alexpoliakov
      about: ""
      name: Alex Poliakov
      isPowerContributor: false
      profileUrl: https://disqus.com/by/alexpoliakov/
      url: ""
      location: ""
      id: "228799165"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Really cool! 


      Why do we get different numbers of results for different genes? If I type in a gene symbol into the browser and then press "export data to csv" - I get different numbers of rows for different genes:


      APOE:   1001 phenotypes

      PCSK9: 1951 phenotypes

      BRCA1: 1950 phenotypes

      IL6:          978 phenotypes


      At first we thought it might be a pvalue threshold but there are entries with pvalue=1 in all cases...
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.19.21259117v1
  tweets:
    - created_at: Tue Jun 29 16:31:22 +0000 2021
      id: 1409912384534294500
      id_str: "1409912384534294539"
      text: |-
        üí¨ medRxiv comment on "Systematic single-variant and ..."

        "Really cool! 

        Why do we get different numbers of result‚Ä¶ https://t.co/m6AMy0VA1U
      truncated: true
      entities:
        urls:
          - url: https://t.co/m6AMy0VA1U
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 29 16:31:22 +0000 2021
      id: 1409912385285013500
      id_str: "1409912385285013516"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/1z26odUPKc
      truncated: false
      entities:
        urls:
          - url: https://t.co/1z26odUPKc
      in_reply_to_status_id: 1409912384534294500
      in_reply_to_status_id_str: "1409912384534294539"
- preprint:
    id: "48879"
    doi: 10.1101/613711
    first_posted: 2019-04-18
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/613711v1
    url: https://api.rxivist.org/v1/papers/48879
    title: Determination of clinical risk factors associated with inflammation in
      hypertensive patients with type-2 diabetes mellitus
    category: epidemiology
    abstract: "Background: Obesity and chronic diseases associated with the
      development of inflammation have remained unclear if the observed
      inflammatory state in diabetic patients is due to excess adipose tissue
      mass and/or directly associated with the diabetic state. Therefore, this
      study determined the risk factors associated with inflammation in
      hypertensive patients with type-2 diabetes mellitus. Methods: A total of
      164 hypertensive diabetic patients aged 38 to 60 years were selected from
      seven primary health care centers in Gaza city, Palestine. Interview and
      questionnaire were employed to collect data related to age, gender,
      smoking habits, and physical activity pattern. Besides, the selection of
      patients depended on objective criteria. Results: The study involved 118
      (72%) women and 46 (28%) men. The mean of age for all patients was 53.7 ¬±
      0.46 years old. 76 patients (46.3%) were categorized as current smokers,
      88 patients (53.7%) categorized as non-smokers. The baseline distribution
      of patients according to physical activity has displayed that 130 (79.3%)
      were low physically active patients, 28 (27.1%) were moderate, and 6
      (3.7%) were highly physically active patients. A tertile of inflammation
      feature with high sensitivity C-reactive protein (hs-CRP) was developed.
      The highest tertile of hs-CRP was significantly associated with women,
      higher obesity indices, metabolic dysregulation involving lipid profile
      markers, fasting blood glucose (FBG) and blood pressure, higher
      interleukin 6 (IL-6), and lower adiponectin. Via ordinal logistic
      regression analysis, after adjusting for age, gender, smoking habits, and
      physical activity; the risk factors for hs-CRP were the increased body
      mass index [OR: 1.17, P=0.018], IL-6 [OR: 2.22, P=0.025] and FBG [OR:
      1.01, P=0.007], as well as reduced adiponectin [OR: 0.81, P=0.002].
      Conclusion: The inflammation state was affected by obesity and had been
      related to altered adipokines levels of IL-6 and adiponectin, as well as
      affected by the disease condition of diabetes, as evidenced by higher
      serum level of FBG."
    authors:
      - name: Mohammed S. Ellulu
        orcid: http://orcid.org/0000-0003-1671-799X
  comment:
    dislikes: 0
    thread: "7366079178"
    numReports: 0
    likes: 0
    id: "5437607291"
    createdAt: 2021-06-29T16:25:35
    author:
      username: mohammedsellulu
      about: ""
      name: Mohammed S. Ellulu
      isPowerContributor: false
      profileUrl: https://disqus.com/by/mohammedsellulu/
      url: ""
      location: ""
      id: "371591956"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: |-
      The study published in the Current Medical Research and Opinion 
      https://doi.org/10.1080/03007995.2021.1941826
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/613711v1
  tweets:
    - created_at: Tue Jun 29 18:24:38 +0000 2021
      id: 1409940890668482600
      id_str: "1409940890668482565"
      text: >-
        üí¨ bioRxiv comment on "Determination of clinical risk..."


        "The study published in the Current Medical Research and‚Ä¶ https://t.co/Gfaxi2u6tI
      truncated: true
      entities:
        urls:
          - url: https://t.co/Gfaxi2u6tI
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 29 18:24:38 +0000 2021
      id: 1409940891414958000
      id_str: "1409940891414958080"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/LeXfACb2fq
      truncated: false
      entities:
        urls:
          - url: https://t.co/LeXfACb2fq
      in_reply_to_status_id: 1409940890668482600
      in_reply_to_status_id_str: "1409940890668482565"
- preprint:
    id: 147500
    metric: 10
    title: A novel flight style allowing the smallest featherwing beetles to excel
    url: https://api.rxivist.org/v1/papers/147500
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.24.449497v1
    doi: 10.1101/2021.06.24.449497
    category: zoology
    first_posted: 2021-06-25
    abstract: Flight speed generally correlates positively with animal body size
      [1]. Surprisingly, miniature featherwing beetles can fly at speeds and
      accelerations of insects three times as large [2]. We show here that this
      performance results from a previously unknown type of wing motion. Our
      experiment combines three-dimensional reconstructions of morphology and
      kinematics in one of the smallest insects, Paratuposa placentis (body
      length 395 m). The flapping bristled wing follows a pronounced
      figure-eight loop that consists of subperpendicular up and down strokes
      followed by claps at stroke reversals, above and below the body.
      Computational analyses suggest a functional decomposition of the flapping
      cycle in two power half strokes producing a large upward force and two
      down-dragging recovery half strokes. In contrast to heavier membranous
      wings, the motion of bristled wings of the same size requires little
      inertial power. Muscle mechanical power requirements thus remain positive
      throughout the wing beat cycle, making elastic energy storage obsolete.
      This novel flight style evolved during miniaturization may compensate for
      costs associated with air viscosity and helps explain how extremely small
      insects preserved superb aerial performance during miniaturization.
      Incorporating this flight style in artificial flappers is a challenge for
      designers of micro aerial vehicles.
    authors:
      - name: Sergey E. Farisenkov
      - name: Dmitry Kolomenskiy
      - name: Pyotr N. Petrov
      - name: Nadejda A. Lapina
      - name: Thomas Engels
      - name: Fritz-Olaf Lehmann
      - name: Ryo Onishi
      - name: Hao Liu
      - name: Alexey A. Polilov
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Tue Jun 29 20:15:51 +0000 2021
      id: 1409968878835302400
      id_str: "1409968878835302401"
      text: >-
        üî• bioRxiv Zoology preprint by S. E. Farisenkov et al:


        "A novel flight style allowing the smallest featherwing beet‚Ä¶ https://t.co/YoO2Qj1Lby
      truncated: true
      entities:
        urls:
          - url: https://t.co/YoO2Qj1Lby
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "123186"
    doi: 10.1101/2020.12.29.424677
    first_posted: 2020-12-30
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.12.29.424677v1
    url: https://api.rxivist.org/v1/papers/123186
    title: Global cognitive performance is not influenced by diurnal rhythm
    category: neuroscience
    abstract: >-
      ObjectiveThe human brain is influenced by different biological rhythms,
      including the daily 24-hour (diurnal) cycle. Past studies have reported
      evidence of variation in cognitive performance over the course of the day,
      and of differences in the peak time for cognition in older age. Here, we
      investigated these questions using two existing longitudinal studies of
      healthy adults.


      MethodsTime of neuropsychological battery testing was extracted from study records, and we analyzed cognitive performance measures from 4 domains (Vocabulary, Processing Speed, Fluid Reasoning, and Episodic Memory) in 543 healthy adults between the ages of 20 and 80. Time of day was dichotomized as morning (281 tested before noon), and afternoon (242 tested after noon).


      ResultsMultivariate analyses controlling for both gender and years of education revealed no significant effect of time of testing (or its interaction with participant age) on cognitive performance. These results suggest that diurnal effects during time periods typically used to test human subjects are unlikely to have a meaningful effect on performance on the neuropsychological tests that are used for standard cognitive assessment.


      ConclusionThis suggests that the effect of time of day on cognition in the context of aging may not be as ubiquitous as previously suggested, and thus is unlikely to represent a large confound in existing studies of cognition across the adult lifespan.
    authors:
      - name: Celine H De Jager
        orcid: null
      - name: Eleanna Varangis
        orcid: http://orcid.org/0000-0002-2688-2297
      - name: Yaakov Stern
        orcid: http://orcid.org/0000-0001-7542-3241
  comment:
    dislikes: 0
    thread: "8336309231"
    numReports: 0
    likes: 0
    id: "5436375524"
    createdAt: 2021-06-28T17:27:15
    author:
      username: disqus_s7SMsaXewm
      about: ""
      name: SkepticalScientist
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_s7SMsaXewm/
      url: ""
      location: ""
      id: "39292732"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Interesting paper, but I think given the lack of information about
      chronotype/circadian rhythms & the lack of control of when people came in
      means I‚Äôm not sure I buy that this says much about time of day - just that
      people generally circumvent detrimental outcomes to cognition by planning
      to come in for experiments when they feel awake and ready to be tested.
      I‚Äôd love to see a study using actigraphy x time of testing effects on
      cognition at the same sort of scale as this study.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.12.29.424677v1
  tweets:
    - created_at: Tue Jun 29 20:19:17 +0000 2021
      id: 1409969745055584300
      id_str: "1409969745055584256"
      text: >-
        üí¨ bioRxiv comment on "Global cognitive performance i..."


        "Interesting paper, but I think given the lack of informa‚Ä¶ https://t.co/HLQzoM2CkE
      truncated: true
      entities:
        urls:
          - url: https://t.co/HLQzoM2CkE
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 29 20:19:18 +0000 2021
      id: 1409969746108326000
      id_str: "1409969746108325889"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/qorwX1oYPW
      truncated: false
      entities:
        urls:
          - url: https://t.co/qorwX1oYPW
      in_reply_to_status_id: 1409969745055584300
      in_reply_to_status_id_str: "1409969745055584256"
- preprint:
    id: "116950"
    doi: 10.1101/2020.09.22.20199521
    first_posted: 2020-09-23
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.09.22.20199521v1
    url: https://api.rxivist.org/v1/papers/116950
    title: "APPLAUSE: Automatic Prediction of PLAcental health via U-net
      Segmentation and statistical Evaluation"
    category: obstetrics-and-gynecology
    abstract: "Purpose: Artificial-intelligence population-based automated
      quantification of placental maturation and health from a rapid functional
      Magnetic Resonance scan. The placenta plays a crucial role for any
      successful human pregnancy. Deviations from the normal dynamic maturation
      throughout gestation are closely linked to major pregnancy complications.
      Antenatal assessment in-vivo using T2* relaxometry has shown great promise
      to inform management and possible interventions but clinical translation
      is hampered by time consuming manual segmentation and analysis techniques
      based on comparison against normative curves over gestation. Methods: This
      study proposes a fully automatic pipeline to predict the biological age
      and health of the placenta based on a rapid (sub-30 second) T2* scan in
      two steps: Automatic segmentation using a U-Net and a Gaussian Process
      regression model to characterize placental maturation and health. These
      are trained and evaluated on 110 3T MRI placental data sets including 20
      high-risk pregnancies diagnosed with pre-eclampsia and/or fetal growth
      restriction. Results: Automatic segmentation achieves comparable
      performance to human experts (mean DICE coefficients automatic-manual
      0.76, Pearson Correlation Coefficient 0.986 for mean T2* within the
      masks). The placental health prediction achieves an excellent ability to
      differentiate early cases of placental insufficiency before 32 weeks. High
      abnormality scores correlate with low birth weight, premature birth and
      histopathological findings. Retrospective application on a different
      cohort imaged at 1.5T illustrates the ability for direct clinical
      translation. Conclusion: The presented automatic pipeline facilitates a
      fast, robust and reliable prediction of placental maturation. It yields
      human-interpretable and verifiable intermediate results and quantifies
      uncertainties on the cohort-level and for individual predictions. The
      proposed machine-learning pipeline runs in close to real-time and,
      deployed in clinical settings, has the potential to become a cornerstone
      of diagnosis and intervention of placental insufficiency."
    authors:
      - name: Maximilian Pietsch
        orcid: http://orcid.org/0000-0002-5581-8489
      - name: Alison Ho
        orcid: null
      - name: Alessia Bardanzellu
        orcid: null
      - name: Aya Mutaz Ahmad Zeidan
        orcid: null
      - name: Lucy C Chappell
        orcid: http://orcid.org/0000-0001-6219-3379
      - name: Joseph V. Hajnal
        orcid: http://orcid.org/0000-0002-2690-5495
      - name: Mary A. Rutherford
        orcid: http://orcid.org/0000-0003-3361-1337
      - name: Jana Hutter
        orcid: http://orcid.org/0000-0003-3476-3500
  comment:
    dislikes: 0
    thread: "8213199510"
    numReports: 0
    likes: 0
    id: "5437175758"
    createdAt: 2021-06-29T08:20:33
    author:
      username: disqus_WS81AqH3rO
      about: ""
      name: Max Pietsch
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_WS81AqH3rO/
      url: ""
      location: ""
      id: "83220687"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "For the peer-reviewed updated version of this paper, please see:
      https://www.sciencedirect.com/science/article/pii/S1361841521001912"
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.09.22.20199521v1
  tweets:
    - created_at: Tue Jun 29 22:19:58 +0000 2021
      id: 1410000112538075100
      id_str: "1410000112538075138"
      text: >-
        üí¨ medRxiv comment on "APPLAUSE: Automatic Prediction..."


        "For the peer-reviewed updated version of this paper, ple‚Ä¶ https://t.co/2veHAsy8pB
      truncated: true
      entities:
        urls:
          - url: https://t.co/2veHAsy8pB
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 29 22:19:58 +0000 2021
      id: 1410000113339150300
      id_str: "1410000113339150340"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/hqiasc1lb0
      truncated: false
      entities:
        urls:
          - url: https://t.co/hqiasc1lb0
      in_reply_to_status_id: 1410000112538075100
      in_reply_to_status_id_str: "1410000112538075138"
- preprint:
    id: "147028"
    doi: 10.1101/2021.06.18.449051
    first_posted: 2021-06-22
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.18.449051v1
    url: https://api.rxivist.org/v1/papers/147028
    title: Recovery of deleted deep sequencing data sheds more light on the early
      Wuhan SARS-CoV-2 epidemic
    category: evolutionary-biology
    abstract: The origin and early spread of SARS-CoV-2 remains shrouded in mystery.
      Here I identify a data set containing SARS-CoV-2 sequences from early in
      the Wuhan epidemic that has been deleted from the NIH's Sequence Read
      Archive. I recover the deleted files from the Google Cloud, and
      reconstruct partial sequences of 13 early epidemic viruses. Phylogenetic
      analysis of these sequences in the context of carefully annotated existing
      data further supports the idea that the Huanan Seafood Market sequences
      are not fully representative of the viruses in Wuhan early in the
      epidemic. Instead, the progenitor of currently known SARS-CoV-2 sequences
      likely contained three mutations relative to the market viruses that made
      it more similar to SARS-CoV-2's bat coronavirus relatives.
    authors:
      - name: Jesse D Bloom
        orcid: http://orcid.org/0000-0003-1267-3408
  comment:
    dislikes: 0
    thread: "8609030409"
    numReports: 0
    likes: 0
    id: "5436280082"
    createdAt: 2021-06-28T16:11:51
    author:
      username: jesse_bloom
      about: ""
      name: Jesse Bloom
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jesse_bloom/
      url: ""
      location: ""
      id: "81828378"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Thanks for the comments. I fully agree that there is relatively little
      phylogenetic signal among early SARS-CoV-2 sequences, but this is an
      unavoidable aspect of working with viral outbreak sequences that are all
      closely related. Because the sequences all differ by just a few mutations,
      there is never extremely strong phylogenetic support for any scenario, but
      it is still possible to make informative analyses.


      Furthermore, it is not true that there is no phylogenetic signal for rooting the tree. As discussed by Pipes and Nielsen (https://academic.oup.com/mbe/article/38/4/1537/6028993), outgroup rooting methods do lead to consistent placement of the root in clade A. The problem is that this root placement is statistically incompatible with the date-based root placements (again, see Pipes and Nielsen). The current study suggests an explanation for this inconsistency: possible biases in which early sequences are known. It also suggests the presence in clade A of an additional mutation towards the outgroup (T29095C) that further strengthens the idea that clade A may be the more ancestral one by providing a second scenario that moves some viruses in clade A three steps closer to the outgroup (the other scenario is proCoV2 by Kumar, Pond, et al https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135569/ who also explain difficulties in rooting using just traditional phylogenetic approaches).


      Also, see the discussion in the 2nd and 3rd to last paragraphs of the Discussion section of the pre-print. I explicitly explain (2nd to last) why I am presenting qualitative / visual conclusions rather than formal phylogenetic statistical hypothesis testing. I think we need to recognize that for outbreak sequences that are closely related (as you point out), the questions are not going to be fully resolved just by using advanced statistical phylogenetic algorithms, and we need to also maximize information from metadata about the sequences (such as I do in the pre-print for the four Guangdong sequences) and also pay attention to any information that suggests the extent to which available sequences may or may not be fully representative of circulating viruses.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.18.449051v1
  tweets:
    - created_at: Wed Jun 30 01:05:21 +0000 2021
      id: 1410041732851548200
      id_str: "1410041732851548165"
      text: >-
        üí¨ bioRxiv comment on "Recovery of deleted deep seque..."


        "Thanks for the comments. I fully agree that there is rel‚Ä¶ https://t.co/ouCvvoiczK
      truncated: true
      entities:
        urls:
          - url: https://t.co/ouCvvoiczK
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 30 01:05:21 +0000 2021
      id: 1410041733639983000
      id_str: "1410041733639983105"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/BSMtoxg74u
      truncated: false
      entities:
        urls:
          - url: https://t.co/BSMtoxg74u
      in_reply_to_status_id: 1410041732851548200
      in_reply_to_status_id_str: "1410041732851548165"
- preprint:
    id: "129781"
    doi: 10.1101/2021.02.12.21251640
    first_posted: 2021-02-18
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.02.12.21251640v1
    url: https://api.rxivist.org/v1/papers/129781
    title: Optimal Allocation of COVID-19 Vaccines in the Philippines
    category: epidemiology
    abstract: Vaccine allocation is a national concern especially for countries such
      as the Philippines that have limited resources in acquiring COVID-19
      vaccines. As such, certain groups are suggested to be prioritized for
      vaccination to protect the most vulnerable before vaccinating others. Our
      model suggests an allocation of vaccines such that COVID-19 deaths are
      minimized while the prioritization framework is satisfied. Results of the
      model show that a vaccine coverage of at least 50 to 70% of the population
      can be enough for a community with limited supplies, and an increase in
      vaccine supply is beneficial if initial coverage is less than the
      specified target range. Also, among the vaccines considered in the study,
      the one with 89.9% effectiveness and has a 183 Philippine peso (Php) price
      per dose projected the least number of deaths. Compared to other model
      variations and common allocation approaches, the model has achieved both
      an optimal and equitable allocation. This will be helpful for policymakers
      in determining a vaccine distribution for a resource-constrained
      community.
    authors:
      - name: Christian Alvin H Buhat
        orcid: http://orcid.org/0000-0003-4742-7688
      - name: Destiny SM Lutero
        orcid: null
      - name: Yancee H. Olave
        orcid: null
      - name: Kemuel M Quindala
        orcid: null
      - name: Mary Grace P Recreo
        orcid: null
      - name: Dylan Antonio SJ Talabis
        orcid: http://orcid.org/0000-0002-4468-688X
      - name: Monica C. Torres
        orcid: http://orcid.org/0000-0003-1628-0759
      - name: Jerrold M. Tubay
        orcid: http://orcid.org/0000-0003-4826-1966
      - name: Jomar F Rabajante
        orcid: http://orcid.org/0000-0002-0655-0893
  comment:
    dislikes: 0
    thread: "8402897593"
    numReports: 0
    likes: 0
    id: "5436131373"
    createdAt: 2021-06-28T14:02:58
    author:
      username: jomarfajardorabajante
      about: ""
      name: Jomar Fajardo Rabajante
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jomarfajardorabajante/
      url: ""
      location: ""
      id: "51463798"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: The updated version of this manuscript is published in
      https://link.springer.com/article/10.1007%2Fs40258-021-00667-z
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.02.12.21251640v1
  tweets:
    - created_at: Wed Jun 30 12:36:30 +0000 2021
      id: 1410215667161342000
      id_str: "1410215667161341957"
      text: |-
        üí¨ medRxiv comment on "Optimal Allocation of COVID-19..."

        "The updated version of this manuscript is published in "

        https://t.co/8xbXsyGCi4
      truncated: false
      entities:
        urls:
          - url: https://t.co/8xbXsyGCi4
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 30 12:36:30 +0000 2021
      id: 1410215667937255400
      id_str: "1410215667937255424"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oIaqJUet4r
      truncated: false
      entities:
        urls:
          - url: https://t.co/oIaqJUet4r
      in_reply_to_status_id: 1410215667161342000
      in_reply_to_status_id_str: "1410215667161341957"
- preprint:
    id: "147790"
    doi: 10.1101/2021.06.27.450013
    first_posted: 2021-06-27
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.27.450013v1
    url: https://api.rxivist.org/v1/papers/147790
    title: Investigating the reliability of molecular estimates of evolutionary time
      when substitution rates and speciation rates vary
    category: evolutionary-biology
    abstract: Background An accurate timescale of evolutionary history is essential
      to testing hypotheses about the influence of historical events and
      processes, and the timescale for evolution is increasingly derived from
      analysis of DNA sequences. But variation in the rate of molecular
      evolution complicates the inference of time from DNA. Evidence is growing
      for numerous factors, such as life history and habitat, that are linked
      both to the molecular processes of mutation and fixation and to rates of
      macroevolutionary diversification. However, the most widely used models of
      molecular rate variation, such as the uncorrelated and autocorrelated
      lognormal clocks, rely on idealised models of rate variation and molecular
      dating methods are rarely tested against complex models of rate change.
      One relationship that is not accounted for in molecular dating is the
      potential for interaction between molecular substitution rates and
      speciation, a relationship that has been supported by empirical studies in
      a growing number of taxa. If these relationships are as widespread as
      evidence indicates, they may have a significant influence on molecular
      dates. Results We simulate phylogenies and molecular sequences under three
      different realistic rate variation models - one in which speciation rates
      and substitution rates both vary but are unlinked, one in which they
      covary continuously and one punctuated model in which molecular change is
      concentrated in speciation events, using empirical case studies to
      parameterise realistic simulations. We test two commonly used "relaxed
      clock" molecular dating methods against these realistic simulations to
      explore the degree of error in molecular dates under each model. We find
      average divergence time inference errors ranging from 12% of node age for
      the unlinked model when reconstructed under an uncorrelated rate prior, to
      up to 93% when punctuated simulations are reconstructed under an
      autocorrelated prior. Conclusions We demonstrate the potential for
      substantial errors in molecular dates when both speciation rates and
      substitution rates vary between lineages. This study highlights the need
      for tests of molecular dating methods against realistic models of rate
      variation generated from empirical parameters and known relationships.
    authors:
      - name: Andrew M Ritchie
        orcid: http://orcid.org/0000-0001-9716-0649
      - name: Xia Hua
        orcid: null
      - name: Lindell Bromham
        orcid: http://orcid.org/0000-0003-2202-2609
  comment:
    dislikes: 0
    thread: "8618678087"
    numReports: 0
    likes: 0
    id: "5435910974"
    createdAt: 2021-06-28T09:11:42
    author:
      username: PalaeoSmith
      about: Assistant Professor in Palaeontology
      name: Martin R. Smith
      isPowerContributor: false
      profileUrl: https://disqus.com/by/PalaeoSmith/
      url: https://community.dur.ac.uk/martin.smith
      location: Durham University
      id: "325420274"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      This is an interesting study; I'm always encouraged to see careful
      examinations of different phylogenetic approaches.  As with similar
      simulation studies, I might be inclined to question would be whether the
      Robinson‚ÄìFoulds distance is the most appropriate here: trees with an RF
      distance of 5 might in fact be more different than trees 

      with an RF distance of 6, depending on whether the five or six unshared clades are major or minor groupings. I've reviewed this problem more fully at https://doi.org/10.1093/bioinformatics/btaa614 (Smith 2020, Bioinformatics). Apologies if I missed it, but I didn't see whether the reconstructed trees were fully bifurcating; if they contained polytomies, then you might also want to consider whether the improved accuracy of some methods came at the expense of precision (see Smith 2019, Biology Letters, https://doi.org/10.1098/rsbl.2018.0632 ).
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.27.450013v1
  tweets:
    - created_at: Wed Jun 30 14:17:50 +0000 2021
      id: 1410241171645993000
      id_str: "1410241171645992962"
      text: >-
        üí¨ bioRxiv comment on "Investigating the reliability ..."


        "This is an interesting study; I'm always encouraged to s‚Ä¶ https://t.co/LyK5R4kptz
      truncated: true
      entities:
        urls:
          - url: https://t.co/LyK5R4kptz
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 30 14:17:51 +0000 2021
      id: 1410241172480614400
      id_str: "1410241172480614403"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/aIPUx3zVLV
      truncated: false
      entities:
        urls:
          - url: https://t.co/aIPUx3zVLV
      in_reply_to_status_id: 1410241171645993000
      in_reply_to_status_id_str: "1410241171645992962"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5438763146"
    createdAt: 2021-06-30T13:51:55
    author:
      username: adam_mercy
      about: ""
      name: Adam Mercy
      isPowerContributor: false
      profileUrl: https://disqus.com/by/adam_mercy/
      url: ""
      location: ""
      id: "360983177"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      It is reassuring to some, but borderline insanity to others that we have
      to prove we have an immune system.  We knew early in 2020, that prior T
      cell immunity was present in probably 50%+ of the population, from prior
      coronaviruses from as far back as 15y (or longer).  




      Covid likely is a patient-specific immune hypersensitivity. Some say MCAS, it may turn out to be.  If that is the case, vaccines or not, those patients need drugs -- which implies drug therapies are the only way out.


      And yet, the conclusion to this piece is about prioritizing vaccines.  Scientists take a look at data from nation states like Mexico. Not small trials, massive interventions at scale.  Or India.  You are making a blunder which will meme''d about till the end of time.  See our twitter on how to save your reputations.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Wed Jun 30 16:32:27 +0000 2021
      id: 1410275045151330300
      id_str: "1410275045151330306"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "It is reassuring to some, but borderline insanity to oth‚Ä¶ https://t.co/p25wulTlJl
      truncated: true
      entities:
        urls:
          - url: https://t.co/p25wulTlJl
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 30 16:32:27 +0000 2021
      id: 1410275045797249000
      id_str: "1410275045797249026"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1410275045151330300
      in_reply_to_status_id_str: "1410275045151330306"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8603406700"
    numReports: 0
    likes: 0
    id: "5438760102"
    createdAt: 2021-06-30T13:49:14
    author:
      username: disqus_LBTT8BpG2p
      about: ""
      name: Toksyuryel
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_LBTT8BpG2p/
      url: http://openid.aol.com/toksyuryel
      location: ""
      id: "14551071"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Conclusion is poorly-worded. This study only looked into the
      potential for re-infection and the conclusion should reflect that. There
      are other studied benefits to vaccinating previously infected individuals
      and you should not imply to invalidate those with a study that looked into
      none of those benefits.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v3
  tweets:
    - created_at: Wed Jun 30 18:29:28 +0000 2021
      id: 1410304495477739500
      id_str: "1410304495477739523"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "Conclusion is poorly-worded. This study only looked into‚Ä¶ https://t.co/Itfouqrpol
      truncated: true
      entities:
        urls:
          - url: https://t.co/Itfouqrpol
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 30 18:29:28 +0000 2021
      id: 1410304496304074800
      id_str: "1410304496304074755"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1410304495477739500
      in_reply_to_status_id_str: "1410304495477739523"
- preprint:
    id: "143297"
    doi: 10.1101/2021.05.23.21257686
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.23.21257686v1
    url: https://api.rxivist.org/v1/papers/143297
    title: Addressing anti-syncytin antibody levels, and fertility and breastfeeding
      concerns, following BNT162B2 COVID-19 mRNA vaccination
    category: obstetrics-and-gynecology
    abstract: "Objective: To determine whether antibodies against the SARS-CoV-2
      spike protein following BNT162B2 (Pfizer-BioNTech) COVID-19 mRNA
      vaccination cross-react with human syncytin-1 protein, and if BNT162B2
      mRNA enters breast milk. Methods: In this observational cohort study of
      female front-line workers with no history of COVID-19 infection, we
      amplified BNT162B2 mRNA in plasma and breast milk and assayed
      anti-SARS-CoV-2 neutralising antibodies and anti-human syncytin-1 binding
      antibodies in plasma, at early (1-4 days) and late (4-7 weeks) time points
      following first-dose vaccination. Results: Fifteen consented participants
      (mean age 40.4 years, various ethnicities) who received at least one dose
      of BNT162B2, including five breast-feeding women and two women who were
      inadvertently vaccinated in early pregnancy, were recruited. BNT162B2
      mRNA, detected by amplifying part of the spike-encoding region, was
      detected in plasma 1-4 days following the first dose (n=13), but not 4-5
      weeks later (n=2), nor was the mRNA isolated from aqueous or lipid breast
      milk fractions collected 0-7 days post-vaccination (n=5). Vaccine
      recipients demonstrated strong SARS-CoV-2 neutralising activity by at
      least four weeks after the first dose (n=15), including the two pregnant
      women. None had placental anti-syncytin-1 binding antibodies at either
      time-point following vaccination. Conclusions: BNT162B2-vaccinated women
      did not transmit vaccine mRNA to breast milk, and did not produce a
      concurrent humoral response to syncytin-1, suggesting that
      cross-reactivity to syncytin-1 on the developing trophoblast, or other
      adverse effects in the breast-fed infant from vaccine mRNA ingestion, are
      unlikely."
    authors:
      - name: Citra Nurfarah Mattar
        orcid: http://orcid.org/0000-0003-0068-6957
      - name: Winston Koh
        orcid: http://orcid.org/0000-0003-4611-6490
      - name: Yiqi Seow
        orcid: http://orcid.org/0000-0001-7040-3006
      - name: Shawn Hoon
        orcid: http://orcid.org/0000-0002-3892-3332
      - name: Aparna VENKATESH
        orcid: http://orcid.org/0000-0001-8639-9232
      - name: Pradip Dashraath
        orcid: http://orcid.org/0000-0002-4095-3186
      - name: Li Min LIM
        orcid: null
      - name: Judith ONG
        orcid: null
      - name: Rachel Jiayu Lee
        orcid: null
      - name: Nuryanti Johana
        orcid: null
      - name: Julie SL Yeo
        orcid: null
      - name: David Shao Hong Chong
        orcid: null
      - name: Lay Kok Tan
        orcid: http://orcid.org/0000-0002-7790-2171
      - name: Jerry Kok Yen Chan
        orcid: http://orcid.org/0000-0002-0246-2159
      - name: Mahesh Choolani
        orcid: http://orcid.org/0000-0001-8336-0973
      - name: Paul Tambyah
        orcid: http://orcid.org/0000-0003-0405-771X
  comment:
    dislikes: 0
    thread: "8551357360"
    numReports: 0
    likes: 0
    id: "5438660103"
    createdAt: 2021-06-30T12:12:11
    author:
      username: sinoben
      about: ""
      name: SinoBen
      isPowerContributor: false
      profileUrl: https://disqus.com/by/sinoben/
      url: ""
      location: ""
      id: "152088436"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: The language used here is seething with something I've not commonly
      found in the typical scientific paper.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.23.21257686v1
  tweets:
    - created_at: Wed Jun 30 20:22:40 +0000 2021
      id: 1410332983207334000
      id_str: "1410332983207333891"
      text: >-
        üí¨ medRxiv comment on "Addressing anti-syncytin antib..."


        "The language used here is seething with something I've n‚Ä¶ https://t.co/IbKhlQqfKw
      truncated: true
      entities:
        urls:
          - url: https://t.co/IbKhlQqfKw
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 30 20:22:40 +0000 2021
      id: 1410332984071397400
      id_str: "1410332984071397382"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/GmRAl2Ix8D
      truncated: false
      entities:
        urls:
          - url: https://t.co/GmRAl2Ix8D
      in_reply_to_status_id: 1410332983207334000
      in_reply_to_status_id_str: "1410332983207333891"
- preprint:
    id: "146616"
    doi: 10.1101/2021.06.11.21258733
    first_posted: 2021-06-18
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.11.21258733v1
    url: https://api.rxivist.org/v1/papers/146616
    title: Impact estimation on COVID-19 infections following school reopening in
      September 2020 in Italy
    category: epidemiology
    abstract: Background Since its outbreak, CoViD-19 (formally known as 2019-nCoV)
      has been triggering many questions among public authorities, social
      organisms and school officials, as to when students should be allowed to
      return to school. Such a decision is critical and must take into account,
      other than its beneficial effects, also those associated with an increased
      exposition of the students to the virus, which, as a result, might spread
      at a faster rate. To date, in Italy, a few studies have rigorously
      investigated the correlation between school reopening and number of people
      tested positive to CoViD-19. Therefore, this paper aims to provide an
      assessment of such an impact as well as to illustrate the methodology
      followed. Methods Official daily data on the cumulative number of people
      tested positive to CoViD-19, in conjunction with external information
      accounting for the different points in time schools reopened in the
      various Italian regions, have been employed to build a stochastic model of
      the type Seasonal Autoregressive Moving Average embodying external
      information. Results There was a statistically significant increase in the
      number of positive cases in all the Italian regions related to schools
      reopening. Such an increase occurred, in average, about 18.9 days after
      the schools have been reopened. Schools reopening have been significantly
      contributed to the diffusion of the pandemic, with an overall estimated
      impact of about 228,724 positive cases. Conclusions The results suggest
      the need for strict control of all in-school activities. This could be
      done by using, to a variable extent, all the non-pharmaceutical
      interventions available, such as limited access to school spaces, no
      overlapping practices between different sports in the same space,
      universal masking, bubble-size classroom. However, in many cases, such
      measures might not be a viable option, at least in the short run, nor be
      reasonably applicable. Therefore, whenever the established safety criteria
      could not be met, school buildings should remain closed.
    authors:
      - name: Livio Fenga
        orcid: http://orcid.org/0000-0002-8185-2680
      - name: Massimo Galli
        orcid: http://orcid.org/0000-0001-8887-6215
  comment:
    dislikes: 0
    thread: "8601010467"
    numReports: 0
    likes: 0
    id: "5438638759"
    createdAt: 2021-06-30T11:46:46
    author:
      username: disqus_kYtHFm97sQ
      about: ""
      name: A Disqus User
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_kYtHFm97sQ/
      url: ""
      location: ""
      id: "371675927"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "This comment seems more the result of the desire to find errors at
      all costs, in a pre-print whose authors criticizes for method and
      reliability a paper by Rainsio that comes to opposite conclusions. What is
      really embarrassing is not the use of inferential statistics by Fienga and
      Galli, but the criticisms of Rainisio that confuses the null hypothesis
      with the alternative: a null hypothesis can always be formulated, both for
      controlled and retrospective studies.  In a time series for example a null
      hypothesis is the absence of a trend. Curiously Rainisio also seems not to
      notice that arguing that a value of Rt has not been observed in relation
      to the opening-closing of schools (as Rainisio and colleagues did in their
      paper cited by Fienga) is equivalent to accepting the null hypothesis of
      no-change over time, even in the absence of a formal test and a p-value.
      Consistently, Rainisio's comment closes with a gloss and demonstration of
      what a null-hypothesis is."
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.11.21258733v1
  tweets:
    - created_at: Wed Jun 30 22:19:30 +0000 2021
      id: 1410362386855477200
      id_str: "1410362386855477248"
      text: >-
        üí¨ medRxiv comment on "Impact estimation on COVID-19 ..."


        "This comment seems more the result of the desire to find‚Ä¶ https://t.co/xnANs1Li6R
      truncated: true
      entities:
        urls:
          - url: https://t.co/xnANs1Li6R
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 30 22:19:31 +0000 2021
      id: 1410362387597860900
      id_str: "1410362387597860865"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/G8ZDRQog2r
      truncated: false
      entities:
        urls:
          - url: https://t.co/G8ZDRQog2r
      in_reply_to_status_id: 1410362386855477200
      in_reply_to_status_id_str: "1410362386855477248"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8552957443"
    numReports: 0
    likes: 0
    id: "5438493470"
    createdAt: 2021-06-30T08:43:03
    author:
      username: ElixerDNB
      about: ""
      name: Steall
      isPowerContributor: false
      profileUrl: https://disqus.com/by/ElixerDNB/
      url: https://www.mixcloud.com/Elixer/
      location: ""
      id: "135374973"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Thank you for clarifying Dr. Niaee!
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v2
  tweets:
    - created_at: Thu Jul 01 01:05:15 +0000 2021
      id: 1410404098093035500
      id_str: "1410404098093035522"
      text: |-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."

        "Thank you for clarifying Dr. Niaee!"

        https://t.co/lu61fkKTt8
      truncated: false
      entities:
        urls:
          - url: https://t.co/lu61fkKTt8
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 01 01:05:15 +0000 2021
      id: 1410404098793431000
      id_str: "1410404098793431042"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1410404098093035500
      in_reply_to_status_id_str: "1410404098093035522"
- preprint:
    id: "144918"
    doi: 10.1101/2021.06.03.21257901
    first_posted: 2021-06-06
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.03.21257901v1
    url: https://api.rxivist.org/v1/papers/144918
    title: "Breadth of neutralising antibody responses to SARS-CoV-2 variants of
      concern is augmented by vaccination following prior infection: studies in
      UK healthcare workers and immunodeficient patients"
    category: infectious-diseases
    abstract: A large portion of the UK general population has currently only
      received a single dose of a COVID-19 vaccination (either BNT162b2 (Pfizer)
      or AZD1222 (Vaxevria, AstraZeneca)), making it critical that we continue
      to track and understand the levels of protection against SARS-CoV-2
      Variants of Concern (VOCs). We undertook a single-centre cross-sectional
      study in order to understand the variations in vaccine-induced immunity to
      the SARS-CoV-2 vaccine strain (B.1) and three major VOCs (B.1.1.7, B.1351
      and P.1). We studied a cohort of outpatients with immunodeficiencies
      (IDPs) and health care workers (HCWs) based at the same critical care
      tertiary NHS Trust, following a single dose of either BNT162b2 or AZD1222
      vaccines. Our serological data revealed either undetectable antibodies or
      low neutralising antibodies (nAbs) in IDPs, with only 5% and 3% showing
      detectable neutralisation of B.1.1.7 and B.1.351, respectively. Healthy
      HCWs without a prior SARS-CoV-2 infection demonstrated a wide range of nAb
      titres post-vaccination. However, their responses are significantly lower
      than HCWs with previous SARS-CoV-2 infection. Neutralisation of VOCs with
      the E484K mutation (B.1.351 and P.1) were consistently lower in HCWs in
      the absence of evidence of prior SARS-CoV-2 infection (p<0.001). Notably,
      in HCWs with prior SARS-CoV-2 infection, there is a significant increase
      of neutralising titres post-vaccination to all four strains, compared to
      their pre-vaccination neutralisation titres. This underscores the
      importance of vaccination even in populations that have been previously
      exposed, and also provides support for the hypothesis that a second-dose
      of vaccination will similarly boost immunity to greater protective levels
      in individuals without prior SARS-CoV-2 exposure. Overall, this
      serological nAb analysis after a single-dose of BNT162b2 or AZD1222
      vaccination demonstrates a wide variety of responses, particularly against
      the VOCs, and suggests limited neutralisation-based protection in
      individuals with immunodeficiencies.
    authors:
      - name: Angalee Nadesalingam
        orcid: null
      - name: Diego Cantoni
        orcid: http://orcid.org/0000-0001-8527-7719
      - name: David A. Wells
        orcid: http://orcid.org/0000-0002-4531-5968
      - name: Ernest T Aguinam
        orcid: null
      - name: Matteo Ferrari
        orcid: null
      - name: Peter Smith
        orcid: null
      - name: Andrew Chan
        orcid: null
      - name: George Carnell
        orcid: null
      - name: Luis Ohlendorf
        orcid: null
      - name: Sebastian Einhauser
        orcid: http://orcid.org/0000-0003-4177-4451
      - name: Ralf Wagner
        orcid: http://orcid.org/0000-0002-2029-3846
      - name: Nigel James Temperton
        orcid: http://orcid.org/0000-0002-7978-3815
      - name: Javier James Castillo-Olivares
        orcid: null
      - name: Dr HE Baxendale
        orcid: http://orcid.org/0000-0003-3838-3900
      - name: Jonathan Luke Heeney
        orcid: null
      - name: Humoral immune Correlates from COVID-19 (HICC) Consortium
        orcid: null
  comment:
    dislikes: 0
    thread: "8577229504"
    numReports: 0
    likes: 0
    id: "5438460210"
    createdAt: 2021-06-30T07:39:55
    author:
      username: viralpseudotypeunit
      about: ""
      name: ViralPseudotypeUnit
      isPowerContributor: false
      profileUrl: https://disqus.com/by/viralpseudotypeunit/
      url: ""
      location: ""
      id: "265733172"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "This has now been published in The Lancet Microbe:
      https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00157-\
      9/fulltext"
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.03.21257901v1
  tweets:
    - created_at: Thu Jul 01 12:36:24 +0000 2021
      id: 1410578032306368500
      id_str: "1410578032306368515"
      text: |-
        üí¨ medRxiv comment on "Breadth of neutralising antibo..."

        "This has now been published in The Lancet Microbe: "

        https://t.co/gSeGUayR3w
      truncated: false
      entities:
        urls:
          - url: https://t.co/gSeGUayR3w
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 01 12:36:25 +0000 2021
      id: 1410578033094934500
      id_str: "1410578033094934532"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/1rY1M16nji
      truncated: false
      entities:
        urls:
          - url: https://t.co/1rY1M16nji
      in_reply_to_status_id: 1410578032306368500
      in_reply_to_status_id_str: "1410578032306368515"
- preprint:
    id: "147515"
    doi: 10.1101/2021.06.22.21259189
    first_posted: 2021-06-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.22.21259189v1
    url: https://api.rxivist.org/v1/papers/147515
    title: Perceptions of immunity and vaccination certificates among the general
      population of Geneva, Switzerland.
    category: public-and-global-health
    abstract: As of June 2021, the European Union (EU) and Switzerland have
      published information about the introduction of COVID certificates in
      order to facilitate the safe free movement of their citizens. With
      implementation underway, little is known about the public perception of
      such certificates with potential differences in acceptability among
      individuals. In March 2021, a self-administered online questionnaire was
      proposed to all individuals 18 years and older participating in the
      longitudinal follow-up of population-based seroprevalence studies in
      Geneva, Switzerland. The questionnaire covered aspects of individual and
      collective benefits, while allowing participants to select contexts in
      which vaccination certificates should be presented. Results were presented
      as the proportion of individuals agreeing or disagreeing with the
      implementation of vaccination certificates, selecting specific contexts
      where certificates should be presented, and agreeing or disagreeing with
      the potential risks related to certificates. Logistic regression was used
      to calculate odds ratios for factors associated with certificate
      non-acceptance. Overall, 4,056 individuals completed the questionnaire
      (response rate 77.6%; mean age 53.3, standard deviation 14.4 years; 56.1%
      were women). About 61.0% of participants agreed or strongly agreed that a
      vaccination certificate was necessary in certain contexts; and 21.6%
      believed there was no context where vaccination certificates should be
      presented. Contexts where a majority of participants perceived a
      vaccination certificate should be presented included jobs where others
      would be at risk of COVID-related complications (60.7%), jobs where
      employees would be at risk of getting infected (58.7%), or to be exempt
      from quarantine when traveling abroad (56.1%). Contexts where fewer
      individuals perceived the need for vaccination certificates to be
      presented were participation in large gatherings (36.9%), access to social
      venues (35.5%), or sharing the same workspace (21.5%). Younger age, an
      absence of willingness to get vaccinated, and an absence of belief in
      vaccination as an important step in surmounting the pandemic were factors
      associated with certificate non-acceptance. This large population-based
      study showed that the general adult population in Geneva, Switzerland,
      agreed with the implementation of vaccination certificates in work-related
      and travel-related contexts. However, this solution was perceived as
      unnecessary for access to large gatherings or social venues, or to share
      the same workspace. Differences were seen with gender, age, education,
      socio-economic status, and vaccination willingness and perception,
      highlighting the importance of taking personal and sociodemographic
      variations into consideration when predicting acceptance of such
      certificates.
    authors:
      - name: Mayssam Nehme
        orcid: http://orcid.org/0000-0001-9189-6495
      - name: Helene Baysson
        orcid: null
      - name: Nick Pullen
        orcid: null
      - name: Ania Wisniak
        orcid: null
      - name: Francesco Penacchio
        orcid: null
      - name: Maria-Eugenia Zaballa
        orcid: null
      - name: Vanessa Fargnoli
        orcid: null
      - name: Didier Trono
        orcid: http://orcid.org/0000-0002-3383-0401
      - name: Laurent Kaiser
        orcid: http://orcid.org/0000-0002-0857-2252
      - name: Samia Hurst
        orcid: null
      - name: Claudine Burton-Jeangros
        orcid: null
      - name: Silvia Stringhini
        orcid: http://orcid.org/0000-0002-4387-8943
      - name: Specchio-COVID19 study group
        orcid: null
      - name: Idris Guessous
        orcid: http://orcid.org/0000-0002-0491-6089
  comment:
    dislikes: 0
    thread: "8614590552"
    numReports: 0
    likes: 0
    id: "5439985987"
    createdAt: 2021-07-01T12:29:35
    author:
      username: disqus_TpYwfhI3Eb
      about: ""
      name: ad4
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_TpYwfhI3Eb/
      url: ""
      location: ""
      id: "363119218"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Very interesting study. 


      One thing that must be considered is whether passports/certificates will push groups in high outbreak probability regions further away from vaccinating. That seems to be the case for the UK: see below for a study I recently conducted in the UK.


      https://www.medrxiv.org/content/10.1101/2021.05.31.21258122v1
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.22.21259189v1
  tweets:
    - created_at: Thu Jul 01 14:22:29 +0000 2021
      id: 1410604728497578000
      id_str: "1410604728497578000"
      text: |-
        üí¨ medRxiv comment on "Perceptions of immunity and va..."

        "Very interesting study. 

        One thing that must be conside‚Ä¶ https://t.co/B7sXygKKT4
      truncated: true
      entities:
        urls:
          - url: https://t.co/B7sXygKKT4
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 01 14:22:29 +0000 2021
      id: 1410604729730695200
      id_str: "1410604729730695183"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/ve14gN52Jk
      truncated: false
      entities:
        urls:
          - url: https://t.co/ve14gN52Jk
      in_reply_to_status_id: 1410604728497578000
      in_reply_to_status_id_str: "1410604728497578000"
- preprint:
    id: "147485"
    doi: 10.1101/2021.06.24.449756
    first_posted: 2021-06-25
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.24.449756v1
    url: https://api.rxivist.org/v1/papers/147485
    title: "The Clade Displacement Index: how to detect horizontal gene transfers in
      unrooted gene trees"
    category: bioinformatics
    abstract: >-
      While most genes of any organism are inherited vertically - i.e. from its
      parent organisms - sometimes they can be exchanged between unrelated
      species in a process known as the horizontal gene transfer (HGT). Studies
      of HGT contribute to our knowledge about the mechanisms of evolution,
      including the emergence of new pathogens, and a great deal of effort has
      been put into different methods of finding transferred genes. The golden
      standard of HGT detection is the analysis of the incongruence between the
      gene and the species trees. Those methods typically require rooted trees,
      in which the direction of evolution is known. Gene trees are typically
      unrooted, and rooting them is yet another step in HGT analysis, prone to
      errors which may lead to wrong conclusions. A natural question arises: can
      HGTs be detected in gene trees without rooting them at all?


      It turns out that, for a particular, yet broad, class of transfers, the answer to this question is: yes. It also turns out that the same methodology can be applied to complement the bootstrap support in assessing the stability of gene tree topology. In this article, we present the Clade Displacement Index, a measure of shift of a given clades location between two trees. We derive algorithms to compute it and give several examples of its applications to HGT detection and gene tree stability analysis. We finish by pointing out directions for further studies and an example that shows that not all HGTs are detectable without knowing the location of the root of the gene tree.


      A Jupyter Notebook with the implementation and applications of CDI described in this paper is available at https://github.com/mciach/CDI
    authors:
      - name: Micha≈Ç Aleksander Ciach
        orcid: http://orcid.org/0000-0003-4961-7071
  comment:
    dislikes: 0
    thread: "8614532600"
    numReports: 0
    likes: 0
    id: "5440136134"
    createdAt: 2021-07-01T14:45:54
    author:
      username: michaciach
      about: ""
      name: Micha≈Ç Ciach
      isPowerContributor: false
      profileUrl: https://disqus.com/by/michaciach/
      url: ""
      location: ""
      id: "371730091"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Thanks! I haven't tried to use information-based approaches. I've analyzed
      the properties of correlation between splits, though (actually, between
      the weights of labels, because I'm dealing with repeating labels; the
      weights are defined roughly as the probability that a leaf with a given
      label is in the first component of the split). Correlation didn't work
      well in this context, because it was very sensitive in the case when one
      of the splits is trivial, and difficult to compute for non-binary trees.
      That was the reason to choose the absolute difference between label
      weights, and it  worked quite well, so I didn't check other approaches. It
      may be worth it, though :) 




      Thanks for the link to your paper. I've actually been looking for alternative metrics of tree similarity recently, so it may turn out be quite useful :)
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.24.449756v1
  tweets:
    - created_at: Thu Jul 01 16:32:04 +0000 2021
      id: 1410637338426835000
      id_str: "1410637338426834950"
      text: >-
        üí¨ bioRxiv comment on "The Clade Displacement Index: ..."


        "Thanks! I haven't tried to use information-based approac‚Ä¶ https://t.co/hznWOLA6gA
      truncated: true
      entities:
        urls:
          - url: https://t.co/hznWOLA6gA
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 01 16:32:04 +0000 2021
      id: 1410637339588587500
      id_str: "1410637339588587525"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/01kxRhsDCW
      truncated: false
      entities:
        urls:
          - url: https://t.co/01kxRhsDCW
      in_reply_to_status_id: 1410637338426835000
      in_reply_to_status_id_str: "1410637338426834950"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8552957443"
    numReports: 0
    likes: 1
    id: "5439607040"
    createdAt: 2021-07-01T02:18:40
    author:
      username: akcita
      about: ""
      name: akcita
      isPowerContributor: false
      profileUrl: https://disqus.com/by/akcita/
      url: ""
      location: ""
      id: "4468108"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: I was hoping that there would be obvious conflicts of
      Interest.  Alas, it seems the Authors barely reviewed their own study and
      left it to a technical editor, and the viewing public to fix their bad
      science...
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v2
  tweets:
    - created_at: Thu Jul 01 18:26:45 +0000 2021
      id: 1410666198325514200
      id_str: "1410666198325514242"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "I was hoping that there would be obvious conflicts of In‚Ä¶ https://t.co/8srKH6pVgr
      truncated: true
      entities:
        urls:
          - url: https://t.co/8srKH6pVgr
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 01 18:26:45 +0000 2021
      id: 1410666199755657200
      id_str: "1410666199755657222"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1410666198325514200
      in_reply_to_status_id_str: "1410666198325514242"
- preprint:
    id: 148003
    metric: 140
    title: Thrombocytopenia and splenic platelet directed immune responses after
      intravenous ChAdOx1 nCov-19 administration
    url: https://api.rxivist.org/v1/papers/148003
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.29.450356v1
    doi: 10.1101/2021.06.29.450356
    category: immunology
    first_posted: 2021-06-29
    abstract: "Vaccines against SARS-CoV-2 are based on a range of novel vaccine
      platforms, with adenovirus-based approaches (like ChAdOx1 nCov-19) being
      one of them. Recently a rare and novel complication of SARS-CoV-2 targeted
      adenovirus vaccines has emerged: thrombosis with thrombocytopenia syndrome
      (TTS). TTS is characterized by low platelet counts, clot formation at
      unusual anatomic sites and platelet-activating PF4-polyanion antibodies
      reminiscent of heparin-induced thrombocytopenia. Here, we employ in vitro
      and in vivo models to characterize the possible mechanisms of this
      platelet-targeted autoimmunity. We show that intravenous but not
      intramuscular injection of ChAdOx1 nCov-19 triggers platelet-adenovirus
      aggregate formation and platelet activation. After intravenous injection,
      these aggregates are phagocytosed by macrophages in the spleen and
      platelet remnants are found in the marginal zone and follicles. This is
      followed by a pronounced B-cell response with the emergence of circulating
      antibodies binding to platelets. Our work contributes to the understanding
      of TTS and highlights accidental intravenous injection as potential
      mechanism for post-vaccination TTS. Hence, safe intramuscular injection,
      with aspiration prior to injection, could be a potential preventive
      measure when administering adenovirus-based vaccines."
    authors:
      - name: Leo Nicolai
      - name: Alexander Leunig
      - name: Kami Pekayvaz
      - name: Afra Anjum
      - name: Eva Riedlinger
      - name: Luke Eivers
      - name: Marie-Louise Hoffknecht
      - name: Dario Rossaro
      - name: Raphael Escaig
      - name: Rainer Kaiser
      - name: Vivien Polewka
      - name: Anna Titova
      - name: Karsten Spiekermann
      - name: Matteo Iannacone
      - name: Konstantin Stark
      - name: Steffen Massberg
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Thu Jul 01 20:18:04 +0000 2021
      id: 1410694211662450700
      id_str: "1410694211662450694"
      text: >-
        üî• bioRxiv Immunology preprint by L. Nicolai et al:


        "Thrombocytopenia and splenic platelet directed immune response‚Ä¶ https://t.co/ZO7j01i3NH
      truncated: true
      entities:
        urls:
          - url: https://t.co/ZO7j01i3NH
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "138914"
    doi: 10.1101/2021.04.20.21255677
    first_posted: 2021-04-21
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.04.20.21255677v1
    url: https://api.rxivist.org/v1/papers/138914
    title: Discrete immune response signature to SARS-CoV-2 mRNA vaccination versus
      infection
    category: infectious-diseases
    abstract: Both SARS-CoV-2 infection and vaccination elicit potent immune
      responses. A number of studies have described immune responses to
      SARS-CoV-2 infection. However, beyond antibody production, immune
      responses to COVID-19 vaccines remain largely uncharacterized. Here, we
      performed multimodal single-cell sequencing on peripheral blood of
      patients with acute COVID- 19 and healthy volunteers before and after
      receiving the SARS-CoV-2 BNT162b2 mRNA vaccine to compare the immune
      responses elicited by the virus and by this vaccine. Phenotypic and
      transcriptional profiling of immune cells, coupled with reconstruction of
      the B and T cell antigen receptor rearrangement of individual lymphocytes,
      enabled us to characterize and compare the host responses to the virus and
      to defined viral antigens. While both infection and vaccination induced
      robust innate and adaptive immune responses, our analysis revealed
      significant qualitative differences between the two types of immune
      challenges. In COVID-19 patients, immune responses were characterized by a
      highly augmented interferon response which was largely absent in vaccine
      recipients. Increased interferon signaling likely contributed to the
      observed dramatic upregulation of cytotoxic genes in the peripheral T
      cells and innate-like lymphocytes in patients but not in immunized
      subjects. Analysis of B and T cell receptor repertoires revealed that
      while the majority of clonal B and T cells in COVID-19 patients were
      effector cells, in vaccine recipients clonally expanded cells were
      primarily circulating memory cells. Importantly, the divergence in immune
      subsets engaged, the transcriptional differences in key immune
      populations, and the differences in maturation of adaptive immune cells
      revealed by our analysis have far-ranging implications for immunity to
      this novel pathogen.
    authors:
      - name: Ellie N Ivanova
        orcid: http://orcid.org/0000-0002-1850-9505
      - name: Joseph C Devlin
        orcid: http://orcid.org/0000-0002-0003-4812
      - name: Terild B Buus
        orcid: http://orcid.org/0000-0001-7180-6384
      - name: Akiko Koide
        orcid: http://orcid.org/0000-0003-1796-7077
      - name: Amber Cornelius
        orcid: null
      - name: Marie I. Samanovic
        orcid: null
      - name: Alberto Herrera
        orcid: http://orcid.org/0000-0003-4189-9051
      - name: Chenzhen Zhang
        orcid: null
      - name: Ludovic Desvignes
        orcid: http://orcid.org/0000-0001-6246-0828
      - name: Niels Odum
        orcid: http://orcid.org/0000-0003-3135-5624
      - name: Robert Ulrich
        orcid: null
      - name: Mark J Mulligan
        orcid: http://orcid.org/0000-0001-7262-9746
      - name: Shohei Koide
        orcid: http://orcid.org/0000-0001-5473-4358
      - name: Kelly V Ruggle
        orcid: http://orcid.org/0000-0002-0152-0863
      - name: Ramin Herati
        orcid: http://orcid.org/0000-0003-2613-4050
      - name: Sergei Koralov
        orcid: http://orcid.org/0000-0002-4843-3791
  comment:
    dislikes: 0
    thread: "8486870753"
    numReports: 0
    likes: 0
    id: "5440403697"
    createdAt: 2021-07-01T18:18:58
    author:
      username: vinuarumugham
      about: ""
      name: vinu arumugham
      isPowerContributor: false
      profileUrl: https://disqus.com/by/vinuarumugham/
      url: http://orcid.org/0000-0003-1047-1626
      location: ""
      id: "289985889"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: You don't seem to have covered T cell homing. T cells induced by
      injected vaccines will home to the skin. T cells induced by infection will
      home to the lungs.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.04.20.21255677v1
  tweets:
    - created_at: Thu Jul 01 20:22:00 +0000 2021
      id: 1410695202956890000
      id_str: "1410695202956890112"
      text: >-
        üí¨ medRxiv comment on "Discrete immune response signa..."


        "You don't seem to have covered T cell homing. T cells in‚Ä¶ https://t.co/q3szS3SWE2
      truncated: true
      entities:
        urls:
          - url: https://t.co/q3szS3SWE2
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 01 20:22:00 +0000 2021
      id: 1410695203766345700
      id_str: "1410695203766345733"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/WjIl7zcz8l
      truncated: false
      entities:
        urls:
          - url: https://t.co/WjIl7zcz8l
      in_reply_to_status_id: 1410695202956890000
      in_reply_to_status_id_str: "1410695202956890112"
- preprint:
    id: "128786"
    doi: 10.1101/2021.02.09.430446
    first_posted: 2021-02-09
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.02.09.430446v1
    url: https://api.rxivist.org/v1/papers/128786
    title: GABA administration limits viral replication and pneumonitis in a mouse
      model of COVID-19
    category: immunology
    abstract: Despite the availability of vaccines for COVID-19, serious illness and
      death induced by coronavirus infection will remain a global health burden
      because of vaccination hesitancy, possible virus mutations, and the
      appearance of novel coronaviruses. Accordingly, there is a need for new
      approaches to limit severe illness stemming from coronavirus infections.
      Cells of the immune system and lung epithelia express receptors for GABA
      (GABA-Rs), a widely used neurotransmitter within the CNS. GABA-R agonists
      have anti-inflammatory effects and can limit acute lung injury. We
      previously showed that GABA treatment effectively reduced disease severity
      and death rates in mice following infection with a coronavirus (MHV-1)
      which provides a potentially lethal model of COVID-19. Here, we report
      that GABA treatment also reduced viral load in the lungs, suggesting that
      GABA-Rs may provide a new druggable target to limit pulmonary coronavirus
      replication. Histopathological analysis revealed that GABA treatment
      reduced lung inflammatory infiltrates and damages. Since GABA is safe for
      human consumption, inexpensive, and available worldwide, it is a promising
      candidate to help treat COVID-19.
    authors:
      - name: Jide Tian
        orcid: http://orcid.org/0000-0002-5127-0970
      - name: Blake Middleton
        orcid: null
      - name: Daniel L. Kaufman
        orcid: null
  comment:
    dislikes: 0
    thread: "8391674617"
    numReports: 0
    likes: 0
    id: "5440532014"
    createdAt: 2021-07-01T20:05:45
    author:
      name: Daniel Kaufman
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      The data in this BioRxiv posting was published in:


      GABA(A)-Receptor Agonists Limit Pneumonitis and Death in Murine Coronavirus-Infected Mice. 

      Tian J, Middleton B, Kaufman DL.

      Viruses. 2021 May 23;13(6):966. doi: 10.3390/v13060966. 

      PMID: 34071034
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.02.09.430446v1
  tweets:
    - created_at: Thu Jul 01 22:19:34 +0000 2021
      id: 1410724791150022700
      id_str: "1410724791150022663"
      text: |-
        üí¨ bioRxiv comment on "GABA administration limits vir..."

        "The data in this BioRxiv posting was published in:

        GABA‚Ä¶ https://t.co/UmxN3241LI
      truncated: true
      entities:
        urls:
          - url: https://t.co/UmxN3241LI
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 01 22:19:35 +0000 2021
      id: 1410724791963639800
      id_str: "1410724791963639811"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/h61ccYbOEi
      truncated: false
      entities:
        urls:
          - url: https://t.co/h61ccYbOEi
      in_reply_to_status_id: 1410724791150022700
      in_reply_to_status_id_str: "1410724791150022663"
- preprint:
    id: "148063"
    doi: 10.1101/2021.06.28.450217
    first_posted: 2021-06-30
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.28.450217v1
    url: https://api.rxivist.org/v1/papers/148063
    title: Genomic characterization of metastatic patterns from prospective clinical
      sequencing of 25,000 patients
    category: cancer-biology
    abstract: Progression to metastatic disease remains the main cause of cancer
      death. Yet, the underlying genomic mechanisms driving metastasis remain
      largely unknown. Here, we present MSK-MET, an integrated pan-cancer cohort
      of tumor genomic and clinical outcome data from more than 25,000 patients.
      We analyzed this dataset to identify associations between tumor genomic
      alterations and patterns of metastatic dissemination across 50 tumor
      types. We found that chromosomal instability is strongly correlated with
      metastatic burden in some tumor types, including prostate adenocarcinoma,
      lung adenocarcinoma and HR-positive breast ductal carcinoma, but not in
      others, such as colorectal adenocarcinoma, pancreatic adenocarcinoma and
      high-grade serous ovarian cancer. We also identified specific somatic
      alterations associated with increased metastatic burden and specific
      routes of metastatic spread. Our data offer a unique resource for the
      investigation of the biological basis for metastatic spread and highlight
      the crucial role of chromosomal instability in cancer progression.
    authors:
      - name: Bastien Nguyen
        orcid: http://orcid.org/0000-0002-6166-4746
      - name: Christopher Fong
        orcid: null
      - name: Anisha Luthra
        orcid: null
      - name: Shaleigh A. Smith
        orcid: null
      - name: Renzo G. DiNatale
        orcid: http://orcid.org/0000-0002-7867-2881
      - name: Subhiksha Nandakumar
        orcid: null
      - name: Henry Walch
        orcid: null
      - name: Walid K Chatila
        orcid: null
      - name: Ramyasree Madupuri
        orcid: null
      - name: Ritika Kundra
        orcid: null
      - name: Craig M. Bielski
        orcid: null
      - name: Brooke Mastrogiacomo
        orcid: null
      - name: Adrienne Boire
        orcid: http://orcid.org/0000-0002-9029-1248
      - name: Sarat Chandarlapaty
        orcid: http://orcid.org/0000-0003-4532-8053
      - name: Karuna Ganesh
        orcid: null
      - name: James J. Harding
        orcid: null
      - name: Christine A. Iacobuzio-Donahue
        orcid: http://orcid.org/0000-0002-4672-3023
      - name: Pedram Razavi
        orcid: null
      - name: Ed Reznik
        orcid: http://orcid.org/0000-0002-6511-5947
      - name: Charles M Rudin
        orcid: http://orcid.org/0000-0001-5204-3465
      - name: Dmitriy Zamarin
        orcid: http://orcid.org/0000-0002-0094-0161
      - name: Wassim Abida
        orcid: null
      - name: Ghassan K. Abou-Alfa
        orcid: null
      - name: Carol Aghajanian
        orcid: null
      - name: Andrea Cercek
        orcid: null
      - name: Ping Chi
        orcid: null
      - name: Darren Feldman
        orcid: null
      - name: Alan L Ho
        orcid: null
      - name: Gopakumar Iyer
        orcid: null
      - name: Yelena Y. Janjigian
        orcid: null
      - name: Michael Morris
        orcid: null
      - name: Robert J. Motzer
        orcid: null
      - name: Eileen M. O'Reilly
        orcid: null
      - name: Michael A. Postow
        orcid: null
      - name: Nitya P. Raj
        orcid: null
      - name: Gregory J Riely
        orcid: null
      - name: Mark E. Robson
        orcid: null
      - name: Jonathan E. Rosenberg
        orcid: null
      - name: Anton Safonov
        orcid: null
      - name: Alexander N. Shoushtari
        orcid: null
      - name: William Tap
        orcid: null
      - name: Min Yuen Teo
        orcid: null
      - name: Anna M. Varghese
        orcid: null
      - name: Martin Voss
        orcid: null
      - name: Rona Yaeger
        orcid: null
      - name: Marjorie G. Zauderer
        orcid: http://orcid.org/0000-0002-6109-5790
      - name: Nadeem Abu-Rustum
        orcid: null
      - name: Julio Garcia-Aguilar
        orcid: null
      - name: Bernard Bochner
        orcid: null
      - name: Abraham Hakimi
        orcid: null
      - name: William R. Jarnagin
        orcid: null
      - name: David R Jones
        orcid: null
      - name: Daniela Molena
        orcid: null
      - name: Luc Morris
        orcid: null
      - name: Eric Rios-Doria
        orcid: null
      - name: Paul Russo
        orcid: null
      - name: Samuel Singer
        orcid: null
      - name: Vivian E. Strong
        orcid: null
      - name: Debyani Chakravarty
        orcid: null
      - name: Lora H. Ellenson
        orcid: null
      - name: Anuradha Gopalan
        orcid: null
      - name: Jorge S Reis-Filho
        orcid: null
      - name: Britta Weigelt
        orcid: null
      - name: Marc Ladanyi
        orcid: http://orcid.org/0000-0001-9055-7213
      - name: Mithat Gonen
        orcid: null
      - name: Sohrab P. Shah
        orcid: http://orcid.org/0000-0001-6402-523X
      - name: Joan Massague
        orcid: null
      - name: Jianjiong Gao
        orcid: null
      - name: Ahmet Zehir
        orcid: null
      - name: Michael F. Berger
        orcid: null
      - name: David B Solit
        orcid: null
      - name: Samuel F. Bakhoum
        orcid: null
      - name: Francisco Sanchez-Vega
        orcid: null
      - name: Nikolaus Schultz
        orcid: null
  comment:
    dislikes: 0
    thread: "8623092665"
    numReports: 0
    likes: 0
    id: "5440508692"
    createdAt: 2021-07-01T19:46:29
    author:
      name: I√±igo Landa
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: 'Great work and fantastic resource! Could you please clarify the
      following point? In the last paragraph of the Results, you state that
      "Thyroid papillary cancer patients with bone metastasis had a higher
      frequency of BRAF mutations", but I understand from Figure 4 that it is
      actually the opposite: BRAF muts are less frequent in bone mets. Am I
      interpreting your data correctly? Thank you.'
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.28.450217v1
  tweets:
    - created_at: Fri Jul 02 01:02:13 +0000 2021
      id: 1410765722142318600
      id_str: "1410765722142318597"
      text: >-
        üí¨ bioRxiv comment on "Genomic characterization of me..."


        "Great work and fantastic resource! Could you please clar‚Ä¶ https://t.co/BMUfUgIVFv
      truncated: true
      entities:
        urls:
          - url: https://t.co/BMUfUgIVFv
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 02 01:02:13 +0000 2021
      id: 1410765722893144000
      id_str: "1410765722893144068"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/a2RC52fZNg
      truncated: false
      entities:
        urls:
          - url: https://t.co/a2RC52fZNg
      in_reply_to_status_id: 1410765722142318600
      in_reply_to_status_id_str: "1410765722142318597"
- preprint:
    id: "128786"
    doi: 10.1101/2021.02.09.430446
    first_posted: 2021-02-09
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.02.09.430446v1
    url: https://api.rxivist.org/v1/papers/128786
    title: GABA administration limits viral replication and pneumonitis in a mouse
      model of COVID-19
    category: immunology
    abstract: Despite the availability of vaccines for COVID-19, serious illness and
      death induced by coronavirus infection will remain a global health burden
      because of vaccination hesitancy, possible virus mutations, and the
      appearance of novel coronaviruses. Accordingly, there is a need for new
      approaches to limit severe illness stemming from coronavirus infections.
      Cells of the immune system and lung epithelia express receptors for GABA
      (GABA-Rs), a widely used neurotransmitter within the CNS. GABA-R agonists
      have anti-inflammatory effects and can limit acute lung injury. We
      previously showed that GABA treatment effectively reduced disease severity
      and death rates in mice following infection with a coronavirus (MHV-1)
      which provides a potentially lethal model of COVID-19. Here, we report
      that GABA treatment also reduced viral load in the lungs, suggesting that
      GABA-Rs may provide a new druggable target to limit pulmonary coronavirus
      replication. Histopathological analysis revealed that GABA treatment
      reduced lung inflammatory infiltrates and damages. Since GABA is safe for
      human consumption, inexpensive, and available worldwide, it is a promising
      candidate to help treat COVID-19.
    authors:
      - name: Jide Tian
        orcid: http://orcid.org/0000-0002-5127-0970
      - name: Blake Middleton
        orcid: null
      - name: Daniel L. Kaufman
        orcid: null
  comment:
    dislikes: 0
    thread: "8400384682"
    numReports: 0
    likes: 0
    id: "5440366430"
    createdAt: 2021-07-01T17:47:56
    author:
      name: Daniel Kaufman
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      The data in this BioRxiv psoting was published in:

      GABA(A)-Receptor Agonists Limit Pneumonitis and Death in Murine Coronavirus-Infected Mice. 

      Tian J, Middleton B, Kaufman DL.

      Viruses. 2021 May 23;13(6):966. doi: 10.3390/v13060966. 

      PMID: 34071034
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.02.09.430446v2
  tweets:
    - created_at: Fri Jul 02 12:31:21 +0000 2021
      id: 1410939149482406000
      id_str: "1410939149482405897"
      text: |-
        üí¨ bioRxiv comment on "GABA administration limits vir..."

        "The data in this BioRxiv psoting was published in:
        GABA(‚Ä¶ https://t.co/tIbKGJpk9L
      truncated: true
      entities:
        urls:
          - url: https://t.co/tIbKGJpk9L
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 02 12:31:22 +0000 2021
      id: 1410939150187090000
      id_str: "1410939150187089925"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/h61ccYtq2S
      truncated: false
      entities:
        urls:
          - url: https://t.co/h61ccYtq2S
      in_reply_to_status_id: 1410939149482406000
      in_reply_to_status_id_str: "1410939149482405897"
- preprint:
    id: "124661"
    doi: 10.1101/2020.12.30.20248888
    first_posted: 2021-01-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.12.30.20248888v1
    url: https://api.rxivist.org/v1/papers/124661
    title: "The Joint Impact of COVID-19 Vaccination and Non-Pharmaceutical
      Interventions on Infections, Hospitalizations, and Mortality: An
      Agent-Based Simulation"
    category: infectious-diseases
    abstract: "Background: Vaccination against SARS-CoV-2 has the potential to
      significantly reduce transmission and morbidity and mortality due to
      COVID-19. This modeling study simulated the comparative and joint impact
      of COVID-19 vaccine efficacy and coverage with and without
      non-pharmaceutical interventions (NPIs) on total infections,
      hospitalizations, and deaths. Methods: An agent-based simulation model was
      employed to estimate incident SARS-CoV-2 infections and
      COVID-19-associated hospitalizations and deaths over 18 months for the
      State of North Carolina, a population of roughly 10.5 million. Vaccine
      efficacy of 50% and 90% and vaccine coverage of 25%, 50%, and 75% (at the
      end of a 6-month distribution period) were evaluated. Six vaccination
      scenarios were simulated with NPIs (i.e., reduced mobility, school
      closings, face mask usage) maintained and removed during the period of
      vaccine distribution. Results: In the worst-case vaccination scenario (50%
      efficacy and 25% coverage), 2,231,134 new SARS-CoV-2 infections occurred
      with NPIs removed and 799,949 infections with NPIs maintained. In
      contrast, in the best-case scenario (90% efficacy and 75% coverage), there
      were 450,575 new infections with NPIs maintained and 527,409 with NPIs
      removed. When NPIs were removed, lower efficacy (50%) and higher coverage
      (75%) reduced infection risk by a greater magnitude than higher efficacy
      (90%) and lower coverage (25%) compared to the worst-case scenario
      (absolute risk reduction 13% and 8%, respectively). Conclusion: Simulation
      results suggest that premature lifting of NPIs while vaccines are
      distributed may result in substantial increases in infections,
      hospitalizations, and deaths. Furthermore, as NPIs are removed, higher
      vaccination coverage with less efficacious vaccines can contribute to a
      larger reduction in risk of SARS-CoV-2 infection compared to more
      efficacious vaccines at lower coverage. Our findings highlight the need
      for well-resourced and coordinated efforts to achieve high vaccine
      coverage and continued adherence to NPIs before many pre-pandemic
      activities can be resumed."
    authors:
      - name: Mehul D. Patel
        orcid: http://orcid.org/0000-0002-1281-3207
      - name: Erik Rosenstrom
        orcid: null
      - name: Julie S. Ivy
        orcid: null
      - name: Maria E. Mayorga
        orcid: null
      - name: Pinar Keskinocak
        orcid: http://orcid.org/0000-0003-2686-546X
      - name: Ross M. Boyce
        orcid: http://orcid.org/0000-0002-9489-6324
      - name: Kristen Hassmiller Lich
        orcid: null
      - name: Raymond L. Smith
        orcid: null
      - name: Karl T. Johnson
        orcid: null
      - name: Julie L Swann
        orcid: http://orcid.org/0000-0003-2151-4396
  comment:
    dislikes: 0
    thread: "8350052383"
    numReports: 0
    likes: 0
    id: "5440364518"
    createdAt: 2021-07-01T17:46:23
    author:
      username: mehuldpatel
      about: ""
      name: mehuldpatel
      isPowerContributor: false
      profileUrl: https://disqus.com/by/mehuldpatel/
      url: ""
      location: ""
      id: "371738012"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "The published version is available at:
      https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780539"
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.12.30.20248888v2
  tweets:
    - created_at: Fri Jul 02 14:20:30 +0000 2021
      id: 1410966615693353000
      id_str: "1410966615693352960"
      text: |-
        üí¨ medRxiv comment on "The Joint Impact of COVID-19 V..."

        "The published version is available at: "

        https://t.co/LroZCBogBj
      truncated: false
      entities:
        urls:
          - url: https://t.co/LroZCBogBj
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 02 14:20:30 +0000 2021
      id: 1410966616364437500
      id_str: "1410966616364437512"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/40k1hjqrM5
      truncated: false
      entities:
        urls:
          - url: https://t.co/40k1hjqrM5
      in_reply_to_status_id: 1410966615693353000
      in_reply_to_status_id_str: "1410966615693352960"
- preprint:
    id: "148232"
    doi: 10.1101/2021.06.29.21259693
    first_posted: 2021-07-01
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.29.21259693v1
    url: https://api.rxivist.org/v1/papers/148232
    title: Recovery of serum testosterone levels is an accurate predictor of
      survival from COVID-19 in male patients
    category: infectious-diseases
    abstract: Infection with SARS-CoV-2 portends a broad range of outcomes, from a
      majority of asymptomatic cases or mild clinical courses to a lethal
      disease. Robust correlates of severe COVID-19 include old age, male sex,
      poverty and co-morbidities such as obesity, diabetes or cardiovascular
      disease. A precise knowledge is still lacking of the molecular and
      biological mechanisms that may explain the association of severe disease
      with male sex. Here, we show that testosterone trajectories are highly
      accurate individual predictors (AUC of ROC = 0.928, p < 0.0001) of
      survival in male COVID-19 patients. Longitudinal determinations of blood
      levels of luteinizing hormone (LH) and androstenedione suggest an early
      modest inhibition of the central LH-androgen biosynthesis axis in a
      majority of patients, followed by either full recovery in survivors or a
      peripheral failure in lethal cases. Moreover, failure to reinstate
      physiological testosterone levels was associated with evidence of impaired
      T helper differentiation and decrease of non-classical monocytes. The
      strong association of recovery or failure to reinstate testosterone levels
      with survival or death from COVID-19 in male patients is suggestive of a
      significant role of testosterone status in the immune responses to
      COVID-19.
    authors:
      - name: Emily Toscano-Guerra
        orcid: http://orcid.org/0000-0003-2718-1684
      - name: Monica Martinez-Gallo
        orcid: http://orcid.org/0000-0002-7340-2161
      - name: Iria Arrese-Munoz
        orcid: null
      - name: Anna Gine
        orcid: null
      - name: Noelia Diaz
        orcid: null
      - name: Pablo Gabriel-Medina
        orcid: http://orcid.org/0000-0003-3079-6364
      - name: Mar Riveiro-Barciela
        orcid: http://orcid.org/0000-0001-9309-2052
      - name: Moises Labrador-Horrillo
        orcid: null
      - name: Fernando Martinez-Valle
        orcid: http://orcid.org/0000-0003-2673-2034
      - name: Manuel Hernandez-Gonzalez
        orcid: http://orcid.org/0000-0002-6932-5853
      - name: Francisco Rodriguez-Frias
        orcid: http://orcid.org/0000-0002-9128-7013
      - name: Ricardo Pujol Borrell
        orcid: http://orcid.org/0000-0001-7833-675X
      - name: Roser Ferrer
        orcid: http://orcid.org/0000-0002-8925-3172
      - name: Timothy M Thomson
        orcid: http://orcid.org/0000-0002-4670-9440
      - name: Rosanna Paciucci
        orcid: http://orcid.org/0000-0002-1087-6378
  comment:
    dislikes: 0
    thread: "8624444724"
    numReports: 0
    likes: 0
    id: "5440192670"
    createdAt: 2021-07-01T15:31:12
    author:
      username: davidgurwitz
      about: Department of Human Molecular Genetics and Biochemistry  Sackler Faculty
        of Medicine  Tel-Aviv University  Tel-Aviv 69978 Israel
      name: David Gurwitz
      isPowerContributor: false
      profileUrl: https://disqus.com/by/davidgurwitz/
      url: http://www.sagol.tau.ac.il/en/people/gurwitz-david/
      location: Tel Aviv, Israel
      id: "221454207"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      This study may potentially allow better prognostics in Covid-19. If
      validated by further studies, it may even indicate that clinical trials of
      testosterone supplementation in male Covid-19 patients with low serum
      testosterone levels are warranted. 


      A recent study by Peruzzo et al. 2021 (Front Pharmacol. 2021 May 13;12:683529), titled ‚ÄúSynergy Between Vitamin D and Sex Hormones in Respiratory Functionality of Patients Affected by COVID-19‚Äù seems supportive for this preprint (and should be cited by the preprint authors). Peruzzo et al. observed ‚Äúa significantly positive correlation between 17Œ≤-estradiol and 25(OH)D in elderly women and between testosterone and 25(OH)D in elderly men‚Äù. As Vitamin D is a well-established immune enhancer, it could be that the positive effects of higher serum testosterone reported in this preprint reflect higher  serum vitamin D. This aspect of their findings should be examined. 


      The authors of this preprint discuss the role of hyper-coagulation in severe Covid-19 as a key risk for fatal outcome. In this context, it is noteworthy that a recent meta-analysis of 13 clinical trials (Ayele et al. 2021; Thrombosis Research; PMID: 33486321) indicated that testosterone replacement therapy in men was not associated with increased risk of venous thromboembolism. 


      Taken together, the authors suggestions that testosterone may be beneficial for male Covid-19 patients with low serum testosterone definitely warrants further research.  


      David Gurwitz, Faculty of Medicine, Tel Aviv University, Israel
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.29.21259693v1
  tweets:
    - created_at: Fri Jul 02 16:33:26 +0000 2021
      id: 1411000069470490600
      id_str: "1411000069470490632"
      text: >-
        üí¨ medRxiv comment on "Recovery of serum testosterone..."


        "This study may potentially allow better prognostics in C‚Ä¶ https://t.co/levg3Kknbt
      truncated: true
      entities:
        urls:
          - url: https://t.co/levg3Kknbt
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 02 16:33:26 +0000 2021
      id: 1411000070426747000
      id_str: "1411000070426746880"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/DWHq6n7WV6
      truncated: false
      entities:
        urls:
          - url: https://t.co/DWHq6n7WV6
      in_reply_to_status_id: 1411000069470490600
      in_reply_to_status_id_str: "1411000069470490632"
- preprint:
    id: "94060"
    doi: 10.1101/2020.08.09.243238
    first_posted: 2020-08-10
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.08.09.243238v3
    url: https://api.rxivist.org/v1/papers/94060
    title: Global inequity in scientific names and who they honor
    category: zoology
    abstract: "Linnaean taxonomy is a cornerstone of Western biology in which
      organisms are given a two-part name (a genus and species), creating
      biological units that help us order and manage our knowledge of the living
      world. In this system, the names of species themselves take on additional
      functions, such as describing features of the organism or honoring
      individuals (known as eponyms). Here, we interrogate how power and
      authority over the natural world are claimed through Western scientific
      naming practices to evaluate the legacies of imperialism, dispossession,
      and exclusion in these practices. We compile and analyze a dataset of all
      bird species descriptions from 1950 to present, asking: who has access and
      power to name species, and who is honored in species names? We show that
      95% of newly described species are described from the global South, but
      the majority of species and eponyms are described by authors, and named
      after individuals, from the global North. We find an increase through time
      in authors from the global South, which is associated with a rise in
      eponyms that honor individuals from global South countries. However, this
      formal inclusion of global South authors has not translated into increases
      in first authorship (a primary form of credit and authority in Western
      science). We contextualize these disparities in naming and authorship
      within broader global structures of access and power put in place through
      centuries of European and U.S. imperialism, but a historical perspective
      alone ignores institutional and individual agency and incentives in
      present-day actions. As we increasingly reflect on the social foundations
      and impacts of our science, these findings show how research and labor in
      the global South continue to be disproportionately translated into power
      and authority in the global North, upholding and re-enacting imperial
      structures of domination."
    authors:
      - name: Shane DuBay
        orcid: null
      - name: Daniela H. Palmer
        orcid: null
      - name: Natalia Piland
        orcid: null
  comment:
    dislikes: 0
    thread: "8294922913"
    numReports: 0
    likes: 0
    id: "5440840992"
    createdAt: 2021-07-01T23:59:27
    author:
      username: mabelcristinagonzlezmontoya
      about: ""
      name: Mabel Cristina Gonz√°lez Montoy
      isPowerContributor: false
      profileUrl: https://disqus.com/by/mabelcristinagonzlezmontoya/
      url: ""
      location: ""
      id: "371751152"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Very interesting article. The link of this citation does not correspond:
      Deb Roy, R. (2018). Decolonise science ‚Äì time to end another imperial era.
      The Conversation.

      479 Available at https://theconversation.com/decolonise-science-time-to-end-another-imperial-era480 89189
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.08.09.243238v4
  tweets:
    - created_at: Fri Jul 02 18:20:59 +0000 2021
      id: 1411027136970903600
      id_str: "1411027136970903553"
      text: >-
        üí¨ bioRxiv comment on "Global inequity in scientific ..."


        "Very interesting article. The link of this citation does‚Ä¶ https://t.co/aEHMMCg7yo
      truncated: true
      entities:
        urls:
          - url: https://t.co/aEHMMCg7yo
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 02 18:20:59 +0000 2021
      id: 1411027137855987700
      id_str: "1411027137855987717"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/5bzwTwa6CB
      truncated: false
      entities:
        urls:
          - url: https://t.co/5bzwTwa6CB
      in_reply_to_status_id: 1411027136970903600
      in_reply_to_status_id_str: "1411027136970903553"
- preprint:
    id: 134112
    metric: 59
    title: Common dandelion (Taraxacum officinale) efficiently blocks the
      interaction between ACE2 cell surface receptor and SARS-CoV-2 spike
      protein D614, mutants D614G, N501Y, K417N and E484K in vitro
    url: https://api.rxivist.org/v1/papers/134112
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.03.19.435959v1
    doi: 10.1101/2021.03.19.435959
    category: microbiology
    first_posted: 2021-03-19
    abstract: On 11th March 2020, coronavirus disease 2019 (COVID-19), caused by the
      SARS-CoV-2 virus, was declared as a global pandemic by the World Health
      Organization (WHO). To date, there are rapidly spreading new "variants of
      concern" of SARS-CoV-2, the United Kingdom (B.1.1.7), the South African
      (B.1.351) or Brasilian (P.1) variant. All of them contain multiple
      mutations in the ACE2 receptor recognition site of the spike protein,
      compared to the original Wuhan sequence, which is of great concern,
      because of their potential for immune escape. Here we report on the
      efficacy of dandelion (Taraxacum officinale) to block protein-protein
      interaction of spike S1 to the human ACE2 cell surface receptor. This
      could be shown for the original spike D614, but also for its mutant forms
      (D614G, N501Y, and mix of K417N, E484K, N501Y) in human HEK293-hACE2
      kidney and A549-hACE2-TMPRSS2 lung cells. High molecular weight compounds
      in the water-based extract account for this effect. Infection of lung
      cells using SARS-CoV-2 spike pseudotyped lentivirus particles was
      efficiently prevented by the extract and so was virus-triggered
      pro-inflammatory interleukin 6 secretion. Modern herbal monographs
      consider the usage of this medicinal plant as safe. Thus, the in vitro
      results reported here should encourage further research on the clinical
      relevance and applicability of the extract as prevention strategy for
      SARS-CoV-2 infection.
    authors:
      - name: Hoai Thi Thu Tran
      - name: Nguyen Phan Khoi Le
      - name: Michael Gigl
      - name: Corinna Dawid
      - name: Evelyn Lamy
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Fri Jul 02 20:16:47 +0000 2021
      id: 1411056276436668400
      id_str: "1411056276436668423"
      text: >-
        üî• bioRxiv Microbiology preprint by H. T. T. Tran et al:


        "Common dandelion (Taraxacum officinale) efficiently block‚Ä¶ https://t.co/bvZB0kUal2
      truncated: true
      entities:
        urls:
          - url: https://t.co/bvZB0kUal2
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "97860"
    doi: 10.1101/2020.09.28.316299
    first_posted: 2020-09-29
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.09.28.316299v1
    url: https://api.rxivist.org/v1/papers/97860
    title: Genomic sequencing confirms absence of introgression despite past
      hybridisation between a critically endangered bird and its common congener
    category: genomics
    abstract: Genetic swamping resulting from interspecific hybridisation can
      increase extinction risk for threatened species. The development of
      high-throughput and reduced-representation genomic sequencing and analyses
      to generate large numbers of high resolution genomic markers has the
      potential to reveal introgression previously undetected using small
      numbers of genetic markers. However, few studies to date have implemented
      genomic tools to assess the extent of interspecific hybridisation in
      threatened species. Here we investigate the utility of genome-wide single
      nucleotide polymorphisms (SNPs) to detect introgression resulting from
      past interspecific hybridisation in one of the world's rarest birds.
      Anthropogenic impacts have resulted in hybridisation and subsequent
      backcrossing of the critically endangered Aotearoa New Zealand endemic
      kak[i] (black stilts; Himantopus novaezelandiae) with the non-threatened
      self-introduced congeneric poaka (Aotearoa New Zealand population of pied
      stilts, Himantopus himantopus leucocephalus), yet genetic analyses with a
      limited set of microsatellite markers revealed no evidence of
      introgression of poaka genetic material in kak[i], excluding one
      individual. We use genomic data for ~63% of the wild adult kak[i]
      population to reassess the extent of introgression resulting from
      hybridisation between kak[i] and poaka. Consistent with previous genetic
      analyses, we detected no introgression from poaka into kak[i]. These
      collective results indicate that, for kak[i], existing microsatellite
      markers provide a robust, cost-effective approach to detect cryptic
      hybrids. Further, for well-differentiated species, the use of genomic
      markers may not be required to detect admixed individuals.
    authors:
      - name: Natalie J Forsdick
        orcid: http://orcid.org/0000-0003-0423-3314
      - name: Denise Martini
        orcid: http://orcid.org/0000-0001-8676-9328
      - name: Liz Brown
        orcid: http://orcid.org/0000-0002-4245-3900
      - name: Hugh B Cross
        orcid: http://orcid.org/0000-0002-6745-9479
      - name: Richard F. Maloney
        orcid: null
      - name: Tammy E Steeves
        orcid: http://orcid.org/0000-0003-2112-5761
      - name: Michael Knapp
        orcid: http://orcid.org/0000-0002-0937-5664
  comment:
    dislikes: 0
    thread: "8588237608"
    numReports: 0
    likes: 0
    id: "5440826327"
    createdAt: 2021-07-01T23:41:12
    author:
      username: natforsdick
      about: ""
      name: natforsdick
      isPowerContributor: false
      profileUrl: https://disqus.com/by/natforsdick/
      url: ""
      location: ""
      id: "371750578"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: This paper has now been peer-reviewed and published in as an Open
      Access article in Global Ecology and Evolution -
      https://doi.org/10.1016/j.gecco.2021.e01681.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.09.28.316299v5
  tweets:
    - created_at: Fri Jul 02 20:20:31 +0000 2021
      id: 1411057217667805200
      id_str: "1411057217667805188"
      text: >-
        üí¨ bioRxiv comment on "Genomic sequencing confirms ab..."


        "This paper has now been peer-reviewed and published in a‚Ä¶ https://t.co/4KFYXQGx5y
      truncated: true
      entities:
        urls:
          - url: https://t.co/4KFYXQGx5y
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 02 20:20:31 +0000 2021
      id: 1411057218561228800
      id_str: "1411057218561228808"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/PjclOtBrMU
      truncated: false
      entities:
        urls:
          - url: https://t.co/PjclOtBrMU
      in_reply_to_status_id: 1411057217667805200
      in_reply_to_status_id_str: "1411057217667805188"
- preprint:
    id: "51056"
    doi: 10.1101/641118
    first_posted: 2019-05-18
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/641118v1
    url: https://api.rxivist.org/v1/papers/51056
    title: The maternal-fetal interface of successful pregnancies and impact of
      fetal sex using single cell sequencing
    category: developmental-biology
    abstract: The first trimester is a critical window of maternal-fetal
      communication for pregnancy. Therefore, we characterized crosstalk in
      ongoing human pregnancies at 11-13 weeks gestation. RNA-sequencing of
      matched maternal decidua and placenta identified 818 receptors and 3502
      ligands, including 126 differentially expressed receptor-ligand pairs.
      Using single cell RNA-sequencing to further dissect placenta
      heterogeneity, we identified five major cell types (trophoblasts, stromal
      cells, hofbauer cells, antigen presenting cells and endothelial cells)
      with unique crosstalk at the maternal-fetal interface. We identified seven
      unique trophoblast subclusters, including new subtypes that transition
      into the terminal cell types, extra-villous trophoblasts and
      syncytiotrophoblasts. As fetal sex impacts pregnancy, we analyzed sex
      differences in each cell type and identified differences in immune cell
      function. TGFŒ≤1, Œ≤-estradiol, and dihydrotestosterone emerge as upstream
      regulators of sexually dimorphic genes in a cell type specific manner.
      Thus, the fetal contribution at the maternal-fetal interface is cell and
      sex specific.
    authors:
      - name: Tianyanxin Sun
        orcid: http://orcid.org/0000-0001-6411-5972
      - name: Tania L Gonzalez
        orcid: http://orcid.org/0000-0003-3825-8544
      - name: Nan Deng
        orcid: http://orcid.org/0000-0003-0914-7220
      - name: Rosemarie DiPentino
        orcid: http://orcid.org/0000-0003-4409-3264
      - name: Ekaterina L Clark
        orcid: http://orcid.org/0000-0003-3050-590X
      - name: Bora Lee
        orcid: null
      - name: Jie Tang
        orcid: http://orcid.org/0000-0002-3991-2539
      - name: Yizhou Wang
        orcid: null
      - name: Barry R Stripp
        orcid: http://orcid.org/0000-0003-4348-2137
      - name: Changfu Yao
        orcid: http://orcid.org/0000-0003-1357-5017
      - name: Hsian-Rong Tseng
        orcid: http://orcid.org/0000-0003-0942-5905
      - name: S. Ananth Karumanchi
        orcid: http://orcid.org/0000-0002-2281-6831
      - name: Alexander F. Koeppel
        orcid: http://orcid.org/0000-0002-2256-2659
      - name: Stephen D Turner
        orcid: http://orcid.org/0000-0001-9140-9028
      - name: Charles Farber
        orcid: http://orcid.org/0000-0002-6748-4711
      - name: Stephen S Rich
        orcid: http://orcid.org/0000-0003-3872-7793
      - name: Erica T Wang
        orcid: null
      - name: John Williams
        orcid: null
      - name: Margareta D. Pisarska
        orcid: http://orcid.org/0000-0003-1096-6506
  comment:
    dislikes: 0
    thread: "7426190486"
    numReports: 0
    likes: 0
    id: "5440825468"
    createdAt: 2021-07-01T23:40:09
    author:
      username: ScienceTania
      about: ""
      name: Tania Gonzalez
      isPowerContributor: false
      profileUrl: https://disqus.com/by/ScienceTania/
      url: https://twitter.com/ScienceTania
      location: ""
      id: "371750295"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "The peer-reviewed version (PMCID: PMC7571453) was published in
      JCEM, see: https://doi.org/10.1210/clinem/dgaa503 and data was deposited
      into NCBI GEO with accessions GSE131696 (single cell RNA-seq data of 6
      placenta) and GSE131874 (bulk RNA-seq of matched placenta and maternal
      decidua samples from 4 patients). Find me on ResearchGate if you need
      anything else!"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/641118v1
  tweets:
    - created_at: Fri Jul 02 22:23:43 +0000 2021
      id: 1411088222243991600
      id_str: "1411088222243991555"
      text: >-
        üí¨ bioRxiv comment on "The maternal-fetal interface o..."


        "The peer-reviewed version (PMCID: PMC7571453) was publis‚Ä¶ https://t.co/t15DLs7WhI
      truncated: true
      entities:
        urls:
          - url: https://t.co/t15DLs7WhI
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 02 22:23:43 +0000 2021
      id: 1411088223120547800
      id_str: "1411088223120547841"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/97wPzr6i7o
      truncated: false
      entities:
        urls:
          - url: https://t.co/97wPzr6i7o
      in_reply_to_status_id: 1411088222243991600
      in_reply_to_status_id_str: "1411088222243991555"
- preprint:
    id: "127020"
    doi: 10.1101/2021.01.27.428294
    first_posted: 2021-01-28
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.01.27.428294v1
    url: https://api.rxivist.org/v1/papers/127020
    title: Design principles of plant root morphogenesis
    category: plant-biology
    abstract: Understanding how an independent organ develops from the stem cell
      populations in the process called morphogenesis is a pressing challenge in
      developmental biology and medicine. Plants build up new organs such as
      roots to adjust their bodies to dynamic changes in the environment,
      thereby providing a tractable model to address this challenge. Here, we
      combined empirical data with advanced computer modeling techniques to
      build a mechanistic cell-based framework for the morphogenesis of the
      plant root. Our framework relies on experimentally supported design
      principles underlying the multi-layered feedback between tissue mechanics,
      cell growth, and directional cell-to-cell transport of growth regulator
      auxin. Model simulations reconstruct experimentally-observed patterns of
      anisotropic growth, auxin distribution, and cell polarity, as well as
      several root phenotypes caused by chemical, mechanical, or genetic
      perturbations. Furthermore, our model provides new insights into
      mechanisms of sustained root growth and cell polarity establishment. This
      work reveals that mobile auxin signal feeds back on cell polarity and
      growth mechanics to instruct the morphogenesis of an independent organ.
    authors:
      - name: Marco Marconi
        orcid: http://orcid.org/0000-0002-3457-1384
      - name: Marcal Gallemi
        orcid: http://orcid.org/0000-0003-4675-6893
      - name: Eva Benkova
        orcid: http://orcid.org/0000-0002-8510-9739
      - name: Krzysztof Wabnik
        orcid: http://orcid.org/0000-0001-7263-0560
  comment:
    dislikes: 0
    thread: "8374900737"
    numReports: 0
    likes: 0
    id: "5440808291"
    createdAt: 2021-07-01T23:18:29
    author:
      username: marcush1
      about: ""
      name: Marcus
      isPowerContributor: false
      profileUrl: https://disqus.com/by/marcush1/
      url: ""
      location: ""
      id: "36832573"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Ref 47 should be Heisler et al.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.01.27.428294v1
  tweets:
    - created_at: Sat Jul 03 01:00:06 +0000 2021
      id: 1411127577784225800
      id_str: "1411127577784225793"
      text: |-
        üí¨ bioRxiv comment on "Design principles of plant roo..."

        "Ref 47 should be Heisler et al."

        https://t.co/sHYcYPG3tb
      truncated: false
      entities:
        urls:
          - url: https://t.co/sHYcYPG3tb
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 03 01:00:06 +0000 2021
      id: 1411127578585448400
      id_str: "1411127578585448449"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/BwJNGxflXz
      truncated: false
      entities:
        urls:
          - url: https://t.co/BwJNGxflXz
      in_reply_to_status_id: 1411127577784225800
      in_reply_to_status_id_str: "1411127577784225793"
- preprint:
    id: "145670"
    doi: 10.1101/2021.06.08.21258427
    first_posted: 2021-06-11
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.08.21258427v1
    url: https://api.rxivist.org/v1/papers/145670
    title: "Intensified stimulation targeting lateral and medial prefrontal cortices
      for the treatment of social anxiety disorder: A randomized, double-blind,
      parallel-group, dose-comparison study"
    category: psychiatry-and-clinical-psychology
    abstract: "Background: Social Anxiety Disorder (SAD) is the most common anxiety
      disorder while remains largely untreated. Disturbed amygdala-frontal
      network functions are central to the pathophysiology of SAD, marked by
      hypoactivity of the lateral prefrontal cortex (PFC), and hypersensitivity
      of the medial PFC and amygdala. The objective of this study was to
      determine whether modulation of dorsolateral and medial PFC activity with
      a novel intensified stimulation protocol reduces SAD core symptoms,
      improves treatment-related variables, and reduces attention bias to
      threatening stimuli. Methods: In this randomized, sham-controlled,
      double-blind trial, we assessed the efficacy of an intensified stimulation
      protocol (20 min, twice-daily sessions with 20 min intervals, 5
      consecutive days) in two intensities (1 vs 2 mA) compared to sham
      stimulations. 45 patients with SAD were randomized in three tDCS arms. SAD
      symptoms, treatment-related variables (worries, depressive state, emotion
      regulation, quality of life), and attention bias to threatening stimuli
      (dot-probe paradigm) were assessed before and right after the
      intervention. SAD symptoms were also assessed at 2-month follow-up.
      Results: Both 1 mA and 2mA protocols significantly reduced fear/avoidance
      symptoms, worries and improved, emotion regulation and quality of life
      after the intervention compared to the sham group. Improving effect of the
      2 mA protocol on avoidance symptoms, worries and depressive state was
      significantly larger than the 1 mA group. Only the 2 mA protocol reduced
      attention bias to threat-related stimuli, the avoidance symptom at
      follow-up, and depressive states, as compared to the sham group.
      Conclusions: Modulation of lateral-medial PFC activity with intensified
      stimulation can improve cognitive control, motivation and emotion networks
      in SAD and thereby results in therapeutic effects. These effects can be
      larger with 2 mA vs 1 mA intensities, though a linear relationship between
      intensity and efficacy should not be concluded."
    authors:
      - name: Eisa Jafari
        orcid: null
      - name: Jaber Alizadehgoradel
        orcid: null
      - name: Fereshteh Pourmohseni Koluri
        orcid: null
      - name: Ezzatollah Nikoozadehkordmirza
        orcid: null
      - name: Meysam Refahi
        orcid: null
      - name: Mina Taherifard
        orcid: null
      - name: Vahid Nejati
        orcid: null
      - name: Amir-Homayun Hallajian
        orcid: http://orcid.org/0000-0001-5848-7841
      - name: Elham Ghanavati
        orcid: http://orcid.org/0000-0001-5944-8123
      - name: Carmelo M. Vicario
        orcid: http://orcid.org/0000-0001-7557-9078
      - name: Michael A. A Nitsche
        orcid: http://orcid.org/0000-0002-2207-5965
      - name: Mohammad Ali Salehinejad
        orcid: http://orcid.org/0000-0003-1913-4677
  comment:
    dislikes: 0
    thread: "8586696789"
    numReports: 0
    likes: 0
    id: "5441987861"
    createdAt: 2021-07-02T23:04:45
    author:
      username: alisalehinejadphd
      about: ""
      name: Ali Salehinejad, PhD
      isPowerContributor: false
      profileUrl: https://disqus.com/by/alisalehinejadphd/
      url: ""
      location: ""
      id: "359942221"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      The peer-reviewed published article (open access) of this preprint can be
      found below:

      https://www.sciencedirect.com/science/article/pii/S1935861X21001248
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.08.21258427v1
  tweets:
    - created_at: Sat Jul 03 12:29:59 +0000 2021
      id: 1411301191355670500
      id_str: "1411301191355670528"
      text: >-
        üí¨ medRxiv comment on "Intensified stimulation target..."


        "The peer-reviewed published article (open access) of thi‚Ä¶ https://t.co/1LLW6PrZS6
      truncated: true
      entities:
        urls:
          - url: https://t.co/1LLW6PrZS6
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 03 12:29:59 +0000 2021
      id: 1411301192140050400
      id_str: "1411301192140050435"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/18AcRCoEmp
      truncated: false
      entities:
        urls:
          - url: https://t.co/18AcRCoEmp
      in_reply_to_status_id: 1411301191355670500
      in_reply_to_status_id_str: "1411301191355670528"
- preprint:
    id: "136868"
    doi: 10.1101/2021.04.05.21254656
    first_posted: 2021-04-07
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.04.05.21254656v1
    url: https://api.rxivist.org/v1/papers/136868
    title: Glucocorticoids and B Cell Depleting Agents Substantially Impair
      Immunogenicity of mRNA Vaccines to SARS-CoV-2
    category: infectious-diseases
    abstract: >-
      BackgroundIndividuals with chronic inflammatory diseases (CID) are
      frequently treated with immunosuppressive medications that can increase
      their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2
      vaccination platforms provide robust protection in immunocompetent
      individuals, the immunogenicity in CID patients on immunosuppression is
      not well established. Therefore, determining the effectiveness of
      SARS-CoV-2 vaccines in the setting of immunosuppression is essential to
      risk-stratify CID patients with impaired protection and provide clinical
      guidance regarding medication management.


      MethodsWe conducted a prospective assessment of mRNA-based vaccine immunogenicity in 133 adults with CIDs and 53 immunocompetent controls. Blood from participants over 18 years of age was collected before initial immunization and 1-2 weeks after the second immunization. Serum anti-SARS-CoV-2 spike (S) IgG+ binding, neutralizing antibody titers, and circulating S-specific plasmablasts were quantified to assess the magnitude and quality of the humoral response following vaccination.


      ResultsCompared to immunocompetent controls, a three-fold reduction in anti-S IgG titers (P=0.009) and SARS-CoV-2 neutralization (p<0.0001) were observed in CID patients. B cell depletion and glucocorticoids exerted the strongest effect with a 36- and 10-fold reduction in humoral responses, respectively (p<0.0001). Janus kinase inhibitors and antimetabolites, including methotrexate, also blunted antibody titers in multivariate regression analysis (P<0.0001, P=0.0023, respectively). Other targeted therapies, such as TNF inhibitors, IL-12/23 inhibitors, and integrin inhibitors, had only modest impacts on antibody formation and neutralization.


      ConclusionsCID patients treated with immunosuppressive therapies exhibit impaired SARS-CoV-2 vaccine-induced immunity, with glucocorticoids and B cell depletion therapy more severely impeding optimal responses.
    authors:
      - name: Parakkal Deepak
        orcid: http://orcid.org/0000-0002-3436-9784
      - name: Wooseob Kim
        orcid: http://orcid.org/0000-0002-9199-1000
      - name: Michael A Paley
        orcid: http://orcid.org/0000-0001-8724-3176
      - name: Monica Yang
        orcid: http://orcid.org/0000-0002-2693-3648
      - name: Alexander B Carvidi
        orcid: null
      - name: Alia A El-Qunni
        orcid: http://orcid.org/0000-0003-0212-8094
      - name: Alem Haile
        orcid: null
      - name: Katherine Huang
        orcid: http://orcid.org/0000-0002-5013-4790
      - name: Baylee Kinnett
        orcid: null
      - name: Mariel J. Liebeskind
        orcid: http://orcid.org/0000-0003-4595-0651
      - name: Zhuoming Liu
        orcid: http://orcid.org/0000-0001-8198-0976
      - name: Lily E McMorrow
        orcid: http://orcid.org/0000-0003-2823-5859
      - name: Diane Paez
        orcid: null
      - name: Dana C Perantie
        orcid: http://orcid.org/0000-0002-6380-8133
      - name: Rebecca E Schriefer
        orcid: http://orcid.org/0000-0002-7430-0626
      - name: Shannon Sides
        orcid: null
      - name: Mahima Thapa
        orcid: null
      - name: Mate Gergely
        orcid: null
      - name: Suha Abushamma
        orcid: null
      - name: Micahel Kelbert
        orcid: null
      - name: Lynne Mitchell
        orcid: null
      - name: Billy Nix
        orcid: null
      - name: Jonathan D Graf
        orcid: null
      - name: Kimberly E Taylor
        orcid: http://orcid.org/0000-0001-6848-9074
      - name: Salim Chahin
        orcid: http://orcid.org/0000-0002-4115-4300
      - name: Matthew A Ciorba
        orcid: http://orcid.org/0000-0002-7656-0982
      - name: Patricia A Katz
        orcid: http://orcid.org/0000-0002-8146-2519
      - name: Mehrdad Matloubian
        orcid: http://orcid.org/0000-0001-6233-985X
      - name: Jane A O'Halloran
        orcid: http://orcid.org/0000-0001-8265-9471
      - name: Rachel M Presti
        orcid: http://orcid.org/0000-0002-5469-0727
      - name: Gregory F Wu
        orcid: http://orcid.org/0000-0003-3588-0637
      - name: Sean P. J. Whelan
        orcid: http://orcid.org/0000-0003-1564-8590
      - name: William J Buchser
        orcid: http://orcid.org/0000-0002-6675-6359
      - name: Lianne S Gensler
        orcid: http://orcid.org/0000-0001-6314-5336
      - name: Mary C Nakamura
        orcid: http://orcid.org/0000-0001-8127-9426
      - name: Ali H. Ellebedy
        orcid: http://orcid.org/0000-0002-6129-2532
      - name: Alfred HJ Kim
        orcid: http://orcid.org/0000-0003-4074-0516
  comment:
    dislikes: 0
    thread: "8468746386"
    numReports: 0
    likes: 0
    id: "5441769063"
    createdAt: 2021-07-02T19:31:41
    author:
      username: eden_ann
      about: ""
      name: Eden Ann
      isPowerContributor: false
      profileUrl: https://disqus.com/by/eden_ann/
      url: ""
      location: ""
      id: "371787176"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: What about medications for allergic asthma - xolair, inhaled
      steroids, and such ?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.04.05.21254656v1
  tweets:
    - created_at: Sat Jul 03 14:16:53 +0000 2021
      id: 1411328093504032800
      id_str: "1411328093504032769"
      text: >-
        üí¨ medRxiv comment on "Glucocorticoids and B Cell Dep..."


        "What about medications for allergic asthma - xolair, inh‚Ä¶ https://t.co/Zgr2KkRf8T
      truncated: true
      entities:
        urls:
          - url: https://t.co/Zgr2KkRf8T
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 03 14:16:53 +0000 2021
      id: 1411328094414246000
      id_str: "1411328094414245888"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/zdork41vHy
      truncated: false
      entities:
        urls:
          - url: https://t.co/zdork41vHy
      in_reply_to_status_id: 1411328093504032800
      in_reply_to_status_id_str: "1411328093504032769"
- preprint:
    id: "147602"
    doi: 10.1101/2021.06.24.21259283
    first_posted: 2021-06-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.24.21259283v1
    url: https://api.rxivist.org/v1/papers/147602
    title: "Diet quality and risk and severity of COVID-19: a prospective cohort
      study"
    category: nutrition
    abstract: "Objective: Poor metabolic health and certain lifestyle factors have
      been associated with risk and severity of coronavirus disease 2019
      (COVID-19), but data for diet are lacking. We aimed to investigate the
      association of diet quality with risk and severity of COVID-19 and its
      intersection with socioeconomic deprivation. Design: We used data from
      592,571 participants of the smartphone-based COVID Symptom Study. Diet
      quality was assessed using a healthful plant-based diet score, which
      emphasizes healthy plant foods such as fruits or vegetables. Multivariable
      Cox models were fitted to calculate hazard ratios (HR) and 95% confidence
      intervals (95% CI) for COVID-19 risk and severity defined using a
      validated symptom-based algorithm or hospitalization with oxygen support,
      respectively. Results: Over 3,886,274 person-months of follow-up, 31,815
      COVID-19 cases were documented. Compared with individuals in the lowest
      quartile of the diet score, high diet quality was associated with lower
      risk of COVID-19 (HR, 0.91; 95% CI, 0.88-0.94) and severe COVID-19 (HR,
      0.59; 95% CI, 0.47-0.74). The joint association of low diet quality and
      increased deprivation on COVID-19 risk was higher than the sum of the risk
      associated with each factor alone (Pinteraction=0.005). The corresponding
      absolute excess rate for lowest vs highest quartile of diet score was 22.5
      (95% CI, 18.8-26.3) and 40.8 (95% CI, 31.7-49.8; 10,000 person-months)
      among persons living in areas with low and high deprivation, respectively.
      Conclusions: A dietary pattern characterized by healthy plant-based foods
      was associated with lower risk and severity of COVID-19. These association
      may be particularly evident among individuals living in areas with higher
      socioeconomic deprivation."
    authors:
      - name: Jordi Merino
        orcid: http://orcid.org/0000-0001-8312-1438
      - name: Amit D. Joshi
        orcid: null
      - name: Long Nguyen
        orcid: http://orcid.org/0000-0002-5436-4219
      - name: Emily Leeming
        orcid: null
      - name: David Alden Drew
        orcid: null
      - name: Rachel Gibson
        orcid: http://orcid.org/0000-0002-5823-6468
      - name: Mark S Graham
        orcid: http://orcid.org/0000-0002-4170-1095
      - name: Mohsen Mazidi
        orcid: http://orcid.org/0000-0003-3059-229X
      - name: Chun-Han Lo
        orcid: http://orcid.org/0000-0001-8202-4513
      - name: Joan Capdevila
        orcid: null
      - name: Ben Murray
        orcid: null
      - name: christina hu
        orcid: null
      - name: Somesh Selvachandran
        orcid: null
      - name: Sohee Kwon
        orcid: http://orcid.org/0000-0002-4201-9522
      - name: Wenjie MA
        orcid: null
      - name: Cristina Menni
        orcid: http://orcid.org/0000-0001-9790-0571
      - name: Alexander Hammers
        orcid: http://orcid.org/0000-0001-9530-4848
      - name: Shilpa Bhupathiraju
        orcid: null
      - name: Shreela Sharma
        orcid: null
      - name: Carole Sudre
        orcid: null
      - name: Christina M Astley
        orcid: http://orcid.org/0000-0002-5063-8470
      - name: Walter Willett
        orcid: null
      - name: Jorge Chavarro
        orcid: null
      - name: Seb Ourselin
        orcid: null
      - name: Claire Steves
        orcid: null
      - name: Jonathan Wolf
        orcid: http://orcid.org/0000-0002-0530-2257
      - name: Paul W Franks
        orcid: http://orcid.org/0000-0002-0520-7604
      - name: Timothy Spector
        orcid: http://orcid.org/0000-0002-9795-0365
      - name: Sarah Berry
        orcid: null
      - name: Andrew T. Chan
        orcid: http://orcid.org/0000-0001-7284-6767
  comment:
    dislikes: 0
    thread: "8614872167"
    numReports: 0
    likes: 0
    id: "5441566886"
    createdAt: 2021-07-02T16:40:01
    author:
      username: disqus_ZxO2BUNoIe
      about: ""
      name: Andrew Carey
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_ZxO2BUNoIe/
      url: ""
      location: ""
      id: "291321327"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      <i><b>a</b> healthful plant-based diet score</i>

      I read the text and couldn't find any further information about what this meant. There is much discussion of hPDI on the internet, but no publicly available calculator for it, and now I learn that there are a number of ways of working out a score for this and your team of researchers has chosen one of them based on your choice of phrase.

      I'm being harsh but unless this diet scoring system chosen was declared in advance of or independently of collecting the data, then this does not deserve to pass peer review.

      Make it public please.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.24.21259283v1
  tweets:
    - created_at: Sat Jul 03 16:30:22 +0000 2021
      id: 1411361685810602000
      id_str: "1411361685810601986"
      text: >-
        üí¨ medRxiv comment on "Diet quality and risk and seve..."


        "&lt;i&gt;&lt;b&gt;a&lt;/b&gt; healthful plant-based diet score&lt;/i&gt;

        I read‚Ä¶ https://t.co/m1bg93NH9h
      truncated: true
      entities:
        urls:
          - url: https://t.co/m1bg93NH9h
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 03 16:30:22 +0000 2021
      id: 1411361686867656700
      id_str: "1411361686867656705"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/24JaAsnPD0
      truncated: false
      entities:
        urls:
          - url: https://t.co/24JaAsnPD0
      in_reply_to_status_id: 1411361685810602000
      in_reply_to_status_id_str: "1411361685810601986"
- preprint:
    id: "148438"
    doi: 10.1101/2021.06.27.21259432
    first_posted: 2021-07-02
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.27.21259432v1
    url: https://api.rxivist.org/v1/papers/148438
    title: SARS-CoV-2 Seroprevalence among First Responders in Northeastern Ohio
    category: infectious-diseases
    abstract: "Objectives: First responders including firefighters, emergency
      medical technicians (EMT), paramedics, and police officers are working on
      the front lines to fight the COVID-19 pandemic and facing a higher risk of
      infection. This study assessed the seroprevalence among first responders
      in northeastern Ohio during May- September 2020. Methods: A survey and IgG
      antibody test against SARS-CoV-2 were offered to University Hospitals
      Health System affiliated first responder departments. Results: A total of
      3080 first responders with diverse job assignments from more than 400 fire
      and police departments participated in the study. Among them, 73 (2.4%)
      were seropositive while only 0.8% had previously positive RT-PCR results.
      Asymptomatic infection accounts for 46.6% of seropositivity. By
      occupation, seropositive rates were highest among administration/support
      staff (3.8%), followed by paramedics (3.0%), EMTs (2.6%), firefighters
      (2.2%), and police officers (0.8%). Seroprevalence was not associated with
      self-reported exposure as work exposure rates were: paramedics 48.2%,
      firefighters 37.1%, EMTs 32.3%, police officers 7.7%, and
      administration/support staff 4.4%. Self-reported community exposure was
      strongly correlated with self-reported work exposure rate rather than
      seroprevalence suggesting a potential impact of risk awareness.
      Additionally, no significant difference was found among gender or age
      groups; however, black Americans have a higher positivity rate than other
      races although they reported lower exposure. Conclusions: Despite the high
      work-associated exposure rate to SARS-CoV-2 infection, first responders
      with different roles demonstrated seroprevalence no higher than their
      administrative/supportive colleagues, which suggests infection control
      measures are effective in preventing work-related infection."
    authors:
      - name: xiaochun zhang
        orcid: http://orcid.org/0000-0002-9816-1034
      - name: Elie Saade
        orcid: null
      - name: Jaime H Noguez
        orcid: null
      - name: Christine Schmotzer
        orcid: http://orcid.org/0000-0002-7235-8728
  comment:
    dislikes: 0
    thread: "8626378702"
    numReports: 0
    likes: 0
    id: "5441418021"
    createdAt: 2021-07-02T14:30:43
    author:
      username: joepsotka
      about: ""
      name: Joe Psotka
      isPowerContributor: false
      profileUrl: https://disqus.com/by/joepsotka/
      url: ""
      location: ""
      id: "164427169"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: I don't understand why they do not report vaccination rates. Did no
      one participate in a  clinical trial?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.27.21259432v1
  tweets:
    - created_at: Sat Jul 03 18:23:52 +0000 2021
      id: 1411390247519326200
      id_str: "1411390247519326208"
      text: >-
        üí¨ medRxiv comment on "SARS-CoV-2 Seroprevalence amon..."


        "I don't understand why they do not report vaccination ra‚Ä¶ https://t.co/R9nOEtegnc
      truncated: true
      entities:
        urls:
          - url: https://t.co/R9nOEtegnc
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 03 18:23:52 +0000 2021
      id: 1411390248278450200
      id_str: "1411390248278450180"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oqgm8u0WjP
      truncated: false
      entities:
        urls:
          - url: https://t.co/oqgm8u0WjP
      in_reply_to_status_id: 1411390247519326200
      in_reply_to_status_id_str: "1411390247519326208"
- preprint:
    id: 148217
    metric: 67
    title: Optogenetic stimulation of medial amygdala GABA neurons with kinetically
      different channelrhodopsin variants yield opposite behavioral outcomes
    url: https://api.rxivist.org/v1/papers/148217
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.30.450543v1
    doi: 10.1101/2021.06.30.450543
    category: neuroscience
    first_posted: 2021-06-30
    abstract: Optogenetic manipulation of genetically-specified neuron populations
      has become a key tool in circuit neuroscience. The medial amygdala (MeA)
      receives pheromone information about conspecifics and has crucial
      functions in social behaviors; interestingly, this amygdalar structure
      contains a majority of GABAergic projection neurons. A previous study
      showed that optogenetic activation of MeA GABA neurons with
      channelrhodopsin-2H134R (ChR2) strongly enhanced inter-male aggression
      (Hong et al. 2014, Cell). When we attempted to reproduce these findings,
      accidentally using a faster channelrhodopsin variant
      (channelrhodopsin-2H134R,E123T or ChETA), we found the opposite results.
      We therefore systematically compared the behavioral outcome of optogenetic
      stimulation of MeApd GABA neurons with ChETA versus ChR2, employing two
      widely used AAV serotypes. This revealed that optogenetic stimulation with
      ChETA suppressed aggression, whereas optogenetic stimulation with ChR2
      increased aggression. Recordings of membrane potential changes following
      optogenetic stimulation with ChETA versus ChR2 revealed larger plateau
      depolarizations, smaller action potential amplitudes, and larger local
      inhibition of neighboring inhibitory neurons with ChR2 as compared to
      ChETA. Our study shows that channelrhodopsin variants have to be chosen
      with care for in-vivo optogenetic experiments. Furthermore, the role of
      MeApd GABA neurons in aggression control should be re-evaluated.
    authors:
      - name: Aiste Baleisyte
      - name: Ralf Schneggenburger
      - name: Olexiy Kochubey
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sat Jul 03 20:15:10 +0000 2021
      id: 1411418258650144800
      id_str: "1411418258650144773"
      text: >-
        üî• bioRxiv Neuroscience preprint by A. Baleisyte et al:


        "Optogenetic stimulation of medial amygdala GABA neurons wi‚Ä¶ https://t.co/e7m1yukvMh
      truncated: true
      entities:
        urls:
          - url: https://t.co/e7m1yukvMh
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 0
    id: "5441357232"
    createdAt: 2021-07-02T13:33:38
    author:
      username: disqus_RKEV1o6t01
      about: Activist against fake news, divisive rhetoric and propaganda.
      name: David
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_RKEV1o6t01/
      url: https://www.facebook.com/david.scheepers.58
      location: ""
      id: "46068584"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Actually, South Africa, where I reside, has an extremely high
      infection and death rate. More than rest of Africa... BUT this could be
      because SA probably has a significantly more accurate and sophisticated
      system for recording of COVID deaths and infections than other countries
      on the continent. Albeit that under the post 1994 ANC Government, our
      health system has been in  steady decline for last 27 years... and well
      below 1st world standards  like US, UK, and richer European countries.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sat Jul 03 20:18:46 +0000 2021
      id: 1411419163764068400
      id_str: "1411419163764068354"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Actually, South Africa, where I reside, has an extremely‚Ä¶ https://t.co/zANixs3KXY
      truncated: true
      entities:
        urls:
          - url: https://t.co/zANixs3KXY
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 03 20:18:46 +0000 2021
      id: 1411419164410056700
      id_str: "1411419164410056707"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1411419163764068400
      in_reply_to_status_id_str: "1411419163764068354"
- preprint:
    id: "148063"
    doi: 10.1101/2021.06.28.450217
    first_posted: 2021-06-30
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.28.450217v1
    url: https://api.rxivist.org/v1/papers/148063
    title: Genomic characterization of metastatic patterns from prospective clinical
      sequencing of 25,000 patients
    category: cancer-biology
    abstract: Progression to metastatic disease remains the main cause of cancer
      death. Yet, the underlying genomic mechanisms driving metastasis remain
      largely unknown. Here, we present MSK-MET, an integrated pan-cancer cohort
      of tumor genomic and clinical outcome data from more than 25,000 patients.
      We analyzed this dataset to identify associations between tumor genomic
      alterations and patterns of metastatic dissemination across 50 tumor
      types. We found that chromosomal instability is strongly correlated with
      metastatic burden in some tumor types, including prostate adenocarcinoma,
      lung adenocarcinoma and HR-positive breast ductal carcinoma, but not in
      others, such as colorectal adenocarcinoma, pancreatic adenocarcinoma and
      high-grade serous ovarian cancer. We also identified specific somatic
      alterations associated with increased metastatic burden and specific
      routes of metastatic spread. Our data offer a unique resource for the
      investigation of the biological basis for metastatic spread and highlight
      the crucial role of chromosomal instability in cancer progression.
    authors:
      - name: Bastien Nguyen
        orcid: http://orcid.org/0000-0002-6166-4746
      - name: Christopher Fong
        orcid: null
      - name: Anisha Luthra
        orcid: null
      - name: Shaleigh A. Smith
        orcid: null
      - name: Renzo G. DiNatale
        orcid: http://orcid.org/0000-0002-7867-2881
      - name: Subhiksha Nandakumar
        orcid: null
      - name: Henry Walch
        orcid: null
      - name: Walid K Chatila
        orcid: null
      - name: Ramyasree Madupuri
        orcid: null
      - name: Ritika Kundra
        orcid: null
      - name: Craig M. Bielski
        orcid: null
      - name: Brooke Mastrogiacomo
        orcid: null
      - name: Adrienne Boire
        orcid: http://orcid.org/0000-0002-9029-1248
      - name: Sarat Chandarlapaty
        orcid: http://orcid.org/0000-0003-4532-8053
      - name: Karuna Ganesh
        orcid: null
      - name: James J. Harding
        orcid: null
      - name: Christine A. Iacobuzio-Donahue
        orcid: http://orcid.org/0000-0002-4672-3023
      - name: Pedram Razavi
        orcid: null
      - name: Ed Reznik
        orcid: http://orcid.org/0000-0002-6511-5947
      - name: Charles M Rudin
        orcid: http://orcid.org/0000-0001-5204-3465
      - name: Dmitriy Zamarin
        orcid: http://orcid.org/0000-0002-0094-0161
      - name: Wassim Abida
        orcid: null
      - name: Ghassan K. Abou-Alfa
        orcid: null
      - name: Carol Aghajanian
        orcid: null
      - name: Andrea Cercek
        orcid: null
      - name: Ping Chi
        orcid: null
      - name: Darren Feldman
        orcid: null
      - name: Alan L Ho
        orcid: null
      - name: Gopakumar Iyer
        orcid: null
      - name: Yelena Y. Janjigian
        orcid: null
      - name: Michael Morris
        orcid: null
      - name: Robert J. Motzer
        orcid: null
      - name: Eileen M. O'Reilly
        orcid: null
      - name: Michael A. Postow
        orcid: null
      - name: Nitya P. Raj
        orcid: null
      - name: Gregory J Riely
        orcid: null
      - name: Mark E. Robson
        orcid: null
      - name: Jonathan E. Rosenberg
        orcid: null
      - name: Anton Safonov
        orcid: null
      - name: Alexander N. Shoushtari
        orcid: null
      - name: William Tap
        orcid: null
      - name: Min Yuen Teo
        orcid: null
      - name: Anna M. Varghese
        orcid: null
      - name: Martin Voss
        orcid: null
      - name: Rona Yaeger
        orcid: null
      - name: Marjorie G. Zauderer
        orcid: http://orcid.org/0000-0002-6109-5790
      - name: Nadeem Abu-Rustum
        orcid: null
      - name: Julio Garcia-Aguilar
        orcid: null
      - name: Bernard Bochner
        orcid: null
      - name: Abraham Hakimi
        orcid: null
      - name: William R. Jarnagin
        orcid: null
      - name: David R Jones
        orcid: null
      - name: Daniela Molena
        orcid: null
      - name: Luc Morris
        orcid: null
      - name: Eric Rios-Doria
        orcid: null
      - name: Paul Russo
        orcid: null
      - name: Samuel Singer
        orcid: null
      - name: Vivian E. Strong
        orcid: null
      - name: Debyani Chakravarty
        orcid: null
      - name: Lora H. Ellenson
        orcid: null
      - name: Anuradha Gopalan
        orcid: null
      - name: Jorge S Reis-Filho
        orcid: null
      - name: Britta Weigelt
        orcid: null
      - name: Marc Ladanyi
        orcid: http://orcid.org/0000-0001-9055-7213
      - name: Mithat Gonen
        orcid: null
      - name: Sohrab P. Shah
        orcid: http://orcid.org/0000-0001-6402-523X
      - name: Joan Massague
        orcid: null
      - name: Jianjiong Gao
        orcid: null
      - name: Ahmet Zehir
        orcid: null
      - name: Michael F. Berger
        orcid: null
      - name: David B Solit
        orcid: null
      - name: Samuel F. Bakhoum
        orcid: null
      - name: Francisco Sanchez-Vega
        orcid: null
      - name: Nikolaus Schultz
        orcid: null
  comment:
    dislikes: 0
    thread: "8623092665"
    numReports: 0
    likes: 0
    id: "5440724925"
    createdAt: 2021-07-01T21:46:01
    author:
      username: bastiennguyen
      about: ""
      name: Bastien Nguyen
      isPowerContributor: false
      profileUrl: https://disqus.com/by/bastiennguyen/
      url: ""
      location: ""
      id: "267706334"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Hello I√±igo, thanks a lot for your feedbacks and for reporting this error
      in the manuscript. You are correct; BRAF mutations are less frequent in
      thyroid papillary cancer patients with bone metastasis (76% vs 52%)
      (Figure 4 and table S8 are correct tho). Preprints are useful.

      Bastien
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.28.450217v1
  tweets:
    - created_at: Sat Jul 03 22:18:41 +0000 2021
      id: 1411449341328466000
      id_str: "1411449341328465923"
      text: >-
        üí¨ bioRxiv comment on "Genomic characterization of me..."


        "Hello I√±igo, thanks a lot for your feedbacks and for rep‚Ä¶ https://t.co/svI3YkRK2V
      truncated: true
      entities:
        urls:
          - url: https://t.co/svI3YkRK2V
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 03 22:18:41 +0000 2021
      id: 1411449342209183700
      id_str: "1411449342209183752"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/a2RC52fZNg
      truncated: false
      entities:
        urls:
          - url: https://t.co/a2RC52fZNg
      in_reply_to_status_id: 1411449341328466000
      in_reply_to_status_id_str: "1411449341328465923"
- preprint:
    id: "96647"
    doi: 10.1101/2020.10.08.329912
    first_posted: 2020-10-09
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.10.08.329912v1
    url: https://api.rxivist.org/v1/papers/96647
    title: "Transcranial Bipolar Direct Current Stimulation of the Frontoparietal
      Cortex Reduces Ketamine-Induced Oscillopathies: A Pilot Study in the
      Sedated Rat"
    category: neuroscience
    abstract: >-
      During the prodromal phase of schizophrenia with its complex and insidious
      clinical picture, electroencephalographic recordings detect widespread
      oscillation disturbances (or oscillopathies). Neural oscillations are
      electro-biomarkers of the connectivity state within systems. A single
      systemic administration of ketamine, a non-competitive NMDA glutamate
      receptor antagonist, transiently reproduces the oscillopathies with a
      clinical picture reminiscent of the psychosis prodrome. This acute
      pharmacological model may help the research and development of innovative
      treatments against the psychotic transition. Transcranial electrical
      stimulation is recognized as an appropriate non-invasive therapeutic
      modality since it can increase cognitive performance and modulate neural
      oscillations with little or no side effects. Therefore, our objective was
      to set up, in the sedated adult rat, a stimulation method able to
      normalize the ketamine-induced oscillopathies. Unilateral transcranial
      frontoparietal anodal stimulation by direct current (<+1 mA) was applied
      in ketamine-treated rats. A concomitant electroencephalographic recording
      of the parietal cortex measured the stimulation effects on its
      spontaneously-occurring oscillations. A 5-min bipolar anodal tDCS
      immediately and quickly reduced, significantly with an intensity-effect
      relationship, the ketamine-induced oscillopathies at least in the
      bilateral parietal cortex. A duration effect was also recorded. These
      preliminary neurophysiological findings are promising for developing a
      therapeutic proof-of-concept against neuropsychiatric disorders.


      ### Competing Interest Statement


      The authors have declared no competing interest.
    authors:
      - name: Caroline Lahogue
        orcid: null
      - name: Didier Pinault
        orcid: http://orcid.org/0000-0003-3807-4817
  comment:
    dislikes: 0
    thread: "8233193028"
    numReports: 0
    likes: 0
    id: "5442563091"
    createdAt: 2021-07-03T14:52:02
    author:
      name: Didier PINAULT
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      The authors thank the anonymous Transl Neurosci reviewers who positively
      assessed with constructive comments the manuscript.


      To better justify and understand the technical design and the statistical approaches, the authors added detailed arguments with new references in both the introduction and the methods. Also, to better clarify the course of the experiments, the repeated protocols/measures in one animal are now the object of a paragraph in the methods section.


      In this pilot study, the used strategy allowed the investigators to quickly move towards another stimulation protocol (a new combination of parameters), predicted effective based on the ongoing datasets, their knowledge, and expertise. As specified in the result section, the parametrization of the FP tDCS began according to an empirical and pragmatic approach. In any animal, it was possible to apply 2 to 3 stimulation protocols. Moreover, when the stimulation was not effective concerning the goal of the present study, there was no interest in pursuing further experiments on a greater number of animals. So, having in mind the 3R rule, the authors attempted to adjust the protocol and reduce the animal number. The present datasets remain ‚Äúpreliminary‚Äù as it was impossible to test, in a reasonable time, all the possible combinations (extraordinarily large number) of the stimulation parameters. As discussed, the authors cannot exclude having missed the best parameters.


      Why ketamine oscillopathies under pentobarbital sedation?

      Pinault‚Äôs laboratory demonstrated that the ketamine-induced gamma hyperactivity recorded in free-behaving rats could also be recorded in (urethane or pentobarbital) anesthetized rats (Hakami et al., 2009). Our multiple experiences with urethane anesthesia (Pinault and Pumain, 1989; Pinault and Deschenes, 1992; Hakami et al., 2009) led us to conclude that the quality of the recordings is not stable over time, preventing us from performing repeated measures. The pentobarbital is also well-known to induce delta-waves and sleep spindles (Connor et al., 2003; Ganes and Andersen, 1975; Pinault et al., 2006), and the pentobarbital preparation is stable and adjustable at will via an EEG-driven infusion rate of the sedative regimen. 

      The major requirement of the present study was to have the equivalent of a stationary stage II non-REM sleep, during which the authors could perform repeated measures using a minimal number of animals. Furthermore, under the present experimental conditions (pentobarbital-induced sedation), a single systemic administration of ketamine at a psychotomimetic dose (2.5 mg/kg, SC, estimated from a study conducted in free-behaving rats: Pinault, Biol Psychiatry, 2008) induces most of the oscillopathies (especially gamma hyperactivity and delta/spindle hypoactivity) recorded in patients having psychotic disorders. 

      One advantage of the pentobarbital-induced sedation - a maintained state electrophysiologically equivalent to stage II non-REM sleep - was its stability over time, allowing to assess the stimulation parameters under more than one condition; also, the repeated measures allowed to decrease the animal number (already discussed in the main text). 

      As a corollary, one major limitation is the dependence of tDCS on brain state (Li et al., Human Brain Mapp, 2019; Luft et al., Brain Stimulation, 2018). So, the tested parameters set under pentobarbital-induced sedation highlight the importance of considering the brain state when it comes to adjusting the stimulation parameters in any, experimental or clinical, studies. A paragraph was added at the end of the subsection ‚ÄúTechnical considerations‚Äù.


      One referee raised an interesting issue to be discussed, the possible relationship between the convulsive therapy of schizophrenia patients by electrical or magnetic stimulation of the frontal lobe. The authors were not convinced it is the heart of the matter in an experimental study focused on TES‚Ä¶ Electro-convulsive therapy is applied in patients with chronic, advanced schizophrenia and resistance to medication, including clozapine (e.g., see Sanghani et al., Curr Opin Psychiatry, 2018). In the present study, we used an acute model for psychosis transition, not for chronic schizophrenia. From a clinical point of view, TES (tDCS or tACS), not ECT, is expected to be applied in patients at a clinically high-risk mental state for transition to psychotic disorders (Rabanea-Souza et al, Trials, 2019). On the other hand, in the discussion, a paragraph was added to present a translational vision mentioning questions the authors thought relevant, regarding the potential clinical application of the tDCS in individuals having a clinically at-risk mental state for developing a psychosis transition while the ketamine model induces a brain state simulating that of patients transitioning to a psychotic state.

      DP, 02 July, 2021.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.10.08.329912v1
  tweets:
    - created_at: Sun Jul 04 01:03:06 +0000 2021
      id: 1411490719357882400
      id_str: "1411490719357882371"
      text: >-
        üí¨ bioRxiv comment on "Transcranial Bipolar Direct Cu..."


        "The authors thank the anonymous Transl Neurosci reviewer‚Ä¶ https://t.co/3K1MsEXJC2
      truncated: true
      entities:
        urls:
          - url: https://t.co/3K1MsEXJC2
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 04 01:03:06 +0000 2021
      id: 1411490720318361600
      id_str: "1411490720318361608"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/ajic2WLoPA
      truncated: false
      entities:
        urls:
          - url: https://t.co/ajic2WLoPA
      in_reply_to_status_id: 1411490719357882400
      in_reply_to_status_id_str: "1411490719357882371"
- preprint:
    id: "148063"
    doi: 10.1101/2021.06.28.450217
    first_posted: 2021-06-30
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.28.450217v1
    url: https://api.rxivist.org/v1/papers/148063
    title: Genomic characterization of metastatic patterns from prospective clinical
      sequencing of 25,000 patients
    category: cancer-biology
    abstract: Progression to metastatic disease remains the main cause of cancer
      death. Yet, the underlying genomic mechanisms driving metastasis remain
      largely unknown. Here, we present MSK-MET, an integrated pan-cancer cohort
      of tumor genomic and clinical outcome data from more than 25,000 patients.
      We analyzed this dataset to identify associations between tumor genomic
      alterations and patterns of metastatic dissemination across 50 tumor
      types. We found that chromosomal instability is strongly correlated with
      metastatic burden in some tumor types, including prostate adenocarcinoma,
      lung adenocarcinoma and HR-positive breast ductal carcinoma, but not in
      others, such as colorectal adenocarcinoma, pancreatic adenocarcinoma and
      high-grade serous ovarian cancer. We also identified specific somatic
      alterations associated with increased metastatic burden and specific
      routes of metastatic spread. Our data offer a unique resource for the
      investigation of the biological basis for metastatic spread and highlight
      the crucial role of chromosomal instability in cancer progression.
    authors:
      - name: Bastien Nguyen
        orcid: http://orcid.org/0000-0002-6166-4746
      - name: Christopher Fong
        orcid: null
      - name: Anisha Luthra
        orcid: null
      - name: Shaleigh A. Smith
        orcid: null
      - name: Renzo G. DiNatale
        orcid: http://orcid.org/0000-0002-7867-2881
      - name: Subhiksha Nandakumar
        orcid: null
      - name: Henry Walch
        orcid: null
      - name: Walid K Chatila
        orcid: null
      - name: Ramyasree Madupuri
        orcid: null
      - name: Ritika Kundra
        orcid: null
      - name: Craig M. Bielski
        orcid: null
      - name: Brooke Mastrogiacomo
        orcid: null
      - name: Adrienne Boire
        orcid: http://orcid.org/0000-0002-9029-1248
      - name: Sarat Chandarlapaty
        orcid: http://orcid.org/0000-0003-4532-8053
      - name: Karuna Ganesh
        orcid: null
      - name: James J. Harding
        orcid: null
      - name: Christine A. Iacobuzio-Donahue
        orcid: http://orcid.org/0000-0002-4672-3023
      - name: Pedram Razavi
        orcid: null
      - name: Ed Reznik
        orcid: http://orcid.org/0000-0002-6511-5947
      - name: Charles M Rudin
        orcid: http://orcid.org/0000-0001-5204-3465
      - name: Dmitriy Zamarin
        orcid: http://orcid.org/0000-0002-0094-0161
      - name: Wassim Abida
        orcid: null
      - name: Ghassan K. Abou-Alfa
        orcid: null
      - name: Carol Aghajanian
        orcid: null
      - name: Andrea Cercek
        orcid: null
      - name: Ping Chi
        orcid: null
      - name: Darren Feldman
        orcid: null
      - name: Alan L Ho
        orcid: null
      - name: Gopakumar Iyer
        orcid: null
      - name: Yelena Y. Janjigian
        orcid: null
      - name: Michael Morris
        orcid: null
      - name: Robert J. Motzer
        orcid: null
      - name: Eileen M. O'Reilly
        orcid: null
      - name: Michael A. Postow
        orcid: null
      - name: Nitya P. Raj
        orcid: null
      - name: Gregory J Riely
        orcid: null
      - name: Mark E. Robson
        orcid: null
      - name: Jonathan E. Rosenberg
        orcid: null
      - name: Anton Safonov
        orcid: null
      - name: Alexander N. Shoushtari
        orcid: null
      - name: William Tap
        orcid: null
      - name: Min Yuen Teo
        orcid: null
      - name: Anna M. Varghese
        orcid: null
      - name: Martin Voss
        orcid: null
      - name: Rona Yaeger
        orcid: null
      - name: Marjorie G. Zauderer
        orcid: http://orcid.org/0000-0002-6109-5790
      - name: Nadeem Abu-Rustum
        orcid: null
      - name: Julio Garcia-Aguilar
        orcid: null
      - name: Bernard Bochner
        orcid: null
      - name: Abraham Hakimi
        orcid: null
      - name: William R. Jarnagin
        orcid: null
      - name: David R Jones
        orcid: null
      - name: Daniela Molena
        orcid: null
      - name: Luc Morris
        orcid: null
      - name: Eric Rios-Doria
        orcid: null
      - name: Paul Russo
        orcid: null
      - name: Samuel Singer
        orcid: null
      - name: Vivian E. Strong
        orcid: null
      - name: Debyani Chakravarty
        orcid: null
      - name: Lora H. Ellenson
        orcid: null
      - name: Anuradha Gopalan
        orcid: null
      - name: Jorge S Reis-Filho
        orcid: null
      - name: Britta Weigelt
        orcid: null
      - name: Marc Ladanyi
        orcid: http://orcid.org/0000-0001-9055-7213
      - name: Mithat Gonen
        orcid: null
      - name: Sohrab P. Shah
        orcid: http://orcid.org/0000-0001-6402-523X
      - name: Joan Massague
        orcid: null
      - name: Jianjiong Gao
        orcid: null
      - name: Ahmet Zehir
        orcid: null
      - name: Michael F. Berger
        orcid: null
      - name: David B Solit
        orcid: null
      - name: Samuel F. Bakhoum
        orcid: null
      - name: Francisco Sanchez-Vega
        orcid: null
      - name: Nikolaus Schultz
        orcid: null
  comment:
    dislikes: 0
    thread: "8623092665"
    numReports: 0
    likes: 0
    id: "5442526160"
    createdAt: 2021-07-03T14:11:35
    author:
      username: gheorgheemilianolteanu
      about: Pathologist, sci-fi addict.
      name: Gheorghe-Emilian Olteanu
      isPowerContributor: false
      profileUrl: https://disqus.com/by/gheorgheemilianolteanu/
      url: https://www.researchgate.net/profile/Olteanu_Gheorghe-Emilian
      location: Romania
      id: "355320913"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Incredible work! So much data. I would love to see an accompaning
      histopathological publication of the 25,000 patients. With primary and
      metastatic WSI analysis.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.28.450217v1
  tweets:
    - created_at: Sun Jul 04 12:30:00 +0000 2021
      id: 1411663585508565000
      id_str: "1411663585508564994"
      text: >-
        üí¨ bioRxiv comment on "Genomic characterization of me..."


        "Incredible work! So much data. I would love to see an ac‚Ä¶ https://t.co/LuqngTjtuc
      truncated: true
      entities:
        urls:
          - url: https://t.co/LuqngTjtuc
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 04 12:30:01 +0000 2021
      id: 1411663586305454000
      id_str: "1411663586305454081"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/a2RC52fZNg
      truncated: false
      entities:
        urls:
          - url: https://t.co/a2RC52fZNg
      in_reply_to_status_id: 1411663585508565000
      in_reply_to_status_id_str: "1411663585508564994"
- preprint:
    id: "119654"
    doi: 10.1101/2020.11.30.403345
    first_posted: 2020-12-01
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.11.30.403345v1
    url: https://api.rxivist.org/v1/papers/119654
    title: On the permeability of cell membranes subjected to lipid oxidation
    category: biophysics
    abstract: >-
      The formation of transient hydrophilic pores in their membranes is a
      well-recognized mechanism of permeabilization of cells exposed to
      high-intensity electric pulses. However, the formation of such pores alone
      is not able to explain all aspects of the so-called electroporation
      phenomenon. In particular, the reasons for the sustained permeability of
      cell membranes, which persist long after the pulses application, remain
      elusive. The complete resealing of the cell membranes takes indeed orders
      of magnitude longer than the time of electropore closure as reported from
      molecular modelling investigations. A possible alternative mechanism to
      explain the observed long-lived permeability of cell membranes, lipid
      peroxidation, has been previously suggested but the theoretical
      investigations of membrane lesions, containing excess amounts of
      hydroperoxides, have shown that the conductivities of such lesions were
      not high enough to reasonably explain the entire range of experimental
      measurements. Here, we expand on these studies and investigate the
      permeability of cell membrane lesions that underwent secondary oxidation.
      Molecular dynamics simulations and free energy calculations on lipid
      bilayers in different states show that such lesions provide a better model
      for post-pulsed permeable and conductive electropermeabilized cells. These
      results are further discussed in context of sonoporation and ferroptosis,
      respectively a procedure and a phenomena, among others, in which alike
      electroporation substantial lipid oxidation might be triggered.


      HighlightsO_LIThe contribution of secondary lipids oxidation to the permeabilization of model membranes is quantitatively assessed

      C_LIO_LISmall patches of secondary lipids oxidation cause formation long-lived pores in lipid bilayers.

      C_LIO_LIThe cholesterol content of membranes enhances the life-time of the formed pores.

      C_LIO_LIA single pore accounts for the measured post-pulse electropermeabilization of cells.

      C_LIO_LIThe diffusion of the secondary oxidation lipids, even after pores closure leads to permeability of lipid membrane.

      C_LI
    authors:
      - name: Daniel Wiczew
        orcid: http://orcid.org/0000-0001-8910-6116
      - name: Natalia Szulc
        orcid: null
      - name: Mounir Tarek
        orcid: http://orcid.org/0000-0002-9451-3215
  comment:
    dislikes: 0
    thread: "8328385521"
    numReports: 0
    likes: 0
    id: "5442299686"
    createdAt: 2021-07-03T07:48:45
    author:
      username: danielwiczew
      about: ""
      name: danielwiczew
      isPowerContributor: false
      profileUrl: https://disqus.com/by/danielwiczew/
      url: ""
      location: ""
      id: "371809072"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: |-
      Here is the accepted version


      https://www.sciencedirect.com/science/article/abs/pii/S1567539421001328
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.11.30.403345v2
  tweets:
    - created_at: Sun Jul 04 14:17:05 +0000 2021
      id: 1411690532145881000
      id_str: "1411690532145881092"
      text: |-
        üí¨ bioRxiv comment on "On the permeability of cell me..."

        "Here is the accepted version

        "

        https://t.co/QSHfmfJs04
      truncated: false
      entities:
        urls:
          - url: https://t.co/QSHfmfJs04
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 04 14:17:05 +0000 2021
      id: 1411690532934389800
      id_str: "1411690532934389764"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/FHA6htfoRm
      truncated: false
      entities:
        urls:
          - url: https://t.co/FHA6htfoRm
      in_reply_to_status_id: 1411690532145881000
      in_reply_to_status_id_str: "1411690532145881092"
- preprint:
    id: "51056"
    doi: 10.1101/641118
    first_posted: 2019-05-18
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/641118v1
    url: https://api.rxivist.org/v1/papers/51056
    title: The maternal-fetal interface of successful pregnancies and impact of
      fetal sex using single cell sequencing
    category: developmental-biology
    abstract: The first trimester is a critical window of maternal-fetal
      communication for pregnancy. Therefore, we characterized crosstalk in
      ongoing human pregnancies at 11-13 weeks gestation. RNA-sequencing of
      matched maternal decidua and placenta identified 818 receptors and 3502
      ligands, including 126 differentially expressed receptor-ligand pairs.
      Using single cell RNA-sequencing to further dissect placenta
      heterogeneity, we identified five major cell types (trophoblasts, stromal
      cells, hofbauer cells, antigen presenting cells and endothelial cells)
      with unique crosstalk at the maternal-fetal interface. We identified seven
      unique trophoblast subclusters, including new subtypes that transition
      into the terminal cell types, extra-villous trophoblasts and
      syncytiotrophoblasts. As fetal sex impacts pregnancy, we analyzed sex
      differences in each cell type and identified differences in immune cell
      function. TGFŒ≤1, Œ≤-estradiol, and dihydrotestosterone emerge as upstream
      regulators of sexually dimorphic genes in a cell type specific manner.
      Thus, the fetal contribution at the maternal-fetal interface is cell and
      sex specific.
    authors:
      - name: Tianyanxin Sun
        orcid: http://orcid.org/0000-0001-6411-5972
      - name: Tania L Gonzalez
        orcid: http://orcid.org/0000-0003-3825-8544
      - name: Nan Deng
        orcid: http://orcid.org/0000-0003-0914-7220
      - name: Rosemarie DiPentino
        orcid: http://orcid.org/0000-0003-4409-3264
      - name: Ekaterina L Clark
        orcid: http://orcid.org/0000-0003-3050-590X
      - name: Bora Lee
        orcid: null
      - name: Jie Tang
        orcid: http://orcid.org/0000-0002-3991-2539
      - name: Yizhou Wang
        orcid: null
      - name: Barry R Stripp
        orcid: http://orcid.org/0000-0003-4348-2137
      - name: Changfu Yao
        orcid: http://orcid.org/0000-0003-1357-5017
      - name: Hsian-Rong Tseng
        orcid: http://orcid.org/0000-0003-0942-5905
      - name: S. Ananth Karumanchi
        orcid: http://orcid.org/0000-0002-2281-6831
      - name: Alexander F. Koeppel
        orcid: http://orcid.org/0000-0002-2256-2659
      - name: Stephen D Turner
        orcid: http://orcid.org/0000-0001-9140-9028
      - name: Charles Farber
        orcid: http://orcid.org/0000-0002-6748-4711
      - name: Stephen S Rich
        orcid: http://orcid.org/0000-0003-3872-7793
      - name: Erica T Wang
        orcid: null
      - name: John Williams
        orcid: null
      - name: Margareta D. Pisarska
        orcid: http://orcid.org/0000-0003-1096-6506
  comment:
    dislikes: 0
    thread: "7426190486"
    numReports: 0
    likes: 0
    id: "5441503038"
    createdAt: 2021-07-02T15:44:56
    author:
      username: ScienceTania
      about: ""
      name: Tania Gonzalez
      isPowerContributor: false
      profileUrl: https://disqus.com/by/ScienceTania/
      url: https://twitter.com/ScienceTania
      location: ""
      id: "371750295"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "The peer-reviewed version (PMCID: PMC7571453) was published in
      JCEM, see: https://doi.org/10.1210/clinem/dgaa503 and data was deposited
      in NCBI GEO with accessions GSE131696 (single cell RNA-seq data of 6
      placenta) and GSE131874 (bulk RNA-seq of matched placenta and maternal
      decidua samples from 4 patients). Find me on ResearchGate if you need
      anything else!"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/641118v1
  tweets:
    - created_at: Sun Jul 04 16:29:59 +0000 2021
      id: 1411723977614004200
      id_str: "1411723977614004227"
      text: >-
        üí¨ bioRxiv comment on "The maternal-fetal interface o..."


        "The peer-reviewed version (PMCID: PMC7571453) was publis‚Ä¶ https://t.co/VSJAOJe7l2
      truncated: true
      entities:
        urls:
          - url: https://t.co/VSJAOJe7l2
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 04 16:29:59 +0000 2021
      id: 1411723978603860000
      id_str: "1411723978603859975"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/97wPzqOGIO
      truncated: false
      entities:
        urls:
          - url: https://t.co/97wPzqOGIO
      in_reply_to_status_id: 1411723977614004200
      in_reply_to_status_id_str: "1411723977614004227"
- preprint:
    id: "142247"
    doi: 10.1101/2021.05.16.21257255
    first_posted: 2021-05-18
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.16.21257255v1
    url: https://api.rxivist.org/v1/papers/142247
    title: "Long-term symptoms after SARS-CoV-2 infection in school children:
      population-based cohort with 6-months follow-up. Short Report"
    category: epidemiology
    abstract: Although nobody doubts the existence of long COVID in children, it is
      still unclear to what extent children are affected. The Ciao Corona study
      is a longitudinal cohort investigating SARS-CoV-2 seroprevalence and
      clustering of cases among around 2500 children from 55 randomly selected
      primary and secondary schools in the canton of Zurich in Switzerland.
      Between June 2020 and April 2021, we completed three testing phases where
      we collected venous blood for serological analysis (ABCORA 2.0 test) and
      asked about symptoms with online questionnaires. We compared children who
      tested positive for SARS-CoV-2 antibodies in October/November 2020 with
      those who tested negative. Children who were seronegative in
      October/November 2020 and seroconverted or were not retested by
      March/April 2021 were excluded from the analysis (n=256). In March-May
      2021 we assessed the presence of symptoms occurring since October 2020,
      lasting for at least 4 weeks, and persisting for either >4 weeks or >12
      weeks. Overall, 1355 of 2503 children with a serology result in
      October/November 2020 and follow up questionnaire in March/April 2021 were
      included. Among seropositive and seronegative 6-to 16-year-old children
      and adolescents, 9% versus 10% reported at least one symptom beyond 4
      weeks, and 4% versus 2% at least one symptom beyond 12 weeks. None of the
      seropositive children reported hospitalization after October 2020.
      Seropositive children, all with a history of pauci-symptomatic SARS-CoV-2
      infection, did not report long COVID more frequently than seronegative
      children. This study suggests a very low prevalence of long COVID in a
      randomly selected population-based cohort of children followed over 6
      months after serological testing.
    authors:
      - name: Thomas Radtke
        orcid: http://orcid.org/0000-0001-6964-6545
      - name: Agne Ulyte
        orcid: http://orcid.org/0000-0001-7419-9778
      - name: Milo Alan Puhan
        orcid: http://orcid.org/0000-0003-4721-1879
      - name: Susi Kriemler
        orcid: http://orcid.org/0000-0002-3384-7940
  comment:
    dislikes: 0
    thread: "8539600665"
    numReports: 0
    likes: 0
    id: "5443637457"
    createdAt: 2021-07-04T15:46:32
    author:
      username: disqus_O4mKnmFJzF
      about: ""
      name: AF
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_O4mKnmFJzF/
      url: ""
      location: ""
      id: "371669853"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: The authors fail to describe the online questionnaire - did it
      restrict the set of symptoms that were able to be reported? Did it allow
      entry of non-predefined symptoms? Did it include a severity scale for each
      reported symptom? The precise questioning schema might have a very
      significant effect on the results which seem obviously in contradiction to
      e.g. UK ONS data.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.16.21257255v2
  tweets:
    - created_at: Sun Jul 04 18:23:46 +0000 2021
      id: 1411752611263438800
      id_str: "1411752611263438852"
      text: >-
        üí¨ medRxiv comment on "Long-term symptoms after SARS-..."


        "The authors fail to describe the online questionnaire -‚Ä¶ https://t.co/5nosZswBWk
      truncated: true
      entities:
        urls:
          - url: https://t.co/5nosZswBWk
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 04 18:23:46 +0000 2021
      id: 1411752612114878500
      id_str: "1411752612114878467"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/XPbzC5oGk2
      truncated: false
      entities:
        urls:
          - url: https://t.co/XPbzC5oGk2
      in_reply_to_status_id: 1411752611263438800
      in_reply_to_status_id_str: "1411752611263438852"
- preprint:
    id: 148509
    metric: 227
    title: Neutralization of Delta variant with sera of Covishield vaccinees and
      COVID-19 recovered vaccinated individuals
    url: https://api.rxivist.org/v1/papers/148509
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.01.450676v1
    doi: 10.1101/2021.07.01.450676
    category: microbiology
    first_posted: 2021-07-02
    abstract: "The recent emergence of B.1.617 lineage has created grave public
      health problem in India. The lineage further mutated to generate
      sub-lineages B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.617.3. Apparently,
      the Delta variant has slowly dominated the other variants including
      B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.617.3. With this, World Health
      Organization has described this sub-lineage as variant of concern. The
      high transmissibility associated with Delta variant has led to second wave
      of pandemic in India which affected millions of people. Besides this,
      variant of concerns has been reported to show lower neutralization to
      several approved vaccines. This has led to breakthrough infections after
      completion of vaccination regimen. There is limited information available
      on the duration of protective immune response post-infection, vaccination
      or breakthrough infection with SARS-CoV-2. In this study, we have
      evaluated immune response in sera of the Covishield vaccinated individuals
      belonging to category: I. one dose vaccinated, II. two doses vaccinated,
      III. COVID-19 recovered plus one dose vaccinated, IV. COVID-19 recovered
      plus two doses vaccinated and V. breakthrough COVID-19 cases. The findings
      of the study demonstrated that the breakthrough cases and the COVID-19
      recovered individuals with one or two dose of vaccine had relatively
      higher protection against Delta variant in comparison to the participants
      who were administered either one or two doses of Covishield. Prior
      vaccination results in less severe disease against subsequent infection
      provide evidence that both humoral and cellular immune response play an
      important role in protection."
    authors:
      - name: Gajanan Sapkal
      - name: Pragya D Yadav
      - name: Rima R Sahay
      - name: Gururaj Deshpande
      - name: Nivedita Gupta
      - name: Dimpal A Nyayanit
      - name: Deepak Y Patil
      - name: Sanjay Kumar
      - name: Priya Abraham
      - name: Samiran Panda
      - name: Balram Bhargava
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sun Jul 04 20:15:13 +0000 2021
      id: 1411780661543854000
      id_str: "1411780661543854087"
      text: >-
        üî• bioRxiv Microbiology preprint by G. Sapkal et al:


        "Neutralization of Delta variant with sera of Covishield vacci‚Ä¶ https://t.co/jX7Ork7acZ
      truncated: true
      entities:
        urls:
          - url: https://t.co/jX7Ork7acZ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "134781"
    doi: 10.1101/2021.03.23.21251968
    first_posted: 2021-03-24
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.03.23.21251968v1
    url: https://api.rxivist.org/v1/papers/134781
    title: Broad decline and subsequent differential re-emergence of respiratory
      viruses during COVID-19 pandemic response measures, Singapore 2020
    category: infectious-diseases
    abstract: Importance. COVID-19 pandemic control measures affect the prevalence
      of other respiratory viruses. Effects on some viruses have been described;
      however, the broader impact and temporal relationship of control measures
      on virus decline and subsequent re-emergence have not been thoroughly
      documented. Understanding these phenomena may influence health policies.
      Objective. To examine the prevalence of unrelated respiratory viruses in
      relation to population-wide pandemic response measures and phases in 2020
      in Singapore. Design, Setting, and Participants. Data from respiratory
      multiplex PCRs from 3 major hospitals (total 3700 beds) in Singapore were
      collated. The full dataset consisted of 42,558 test results, 19,898 from
      2019 and 22,660 from 2020. Main Outcomes and Measures. Weekly virus
      prevalence data were mapped onto prevailing pandemic response measures, in
      order to elucidate temporal relationships and differential virus
      responses. Pre-pandemic data from 2019 were compared with data from 2020.
      Results. Early response measures, even before national lockdown, were
      followed by a dramatic reduction of influenza viruses and a more gradual
      decline of other respiratory viruses, including respiratory syncytial
      virus, parainfluenza viruses, endemic coronaviruses and metapneumovirus.
      Marked decline of enterovirus/rhinovirus and adenovirus, however, was only
      observed during lockdown. About 13 weeks into phased reopening,
      enterovirus/rhinovirus re-emerged, followed by adenovirus, the latter
      mainly in the pediatric population. All other viruses remained at low
      levels until the end of 2020. Conclusions and Relevance. COVID-19 control
      measures in Singapore had a significant impact on a broad range of
      respiratory viruses. Effects of various control measures varied between
      phases and different viruses. Influenza viruses declined earliest and most
      dramatically; relaxation of measures was followed by re-emergence of
      enterovirus/rhinovirus and adenovirus. These patterns are presumably a
      result of different propensities for contact versus droplet and overall
      ease of transmission, and different virus reservoirs. Further studies into
      these phenomena are a matter of public health importance.
    authors:
      - name: Wei Yee Wan
        orcid: http://orcid.org/0000-0002-7426-3167
      - name: Koh Cheng Thoon
        orcid: http://orcid.org/0000-0002-2844-010X
      - name: Liat Hui Loo
        orcid: http://orcid.org/0000-0003-2747-9544
      - name: Kian Sing Chan
        orcid: http://orcid.org/0000-0003-1941-779X
      - name: Lynette L. E. Oon
        orcid: http://orcid.org/0000-0002-0721-1551
      - name: Adaikalavan Ramasamy
        orcid: http://orcid.org/0000-0002-7598-2892
      - name: Matthias Maiwald
        orcid: http://orcid.org/0000-0001-5448-8417
  comment:
    dislikes: 0
    thread: "8450231152"
    numReports: 0
    likes: 0
    id: "5443508685"
    createdAt: 2021-07-04T13:24:54
    author:
      username: matthiasmaiwald
      about: ""
      name: Matthias Maiwald
      isPowerContributor: false
      profileUrl: https://disqus.com/by/matthiasmaiwald/
      url: ""
      location: ""
      id: "331888014"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Our article has now appeared here: 

      Wan WY, Thoon KC, Loo LH, Chan KS, Oon LLE, Ramasamy A, Maiwald M. Trends in Respiratory Virus Infections During the COVID-19 Pandemic in Singapore, 2020. JAMA Netw Open. 2021 Jun 1;4(6):e2115973. doi: 10.1001/jamanetworkopen.2021.15973. 

      https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2781461
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.03.23.21251968v1
  tweets:
    - created_at: Sun Jul 04 20:18:39 +0000 2021
      id: 1411781522730979300
      id_str: "1411781522730979328"
      text: |-
        üí¨ medRxiv comment on "Broad decline and subsequent d..."

        "Our article has now appeared here: 
        Wan WY, Thoon KC, Lo‚Ä¶ https://t.co/H66SysHkNm
      truncated: true
      entities:
        urls:
          - url: https://t.co/H66SysHkNm
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 04 20:18:39 +0000 2021
      id: 1411781523595055000
      id_str: "1411781523595055111"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/0nGtu8iqbJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/0nGtu8iqbJ
      in_reply_to_status_id: 1411781522730979300
      in_reply_to_status_id_str: "1411781522730979328"
- preprint:
    id: "127169"
    doi: 10.1101/2021.01.27.21250604
    first_posted: 2021-01-29
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.01.27.21250604v1
    url: https://api.rxivist.org/v1/papers/127169
    title: "The World Mortality Dataset: Tracking excess mortality across countries
      during the COVID-19 pandemic"
    category: epidemiology
    abstract: Comparing the impact of the COVID-19 pandemic between countries or
      across time is difficult because the reported numbers of cases and deaths
      can be strongly affected by testing capacity and reporting policy. Excess
      mortality, defined as the increase in all-cause mortality relative to the
      recent average, is widely considered as a more objective indicator of the
      COVID-19 death toll. However, there has been no central,
      frequently-updated repository of the all-cause mortality data across
      countries. To fill this gap, we have collected weekly, monthly, or
      quarterly all-cause mortality data from 77 countries, openly available as
      the regularly-updated World Mortality Dataset. We used this dataset to
      compute the excess mortality in each country during the COVID-19 pandemic.
      We found that in the worst-affected countries the annual mortality
      increased by over 50%, while in several other countries it decreased by
      over 5%, presumably due to lockdown measures decreasing the non-COVID
      mortality. Moreover, we found that while some countries have been
      reporting the COVID-19 deaths very accurately, many countries have been
      underreporting their COVID-19 deaths by an order of magnitude or more.
      Averaging across the entire dataset suggests that the world's COVID-19
      death toll may be at least 1.6 times higher than the reported number of
      confirmed deaths.
    authors:
      - name: Ariel Karlinsky
        orcid: null
      - name: Dmitry Kobak
        orcid: http://orcid.org/0000-0002-5639-7209
  comment:
    dislikes: 0
    thread: "8573176341"
    numReports: 0
    likes: 0
    id: "5443499963"
    createdAt: 2021-07-04T13:13:09
    author:
      username: sebastian_rosemann
      about: ""
      name: Sebastian Rosemann
      isPowerContributor: false
      profileUrl: https://disqus.com/by/sebastian_rosemann/
      url: ""
      location: ""
      id: "351110721"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Dear authors,


      you write: "For each country we predicted the ‚Äòbaseline‚Äô mortality in 2020 based on the 2015‚Äì2019 data (accounting for linear trend and seasonal variation; see Methods). We then obtained excess mortality as the difference between the actual 2020 and 2021 all-cause mortality and our baseline. For each country we computed the total excess mortality from the beginning of the COVID-19 pandemic (from March 2020) (Figure 2, Table 1)"


      For Germany Table 1 shows 36.000 excess deaths, which makes up 4% increase, suggesting a baseline of 900.000 for March 2020 - Mai 23th 2021.

      According to destatis

      https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Bevoelkerung/Sterbefaelle-Lebenserwartung/Tabellen/sonderauswertung-sterbefaelle.html

      the yearly number of deaths for 2015-2019 in Germany was always above 900.000.

      How can your baseline for a timespan of ~14 month be lower than the actual number of deaths for 12 months within the last years?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.01.27.21250604v3
  tweets:
    - created_at: Sun Jul 04 22:19:03 +0000 2021
      id: 1411811823226167300
      id_str: "1411811823226167298"
      text: |-
        üí¨ medRxiv comment on "The World Mortality Dataset: T..."

        "Dear authors,

        you write: "For each country we predicted‚Ä¶ https://t.co/jWYB9TJpmk
      truncated: true
      entities:
        urls:
          - url: https://t.co/jWYB9TJpmk
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 04 22:19:03 +0000 2021
      id: 1411811824173977600
      id_str: "1411811824173977612"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/SYOosLmQld
      truncated: false
      entities:
        urls:
          - url: https://t.co/SYOosLmQld
      in_reply_to_status_id: 1411811823226167300
      in_reply_to_status_id_str: "1411811823226167298"
- preprint:
    id: "141912"
    doi: 10.1101/2021.05.15.21257017
    first_posted: 2021-05-17
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.15.21257017v1
    url: https://api.rxivist.org/v1/papers/141912
    title: Extended interval BNT162b2 vaccination enhances peak antibody generation
      in older people
    category: infectious-diseases
    abstract: "Abstract Objectives: To assess the relative immunogenicity of
      standard or extended interval BNT162b2 vaccination. Design: Population
      based cohort study comparing immune responses 2 weeks after the second
      vaccine, with appropriate time-matched samples in participants who
      received standard or extended interval double vaccination. Setting:
      Primary care networks, Birmingham, UK. December 2020 to April 2021.
      Participants: 175 people aged over 80 years of age. All donors received
      the BNT162b2 Pfizer/BioNTech vaccination and were vaccinated with either a
      standard 3 week interval between doses or an extended interval schedule.
      Main outcome measures: Peak quantitative spike-specific antibody and
      cellular immune responses. Results: In donors without evidence of previous
      infection the peak antibody response was 3.5-fold higher in donors who had
      undergone delayed interval vaccination. Cellular immune responses were
      3.6-fold lower. Conclusion: Peak antibody responses after the second
      BNT162b2 vaccine are markedly enhanced in older people when this is
      delayed to 12 weeks although cellular responses are lower. Extended
      interval vaccination may therefore offer the potential to enhance and
      extend humoral immunity. Further follow up is now required to assess long
      term immunity and clinical protection."
    authors:
      - name: Helen M Parry
        orcid: http://orcid.org/0000-0002-9707-8167
      - name: Rachel Bruton
        orcid: null
      - name: Christine Stephens
        orcid: null
      - name: Kevin Brown
        orcid: null
      - name: Gayatri Amirthalingam
        orcid: http://orcid.org/0000-0003-2078-0975
      - name: Bassam Hallis
        orcid: http://orcid.org/0000-0002-8461-0038
      - name: Ashley Otter
        orcid: null
      - name: Jianmin Zuo
        orcid: http://orcid.org/0000-0002-8341-465X
      - name: Paul Moss
        orcid: null
  comment:
    dislikes: 0
    thread: "8524358522"
    numReports: 0
    likes: 0
    id: "5443349031"
    createdAt: 2021-07-04T08:41:03
    author:
      username: dai_hendrix
      about: ""
      name: DainHendrix
      isPowerContributor: false
      profileUrl: https://disqus.com/by/dai_hendrix/
      url: ""
      location: ""
      id: "371853765"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      The JVCI seem to be using this paper as the sole source for justifying an
      8-week gap for Pfizer in younger cohorts, despite the fact that the sample
      for this paper is 172 people aged 80 or over. Not by any stretch a fair
      representation of the population. It would be hard to argue that it is
      even possible to get a fair representation of genders, ages and
      ethnicities with a sample of 172 alone. 


      With this is mind, what response do the authors give to the fact that this paper is being used to justify the current 8-week policy for second doses of Pfizer and Moderna when this paper does not make any attempt to back up that justification for younger cohorts, especially when the manufacturer and WHO recommend a 21-28 day gap between doses?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.15.21257017v1
  tweets:
    - created_at: Mon Jul 05 01:00:42 +0000 2021
      id: 1411852505743569000
      id_str: "1411852505743568905"
      text: >-
        üí¨ medRxiv comment on "Extended interval BNT162b2 vac..."


        "The JVCI seem to be using this paper as the sole source‚Ä¶ https://t.co/2rxLfa70Ig
      truncated: true
      entities:
        urls:
          - url: https://t.co/2rxLfa70Ig
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 05 01:00:43 +0000 2021
      id: 1411852506490101800
      id_str: "1411852506490101764"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/x0AIV3f5Lu
      truncated: false
      entities:
        urls:
          - url: https://t.co/x0AIV3f5Lu
      in_reply_to_status_id: 1411852505743569000
      in_reply_to_status_id_str: "1411852505743568905"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5439626429"
    createdAt: 2021-07-01T02:43:16
    author:
      username: killshot
      about: ""
      name: killshot
      isPowerContributor: false
      profileUrl: https://disqus.com/by/killshot/
      url: ""
      location: ""
      id: "2384202"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      No mention of vitamin D levels here. A vitamin D level above 50 ng/ML
      reduces mortality by 900% and significant morbidity requiring
      hospitalization by 300%. Masks have never been shown to do any of this.
      The fact is, masks were nothing more than virtue signaling and really
      didn't do very much at all. You failed to mention previous studies on
      influenza where it was proven that masks a little difference. Plus, you
      conveniently avoid the downside of masks. Remember "risk versus benefit",
      no? To wit:


      "Prolonged mask use (>4 hours per day) promotes facial alkalinization and inadvertently encourages dehydration, which in turn can enhance barrier breakdown and bacterial infection risk. British clinicians have reported masks to increase headaches and sweating and decrease cognitive precision. Survey bias notwithstanding, these sequelae are associated with medical errors. By obscuring nonverbal communication, masks interfere with social learning in children. Likewise, masks can distort verbal speech and remove visual cues to the detriment of individuals with hearing loss; clear face-shields improve visual integration, but there is a corresponding loss of sound quality."


      Please look at the ridiculous downside of wearing the silly things that do nothing for protection. If you want me to pull up all the references, I will. But it is tiresome. Please do your own research. Masks are silly and did absolutely nothing for transmission.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon Jul 05 12:31:47 +0000 2021
      id: 1412026421069987800
      id_str: "1412026421069987841"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "No mention of vitamin D levels here. A vitamin D level a‚Ä¶ https://t.co/OsYAchgggm
      truncated: true
      entities:
        urls:
          - url: https://t.co/OsYAchgggm
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 05 12:31:47 +0000 2021
      id: 1412026421778780200
      id_str: "1412026421778780168"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1412026421069987800
      in_reply_to_status_id_str: "1412026421069987841"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 0
    id: "5443093618"
    createdAt: 2021-07-04T00:42:24
    author:
      username: rusbowden
      about: ""
      name: rusbowden
      isPowerContributor: false
      profileUrl: https://disqus.com/by/rusbowden/
      url: ""
      location: ""
      id: "10245173"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      I pulled up a bunch of studies that showed how masks work and posted them
      earlier, none of them called masks silly. You did nothing to address
      either them or what I just write, so why would I care what your sources
      are. You ae not rigorous enough. 


      I should point out that those of us who wear masks, change them, throwing away the disposable ones, and washing the others. If "prolonged mask use" is what you've been afraid of, you can change them.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon Jul 05 14:22:29 +0000 2021
      id: 1412054279574020000
      id_str: "1412054279574020097"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "I pulled up a bunch of studies that showed how masks wor‚Ä¶ https://t.co/JMPVrMxkez
      truncated: true
      entities:
        urls:
          - url: https://t.co/JMPVrMxkez
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 05 14:22:29 +0000 2021
      id: 1412054280496840700
      id_str: "1412054280496840710"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU30MFJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU30MFJ
      in_reply_to_status_id: 1412054279574020000
      in_reply_to_status_id_str: "1412054279574020097"
- preprint:
    id: "142748"
    doi: 10.1101/2021.05.21.445091
    first_posted: 2021-05-21
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.21.445091v1
    url: https://api.rxivist.org/v1/papers/142748
    title: Identification of a novel lineage bat SARS-related coronaviruses that use
      bat ACE2 receptor
    category: microbiology
    abstract: Severe respiratory disease coronavirus-2 (SARS-CoV-2) causes the most
      devastating disease, COVID-19, of the recent century. One of the unsolved
      scientific questions around SARS-CoV-2 is the animal origin of this virus.
      Bats and pangolins are recognized as the most probable reservoir hosts
      that harbor the highly similar SARS-CoV-2 related viruses (SARSr-CoV-2).
      Here, we report the identification of a novel lineage of SARSr-CoVs,
      including RaTG15 and seven other viruses, from bats at the same location
      where we found RaTG13 in 2015. Although RaTG15 and the related viruses
      share 97.2% amino acid sequence identities to SARS-CoV-2 in the conserved
      ORF1b region, but only show less than 77.6% to all known SARSr-CoVs in
      genome level, thus forms a distinct lineage in the Sarbecovirus
      phylogenetic tree. We then found that RaTG15 receptor binding domain (RBD)
      can bind to and use Rhinolophus affinis bat ACE2 (RaACE2) but not human
      ACE2 as entry receptor, although which contains a short deletion and has
      different key residues responsible for ACE2 binding. In addition, we show
      that none of the known viruses in bat SARSr-CoV-2 lineage or the novel
      lineage discovered so far use human ACE2 efficiently compared to
      SARSr-CoV-2 from pangolin or some of the SARSr-CoV-1 lineage viruses.
      Collectively, we suggest more systematic and longitudinal work in bats to
      prevent future spillover events caused by SARSr-CoVs or to better
      understand the origin of SARS-CoV-2.
    authors:
      - name: Hua Guo
        orcid: null
      - name: Ben Hu
        orcid: null
      - name: Hao-rui Si
        orcid: null
      - name: Yan Zhu
        orcid: http://orcid.org/0000-0003-1105-6491
      - name: Wei Zhang
        orcid: http://orcid.org/0000-0001-6428-2033
      - name: Bei Li
        orcid: null
      - name: Ang Li
        orcid: http://orcid.org/0000-0002-1186-3448
      - name: Rong Geng
        orcid: null
      - name: Hao-Feng Lin
        orcid: null
      - name: Xing-Lou Yang
        orcid: null
      - name: Peng Zhou
        orcid: http://orcid.org/0000-0001-5684-2256
      - name: Zhengli Shi
        orcid: null
  comment:
    dislikes: 0
    thread: "8540448791"
    numReports: 0
    likes: 0
    id: "5444588887"
    createdAt: 2021-07-05T14:11:13
    author:
      username: zaishuiyifang
      about: ""
      name: zaishuiyifang
      isPowerContributor: false
      profileUrl: https://disqus.com/by/zaishuiyifang/
      url: ""
      location: ""
      id: "371294301"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Why does the R.Affinis ACE2 not bind to the RATG13, which was
      discovered from R.Affinis? Why does the RATG13 bind even better to human
      ACE2?
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.05.21.445091v1
  tweets:
    - created_at: Mon Jul 05 16:31:09 +0000 2021
      id: 1412086660632879000
      id_str: "1412086660632879111"
      text: >-
        üí¨ bioRxiv comment on "Identification of a novel line..."


        "Why does the R.Affinis ACE2 not bind to the RATG13, whic‚Ä¶ https://t.co/1EKpsgZ5FO
      truncated: true
      entities:
        urls:
          - url: https://t.co/1EKpsgZ5FO
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 05 16:31:10 +0000 2021
      id: 1412086661555671000
      id_str: "1412086661555671040"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/ICHGzR5kgK
      truncated: false
      entities:
        urls:
          - url: https://t.co/ICHGzR5kgK
      in_reply_to_status_id: 1412086660632879000
      in_reply_to_status_id_str: "1412086660632879111"
- preprint:
    id: "148485"
    doi: 10.1101/2021.06.30.21259439
    first_posted: 2021-07-02
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.30.21259439v1
    url: https://api.rxivist.org/v1/papers/148485
    title: "Efficacy, safety, and lot to lot immunogenicity of an inactivated
      SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase
      3 trial"
    category: infectious-diseases
    abstract: "Background: We report the clinical efficacy against COVID 19
      infection of BBV152, a whole virion inactivated SARS CoV 2 vaccine
      formulated with a Toll like receptor 7/8 agonist molecule adsorbed to alum
      (Algel IMDG). Methods: We did a double-blind, randomised, multicentre,
      phase 3 clinical trial in 25 Indian hospitals to evaluate the efficacy,
      safety, and immunological lot consistency of BBV152. Healthy adults (age
      18 to 98 years) randomised 1:1 using a sponsor-supplied randomisation
      scheme received two intramuscular doses of vaccine or placebo administered
      four weeks apart. The primary outcome was laboratory confirmed symptomatic
      COVID 19, occurring at least 14 days after the second dose. Secondary
      outcomes were efficacy in subgroups for age (18 to < 60 years and >=60
      years) and in participants with pre-existing stable medical conditions. We
      also evaluated safety, reactogenicity, and consistency of immune responses
      for three consecutive manufacturing lots. Findings: Between November 16,
      2020 and January 7, 2021 we recruited 25,798 participants who were
      randomised to BBV152 or placebo groups; 24,419 received two doses of
      BBV152 (n = 12,221) or placebo (n = 12,198). In a case-driven analysis,
      130 cases of symptomatic COVID-19 were reported in 16,973 (0.77%)
      participants with follow-up at least two weeks after the second
      vaccination; 24 occurred in the vaccine group and 106 in placebo
      recipients giving an overall vaccine efficacy of 77.8% (95% CI:
      65.2,86.4). Sixteen cases, one vaccinee and 15 placebo recipients, met the
      severe symptomatic COVID-19 case definition giving a vaccine efficacy of
      93.4% (57.1,99.8). Efficacy against asymptomatic COVID 19 was 63.6% (29.0,
      82.4). BBV152 conferred 65.2% (95% CI: 33.1, 83.0) protection against the
      SARS CoV 2 Variant of Concern, B.1.617.2 (Delta). BBV152 was well
      tolerated with no clinically or statistically significant differences in
      the distributions of solicited, unsolicited, or serious adverse events
      between vaccine and placebo groups. No cases of anaphylaxis or
      vaccine-related deaths were reported. Interpretation: BBV152 was
      immunogenic and highly efficacious against symptomatic and asymptomatic
      COVID 19 variant associated disease, particularly against severe disease
      in adults. Vaccination was well tolerated with an overall incidence of
      adverse events observed over a median of 146 days that was lower than that
      observed with other COVID-19 vaccines."
    authors:
      - name: Raches Ella
        orcid: http://orcid.org/0000-0002-4646-4471
      - name: Siddharth Reddy
        orcid: null
      - name: William Blackwelder
        orcid: null
      - name: Varsha Potdar
        orcid: null
      - name: Pragya Yadav
        orcid: null
      - name: Vamshi Sarangi
        orcid: null
      - name: Vinay Kumar Aileni
        orcid: null
      - name: Suman Kanungo
        orcid: null
      - name: Sanjay Rai
        orcid: null
      - name: Prabhakar Reddy
        orcid: null
      - name: Savitha Verma
        orcid: null
      - name: Chandramani Singh
        orcid: null
      - name: Sagar Redkar
        orcid: null
      - name: Satyajit Mohapatra
        orcid: null
      - name: Anil Pandey
        orcid: null
      - name: Pajanivel Ranganadin
        orcid: null
      - name: Raghavendra Gumashta
        orcid: null
      - name: Manish Multani
        orcid: null
      - name: Shameem Mohammad
        orcid: null
      - name: Parul Bhatt
        orcid: null
      - name: Laxmi Kumari
        orcid: null
      - name: Gajanan Sapkal
        orcid: null
      - name: Nivedita Gupta
        orcid: null
      - name: Priya Abraham
        orcid: null
      - name: Samiran Panda
        orcid: http://orcid.org/0000-0002-5077-6275
      - name: Sai Prasad
        orcid: null
      - name: Balram Bhargava
        orcid: null
      - name: Krishna Ella
        orcid: null
      - name: Krishna Mohan Vadrevu
        orcid: null
      - name: COVAXIN Study Group
        orcid: null
  comment:
    dislikes: 0
    thread: "8626986725"
    numReports: 0
    likes: 0
    id: "5444722234"
    createdAt: 2021-07-05T16:18:54
    author:
      username: disqus_dozmZuygBM
      about: Research student
      name: sdas
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_dozmZuygBM/
      url: ""
      location: Pune
      id: "97742102"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "There are many issues from overlooking if numbers add up to
      inconsistencies in safety and efficacy analysis. Points have been raised
      and pointed out with brief descriptions in this thread:
      https://twitter.com/das_seed/status/1411069675623043072 . To provide an
      example: Number of asymptomatic COVID19 cases analyzed is said to be 47,
      however paper mentions 13 in COVAXIN group and 33 in placebo group which
      add to 46. In section Safety, it says 2 SAEs related to vaccine were
      reported but in conclusion it mentions 1 SAE which was probably related to
      vaccine. More concerning issues are discussed in tweet thread:
      https://twitter.com/das_seed/status/1411069675623043072."
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.30.21259439v1
  tweets:
    - created_at: Mon Jul 05 18:24:24 +0000 2021
      id: 1412115160412606500
      id_str: "1412115160412606465"
      text: >-
        üí¨ medRxiv comment on "Efficacy, safety, and lot to l..."


        "There are many issues from overlooking if numbers add up‚Ä¶ https://t.co/ZHaEmqsqt1
      truncated: true
      entities:
        urls:
          - url: https://t.co/ZHaEmqsqt1
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 05 18:24:24 +0000 2021
      id: 1412115161196937200
      id_str: "1412115161196937220"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/lioZaI4Yvd
      truncated: false
      entities:
        urls:
          - url: https://t.co/lioZaI4Yvd
      in_reply_to_status_id: 1412115160412606500
      in_reply_to_status_id_str: "1412115160412606465"
- preprint:
    id: 148689
    metric: 15
    title: The role of feedback in the production of skilled finger sequences
    url: https://api.rxivist.org/v1/papers/148689
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.02.450916v1
    doi: 10.1101/2021.07.02.450916
    category: neuroscience
    first_posted: 2021-07-03
    abstract: Actions involving fine control of the hand, for example grasping an
      object, rely heavily on sensory information from the fingertips. While the
      integration of feedback during execution of individual movements is well
      understood, less is known about the use of sensory feedback in the control
      of skilled movement sequences. To address this gap, we trained
      participants to produce sequences of finger movements on a keyboard-like
      device over a four-day training period. Participants received haptic,
      visual, and auditory feedback indicating the occurrence of each finger
      press. We then either transiently delayed or advanced the feedback for a
      single press by a small amount of time (30 or 60 ms). We observed that
      participants rapidly adjusted their ongoing finger press by either
      accelerating or prolonging the ongoing press, in accordance with the
      direction of the perturbation. Furthermore, we could show that this rapid
      behavioural modulation was driven by haptic feedback. While these
      feedback-driven adjustments reduced in size with practice, they were still
      clearly present at the end of training. In contrast to the
      directionally-specific effect we observed on the perturbed press, a
      feedback perturbation resulted in a delayed onset of the subsequent
      presses irrespective of perturbation direction or feedback modality. This
      observation is consistent with a hierarchical organization of skilled
      movement sequences, with different levels reacting distinctly to sensory
      perturbations.
    authors:
      - name: Nicola J Popp
      - name: Carlos R. Hernandez-Castillo
      - name: Paul L Gribble
      - name: Joern Diedrichsen
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Mon Jul 05 20:15:37 +0000 2021
      id: 1412143147010990000
      id_str: "1412143147010990087"
      text: >-
        üî• bioRxiv Neuroscience preprint by N. J. Popp et al:


        "The role of feedback in the production of skilled finger seq‚Ä¶ https://t.co/qI4p6EbjxO
      truncated: true
      entities:
        urls:
          - url: https://t.co/qI4p6EbjxO
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 0
    id: "5444621009"
    createdAt: 2021-07-05T14:43:37
    author:
      username: davidsbabo
      about: ""
      name: David Sbabo
      isPowerContributor: false
      profileUrl: https://disqus.com/by/davidsbabo/
      url: ""
      location: ""
      id: "62494432"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      "And in a simplistic analysis, we removed all pts who died by Day 5 or
      earlier."


      A.k.a. immortal time bias.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Mon Jul 05 20:19:14 +0000 2021
      id: 1412144059649511400
      id_str: "1412144059649511424"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        ""And in a simplistic analysis, we removed all pts who di‚Ä¶ https://t.co/7HArMbvQBT
      truncated: true
      entities:
        urls:
          - url: https://t.co/7HArMbvQBT
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 05 20:19:15 +0000 2021
      id: 1412144060358348800
      id_str: "1412144060358348803"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1412144059649511400
      in_reply_to_status_id_str: "1412144059649511424"
- preprint:
    id: "148801"
    doi: 10.1101/2021.07.05.451120
    first_posted: 2021-07-05
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.05.451120v1
    url: https://api.rxivist.org/v1/papers/148801
    title: A new transgene mouse model using an extravesicular EGFP tag to elucidate
      the in vivo function of extracellular vesicles
    category: molecular-biology
    abstract: The in vivo function of cell-derived extracellular vesicles (EVs) is
      challenging to establish since cell-specific EVs are difficult to isolate.
      We therefore created an EV reporter using CD9 to display enhanced green
      fluorescent protein (EGFP) on the EV surface. CD9-EGFP expression in cells
      did not affect EV size and concentration, but allowed for co-precipitation
      of EV markers TSG101 and ALIX from cell-conditioned medium by anti-GFP
      immunoprecipitation. We created a transgenic mouse where CD9-EGFP was
      inserted in the inverse orientation and double-floxed, ensuring Cre
      recombinase-dependent EV reporter expression. We crossed the EV reporter
      mice with mice expressing Cre ubiquitously (CMV-Cre), in cardiomyocytes
      (AMHC-Cre) and kidney epithelium (Pax8-Cre), respectively. The mice showed
      tissue-specific EGFP expression, and plasma and urine samples were used to
      immunoprecipitate EVs. CD9-EGFP EVs was detected in plasma samples from
      CMV-Cre/CD9-EGFP and AMHC-Cre/CD9-EGFP mice, but not in PAX8-Cre/CD9-EGFP
      mice. On the other hand, CD9-EGFP EVs were detected in urine samples from
      CMV-Cre/CD9-EGFP and PAX8-Cre/CD9-EGFP mice, but not AMHC-Cre/CD9-EGFP,
      indicating that plasma EVs are not filtered to the urine. In conclusion,
      our EV reporter mouse model enables Cre-dependent EV labeling, providing a
      new approach to study cell-specific EVs in vivo and gain new insight into
      their physiological and pathophysiological function.
    authors:
      - name: Mikkel Oernfeldt Noegaard
        orcid: null
      - name: Lasse Bach Steffensen
        orcid: null
      - name: Didde Hansen
        orcid: null
      - name: Ernst-Martin Fuchtbauer
        orcid: null
      - name: Morten Buch Engelund
        orcid: null
      - name: Henrik Dimke
        orcid: http://orcid.org/0000-0002-9170-2168
      - name: Ditte Caroline Andersen
        orcid: null
      - name: Per Svenningsen
        orcid: null
  comment:
    dislikes: 0
    thread: "8631592431"
    numReports: 0
    likes: 0
    id: "5444837153"
    createdAt: 2021-07-05T18:04:47
    author:
      username: michaelkoksharov
      about: "Postdoc: molecular biology & protein engineering"
      name: Misha Koksharov
      isPowerContributor: false
      profileUrl: https://disqus.com/by/michaelkoksharov/
      url: ""
      location: ""
      id: "59911792"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      The authors report mouse lines producing a ‚ÄúCD9-truncated‚Äù-EGFP reporter
      protein with a

      purpose of labeling the surface of extracellular vesicles with EGFP. However, the original version of EGFP is prone to two well described artifacts when expressed as 1) a membrane-tethered protein; 2) a protein passing the oxidizing intracellular compartments (ER, secretory pathways, etc). The current reporter construct is subject to both of these factors because it is membrane-tethered and passes through the ER interior being on ER/extracellular-side of the membrane in this fusion (tethered to the extracellular side of CD9 truncated after the first 117 amino acid residues). In the first case, the tendency of FP to oligomerize causes aggregate-like membrane structures; in the second case, the ER is flooded with a ‚Äúdark‚Äù FP pool due to intermolecular cysteine cross-linking as described on Addgene blog (and in the original paper by Constantini et al, 2012, https://doi.org/10.1111/j.1600-0854.2012.01336.x):



      1) https://blog.addgene.org/when-is-a-monomer-not-a-monomer-the-top-three-ways-your-favorite-fluorescent-protein-oligomerizes-in-cells



      2) https://blog.addgene.org/avoiding-the-dark-side-of-fluorescent-protein-fusions-with-mox-fps



      These two problems were extensively reported by groups developing improved fluorescent proteins (FPs) over the last decade. Monomeric (widely used now) and cysteine-less (less

      widely used) variants of FPs are available to address both of these problems. In case of EGFP, these are monomeric (mEGFP) and monomeric+cysteine-less versions (moxGFP) but currently there are many newer fluorescent proteins which are superior to EGFP (even if considering ones having similar spectral characteristics).



      Therefore, the use of the current described reporter should be generally avoided. Ideally, these reporters should be redone using moxGFP or other suitable FP.



      The use of protein tools representing the best current state-of-the-art is particular important for rodent work due to ethical considerations. Currently in most countries there is a pressure to reduce unnecessary use of vertebrate animals in research. The use of constructs prone to artifacts in vertebrate models could result in using more animals than needed since it may be required to redo the live animal tools or redo some of the research obtained with less than optimal tools.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.07.05.451120v1
  tweets:
    - created_at: Mon Jul 05 22:19:09 +0000 2021
      id: 1412174234223272000
      id_str: "1412174234223271940"
      text: >-
        üí¨ bioRxiv comment on "A new transgene mouse model us..."


        "The authors report mouse lines producing a ‚ÄúCD9-truncate‚Ä¶ https://t.co/KCTDqo2dvT
      truncated: true
      entities:
        urls:
          - url: https://t.co/KCTDqo2dvT
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 05 22:19:09 +0000 2021
      id: 1412174235011793000
      id_str: "1412174235011792897"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/1rZ4gaWIJw
      truncated: false
      entities:
        urls:
          - url: https://t.co/1rZ4gaWIJw
      in_reply_to_status_id: 1412174234223272000
      in_reply_to_status_id_str: "1412174234223271940"
- preprint:
    id: "147586"
    doi: 10.1101/2021.06.24.449838
    first_posted: 2021-06-25
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.24.449838v1
    url: https://api.rxivist.org/v1/papers/147586
    title: Discovery and visualization of uncharacterized drug-protein adducts using
      mass spectrometry.
    category: pharmacology-and-toxicology
    abstract: Drugs are often metabolized to reactive intermediates that form
      protein adducts. Adducts can inhibit protein activity, elicit immune
      responses, and cause life threatening adverse drug reactions. The masses
      of reactive metabolites are frequently unknown, rendering traditional mass
      spectrometry-based proteomics approaches incapable of adduct
      identification. Here, we present Magnum, an open-mass search algorithm
      optimized for adduct identification, and Limelight, a web-based data
      processing package for analysis and visualization of data from all
      existing algorithms. Limelight incorporates tools for sample comparisons
      and xenobiotic-adduct discovery. We validate our tools with two
      drug/protein combinations and apply our workflow to identify novel
      xenobiotic-protein adducts in CYP3A4. Our new methods and software enable
      accurate identification of xenobiotic-protein adducts with no prior
      knowledge of adduct masses or protein targets. Magnum outperforms existing
      tools in xenobiotic-protein adduct discovery, while Limelight fulfills a
      major need in the rapidly developing field of open-mass searching, which
      until now lacked comprehensive data visualization tools.
    authors:
      - name: Michael Riffle
        orcid: http://orcid.org/0000-0003-1633-8607
      - name: Michael R. Hoopmann
        orcid: http://orcid.org/0000-0001-7029-7792
      - name: Daniel Jaschob
        orcid: http://orcid.org/0000-0002-5383-9702
      - name: Guo Zhong
        orcid: http://orcid.org/0000-0002-6056-9472
      - name: Robert L. Moritz
        orcid: http://orcid.org/0000-0002-3216-9447
      - name: Michael J. MacCoss
        orcid: http://orcid.org/0000-0003-1853-0256
      - name: Trisha N. Davis
        orcid: http://orcid.org/0000-0003-4797-3152
      - name: Nina Isoherranen
        orcid: http://orcid.org/0000-0002-9548-3126
      - name: Alex Zelter
        orcid: http://orcid.org/0000-0002-5331-0577
  comment:
    dislikes: 0
    thread: "8614966367"
    numReports: 0
    likes: 0
    id: "5444776096"
    createdAt: 2021-07-05T17:08:25
    author:
      username: disqus_oQ7hEbf7ti
      about: ""
      name: George Preston
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_oQ7hEbf7ti/
      url: ""
      location: ""
      id: "371913890"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: This is a very nice piece of work, which addresses some of the
      major difficulties associated with protein adduct discovery. I would just
      like to draw the authors' attention to a recent publication of mine, which
      describes the development of tools for visualizing 'dependent peptides'
      (Preston et al., 2020; <a
      href="#">https://doi.org/10.1371/journal.pone.0235263</a>). My co-authors'
      and my motivation was similar to that of the authors, in that we sought to
      selectively visualize modifications associated with a particular treatment
      (in our case, 'treatment' meant addition of a reactive chemical in vitro,
      and we used some data from others' studies - one involving a probe and one
      involving a drug).
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.24.449838v1
  tweets:
    - created_at: Tue Jul 06 01:05:12 +0000 2021
      id: 1412216023462383600
      id_str: "1412216023462383617"
      text: >-
        üí¨ bioRxiv comment on "Discovery and visualization of..."


        "This is a very nice piece of work, which addresses some‚Ä¶ https://t.co/CbAExm4qPb
      truncated: true
      entities:
        urls:
          - url: https://t.co/CbAExm4qPb
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 06 01:05:12 +0000 2021
      id: 1412216024267690000
      id_str: "1412216024267689987"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/oaWRaZ2FPs
      truncated: false
      entities:
        urls:
          - url: https://t.co/oaWRaZ2FPs
      in_reply_to_status_id: 1412216023462383600
      in_reply_to_status_id_str: "1412216023462383617"
- preprint:
    id: "148485"
    doi: 10.1101/2021.06.30.21259439
    first_posted: 2021-07-02
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.30.21259439v1
    url: https://api.rxivist.org/v1/papers/148485
    title: "Efficacy, safety, and lot to lot immunogenicity of an inactivated
      SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase
      3 trial"
    category: infectious-diseases
    abstract: "Background: We report the clinical efficacy against COVID 19
      infection of BBV152, a whole virion inactivated SARS CoV 2 vaccine
      formulated with a Toll like receptor 7/8 agonist molecule adsorbed to alum
      (Algel IMDG). Methods: We did a double-blind, randomised, multicentre,
      phase 3 clinical trial in 25 Indian hospitals to evaluate the efficacy,
      safety, and immunological lot consistency of BBV152. Healthy adults (age
      18 to 98 years) randomised 1:1 using a sponsor-supplied randomisation
      scheme received two intramuscular doses of vaccine or placebo administered
      four weeks apart. The primary outcome was laboratory confirmed symptomatic
      COVID 19, occurring at least 14 days after the second dose. Secondary
      outcomes were efficacy in subgroups for age (18 to < 60 years and >=60
      years) and in participants with pre-existing stable medical conditions. We
      also evaluated safety, reactogenicity, and consistency of immune responses
      for three consecutive manufacturing lots. Findings: Between November 16,
      2020 and January 7, 2021 we recruited 25,798 participants who were
      randomised to BBV152 or placebo groups; 24,419 received two doses of
      BBV152 (n = 12,221) or placebo (n = 12,198). In a case-driven analysis,
      130 cases of symptomatic COVID-19 were reported in 16,973 (0.77%)
      participants with follow-up at least two weeks after the second
      vaccination; 24 occurred in the vaccine group and 106 in placebo
      recipients giving an overall vaccine efficacy of 77.8% (95% CI:
      65.2,86.4). Sixteen cases, one vaccinee and 15 placebo recipients, met the
      severe symptomatic COVID-19 case definition giving a vaccine efficacy of
      93.4% (57.1,99.8). Efficacy against asymptomatic COVID 19 was 63.6% (29.0,
      82.4). BBV152 conferred 65.2% (95% CI: 33.1, 83.0) protection against the
      SARS CoV 2 Variant of Concern, B.1.617.2 (Delta). BBV152 was well
      tolerated with no clinically or statistically significant differences in
      the distributions of solicited, unsolicited, or serious adverse events
      between vaccine and placebo groups. No cases of anaphylaxis or
      vaccine-related deaths were reported. Interpretation: BBV152 was
      immunogenic and highly efficacious against symptomatic and asymptomatic
      COVID 19 variant associated disease, particularly against severe disease
      in adults. Vaccination was well tolerated with an overall incidence of
      adverse events observed over a median of 146 days that was lower than that
      observed with other COVID-19 vaccines."
    authors:
      - name: Raches Ella
        orcid: http://orcid.org/0000-0002-4646-4471
      - name: Siddharth Reddy
        orcid: null
      - name: William Blackwelder
        orcid: null
      - name: Varsha Potdar
        orcid: null
      - name: Pragya Yadav
        orcid: null
      - name: Vamshi Sarangi
        orcid: null
      - name: Vinay Kumar Aileni
        orcid: null
      - name: Suman Kanungo
        orcid: null
      - name: Sanjay Rai
        orcid: null
      - name: Prabhakar Reddy
        orcid: null
      - name: Savitha Verma
        orcid: null
      - name: Chandramani Singh
        orcid: null
      - name: Sagar Redkar
        orcid: null
      - name: Satyajit Mohapatra
        orcid: null
      - name: Anil Pandey
        orcid: null
      - name: Pajanivel Ranganadin
        orcid: null
      - name: Raghavendra Gumashta
        orcid: null
      - name: Manish Multani
        orcid: null
      - name: Shameem Mohammad
        orcid: null
      - name: Parul Bhatt
        orcid: null
      - name: Laxmi Kumari
        orcid: null
      - name: Gajanan Sapkal
        orcid: null
      - name: Nivedita Gupta
        orcid: null
      - name: Priya Abraham
        orcid: null
      - name: Samiran Panda
        orcid: http://orcid.org/0000-0002-5077-6275
      - name: Sai Prasad
        orcid: null
      - name: Balram Bhargava
        orcid: null
      - name: Krishna Ella
        orcid: null
      - name: Krishna Mohan Vadrevu
        orcid: null
      - name: COVAXIN Study Group
        orcid: null
  comment:
    dislikes: 2
    thread: "8626986725"
    numReports: 0
    likes: 5
    id: "5443263892"
    createdAt: 2021-07-04T05:23:23
    author:
      username: disqus_5QZalQ1Kbr
      about: ""
      name: PriyankaPulla
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_5QZalQ1Kbr/
      url: ""
      location: ""
      id: "371848958"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Major protocol violations occurred at the largest site of the Covaxin
      phase 3 trial, a private hospital called People's Hospital, which
      recruited 1700 participants. These violations are documented extensively
      by multiple media outlets. And these violations raise questions about the
      integrity of the Phase 3 trial data. They also raise questions about the
      sponsors' attitude to due process, and the independence/training of the
      DSMB: both sponsors (the Indian Council of Medical Research and Bharat
      Biotech) responded to the allegations with cursory dismissals, while the
      DSMB remained mum.


      Further details here: https://www.thequint.com/coronavirus/explained-is-the-data-from-covaxin-trials-bhopal-site-tainted-bharat-biotech-icmr 


      I am listing a few of the documented irregularities:


      1. Participants told media outlets that they didn't give their informed consent, an Indian legal requirement. Many participants belonged to disadvantaged tribal communities/were illiterate, which necessitates special consent protocols under Indian law, which investigators didn't follow. 


      Investigators admitted in a video-recorded press conference that they didn't give participants a copy of their informed-consent form during their first visit, unless participants explicitly asked for it. This strongly suggests that the investigators weren't trained in Indian legal requirements or Good Clinical Practices.



      2. Investigators allegedly advertised the trial as a vaccination drive in communities of poor and illiterate people.



      3. Dozens of participants say the trial team did not contact them to record solicited adverse events. These participants often didn't have their own mobile phones (mobile phones are the mode through which solicited adverse events were to be collected, as per trial protocol). Even though these participants came from poor communities, investigators didn't foresee the fact that they may not have their own mobile phones, and may be hard to contact. Nor did they attempt to contact them in their homes in the days following the doses. 



      4. People's Hospital recruited a record 1700 participants in 1.5 months (no other Covaxin trial site in India managed such numbers). In contrast, another government-run  Covaxin site in Bhopal struggled to even recruit a few hundred participants, and was, therefore, excluded from the trial. This supports the allegation that People's Hospital misadvertised the trial as a vaccination drive.



      5. Many participants told media outlets that they suffered Covid-like symptoms post jab, but the investigators never called them to collect this information. Nor did the participants know where to report their symptoms. This raises questions about how well Covid cases were recorded. 



      6. Participants say they were denied medical treatment at People's Hospital when they fell sick. This, again, raises questions about how well the investigators captured adverse-events.



      7. When one participant at the Bhopal site died, investigators ignored his family's version of the participant's symptoms in their causality analysis. In the family's version, the participant suffered from very severe symptoms (vomiting, dizziness, weakness) for 7-8 days before death, while the investigators claimed he was fine during solicited-adverse event monitoring, and died suddenly. 


      The dismissal of the family's version of events, when the family was present during the participant's death (but the investigators weren't), raises serious questions about how Serious Adverse Events are investigated. No post-mortem report or causality analysis was shared with the family despite multiple requests. Further, the family alleges that the deceased participant received no phone calls from the investigators to record solicited adverse events in the days leading up to his death. 


      The investigators could easily have shared proof of their claims by sharing a record of the phone calls with the family. They haven't. 


      --------------------------------------------------------------


      Despite the above serious concerns (which are supported by video testimony from participants broadcast on multiple media outlets, specifically NDTV),  the trial's government sponsor, ICMR, and Bharat Biotech, denied all allegations in a cursory manner. Further, the preprint makes no mention of them, or explain how these irregularities were handled. 


      This raises questions about overall data integrity in Bharat Biotech's phase 3 trial. Bharat Biotech has been under substantial pressure from the government to roll out Covaxin fast, which may explain why the company is overlooking such data integrity issues. More details here: https://www.livemint.com/science/news/how-covaxin-became-a-victim-of-vaccine-triumphalism-11622022760541.html


      Reviewers of this paper, and licensing authorities, including the World Health Organisation, must investigate these allegations thoroughly.
    forum: medrxiv
    points: 3
    link: https://www.medrxiv.org/content/10.1101/2021.06.30.21259439v1
  tweets:
    - created_at: Tue Jul 06 12:35:26 +0000 2021
      id: 1412389725000847400
      id_str: "1412389725000847368"
      text: >-
        üí¨ medRxiv comment on "Efficacy, safety, and lot to l..."


        "Major protocol violations occurred at the largest site o‚Ä¶ https://t.co/ZYZNuLSSKN
      truncated: true
      entities:
        urls:
          - url: https://t.co/ZYZNuLSSKN
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 06 12:35:26 +0000 2021
      id: 1412389725764210700
      id_str: "1412389725764210697"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/lioZaI4Yvd
      truncated: false
      entities:
        urls:
          - url: https://t.co/lioZaI4Yvd
      in_reply_to_status_id: 1412389725000847400
      in_reply_to_status_id_str: "1412389725000847368"
- preprint:
    id: "148485"
    doi: 10.1101/2021.06.30.21259439
    first_posted: 2021-07-02
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.30.21259439v1
    url: https://api.rxivist.org/v1/papers/148485
    title: "Efficacy, safety, and lot to lot immunogenicity of an inactivated
      SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase
      3 trial"
    category: infectious-diseases
    abstract: "Background: We report the clinical efficacy against COVID 19
      infection of BBV152, a whole virion inactivated SARS CoV 2 vaccine
      formulated with a Toll like receptor 7/8 agonist molecule adsorbed to alum
      (Algel IMDG). Methods: We did a double-blind, randomised, multicentre,
      phase 3 clinical trial in 25 Indian hospitals to evaluate the efficacy,
      safety, and immunological lot consistency of BBV152. Healthy adults (age
      18 to 98 years) randomised 1:1 using a sponsor-supplied randomisation
      scheme received two intramuscular doses of vaccine or placebo administered
      four weeks apart. The primary outcome was laboratory confirmed symptomatic
      COVID 19, occurring at least 14 days after the second dose. Secondary
      outcomes were efficacy in subgroups for age (18 to < 60 years and >=60
      years) and in participants with pre-existing stable medical conditions. We
      also evaluated safety, reactogenicity, and consistency of immune responses
      for three consecutive manufacturing lots. Findings: Between November 16,
      2020 and January 7, 2021 we recruited 25,798 participants who were
      randomised to BBV152 or placebo groups; 24,419 received two doses of
      BBV152 (n = 12,221) or placebo (n = 12,198). In a case-driven analysis,
      130 cases of symptomatic COVID-19 were reported in 16,973 (0.77%)
      participants with follow-up at least two weeks after the second
      vaccination; 24 occurred in the vaccine group and 106 in placebo
      recipients giving an overall vaccine efficacy of 77.8% (95% CI:
      65.2,86.4). Sixteen cases, one vaccinee and 15 placebo recipients, met the
      severe symptomatic COVID-19 case definition giving a vaccine efficacy of
      93.4% (57.1,99.8). Efficacy against asymptomatic COVID 19 was 63.6% (29.0,
      82.4). BBV152 conferred 65.2% (95% CI: 33.1, 83.0) protection against the
      SARS CoV 2 Variant of Concern, B.1.617.2 (Delta). BBV152 was well
      tolerated with no clinically or statistically significant differences in
      the distributions of solicited, unsolicited, or serious adverse events
      between vaccine and placebo groups. No cases of anaphylaxis or
      vaccine-related deaths were reported. Interpretation: BBV152 was
      immunogenic and highly efficacious against symptomatic and asymptomatic
      COVID 19 variant associated disease, particularly against severe disease
      in adults. Vaccination was well tolerated with an overall incidence of
      adverse events observed over a median of 146 days that was lower than that
      observed with other COVID-19 vaccines."
    authors:
      - name: Raches Ella
        orcid: http://orcid.org/0000-0002-4646-4471
      - name: Siddharth Reddy
        orcid: null
      - name: William Blackwelder
        orcid: null
      - name: Varsha Potdar
        orcid: null
      - name: Pragya Yadav
        orcid: null
      - name: Vamshi Sarangi
        orcid: null
      - name: Vinay Kumar Aileni
        orcid: null
      - name: Suman Kanungo
        orcid: null
      - name: Sanjay Rai
        orcid: null
      - name: Prabhakar Reddy
        orcid: null
      - name: Savitha Verma
        orcid: null
      - name: Chandramani Singh
        orcid: null
      - name: Sagar Redkar
        orcid: null
      - name: Satyajit Mohapatra
        orcid: null
      - name: Anil Pandey
        orcid: null
      - name: Pajanivel Ranganadin
        orcid: null
      - name: Raghavendra Gumashta
        orcid: null
      - name: Manish Multani
        orcid: null
      - name: Shameem Mohammad
        orcid: null
      - name: Parul Bhatt
        orcid: null
      - name: Laxmi Kumari
        orcid: null
      - name: Gajanan Sapkal
        orcid: null
      - name: Nivedita Gupta
        orcid: null
      - name: Priya Abraham
        orcid: null
      - name: Samiran Panda
        orcid: http://orcid.org/0000-0002-5077-6275
      - name: Sai Prasad
        orcid: null
      - name: Balram Bhargava
        orcid: null
      - name: Krishna Ella
        orcid: null
      - name: Krishna Mohan Vadrevu
        orcid: null
      - name: COVAXIN Study Group
        orcid: null
  comment:
    dislikes: 2
    thread: "8626986725"
    numReports: 0
    likes: 1
    id: "5444281404"
    createdAt: 2021-07-05T05:35:47
    author:
      username: TheScrutinizer2018
      about: I am a biochemical geneticist with 15yrs of stem cell and gene therapy
        research experience
      name: The Scrutinizer
      isPowerContributor: false
      profileUrl: https://disqus.com/by/TheScrutinizer2018/
      url: https://www.thescrutinizer.org
      location: ""
      id: "140178545"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "@sumedhbhagwat:disqus you are really worried about the difference
      of 0.5% error? That is not the most imp thing to worry about right now. If
      you don't know this vaccine might be the best so far in comparison to all
      the genetic vax"
    forum: medrxiv
    points: -1
    link: https://www.medrxiv.org/content/10.1101/2021.06.30.21259439v1
  tweets:
    - created_at: Tue Jul 06 14:17:34 +0000 2021
      id: 1412415429960736800
      id_str: "1412415429960736784"
      text: >-
        üí¨ medRxiv comment on "Efficacy, safety, and lot to l..."


        "@sumedhbhagwat:disqus you are really worried about the d‚Ä¶ https://t.co/eERuPwwK9P
      truncated: true
      entities:
        urls:
          - url: https://t.co/eERuPwwK9P
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 06 14:17:34 +0000 2021
      id: 1412415431441358800
      id_str: "1412415431441358860"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/lioZaI4Yvd
      truncated: false
      entities:
        urls:
          - url: https://t.co/lioZaI4Yvd
      in_reply_to_status_id: 1412415429960736800
      in_reply_to_status_id_str: "1412415429960736784"
- preprint:
    id: "148485"
    doi: 10.1101/2021.06.30.21259439
    first_posted: 2021-07-02
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.30.21259439v1
    url: https://api.rxivist.org/v1/papers/148485
    title: "Efficacy, safety, and lot to lot immunogenicity of an inactivated
      SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase
      3 trial"
    category: infectious-diseases
    abstract: "Background: We report the clinical efficacy against COVID 19
      infection of BBV152, a whole virion inactivated SARS CoV 2 vaccine
      formulated with a Toll like receptor 7/8 agonist molecule adsorbed to alum
      (Algel IMDG). Methods: We did a double-blind, randomised, multicentre,
      phase 3 clinical trial in 25 Indian hospitals to evaluate the efficacy,
      safety, and immunological lot consistency of BBV152. Healthy adults (age
      18 to 98 years) randomised 1:1 using a sponsor-supplied randomisation
      scheme received two intramuscular doses of vaccine or placebo administered
      four weeks apart. The primary outcome was laboratory confirmed symptomatic
      COVID 19, occurring at least 14 days after the second dose. Secondary
      outcomes were efficacy in subgroups for age (18 to < 60 years and >=60
      years) and in participants with pre-existing stable medical conditions. We
      also evaluated safety, reactogenicity, and consistency of immune responses
      for three consecutive manufacturing lots. Findings: Between November 16,
      2020 and January 7, 2021 we recruited 25,798 participants who were
      randomised to BBV152 or placebo groups; 24,419 received two doses of
      BBV152 (n = 12,221) or placebo (n = 12,198). In a case-driven analysis,
      130 cases of symptomatic COVID-19 were reported in 16,973 (0.77%)
      participants with follow-up at least two weeks after the second
      vaccination; 24 occurred in the vaccine group and 106 in placebo
      recipients giving an overall vaccine efficacy of 77.8% (95% CI:
      65.2,86.4). Sixteen cases, one vaccinee and 15 placebo recipients, met the
      severe symptomatic COVID-19 case definition giving a vaccine efficacy of
      93.4% (57.1,99.8). Efficacy against asymptomatic COVID 19 was 63.6% (29.0,
      82.4). BBV152 conferred 65.2% (95% CI: 33.1, 83.0) protection against the
      SARS CoV 2 Variant of Concern, B.1.617.2 (Delta). BBV152 was well
      tolerated with no clinically or statistically significant differences in
      the distributions of solicited, unsolicited, or serious adverse events
      between vaccine and placebo groups. No cases of anaphylaxis or
      vaccine-related deaths were reported. Interpretation: BBV152 was
      immunogenic and highly efficacious against symptomatic and asymptomatic
      COVID 19 variant associated disease, particularly against severe disease
      in adults. Vaccination was well tolerated with an overall incidence of
      adverse events observed over a median of 146 days that was lower than that
      observed with other COVID-19 vaccines."
    authors:
      - name: Raches Ella
        orcid: http://orcid.org/0000-0002-4646-4471
      - name: Siddharth Reddy
        orcid: null
      - name: William Blackwelder
        orcid: null
      - name: Varsha Potdar
        orcid: null
      - name: Pragya Yadav
        orcid: null
      - name: Vamshi Sarangi
        orcid: null
      - name: Vinay Kumar Aileni
        orcid: null
      - name: Suman Kanungo
        orcid: null
      - name: Sanjay Rai
        orcid: null
      - name: Prabhakar Reddy
        orcid: null
      - name: Savitha Verma
        orcid: null
      - name: Chandramani Singh
        orcid: null
      - name: Sagar Redkar
        orcid: null
      - name: Satyajit Mohapatra
        orcid: null
      - name: Anil Pandey
        orcid: null
      - name: Pajanivel Ranganadin
        orcid: null
      - name: Raghavendra Gumashta
        orcid: null
      - name: Manish Multani
        orcid: null
      - name: Shameem Mohammad
        orcid: null
      - name: Parul Bhatt
        orcid: null
      - name: Laxmi Kumari
        orcid: null
      - name: Gajanan Sapkal
        orcid: null
      - name: Nivedita Gupta
        orcid: null
      - name: Priya Abraham
        orcid: null
      - name: Samiran Panda
        orcid: http://orcid.org/0000-0002-5077-6275
      - name: Sai Prasad
        orcid: null
      - name: Balram Bhargava
        orcid: null
      - name: Krishna Ella
        orcid: null
      - name: Krishna Mohan Vadrevu
        orcid: null
      - name: COVAXIN Study Group
        orcid: null
  comment:
    dislikes: 2
    thread: "8626986725"
    numReports: 0
    likes: 1
    id: "5442209857"
    createdAt: 2021-07-03T04:25:21
    author:
      username: sumedhbhagwat
      about: ""
      name: Sumedh Bhagwat
      isPowerContributor: false
      profileUrl: https://disqus.com/by/sumedhbhagwat/
      url: ""
      location: ""
      id: "371803587"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      COVAXIN preprint says: (Protocol, Supplementary appendix 2) but there is
      just a single supplementary file which is not the protocol .

      Please attach Supplementary appendix 2.



      Actual Vaccine Efficacy against symptomatic Covid  when calculated using formula is 77.27% ~77.3%

      Paper reports 77.8% which is due to rounding off of fractions
    forum: medrxiv
    points: -1
    link: https://www.medrxiv.org/content/10.1101/2021.06.30.21259439v1
  tweets:
    - created_at: Tue Jul 06 16:31:00 +0000 2021
      id: 1412449009021694000
      id_str: "1412449009021693955"
      text: >-
        üí¨ medRxiv comment on "Efficacy, safety, and lot to l..."


        "COVAXIN preprint says: (Protocol, Supplementary appendix‚Ä¶ https://t.co/yxEnO2nIhk
      truncated: true
      entities:
        urls:
          - url: https://t.co/yxEnO2nIhk
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 06 16:31:00 +0000 2021
      id: 1412449009973739500
      id_str: "1412449009973739526"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/lioZaI4Yvd
      truncated: false
      entities:
        urls:
          - url: https://t.co/lioZaI4Yvd
      in_reply_to_status_id: 1412449009021694000
      in_reply_to_status_id_str: "1412449009021693955"
- preprint:
    id: "138848"
    doi: 10.1101/2021.04.20.440611
    first_posted: 2021-04-20
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.20.440611v1
    url: https://api.rxivist.org/v1/papers/138848
    title: Modular biosynthesis of plant hemicellulose and its impact on yeast cells
    category: bioengineering
    abstract: "Background: The carbohydrate polymers that encapsulate plants cells
      have benefited humans for centuries and have valuable biotechnological
      uses. In the past five years, exciting possibilities have emerged in the
      engineering of polysaccharide-based biomaterials. Despite impressive
      advances on bacterial cellulose-based hydrogels, comparatively little is
      known about how plant hemicelluloses can be reconstituted and modulated in
      cells suitable for biotechnological purposes. Results: Here, we assembled
      cellulose synthase-like A (CSLA) enzymes using an optimized Pichia
      pastoris platform to produce tunable heteromannan (HM) polysaccharides in
      yeast. By swapping the domains of plant mannan and glucomannan synthases,
      we engineered chimeric CSLA proteins that made {beta}-1,4-linked mannan in
      quantities surpassing those of the native enzymes while minimizing the
      burden on yeast growth. Prolonged expression of a glucomannan synthase
      from Amorphophallus konjac was toxic to yeast cells: reducing biomass
      accumulation and ultimately leading to compromised cell viability.
      However, an engineered glucomannan synthase as well as CSLA pure mannan
      synthases and a CSLC glucan synthase did not inhibit growth.
      Interestingly, Pichia cell size could be increased or decreased depending
      on the composition of the CSLA protein sequence. HM yield and glucose
      incorporation could be further increased by co-expressing chimeric CSLA
      proteins with a MANNAN-SYNTHESIS-RELATED (MSR) co-factor from Arabidopsis
      thaliana. Conclusion: The results provide novel routes for the engineering
      of polysaccharide-based biomaterials that are needed for a sustainable
      bioeconomy. The characterization of chimeric cellulose synthase-like
      enzymes in yeast offers an exciting avenue to produce plant
      polysaccharides in a tunable manner. Furthermore, cells modified with
      non-toxic plant polysaccharides such as {beta}-mannan offer a modular
      chassis to produce and encapsulate sensitive cargo such as therapeutic
      proteins."
    authors:
      - name: Madalen Robert
        orcid: null
      - name: Julian Waldhauer
        orcid: null
      - name: Fabian Stritt
        orcid: null
      - name: Bo Yang
        orcid: http://orcid.org/0000-0003-4446-0415
      - name: Markus Pauly
        orcid: http://orcid.org/0000-0002-3116-2198
      - name: CƒÉtƒÉlin Voiniciuc
        orcid: http://orcid.org/0000-0001-9105-014X
  comment:
    dislikes: 0
    thread: "8559102940"
    numReports: 0
    likes: 0
    id: "5445553031"
    createdAt: 2021-07-06T11:03:33
    author:
      username: catalin_voiniciuc
      about: ""
      name: Catalin Voiniciuc
      isPowerContributor: false
      profileUrl: https://disqus.com/by/catalin_voiniciuc/
      url: ""
      location: ""
      id: "371948982"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "The final version of this manuscript is now published in
      Biotechnology for Biofuels: https://doi.org/10.1186/s13068-021-01985-z"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.04.20.440611v2
  tweets:
    - created_at: Tue Jul 06 18:24:20 +0000 2021
      id: 1412477530611855400
      id_str: "1412477530611855368"
      text: >-
        üí¨ bioRxiv comment on "Modular biosynthesis of plant ..."


        "The final version of this manuscript is now published in‚Ä¶ https://t.co/5WvgSMMROp
      truncated: true
      entities:
        urls:
          - url: https://t.co/5WvgSMMROp
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 06 18:24:20 +0000 2021
      id: 1412477531375259600
      id_str: "1412477531375259650"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/mik1ydXZ3B
      truncated: false
      entities:
        urls:
          - url: https://t.co/mik1ydXZ3B
      in_reply_to_status_id: 1412477530611855400
      in_reply_to_status_id_str: "1412477530611855368"
- preprint:
    id: 148793
    metric: 41
    title: Towards a Neurometric-based Construct Validity of Trust
    url: https://api.rxivist.org/v1/papers/148793
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.04.451074v1
    doi: 10.1101/2021.07.04.451074
    category: neuroscience
    first_posted: 2021-07-05
    abstract: Trust is a nebulous construct central to successful cooperative
      exchanges and interpersonal relationships. In this study, we introduce a
      new approach to establishing construct validity of trust using
      neurometrics. We develop a whole-brain multivariate pattern capable of
      classifying whether new participants will trust a relationship partner in
      the context of a cooperative interpersonal investment game (n=40) with 90%
      accuracy and find that it also generalizes to a variant of the same task
      collected in a different country with 82% accuracy (n=17). Moreover, we
      establish the convergent and discriminant validity by testing the pattern
      on eleven separate datasets (n=496) and find that trust is reliably
      related to beliefs of safety, inversely related to negative affect, but
      unrelated to reward, cognitive control, social perception, and
      self-referential processing. Together these results provide support for
      the notion that the psychological experience of trust contains elements of
      beliefs of reciprocation and fear of betrayal aversion. Contrary to our
      predictions, we found no evidence that trust is related to anticipated
      reward. This work demonstrates how neurometrics can be used to
      characterize the psychological processes associated with brain-based
      multivariate representations.
    authors:
      - name: Pin-Hao Andy Chen
      - name: Dominic Fareri
      - name: Berna Guroglu
      - name: Mauricio R Delgado
      - name: Luke J Chang
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Tue Jul 06 20:15:43 +0000 2021
      id: 1412505560906408000
      id_str: "1412505560906407940"
      text: >-
        üî• bioRxiv Neuroscience preprint by P. A. Chen et al:


        "Towards a Neurometric-based Construct Validity of Trust"‚Ä¶ https://t.co/fK2N8PGpfU
      truncated: true
      entities:
        urls:
          - url: https://t.co/fK2N8PGpfU
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "136062"
    doi: 10.1101/2021.03.31.437725
    first_posted: 2021-03-31
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.03.31.437725v1
    url: https://api.rxivist.org/v1/papers/136062
    title: Single-Cell Transcriptomic Analysis of Livers During NLRP3 Inflammasome
      Activation Reveals a Novel Immune Niche
    category: immunology
    abstract: The NOD-like receptor protein 3 (NLRP3) inflammasome is a central
      contributor to human acute and chronic liver disease, yet the molecular
      and cellular mechanisms by which its activation precipitates injury remain
      incompletely understood. Here, we present single cell transcriptomic
      profiling of livers from a global transgenic Tamoxifen-inducible
      constitutively-activated Nlrp3A350V mutant mouse, and we investigate the
      changes in parenchymal and non-parenchymal liver cell gene expression that
      accompany inflammation and fibrosis. Our results demonstrate that NLRP3
      activation causes chronic extramedullary myelopoiesis marked by an
      increase in proliferating myeloid progenitors that differentiate into
      neutrophils, monocytes, and monocyte-derived macrophages, results that
      were corroborated by flow cytometry and histological staining. We observed
      prominent neutrophil infiltrates with increased Ly6gHI and Ly6gINT cells
      exhibiting transcriptomic signatures of granulopoiesis typically found in
      the bone marrow. This was accompanied by a marked increase in Ly6cHI
      monocytes differentiating into Cd11bHITim4HIClec-4fHI macrophages that
      express proinflammatory transcriptional programs similar to macrophages of
      non-alcoholic steatohepatitis (NASH) models. NLRP3 activation also
      downregulated metabolic pathways in hepatocytes and shifted hepatic
      stellate cells towards an activated pro-fibrotic state based on expression
      of collagen and extracellular matrix (ECM) regulatory genes. These
      results, which highlight abundant neutrophils and extramedullary
      granulopoiesis define an inflamed and fibrotic hepatic single cell
      microenvironment, precipitated solely by NLRP3 activation. Clinically, our
      data support the notion that neutrophils and NLRP3 should be explored as
      therapeutic targets in NASH-like inflammation.
    authors:
      - name: David M Calcagno
        orcid: null
      - name: Angela Chu
        orcid: null
      - name: Susanne Gaul
        orcid: null
      - name: Nika Taghdiri
        orcid: null
      - name: Avinash Toomu
        orcid: null
      - name: Aleksandra Leszczynska
        orcid: null
      - name: Benedikt Kaufmann
        orcid: null
      - name: Alexander Wree
        orcid: null
      - name: Lukas Geisler
        orcid: null
      - name: Hal M. Hoffman
        orcid: null
      - name: Ariel E Feldstein
        orcid: null
      - name: Kevin R King
        orcid: null
  comment:
    dislikes: 0
    thread: "8460443339"
    numReports: 0
    likes: 0
    id: "5445484407"
    createdAt: 2021-07-06T09:05:56
    author:
      name: ML
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Despite being a very interesting draft, the author's trascriptomics
      datasets are not avaiable. 

      Their reported Gene Expression Omnibus accession number actually is linked to an unrelated paper, as stated "RNA-seq data generated in this study were deposited in the Gene Expression Omnibus (http://www.ncbi.nlm.nih. gov/geo) with accession number GSE140742" at page 4.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.03.31.437725v1
  tweets:
    - created_at: Tue Jul 06 20:19:24 +0000 2021
      id: 1412506487318999000
      id_str: "1412506487318999040"
      text: >-
        üí¨ bioRxiv comment on "Single-Cell Transcriptomic Ana..."


        "Despite being a very interesting draft, the author's tra‚Ä¶ https://t.co/lqHUyzhNFH
      truncated: true
      entities:
        urls:
          - url: https://t.co/lqHUyzhNFH
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 06 20:19:24 +0000 2021
      id: 1412506488321417200
      id_str: "1412506488321417222"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/wfv8C6DG9k
      truncated: false
      entities:
        urls:
          - url: https://t.co/wfv8C6DG9k
      in_reply_to_status_id: 1412506487318999000
      in_reply_to_status_id_str: "1412506487318999040"
- preprint:
    id: "140054"
    doi: 10.1101/2021.04.28.441722
    first_posted: 2021-04-28
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.28.441722v1
    url: https://api.rxivist.org/v1/papers/140054
    title: Mechanistic Insights on ATP's role as Hydrotrope
    category: biophysics
    abstract: Hydrotropes are small amphiphilic molecules which help in solubilizing
      hydrophobic entities in aqueous medium. Recent experimental investigation
      has provided convincing evidences that, adenosine triphosphate (ATP),
      besides being an energy currency of cell, also can act as hydrotrope to
      inhibit the formation of protein condensates. In this work, we have
      designed computer simulations of prototypical macromolecules in aqueous
      ATP solution to dissect the molecular mechanism underlying ATP's newly
      discovered role as a hydrotrope. The simulation demonstrates that ATP can
      unfold a single-chain of hydrophobic macromolecule as well as can disrupt
      the aggregation process of a hydrophobic assembly. Moreover, the
      introduction of charges in the macromolecule is found to reinforce ATP's
      disaggregation effects in a synergistic fashion, a behaviour reminiscent
      of recent experimental observation of pronounced hydrotropic action of ATP
      in intrinsically disordered proteins. A molecular analysis indicates that
      this new-found ability of ATP are ingrained in its propensity of
      preferential binding to the polymer surface ,which gets fortified in
      presence of charges. The investigation also renders evidence that the key
      to the ATP's superior hydrotropic role over chemical hydrotrope (Sodium
      xylene sulfonate, NaXS) may lie in its inherent self-aggregation
      propensity. Overall, via employing a bottom-up approach the current
      investigation provides fresh mechanistic insights into the dual
      solubilizing and denaturing abilities of ATP.
    authors:
      - name: Susmita Sarkar
        orcid: null
      - name: Jagannath Mondal
        orcid: null
  comment:
    dislikes: 0
    thread: "8497808773"
    numReports: 0
    likes: 0
    id: "5444756257"
    createdAt: 2021-07-05T16:50:14
    author:
      username: doris_loh
      about: Independent Researcher
      name: Doris Loh
      isPowerContributor: false
      profileUrl: https://disqus.com/by/doris_loh/
      url: https://www.evolutamente.it/category/doris-loh
      location: USA
      id: "371913611"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: The authors used  0.08 M , 0.3 M and 0.6 M aqueous ATP solution in
      their simulations. Can someone help clarify the metrics used? Previous
      literature on ATP as a hydrotrope discussed the use of higher
      physiological concentrations between  2 to 8 mM ATP capable of
      solubilizing proteins.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.04.28.441722v1
  tweets:
    - created_at: Tue Jul 06 22:19:10 +0000 2021
      id: 1412536628887933000
      id_str: "1412536628887932937"
      text: >-
        üí¨ bioRxiv comment on "Mechanistic Insights on ATP's ..."


        "The authors used  0.08 M , 0.3 M and 0.6 M aqueous ATP s‚Ä¶ https://t.co/5iAjaofwnb
      truncated: true
      entities:
        urls:
          - url: https://t.co/5iAjaofwnb
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 06 22:19:10 +0000 2021
      id: 1412536629902860300
      id_str: "1412536629902860288"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/4mjWJ4V1oa
      truncated: false
      entities:
        urls:
          - url: https://t.co/4mjWJ4V1oa
      in_reply_to_status_id: 1412536628887933000
      in_reply_to_status_id_str: "1412536628887932937"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5446280881"
    createdAt: 2021-07-06T21:26:06
    author:
      username: disqus_bIWbhK2XtJ
      about: ""
      name: susan fischer
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_bIWbhK2XtJ/
      url: ""
      location: ""
      id: "257064361"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: We had covid THIRTEEN months ago and still tested positive for antibodies.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Wed Jul 07 01:05:18 +0000 2021
      id: 1412578438905569300
      id_str: "1412578438905569281"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "We had covid THIRTEEN months ago and still tested positi‚Ä¶ https://t.co/oPTkeTkFPV
      truncated: true
      entities:
        urls:
          - url: https://t.co/oPTkeTkFPV
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 07 01:05:19 +0000 2021
      id: 1412578439626956800
      id_str: "1412578439626956802"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1412578438905569300
      in_reply_to_status_id_str: "1412578438905569281"
- preprint:
    id: "148902"
    doi: 10.1101/2021.06.30.21259787
    first_posted: 2021-07-05
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.30.21259787v1
    url: https://api.rxivist.org/v1/papers/148902
    title: Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and
      antibodies enhanced by pre-existing crossreactive T cell memory
    category: infectious-diseases
    abstract: Understanding human immune responses to SARS-CoV-2 RNA vaccines is of
      interest for a panoply of reasons. Here we examined vaccine-specific CD4+
      T cell, CD8+ T cell, binding antibody, and neutralizing antibody responses
      to the 25 ug Moderna mRNA-1273 vaccine over 7 months post-immunization,
      including multiple age groups, with a particular interest in assessing
      whether pre-existing crossreactive T cell memory impacts vaccine-generated
      immunity. Low dose (25 ug) mRNA-1273 elicited durable Spike binding
      antibodies comparable to that of convalescent COVID-19 cases.
      Vaccine-generated Spike memory CD4+ T cells 6 months post-boost were
      comparable in quantity and quality to COVID-19 cases, including the
      presence of TFH cells and IFNg-expressing cells. Spike CD8+ T cells were
      generated in 88% of subjects, with equivalent percentages of CD8+ T cell
      memory responders at 6 months post-boost compared to COVID-19 cases.
      Lastly, subjects with pre-existing crossreactive CD4+ T cell memory had
      increased CD4+ T cell and antibody responses to the vaccine, demonstrating
      a biological relevance of SARS-CoV-2 crossreactive CD4+ T cells.
    authors:
      - name: Jose Mateus
        orcid: http://orcid.org/0000-0002-1402-3452
      - name: Jennifer M Dan
        orcid: http://orcid.org/0000-0002-1672-0657
      - name: Zeli Zhang
        orcid: null
      - name: Carolyn Rydyznski Moderbacher
        orcid: http://orcid.org/0000-0002-7965-9902
      - name: Marshall Lammers
        orcid: http://orcid.org/0000-0003-2237-847X
      - name: Benjamin Goodwin
        orcid: http://orcid.org/0000-0002-5485-2861
      - name: Alessandro Sette
        orcid: http://orcid.org/0000-0001-7013-2250
      - name: Shane Crotty
        orcid: http://orcid.org/0000-0002-6484-6262
      - name: Daniela Weiskopf
        orcid: http://orcid.org/0000-0003-2968-7371
  comment:
    dislikes: 0
    thread: "8631860611"
    numReports: 0
    likes: 0
    id: "5446461988"
    createdAt: 2021-07-07T00:18:31
    author:
      username: itellu3times
      about: ""
      name: itellu3times
      isPowerContributor: false
      profileUrl: https://disqus.com/by/itellu3times/
      url: ""
      location: ""
      id: "49572364"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: For gosh sakes please mention the size of the current standard
      dose!  Current standard for Moderna is 100 micrograms, study here is 25
      micrograms?  In both cases, two doses.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.30.21259787v1
  tweets:
    - created_at: Wed Jul 07 12:31:23 +0000 2021
      id: 1412751097106559000
      id_str: "1412751097106558982"
      text: >-
        üí¨ medRxiv comment on "Low dose mRNA-1273 COVID-19 va..."


        "For gosh sakes please mention the size of the current st‚Ä¶ https://t.co/zavCIVJHDd
      truncated: true
      entities:
        urls:
          - url: https://t.co/zavCIVJHDd
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 07 12:31:24 +0000 2021
      id: 1412751098109055000
      id_str: "1412751098109054978"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/VhOpaz8C3e
      truncated: false
      entities:
        urls:
          - url: https://t.co/VhOpaz8C3e
      in_reply_to_status_id: 1412751097106559000
      in_reply_to_status_id_str: "1412751097106558982"
- preprint:
    id: "148485"
    doi: 10.1101/2021.06.30.21259439
    first_posted: 2021-07-02
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.30.21259439v1
    url: https://api.rxivist.org/v1/papers/148485
    title: "Efficacy, safety, and lot to lot immunogenicity of an inactivated
      SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase
      3 trial"
    category: infectious-diseases
    abstract: "Background: We report the clinical efficacy against COVID 19
      infection of BBV152, a whole virion inactivated SARS CoV 2 vaccine
      formulated with a Toll like receptor 7/8 agonist molecule adsorbed to alum
      (Algel IMDG). Methods: We did a double-blind, randomised, multicentre,
      phase 3 clinical trial in 25 Indian hospitals to evaluate the efficacy,
      safety, and immunological lot consistency of BBV152. Healthy adults (age
      18 to 98 years) randomised 1:1 using a sponsor-supplied randomisation
      scheme received two intramuscular doses of vaccine or placebo administered
      four weeks apart. The primary outcome was laboratory confirmed symptomatic
      COVID 19, occurring at least 14 days after the second dose. Secondary
      outcomes were efficacy in subgroups for age (18 to < 60 years and >=60
      years) and in participants with pre-existing stable medical conditions. We
      also evaluated safety, reactogenicity, and consistency of immune responses
      for three consecutive manufacturing lots. Findings: Between November 16,
      2020 and January 7, 2021 we recruited 25,798 participants who were
      randomised to BBV152 or placebo groups; 24,419 received two doses of
      BBV152 (n = 12,221) or placebo (n = 12,198). In a case-driven analysis,
      130 cases of symptomatic COVID-19 were reported in 16,973 (0.77%)
      participants with follow-up at least two weeks after the second
      vaccination; 24 occurred in the vaccine group and 106 in placebo
      recipients giving an overall vaccine efficacy of 77.8% (95% CI:
      65.2,86.4). Sixteen cases, one vaccinee and 15 placebo recipients, met the
      severe symptomatic COVID-19 case definition giving a vaccine efficacy of
      93.4% (57.1,99.8). Efficacy against asymptomatic COVID 19 was 63.6% (29.0,
      82.4). BBV152 conferred 65.2% (95% CI: 33.1, 83.0) protection against the
      SARS CoV 2 Variant of Concern, B.1.617.2 (Delta). BBV152 was well
      tolerated with no clinically or statistically significant differences in
      the distributions of solicited, unsolicited, or serious adverse events
      between vaccine and placebo groups. No cases of anaphylaxis or
      vaccine-related deaths were reported. Interpretation: BBV152 was
      immunogenic and highly efficacious against symptomatic and asymptomatic
      COVID 19 variant associated disease, particularly against severe disease
      in adults. Vaccination was well tolerated with an overall incidence of
      adverse events observed over a median of 146 days that was lower than that
      observed with other COVID-19 vaccines."
    authors:
      - name: Raches Ella
        orcid: http://orcid.org/0000-0002-4646-4471
      - name: Siddharth Reddy
        orcid: null
      - name: William Blackwelder
        orcid: null
      - name: Varsha Potdar
        orcid: null
      - name: Pragya Yadav
        orcid: null
      - name: Vamshi Sarangi
        orcid: null
      - name: Vinay Kumar Aileni
        orcid: null
      - name: Suman Kanungo
        orcid: null
      - name: Sanjay Rai
        orcid: null
      - name: Prabhakar Reddy
        orcid: null
      - name: Savitha Verma
        orcid: null
      - name: Chandramani Singh
        orcid: null
      - name: Sagar Redkar
        orcid: null
      - name: Satyajit Mohapatra
        orcid: null
      - name: Anil Pandey
        orcid: null
      - name: Pajanivel Ranganadin
        orcid: null
      - name: Raghavendra Gumashta
        orcid: null
      - name: Manish Multani
        orcid: null
      - name: Shameem Mohammad
        orcid: null
      - name: Parul Bhatt
        orcid: null
      - name: Laxmi Kumari
        orcid: null
      - name: Gajanan Sapkal
        orcid: null
      - name: Nivedita Gupta
        orcid: null
      - name: Priya Abraham
        orcid: null
      - name: Samiran Panda
        orcid: http://orcid.org/0000-0002-5077-6275
      - name: Sai Prasad
        orcid: null
      - name: Balram Bhargava
        orcid: null
      - name: Krishna Ella
        orcid: null
      - name: Krishna Mohan Vadrevu
        orcid: null
      - name: COVAXIN Study Group
        orcid: null
  comment:
    dislikes: 0
    thread: "8626986725"
    numReports: 0
    likes: 1
    id: "5445649651"
    createdAt: 2021-07-06T13:02:30
    author:
      username: saswatdash
      about: ""
      name: Saswat Dash
      isPowerContributor: false
      profileUrl: https://disqus.com/by/saswatdash/
      url: ""
      location: ""
      id: "79131088"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Not a very significant report. Dr. Fauci has already admitted that COVAXIN
      is very effective against most of the variants.  So, I don't really
      understand what is the point of highlighting it now. If there are any
      irregularities, then hopspital administration should be held responsible
      and not ICMR and Bharat Biotech. Reviewers will definitely ask question on
      the data if they find any inconsistencies.
       
      Please see the links below-


      https://www.ndtv.com/india-news/coronavirus-vaccine-covaxin-found-to-neutralise-617-variant-us-health-expert-anthony-fauci-2423455


      https://hwnews.in/news/national-news/covaxin-found-neutralise-double-mutant-strain-anthony-fauci/155743
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.06.30.21259439v1
  tweets:
    - created_at: Wed Jul 07 14:20:29 +0000 2021
      id: 1412778549526683600
      id_str: "1412778549526683648"
      text: >-
        üí¨ medRxiv comment on "Efficacy, safety, and lot to l..."


        "Not a very significant report. Dr. Fauci has already adm‚Ä¶ https://t.co/LWKEv8bfso
      truncated: true
      entities:
        urls:
          - url: https://t.co/LWKEv8bfso
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 07 14:20:29 +0000 2021
      id: 1412778550621466600
      id_str: "1412778550621466632"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/lioZaHNn6D
      truncated: false
      entities:
        urls:
          - url: https://t.co/lioZaHNn6D
      in_reply_to_status_id: 1412778549526683600
      in_reply_to_status_id_str: "1412778549526683648"
- preprint:
    id: "126823"
    doi: 10.1101/2021.01.25.428175
    first_posted: 2021-01-27
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.01.25.428175v1
    url: https://api.rxivist.org/v1/papers/126823
    title: Can we put Humpty Dumpty back together again? What does protein
      quantification mean in bottom-up proteomics?
    category: biochemistry
    abstract: Bottom-up proteomics provides peptide measurements and has been
      invaluable for moving proteomics into large-scale analyses. In bottom-up
      proteomics, protein parsimony and protein inference derived from these
      measured peptides are important for determining which protein coding genes
      are present. However, given the complexity of RNA splicing processes, and
      how proteins can be modified post-translationally, it is overly simplistic
      to assume that all peptides that map to a singular protein coding gene
      will demonstrate the same quantitative response. Accordingly, by assuming
      all peptides from a protein coding sequence are representative of the same
      protein we may be missing out on detecting important biological
      differences. To better account for the complexity of the proteome we need
      to think of new or better ways of handling peptide data.
    authors:
      - name: Deanna L Plubell
        orcid: http://orcid.org/0000-0002-6580-8073
      - name: Lukas K√§ll
        orcid: http://orcid.org/0000-0001-5689-9797
      - name: Bobbie-Jo Webb-Robertson
        orcid: http://orcid.org/0000-0002-4744-2397
      - name: Lisa Bramer
        orcid: http://orcid.org/0000-0002-8384-1926
      - name: Ashley Ives
        orcid: null
      - name: Neil L Kelleher
        orcid: http://orcid.org/0000-0002-8815-3372
      - name: Lloyd M. Smith
        orcid: http://orcid.org/0000-0002-6652-8639
      - name: Thomas J. Montine
        orcid: http://orcid.org/0000-0002-1346-2728
      - name: Christine C Wu
        orcid: null
      - name: Michael J. MacCoss
        orcid: http://orcid.org/0000-0003-1853-0256
  comment:
    dislikes: 0
    thread: "8372988945"
    numReports: 0
    likes: 0
    id: "5447108268"
    createdAt: 2021-07-07T15:09:11
    author:
      username: disqus_fLkycAbh7b
      about: ""
      name: Richard Unwin
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_fLkycAbh7b/
      url: ""
      location: ""
      id: "333118172"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      I 100% agree that this is an issue. I think the key observation here is
      that we effectively miss data by not taking this peptide level variance
      into account.


      However there is an issue, I think, when considering data e.g. in Fig 5c where you infer isoforms based upon variance of different peptides across the proteins. IF the different isoforms of that protein (PTMs, processing etc) are known, one can map peptides onto that knowledge. But it's fair to assume, I think that most PTMs or splice forms are not known (currently). 


      In either case (isoforms known or unknown), I think you are assuming that digestion efficiency, and release of each peptide, is equal across samples. We've done studies where we've digested the same pure protein 10x and run SRMs for 15 or so peptides and you clearly observe high levels of variance, so it's clear that, from a quantitative perspective, not all peptides are equal. I *think* for this to work, you need either a predefined set of 'good' peptides (highly reproducible signals in replicate digests of the same sample), or technical replicates on top of biological replicates in each study to be able to determine that peptide-level differences  are down to real peptide-level differences rather than variable digestion kinetics?
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.01.25.428175v1
  tweets:
    - created_at: Wed Jul 07 16:38:15 +0000 2021
      id: 1412813219626950700
      id_str: "1412813219626950660"
      text: >-
        üí¨ bioRxiv comment on "Can we put Humpty Dumpty back ..."


        "I 100% agree that this is an issue. I think the key obse‚Ä¶ https://t.co/DDJiuKA8T4
      truncated: true
      entities:
        urls:
          - url: https://t.co/DDJiuKA8T4
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 07 16:38:15 +0000 2021
      id: 1412813220507795500
      id_str: "1412813220507795456"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/6NwfZ9Yh0D
      truncated: false
      entities:
        urls:
          - url: https://t.co/6NwfZ9Yh0D
      in_reply_to_status_id: 1412813219626950700
      in_reply_to_status_id_str: "1412813219626950660"
- preprint:
    id: "148827"
    doi: 10.1101/2021.07.01.21259833
    first_posted: 2021-07-05
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.01.21259833v1
    url: https://api.rxivist.org/v1/papers/148827
    title: "COVID-19 vaccines dampen genomic diversity of SARS-CoV-2: Unvaccinated
      patients exhibit more antigenic mutational variance"
    category: infectious-diseases
    abstract: Variants of SARS-CoV-2 are evolving under a combination of immune
      selective pressure in infected hosts and natural genetic drift, raising a
      global alarm regarding the durability of COVID-19 vaccines. Here, we
      conducted longitudinal analysis over 1.8 million SARS-CoV-2 genomes from
      183 countries or territories to capture vaccination-associated viral
      evolutionary patterns. To augment this macroscale analysis, we performed
      viral genome sequencing in 23 vaccine breakthrough COVID-19 patients and
      30 unvaccinated COVID-19 patients for whom we also conducted
      machine-augmented curation of the electronic health records (EHRs).
      Strikingly, we find the diversity of the SARS-CoV-2 lineages is declining
      at the country-level with increased rate of mass vaccination (n = 25
      countries, mean correlation coefficient = -0.72, S.D. = 0.20). Given that
      the COVID-19 vaccines leverage B-cell and T-cell epitopes, analysis of
      mutation rates shows neutralizing B-cell epitopes to be particularly more
      mutated than comparable amino acid clusters (4.3-fold, p < 0.001).
      Prospective validation of these macroscale evolutionary patterns using
      clinically annotated SARS-CoV-2 whole genome sequences confirms that
      vaccine breakthrough patients indeed harbor viruses with significantly
      lower diversity in known B cell epitopes compared to unvaccinated COVID-19
      patients (2.3-fold, 95% C.I. 1.4-3.7). Incidentally, in these study
      cohorts, vaccinated breakthrough patients also displayed fewer
      COVID-associated complications and pre-existing conditions relative to
      unvaccinated COVID-19 patients. This study presents the first known
      evidence that COVID-19 vaccines are fundamentally restricting the
      evolutionary and antigenic escape pathways accessible to SARS-CoV-2. The
      societal benefit of mass vaccination may consequently go far beyond the
      widely reported mitigation of SARS-CoV-2 infection risk and amelioration
      of community transmission, to include stemming of rampant viral evolution.
    authors:
      - name: Michiel Niesen
        orcid: http://orcid.org/0000-0002-9255-6203
      - name: Praveen Anand
        orcid: http://orcid.org/0000-0002-2478-7042
      - name: Eli Silvert
        orcid: null
      - name: Rohit Suratekar
        orcid: http://orcid.org/0000-0002-6281-5526
      - name: Colin Pawlowski
        orcid: http://orcid.org/0000-0003-2781-7507
      - name: Pritha Ghosh
        orcid: http://orcid.org/0000-0003-3641-6393
      - name: Patrick Lenehan
        orcid: http://orcid.org/0000-0002-1950-9179
      - name: Travis Hughes
        orcid: http://orcid.org/0000-0002-5764-5884
      - name: David Zemmour
        orcid: http://orcid.org/0000-0002-0990-217X
      - name: John C OHoro
        orcid: null
      - name: Joseph D Yao
        orcid: http://orcid.org/0000-0002-5988-8927
      - name: Bobbi S Pritt
        orcid: http://orcid.org/0000-0003-0261-1326
      - name: Andrew Norgan
        orcid: http://orcid.org/0000-0002-2955-2066
      - name: Ryan T Hurt
        orcid: http://orcid.org/0000-0003-1158-7559
      - name: Andrew D Badley
        orcid: http://orcid.org/0000-0001-7796-7680
      - name: AJ Venkatakrishnan
        orcid: http://orcid.org/0000-0003-2819-3214
      - name: Venky Soundararajan
        orcid: http://orcid.org/0000-0001-7434-9211
  comment:
    dislikes: 0
    thread: "8631633721"
    numReports: 0
    likes: 1
    id: "5446735446"
    createdAt: 2021-07-07T07:10:46
    author:
      username: dklimentidis
      about: Clinical Pharmacy Specialist with an interest in Infectious Diseases and
        Geriatrics
      name: D. Klimentidis
      isPowerContributor: false
      profileUrl: https://disqus.com/by/dklimentidis/
      url: https://clinicalpharmacist.gr
      location: Greece
      id: "60746886"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Only Œí cells produce antibodies, that's what they do. Moreover, if
      there are no mutations to the spike protein then vaccines don't lose
      effectiveness over time, since this specific protein is their target. So I
      fail to see your point.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.07.01.21259833v1
  tweets:
    - created_at: Wed Jul 07 18:25:25 +0000 2021
      id: 1412840192180953000
      id_str: "1412840192180953088"
      text: >-
        üí¨ medRxiv comment on "COVID-19 vaccines dampen genom..."


        "Only Œí cells produce antibodies, that's what they do. Mo‚Ä¶ https://t.co/NLwvqJ2NT8
      truncated: true
      entities:
        urls:
          - url: https://t.co/NLwvqJ2NT8
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 07 18:25:25 +0000 2021
      id: 1412840193107890200
      id_str: "1412840193107890182"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/JlZag63NBW
      truncated: false
      entities:
        urls:
          - url: https://t.co/JlZag63NBW
      in_reply_to_status_id: 1412840192180953000
      in_reply_to_status_id_str: "1412840192180953088"
- preprint:
    id: 148961
    metric: 24
    title: The crucial role of genome-wide genetic variation in conservation
    url: https://api.rxivist.org/v1/papers/148961
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.05.451163v1
    doi: 10.1101/2021.07.05.451163
    category: evolutionary-biology
    first_posted: 2021-07-06
    abstract: The unprecedented rate of extinction calls for efficient use of
      genetics to help conserve biodiversity. Several recent genomic and
      simulation-based studies have argued that the field of conservation
      biology has placed too much focus on the conservation of genome-wide
      genetic variation, and that this approach should be replaced with another
      that focuses instead on managing the subset of functional genetic
      variation that is thought to affect fitness. Here, we critically evaluate
      the feasibility and likely benefits of this approach in conservation. We
      find that population genetics theory and empirical results show that the
      conserving genome-wide genetic variation is generally the best approach to
      prevent inbreeding depression and loss of adaptive potential from driving
      populations towards extinction. Focusing conservation efforts on
      presumably functional genetic variation will only be feasible
      occasionally, often misleading, and counterproductive when prioritized
      over genome-wide genetic variation. Given the increasing rate of habitat
      loss and other environmental changes, failure to recognize the detrimental
      effects of lost genome-wide variation on long-term population viability
      will only worsen the biodiversity crisis.
    authors:
      - name: Martin Kardos
      - name: Ellie Armstrong
      - name: Sarah W. Fitzpatrick
      - name: Samantha Hauser
      - name: Philip Hedrick
      - name: Joshua Miller
      - name: David Tallmon
      - name: W. Chris Funk
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Wed Jul 07 20:16:09 +0000 2021
      id: 1412868057815519200
      id_str: "1412868057815519233"
      text: >-
        üî• bioRxiv Evolutionary-biology preprint by M. Kardos et al:


        "The crucial role of genome-wide genetic variation in‚Ä¶ https://t.co/d9IaHu5MPd
      truncated: true
      entities:
        urls:
          - url: https://t.co/d9IaHu5MPd
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "127169"
    doi: 10.1101/2021.01.27.21250604
    first_posted: 2021-01-29
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.01.27.21250604v1
    url: https://api.rxivist.org/v1/papers/127169
    title: "The World Mortality Dataset: Tracking excess mortality across countries
      during the COVID-19 pandemic"
    category: epidemiology
    abstract: Comparing the impact of the COVID-19 pandemic between countries or
      across time is difficult because the reported numbers of cases and deaths
      can be strongly affected by testing capacity and reporting policy. Excess
      mortality, defined as the increase in all-cause mortality relative to the
      recent average, is widely considered as a more objective indicator of the
      COVID-19 death toll. However, there has been no central,
      frequently-updated repository of the all-cause mortality data across
      countries. To fill this gap, we have collected weekly, monthly, or
      quarterly all-cause mortality data from 77 countries, openly available as
      the regularly-updated World Mortality Dataset. We used this dataset to
      compute the excess mortality in each country during the COVID-19 pandemic.
      We found that in the worst-affected countries the annual mortality
      increased by over 50%, while in several other countries it decreased by
      over 5%, presumably due to lockdown measures decreasing the non-COVID
      mortality. Moreover, we found that while some countries have been
      reporting the COVID-19 deaths very accurately, many countries have been
      underreporting their COVID-19 deaths by an order of magnitude or more.
      Averaging across the entire dataset suggests that the world's COVID-19
      death toll may be at least 1.6 times higher than the reported number of
      confirmed deaths.
    authors:
      - name: Ariel Karlinsky
        orcid: null
      - name: Dmitry Kobak
        orcid: http://orcid.org/0000-0002-5639-7209
  comment:
    dislikes: 0
    thread: "8573176341"
    numReports: 0
    likes: 0
    id: "5446988699"
    createdAt: 2021-07-07T13:28:03
    author:
      username: arielkarlinsky
      about: ""
      name: Ariel Karlinsky
      isPowerContributor: false
      profileUrl: https://disqus.com/by/arielkarlinsky/
      url: ""
      location: ""
      id: "344436454"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Dear Sebastian,


      For the % increase estimate, our denominator is *annual* baseline. You can see the weekly/monthly/quartelry baselines for each country here: https://github.com/dkobak/excess-mortality/blob/main/baselines.csv


      Our predicted annual baseline for Germany is 978,953 deaths (as Germany has an upward trend in mortality based on previous 5 years) so 36K excess deaths is 3.7% which is rounded in the table and figure to 4%, as we mention in the text. 


      Generally, for the exact estimated numbers please turn to our publicly open and always updated repo which contains the code/CSV and everything else: https://github.com/dkobak/excess-mortality
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.01.27.21250604v3
  tweets:
    - created_at: Wed Jul 07 20:19:41 +0000 2021
      id: 1412868949222559700
      id_str: "1412868949222559755"
      text: |-
        üí¨ medRxiv comment on "The World Mortality Dataset: T..."

        "Dear Sebastian,

        For the % increase estimate, our denomi‚Ä¶ https://t.co/VnLgl0vKS1
      truncated: true
      entities:
        urls:
          - url: https://t.co/VnLgl0vKS1
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 07 20:19:42 +0000 2021
      id: 1412868949981683700
      id_str: "1412868949981683716"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/SYOosLmQld
      truncated: false
      entities:
        urls:
          - url: https://t.co/SYOosLmQld
      in_reply_to_status_id: 1412868949222559700
      in_reply_to_status_id_str: "1412868949222559755"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5446824396"
    createdAt: 2021-07-07T10:03:14
    author:
      username: ateamrdr
      about: ""
      name: ateamrdr
      isPowerContributor: false
      profileUrl: https://disqus.com/by/ateamrdr/
      url: ""
      location: ""
      id: "123288994"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: This is very interesting. What about the issue of transmission? If
      you do come into contact with the virus after having been previously
      infected, you might recover faster, but are you more likely to transmit if
      you have natural immunity vs vaccine immunity?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Wed Jul 07 22:19:28 +0000 2021
      id: 1412899090388631600
      id_str: "1412899090388631554"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "This is very interesting. What about the issue of transm‚Ä¶ https://t.co/2Ah0gkSZjW
      truncated: true
      entities:
        urls:
          - url: https://t.co/2Ah0gkSZjW
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 07 22:19:28 +0000 2021
      id: 1412899091437260800
      id_str: "1412899091437260805"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1412899090388631600
      in_reply_to_status_id_str: "1412899090388631554"
- preprint:
    id: "147698"
    doi: 10.1101/2021.06.25.450004
    first_posted: 2021-06-26
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.25.450004v1
    url: https://api.rxivist.org/v1/papers/147698
    title: Dynamic rewiring of biological activity across genotype and lineage
      revealed by context-dependent functional interactions
    category: systems-biology
    abstract: Coessentiality networks derived from CRISPR screens in cell lines
      provide a powerful framework for identifying functional modules in the
      cell and for inferring the role of uncharacterized genes. However, these
      networks integrate signal across all underlying data, and can mask strong
      interactions that occur in only a subset of the cell lines analyzed. Here
      we decipher dynamic functional interactions by identifying significant
      cellular contexts, primarily by oncogenic mutation, lineage, and tumor
      type, and discovering coessentiality relationships that depend on these
      contexts. We recapitulate well-known gene-context interactions such as
      oncogene-mutation, paralog buffering, and tissue-specific essential genes,
      show how mutation rewires known signal transduction pathways, including
      RAS/RAF and IGF1R-PIK3CA, and illustrate the implications for drug
      targeting. We further demonstrate how context-dependent functional
      interactions can elucidate lineage-specific gene function, as illustrated
      by the maturation of proreceptors IGF1R and MET by proteases FURIN and
      CPD. This approach advances our understanding of context-dependent
      interactions and how they can be gleaned from these data.
    authors:
      - name: Eiru Kim
        orcid: http://orcid.org/0000-0002-1901-5670
      - name: Veronica Gheorghe
        orcid: null
      - name: Traver Hart
        orcid: http://orcid.org/0000-0002-1880-3341
  comment:
    dislikes: 0
    thread: "8616679379"
    numReports: 0
    likes: 0
    id: "5447399344"
    createdAt: 2021-07-07T18:51:49
    author:
      username: paulaweidemueller
      about: ""
      name: Paula Weidemueller
      isPowerContributor: false
      profileUrl: https://disqus.com/by/paulaweidemueller/
      url: ""
      location: ""
      id: "372013675"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Cool project!

      I can't seem to find Supplementary Figure 1. Is this also uploaded or will you update this at a later stage?



      I also have a question to the scatter plots you show in the different figures. When you show the coloured linear fit lines: are these the linear fits obtained from the Pearson correlation of all cell lines excluding the context (seems to be the case for e.g. Fig 3 D/E)? Or are these fits obtained when considering only cell lines of that specific context (seeems to be the case for e.g. Fig 4 B-E)?
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.25.450004v1
  tweets:
    - created_at: Thu Jul 08 01:01:39 +0000 2021
      id: 1412939904946933800
      id_str: "1412939904946933762"
      text: |-
        üí¨ bioRxiv comment on "Dynamic rewiring of biological..."

        "Cool project!
        I can't seem to find Supplementary Figure‚Ä¶ https://t.co/3pXMmnUJRW
      truncated: true
      entities:
        urls:
          - url: https://t.co/3pXMmnUJRW
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 08 01:01:39 +0000 2021
      id: 1412939905685246000
      id_str: "1412939905685245958"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/ojG5FT3RCZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/ojG5FT3RCZ
      in_reply_to_status_id: 1412939904946933800
      in_reply_to_status_id_str: "1412939904946933762"
- preprint:
    id: "144220"
    doi: 10.1101/2021.06.01.446559
    first_posted: 2021-06-01
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.01.446559v1
    url: https://api.rxivist.org/v1/papers/144220
    title: "AltumAge: A Pan-Tissue DNA-Methylation Epigenetic Clock Based on Deep
      Learning"
    category: bioinformatics
    abstract: Several age predictors based on DNA methylation, dubbed epigenetic
      clocks, have been created in recent years. Their accuracy and potential
      for generalization vary widely based on the training data. Here, we
      gathered 143 publicly available data sets from several human tissues to
      develop AltumAge, a highly accurate and precise age predictor based on
      deep learning. Compared to Horvath's 2013 model, AltumAge performs better
      across both normal and malignant tissues and is more generalizable to new
      data sets. Interestingly, it can predict gestational week from placental
      tissue with low error. Lastly, we used deep learning interpretation
      methods to learn which methylation sites contributed to the final model
      predictions. We observed that while most important CpG sites are linearly
      related to age, some highly-interacting CpG sites can influence the
      relevance of such relationships. We studied the associated genes of these
      CpG sites and found literary evidence of their involvement in age-related
      gene regulation. Using chromatin annotations, we observed that the CpG
      sites with the highest contribution to the model predictions were related
      to heterochromatin and gene regulatory regions in the genome. We also
      found age-related KEGG pathways for genes containing these CpG sites. In
      general, neural networks are better predictors due to their ability to
      capture complex feature interactions compared to the typically used
      regularized linear regression. Altogether, our neural network approach
      provides significant improvement and flexibility to current epigenetic
      clocks without sacrificing model interpretability.
    authors:
      - name: Lucas Paulo de Lima Camillo
        orcid: http://orcid.org/0000-0001-8166-0761
      - name: Louis R Lapierre
        orcid: http://orcid.org/0000-0002-8154-141X
      - name: Ritambhara Singh
        orcid: http://orcid.org/0000-0002-7523-160X
  comment:
    dislikes: 0
    thread: "8597997093"
    numReports: 0
    likes: 0
    id: "5447381316"
    createdAt: 2021-07-07T18:37:33
    author:
      name: Louis El Khoury
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Very nice read.

      I think there is a typo in line 182. It says "(cg10523019 and cg26394940 [...]" while I think it is meant to say (cg10523019 and cg13460409 [...]". Right?
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.01.446559v3
  tweets:
    - created_at: Thu Jul 08 12:36:45 +0000 2021
      id: 1413114835148083200
      id_str: "1413114835148083205"
      text: |-
        üí¨ bioRxiv comment on "AltumAge: A Pan-Tissue DNA-Met..."

        "Very nice read.
        I think there is a typo in line 182. It‚Ä¶ https://t.co/zgkk9R7vd0
      truncated: true
      entities:
        urls:
          - url: https://t.co/zgkk9R7vd0
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 08 12:36:45 +0000 2021
      id: 1413114835986960400
      id_str: "1413114835986960386"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/IIPosDD3TG
      truncated: false
      entities:
        urls:
          - url: https://t.co/IIPosDD3TG
      in_reply_to_status_id: 1413114835148083200
      in_reply_to_status_id_str: "1413114835148083205"
- preprint:
    id: "84475"
    doi: 10.1101/2020.05.21.106914
    first_posted: 2020-05-23
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.05.21.106914v1
    url: https://api.rxivist.org/v1/papers/84475
    title: Association between erythrocyte dynamics and vessel remodelling in
      developmental vascular networks
    category: developmental-biology
    abstract: >-
      Sprouting angiogenesis is an essential vascularisation mechanism
      consisting of sprouting and remodelling. The remodelling phase is driven
      by rearrangements of endothelial cells (ECs) within the post-sprouting
      vascular plexus. Prior work has uncovered how ECs polarise and migrate in
      response to flow-induced wall shear stress (WSS). However, the question of
      how the presence of erythrocytes (well-known as RBCs) and their
      haemodynamics impact affects vascular remodelling remains unanswered.
      Here, we devise a computational framework to model cellular blood flow in
      developmental mouse retina. We demonstrate a previously unreported highly
      heterogeneous distribution of RBCs in primitive vasculature. Furthermore,
      we report a strong association between vessel regression and RBC
      depletion, and identify plasma skimming as the driving mechanism. Live
      imaging in a developmental zebrafish model confirms this association.
      Taken together, our results indicate that RBC dynamics are fundamental to
      establishing the regional WSS differences driving vascular remodelling via
      their ability to modulate effective viscosity.


      SummaryRecent studies demonstrate that during sprouting angiogenesis, blood flow provides crucial hydrodynamic cues (e.g. wall shear stress) for the remodelling of primitive plexuses towards a functional network. Notwithstanding, the role of RBCs in this process remains poorly understood. We report on the inherent heterogeneity of RBC perfusion within primitive vasculatures, and uncover a strong association between RBC depletion and vessel regression. Our work indicates the essential role of RBC dynamics in the establishment of regional WSS differences driving vascular remodelling. The RBC-driven process of pruning cell-depleted vessels not only importantly contributes to the optimal patterning of vascular networks during development, but also provides a remodelling mechanism to support clinical findings of microangiopathic complications associated with impaired RBC deformability in diseases such as diabetes mellitus and hypertension.
    authors:
      - name: Qi Zhou
        orcid: http://orcid.org/0000-0003-3560-2311
      - name: Tijana Perovic
        orcid: null
      - name: Ines Fechner
        orcid: null
      - name: Lowell T. Edgar
        orcid: http://orcid.org/0000-0002-8586-1605
      - name: Peter R. Hoskins
        orcid: null
      - name: Holger Gerhardt
        orcid: http://orcid.org/0000-0002-3030-0384
      - name: Timm Kr√ºger
        orcid: http://orcid.org/0000-0003-2934-2699
      - name: Miguel O. Bernabeu
        orcid: http://orcid.org/0000-0002-6456-3756
  comment:
    dislikes: 0
    thread: "8321851921"
    numReports: 0
    likes: 0
    id: "5447318200"
    createdAt: 2021-07-07T17:49:00
    author:
      username: charlesqzhou
      about: ""
      name: charlesqzhou
      isPowerContributor: false
      profileUrl: https://disqus.com/by/charlesqzhou/
      url: ""
      location: ""
      id: "372012989"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "Our preprint is now out in Royal Society Interface. Check it here:
      https://royalsocietypublishing.org/doi/10.1098/rsif.2021.0113"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.05.21.106914v2
  tweets:
    - created_at: Thu Jul 08 14:25:32 +0000 2021
      id: 1413142210464292900
      id_str: "1413142210464292864"
      text: >-
        üí¨ bioRxiv comment on "Association between erythrocyt..."


        "Our preprint is now out in Royal Society Interface. Chec‚Ä¶ https://t.co/lb3YMZOcVe
      truncated: true
      entities:
        urls:
          - url: https://t.co/lb3YMZOcVe
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 08 14:25:32 +0000 2021
      id: 1413142211575750700
      id_str: "1413142211575750663"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/Zp9CXuHtMW
      truncated: false
      entities:
        urls:
          - url: https://t.co/Zp9CXuHtMW
      in_reply_to_status_id: 1413142210464292900
      in_reply_to_status_id_str: "1413142210464292864"
- preprint:
    id: "78794"
    doi: 10.1101/2020.04.03.023465
    first_posted: 2020-04-03
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.04.03.023465v1
    url: https://api.rxivist.org/v1/papers/78794
    title: Incorrect Molecular Weights due to inaccurate Prestained Protein
      Molecular Weight Markers that are used for Gel Electrophoresis and Western
      Blotting
    category: cell-biology
    abstract: The most widely used Western blotting protein standards are prestained
      proteins of known molecular mass (kDa). They are also utilized for sodium
      dodecyl sulphate (SDS) Polyacrylamide Gel Electrophoresis (PAGE) to
      determine the molecular mass of proteins separated by electrophoresis. The
      objective of this study was to assess the reliability of different
      commercially available protein standards in predicting accurate protein
      molecular weights. We performed this experiment by running Criterion TGX
      gels with five prestained protein standards (Thermo Fisher SeeBlue Plus 2,
      Bio-Rad Precision Plus Protein Dual-color, Thermo Fisher Spectra
      Multi-color, Novex-Sharp Pre-stained, and Invitrogen iBright Pre-Stained).
      To evaluate their accuracy, we utilized highly purified Bovine Serum
      Albumin (BSA, 66.44 kDa) and Cytochrome C (Cyto C, 11.62 kDa). We also
      made use of the dimers of BSA (132.88 kDa) and Cyt C (23.24 kDa) that are
      present on SDS-PAGE gels. Our results suggest that three of the standards
      were less accurate at higher molecular masses with the iBright marker
      having the highest error in determining the expected 132.88 kDa molecular
      weight. The SeeBlue Plus 2 was accurate at identifying the 132.88 kDa
      molecular weight protein band but was less reliable for the three other
      lower molecular weight proteins. These findings have significant
      implications for the determination of protein masses because researchers
      rely on these standards to evaluate the molecular masses of their
      protein(s). We suggest that at least two different protein standards
      should be initially used in electrophoresis gels and for Western blotting
      in order to get accurate protein molecular weight results.
    authors:
      - name: R√¥mulo Le√£o Silva Neris
        orcid: null
      - name: Ajuni Kaur
        orcid: null
      - name: Aldrin V. Gomes
        orcid: http://orcid.org/0000-0002-9819-3036
  comment:
    dislikes: 0
    thread: "7950110041"
    numReports: 0
    likes: 0
    id: "5447167403"
    createdAt: 2021-07-07T15:55:33
    author:
      username: jonaszweber
      about: ""
      name: Jonasz Weber
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jonaszweber/
      url: ""
      location: ""
      id: "372008177"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Dear authors,


      Thank you very much for your scientific work on assessing the reliability of molecular weight (MW) markers in SDS-PAGE. The findings of your study are highly relevant for researchers using this methodology for analyzing proteins. Also, in our lab, where we are using different MW markers, we have experienced variations and discrepancies. In your work, you have tested all MW markers on TGX pre-cast gels. We preferentially use Bis-Tris and Tris-acetate gels, and we see differences between the MW prediction precision divergent from your results. Did you consider expanding your dataset using more gel types as the earlier mentioned BT and TA gels? 


      I look forward to your reply.


      Best regards,

      Jonasz Weber
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.04.03.023465v1
  tweets:
    - created_at: Thu Jul 08 16:41:23 +0000 2021
      id: 1413176398446043100
      id_str: "1413176398446043136"
      text: |-
        üí¨ bioRxiv comment on "Incorrect Molecular Weights du..."

        "Dear authors,

        Thank you very much for your scientific w‚Ä¶ https://t.co/09yp52zNkk
      truncated: true
      entities:
        urls:
          - url: https://t.co/09yp52zNkk
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 08 16:41:23 +0000 2021
      id: 1413176399343595500
      id_str: "1413176399343595522"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/bxv4gMDcu7
      truncated: false
      entities:
        urls:
          - url: https://t.co/bxv4gMDcu7
      in_reply_to_status_id: 1413176398446043100
      in_reply_to_status_id_str: "1413176398446043136"
- preprint:
    id: "104181"
    doi: 10.1101/2020.11.15.383323
    first_posted: 2020-11-16
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.11.15.383323v1
    url: https://api.rxivist.org/v1/papers/104181
    title: Immunological memory to SARS-CoV-2 assessed for up to eight months after
      infection
    category: immunology
    abstract: Understanding immune memory to SARS-CoV-2 is critical for improving
      diagnostics and vaccines, and for assessing the likely future course of
      the COVID-19 pandemic. We analyzed multiple compartments of circulating
      immune memory to SARS-CoV-2 in 254 samples from 188 COVID-19 cases,
      including 43 samples at [&ge;] 6 months post-infection. IgG to the Spike
      protein was relatively stable over 6+ months. Spike-specific memory B
      cells were more abundant at 6 months than at 1 month post symptom onset.
      SARS-CoV-2-specific CD4+ T cells and CD8+ T cells declined with a
      half-life of 3-5 months. By studying antibody, memory B cell, CD4+ T cell,
      and CD8+ T cell memory to SARS-CoV-2 in an integrated manner, we observed
      that each component of SARS-CoV-2 immune memory exhibited distinct
      kinetics.
    authors:
      - name: Jennifer M Dan
        orcid: http://orcid.org/0000-0002-1672-0657
      - name: Jose Mateus
        orcid: http://orcid.org/0000-0002-1402-3452
      - name: Yu Kato
        orcid: http://orcid.org/0000-0003-4743-1775
      - name: Kathryn M Hastie
        orcid: null
      - name: Esther Dawen Yu
        orcid: null
      - name: Caterina E. Faliti
        orcid: null
      - name: Alba Grifoni
        orcid: http://orcid.org/0000-0002-2209-5966
      - name: Sydney I Ramirez
        orcid: http://orcid.org/0000-0002-7166-5195
      - name: Sonya Haupt
        orcid: null
      - name: April Frazier
        orcid: http://orcid.org/0000-0002-4722-7304
      - name: Catherine Nakao
        orcid: null
      - name: Vamseedhar Rayaprolu
        orcid: null
      - name: Stephen A Rawlings
        orcid: null
      - name: Bjoern Peters
        orcid: http://orcid.org/0000-0002-8457-6693
      - name: Florian Krammer
        orcid: http://orcid.org/0000-0003-4121-776X
      - name: Viviana Simon
        orcid: http://orcid.org/0000-0002-6416-5096
      - name: Erica Ollmann Saphire
        orcid: http://orcid.org/0000-0002-1206-7451
      - name: Davey M Smith
        orcid: http://orcid.org/0000-0003-3603-1733
      - name: Daniela Weiskopf
        orcid: http://orcid.org/0000-0003-2968-7371
      - name: Alessandro Sette
        orcid: http://orcid.org/0000-0001-7013-2250
      - name: Shane Crotty
        orcid: http://orcid.org/0000-0002-6484-6262
  comment:
    dislikes: 0
    thread: "8320700571"
    numReports: 0
    likes: 0
    id: "5447138839"
    createdAt: 2021-07-07T15:33:36
    author:
      username: vinyanalista
      about: ""
      name: Ant√¥nio Vin√≠cius
      isPowerContributor: false
      profileUrl: https://disqus.com/by/vinyanalista/
      url: http://vinyanalista.com.br
      location: Terra / Earth
      id: "143189420"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "Now published in Science: https://doi.org/10.1126/science.abf4063"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.11.15.383323v2
  tweets:
    - created_at: Thu Jul 08 18:29:28 +0000 2021
      id: 1413203598788366300
      id_str: "1413203598788366344"
      text: |-
        üí¨ bioRxiv comment on "Immunological memory to SARS-C..."

        "Now published in Science: "

        https://t.co/UwIXDhBrWP
      truncated: false
      entities:
        urls:
          - url: https://t.co/UwIXDhBrWP
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 08 18:29:28 +0000 2021
      id: 1413203599560114200
      id_str: "1413203599560114178"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/4qkldYdFrA
      truncated: false
      entities:
        urls:
          - url: https://t.co/4qkldYdFrA
      in_reply_to_status_id: 1413203598788366300
      in_reply_to_status_id_str: "1413203598788366344"
- preprint:
    id: 122405
    metric: 344
    title: "The SARS-CoV-2 spike protein disrupts the cooperative function of human
      cardiac pericytes - endothelial cells through CD147 receptor-mediated
      signalling: a potential non-infective mechanism of COVID-19 microvascular
      disease"
    url: https://api.rxivist.org/v1/papers/122405
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.12.21.423721v1
    doi: 10.1101/2020.12.21.423721
    category: cell-biology
    first_posted: 2020-12-21
    abstract: >-
      BackgroundSevere coronavirus disease 2019 (COVID-19) manifests as a
      life-threatening microvascular syndrome. The severe acute respiratory
      syndrome coronavirus 2 (SARS-CoV-2) uses primarily the capsid spike (S)
      protein to engage with its receptors and infect host cells. To date, it is
      still not known if the S protein alone, without the other viral elements,
      is able to trigger vascular cell signalling and provoke cell dysfunction.


      MethodsWe investigated the effects of the recombinant, stabilised S protein on primary human cardiac pericytes (PCs) signalling and function. Endpoints included cell viability, proliferation, migration, cooperation with endothelial cells (ECs) in angiogenesis assays, and release of pro-inflammatory cytokines. Adopting a blocking strategy against the S protein receptors ACE2 and CD147, we explored which receptor mediates the S protein signalling in PCs.


      FindingsWe show, for the first time, that the recombinant S protein alone elicits functional alterations in cardiac PCs. This was documented as: (1) increased migration, (2) reduced ability to support EC network formation on Matrigel, (3) secretion of pro-inflammatory molecules typically involved in the cytokine storm, and (4) production of pro-apoptotic factors responsible for EC death. Furthermore, the S protein stimulates the phosphorylation/activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) through the CD147 receptor, but not ACE2, in cardiac PCs. Accordingly, the neutralization of CD147, using a blocking antibody, prevented the activation of ERK1/2 and partially rescued the PC function in the presence of the S protein.


      InterpretationOur findings suggest the new, intriguing hypothesis that the S protein may elicit vascular cell dysfunction, potentially amplifying, or perpetuating, the damage caused by the whole coronavirus. This mechanism may have clinical and therapeutic implication.


      FundingElizabeth Blackwell Institute (EBI) Rapid Response COVID-19 award.


      Research in contextO_ST_ABSEvidence before this studyC_ST_ABSThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses primarily the capsid spike (S) protein to engage with its receptors and infect host cells. Co-receptors and host cell proteases may also be involved. Angiotensin-converting enzyme 2 (ACE2) is the well-recognized entry receptor used by the virus in respiratory epithelial cells; it is also abundantly expressed in the human heart. Alongside ACE2, CD147 has recently emerged as a novel receptor for SARS-CoV-2. Yet, it is not clear if SARS-CoV-2 triggers adverse responses in cardiac vascular mural cells. Likewise, no investigation was devoted to verifying if the recombinant S protein alone can mimic the whole virus signalling.


      Added value of this studyThis study provides the first evidence that the recombinant S protein alone, without the other viral elements, is capable of eliciting cellular signalling in human cardiac pericytes, thereby inducing cell dysfunction. In addition, this study proposes CD147 as the leading receptor mediating S protein signalling in cardiac pericytes.


      Implications of all the available evidenceThese reports imply that fragments of the S protein might be able to elicit vascular cell dysfunction. Blocking the CD147 receptor may help protect the vasculature not only from infection, but also from the collateral damage caused by the S protein.
    authors:
      - name: Elisa Avolio
      - name: Monica Gamez
      - name: Kapil Gupta
      - name: Rebecca Foster
      - name: Imre Berger
      - name: Massimo Caputo
      - name: Andrew Davidson
      - name: Darryl Hill
      - name: Paolo Madeddu
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Thu Jul 08 20:16:07 +0000 2021
      id: 1413230436319326200
      id_str: "1413230436319326210"
      text: >-
        üî• bioRxiv Cell-biology preprint by E. Avolio et al:


        "The SARS-CoV-2 spike protein disrupts the cooperative functio‚Ä¶ https://t.co/pYAq5c1Fd7
      truncated: true
      entities:
        urls:
          - url: https://t.co/pYAq5c1Fd7
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 0
    id: "5446726910"
    createdAt: 2021-07-07T06:53:23
    author:
      username: yuribudilov
      about: ""
      name: Yuri Budilov
      isPowerContributor: false
      profileUrl: https://disqus.com/by/yuribudilov/
      url: ""
      location: ""
      id: "220708693"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "masks do work <b>in theory</b> but <b>in practice</b> most of the
      mask benefits evaporate due to factors like: incorrect use of masks, wrong
      types of masks and inability to police everyone wearing a mask and wearing
      it correctly. There are a handful of high-risk environments where masks
      are very beneficial and can be policed effectively such as medical,
      quarantine, international exposure, age-care. With large mass gathering
      (sports) banned, it makes it easier. Elsewhere, masks give only the
      illusion of safety - in the shops, restaurants, outdoors, private homes,
      schools, child-care. They should have been recommended in those places,
      but not mandated.IMO."
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Thu Jul 08 20:19:41 +0000 2021
      id: 1413231333762031600
      id_str: "1413231333762031617"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "masks do work &lt;b&gt;in theory&lt;/b&gt; but &lt;b&gt;in practice&lt;/b&gt; mo‚Ä¶ https://t.co/Qqs4szl1Xx
      truncated: true
      entities:
        urls:
          - url: https://t.co/Qqs4szl1Xx
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 08 20:19:41 +0000 2021
      id: 1413231334642921500
      id_str: "1413231334642921477"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1413231333762031600
      in_reply_to_status_id_str: "1413231333762031617"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 0
    id: "5446172783"
    createdAt: 2021-07-06T20:07:34
    author:
      username: disqus_w8LdLejsM2
      about: ""
      name: Stephen Smith
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_w8LdLejsM2/
      url: ""
      location: ""
      id: "371160113"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Hello Scott and thanks for taking the time to post your concerns and
      thoughts.


      Actually, over 87% were prescribed HCQ. In other posts, I explain in several ways why cumulative HCQ dose is not simply a marker of survival. The cumulative HCQ dose was based upon the ID doc seeing the pts. Different ID docs interpreted the available data differently. 

      The most commonly used dose = 2,400 mg over 5 days. 

      Please see the other posts for details. 

      And, I have tried very hard to explain why HCQ cumulative dose isn't a marker of survival. 


      Thanks,

      Stephen
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Thu Jul 08 22:19:13 +0000 2021
      id: 1413261417357140000
      id_str: "1413261417357139973"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "Hello Scott and thanks for taking the time to post your‚Ä¶ https://t.co/UPONw4XMhA
      truncated: true
      entities:
        urls:
          - url: https://t.co/UPONw4XMhA
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 08 22:19:13 +0000 2021
      id: 1413261418099523600
      id_str: "1413261418099523587"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1413261417357140000
      in_reply_to_status_id_str: "1413261417357139973"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 0
    id: "5446165126"
    createdAt: 2021-07-06T20:02:04
    author:
      username: disqus_w8LdLejsM2
      about: ""
      name: Stephen Smith
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_w8LdLejsM2/
      url: ""
      location: ""
      id: "371160113"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Hello Semper and thanks for taking the time to post your concerns.


      I will address your questions in reverse order. 

      First, the VA Study included anyone, who had a pill of HCQ dispensed to them, in the HCQ arm. That means if a pt got 1 pill or 60 pills of HCQ, that pt was in the HCQ arm. That's not medically sound. Second, none of the VA Study's authors treated a single pt with Covid. That's very important. When clinical data are being analyzed by statisticians, a clinician needs to able to explain what this means and that means. I am unsure what the motivation was for basic science ophthalmologists to do a Covid study. 

      Second, we looked at all medications given, esp. steroids, toci and CP. We looked antibiotics in general and by potency. AZM alone was not associated in an increase in survival. In reviewing the >3 g HCQ/>1 g AZM group, we, of course, went through their other therapies to see if something else could explain this large difference in survival. BTW, we didn't see much secondary bacterial pneumonia in Covid pts. We expected to. That's how influenza often or usually kills people. Diagnosing secondary bacterial pneumonia in intubated pts isn't easy. That's one of the reasons we looked at antibiotics, to see if empiric antibiotic therapy for secondary bacterial pneumonia improved outcomes. As best we could tell, it did not. 

      Third, the mortality rates of similar studies were similar to this cohorts mortality rate. Early reports used short data collection periods, such as 14 days or time to discharge from the ICU. Those earlier reports had large percentages of pts still in the hospital and on the ventilator. So, the mortality rates were underestimated, as they noted that in their discussion sections. I cited references, which looked at longer times after admission and had similar mortality rates after IMV. 

      Fourth, I don't understand your criticism about the statistics. A p-value means the chance the difference between the two groups is due to chance. A p-value = 0.05 means there is a 5% chance the observed difference is due to random chance. The lower the p-value, the less likely the difference is secondary to chance. These p-values were often well below 0.05, the arbitrary cut-off for scientific significance. These statistics were performed by professionals. In fact, we used more than one statistics group to make sure they agreed and they did. 

      Fifth, the study doesn't show HCQ improves survival. The data show that HCQ and AZM given together and both above a certain threshold are very strongly associated or cause improvement in survival even after controlling for other factors. The HCQ RCTs I am aware of only reported ITT analyses of the data, meaning they did not report Per Protocol analyses. The only inpatient HCQ/AZM RCT was done in Brazil. In this study, the mortality rate in each group, including the control group mortality, was very low, they only enrolled pts who had <= 4L NC and 24% of subjects had a negative Covid test or none available. The data from this study do not apply to this Cohort, over 95% tested Covid+ and all required intubation and mechanical ventilation. 

      Sixth, I prefer good RCT data to good observational data. The restrictions of observational data are known and discussed. However, many RCTs have serious flaws. Usually, where the RCT data differ from the observational data, the RCT data are correct, but not always. Regardless, there exists no RCT which looked at HCQ/AZM therapy in IMV-requiring Covid pts.

      Since the beginning of Medicine, observational data have been very helpful in many settings. As mentioned, the HCQ RCTs didn't even report PP analysis. Perhaps, there is no dose-response from HCQ in Covid, but the studies I have read didn't look at cumulative dose. 

      From an historic perspective, many current, first-line therapies and many FDA approved drugs lack RCT data. Of course, RCTs are not always so R. In many instances, the randomization process can be or is affected by someone/something. It wasn't an RCT, but was expanded use. I had an AIDS pts many yrs ago. The pt was dying. The pt had several, active opportunistic infections. We had participated in the RCT and knew the expanded access protocol. If I were honest about the pt's clinical situation, the company running the expanded access would not have given the pt the drug. I also knew the drug worked, and it was awaiting FDA approval based on the published RCT data. 

      I did the only ethical thing I could do; I lied. The pt got the drug and the recovery was miraculous. Last I checked, the pt was still doing well. 

      Doctors are notorious liars, when it comes to helping their pts. So, even well meaning doctors can screw up an RCT. Or, the analyses can be done in a way to confuse the results. Or the protocols are not adhered to as they should be. Take the Brazil RCT, 24% had a negative Covid test or did not have one available. Why did they include those pts? It's one thing if you have positive results, but if the results are negative, you need to do everything you can to make sure the enrolled pts have the disease you are testing. 


      Thanks,

      Stephen
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Fri Jul 09 01:03:07 +0000 2021
      id: 1413302662175596500
      id_str: "1413302662175596544"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "Hello Semper and thanks for taking the time to post your‚Ä¶ https://t.co/3Bu5Qmo5V2
      truncated: true
      entities:
        urls:
          - url: https://t.co/3Bu5Qmo5V2
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 09 01:03:07 +0000 2021
      id: 1413302662955667500
      id_str: "1413302662955667458"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1413302662175596500
      in_reply_to_status_id_str: "1413302662175596544"
- preprint:
    id: "145589"
    doi: 10.1101/2021.06.07.21258461
    first_posted: 2021-06-10
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.07.21258461v1
    url: https://api.rxivist.org/v1/papers/145589
    title: Social inequalities in hostility toward vaccination against Covid-19
    category: public-and-global-health
    abstract: In recent decades, France has appeared as a country particularly
      hostile to vaccination in general. When asked in November 2020 about the
      intention to take the Covid-19 vaccine, the French public showed, once
      again, reluctance. Therefore, France appeared as an ideal case study to
      analyze whether the hostility toward the Covid-19 vaccine has its own
      reasons or whether it is related to the reluctance to the principle of
      vaccination itself. Our objective was to determine the specificity of the
      social determinants of the intention to get the Covid-19 vaccine. Thanks
      to the use of a large random sample of the general population in France
      (86,000 individuals), the reluctant to Covid-19 vaccine could be clearly
      distinguished from the hesitant and the convinced, and thereby thoroughly
      analyzed. Our analysis highlighted a gendered reluctance toward
      vaccination in general but even more so regarding vaccination against
      Covid-19. It might refer to women being more concerned about the possible
      effects of an injection in their body, especially at the age of maternity
      and a differentiated socialization making them more sensitive than men to
      long-term risks and more apprehensive toward rapid technological change.
      We also found that people at the bottom of the social hierarchy, in terms
      of level of education, financial resources, and immigration status, were
      more likely to refuse the Covid-19 vaccine. Nevertheless, this reluctance
      was less prominent than for vaccination in general, reflecting the actual
      spread of the epidemic in various social milieux. Finally, our analysis
      showed that trust in the government's actions was significantly associated
      with reluctance toward the Covid-19 vaccine, even more than toward
      vaccination in general. Specific campaigns should be thought beforehand to
      reach women and people at the bottom of the social hierarchy to avoid
      furthering social inequalities in terms of morbidity and mortality.
    authors:
      - name: Alexis Spire
        orcid: null
      - name: Lena Silberzan
        orcid: null
      - name: Nathalie Bajos
        orcid: null
      - name: The EpiCov study group
        orcid: null
  comment:
    dislikes: 0
    thread: "8585059061"
    numReports: 0
    likes: 0
    id: "5449336445"
    createdAt: 2021-07-09T09:39:24
    author:
      username: disqus_NajR06gaBq
      about: ""
      name: Alice Ka
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_NajR06gaBq/
      url: ""
      location: ""
      id: "372090481"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Another possible interpretation for hesitation/reluctance to get
      vaccinated could be that people who did not get Covid do not see the
      interest of getting vaccinated since they managed to avoid Covid by using
      masks, washing hands, etc. This could be even more relevant for workers
      who attended their work as usual during the three lockdowns. It could be
      worth to look into this if you have access to these information.


      Other interpretation: poorer people tend to travel less frequently and may have less interest in the vaccine since it is not mandatory for conducting daily activities.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.07.21258461v1
  tweets:
    - created_at: Fri Jul 09 12:30:48 +0000 2021
      id: 1413475724342743000
      id_str: "1413475724342743041"
      text: >-
        üí¨ medRxiv comment on "Social inequalities in hostili..."


        "Another possible interpretation for hesitation/reluctanc‚Ä¶ https://t.co/QEO8VOC4WW
      truncated: true
      entities:
        urls:
          - url: https://t.co/QEO8VOC4WW
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 09 12:30:48 +0000 2021
      id: 1413475725336744000
      id_str: "1413475725336743936"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/zCeHPXNUH6
      truncated: false
      entities:
        urls:
          - url: https://t.co/zCeHPXNUH6
      in_reply_to_status_id: 1413475724342743000
      in_reply_to_status_id_str: "1413475724342743041"
- preprint:
    id: "148837"
    doi: 10.1101/2021.07.01.21259785
    first_posted: 2021-07-05
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.01.21259785v1
    url: https://api.rxivist.org/v1/papers/148837
    title: Risk factors for intensive care admission and death amongst children and
      young people admitted to hospital with COVID-19 and PIMS-TS in England
      during the first pandemic year
    category: pediatrics
    abstract: Identifying which children and young people (CYP) are vulnerable to
      severe disease following SARS-CoV-2 is important to guide shielding and
      vaccination policy. Methods We used data for all inpatient hospital
      admissions in England in CYP aged 0-17 between March 1st 2015 to Feb 28th
      2021, linked to paediatric intensive care unit (PICU) admission, and
      SARS-CoV-2 PCR testing, and deaths. We calculated odds ratios and
      predicted probability of PICU admission using generalized estimation
      equations, and compared these between COVID-19, PIMS-TS, other admissions
      in 2020/21, all admissions in 2019/20, and admissions due to influenza in
      20219/20. Findings There were 6,338 COVID-19 hospitalisations, 259 PICU
      admissions and 8 deaths as well as 712 PIMS-TS hospitalisations, 312 PICU
      admissions and <5 deaths. Odds of PICU admission were increased amongst
      neonates and decreased amongst 15-17 compared with 1-4 year olds with
      COVID-19, increased in older CYP and females with PIMS-TS, and increased
      for Black compared with White ethnicity for both conditions. Odds of PICU
      admission with COVID-19 were increased for CYP with any comorbidity and
      were highest for CYP with multiple medical problems. Comorbidities
      associated with PICU admission among COVID-19 patients were similar to
      overall PICU admissions in 2019/20 and to influenza PICU admissions in
      2019/20, but with higher odds. Interpreting associations with
      comorbidities within PIMS-TS was complex due to the multisystem nature of
      the disease. Interpretation CYP were at very low risk of severe disease
      and death from COVID-19 or PIMS-TS. Patterns of vulnerability for severe
      COVID-19 appear to magnify background risk factors for serious illness in
      CYP.
    authors:
      - name: Joseph Ward
        orcid: http://orcid.org/0000-0001-7263-8845
      - name: Rachel Harwood
        orcid: http://orcid.org/0000-0003-3440-3142
      - name: Clare Smith
        orcid: null
      - name: Simon E Kenny
        orcid: null
      - name: Matthew Clark
        orcid: null
      - name: Peter J Davis
        orcid: null
      - name: Elizabeth S Draper
        orcid: null
      - name: Dougal Hargreaves
        orcid: null
      - name: Shamez N Ladhani
        orcid: http://orcid.org/0000-0002-0856-2476
      - name: Michael Linney
        orcid: null
      - name: Karen Luyt
        orcid: null
      - name: Elizabeth Whittaker
        orcid: null
      - name: Lorna K Fraser
        orcid: http://orcid.org/0000-0002-1360-4191
      - name: Russell M Viner
        orcid: null
  comment:
    dislikes: 0
    thread: "8631646124"
    numReports: 0
    likes: 0
    id: "5449309023"
    createdAt: 2021-07-09T08:48:07
    author:
      username: disqus_OBKA6kftN5
      about: ""
      name: JN
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_OBKA6kftN5/
      url: ""
      location: ""
      id: "123143065"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      "We defined admissions resulting in death as the last admission for each
      CYP that occur within 28 days of death identified through ONS or NCMD. "


      ONS puts no such 28-day limit on deaths involving Covid (or any condition) so why does the study?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.07.01.21259785v1
  tweets:
    - created_at: Fri Jul 09 14:23:32 +0000 2021
      id: 1413504093629259800
      id_str: "1413504093629259785"
      text: >-
        üí¨ medRxiv comment on "Risk factors for intensive car..."


        ""We defined admissions resulting in death as the last ad‚Ä¶ https://t.co/CmbG3ID25N
      truncated: true
      entities:
        urls:
          - url: https://t.co/CmbG3ID25N
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 09 14:23:32 +0000 2021
      id: 1413504094686175200
      id_str: "1413504094686175237"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/khWTo6pNxQ
      truncated: false
      entities:
        urls:
          - url: https://t.co/khWTo6pNxQ
      in_reply_to_status_id: 1413504093629259800
      in_reply_to_status_id_str: "1413504093629259785"
- preprint:
    id: "141912"
    doi: 10.1101/2021.05.15.21257017
    first_posted: 2021-05-17
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.15.21257017v1
    url: https://api.rxivist.org/v1/papers/141912
    title: Extended interval BNT162b2 vaccination enhances peak antibody generation
      in older people
    category: infectious-diseases
    abstract: "Abstract Objectives: To assess the relative immunogenicity of
      standard or extended interval BNT162b2 vaccination. Design: Population
      based cohort study comparing immune responses 2 weeks after the second
      vaccine, with appropriate time-matched samples in participants who
      received standard or extended interval double vaccination. Setting:
      Primary care networks, Birmingham, UK. December 2020 to April 2021.
      Participants: 175 people aged over 80 years of age. All donors received
      the BNT162b2 Pfizer/BioNTech vaccination and were vaccinated with either a
      standard 3 week interval between doses or an extended interval schedule.
      Main outcome measures: Peak quantitative spike-specific antibody and
      cellular immune responses. Results: In donors without evidence of previous
      infection the peak antibody response was 3.5-fold higher in donors who had
      undergone delayed interval vaccination. Cellular immune responses were
      3.6-fold lower. Conclusion: Peak antibody responses after the second
      BNT162b2 vaccine are markedly enhanced in older people when this is
      delayed to 12 weeks although cellular responses are lower. Extended
      interval vaccination may therefore offer the potential to enhance and
      extend humoral immunity. Further follow up is now required to assess long
      term immunity and clinical protection."
    authors:
      - name: Helen M Parry
        orcid: http://orcid.org/0000-0002-9707-8167
      - name: Rachel Bruton
        orcid: null
      - name: Christine Stephens
        orcid: null
      - name: Kevin Brown
        orcid: null
      - name: Gayatri Amirthalingam
        orcid: http://orcid.org/0000-0003-2078-0975
      - name: Bassam Hallis
        orcid: http://orcid.org/0000-0002-8461-0038
      - name: Ashley Otter
        orcid: null
      - name: Jianmin Zuo
        orcid: http://orcid.org/0000-0002-8341-465X
      - name: Paul Moss
        orcid: null
  comment:
    dislikes: 0
    thread: "8524358522"
    numReports: 0
    likes: 1
    id: "5448313813"
    createdAt: 2021-07-08T13:48:55
    author:
      username: disqus_xWYbnXW5Sk
      about: ""
      name: Eric
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_xWYbnXW5Sk/
      url: ""
      location: ""
      id: "372050360"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      So is there a study that backs up 6 or 8 weeks for young and middle aged
      adults?


      In Germany, the recommendation until last week was to hit exactly six weeks to stay within EMA licence but spread out the vaccine. Now, with more vaccine available and Delta looming, the allow 3 - 6 weeks but without any recommendation as to which end of that window to prefer. 


      EMA recommends 19 - 23 days but their reasoning is that 93% of trial participants fell into that bracket. So maybe they have simply no data to say that six weeks are better?


      Unlike with the AZ vaccine, there is no vector immunity to overcome so it is not clear why a longer interval should be better.


      Back to those seniors in this study here, is it even good for them to have more antibodies and less T-cells? My understanding is that they are typically T-cell challenged, so is it not better to boost T-cells?
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.15.21257017v1
  tweets:
    - created_at: Fri Jul 09 16:31:45 +0000 2021
      id: 1413536362763018200
      id_str: "1413536362763018243"
      text: >-
        üí¨ medRxiv comment on "Extended interval BNT162b2 vac..."


        "So is there a study that backs up 6 or 8 weeks for young‚Ä¶ https://t.co/Upi6x7GMQF
      truncated: true
      entities:
        urls:
          - url: https://t.co/Upi6x7GMQF
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 09 16:31:46 +0000 2021
      id: 1413536363970969600
      id_str: "1413536363970969606"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/x0AIV3f5Lu
      truncated: false
      entities:
        urls:
          - url: https://t.co/x0AIV3f5Lu
      in_reply_to_status_id: 1413536362763018200
      in_reply_to_status_id_str: "1413536362763018243"
- preprint:
    id: "149451"
    doi: 10.1101/2021.07.09.451738
    first_posted: 2021-07-09
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.09.451738v1
    url: https://api.rxivist.org/v1/papers/149451
    title: The molecular appearance of native TRPM7 channel complexes identified by
      high-resolution proteomics
    category: biochemistry
    abstract: The transient receptor potential melastatin-subfamily member 7 (TRPM7)
      is a ubiquitously expressed membrane protein consisting of ion channel and
      protein kinase domains. TRPM7 plays a fundamental role in the cellular
      uptake of divalent cations such as Zn2+, Mg2+ and Ca2+, and thus shapes
      cellular excitability, plasticity and metabolic activity. The molecular
      appearance and operation of TRPM7 channel complexes in native tissues have
      remained unresolved. Here, we investigated the subunit composition of
      endogenous TRPM7 channels in rodent brain by multi-epitope affinity
      purification and high-resolution quantitative MS analysis. We found that
      native TRPM7 channels are high molecular-weight multi-protein complexes
      that contain the putative metal transporter proteins CNNM1-4 and a small
      G-protein ARL15. Heterologous reconstitution experiments confirmed the
      formation of TRPM7/CNNM/ARL15 ternary complexes and indicated that ARL15
      effectively and specifically impacts TRPM7 channel activity. These results
      open up new avenues towards a mechanistic understanding of the cellular
      regulation and function of TRPM7 channels.
    authors:
      - name: Astrid Kollewe
        orcid: null
      - name: Vladimir Chubanov
        orcid: http://orcid.org/0000-0002-6042-4193
      - name: Fong Tsuen Tseung
        orcid: null
      - name: Alexander Haupt
        orcid: null
      - name: Catrin Swantje M&amp;uumlller
        orcid: null
      - name: Wolfgang Bildl
        orcid: null
      - name: Schulte Schulte
        orcid: null
      - name: Annette Nicke
        orcid: http://orcid.org/0000-0001-6798-505X
      - name: Bernd Fakler
        orcid: null
      - name: Thomas Gudermann
        orcid: http://orcid.org/0000-0002-0323-7965
  comment:
    dislikes: 0
    thread: "8638780784"
    numReports: 0
    likes: 0
    id: "5449554713"
    createdAt: 2021-07-09T14:09:26
    author:
      username: vladimirchubanov
      about: ""
      name: Vladimir Chubanov
      isPowerContributor: false
      profileUrl: https://disqus.com/by/vladimirchubanov/
      url: ""
      location: ""
      id: "330085578"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "The molecular appearance of native TRPM7 channel complexes
      identified by high-resolution proteomics. doi:
      https://doi.org/10.1101/2021.07.09.451738"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.07.09.451738v1
  tweets:
    - created_at: Fri Jul 09 18:27:05 +0000 2021
      id: 1413565385945849900
      id_str: "1413565385945849856"
      text: >-
        üí¨ bioRxiv comment on "The molecular appearance of na..."


        "The molecular appearance of native TRPM7 channel complex‚Ä¶ https://t.co/dJNTLKGj7E
      truncated: true
      entities:
        urls:
          - url: https://t.co/dJNTLKGj7E
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 09 18:27:05 +0000 2021
      id: 1413565386805686300
      id_str: "1413565386805686277"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/sWJwh4u5dC
      truncated: false
      entities:
        urls:
          - url: https://t.co/sWJwh4u5dC
      in_reply_to_status_id: 1413565385945849900
      in_reply_to_status_id_str: "1413565385945849856"
- preprint:
    id: 149291
    metric: 5
    title: Synthetic genomic reconstitution reveals principles of mammalian Hox
      cluster regulation
    url: https://api.rxivist.org/v1/papers/149291
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.07.451065v1
    doi: 10.1101/2021.07.07.451065
    category: synthetic-biology
    first_posted: 2021-07-07
    abstract: Precise Hox gene expression is crucial for embryonic patterning.
      Intra-Hox transcription factor binding and distal enhancer elements have
      emerged as the major regulatory modes controlling Hox gene expression.
      However, quantifying their relative contributions has remained elusive.
      Here, we introduce 'synthetic regulatory reconstitution', a novel
      conceptual framework for studying gene regulation and apply it to the HoxA
      cluster. We synthesized and delivered variant rat HoxA clusters (130-170
      kilobases each) to an ectopic location in the mouse genome. We find that a
      HoxA cluster lacking distal enhancers recapitulates correct patterns of
      chromatin remodeling and transcription in response to patterning signals,
      while distal enhancers are required for full transcriptional output.
      Synthetic regulatory reconstitution is a generalizable strategy to
      decipher the regulatory logic of gene expression in complex genomes.
    authors:
      - name: Sudarshan Pinglay
      - name: Milica Bulajic
      - name: Dylan P Rahe
      - name: Emily Huang
      - name: Ran Brosh
      - name: Sergei German
      - name: John A Cadley
      - name: Lila Rieber
      - name: Nicole Easo
      - name: Shaun Mahony
      - name: Matt T Maurano
      - name: Liam J Holt
      - name: Esteban O Mazzoni
      - name: Jef D Boeke
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Fri Jul 09 20:16:05 +0000 2021
      id: 1413592815330750500
      id_str: "1413592815330750465"
      text: >-
        üî• bioRxiv Synthetic-biology preprint by S. Pinglay et al:


        "Synthetic genomic reconstitution reveals principles of‚Ä¶ https://t.co/Hdu6b4o5G0
      truncated: true
      entities:
        urls:
          - url: https://t.co/Hdu6b4o5G0
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "148806"
    doi: 10.1101/2021.07.04.451050
    first_posted: 2021-07-05
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.04.451050v1
    url: https://api.rxivist.org/v1/papers/148806
    title: "Fly Cell Atlas: a single-cell transcriptomic atlas of the adult fruit fly"
    category: genomics
    abstract: The ability to obtain single cell transcriptomes for stable cell types
      and dynamic cell states is ushering in a new era for biology. We created
      the Tabula Drosophilae, a single cell atlas of the adult fruit fly which
      includes 580k cells from 15 individually dissected sexed tissues as well
      as the entire head and body. Over 100 researchers from the fly community
      contributed annotations to >250 distinct cell types across all tissues. We
      provide an in-depth analysis of cell type-related gene signatures and
      transcription factor markers, as well as sexual dimorphism, across the
      whole animal. Analysis of common cell types that are shared between
      tissues, such as blood and muscle cells, allowed the discovery of rare
      cell types and tissue-specific subtypes. This atlas provides a valuable
      resource for the entire Drosophila community and serves as a comprehensive
      reference to study genetic perturbations and disease models at single-cell
      resolution.
    authors:
      - name: Hongjie Li
        orcid: null
      - name: Jasper Janssens
        orcid: http://orcid.org/0000-0001-9264-0782
      - name: Maxime De Waegeneer
        orcid: http://orcid.org/0000-0002-4535-3737
      - name: Sai Saroja Kolluru
        orcid: null
      - name: Kristofer Davie
        orcid: http://orcid.org/0000-0003-2182-1249
      - name: Vincent Gardeux
        orcid: http://orcid.org/0000-0001-8954-2161
      - name: Wouter Sealens
        orcid: null
      - name: Fabrice David
        orcid: null
      - name: Maria Brbic
        orcid: null
      - name: Jure Leskovec
        orcid: http://orcid.org/0000-0002-5411-923X
      - name: Colleen McLaughlin
        orcid: null
      - name: Qijing Xie
        orcid: null
      - name: Robert Jones
        orcid: http://orcid.org/0000-0003-3543-2877
      - name: Katja Brueckner
        orcid: null
      - name: Jiwon Shim
        orcid: http://orcid.org/0000-0003-2409-1130
      - name: Sudhir Gopal Tattikota
        orcid: http://orcid.org/0000-0003-0318-5533
      - name: Frank Schnorrer
        orcid: http://orcid.org/0000-0002-9518-7263
      - name: Katja Rust
        orcid: null
      - name: Todd Nystul
        orcid: http://orcid.org/0000-0002-6250-2394
      - name: Zita Carvalho-Santos
        orcid: http://orcid.org/0000-0001-7100-308X
      - name: Carlos Ribeiro
        orcid: http://orcid.org/0000-0002-9542-7335
      - name: Soumitra Pal
        orcid: http://orcid.org/0000-0003-4840-3944
      - name: Teresa Maria Przytycka
        orcid: null
      - name: Aaron Allen
        orcid: null
      - name: Stephen Goodwin
        orcid: null
      - name: Cameron Berry
        orcid: null
      - name: Margaret T. (MINX) Fuller
        orcid: null
      - name: Helen White-Cooper
        orcid: http://orcid.org/0000-0002-3373-8023
      - name: Erika Matunis
        orcid: http://orcid.org/0000-0001-5439-4656
      - name: Stephen DiNardo
        orcid: http://orcid.org/0000-0003-4131-5511
      - name: Anthony Galenza
        orcid: null
      - name: Lucy Erin O'Brien
        orcid: null
      - name: Julian A.T. Dow
        orcid: http://orcid.org/0000-0002-9595-5146
      - name: FCA Consortium
        orcid: null
      - name: Heinrich Jasper
        orcid: null
      - name: Brian Oliver
        orcid: http://orcid.org/0000-0002-3455-4891
      - name: Norbert Perrimon
        orcid: http://orcid.org/0000-0001-7542-472X
      - name: Bart Deplancke
        orcid: http://orcid.org/0000-0001-9935-843X
      - name: Stephen Quake
        orcid: null
      - name: Liqun Luo
        orcid: http://orcid.org/0000-0001-5467-9264
      - name: Stein Aerts
        orcid: http://orcid.org/0000-0002-8006-0315
  comment:
    dislikes: 0
    thread: "8631560587"
    numReports: 0
    likes: 0
    id: "5449426843"
    createdAt: 2021-07-09T11:56:16
    author:
      username: bplazzaro
      about: Professor, Cornell University
      name: Brian Lazzaro
      isPowerContributor: false
      profileUrl: https://disqus.com/by/bplazzaro/
      url: http://www.lazzaro.entomology.cornell.edu
      location: ""
      id: "372093623"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      <blockquote>For example, in the fat body (fig. S16), the main fat body
      cells formed one big cluster, but our metabolic pathway enrichment
      analysis performed through ASAP (David et al., 2020) revealed that fatty
      acid biosynthesis and degradation are in fact compartmentalized,
      highlighting possible fat body cell heterogeneity in terms of metabolic
      capacities.</blockquote>


      This is a really interesting observation. We saw the same thing in our preprint posted a few months ago, and the heterogeneity was stable in biologically replicated samples across multiple treatments (factorial design of mated, unmated, bacterially infected, uninfected). 


      We discussed some specific clusters and their apparent functional enrichment based on the expression data:


      <blockquote>GO enrichment analysis of differentially regulated genes in each of the six subpopulations showed enrichment for diverse functions (Table S3). Upregulated genes in both Clusters 0 and 1 were enriched for one-carbon metabolism but mediated by two different mechanisms: s-adenosyl methionine (SAM; Cluster 0) and folate (Cluster 1). Cluster 1 also showed enriched upregulation of genes encoding ribosomal proteins, which were downregulated in Cluster 2. Upregulated genes in Cluster 2 showed enrichment for amino acid biosynthesis. We identified metabolic and detoxification pathways enriched in genes upregulated in Cluster 5, and upregulated genes in both Clusters 7 and 10 were related to phospholipase A1 activity. Therefore, while all six fat body subpopulations respond to mating stimulus, their heterogeneous response suggests subfunctionalization of the cellular populations.</blockquote>


      https://www.biorxiv.org/content/10.1101/2021.01.28.428655v1


      Is this similar to the heterogeneity you see in the present analysis of the fat body?
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.07.04.451050v1
  tweets:
    - created_at: Fri Jul 09 20:19:35 +0000 2021
      id: 1413593697908707300
      id_str: "1413593697908707330"
      text: >-
        üí¨ bioRxiv comment on "Fly Cell Atlas: a single-cell ..."


        "&lt;blockquote&gt;For example, in the fat body (fig. S16), the‚Ä¶ https://t.co/NVhVDrTCoM
      truncated: true
      entities:
        urls:
          - url: https://t.co/NVhVDrTCoM
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 09 20:19:35 +0000 2021
      id: 1413593698890178600
      id_str: "1413593698890178562"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/EGW2mV2UPs
      truncated: false
      entities:
        urls:
          - url: https://t.co/EGW2mV2UPs
      in_reply_to_status_id: 1413593697908707300
      in_reply_to_status_id_str: "1413593697908707330"
- preprint:
    id: "111336"
    doi: 10.1101/2020.05.26.20104497
    first_posted: 2020-05-26
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.05.26.20104497v1
    url: https://api.rxivist.org/v1/papers/111336
    title: "Knowledge and attitude towards COVID-19 in Bangladesh: Population-level
      estimation and a comparison of data obtained by phone and online survey
      methods"
    category: epidemiology
    abstract: Adherence of people to the guidelines and measures suggested in
      fighting the ongoing COVID-19 pandemic is partly determined by the
      Knowledge, Attitude, and Practices (KAP) of the population. In this
      cross-sectional study, we primarily addressed two key issues. First, we
      tried to determine whether there is a significant difference in the
      estimated COVID-19 knowledge level from the online and phone survey
      methods. Second, we tried to quantify the knowledge and attitude of
      COVID-19 in Bangladeshi adult population. Data were collected through
      phone calls (April 14-23, 2020) and online survey (April 18-19, 2020) in
      Bangladesh. The questionnaire had 20 knowledge questions with each correct
      response getting one point and incorrect/do not know response getting no
      point (maximum total knowledge score 20). Participants scoring >17 were
      categorized as having good knowledge. The percentages of good knowledge
      holders were 57.6%, 75.1%, and 95.8% in the phone (n=1426), online
      non-medical (n=1097), and online medical participants (n=382),
      respectively. Comparison between phone and online survey showed that,
      overall, online survey might overestimate knowledge level than that of
      phone survey, although there was no difference for elderly, poor, and
      rural people. Male gender, higher education, living in town/urban areas,
      good financial condition, and use of internet were positively associated
      with good knowledge. However, higher knowledge was associated with having
      less confidence in the final control of COVID-19. Our adult
      population-level estimates showed that only 32.6% (95% CI 30.1-35.2%) had
      good knowledge. This study provides crucial information that could be
      useful for the researchers and policymakers to develop effective
      strategies.
    authors:
      - name: Anwarul Karim
        orcid: http://orcid.org/0000-0002-5795-6674
      - name: Mastura Akter
        orcid: http://orcid.org/0000-0003-0007-6075
      - name: AHM Thafikul Mazid
        orcid: http://orcid.org/0000-0002-5368-814X
      - name: Orindom Shing Pulock
        orcid: http://orcid.org/0000-0002-0254-9406
      - name: Tasmiah Tahera Aziz
        orcid: http://orcid.org/0000-0002-0967-7689
      - name: Samira Hayee
        orcid: null
      - name: Nowrin Tamanna
        orcid: http://orcid.org/0000-0002-1504-7237
      - name: GS Chuwdhury
        orcid: null
      - name: Afsana Haque
        orcid: null
      - name: Farhana Yeasmin
        orcid: null
      - name: Mashkura Akter Mitu
        orcid: null
      - name: Farjana Yeasmin
        orcid: null
      - name: Humayun Rashid
        orcid: null
      - name: Ashish Kumar Kuri
        orcid: http://orcid.org/0000-0002-0364-8537
      - name: Arni Das
        orcid: http://orcid.org/0000-0001-5960-7809
      - name: Koushik Majumder
        orcid: http://orcid.org/0000-0002-2858-5472
      - name: Dipen Barua
        orcid: null
      - name: Md Mahabubur Rahaman
        orcid: null
      - name: Sanjida Akter
        orcid: null
      - name: Nashid Niaz Munia
        orcid: null
      - name: Jabin Sultana
        orcid: http://orcid.org/0000-0003-1771-3368
      - name: Faeeqa Usaila
        orcid: null
      - name: Sabrina Sifat
        orcid: null
      - name: Nishat Anjum Nourin
        orcid: http://orcid.org/0000-0003-1663-8423
      - name: Md Forhad Uddin
        orcid: null
      - name: Mrinmoy Bhowmik
        orcid: null
      - name: Tanvir Ahammed
        orcid: http://orcid.org/0000-0002-6472-1726
      - name: Nabil Sharik
        orcid: null
      - name: Quddus Mehnaz
        orcid: null
      - name: Md Nur Hossain Bhuiyan
        orcid: null
      - name: Tahmina Banu
        orcid: null
  comment:
    dislikes: 0
    thread: "8059615931"
    numReports: 0
    likes: 0
    id: "5449303553"
    createdAt: 2021-07-09T08:37:24
    author:
      username: mdanwarulkarimmijan
      about: ""
      name: Md Anwarul Karim Mijan
      isPowerContributor: false
      profileUrl: https://disqus.com/by/mdanwarulkarimmijan/
      url: ""
      location: ""
      id: "350041482"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Peer-reviewed published version can be found here:

      https://www.jceionline.org/article/knowledge-and-attitude-towards-covid-19-a-cross-sectional-study-in-bangladesh-through-phone-and-9143
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.05.26.20104497v2
  tweets:
    - created_at: Fri Jul 09 22:19:17 +0000 2021
      id: 1413623821706293200
      id_str: "1413623821706293251"
      text: |-
        üí¨ medRxiv comment on "Knowledge and attitude towards..."

        "Peer-reviewed published version can be found here:
        "

        https://t.co/k1C9FIjTjO
      truncated: false
      entities:
        urls:
          - url: https://t.co/k1C9FIjTjO
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 09 22:19:17 +0000 2021
      id: 1413623822578688000
      id_str: "1413623822578688002"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/56RNHA8xib
      truncated: false
      entities:
        urls:
          - url: https://t.co/56RNHA8xib
      in_reply_to_status_id: 1413623821706293200
      in_reply_to_status_id_str: "1413623821706293251"
- preprint:
    id: "149435"
    doi: 10.1101/2021.07.08.21259776
    first_posted: 2021-07-08
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.08.21259776v1
    url: https://api.rxivist.org/v1/papers/149435
    title: Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19
      Hospitalizations in the United States
    category: infectious-diseases
    abstract: "Background: As SARS-CoV-2 vaccination coverage increases in the
      United States (US), there is a need to understand the real-world
      effectiveness against severe Covid-19 and among people at increased risk
      for poor outcomes. Methods: In a multicenter case-control analysis of US
      adults hospitalized March 11 through May 5, 2021, we evaluated vaccine
      effectiveness to prevent Covid-19 hospitalizations by comparing odds of
      prior vaccination with an mRNA vaccine (Pfizer-BioNTech or Moderna)
      between cases hospitalized with Covid-19 and hospital-based controls who
      tested negative for SARS-CoV-2. Results: Among 1210 participants, median
      age was 58 years, 22.8% were Black, 13.8% were Hispanic, and 20.6% had
      immunosuppression. SARS-CoV-2 lineage B.1.1.7 was most common variant
      (59.7% of sequenced viruses). Full vaccination (receipt of two vaccine
      doses at least 14 days before illness onset) had been received by 45/590
      (7.6%) cases and 215/620 (34.7%) controls. Overall vaccine effectiveness
      was 86.9% (95% CI: 80.4 to 91.2%). Vaccine effectiveness was similar for
      Pfizer-BioNTech and Moderna vaccines, and highest in adults aged 18-49
      years (97.3%; 95% CI: 78.9 to 99.7%). Among 45 patients with
      vaccine-breakthrough Covid hospitalizations, 44 (97.8%) were at least 50
      years old and 20 (44.4%) had immunosuppression. Vaccine effectiveness was
      lower among patients with immunosuppression (59.2%; 95% CI: 11.9 to 81.1%)
      than without immunosuppression (91.3%; 95% CI: 85.5 to 94.7%). Conclusion:
      During March through May 2021, SARS-CoV-2 mRNA vaccines were highly
      effective for preventing Covid-19 hospitalizations among US adults.
      SARS-CoV-2 vaccination was beneficial for patients with immunosuppression,
      but effectiveness was lower in the immunosuppressed population."
    authors:
      - name: Mark W Tenforde
        orcid: null
      - name: Manish M Patel
        orcid: null
      - name: Adit A. Ginde
        orcid: null
      - name: David J. Douin
        orcid: null
      - name: H. Keipp Talbot
        orcid: null
      - name: Jonathan D. Casey
        orcid: null
      - name: Nicholas M Mohr
        orcid: http://orcid.org/0000-0003-0497-5828
      - name: Anne Zepeski
        orcid: null
      - name: Manjusha Gaglani
        orcid: http://orcid.org/0000-0002-3952-9230
      - name: Tresa McNeal
        orcid: null
      - name: Shekhar Ghamande
        orcid: null
      - name: Nathan I Shapiro
        orcid: null
      - name: Kevin W. Gibbs
        orcid: null
      - name: D. Clark Files
        orcid: null
      - name: David N. Hager
        orcid: null
      - name: Arber Shehu
        orcid: null
      - name: Matthew E. Prekker
        orcid: null
      - name: Heidi L Erickson
        orcid: null
      - name: Matthew C. Exline
        orcid: null
      - name: Michelle N Gong
        orcid: null
      - name: Amira Mohamed
        orcid: null
      - name: Daniel J. Henning
        orcid: null
      - name: Jay S. Steingrub
        orcid: null
      - name: Ithan D Peltan
        orcid: http://orcid.org/0000-0003-1730-234X
      - name: Samuel M Brown
        orcid: http://orcid.org/0000-0003-1206-6261
      - name: Emily T. Martin
        orcid: http://orcid.org/0000-0002-5771-8895
      - name: Arnold S Monto
        orcid: http://orcid.org/0000-0003-3018-435X
      - name: Akram Khan
        orcid: null
      - name: C. Terri Hough
        orcid: null
      - name: Laurence Busse
        orcid: null
      - name: Caitlin C. ten Lohuis
        orcid: null
      - name: Abhijit Duggal
        orcid: http://orcid.org/0000-0003-4220-2359
      - name: Jennifer G Wilson
        orcid: null
      - name: Alexandra June Gordon
        orcid: null
      - name: Nida Qadir
        orcid: http://orcid.org/0000-0001-7791-049X
      - name: Steven Y Chang
        orcid: null
      - name: Christopher Mallow
        orcid: null
      - name: Hayley B. Gershengorn
        orcid: null
      - name: Hilary M. Babcock
        orcid: null
      - name: Jennie H. Kwon
        orcid: null
      - name: Natasha Halasa
        orcid: null
      - name: James D. Chappell
        orcid: null
      - name: Adam S. Lauring
        orcid: http://orcid.org/0000-0003-2906-8335
      - name: Carlos G Grijalva
        orcid: null
      - name: Todd W. Rice
        orcid: null
      - name: Ian D. Jones
        orcid: null
      - name: William B. Stubblefield
        orcid: null
      - name: Adrienne Baughman
        orcid: null
      - name: Kelsey N. Womack
        orcid: null
      - name: Christopher J. Lindsell
        orcid: null
      - name: Kimerly W. Hart
        orcid: null
      - name: Yuwei Zhu
        orcid: null
      - name: Samantha M. Olson
        orcid: null
      - name: Meagan Stephenson
        orcid: null
      - name: Stephanie J. Schrag
        orcid: null
      - name: Miwako Kobayashi
        orcid: null
      - name: Jennifer R. Verani
        orcid: null
      - name: Wesley H. Self
        orcid: http://orcid.org/0000-0002-9300-3045
  comment:
    dislikes: 0
    thread: "8638037382"
    numReports: 0
    likes: 0
    id: "5449238366"
    createdAt: 2021-07-09T06:37:13
    author:
      username: disqus_izqxCwTIVY
      about: ""
      name: ndk
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_izqxCwTIVY/
      url: ""
      location: ""
      id: "241927233"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: This is a retrospective study as the predominant strain at the time
      was Alpha, in concurrence with their findings, but we currently face the
      radically different strain Delta, and perhaps Lambda.  We can't glean much
      from it other than a snapshot in time.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.07.08.21259776v1
  tweets:
    - created_at: Sat Jul 10 01:01:10 +0000 2021
      id: 1413664562373595100
      id_str: "1413664562373595145"
      text: >-
        üí¨ medRxiv comment on "Effectiveness of SARS-CoV-2 mR..."


        "This is a retrospective study as the predominant strain‚Ä¶ https://t.co/4hL6eQ2GNG
      truncated: true
      entities:
        urls:
          - url: https://t.co/4hL6eQ2GNG
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 10 01:01:11 +0000 2021
      id: 1413664563262902300
      id_str: "1413664563262902273"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/FJpsihv8pw
      truncated: false
      entities:
        urls:
          - url: https://t.co/FJpsihv8pw
      in_reply_to_status_id: 1413664562373595100
      in_reply_to_status_id_str: "1413664562373595145"
- preprint:
    id: "144098"
    doi: 10.1101/2021.05.28.21257989
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21257989v1
    url: https://api.rxivist.org/v1/papers/144098
    title: UV-A and UV-B Can Neutralize SARS-CoV-2 Infectivity
    category: epidemiology
    abstract: "We performed an in-depth analysis of the virucidal effect of discrete
      wavelengths: UV-C (278 nm), UV-B (308 nm), UV-A (366 nm) and violet (405
      nm) on SARS-CoV-2. By using a highly infectious titer of SARS-CoV-2 we
      observed that the violet light-dose resulting in a 2-log viral
      inactivation is only 10-4 times less efficient than UV-C light. Moreover,
      by qPCR and fluorescence in situ hybridization (FISH) approach we verified
      that the viral titer typically found in the sputum of COVID-19 patients
      can be completely inactivated by the long UV-wavelengths corresponding to
      UV- A and UV-B solar irradiation. The comparison of the UV action spectrum
      on SARS-CoV-2 to previous results obtained on other pathogens suggests
      that RNA viruses might be particularly sensitive to long UV wavelengths.
      Our data extend previous results showing that SARS-CoV-2 is highly
      susceptible to UV light and offer an explanation to the reduced incidence
      of SARS-CoV-2 infection seen in the summer season."
    authors:
      - name: Mara Biasin
        orcid: http://orcid.org/0000-0003-3671-4235
      - name: Sergio Strizzi
        orcid: null
      - name: Andrea Bianco
        orcid: http://orcid.org/0000-0002-7691-404X
      - name: Alberto Macchi
        orcid: null
      - name: Olga Utyro
        orcid: http://orcid.org/0000-0002-9571-6057
      - name: Giovanni Pareschi
        orcid: http://orcid.org/0000-0003-3967-403X
      - name: Alessia Loffreda
        orcid: http://orcid.org/0000-0003-4523-5666
      - name: Adalberto Cavalleri
        orcid: http://orcid.org/0000-0001-7607-3693
      - name: Manuela Lualdi
        orcid: http://orcid.org/0000-0002-1757-468X
      - name: Daria Trabattoni
        orcid: http://orcid.org/0000-0001-9535-3359
      - name: Carlo Tacchetti
        orcid: http://orcid.org/0000-0003-4602-000X
      - name: Davide Mazza
        orcid: http://orcid.org/0000-0003-2776-4142
      - name: Mario Salvatore Clerici
        orcid: http://orcid.org/0000-0001-5920-6191
  comment:
    dislikes: 0
    thread: "8564708855"
    numReports: 0
    likes: 0
    id: "5449039880"
    createdAt: 2021-07-09T01:05:25
    author:
      username: steven_scullion
      about: ""
      name: Steven Scullion
      isPowerContributor: false
      profileUrl: https://disqus.com/by/steven_scullion/
      url: ""
      location: ""
      id: "372075607"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "Is this study connected in any way to the research being done by
      Cedars-Sinai:
      https://link.springer.com/article/10.1007/s12325-021-01830-7"
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21257989v1
  tweets:
    - created_at: Sat Jul 10 12:29:52 +0000 2021
      id: 1413837877440520200
      id_str: "1413837877440520194"
      text: >-
        üí¨ medRxiv comment on "UV-A and UV-B Can Neutralize S..."


        "Is this study connected in any way to the research being‚Ä¶ https://t.co/IIM7OxVOyz
      truncated: true
      entities:
        urls:
          - url: https://t.co/IIM7OxVOyz
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 10 12:29:52 +0000 2021
      id: 1413837878442946600
      id_str: "1413837878442946565"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/Deuy2gVi18
      truncated: false
      entities:
        urls:
          - url: https://t.co/Deuy2gVi18
      in_reply_to_status_id: 1413837877440520200
      in_reply_to_status_id_str: "1413837877440520194"
- preprint:
    id: "124526"
    doi: 10.1101/2020.12.25.20248427
    first_posted: 2020-12-28
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.12.25.20248427v1
    url: https://api.rxivist.org/v1/papers/124526
    title: Maori and Pacific People in New Zealand have higher risk of
      hospitalisation for COVID-19
    category: infectious-diseases
    abstract: Aims. We aim to quantify differences in clinical outcomes from
      COVID-19 infection in Aotearoa New Zealand by ethnicity with a focus on
      risk of hospitalisation. Methods. We used data on age, ethnicity,
      deprivation index, pre-existing health conditions, and clinical outcomes
      on 1,829 COVID-19 cases reported in New Zealand. We used a logistic
      regression model to calculate odds ratios for the risk of hospitalisation
      by ethnicity. We also consider length of hospital stay and risk of
      fatality. Results. M[a]ori have 2.50 times greater odds of hospitalisation
      (95% CI 1.39 - 4.51) than non-M[a]ori, non-Pacific people, after
      controlling for age and pre-existing conditions. Pacific people have 3
      times greater odds (95% CI 1.75 - 5.33). Conclusions. Structural
      inequities and systemic racism in the healthcare system mean that M[a]ori
      and Pacific communities face a much greater health burden from COVID-19.
      Older people and those with pre-existing health conditions are also at
      greater risk. This should inform future policy decisions including
      prioritising groups for vaccination.
    authors:
      - name: Nicholas Steyn
        orcid: null
      - name: Rachelle N Binny
        orcid: http://orcid.org/0000-0002-3433-0417
      - name: Kate Hannah
        orcid: http://orcid.org/0000-0002-4934-7377
      - name: Shaun Hendy
        orcid: http://orcid.org/0000-0003-3468-6517
      - name: Alex James
        orcid: http://orcid.org/0000-0002-1543-7139
      - name: Audrey Lustig
        orcid: http://orcid.org/0000-0002-0869-3847
      - name: Kannan Ridings
        orcid: null
      - name: Michael J Plank
        orcid: http://orcid.org/0000-0002-7539-3465
      - name: Andrew Sporle
        orcid: null
  comment:
    dislikes: 0
    thread: "8555562958"
    numReports: 0
    likes: 0
    id: "5448907132"
    createdAt: 2021-07-08T22:19:15
    author:
      username: disqus_Pc9ZQufNd1
      about: ""
      name: Michael Plank
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_Pc9ZQufNd1/
      url: ""
      location: ""
      id: "369642137"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: This paper has now been published in the New Zealand Medical
      Journal and is available open access
      at:https://www.nzma.org.nz/journal-articles/maori-and-pacific-people-in-new-zealand-have-a-higher-risk-of-hospitalisation-for-covid-19-open-access
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.12.25.20248427v2
  tweets:
    - created_at: Sat Jul 10 14:16:51 +0000 2021
      id: 1413864800585756700
      id_str: "1413864800585756675"
      text: >-
        üí¨ medRxiv comment on "Maori and Pacific People in Ne..."


        "This paper has now been published in the New Zealand Med‚Ä¶ https://t.co/2jHIBY4vb4
      truncated: true
      entities:
        urls:
          - url: https://t.co/2jHIBY4vb4
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 10 14:16:51 +0000 2021
      id: 1413864801579765800
      id_str: "1413864801579765761"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/lzJa2e10TT
      truncated: false
      entities:
        urls:
          - url: https://t.co/lzJa2e10TT
      in_reply_to_status_id: 1413864800585756700
      in_reply_to_status_id_str: "1413864800585756675"
- preprint:
    id: "140191"
    doi: 10.1101/2021.04.29.441886
    first_posted: 2021-04-29
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.29.441886v1
    url: https://api.rxivist.org/v1/papers/140191
    title: NEU1 and NEU3 enzymes alter CD22 organization on B cells
    category: immunology
    abstract: The B cell membrane expresses sialic acid binding Immunoglobulin-like
      lectins, also called Siglecs, that are important for modulating immune
      response. Siglecs have interactions with sialoglycoproteins found on the
      same membrane (cis ligands) that result in homotypic and heterotypic
      receptor clusters. The regulation and organization of these clusters, and
      their effect on cell activation, is not clearly understood. We
      investigated the role of human neuraminidase enzymes, NEU1 and NEU3, on
      the clustering of CD22 on B cells using confocal microscopy. We observed
      that native NEU1 and NEU3 activity influence the cluster size of CD22.
      Using single-particle tracking, we observed that NEU3 activity increased
      the lateral mobility of CD22, which was in contrast to the effect of
      exogenous bacterial NEU enzymes. Moreover, we show that native NEU1 and
      NEU3 activity influenced cellular Ca2+ levels, supporting a role for these
      enzymes in regulating B cell activation. Our results establish a role for
      native NEU activity in modulating CD22 organization and function on B
      cells.
    authors:
      - name: Hanh-Thuc Ton Tran
        orcid: http://orcid.org/0000-0001-6294-2448
      - name: Caishun Li
        orcid: null
      - name: Radhika Chakraberty
        orcid: null
      - name: Christopher W Cairo
        orcid: http://orcid.org/0000-0003-3363-8708
  comment:
    dislikes: 0
    thread: "8499482376"
    numReports: 0
    likes: 0
    id: "5448825633"
    createdAt: 2021-07-08T20:58:29
    author:
      username: rishi_kulkarni
      about: ""
      name: rishi_kulkarni
      isPowerContributor: false
      profileUrl: https://disqus.com/by/rishi_kulkarni/
      url: ""
      location: ""
      id: "372067268"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: I am curious what these statistical comparisons would look like
      with cluster-robust tests rather than the t-test.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.04.29.441886v1
  tweets:
    - created_at: Sat Jul 10 16:29:54 +0000 2021
      id: 1413898282863112200
      id_str: "1413898282863112195"
      text: >-
        üí¨ bioRxiv comment on "NEU1 and NEU3 enzymes alter CD..."


        "I am curious what these statistical comparisons would lo‚Ä¶ https://t.co/NGmtb8ZsLa
      truncated: true
      entities:
        urls:
          - url: https://t.co/NGmtb8ZsLa
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 10 16:29:54 +0000 2021
      id: 1413898284448501800
      id_str: "1413898284448501767"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/V1JsI8uhb0
      truncated: false
      entities:
        urls:
          - url: https://t.co/V1JsI8uhb0
      in_reply_to_status_id: 1413898282863112200
      in_reply_to_status_id_str: "1413898282863112195"
- preprint:
    id: "147526"
    doi: 10.1101/2021.06.22.21259345
    first_posted: 2021-06-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.22.21259345v1
    url: https://api.rxivist.org/v1/papers/147526
    title: Multi-centre post-implementation evaluation of SARS-CoV-2 antigen-based
      point of care tests used for asymptomatic screening of continuing care
      healthcare workers
    category: infectious-diseases
    abstract: Frequent screening of SARS-CoV-2 among asymptomatic populations using
      antigen-based point of care tests (APOCT) is occurring globally with
      limited clinical performance data. The positive predictive value (PPV) of
      two APOCT used in the asymptomatic screening of SARS-CoV-2 among
      healthcare workers (HCW) at continuing care (CC) sites across Alberta,
      Canada was evaluated. Between February 22 and May 2, 2021, CC sites
      implemented SARS-CoV-2 voluntary screening of their asymptomatic HCW.
      Onsite testing with Abbott Panbio or BD Veritor occurred on a weekly or
      twice weekly basis. Positive APOCT were confirmed with a real-time
      reverse-transcriptase polymerase chain reaction (rRT-PCR) reference
      method. A total of 71,847 APOCT (17,689 Veritor and 54,158 Panbio) were
      performed among 369 CC sites. Eighty-seven (0.12%) APOCT were positive, of
      which 39 (0.05%) confirmed as true positives using rRT-PCR. Use of the
      Veritor and Panbio resulted in a 76.6% and 30.0% false positive detection,
      respectively (p<0.001). This corresponded to a 23.4% and 70.0% PPV for the
      Veritor and Panbio, respectively. Frequent screening of SARS-CoV-2 among
      asymptomatic HCW in CC, using APOCT, resulted in a very low detection rate
      and a high detection of false positives. Careful assessment between the
      risks vs benefits of APOCT programs in this population needs to be
      thoroughly considered before implementation.
    authors:
      - name: Jamil N Kanji
        orcid: http://orcid.org/0000-0002-1043-6807
      - name: Dustin Proctor
        orcid: null
      - name: William Stokes
        orcid: null
      - name: Byron M Berenger
        orcid: http://orcid.org/0000-0001-9062-6346
      - name: James Silvius
        orcid: null
      - name: Graham Tipples
        orcid: null
      - name: A Mark Joffe
        orcid: null
      - name: Allison A Venner
        orcid: null
  comment:
    dislikes: 0
    thread: "8614606904"
    numReports: 0
    likes: 0
    id: "5448647128"
    createdAt: 2021-07-08T18:27:10
    author:
      username: jeffandrewsmd
      about: ""
      name: Jeff Andrews M.D.
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jeffandrewsmd/
      url: ""
      location: ""
      id: "372061559"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      The authors have misrepresented the use of biostatistics. In line 99 they
      state that APOCT have poor specificity. The authors cannot comment on
      specificity because they do not know the number of true negatives (line
      156-7). However, the prevalence is so low that using the [total number of
      tests ‚Äì known PCR positives] approximates the true negatives. The
      approximate specificity in this study would be 71768/71808 = 99.94%. This
      is an incredibly high specificity, not poor.

      In lines 106-107, the authors ask us to consider the negative impact of a false positive result, without putting it in context. Every HCW with a positive APOCT had confirmatory PCR. The authors do not state the interval between the two tests; the impact was likely over a period of two days. Moreover, the authors do not consider the alternative scenario, which would be two days of HCW exposures to other HCWs and patients in a HC setting, while waiting for the PCR results. If 39 HCWs were identified with COVID-19, immediately put on isolation (due to 15-minute APOCT), what value did that have for the healthcare system, and for all of their HC and personal contacts? And was that protective value greater than the collective harm caused by identifying 48 HCWs as positive by APOCT who were released from isolation two days later when the PCR result was known?

      ‚ÄúFalse detection rate‚Äù is not a terminology of biosciences and was not defined by the authors. In fact, they are presenting [1-PPV]; which seems pointless since they also present PPV in the next sentence.

      When prevalence is very low, 5 per 10,000 in this study, a slight difference in prevalence can greatly influence PPV. The reason is that false positives tend be fairly static and not influenced by prevalence, but true positives are directly influenced by prevalence. It is wrong to say that APOCTs have a low PPV, unless the sentence includes the prevalence. 

      Because the two tests were not conducted on the same subjects, it is wrong to publish results that represent a head to head comparison. In such a case, the authors were required to use more sophisticated Bayesian statistics, in order to apply a ‚Äòpenalty‚Äô or adjustment to account for possible differences due to the differences between the two different populations and the two different test workflows.  

      The authors fail to describe in Methods that one test was visually-read and the other test was read by an analyzer device, and to point out that human variation in ‚Äòreading‚Äô lines on the visually-read test could contribute to the differences. 

      The authors fail to acknowledge that they do not know the numbers of cases of APOCT negative and PCR-positive (false negatives) for each of the two tests; it is possible that one test has a much lower sensitivity and that would need to be considered in context with the false positives and prevalence.

      Finally, the authors did not take the opportunity to discuss what the reasonable prevalence level is for APOCT. In their study, prevalence was 0.05% or 5/10,000. They do not discuss whether it is reasonable to test asymptomatic HCWs at this prevalence level or lower. They do not discuss whether it is reasonable to test asymptomatic non-HCWs at this prevalence level or lower.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.22.21259345v1
  tweets:
    - created_at: Sat Jul 10 18:23:49 +0000 2021
      id: 1413926952986157000
      id_str: "1413926952986157056"
      text: >-
        üí¨ medRxiv comment on "Multi-centre post-implementati..."


        "The authors have misrepresented the use of biostatistics‚Ä¶ https://t.co/JBY10OscxG
      truncated: true
      entities:
        urls:
          - url: https://t.co/JBY10OscxG
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 10 18:23:49 +0000 2021
      id: 1413926953795694600
      id_str: "1413926953795694592"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/1YEh1uweOH
      truncated: false
      entities:
        urls:
          - url: https://t.co/1YEh1uweOH
      in_reply_to_status_id: 1413926952986157000
      in_reply_to_status_id_str: "1413926952986157056"
- preprint:
    id: 148171
    metric: 21
    title: Varenicline Prevents SARS-CoV-2 Infection In Vitro and in Rhesus Macaques
    url: https://api.rxivist.org/v1/papers/148171
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.29.450426v1
    doi: 10.1101/2021.06.29.450426
    category: immunology
    first_posted: 2021-06-30
    abstract: Background SARS-CoV-2 infections have resulted in a global pandemic,
      but an antiviral therapy for this novel strain of coronavirus does not
      currently exist. The objective of our study was to investigate the
      antiviral potential of the nicotinic acetylcholine receptor (nACHR)
      agonist varenicline tartrate against SARS-CoV-2. Methods We assessed
      antiviral activity using in vitro human cell assays and we assessed in
      vivo efficacy in a rhesus macaque model. Results In vitro studies found
      that varenicline tartrate, over a range of concentrations, reduced the
      infectivity of SARS-CoV-2 wildtype, alpha, and beta variants in Calu-3
      cells and Caco-2 cells, with maintenance of cell viability. In vivo
      studies found that varenicline tartrate, administered as a nasal spray to
      rhesus macaques, reduced SARS-CoV-2 wildtype viral load and inhibited
      viral replication in the nasal mucosa and upper airway. Conclusion
      Although the study reported here was exploratory, we have confirmed that
      the nAChR agonist varenicline has the potential to interact with and
      inhibit SARS-CoV-2 infection and replication.
    authors:
      - name: Jeffrey Nau
      - name: Priya Luthra
      - name: Kathleen Lanzer
      - name: Frank Szaba
      - name: Tres Cookenham
      - name: Eric Carlson
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sat Jul 10 20:15:17 +0000 2021
      id: 1413955004956823600
      id_str: "1413955004956823563"
      text: >-
        üî• bioRxiv Immunology preprint by J. Nau et al:


        "Varenicline Prevents SARS-CoV-2 Infection In Vitro and in Rhesus M‚Ä¶ https://t.co/0L19RZyUTi
      truncated: true
      entities:
        urls:
          - url: https://t.co/0L19RZyUTi
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "104460"
    doi: 10.1101/2020.11.18.388413
    first_posted: 2020-11-18
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.11.18.388413v1
    url: https://api.rxivist.org/v1/papers/104460
    title: "Long-chain polyphosphates impair SARS-CoV-2 infection and replication: a
      route for therapy in man"
    category: genetics
    abstract: >-
      Antiviral activities of long chain inorganic polyphosphates (PolyPs)
      against severe acute respiratory syndrome coronavirus SARS CoV2 infection
      were investigated. In molecular docking analyses, PolyPs interacted with
      several conserved angiotensin converting enzyme (ACE)2 and RNA-dependent
      RNA polymerase (RdRp) amino acids. We thus tested PolyPs for functional
      interactions in vitro in SARS CoV2 infected Vero E6, Caco2 and human
      primary nasal epithelial cells. Immunofluorescence, qPCR, direct RNA
      sequencing, FISH and Immunoblotting were used to determine virus loads and
      transcription levels of genomic(g)RNAs and subgenomic(sg)RNAs. We show
      that PolyP120 binds to ACE2 and enhances its proteasomal degradation.
      PolyP120 shows steric hindrance of the genomic SARS CoV2 RNA/RdRP complex,
      to impair synthesis of positive-sense gRNAs, viral subgenomic transcripts
      and structural proteins needed for viral replication. Thus, PolyP120
      impairs infection and replication of Korean and European (containing non
      synonymous variants) SARS CoV2 strains. As PolyPs have no toxic
      activities, we envision their use as a nebulised formula for oropharyngeal
      delivery to prevent infections of SARS CoV2 and during early phases of
      antiviral therapy


      ### Competing Interest Statement


      The authors have declared no competing interest.
    authors:
      - name: Veronica Ferrucci
        orcid: null
      - name: Young Kong Dae
        orcid: null
      - name: Fatemeh Asadzadeh
        orcid: null
      - name: Laura Marrone
        orcid: null
      - name: Roberto Siciliano
        orcid: null
      - name: Pellegrino Cerino
        orcid: null
      - name: Giuseppina Criscuolo
        orcid: null
      - name: Ida Pisano
        orcid: null
      - name: Fabrizio Quarantelli
        orcid: null
      - name: Barbara Izzo
        orcid: null
      - name: Giovanna Fusco
        orcid: null
      - name: Marika Comegna
        orcid: null
      - name: Angelo Boccia
        orcid: null
      - name: Maurizio Viscardi
        orcid: null
      - name: Giorgia Borriello
        orcid: null
      - name: Sergio Brandi
        orcid: null
      - name: Bianca Maria Pierri
        orcid: null
      - name: Claudia Tiberio
        orcid: null
      - name: Luigi Atripaldi
        orcid: null
      - name: Giovanni Paolella
        orcid: null
      - name: Giuseppe Castaldo
        orcid: null
      - name: Stefano Pascarella
        orcid: null
      - name: Martina Bianchi
        orcid: null
      - name: Rosa Della Monica
        orcid: null
      - name: Lorenzo Chiariotti
        orcid: null
      - name: Kyong Seop Yun
        orcid: null
      - name: Jae Ho Cheong
        orcid: null
      - name: Hong Yeoul Kim
        orcid: null
      - name: Massimo Zollo
        orcid: http://orcid.org/0000-0002-0970-7243
  comment:
    dislikes: 0
    thread: "8282253330"
    numReports: 0
    likes: 0
    id: "5448434674"
    createdAt: 2021-07-08T15:33:11
    author:
      name: Massimo Zollo
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: |-
      https://pubmed.ncbi.nlm.nih.gov/34230209/

      See paper published on Science Signaling
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.11.18.388413v1
  tweets:
    - created_at: Sat Jul 10 20:18:36 +0000 2021
      id: 1413955839841521700
      id_str: "1413955839841521670"
      text: |-
        üí¨ bioRxiv comment on "Long-chain polyphosphates impa..."

        " paper published on Science Signaling"

        https://t.co/rvewaMQ02c
      truncated: false
      entities:
        urls:
          - url: https://t.co/rvewaMQ02c
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 10 20:18:37 +0000 2021
      id: 1413955840588005400
      id_str: "1413955840588005382"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/FBjioh0n1S
      truncated: false
      entities:
        urls:
          - url: https://t.co/FBjioh0n1S
      in_reply_to_status_id: 1413955839841521700
      in_reply_to_status_id_str: "1413955839841521670"
- preprint:
    id: "148358"
    doi: 10.1101/2021.07.01.450699
    first_posted: 2021-07-01
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.01.450699v1
    url: https://api.rxivist.org/v1/papers/148358
    title: Inverse design of cholesterol attracting transmembrane helices reveals a
      paradoxical role of hydrophobic length
    category: biophysics
    abstract: >-
      The occurrence of linear cholesterol-recognition motifs in alpha-helical
      transmembrane domains has long been debated. Here, we demonstrate the
      ability of a genetic algorithm guided by coarse-grained molecular dynamics
      simulations--a method coined evolutionary molecular dynamics (evo-MD)--to
      directly resolve the sequence which maximally attracts/sorts cholesterol
      within a single-pass alpha-helical transmembrane domain (TMDs). We
      illustrate that the evolutionary landscape of cholesterol attraction in
      membrane proteins is characterized by a sharp, well-defined global
      optimum. Surprisingly, this optimal solution features an unusual short
      hydrophobic block, consisting of typically only eight short chain
      hydrophobic amino acids, surrounded by three successive lysines. Owing to
      the membrane thickening effect of cholesterol, cholesterol-enriched
      ordered phases favor TMDs characterized by a long rather than a short
      hydrophobic length. However, this short hydrophobic pattern evidently
      offers a pronounced net advantage for the binding of free cholesterol in
      both coarse-grained and atomistic simulations. Attraction is mediated by
      the unique ability of cholesterol to snorkel within the hydrophobic core
      of the membrane and thereby shield deeply located lysines from the
      unfavorable hydrophobic surrounding. Since this mechanism of attraction is
      of a thermodynamic nature and is not based on molecular shape specificity,
      a large diversity of sub-optimal cholesterol attracting sequences can
      exist. The puzzling sequence variability of proposed linear
      cholesterol-recognition motifs is thus consistent with sub-optimal,
      unspecific binding of cholesterol. Importantly, since evo-MD uniquely
      enables the targeted design of recognition motifs for distinct fluid lipid
      membranes, we foresee wide applications for evo-MD in the biological and
      biomedical fields.


      Significance StatementOur work demonstrates how a synergy between evolutionary algorithms and high-throughput coarse-grained molecular dynamics can yield fundamentally new insights into the evolutionary fingerprints of protein-mediated lipid sorting. We illustrate that the evolutionary landscape of cholesterol attraction in isolated transmembrane domains is characterized by a sharp, well-defined global optimum. In contrast, sub-optimal attraction of cholesterol is associated with a diverse solution space and features a high sequence variability despite binding the same unique molecule. The contrasting physicochemical nature of the resolved attraction optimum suggests that cholesterol attraction/binding via linear motifs does not pose a dominant pressure/constrain on the evolution of transmembrane proteins.
    authors:
      - name: Jeroen Methorst
        orcid: null
      - name: Niek van Hilten
        orcid: null
      - name: Herre Jelger Risselada
        orcid: null
  comment:
    dislikes: 0
    thread: "8632634388"
    numReports: 0
    likes: 0
    id: "5448159540"
    createdAt: 2021-07-08T10:55:42
    author:
      name: Jelger Risselada
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: After the manuscript has been accepted via the regular peer
      reviewed process the here-used EVOMD code will be made publicly accessible
      on github. Nevertheless, if you are willing to already try out or use our
      evoMD method simply drop us a line.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.07.01.450699v2
  tweets:
    - created_at: Sat Jul 10 22:18:44 +0000 2021
      id: 1413986069759111200
      id_str: "1413986069759111170"
      text: >-
        üí¨ bioRxiv comment on "Inverse design of cholesterol ..."


        "After the manuscript has been accepted via the regular p‚Ä¶ https://t.co/11v9AnwkUk
      truncated: true
      entities:
        urls:
          - url: https://t.co/11v9AnwkUk
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 10 22:18:44 +0000 2021
      id: 1413986070572769300
      id_str: "1413986070572769280"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/MyKpCYq9yT
      truncated: false
      entities:
        urls:
          - url: https://t.co/MyKpCYq9yT
      in_reply_to_status_id: 1413986069759111200
      in_reply_to_status_id_str: "1413986069759111170"
- preprint:
    id: "149252"
    doi: 10.1101/2021.07.05.21260050
    first_posted: 2021-07-07
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.05.21260050v1
    url: https://api.rxivist.org/v1/papers/149252
    title: Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in
      Ontario, Canada, February to June, 2021
    category: infectious-diseases
    abstract: "The period from February to June 2021 was one during which initial
      wild-type SARS-CoV-2 strains were supplanted in Ontario, Canada, first by
      variants of concern (VOC) with the N501Y mutation (principally alpha, beta
      and gamma variants), and then by the delta variant. We demonstrate that
      these emerging VOCs were associated with an increase in virulence, as
      measured by risk of hospitalization, intensive care unit admission, and
      death. Compared to non-VOC SARS-CoV-2 strains, and adjusting for
      comorbidity, age and sex of cases, and temporal trends, the elevation in
      risk associated with N501Y-positive variants was 74% (62-86%) for
      hospitalization; 138% (105-176%) for ICU admission; and 83% (57-114%) for
      death. Increases with delta variant were even larger: 105% (80-133%) for
      hospitalization; 241% (163-344%) for ICU admission; and 121% (57-211%) for
      death. The progressive increase in transmissibility and virulence of
      SARS-CoV-2 variants will result in a significantly larger, and more
      deadly, pandemic."
    authors:
      - name: David Fisman
        orcid: http://orcid.org/0000-0001-5009-6926
      - name: Ashleigh Tuite
        orcid: http://orcid.org/0000-0002-4373-9337
  comment:
    dislikes: 0
    thread: "8636008413"
    numReports: 0
    likes: 0
    id: "5451153116"
    createdAt: 2021-07-10T22:08:06
    author:
      username: disqus_kvuMWTcJ26
      about: ""
      name: Mazzs
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_kvuMWTcJ26/
      url: ""
      location: ""
      id: "372157635"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Australia is currently showing good data on precise outcomes for
      delta variant cases.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.07.05.21260050v1
  tweets:
    - created_at: Sun Jul 11 01:07:47 +0000 2021
      id: 1414028613075284000
      id_str: "1414028613075283972"
      text: >-
        üí¨ medRxiv comment on "Progressive Increase in Virule..."


        "Australia is currently showing good data on precise outc‚Ä¶ https://t.co/hTCJjLUP6G
      truncated: true
      entities:
        urls:
          - url: https://t.co/hTCJjLUP6G
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 11 01:07:47 +0000 2021
      id: 1414028613960220700
      id_str: "1414028613960220673"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/puR7zuGbpW
      truncated: false
      entities:
        urls:
          - url: https://t.co/puR7zuGbpW
      in_reply_to_status_id: 1414028613075284000
      in_reply_to_status_id_str: "1414028613075283972"
- preprint:
    id: "130178"
    doi: 10.1101/2021.02.12.21249710
    first_posted: 2021-02-15
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.02.12.21249710v1
    url: https://api.rxivist.org/v1/papers/130178
    title: Risk of Corona virus disease 2019 (COVID-19) among spectacles wearing
      population of Northern India
    category: ophthalmology
    abstract: >-
      IntroductionSevere Acute Respiratory Syndrome Corona virus-2 (SARS-CoV-2)
      spread mainly through respiratory droplets and contact routes. Long term
      use of spectacles may prevent repeated touching and rubbing of the eyes.
      Aim of the study is to compare the risk of COVID-19 in long term
      spectacles wearers with the risk in persons not using spectacles.


      ObjectivesTo know the association between infection with SARSCoV-2 and wearing of spectacles.


      Materials and methodsIn this study, 304 patients of Corona virus disease 2019 (COVID-19) were selected. Their spectacles wearing behaviour was assessed through a questionnaire. Spectacles wearing behaviour of general population was obtained from older studies (for comparison). Risk of COVID-19 was calculated in long term spectacles wearers as well as in persons not using spectacles. Chi-Square test was used for statistical analysis.


      ResultsIn this study, total 58 patients showed the behavior of using spectacles continuously during day time and always on outdoor activities. The risk of COVID-19 was found 0.48 in spectacles wearing population as compared to 1.35 in population not using spectacles. The calculated risk ratio was 0.36. The protective effectiveness of the spectacles was found statistically significant (p-value .00113).


      ConclusionThe present study showed that the risk of Covid-19 was about 2-3 times less in spectacles wearing population than the population not wearing those. The nasolacrimal duct may be a route of virus transmission from conjunctival sac to the nasopharynx.
    authors:
      - name: Amit Kumar Saxena
        orcid: null
  comment:
    dislikes: 0
    thread: "8469455684"
    numReports: 0
    likes: 0
    id: "5451135552"
    createdAt: 2021-07-10T21:46:46
    author:
      username: merjarantala
      about: ""
      name: Merja Rantala
      isPowerContributor: false
      profileUrl: https://disqus.com/by/merjarantala/
      url: ""
      location: ""
      id: "365735823"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: But you did not have a proper control group! You can't say anything
      about association of spectacles with covid based on this work.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.02.12.21249710v3
  tweets:
    - created_at: Sun Jul 11 12:29:45 +0000 2021
      id: 1414200236621410300
      id_str: "1414200236621410304"
      text: >-
        üí¨ medRxiv comment on "Risk of Corona virus disease 2..."


        "But you did not have a proper control group! You can't s‚Ä¶ https://t.co/heE15gXQSu
      truncated: true
      entities:
        urls:
          - url: https://t.co/heE15gXQSu
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 11 12:29:45 +0000 2021
      id: 1414200237418328000
      id_str: "1414200237418328067"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/YJ1mJxsnmB
      truncated: false
      entities:
        urls:
          - url: https://t.co/YJ1mJxsnmB
      in_reply_to_status_id: 1414200236621410300
      in_reply_to_status_id_str: "1414200236621410304"
- preprint:
    id: "118473"
    doi: 10.1101/2020.10.30.20217364
    first_posted: 2020-11-03
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.10.30.20217364v1
    url: https://api.rxivist.org/v1/papers/118473
    title: "Honey and Nigella sativa against COVID-19 in Pakistan (HNS-COVID-PK): A
      multi-center placebo-controlled randomized clinical trial"
    category: infectious-diseases
    abstract: "BACKGROUND: No definitive treatment exists for Coronavirus Disease
      2019 (COVID-19). Honey and Nigella sativa (HNS) have established antiviral
      properties. Hence, we investigated the efficacy of HNS against COVID-19.
      METHODS: We conducted a multicenter, placebo-controlled, randomized
      clinical trial at 4 centers in Pakistan. RT-PCR confirmed COVID-19 adults
      showing moderate or severe disease were enrolled in the study. Patients
      presenting with multi-organ failure, ventilator support, and chronic
      diseases (except diabetes mellitus and hypertension) were excluded.
      Patients were randomly assigned in 1:1 ratio to receive either honey (1
      gm/Kg/day) and Nigella sativa seeds (80 mg/Kg/day) or placebo up-to 13
      days along with standard care. The outcomes included symptom alleviation,
      viral clearance, and 30-day mortality in the intention-to-treat
      population. This trial was registered with ClinicalTrials.gov,
      NCT04347382. FINDINGS Three hundred and thirteen patients - 210 moderate
      and 103 severe - underwent randomization from April 30 to July 29, 2020.
      Among these, 107 were assigned to HNS whereas 103 to placebo for moderate
      cases. For severe cases, 50 were given HNS, and 53 were given placebos.
      HNS resulted in ~50% reduction in time taken to alleviate symptoms as
      compared to placebo (Moderate (4 versus 7 days), Hazard Ratio [HR]: 6.11;
      95% Confidence Interval [CI]: 4.23-8.84, P<0.0001 and severe (6 versus 13
      days) HR: 4.04; 95% CI, 2.46-6.64, P<0.0001). HNS also cleared the virus 4
      days earlier than the placebo group in moderate (6 versus 10 days, HR:
      5.53; 95% CI: 3.76-8.14, P<0.0001) and severe cases (8.5 versus 12 days,
      HR: 4.32; 95% CI: 2.62-7.13, P<0.0001). HNS further led to a better
      clinical score on day 6 with normal activity resumption in 63.6% versus
      10.9% among moderate cases (OR: 0.07; 95% CI: 0.03-0.13, P<0.0001) and
      hospital discharge in 50% versus 2.8% in severe cases (OR: 0.03; 95% CI:
      0.01-0.09, P<0.0001). In severe cases, mortality rate was four-fold lower
      in HNS group than placebo (4% versus 18.87%, OR: 0.18; 95% CI: 0.02-0.92,
      P=0.029). No HNS-related adverse effects were observed. INTERPRETATION HNS
      significantly improved symptoms, viral clearance, and mortality in
      COVID-19 patients. Thus, HNS represents an affordable over the counter
      therapy and can either be used alone or in combination with other
      treatments to achieve potentiating effects against COVID-19. FUNDING:
      Funded by Smile Welfare Organization, Shaikh Zayed Medical Complex, and
      Services Institute of Medical Sciences."
    authors:
      - name: Sohaib Ashraf
        orcid: http://orcid.org/0000-0003-3127-3557
      - name: Shoaib Ashraf
        orcid: http://orcid.org/0000-0002-1218-4877
      - name: Moneeb Ashraf
        orcid: http://orcid.org/0000-0002-5769-9524
      - name: Muhammad Ahmad Imran
        orcid: http://orcid.org/0000-0003-3358-229X
      - name: Larab Kalsoom
        orcid: http://orcid.org/0000-0003-1075-6285
      - name: Uzma Nasim Siddiqui
        orcid: null
      - name: Iqra Farooq
        orcid: null
      - name: Zaigham Habib
        orcid: null
      - name: Sidra Ashraf
        orcid: http://orcid.org/0000-0002-4254-2583
      - name: Muhammad Ghufran
        orcid: null
      - name: Muhammad Kiwan Akram
        orcid: http://orcid.org/0000-0002-8415-9363
      - name: Nighat Majeed
        orcid: http://orcid.org/0000-0003-0238-7520
      - name: Zain ul Abdin
        orcid: null
      - name: Rutaba Akmal
        orcid: null
      - name: Sundas Rafique
        orcid: null
      - name: Khawar Nawaz
        orcid: null
      - name: Muhammad Ismail Khalid Yousaf
        orcid: null
      - name: Sohail Ahmad
        orcid: null
      - name: Muhammad Sarmad Shahab
        orcid: null
      - name: Muhammad Faisal Nadeem
        orcid: http://orcid.org/0000-0002-1356-103X
      - name: Abubakar Hilal
        orcid: null
      - name: Arz Muhammad
        orcid: null
      - name: Zeeshan Shoukat
        orcid: null
      - name: Ayesha Khaqan
        orcid: null
      - name: Kanwal Hayat
        orcid: null
      - name: Shahroz Arshad
        orcid: null
      - name: Muhammad Hassan
        orcid: null
      - name: Abeer bin Awais
        orcid: null
      - name: Abdur Rehman Virk
        orcid: null
      - name: Ammara Ahmad
        orcid: null
      - name: Tayyab Mughal
        orcid: null
      - name: Muhammad Umer
        orcid: null
      - name: Muhammad Suhail
        orcid: null
      - name: Sibgha Zulfiqar
        orcid: null
      - name: Saulat Sarfraz
        orcid: null
      - name: Imran Anwar
        orcid: http://orcid.org/0000-0002-8540-0139
      - name: Ayesha Humayun
        orcid: null
      - name: Muhammad Azam
        orcid: null
      - name: Hui Zheng
        orcid: null
      - name: Amber Malik
        orcid: null
      - name: Mahmood Ayyaz
        orcid: http://orcid.org/0000-0003-1957-383X
      - name: Ali Ahmad
        orcid: http://orcid.org/0000-0001-7689-7115
      - name: Talha Mahmud
        orcid: http://orcid.org/0000-0003-4585-0765
      - name: Qazi Abdul Saboor
        orcid: null
      - name: Muhammad Ashraf
        orcid: null
      - name: Mateen Izhar
        orcid: null
  comment:
    dislikes: 0
    thread: "8266500533"
    numReports: 0
    likes: 0
    id: "5451065140"
    createdAt: 2021-07-10T20:28:13
    author:
      username: michelprmont
      about: ""
      name: Michel Pr√©mont
      isPowerContributor: false
      profileUrl: https://disqus.com/by/michelprmont/
      url: ""
      location: ""
      id: "371875808"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Interesting study but I have two questions.


      1. The study indicates "honey (1 gm/Kg/day) and Nigella sativa (80 mg/Kg/day)". The quantity of honey: is it 1 milligram/kg or 1 gram/kg ?  1 g/kg  is a huge quantity (70 g/day for a 70 kg person.

      2. Under what form was the nigella ? Seed, oil, ground seeds....


      Thank you.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.10.30.20217364v2
  tweets:
    - created_at: Sun Jul 11 14:16:59 +0000 2021
      id: 1414227223813501000
      id_str: "1414227223813500930"
      text: |-
        üí¨ medRxiv comment on "Honey and Nigella sativa again..."

        "Interesting study but I have two questions.

        1. The stud‚Ä¶ https://t.co/6dVdMD14Jg
      truncated: true
      entities:
        urls:
          - url: https://t.co/6dVdMD14Jg
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 11 14:17:00 +0000 2021
      id: 1414227224690049000
      id_str: "1414227224690049026"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/4lT0fD4fj5
      truncated: false
      entities:
        urls:
          - url: https://t.co/4lT0fD4fj5
      in_reply_to_status_id: 1414227223813501000
      in_reply_to_status_id_str: "1414227223813500930"
- preprint:
    id: "114755"
    doi: 10.1101/2020.07.24.20160101
    first_posted: 2020-07-30
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.07.24.20160101v1
    url: https://api.rxivist.org/v1/papers/114755
    title: Red blood cells injuries and hypersegmented neutrophils in COVID-19
      peripheral blood film
    category: hematology
    abstract: "In the current investigation, peripheral blood films of 15 COVID-19
      patients (44.78{+/-}16.55 years), proven by computed tomographic imaging
      and RT-PCR for coronavirus SARS-CoV-2, were analyzed at the moment of
      hospital admission. Blood tests showed raised inflammatory markers
      (C-reactive protein 58.2{+/-}61.2 mg/L) with normal values for hemoglobin
      (126.2{+/-}2.6 g/L), WBC (6.8{+/-}18.74 109/L) RBC (4.55{+/-}0.99 1012/L)
      platelets (262.4{+/-}41.8, 109/L) MCV (79.84{+/-}8.2 fL) MCH (28{+/-}3.31
      pg) and MCHC (350.3{+/-}1.15 g/L). The results revealed the presence of
      hypersegmented neutrophils in 66.66%% of the patients. The percentages of
      neutrophils with 4 and 5 lobes were 46.25{+/-}4.83% and 31.5{+/-}14.84%,
      respectively. Three major red blood cells morphological alteration were
      observed: (1) erythrocytes in double primerouleauxdouble prime formation
      represented by linear erythrocytes aggregation, (2) spherocytes with the
      disappearance of the usual biconcave disk, and (3) echinocytes showing
      spiky projections. Apparent reorganization of hemoglobin is found in the
      majority of the analyzed erythrocytes. Rouleaux formation is observed in
      33.33% of patients and spherocytes and echinocytes are present at variable
      levels in the all analyzed patients. The current results revealed
      erythrocytes injuries in COVID-19 peripheral blood, in association with
      hypersegmented neutrophils, alterations that could be involved in the
      respiratory syndrome."
    authors:
      - name: Nordine Lakhdari
        orcid: null
      - name: Boualem Tabet
        orcid: null
      - name: Lila Boudraham
        orcid: null
      - name: Malha Laoussati
        orcid: null
      - name: Sofiane Aissanou
        orcid: null
      - name: Lamia Beddou
        orcid: null
      - name: Sihem Bensalem
        orcid: null
      - name: Yuva Bellik
        orcid: null
      - name: Lamine Bournine
        orcid: null
      - name: Sofiane Fatmi
        orcid: null
      - name: Mokrane Iguer-Ouada
        orcid: http://orcid.org/0000-0002-3218-0670
  comment:
    dislikes: 0
    thread: "8146686091"
    numReports: 0
    likes: 0
    id: "5450816169"
    createdAt: 2021-07-10T16:09:38
    author:
      username: jaroslavpobeha
      about: ""
      name: Jaroslav Pobeha
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jaroslavpobeha/
      url: ""
      location: ""
      id: "257658057"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: I read in another study the rouleaux formation can be by created by
      in inflamation acute-phase proteins..
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.07.24.20160101v1
  tweets:
    - created_at: Sun Jul 11 16:29:58 +0000 2021
      id: 1414260690471227400
      id_str: "1414260690471227396"
      text: >-
        üí¨ medRxiv comment on "Red blood cells injuries and h..."


        "I read in another study the rouleaux formation can be by‚Ä¶ https://t.co/yWzWhTn6ZT
      truncated: true
      entities:
        urls:
          - url: https://t.co/yWzWhTn6ZT
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 11 16:29:59 +0000 2021
      id: 1414260691607896000
      id_str: "1414260691607896072"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/zByEJds1Lw
      truncated: false
      entities:
        urls:
          - url: https://t.co/zByEJds1Lw
      in_reply_to_status_id: 1414260690471227400
      in_reply_to_status_id_str: "1414260690471227396"
- preprint:
    id: "137204"
    doi: 10.1101/2021.04.06.21254993
    first_posted: 2021-04-09
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.04.06.21254993v1
    url: https://api.rxivist.org/v1/papers/137204
    title: "Reopening Italy's Schools in September 2020: A Bayesian Estimation of
      the Change in the Growth Rate of New SARS-CoV-2 Cases"
    category: public-and-global-health
    abstract: "Abstract Objectives: CoViD-19's second wave started a debate on the
      potential role of schools as a primary factor in the contagion resurgence.
      Two opposite positions appeared: those convinced that schools played a
      major role in spreading SARS-CoV-2 infections and those who were not. We
      studied the growth rate of the total number of SARS-CoV-2 infections in
      all the Italian regions, before and after the school reopening (September
      - October 2020), investigating the hypothesis of an association between
      schools and the resurgence of the virus in Italy. Methods: Using Bayesian
      piecewise linear regression to scrutinize the number of daily SARS-CoV-2
      infections in each Italian, we looked for an estimate of a changepoint in
      the growth rate of those confirmed cases. We compared the changepoints
      with the school opening dates, for each Italian region. The regression
      allows to discuss the change in steepness of the infection curve, before
      and after the changepoint. Results: In 15 out of 21 Italian regions (71%),
      an estimated change in the rate of growth of the total number of daily
      SARS-CoV-2 infection cases occurred after an average of 16.66 days (CI 95%
      14.47 to 18.73) since the school reopening. The number of days required
      for the SARS-CoV-2 daily cases to double went from an average of 47.50
      days (CI 95% 37.18 to 57.61) before the changepoint to an average of 7.72
      days (CI 95% 7.00 to 8.48) after it. Conclusion: Studying the rate of
      growth of daily SARS-CoV-2 cases in all the Italian regions provides some
      evidence in favor of a link between school reopening and the resurgence of
      the virus in Italy. The number of factors that could have played a role
      are too many to give a definitive answer. Still, the temporal
      correspondence warrants for a controlled experiment to clarify how much
      reopening schools mattered."
    authors:
      - name: Luca Casini
        orcid: http://orcid.org/0000-0002-3468-6974
      - name: Marco Roccetti
        orcid: http://orcid.org/0000-0003-1264-8595
  comment:
    dislikes: 0
    thread: "8471585559"
    numReports: 0
    likes: 0
    id: "5450676156"
    createdAt: 2021-07-10T13:39:38
    author:
      username: marcoroccetti
      about: ""
      name: Marco Roccetti
      isPowerContributor: false
      profileUrl: https://disqus.com/by/marcoroccetti/
      url: ""
      location: ""
      id: "371081903"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Final version of this study available on BMJ Open:
      https://bmjopen.bmj.com/content/11/7/e051458


      regards

      The Authors
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.04.06.21254993v1
  tweets:
    - created_at: Sun Jul 11 18:23:59 +0000 2021
      id: 1414289380496314400
      id_str: "1414289380496314369"
      text: >-
        üí¨ medRxiv comment on "Reopening Italy's Schools in S..."


        "Final version of this study available on BMJ Open:  Auth‚Ä¶ https://t.co/S7nOtOq7vU
      truncated: true
      entities:
        urls:
          - url: https://t.co/S7nOtOq7vU
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 11 18:23:59 +0000 2021
      id: 1414289381540569000
      id_str: "1414289381540569089"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/cIRnxwgahq
      truncated: false
      entities:
        urls:
          - url: https://t.co/cIRnxwgahq
      in_reply_to_status_id: 1414289380496314400
      in_reply_to_status_id_str: "1414289380496314369"
- preprint:
    id: 149635
    metric: 16
    title: The PD-1 checkpoint receptor maintains tolerance of self-reactive CD8 T
      cell in skin
    url: https://api.rxivist.org/v1/papers/149635
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.09.451765v1
    doi: 10.1101/2021.07.09.451765
    category: immunology
    first_posted: 2021-07-10
    abstract: Peripheral tolerance is thought to result from anergy or deletion of
      self-reactive T cells shortly after antigen encounter. However, the
      frequent occurrences of immune-related Adverse Events (irAEs) following
      checkpoint inhibitor (CPI) treatment suggest a hypothesis that
      immunologically healthy individuals have self-reactive effector T cells
      that are kept in a non-pathogenic state through checkpoint
      receptor-mediated suppression, instead of anergy or deletion. We expressed
      self-antigens in healthy skin and found that antigen-specific CD8 T cells
      infiltrated the tissue, but remained tolerant, despite having a
      transcriptional program that resembled effector T cells found after CPIs.
      These self-reactive PD-1+ CD8 T cells drove IFNg-dependent increases in
      PD-L1 on skin myeloid cells. Blockade of PD-1 or PD-1/CTLA-4 led to
      post-transcriptional upregulation of effector proteins by antigen-specific
      CD8 T cells and elimination of antigen-expressing epithelial cells,
      resulting in localized tissue pathology with features of human cutaneous
      irAEs. This data supports the hypothesis that myeloid cells in healthy
      skin prevent pathology from self-reactive effector CD8 T cells through the
      PD-1/PD-L1 pathway.
    authors:
      - name: Martina Damo
      - name: Can Cui
      - name: Ivana William
      - name: Noah I Hornick
      - name: Darwin Kwok
      - name: Kathryn Clulo
      - name: William E Damsky
      - name: Jonathan S Leventhal
      - name: Nikhil S Joshi
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sun Jul 11 20:15:22 +0000 2021
      id: 1414317413202632700
      id_str: "1414317413202632704"
      text: >-
        üî• bioRxiv Immunology preprint by M. Damo et al:


        "The PD-1 checkpoint receptor maintains tolerance of self-reactive‚Ä¶ https://t.co/cI6ZKOhyoZ
      truncated: true
      entities:
        urls:
          - url: https://t.co/cI6ZKOhyoZ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "149428"
    doi: 10.1101/2021.07.08.21259871
    first_posted: 2021-07-08
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.08.21259871v1
    url: https://api.rxivist.org/v1/papers/149428
    title: Symptomatic, Presymptomatic, and Asymptomatic Transmission of SARS-CoV-2
    category: public-and-global-health
    abstract: "Importance: Asymptomatic and presymptomatic carriers of SARS-CoV-2
      are an ongoing and significant risk for community spread of the virus,
      especially with the majority of the world still unvaccinated and new
      variants emerging. Objective: To quantify the presence and effects of
      symptom presentation (or lack thereof) on the community transmission
      ofSARS-CoV-2. Design: A cohort of 12,960 young adults participated in
      health reporting, contact tracing, and COVID-19 testing for 103 days
      between August 10 and November 20, 2020. Setting: A mid-sized university
      campus in Indiana, United States. Participants: University students, most
      of whom are 18-23 years old (67%) and living in congregate on-campus
      housing (60%). Of the 12,960 students, 1,556 (12.0%) tested positive for
      COVID-19 during the 103 day period. Of the positive cases, 1,198 reported
      sufficient health check data (7 days prior and 7 days post diagnosis) to
      be classified as asymptomatic or symptomatic. Main Outcome: Secondary
      attack rate, based on presentation or absence of symptoms and type of
      symptoms calculated with respect to confirmed close contacts and a 14-day
      incubation period, varies on the type of symptom, timing of symptoms, and
      absence of symptoms. A quantifiable understanding of SAR on the
      longitudinal data of more than one thousand subjects in a university
      environment provides keen insights about developing strategies to respond
      to the continued prevalence of COVID-19 in the unvaccinated world and
      growth of variants. Results: 32.5% of all cases reported no symptoms
      within a 15-day window centered on their positive test (7 days prior, the
      day of the positive test, and 7 days after). The secondary attack rate
      (SAR) of asymptomatic COVID-19 index cases was 19.1%. The SAR of
      symptomatic index cases was 25.4%, and while the onset timing of symptoms
      did not affect transmission, the presence of certain symptoms like fever,
      shortness of breath, and dry cough increased the SAR as high as 30.0%.
      Conclusions and Relevance: Asymptomatic rates of transmission of
      SARS-CoV-2 are much higher than has been estimated in prior studies and
      continue to pose a significant and ongoing risk in the pandemic,
      especially with the prevalence of variants like the Delta variant. In
      addition, different symptoms are associated with varying rates of
      transmission, posing a significant challenge in how to diagnose or assess
      risk through mechanisms such as daily health checks for symptom reporting,
      a practice commonly in place for entry into schools, offices, restaurants,
      etc. Given the uncertain nature of symptoms and varied transmission rates,
      this study suggests a broader embrace of masking, social distancing and
      testing might be needed to counter the variants until higher global
      vaccination rates can be achieved."
    authors:
      - name: Steven J Krieg
        orcid: null
      - name: Jennifer J Schnur
        orcid: null
      - name: Marie L Miranda
        orcid: null
      - name: Michael E. Pfrender
        orcid: http://orcid.org/0000-0001-6861-0655
      - name: Nitesh V Chawla
        orcid: null
  comment:
    dislikes: 0
    thread: "8637992499"
    numReports: 0
    likes: 0
    id: "5450536528"
    createdAt: 2021-07-10T10:07:37
    author:
      username: caio_salvino
      about: ""
      name: Caio Salvino
      isPowerContributor: false
      profileUrl: https://disqus.com/by/caio_salvino/
      url: ""
      location: ""
      id: "372135561"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Hi.

      In my opinion, it‚Äôs impossible affirm that the ‚Äúassymptomatic‚Äù cases was transmiting the virus without verify the cycle threshold of RT-PCR detecting RNA at oropharyngeal swabs samples. Only reporting like positive or negative is insuficient for affirm infectivity.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.07.08.21259871v1
  tweets:
    - created_at: Sun Jul 11 20:18:41 +0000 2021
      id: 1414318248917602300
      id_str: "1414318248917602306"
      text: >-
        üí¨ medRxiv comment on "Symptomatic, Presymptomatic, a..."


        "Hi.

        In my opinion, it‚Äôs impossible affirm that the ‚Äúassy‚Ä¶ https://t.co/9CEGHUOuIe
      truncated: true
      entities:
        urls:
          - url: https://t.co/9CEGHUOuIe
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 11 20:18:42 +0000 2021
      id: 1414318249706205200
      id_str: "1414318249706205186"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/RFYzsKvVw3
      truncated: false
      entities:
        urls:
          - url: https://t.co/RFYzsKvVw3
      in_reply_to_status_id: 1414318248917602300
      in_reply_to_status_id_str: "1414318248917602306"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5450499619"
    createdAt: 2021-07-10T08:48:35
    author:
      username: disqus_8qooljlPZl
      about: ""
      name: James O'Neill
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_8qooljlPZl/
      url: ""
      location: ""
      id: "246806048"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Yeah the criteria for confirmed reinfections is limited to those
      who had their initial infection sequenced (last I looked), I wouldn't use
      that figure as any total sum of reinfections.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Sun Jul 11 22:18:43 +0000 2021
      id: 1414348456433422300
      id_str: "1414348456433422340"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "Yeah the criteria for confirmed reinfections is limited‚Ä¶ https://t.co/97gRH0itk8
      truncated: true
      entities:
        urls:
          - url: https://t.co/97gRH0itk8
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 11 22:18:44 +0000 2021
      id: 1414348457779814400
      id_str: "1414348457779814402"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1414348456433422300
      in_reply_to_status_id_str: "1414348456433422340"
- preprint:
    id: "149207"
    doi: 10.1101/2021.07.03.21259976
    first_posted: 2021-07-07
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.03.21259976v1
    url: https://api.rxivist.org/v1/papers/149207
    title: Incidence of Severe Acute Respiratory Syndrome Coronavirus-2 infection
      among previously infected or vaccinated employees
    category: infectious-diseases
    abstract: "Introduction: The protective effect of previous infection versus
      vaccination is poorly studied. Among a clinical laboratory that has been
      conducting routine workforce screening since the beginning of the
      pandemic, we aimed to assess the relative risk of Severe Acute Respiratory
      Syndrome Coronavirus-2 (SARS-CoV-2) infection among individuals who were
      SARS-CoV-2 naive, previously infected, or vaccinated. Methods: Using an
      electronic laboratory information system, employees were divided into
      three groups: (1) SARS-CoV-2 naive and unvaccinated, (2) previous
      SARS-CoV-2 infection, and (3) vaccinated. Person-days were measured from
      the date of the employee first test and truncated at the end of the
      observation period. SARS-CoV-2 infection was defined as two positive
      SARS-CoV-2 PCR tests in a 30-day period. Individuals with fewer than 14
      days of follow up were excluded. Incidence estimates and the 95%
      confidence intervals were calculated using the Poisson Exact equation. The
      incidence rate ratio (IRR) was used as a measure of association between
      groups. Analyses were performed on StataSE (StataCorp, College Station,
      TX). Results: We identified 4313, 254 and 739 employee records for groups
      1, 2, and 3, respectively. The median age of employees was 29.0 years
      (interquartile range: 23.6, 39.9). During the observation period, 254, 0,
      and 4 infections were identified among groups 1, 2, and 3, respectively.
      Group 1 had an incidence of 25.9 per 100 person-years (95% CI: 22.8-29.3).
      Group 2 had an incidence of 0 per 100 person-years (95% CI: 0-5.0). Group
      3 had an incidence of 1.6 per 100 person-years (95% CI: 0.04-4.2). The IRR
      of reinfection among those with previous infection compared to SARS-CoV-2
      naive was 0 (95% CI: 0-0.19). The IRR of those vaccinated compared to
      SARS-CoV-2 naive was 0.06 (95% CI: 0.02-0.16). The IRR of those vaccinated
      compared to prior SARS-CoV-2 was 0 (95% CI: 0-4.98). Conclusion: Previous
      SARS-CoV-2 infection and vaccination for SARS-CoV-2 were associated with
      decreased risk for infection or re-infection with SARS-CoV-2 in a
      routinely screened workforce. The was no difference in the infection
      incidence between vaccinated individuals and individuals with previous
      infection. Further research is needed to determine whether our results are
      consistent with the emergence of new SARS-CoV-2 variants."
    authors:
      - name: Noah Kojima
        orcid: http://orcid.org/0000-0002-3667-9719
      - name: Arash Roshani
        orcid: null
      - name: Matthew Brobeck
        orcid: null
      - name: Arthur Baca
        orcid: null
      - name: Jeffrey D Klausner
        orcid: http://orcid.org/0000-0002-6922-7364
  comment:
    dislikes: 0
    thread: "8637067806"
    numReports: 0
    likes: 0
    id: "5452039382"
    createdAt: 2021-07-11T19:31:18
    author:
      username: disqus_KbE9OrjbFH
      about: ""
      name: geek49203
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_KbE9OrjbFH/
      url: ""
      location: ""
      id: "367229492"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Published reports state:  "‚ÄúThe big takeaway was that if you are not
      vaccinated, and were not previously infected, one, you have a very high
      risk getting infected‚Äî24 percent of employees over a year tested
      positive." (Epoch times).  But I see only 254 out of 4,313, which is
      5.8%.  Even allowing for a doubling of the timeline (to a full year?)
      that's around 11-12%, which is fairly in line with what the Brits
      published in May in The Lancet.

      SECOND - it's obvious to me that there is a likelihood that the number of infections are seasonal.  IF those who got injections were vaccinated on the downward slope (ie, Feb 21 forward) instead of the upward slope of Dec 20-Jan 21, wouldn't the results be much different?  So studying those who got the vaccine would have to take into account the prevailing non-study environment, correct?  A non-vaccinated person wasn't very likely to get COVID in June of this year, or June of last year, correct?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.07.03.21259976v2
  tweets:
    - created_at: Mon Jul 12 01:01:12 +0000 2021
      id: 1414389343641378800
      id_str: "1414389343641378821"
      text: >-
        üí¨ medRxiv comment on "Incidence of Severe Acute Resp..."


        "Published reports state:  "‚ÄúThe big takeaway was that if‚Ä¶ https://t.co/Su4qfxocBf
      truncated: true
      entities:
        urls:
          - url: https://t.co/Su4qfxocBf
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 12 01:01:12 +0000 2021
      id: 1414389344568320000
      id_str: "1414389344568320002"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/RNtGMoKX2m
      truncated: false
      entities:
        urls:
          - url: https://t.co/RNtGMoKX2m
      in_reply_to_status_id: 1414389343641378800
      in_reply_to_status_id_str: "1414389343641378821"
- preprint:
    id: "143071"
    doi: 10.1101/2021.05.22.21257658
    first_posted: 2021-05-24
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.22.21257658v1
    url: https://api.rxivist.org/v1/papers/143071
    title: Effectiveness of COVID-19 vaccines against the B.1.617.2 variant
    category: epidemiology
    abstract: "Background: The B.1.617.2 COVID-19 variant has contributed to the
      surge in cases in India and has now been detected across the globe,
      including a notable increase in cases in the UK. We estimate the
      effectiveness of the BNT162b2 and ChAdOx1 COVID-19 vaccines against this
      variant. Methods: A test negative case control design was used to estimate
      the effectiveness of vaccination against symptomatic disease with both
      variants over the period that B.1.617.2 began circulating with cases
      identified based on sequencing and S-gene target status. Data on all
      symptomatic sequenced cases of COVID-19 in England was used to estimate
      the proportion of cases with B.1.617.2 compared to the predominant strain
      (B.1.1.7) by vaccination status. Results: Effectiveness was notably lower
      after 1 dose of vaccine with B.1.617.2 cases 33.5% (95%CI: 20.6 to 44.3)
      compared to B.1.1.7 cases 51.1% (95%CI: 47.3 to 54.7) with similar results
      for both vaccines. With BNT162b2 2 dose effectiveness reduced from 93.4%
      (95%CI: 90.4 to 95.5) with B.1.1.7 to 87.9% (95%CI: 78.2 to 93.2) with
      B.1.617.2. With ChAdOx1 2 dose effectiveness reduced from 66.1% (95% CI:
      54.0 to 75.0) with B.1.1.7 to 59.8% (95%CI: 28.9 to 77.3) with B.1.617.2.
      Sequenced cases detected after 1 or 2 doses of vaccination had a higher
      odds of infection with B.1.617.2 compared to unvaccinated cases (OR 1.40;
      95%CI: 1.13-1.75). Conclusions: After 2 doses of either vaccine there were
      only modest differences in vaccine effectiveness with the B.1.617.2
      variant. Absolute differences in vaccine effectiveness were more marked
      with dose 1. This would support maximising vaccine uptake with two doses
      among vulnerable groups."
    authors:
      - name: Jamie Lopez Bernal
        orcid: http://orcid.org/0000-0002-1301-5653
      - name: Nick Andrews
        orcid: null
      - name: Charlotte Gower
        orcid: null
      - name: Eileen Gallagher
        orcid: null
      - name: Ruth Simmons
        orcid: http://orcid.org/0000-0001-8156-0146
      - name: Simon Thelwall
        orcid: http://orcid.org/0000-0002-0434-2724
      - name: Elise Tessier
        orcid: null
      - name: Natalie Groves
        orcid: null
      - name: Gavin Dabrera
        orcid: http://orcid.org/0000-0003-4606-5945
      - name: Richard Myers
        orcid: null
      - name: Colin Campbell
        orcid: null
      - name: Gayatri Amirthalingam
        orcid: http://orcid.org/0000-0003-2078-0975
      - name: Matt Edmunds
        orcid: null
      - name: Maria Zambon
        orcid: http://orcid.org/0000-0002-8897-7881
      - name: Kevin Brown
        orcid: null
      - name: Susan Hopkins
        orcid: http://orcid.org/0000-0001-5179-5702
      - name: Meera Chand
        orcid: http://orcid.org/0000-0001-9697-0340
      - name: Mary Ramsay
        orcid: null
  comment:
    dislikes: 0
    thread: "8547961204"
    numReports: 0
    likes: 0
    id: "5451869451"
    createdAt: 2021-07-11T16:46:18
    author:
      username: disqus_Vi5jT9nyrL
      about: ""
      name: A Clarke
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_Vi5jT9nyrL/
      url: ""
      location: ""
      id: "372189720"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Also, what effectiveness are you measuring? Symptomatic desease it
      seems however hospitalization and death is the real problem and this
      report out of the UK seems to say those rates are higher among the
      vaccinated; see page 13;
      https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/997418/Variants_of_Concern_VOC_Technical_Briefing_17.pdf
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.22.21257658v1
  tweets:
    - created_at: Mon Jul 12 12:34:55 +0000 2021
      id: 1414563922359824400
      id_str: "1414563922359824386"
      text: >-
        üí¨ medRxiv comment on "Effectiveness of COVID-19 vacc..."


        "Also, what effectiveness are you measuring? Symptomatic‚Ä¶ https://t.co/b4hMntmxBW
      truncated: true
      entities:
        urls:
          - url: https://t.co/b4hMntmxBW
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 12 12:34:55 +0000 2021
      id: 1414563923366383600
      id_str: "1414563923366383619"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/eQVSQuTGsy
      truncated: false
      entities:
        urls:
          - url: https://t.co/eQVSQuTGsy
      in_reply_to_status_id: 1414563922359824400
      in_reply_to_status_id_str: "1414563922359824386"
- preprint:
    id: "144220"
    doi: 10.1101/2021.06.01.446559
    first_posted: 2021-06-01
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.01.446559v1
    url: https://api.rxivist.org/v1/papers/144220
    title: "AltumAge: A Pan-Tissue DNA-Methylation Epigenetic Clock Based on Deep
      Learning"
    category: bioinformatics
    abstract: Several age predictors based on DNA methylation, dubbed epigenetic
      clocks, have been created in recent years. Their accuracy and potential
      for generalization vary widely based on the training data. Here, we
      gathered 143 publicly available data sets from several human tissues to
      develop AltumAge, a highly accurate and precise age predictor based on
      deep learning. Compared to Horvath's 2013 model, AltumAge performs better
      across both normal and malignant tissues and is more generalizable to new
      data sets. Interestingly, it can predict gestational week from placental
      tissue with low error. Lastly, we used deep learning interpretation
      methods to learn which methylation sites contributed to the final model
      predictions. We observed that while most important CpG sites are linearly
      related to age, some highly-interacting CpG sites can influence the
      relevance of such relationships. We studied the associated genes of these
      CpG sites and found literary evidence of their involvement in age-related
      gene regulation. Using chromatin annotations, we observed that the CpG
      sites with the highest contribution to the model predictions were related
      to heterochromatin and gene regulatory regions in the genome. We also
      found age-related KEGG pathways for genes containing these CpG sites. In
      general, neural networks are better predictors due to their ability to
      capture complex feature interactions compared to the typically used
      regularized linear regression. Altogether, our neural network approach
      provides significant improvement and flexibility to current epigenetic
      clocks without sacrificing model interpretability.
    authors:
      - name: Lucas Paulo de Lima Camillo
        orcid: http://orcid.org/0000-0001-8166-0761
      - name: Louis R Lapierre
        orcid: http://orcid.org/0000-0002-8154-141X
      - name: Ritambhara Singh
        orcid: http://orcid.org/0000-0002-7523-160X
  comment:
    dislikes: 0
    thread: "8597997093"
    numReports: 0
    likes: 0
    id: "5452671137"
    createdAt: 2021-07-12T10:40:06
    author:
      name: Lucas Paulo de Lima Camillo
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Dear Louis, thank you for your feedback. You are correct ‚Äî there
      was a typo there. Thank you so much for letting us know!
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.01.446559v3
  tweets:
    - created_at: Mon Jul 12 14:22:25 +0000 2021
      id: 1414590978162319400
      id_str: "1414590978162319368"
      text: >-
        üí¨ bioRxiv comment on "AltumAge: A Pan-Tissue DNA-Met..."


        "Dear Louis, thank you for your feedback. You are correct‚Ä¶ https://t.co/JGNHVI6XRP
      truncated: true
      entities:
        urls:
          - url: https://t.co/JGNHVI6XRP
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 12 14:22:25 +0000 2021
      id: 1414590979047370800
      id_str: "1414590979047370754"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/IIPosDD3TG
      truncated: false
      entities:
        urls:
          - url: https://t.co/IIPosDD3TG
      in_reply_to_status_id: 1414590978162319400
      in_reply_to_status_id_str: "1414590978162319368"
- preprint:
    id: "149537"
    doi: 10.1101/2021.07.08.451645
    first_posted: 2021-07-09
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.08.451645v1
    url: https://api.rxivist.org/v1/papers/149537
    title: Microbiome divergence of marine gastropod species separated by the
      Isthmus of Panama
    category: ecology
    abstract: The rise of the Isthmus of Panama ~3.5 mya separated populations of
      many marine organisms, which then diverged into new geminate sister
      species currently living in the Eastern Pacific Ocean and Caribbean Sea.
      However, we know very little about how such evolutionary divergences of
      host species have shaped their microbiomes. Here, we compared the
      microbiomes of whole-body and shell-surface samples of geminate species of
      marine gastropods in the genera Cerithium and Cerithideopsis to those of
      congeneric outgroups. Our results show that the effects of the Isthmus on
      microbiome composition varied among host genera and between sample types
      within the same hosts. In the whole-body samples, microbiome compositions
      of geminate species pairs in the focal genera tended to be similar, likely
      due to host filtering, although the strength of this relationship varied
      among the two groups and across similarity metrics. Shell-surface
      communities show contrasting patterns, with co-divergence between the host
      taxa and a small number of microbial clades evident in Cerithideopsis, but
      not Cerithium. These results suggest that (i) the rise of the Isthmus of
      Panama affected microbiomes of geminate hosts in a complex and
      clade-specific manner and (ii) host-associated microbial taxa respond
      differently to vicariance events than the hosts themselves.
    authors:
      - name: Alexander T Neu
        orcid: http://orcid.org/0000-0003-0833-1704
      - name: Mark E Torchin
        orcid: null
      - name: Eric E Allen
        orcid: http://orcid.org/0000-0002-1229-8794
      - name: Kaustuv Roy
        orcid: null
  comment:
    dislikes: 0
    thread: "8639588578"
    numReports: 0
    likes: 0
    id: "5452600016"
    createdAt: 2021-07-12T08:27:31
    author:
      username: PalaeoSmith
      about: Assistant Professor in Palaeontology
      name: Martin R. Smith
      isPowerContributor: false
      profileUrl: https://disqus.com/by/PalaeoSmith/
      url: https://community.dur.ac.uk/martin.smith
      location: Durham University
      id: "325420274"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Just a small comment to suggest that you might find other measures
      of congruence more suitable than the Robinson‚ÄìFoulds, which has a number
      of shortcomings; see the 'TreeDist' R package and Smith (2020,
      Bioinformatics, <a
      href="https://doi.org/10.1093/bioinformatics/btaa614">10.1093/bioinformatics/btaa614</a>)
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.07.08.451645v1
  tweets:
    - created_at: Mon Jul 12 16:31:23 +0000 2021
      id: 1414623434139652000
      id_str: "1414623434139652102"
      text: >-
        üí¨ bioRxiv comment on "Microbiome divergence of marin..."


        "Just a small comment to suggest that you might find othe‚Ä¶ https://t.co/7KoTBtzAlg
      truncated: true
      entities:
        urls:
          - url: https://t.co/7KoTBtzAlg
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 12 16:31:24 +0000 2021
      id: 1414623435460862000
      id_str: "1414623435460861954"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/Z4rvSKgJJt
      truncated: false
      entities:
        urls:
          - url: https://t.co/Z4rvSKgJJt
      in_reply_to_status_id: 1414623434139652000
      in_reply_to_status_id_str: "1414623434139652102"
- preprint:
    id: "130238"
    doi: 10.1101/2021.02.19.431761
    first_posted: 2021-02-19
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.02.19.431761v1
    url: https://api.rxivist.org/v1/papers/130238
    title: Using Y-chromosome capture enrichment to resolve haplogroup H2 shows new
      evidence for a two-Path Neolithic expansion to Western Europe
    category: genetics
    abstract: >-
      Uniparentally-inherited markers on mitochondrial DNA (mtDNA) and the
      non-recombining regions of the Y chromosome (NRY), have been used for the
      past 30 years to investigate the history of humans from a maternal and
      paternal perspective.


      Researchers have preferred mtDNA due to its abundance in the cells, and comparatively high substitution rate. Conversely, the NRY is less susceptible to back mutations and saturation, and is potentially more informative than mtDNA owing to its longer sequence length. However, due to comparatively poor NRY coverage via shotgun sequencing, and the relatively low and biased representation of Y-chromosome variants on capture arrays such as the 1240K, ancient DNA studies often fail to utilize the unique perspective that the NRY can yield.


      Here we introduce a new DNA enrichment assay, coined YMCA (Y-mappable capture assay), that targets the "mappable" regions of the NRY. We show that compared to low-coverage shotgun sequencing and 1240K capture, YMCA significantly improves the coverage and number of sites hit on the NRY, increasing the number of Y-haplogroup informative SNPs, and allowing for the identification of previously undiscovered variants.


      To illustrate the power of YMCA, we show that the analysis of ancient Y-chromosome lineages can help to resolve Y-chromosomal haplogroups. As a case study, we focus on H2, a haplogroup associated with a critical event in European human history: the Neolithic transition. By disentangling the evolutionary history of this haplogroup, we further elucidate the two separate paths by which early farmers expanded from Anatolia and the Near East to western Europe.
    authors:
      - name: Adam B Rohrlach
        orcid: http://orcid.org/0000-0002-4204-5018
      - name: Luka Papac
        orcid: null
      - name: Ainash Childebayeva
        orcid: null
      - name: Ma√Øt√© Rivollat
        orcid: null
      - name: Vanessa Villalba-Mouco
        orcid: null
      - name: Gunnar U. Neumann
        orcid: null
      - name: Sandra Penske
        orcid: null
      - name: Eirini Skourtanioti
        orcid: null
      - name: Marieke van de Loosdrecht
        orcid: null
      - name: Murat Akar
        orcid: null
      - name: Kamen Boyadzhiev
        orcid: null
      - name: Yavor Boyadzhiev
        orcid: null
      - name: Marie-France Deguilloux
        orcid: null
      - name: Miroslav Dobe≈°
        orcid: null
      - name: Yilmaz S. Erdal
        orcid: null
      - name: Michal Ern√©e
        orcid: null
      - name: Marcella Frangipane
        orcid: null
      - name: Miroslaw Furmanek
        orcid: null
      - name: Susanne Friederich
        orcid: null
      - name: Emmanuel Ghesqui√®re
        orcid: null
      - name: Agata Ha≈Çuszko
        orcid: null
      - name: Svend Hansen
        orcid: null
      - name: Mario K√º√üner
        orcid: null
      - name: Marcello Mannino
        orcid: null
      - name: Rana √ñzbal
        orcid: null
      - name: Sabine Reinhold
        orcid: null
      - name: St√©phane Rottier
        orcid: null
      - name: Domingo Carlos Salazar-Garc√≠a
        orcid: null
      - name: Jorge Soler Diaz
        orcid: null
      - name: Philipp W. Stockhammer
        orcid: null
      - name: Consuelo Roca de Togores Mu√±oz
        orcid: null
      - name: K Aslihan Yener
        orcid: null
      - name: Cosimo Posth
        orcid: http://orcid.org/0000-0002-8206-3907
      - name: Johannes Krause
        orcid: http://orcid.org/0000-0001-9144-3920
      - name: Alexander Herbig
        orcid: http://orcid.org/0000-0003-1176-1166
      - name: Wolfgang Haak
        orcid: http://orcid.org/0000-0003-2475-2007
  comment:
    dislikes: 0
    thread: "8405191529"
    numReports: 0
    likes: 0
    id: "5452377317"
    createdAt: 2021-07-12T01:32:59
    author:
      username: disqus_qfLs8Uh7wF
      about: ""
      name: MH-82
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_qfLs8Uh7wF/
      url: ""
      location: ""
      id: "95890949"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Great paper & new appraoch


      One minor issue regarding:

      ''The YHG H (H-L901) is thought to have formed in South Asia approximately ~48 kya (Sengupta et al. 2006).''


      As a modern aDNA paper, it should not rely on older, modern DNA based inferences. Instead, aDNA points to western Asia (Lazaridis; Nature 2016)
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.02.19.431761v1
  tweets:
    - created_at: Mon Jul 12 18:28:06 +0000 2021
      id: 1414652806095540200
      id_str: "1414652806095540225"
      text: |-
        üí¨ bioRxiv comment on "Using Y-chromosome capture enr..."

        "Great paper &amp; new appraoch

        One minor issue regarding:
        '‚Ä¶ https://t.co/79fSluXvkR
      truncated: true
      entities:
        urls:
          - url: https://t.co/79fSluXvkR
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 12 18:28:06 +0000 2021
      id: 1414652807144112000
      id_str: "1414652807144112128"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/0UqdemFYP7
      truncated: false
      entities:
        urls:
          - url: https://t.co/0UqdemFYP7
      in_reply_to_status_id: 1414652806095540200
      in_reply_to_status_id_str: "1414652806095540225"
- preprint:
    id: "149556"
    doi: 10.1101/2021.07.09.451701
    first_posted: 2021-07-09
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.09.451701v1
    url: https://api.rxivist.org/v1/papers/149556
    title: "Your head is there to move you around: Goal-driven models of the primate
      dorsal pathway"
    category: neuroscience
    abstract: "Neurons in the dorsal visual pathway of the mammalian brain are
      selective for motion stimuli, with the complexity of stimulus
      representations increasing along the hierarchy. This progression is
      similar to that of the ventral visual pathway, which is well characterized
      by artificial neural networks (ANNs) optimized for object recognition. In
      contrast, there are no image-computable models of the dorsal stream with
      comparable explanatory power. We hypothesized that the properties of
      dorsal stream neurons could be explained by a simple learning objective:
      the need for an organism to orient itself during self-motion. To test this
      hypothesis, we trained a 3D ResNet in a self-supervised manner to predict
      an agent's self-motion parameters from visual stimuli in a simulated
      environment. We found that the responses in this network accounted well
      for the selectivity of neurons in a large database of single-neuron
      recordings from the dorsal visual stream of non-human primates. In
      contrast, ANNs trained for action recognition or with a contrastive
      objective could not explain responses in the dorsal stream, despite also
      being trained on naturalistic videos with moving objects. These results
      demonstrate that an ecologically relevant, self-supervised cost function
      can account for dorsal stream properties in the primate brain."
    authors:
      - name: Patrick J Mineault
        orcid: http://orcid.org/0000-0001-5519-842X
      - name: Shahab Bakhtiari
        orcid: http://orcid.org/0000-0003-2439-7252
      - name: Blake A Richards
        orcid: http://orcid.org/0000-0001-9662-2151
      - name: Christopher C. Pack
        orcid: null
  comment:
    dislikes: 0
    thread: "8639713497"
    numReports: 0
    likes: 0
    id: "5452307067"
    createdAt: 2021-07-11T23:55:40
    author:
      username: reubenrideaux
      about: ""
      name: Reuben Rideaux
      isPowerContributor: false
      profileUrl: https://disqus.com/by/reubenrideaux/
      url: ""
      location: ""
      id: "323434229"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Very interesting work, congratulations. In the original MotionNet,
      the MT units were constrained to represent pre-specified velocities. In
      a  paper we published earlier this year in Journal of Vision
      (https://jov.arvojournals.org/article.aspx?articleid=2772326), we show
      that were able to capture other characteristics of MT neurons when the MT
      layer was unconstrained. I would be quite interested to see how the
      network in the more recent paper (MotionNetxy) performs in your test.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.07.09.451701v1
  tweets:
    - created_at: Mon Jul 12 20:22:34 +0000 2021
      id: 1414681611090735000
      id_str: "1414681611090735105"
      text: >-
        üí¨ bioRxiv comment on "Your head is there to move you..."


        "Very interesting work, congratulations. In the original‚Ä¶ https://t.co/VtdgeOjRoT
      truncated: true
      entities:
        urls:
          - url: https://t.co/VtdgeOjRoT
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 12 20:22:34 +0000 2021
      id: 1414681611900178400
      id_str: "1414681611900178437"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/XgnQTomjWN
      truncated: false
      entities:
        urls:
          - url: https://t.co/XgnQTomjWN
      in_reply_to_status_id: 1414681611090735000
      in_reply_to_status_id_str: "1414681611090735105"
- preprint:
    id: "148421"
    doi: 10.1101/2021.07.01.450370
    first_posted: 2021-07-01
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.01.450370v1
    url: https://api.rxivist.org/v1/papers/148421
    title: Bayesian inference of clonal expansions in a dated phylogeny
    category: evolutionary-biology
    abstract: Microbial population genetics models often assume that all lineages
      are constrained by the same population size dynamics over time. However,
      many neutral and selective events can invalidate this assumption, and can
      contribute to the clonal expansion of a specific lineage relative to the
      rest of the population. Such differential phylodynamic properties between
      lineages result in asymmetries and imbalances in phylogenetic trees that
      are sometimes described informally but difficult to analyse formally. To
      this end, we developed a model of how clonal expansions occur and affect
      the branching patterns of a phylogeny. We show how the parameters of this
      model can be inferred from a given dated phylogeny using Bayesian
      statistics, which allows us to assess the probability that one or more
      clonal expansion events occurred. For each putative clonal expansion event
      we estimate their date of emergence and subsequent phylodynamic
      trajectories, including their long-term evolutionary potential which is
      important to determine how much effort should be placed on specific
      control measures. We demonstrate the usefulness of our methodology on
      simulated and real datasets.
    authors:
      - name: David Helekal
        orcid: null
      - name: Alice Ledda
        orcid: http://orcid.org/0000-0002-2387-3774
      - name: Erik Volz
        orcid: http://orcid.org/0000-0001-6268-8937
      - name: David Wyllie
        orcid: null
      - name: Xavier Didelot
        orcid: http://orcid.org/0000-0003-1885-500X
  comment:
    dislikes: 0
    thread: "8625817333"
    numReports: 0
    likes: 0
    id: "5453199057"
    createdAt: 2021-07-12T19:00:49
    author:
      username: tajazarian
      about: ""
      name: Taj Azarian
      isPowerContributor: false
      profileUrl: https://disqus.com/by/tajazarian/
      url: ""
      location: ""
      id: "257734957"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Great idea and a very nicely implemented tool! We particularly appreciated
      the analysis vignettes with strep pnuemo and staph aureus. We started
      experimenting with it last week as it provides a nice addition to one of
      our current studies.  


      We do have a couple practical questions about "best practices"...

      1) Are there any considerations for how the initial time-scaled tree is inferred?  For example, if you performed model testing with BEAST and found that a skygrid demographic model with relaxed clock best fit, would this violate the underlying assumption of constant background population size?  In this scenario, would it correctly identify the expanding lineages but underestimate the effective population size of the expansion?  Would a better approach be to infer an initial tree using a relaxed clock and constant population size?


      2) Regarding the analysis of SPN, are there any thoughts to how recombination would impact the performance of the tool? I am less concerned about ancestral recombination that is generally shared by all members of the population of interest. However, if the expansion of a lineage was associated with a recombination event (e.g., a capsule switch in pneumo or even just a large recombination block impacting protein antigens), how would that bias the detection of the expansion or the population size in relation to the background? (We can assume these events were detected and censored before coalescent analysis)


      I don't expect endless simulations to address all the different possible population dynamics, but I think some comments about the recombination questions would be of general interest to those of us that work on highly recombining bacteria.  


      Thanks again and great work!
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.07.01.450370v1
  tweets:
    - created_at: Mon Jul 12 22:16:11 +0000 2021
      id: 1414710203728138200
      id_str: "1414710203728138242"
      text: >-
        üí¨ bioRxiv comment on "Bayesian inference of clonal e..."


        "Great idea and a very nicely implemented tool! We partic‚Ä¶ https://t.co/MDRbK0FnHG
      truncated: true
      entities:
        urls:
          - url: https://t.co/MDRbK0FnHG
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 12 22:16:11 +0000 2021
      id: 1414710204650885000
      id_str: "1414710204650885121"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/DQGNZW9UoR
      truncated: false
      entities:
        urls:
          - url: https://t.co/DQGNZW9UoR
      in_reply_to_status_id: 1414710203728138200
      in_reply_to_status_id_str: "1414710203728138242"
- preprint:
    id: "83480"
    doi: 10.1101/2020.05.13.093591
    first_posted: 2020-05-15
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.05.13.093591v1
    url: https://api.rxivist.org/v1/papers/83480
    title: A druggable oxidative folding pathway in the endoplasmic reticulum of
      human malaria parasites
    category: microbiology
    abstract: >-
      Malaria remains a major global health problem, and there exists a constant
      need to identify druggable weaknesses in P. falciparum biology. The
      endoplasmic reticulum (ER) has many essential roles in the asexual
      lifecycle and may offer new drug targets, but it remains critically
      understudied. We generated conditional mutants of the putative
      redox-active, ER chaperone PfJ2, and show that it is essential for
      parasite survival. Using a redox-active cysteine crosslinker, we identify
      its substrates to be other mediators of oxidative folding, PfPDI8 and
      PfPDI11, suggesting a redox-regulatory role for PfJ2. Knockdown of these
      protein disulfide isomerases in PfJ2 conditional mutants show that PfPDI11
      is not essential, while PfPDI8 is essential for asexual growth and may
      work in a complex with PfJ2 and other ER chaperones. Finally, we show that
      these redox interactions in the parasite ER are sensitive to small
      molecule inhibition. Together these data build a model for how oxidative
      folding occurs in the P. falciparum ER and demonstrate its suitability for
      antimalarial drug development.


      ### Competing Interest Statement


      The authors have declared no competing interest.
    authors:
      - name: David W Cobb
        orcid: null
      - name: Heather M Kudyba
        orcid: null
      - name: Alejandra Villegas
        orcid: null
      - name: Michael R. Hoopmann
        orcid: http://orcid.org/0000-0001-7029-7792
      - name: Rodrigo Baptista
        orcid: null
      - name: Baylee Bruton
        orcid: null
      - name: Michelle Krakowiak
        orcid: null
      - name: Robert L. Moritz
        orcid: http://orcid.org/0000-0002-3216-9447
      - name: V Muralidharan
        orcid: http://orcid.org/0000-0001-6367-6284
  comment:
    dislikes: 0
    thread: "8025685926"
    numReports: 0
    likes: 0
    id: "5453147310"
    createdAt: 2021-07-12T18:18:35
    author:
      name: Vasant Muralidharan
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "This preprint has been published:
      https://journals.plos.org/plospathogens/article?id=10.1371%2Fjournal.ppat\
      .1009293"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.05.13.093591v1
  tweets:
    - created_at: Tue Jul 13 01:04:04 +0000 2021
      id: 1414752453954842600
      id_str: "1414752453954842624"
      text: |-
        üí¨ bioRxiv comment on "A druggable oxidative folding ..."

        "This preprint has been published: "

        https://t.co/KE5e85ji9T
      truncated: false
      entities:
        urls:
          - url: https://t.co/KE5e85ji9T
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 13 01:04:04 +0000 2021
      id: 1414752454621679600
      id_str: "1414752454621679623"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/H8TrPXuovJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/H8TrPXuovJ
      in_reply_to_status_id: 1414752453954842600
      in_reply_to_status_id_str: "1414752453954842624"
- preprint:
    id: "111184"
    doi: 10.1101/2020.05.22.20109231
    first_posted: 2020-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.05.22.20109231v1
    url: https://api.rxivist.org/v1/papers/111184
    title: Association of country-wide coronavirus mortality with demographics,
      testing, lockdowns, and public wearing of masks.
    category: epidemiology
    abstract: Purpose. To determine sources of variation between countries in
      per-capita mortality from COVID-19 (caused by the SARS-CoV-2 virus).
      Methods. Potential predictors of per-capita coronavirus-related mortality
      in 200 countries by May 9, 2020 were examined, including age, sex, obesity
      prevalence, temperature, urbanization, smoking, duration of infection,
      lockdowns, viral testing, contact tracing policies, and public
      mask-wearing norms and policies. Multivariable linear regression analysis
      was performed. Results. In univariate analyses, the prevalence of smoking,
      per-capita gross domestic product, urbanization, and colder average
      country temperature were positively associated with coronavirus-related
      mortality. In a multivariable analysis of 196 countries, the duration of
      infection in the country, and the proportion of the population 60 years of
      age or older were positively associated with per-capita mortality, while
      duration of mask-wearing by the public was negatively associated with
      mortality (all p<0.001). International travel restrictions and a lower
      prevalence of obesity were independently associated with mortality in a
      model which controlled for testing policy. Internal lockdown requirements
      and viral testing policies and levels were not associated with mortality.
      The association of contact tracing policy with mortality approached
      statistical significance (p=0.06). In countries with cultural norms or
      government policies supporting public mask-wearing, per-capita coronavirus
      mortality increased on average by just 15.8% each week, as compared with
      62.1% each week in remaining countries. Conclusions. Societal norms and
      government policies supporting the wearing of masks by the public, as well
      as international travel controls, are independently associated with lower
      per-capita mortality from COVID-19.
    authors:
      - name: Christopher T Leffler
        orcid: null
      - name: Edsel B. Ing
        orcid: null
      - name: Joseph D. Lykins
        orcid: null
      - name: Matthew C Hogan
        orcid: null
      - name: Craig A. McKeown
        orcid: null
      - name: Andrzej Grzybowski
        orcid: null
  comment:
    dislikes: 0
    thread: "8114796774"
    numReports: 0
    likes: 0
    id: "5453859304"
    createdAt: 2021-07-13T06:37:34
    author:
      username: disqus_NgYX9EX7px
      about: ""
      name: Joel Harper
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_NgYX9EX7px/
      url: ""
      location: ""
      id: "165279467"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: I was referring to aerosolised droplets!!
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.05.22.20109231v4
  tweets:
    - created_at: Tue Jul 13 12:33:51 +0000 2021
      id: 1414926041882275800
      id_str: "1414926041882275854"
      text: |-
        üí¨ medRxiv comment on "Association of country-wide co..."

        "I was referring to aerosolised droplets!!"

        https://t.co/fn7UsvFygW
      truncated: false
      entities:
        urls:
          - url: https://t.co/fn7UsvFygW
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 13 12:33:51 +0000 2021
      id: 1414926042716852200
      id_str: "1414926042716852236"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/93kS5Ts5OM
      truncated: false
      entities:
        urls:
          - url: https://t.co/93kS5Ts5OM
      in_reply_to_status_id: 1414926041882275800
      in_reply_to_status_id_str: "1414926041882275854"
- preprint:
    id: "148746"
    doi: 10.1101/2021.06.28.21258780
    first_posted: 2021-07-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.28.21258780v1
    url: https://api.rxivist.org/v1/papers/148746
    title: Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine
      breakthrough infections
    category: epidemiology
    abstract: >-
      ImportanceVaccine breakthrough by an emergent SARS-CoV-2 variant poses a
      great risk to global public health.


      ObjectiveTo determine the SARS-CoV-2 variant responsible for 6 cases of vaccine breakthrough.


      DesignNasopharyngeal swabs from suspected vaccine breakthrough cases were tested for SARS-CoV-2 by qPCR for Wuhan-Hu1 and Alpha variant. Positive samples were then sequenced by Swift Normalase Amplicon Panels to determine the causal variant.


      SettingTransmission event occurred at events surrounding a wedding outside of Houston, TX. Two patients from India, likely transmitted the Delta variant to other guests.


      ParticipantsFollowing a positive SARS-CoV-2 qPCR test at a third-party site, six fully vaccinated patients were investigated. Three males and three females ranged from 53 to 69 years old. One patient suffered from diabetes while three others were classified as overweight. No significant other comorbidities were identified. None of the patients had a history of failed vaccination.


      Key PointsO_ST_ABSQuestionC_ST_ABSWhich SARS-CoV-2 variant is responsible for 6 cases of vaccine breakthrough, one interventional monoclonal antibody treatment, and one death?


      FindingsViral sequencing revealed 6 vaccinated patients were infected with the Delta SARS-CoV-2 variant. With no histories of vaccine breakthrough, this suggests Delta variant may possess immune evasion in patients that received the Pfizer BNT162b2, Moderna mRNA-1273, and Covaxin BBV152.


      MeaningDelta variant may pose the highest risk out of any currently circulating SARS-CoV-2 variants, with increased transmissibility over Alpha variant and possible vaccine breakthrough.
    authors:
      - name: Timothy Farinholt
        orcid: http://orcid.org/0000-0003-1889-3102
      - name: Harshavardhan Doddapaneni
        orcid: http://orcid.org/0000-0002-2433-633X
      - name: Xiang Qin
        orcid: null
      - name: Vipin Menon
        orcid: http://orcid.org/0000-0001-7404-678X
      - name: Qingchang Meng
        orcid: null
      - name: Ginger Metcalf
        orcid: null
      - name: Hsu Chao
        orcid: null
      - name: Marie-Claude Gingras
        orcid: http://orcid.org/0000-0003-2570-6360
      - name: Paige Farinholt
        orcid: null
      - name: Charu Agrawal
        orcid: null
      - name: Donna Muzny
        orcid: http://orcid.org/0000-0002-3055-0359
      - name: Pedro A. Piedra
        orcid: http://orcid.org/0000-0002-5839-0879
      - name: Richard A. Gibbs
        orcid: null
      - name: Joseph Petrosino
        orcid: http://orcid.org/0000-0002-4046-6898
  comment:
    dislikes: 0
    thread: "8630584355"
    numReports: 0
    likes: 0
    id: "5453785631"
    createdAt: 2021-07-13T04:10:46
    author:
      username: disqus_JTLv0BKGMX
      about: ""
      name: jackson c
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_JTLv0BKGMX/
      url: ""
      location: ""
      id: "75315685"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Did they carpool before the event?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.28.21258780v1
  tweets:
    - created_at: Tue Jul 13 14:17:39 +0000 2021
      id: 1414952167442681900
      id_str: "1414952167442681862"
      text: |-
        üí¨ medRxiv comment on "Transmission event of SARS-CoV..."

        "Did they carpool before the event?"

        https://t.co/p1zpsZnDor
      truncated: false
      entities:
        urls:
          - url: https://t.co/p1zpsZnDor
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 13 14:17:40 +0000 2021
      id: 1414952168306708500
      id_str: "1414952168306708502"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/ifdUoU85Ao
      truncated: false
      entities:
        urls:
          - url: https://t.co/ifdUoU85Ao
      in_reply_to_status_id: 1414952167442681900
      in_reply_to_status_id_str: "1414952167442681862"
- preprint:
    id: "139225"
    doi: 10.1101/2021.04.21.21255873
    first_posted: 2021-04-23
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.04.21.21255873v1
    url: https://api.rxivist.org/v1/papers/139225
    title: Real World Effectiveness of COVID-19 mRNA Vaccines against
      Hospitalizations and Deaths in the United States
    category: infectious-diseases
    abstract: "Background: Covid-19 has caused significant global mortality.
      Multiple vaccines have demonstrated efficacy in clinical trials though
      real-world effectiveness of vaccines against Covid-19 mortality in
      clinically and demographically diverse populations has not yet been
      reported. Methods: We used a retrospective cohort assembled from a
      cross-institution comprehensive data repository. Established patients of
      the health care system were categorized as not immunized, partially
      immunized, or fully immunized against SARS-CoV-2 with an mRNA vaccine
      through April 4, 2021. Outcomes were Covid-19 related hospitalization and
      death. Results: Of the 91,134 established patients, 70.2% were not
      immunized, 4.5% were partially immunized and 25.4% were fully immunized.
      Among the fully immunized 0.7% had a Covid-19 hospitalization, whereas
      3.4% among the partially immunized and 2.7% non-immunized individuals were
      hospitalized with Covid-19. Of the 225 deaths among Covid-19
      hospitalizations, 219 (97.3%) were in the not immunized, 5 (2.2%) in the
      partially immunized, and 1 (0.0041%) in the fully immunized group. mRNA
      vaccines were 96% (95%CI: 95 - 99) effective at preventing Covid-19
      related hospitalization and 98.7% (95%CI: 91.0 - 99.8) effective at
      preventing Covid-19 related death when participants were fully vaccinated.
      Partial vaccination was 77% (95%CI: 71 - 82) effective at preventing
      hospitalization and 64.2% (95%CI: 13.0 - 85.2) effective at preventing
      death. Vaccine effectiveness at preventing hospitalization was conserved
      across subgroups of age, race, ethnicity, Area Deprivation Index, and
      Charlson Comorbidity Index. Conclusions: In a large, diverse cohort in the
      United States, full immunization with mRNA vaccines was highly effective
      in the real-world scenario at preventing Covid-19 related hospitalization
      and death."
    authors:
      - name: Farhaan S Vahidy
        orcid: http://orcid.org/0000-0002-3464-2111
      - name: Lauren Pischel
        orcid: http://orcid.org/0000-0002-7697-0084
      - name: Mauricio E Tano
        orcid: null
      - name: Alan P Pan
        orcid: null
      - name: Marc L Boom
        orcid: null
      - name: Henry Dirk Sostman
        orcid: null
      - name: Khurram Nasir
        orcid: null
      - name: Saad B Omer
        orcid: http://orcid.org/0000-0002-5383-3474
  comment:
    dislikes: 0
    thread: "8488960600"
    numReports: 0
    likes: 0
    id: "5453701355"
    createdAt: 2021-07-13T02:15:24
    author:
      username: ThetaNought
      about: ""
      name: Œò0
      isPowerContributor: false
      profileUrl: https://disqus.com/by/ThetaNought/
      url: ""
      location: ""
      id: "372256046"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Will note that absolute risk reduction between vaccinated and unvaccinated
      is 0.32%. The authors‚Äô claims that the vaccines prevented death are not
      supported by the evidence provided, which is correlated in nature, not
      causative. 


      A good paper on this issue: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996517/
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.04.21.21255873v1
  tweets:
    - created_at: Tue Jul 13 16:36:22 +0000 2021
      id: 1414987075980497000
      id_str: "1414987075980496897"
      text: >-
        üí¨ medRxiv comment on "Real World Effectiveness of CO..."


        "Will note that absolute risk reduction between vaccinate‚Ä¶ https://t.co/lqUM5vCi35
      truncated: true
      entities:
        urls:
          - url: https://t.co/lqUM5vCi35
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 13 16:36:23 +0000 2021
      id: 1414987077029187600
      id_str: "1414987077029187584"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/NlPDqpycFg
      truncated: false
      entities:
        urls:
          - url: https://t.co/NlPDqpycFg
      in_reply_to_status_id: 1414987075980497000
      in_reply_to_status_id_str: "1414987075980496897"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8603406700"
    numReports: 0
    likes: 1
    id: "5453692528"
    createdAt: 2021-07-13T02:04:31
    author:
      username: mattjolley
      about: ""
      name: Matt Jolley
      isPowerContributor: false
      profileUrl: https://disqus.com/by/mattjolley/
      url: ""
      location: ""
      id: "88523447"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Thank you for the data collection.  I hope you continue the study for some
      months. The infected immunity indicated here may be less for other Covid
      variants.
       Delving into recent UK variant Delta sequence confirmed reinfections of 285 as of May 31 out of 22571 sequences by sample date. For Delta prior infection immunity appears similar to two shot vaccination immunity. Just taking the last two or three months of your data if similar infected immunity to vaccinated immunity was tested the smaller prior infected unvaccinated population would be expected to have 1.2 or so cases compared to the 15 from the larger vaccinated population. Thus the very large confidence interval reported.
       I prefer seeing person days used as in the Haas et al paper.  https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00947-8/fulltext
       How many cases of reinfection if any occurred within the 90 day post positive sample period? Figure 3. the sums of previous infected and not previously infected both monotonically decrease until increasing in the last column.  Better to note the number of persons who have passed the 90 day interval since prior infection as this number would be increasing especially around the beginning of the study.  The UK study had a vast majority of possible reinfections sampled just after that 90 day interval.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v3
  tweets:
    - created_at: Tue Jul 13 18:25:07 +0000 2021
      id: 1415014442480259000
      id_str: "1415014442480259074"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "Thank you for the data collection.  I hope you continue‚Ä¶ https://t.co/QwHJDT8JRG
      truncated: true
      entities:
        urls:
          - url: https://t.co/QwHJDT8JRG
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 13 18:25:07 +0000 2021
      id: 1415014443495346200
      id_str: "1415014443495346176"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1415014442480259000
      in_reply_to_status_id_str: "1415014442480259074"
- preprint:
    id: 149755
    metric: 29
    title: Molecular architecture of the human tRNA ligase complex
    url: https://api.rxivist.org/v1/papers/149755
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.11.451954v1
    doi: 10.1101/2021.07.11.451954
    category: biochemistry
    first_posted: 2021-07-12
    abstract: RtcB enzymes are RNA ligases that play essential roles in tRNA
      splicing, unfolded protein response, and RNA repair. In metazoa, RtcB
      functions as part of a five-subunit tRNA ligase complex (tRNA-LC) along
      with Ddx1, Cgi-99, Fam98B and Ashwin. The human tRNA-LC or its individual
      subunits have been implicated in additional cellular processes including
      microRNA maturation, viral replication, DNA double-strand break repair and
      mRNA transport. Here we present a biochemical analysis of the intersubunit
      interactions within the human tRNA-LC along with crystal structures of the
      catalytic subunit RTCB and the N-terminal domain of CGI-99. We show that
      the core of the human tRNA-LC is assembled from RTCB and the C-terminal
      alpha-helical regions of DDX1, CGI-99, and FAM98B, all of which are
      required for complex integrity. The N-terminal domain of CGI-99 displays
      structural homology to calponin-homology domains, and CGI-99 and FAM98B
      associate via their N-terminal domains to form a stable subcomplex. The
      crystal structure of GMP-bound RTCB reveals divalent metal coordination
      geometry in the active site, providing insights into its catalytic
      mechanism. Collectively, these findings shed light on the molecular
      architecture and mechanism of the human tRNA ligase complex, and provide a
      structural framework for understanding its functions in cellular RNA
      metabolism.
    authors:
      - name: Alena Kroupova
      - name: Fabian Ackle
      - name: Franziska M Boneberg
      - name: Alessia Chui
      - name: Stefan Weitzer
      - name: Marco Faini
      - name: Alexander Leitner
      - name: Ruedi Aebersold
      - name: Javier Martinez
      - name: Martin Jinek
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Tue Jul 13 20:20:22 +0000 2021
      id: 1415043447547994000
      id_str: "1415043447547994118"
      text: >-
        üî• bioRxiv Biochemistry preprint by A. Kroupova et al:


        "Molecular architecture of the human tRNA ligase complex"‚Ä¶ https://t.co/kqfv9NALAm
      truncated: true
      entities:
        urls:
          - url: https://t.co/kqfv9NALAm
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "148746"
    doi: 10.1101/2021.06.28.21258780
    first_posted: 2021-07-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.28.21258780v1
    url: https://api.rxivist.org/v1/papers/148746
    title: Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine
      breakthrough infections
    category: epidemiology
    abstract: >-
      ImportanceVaccine breakthrough by an emergent SARS-CoV-2 variant poses a
      great risk to global public health.


      ObjectiveTo determine the SARS-CoV-2 variant responsible for 6 cases of vaccine breakthrough.


      DesignNasopharyngeal swabs from suspected vaccine breakthrough cases were tested for SARS-CoV-2 by qPCR for Wuhan-Hu1 and Alpha variant. Positive samples were then sequenced by Swift Normalase Amplicon Panels to determine the causal variant.


      SettingTransmission event occurred at events surrounding a wedding outside of Houston, TX. Two patients from India, likely transmitted the Delta variant to other guests.


      ParticipantsFollowing a positive SARS-CoV-2 qPCR test at a third-party site, six fully vaccinated patients were investigated. Three males and three females ranged from 53 to 69 years old. One patient suffered from diabetes while three others were classified as overweight. No significant other comorbidities were identified. None of the patients had a history of failed vaccination.


      Key PointsO_ST_ABSQuestionC_ST_ABSWhich SARS-CoV-2 variant is responsible for 6 cases of vaccine breakthrough, one interventional monoclonal antibody treatment, and one death?


      FindingsViral sequencing revealed 6 vaccinated patients were infected with the Delta SARS-CoV-2 variant. With no histories of vaccine breakthrough, this suggests Delta variant may possess immune evasion in patients that received the Pfizer BNT162b2, Moderna mRNA-1273, and Covaxin BBV152.


      MeaningDelta variant may pose the highest risk out of any currently circulating SARS-CoV-2 variants, with increased transmissibility over Alpha variant and possible vaccine breakthrough.
    authors:
      - name: Timothy Farinholt
        orcid: http://orcid.org/0000-0003-1889-3102
      - name: Harshavardhan Doddapaneni
        orcid: http://orcid.org/0000-0002-2433-633X
      - name: Xiang Qin
        orcid: null
      - name: Vipin Menon
        orcid: http://orcid.org/0000-0001-7404-678X
      - name: Qingchang Meng
        orcid: null
      - name: Ginger Metcalf
        orcid: null
      - name: Hsu Chao
        orcid: null
      - name: Marie-Claude Gingras
        orcid: http://orcid.org/0000-0003-2570-6360
      - name: Paige Farinholt
        orcid: null
      - name: Charu Agrawal
        orcid: null
      - name: Donna Muzny
        orcid: http://orcid.org/0000-0002-3055-0359
      - name: Pedro A. Piedra
        orcid: http://orcid.org/0000-0002-5839-0879
      - name: Richard A. Gibbs
        orcid: null
      - name: Joseph Petrosino
        orcid: http://orcid.org/0000-0002-4046-6898
  comment:
    dislikes: 0
    thread: "8630584355"
    numReports: 0
    likes: 0
    id: "5453477878"
    createdAt: 2021-07-12T23:16:53
    author:
      username: TheSailor
      about: ""
      name: TheSailor
      isPowerContributor: false
      profileUrl: https://disqus.com/by/TheSailor/
      url: ""
      location: ""
      id: "5294608"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Did I miss the part where it was confirmed that all were fully vaccinated?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.28.21258780v1
  tweets:
    - created_at: Wed Jul 14 12:33:52 +0000 2021
      id: 1415288435942858800
      id_str: "1415288435942858752"
      text: >-
        üí¨ medRxiv comment on "Transmission event of SARS-CoV..."


        "Did I miss the part where it was confirmed that all were‚Ä¶ https://t.co/ZRlfQh9s7l
      truncated: true
      entities:
        urls:
          - url: https://t.co/ZRlfQh9s7l
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 14 12:33:52 +0000 2021
      id: 1415288436618055700
      id_str: "1415288436618055684"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/ifdUoU85Ao
      truncated: false
      entities:
        urls:
          - url: https://t.co/ifdUoU85Ao
      in_reply_to_status_id: 1415288435942858800
      in_reply_to_status_id_str: "1415288435942858752"
- preprint:
    id: "148746"
    doi: 10.1101/2021.06.28.21258780
    first_posted: 2021-07-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.28.21258780v1
    url: https://api.rxivist.org/v1/papers/148746
    title: Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine
      breakthrough infections
    category: epidemiology
    abstract: >-
      ImportanceVaccine breakthrough by an emergent SARS-CoV-2 variant poses a
      great risk to global public health.


      ObjectiveTo determine the SARS-CoV-2 variant responsible for 6 cases of vaccine breakthrough.


      DesignNasopharyngeal swabs from suspected vaccine breakthrough cases were tested for SARS-CoV-2 by qPCR for Wuhan-Hu1 and Alpha variant. Positive samples were then sequenced by Swift Normalase Amplicon Panels to determine the causal variant.


      SettingTransmission event occurred at events surrounding a wedding outside of Houston, TX. Two patients from India, likely transmitted the Delta variant to other guests.


      ParticipantsFollowing a positive SARS-CoV-2 qPCR test at a third-party site, six fully vaccinated patients were investigated. Three males and three females ranged from 53 to 69 years old. One patient suffered from diabetes while three others were classified as overweight. No significant other comorbidities were identified. None of the patients had a history of failed vaccination.


      Key PointsO_ST_ABSQuestionC_ST_ABSWhich SARS-CoV-2 variant is responsible for 6 cases of vaccine breakthrough, one interventional monoclonal antibody treatment, and one death?


      FindingsViral sequencing revealed 6 vaccinated patients were infected with the Delta SARS-CoV-2 variant. With no histories of vaccine breakthrough, this suggests Delta variant may possess immune evasion in patients that received the Pfizer BNT162b2, Moderna mRNA-1273, and Covaxin BBV152.


      MeaningDelta variant may pose the highest risk out of any currently circulating SARS-CoV-2 variants, with increased transmissibility over Alpha variant and possible vaccine breakthrough.
    authors:
      - name: Timothy Farinholt
        orcid: http://orcid.org/0000-0003-1889-3102
      - name: Harshavardhan Doddapaneni
        orcid: http://orcid.org/0000-0002-2433-633X
      - name: Xiang Qin
        orcid: null
      - name: Vipin Menon
        orcid: http://orcid.org/0000-0001-7404-678X
      - name: Qingchang Meng
        orcid: null
      - name: Ginger Metcalf
        orcid: null
      - name: Hsu Chao
        orcid: null
      - name: Marie-Claude Gingras
        orcid: http://orcid.org/0000-0003-2570-6360
      - name: Paige Farinholt
        orcid: null
      - name: Charu Agrawal
        orcid: null
      - name: Donna Muzny
        orcid: http://orcid.org/0000-0002-3055-0359
      - name: Pedro A. Piedra
        orcid: http://orcid.org/0000-0002-5839-0879
      - name: Richard A. Gibbs
        orcid: null
      - name: Joseph Petrosino
        orcid: http://orcid.org/0000-0002-4046-6898
  comment:
    dislikes: 0
    thread: "8640046322"
    numReports: 0
    likes: 0
    id: "5453329795"
    createdAt: 2021-07-12T20:50:31
    author:
      username: david_epperly
      about: ""
      name: David Epperly
      isPowerContributor: false
      profileUrl: https://disqus.com/by/david_epperly/
      url: ""
      location: ""
      id: "358721953"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "Some good details. Should add diary info from each of the infected
      as available to include: recollection of interactions with patients 0a and
      0b and 0b's recollection of all interactions with all infected. Each
      interaction should include distance, time, and environment. More info
      about tent structure, identity blurred photos of event wide-shots, and
      historical prevailing wind conditions for area. Help us understand how
      transmission likely occurred. Also state relationships of each infected
      (spouse, close friend, acquaintance, ...) to help understand likely
      interaction levels. It appears 0a and 0b are related. Tell us. Move info
      on Delta into a supplement and focus on details of the event. Create a
      supplement for additional event / relationship / transmission details.
      Capture more of what happened."
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.28.21258780v3
  tweets:
    - created_at: Wed Jul 14 14:17:39 +0000 2021
      id: 1415314552632213500
      id_str: "1415314552632213504"
      text: >-
        üí¨ medRxiv comment on "Transmission event of SARS-CoV..."


        "Some good details. Should add diary info from each of th‚Ä¶ https://t.co/b8fqNAbEph
      truncated: true
      entities:
        urls:
          - url: https://t.co/b8fqNAbEph
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 14 14:17:39 +0000 2021
      id: 1415314553647231000
      id_str: "1415314553647230976"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/ifdUoTQubO
      truncated: false
      entities:
        urls:
          - url: https://t.co/ifdUoTQubO
      in_reply_to_status_id: 1415314552632213500
      in_reply_to_status_id_str: "1415314552632213504"
- preprint:
    id: "143297"
    doi: 10.1101/2021.05.23.21257686
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.23.21257686v1
    url: https://api.rxivist.org/v1/papers/143297
    title: Addressing anti-syncytin antibody levels, and fertility and breastfeeding
      concerns, following BNT162B2 COVID-19 mRNA vaccination
    category: obstetrics-and-gynecology
    abstract: "Objective: To determine whether antibodies against the SARS-CoV-2
      spike protein following BNT162B2 (Pfizer-BioNTech) COVID-19 mRNA
      vaccination cross-react with human syncytin-1 protein, and if BNT162B2
      mRNA enters breast milk. Methods: In this observational cohort study of
      female front-line workers with no history of COVID-19 infection, we
      amplified BNT162B2 mRNA in plasma and breast milk and assayed
      anti-SARS-CoV-2 neutralising antibodies and anti-human syncytin-1 binding
      antibodies in plasma, at early (1-4 days) and late (4-7 weeks) time points
      following first-dose vaccination. Results: Fifteen consented participants
      (mean age 40.4 years, various ethnicities) who received at least one dose
      of BNT162B2, including five breast-feeding women and two women who were
      inadvertently vaccinated in early pregnancy, were recruited. BNT162B2
      mRNA, detected by amplifying part of the spike-encoding region, was
      detected in plasma 1-4 days following the first dose (n=13), but not 4-5
      weeks later (n=2), nor was the mRNA isolated from aqueous or lipid breast
      milk fractions collected 0-7 days post-vaccination (n=5). Vaccine
      recipients demonstrated strong SARS-CoV-2 neutralising activity by at
      least four weeks after the first dose (n=15), including the two pregnant
      women. None had placental anti-syncytin-1 binding antibodies at either
      time-point following vaccination. Conclusions: BNT162B2-vaccinated women
      did not transmit vaccine mRNA to breast milk, and did not produce a
      concurrent humoral response to syncytin-1, suggesting that
      cross-reactivity to syncytin-1 on the developing trophoblast, or other
      adverse effects in the breast-fed infant from vaccine mRNA ingestion, are
      unlikely."
    authors:
      - name: Citra Nurfarah Mattar
        orcid: http://orcid.org/0000-0003-0068-6957
      - name: Winston Koh
        orcid: http://orcid.org/0000-0003-4611-6490
      - name: Yiqi Seow
        orcid: http://orcid.org/0000-0001-7040-3006
      - name: Shawn Hoon
        orcid: http://orcid.org/0000-0002-3892-3332
      - name: Aparna VENKATESH
        orcid: http://orcid.org/0000-0001-8639-9232
      - name: Pradip Dashraath
        orcid: http://orcid.org/0000-0002-4095-3186
      - name: Li Min LIM
        orcid: null
      - name: Judith ONG
        orcid: null
      - name: Rachel Jiayu Lee
        orcid: null
      - name: Nuryanti Johana
        orcid: null
      - name: Julie SL Yeo
        orcid: null
      - name: David Shao Hong Chong
        orcid: null
      - name: Lay Kok Tan
        orcid: http://orcid.org/0000-0002-7790-2171
      - name: Jerry Kok Yen Chan
        orcid: http://orcid.org/0000-0002-0246-2159
      - name: Mahesh Choolani
        orcid: http://orcid.org/0000-0001-8336-0973
      - name: Paul Tambyah
        orcid: http://orcid.org/0000-0003-0405-771X
  comment:
    dislikes: 0
    thread: "8551357360"
    numReports: 0
    likes: 0
    id: "5455548607"
    createdAt: 2021-07-14T15:13:44
    author:
      username: fatinfaten
      about: ""
      name: Fatin Faten
      isPowerContributor: false
      profileUrl: https://disqus.com/by/fatinfaten/
      url: ""
      location: ""
      id: "81340290"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Well  it is still under the positive control because naturally it
      is controlled by the body so they counted it as negative
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.23.21257686v1
  tweets:
    - created_at: Wed Jul 14 16:31:30 +0000 2021
      id: 1415348237146468400
      id_str: "1415348237146468356"
      text: >-
        üí¨ medRxiv comment on "Addressing anti-syncytin antib..."


        "Well  it is still under the positive control because nat‚Ä¶ https://t.co/gtDzmNPIra
      truncated: true
      entities:
        urls:
          - url: https://t.co/gtDzmNPIra
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 14 16:31:30 +0000 2021
      id: 1415348237855301600
      id_str: "1415348237855301634"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/GmRAl2Ix8D
      truncated: false
      entities:
        urls:
          - url: https://t.co/GmRAl2Ix8D
      in_reply_to_status_id: 1415348237146468400
      in_reply_to_status_id_str: "1415348237146468356"
- preprint:
    id: "110815"
    doi: 10.1101/2020.05.14.20101162
    first_posted: 2020-05-19
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.05.14.20101162v1
    url: https://api.rxivist.org/v1/papers/110815
    title: Estimation of COVID-19 transmission rates in California and the U.S. with
      reporting delays
    category: epidemiology
    abstract: We estimated time-varying reproduction numbers of COVID-19
      transmission in counties and regions of California and in states of the
      United States, using the Wallinga-Teunis method of estimations applied to
      publicly available data. The serial interval distribution assumed
      incorporates wide uncertainty in delays from symptom onset to case
      reporting. This assumption contributes smoothing and a small but
      meaningful increase in numerical estimates of reproduction numbers due to
      the likely existence of secondary cases not yet reported. Transmission in
      many areas of the U.S. may not yet be controlled, including areas in which
      case counts appear to be stable or slowly declining.
    authors:
      - name: Lee Worden
        orcid: http://orcid.org/0000-0001-9799-0183
      - name: Rae Wannier
        orcid: null
      - name: Micaela Neus
        orcid: null
      - name: Jennifer C. Kwan
        orcid: null
      - name: Alex Y Ge
        orcid: null
      - name: Eugene T Richardson
        orcid: http://orcid.org/0000-0001-8437-0671
      - name: Travis C Porco
        orcid: http://orcid.org/0000-0001-8813-3171
  comment:
    dislikes: 0
    thread: "8032332649"
    numReports: 0
    likes: 0
    id: "5455450543"
    createdAt: 2021-07-14T13:52:21
    author:
      username: djconnel
      about: ""
      name: djconnel
      isPowerContributor: false
      profileUrl: https://disqus.com/by/djconnel/
      url: ""
      location: ""
      id: "1542016"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Cases in San Francisco have gone from a 7-day average of 10, to
      over 70 in just 20 days, with positivity rates from 0.5% up to 3.2%, which
      for a serial interval of 5 days, corresponds to an R of exp(5*ln(6.4)/20)
      = 1.6 (using positivity).  Your algorithm needs to be tuned if it's
      yielding < 1.1.  <a
      href="https://twitter.com/djconnel/status/1414955676804202506">Plot of
      rolling 7-day case totals</a>.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.05.14.20101162v1
  tweets:
    - created_at: Wed Jul 14 18:29:35 +0000 2021
      id: 1415377955019055000
      id_str: "1415377955019055106"
      text: >-
        üí¨ medRxiv comment on "Estimation of COVID-19 transmi..."


        "Cases in San Francisco have gone from a 7-day average of‚Ä¶ https://t.co/GLvkygzB5z
      truncated: true
      entities:
        urls:
          - url: https://t.co/GLvkygzB5z
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 14 18:29:35 +0000 2021
      id: 1415377956659077000
      id_str: "1415377956659077120"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/ISVWDyCul4
      truncated: false
      entities:
        urls:
          - url: https://t.co/ISVWDyCul4
      in_reply_to_status_id: 1415377955019055000
      in_reply_to_status_id_str: "1415377955019055106"
- preprint:
    id: 149183
    metric: 33
    title: Ultrastructural readout of in vivo synaptic activity for functional
      connectomics.
    url: https://api.rxivist.org/v1/papers/149183
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.07.451278v1
    doi: 10.1101/2021.07.07.451278
    category: neuroscience
    first_posted: 2021-07-07
    abstract: Large-volume ultrastructural mapping approaches yield detailed circuit
      wiring diagrams but lack an integrated synaptic activity readout which is
      essential for functional interpretation of the connectome. Here we resolve
      this limitation by combining functional synaptic labelling in vivo with
      focused ion-beam scanning electron microscopy (FIBSEM) and machine
      learning-based segmentation. Our approach generates high-resolution
      near-isotropic three-dimensional readouts of activated vesicle pools
      across large populations of individual synapses in a volume of tissue,
      opening the way for detailed functional connectomics studies. We apply
      this method to measure presynaptic activity in an ultrastructural context
      in synapses activated by sensory input in primary visual cortex in awake
      head-fixed mice, showing that the numbers of recycling and non-recycling
      vesicles approximate to a lognormal distribution across a large number of
      synapses. We also demonstrate that neighbouring boutons of the same axon,
      which share the same spiking activity, can differ greatly in their
      presynaptic release probability.
    authors:
      - name: Anna Simon
      - name: Arnd Roth
      - name: Arlo Sheridan
      - name: Mehmet Fisek
      - name: Vincenzo Marra
      - name: Claudia Racca
      - name: Jan Funke
      - name: Kevin Staras
      - name: Michael Hausser
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Wed Jul 14 20:16:08 +0000 2021
      id: 1415404769900994600
      id_str: "1415404769900994561"
      text: >-
        üî• bioRxiv Neuroscience preprint by A. Simon et al:


        "Ultrastructural readout of in vivo synaptic activity for funct‚Ä¶ https://t.co/TVacMapIf5
      truncated: true
      entities:
        urls:
          - url: https://t.co/TVacMapIf5
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "148746"
    doi: 10.1101/2021.06.28.21258780
    first_posted: 2021-07-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.28.21258780v1
    url: https://api.rxivist.org/v1/papers/148746
    title: Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine
      breakthrough infections
    category: epidemiology
    abstract: >-
      ImportanceVaccine breakthrough by an emergent SARS-CoV-2 variant poses a
      great risk to global public health.


      ObjectiveTo determine the SARS-CoV-2 variant responsible for 6 cases of vaccine breakthrough.


      DesignNasopharyngeal swabs from suspected vaccine breakthrough cases were tested for SARS-CoV-2 by qPCR for Wuhan-Hu1 and Alpha variant. Positive samples were then sequenced by Swift Normalase Amplicon Panels to determine the causal variant.


      SettingTransmission event occurred at events surrounding a wedding outside of Houston, TX. Two patients from India, likely transmitted the Delta variant to other guests.


      ParticipantsFollowing a positive SARS-CoV-2 qPCR test at a third-party site, six fully vaccinated patients were investigated. Three males and three females ranged from 53 to 69 years old. One patient suffered from diabetes while three others were classified as overweight. No significant other comorbidities were identified. None of the patients had a history of failed vaccination.


      Key PointsO_ST_ABSQuestionC_ST_ABSWhich SARS-CoV-2 variant is responsible for 6 cases of vaccine breakthrough, one interventional monoclonal antibody treatment, and one death?


      FindingsViral sequencing revealed 6 vaccinated patients were infected with the Delta SARS-CoV-2 variant. With no histories of vaccine breakthrough, this suggests Delta variant may possess immune evasion in patients that received the Pfizer BNT162b2, Moderna mRNA-1273, and Covaxin BBV152.


      MeaningDelta variant may pose the highest risk out of any currently circulating SARS-CoV-2 variants, with increased transmissibility over Alpha variant and possible vaccine breakthrough.
    authors:
      - name: Timothy Farinholt
        orcid: http://orcid.org/0000-0003-1889-3102
      - name: Harshavardhan Doddapaneni
        orcid: http://orcid.org/0000-0002-2433-633X
      - name: Xiang Qin
        orcid: null
      - name: Vipin Menon
        orcid: http://orcid.org/0000-0001-7404-678X
      - name: Qingchang Meng
        orcid: null
      - name: Ginger Metcalf
        orcid: null
      - name: Hsu Chao
        orcid: null
      - name: Marie-Claude Gingras
        orcid: http://orcid.org/0000-0003-2570-6360
      - name: Paige Farinholt
        orcid: null
      - name: Charu Agrawal
        orcid: null
      - name: Donna Muzny
        orcid: http://orcid.org/0000-0002-3055-0359
      - name: Pedro A. Piedra
        orcid: http://orcid.org/0000-0002-5839-0879
      - name: Richard A. Gibbs
        orcid: null
      - name: Joseph Petrosino
        orcid: http://orcid.org/0000-0002-4046-6898
  comment:
    dislikes: 0
    thread: "8630584355"
    numReports: 0
    likes: 1
    id: "5454409248"
    createdAt: 2021-07-13T17:09:58
    author:
      username: disqus_nJtd6cXWFa
      about: ""
      name: intros pector
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_nJtd6cXWFa/
      url: ""
      location: ""
      id: "18066088"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: '"Fully vaccinated"? Full immunity by Covaxin is considered to be
      achieved <a
      href="https://www.thehindu.com/sci-tech/health/covid-vaccination-voluntary-antibodies-develop-2-weeks-after-second-dose-aiims-director/article33504935.ece">only
      2 weeks after the second dose</a>, but patients 0a and 0b are reported
      above to have travelled a few days before that, unfortunately. Plus,
      sitting in a plane for ~20 hours would have resulted in virus overload for
      patients 0a and 0b. Providng more such details would make the paper more
      amenable to detailed conclusions.'
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.06.28.21258780v1
  tweets:
    - created_at: Wed Jul 14 20:19:26 +0000 2021
      id: 1415405598020145200
      id_str: "1415405598020145156"
      text: >-
        üí¨ medRxiv comment on "Transmission event of SARS-CoV..."


        ""Fully vaccinated"? Full immunity by Covaxin is consider‚Ä¶ https://t.co/y6NpneQ0IT
      truncated: true
      entities:
        urls:
          - url: https://t.co/y6NpneQ0IT
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 14 20:19:26 +0000 2021
      id: 1415405599160901600
      id_str: "1415405599160901638"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/ifdUoTQubO
      truncated: false
      entities:
        urls:
          - url: https://t.co/ifdUoTQubO
      in_reply_to_status_id: 1415405598020145200
      in_reply_to_status_id_str: "1415405598020145156"
- preprint:
    id: "148746"
    doi: 10.1101/2021.06.28.21258780
    first_posted: 2021-07-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.28.21258780v1
    url: https://api.rxivist.org/v1/papers/148746
    title: Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine
      breakthrough infections
    category: epidemiology
    abstract: >-
      ImportanceVaccine breakthrough by an emergent SARS-CoV-2 variant poses a
      great risk to global public health.


      ObjectiveTo determine the SARS-CoV-2 variant responsible for 6 cases of vaccine breakthrough.


      DesignNasopharyngeal swabs from suspected vaccine breakthrough cases were tested for SARS-CoV-2 by qPCR for Wuhan-Hu1 and Alpha variant. Positive samples were then sequenced by Swift Normalase Amplicon Panels to determine the causal variant.


      SettingTransmission event occurred at events surrounding a wedding outside of Houston, TX. Two patients from India, likely transmitted the Delta variant to other guests.


      ParticipantsFollowing a positive SARS-CoV-2 qPCR test at a third-party site, six fully vaccinated patients were investigated. Three males and three females ranged from 53 to 69 years old. One patient suffered from diabetes while three others were classified as overweight. No significant other comorbidities were identified. None of the patients had a history of failed vaccination.


      Key PointsO_ST_ABSQuestionC_ST_ABSWhich SARS-CoV-2 variant is responsible for 6 cases of vaccine breakthrough, one interventional monoclonal antibody treatment, and one death?


      FindingsViral sequencing revealed 6 vaccinated patients were infected with the Delta SARS-CoV-2 variant. With no histories of vaccine breakthrough, this suggests Delta variant may possess immune evasion in patients that received the Pfizer BNT162b2, Moderna mRNA-1273, and Covaxin BBV152.


      MeaningDelta variant may pose the highest risk out of any currently circulating SARS-CoV-2 variants, with increased transmissibility over Alpha variant and possible vaccine breakthrough.
    authors:
      - name: Timothy Farinholt
        orcid: http://orcid.org/0000-0003-1889-3102
      - name: Harshavardhan Doddapaneni
        orcid: http://orcid.org/0000-0002-2433-633X
      - name: Xiang Qin
        orcid: null
      - name: Vipin Menon
        orcid: http://orcid.org/0000-0001-7404-678X
      - name: Qingchang Meng
        orcid: null
      - name: Ginger Metcalf
        orcid: null
      - name: Hsu Chao
        orcid: null
      - name: Marie-Claude Gingras
        orcid: http://orcid.org/0000-0003-2570-6360
      - name: Paige Farinholt
        orcid: null
      - name: Charu Agrawal
        orcid: null
      - name: Donna Muzny
        orcid: http://orcid.org/0000-0002-3055-0359
      - name: Pedro A. Piedra
        orcid: http://orcid.org/0000-0002-5839-0879
      - name: Richard A. Gibbs
        orcid: null
      - name: Joseph Petrosino
        orcid: http://orcid.org/0000-0002-4046-6898
  comment:
    dislikes: 0
    thread: "8630584355"
    numReports: 0
    likes: 0
    id: "5455824472"
    createdAt: 2021-07-14T18:50:05
    author:
      username: disqus_WzyIysfFkp
      about: ""
      name: marymig
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_WzyIysfFkp/
      url: ""
      location: ""
      id: "263855827"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Not clear ‚Ä¶it appears one patient tested positive but did not
      exhibit symptoms.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.28.21258780v1
  tweets:
    - created_at: Wed Jul 14 22:19:21 +0000 2021
      id: 1415435777425789000
      id_str: "1415435777425788929"
      text: >-
        üí¨ medRxiv comment on "Transmission event of SARS-CoV..."


        "Not clear ‚Ä¶it appears one patient tested positive but di‚Ä¶ https://t.co/xhs0YxY5On
      truncated: true
      entities:
        urls:
          - url: https://t.co/xhs0YxY5On
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 14 22:19:21 +0000 2021
      id: 1415435778159751200
      id_str: "1415435778159751172"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/ifdUoU85Ao
      truncated: false
      entities:
        urls:
          - url: https://t.co/ifdUoU85Ao
      in_reply_to_status_id: 1415435777425789000
      in_reply_to_status_id_str: "1415435777425788929"
- preprint:
    id: "132226"
    doi: 10.1101/2021.02.26.21252546
    first_posted: 2021-03-01
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.02.26.21252546v1
    url: https://api.rxivist.org/v1/papers/132226
    title: "The accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living
      systematic review and meta-analysis."
    category: infectious-diseases
    abstract: "Background: SARS-CoV-2 antigen rapid diagnostic tests (Ag-RDTs) are
      increasingly being inte-grated in testing strategies around the world.
      Studies of the Ag-RDTs have shown variable performance. In this systematic
      review and meta-analysis, we assessed the clinical accuracy (sensi-tivity
      and specificity) of commercially available Ag-RDTs. Methods: We registered
      the review on PROSPERO (Registration number: CRD42020225140). We
      systematically searched multiple databases (PubMed, Web of Science Core
      Collection, medRvix and bioRvix, FINDdx) for publications up until
      December 11th, 2020. Descriptive analyses of all studies were performed
      and when more than four studies were avail-able, a random-effects
      meta-analysis was used to estimate pooled sensitivity and specificity in
      comparison to reverse transcriptase polymerase chain reaction testing. We
      assessed heterogeneity by subgroup analyses ((1) performed conform with
      manufacturers instructions for use (IFU) or not, (2) symptomatic vs.
      asymptomatic, (3) duration of symptoms less than seven days vs. more than
      seven days, (4) Ct-value <25 vs. <30 vs. >30, (5) by sample type)) and
      with meta-regression. We assessed study quality and risk of bias using the
      QUADAS 2 assessment tool. Results: From a total of 11,715 articles, we
      extracted 98 analytical and clinical data sets. 74 clinical accuracy data
      sets were evaluated that included 31,202 samples. Across all meta-analyzed
      samples, the pooled Ag-RDT sensitivity was 73.8% (CI 68.6 to 78.5). If
      analysis was re-stricted to studies that followed the Ag-RDT manufacturers
      instructions using fresh upper res-piratory swab samples, the sensitivity
      increased to 79.1% (95%CI 75.0 to 82.8). The SD Biosensor Standard Q and
      Abbott Panbio showed the highest sensitivity with 81.7% and 72.7%,
      respectively. The best Ag-RDT performance was found with nasopharyngeal
      sampling (77.3%, CI 72.0 to 81.9) in comparison to other sample types
      (e.g., anterior nasal or mid turbinate 63.5%, CI 49.5 to 75.5). Testing in
      the first week from symptom onset resulted in higher sensitivity (87.5%,
      CI 86.0 to 89.1) compared to testing after one week (64.1%, CI 54.4 to
      73.8). The tests performed markedly better on samples with lower
      Ct-values, i.e., <30 (87.9%, CI 86.7 to 88.8), in comparison to those with
      Ct >30 (47.8%, CI 41.1 to 54.5). Bias concerns were raised across all data
      sets, and financial support from the manufacturer was reported in 28.2% of
      data sets. Conclusion: As Ag-RDTs detect most cases within the first week
      of symptom onset and those with high viral load, they can have high
      utility for screening purposes in the early phase of disease, and thus can
      be a valuable tool to fight the spread of SARS-CoV-2. Standardization of
      con-duct and reporting of clinical accuracy studies would improve
      comparability and use of data."
    authors:
      - name: Lukas E Bruemmer
        orcid: http://orcid.org/0000-0002-8812-7975
      - name: Stephan Katzenschlager
        orcid: http://orcid.org/0000-0003-4977-7999
      - name: Mary Gaeddert
        orcid: http://orcid.org/0000-0002-6713-3495
      - name: Christian Erdmann
        orcid: null
      - name: Stephani Schmitz
        orcid: null
      - name: Marc Bota
        orcid: null
      - name: Maurizio Grilli
        orcid: null
      - name: Jan Larmann
        orcid: null
      - name: Markus A. Weigand
        orcid: null
      - name: Nira Pollock
        orcid: http://orcid.org/0000-0002-6396-2915
      - name: Aurelien Mace
        orcid: http://orcid.org/0000-0002-3282-1650
      - name: Sergio Carmona
        orcid: http://orcid.org/0000-0002-6792-4748
      - name: Stefano Ongarello
        orcid: http://orcid.org/0000-0002-0032-0691
      - name: Jilian A. Sacks
        orcid: http://orcid.org/0000-0003-4815-4693
      - name: Claudia M Denkinger
        orcid: http://orcid.org/0000-0002-7216-7067
  comment:
    dislikes: 0
    thread: "8603310880"
    numReports: 0
    likes: 0
    id: "5455770286"
    createdAt: 2021-07-14T18:07:08
    author:
      username: alexanderdomnich
      about: ""
      name: Alexander Domnich
      isPowerContributor: false
      profileUrl: https://disqus.com/by/alexanderdomnich/
      url: ""
      location: ""
      id: "372336688"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      It seems that this SRMA lacks of data elaboration/transformation procedure
      at all. For instance, in our paper (icluded in this review) it has been
      clearly stated that no false positive results were detected. It is
      therefore obvious that the specificity is 100%. The overall specificity
      with 95% CIs was reported "The overall sensitivity and specificity were
      therefore 78.7% (95% CI: 73.2%‚Äì83.3%) and 100% (95% CI: 94.7%‚Äì100%),
      respectively". The authors instead stated that the specificity estimate
      was not reported. I agree that we had not reported the 100% specificity
      for each test analyzed in order to save the space. To us, it was clear.
       You only needed to calculate the 95% CI from the available raw data.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.02.26.21252546v2
  tweets:
    - created_at: Thu Jul 15 01:03:41 +0000 2021
      id: 1415477134739579000
      id_str: "1415477134739578881"
      text: >-
        üí¨ medRxiv comment on "The accuracy of novel antigen ..."


        "It seems that this SRMA lacks of data elaboration/transf‚Ä¶ https://t.co/eSLQRCe219
      truncated: true
      entities:
        urls:
          - url: https://t.co/eSLQRCe219
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 15 01:03:42 +0000 2021
      id: 1415477135611940900
      id_str: "1415477135611940864"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/bR6lsdNZaY
      truncated: false
      entities:
        urls:
          - url: https://t.co/bR6lsdNZaY
      in_reply_to_status_id: 1415477134739579000
      in_reply_to_status_id_str: "1415477134739578881"
- preprint:
    id: "148746"
    doi: 10.1101/2021.06.28.21258780
    first_posted: 2021-07-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.28.21258780v1
    url: https://api.rxivist.org/v1/papers/148746
    title: Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine
      breakthrough infections
    category: epidemiology
    abstract: >-
      ImportanceVaccine breakthrough by an emergent SARS-CoV-2 variant poses a
      great risk to global public health.


      ObjectiveTo determine the SARS-CoV-2 variant responsible for 6 cases of vaccine breakthrough.


      DesignNasopharyngeal swabs from suspected vaccine breakthrough cases were tested for SARS-CoV-2 by qPCR for Wuhan-Hu1 and Alpha variant. Positive samples were then sequenced by Swift Normalase Amplicon Panels to determine the causal variant.


      SettingTransmission event occurred at events surrounding a wedding outside of Houston, TX. Two patients from India, likely transmitted the Delta variant to other guests.


      ParticipantsFollowing a positive SARS-CoV-2 qPCR test at a third-party site, six fully vaccinated patients were investigated. Three males and three females ranged from 53 to 69 years old. One patient suffered from diabetes while three others were classified as overweight. No significant other comorbidities were identified. None of the patients had a history of failed vaccination.


      Key PointsO_ST_ABSQuestionC_ST_ABSWhich SARS-CoV-2 variant is responsible for 6 cases of vaccine breakthrough, one interventional monoclonal antibody treatment, and one death?


      FindingsViral sequencing revealed 6 vaccinated patients were infected with the Delta SARS-CoV-2 variant. With no histories of vaccine breakthrough, this suggests Delta variant may possess immune evasion in patients that received the Pfizer BNT162b2, Moderna mRNA-1273, and Covaxin BBV152.


      MeaningDelta variant may pose the highest risk out of any currently circulating SARS-CoV-2 variants, with increased transmissibility over Alpha variant and possible vaccine breakthrough.
    authors:
      - name: Timothy Farinholt
        orcid: http://orcid.org/0000-0003-1889-3102
      - name: Harshavardhan Doddapaneni
        orcid: http://orcid.org/0000-0002-2433-633X
      - name: Xiang Qin
        orcid: null
      - name: Vipin Menon
        orcid: http://orcid.org/0000-0001-7404-678X
      - name: Qingchang Meng
        orcid: null
      - name: Ginger Metcalf
        orcid: null
      - name: Hsu Chao
        orcid: null
      - name: Marie-Claude Gingras
        orcid: http://orcid.org/0000-0003-2570-6360
      - name: Paige Farinholt
        orcid: null
      - name: Charu Agrawal
        orcid: null
      - name: Donna Muzny
        orcid: http://orcid.org/0000-0002-3055-0359
      - name: Pedro A. Piedra
        orcid: http://orcid.org/0000-0002-5839-0879
      - name: Richard A. Gibbs
        orcid: null
      - name: Joseph Petrosino
        orcid: http://orcid.org/0000-0002-4046-6898
  comment:
    dislikes: 0
    thread: "8630584355"
    numReports: 0
    likes: 0
    id: "5455760146"
    createdAt: 2021-07-14T17:59:02
    author:
      username: joebongiovanni
      about: ""
      name: joe bongiovanni
      isPowerContributor: false
      profileUrl: https://disqus.com/by/joebongiovanni/
      url: ""
      location: ""
      id: "277528119"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      It's mentioned twice. Once here- SETTINGS - 

      "Participants Following a positive SARS-CoV-2 qPCR test at a third-party site, six fully vaccinated patients were investigated."
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.28.21258780v1
  tweets:
    - created_at: Thu Jul 15 12:31:55 +0000 2021
      id: 1415650332743397400
      id_str: "1415650332743397383"
      text: |-
        üí¨ medRxiv comment on "Transmission event of SARS-CoV..."

        "It's mentioned twice. Once here- SETTINGS - 
        "Participan‚Ä¶ https://t.co/V83pTiK0wJ
      truncated: true
      entities:
        urls:
          - url: https://t.co/V83pTiK0wJ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 15 12:31:55 +0000 2021
      id: 1415650333615804400
      id_str: "1415650333615804424"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/ifdUoTQubO
      truncated: false
      entities:
        urls:
          - url: https://t.co/ifdUoTQubO
      in_reply_to_status_id: 1415650332743397400
      in_reply_to_status_id_str: "1415650332743397383"
- preprint:
    id: "116729"
    doi: 10.1101/2020.09.16.20195826
    first_posted: 2020-09-18
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.09.16.20195826v1
    url: https://api.rxivist.org/v1/papers/116729
    title: Modeling the Spread and Control of COVID-19
    category: epidemiology
    abstract: Data-centric models of COVID-19 have been tried, but have certain
      limitations. In this work, we propose an agent-based model of the epidemic
      in a confined space of agents representing humans. An extension to the
      SEIR model allows us to consider the difference between the appearance
      (black-box view) of the spread of disease, and the real situation
      (glass-box view). Our model allows for simulations of lockdowns, social
      distancing, personal hygiene, quarantine, and hospitalization, with
      further considerations of different parameters such as the extent to which
      hygiene and social distancing are observed in a population. Our results
      give qualitative indications of the effects of various policies and
      parameters; for instance, that lockdowns by themselves are extremely
      unlikely to bring an end to an epidemic and may indeed make things worse,
      that social distancing matters more than personal hygiene, and that the
      growth of infection comes down significantly for moderately high levels of
      social distancing and hygiene, even in the absence of herd immunity.
    authors:
      - name: Ashutosh Trivedi
        orcid: null
      - name: Nanda Kishore Sreenivas
        orcid: null
      - name: Shrisha Rao
        orcid: http://orcid.org/0000-0003-0625-5103
  comment:
    dislikes: 0
    thread: "8241024397"
    numReports: 0
    likes: 0
    id: "5455702742"
    createdAt: 2021-07-14T17:14:11
    author:
      username: shrisharao
      about: ""
      name: Shrisha Rao
      isPowerContributor: false
      profileUrl: https://disqus.com/by/shrisharao/
      url: ""
      location: ""
      id: "338764632"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: This paper has been published as
      https://doi.org/10.3390/systems9030053 -- refer/cite that version only.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.09.16.20195826v2
  tweets:
    - created_at: Thu Jul 15 14:22:33 +0000 2021
      id: 1415678172935327700
      id_str: "1415678172935327754"
      text: >-
        üí¨ medRxiv comment on "Modeling the Spread and Contro..."


        "This paper has been published as  -- refer/cite that ver‚Ä¶ https://t.co/AlXIOPXwKj
      truncated: true
      entities:
        urls:
          - url: https://t.co/AlXIOPXwKj
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 15 14:22:33 +0000 2021
      id: 1415678174092939300
      id_str: "1415678174092939268"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/Lelsrg8TMP
      truncated: false
      entities:
        urls:
          - url: https://t.co/Lelsrg8TMP
      in_reply_to_status_id: 1415678172935327700
      in_reply_to_status_id_str: "1415678172935327754"
- preprint:
    id: "136537"
    doi: 10.1101/2021.04.03.437906
    first_posted: 2021-04-05
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.03.437906v1
    url: https://api.rxivist.org/v1/papers/136537
    title: Design considerations for workflow management systems use in production
      genomics research and the clinic
    category: bioinformatics
    abstract: 'Background: The changing landscape of genomics research and clinical
      practice has created a need for computational pipelines capable of
      efficiently orchestrating complex analysis stages while handling large
      volumes of data across heterogeneous computational environments. Workflow
      Management Systems (WfMSs) are the software components employed to fill
      this gap. Results: This work provides an approach and systematic
      evaluation of key features of popular bioinformatics WfMSs in use today:
      Nextflow, CWL, and WDL and some of their executors, along with Swift/T, a
      workflow manager commonly used in high-scale physics applications. We
      employed two use cases: a variant-calling genomic pipeline and a
      scalability-testing framework, where both were run locally, on an HPC
      cluster, and in the cloud. This allowed for evaluation of those four WfMSs
      in terms of language expressiveness, modularity, scalability, robustness,
      reproducibility, interoperability, ease of development, along with
      adoption and usage in research labs and healthcare settings. This article
      is trying to answer, "which WfMS should be chosen for a given
      bioinformatics application regardless of analysis type?". Conclusions: The
      choice of a given WfMS is a function of both its intrinsic language and
      engine features. Within bioinformatics, where analysts are a mix of dry
      and wet lab scientists, the choice is also governed by collaborations and
      adoption within large consortia and technical support provided by the WfMS
      team/community. As the community and its needs continue to evolve along
      with computational infrastructure, WfMSs will also evolve, especially
      those with permissive licenses that allow commercial use. In much the same
      way as the dataflow paradigm and containerization are now well understood
      to be very useful in bioinformatics applications, we will continue to see
      innovations of tools and utilities for other purposes, like big data
      technologies, interoperability, and provenance.'
    authors:
      - name: Azza E Ahmed
        orcid: http://orcid.org/0000-0002-1358-8371
      - name: Joshua Allen
        orcid: null
      - name: Tajesvi Bhat
        orcid: null
      - name: Prakruthi Burra
        orcid: http://orcid.org/0000-0002-1502-8095
      - name: Christina E Fliege
        orcid: null
      - name: Steven N Hart
        orcid: http://orcid.org/0000-0001-7714-2734
      - name: Jacob R Heldenbrand
        orcid: null
      - name: Matthew E Hudson
        orcid: http://orcid.org/0000-0002-4737-0936
      - name: Dave Deandre Istanto
        orcid: null
      - name: Michael T Kalmbach
        orcid: null
      - name: Gregory D. Kapraun
        orcid: null
      - name: Katherine I. Kendig
        orcid: null
      - name: Matthew Charles Kendzior
        orcid: null
      - name: Eric W Klee
        orcid: http://orcid.org/0000-0003-2946-5795
      - name: Nate Mattson
        orcid: null
      - name: Christian A Ross
        orcid: http://orcid.org/0000-0002-4157-3951
      - name: Sami M Sharif
        orcid: null
      - name: Ramshankar Venkatakrishnan
        orcid: http://orcid.org/0000-0001-8539-8115
      - name: Faisal M Fadlelmola
        orcid: http://orcid.org/0000-0001-8351-264X
      - name: Liudmila Sergeevna Mainzer
        orcid: http://orcid.org/0000-0001-7121-0214
  comment:
    dislikes: 0
    thread: "8466513971"
    numReports: 0
    likes: 0
    id: "5456853410"
    createdAt: 2021-07-15T15:34:34
    author:
      username: disqus_mSccjj7oYN
      about: ""
      name: Azza Ahmed
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_mSccjj7oYN/
      url: https://www.facebook.com/app_scoped_user_id/YXNpZADpBWEhVNVB6d092czhGcHVpN3dEbFJJN2JFOTRMQW5MTE9WNVVFN3daUENncDhIU0E3bi12a2xvcGw3TDRBa2MtdEU5dTJxMVk3QWdvZAm91aV9OZAGlpdXJLZADAzbkFYcGFpa3lv
      location: ""
      id: "187794365"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Thank you much for the valuable comments. We noticed the `queueSize`
      directive after having finished our testing phase, and it was too late
      then, hence we reported this possibility in this version.



      We have now re-done the scalability benchmarks with more recent versions of the runners, and for Nextflow, using the `queueSize` in tandem with the `maxForks` directive. The results we obtained were done on our HPC in a repeated set of 5 experiments (https://github.com/azzaea/scalability-tst#references). To some extent, we still see the same general patterns in terms of which runner is faster, and how runners distribute tasks across nodes. Admittedly though, we did not run these experiments on AWS, so we did not reach the previously tested high limits of performance.



      That said, a nice realization from these re-runs is the improved performance overall obtained by the new versions of the tools- kudos to all the developers and the community indeed!



      Finally, an update version of the manuscript should be up promptly as well, with these edits and others (and our apologies for mis-writing your last name @pditommaso:disqus).
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.04.03.437906v1
  tweets:
    - created_at: Thu Jul 15 16:31:29 +0000 2021
      id: 1415710620280889300
      id_str: "1415710620280889345"
      text: >-
        üí¨ bioRxiv comment on "Design considerations for work..."


        "Thank you much for the valuable comments. We noticed the‚Ä¶ https://t.co/6FmdZN1AAb
      truncated: true
      entities:
        urls:
          - url: https://t.co/6FmdZN1AAb
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 15 16:31:29 +0000 2021
      id: 1415710621061025800
      id_str: "1415710621061025797"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/uR9zjl4BxP
      truncated: false
      entities:
        urls:
          - url: https://t.co/uR9zjl4BxP
      in_reply_to_status_id: 1415710620280889300
      in_reply_to_status_id_str: "1415710620280889345"
- preprint:
    id: "150159"
    doi: 10.1101/2021.07.10.21260232
    first_posted: 2021-07-14
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.10.21260232v1
    url: https://api.rxivist.org/v1/papers/150159
    title: SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus
      neutralization in sera from CoronaVac vaccinees and naturally infected
      COVID-19 patients
    category: infectious-diseases
    abstract: Recent surges in SARS-CoV-2 variants of concern (VOCs) call for the
      need to evaluate levels of vaccine- and infection- induced SARS-CoV-2
      neutralizing antibodies (NAbs). CoronaVac (Sinovac Biotech, Beijing,
      China) is currently being used for mass vaccination in Thailand as well as
      other low-income countries. Three VOCs currently circulating within
      Thailand include the B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2
      (Delta) strains. We assessed NAb potency against the prototypic strain
      containing the original spike sequence (WT) compared to that against the 3
      VOCs using sera derived from a cohort of healthcare workers who received a
      full 2-dose regimen of CoronaVac. Sera from two other cohorts consisting
      of COVID-19 patients who had been hospitalized in 2020 and 2021 were
      evaluated for comparison. We found that, despite equally robust production
      of S1-RBD-binding IgG and 100% seropositivity, sera from both CoronaVac
      vaccinees and naturally infected individuals had significantly reduced
      neutralizing capacity against all 3 VOCs compared to WT. Strikingly, NAb
      titers against Alpha and Beta were comparable, but Delta appears to be
      significantly more refractory to NAbs in all groups. Our results may help
      inform on CoronaVac NAb-inducing capacity, which is a proxy for vaccine
      efficacy, in the context of the WT strain and 3 VOCs. Our results also
      have critical implications for public health decisionmakers who may need
      to maintain efficient mitigation strategies amid a potentially high risk
      for infection with VOCs even in those who have been previously infected.
    authors:
      - name: Vimvara Vacharathit
        orcid: http://orcid.org/0000-0002-5173-8238
      - name: Pakorn Aiewsakun
        orcid: http://orcid.org/0000-0002-5665-4041
      - name: Suwimon Manopwisedjaroen
        orcid: http://orcid.org/0000-0002-7571-8733
      - name: Chanya Srisaowakarn
        orcid: http://orcid.org/0000-0003-3652-4757
      - name: Thanida Laopanupong
        orcid: http://orcid.org/0000-0003-3589-0843
      - name: Natali Ludowyke
        orcid: http://orcid.org/0000-0001-9159-450X
      - name: Angsana Phuphuakrat
        orcid: http://orcid.org/0000-0003-2474-1850
      - name: Chavachol Setthaudom
        orcid: http://orcid.org/0000-0001-8821-9143
      - name: Supanuch Ekronarongchai
        orcid: http://orcid.org/0000-0003-2231-2163
      - name: Sirawat Srichatrapimuk
        orcid: http://orcid.org/0000-0001-9649-6191
      - name: Pattama Wongsirisin
        orcid: http://orcid.org/0000-0001-7884-2484
      - name: Suleeporn Sangrajrang
        orcid: http://orcid.org/0000-0003-2653-6383
      - name: Thanarath Imsuwansri
        orcid: http://orcid.org/0000-0001-5133-7488
      - name: Suppachok Kirdlarp
        orcid: http://orcid.org/0000-0003-3444-4796
      - name: Sureeporn Nualkaew
        orcid: null
      - name: Insee Sensorn
        orcid: http://orcid.org/0000-0002-1283-5799
      - name: Waritta Sawaengdee
        orcid: http://orcid.org/0000-0002-3982-1434
      - name: Nuanjun Wichukchinda
        orcid: http://orcid.org/0000-0002-9801-3111
      - name: Somnuek Sungkanuparph
        orcid: http://orcid.org/0000-0002-1055-2963
      - name: Wasun Chantratita
        orcid: http://orcid.org/0000-0002-8821-3945
      - name: Mongkol Kunakorn
        orcid: http://orcid.org/0000-0002-1214-2861
      - name: Jinda Rojanamatin
        orcid: null
      - name: Suradej Hongeng
        orcid: http://orcid.org/0000-0002-7376-9393
      - name: Arunee Thitithanyanont
        orcid: http://orcid.org/0000-0002-9756-4763
  comment:
    dislikes: 0
    thread: "8648020596"
    numReports: 0
    likes: 0
    id: "5456714561"
    createdAt: 2021-07-15T13:36:08
    author:
      username: khoobookian
      about: ""
      name: Merlin Khoo
      isPowerContributor: false
      profileUrl: https://disqus.com/by/khoobookian/
      url: ""
      location: ""
      id: "215537358"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: This laboratory study seems to indicate the need for a booster 3rd
      jab based on the latest variant as the virus mutates further and further
      from the original wild type
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.07.10.21260232v1
  tweets:
    - created_at: Thu Jul 15 18:27:22 +0000 2021
      id: 1415739783545081900
      id_str: "1415739783545081861"
      text: >-
        üí¨ medRxiv comment on "SARS-CoV-2 variants of concern..."


        "This laboratory study seems to indicate the need for a b‚Ä¶ https://t.co/2wVpvGbA2f
      truncated: true
      entities:
        urls:
          - url: https://t.co/2wVpvGbA2f
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 15 18:27:22 +0000 2021
      id: 1415739784530731000
      id_str: "1415739784530731009"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/LeJWMPGeE4
      truncated: false
      entities:
        urls:
          - url: https://t.co/LeJWMPGeE4
      in_reply_to_status_id: 1415739783545081900
      in_reply_to_status_id_str: "1415739783545081861"
- preprint:
    id: 150122
    metric: 11
    title: "PyLipID: A Python package for analysis of protein-lipid interactions
      from MD simulations"
    url: https://api.rxivist.org/v1/papers/150122
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.14.452312v1
    doi: 10.1101/2021.07.14.452312
    category: biophysics
    first_posted: 2021-07-14
    abstract: Lipids play important modulatory and structural roles for membrane
      proteins. Molecular dynamics simulations are frequently used to provide
      insights into the nature of these protein-lipid interactions. Systematic
      comparative analysis requires tools that provide algorithms for objective
      assessment of such interactions. We introduce PyLipID, a python package
      for the identification and characterization of specific lipid interactions
      and binding sites on membrane proteins from molecular dynamics
      simulations. PyLipID uses a community analysis approach for binding site
      detection, calculating lipid residence times for both the individual
      protein residues and the detected binding sites. To assist structural
      analysis, PyLipID produces representative bound lipid poses from
      simulation data, using a density-based scoring function. To estimate
      residue contacts robustly, PyLipID uses a dual-cutoff scheme to
      differentiate between lipid conformational rearrangements whilst bound
      from full dissociation events. In addition to the characterization of
      protein-lipid interactions, PyLipID is applicable to analysis of the
      interactions of membrane proteins with other ligands. By combining
      automated analysis, efficient algorithms, and open-source distribution,
      PyLipID facilitates the systematic analysis of lipid interactions from
      large simulation datasets of multiple species of membrane proteins.
    authors:
      - name: Wanling Song
      - name: Robin A. Corey
      - name: Bertie Ansell
      - name: Keith Cassidy
      - name: Michael Horrell
      - name: Anna Duncan
      - name: Phillip James Stansfeld
      - name: Mark Sansom
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Thu Jul 15 20:17:51 +0000 2021
      id: 1415767589826056200
      id_str: "1415767589826056198"
      text: >-
        üî• bioRxiv Biophysics preprint by W. Song et al:


        "PyLipID: A Python package for analysis of protein-lipid interacti‚Ä¶ https://t.co/Gd8YLQUybA
      truncated: true
      entities:
        urls:
          - url: https://t.co/Gd8YLQUybA
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "147602"
    doi: 10.1101/2021.06.24.21259283
    first_posted: 2021-06-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.24.21259283v1
    url: https://api.rxivist.org/v1/papers/147602
    title: "Diet quality and risk and severity of COVID-19: a prospective cohort
      study"
    category: nutrition
    abstract: "Objective: Poor metabolic health and certain lifestyle factors have
      been associated with risk and severity of coronavirus disease 2019
      (COVID-19), but data for diet are lacking. We aimed to investigate the
      association of diet quality with risk and severity of COVID-19 and its
      intersection with socioeconomic deprivation. Design: We used data from
      592,571 participants of the smartphone-based COVID Symptom Study. Diet
      quality was assessed using a healthful plant-based diet score, which
      emphasizes healthy plant foods such as fruits or vegetables. Multivariable
      Cox models were fitted to calculate hazard ratios (HR) and 95% confidence
      intervals (95% CI) for COVID-19 risk and severity defined using a
      validated symptom-based algorithm or hospitalization with oxygen support,
      respectively. Results: Over 3,886,274 person-months of follow-up, 31,815
      COVID-19 cases were documented. Compared with individuals in the lowest
      quartile of the diet score, high diet quality was associated with lower
      risk of COVID-19 (HR, 0.91; 95% CI, 0.88-0.94) and severe COVID-19 (HR,
      0.59; 95% CI, 0.47-0.74). The joint association of low diet quality and
      increased deprivation on COVID-19 risk was higher than the sum of the risk
      associated with each factor alone (Pinteraction=0.005). The corresponding
      absolute excess rate for lowest vs highest quartile of diet score was 22.5
      (95% CI, 18.8-26.3) and 40.8 (95% CI, 31.7-49.8; 10,000 person-months)
      among persons living in areas with low and high deprivation, respectively.
      Conclusions: A dietary pattern characterized by healthy plant-based foods
      was associated with lower risk and severity of COVID-19. These association
      may be particularly evident among individuals living in areas with higher
      socioeconomic deprivation."
    authors:
      - name: Jordi Merino
        orcid: http://orcid.org/0000-0001-8312-1438
      - name: Amit D. Joshi
        orcid: null
      - name: Long Nguyen
        orcid: http://orcid.org/0000-0002-5436-4219
      - name: Emily Leeming
        orcid: null
      - name: David Alden Drew
        orcid: null
      - name: Rachel Gibson
        orcid: http://orcid.org/0000-0002-5823-6468
      - name: Mark S Graham
        orcid: http://orcid.org/0000-0002-4170-1095
      - name: Mohsen Mazidi
        orcid: http://orcid.org/0000-0003-3059-229X
      - name: Chun-Han Lo
        orcid: http://orcid.org/0000-0001-8202-4513
      - name: Joan Capdevila
        orcid: null
      - name: Ben Murray
        orcid: null
      - name: christina hu
        orcid: null
      - name: Somesh Selvachandran
        orcid: null
      - name: Sohee Kwon
        orcid: http://orcid.org/0000-0002-4201-9522
      - name: Wenjie MA
        orcid: null
      - name: Cristina Menni
        orcid: http://orcid.org/0000-0001-9790-0571
      - name: Alexander Hammers
        orcid: http://orcid.org/0000-0001-9530-4848
      - name: Shilpa Bhupathiraju
        orcid: null
      - name: Shreela Sharma
        orcid: null
      - name: Carole Sudre
        orcid: null
      - name: Christina M Astley
        orcid: http://orcid.org/0000-0002-5063-8470
      - name: Walter Willett
        orcid: null
      - name: Jorge Chavarro
        orcid: null
      - name: Seb Ourselin
        orcid: null
      - name: Claire Steves
        orcid: null
      - name: Jonathan Wolf
        orcid: http://orcid.org/0000-0002-0530-2257
      - name: Paul W Franks
        orcid: http://orcid.org/0000-0002-0520-7604
      - name: Timothy Spector
        orcid: http://orcid.org/0000-0002-9795-0365
      - name: Sarah Berry
        orcid: null
      - name: Andrew T. Chan
        orcid: http://orcid.org/0000-0001-7284-6767
  comment:
    dislikes: 0
    thread: "8614872167"
    numReports: 0
    likes: 0
    id: "5456473815"
    createdAt: 2021-07-15T07:57:35
    author:
      username: johnlambiase
      about: ""
      name: John Lambiase
      isPowerContributor: false
      profileUrl: https://disqus.com/by/johnlambiase/
      url: ""
      location: ""
      id: "348484864"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      What's truly interesting is that no one is talking about Fructose and
      refined sugar  activating long term NLRP3 inflammasome in the Monocyte
      which reprograms the monocyte on a path of inflammation and upregulation
      of Reactive oxygen species which lowers nitric oxide in Endothelium.  Sars
      CoV-2 seems to have a knack of exploiting and exacerbating this chronic
      inflammation in patients leading to an acute medical malody.  


      What deactivates NLRP3 inflammasome?  Olive Oil, Melatonin, Vitamin D Fish Oil, Resveritrol, Quercetin etal.  Been taking doses of Oleic Acid for months because of all the research I was finding.  Cashews high in Oleic Acid.  If this all comes down to Anti Oxidants vs Oxidants then medicine is going to have serious explaining to do.  Unfortunately that would never get out.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.24.21259283v1
  tweets:
    - created_at: Thu Jul 15 20:19:48 +0000 2021
      id: 1415768077552078800
      id_str: "1415768077552078850"
      text: >-
        üí¨ medRxiv comment on "Diet quality and risk and seve..."


        "What's truly interesting is that no one is talking about‚Ä¶ https://t.co/eJsUCTt9YF
      truncated: true
      entities:
        urls:
          - url: https://t.co/eJsUCTt9YF
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 15 20:19:48 +0000 2021
      id: 1415768078537822200
      id_str: "1415768078537822210"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/24JaAs6eeq
      truncated: false
      entities:
        urls:
          - url: https://t.co/24JaAs6eeq
      in_reply_to_status_id: 1415768077552078800
      in_reply_to_status_id_str: "1415768077552078850"
- preprint:
    id: "124277"
    doi: 10.1101/2020.12.18.20245068
    first_posted: 2020-12-22
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.12.18.20245068v1
    url: https://api.rxivist.org/v1/papers/124277
    title: Bayesian modeling for the detection of adverse events underreporting in
      clinical trials
    category: health-systems-and-quality-improvement
    abstract: Introduction Safety underreporting is a recurrent issue in clinical
      trials that can impact patient safety and data integrity. Clinical Quality
      Assurance (QA) practices used to detect underreporting rely on on-site
      audits, however adverse events underreporting remains a recurrent issue.
      In a recent project, we developed a predictive model that enables
      oversight of Adverse Event (AE) reporting for clinical Quality Program
      Leads (QPL). However, there were limitations to using solely a machine
      learning model. Objective Our primary objective was to propose a robust
      method to compute the probability of AE underreporting that could
      complement our machine learning model. Our model was developed to enhance
      patients safety while reducing the need for on-site and manual QA
      activities in clinical trials. Methods We used a Bayesian hierarchical
      model to estimate the site reporting rates and assess the risk of
      underreporting. We designed the model with Project Data Sphere clinical
      trial data that is public and anonymized. Results We built a model that
      infers the site reporting behavior from patient-level observations and
      compares them across a study to enable a robust detection of outliers
      between clinical sites. Conclusion The new model will be integrated into
      the current dashboard designed for clinical Quality Program Leads. This
      approach reduces the need for on-site audits, shifting focus from source
      data verification (SDV) to pre-identified, higher risk areas. It will
      enhance further quality assurance activities for safety reporting from
      clinical trials and generate quality evidence during pre-approval
      inspections.
    authors:
      - name: Yves Barmaz
        orcid: http://orcid.org/0000-0003-1600-9010
      - name: Timoth√© M√©nard
        orcid: http://orcid.org/0000-0003-4545-6944
  comment:
    dislikes: 0
    thread: "8517637937"
    numReports: 0
    likes: 0
    id: "5456461267"
    createdAt: 2021-07-15T07:33:35
    author:
      username: timothemenard
      about: ""
      name: Timothe Menard
      isPowerContributor: false
      profileUrl: https://disqus.com/by/timothemenard/
      url: ""
      location: ""
      id: "372362362"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: It has been published in<a
      href="https://www.springer.com/journal/40264"> Drug Safety</a> and is now
      available <a href="https://doi.org/10.1007/s40264-021-01094-8">online</a>
      - DOI:10.1007/s40264-021-01094-8
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.12.18.20245068v2
  tweets:
    - created_at: Thu Jul 15 22:19:22 +0000 2021
      id: 1415798170412540000
      id_str: "1415798170412539905"
      text: >-
        üí¨ medRxiv comment on "Bayesian modeling for the dete..."


        "It has been published in&lt;a href=" Drug Safety&lt;/a&gt; and is‚Ä¶ https://t.co/3C3t6mpeIV
      truncated: true
      entities:
        urls:
          - url: https://t.co/3C3t6mpeIV
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 15 22:19:22 +0000 2021
      id: 1415798171385614300
      id_str: "1415798171385614336"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jW1tTmHkxD
      truncated: false
      entities:
        urls:
          - url: https://t.co/jW1tTmHkxD
      in_reply_to_status_id: 1415798170412540000
      in_reply_to_status_id_str: "1415798170412539905"
- preprint:
    id: "149993"
    doi: 10.1101/2021.07.13.452179
    first_posted: 2021-07-14
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.13.452179v1
    url: https://api.rxivist.org/v1/papers/149993
    title: Long-read isoform sequencing reveals tissue-specific isoform expression
      between active and hibernating brown bears (Ursus arctos)
    category: genomics
    abstract: Understanding hibernation in brown bears (Ursus arctos) can provide
      insight into many human diseases. During hibernation, brown bears
      experience states of insulin resistance, physical inactivity, extreme
      bradycardia, obesity, and the absence of urine production. These states
      closely mimic human diseases such as type 2 diabetes, muscle atrophy,
      renal and heart failure, cachexia, and obesity. The reversibility of these
      states from hibernation to active season allows for the identification of
      novel mediators with possible therapeutic value for humans. Recent studies
      have identified genes and pathways that are differentially expressed
      between active and hibernation seasons. However, little is known about the
      role of differential expression of gene isoforms on hibernation
      physiology. To identify both distinct and novel mRNA isoforms, we
      performed full-length RNA-sequencing (Iso-Seq) on three tissue types from
      three individuals sampled during both active and hibernation seasons. We
      combined the long-read data with the reference annotation for an improved
      transcriptome and mapped RNA-seq data from six individuals to the improved
      transcriptome to quantify differential isoform usage between tissues and
      seasons. We identified differentially expressed isoforms in all study
      tissues and showed that adipose has a high level of differential isoform
      usage with isoform switching, regardless of whether the genes were
      differentially expressed. Our analyses provide a comprehensive evaluation
      of isoform usage between active and hibernation states, revealing that
      differential isoform usage, even in the absence of differential gene
      expression, is an important mechanism for modulating genes during
      hibernation. These findings demonstrate the value of isoform expression
      studies and will serve as the basis for deeper exploration into
      hibernation biology.
    authors:
      - name: Elizabeth Tseng
        orcid: http://orcid.org/0000-0002-1074-5095
      - name: Jason G Underwood
        orcid: null
      - name: Brandon D Evans Hutzenbiler
        orcid: null
      - name: Shawn Trojahn
        orcid: null
      - name: Brewster Kingham
        orcid: http://orcid.org/0000-0003-3862-7442
      - name: Olga Shevchenko
        orcid: null
      - name: Erin Bernberg
        orcid: null
      - name: Charles T Robbins
        orcid: null
      - name: Heiko T. Jansen
        orcid: http://orcid.org/0000-0003-0178-396X
      - name: Joanna L. Kelley
        orcid: http://orcid.org/0000-0002-7731-605X
  comment:
    dislikes: 0
    thread: "8647389057"
    numReports: 0
    likes: 0
    id: "5456441626"
    createdAt: 2021-07-15T06:54:53
    author:
      username: marcrobinsonrechavi
      about: ""
      name: Marc RobinsonRechavi
      isPowerContributor: false
      profileUrl: https://disqus.com/by/marcrobinsonrechavi/
      url: ""
      location: ""
      id: "67492738"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      The github referenced in this manuscript is empty:









      <blockquote>The code for this project is available at: https://github.com/jokelley/brownbear-isoseq-act-hib</blockquote>









      At this url I only find a README which contains the title of this manuscript.









      This is a publication, i.e. it is made public as part of the scientific record and is citable, thus I strongly invite the authors to make the corresponding code available without delay.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.07.13.452179v1
  tweets:
    - created_at: Fri Jul 16 01:03:22 +0000 2021
      id: 1415839443257286700
      id_str: "1415839443257286660"
      text: |-
        üí¨ bioRxiv comment on "Long-read isoform sequencing r..."

        "The github referenced in this manuscript is empty:

        &lt;blo‚Ä¶ https://t.co/6yagDrRQqp
      truncated: true
      entities:
        urls:
          - url: https://t.co/6yagDrRQqp
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 16 01:03:23 +0000 2021
      id: 1415839444175831000
      id_str: "1415839444175831041"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/p3SbpoWpUE
      truncated: false
      entities:
        urls:
          - url: https://t.co/p3SbpoWpUE
      in_reply_to_status_id: 1415839443257286700
      in_reply_to_status_id_str: "1415839443257286660"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8603406700"
    numReports: 0
    likes: 0
    id: "5457307054"
    createdAt: 2021-07-15T21:52:38
    author:
      username: brian_mowrey
      about: ""
      name: Brian Mowrey
      isPowerContributor: false
      profileUrl: https://disqus.com/by/brian_mowrey/
      url: http://unglossed.substack.com
      location: ""
      id: "372391488"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Results for the not-previously-infected group are barely
      presented/summarized. Without a calendar of absolute case counts, it is
      very difficult to get an idea of the real infection rate. I gave it a
      shot, using the relative plot in Figure 3. More at blog link.


      <b>Not previously PCR-confirmed-infected infection rate: 2,154 / 49,652 = 4.3%</b>

      -Completely Vaccinated infection rate: 15 / 28836 = 0.05%

      -Unvaccinated / Incompletely Vaccinated infection rate: 2,139 / 49,652 = 4.3%

      -Estimated Day 0 - 80 U/IV infection rate in 150-day units: (1620/49652)(15/8) = 6.1%

      -Estimated Day 80 - 150 U/IV infection rate in 150-day units: (529/21,332)(15/7) = 5.3%

      -Estimated Day 0 - 150 U/IV real infection rate (1620/49652) + (529/21,332) = 5.7%

      https://unglossed.substack.com/p/the-natural-immunity-illusion-illusion#footnote-14
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v3
  tweets:
    - created_at: Fri Jul 16 12:31:48 +0000 2021
      id: 1416012690183630800
      id_str: "1416012690183630848"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "Results for the not-previously-infected group are barely‚Ä¶ https://t.co/z1OsiQmFd2
      truncated: true
      entities:
        urls:
          - url: https://t.co/z1OsiQmFd2
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 16 12:31:48 +0000 2021
      id: 1416012691529998300
      id_str: "1416012691529998337"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1416012690183630800
      in_reply_to_status_id_str: "1416012690183630848"
- preprint:
    id: "149692"
    doi: 10.1101/2021.07.08.21259744
    first_posted: 2021-07-10
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.08.21259744v1
    url: https://api.rxivist.org/v1/papers/149692
    title: "Detection and Quantification of Infectious Severe Acute Respiratory
      Coronavirus-2 in Diverse Clinical and Environmental Samples from Infected
      Patients: Evidence to Support Respiratory Droplet, and Direct and Indirect
      Contact as Significant Modes of Transmission"
    category: infectious-diseases
    abstract: Few studies have assessed for infectious SARS-CoV-2 in multiple types
      of clinical and environmental samples. In almost 500 samples from 75
      hospitalized and community cases, we detected infectious virus with
      quantitative burdens varying from 5.0 plaque-forming units/mL (PFU/mL) up
      to 1.0x106 PFU/mL in clinical specimens and up to 1.3x106 PFU/mL on
      fomites including facial tissues, nasal prongs, call bells/cell phones,
      dentures, and sputum deposits with confirmation by plaque morphology, PCR,
      immunohistochemistry, and sequencing. Expectorated sputum samples had the
      highest percentage of positive samples and virus titers (71%, 2.9x102 to
      5.2x105 PFU/mL), followed by saliva (58%, 10 to 4.6x104 PFU/mL), and cough
      samples without sputum (19%, 5 to 1.9x103 PFU/mL). We also detected
      infectious SARS-CoV-2 from patients' hands (28%, 60 to 2.3x102 PFU/mL) but
      no infectious virus was found in continuous speech samples despite finding
      high levels of infectious virus in the associated nasopharynx, throat, or
      saliva specimens. We demonstrated infectious virus stability in clinical
      samples, including those dried for prolonged periods of time. Infectious
      virus correlated with time since symptom onset with no detection after 7-8
      days in immunocompetent hosts and with N-gene based Ct values [&le;]25
      significantly predictive of yielding plaques in culture. One PFU was
      associated with ~105 copies of N gene RNA across a diversity of samples
      and times from symptom onset. Clinical salivary isolates caused illness in
      a hamster model with a minimum infectious dose of [&le;]14 PFU/mL. Our
      findings of high quantitative burdens of infectious virus, stability even
      with drying, and a very low minimal infectious dose suggest multiple modes
      of transmission are exploited by SARS-CoV-2, including direct contact,
      large respiratory droplet, and fomite transmission and in the context of a
      high binding avidity to human cellular receptors, offer an explanation of
      the high contagiousness of this virus.
    authors:
      - name: Yi-Chan Lin
        orcid: http://orcid.org/0000-0003-0867-220X
      - name: Rebecca J. Malott
        orcid: http://orcid.org/0000-0002-8988-2358
      - name: Linda Ward
        orcid: null
      - name: Linet Kiplagat
        orcid: null
      - name: Kanti Pabbaraju
        orcid: http://orcid.org/0000-0002-7409-579X
      - name: Kara Gill
        orcid: null
      - name: Byron M. Berenger
        orcid: http://orcid.org/0000-0001-9062-6346
      - name: Jia Hu
        orcid: http://orcid.org/0000-0002-6548-3985
      - name: Kevin Fonseca
        orcid: null
      - name: Ryan Noyce
        orcid: null
      - name: Thomas Louie
        orcid: null
      - name: David H. Evans
        orcid: http://orcid.org/0000-0001-5871-299X
      - name: John M. Conly
        orcid: http://orcid.org/0000-0002-3348-0157
  comment:
    dislikes: 0
    thread: "8641320019"
    numReports: 0
    likes: 0
    id: "5457177743"
    createdAt: 2021-07-15T19:57:15
    author:
      username: linsey_marr
      about: ""
      name: Linsey Marr
      isPowerContributor: false
      profileUrl: https://disqus.com/by/linsey_marr/
      url: ""
      location: ""
      id: "208486826"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      The conclusions on cough samples, sputum, nasal secretions, hands, and
      high-touch surfaces seem sound, but I do not agree that this study can
      rule out speech as a source of virus because the sampling method was not
      appropriate for collecting aerosols (which might carry virus) generated by
      speech. Subjects spoke into a 18x19 cm or 27x27 cm polyethylene bag, to
      which "2 to 5 mL of DMEM+ was added and residual air was expelled." First,
      the ~1 L volume of air sampled, representing 1-2 breaths worth, is orders
      of magnitude too small to capture enough viruses to detect. Second, the
      act of expelling the air would push almost all aerosols out of the bag. An
      analogy is that it's like trying to catch a fish by dipping a hula hoop
      into the water. The authors should consider removing this portion of the
      study from the manuscript.




      Linsey C. Marr, Ph.D.

      Charles P. Lunsford Professor

      Civil and Environmental Engineering

      Virginia Tech
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.07.08.21259744v1
  tweets:
    - created_at: Fri Jul 16 14:22:28 +0000 2021
      id: 1416040539921784800
      id_str: "1416040539921784835"
      text: >-
        üí¨ medRxiv comment on "Detection and Quantification o..."


        "The conclusions on cough samples, sputum, nasal secretio‚Ä¶ https://t.co/DvPKQyiU1n
      truncated: true
      entities:
        urls:
          - url: https://t.co/DvPKQyiU1n
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 16 14:22:28 +0000 2021
      id: 1416040540815204400
      id_str: "1416040540815204358"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/5MGQEuR3y8
      truncated: false
      entities:
        urls:
          - url: https://t.co/5MGQEuR3y8
      in_reply_to_status_id: 1416040539921784800
      in_reply_to_status_id_str: "1416040539921784835"
- preprint:
    id: "150159"
    doi: 10.1101/2021.07.10.21260232
    first_posted: 2021-07-14
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.10.21260232v1
    url: https://api.rxivist.org/v1/papers/150159
    title: SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus
      neutralization in sera from CoronaVac vaccinees and naturally infected
      COVID-19 patients
    category: infectious-diseases
    abstract: Recent surges in SARS-CoV-2 variants of concern (VOCs) call for the
      need to evaluate levels of vaccine- and infection- induced SARS-CoV-2
      neutralizing antibodies (NAbs). CoronaVac (Sinovac Biotech, Beijing,
      China) is currently being used for mass vaccination in Thailand as well as
      other low-income countries. Three VOCs currently circulating within
      Thailand include the B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2
      (Delta) strains. We assessed NAb potency against the prototypic strain
      containing the original spike sequence (WT) compared to that against the 3
      VOCs using sera derived from a cohort of healthcare workers who received a
      full 2-dose regimen of CoronaVac. Sera from two other cohorts consisting
      of COVID-19 patients who had been hospitalized in 2020 and 2021 were
      evaluated for comparison. We found that, despite equally robust production
      of S1-RBD-binding IgG and 100% seropositivity, sera from both CoronaVac
      vaccinees and naturally infected individuals had significantly reduced
      neutralizing capacity against all 3 VOCs compared to WT. Strikingly, NAb
      titers against Alpha and Beta were comparable, but Delta appears to be
      significantly more refractory to NAbs in all groups. Our results may help
      inform on CoronaVac NAb-inducing capacity, which is a proxy for vaccine
      efficacy, in the context of the WT strain and 3 VOCs. Our results also
      have critical implications for public health decisionmakers who may need
      to maintain efficient mitigation strategies amid a potentially high risk
      for infection with VOCs even in those who have been previously infected.
    authors:
      - name: Vimvara Vacharathit
        orcid: http://orcid.org/0000-0002-5173-8238
      - name: Pakorn Aiewsakun
        orcid: http://orcid.org/0000-0002-5665-4041
      - name: Suwimon Manopwisedjaroen
        orcid: http://orcid.org/0000-0002-7571-8733
      - name: Chanya Srisaowakarn
        orcid: http://orcid.org/0000-0003-3652-4757
      - name: Thanida Laopanupong
        orcid: http://orcid.org/0000-0003-3589-0843
      - name: Natali Ludowyke
        orcid: http://orcid.org/0000-0001-9159-450X
      - name: Angsana Phuphuakrat
        orcid: http://orcid.org/0000-0003-2474-1850
      - name: Chavachol Setthaudom
        orcid: http://orcid.org/0000-0001-8821-9143
      - name: Supanuch Ekronarongchai
        orcid: http://orcid.org/0000-0003-2231-2163
      - name: Sirawat Srichatrapimuk
        orcid: http://orcid.org/0000-0001-9649-6191
      - name: Pattama Wongsirisin
        orcid: http://orcid.org/0000-0001-7884-2484
      - name: Suleeporn Sangrajrang
        orcid: http://orcid.org/0000-0003-2653-6383
      - name: Thanarath Imsuwansri
        orcid: http://orcid.org/0000-0001-5133-7488
      - name: Suppachok Kirdlarp
        orcid: http://orcid.org/0000-0003-3444-4796
      - name: Sureeporn Nualkaew
        orcid: null
      - name: Insee Sensorn
        orcid: http://orcid.org/0000-0002-1283-5799
      - name: Waritta Sawaengdee
        orcid: http://orcid.org/0000-0002-3982-1434
      - name: Nuanjun Wichukchinda
        orcid: http://orcid.org/0000-0002-9801-3111
      - name: Somnuek Sungkanuparph
        orcid: http://orcid.org/0000-0002-1055-2963
      - name: Wasun Chantratita
        orcid: http://orcid.org/0000-0002-8821-3945
      - name: Mongkol Kunakorn
        orcid: http://orcid.org/0000-0002-1214-2861
      - name: Jinda Rojanamatin
        orcid: null
      - name: Suradej Hongeng
        orcid: http://orcid.org/0000-0002-7376-9393
      - name: Arunee Thitithanyanont
        orcid: http://orcid.org/0000-0002-9756-4763
  comment:
    dislikes: 0
    thread: "8648020596"
    numReports: 0
    likes: 0
    id: "5456901526"
    createdAt: 2021-07-15T16:14:14
    author:
      username: tanavijjoobpannoi
      about: ""
      name: Tanavij Joob Pannoi
      isPowerContributor: false
      profileUrl: https://disqus.com/by/tanavijjoobpannoi/
      url: ""
      location: ""
      id: "372378851"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: I am wondering about the total number of recruited participants
      divided by VOC, particularly in figure 2A, while, the results  from linear
      mixed model were not reported elsewhere. Researchers should provide more
      details of study limitations since it could be published on social media,
      while, many audience might misinterpret or exaggerate the result.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.07.10.21260232v1
  tweets:
    - created_at: Fri Jul 16 16:32:02 +0000 2021
      id: 1416073148814958600
      id_str: "1416073148814958592"
      text: >-
        üí¨ medRxiv comment on "SARS-CoV-2 variants of concern..."


        "I am wondering about the total number of recruited parti‚Ä¶ https://t.co/vg515sYm4g
      truncated: true
      entities:
        urls:
          - url: https://t.co/vg515sYm4g
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 16 16:32:02 +0000 2021
      id: 1416073149733490700
      id_str: "1416073149733490702"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/LeJWMPXPvC
      truncated: false
      entities:
        urls:
          - url: https://t.co/LeJWMPXPvC
      in_reply_to_status_id: 1416073148814958600
      in_reply_to_status_id_str: "1416073148814958592"
- preprint:
    id: 95186
    metric: 17
    title: Towards Reproducible Brain-Wide Association Studies
    url: https://api.rxivist.org/v1/papers/95186
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.08.21.257758v1
    doi: 10.1101/2020.08.21.257758
    category: neuroscience
    first_posted: 2020-08-22
    abstract: >-
      Magnetic resonance imaging (MRI) continues to drive many important
      neuroscientific advances. However, progress in uncovering reproducible
      associations between individual differences in brain structure/function
      and behavioral phenotypes (e.g., cognition, mental health) may have been
      undermined by typical neuroimaging sample sizes (median N=25)1,2.
      Leveraging the Adolescent Brain Cognitive Development (ABCD) Study3
      (N=11,878), we estimated the effect sizes and reproducibility of these
      brain wide associations studies (BWAS) as a function of sample size. The
      very largest, replicable brain wide associations for univariate and
      multivariate methods were r=0.14 and r=0.34, respectively. In smaller
      samples, typical for brain wide association studies, irreproducible,
      inflated effect sizes were ubiquitous, no matter the method (univariate,
      multivariate). Until sample sizes started to approach consortium levels,
      BWAS were underpowered and statistical errors assured. Multiple factors
      contribute to replication failures4,5,6; here, we show that the pairing of
      small brain behavioral phenotype effect sizes with sampling variability is
      a key element in widespread BWAS replication failure. Brain behavioral
      phenotype associations stabilize and become more reproducible with sample
      sizes of N>2,000. While investigator initiated brain behavior research
      continues to generate hypotheses and propel innovation, large consortia
      are needed to usher in a new era of reproducible human brain wide
      association studies.


      ### Competing Interest Statement


      Nico Dosenbach and Damien Fair are co-founders of Nous Imaging
    authors:
      - name: Scott Marek
      - name: Brenden Tervo-Clemmens
      - name: Finnegan J. Calabro
      - name: David F. Montez
      - name: Benjamin P. Kay
      - name: Alexander Hatoum
      - name: Meghan Rose Donohue
      - name: William Foran
      - name: Ryland L. Miller
      - name: Eric Feczko
      - name: Oscar Miranda Dominguez
      - name: Alice Graham
      - name: Eric A. Earl
      - name: Anders Perrone
      - name: Michaela Cordova
      - name: Olivia Doyle
      - name: Lucille A. Moore
      - name: Greg Conan
      - name: Johnny Uriarte
      - name: Kathy Snider
      - name: Angela Tam
      - name: Jianzhong Chen
      - name: Dillan J. Newbold
      - name: Annie Zheng
      - name: Nicole A. Seider
      - name: Andrew N. Van
      - name: Timothy O. Laumann
      - name: Wesley K Thompson
      - name: Deanna J. Greene
      - name: Steven E. Petersen
      - name: Thomas Nichols
      - name: B.T. Thomas Yeo
      - name: Deanna M Barch
      - name: Hugh Garavan
      - name: Beatriz Luna
      - name: Damien A. Fair
      - name: Nico UF Dosenbach
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Fri Jul 16 20:16:00 +0000 2021
      id: 1416129512744669200
      id_str: "1416129512744669196"
      text: >-
        üî• bioRxiv Neuroscience preprint by S. Marek et al:


        "Towards Reproducible Brain-Wide Association Studies"‚Ä¶ https://t.co/pPkHjZ9jW1
      truncated: true
      entities:
        urls:
          - url: https://t.co/pPkHjZ9jW1
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "148234"
    doi: 10.1101/2021.06.28.21259673
    first_posted: 2021-07-01
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.28.21259673v1
    url: https://api.rxivist.org/v1/papers/148234
    title: Infectivity and immune escape of the new SARS-CoV-2 variant of interest
      Lambda
    category: infectious-diseases
    abstract: "Background: The newly described SARS-CoV-2 lineage C.37 was recently
      classified as a variant of interest by the WHO (Lambda variant) based on
      its high circulation rates in South American countries and the presence of
      critical mutations in the spike protein. The impact of such mutations in
      infectivity and immune escape from neutralizing antibodies are entirely
      unknown. Methods: We performed a pseudotyped virus neutralization assay
      and determined the impact of the Lambda variant on infectivity and immune
      escape using plasma samples from healthcare workers (HCW) from two centers
      in Santiago, Chile who received the two-doses scheme of the inactivated
      virus vaccine CoronaVac. Results: We observed an increased infectivity
      mediated by the Lambda spike protein that was even higher than that of the
      D614G (lineage B) or the Alpha and Gamma variants. Compared to the Wild
      type (lineage A), neutralization was decreased by 3.05-fold for the Lambda
      variant while it was 2.33-fold for the Gamma variant and 2.03-fold for the
      Alpha variant. Conclusions: Our results indicate that mutations present in
      the spike protein of the Lambda variant of interest confer increased
      infectivity and immune escape from neutralizing antibodies elicited by
      CoronaVac. These data reinforce the idea that massive vaccination
      campaigns in countries with high SARS-CoV-2 circulation must be
      accompanied by strict genomic surveillance allowing the identification of
      new isolates carrying spike mutations and immunology studies aimed to
      determine the impact of these mutations in immune escape and vaccines
      breakthrough."
    authors:
      - name: M&amp;oacutenica L. Acevedo
        orcid: null
      - name: Luis Alonso-Palomares
        orcid: null
      - name: Andr&amp;eacutes Bustamante
        orcid: null
      - name: Aldo Gaggero
        orcid: http://orcid.org/0000-0003-2657-0776
      - name: Fabio Paredes
        orcid: null
      - name: Claudia Cort&amp;eacutes
        orcid: null
      - name: Fernando Valiente-Echeverr&amp;iacutea
        orcid: http://orcid.org/0000-0001-9156-2516
      - name: Ricardo Soto-Rifo
        orcid: http://orcid.org/0000-0003-0945-2970
  comment:
    dislikes: 0
    thread: "8624417675"
    numReports: 0
    likes: 0
    id: "5458600918"
    createdAt: 2021-07-16T22:51:17
    author:
      username: arihalperin
      about: ""
      name: Leo G.
      isPowerContributor: false
      profileUrl: https://disqus.com/by/arihalperin/
      url: https://defyccc.com
      location: Texas, USA
      id: "197915327"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Another way to slow down immune escape might be prophylaxis (IVM or
      HCQ + Zinc), starting about a week before the first jab and ending (or
      calculated to end) when the person acquires maximum immunity.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.28.21259673v1
  tweets:
    - created_at: Sat Jul 17 12:30:23 +0000 2021
      id: 1416374722657460200
      id_str: "1416374722657460225"
      text: >-
        üí¨ medRxiv comment on "Infectivity and immune escape ..."


        "Another way to slow down immune escape might be prophyla‚Ä¶ https://t.co/nK6eFxzPSX
      truncated: true
      entities:
        urls:
          - url: https://t.co/nK6eFxzPSX
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 17 12:30:23 +0000 2021
      id: 1416374723521486800
      id_str: "1416374723521486865"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/P2QoitLagV
      truncated: false
      entities:
        urls:
          - url: https://t.co/P2QoitLagV
      in_reply_to_status_id: 1416374722657460200
      in_reply_to_status_id_str: "1416374722657460225"
- preprint:
    id: "147602"
    doi: 10.1101/2021.06.24.21259283
    first_posted: 2021-06-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.24.21259283v1
    url: https://api.rxivist.org/v1/papers/147602
    title: "Diet quality and risk and severity of COVID-19: a prospective cohort
      study"
    category: nutrition
    abstract: "Objective: Poor metabolic health and certain lifestyle factors have
      been associated with risk and severity of coronavirus disease 2019
      (COVID-19), but data for diet are lacking. We aimed to investigate the
      association of diet quality with risk and severity of COVID-19 and its
      intersection with socioeconomic deprivation. Design: We used data from
      592,571 participants of the smartphone-based COVID Symptom Study. Diet
      quality was assessed using a healthful plant-based diet score, which
      emphasizes healthy plant foods such as fruits or vegetables. Multivariable
      Cox models were fitted to calculate hazard ratios (HR) and 95% confidence
      intervals (95% CI) for COVID-19 risk and severity defined using a
      validated symptom-based algorithm or hospitalization with oxygen support,
      respectively. Results: Over 3,886,274 person-months of follow-up, 31,815
      COVID-19 cases were documented. Compared with individuals in the lowest
      quartile of the diet score, high diet quality was associated with lower
      risk of COVID-19 (HR, 0.91; 95% CI, 0.88-0.94) and severe COVID-19 (HR,
      0.59; 95% CI, 0.47-0.74). The joint association of low diet quality and
      increased deprivation on COVID-19 risk was higher than the sum of the risk
      associated with each factor alone (Pinteraction=0.005). The corresponding
      absolute excess rate for lowest vs highest quartile of diet score was 22.5
      (95% CI, 18.8-26.3) and 40.8 (95% CI, 31.7-49.8; 10,000 person-months)
      among persons living in areas with low and high deprivation, respectively.
      Conclusions: A dietary pattern characterized by healthy plant-based foods
      was associated with lower risk and severity of COVID-19. These association
      may be particularly evident among individuals living in areas with higher
      socioeconomic deprivation."
    authors:
      - name: Jordi Merino
        orcid: http://orcid.org/0000-0001-8312-1438
      - name: Amit D. Joshi
        orcid: null
      - name: Long Nguyen
        orcid: http://orcid.org/0000-0002-5436-4219
      - name: Emily Leeming
        orcid: null
      - name: David Alden Drew
        orcid: null
      - name: Rachel Gibson
        orcid: http://orcid.org/0000-0002-5823-6468
      - name: Mark S Graham
        orcid: http://orcid.org/0000-0002-4170-1095
      - name: Mohsen Mazidi
        orcid: http://orcid.org/0000-0003-3059-229X
      - name: Chun-Han Lo
        orcid: http://orcid.org/0000-0001-8202-4513
      - name: Joan Capdevila
        orcid: null
      - name: Ben Murray
        orcid: null
      - name: christina hu
        orcid: null
      - name: Somesh Selvachandran
        orcid: null
      - name: Sohee Kwon
        orcid: http://orcid.org/0000-0002-4201-9522
      - name: Wenjie MA
        orcid: null
      - name: Cristina Menni
        orcid: http://orcid.org/0000-0001-9790-0571
      - name: Alexander Hammers
        orcid: http://orcid.org/0000-0001-9530-4848
      - name: Shilpa Bhupathiraju
        orcid: null
      - name: Shreela Sharma
        orcid: null
      - name: Carole Sudre
        orcid: null
      - name: Christina M Astley
        orcid: http://orcid.org/0000-0002-5063-8470
      - name: Walter Willett
        orcid: null
      - name: Jorge Chavarro
        orcid: null
      - name: Seb Ourselin
        orcid: null
      - name: Claire Steves
        orcid: null
      - name: Jonathan Wolf
        orcid: http://orcid.org/0000-0002-0530-2257
      - name: Paul W Franks
        orcid: http://orcid.org/0000-0002-0520-7604
      - name: Timothy Spector
        orcid: http://orcid.org/0000-0002-9795-0365
      - name: Sarah Berry
        orcid: null
      - name: Andrew T. Chan
        orcid: http://orcid.org/0000-0001-7284-6767
  comment:
    dislikes: 0
    thread: "8614872167"
    numReports: 0
    likes: 0
    id: "5458498352"
    createdAt: 2021-07-16T21:02:56
    author:
      username: disqus_ZxO2BUNoIe
      about: ""
      name: Andrew Carey
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_ZxO2BUNoIe/
      url: ""
      location: ""
      id: "291321327"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      @Hugo - you asked "We should consider if we want to review studies that do
      not use hPDI in the future?"

      Could you explain that question please? I've read it a few times and cannot understand whether you are making a point or making an enquiry.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.24.21259283v1
  tweets:
    - created_at: Sat Jul 17 14:17:09 +0000 2021
      id: 1416401593134637000
      id_str: "1416401593134637058"
      text: >-
        üí¨ medRxiv comment on "Diet quality and risk and seve..."


        "@Hugo - you asked "We should consider if we want to revi‚Ä¶ https://t.co/dkjNjYqvLC
      truncated: true
      entities:
        urls:
          - url: https://t.co/dkjNjYqvLC
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 17 14:17:10 +0000 2021
      id: 1416401593889611800
      id_str: "1416401593889611781"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/24JaAsnPD0
      truncated: false
      entities:
        urls:
          - url: https://t.co/24JaAsnPD0
      in_reply_to_status_id: 1416401593134637000
      in_reply_to_status_id_str: "1416401593134637058"
- preprint:
    id: "139760"
    doi: 10.1101/2021.04.21.21255898
    first_posted: 2021-04-27
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.04.21.21255898v1
    url: https://api.rxivist.org/v1/papers/139760
    title: Practical Indicators for Risk of Airborne Transmission in Shared Indoor
      Environments and their application to COVID-19 Outbreaks
    category: infectious-diseases
    abstract: "Some infectious diseases, including COVID-19, can be transmitted via
      aerosols that are emitted by an infectious person and inhaled by
      susceptible individuals. Although physical distancing effectively reduces
      short-range airborne transmission, many infections have occurred when
      sharing room air despite maintaining distancing. We propose two simple
      parameters as indicators of infection risk for this situation. They
      combine the key factors that control airborne disease transmission
      indoors: virus-containing aerosol generation rate, breathing flow rate,
      masking and its quality, ventilation and air cleaning rates, number of
      occupants, and duration of exposure. COVID-19 outbreaks show a clear trend
      in relation to these parameters that is consistent with an airborne
      infection model, supporting the importance of airborne transmission for
      these outbreaks. The observed trends of outbreak size vs. risk parameters
      allow us to recommend values of the parameters to minimize COVID-19 indoor
      infection risk. All of the pre-pandemic spaces are in a regime where they
      are highly sensitive to mitigation efforts. Measles outbreaks occur at
      much lower risk parameter values than COVID-19, while tuberculosis
      outbreaks are observed at much higher risk parameter values. Since both
      diseases are accepted as airborne, the fact that COVID-19 is less
      contagious than measles does not rule out airborne transmission. It is
      important that future outbreak reports include ventilation information, to
      allow expanding our knowledge of the circumstances conducive to airborne
      transmission of different diseases."
    authors:
      - name: Zhe Peng
        orcid: http://orcid.org/0000-0002-6823-452X
      - name: William Bahnfleth
        orcid: null
      - name: Giorgio Buonanno
        orcid: null
      - name: Stephanie J. Dancer
        orcid: null
      - name: Jarek Kurnitski
        orcid: null
      - name: Yuguo Li
        orcid: http://orcid.org/0000-0002-2281-4529
      - name: Marcel G.L.C. Loomans
        orcid: null
      - name: Linsey C. Marr
        orcid: http://orcid.org/0000-0003-3628-6891
      - name: Lidia Morawska
        orcid: null
      - name: William Nazaroff
        orcid: null
      - name: Catherine Noakes
        orcid: null
      - name: Xavier Querol
        orcid: null
      - name: Chandra Sekhar
        orcid: null
      - name: Raymond Tellier
        orcid: null
      - name: Trisha Greenhalgh
        orcid: http://orcid.org/0000-0003-2369-8088
      - name: Lydia Bourouiba
        orcid: null
      - name: Atze Boerstra
        orcid: null
      - name: Julian Tang
        orcid: null
      - name: Shelly Miller
        orcid: http://orcid.org/0000-0002-1967-7551
      - name: Jose L Jimenez
        orcid: http://orcid.org/0000-0001-6203-1847
  comment:
    dislikes: 0
    thread: "8509938572"
    numReports: 0
    likes: 0
    id: "5458478122"
    createdAt: 2021-07-16T20:44:43
    author:
      username: temporalista
      about: ""
      name: temporalista
      isPowerContributor: false
      profileUrl: https://disqus.com/by/temporalista/
      url: ""
      location: ""
      id: "95399837"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      I reviewed the spreadhseet and replicated the computations in different
      software for both analysis (R) and visualisation (PowerBI, Tableau). In
      all cases the formulae seems correct and consistent.


      I've been able to follow the modelling reasoning (is not complicated) and check the referenced sources. It seems consistent.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.04.21.21255898v2
  tweets:
    - created_at: Sat Jul 17 16:30:39 +0000 2021
      id: 1416435188079411200
      id_str: "1416435188079411202"
      text: >-
        üí¨ medRxiv comment on "Practical Indicators for Risk ..."


        "I reviewed the spreadhseet and replicated the computatio‚Ä¶ https://t.co/ZfxVvDKFEJ
      truncated: true
      entities:
        urls:
          - url: https://t.co/ZfxVvDKFEJ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 17 16:30:39 +0000 2021
      id: 1416435188939337700
      id_str: "1416435188939337729"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/t6Sw09nOAz
      truncated: false
      entities:
        urls:
          - url: https://t.co/t6Sw09nOAz
      in_reply_to_status_id: 1416435188079411200
      in_reply_to_status_id_str: "1416435188079411202"
- preprint:
    id: "149829"
    doi: 10.1101/2021.07.10.21260304
    first_posted: 2021-07-12
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.10.21260304v1
    url: https://api.rxivist.org/v1/papers/149829
    title: Analyzing the U.S. Post-marketing safety surveillance of COVID-19 vaccines
    category: public-and-global-health
    abstract: "Background: Since December 2020, three COVID-19 vaccines have been
      authorized in the United States (U.S.) and were proceeded by large
      immunization programs. The aim of this study was to characterize the U.S.
      post-marketing safety (PMS) profiles of these vaccines with an in-depth
      analysis of mortality data. Methods: This was a retrospective database
      analysis study. Details of the U.S. PMS reports (15 December 2020 to 19
      March 2021) of the three vaccines (Pfizer-BioNTech, Moderna, and Janssen
      Ad26.COV2.S) were retrieved from the U.S. Vaccine Adverse Event Reporting
      System (VAERS). A descriptive analysis was conducted to characterize the
      reported adverse events (AEs). A comparative (Pfizer-BioNTech vs. Moderna)
      analysis of mortality was conducted. The mean count ratio of death between
      the two vaccines was estimated using a negative binomial regression model
      adjusting for the measured confounders. Results: A total of 44,451 AE
      reports were retrieved (corresponding to 0.05% of the U.S. population who
      received at least one dose). The most commonly reported AEs were injection
      site reactions (30.4% of the reports), pain (reported in 26.7% of the
      reports), and headache (18.6% of the reports). Serious AEs were reported
      in only 14.6% of the reports with 4,108 hospitalizations. The total number
      of deaths was 1,919 with a mean count ratio of Moderna (n=997) vs.
      Pfizer-BioNTech (n=899) of 1.07 (95% confidence interval 0.86 to 1.33).
      Conclusions: The vast majority of PMS AEs in the U.S. were non-serious,
      and the number of serious AEs is very low given the total number of
      vaccinated U.S. population."
    authors:
      - name: Omar M Albalawi
        orcid: http://orcid.org/0000-0003-1017-260X
      - name: Maha I Alomran
        orcid: null
      - name: Ghada M Alsagri
        orcid: null
      - name: Turki A Althunian
        orcid: http://orcid.org/0000-0002-8030-7963
      - name: Thamir M Alshammari
        orcid: http://orcid.org/0000-0002-5630-2468
  comment:
    dislikes: 0
    thread: "8644373560"
    numReports: 0
    likes: 0
    id: "5459223044"
    createdAt: 2021-07-17T15:00:07
    author:
      username: pfwag
      about: ""
      name: pfwag
      isPowerContributor: false
      profileUrl: https://disqus.com/by/pfwag/
      url: ""
      location: ""
      id: "3367981"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      The VAERS reported death toll is now almost 11,000.  



      In 2010 the Department of Health and Human Services (HHS) awarded a million-dollar grant to the Harvard Medical School to investigate the accuracy of the reporting. Their report concluded that ‚ÄúFewer than one percent of vaccine adverse events are reported by the VAERS System.



      https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf



      As of July 16, according to VAERS, more people have died from the Covid-19 vaccinations than from all other vaccines in the previous 25 years combined. I wonder how many people have to die before the AEs become "serious"?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.07.10.21260304v1
  tweets:
    - created_at: Sat Jul 17 18:23:51 +0000 2021
      id: 1416463673514762200
      id_str: "1416463673514762240"
      text: |-
        üí¨ medRxiv comment on "Analyzing the U.S. Post-market..."

        "The VAERS reported death toll is now almost 11,000.  

        I‚Ä¶ https://t.co/l5BqSkXfeN
      truncated: true
      entities:
        urls:
          - url: https://t.co/l5BqSkXfeN
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 17 18:23:51 +0000 2021
      id: 1416463674231959600
      id_str: "1416463674231959562"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/Ilo6974SA6
      truncated: false
      entities:
        urls:
          - url: https://t.co/Ilo6974SA6
      in_reply_to_status_id: 1416463673514762200
      in_reply_to_status_id_str: "1416463673514762240"
- preprint:
    id: 142193
    metric: 132
    title: SARS-CoV-2 B.1.617.2 Delta variant emergence, replication and immune
      evasion
    url: https://api.rxivist.org/v1/papers/142193
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.08.443253v2
    doi: 10.1101/2021.05.08.443253
    category: microbiology
    first_posted: 2021-05-09
    abstract: The SARS-CoV-2 B.1.617.2 (Delta) variant was first identified in the
      state of Maharashtra in late 2020 and has spread throughout India,
      displacing the B.1.1.7 (Alpha) variant and other pre-existing lineages.
      Mathematical modelling indicates that the growth advantage is most likely
      explained by a combination of increased transmissibility and immune
      evasion. Indeed in vitro, the delta variant is less sensitive to
      neutralising antibodies in sera from recovered individuals, with higher
      replication efficiency as compared to the Alpha variant. In an analysis of
      vaccine breakthrough in over 100 healthcare workers across three centres
      in India, the Delta variant not only dominates vaccine-breakthrough
      infections with higher respiratory viral loads compared to non-delta
      infections (Ct value of 16.5 versus 19), but also generates greater
      transmission between HCW as compared to B.1.1.7 or B.1.617.1 (mean cluster
      size 1.1 versus 3.3 p=0.03). In vitro, the Delta variant shows 8 fold
      approximately reduced sensitivity to vaccine-elicited antibodies compared
      to wild type Wuhan-1 bearing D614G. Serum neutralising titres against the
      SARS-CoV-2 Delta variant were significantly lower in participants
      vaccinated with ChadOx-1 as compared to BNT162b2 (GMT 3372 versus 654,
      p<0001). These combined epidemiological and in vitro data indicate that
      the dominance of the Delta variant in India has been most likely driven by
      a combination of evasion of neutralising antibodies in previously infected
      individuals and increased virus infectivity. Whilst severe disease in
      fully vaccinated HCW was rare, breakthrough transmission clusters in
      hospitals associated with the Delta variant are concerning and indicate
      that infection control measures need continue in the post-vaccination era.
    authors:
      - name: Petra Mlcochova
      - name: Steven A Kemp
      - name: Mahesh Shanker Dhar
      - name: Guido Papa
      - name: Bo Meng
      - name: Swapnil Mishra
      - name: Charlie Whittaker
      - name: Thomas Mellan
      - name: Isabella Ferreira
      - name: Rawlings Datir
      - name: Dami Collier
      - name: Sujeet Singh
      - name: Rajesh Pandey
      - name: Kalaiarasan Ponnusamy
      - name: V S Radhakrishnan
      - name: Shantanu Sengupta
      - name: Jonathan Brown
      - name: Robin Marwal
      - name: V.S. Radhakrishnan
      - name: Niluka Goonawardne
      - name: Adam Abdullahi
      - name: Priti Devi
      - name: Chand Wattal
      - name: Daniela Caputo
      - name: Tom Peacock
      - name: Neeraj Goel
      - name: Raju Vaishya
      - name: Oscar Charles
      - name: Partha Chattopadhyay
      - name: Meenakshi Agarwal
      - name: Ambrish Satwik
      - name: INSACOG CONSORTIUM
      - name: NIHR Bioresource Collaboration
      - name: Antranik Mavousian
      - name: Jie Zhou
      - name: Joo Hyeon Lee
      - name: Jessica Bassi
      - name: Chiara Silacci-Fegni
      - name: Christian Saliba
      - name: Dora Pinto
      - name: Takashi Irie
      - name: Isao Yoshida
      - name: William L Hamilton
      - name: Kei Sato
      - name: Leo James
      - name: Davide Corti
      - name: Luca Piccoli
      - name: Samir Bhatt
      - name: Seth Flaxman
      - name: Wendy Barlcay
      - name: Partha Rakshit
      - name: Anurag Agrawal
      - name: Ravindra K Gupta
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sat Jul 17 20:15:35 +0000 2021
      id: 1416491795379363800
      id_str: "1416491795379363840"
      text: >-
        üî• bioRxiv Microbiology preprint by P. Mlcochova et al:


        "SARS-CoV-2 B.1.617.2 Delta variant emergence, replication‚Ä¶ https://t.co/D0aiA2m5MJ
      truncated: true
      entities:
        urls:
          - url: https://t.co/D0aiA2m5MJ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 0
    id: "5459214610"
    createdAt: 2021-07-17T14:51:24
    author:
      username: jayalanerdman
      about: ""
      name: Jay Alan Erdman
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jayalanerdman/
      url: ""
      location: ""
      id: "370790190"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      I agree with you, statistics is a valid science and I grant that you
      collected the data fairly.  But even if your numbers and methods are
      immaculate; the strongest conclusion you can reach is that there was a
      correlation between HCQ and survival in a small cohort over a year ago
      (btw, ventilation management is much different now).  If your paper had
      been submitted 15 months ago; the medical community would have been right
      in asking for some RCTs.  And in fact, there have been multiple well run
      trials done over the past year; none show any clear benefit.


      The big concern (and one that you may not be responsible for) is how some in the media have reported your results.  A commentator on a major network concluded his story with a shrug of the shoulders and said,  "See, Trump was right".  As we are seeing now with the mortality rates among the unvaccinated vs vaccinated; believing disinformation is a risk factor for hospitalization and death. I just heard a news source touting new evidence about Ivermectin.  Again, there have been multiple negative RCTs a few clicks away that are available to anyone.


      I ask you on this public forum;  do you believe, in light of current science, that HCQ is beneficial in the treatment of Covid-19?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Sat Jul 17 20:19:02 +0000 2021
      id: 1416492662580994000
      id_str: "1416492662580994052"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "I agree with you, statistics is a valid science and I gr‚Ä¶ https://t.co/JokIF2i02C
      truncated: true
      entities:
        urls:
          - url: https://t.co/JokIF2i02C
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 17 20:19:02 +0000 2021
      id: 1416492663323377700
      id_str: "1416492663323377664"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1416492662580994000
      in_reply_to_status_id_str: "1416492662580994052"
- preprint:
    id: "141058"
    doi: 10.1101/2021.05.03.21256556
    first_posted: 2021-05-06
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.03.21256556v1
    url: https://api.rxivist.org/v1/papers/141058
    title: Estimating vaccine efficacy against transmission via effect on viral load
    category: infectious-diseases
    abstract: Determining policies to end the SARS-CoV-2 pandemic will require an
      understanding of the efficacy and effectiveness (hereafter, efficacy) of
      vaccines. Beyond the efficacy against severe disease and symptomatic and
      asymptomatic infection, understanding vaccine efficacy against
      transmission will help model epidemic trajectory and determine appropriate
      control measures. Recent studies have proposed using random virologic
      testing in individual randomized controlled trials to improve estimation
      of vaccine efficacy against infection. We propose to further use the viral
      load measures from these tests to estimate efficacy against transmission.
      This estimation requires a model of the relationship between viral load
      and transmissibility and assumptions about the vaccine effect on
      transmission and the progress of the epidemic. We describe these key
      assumptions, potential violations of them, and solutions that can be
      implemented to mitigate these violations. Assessing these assumptions and
      implementing this random sampling, with viral load measures, will enable
      better estimation of the crucial measure of vaccine efficacy against
      transmission.
    authors:
      - name: Lee Kennedy-Shaffer
        orcid: http://orcid.org/0000-0001-7604-3638
      - name: Rebecca Kahn
        orcid: http://orcid.org/0000-0001-9511-6142
      - name: Marc Lipsitch
        orcid: http://orcid.org/0000-0003-1504-9213
  comment:
    dislikes: 0
    thread: "8508857455"
    numReports: 0
    likes: 0
    id: "5459185054"
    createdAt: 2021-07-17T14:18:34
    author:
      username: killshot
      about: ""
      name: killshot
      isPowerContributor: false
      profileUrl: https://disqus.com/by/killshot/
      url: ""
      location: ""
      id: "2384202"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Make sure there is some effort to randomize according to vitamin D
      status!  Otherwise the data is quite flawed and meaningless.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.03.21256556v1
  tweets:
    - created_at: Sat Jul 17 22:19:10 +0000 2021
      id: 1416522895107543000
      id_str: "1416522895107543042"
      text: >-
        üí¨ medRxiv comment on "Estimating vaccine efficacy ag..."


        "Make sure there is some effort to randomize according to‚Ä¶ https://t.co/blYMY9molS
      truncated: true
      entities:
        urls:
          - url: https://t.co/blYMY9molS
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 17 22:19:10 +0000 2021
      id: 1416522896885813200
      id_str: "1416522896885813253"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/asraWHSyyf
      truncated: false
      entities:
        urls:
          - url: https://t.co/asraWHSyyf
      in_reply_to_status_id: 1416522895107543000
      in_reply_to_status_id_str: "1416522895107543042"
- preprint:
    id: "131447"
    doi: 10.1101/2021.02.25.21252415
    first_posted: 2021-02-28
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.02.25.21252415v1
    url: https://api.rxivist.org/v1/papers/131447
    title: Interpreting vaccine efficacy trial results for infection and transmission
    category: epidemiology
    abstract: Randomized controlled trials (RCTs) have shown high efficacy of
      multiple vaccines against SARS-CoV-2 disease (COVID-19), and recent
      studies have shown the vaccines are also effective against infection.
      Evidence for the effect of each of these vaccines on ability to transmit
      the virus is also beginning to emerge. We describe an approach to estimate
      these vaccines' effects on viral positivity, a prevalence measure which
      under the reasonable assumption that vaccinated individuals who become
      infected are no more infectious than unvaccinated individuals forms a
      lower bound on efficacy against transmission. Specifically, we recommend
      separate analysis of positive tests triggered by symptoms (usually the
      primary outcome) and cross-sectional prevalence of positive tests obtained
      regardless of symptoms. The odds ratio of carriage for vaccine vs. placebo
      provides an unbiased estimate of vaccine effectiveness against viral
      positivity, under certain assumptions, and we show through simulations
      that likely departures from these assumptions will only modestly bias this
      estimate. Applying this approach to published data from the RCT of the
      Moderna vaccine, we estimate that one dose of vaccine reduces the
      potential for transmission by at least 61%, possibly considerably more. We
      describe how these approaches can be translated into observational studies
      of vaccine effectiveness.
    authors:
      - name: Marc Lipsitch
        orcid: http://orcid.org/0000-0003-1504-9213
      - name: Rebecca Kahn
        orcid: http://orcid.org/0000-0001-9511-6142
  comment:
    dislikes: 0
    thread: "8554817533"
    numReports: 0
    likes: 0
    id: "5459183896"
    createdAt: 2021-07-17T14:17:15
    author:
      username: killshot
      about: ""
      name: killshot
      isPowerContributor: false
      profileUrl: https://disqus.com/by/killshot/
      url: ""
      location: ""
      id: "2384202"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Unless "efficacy" and "positivity" are more clearly defined, this
      is meaningless.  Eg, using PCR amplification of 35 or greater for
      diagnosis then using an amplification of 24 for "transmission" would
      greatly favor vaccine-related prevention of transmission but would be faux
      data.  Also, unless there is randomization for vitamin D levels -- shown
      to impair virulence if > 36 ng/mL -- the data is also meaningless.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.02.25.21252415v2
  tweets:
    - created_at: Sun Jul 18 01:04:44 +0000 2021
      id: 1416564559863861200
      id_str: "1416564559863861255"
      text: >-
        üí¨ medRxiv comment on "Interpreting vaccine efficacy ..."


        "Unless "efficacy" and "positivity" are more clearly defi‚Ä¶ https://t.co/woRMUvGxiA
      truncated: true
      entities:
        urls:
          - url: https://t.co/woRMUvGxiA
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 18 01:04:44 +0000 2021
      id: 1416564560782315500
      id_str: "1416564560782315520"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/bO5QmOLOny
      truncated: false
      entities:
        urls:
          - url: https://t.co/bO5QmOLOny
      in_reply_to_status_id: 1416564559863861200
      in_reply_to_status_id_str: "1416564559863861255"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5459169725"
    createdAt: 2021-07-17T14:00:49
    author:
      username: killshot
      about: ""
      name: killshot
      isPowerContributor: false
      profileUrl: https://disqus.com/by/killshot/
      url: ""
      location: ""
      id: "2384202"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Agree...but some of us informed practitioners were saying this long
      ago.  Do you have a reference re the "those that recovered from COVID were
      at somewhat higher risk of complications from the shot."?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Sun Jul 18 12:29:58 +0000 2021
      id: 1416737004113600500
      id_str: "1416737004113600525"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "Agree...but some of us informed practitioners were sayin‚Ä¶ https://t.co/CuZdO9gP6j
      truncated: true
      entities:
        urls:
          - url: https://t.co/CuZdO9gP6j
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 18 12:29:58 +0000 2021
      id: 1416737004965044200
      id_str: "1416737004965044224"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1416737004113600500
      in_reply_to_status_id_str: "1416737004113600525"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 0
    id: "5459166879"
    createdAt: 2021-07-17T13:57:35
    author:
      username: jayalanerdman
      about: ""
      name: Jay Alan Erdman
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jayalanerdman/
      url: ""
      location: ""
      id: "370790190"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Please explain a 290% reduction of mortality.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Sun Jul 18 14:17:06 +0000 2021
      id: 1416763967167402000
      id_str: "1416763967167401987"
      text: |-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."

        "Please explain a 290% reduction of mortality."

        https://t.co/pwOlr48mC5
      truncated: false
      entities:
        urls:
          - url: https://t.co/pwOlr48mC5
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 18 14:17:06 +0000 2021
      id: 1416763968077680600
      id_str: "1416763968077680641"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1416763967167402000
      in_reply_to_status_id_str: "1416763967167401987"
- preprint:
    id: "124863"
    doi: 10.1101/2021.01.05.21249310
    first_posted: 2021-01-09
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.01.05.21249310v1
    url: https://api.rxivist.org/v1/papers/124863
    title: "Ivermectin as a potential treatment for mild to moderate COVID-19: A
      double blind randomized placebo-controlled trial"
    category: infectious-diseases
    abstract: >-
      ObjectiveIvermectin has been suggested as a treatment for COVID-19.This
      randomised control trial was conducted to test the efficacy of Ivermectin
      in the treatment of mild and moderate COVID-19.


      DesignParallel, double blind, randomised, placebo controlled trial Setting: A tertiary care dedicated COVID-19 hospital in Bihar, India


      ParticipantsAdult patients (> 18 years) admitted with mild to moderate COVID 19 disease (saturation > 90% on room air, respiratory rate < 30 and no features of shock) with no contraindications to ivermectin and willing to participate in the study


      InterventionPatients in the intervention arm were given ivermectin 12 mg on day 1 and day 2 of admission. Patients in the placebo arm were given identical looking placebo tablets. Rest of the treatment was continued as per the existing protocol and the clinical judgment of the treating teams.


      Outcome MeasuresThe primary outcome measure was a negative RT-PCR test for SARS-CoV-2 on day 6 of admission. The secondary outcome measures were symptom status on day 6, discharge status on day 10, admission to ICU, need for invasive mechanical ventilation and in-hospital mortality.


      ResultsA total of 115 patients were enrolled for the study of which 112 were included in the final analysis. Of them, 55 were randomised to the intervention arm while 57 were randomised to the placebo arm. There was no significant difference in the baseline characteristics of the two arms. There was no significant difference in the primary outcome, i.e. negative RT-PCR status on day 6 between the two groups. Similarly, there was no significant difference between the two groups in most of the secondary outcome measures, viz. symptom status on day 6, discharge status on day 10, admission to ICU, and need for invasive mechanical ventilation. However, while there was no in-hospital mortality in the intervention arm, there were 4 deaths in the placebo arm. As a result, all patients in the intervention arm (n=56) were successfully discharged as compared to 93.1% (n=54/58) in the placebo arm (RR 1.1, 95% CI 1.0 to 1.2, p=0.019).


      ConclusionThere was no difference in the primary outcome i.e. negative RT-PCR status on day 6 of admission with the use of ivermectin. However, a significantly higher proportion of patients were discharged alive from the hospital when they received ivermectin.


      Strengths and Limitations of the StudyO_LIThis study was randomised and double blind, thereby minimizing the chance of bias.

      C_LIO_LIAll outcome measures except symptom status on day 6 were objective and placebo control was used for comparison.

      C_LIO_LIOnly single repeat RT-PCR was done. So median time to viral clearance in the two groups could not be calculated.

      C_LIO_LISevere cases were not included in the study.

      C_LI
    authors:
      - name: Ravikirti
        orcid: null
      - name: Ranjini Roy
        orcid: null
      - name: Chandrima Pattadar
        orcid: null
      - name: Rishav Raj
        orcid: null
      - name: Neeraj Agarwal
        orcid: null
      - name: Bijit Biswas
        orcid: null
      - name: Pramod Kumar Majhi
        orcid: null
      - name: Deependra Kumar Rai
        orcid: null
      - name: Shyama
        orcid: null
      - name: Anjani Kumar
        orcid: null
      - name: Asim Sarfaraz
        orcid: null
  comment:
    dislikes: 0
    thread: "8349213864"
    numReports: 0
    likes: 0
    id: "5458970302"
    createdAt: 2021-07-17T08:53:42
    author:
      username: disqus_z3JbLWlo5D
      about: ""
      name: Le Bon
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_z3JbLWlo5D/
      url: ""
      location: ""
      id: "54104695"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      It is in the article. You just had to read.

      Mild: No evidence of breathlessness or Hypoxia (normal saturation)

      Moderate: Breathlessness and/or hypoxia (saturation 90-94% on room air), respiratory rate of 24 or

      more and no features of severe disease
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.01.05.21249310v1
  tweets:
    - created_at: Sun Jul 18 16:30:10 +0000 2021
      id: 1416797452913492000
      id_str: "1416797452913491972"
      text: |-
        üí¨ medRxiv comment on "Ivermectin as a potential trea..."

        "It is in the article. You just had to read.
        Mild: No evi‚Ä¶ https://t.co/NladFG0Hpc
      truncated: true
      entities:
        urls:
          - url: https://t.co/NladFG0Hpc
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 18 16:30:10 +0000 2021
      id: 1416797453815357400
      id_str: "1416797453815357446"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/DjN3725s7t
      truncated: false
      entities:
        urls:
          - url: https://t.co/DjN3725s7t
      in_reply_to_status_id: 1416797452913492000
      in_reply_to_status_id_str: "1416797452913491972"
- preprint:
    id: "130048"
    doi: 10.1101/2021.03.05.21252960
    first_posted: 2021-03-08
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.03.05.21252960v1
    url: https://api.rxivist.org/v1/papers/130048
    title: "SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to
      fibrinolysis: Implications for microclot formation in COVID-19"
    category: infectious-diseases
    abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) -induced
      infection, the cause of coronavirus disease 2019 (COVID-19), is
      characterized by unprecedented clinical pathologies. One of the most
      important pathologies, is hypercoagulation and microclots in the lungs of
      patients. Here we study the effect of isolated SARS-CoV-2 spike protein S1
      subunit as potential inflammagen sui generis. Using scanning electron and
      fluorescence microscopy as well as mass spectrometry, we investigate the
      potential of this inflammagen to interact with platelets and fibrin(ogen)
      directly to cause blood hypercoagulation. Using platelet poor plasma
      (PPP), we show that spike protein may interfere with blood flow. Mass
      spectrometry also showed that when spike protein S1 is added to healthy
      PPP, it results in structural changes to {beta} and {gamma} fibrin(ogen),
      complement 3, and prothrombin. These proteins were substantially resistant
      to trypsinization, in the presence of spike protein S1. Here we suggest
      that, in part, the presence of spike protein in circulation may contribute
      to the hypercoagulation in COVID-19 positive patients and may cause
      substantial impairment of fibrinolysis. Such lytic impairment may result
      in the persistent large microclots we have noted here and previously in
      plasma samples of COVID-19 patients. This observation may have important
      clinical relevance in the treatment of hypercoagulability in COVID-19
      patients.
    authors:
      - name: Lize M Grobbelaar
        orcid: null
      - name: Chantelle Venter
        orcid: null
      - name: Mare Vlok
        orcid: null
      - name: Malebogo Ngoepe
        orcid: null
      - name: Gert J Laubscher
        orcid: null
      - name: Petrus J Lourens
        orcid: null
      - name: Janami Steenkamp
        orcid: null
      - name: Douglas B. Kell
        orcid: http://orcid.org/0000-0001-5838-7963
      - name: Etheresia Pretorius
        orcid: http://orcid.org/0000-0002-9108-2384
  comment:
    dislikes: 0
    thread: "8428794041"
    numReports: 0
    likes: 0
    id: "5457784323"
    createdAt: 2021-07-16T09:48:28
    author:
      username: disqus_0bKIt9q5Jq
      about: ""
      name: ≈†afo
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_0bKIt9q5Jq/
      url: ""
      location: Nitra
      id: "75414309"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "Question: Do patients who have overcome the disease have the
      mentioned S-protein S1 in the body? Or only vaccinated people have
      S-protein in their body!"
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.03.05.21252960v1
  tweets:
    - created_at: Sun Jul 18 18:24:24 +0000 2021
      id: 1416826203307135000
      id_str: "1416826203307134982"
      text: >-
        üí¨ medRxiv comment on "SARS-CoV-2 spike protein S1 in..."


        "Question: Do patients who have overcome the disease have‚Ä¶ https://t.co/DZynnhN1xq
      truncated: true
      entities:
        urls:
          - url: https://t.co/DZynnhN1xq
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 18 18:24:25 +0000 2021
      id: 1416826204217356300
      id_str: "1416826204217356289"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/YphzEME29c
      truncated: false
      entities:
        urls:
          - url: https://t.co/YphzEME29c
      in_reply_to_status_id: 1416826203307135000
      in_reply_to_status_id_str: "1416826203307134982"
- preprint:
    id: 148164
    metric: 7
    title: Clonally expanded virus-specific CD8 T cells acquire diverse
      transcriptional phenotypes during acute, chronic, and latent infections
    url: https://api.rxivist.org/v1/papers/148164
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.29.450285v1
    doi: 10.1101/2021.06.29.450285
    category: immunology
    first_posted: 2021-06-30
    abstract: CD8+ T cells play a crucial role in the control and resolution of
      viral infections and can adopt a wide range of phenotypes and effector
      functions depending on the inflammatory context and the duration and
      extent of antigen exposure. Similarly, viral infections can exert diverse
      selective pressures on populations of clonally related T cells. Technical
      limitations have nevertheless made it challenging to investigate the
      relationship between clonal selection and transcriptional phenotypes of
      virus-specific T cells. We therefore performed single-cell T cell receptor
      (TCR) repertoire and transcriptome sequencing of virus-specific CD8 T
      cells in murine models of acute, chronic and latent infection. We observed
      clear infection-specific populations corresponding to memory, effector,
      exhausted, and inflationary phenotypes. We further uncovered a
      mouse-specific and polyclonal T cell response, despite all T cells sharing
      specificity to a single viral epitope, which was accompanied by
      stereotypic TCR germline gene usage in all three infection types.
      Persistent antigen exposure during chronic and latent viral infections
      resulted in a higher proportion of clonally expanded T cells relative to
      acute infection. We furthermore observed a relationship between
      transcriptional heterogeneity and clonal expansion for all three
      infections, with highly expanded clones having distinct transcriptional
      phenotypes relative to lowly expanded clones. Finally, we developed and
      utilized a bioinformatic pipeline integrating pseudotime and clonality,
      termed Clonotyme, to further support a model in which expanded
      virus-specific CD8+ T cells adopt heterogenic, yet preferentially,
      effector-like phenotypes. Together our work relates clonal selection to
      gene expression in the context of viral infection and further provides a
      dataset and accompanying software for the immunological community.
    authors:
      - name: Raphael Kuhn
      - name: Ioana Sandu
      - name: Andreas Agrafiotis
      - name: Kai-Lin Hong
      - name: Daniel Neumeier
      - name: Doron Merkler
      - name: Annette Oxenius
      - name: Sai T. Reddy
      - name: Alexander Yermanos
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sun Jul 18 20:15:42 +0000 2021
      id: 1416854212521173000
      id_str: "1416854212521172997"
      text: >-
        üî• bioRxiv Immunology preprint by R. Kuhn et al:


        "Clonally expanded virus-specific CD8 T cells acquire diverse tran‚Ä¶ https://t.co/pE3tDBKmvK
      truncated: true
      entities:
        urls:
          - url: https://t.co/pE3tDBKmvK
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "126910"
    doi: 10.1101/2021.01.23.21250327
    first_posted: 2021-01-27
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.01.23.21250327v1
    url: https://api.rxivist.org/v1/papers/126910
    title: "Diurnal brain temperature rhythms and mortality after brain injury: a
      prospective and retrospective cohort study"
    category: intensive-care-and-critical-care-medicine
    abstract: "Objective: To determine the clinical relevance of brain temperature
      (TBr) variation in patients after traumatic brain injury (TBI). Design:
      Cohort study with prospective (healthy participant) and retrospective (TBI
      patient) arms. Setting: Single neuroimaging site in the UK (prospective
      arm); intensive care sites contributing to the Collaborative European
      NeuroTrauma Effectiveness Research in TBI (CENTER-TBI) High Resolution ICU
      (HR ICU) Sub-Study (retrospective arm). Participants: 40 healthy adults
      aged 20-40 years recruited for non-invasive brain thermometry and all
      patients up to May 2020 that had TBr measured directly and were not
      subjected to Targeted Temperature Management (TTM). Main outcome measures:
      A diurnal change in TBr (healthy participants); death in intensive care
      (patients). Results: In healthy participants, mean TBr (38.5 SD
      0.4{degrees}C) was higher than oral temperature (36.0 SD 0.5{degrees}C),
      and 0.36{degrees}C higher in luteal females relative to follicular females
      and males (95% confidence interval 0.17 to 0.55, P=0.0006 and 0.23 to
      0.49, P<0.0001, respectively). TBr increased with age, most notably in
      deep brain regions (0.6{degrees}C over 20 years; 0.11 to 1.07, P=0.0002).
      The mean maximal spatial TBr range was 2.41 (SD 0.46){degrees}C, with
      highest temperatures in the thalamus. TBr varied significantly by time of
      day, especially in deep brain regions (0.86{degrees}C ; 0.37 to 1.26,
      P=0.0001), and was lowest in the late evening. Diurnal TBr in cortical
      white matter across participants ranged from 37.0 to 40.3{degrees}C. In
      TBI patients (n=114), mean TBr (38.5 SD 0.8{degrees}C) was significantly
      higher than body temperature (TBo 37.5 SD 0.5{degrees}C ; P<0.0001) and
      ranged from 32.6 to 42.3{degrees}C. Only 25/110 patients displayed a
      diurnal temperature rhythm; TBr amplitude was reduced in older patients
      (P=0.018), and 25/113 patients died in intensive care. Lack of a daily TBr
      rhythm, or an age increase of 10 years, increased the odds of death
      12-fold and 11-fold, respectively (OR for death with rhythm 0.09; 0.01 to
      0.84, P=0.035 and for death with ageing by 1 year 1.10; 1.05 to 1.16,
      P=0.0002). Mean TBr was positively associated with survival (OR for death
      0.45 for 1{degrees}C increase; 0.21 to 0.96, P=0.040). Conclusions:
      Healthy TBr exceeds TBo and varies by sex, age, menstrual cycle, brain
      region, and time of day. Our 4-dimensional reference resource for healthy
      TBr can guide interpretation of TBr data in multiple clinical settings.
      Daily temperature variation is frequently disrupted or absent in TBI
      patients, in which TBr variation is of greater prognostic use than
      absolute TBr. Older TBI patients lacking a daily TBr rhythm are at
      greatest risk of death in intensive care. Appropriately controlled trials
      are needed to confirm the predictive power of TBr rhythmicity in relation
      to patient outcome, as well as the clinical utility of TTM protocols in
      brain-injured patients. Registration: UK CRN NIHR CPMS 42644;
      ClinicalTrials.gov number, NCT02210221."
    authors:
      - name: Nina Marie Rzechorzek
        orcid: http://orcid.org/0000-0003-3209-5019
      - name: Michael J Thrippleton
        orcid: http://orcid.org/0000-0001-7858-9917
      - name: Francesca M Chappell
        orcid: http://orcid.org/0000-0002-7742-1757
      - name: Grant Mair
        orcid: http://orcid.org/0000-0003-2189-443X
      - name: Ari Ercole
        orcid: http://orcid.org/0000-0001-8350-8093
      - name: Manuel Cabeleira
        orcid: http://orcid.org/0000-0002-1710-6544
      - name: The CENTER-TBI High Resolution ICU (HR ICU) Sub-Study Participants and
          Investigators
        orcid: null
      - name: Jonathan Rhodes
        orcid: http://orcid.org/0000-0003-2015-4579
      - name: Ian Marshall
        orcid: http://orcid.org/0000-0003-4445-1551
      - name: John S O'Neill
        orcid: http://orcid.org/0000-0003-2204-6096
  comment:
    dislikes: 0
    thread: "8373320750"
    numReports: 0
    likes: 0
    id: "5457773268"
    createdAt: 2021-07-16T09:27:55
    author:
      username: disqus_5l1M2d3eUR
      about: ""
      name: ÈÉ≠ÈÄ∏ÊÅ©
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_5l1M2d3eUR/
      url: ""
      location: ""
      id: "372410789"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      There's recently published article presenting the application of brain
      temperature rhythm in outcome prediction after traumatic brain injury.
      This paper should be cited.

      "Kuo, L.-T.; Lu, H.-Y.; Huang, A.P.-H. Prognostic Value of Circadian Rhythm of Brain Temperature in Traumatic Brain Injury. J. Pers. Med. 2021, 11, 620. https://doi.org/10.3390/jpm11070620"
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.01.23.21250327v1
  tweets:
    - created_at: Sun Jul 18 20:19:01 +0000 2021
      id: 1416855046365589500
      id_str: "1416855046365589505"
      text: >-
        üí¨ medRxiv comment on "Diurnal brain temperature rhyt..."


        "There's recently published article presenting the applic‚Ä¶ https://t.co/QfQJMYoAnE
      truncated: true
      entities:
        urls:
          - url: https://t.co/QfQJMYoAnE
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 18 20:19:01 +0000 2021
      id: 1416855047510573000
      id_str: "1416855047510573057"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/nCc58NxTXQ
      truncated: false
      entities:
        urls:
          - url: https://t.co/nCc58NxTXQ
      in_reply_to_status_id: 1416855046365589500
      in_reply_to_status_id_str: "1416855046365589505"
- preprint:
    id: "148746"
    doi: 10.1101/2021.06.28.21258780
    first_posted: 2021-07-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.28.21258780v1
    url: https://api.rxivist.org/v1/papers/148746
    title: Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine
      breakthrough infections
    category: epidemiology
    abstract: >-
      ImportanceVaccine breakthrough by an emergent SARS-CoV-2 variant poses a
      great risk to global public health.


      ObjectiveTo determine the SARS-CoV-2 variant responsible for 6 cases of vaccine breakthrough.


      DesignNasopharyngeal swabs from suspected vaccine breakthrough cases were tested for SARS-CoV-2 by qPCR for Wuhan-Hu1 and Alpha variant. Positive samples were then sequenced by Swift Normalase Amplicon Panels to determine the causal variant.


      SettingTransmission event occurred at events surrounding a wedding outside of Houston, TX. Two patients from India, likely transmitted the Delta variant to other guests.


      ParticipantsFollowing a positive SARS-CoV-2 qPCR test at a third-party site, six fully vaccinated patients were investigated. Three males and three females ranged from 53 to 69 years old. One patient suffered from diabetes while three others were classified as overweight. No significant other comorbidities were identified. None of the patients had a history of failed vaccination.


      Key PointsO_ST_ABSQuestionC_ST_ABSWhich SARS-CoV-2 variant is responsible for 6 cases of vaccine breakthrough, one interventional monoclonal antibody treatment, and one death?


      FindingsViral sequencing revealed 6 vaccinated patients were infected with the Delta SARS-CoV-2 variant. With no histories of vaccine breakthrough, this suggests Delta variant may possess immune evasion in patients that received the Pfizer BNT162b2, Moderna mRNA-1273, and Covaxin BBV152.


      MeaningDelta variant may pose the highest risk out of any currently circulating SARS-CoV-2 variants, with increased transmissibility over Alpha variant and possible vaccine breakthrough.
    authors:
      - name: Timothy Farinholt
        orcid: http://orcid.org/0000-0003-1889-3102
      - name: Harshavardhan Doddapaneni
        orcid: http://orcid.org/0000-0002-2433-633X
      - name: Xiang Qin
        orcid: null
      - name: Vipin Menon
        orcid: http://orcid.org/0000-0001-7404-678X
      - name: Qingchang Meng
        orcid: null
      - name: Ginger Metcalf
        orcid: null
      - name: Hsu Chao
        orcid: null
      - name: Marie-Claude Gingras
        orcid: http://orcid.org/0000-0003-2570-6360
      - name: Paige Farinholt
        orcid: null
      - name: Charu Agrawal
        orcid: null
      - name: Donna Muzny
        orcid: http://orcid.org/0000-0002-3055-0359
      - name: Pedro A. Piedra
        orcid: http://orcid.org/0000-0002-5839-0879
      - name: Richard A. Gibbs
        orcid: null
      - name: Joseph Petrosino
        orcid: http://orcid.org/0000-0002-4046-6898
  comment:
    dislikes: 0
    thread: "8630584355"
    numReports: 0
    likes: 0
    id: "5457759912"
    createdAt: 2021-07-16T09:03:00
    author:
      username: disqus_XeOjqtDbCX
      about: ""
      name: Ashish Agrawal
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_XeOjqtDbCX/
      url: http://www.theindiantalks.com/
      location: Delhi
      id: "93450579"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      I am myself fully vaccinated with Covaxin with no side effects and have an
      IGG antibody score of 150.00 which is apparently enough as per many
      studies. 

      While vaccinating with Inactivated virus vaccines one should maintain proper isolation from those who're not vaccinated with it. I don't think travelling between the dose 1 and dose 2+ 14 days was a good idea. Vaccines work but they take time in changing environment
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.28.21258780v1
  tweets:
    - created_at: Sun Jul 18 22:19:06 +0000 2021
      id: 1416885263859699700
      id_str: "1416885263859699712"
      text: >-
        üí¨ medRxiv comment on "Transmission event of SARS-CoV..."


        "I am myself fully vaccinated with Covaxin with no side e‚Ä¶ https://t.co/y53tBJhOJM
      truncated: true
      entities:
        urls:
          - url: https://t.co/y53tBJhOJM
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 18 22:19:06 +0000 2021
      id: 1416885264702656500
      id_str: "1416885264702656514"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/ifdUoU85Ao
      truncated: false
      entities:
        urls:
          - url: https://t.co/ifdUoU85Ao
      in_reply_to_status_id: 1416885263859699700
      in_reply_to_status_id_str: "1416885263859699712"
- preprint:
    id: "133087"
    doi: 10.1101/2021.03.11.21253356
    first_posted: 2021-03-12
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.03.11.21253356v1
    url: https://api.rxivist.org/v1/papers/133087
    title: Optimal vaccination strategies for COVID-19 based on dynamical social
      networks with real-time updating
    category: infectious-diseases
    abstract: Vaccination strategy is crucial in fighting against the COVID-19
      pandemic. Since the supply is limited, contact network-based interventions
      can be most powerful to set an optimal strategy by identifying high-risk
      individuals or communities. However, due to the high dimension, only
      partial and noisy network information can be available in practice,
      especially for dynamical systems where the contact networks are highly
      time-variant. Furthermore, numerous mutations of SARS-CoV-2 impact
      considerably the current infectious probability, requiring real-time
      network updating algorithms. In this study, we propose a sequential
      network updating approach based on data assimilation techniques to combine
      different sources of temporal information. We then prioritise the
      individuals with high-degree or high-centrality, obtained from the
      assimilated networks, for vaccination. The assimilation-based approach is
      compared with the standard method (based on partially observed networks)
      and a random selection strategy in terms of vaccination effectiveness in a
      SIR model. The numerical comparison is first carried out using real-world
      face-to-face dynamical networks collected in a high school, following by
      sequential multi-layer networks, generated relying on the Barabasi-Albert
      model emulating the department of Computing at Imperial College London in
      the UK as an example.
    authors:
      - name: Sibo Cheng
        orcid: http://orcid.org/0000-0002-8707-2589
      - name: Rossella Arcucci
        orcid: http://orcid.org/0000-0002-9471-0585
      - name: Christopher Pain
        orcid: http://orcid.org/0000-0003-4194-2590
      - name: Yike Guo
        orcid: http://orcid.org/0000-0002-3075-2161
  comment:
    dislikes: 0
    thread: "8434540520"
    numReports: 0
    likes: 0
    id: "5457652794"
    createdAt: 2021-07-16T05:35:56
    author:
      username: altamirgomesbispojunior
      about: ""
      name: Altamir Gomes Bispo Junior
      isPowerContributor: false
      profileUrl: https://disqus.com/by/altamirgomesbispojunior/
      url: ""
      location: ""
      id: "59773983"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Hi, I'm one of the authors of [49].



      I will make the following suggestions:



      1- I see that medical doctors in several countries (India, China, South Korea etc.) are repurposing drugs and nutraceuticals and they are making huge strides on COVID-19 treatment guidelines. It will for sure be interesting to inform the general public about these possibilities, even if these possibilities are not currently acknowledged by organizations such as the WHO.



      2- Many of the current COVID-19 vaccines are not sterilizing and thus cannot block transmission efficiently. Virus spread may vary due to different vaccine platforms.



      3- Vaccines for respiratory viruses are known to have lower immunogenicity on older age cohorts and to have also a vanishing protection against infection and symptomatic infection. This could be added to the model.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.03.11.21253356v1
  tweets:
    - created_at: Mon Jul 19 01:03:17 +0000 2021
      id: 1416926583760330800
      id_str: "1416926583760330752"
      text: |-
        üí¨ medRxiv comment on "Optimal vaccination strategies..."

        "Hi, I'm one of the authors of [49].

        I will make the fol‚Ä¶ https://t.co/Zv3WdmwUG8
      truncated: true
      entities:
        urls:
          - url: https://t.co/Zv3WdmwUG8
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 19 01:03:17 +0000 2021
      id: 1416926584670462000
      id_str: "1416926584670461961"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/hKGoxg98Q8
      truncated: false
      entities:
        urls:
          - url: https://t.co/hKGoxg98Q8
      in_reply_to_status_id: 1416926583760330800
      in_reply_to_status_id_str: "1416926583760330752"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 0
    id: "5457574655"
    createdAt: 2021-07-16T03:17:39
    author:
      username: rusbowden
      about: ""
      name: rusbowden
      isPowerContributor: false
      profileUrl: https://disqus.com/by/rusbowden/
      url: ""
      location: ""
      id: "10245173"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: This study proves you wrong.  Period. It's not me. I'm the
      messenger. What you read is a quote from researchers. Your response goes
      sideways in two serious ways. First, you include no research to support
      your point, only some vague reference that you read or heard of something
      somewhere and need us to know that you know something we do not. Second,
      you do not address the study itself. You must look at the study before you
      can give an intelligent response. That's what I posted a link to and
      quoted, an actual research paper by scientists. That's what you are
      responding to.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon Jul 19 12:32:00 +0000 2021
      id: 1417099906712539100
      id_str: "1417099906712539140"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "This study proves you wrong.  Period. It's not me. I'm t‚Ä¶ https://t.co/h565Sg09Lu
      truncated: true
      entities:
        urls:
          - url: https://t.co/h565Sg09Lu
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 19 12:32:01 +0000 2021
      id: 1417099907530477600
      id_str: "1417099907530477571"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1417099906712539100
      in_reply_to_status_id_str: "1417099906712539140"
- preprint:
    id: "133737"
    doi: 10.1101/2021.03.14.21253544
    first_posted: 2021-03-17
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.03.14.21253544v1
    url: https://api.rxivist.org/v1/papers/133737
    title: "Vaccine escape in a heterogeneous population: insights for SARS-CoV-2
      from a simple model"
    category: epidemiology
    abstract: As a counter measure to the SARS-CoV-2 pandemic there has been swift
      development and clinical trial assessment of candidate vaccines, with
      subsequent deployment as part of mass vaccination campaigns. However, the
      SARS-CoV-2 virus has demonstrated the ability to mutate and develop
      variants, which can modify epidemiological properties and potentially also
      the effectiveness of vaccines. The widespread deployment of highly
      effective vaccines may rapidly exert selection pressure on the SARS-CoV-2
      virus directed towards mutations that escape the vaccine induced immune
      response. This is particularly concerning whilst infection is widespread.
      By developing and analysing a mathematical model of two population
      groupings with differing vulnerability and contact rates, we explore the
      impact of the deployment of vaccine amongst the population on R, cases,
      disease abundance and vaccine escape pressure. The results from this model
      illustrate two insights (i) vaccination aimed at reducing prevalence could
      be more effective at reducing disease than directly vaccinating the
      vulnerable; (ii) the highest risk for vaccine escape can occur at
      intermediate levels of vaccination. This work demonstrates a key principle
      that the careful targeting of vaccines towards particular population
      groups could reduce disease as much as possible whilst limiting the risk
      of vaccine escape.
    authors:
      - name: Julia R Gog
        orcid: http://orcid.org/0000-0003-1240-7214
      - name: Edward M Hill
        orcid: http://orcid.org/0000-0002-2992-2004
      - name: Leon Danon
        orcid: http://orcid.org/0000-0002-7076-1871
      - name: Robin N Thompson
        orcid: http://orcid.org/0000-0001-8545-5212
  comment:
    dislikes: 0
    thread: "8455822264"
    numReports: 0
    likes: 0
    id: "5461402704"
    createdAt: 2021-07-19T14:49:56
    author:
      username: juliargog
      about: ""
      name: Julia R. Gog
      isPowerContributor: false
      profileUrl: https://disqus.com/by/juliargog/
      url: ""
      location: ""
      id: "372548794"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      A final version is now published at Royal Society Open Science:

      https://doi.org/10.1098/rsos.210530



      (Since medRxiv V2: Expanded detail in the methods section, new section in SI on sensitivity to higher d, fixed typos and minor changes for clarity throughout)
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.03.14.21253544v2
  tweets:
    - created_at: Mon Jul 19 16:31:43 +0000 2021
      id: 1417160231747002400
      id_str: "1417160231747002374"
      text: >-
        üí¨ medRxiv comment on "Vaccine escape in a heterogene..."


        "A final version is now published at Royal Society Open S‚Ä¶ https://t.co/v2DLkrOCKx
      truncated: true
      entities:
        urls:
          - url: https://t.co/v2DLkrOCKx
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 19 16:31:43 +0000 2021
      id: 1417160232762024000
      id_str: "1417160232762023949"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/ReKZs1I4wV
      truncated: false
      entities:
        urls:
          - url: https://t.co/ReKZs1I4wV
      in_reply_to_status_id: 1417160231747002400
      in_reply_to_status_id_str: "1417160231747002374"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 0
    id: "5461214833"
    createdAt: 2021-07-19T11:37:13
    author:
      username: trashpandax
      about: ""
      name: TrashPanda-x
      isPowerContributor: false
      profileUrl: https://disqus.com/by/trashpandax/
      url: ""
      location: ""
      id: "355694689"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: That's not what that study says.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon Jul 19 18:25:53 +0000 2021
      id: 1417188962469298200
      id_str: "1417188962469298176"
      text: |-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."

        "That's not what that study says."

        https://t.co/UxDCA69tQL
      truncated: false
      entities:
        urls:
          - url: https://t.co/UxDCA69tQL
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 19 18:25:53 +0000 2021
      id: 1417188963232649200
      id_str: "1417188963232649222"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1417188962469298200
      in_reply_to_status_id_str: "1417188962469298176"
- preprint:
    id: 133905
    metric: 14
    title: Geographic Confounding in Genome-Wide Association Studies
    url: https://api.rxivist.org/v1/papers/133905
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.03.18.435971v1
    doi: 10.1101/2021.03.18.435971
    category: genetics
    first_posted: 2021-03-18
    abstract: Gene-environment correlations can bias associations between genetic
      variants and complex traits in genome-wide association studies (GWASs).
      Here, we control for geographic sources of gene-environment correlation in
      GWASs on 56 complex traits (N=69,772-271,457). Controlling for geographic
      region significantly decreases heritability signals for SES-related
      traits, most strongly for educational attainment and income, indicating
      that socio-economic differences between regions induce gene-environment
      correlations that become part of the polygenic signal. For most other
      complex traits investigated, genetic correlations with educational
      attainment and income are significantly reduced, most significantly for
      traits related to BMI, sedentary behavior, and substance use. Controlling
      for current address has greater impact on the polygenic signal than birth
      place, suggesting both active and passive sources of gene-environment
      correlations. Our results show that societal sources of social
      stratification that extend beyond families introduce regional-level
      gene-environment correlations that affect GWAS results.
    authors:
      - name: Abdel Abdellaoui
      - name: Karin J.H. Verweij
      - name: Michel G Nivard
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Mon Jul 19 20:16:55 +0000 2021
      id: 1417216907372028000
      id_str: "1417216907372027907"
      text: >-
        üî• bioRxiv Genetics preprint by A. Abdellaoui et al:


        "Geographic Confounding in Genome-Wide Association Studies"‚Ä¶ https://t.co/v7TcoohSCF
      truncated: true
      entities:
        urls:
          - url: https://t.co/v7TcoohSCF
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "139315"
    doi: 10.1101/2021.04.20.21255806
    first_posted: 2021-04-23
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.04.20.21255806v1
    url: https://api.rxivist.org/v1/papers/139315
    title: Cerebral venous sinus thrombosis (CVST) is not significantly linked to
      COVID-19 vaccines or non-COVID vaccines in a large multi-state US health
      system
    category: public-and-global-health
    abstract: "Cerebral venous sinus thrombosis (CVST) has been reported in a small
      number of individuals who have received the mRNA vaccines or the
      adenoviral vector vaccines for COVID-19 in the US and Europe. Continued
      pharmacovigilance is integral to mitigating the risk of rare adverse
      events that clinical trials are underpowered to detect, however, these
      anecdotal reports have led to the pause or withdrawal of some vaccines in
      many jurisdictions and exacerbated vaccine hesitancy at a critical moment
      in the fight against the COVID-19 pandemic. We investigated the
      frequencies of CVST seen among individuals who received FDA-authorized
      COVID-19 vaccines from Pfizer-BioNTech (n = 94,818 doses), Moderna (n =
      36,350 doses) and Johnson & Johnson - J&J (n = 1,745 doses), and among
      individuals receiving one of 10 FDA-approved non-COVID-19 vaccines (n =
      771,805 doses). Comparing the incidence rates of CVST in 30-day time
      windows before and after vaccination, we found no statistically
      significant differences for the COVID-19 vaccines or any other vaccines
      studied in this population. In total, we observed 3 cases of CVST within
      the 30 days following Pfizer-BioNTech vaccination (2 females, 1 male; Ages
      (years): [79, 80, 84]), including one individual with a prior history of
      thrombosis and another individual with recent trauma in the past 30 days.
      We did not observe any cases of CVST among the patients receiving Moderna
      or J&J vaccines in this study population. We further found the baseline
      CVST incidence in the study population between 2017 and 2021 to be 45 to
      98 per million patient years. Overall, this real-world evidence-based
      study highlights that CVST is rare and is not significantly associated
      with COVID-19 vaccination. In addition, there is a need for a concerted
      international effort to monitor EHR data across diverse patient
      populations and to investigate the underlying biological mechanisms
      leading to these rare clotting events."
    authors:
      - name: Colin Pawlowski
        orcid: http://orcid.org/0000-0003-2781-7507
      - name: John Rincon-Hekking
        orcid: http://orcid.org/0000-0003-1584-3943
      - name: Samir Awasthi
        orcid: http://orcid.org/0000-0001-8392-0205
      - name: Viral Pandey
        orcid: null
      - name: Patrick Lenehan
        orcid: http://orcid.org/0000-0002-1950-9179
      - name: AJ Venkatakrishnan
        orcid: http://orcid.org/0000-0003-2819-3214
      - name: Sairam Bade
        orcid: null
      - name: John C OHoro
        orcid: null
      - name: Abinash Virk
        orcid: http://orcid.org/0000-0003-3437-7159
      - name: Melanie Swift
        orcid: http://orcid.org/0000-0002-5900-5573
      - name: Amy W Williams
        orcid: null
      - name: Gregory J Gores
        orcid: http://orcid.org/0000-0003-3151-009X
      - name: Andrew D Badley
        orcid: http://orcid.org/0000-0001-7796-7680
      - name: John D Halamka
        orcid: http://orcid.org/0000-0003-2305-6755
      - name: Venky Soundararajan
        orcid: http://orcid.org/0000-0001-7434-9211
  comment:
    dislikes: 0
    thread: "8489654099"
    numReports: 0
    likes: 0
    id: "5461088102"
    createdAt: 2021-07-19T07:58:32
    author:
      username: disqus_2AKoVutrSr
      about: ""
      name: Nikki
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_2AKoVutrSr/
      url: ""
      location: ""
      id: "244685875"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: And so does the contraceptive pill, knee replacement surgery,
      sitting for hours, long haul flights. What‚Äôs your point?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.04.20.21255806v1
  tweets:
    - created_at: Mon Jul 19 20:20:32 +0000 2021
      id: 1417217816969818000
      id_str: "1417217816969818115"
      text: >-
        üí¨ medRxiv comment on "Cerebral venous sinus thrombos..."


        "And so does the contraceptive pill, knee replacement sur‚Ä¶ https://t.co/69gw79DzUp
      truncated: true
      entities:
        urls:
          - url: https://t.co/69gw79DzUp
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 19 20:20:33 +0000 2021
      id: 1417217817926115300
      id_str: "1417217817926115328"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/qLh4uladPn
      truncated: false
      entities:
        urls:
          - url: https://t.co/qLh4uladPn
      in_reply_to_status_id: 1417217816969818000
      in_reply_to_status_id_str: "1417217816969818115"
- preprint:
    id: "125341"
    doi: 10.1101/2021.01.15.21249731
    first_posted: 2021-01-15
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.01.15.21249731v1
    url: https://api.rxivist.org/v1/papers/125341
    title: SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive
      individuals followed for up to 35 weeks
    category: epidemiology
    abstract: "Background: Reinfection with the severe acute respiratory syndrome
      coronavirus 2 (SARS-CoV-2) has been documented, raising public health
      concerns. Risk and incidence rate of SARS-CoV-2 reinfection were assessed
      in a large cohort of antibody-positive persons in Qatar. Methods: All
      SARS-CoV-2 antibody-positive persons with a PCR-positive swab [&ge;]14
      days after the first-positive antibody test were individually investigated
      for evidence of reinfection. Viral genome sequencing was conducted for
      paired viral specimens to confirm reinfection. Incidence of reinfection
      was compared to incidence of infection in the complement cohort of those
      antibody-negative. Results: Among 43,044 anti-SARS-CoV-2 positive persons
      who were followed for a median of 16.3 weeks (range: 0-34.6), 314
      individuals (0.7%) had at least one PCR positive swab [&ge;]14 days after
      the first-positive antibody test. Of these individuals, 129 (41.1%) had
      supporting epidemiological evidence for reinfection. Reinfection was next
      investigated using viral genome sequencing. Applying the
      viral-genome-sequencing confirmation rate, the risk of reinfection was
      estimated at 0.10% (95% CI: 0.08-0.11%). The incidence rate of reinfection
      was estimated at 0.66 per 10,000 person-weeks (95% CI: 0.56-0.78).
      Incidence rate of reinfection versus month of follow-up did not show any
      evidence of waning of immunity for over seven months of follow-up.
      Meanwhile, in the complement cohort of 149,923 antibody-negative persons
      followed for a median of 17.0 weeks (range: 0-45.6), risk of infection was
      estimated at 2.15% (95% CI: 2.08-2.22%) and incidence rate of infection
      was estimated at 13.69 per 10,000 person-weeks (95% CI: 13.22-14.14).
      Efficacy of natural infection against reinfection was estimated at 95.2%
      (95% CI: 94.1-96.0%). Reinfections were less severe than primary
      infections. Only one reinfection was severe, two were moderate, and none
      were critical or fatal. Most reinfections (66.7%) were diagnosed
      incidentally through random or routine testing, or through contact
      tracing. Conclusions: Reinfection is rare. Natural infection appears to
      elicit strong protection against reinfection with an efficacy ~95% for at
      least seven months."
    authors:
      - name: Laith J Abu-Raddad
        orcid: http://orcid.org/0000-0003-0790-0506
      - name: Hiam Chemaitelly
        orcid: http://orcid.org/0000-0002-8756-6968
      - name: Peter J Coyle
        orcid: http://orcid.org/0000-0002-0819-6103
      - name: Joel A Malek
        orcid: http://orcid.org/0000-0002-1516-8477
      - name: Ayeda A Ahmed
        orcid: null
      - name: Yasmin A. Mohamoud
        orcid: http://orcid.org/0000-0002-0614-2750
      - name: Shameem Younuskunju
        orcid: null
      - name: Houssein H. Ayoub
        orcid: http://orcid.org/0000-0003-2512-6657
      - name: Zaina Al Kanaani
        orcid: http://orcid.org/0000-0003-2297-4255
      - name: Einas Al Kuwari
        orcid: http://orcid.org/0000-0001-8849-2334
      - name: Adeel A Butt
        orcid: http://orcid.org/0000-0002-9436-0618
      - name: Andrew Jeremijenko
        orcid: http://orcid.org/0000-0002-0375-2713
      - name: Anvar Hassan Kaleeckal
        orcid: http://orcid.org/0000-0002-9650-4750
      - name: Ali Nizar Latif
        orcid: null
      - name: Riyazuddin Mohammad Shaik
        orcid: http://orcid.org/0000-0002-9844-5854
      - name: Hanan F. Abdul Rahim
        orcid: http://orcid.org/0000-0002-3719-5142
      - name: Gheyath K. Nasrallah
        orcid: http://orcid.org/0000-0001-9252-1038
      - name: HADI M. YASSINE
        orcid: http://orcid.org/0000-0001-7592-2788
      - name: Mohamed G. Al Kuwari
        orcid: http://orcid.org/0000-0002-9158-5395
      - name: Hamad Eid Al Romaihi
        orcid: http://orcid.org/0000-0003-1416-8499
      - name: Mohamed H. Al-Thani
        orcid: http://orcid.org/0000-0003-2501-6941
      - name: Abdullatif Al Khal
        orcid: null
      - name: Roberto Bertollini
        orcid: http://orcid.org/0000-0003-3606-9344
  comment:
    dislikes: 0
    thread: "8389709853"
    numReports: 0
    likes: 0
    id: "5460944306"
    createdAt: 2021-07-19T03:14:17
    author:
      username: vinyanalista
      about: ""
      name: Ant√¥nio Vin√≠cius
      isPowerContributor: false
      profileUrl: https://disqus.com/by/vinyanalista/
      url: http://vinyanalista.com.br
      location: Terra / Earth
      id: "143189420"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "Now published in EClinicalMedicine:
      https://doi.org/10.1016/j.eclinm.2021.100861"
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.01.15.21249731v2
  tweets:
    - created_at: Mon Jul 19 22:19:31 +0000 2021
      id: 1417247757815976000
      id_str: "1417247757815975943"
      text: |-
        üí¨ medRxiv comment on "SARS-CoV-2 reinfection in a co..."

        "Now published in EClinicalMedicine: "

        https://t.co/Y0vzulDPTo
      truncated: false
      entities:
        urls:
          - url: https://t.co/Y0vzulDPTo
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 19 22:19:31 +0000 2021
      id: 1417247758570987500
      id_str: "1417247758570987525"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/Us5ECPdQ2j
      truncated: false
      entities:
        urls:
          - url: https://t.co/Us5ECPdQ2j
      in_reply_to_status_id: 1417247757815976000
      in_reply_to_status_id_str: "1417247757815975943"
- preprint:
    id: "136728"
    doi: 10.1101/2021.04.06.438463
    first_posted: 2021-04-06
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.06.438463v1
    url: https://api.rxivist.org/v1/papers/136728
    title: Universal prediction of cell cycle position using transfer learning
    category: genomics
    abstract: The cell cycle is a highly conserved, continuous process which
      controls faithful replication and division of cells. Single-cell
      technologies have enabled increasingly precise measurements of the cell
      cycle as both as a biological process of interest and as a possible
      confounding factor. Despite its importance and conservation, there is no
      universally applicable approach to infer position in the cell cycle with
      high-resolution from single-cell RNA-seq data. Here, we present tricycle,
      an R/Bioconductor package, to address this challenge by leveraging key
      features of the biology of the cell cycle, the mathematical properties of
      principal component analysis of periodic functions, and the ubiquitous
      applicability of transfer learning. We show that tricycle can predict any
      cells position in the cell cycle regardless of the cell type, species of
      origin, and even sequencing assay. The accuracy of tricycle compares
      favorably to gold-standard experimental assays which generally require
      specialized measurements in specifically constructed in vitro systems.
      Unlike gold-standard assays, tricycle is easily applicable to any
      single-cell RNA-seq dataset. Tricycle is highly scalable, universally
      accurate, and eminently pertinent for atlas-level data.
    authors:
      - name: Shijie C. Zheng
        orcid: http://orcid.org/0000-0002-2902-3164
      - name: Genevieve Stein-O'Brien
        orcid: http://orcid.org/0000-0001-8681-9110
      - name: Jonathan J Augustin
        orcid: http://orcid.org/0000-0002-3302-4426
      - name: Jared Slosberg
        orcid: http://orcid.org/0000-0002-1803-2815
      - name: Giovanni A. Carosso
        orcid: http://orcid.org/0000-0002-9142-8525
      - name: Briana Winer
        orcid: http://orcid.org/0000-0001-8084-039X
      - name: Gloria Shin
        orcid: null
      - name: Hans T. Bjornsson
        orcid: http://orcid.org/0000-0001-6635-6753
      - name: Loyal A. Goff
        orcid: http://orcid.org/0000-0003-2875-451X
      - name: Kasper D. Hansen
        orcid: http://orcid.org/0000-0003-0086-0687
  comment:
    dislikes: 0
    thread: "8474469399"
    numReports: 0
    likes: 0
    id: "5461857342"
    createdAt: 2021-07-19T20:54:30
    author:
      username: stephens999
      about: ""
      name: stephens999
      isPowerContributor: false
      profileUrl: https://disqus.com/by/stephens999/
      url: ""
      location: ""
      id: "131896521"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      A Review of Zheng et al, Universal prediction of cell cycle position using
      transfer learning, by Matthew Stephens


      This paper provides a new approach (tricycle) for predicting the

      position of a cell in the cell cycle. The approach claims to work

      regardless of cell type, species and sequencing assay.

      There are several things to like about the paper. In particular,

      the tricycle method is very

      simple: i) compute the first two PCs on

      500 annotated cell-cycle genes in a data set where cell cycle

      is the primary source of variation; ii) project

      any future observations to this 2-d embedding and compute

      the polar angle to predict its cell cycle

      position. Further, the empirical results are promising.

      At the same time I think the paper

      could be substantially improved by removing or

      reducing some of the less innovative parts, toning down some of the rhetoric,

      and focussing on the most convincing empirical results. My comments expand

      on these suggestions.


      Main comments:


      1. I found most of the material on PCA not to be

      especially novel or interesting. The use of PCA to determine cell cycle

      position has a long history (including many papers cited here),

      and existing mathematical results already go far beyond

      the analysis presented here. The behavior of PCA on cyclic phenomena

      is much more general than presented here, and does not rely on sinusoidal

      functions or "two distinct peaks" etc. Rather it stems

      from the result that cyclic phenomona lead to circulant covariance matrices,

      and all circulant matrices have the same eigenvectors:

      the columns of the discrete Fourier transform matrix. The result

      is that, when the covariance patterns primarily reflect cyclic phenomoena,

      the first two PCs will form a circle/ellipse.

      See Novembre and Stephens (2008) and references therein for further discussion.

      Figure 1 is useful for summarizing the method, but most of the other

      material could be condensed or removed and I think the paper would be improved because

      it would better focus on what is actually new and interesting, the tricycle

      method (currently not introduced until p6) and the empirical assessments of its performance.


      2. The paper left me asking myself this: what is the strongest empirical support that tricycle cell

      cycle assignments work in practice? To me, Fig 5 panels c and g are the most convincing, because they are quantitative

      comparisons with an alternative technology (and one that is often considered the

      "gold standard" in this area). I also liked the quantitative comparisons with other

      methods,  and it seems some of those might

      be worth including in the main text. In contrast, the results in Fig 4 are not

      quantitative, and overall not that compelling. The top row

      of panels are kind of useful in demonstrating you get something like a circle.

      but we don't actually know that this corresponds to cell cycle from this picture

      (unless I misunderstood, the colors are inferred, not known).

      And looking at the mPancreas results one might be tempted to use (-3,0) as the

      center of the circle, which would change computation of polar angle quite a bit.

      Is there reason to think that sticking with (0,0) is better? If so, any idea why does

      the circle show this shift? (Similar issues arise, to a lesser extent, with HippNPC).

      The Top2A results are, on their own, too noisy to be convincing -- why not show R2 plots for

      all cell-cycle genes (which could be contrasted with non-cell-cycle genes, and also compared

      with other methods). And as far as I can

      see Fig 4c is, at best, only interesting once one is convinced that the cell cycle

      is being correctly inferred -- nothing here to say that the cell cycle inferences are accurate.

      To be clear, I'm not saying the method does not generalize well across

      data sets; I'm saying that the evidence for this needs to be more clearly presented.



      3. A less fundamental issue: I don't really think describing this as an example of "transfer learning"

      is helpful. Indeed it is not even clear to me it is accurate.

      For example, in the cited Pan et al 2008, they describe the transfer

      learning problem as follows: "In a transfer learning setting, some labeled data Dsrc are

      available in a source domain, while only unlabeled data Dtar

      are available in the target domain." That does not apply here - everything

      is based on unlabelled data.


      More generally, giving the approach a name like "transfer learning" seems to

      suggest that there is something going on to actually make this transfer

      from one dataset to another, or some deeper theoretical reason to think it should work

      --  but I don't believe either of these is true. You are just hoping

      that the PC weights learned in one (carefully chosen) data set will

      also work to capture cell cycle on other data sets.

      It isn't obvious in advance that this rather simple approach

      would work well, and the major contribution of the paper is to assess this
       empirically.


      4. The abstract is hyperbolic. "ubiquitous applicability of transfer learning";

      "can predict any cell's position in the cell cycle",

      "universally accurate", "eminently pertinent"...



      Minor:


      - p2 you introduce the term "cell cycle pseudotime" only to explain later that it is not really a time at all. Why not just go straight into "cell cycle position"

      or "cell cycle phase"? (Also, the term "wall time" may not be familiar to all readers?)


      -p5 left column: Figure 2d-> 2f?


      - p8, right column:  is "superficial" the right word here?


      - Some of the loess fits (eg Fig 2 d-f; Fig 4 panel b, especially mHippNPC) don't look visually very good. Is this

      just an artifact of having 0s, whose density is impossible to see due to overplotting, or is loess over-smoothing? Might trend filtering, as used in Hsiao et al, work better?



      Refs:


      J Novembre and M Stephens. Interpreting principal component analyses of spatial population genetic variation.

      Nat Genet 40(5):646-649, May 2008A Review of Zheng et al, Universal prediction of cell cycle position using transfer learning, by Matthew Stephens


      This paper provides a new approach (tricycle) for predicting the

      position of a cell in the cell cycle. The approach claims to work

      regardless of cell type, species and sequencing assay.

      There are several things to like about the paper. In particular,

      the tricycle method is very

      simple: i) compute the first two PCs on

      500 annotated cell-cycle genes in a data set where cell cycle

      is the primary source of variation; ii) project

      any future observations to this 2-d embedding and compute

      the polar angle to predict its cell cycle

      position. Further, the empirical results are promising.

      At the same time I think the paper

      could be substantially improved by removing or

      reducing some of the less innovative parts, toning down some of the rhetoric,

      and focussing on the most convincing empirical results. My comments expand

      on these suggestions.


      Main comments:


      1. I found most of the material on PCA not to be

      especially novel or interesting. The use of PCA to determine cell cycle

      position has a long history (including many papers cited here),

      and existing mathematical results already go far beyond

      the analysis presented here. The behavior of PCA on cyclic phenomena

      is much more general than presented here, and does not rely on sinusoidal

      functions or "two distinct peaks" etc. Rather it stems

      from the result that cyclic phenomona lead to circulant covariance matrices,

      and all circulant matrices have the same eigenvectors:

      the columns of the discrete Fourier transform matrix. The result

      is that, when the covariance patterns primarily reflect cyclic phenomoena,

      the first two PCs will form a circle/ellipse.

      See Novembre and Stephens (2008) and references therein for further discussion.

      Figure 1 is useful for summarizing the method, but most of the other

      material could be condensed or removed and I think the paper would be improved because

      it would better focus on what is actually new and interesting, the tricycle

      method (currently not introduced until p6) and the empirical assessments of its performance.


      2. The paper left me asking myself this: what is the strongest empirical support that tricycle cell

      cycle assignments work in practice? To me, Fig 5 panels c and g are the most convincing, because they are quantitative

      comparisons with an alternative technology (and one that is often considered the

      "gold standard" in this area). I also liked the quantitative comparisons with other

      methods,  and it seems some of those might

      be worth including in the main text. In contrast, the results in Fig 4 are not

      quantitative, and overall not that compelling. The top row

      of panels are kind of useful in demonstrating you get something like a circle.

      but we don't actually know that this corresponds to cell cycle from this picture

      (unless I misunderstood, the colors are inferred, not known).

      And looking at the mPancreas results one might be tempted to use (-3,0) as the

      center of the circle, which would change computation of polar angle quite a bit.

      Is there reason to think that sticking with (0,0) is better? If so, any idea why does

      the circle show this shift? (Similar issues arise, to a lesser extent, with HippNPC).

      The Top2A results are, on their own, too noisy to be convincing -- why not show R2 plots for

      all cell-cycle genes (which could be contrasted with non-cell-cycle genes, and also compared

      with other methods). And as far as I can

      see Fig 4c is, at best, only interesting once one is convinced that the cell cycle

      is being correctly inferred -- nothing here to say that the cell cycle inferences are accurate.

      To be clear, I'm not saying the method does not generalize well across

      data sets; I'm saying that the evidence for this needs to be more clearly presented.



      3. A less fundamental issue: I don't really think describing this as an example of "transfer learning"

      is helpful. Indeed it is not even clear to me it is accurate.

      For example, in the cited Pan et al 2008, they describe the transfer

      learning problem as follows: "In a transfer learning setting, some labeled data Dsrc are

      available in a source domain, while only unlabeled data Dtar

      are available in the target domain." That does not apply here - everything

      is based on unlabelled data.


      More generally, giving the approach a name like "transfer learning" seems to

      suggest that there is something going on to actually make this transfer

      from one dataset to another, or some deeper theoretical reason to think it should work

      --  but I don't believe either of these is true. You are just hoping

      that the PC weights learned in one (carefully chosen) data set will

      also work to capture cell cycle on other data sets.

      It isn't obvious in advance that this rather simple approach

      would work well, and the major contribution of the paper is to assess this
       empirically.


      4. The abstract is hyperbolic. "ubiquitous applicability of transfer learning";

      "can predict any cell's position in the cell cycle",

      "universally accurate", "eminently pertinent"...



      Minor:


      - p2 you introduce the term "cell cycle pseudotime" only to explain later that it is not really a time at all. Why not just go straight into "cell cycle position"

      or "cell cycle phase"? (Also, the term "wall time" may not be familiar to all readers?)


      -p5 left column: Figure 2d-> 2f?


      - p8, right column:  is "superficial" the right word here?


      - Some of the loess fits (eg Fig 2 d-f; Fig 4 panel b, especially mHippNPC) don't look visually very good. Is this

      just an artifact of having 0s, whose density is impossible to see due to overplotting, or is loess over-smoothing? Might trend filtering, as used in Hsiao et al, work better?



      Refs:


      J Novembre and M Stephens. Interpreting principal component analyses of spatial population genetic variation.

      Nat Genet 40(5):646-649, May 2008
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.04.06.438463v2
  tweets:
    - created_at: Tue Jul 20 01:07:28 +0000 2021
      id: 1417290026505879600
      id_str: "1417290026505879553"
      text: >-
        üí¨ bioRxiv comment on "Universal prediction of cell c..."


        "A Review of Zheng et al, Universal prediction of cell cy‚Ä¶ https://t.co/0uFH79dRIT
      truncated: true
      entities:
        urls:
          - url: https://t.co/0uFH79dRIT
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 20 01:07:29 +0000 2021
      id: 1417290027340550100
      id_str: "1417290027340550144"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/52W1p4SYI2
      truncated: false
      entities:
        urls:
          - url: https://t.co/52W1p4SYI2
      in_reply_to_status_id: 1417290026505879600
      in_reply_to_status_id_str: "1417290026505879553"
- preprint:
    id: "90185"
    doi: 10.1101/2020.07.06.190595
    first_posted: 2020-07-06
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.07.06.190595v1
    url: https://api.rxivist.org/v1/papers/90185
    title: Multi-omic profiling of primary mouse neutrophils reveals a pattern of
      sex and age-related functional regulation
    category: genomics
    abstract: >-
      Neutrophils are the most abundant white blood cells in humans and
      constitute one of the first lines of defense in the innate immune
      response. Neutrophils are extremely short-lived cells, which survive less
      than a day after reaching terminal differentiation. Thus, little is known
      about how organismal aging, rather than the daily cellular aging process,
      may impact neutrophil biology. In addition, accumulating evidence suggests
      that both immunity and organismal aging are sex-dimorphic. Here, we
      describe a multi-omic resource of mouse primary bone marrow neutrophils
      from young and old female and male mice, at the transcriptomic,
      metabolomic and lipidomic levels. Importantly, we identify widespread
      age-related and sex-dimorphic regulation of 'omics' in neutrophils,
      specifically regulation of chromatin. Using machine-learning, we identify
      candidate molecular drivers of age-related and sex-dimorphic
      transcriptional regulation of neutrophils. We leverage our resource to
      predict increased levels/release of neutrophil elastase in male mice. To
      date, this dataset represents the largest multi-omics resource for the
      study of neutrophils across biological sex and ages. This resource
      identifies molecular states linked to neutrophil characteristics linked to
      organismal age or sex, which could be targeted to improve immune responses
      across individuals.


      ### Competing Interest Statement


      The authors have declared no competing interest.
    authors:
      - name: Ryan Lu
        orcid: http://orcid.org/0000-0001-8627-2880
      - name: Shalina Taylor
        orcid: http://orcid.org/0000-0002-5573-6483
      - name: K√©vin Contrepois
        orcid: http://orcid.org/0000-0001-9678-5161
      - name: Mathew Ellenberger
        orcid: null
      - name: Nirmal K. Sampathkumar
        orcid: http://orcid.org/0000-0002-5125-9114
      - name: B√©r√©nice A. Benayoun
        orcid: http://orcid.org/0000-0002-7401-4777
  comment:
    dislikes: 0
    thread: "8113488291"
    numReports: 0
    likes: 0
    id: "5461604854"
    createdAt: 2021-07-19T17:34:53
    author:
      name: B√©r√©nice Anath Benayoun
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "The study from this preprint has been published in Nature Aging
      7/19/2021: https://www.nature.com/articles/s43587-021-00086-8#Ack1"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.07.06.190595v1
  tweets:
    - created_at: Tue Jul 20 12:31:44 +0000 2021
      id: 1417462226332565500
      id_str: "1417462226332565514"
      text: >-
        üí¨ bioRxiv comment on "Multi-omic profiling of primar..."


        "The study from this preprint has been published in Natur‚Ä¶ https://t.co/nqzzgGMpRF
      truncated: true
      entities:
        urls:
          - url: https://t.co/nqzzgGMpRF
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 20 12:31:44 +0000 2021
      id: 1417462227360272400
      id_str: "1417462227360272386"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/xn3KeDYtZU
      truncated: false
      entities:
        urls:
          - url: https://t.co/xn3KeDYtZU
      in_reply_to_status_id: 1417462226332565500
      in_reply_to_status_id_str: "1417462226332565514"
- preprint:
    id: "147786"
    doi: 10.1101/2021.06.26.449999
    first_posted: 2021-06-27
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.26.449999v1
    url: https://api.rxivist.org/v1/papers/147786
    title: Genetic basis and dual adaptive role of floral pigmentation in sunflowers
    category: evolutionary-biology
    abstract: Variation in floral displays, both between and within species, has
      been long known to be shaped by the mutualistic interactions that plants
      establish with their pollinators. However, increasing evidence suggests
      that abiotic selection pressures influence floral diversity as well. Here
      we analyze the genetic and environmental factors that underlie patterns of
      floral pigmentation in wild sunflowers. While sunflower inflorescences
      appear invariably yellow to the human eye, they display extreme diversity
      for patterns of ultraviolet pigmentation, which are visible to most
      pollinators. We show that this diversity is largely controlled by
      cis-regulatory variation at a single MYB transcription factor, HaMYB111,
      through accumulation of UV-absorbing flavonol glycosides. As expected,
      different patterns of ultraviolet pigments in flowers have a strong effect
      on pollinator preferences. However, variation for floral ultraviolet
      patterns is also associated with environmental variables, especially
      relative humidity, across populations of wild sunflowers. Larger
      ultraviolet patterns, which are found in drier environments, limit
      transpiration, therefore reducing water loss. The dual role of floral UV
      patterns in pollination attraction and abiotic responses reveals the
      complex adaptive balance underlying the evolution of floral traits.
    authors:
      - name: Marco Todesco
        orcid: http://orcid.org/0000-0002-6227-4096
      - name: Natalia Bercovich
        orcid: http://orcid.org/0000-0002-7703-2858
      - name: Amy Kim
        orcid: null
      - name: Ivana Imerovski
        orcid: http://orcid.org/0000-0002-1164-3664
      - name: Gregory L Owens
        orcid: http://orcid.org/0000-0002-4019-5215
      - name: √ìscar Dorado Ruiz
        orcid: null
      - name: Srinidhi V. Holalu
        orcid: http://orcid.org/0000-0002-1948-8216
      - name: Lufiani L Madilao
        orcid: http://orcid.org/0000-0003-4161-2540
      - name: Mojtaba Jahani
        orcid: http://orcid.org/0000-0003-1844-1464
      - name: Jean-S√©bastein L√©gar√©
        orcid: null
      - name: Benjamin K Blackman
        orcid: http://orcid.org/0000-0003-4936-6153
      - name: Loren Reiseberg
        orcid: http://orcid.org/0000-0002-2712-2417
  comment:
    dislikes: 0
    thread: "8618581326"
    numReports: 0
    likes: 0
    id: "5461587933"
    createdAt: 2021-07-19T17:21:41
    author:
      username: marcotodesco
      about: ""
      name: Marco Todesco
      isPowerContributor: false
      profileUrl: https://disqus.com/by/marcotodesco/
      url: ""
      location: ""
      id: "200033762"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Hi Nate, thank you! I am glad you found our manuscript interesting.


      1) As per you suggestion, we did check VPD, but there is not much correlation with floral UV patterns. What we see is that floral UV patterns in sunflowers are inversely correlated with both temperature and relative humidity, while VPD increases with temperature and decreases with relative humidity. Our interpretation is that in hot, humid places, preventing over-heating of the ligules through transpiration/evaporative cooling is a priority over reducing water loss (even if VDP might be similar to that of colder, drier places).


      2) We did measure flower and ligule size on a subset of ~700 individuals that were grown in the first of our common garden experiments, and there is plenty of variation in flower and ligule size, ligule shape and ligule number (that data is included in a recent paper, Todesco et al., Nature 2020). However, this variation is more difficult to interpret because inflorescence size is very well correlated with flowering time in wild sunflowers (plants that flower later are bigger, and bigger plants make bigger inflorescences). There was extensive variation in flowering time between populations of wild <i>H. annuus</i> in our common garden experiment, with plants flowering anywhere between 30 and more than 130 days after being transplanted. While we can control for when these plants flowered in our common garden, we don‚Äôt really know how flowering time in Vancouver translates to flowering time in the location of origin of these plants. Measuring flower/ligule size in situ would be much more informative, but we do not have that data.


      That said, there is some decent correlation, particularly between relative humidity and relative ligule size (that is, the size of the ligule relative to the size of the whole inflorescence), with plants coming from population with higher humidity having larger ligules. The correlation might be clearer for relative ligule size because it is be less likely to be affected by flowering time/plant size; we use ligule UV proportion (LUVp) to measure floral UV patterns instead of absolute measurements of UV bullseye size exactly for that reason. A previous study from our lab (in <i>H. argophyllus</i>, a different sunflower species) found that in a segregating population, all absolute measures of floral UV pigmentation (e.g. diameter of UV bullseye) mapped to a big flowering time QTL, while LUVp measurements mapped to different regions of the genome (incidentally, in the paper I mentioned before we also confirmed that that QTL in <i>H. argophyllus</i> is indeed due to a well-known flowering time regulator, which was part of a recent large introgression).

      To sum up, while there is some indication that sunflowers have smaller flowers/ligules in drier climates, it would take in-depth field studies to be able to say something with a modicum of certainty.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.26.449999v1
  tweets:
    - created_at: Tue Jul 20 14:17:45 +0000 2021
      id: 1417488904907808800
      id_str: "1417488904907808770"
      text: >-
        üí¨ bioRxiv comment on "Genetic basis and dual adaptiv..."


        "Hi Nate, thank you! I am glad you found our manuscript i‚Ä¶ https://t.co/coNQpU7VBt
      truncated: true
      entities:
        urls:
          - url: https://t.co/coNQpU7VBt
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 20 14:17:45 +0000 2021
      id: 1417488905792852000
      id_str: "1417488905792851978"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/w1lLGsVgol
      truncated: false
      entities:
        urls:
          - url: https://t.co/w1lLGsVgol
      in_reply_to_status_id: 1417488904907808800
      in_reply_to_status_id_str: "1417488904907808770"
- preprint:
    id: "136537"
    doi: 10.1101/2021.04.03.437906
    first_posted: 2021-04-05
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.03.437906v1
    url: https://api.rxivist.org/v1/papers/136537
    title: Design considerations for workflow management systems use in production
      genomics research and the clinic
    category: bioinformatics
    abstract: 'Background: The changing landscape of genomics research and clinical
      practice has created a need for computational pipelines capable of
      efficiently orchestrating complex analysis stages while handling large
      volumes of data across heterogeneous computational environments. Workflow
      Management Systems (WfMSs) are the software components employed to fill
      this gap. Results: This work provides an approach and systematic
      evaluation of key features of popular bioinformatics WfMSs in use today:
      Nextflow, CWL, and WDL and some of their executors, along with Swift/T, a
      workflow manager commonly used in high-scale physics applications. We
      employed two use cases: a variant-calling genomic pipeline and a
      scalability-testing framework, where both were run locally, on an HPC
      cluster, and in the cloud. This allowed for evaluation of those four WfMSs
      in terms of language expressiveness, modularity, scalability, robustness,
      reproducibility, interoperability, ease of development, along with
      adoption and usage in research labs and healthcare settings. This article
      is trying to answer, "which WfMS should be chosen for a given
      bioinformatics application regardless of analysis type?". Conclusions: The
      choice of a given WfMS is a function of both its intrinsic language and
      engine features. Within bioinformatics, where analysts are a mix of dry
      and wet lab scientists, the choice is also governed by collaborations and
      adoption within large consortia and technical support provided by the WfMS
      team/community. As the community and its needs continue to evolve along
      with computational infrastructure, WfMSs will also evolve, especially
      those with permissive licenses that allow commercial use. In much the same
      way as the dataflow paradigm and containerization are now well understood
      to be very useful in bioinformatics applications, we will continue to see
      innovations of tools and utilities for other purposes, like big data
      technologies, interoperability, and provenance.'
    authors:
      - name: Azza E Ahmed
        orcid: http://orcid.org/0000-0002-1358-8371
      - name: Joshua Allen
        orcid: null
      - name: Tajesvi Bhat
        orcid: null
      - name: Prakruthi Burra
        orcid: http://orcid.org/0000-0002-1502-8095
      - name: Christina E Fliege
        orcid: null
      - name: Steven N Hart
        orcid: http://orcid.org/0000-0001-7714-2734
      - name: Jacob R Heldenbrand
        orcid: null
      - name: Matthew E. Hudson
        orcid: http://orcid.org/0000-0002-4737-0936
      - name: Dave Deandre Istanto
        orcid: null
      - name: Michael T Kalmbach
        orcid: null
      - name: Gregory D. Kapraun
        orcid: null
      - name: Katherine I. Kendig
        orcid: null
      - name: Matthew Charles Kendzior
        orcid: null
      - name: Eric W Klee
        orcid: http://orcid.org/0000-0003-2946-5795
      - name: Nate Mattson
        orcid: null
      - name: Christian A Ross
        orcid: http://orcid.org/0000-0002-4157-3951
      - name: Sami M Sharif
        orcid: null
      - name: Ramshankar Venkatakrishnan
        orcid: http://orcid.org/0000-0001-8539-8115
      - name: Faisal M Fadlelmola
        orcid: http://orcid.org/0000-0001-8351-264X
      - name: Liudmila Sergeevna Mainzer
        orcid: http://orcid.org/0000-0001-7121-0214
  comment:
    dislikes: 0
    thread: "8466513971"
    numReports: 0
    likes: 0
    id: "5461310331"
    createdAt: 2021-07-19T13:26:08
    author:
      username: pditommaso
      about: ""
      name: Paolo Di Tommaso
      isPowerContributor: false
      profileUrl: https://disqus.com/by/pditommaso/
      url: ""
      location: ""
      id: "120142873"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Thanks for following up on this comparison, however, as I was
      pointing out in the previous comment, the use of the nextflow directive
      `maxForks` makes no sense at all in this benchmark, on the contrary causes
      the execution to fail in this scenario. It's a pity the test was repeated
      still using it.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.04.03.437906v1
  tweets:
    - created_at: Tue Jul 20 16:36:28 +0000 2021
      id: 1417523816985682000
      id_str: "1417523816985681920"
      text: >-
        üí¨ bioRxiv comment on "Design considerations for work..."


        "Thanks for following up on this comparison, however, as‚Ä¶ https://t.co/XZkCfFvvUJ
      truncated: true
      entities:
        urls:
          - url: https://t.co/XZkCfFvvUJ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 20 16:36:29 +0000 2021
      id: 1417523817837219800
      id_str: "1417523817837219854"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/uR9zjl4BxP
      truncated: false
      entities:
        urls:
          - url: https://t.co/uR9zjl4BxP
      in_reply_to_status_id: 1417523816985682000
      in_reply_to_status_id_str: "1417523816985681920"
- preprint:
    id: "141057"
    doi: 10.1101/2021.05.03.21256520
    first_posted: 2021-05-06
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.03.21256520v1
    url: https://api.rxivist.org/v1/papers/141057
    title: The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and
      innate immune responses
    category: infectious-diseases
    abstract: The mRNA-based BNT162b2 vaccine from Pfizer/BioNTech was the first
      registered COVID-19 vaccine and has been shown to be up to 95% effective
      in preventing SARS-CoV-2 infections. Little is known about the broad
      effects of the new class of mRNA vaccines, especially whether they have
      combined effects on innate and adaptive immune responses. Here we
      confirmed that BNT162b2 vaccination of healthy individuals induced
      effective humoral and cellular immunity against several SARS-CoV-2
      variants. Interestingly, however, the BNT162b2 vaccine also modulated the
      production of inflammatory cytokines by innate immune cells upon
      stimulation with both specific (SARS-CoV-2) and non-specific (viral,
      fungal and bacterial) stimuli. The response of innate immune cells to TLR4
      and TLR7/8 ligands was lower after BNT162b2 vaccination, while
      fungi-induced cytokine responses were stronger. In conclusion, the mRNA
      BNT162b2 vaccine induces complex functional reprogramming of innate immune
      responses, which should be considered in the development and use of this
      new class of vaccines.
    authors:
      - name: F. Konstantin F√∂hse
        orcid: http://orcid.org/0000-0002-4708-6943
      - name: B√ºsranur Geckin
        orcid: http://orcid.org/0000-0002-4751-4960
      - name: Gijs Overheul
        orcid: http://orcid.org/0000-0002-8356-8165
      - name: Josephine van de Maat
        orcid: http://orcid.org/0000-0001-7351-4596
      - name: Gizem Kilic
        orcid: http://orcid.org/0000-0002-8251-1909
      - name: Ozlem Bulut
        orcid: http://orcid.org/0000-0001-7077-6216
      - name: Helga Dijkstra
        orcid: null
      - name: Heidi Lemmers
        orcid: null
      - name: S. Andrei Sarlea
        orcid: null
      - name: Maartje Reijnders
        orcid: null
      - name: Jacobien Hoogerwerf
        orcid: http://orcid.org/0000-0001-9957-3703
      - name: Jaap ten Oever
        orcid: http://orcid.org/0000-0003-2397-0125
      - name: Elles Simonetti
        orcid: null
      - name: Frank L van de Veerdonk
        orcid: http://orcid.org/0000-0002-1121-4894
      - name: Leo A.B. Joosten
        orcid: http://orcid.org/0000-0001-6166-9830
      - name: Bart L. Haagmans
        orcid: http://orcid.org/0000-0001-6221-2015
      - name: Reinout van Crevel
        orcid: null
      - name: Yang Li
        orcid: http://orcid.org/0000-0003-4022-7341
      - name: Ronald P. van Rij
        orcid: http://orcid.org/0000-0003-0221-4689
      - name: Corine GeurtsvanKessel
        orcid: http://orcid.org/0000-0002-7678-314X
      - name: Marien I. de Jonge
        orcid: http://orcid.org/0000-0003-2812-5895
      - name: Jorge Dom√≠nguez-Andr√©s
        orcid: http://orcid.org/0000-0002-9091-1961
      - name: Mihai G. Netea
        orcid: http://orcid.org/0000-0003-2421-6052
  comment:
    dislikes: 0
    thread: "8508876244"
    numReports: 0
    likes: 0
    id: "5460939936"
    createdAt: 2021-07-19T03:08:20
    author:
      username: milesbabbage
      about: ""
      name: Miles Babbage
      isPowerContributor: false
      profileUrl: https://disqus.com/by/milesbabbage/
      url: ""
      location: ""
      id: "372527611"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      OK, authors, there are problems here. You don't have the sample numbers to
      make the claims you do, and your data do not bear it. 


      Interferon alpha effect you report here seems, from your own graphs, to be an artifact of changes between the first and the second dose, not between vaccine and lack of vaccine. I.e. you have a very minor shift up at t2, which makes the drop at t3 significant - but there is no actual effect between t1 and t3. 


      For TNFa data, the R848 seems to be based on one single patient who had a strong increase at t2 that declined in t3. The only significant observation that holds is the one with candida, which then brings up the problem of sampling (test enough things, and you'll get a result somewhere). You need to state your statistics much more clearly. 


      There is an possible trend here, but that trend a) needs to also be interpreted in the light of known post-viral effects on the innate immune system (such as e.g. those seen with post-influenza effects on bacterial resistance), and b) needs to stated as trend, not as a definite finding.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.03.21256520v1
  tweets:
    - created_at: Tue Jul 20 18:29:22 +0000 2021
      id: 1417552227443544000
      id_str: "1417552227443544066"
      text: >-
        üí¨ medRxiv comment on "The BNT162b2 mRNA vaccine agai..."


        "OK, authors, there are problems here. You don't have the‚Ä¶ https://t.co/xSrj7ELv2G
      truncated: true
      entities:
        urls:
          - url: https://t.co/xSrj7ELv2G
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 20 18:29:22 +0000 2021
      id: 1417552228290900000
      id_str: "1417552228290899971"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/dJAkyRxqBb
      truncated: false
      entities:
        urls:
          - url: https://t.co/dJAkyRxqBb
      in_reply_to_status_id: 1417552227443544000
      in_reply_to_status_id_str: "1417552227443544066"
- preprint:
    id: 146540
    metric: 42
    title: SARS-CoV-2 spike P681R mutation, a hallmark of the Delta variant,
      enhances viral fusogenicity and pathogenicity
    url: https://api.rxivist.org/v1/papers/146540
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.17.448820v1
    doi: 10.1101/2021.06.17.448820
    category: microbiology
    first_posted: 2021-06-17
    abstract: During the current SARS-CoV-2 pandemic, a variety of mutations have
      been accumulated in the viral genome, and currently, four variants of
      concerns (VOCs) are considered as the hazardous SARS-CoV-2 variants to the
      human society1. The newly emerging VOC, the B.1.617.2/Delta variant,
      closely associates with a huge COVID-19 surge in India in Spring 20212.
      However, its virological property remains unclear. Here, we show that the
      B.1.617.2/Delta variant is highly fusogenic, and notably, more pathogenic
      than prototypic SARS-CoV-2 in infected hamsters. The P681R mutation in the
      spike protein, which is highly conserved in this lineage, facilitates the
      spike protein cleavage and enhances viral fusogenicity. Moreover, we
      demonstrate that the P681R-bearing virus exhibits higher pathogenicity
      than the parental virus. Our data suggest that the P681R mutation is a
      hallmark that characterizes the virological phenotype of the
      B.1.617.2/Delta variant and is closely associated with enhanced
      pathogenicity.
    authors:
      - name: Akatsuki Saito
      - name: Takashi Irie
      - name: Rigel Suzuki
      - name: Tadashi Maemura
      - name: Hesham Nasser
      - name: Keiya Uriu
      - name: Yusuke Kosugi
      - name: Kotaro Shirakawa
      - name: Kenji Sadamasu
      - name: Izumi Kimura
      - name: Jumpei Ito
      - name: Jiaqi Wu
      - name: Kiyoko Iwatsuki-Horimoto
      - name: Mutsumi Ito
      - name: Seiya Yamayoshi
      - name: Seiya Ozono
      - name: Erika P Butlertanaka
      - name: Yuri L Tanaka
      - name: Ryo Shimizu
      - name: Kenta Shimizu
      - name: Kumiko Yoshimatsu
      - name: Ryoko Kawabata
      - name: Takemasa Sakaguchi
      - name: Kenzo Tokunaga
      - name: Isao Yoshida
      - name: Hiroyuki Asakura
      - name: Mami Nagashima
      - name: Yasuhiro Kazuma
      - name: Ryosuke Nomura
      - name: Yasuhito Horisawa
      - name: Kazuhisa Yoshimura
      - name: Akifumi Takaori-Kondo
      - name: Masaki Imai
      - name: The Genotype to Phenotype Japan (G2P-Japan) Consortium
      - name: So Nakagawa
      - name: Terumasa Ikeda
      - name: Takasuke Fukuhara
      - name: Yoshihiro Kawaoka
      - name: Kei Sato
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Tue Jul 20 20:16:36 +0000 2021
      id: 1417579215013224400
      id_str: "1417579215013224454"
      text: >-
        üî• bioRxiv Microbiology preprint by A. Saito et al:


        "SARS-CoV-2 spike P681R mutation, a hallmark of the Delta varia‚Ä¶ https://t.co/p9u5eebCDB
      truncated: true
      entities:
        urls:
          - url: https://t.co/p9u5eebCDB
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "147094"
    doi: 10.1101/2021.06.21.449316
    first_posted: 2021-06-22
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.21.449316v1
    url: https://api.rxivist.org/v1/papers/147094
    title: "ShinyArchR.UiO: User-friendly, integrative and open-source tool for
      visualisation of single-cell ATAC-seq data using ArchR"
    category: bioinformatics
    abstract: "Motivation: Mapping of chromatin accessibility landscapes in
      single-cells and the integration with gene expression enables a better
      understanding of gene regulatory mechanisms defining cell identities and
      cell-fate determination in development and disease. Generally, raw data
      generated from single-cell Assay for Transposase-Accessible Chromatin
      sequencing (scATAC-seq) are deposited in reposito-ries that are
      inaccessible due to lack of in-depth knowledge of computational
      programming. Results: We have developed ShinyArchR.UiO, an R-based shiny
      app, that facilitates scATAC-seq data accessibility and visualisation in a
      user-friendly, interactive, and open-source web interface. ShinyArchR.UiO
      is a tool that can streamline collaborative efforts for interpretation of
      massive chro-matin accessible data and promotes open access data sharing
      for wider audiences."
    authors:
      - name: Ankush Sharma
        orcid: http://orcid.org/0000-0002-1399-7503
      - name: Akshay Akshay
        orcid: null
      - name: Marie Rogne
        orcid: http://orcid.org/0000-0002-3594-9000
      - name: Ragnhild Eskeland
        orcid: http://orcid.org/0000-0003-2789-3171
  comment:
    dislikes: 0
    thread: "8609164645"
    numReports: 0
    likes: 0
    id: "5462601768"
    createdAt: 2021-07-20T13:19:09
    author:
      username: ankushsak
      about: ""
      name: Ankush
      isPowerContributor: false
      profileUrl: https://disqus.com/by/ankushsak/
      url: ""
      location: ""
      id: "510510"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: The typographical error in Github repository link . Correct link
      for accessing the repository is
      https://Github.com/EskelandLab/ShinyArchRUiO
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.21.449316v1
  tweets:
    - created_at: Tue Jul 20 20:20:24 +0000 2021
      id: 1417580169410265000
      id_str: "1417580169410265089"
      text: >-
        üí¨ bioRxiv comment on "ShinyArchR.UiO: User-friendly,..."


        "The typographical error in Github repository link . Corr‚Ä¶ https://t.co/0Cn36zeeSk
      truncated: true
      entities:
        urls:
          - url: https://t.co/0Cn36zeeSk
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 20 20:20:24 +0000 2021
      id: 1417580170572013600
      id_str: "1417580170572013569"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/qEvO1vUrTQ
      truncated: false
      entities:
        urls:
          - url: https://t.co/qEvO1vUrTQ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "129426"
    doi: 10.1101/2021.02.15.431157
    first_posted: 2021-02-16
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.02.15.431157v1
    url: https://api.rxivist.org/v1/papers/129426
    title: A new field instrument for leaf volatiles reveals an unexpected vertical
      profile of isoprenoid emission capacities in a tropical forest
    category: plant-biology
    abstract: "Both plant physiology and atmospheric chemistry are substantially
      altered by the emission of volatile isoprenoids (VI), such as isoprene and
      monoterpenes, from plant leaves. Yet, since gaining scientific attention
      in the 1950's, empirical research on leaf VI has been largely confined to
      laboratory experiments and atmospheric observations. Here, we introduce a
      new field instrument designed to bridge the scales from leaf to
      atmosphere, by enabling precision VI detection in real time from plants in
      their natural ecological setting. With a field campaign in the Brazilian
      Amazon, we reveal an unexpected distribution of leaf emission capacities
      (EC) across the vertical axis of the forest canopy, with EC peaking in the
      mid-canopy instead of the sun-exposed canopy surface, and high emissions
      occurring in understory specialist species. Compared to the simple
      interpretation that VI protect leaves from heat stress at the hot canopy
      surface, our results encourage a more nuanced view of the adaptive role of
      VI in plants. We infer that forest emissions to the atmosphere depend on
      the dynamic microenvironments imposed by canopy structure, and not simply
      on canopy surface conditions. We provide a new emissions inventory from 51
      tropical tree species, revealing moderate consistency in EC within
      taxonomic groups. Our self-contained, portable instrument provides
      real-time detection and live measurement feedback with precision and
      detection limits better than 0.5 nmol m-2leaf s-1. We call the instrument
      'PORCO' based on the gas detection method: photoionization of organic
      compounds. We provide a thorough validation of PORCO and demonstrate its
      capacity to detect ecologically driven variation in leaf emission rates
      and thus accelerate a nascent field of science: the ecology and
      ecophysiology of plant volatiles."
    authors:
      - name: Tyeen C Taylor
        orcid: http://orcid.org/0000-0002-0926-098X
      - name: Wit T Wisniewski
        orcid: http://orcid.org/0000-0001-7527-4450
      - name: Eliane G Alves
        orcid: http://orcid.org/0000-0001-5245-1952
      - name: Raimundo Cosme de Oliveira
        orcid: null
      - name: Scott R Saleska
        orcid: http://orcid.org/0000-0002-4974-3628
  comment:
    dislikes: 0
    thread: "8400849189"
    numReports: 0
    likes: 0
    id: "5462402679"
    createdAt: 2021-07-20T08:45:57
    author:
      username: tyeentaylor
      about: "Dr. Tyeen Taylor studies the shifting ecology of tropical forests amid
        the onset of rapid climate warming. He avidly shares the joy and
        practicality of scientific knowledge with non-scientists through films,
        photography, writing, and public events. Public Facebook page:
        @TyeenCTscience. Twitter: @TyeenTaylor. YouTube: Tyeen Taylor. Website:
        www.ttphilos.org."
      name: Dr. Tyeen C Taylor
      isPowerContributor: false
      profileUrl: https://disqus.com/by/tyeentaylor/
      url: ""
      location: Tucson, AZ
      id: "259523735"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "This article is now published in Frontiers in Forests and Global
      Change at: https://doi.org/10.3389/ffgc.2021.668228"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.02.15.431157v1
  tweets:
    - created_at: Tue Jul 20 22:19:50 +0000 2021
      id: 1417610225083949000
      id_str: "1417610225083949056"
      text: >-
        üí¨ bioRxiv comment on "A new field instrument for lea..."


        "This article is now published in Frontiers in Forests an‚Ä¶ https://t.co/lWo0jmumaB
      truncated: true
      entities:
        urls:
          - url: https://t.co/lWo0jmumaB
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 20 22:19:50 +0000 2021
      id: 1417610225918619600
      id_str: "1417610225918619650"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/rC1L76S9pZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/rC1L76S9pZ
      in_reply_to_status_id: 1417610225083949000
      in_reply_to_status_id_str: "1417610225083949056"
- preprint:
    id: "147637"
    doi: 10.1101/2021.06.25.449905
    first_posted: 2021-06-25
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.25.449905v1
    url: https://api.rxivist.org/v1/papers/147637
    title: Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute
      Sequelae of COVID-19 (PASC) Up to 15 Months Post-Infection
    category: immunology
    abstract: The recent COVID-19 pandemic is a treatment challenge in the acute
      infection stage but the recognition of chronic COVID-19 symptoms termed
      post-acute sequelae SARS-CoV-2 infection (PASC) may affect up to 30% of
      all infected individuals. The underlying mechanism and source of this
      distinct immunologic condition three months or more after initial
      infection remains elusive. Here, we investigated the presence of
      SARS-CoV-2 S1 protein in 46 individuals. We analyzed T-cell, B-cell, and
      monocytic subsets in both severe COVID-19 patients and in patients with
      post-acute sequelae of COVID-19 (PASC). The levels of both intermediate
      (CD14+, CD16+) and non-classical monocyte (CD14Lo, CD16+) were
      significantly elevated in PASC patients up to 15 months post-acute
      infection compared to healthy controls (P=0.002 and P=0.01, respectively).
      A statistically significant number of non-classical monocytes contained
      SARS-CoV-2 S1 protein in both severe (P=0.004) and PASC patients (P=0.02)
      out to 15 months post-infection. Non-classical monocytes were sorted from
      PASC patients using flow cytometric sorting and the SARS-CoV-2 S1 protein
      was confirmed by mass spectrometry. Cells from 4 out of 11 severe COVID-19
      patients and 1 out of 26 PASC patients contained ddPCR+ peripheral blood
      mononuclear cells, however, only fragmented SARS-CoV-2 RNA was found in
      PASC patients. No full length sequences were identified, and no sequences
      that could account for the observed S1 protein were identified in any
      patient. Non-classical monocytes are capable of causing inflammation
      throughout the body in response to fractalkine/CX3CL1 and RANTES/CCR5.
    authors:
      - name: Bruce Patterson
        orcid: null
      - name: Edgar B Francisco
        orcid: null
      - name: Ram Yogendra
        orcid: null
      - name: Emily Long
        orcid: null
      - name: Amruta Pise
        orcid: null
      - name: Hallison Rodrigues
        orcid: null
      - name: Eric Hall
        orcid: null
      - name: Monica Herrera
        orcid: null
      - name: Purvi Parikh
        orcid: null
      - name: Jose Guevara-Coto
        orcid: null
      - name: Timothy Triche
        orcid: null
      - name: Paul Scott
        orcid: null
      - name: Saboor Hekmati
        orcid: null
      - name: Dennis Maglinte
        orcid: null
      - name: Xaiolan Chang
        orcid: null
      - name: Rodrigo Rodriguez
        orcid: null
      - name: Javier Mora
        orcid: null
  comment:
    dislikes: 0
    thread: "8639378797"
    numReports: 0
    likes: 0
    id: "5462653813"
    createdAt: 2021-07-20T14:01:52
    author:
      username: msymeonides
      about: ""
      name: Mel Symeonides
      isPowerContributor: false
      profileUrl: https://disqus.com/by/msymeonides/
      url: ""
      location: ""
      id: "371521897"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      (My peer review no longer appears because it was made on the first version
      of the article, and it unfortunately did not receive a response before the
      manuscript was updated. I am thus reposting it here on the second version,
      hoping for a response. The review is identical to the first one, apart
      from the comment on the new sequencing data.)


      With this study, Patterson et al. present a potentially very significant finding: that SARS-CoV-2 antigen persists in non-classical monocytes from Long COVID patients up to 15 months after the initial infection. The data supporting this finding are of moderate to low strength, as presented, primarily due to a wide range of major and minor presentation issues that are listed below. Most of these can be addressed easily, though it is unclear if some additional controls may be required. Finally, some orthogonal approaches are suggested that could be potentially very valuable in terms of increasing confidence in the findings (namely microscopy and immunoblotting), though these are not essential for the interpretation of the results as shown.



      The authors are to be commended for tackling Long COVID head-on and getting right to the heart of the matter in terms of finding the pathological cause of this disease. That said, unfortunately, this manuscript requires considerable revision in order to be interpretable and allow others to reproduce the findings (which will be of critical importance, given their potential significance).





      Major issues:



      - Table 1 and the accompanying text seems to indicate that PBMCs were tested for the presence of viral RNA by ddPCR. However, in the Material/Methods section, it is stated that nucleic acids were extracted from plasma, not from PBMCs. Please clarify this point as it is of critical relevance. Indeed, both plasma and PBMCs should have been individually tested in order to determine whether viral RNA was solely intracellular.



      - It is very unclear what Figure 2 is presenting. Presumably each row represents a different subject, but it is not denoted which subject belongs to which group, making intepretation very difficult. I presume this was an ommission.



      - Supplementary Table 1 was not provided, making it very difficult to evaluate the flow cytometry data. Even if that table were present, the methods provided for flow cytometry are very sparse. What steps were undertaken to establish the specificity of the Spike antibody? Was the Spike staining done after fixation and permeabilization? Was PE conjugation of this antibody done in-house, and if so, using which kit, and how was it verified that the conjugation and quenching were successful and that staining was specific within the context of the entire antibody panel? Were FMO controls done in the context of this new panel that includes the S1 antibody? Was Fc block included? etc.



      - The newly-added sequencing data are difficult to interpret. It seems that the authors interpret the poor sequence coverage as indicative of non-replicating virus and in line with high Ct values, yet they do not seem to comment on the fact that there is nevertheless some seemingly full-length viral genome present in these cells! This is a potentially very important finding and its source will need to be investigated. Additionally, the sequencing results are inconsistent with the PBMC RT-PCR results, where only LH5 was positive, yet LH1-5 all had similar sequence coverage. The names of the samples in Table 2 do not correspond to any other name in this manuscript, clearly they were not renamed as they should have been. In fact, some of these sample names look curiously like name initials, which is a potential study subject data privacy issue. Finally, it does not seem that any healthy controls or previous COVID/non-LH subjects were tested in the same manner, which would be very valuable information.




      - In general, the Figure Legends are very sparse and should be much more descriptive.





      Minor/moderate issues:



      - Table 1 shows that one of the study subjects was asymptomatic. Where is this subject grouped in the subsequent analysis? ALso, "NS" is not defined, presumably it means "nasopharyngeal swab"?



      - In Figure 2, left column, the CD14/CD16 gates shown were not applied equally from sample to sample. Furthermore, in the middle column it looks like S1+ non-classical cells tend to have a low-SSC profile, while S1- cells have a high-SSC profile that clusters together with intermediate cells. This suggests that the intermediate/non-classical discriminating gates may not have been set appropriately. 



      - The quantification shown in the middle column of Figure 2 is labeled "CD16+CD14+COVIDS1+", however no "CD16+CD14+" subset is defined. Presumably the authors refer to the aggregate of the "CD14++CD16+" intermediate and "CD14loCD16+" non-classical subsets. This should be clearly stated as it makes interpretation of the data shown very difficult. Additionally, the quantification is based on the aggregate population, whereas based on the color coding, one would expect individual quantification for each subset. Given the relatively very minor contribution of the intermediate subset to the observed Spike S1 signal, it is unclear why this was included at all in this plot - why not just show the non-classical subset and base the quantification solely based on that, or alternatively, show quantification of each subset rather than their aggregate?



      - The labeling in Figure 3 could be better, the angled X axis labels are very difficult to follow. Maybe just indicate the monocyte subset as a title above each plot, and/or label each plot as a subfigure?



      - No information is provided on the statistical analyses done.



      - I did not look into all the cited work, but in one case (ref. no. 19) was puzzled to see that a review article was cited in which the relevant information was in turn derived from a single primary research article. Surely it makes more sense to just cite that primary research paper rather than the review?





      General comments:



      - Why was S1 the only SARS-CoV-2 antigen stained for? One would expect that you would have quickly tried to look for other viral antigens, particularly Nucleocapsid, in order to begin to understand whether there might be virus particles present, especially since you found viral RNA in some samples. Additionally, some microscopy data on sorted non-classical monocytes would have been very valuable to validate what you see by flow cytometry, also because one could then evaluate whether the Spike signal in these cells looks like the expected pattern for protein being actively synthesized by the cell and present on the cell surface, or whether it is captured antigen from some site of viral persistence and is sequestered in some intracellular compartment. Finally, a Western blot for Spike (and other viral antigens) in flow-sorted monocytes would be of immense value to further validate the presence of this antigen and observe the state of the protein - indeed, it is rather odd that you seemingly went for LCMS before trying either microscopy or a Western blot!



      - The potential connections with the CX3CL1 pathway mentioned in Discussion are very interesting. Unfortunately, the authors have not demonstrated any elevation of CX3CL1 associated with severe acute COVID or long COVID disease, nor the presence of CX3CR1 on the particular cells of interest. If such data exist, please present them, otherwise this Discussion is rather speculative and much more work will be required to frame it in the appropriate context for a primary research paper. Alternatively, this discussion might be better suited for a separate Review article.



      - Much of the published work on Long COVID and other post-COVID conditions such as MIS-C is omitted here, and should be cited and discussed as appropriate.





      Mel Symeonides, Ph.D.

      Postdoctoral Associate

      Department of Microbiology & Molecular Genetics

      University of Vermont

      Burlington, VT
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.25.449905v2
  tweets:
    - created_at: Wed Jul 21 01:04:38 +0000 2021
      id: 1417651697984450600
      id_str: "1417651697984450570"
      text: >-
        üí¨ bioRxiv comment on "Persistence of SARS CoV-2 S1 P..."


        "(My peer review no longer appears because it was made on‚Ä¶ https://t.co/7XZJj878Z0
      truncated: true
      entities:
        urls:
          - url: https://t.co/7XZJj878Z0
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 21 01:04:38 +0000 2021
      id: 1417651698907156500
      id_str: "1417651698907156490"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/cWG31NeMoQ
      truncated: false
      entities:
        urls:
          - url: https://t.co/cWG31NeMoQ
      in_reply_to_status_id: 1417651697984450600
      in_reply_to_status_id_str: "1417651697984450570"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8603406700"
    numReports: 0
    likes: 1
    id: "5459619628"
    createdAt: 2021-07-17T21:41:27
    author:
      username: disqus_V0SXA888Fs
      about: ""
      name: David Timmons
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_V0SXA888Fs/
      url: ""
      location: ""
      id: "372475086"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Do we have an estimate of when this article will be peer reviewed
      and move out of the preprint shadow?  Many skeptics ignore anything listed
      as a preprint, no matter how much work has been done.  Including those
      unvaccinated who test positive for Covid 19 antibodies would put the US
      population with some form of immunity at about 75%.  That means our
      vulnerable population (unvaccinated with no prior Covid 19 infection) at
      25% or less.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v3
  tweets:
    - created_at: Wed Jul 21 12:31:38 +0000 2021
      id: 1417824588713676800
      id_str: "1417824588713676808"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "Do we have an estimate of when this article will be peer‚Ä¶ https://t.co/7ZMhYrLkAL
      truncated: true
      entities:
        urls:
          - url: https://t.co/7ZMhYrLkAL
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 21 12:31:38 +0000 2021
      id: 1417824589560823800
      id_str: "1417824589560823810"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1417824588713676800
      in_reply_to_status_id_str: "1417824588713676808"
- preprint:
    id: "143052"
    doi: 10.1101/2021.05.20.21257520
    first_posted: 2021-05-24
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.20.21257520v1
    url: https://api.rxivist.org/v1/papers/143052
    title: "ACTIVATE-2: A DOUBLE-BLIND RANDOMIZED TRIAL OF BCG VACCINATION AGAINST
      COVID19 IN INDIVIDUALS AT RISK"
    category: infectious-diseases
    abstract: BCG vaccination induces heterologous protection against respiratory
      tract infections, and in children improves survival independently of
      tuberculosis prevention. The phase III ACTIVATE-2 study assessed whether
      BCG could also protect against COVID19 in the elderly. In this
      double-blind, randomized trial, elderly Greek patients were randomized
      (1:1) to receive either BCG revaccination or placebo at hospital
      discharge, followed by 6 months observation for incidence of COVID19
      infection. BCG revaccination resulted in 68% risk reduction for total
      COVID19 clinical and microbiological diagnoses (OR 0.32, 95% CI
      0.13-0.79). Five patients in the placebo group and one in the
      BCG-vaccinated group had severe COVID19 that necessitated hospitalization.
      3 months after BCG vaccination 1.3% of placebo and 4.7% of BCG-vaccinated
      volunteers had anti-SARS-CoV-2 antibodies. These data argue that BCG
      revaccination is safe and protects the elderly against COVID19. BCG
      revaccination may represent a viable preventive measure against COVID19.
    authors:
      - name: Maria Tsilika
        orcid: null
      - name: Esther Taks
        orcid: null
      - name: Konstantinos Dolianitis
        orcid: null
      - name: Antigone Kotsaki
        orcid: null
      - name: Konstantinos Leventogiannis
        orcid: null
      - name: Christina Damoulari
        orcid: null
      - name: Maria Kostoula
        orcid: null
      - name: Maria Paneta
        orcid: null
      - name: Gerogios Adamis
        orcid: null
      - name: Ilias C. Papanikolaou
        orcid: null
      - name: Kimon Stamatelopoulos
        orcid: null
      - name: Amalia Bolanou
        orcid: null
      - name: Konstantinos Katsaros
        orcid: null
      - name: Christina Delavinia
        orcid: null
      - name: Ioannis Perdios
        orcid: null
      - name: Aggeliki Pandi
        orcid: null
      - name: Konstantinos Tsiakos
        orcid: null
      - name: Nektarios Proios
        orcid: null
      - name: Emmanouela Kalogianni
        orcid: null
      - name: Ioannis Delis
        orcid: http://orcid.org/0000-0001-8940-5036
      - name: Efstathios Skliros
        orcid: null
      - name: Karolina Akinosoglou
        orcid: http://orcid.org/0000-0002-4289-9494
      - name: Aggeliki Perdikouli
        orcid: null
      - name: Garyfallia Poulakou
        orcid: null
      - name: Haralampos Milionis
        orcid: http://orcid.org/0000-0003-3958-2266
      - name: Eva Athanasopoulou
        orcid: null
      - name: Eleftheria Kalpaki
        orcid: null
      - name: Leda Efstratiou
        orcid: null
      - name: Varvara Perraki
        orcid: null
      - name: Antonios Papadopoulos
        orcid: null
      - name: Mihai G. Netea
        orcid: http://orcid.org/0000-0003-2421-6052
      - name: Evangelos Giamarellos-Bourboulis
        orcid: null
  comment:
    dislikes: 0
    thread: "8547318416"
    numReports: 0
    likes: 0
    id: "5463652957"
    createdAt: 2021-07-21T07:38:44
    author:
      username: emelineoudin
      about: ""
      name: emeline OUDIN
      isPowerContributor: false
      profileUrl: https://disqus.com/by/emelineoudin/
      url: ""
      location: ""
      id: "372629618"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Hello, i've check. Gr√®ce street vaccination on 27 d√©cembre 

      https://www.reuters.com/business/healthcare-pharmaceuticals/greek-nursing-home-gets-best-new-years-present-vaccinations-begin-2021-01-04/.

      26.000 vaccinated at january 8th. 5000 jab per day so mathematiquely 125.000 on January 28th (only healthcare and eldery)
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.20.21257520v1
  tweets:
    - created_at: Wed Jul 21 14:17:50 +0000 2021
      id: 1417851313149423600
      id_str: "1417851313149423616"
      text: >-
        üí¨ medRxiv comment on "ACTIVATE-2: A DOUBLE-BLIND RAN..."


        "Hello, i've check. Gr√®ce street vaccination on 27 d√©cemb‚Ä¶ https://t.co/KtDDIxSjr2
      truncated: true
      entities:
        urls:
          - url: https://t.co/KtDDIxSjr2
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 21 14:17:50 +0000 2021
      id: 1417851314034421800
      id_str: "1417851314034421764"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/aYnY2HA5IH
      truncated: false
      entities:
        urls:
          - url: https://t.co/aYnY2HA5IH
      in_reply_to_status_id: 1417851313149423600
      in_reply_to_status_id_str: "1417851313149423616"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 0
    id: "5462882434"
    createdAt: 2021-07-20T16:53:23
    author:
      username: KKRay
      about: ""
      name: KKRay
      isPowerContributor: false
      profileUrl: https://disqus.com/by/KKRay/
      url: ""
      location: ""
      id: "570329"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Why would anyone need to ‚Äúmention vitamin D‚Äù here? It‚Äôs a study
      about masks.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Wed Jul 21 16:32:05 +0000 2021
      id: 1417885098469253000
      id_str: "1417885098469253123"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Why would anyone need to ‚Äúmention vitamin D‚Äù here? It‚Äôs‚Ä¶ https://t.co/7cc2qikDSV
      truncated: true
      entities:
        urls:
          - url: https://t.co/7cc2qikDSV
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 21 16:32:05 +0000 2021
      id: 1417885099408822300
      id_str: "1417885099408822273"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU30MFJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU30MFJ
      in_reply_to_status_id: 1417885098469253000
      in_reply_to_status_id_str: "1417885098469253123"
- preprint:
    id: "149556"
    doi: 10.1101/2021.07.09.451701
    first_posted: 2021-07-09
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.09.451701v1
    url: https://api.rxivist.org/v1/papers/149556
    title: "Your head is there to move you around: Goal-driven models of the primate
      dorsal pathway"
    category: neuroscience
    abstract: "Neurons in the dorsal visual pathway of the mammalian brain are
      selective for motion stimuli, with the complexity of stimulus
      representations increasing along the hierarchy. This progression is
      similar to that of the ventral visual pathway, which is well characterized
      by artificial neural networks (ANNs) optimized for object recognition. In
      contrast, there are no image-computable models of the dorsal stream with
      comparable explanatory power. We hypothesized that the properties of
      dorsal stream neurons could be explained by a simple learning objective:
      the need for an organism to orient itself during self-motion. To test this
      hypothesis, we trained a 3D ResNet in a self-supervised manner to predict
      an agent's self-motion parameters from visual stimuli in a simulated
      environment. We found that the responses in this network accounted well
      for the selectivity of neurons in a large database of single-neuron
      recordings from the dorsal visual stream of non-human primates. In
      contrast, ANNs trained for action recognition or with a contrastive
      objective could not explain responses in the dorsal stream, despite also
      being trained on naturalistic videos with moving objects. These results
      demonstrate that an ecologically relevant, self-supervised cost function
      can account for dorsal stream properties in the primate brain."
    authors:
      - name: Patrick J Mineault
        orcid: http://orcid.org/0000-0001-5519-842X
      - name: Shahab Bakhtiari
        orcid: http://orcid.org/0000-0003-2439-7252
      - name: Blake A Richards
        orcid: http://orcid.org/0000-0001-9662-2151
      - name: Christopher C. Pack
        orcid: null
  comment:
    dislikes: 0
    thread: "8639713497"
    numReports: 0
    likes: 0
    id: "5462193939"
    createdAt: 2021-07-20T02:42:17
    author:
      username: patrickmineault
      about: ""
      name: Patrick Mineault
      isPowerContributor: false
      profileUrl: https://disqus.com/by/patrickmineault/
      url: ""
      location: ""
      id: "216580447"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Thanks! I'm curious as well, will definitely add that to the next revision.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.07.09.451701v1
  tweets:
    - created_at: Wed Jul 21 18:25:50 +0000 2021
      id: 1417913727681183700
      id_str: "1417913727681183744"
      text: >-
        üí¨ bioRxiv comment on "Your head is there to move you..."


        "Thanks! I'm curious as well, will definitely add that to‚Ä¶ https://t.co/2mIgxiaqC3
      truncated: true
      entities:
        urls:
          - url: https://t.co/2mIgxiaqC3
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 21 18:25:51 +0000 2021
      id: 1417913728520032300
      id_str: "1417913728520032260"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/XgnQTomjWN
      truncated: false
      entities:
        urls:
          - url: https://t.co/XgnQTomjWN
      in_reply_to_status_id: 1417913727681183700
      in_reply_to_status_id_str: "1417913727681183744"
- preprint:
    id: 100751
    metric: 22
    title: Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that
      blocks replication of SARS-CoV-2 in vitro
    url: https://api.rxivist.org/v1/papers/100751
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.08.31.274639v1
    doi: 10.1101/2020.08.31.274639
    category: microbiology
    first_posted: 2020-09-01
    abstract: >-
      There is an urgent need for anti-viral agents that treat SARS-CoV-2
      infection. The shortest path to clinical use is repurposing of drugs that
      have an established safety profile in humans. Here, we first screened a
      library of 1,900 clinically safe drugs for inhibiting replication of OC43,
      a human beta-coronavirus that causes the common-cold and is a relative of
      SARS-CoV-2, and identified 108 effective drugs. We further evaluated the
      top 26 hits and determined their ability to inhibit SARS-CoV-2, as well as
      other pathogenic RNA viruses. 20 of the 26 drugs significantly inhibited
      SARS-CoV-2 replication in human lung cells (A549 epithelial cell line),
      with EC50 values ranging from 0.1 to 8 micromolar. We investigated the
      mechanism of action for these and found that masitinib, a drug originally
      developed as a tyrosine-kinase inhibitor for cancer treatment, strongly
      inhibited the activity of the SARS-CoV-2 main protease 3CLpro. X-ray
      crystallography revealed that masitinib directly binds to the active site
      of 3CLpro, thereby blocking its enzymatic activity. Mastinib also
      inhibited the related viral protease of picornaviruses and blocked
      picornaviruses replication. Thus, our results show that masitinib has
      broad anti-viral activity against two distinct beta-coronaviruses and
      multiple picornaviruses that cause human disease and is a strong candidate
      for clinical trials to treat SARS-CoV-2 infection.


      ### Competing Interest Statement


      The authors have declared no competing interest.
    authors:
      - name: Nir Drayman
      - name: Krysten A. Jones
      - name: Saara-Anne Azizi
      - name: Heather M Froggatt
      - name: Kemin Tan
      - name: Natalia Ivanovna Maltseva
      - name: Siquan Chen
      - name: Vlad Nicolaescu
      - name: Steve Dvorkin
      - name: Kevin Furlong
      - name: Rahul S. Kathayat
      - name: Mason R. Firpo
      - name: Vincent Mastrodomenico
      - name: Emily A Bruce
      - name: Madaline M. Schmidt
      - name: Robert Jedrzejczak
      - name: Miguel √Å. Mu√±oz-Al√≠a
      - name: Brooke Schuster
      - name: Vishnu Nair
      - name: Jason W. Botten
      - name: Christopher Byron Brooke
      - name: Susan C. Baker
      - name: Bryan C. Mounce
      - name: Nicholas S Heaton
      - name: Bryan C. Dickinson
      - name: Andrzej Jaochimiak
      - name: Glenn Randall
      - name: Sava≈ü Tay
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Wed Jul 21 20:17:34 +0000 2021
      id: 1417941844579610600
      id_str: "1417941844579610624"
      text: >-
        üî• bioRxiv Microbiology preprint by N. Drayman et al:


        "Drug repurposing screen identifies masitinib as a 3CLpro inh‚Ä¶ https://t.co/4DrtbmPRIu
      truncated: true
      entities:
        urls:
          - url: https://t.co/4DrtbmPRIu
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "93903"
    doi: 10.1101/2020.08.07.238329
    first_posted: 2020-08-07
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.08.07.238329v3
    url: https://api.rxivist.org/v1/papers/93903
    title: Genome Diversity in Ukraine
    category: genomics
    abstract: >-
      The main goal of this collaborative effort is to provide genome wide data
      for the previously underrepresented population in Eastern Europe, and to
      provide cross-validation of the data from genome sequences and genotypes
      of the same individuals acquired by different technologies. We collected
      97 genome-grade DNA samples from consented individuals representing major
      regions of Ukraine that were consented for the public data release.
      DNBSEQ-G50 sequences, and genotypes by an Illumina GWAS chip were
      cross-validated on multiple samples, and additionally referenced to one
      sample that has been resequenced by Illumina NovaSeq6000 S4 at high
      coverage. The genome data has been searched for genomic variation
      represented in this population, and a number of variants have been
      reported: large structural variants, indels, CNVs, SNPs and
      microsatellites. This study provides the largest to-date survey of genetic
      variation in Ukraine, creating a public reference resource aiming to
      provide data for historic and medical research in a large understudied
      population. While most of the common variation is shared with other
      European populations, this survey of population variation contributes a
      number of novel SNPs and structural variants that have not been reported
      in the gnomAD/1KG databases representing global distribution of genomic
      variation. This data will contribute a wealth of new information bringing
      forth different risk and/or protective alleles. The newly discovered low
      frequency and local variants can be added to the current genotyping arrays
      for genome wide association studies, clinical trials, and in genome
      assessment of proliferating cancer cells.


      ### Competing Interest Statement


      The following authors declare that they have no competing interests: Taras K. Oleksyk, Walter W. Wolfsberger, Alexandra Weber, Khrystyna Shchubelka, Stephanie O. Castro-Marquez, Sarah Medley, Alina Urbanovych, Patricia Boldyzhar, Viktoriya Stakhovska, Kateryna Malyar, Yaroslava Hasynets, Juan L. Rodriguez-Flores, Fabia Battistuzzi, Siru Chen, Meredith Yeager, Michael Dean, Olga T. Oleksyk, Ryan E. Mills , and Volodymyr Smolanka The following authors may have competing interests: Yuan Liu, Huanming Yang, Olga Levchuk, Alla Patrus, Nelya Lazar
    authors:
      - name: Taras K. Oleksyk
        orcid: http://orcid.org/0000-0002-8148-3918
      - name: Walter W. Wolfsberger
        orcid: null
      - name: Alexandra Weber
        orcid: null
      - name: Khrystyna Shchubelka
        orcid: null
      - name: Olga T. Oleksyk
        orcid: null
      - name: Olga Levchuk
        orcid: null
      - name: Alla Patrus
        orcid: null
      - name: Nelya Lazar
        orcid: null
      - name: Stephanie O. Castro-Marquez
        orcid: null
      - name: Patricia Boldyzhar
        orcid: null
      - name: Alina Urbanovych
        orcid: null
      - name: Viktoriya Stakhovska
        orcid: null
      - name: Kateryna Malyar
        orcid: null
      - name: Svitlana Chervyakova
        orcid: null
      - name: Olena Podoroha
        orcid: null
      - name: Natalia Kovalchuk
        orcid: null
      - name: Mikhailo Neymet
        orcid: null
      - name: Yaroslava Hasynets
        orcid: null
      - name: Juan L. Rodriguez-Flores
        orcid: null
      - name: Sarah Medley
        orcid: null
      - name: Fabia Ursula Battistuzzi
        orcid: http://orcid.org/0000-0003-1852-2934
      - name: Ryan Liu
        orcid: null
      - name: Yong Hou
        orcid: http://orcid.org/0000-0002-0420-0726
      - name: Siru Chen
        orcid: null
      - name: Huanming Yang
        orcid: null
      - name: Meredith Yeager
        orcid: null
      - name: Michael Dean
        orcid: http://orcid.org/0000-0003-2234-0631
      - name: Ryan E. Mills
        orcid: http://orcid.org/0000-0003-3425-6998
      - name: Volodymyr Smolanka
        orcid: null
  comment:
    dislikes: 0
    thread: "8157107909"
    numReports: 0
    likes: 0
    id: "5463979521"
    createdAt: 2021-07-21T14:37:48
    author:
      username: tarasoleksyk
      about: ""
      name: Taras Oleksyk
      isPowerContributor: false
      profileUrl: https://disqus.com/by/tarasoleksyk/
      url: ""
      location: ""
      id: "99396374"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      A modified and improved 

      version of this article has been published in GigaScience.   doi: 10.1093/gigascience/giaa159
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.08.07.238329v1
  tweets:
    - created_at: Wed Jul 21 20:21:25 +0000 2021
      id: 1417942813405188000
      id_str: "1417942813405188097"
      text: |-
        üí¨ bioRxiv comment on "Genome Diversity in Ukraine..."

        "A modified and improved 
        version of this article has been p‚Ä¶ https://t.co/ErGfNsH9JO
      truncated: true
      entities:
        urls:
          - url: https://t.co/ErGfNsH9JO
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 21 20:21:25 +0000 2021
      id: 1417942814378270700
      id_str: "1417942814378270720"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/IBV3Qxtnum
      truncated: false
      entities:
        urls:
          - url: https://t.co/IBV3Qxtnum
      in_reply_to_status_id: 1417942813405188000
      in_reply_to_status_id_str: "1417942813405188097"
- preprint:
    id: "143071"
    doi: 10.1101/2021.05.22.21257658
    first_posted: 2021-05-24
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.22.21257658v1
    url: https://api.rxivist.org/v1/papers/143071
    title: Effectiveness of COVID-19 vaccines against the B.1.617.2 variant
    category: epidemiology
    abstract: "Background: The B.1.617.2 COVID-19 variant has contributed to the
      surge in cases in India and has now been detected across the globe,
      including a notable increase in cases in the UK. We estimate the
      effectiveness of the BNT162b2 and ChAdOx1 COVID-19 vaccines against this
      variant. Methods: A test negative case control design was used to estimate
      the effectiveness of vaccination against symptomatic disease with both
      variants over the period that B.1.617.2 began circulating with cases
      identified based on sequencing and S-gene target status. Data on all
      symptomatic sequenced cases of COVID-19 in England was used to estimate
      the proportion of cases with B.1.617.2 compared to the predominant strain
      (B.1.1.7) by vaccination status. Results: Effectiveness was notably lower
      after 1 dose of vaccine with B.1.617.2 cases 33.5% (95%CI: 20.6 to 44.3)
      compared to B.1.1.7 cases 51.1% (95%CI: 47.3 to 54.7) with similar results
      for both vaccines. With BNT162b2 2 dose effectiveness reduced from 93.4%
      (95%CI: 90.4 to 95.5) with B.1.1.7 to 87.9% (95%CI: 78.2 to 93.2) with
      B.1.617.2. With ChAdOx1 2 dose effectiveness reduced from 66.1% (95% CI:
      54.0 to 75.0) with B.1.1.7 to 59.8% (95%CI: 28.9 to 77.3) with B.1.617.2.
      Sequenced cases detected after 1 or 2 doses of vaccination had a higher
      odds of infection with B.1.617.2 compared to unvaccinated cases (OR 1.40;
      95%CI: 1.13-1.75). Conclusions: After 2 doses of either vaccine there were
      only modest differences in vaccine effectiveness with the B.1.617.2
      variant. Absolute differences in vaccine effectiveness were more marked
      with dose 1. This would support maximising vaccine uptake with two doses
      among vulnerable groups."
    authors:
      - name: Jamie Lopez Bernal
        orcid: http://orcid.org/0000-0002-1301-5653
      - name: Nick Andrews
        orcid: null
      - name: Charlotte Gower
        orcid: null
      - name: Eileen Gallagher
        orcid: null
      - name: Ruth Simmons
        orcid: http://orcid.org/0000-0001-8156-0146
      - name: Simon Thelwall
        orcid: http://orcid.org/0000-0002-0434-2724
      - name: Elise Tessier
        orcid: null
      - name: Natalie Groves
        orcid: null
      - name: Gavin Dabrera
        orcid: http://orcid.org/0000-0003-4606-5945
      - name: Richard Myers
        orcid: null
      - name: Colin Campbell
        orcid: null
      - name: Gayatri Amirthalingam
        orcid: http://orcid.org/0000-0003-2078-0975
      - name: Matt Edmunds
        orcid: null
      - name: Maria Zambon
        orcid: http://orcid.org/0000-0002-8897-7881
      - name: Kevin Brown
        orcid: null
      - name: Susan Hopkins
        orcid: http://orcid.org/0000-0001-5179-5702
      - name: Meera Chand
        orcid: http://orcid.org/0000-0001-9697-0340
      - name: Mary Ramsay
        orcid: null
  comment:
    dislikes: 0
    thread: "8547961204"
    numReports: 0
    likes: 0
    id: "5461457742"
    createdAt: 2021-07-19T15:36:28
    author:
      username: disqus_LzEkLC0OVJ
      about: ""
      name: Rodolfo
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_LzEkLC0OVJ/
      url: ""
      location: ""
      id: "147606095"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "First of all, yes, they report more deaths in the >50 years group
      among vaccinated people (50) vs not vaccinated (38) BUT, it's not wise to
      directly associate those numbers with receiving the vaccine. There are
      many factors that aren't mentioned/accounted in that report... For
      example: if vaccinated people were more exposed (or not) to covid19 since
      they could have gotten a false sense of safety, which IS something that is
      happening... comorbidities (obesity, diabetes, hypertension, etc), gender,
      habits and list goes on... it also important to notice that on the <50
      years group, there is a 3 fold increase in deaths among not vaccinated (6)
      vs vaccinated (2)... This report is more focused for variant tracking than
      actual effects or study of vaccines."
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.22.21257658v1
  tweets:
    - created_at: Wed Jul 21 22:19:23 +0000 2021
      id: 1417972499002843100
      id_str: "1417972499002843144"
      text: >-
        üí¨ medRxiv comment on "Effectiveness of COVID-19 vacc..."


        "First of all, yes, they report more deaths in the &gt;50 ye‚Ä¶ https://t.co/0rxkNSZPcT
      truncated: true
      entities:
        urls:
          - url: https://t.co/0rxkNSZPcT
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 21 22:19:23 +0000 2021
      id: 1417972499724349400
      id_str: "1417972499724349446"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/eQVSQuTGsy
      truncated: false
      entities:
        urls:
          - url: https://t.co/eQVSQuTGsy
      in_reply_to_status_id: 1417972499002843100
      in_reply_to_status_id_str: "1417972499002843144"
- preprint:
    id: "118350"
    doi: 10.1101/2020.10.28.20221671
    first_posted: 2020-10-29
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.10.28.20221671v1
    url: https://api.rxivist.org/v1/papers/118350
    title: Accurate Prediction of Breast Cancer Survival through Coherent Voting
      Networks with Gene Expression Profiling
    category: oncology
    abstract: We describe a novel machine learning methodology which we call
      Coherent Voting Network (CVN) and we demonstrate its usefulness by
      building a 5-years prognostic predictor for post-surgery breast cancer
      patients based on CVNs. Coherent Voting Network (CVN) is a supervised
      learning paradigm designed explicitly to uncover non-linear, combinatorial
      patterns in complex data, within a statistical robust framework. Breast
      Cancer patients after surgery may receive several types of post-surgery
      adjuvant therapeutic regimen (endocrine, radio- or chemo-therapy, and
      combinations thereof) aiming at reducing relapse and the formation of
      metastases, and thus favouring log term survival. We wish to predict the
      outcome of adjuvant therapy using just small molecular fingerprints (mRNA)
      of the patients transcriptome. Our aim is to have simultaneously high
      scores for PPV (positive predictive value) and NPV (negative predictive
      value) as these are important indices for the final clinical applications
      of the predictor. A Training-validate-test protocol is applied onto CVN
      built on patient data from the Metabric Consortium (about 2000 patients).
      For the testing pool of 82 lymph node positive patients we obtain PPV 0.77
      and NPV 0.78 (Odds Ratio 11.50); for the pool of 61 lymph node negative
      patients we obtain PPV 0.68 and NPV 0.88 (Odds Ratio 16.07). Improved
      results are obtained on some specific sub-types of BC. For the testing
      pool of 16 TNBC patients we obtain PPV 1.0 and NPV 0.83 (Odds Ratio
      45.00). For the testing pool of 18 HER2+ patients we obtain PPV 0.91 and
      NPV 1.0 (Odds Ratio 40.00). For the testing pool of 41 Luminal B patients
      we obtain PPV 0.75 and NPV 0.95 (Odds Ratio 60.00). Effectiveness of the
      selected fingerprints is confirmed also on several independent data sets
      (for a total of 601 patients) from the NCBI Gene Expression Omnibus (GEO).
    authors:
      - name: Marco Pellegrini
        orcid: http://orcid.org/0000-0003-3151-9481
  comment:
    dislikes: 0
    thread: "8256904447"
    numReports: 0
    likes: 0
    id: "5461453536"
    createdAt: 2021-07-19T15:32:51
    author:
      username: disqus_t3OZvRuTx3
      about: ""
      name: Marco Pellegrini
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_t3OZvRuTx3/
      url: ""
      location: ""
      id: "372550626"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      This paper in revised form  has been accepted in a peer-reviewed journal:

      Pellegrini, 

      M. Accurate prediction of breast cancer survival through coherent voting networks with gene expression profiling.

      Sci Rep 11, 14645 (2021). https://doi.org/10.1038/s41598-021-94243-z

      link: https://www.nature.com/articles/s41598-021-94243-z
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.10.28.20221671v1
  tweets:
    - created_at: Thu Jul 22 01:04:54 +0000 2021
      id: 1418014154338799600
      id_str: "1418014154338799619"
      text: >-
        üí¨ medRxiv comment on "Accurate Prediction of Breast ..."


        "This paper in revised form  has been accepted in a peer-‚Ä¶ https://t.co/PK4PDP5qaG
      truncated: true
      entities:
        urls:
          - url: https://t.co/PK4PDP5qaG
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 22 01:04:54 +0000 2021
      id: 1418014155030900700
      id_str: "1418014155030900741"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/s0H6bv4vzD
      truncated: false
      entities:
        urls:
          - url: https://t.co/s0H6bv4vzD
      in_reply_to_status_id: 1418014154338799600
      in_reply_to_status_id_str: "1418014154338799619"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5460528285"
    createdAt: 2021-07-18T19:04:01
    author:
      username: disqus_RdasvD8MPO
      about: Hairy Jewish Guy
      name: Jewbacca
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_RdasvD8MPO/
      url: ""
      location: Jerusalem, Israel
      id: "144224121"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      There‚Äôs a ton of studies one web search away. Here‚Äôs the most commonly
      cited:


      https://www.medrxiv.org/content/10.1101/2021.01.29.21250653v1
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Thu Jul 22 12:32:34 +0000 2021
      id: 1418187210734637000
      id_str: "1418187210734637059"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "There‚Äôs a ton of studies one web search away. Here‚Äôs the‚Ä¶ https://t.co/iCf31Mqbyg
      truncated: true
      entities:
        urls:
          - url: https://t.co/iCf31Mqbyg
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 22 12:32:34 +0000 2021
      id: 1418187211615481900
      id_str: "1418187211615481859"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1418187210734637000
      in_reply_to_status_id_str: "1418187210734637059"
- preprint:
    id: "146930"
    doi: 10.1101/2021.06.20.21259195
    first_posted: 2021-06-21
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.20.21259195v1
    url: https://api.rxivist.org/v1/papers/146930
    title: Rapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in
      the United States
    category: infectious-diseases
    abstract: The SARS-CoV-2 variant of concern B.1.617.2 displaced B.1.1.7 as the
      dominant variant in England and other countries. This study aimed to
      determine whether B.1.617.2 was also displacing B.1.1.7 in the United
      States. We analyzed PCR testing results and viral sequencing results of
      samples collected across the United States, and showed that B.1.1.7 was
      rapidly being displaced and is no longer responsible for the majority of
      new cases. The percentage of SARS-CoV-2 positive cases that are B.1.1.7
      dropped from 67% in May 2021 to 33.4% in just 5 weeks. Our analysis showed
      rapid growth of variants B.1.617.2 and P.1 as the primary drivers for this
      displacement. Currently, the growth rate of B.1.617.2 was higher than P.1
      in the US (0.66 vs. 0.34), which is consistent with reports from other
      countries.
    authors:
      - name: Alexandre Bolze
        orcid: http://orcid.org/0000-0001-7399-2766
      - name: Elizabeth T Cirulli
        orcid: http://orcid.org/0000-0001-7808-2809
      - name: Shishi Luo
        orcid: null
      - name: Simon White
        orcid: http://orcid.org/0000-0001-6375-2363
      - name: Dana Wyman
        orcid: null
      - name: Andrew Dei Rossi
        orcid: null
      - name: Tyler Cassens
        orcid: null
      - name: Sharoni Jacobs
        orcid: null
      - name: Jason Nguyen
        orcid: http://orcid.org/0000-0002-6812-9017
      - name: Jimmy M Ramirez
        orcid: null
      - name: Efren Sandoval
        orcid: null
      - name: Xueqing Wang
        orcid: http://orcid.org/0000-0002-2049-8403
      - name: David Wong
        orcid: null
      - name: David Becker
        orcid: null
      - name: Marc Laurent
        orcid: null
      - name: James Lu
        orcid: http://orcid.org/0000-0002-1873-7049
      - name: Magnus Isaksson
        orcid: null
      - name: Nicole L Washington
        orcid: http://orcid.org/0000-0001-8936-9143
      - name: William Lee
        orcid: http://orcid.org/0000-0001-9582-4413
  comment:
    dislikes: 0
    thread: "8623269636"
    numReports: 0
    likes: 0
    id: "5460493630"
    createdAt: 2021-07-18T18:29:06
    author:
      username: paulbuehrens
      about: ""
      name: Paul Buehrens
      isPowerContributor: false
      profileUrl: https://disqus.com/by/paulbuehrens/
      url: ""
      location: ""
      id: "64878129"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Who is modeling the rapid growth of the delta variant in the US?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.20.21259195v2
  tweets:
    - created_at: Thu Jul 22 14:21:39 +0000 2021
      id: 1418214664228331500
      id_str: "1418214664228331523"
      text: >-
        üí¨ medRxiv comment on "Rapid displacement of SARS-CoV..."


        "Who is modeling the rapid growth of the delta variant in‚Ä¶ https://t.co/8ElHPHHmui
      truncated: true
      entities:
        urls:
          - url: https://t.co/8ElHPHHmui
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 22 14:21:40 +0000 2021
      id: 1418214665323114500
      id_str: "1418214665323114499"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/M9ds9DVYq7
      truncated: false
      entities:
        urls:
          - url: https://t.co/M9ds9DVYq7
      in_reply_to_status_id: 1418214664228331500
      in_reply_to_status_id_str: "1418214664228331523"
- preprint:
    id: "146991"
    doi: 10.1101/2021.06.22.21259318
    first_posted: 2021-06-22
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.22.21259318v1
    url: https://api.rxivist.org/v1/papers/146991
    title: "Efficacy of Proxalutamide in Hospitalized COVID-19 Patients: A
      Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Clinical
      Trial"
    category: infectious-diseases
    abstract: "Background: Severe acute respiratory syndrome coronavirus 2
      (SARS-CoV-2) infectivity is mediated by the androgen-promoted protease,
      transmembrane protease, serine 2 (TMPRSS2). Previously, we have shown that
      treatment with proxalutamide, a non-steroidal androgen receptor
      antagonist, accelerates viral clearance and clinical remission in
      outpatients with coronavirus disease 2019 (COVID-19) compared to placebo.
      The effects in hospitalized COVID-19 patients were unknown. Methods: Men
      and women hospitalized but not requiring mechanical ventilation were
      randomized (1:1 ratio) to receive 300 mg of proxalutamide per day or
      placebo for 14 days. The study was conducted at eight sites in the state
      of Amazonas, Brazil. The primary outcome measure was the clinical status
      (8-point ordinal scale) at 14-days post-randomization. The primary
      efficacy endpoint was the 14-day recovery ratio (alive hospital discharge
      [scores 1, 2]). Findings: A total of 645 patients were randomized (317
      received proxalutamide, 328 placebo) and underwent intention-to-treat
      analysis. The 14-day median ordinal scale score in the proxalutamide group
      was 1 (interquartile range [IQR]=1-2) versus 7 (IQR=2-8) for placebo,
      P<0.001. The 14-day recovery rate was 81.4% for proxalutamide and 35.7%
      for placebo (recovery ratio, 2.28; 95% CI 1.95-2.66 [P<0.001]). The 28-day
      all-cause mortality rate was 11.0% for proxalutamide versus 49.4% for
      placebo (hazard ratio, 0.16; 95% CI 0.11-0.24). The median
      post-randomization time to recovery was 5 days (IQR=3-8) for proxalutamide
      versus 10 days (IQR=6-15) for placebo. Interpretation: Hospitalized
      COVID-19 patients not requiring mechanical ventilation receiving
      proxalutamide had a 128% higher recovery rate than those treated with
      placebo. All-cause mortality was reduced by 77.7% over 28 days.
      (ClinicalTrials.gov number, NCT04728802)."
    authors:
      - name: Flavio A Cadegiani
        orcid: http://orcid.org/0000-0002-2699-4344
      - name: Daniel N Fonseca
        orcid: null
      - name: John McCoy
        orcid: http://orcid.org/0000-0003-1577-9910
      - name: Ricardo A. Zimerman
        orcid: null
      - name: Fatima N Mirza
        orcid: http://orcid.org/0000-0003-1299-6258
      - name: Michael N Correia
        orcid: null
      - name: Renan N Barros
        orcid: null
      - name: Dirce C Onety
        orcid: null
      - name: Karla Cristina P Israel
        orcid: null
      - name: Brenda G Almeida
        orcid: null
      - name: Emilyn O Guerreiro
        orcid: null
      - name: Jose Enrique M Medeiros
        orcid: null
      - name: Raquel N Nicolau
        orcid: null
      - name: Luiza FM Nicolau
        orcid: null
      - name: Rafael X Cunha
        orcid: null
      - name: Maria Fernanda R Barroco
        orcid: null
      - name: Patricia S da Silva
        orcid: null
      - name: Gabriel S. Ferreira
        orcid: http://orcid.org/0000-0003-1554-8346
      - name: Flavio Renan PC Alcantara
        orcid: null
      - name: Angelo M Ribeiro
        orcid: null
      - name: Felipe O de Almeida
        orcid: null
      - name: Adailson A de Souza
        orcid: null
      - name: Suzyane S do Rosario
        orcid: null
      - name: Raysa WS Paulain
        orcid: null
      - name: Alessandra Reis
        orcid: null
      - name: Marissa Li
        orcid: null
      - name: Claudia E Thompson
        orcid: null
      - name: Gerald J Nau
        orcid: null
      - name: Carlos Gustavo Wambier
        orcid: http://orcid.org/0000-0002-4636-4489
      - name: Andy Goren
        orcid: http://orcid.org/0000-0002-8190-2289
  comment:
    dislikes: 0
    thread: "8608446739"
    numReports: 0
    likes: 0
    id: "5460452230"
    createdAt: 2021-07-18T17:48:18
    author:
      username: olavoamaral
      about: ""
      name: Olavo Amaral
      isPowerContributor: false
      profileUrl: https://disqus.com/by/olavoamaral/
      url: ""
      location: ""
      id: "331288656"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      In their discussion, the authors attribute the imbalance between study
      arms within hospital sites in Table S1 to the fact that randomization was
      not stratified by study site and to batch delivery of drugs to remote
      sites. However, if the trial was truly randomized as described in the
      Supplementary Appendix, it is hard to understand how the extreme imbalance
      in the distribution of arms in each site could have happened by chance
      alone.

      When one considers the distribution of arms in the 3 centers located in Manaus, where patients are described to have been randomized independently, there is a total of 97 patients in the active group vs. 298 in the placebo group. Using the chisq.test function in R, the p value for obtaining this distribution if patients had an equal chance of being randomized to either group is 4.8e-24 (amounting to a chance of roughly 1 in 200 sextillion).

      For the remote sites, one cannot estimate this chance exactly, as the authors report that randomization was performed for batches of 5-50 patients. Nevertheless, the distribution is even more unbalanced (220 patients in the active group vs. 30 patients in the placebo group), and also seems unlikely to have occurred by chance (and in the opposite direction as that of Manaus, thus balancing the distribution in the whole trial almost exactly).

      Although this imbalance would not explain the difference in the main outcomes between groups by itself, as the stratified analyses in Tables S3 and S4 show effects favoring the active treatment at all sites, it does call into question whether randomization was really carried out as described. Can the authors please clarify on what happened?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.22.21259318v1
  tweets:
    - created_at: Thu Jul 22 16:33:45 +0000 2021
      id: 1418247907074101200
      id_str: "1418247907074101255"
      text: >-
        üí¨ medRxiv comment on "Efficacy of Proxalutamide in H..."


        "In their discussion, the authors attribute the imbalance‚Ä¶ https://t.co/7Ilu3zx1Ps
      truncated: true
      entities:
        urls:
          - url: https://t.co/7Ilu3zx1Ps
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 22 16:33:45 +0000 2021
      id: 1418247907996835800
      id_str: "1418247907996835843"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/0z3rHjK5bK
      truncated: false
      entities:
        urls:
          - url: https://t.co/0z3rHjK5bK
      in_reply_to_status_id: 1418247907074101200
      in_reply_to_status_id_str: "1418247907074101255"
- preprint:
    id: "130285"
    doi: 10.1101/2021.02.19.431951
    first_posted: 2021-02-19
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.02.19.431951v1
    url: https://api.rxivist.org/v1/papers/130285
    title: "Countering reproducibility issues in mathematical models with software
      engineering techniques: A case study using a one-dimensional mathematical
      model of the atrioventricular node"
    category: systems-biology
    abstract: One should assume that in silico experiments in systems biology are
      less susceptible to reproducibility issues than their wet-lab
      counterparts, because they are free from natural biological variations and
      their environment can be fully controlled. However, recent studies show
      that only half of the published mathematical models of biological systems
      can be reproduced without substantial effort. In this article we examine
      the potential causes for failed or cumbersome reproductions in a case
      study of a one-dimensional mathematical model of the atrioventricular
      node, which took us four months to reproduce. The model demonstrates that
      even otherwise rigorous studies can be hard to reproduce due to missing
      information, errors in equations and parameters, a lack in available data
      files, non-executable code, missing or incomplete experiment protocols,
      and missing rationales behind equations. Many of these issues seem similar
      to problems that have been solved in software engineering using techniques
      such as unit testing, regression tests, continuous integration, version
      control, archival services, and a thorough modular design with extensive
      documentation. Applying these techniques, we reimplement the examined
      model using the modeling language Modelica. The resulting workflow is
      independent of the model and can be translated to SBML, CellML, and other
      languages. It guarantees methods reproducibility by executing automated
      tests in a virtual machine on a server that is physically separated from
      the development environment. Additionally, it facilitates results
      reproducibility, because the model is more understandable and because the
      complete model code, experiment protocols, and simulation data are
      published and can be accessed in the exact version that was used in this
      article. We found the additional design and documentation effort well
      justified, even just considering the immediate benefits during development
      such as easier and faster debugging, increased understandability of
      equations, and a reduced requirement for looking up details from the
      literature.
    authors:
      - name: Christopher Sch√∂lzel
        orcid: http://orcid.org/0000-0001-8627-0594
      - name: Valeria Blesius
        orcid: http://orcid.org/0000-0002-2391-242X
      - name: Gernot Ernst
        orcid: http://orcid.org/0000-0001-5224-0338
      - name: Alexander Goesmann
        orcid: http://orcid.org/0000-0002-7086-2568
      - name: Andreas Dominik
        orcid: http://orcid.org/0000-0002-9368-0812
  comment:
    dislikes: 0
    thread: "8405583259"
    numReports: 0
    likes: 0
    id: "5465443872"
    createdAt: 2021-07-22T15:20:36
    author:
      username: yoramreich
      about: ""
      name: Yoram Reich
      isPowerContributor: false
      profileUrl: https://disqus.com/by/yoramreich/
      url: ""
      location: ""
      id: "365367826"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      You are correct that MBSE in general have usability problems. We wrote a
      paper about it (Shaked and Reich, 2021), demonstrating that
      domain-specific modeling - a particular way of MBSE - is much more
      approachable and the paper I pointed to in my previous message (Shaked and
      reich, 2020), is exactly such domain-specific modeling. It is much easier
      than general purpose and could be tailored to fit particular purposed. 


      Shaked, A., & Reich, Y. (2021). Using Domain-Specific Models to Facilitate Model-Based Systems-Engineering: Development Process Design Modeling with OPM and PROVE. Applied Sciences, 11(4), 1532.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.02.19.431951v1
  tweets:
    - created_at: Thu Jul 22 18:24:45 +0000 2021
      id: 1418275839351922700
      id_str: "1418275839351922689"
      text: >-
        üí¨ bioRxiv comment on "Countering reproducibility iss..."


        "You are correct that MBSE in general have usability prob‚Ä¶ https://t.co/3lV6yJCxfr
      truncated: true
      entities:
        urls:
          - url: https://t.co/3lV6yJCxfr
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 22 18:24:45 +0000 2021
      id: 1418275840211701800
      id_str: "1418275840211701761"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/X7tff3Zz4b
      truncated: false
      entities:
        urls:
          - url: https://t.co/X7tff3Zz4b
      in_reply_to_status_id: 1418275839351922700
      in_reply_to_status_id_str: "1418275839351922689"
- preprint:
    id: 150999
    metric: 52
    title: Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in
      physiologically relevant cells and does not induce viral variants.
    url: https://api.rxivist.org/v1/papers/150999
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.21.451321v1
    doi: 10.1101/2021.07.21.451321
    category: microbiology
    first_posted: 2021-07-21
    abstract: Repositioning of clinical approved drugs could represent the fastest
      way to identify therapeutic options during public health emergencies, the
      majority of drugs explored for repurposing as antivirals for 2019
      coronavirus disease (COVID-19) have failed to demonstrate clinical
      benefit. Without specific antivirals, the severe acute respiratory
      syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to cause major
      global mortality. Antimalarial drugs, such as chloroquine
      (CQ)/hydroxychloroquine (HCQ) and mefloquine have emerged as potential
      anti-SARS-CoV-2 antivirals. CQ/HCQ entered the Solidarity and RECOVERY
      clinical trials against COVID-19 and showed lack of efficacy. Importantly,
      mefloquine is not a 4-aminoquinoline like CQ and HCQ and has been
      previously repurposed for other respiratory diseases. Unlike the
      4-aminoquinolines that accumulate in the high pH of intracellular
      lysosomes of the lung, the high respiratory tract penetration of
      mefloquine is driven by its high lipophilicity. While CQ and HCQ exhibit
      activity in Vero E6 cells, their activity is obviated in
      TMPRSS2-expressing cells, such as Calu-3 cells, which more accurately
      recapitulate in vivo entry mechanisms for SARS-CoV-2. Accordingly, here we
      report the anti-SARS-CoV-2 activity of mefloquine in Calu-3 type II
      pneumocytes and primary human monocytes. Mefloquine inhibited SARS-CoV-2
      replication, including the gamma variant, in Calu-3 cells with low
      cytotoxicity and EC50 and EC90 values of 1.2 and 5.3 uM, respectively. In
      addition, mefloquine reduced up to 68% the SARS-CoV-2 RNA levels in
      infected monocytes, reducing viral-induced inflammation. Mefloquine
      blocked early steps of the SARS-CoV-2 replicative cycle and was less prone
      than CQ to induce drug-associated viral mutations and synergized with RNA
      polymerase inhibitor. The pharmacological parameters of mefloquine are
      consistent with its plasma exposure in humans and its tissue-to-plasma
      predicted coefficient points that this drug may accumulate in the lungs.
      These data indicate that mefloquine could represent an orally available
      clinically approved drug option against COVID-19 and should not be
      neglected on the basis of the failure of CQ and HCQ.
    authors:
      - name: Carolina Q. Sacramento
      - name: Natalia Fintelman-Rodrigues
      - name: Suelen S. G. Dias
      - name: Jairo R Temerozo
      - name: Aline de Paula D. Da Silva
      - name: Carine S. da Silva
      - name: Andre C. Ferreira
      - name: Mayara Mattos
      - name: Vinicius C. Soares
      - name: Filipe Pereira-Dutra
      - name: Milene D. Miranda
      - name: Debora F. Barreto-Vieira
      - name: Marcos Alexandre N. da Silva
      - name: Suzana de Siqueira Santos
      - name: Mateo Torres
      - name: Rajith K. R. Rajoli
      - name: Alberto Paccanaro
      - name: Andrew Owen
      - name: Dumith C Bou-Habib
      - name: Patricia T Bozza
      - name: Thiago Moreno L. Souza
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Thu Jul 22 20:17:02 +0000 2021
      id: 1418304096545640400
      id_str: "1418304096545640448"
      text: >-
        üî• bioRxiv Microbiology preprint by C. Q. Sacramento et al:


        "Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 inf‚Ä¶ https://t.co/RovD70PgU0
      truncated: true
      entities:
        urls:
          - url: https://t.co/RovD70PgU0
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "145989"
    doi: 10.1101/2021.06.14.448057
    first_posted: 2021-06-14
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.14.448057v1
    url: https://api.rxivist.org/v1/papers/145989
    title: Early functional connectivity in the developing sensorimotor network that
      is independent of sensory experience
    category: neuroscience
    abstract: Neonatal sensory experience shapes development of neural pathways
      carrying sensory information to the cortex. These pathways link to wider
      functional networks that coordinate activity of separate cortical regions,
      but it remains unknown when these broader networks emerge or how their
      maturation is influenced by sensory experience. By imaging activity across
      the cortex in neonatal mice, we have found unexpectedly early emergence of
      coordinated activity within a sensorimotor network that includes
      whisker-related somatosensory cortex and motor cortex. This network is
      spontaneously active but is not engaged by sensory stimulation, even
      though whisker deflection reliably drives cortical activity within barrel
      cortex. Acute silencing of the sensory periphery ablated spontaneous
      activity that was restricted to barrel cortex but spared this early
      sensorimotor network coactivity, suggesting that it is driven from
      elsewhere. Furthermore, perturbing sensory experience by whisker trimming
      did not impact emergence or early maturation of spontaneous activity in
      the sensorimotor network. As such, functional sensorimotor cortical
      networks develop early and, in contrast to development of ascending
      sensory pathways, their initial maturation is independent of sensory
      experience.
    authors:
      - name: Christine M Cross
        orcid: null
      - name: Laura Mediavilla Santos
        orcid: null
      - name: Nick Whiteley
        orcid: null
      - name: Karen Luyt
        orcid: http://orcid.org/0000-0002-9806-1092
      - name: Michael C Ashby
        orcid: http://orcid.org/0000-0002-8593-8473
  comment:
    dislikes: 0
    thread: "8621187594"
    numReports: 0
    likes: 0
    id: "5465141221"
    createdAt: 2021-07-22T11:25:14
    author:
      name: Michael Ashby
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Many thanks for your comment. I agree that we haven't covered that
      experience-independent phase of visual system development enough. We will
      definitely update the paper and adjust to emphasise the independence from
      activity generated at the sensory periphery (as opposed to spontaneous
      activity from there).
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.14.448057v2
  tweets:
    - created_at: Thu Jul 22 20:20:50 +0000 2021
      id: 1418305053530771500
      id_str: "1418305053530771465"
      text: >-
        üí¨ bioRxiv comment on "Early functional connectivity ..."


        "Many thanks for your comment. I agree that we haven't co‚Ä¶ https://t.co/MPV1kaIwOs
      truncated: true
      entities:
        urls:
          - url: https://t.co/MPV1kaIwOs
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 22 20:20:50 +0000 2021
      id: 1418305054533210000
      id_str: "1418305054533210121"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/LzakIG4zNj
      truncated: false
      entities:
        urls:
          - url: https://t.co/LzakIG4zNj
      in_reply_to_status_id: 1418305053530771500
      in_reply_to_status_id_str: "1418305053530771465"
- preprint:
    id: "150257"
    doi: 10.1101/2021.07.15.452392
    first_posted: 2021-07-15
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.15.452392v1
    url: https://api.rxivist.org/v1/papers/150257
    title: Measuring biodiversity from DNA in the air
    category: ecology
    abstract: Impacts of the biodiversity crisis far exceed our ability to monitor
      changes in terrestrial ecosystems. Environmental DNA has revolutionized
      aquatic biomonitoring, permitting remote population and diversity
      assessments. Here we demonstrate that DNA from terrestrial animals can now
      be collected from the air under natural conditions, a ground-breaking
      advance for terrestrial biomonitoring. Using air samples from a zoological
      park, where species are spatially confined and unique compared to native
      fauna, we show that DNA in air can be used to identify the captive species
      and their potential interactions with local taxa. Air samples contained
      DNA from 25 species of mammal and bird including 17 known (and distinct)
      terrestrial zoo species. We also identified food items from air sampled in
      enclosures and detected four taxa native to the local area, including the
      Eurasian hedgehog, endangered in the UK, and the muntjac deer, a locally
      established invasive species. Our data provide evidence that airDNA is
      concentrated around recently inhabited areas (e.g., indoor enclosures) but
      that there is dispersal away from the source suggesting an ecology to
      airDNA movement which highlights the potential for airDNA sampling at
      distance. Our data clearly demonstrate the profound potential of air as a
      source of DNA for global terrestrial biomonitoring and ecological
      analysis.
    authors:
      - name: Elizabeth L. Clare
        orcid: http://orcid.org/0000-0002-6563-3365
      - name: Chloe K Economou
        orcid: null
      - name: Frances J Bennett
        orcid: null
      - name: Caitlin E Dyer
        orcid: null
      - name: Katherine Adams
        orcid: null
      - name: Benjamin McRobie
        orcid: null
      - name: Rosie Drinkwater
        orcid: http://orcid.org/0000-0001-6892-1664
      - name: Joanne E. Littlefair
        orcid: http://orcid.org/0000-0002-4481-0211
  comment:
    dislikes: 0
    thread: "8650063202"
    numReports: 0
    likes: 0
    id: "5465076409"
    createdAt: 2021-07-22T09:52:07
    author:
      username: disqus_1vZFHMsvy7
      about: ""
      name: Isabella H
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_1vZFHMsvy7/
      url: ""
      location: ""
      id: "372678581"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Dear Authors,

      I have some suggestions regarding your preprint.

      Although the investigation of eDNA from air is an understudied field let me make you aware of some studies which were mainly focused on microbial an fungal bioaerosols (10.1016/j.scitotenv.2020.144092, 10.1073/pnas.0811003106, 10.1093/femsec/fiy031) and collection methods (e.g. 10.1021/acs.est.7b01480, 10.1371/journal.pone.0141158, 10.1128/AEM.01589-18). Maybe you want to include some of this literature in your manuscript.

      In addition it would be great if you could add the primer sequence of Mam1 and Mam2 to the manuscript. Regarding figure 2, I guess it could help if you included boxplots in 2a and maybe a logarithmic scale for Fig.2b or you may think to exclude the two outliers form the visualization.

      All the best

      Isabella
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.07.15.452392v1
  tweets:
    - created_at: Thu Jul 22 22:19:30 +0000 2021
      id: 1418334917797171200
      id_str: "1418334917797171200"
      text: |-
        üí¨ bioRxiv comment on "Measuring biodiversity from DN..."

        "Dear Authors,
        I have some suggestions regarding your pre‚Ä¶ https://t.co/QpXDu02YiY
      truncated: true
      entities:
        urls:
          - url: https://t.co/QpXDu02YiY
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 22 22:19:30 +0000 2021
      id: 1418334918904488000
      id_str: "1418334918904487940"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/NK7Mc8HReC
      truncated: false
      entities:
        urls:
          - url: https://t.co/NK7Mc8HReC
      in_reply_to_status_id: 1418334917797171200
      in_reply_to_status_id_str: "1418334917797171200"
- preprint:
    id: "148199"
    doi: 10.1101/2021.06.30.450627
    first_posted: 2021-06-30
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.30.450627v1
    url: https://api.rxivist.org/v1/papers/148199
    title: A Genetic Screen for Suppressors of Cryptic 5' Splicing in C. elegans
      Reveals Roles for KIN17 and PRCC in Maintaining Both 5' and 3' Splice Site
      Identity
    category: molecular-biology
    abstract: Pre-mRNA splicing is an essential step of eukaryotic gene expression
      carried out by a series of dynamic macromolecular protein/RNA complexes,
      known collectively and individually as the spliceosome. This series of
      spliceosomal complexes define, assemble on, and catalyze the removal of
      introns. Molecular model snapshots of intermediates in the process have
      been created from cryo-EM data, however, many aspects of the dynamic
      changes that occur in the spliceosome are not fully understood.
      Caenorhabditis elegans follow the GU-AG rule of splicing, with almost all
      introns beginning with 5' GU and ending with 3' AG. These splice sites are
      identified early in the splicing cycle, but as the cycle progresses and
      ''custody'' of the pre-mRNA splice sites is passed from factor to factor
      as the catalytic site is built, the mechanism by which splice site
      identity is maintained or re-established through these dynamic changes is
      unclear. We performed a genetic screen in C. elegans for factors that are
      capable of changing 5' splice site choice. We report that KIN17 and PRCC
      are involved in splice site choice, the first functional splicing role
      proposed for either of these proteins. Previously identified suppressors
      of cryptic 5' splicing promote distal cryptic GU splice sites, however,
      mutations in KIN17 and PRCC instead promote usage of an unusual proximal
      5' splice site which defines an intron beginning with UU, separated by 1nt
      from a GU donor. We performed high-throughput mRNA sequencing analysis and
      found that mutations in PRCC but not KIN17 changed 5' splice sites
      genome-wide, promoting usage of nearby non-consensus sites. We further
      found that mutations in KIN17 and PRCC changed dozens of 3' splice sites,
      promoting non-consensus sites upstream of canonical splice sites. Our work
      has uncovered both fine and coarse mechanisms by which the spliceosome
      maintains splice site identity during the complex assembly process.
    authors:
      - name: Jessie MNG Lopez
        orcid: http://orcid.org/0000-0002-9222-6749
      - name: Kenneth Osterhoudt
        orcid: null
      - name: Catiana Holland Cartwright
        orcid: null
      - name: Sol Katzman
        orcid: http://orcid.org/0000-0002-1787-1246
      - name: Alan M. Zahler
        orcid: http://orcid.org/0000-0003-0027-1647
  comment:
    dislikes: 0
    thread: "8624080045"
    numReports: 0
    likes: 0
    id: "5466000558"
    createdAt: 2021-07-22T23:32:19
    author:
      username: JMNGLOPEZ
      about: ""
      name: Jessie Lopez
      isPowerContributor: false
      profileUrl: https://disqus.com/by/JMNGLOPEZ/
      url: ""
      location: ""
      id: "372707708"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      There is a DIY audiobook of this paper available on YouTube if you would
      rather hear the author read the paper.


      https://www.youtube.com/watch?v=46SZygXZwOs
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.30.450627v1
  tweets:
    - created_at: Fri Jul 23 01:04:13 +0000 2021
      id: 1418376369034170400
      id_str: "1418376369034170368"
      text: >-
        üí¨ bioRxiv comment on "A Genetic Screen for Suppresso..."


        "There is a DIY audiobook of this paper available on YouT‚Ä¶ https://t.co/6wKPwEbDDx
      truncated: true
      entities:
        urls:
          - url: https://t.co/6wKPwEbDDx
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 23 01:04:13 +0000 2021
      id: 1418376369810165800
      id_str: "1418376369810165766"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/sUpgXQ9kCx
      truncated: false
      entities:
        urls:
          - url: https://t.co/sUpgXQ9kCx
      in_reply_to_status_id: 1418376369034170400
      in_reply_to_status_id_str: "1418376369034170368"
- preprint:
    id: "75352"
    doi: 10.1101/2020.02.26.966580
    first_posted: 2020-02-29
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.02.26.966580v1
    url: https://api.rxivist.org/v1/papers/75352
    title: ACCLIMATION OF PHOTOSYNTHESIS TO THE ENVIRONMENT 1 regulates Photosystem
      II Supercomplex dynamics in response to light in Chlamydomonas reinhardtii
    category: plant-biology
    abstract: Photosynthetic organisms require acclimation mechanisms to regulate
      photosynthesis in response to light conditions. Here, two mutant alleles
      of ACCLIMATION OF PHOTOSYNTHESIS TO THE ENVIRONMENT 1 (ape1) have been
      characterized in Chlamydomonas reinhardtii. The ape1 mutants are
      photosensitive and show PSII photoinhibition during high light acclimation
      or under high light stress. The ape1 mutants retain more PSII
      super-complexes and have changes to thylakoid stacking relative to control
      strains during photosynthetic growth at different light intensities. The
      APE1 protein is found in all oxygenic phototrophs and encodes a 25 kDa
      thylakoid protein that interacts with the Photosystem II core complex as
      monomers, dimers and supercomplexes. We propose a model where APE1 bound
      to PSII supercomplexes releases core complexes and promotes PSII
      heterogeneity influencing the stacking of Chlamydomonas thylakoids. APE1
      is a regulator in light acclimation and its function is to reduce
      over-excitation of PSII centres and avoid PSII photoinhibition to increase
      the resilience of photosynthesis to high light.
    authors:
      - name: Marie Chazaux
        orcid: http://orcid.org/0000-0002-5023-2948
      - name: Stefano Caffarri
        orcid: http://orcid.org/0000-0002-4729-7679
      - name: Juliane Da Gra√ßa
        orcid: http://orcid.org/0000-0002-1879-617X
      - name: Stephan Cuin√©
        orcid: http://orcid.org/0000-0002-3000-3355
      - name: Magali Floriani
        orcid: http://orcid.org/0000-0001-5461-0486
      - name: Pawel Brzezowski
        orcid: http://orcid.org/0000-0003-3082-6818
      - name: Gilles Peltier
        orcid: http://orcid.org/0000-0002-2226-3931
      - name: Bernard Genty
        orcid: null
      - name: Jean Alric
        orcid: http://orcid.org/0000-0003-3574-2234
      - name: Xenie Johnson
        orcid: http://orcid.org/0000-0003-3424-7047
  comment:
    dislikes: 0
    thread: "7893966768"
    numReports: 0
    likes: 0
    id: "5465033852"
    createdAt: 2021-07-22T08:29:35
    author:
      username: alizee_malnoe
      about: I am an Assistant Professor at Ume√• Plant Science Centre. My research
        group investigates the molecular mechanisms of plant photoprotection.
      name: Aliz√©e Malno√´
      isPowerContributor: false
      profileUrl: https://disqus.com/by/alizee_malnoe/
      url: https://malnoelab.com
      location: Ume√•, Sweden
      id: "372667583"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      The manuscript by Chazaux et al. presents the characterisation of
      <i>ape1</i> mutant alleles of Chlamydomonas and shows that they do not
      acclimate as well to increases in light intensity as does the wild type,
      consistent with the Arabidopsis <i>ape1</i> mutant described in 2003
      (Walters et al.). The authors have clearly shown that APE1 is a thylakoid
      membrane protein required for the proper function of PSII at high light
      intensities. The absence of APE1 leads to changes in thylakoid
      architecture and an altered composition of photosynthetic complexes (20%
      less D1/D2 and 20% more LHCII in ape1). In this new submission, they have
      unequivocally demonstrated that APE1 directly interacts with PSII
      (co-migration of APE1 with the monomer and dimer of PSII which is altered
      in deltaPSII but not in deltaPSI as well as cross-linking with PSII).
      Furthermore, they have shown that in the absence of APE1, PSII
      supercomplexes (sc) accumulate (BN-2D and in vivo measurements of antenna
      size). This accumulation of PSII sc leads to photoinhibition and the
      authors propose that the role of APE1 is to modulate the formation of
      supercomplexes for optimal photosynthesis.


      I largely agree with these conclusions and think that this body of work moves the field forward. I have several comments however that should be addressed (see below). My main issue lies in the interpretation of Figure 7A and B (photoinhibition experiment) and lines 314-318. My previous comment on that point still stands: if D1 damage would be increased in <i>ape1</i>, we should expect a lower amount of D1 upon inhibition of repair. However according to Fig7B, this is not the case (<i>ape1</i> has apparently the same level of D1 as in wt). The <i>mph1</i> mutant described by Liu and Last 2015 Plant Journal 82:731‚Äì743, is proposed to have more PSII damage which translates as less D1 accumulation upon inhibition of repair (coincidentally also in Figure 7B!) Granted this is in Arabidopsis and the timepoint for D1 is 2h HL, I would still recommend repeating that experiment e.g. a 2h HL+inh checking D1 accumulation. As is, what I take away from Fig7B is that the rate of repair is slower in ape1. If I understand correctly, the authors imply that because of the large antenna size, D1 is more prone to photodamage but given this other interpretation (slower D1 repair), how about the idea that repair is slower due to D1 being more trapped in PSII dimer and sc? You discuss this idea in paragraph from line 519.


      This interpretation better fits the conservation of APE1 in cyanobacteria which do not possess PSII sc and agrees with the possible constitutive function in maintenance of PSII state described line 516. The title of the article should then be changed accordingly.


      Major comments


      Line 71 - I understand the decision from the authors to cite reviews and state that ‚Äúmany‚Äù proteins are involved in PSII biogenesis, maintenance and repair. I would however recommend citing Liu and Last 2019 Frontiers in Plant Science 10:975 and either introduce or discuss more what factors are known to modulate PSII sc (e.g. from this review MET1; in <i>met1</i> mutant less PSII SC, accelerated D1 degradation; as stated above should we expect <i>ape1</i>, more PSII SC, slower D1 degradation?)

      Line 114, line 256 - RC47 should be defined as reaction center 47 (see Komenda J 2006 J Biol Chem 281: 1145‚Äì1151), it can be both an assembly or repair intermediate.

      Line 129 - ‚ÄúAtape1‚Äù should be written as ‚ÄúThe Arabidopsis <i>ape1</i> mutant‚Äù for clarity.

      Line 229 ‚Äì ‚Äúand is not strictly required for their assembly‚Äù, I do not agree with that statement, chaperone required for assembly can accumulate to wild type level in absence of the main subunit of a given complex.

      Line 319 to 325 ‚Äì Description of partial complementation (lower chla/b in HL and intermediate GPX5 accumulation) and possible explanation (since APE1 protein accumulates to wild type level) should be provided.

      Line 341 ‚Äì for this paragraph, it would help the non-initiated to add more introduction on alpha and beta centres and what is meant exactly by ‚ÄúPSII heterogeneity‚Äù.

      Line 573 ‚Äì The method for generating the mutant library that led to isolation of <i>ape1-1</i> is missing

      Line 676 -  Provide amino acid number where the sequence used for recombinant proteins starts

      Fig1D,E ‚Äì The data is the same as in the previous submitted version, <i>ape1-1</i> should say <i>drbcL ape1-1</i> in Fig1D,F and 1E control is cc-4533.

      Figure 2B ‚Äì orientation of protein? please indicate stroma and lumen compartment

      Fig2C ‚Äì comment on reason for signal to be lower in isolated thylakoid compared to total cell extracts, usually the opposite occurs, unless APE1 is dual-targeted?

      Fig4B ‚Äì comment on more PSI(2) band in <i>ape1</i> mutant

      Fig5 ‚Äì comment on APE1 oligomers. I agree that cross-linking with PSII demonstrates that APE1 is not a free protein but upon solubilization different subcomplexes are resolved, especially in the deltaPSI and deltaPSII mutants.

      Fig7C ‚Äì comment on nature of the band right below E and above F enriched in the complemented line.


      Minor comments

      Line 147 and other instances ‚Äì Figures are called twice

      Line 184 ‚Äì should read ‚Äúviolaceus‚Äù

      Line 286 ‚Äì change decorated to probed

      Line 401 ‚Äì should read ‚Äúphotoinhibition‚Äù

      Fig6A ‚Äì annotate nature of B5 and 8 to help reader

      Fig9 ‚Äì is this in MIN? how many days? Light intensity?


      Aliz√©e Malno√´ (Ume√• University) ‚Äì prompted by a journal; I‚Äôm an assistant professor, my research group investigates the molecular mechanisms of plant photoprotection. I performed a bachelor project internship in Gilles Peltier‚Äôs group, Jean Alric and Xenie Johnson are former colleagues from the group I performed my PhD studies in.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.02.26.966580v1
  tweets:
    - created_at: Fri Jul 23 12:31:32 +0000 2021
      id: 1418549337164943400
      id_str: "1418549337164943362"
      text: >-
        üí¨ bioRxiv comment on "ACCLIMATION OF PHOTOSYNTHESIS ..."


        "The manuscript by Chazaux et al. presents the characteri‚Ä¶ https://t.co/hexgzwApYe
      truncated: true
      entities:
        urls:
          - url: https://t.co/hexgzwApYe
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 23 12:31:32 +0000 2021
      id: 1418549338217730000
      id_str: "1418549338217730053"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/6a8O2ReBkG
      truncated: false
      entities:
        urls:
          - url: https://t.co/6a8O2ReBkG
      in_reply_to_status_id: 1418549337164943400
      in_reply_to_status_id_str: "1418549337164943362"
- preprint:
    id: "134158"
    doi: 10.1101/2021.03.17.21252755
    first_posted: 2021-03-20
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.03.17.21252755v1
    url: https://api.rxivist.org/v1/papers/134158
    title: The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia
      Variant Curation Expert Panel consensus guidelines for LDLR variant
      classification
    category: genetic-and-genomic-medicine
    abstract: "Purpose: In 2015, the American College of Medical Genetics and
      Genomics (ACMG) and the Association for Molecular Pathology (AMP)
      published consensus standardized guidelines for variant classification in
      Mendelian disorders. To increase accuracy and consistency, the Clinical
      Genome Resource (ClinGen) Familial Hypercholesterolemia (FH) Variant
      Curation Expert Panel (VCEP) was tasked with optimizing the existing
      ACMG/AMP framework for disease-specific classification in FH. Here, we
      provide consensus recommendations for the most common FH-causing gene,
      LDLR, where >2,300 unique FH-associated variants have been identified.
      Methods: The multidisciplinary FH VCEP met in person and through frequent
      emails and conference calls to develop LDLR-specific modifications of
      ACMG/AMP guidelines. Through iteration, pilot testing, debate and
      commentary, consensus among experts was reached. Results: The consensus
      LDLR variant modifications to existing ACMG/AMP guidelines include: 1)
      alteration of population frequency thresholds; 2) delineation of
      loss-of-function variant types; 3) functional study criteria
      specifications; 4) co-segregation criteria specifications; and 5) specific
      use and thresholds for in silico prediction tools, among others.
      Conclusion: Establishment of these guidelines as the new standard in the
      clinical laboratory setting will result in a more evidence-based,
      harmonized method for LDLR variant classification worldwide, thereby
      improving the care of FH patients."
    authors:
      - name: Joana R. Chora
        orcid: null
      - name: Michael A Iacocca
        orcid: null
      - name: Lukas Tichy
        orcid: null
      - name: Hannah Wand
        orcid: http://orcid.org/0000-0001-8662-3353
      - name: C. Lisa Kurtz
        orcid: null
      - name: Heather Zimmermann
        orcid: null
      - name: Annette Leon
        orcid: null
      - name: Maggie Williams
        orcid: null
      - name: Steve E Humphries
        orcid: null
      - name: Amanda J Hooper
        orcid: null
      - name: Mark Trinder
        orcid: null
      - name: Liam R. Brunham
        orcid: http://orcid.org/0000-0002-3686-3807
      - name: Alexandre Costa Pereira
        orcid: null
      - name: Cinthia E. Jannes
        orcid: null
      - name: Margaret Chen
        orcid: null
      - name: Jessica Chonis
        orcid: null
      - name: Jian Wang
        orcid: http://orcid.org/0000-0002-0788-6604
      - name: Serra Kim
        orcid: null
      - name: Tami Johnston
        orcid: null
      - name: Premysl Soucek
        orcid: null
      - name: Michal Kramarek
        orcid: null
      - name: Sarah E. Leigh
        orcid: null
      - name: Alain Carrie
        orcid: null
      - name: Eric J Sijbrands
        orcid: null
      - name: Robert A Hegele
        orcid: http://orcid.org/0000-0003-2861-5325
      - name: Tomas Freiberger
        orcid: null
      - name: Joshua W. Knowles
        orcid: null
      - name: Mafalda Bourbon
        orcid: null
  comment:
    dislikes: 0
    thread: "8444797689"
    numReports: 0
    likes: 1
    id: "5463703297"
    createdAt: 2021-07-21T09:05:50
    author:
      username: haowenguan
      about: ""
      name: haowen guan
      isPowerContributor: false
      profileUrl: https://disqus.com/by/haowenguan/
      url: ""
      location: ""
      id: "372631791"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      I have a few questions about this guideline:

      1.Could i use this guideline to other genes or panels ?

      2. Is there any chance that i can get the code about <i>In silico prediction of splicing effects in LDLR</i>
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.03.17.21252755v1
  tweets:
    - created_at: Fri Jul 23 14:17:56 +0000 2021
      id: 1418576114906275800
      id_str: "1418576114906275842"
      text: |-
        üí¨ medRxiv comment on "The Clinical Genome Resource (..."

        "I have a few questions about this guideline:
        1.Could i u‚Ä¶ https://t.co/aGDmHfAo73
      truncated: true
      entities:
        urls:
          - url: https://t.co/aGDmHfAo73
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 23 14:17:56 +0000 2021
      id: 1418576115808018400
      id_str: "1418576115808018437"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/FJPPxN9YkE
      truncated: false
      entities:
        urls:
          - url: https://t.co/FJPPxN9YkE
      in_reply_to_status_id: 1418576114906275800
      in_reply_to_status_id_str: "1418576114906275842"
- preprint:
    id: "124614"
    doi: 10.1101/2020.12.28.20248193
    first_posted: 2021-01-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.12.28.20248193v1
    url: https://api.rxivist.org/v1/papers/124614
    title: "GestaltMatcher: Overcoming the limits of rare disease matching using
      facial phenotypic descriptors"
    category: genetic-and-genomic-medicine
    abstract: A large fraction of monogenic disorders causes craniofacial
      abnormalities with characteristic facial morphology. These disorders can
      be diagnosed more efficiently with the support of computer-aided
      next-generation phenotyping tools, such as DeepGestalt. These tools have
      learned to associate facial phenotypes with the underlying syndrome
      through training on thousands of patient photographs. However, this
      "supervised" approach means that diagnoses are only possible if the
      disorder was part of the training set. To improve recognition of
      ultra-rare disorders, we created GestaltMatcher, which uses a deep
      convolutional neural network based on the DeepGestalt framework. We used
      photographs of 17,560 patients with 1,115 rare disorders to define a
      "Clinical Face Phenotype Space". Distance between cases in the phenotype
      space defines syndromic similarity, allowing test patients to be matched
      to a molecular diagnosis even when the disorder was not included in the
      training set. Similarities among patients with previously unknown disease
      genes can also be detected. Therefore, in concert with mutation data,
      GestaltMatcher could accelerate the clinical diagnosis of patients with
      ultra-rare disorders and facial dysmorphism, as well as enable the
      delineation of novel phenotypes.
    authors:
      - name: Tzung-Chien Hsieh
        orcid: http://orcid.org/0000-0003-3828-4419
      - name: Aviram Bar-Haim
        orcid: null
      - name: Shahida Moosa
        orcid: http://orcid.org/0000-0002-4463-3067
      - name: Nadja Ehmke
        orcid: http://orcid.org/0000-0003-1449-9909
      - name: Karen W Gripp
        orcid: null
      - name: Jean Tori Pantel
        orcid: http://orcid.org/0000-0002-2674-4660
      - name: Magdalena Danyel
        orcid: http://orcid.org/0000-0001-6631-3198
      - name: Martin Atta Mensah
        orcid: http://orcid.org/0000-0001-8080-8779
      - name: Denise Horn
        orcid: http://orcid.org/0000-0003-0870-8911
      - name: Stanislav Rosnev
        orcid: http://orcid.org/0000-0003-0256-7038
      - name: Nicole Fleischer
        orcid: http://orcid.org/0000-0002-1313-9429
      - name: Guilherme Bonini
        orcid: null
      - name: Alexander Hustinx
        orcid: null
      - name: Alexander Schmid
        orcid: null
      - name: Alexej Knaus
        orcid: http://orcid.org/0000-0003-0366-0533
      - name: Behnam Javanmardi
        orcid: null
      - name: Hannah Klinkhammer
        orcid: null
      - name: Hellen Lesmann
        orcid: null
      - name: Sugirthan Sivalingam
        orcid: null
      - name: Tom Kamphans
        orcid: http://orcid.org/0000-0003-4848-7885
      - name: Wolfgang Meiswinkel
        orcid: null
      - name: Fr√©d√©ric Ebstein
        orcid: http://orcid.org/0000-0002-3729-7878
      - name: Elke Kr√ºger
        orcid: http://orcid.org/0000-0002-2551-242X
      - name: S√©bastien K√ºry
        orcid: http://orcid.org/0000-0001-5497-0465
      - name: St√©phane B√©zieau
        orcid: http://orcid.org/0000-0003-0095-1319
      - name: Axel Schmidt
        orcid: http://orcid.org/0000-0002-4318-0799
      - name: Sophia Peters
        orcid: null
      - name: Hartmut Engels
        orcid: null
      - name: Elisabeth Mangold
        orcid: null
      - name: Martina Krei√ü
        orcid: null
      - name: Kirsten Cremer
        orcid: null
      - name: Claudia Perne
        orcid: null
      - name: Regina C. Betz
        orcid: null
      - name: Tim Bender
        orcid: null
      - name: Kathrin Grundmann-Hauser
        orcid: null
      - name: Tobias B Haack
        orcid: null
      - name: Matias Wagner
        orcid: http://orcid.org/0000-0002-4454-8823
      - name: Theresa Brunet
        orcid: http://orcid.org/0000-0002-5183-780X
      - name: Heidi Beate Bentzen
        orcid: http://orcid.org/0000-0001-8285-818X
      - name: Luisa Averdunk
        orcid: null
      - name: Kimberly Christine Coetzer
        orcid: null
      - name: Gholson J Lyon
        orcid: http://orcid.org/0000-0002-5869-0716
      - name: Malte Spielmann
        orcid: http://orcid.org/0000-0002-0583-4683
      - name: Christian Schaaf
        orcid: http://orcid.org/0000-0002-2148-7490
      - name: Stefan Mundlos
        orcid: http://orcid.org/0000-0002-9788-3166
      - name: Markus M. N√∂then
        orcid: http://orcid.org/0000-0002-8770-2464
      - name: Peter Krawitz
        orcid: http://orcid.org/0000-0002-3194-8625
  comment:
    dislikes: 0
    thread: "8342022961"
    numReports: 0
    likes: 0
    id: "5466478070"
    createdAt: 2021-07-23T12:04:42
    author:
      username: disqus_lvszrxlx7e
      about: ""
      name: Harry Matthews
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_lvszrxlx7e/
      url: ""
      location: ""
      id: "372728376"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Very fascinating work. I read it with great interest. I think some
      Supplementary Tables are missing, though. In the supplementary pdf I see
      up to Supplementary Table 3. But in the caption of main figure 5 there is
      reference to a Supplementary Table 6.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.12.28.20248193v1
  tweets:
    - created_at: Fri Jul 23 16:32:02 +0000 2021
      id: 1418609863299674000
      id_str: "1418609863299674113"
      text: >-
        üí¨ medRxiv comment on "GestaltMatcher: Overcoming the..."


        "Very fascinating work. I read it with great interest. I‚Ä¶ https://t.co/P4GhYjiybV
      truncated: true
      entities:
        urls:
          - url: https://t.co/P4GhYjiybV
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 23 16:32:02 +0000 2021
      id: 1418609864402604000
      id_str: "1418609864402604036"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/sbDfLznZQZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/sbDfLznZQZ
      in_reply_to_status_id: 1418609863299674000
      in_reply_to_status_id_str: "1418609863299674113"
- preprint:
    id: "150663"
    doi: 10.1101/2021.07.15.21260561
    first_posted: 2021-07-19
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.15.21260561v1
    url: https://api.rxivist.org/v1/papers/150663
    title: Viral Load of SARS-CoV-2 in Respiratory Aerosols Emitted by COVID-19
      Patients while Breathing, Talking, and Singing
    category: infectious-diseases
    abstract: "Background: Multiple SARS-CoV-2 superspreading events suggest that
      aerosols play an important role in driving the COVID-19 pandemic. However,
      the detailed roles of coarse (>5m) and fine ([&le;]5m) respiratory
      aerosols produced when breathing, talking, and singing are not
      well-understood. Methods: Using a G-II exhaled breath collector, we
      measured viral RNA in coarse and fine respiratory aerosols emitted by
      COVID-19 patients during 30 minutes of breathing, 15 minutes of talking,
      and 15 minutes of singing. Results: Among the 22 study participants, 13
      (59%) emitted detectable levels of SARS-CoV-2 RNA in respiratory aerosols,
      including 3 asymptomatic patients and 1 presymptomatic patient. Viral
      loads ranged from 63 - 5,821 N gene copies per expiratory activity.
      Patients earlier in illness were more likely to emit detectable RNA, and
      loads differed significantly between breathing, talking, and singing. The
      largest proportion of SARS-CoV-2 RNA copies was emitted by singing (53%),
      followed by talking (41%) and breathing (6%). Overall, fine aerosols
      constituted 85% of the viral load detected in our study. Virus cultures
      were negative. Conclusions: Fine aerosols produced by talking and singing
      contain more SARS-CoV-2 copies than coarse aerosols and may play a
      significant role in the transmission of SARS-CoV-2. Exposure to fine
      aerosols should be mitigated, especially in indoor environments where
      airborne transmission of SARS-CoV-2 is likely to occur. Isolating viable
      SARS-CoV-2 from respiratory aerosol samples remains challenging, and
      whether this can be more easily accomplished for emerging SARS-CoV-2
      variants is an important enquiry for future studies."
    authors:
      - name: Kristen K. Coleman
        orcid: http://orcid.org/0000-0003-0024-3400
      - name: Douglas Jie Wen Tay
        orcid: null
      - name: Kai Sen Tan
        orcid: null
      - name: Sean Wei Xiang Ong
        orcid: http://orcid.org/0000-0002-8570-436X
      - name: Than The Son
        orcid: null
      - name: Ming Hui Koh
        orcid: null
      - name: Yi Qing Chin
        orcid: null
      - name: Haziq Nasir
        orcid: null
      - name: Tze Minn Mak
        orcid: null
      - name: Justin Jang Hann Chu
        orcid: null
      - name: Donald K. Milton
        orcid: http://orcid.org/0000-0002-0550-7834
      - name: Vincent T.K. Chow
        orcid: null
      - name: Paul Anantharajah Tambyah
        orcid: null
      - name: Mark Chen
        orcid: null
      - name: Tham Kwok Wai
        orcid: null
  comment:
    dislikes: 0
    thread: "8660749285"
    numReports: 0
    likes: 0
    id: "5466460591"
    createdAt: 2021-07-23T11:43:39
    author:
      username: andyround
      about: ""
      name: andyround
      isPowerContributor: false
      profileUrl: https://disqus.com/by/andyround/
      url: ""
      location: ""
      id: "372727738"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Fascinating, thanks. What I can‚Äôt square between studies like yours
      and the one on cynomolgus monkeys on the one hand, and the range of
      estimates of sizes of droplets in respiratory exhalations on the other (as
      recently reviewed by Lydia Bourouiba for example), is how the quantity of
      viral RNA apparently scales with the *number* of droplets rather than
      their volume. It implies that the concentration of viruses per droplet is
      hugely dependent on the size of the droplet and I can‚Äôt think of a
      mechanism to achieve this - are viruses massively self-repelling? (over
      micron-scale distances?) Are they highly surface active? I wonder if you
      have thought about this.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.07.15.21260561v2
  tweets:
    - created_at: Fri Jul 23 18:24:32 +0000 2021
      id: 1418638173551399000
      id_str: "1418638173551398916"
      text: >-
        üí¨ medRxiv comment on "Viral Load of SARS-CoV-2 in Re..."


        "Fascinating, thanks. What I can‚Äôt square between studies‚Ä¶ https://t.co/n5wBKXkVbc
      truncated: true
      entities:
        urls:
          - url: https://t.co/n5wBKXkVbc
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 23 18:24:32 +0000 2021
      id: 1418638174327296000
      id_str: "1418638174327296005"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jkD92sUM09
      truncated: false
      entities:
        urls:
          - url: https://t.co/jkD92sUM09
      in_reply_to_status_id: 1418638173551399000
      in_reply_to_status_id_str: "1418638173551398916"
- preprint:
    id: 119230
    metric: 29
    title: Ultrafast end-to-end protein structure prediction enables high-throughput
      exploration of uncharacterised proteins
    url: https://api.rxivist.org/v1/papers/119230
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.11.27.401232v1
    doi: 10.1101/2020.11.27.401232
    category: bioinformatics
    first_posted: 2020-11-27
    abstract: Deep learning-based prediction of protein structure usually begins by
      constructing a multiple sequence alignment (MSA) containing homologues of
      the target protein. The most successful approaches combine large feature
      sets derived from MSAs, and considerable computational effort is spent
      deriving these input features. We present a method that greatly reduces
      the amount of preprocessing required for a target MSA, while producing
      main chain coordinates as a direct output of a deep neural network. The
      network makes use of just three recurrent networks and a stack of residual
      convolutional layers, making the predictor very fast to run, and easy to
      install and use. Our approach constructs a directly learned representation
      of the sequences in an MSA, starting from a one-hot encoding of the
      sequences. When supplemented with an approximate precision matrix, the
      learned representation can be used to produce structural models of
      comparable or greater accuracy as compared to our original DMPfold method,
      while requiring less than a second to produce a typical model. This level
      of accuracy and speed allows very large-scale 3-D modelling of proteins on
      minimal hardware, and we demonstrate that by producing models for over 1.3
      million uncharacterized regions of proteins extracted from the BFD
      sequence clusters. After constructing an initial set of approximate
      models, we select a confident subset of over 30,000 models for further
      refinement and analysis, revealing putative novel protein folds. We also
      provide updated models for over 5,000 Pfam families studied in the
      original DMPfold paper.
    authors:
      - name: Shaun M Kandathil
      - name: Joe G Greener
      - name: Andy M Lau
      - name: David T Jones
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Fri Jul 23 20:16:07 +0000 2021
      id: 1418666255704338400
      id_str: "1418666255704338433"
      text: >-
        üî• bioRxiv Bioinformatics preprint by S. M. Kandathil et al:


        "Ultrafast end-to-end protein structure prediction ena‚Ä¶ https://t.co/hhgi4SpP5o
      truncated: true
      entities:
        urls:
          - url: https://t.co/hhgi4SpP5o
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "119582"
    doi: 10.1101/2020.11.30.397463
    first_posted: 2020-11-30
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.11.30.397463v1
    url: https://api.rxivist.org/v1/papers/119582
    title: Loss of a subunit of vacuolar ATPase identifies unexpected biological
      signatures of reduced organelle acidification in vivo
    category: molecular-biology
    abstract: The inability to maintain a strictly regulated endo(lyso)somal acidic
      pH through the proton-pumping action of the vacuolar-ATPases has been
      associated with various human diseases including heritable connective
      tissue disorders, neurodegenerative diseases and cancer. Multiple studies
      have investigated the pleiotropic effects of reduced acidification in
      vitro, but the mechanisms elicited by impaired endo(lyso)somal
      acidification in vivo remain poorly understood. Here, we show that loss of
      atp6v1e1b in zebrafish leads to early mortality, associated with
      craniofacial dysmorphisms, vascular anomalies, cardiac dysfunction,
      hypotonia and epidermal structural defects, reminiscent of the phenotypic
      manifestations in cutis laxa patients carrying a defect in the ATP6V1E1
      gene. Mechanistically, we found that in vivo genetic depletion of
      atp6v1e1b leads to N-glycosylation defects and reduced maturation of
      endosomal and lysosomal vesicles, but retains the hypoxia-mediated
      response. In order to gain further insights into the processes affected by
      aberrant organelle acidification, we performed an untargeted analysis of
      the transcriptome and metabolome in early atp6v1e1b-deficient larvae. We
      report multiple affected pathways including but not limited to oxidative
      phosphorylation, sphingolipid and fatty acid metabolism with profound
      defects in mitochondrial respiration. Taken together, our results identify
      new complex biological effects of reduced organelle acidification in vivo,
      which likely contribute to the multisystemic manifestations observed in
      disorders caused by v-ATPase deficiency.
    authors:
      - name: Lore Pottie
        orcid: http://orcid.org/0000-0001-5102-975X
      - name: Wouter Van Gool
        orcid: null
      - name: Michiel Vanhooydonck
        orcid: http://orcid.org/0000-0001-7350-9009
      - name: Franz-Georg Hanisch
        orcid: http://orcid.org/0000-0003-3619-7039
      - name: Geert Goeminne
        orcid: http://orcid.org/0000-0002-0337-2999
      - name: Andreja Rajkovic
        orcid: http://orcid.org/0000-0003-1062-0564
      - name: Paul Coucke
        orcid: http://orcid.org/0000-0001-7119-586X
      - name: Patrick Sips
        orcid: http://orcid.org/0000-0001-9241-5980
      - name: Bert Callewaert
        orcid: http://orcid.org/0000-0002-9743-4205
  comment:
    dislikes: 0
    thread: "8296640576"
    numReports: 0
    likes: 0
    id: "5466404214"
    createdAt: 2021-07-23T10:24:10
    author:
      name: Lore Pottie
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Our preprint has been published
      (https://doi.org/10.1371/journal.pgen.1009603). The link will follow
      forthcoming.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.11.30.397463v1
  tweets:
    - created_at: Fri Jul 23 20:19:37 +0000 2021
      id: 1418667137728610300
      id_str: "1418667137728610305"
      text: >-
        üí¨ bioRxiv comment on "Loss of a subunit of vacuolar ..."


        "Our preprint has been published ( The link will follow f‚Ä¶ https://t.co/Pncb1bQe8J
      truncated: true
      entities:
        urls:
          - url: https://t.co/Pncb1bQe8J
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 23 20:19:38 +0000 2021
      id: 1418667138705879000
      id_str: "1418667138705879041"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/Mg5rYPMLch
      truncated: false
      entities:
        urls:
          - url: https://t.co/Mg5rYPMLch
      in_reply_to_status_id: 1418667137728610300
      in_reply_to_status_id_str: "1418667137728610305"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 0
    id: "5466221789"
    createdAt: 2021-07-23T04:36:35
    author:
      username: disqus_UGLefoQbcU
      about: ""
      name: robert brown
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_UGLefoQbcU/
      url: ""
      location: ""
      id: "193978307"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Masks work. This is a statement of fact. I can make this statement
      because viruses must follow physical laws. So until you or anyone else can
      provide a body of evidence showing that viruses are not bound by physical
      laws you have no argument. We do however need to deal with that body of
      evidence how is it some studies reach a conclusion that‚Äôs opposed to
      reality? By having a fatal flaw. This study has it. The goal is to
      determine if masks are effective. So why are they studying if people are
      actually wearing them? Assuming that a mandate means higher mask usage is
      a bad assumption. Assuming no mandate lowers usage is another bad
      assumption. Assuming that areas with and without mandates are closed
      systems is a really bad assumption. Yet for this study and indeed the body
      of evidence you claim supports the masks don‚Äôt work conclusion to work as
      intended and be capable of answering the question all these things would
      need to be true. And as someone who has traveled through areas with and
      without mandates I can say none of those appear to be true. So how do
      masks work? This is important to understand many people assume that the
      goal is filtration but it‚Äôs not. Sure a cloth or paper mask can filter a
      lot of droplets and the particles with them but that‚Äôs not the primary
      mechanism here. How does a sail catch the wind? The air is perfectly
      capable of passing right through a cloth sail so how does that work? Air
      is a fluid which for our purposes means it takes the path of least
      resistance. If you take the carrier of a virus no mask and just normal
      breathing droplets containing viral particles will quickly spread out into
      the surrounding area where they will be inhaled by others thus infecting
      them as well. However if you have some sort of barrier in place like say a
      mask the air will quickly loose energy the droplets as well and they will
      fall quickly and for the most part harmlessly to the ground. Why mandates
      and not just choice? Well if you could not guess by the description the
      mechanic at play isn‚Äôt filtration. Yes a cloth or paper mask can capture
      some droplets but respiration has a vacuum element and if someone infected
      without a mask is spewing particles people around them are still going to
      suck those in. So the function of a mask isn‚Äôt to protect yourself it‚Äôs to
      protect other people. That wraps up this mini lecture any questions?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri Jul 23 22:19:29 +0000 2021
      id: 1418697299811778600
      id_str: "1418697299811778565"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Masks work. This is a statement of fact. I can make this‚Ä¶ https://t.co/0Me7dJMsP5
      truncated: true
      entities:
        urls:
          - url: https://t.co/0Me7dJMsP5
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 23 22:19:29 +0000 2021
      id: 1418697300667510800
      id_str: "1418697300667510785"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1418697299811778600
      in_reply_to_status_id_str: "1418697299811778565"
- preprint:
    id: "143297"
    doi: 10.1101/2021.05.23.21257686
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.23.21257686v1
    url: https://api.rxivist.org/v1/papers/143297
    title: Addressing anti-syncytin antibody levels, and fertility and breastfeeding
      concerns, following BNT162B2 COVID-19 mRNA vaccination
    category: obstetrics-and-gynecology
    abstract: "Objective: To determine whether antibodies against the SARS-CoV-2
      spike protein following BNT162B2 (Pfizer-BioNTech) COVID-19 mRNA
      vaccination cross-react with human syncytin-1 protein, and if BNT162B2
      mRNA enters breast milk. Methods: In this observational cohort study of
      female front-line workers with no history of COVID-19 infection, we
      amplified BNT162B2 mRNA in plasma and breast milk and assayed
      anti-SARS-CoV-2 neutralising antibodies and anti-human syncytin-1 binding
      antibodies in plasma, at early (1-4 days) and late (4-7 weeks) time points
      following first-dose vaccination. Results: Fifteen consented participants
      (mean age 40.4 years, various ethnicities) who received at least one dose
      of BNT162B2, including five breast-feeding women and two women who were
      inadvertently vaccinated in early pregnancy, were recruited. BNT162B2
      mRNA, detected by amplifying part of the spike-encoding region, was
      detected in plasma 1-4 days following the first dose (n=13), but not 4-5
      weeks later (n=2), nor was the mRNA isolated from aqueous or lipid breast
      milk fractions collected 0-7 days post-vaccination (n=5). Vaccine
      recipients demonstrated strong SARS-CoV-2 neutralising activity by at
      least four weeks after the first dose (n=15), including the two pregnant
      women. None had placental anti-syncytin-1 binding antibodies at either
      time-point following vaccination. Conclusions: BNT162B2-vaccinated women
      did not transmit vaccine mRNA to breast milk, and did not produce a
      concurrent humoral response to syncytin-1, suggesting that
      cross-reactivity to syncytin-1 on the developing trophoblast, or other
      adverse effects in the breast-fed infant from vaccine mRNA ingestion, are
      unlikely."
    authors:
      - name: Citra Nurfarah Mattar
        orcid: http://orcid.org/0000-0003-0068-6957
      - name: Winston Koh
        orcid: http://orcid.org/0000-0003-4611-6490
      - name: Yiqi Seow
        orcid: http://orcid.org/0000-0001-7040-3006
      - name: Shawn Hoon
        orcid: http://orcid.org/0000-0002-3892-3332
      - name: Aparna VENKATESH
        orcid: http://orcid.org/0000-0001-8639-9232
      - name: Pradip Dashraath
        orcid: http://orcid.org/0000-0002-4095-3186
      - name: Li Min LIM
        orcid: null
      - name: Judith ONG
        orcid: null
      - name: Rachel Jiayu Lee
        orcid: null
      - name: Nuryanti Johana
        orcid: null
      - name: Julie SL Yeo
        orcid: null
      - name: David Shao Hong Chong
        orcid: null
      - name: Lay Kok Tan
        orcid: http://orcid.org/0000-0002-7790-2171
      - name: Jerry Kok Yen Chan
        orcid: http://orcid.org/0000-0002-0246-2159
      - name: Mahesh Choolani
        orcid: http://orcid.org/0000-0001-8336-0973
      - name: Paul Tambyah
        orcid: http://orcid.org/0000-0003-0405-771X
  comment:
    dislikes: 0
    thread: "8551357360"
    numReports: 0
    likes: 0
    id: "5466206574"
    createdAt: 2021-07-23T04:09:03
    author:
      username: gralinjamespritchard
      about: ""
      name: Gralin James Pritchard
      isPowerContributor: false
      profileUrl: https://disqus.com/by/gralinjamespritchard/
      url: ""
      location: ""
      id: "370175272"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: '"Naturally controlled by the body"? Source?'
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.23.21257686v1
  tweets:
    - created_at: Sat Jul 24 01:03:40 +0000 2021
      id: 1418738620844945400
      id_str: "1418738620844945419"
      text: |-
        üí¨ medRxiv comment on "Addressing anti-syncytin antib..."

        ""Naturally controlled by the body"? Source?"

        https://t.co/piHvN4JBJf
      truncated: false
      entities:
        urls:
          - url: https://t.co/piHvN4JBJf
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 24 01:03:40 +0000 2021
      id: 1418738621713162200
      id_str: "1418738621713162245"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/GmRAl2Ix8D
      truncated: false
      entities:
        urls:
          - url: https://t.co/GmRAl2Ix8D
      in_reply_to_status_id: 1418738620844945400
      in_reply_to_status_id_str: "1418738620844945419"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8603406700"
    numReports: 0
    likes: 1
    id: "5464323719"
    createdAt: 2021-07-21T19:03:10
    author:
      username: happyches
      about: "- Giving anything a go.\r

        - Love to laugh and have fun.\r

        - Motivated and Goal-Driven.\r

        - Getting \"out\" There.\r

        - Love knowledge, learning.\r

        - Helping others."
      name: Penny Butler
      isPowerContributor: false
      profileUrl: https://disqus.com/by/happyches/
      url: http://webwooky.com
      location: The Universe
      id: "52026"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "Comments: #82  (but I only see 8) ummm? #pleaseexplain"
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v3
  tweets:
    - created_at: Sat Jul 24 12:30:25 +0000 2021
      id: 1418911444465242000
      id_str: "1418911444465242115"
      text: |-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."

        "Comments: #82  (but I only see 8) ummm? #pleaseexplain"

        https://t.co/eDJfG9UGoo
      truncated: false
      entities:
        urls:
          - url: https://t.co/eDJfG9UGoo
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 24 12:30:25 +0000 2021
      id: 1418911445178364000
      id_str: "1418911445178363904"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1418911444465242000
      in_reply_to_status_id_str: "1418911444465242115"
- preprint:
    id: "143297"
    doi: 10.1101/2021.05.23.21257686
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.23.21257686v1
    url: https://api.rxivist.org/v1/papers/143297
    title: Addressing anti-syncytin antibody levels, and fertility and breastfeeding
      concerns, following BNT162B2 COVID-19 mRNA vaccination
    category: obstetrics-and-gynecology
    abstract: "Objective: To determine whether antibodies against the SARS-CoV-2
      spike protein following BNT162B2 (Pfizer-BioNTech) COVID-19 mRNA
      vaccination cross-react with human syncytin-1 protein, and if BNT162B2
      mRNA enters breast milk. Methods: In this observational cohort study of
      female front-line workers with no history of COVID-19 infection, we
      amplified BNT162B2 mRNA in plasma and breast milk and assayed
      anti-SARS-CoV-2 neutralising antibodies and anti-human syncytin-1 binding
      antibodies in plasma, at early (1-4 days) and late (4-7 weeks) time points
      following first-dose vaccination. Results: Fifteen consented participants
      (mean age 40.4 years, various ethnicities) who received at least one dose
      of BNT162B2, including five breast-feeding women and two women who were
      inadvertently vaccinated in early pregnancy, were recruited. BNT162B2
      mRNA, detected by amplifying part of the spike-encoding region, was
      detected in plasma 1-4 days following the first dose (n=13), but not 4-5
      weeks later (n=2), nor was the mRNA isolated from aqueous or lipid breast
      milk fractions collected 0-7 days post-vaccination (n=5). Vaccine
      recipients demonstrated strong SARS-CoV-2 neutralising activity by at
      least four weeks after the first dose (n=15), including the two pregnant
      women. None had placental anti-syncytin-1 binding antibodies at either
      time-point following vaccination. Conclusions: BNT162B2-vaccinated women
      did not transmit vaccine mRNA to breast milk, and did not produce a
      concurrent humoral response to syncytin-1, suggesting that
      cross-reactivity to syncytin-1 on the developing trophoblast, or other
      adverse effects in the breast-fed infant from vaccine mRNA ingestion, are
      unlikely."
    authors:
      - name: Citra Nurfarah Mattar
        orcid: http://orcid.org/0000-0003-0068-6957
      - name: Winston Koh
        orcid: http://orcid.org/0000-0003-4611-6490
      - name: Yiqi Seow
        orcid: http://orcid.org/0000-0001-7040-3006
      - name: Shawn Hoon
        orcid: http://orcid.org/0000-0002-3892-3332
      - name: Aparna VENKATESH
        orcid: http://orcid.org/0000-0001-8639-9232
      - name: Pradip Dashraath
        orcid: http://orcid.org/0000-0002-4095-3186
      - name: Li Min LIM
        orcid: null
      - name: Judith ONG
        orcid: null
      - name: Rachel Jiayu Lee
        orcid: null
      - name: Nuryanti Johana
        orcid: null
      - name: Julie SL Yeo
        orcid: null
      - name: David Shao Hong Chong
        orcid: null
      - name: Lay Kok Tan
        orcid: http://orcid.org/0000-0002-7790-2171
      - name: Jerry Kok Yen Chan
        orcid: http://orcid.org/0000-0002-0246-2159
      - name: Mahesh Choolani
        orcid: http://orcid.org/0000-0001-8336-0973
      - name: Paul Tambyah
        orcid: http://orcid.org/0000-0003-0405-771X
  comment:
    dislikes: 0
    thread: "8551357360"
    numReports: 0
    likes: 0
    id: "5466206113"
    createdAt: 2021-07-23T04:08:13
    author:
      username: gralinjamespritchard
      about: ""
      name: Gralin James Pritchard
      isPowerContributor: false
      profileUrl: https://disqus.com/by/gralinjamespritchard/
      url: ""
      location: ""
      id: "370175272"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Nobody can. I'm guessing they just drew a line above the cluster
      and called it a a day. Apparently, a low threshold = none. Tell that to
      pregnant womens' TLR-9, I guess.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.23.21257686v1
  tweets:
    - created_at: Sat Jul 24 14:17:00 +0000 2021
      id: 1418938268461289500
      id_str: "1418938268461289480"
      text: >-
        üí¨ medRxiv comment on "Addressing anti-syncytin antib..."


        "Nobody can. I'm guessing they just drew a line above the‚Ä¶ https://t.co/XAqBd4dVDF
      truncated: true
      entities:
        urls:
          - url: https://t.co/XAqBd4dVDF
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 24 14:17:00 +0000 2021
      id: 1418938269308444700
      id_str: "1418938269308444678"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/GmRAl2Ix8D
      truncated: false
      entities:
        urls:
          - url: https://t.co/GmRAl2Ix8D
      in_reply_to_status_id: 1418938268461289500
      in_reply_to_status_id_str: "1418938268461289480"
- preprint:
    id: "151054"
    doi: 10.1101/2021.07.19.21260808
    first_posted: 2021-07-22
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.19.21260808v1
    url: https://api.rxivist.org/v1/papers/151054
    title: Delta variants of SARS-CoV-2 cause significantly increased vaccine
      breakthrough COVID-19 cases in Houston, Texas
    category: pathology
    abstract: Genetic variants of SARS-CoV-2 have repeatedly altered the course of
      the COVID-19 pandemic, and disease in individual patients. Delta variants
      (B.1.617.2, AY.2, and AY.3) are now the focus of international concern
      because they are causing widespread COVID-19 disease globally. Vaccine
      breakthrough cases caused by SARS-CoV-2 variants also are of considerable
      public health and medical concern worldwide. As part of a comprehensive
      project, we sequenced the genomes of 3,913 SARS-CoV-2 from patient samples
      acquired March 15, 2021 through July 3, 2021 in the Houston Methodist
      hospital system and studied vaccine breakthrough cases. During the study
      period Delta variants increased to cause 58% of all COVID-19 cases and
      spread throughout the metropolitan Houston area. In addition, Delta
      variants caused a significantly higher rate of vaccine breakthrough cases
      (19.7% compared to 5.8% for all other variants). Importantly, only 6.5% of
      all COVID-19 cases occurred in fully immunized individuals, and relatively
      few of these patients required hospitalization. Our genomic and
      epidemiologic data emphasize that vaccines used in the United States are
      highly effective in decreasing severe COVID-19 disease, hospitalizations,
      and deaths.
    authors:
      - name: James M. Musser
        orcid: http://orcid.org/0000-0002-7765-4956
      - name: Paul A. Christensen
        orcid: null
      - name: Randall J. Olsen
        orcid: http://orcid.org/0000-0003-4828-7322
      - name: Scott Wesley Long
        orcid: http://orcid.org/0000-0003-3043-5307
      - name: Sishir Subedi
        orcid: null
      - name: James J Davis
        orcid: null
      - name: Parsa Hodjat
        orcid: null
      - name: Debbie R. Walley
        orcid: null
      - name: Jacob C. Kinskey
        orcid: null
      - name: Jimmy D Gollihar
        orcid: null
  comment:
    dislikes: 0
    thread: "8663912566"
    numReports: 0
    likes: 0
    id: "5467514050"
    createdAt: 2021-07-24T06:42:21
    author:
      username: itellu3times
      about: ""
      name: itellu3times
      isPowerContributor: false
      profileUrl: https://disqus.com/by/itellu3times/
      url: ""
      location: ""
      id: "49572364"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Need to compare with background - what is the vaccination rate for
      Houston, during the period of the study?  This may completely dominate the
      purported findings.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.07.19.21260808v1
  tweets:
    - created_at: Sat Jul 24 16:30:24 +0000 2021
      id: 1418971839225860000
      id_str: "1418971839225860105"
      text: >-
        üí¨ medRxiv comment on "Delta variants of SARS-CoV-2 c..."


        "Need to compare with background - what is the vaccinatio‚Ä¶ https://t.co/kPzqtoQK1U
      truncated: true
      entities:
        urls:
          - url: https://t.co/kPzqtoQK1U
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 24 16:30:24 +0000 2021
      id: 1418971840085627000
      id_str: "1418971840085626880"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/vSwaatj7aM
      truncated: false
      entities:
        urls:
          - url: https://t.co/vSwaatj7aM
      in_reply_to_status_id: 1418971839225860000
      in_reply_to_status_id_str: "1418971839225860105"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 0
    id: "5467165585"
    createdAt: 2021-07-23T22:14:04
    author:
      username: johnivyping
      about: ""
      name: John Ivy Ping
      isPowerContributor: false
      profileUrl: https://disqus.com/by/johnivyping/
      url: ""
      location: ""
      id: "372749224"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Mask didn't work in 1918 because less than half wore mask,  however, those
      cities that did have mask. Mandates did fair better than those without. 


      Cloth mask are not 100% effective and air tight suit is.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sat Jul 24 18:24:11 +0000 2021
      id: 1419000474724876300
      id_str: "1419000474724876292"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Mask didn't work in 1918 because less than half wore mas‚Ä¶ https://t.co/KEYy2Bhjrm
      truncated: true
      entities:
        urls:
          - url: https://t.co/KEYy2Bhjrm
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 24 18:24:11 +0000 2021
      id: 1419000475509313500
      id_str: "1419000475509313536"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1419000474724876300
      in_reply_to_status_id_str: "1419000474724876292"
- preprint:
    id: 125092
    metric: 12
    title: Fatal neuroinvasion of SARS-CoV-2 in K18-hACE2 mice is partially
      dependent on hACE2 expression
    url: https://api.rxivist.org/v1/papers/125092
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.01.13.425144v1
    doi: 10.1101/2021.01.13.425144
    category: pathology
    first_posted: 2021-01-13
    abstract: >-
      Animal models recapitulating the distinctive features of severe COVID-19
      are critical to enhance our understanding of SARS-CoV-2 pathogenesis.
      Transgenic mice expressing human angiotensin-converting enzyme 2 (hACE2)
      under the cytokeratin 18 promoter (K18-hACE2) represent a lethal model of
      SARS-CoV-2 infection. However, the cause(s) and mechanisms of lethality in
      this mouse model remain unclear. Here, we evaluated the spatiotemporal
      dynamics of SARS-CoV-2 infection for up to 14 days post-infection. Despite
      infection and moderate inflammation in the lungs, lethality was invariably
      associated with viral neuroinvasion and neuronal damage (including spinal
      motor neurons). Neuroinvasion occurred following virus transport through
      the olfactory neuroepithelium in a manner that was only partially
      dependent on hACE2. Interestingly, SARS-CoV-2 tropism was overall neither
      widespread among nor restricted to only ACE2-expressing cells. Although
      our work incites caution in the utility of the K18-hACE2 model to study
      global aspects of SARS-CoV-2 pathogenesis, it underscores this model as a
      unique platform for exploring the mechanisms of SARS-CoV-2
      neuropathogenesis.


      SUMMARYCOVID-19 is a respiratory disease caused by SARS-CoV-2, a betacoronavirus. Here, we show that in a widely used transgenic mouse model of COVID-19, lethality is invariably associated with viral neuroinvasion and the ensuing neuronal disease, while lung inflammation remains moderate.
    authors:
      - name: Mariano Carossino
      - name: Paige Montanaro
      - name: Aoife O'Connell
      - name: Devin Kenney
      - name: Hans Gertje
      - name: Kyle Grosz
      - name: Susanna Kurnick
      - name: Markus Bosmann
      - name: Mohsan Saeed
      - name: Udeni Balasuriya
      - name: Florian Douam
      - name: Nicholas A. Crossland
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sat Jul 24 20:15:39 +0000 2021
      id: 1419028523998716000
      id_str: "1419028523998715906"
      text: >-
        üî• bioRxiv Pathology preprint by M. Carossino et al:


        "Fatal neuroinvasion of SARS-CoV-2 in K18-hACE2 mice is partia‚Ä¶ https://t.co/LlgmhhKAyC
      truncated: true
      entities:
        urls:
          - url: https://t.co/LlgmhhKAyC
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 0
    id: "5467161909"
    createdAt: 2021-07-23T22:10:04
    author:
      username: johnivyping
      about: ""
      name: John Ivy Ping
      isPowerContributor: false
      profileUrl: https://disqus.com/by/johnivyping/
      url: ""
      location: ""
      id: "372749224"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: I am only aware of one such study which compared cloth mask to M95
      mask,  they did not compare mask to no mask.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sat Jul 24 20:19:01 +0000 2021
      id: 1419029374368628700
      id_str: "1419029374368628743"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "I am only aware of one such study which compared cloth m‚Ä¶ https://t.co/o1QMb1M8wp
      truncated: true
      entities:
        urls:
          - url: https://t.co/o1QMb1M8wp
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 24 20:19:02 +0000 2021
      id: 1419029375224369200
      id_str: "1419029375224369155"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1419029374368628700
      in_reply_to_status_id_str: "1419029374368628743"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 0
    id: "5467160353"
    createdAt: 2021-07-23T22:08:18
    author:
      username: johnivyping
      about: ""
      name: John Ivy Ping
      isPowerContributor: false
      profileUrl: https://disqus.com/by/johnivyping/
      url: ""
      location: ""
      id: "372749224"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Actually he's very right, as someone who lives on the border of a
      state that required mask and a state that did not,  the laws made no
      difference.  Many workers did not enforce mask usage despite them being
      required to.  For this study to have validity it needs to measure how many
      people were following the guidelines.  Further a great number of
      businesses in the state that required mask refused to enforce the mask
      mandate,  the police in my metropolitan area also refused to enforce mask
      mandates.  These are all important things.  What this study measures is
      not the efficancy of mask, but how well mask mandates had on the impact of
      the spread,  this is two different things.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sat Jul 24 22:18:59 +0000 2021
      id: 1419059564800999400
      id_str: "1419059564800999428"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Actually he's very right, as someone who lives on the bo‚Ä¶ https://t.co/i0SCLmrBOh
      truncated: true
      entities:
        urls:
          - url: https://t.co/i0SCLmrBOh
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 24 22:18:59 +0000 2021
      id: 1419059565593710600
      id_str: "1419059565593710592"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU30MFJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU30MFJ
      in_reply_to_status_id: 1419059564800999400
      in_reply_to_status_id_str: "1419059564800999428"
- preprint:
    id: "127482"
    doi: 10.1101/2021.01.24.21250418
    first_posted: 2021-02-01
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.01.24.21250418v1
    url: https://api.rxivist.org/v1/papers/127482
    title: Targeting TGF-b pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal
      Accelerates Recovery from Mild-Moderate COVID-19
    category: infectious-diseases
    abstract: "Our COVID-19 drug candidate ARTIVeda/PulmoHeal is a novel gelatin
      capsule formulation of the Artemisia extract Ayurveda for oral delivery of
      TGF-b targeting anti-malaria phytomedicine Artemisinin with documented
      anti-inflammatory and anti-SARS-CoV-2 activity. Here we report the safety
      and efficacy of ARTIVeda in adult COVID-19 patients with symptomatic
      mild-moderate COVID-19, who were treated in a randomized, open-label Phase
      IV study in Bangalore, Karnataka, India (Clinical Trials Registry India
      identifier: CTRI/2020/09/028044). ARTIVeda showed a very favorable safety
      profile, and the only ARTIVeda-related adverse events were transient mild
      rash and mild hypertension. Notably, ARTIVeda, when added to the SOC,
      accelerated the recovery of patients with mild-moderate COVID-19. While
      all patients were symptomatic at baseline (WHO score = 2-4), 31 of 39
      (79.5%) of patients treated with ARTIVeda plus SOC became asymptomatic
      (WHO score = 1) by the end of the 5-day therapy, including 10 of 10
      patients with severe dry cough 7 of 7 patients with severe fever. By
      comparison, 12 of 21 control patients (57.1%) treated with SOC alone
      became asymptomatic on day 5 (P=0.028, Fishers exact test). This clinical
      benefit was particularly evident when the treatment outcomes of
      hospitalized COVID-19 patients (WHO score = 4) treated with SOC alone
      versus SOC plus ARTIVeda were compared. The median time to becoming
      asymptomatic was only 5 days for the SOC plus ARTIVeda group (N=18) but 14
      days for the SOC alone group (N=10) (P=0.004, Log-rank test). These data
      provide clinical proof of concept that targeting the TGF-b pathway with
      ARTIVeda may contribute to a faster recovery of patients with
      mild-moderate COVID-19 when administered early in the course of their
      disease."
    authors:
      - name: Vuong Trieu
        orcid: null
      - name: Saran Saund
        orcid: null
      - name: Prashant Rahate
        orcid: null
      - name: Viljay Barge
        orcid: null
      - name: Sunil Nalk
        orcid: null
      - name: Hitesh Windlass
        orcid: null
      - name: Fatih Uckun
        orcid: http://orcid.org/0000-0001-9334-183X
  comment:
    dislikes: 0
    thread: "8379959167"
    numReports: 0
    likes: 0
    id: "5467152463"
    createdAt: 2021-07-23T21:59:46
    author:
      username: vuong_trieu
      about: ""
      name: Vuong Trieu
      isPowerContributor: false
      profileUrl: https://disqus.com/by/vuong_trieu/
      url: ""
      location: ""
      id: "372749248"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      This paper is now published at





      https://www.openaccessjournals.com/articles/targeting-tgf-pathway-with-covid19-drug-candidate-artivedapulmoheal-accelerates-recovery-from-mildmoderate-covid19.pdf
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.01.24.21250418v1
  tweets:
    - created_at: Sun Jul 25 01:05:04 +0000 2021
      id: 1419101358293229600
      id_str: "1419101358293229571"
      text: |-
        üí¨ medRxiv comment on "Targeting TGF-b pathway with C..."

        "This paper is now published at

        "

        https://t.co/YVAwn5hkw1
      truncated: false
      entities:
        urls:
          - url: https://t.co/YVAwn5hkw1
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 25 01:05:04 +0000 2021
      id: 1419101359102742500
      id_str: "1419101359102742533"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/CoQvYKR7A5
      truncated: false
      entities:
        urls:
          - url: https://t.co/CoQvYKR7A5
      in_reply_to_status_id: 1419101358293229600
      in_reply_to_status_id_str: "1419101358293229571"
- preprint:
    id: "102545"
    doi: 10.1101/2020.10.30.361584
    first_posted: 2020-10-30
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.10.30.361584v1
    url: https://api.rxivist.org/v1/papers/102545
    title: Allosteric regulation in CRISPR/Cas1-Cas2 protospacer acquisition
      mediated by DNA in association with Cas2
    category: biophysics
    abstract: >-
      Cas1 and Cas2 are highly conserved proteins across CRISPR-Cas systems and
      play a significant role in protospacer acquisition. Here we study the
      protospacer (or ps) DNA binding, recognition, and response to cleavage on
      the protospacer-adjacent-motif complementary sequence or PAMc by
      Cas1-Cas2, implementing all-atom molecular dynamics simulations. First, we
      noticed that two active sites of Cas1&1‚Ä≤ bind asymmetrically to two
      identical PAMc in the simulation. For psDNA containing only one PAMc to be
      recognized, it is then found that the non-PAMc association site remains
      destabilized until after the bound PAMc being cleaved. Thus, correlation
      appears to exist between the two active sites, which can be allosterically
      mediated by psDNA and Cas2&2‚Ä≤ in bridging. To substantiate such findings,
      we further simulated Cas1-Cas2 in complex with synthesized psDNA sequences
      psL and psH, which have been measured with low and high efficiency in
      acquisition, respectively. Notably, such inter-site correlation becomes
      largely enhanced for Cas1-Cas2 in complex with psH, and remains low with
      psL. Hence, our studies demonstrate that PAMc recognition and cleavage in
      one active site of Cas1-Cas2 allosterically regulates non-PAMc
      association/reaction in the other site, and such allosteric regulation is
      mediated by non-catalytic Cas2 and DNA protospacer in acquisition.


      ### Competing Interest Statement


      The authors have declared no competing interest.
    authors:
      - name: Chunhong Long
        orcid: null
      - name: Liqiang Dai
        orcid: http://orcid.org/0000-0001-9842-2524
      - name: Chao E
        orcid: null
      - name: Lin-Tai Da
        orcid: http://orcid.org/0000-0002-1589-5754
      - name: Jin Yu
        orcid: http://orcid.org/0000-0001-8224-1374
  comment:
    dislikes: 0
    thread: "8258395722"
    numReports: 0
    likes: 0
    id: "5468016963"
    createdAt: 2021-07-24T18:06:14
    author:
      username: disqus_hr2VghaKIp
      about: ""
      name: Jin Yu
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_hr2VghaKIp/
      url: ""
      location: ""
      id: "344891414"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "published online: https://doi.org/10.1016/j.bpj.2021.06.007"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.10.30.361584v1
  tweets:
    - created_at: Sun Jul 25 12:30:26 +0000 2021
      id: 1419273839427600400
      id_str: "1419273839427600393"
      text: |-
        üí¨ bioRxiv comment on "Allosteric regulation in CRISP..."

        "published online: "

        https://t.co/ESSJ9dDrHk
      truncated: false
      entities:
        urls:
          - url: https://t.co/ESSJ9dDrHk
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 25 12:30:26 +0000 2021
      id: 1419273840220377000
      id_str: "1419273840220377089"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/k8ccuJIJfN
      truncated: false
      entities:
        urls:
          - url: https://t.co/k8ccuJIJfN
      in_reply_to_status_id: 1419273839427600400
      in_reply_to_status_id_str: "1419273839427600393"
- preprint:
    id: "140726"
    doi: 10.1101/2021.05.03.442491
    first_posted: 2021-05-04
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.03.442491v1
    url: https://api.rxivist.org/v1/papers/140726
    title: A proteomics database for CNS proteins of the great pond snail Lymnaea
      stagnalis
    category: bioinformatics
    abstract: Applications of key technologies in bioscientific and biomedical
      research, such as qRT-PCR or LC-MS based proteomics, are generating large
      biological data sets (omics data) which are useful for the identification
      and quantification of biomarkers involved in molecular mechanisms of any
      research area of interest. Genome, transcriptome and proteome databases
      are already available for a number of model organisms including
      vertebrates and invertebrates. However, there is insufficient information
      available for protein sequences of certain invertebrates, such as the
      great pond snail Lymnaea stagnalis, a model organism that has been used
      highly successfully in elucidating evolutionarily conserved mechanisms of
      learning and memory, ageing and age-related as well as amyloid beta
      induced memory decline. Here, we present the design and benchmarking of a
      new proteomics database (LymSt-PDB) for the identification of proteins
      from the Central Nervous System (CNS) of Lymnaea stagnalis by LC-MS based
      proteomics.
    authors:
      - name: Sarah Wooller
        orcid: null
      - name: Aikaterini Anagnostopoulou
        orcid: null
      - name: Benno Kuropka
        orcid: http://orcid.org/0000-0001-5088-6346
      - name: Michael Crossley
        orcid: null
      - name: Paul R Benjamin
        orcid: null
      - name: Frances Pearl
        orcid: null
      - name: Ildik√≥ Kemenes
        orcid: http://orcid.org/0000-0002-8722-8766
      - name: Gy√∂rgy Kemenes
        orcid: http://orcid.org/0000-0003-2004-8725
      - name: Murat Eravci
        orcid: null
  comment:
    dislikes: 0
    thread: "8506026938"
    numReports: 0
    likes: 0
    id: "5467099138"
    createdAt: 2021-07-23T21:07:12
    author:
      username: etsuroito
      about: ""
      name: Etsuro Ito
      isPowerContributor: false
      profileUrl: https://disqus.com/by/etsuroito/
      url: ""
      location: ""
      id: "372747559"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Dear my Lymnaea friends,

      Thank you for your wonderful job for the preparation of database of proteomics.

      We are now applying LC-MS to our Lymnaea studies and thus your database encourages to advance our studies.

      Please continue such useful work to not only Lymnaea researchers but also other molluscan researchers.

      Best,

      Etsu
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.05.03.442491v1
  tweets:
    - created_at: Sun Jul 25 14:17:11 +0000 2021
      id: 1419300703168782300
      id_str: "1419300703168782339"
      text: |-
        üí¨ bioRxiv comment on "A proteomics database for CNS ..."

        "Dear my Lymnaea friends,
        Thank you for your wonderful jo‚Ä¶ https://t.co/isuNiuXV96
      truncated: true
      entities:
        urls:
          - url: https://t.co/isuNiuXV96
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 25 14:17:11 +0000 2021
      id: 1419300704192237600
      id_str: "1419300704192237571"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/Kx5QsJW68D
      truncated: false
      entities:
        urls:
          - url: https://t.co/Kx5QsJW68D
      in_reply_to_status_id: 1419300703168782300
      in_reply_to_status_id_str: "1419300703168782339"
- preprint:
    id: "150667"
    doi: 10.1101/2021.07.15.21260621
    first_posted: 2021-07-19
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.15.21260621v1
    url: https://api.rxivist.org/v1/papers/150667
    title: Antibody and T cell responses to Sinopharm/BBIBP-CorV in naive and
      previously infected individuals in Sri Lanka
    category: allergy-and-immunology
    abstract: "Background: As there are limited data of the immunogenicity of the
      Sinopharm/BBIBP-CorV in different populations, antibody responses against
      different SARS-CoV-2 variants of concern and T cell responses, we
      investigated the immunogenicity of the vaccine, in individuals in Sri
      Lanka. Methods: SARS-CoV-2-specific antibodies were measured in 282
      individuals who were seronegative at baseline, and ACE2 receptor blocking
      antibodies, antibodies to the receptor binding domain (RBD) of the wild
      type (WT), B.1.1.7, B.1.351 and B.1.617.2, ex vivo and cultured IFN{gamma}
      ELISpot assays, intracellular cytokine secretion assays and B cell ELISpot
      assays were carried out in a sub cohort of the vaccinees at 4 weeks and at
      6 weeks (2 weeks after the second dose). Results: 95% of the vaccinees
      seroconverted, although the seroconversion rates were significantly lower
      (p<0.001) in individuals >60 years (93.3%) compared to those who were 20
      to 39 years (98.9%). 81.25% had ACE2 receptor blocking antibodies at 6
      weeks, and there was no difference in these antibody titres in vaccine
      sera compared to convalescent sera (p=0.44). Vaccinees had significantly
      less (p<0.0001) antibodies to the RBD of WT and B.1.1.7, although there
      was no difference in antibodies to the RBD of B.1.351 and B.1.617.2
      compared to convalescent sera. 27.7% of 46.4% of vaccinees had ex vivo
      IFN{gamma} and cultured ELISpot responses respectively, and IFN{gamma} and
      CD107a responses were detected by flow cytometry. Conclusions:
      Sinopharm/BBIBP-CorV appeared to induce high seroconversion rates and
      induce a similar level of antibody responses against ACE2 receptor,
      B.1.617.2 and B.1.351 as seen following natural infection."
    authors:
      - name: Chandima Jeewandara
        orcid: http://orcid.org/0000-0002-5150-6648
      - name: Inoka Sepali Aberathna
        orcid: null
      - name: Pradeep Dharshana Pushpakumara
        orcid: null
      - name: Achala Kamaladasa
        orcid: null
      - name: Dinuka Guruge
        orcid: null
      - name: Deshni Jayathilaka
        orcid: null
      - name: Banuri Gunesekara
        orcid: null
      - name: Shyrar Tanussiya
        orcid: null
      - name: Heshan Kuruppu
        orcid: null
      - name: Thushali Ranasinghe
        orcid: null
      - name: Shashika Dayarathne
        orcid: null
      - name: Osanda Dissanayaka
        orcid: null
      - name: Nayanathara Gamalath
        orcid: null
      - name: Dinithi Ekanayaka
        orcid: null
      - name: M.P.D.J. Jayamali
        orcid: null
      - name: Ayesha Wijesinghe
        orcid: null
      - name: Madushika Dissanayaka
        orcid: null
      - name: Deshan Madushanka
        orcid: null
      - name: Tibutius Jayadas
        orcid: null
      - name: Anushika Mudunkotuwa
        orcid: null
      - name: Gayasha Somathilaka
        orcid: null
      - name: Michael James Harvie
        orcid: null
      - name: Thashmi Nimasha
        orcid: null
      - name: Saubhagya Danasekara
        orcid: null
      - name: Ruwan Wijayamuni
        orcid: null
      - name: Lisa Schimanski
        orcid: null
      - name: Tiong Tan
        orcid: null
      - name: Tao Dong
        orcid: http://orcid.org/0000-0002-3702-3965
      - name: Alain Townsend
        orcid: http://orcid.org/0000-0002-3702-0107
      - name: Graham Ogg
        orcid: http://orcid.org/0000-0002-3097-045X
      - name: Gathsaurie Neelika Malavige
        orcid: http://orcid.org/0000-0001-9201-0449
  comment:
    dislikes: 0
    thread: "8657232403"
    numReports: 0
    likes: 0
    id: "5466953165"
    createdAt: 2021-07-23T18:58:56
    author:
      username: jayamaara
      about: ""
      name: Jayamaara
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jayamaara/
      url: ""
      location: ""
      id: "372741630"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      This study shows there is some immunity has built up in vaccinated
      individuals. But we still don't know whether this immunity can prevent the
      infection or the severity of disease if infected. 


      This study is not an assessment of the risk of severe disease, hospitalization, and death of vaccinated group against a non-vaccinated group, nor a comparison between different vaccines. We still don't know the efficacy of most vaccines against VOCs like delta. It's better to adhere to safety measures even if you are vaccinated, until we have better data to say otherwise.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.07.15.21260621v1
  tweets:
    - created_at: Sun Jul 25 16:30:08 +0000 2021
      id: 1419334162532733000
      id_str: "1419334162532732930"
      text: >-
        üí¨ medRxiv comment on "Antibody and T cell responses ..."


        "This study shows there is some immunity has built up in‚Ä¶ https://t.co/7ArPxuyJ0p
      truncated: true
      entities:
        urls:
          - url: https://t.co/7ArPxuyJ0p
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 25 16:30:09 +0000 2021
      id: 1419334163354763300
      id_str: "1419334163354763271"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/JVRxUJSWxJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/JVRxUJSWxJ
      in_reply_to_status_id: 1419334162532733000
      in_reply_to_status_id_str: "1419334162532732930"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8552957443"
    numReports: 0
    likes: 0
    id: "5466678084"
    createdAt: 2021-07-23T15:12:27
    author:
      username: disqus_Zm7LobAjov
      about: ""
      name: mef
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_Zm7LobAjov/
      url: ""
      location: ""
      id: "326017482"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "More corrections here:
      https://covid19criticalcare.com/wp-content/uploads/2021/07/RomanRebuttal_\
      v7_EF_letterhead_ML-1.pdf"
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v2
  tweets:
    - created_at: Sun Jul 25 18:23:58 +0000 2021
      id: 1419362807640961000
      id_str: "1419362807640961025"
      text: |-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."

        "More corrections here: "

        https://t.co/lu61fkKTt8
      truncated: false
      entities:
        urls:
          - url: https://t.co/lu61fkKTt8
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 25 18:23:58 +0000 2021
      id: 1419362808379097000
      id_str: "1419362808379097088"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1419362807640961000
      in_reply_to_status_id_str: "1419362807640961025"
- preprint:
    id: 131736
    metric: 72
    title: Blockade of SARS-CoV-2 infection in-vitro by highly potent
      PI3K-Œ±/mTOR/BRD4 inhibitor
    url: https://api.rxivist.org/v1/papers/131736
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.03.02.433604v1
    doi: 10.1101/2021.03.02.433604
    category: pharmacology-and-toxicology
    first_posted: 2021-03-03
    abstract: >-
      Pathogenic viruses like SARS-CoV-2 and HIV hijack the host molecular
      machinery to establish infection and survival in infected cells. This has
      led the scientific community to explore the molecular mechanisms by which
      SARS-CoV-2 infects host cells, establishes productive infection, and
      causes life-threatening pathophysiology. Very few targeted therapeutics
      for COVID-19 currently exist, such as remdesivir. Recently, a proteomic
      approach explored the interactions of 26 of 29 SARS-CoV-2 proteins with
      cellular targets in human cells and identified 67 interactions as
      potential targets for drug development. Two of the critical targets, the
      bromodomain and extra-terminal domain proteins (BETs): BRD2/BRD4 and mTOR,
      are inhibited by the dual inhibitory small molecule SF2523 at nanomolar
      potency. SF2523 is the only known mTOR PI3K-/(BRD2/BRD4) inhibitor with
      potential to block two orthogonal pathways necessary for SARS-CoV-2
      pathogenesis in human cells. Our results demonstrate that SF2523
      effectively blocks SARS-CoV-2 replication in lung bronchial epithelial
      cells in vitro, showing an IC50 value of 1.5 {micro}M, comparable to IC50
      value of remdesivir (1.1 {micro}M). Further, we demonstrated that the
      combination of doses of SF2523 and remdesivir is highly synergistic: it
      allows for the reduction of doses of SF2523 and remdesivir by 25-fold and
      4-fold, respectively, to achieve the same potency observed for a single
      inhibitor. Because SF2523 inhibits two SARS-CoV-2 driven pathogenesis
      mechanisms involving BRD2/BRD4 and mTOR signaling, our data suggest that
      SF2523 alone or in combination with remdesivir could be a novel and
      efficient therapeutic strategy to block SARS-CoV-2 infection and hence be
      beneficial in preventing severe COVID-19 disease evolution.


      One Sentence SummaryEvidence of in silico designed chemotype (SF2523) targeting PI3K-/mTOR/BRD4 inhibits SARS-CoV-2 infection and is highly synergistic with remdesivir.
    authors:
      - name: Arpan Acharya
      - name: Kabita Pandey
      - name: Michellie Thurman
      - name: Kishore B. Challagundala
      - name: Kendra R. Vann
      - name: Tatiana G. Kutateladze
      - name: Guillermo A Morales
      - name: Donald L. Durden
      - name: Siddappa N. Byrareddy
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sun Jul 25 20:15:36 +0000 2021
      id: 1419390902477500400
      id_str: "1419390902477500421"
      text: |-
        üî• bioRxiv Pharmacology-and-toxicology preprint by A. Acharya et al:

        "Blockade of SARS-CoV-2 infection in-vitro by‚Ä¶ https://t.co/x1UU0dcSiB
      truncated: true
      entities:
        urls:
          - url: https://t.co/x1UU0dcSiB
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8603406700"
    numReports: 0
    likes: 0
    id: "5466071360"
    createdAt: 2021-07-23T00:58:53
    author:
      username: disqus_yGNk03DRU9
      about: ""
      name: Fernando
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_yGNk03DRU9/
      url: ""
      location: ""
      id: "372710314"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: |-
      You can be infected outside of work. How do you think health care 
      workers live their regular lives? Hint: just like the rest of us.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v3
  tweets:
    - created_at: Sun Jul 25 20:19:03 +0000 2021
      id: 1419391770069196800
      id_str: "1419391770069196804"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "You can be infected outside of work. How do you think he‚Ä¶ https://t.co/brXa8ElWWy
      truncated: true
      entities:
        urls:
          - url: https://t.co/brXa8ElWWy
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 25 20:19:03 +0000 2021
      id: 1419391770828365800
      id_str: "1419391770828365834"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1419391770069196800
      in_reply_to_status_id_str: "1419391770069196804"
- preprint:
    id: "150671"
    doi: 10.1101/2021.07.16.21260608
    first_posted: 2021-07-19
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.16.21260608v1
    url: https://api.rxivist.org/v1/papers/150671
    title: Genome-wide association analysis reveals extensive genetic overlap
      between mood instability and psychiatric disorders but divergent patterns
      of genetic effects
    category: psychiatry-and-clinical-psychology
    abstract: Mood instability (MOOD) is a transdiagnostic phenomenon with a
      prominent neurobiological basis. Recent genome-wide association studies
      found significant positive genetic correlation between MOOD and major
      depression (DEP) and weak correlations with other psychiatric disorders.
      We investigated the polygenic overlap between MOOD and psychiatric
      disorders beyond genetic correlation to better characterize putative
      shared genetic determinants. Summary statistics for schizophrenia (SCZ,
      n=105,318), bipolar disorder (BIP, n=413,466), DEP (n=450,619),
      attention-deficit hyperactivity disorder (ADHD, n=53,293) and MOOD
      (n=363,705), were analysed using the bivariate causal mixture model and
      conjunctional false discovery rate methods to estimate the proportion of
      shared variants influencing MOOD and each disorder, and identify jointly
      associated genomic loci. MOOD correlated positively with all psychiatric
      disorders, but with wide variation in strength (rg=0.10-0.62). Of 10.4K
      genomic variants influencing MOOD, 4K-9.4K were estimated to influence
      psychiatric disorders. MOOD was jointly associated with DEP at 163 loci,
      SCZ at 110, BIP at 60 and ADHD at 25, with consistent genetic effects in
      independent samples. Fifty-three jointly associated loci were overlapping
      across two or more disorders (transdiagnostic), seven of which had
      discordant effect directions on psychiatric disorders. Genes mapped to
      loci associated with MOOD and all four disorders were enriched in a single
      gene-set, synapse organization. The extensive polygenic overlap indicates
      shared molecular underpinnings across MOOD and psychiatric disorders.
      However, distinct patterns of genetic correlation and effect directions of
      shared loci suggest divergent effects on corresponding neurobiological
      mechanisms which may relate to differences in the core clinical features
      of each disorder.
    authors:
      - name: Guy Hindley
        orcid: http://orcid.org/0000-0003-1666-4701
      - name: Kevin S. O'Connell
        orcid: http://orcid.org/0000-0002-6865-8795
      - name: Zillur Rahman
        orcid: null
      - name: Oleksandr Frei
        orcid: http://orcid.org/0000-0002-6427-2625
      - name: Shahram Bahrami
        orcid: null
      - name: Alexey A Shadrin
        orcid: http://orcid.org/0000-0002-7467-250X
      - name: Margrethe Collier Hoegh
        orcid: null
      - name: Weiqiu Cheng
        orcid: null
      - name: Naz Karadag
        orcid: null
      - name: Aihua Lin
        orcid: null
      - name: Linn Rodevand
        orcid: null
      - name: Chun Chieh Fan
        orcid: http://orcid.org/0000-0001-9437-2128
      - name: Srdjan Djurovic
        orcid: http://orcid.org/0000-0002-8140-8061
      - name: Trine Vik Lagerberg
        orcid: http://orcid.org/0000-0003-3579-0789
      - name: Anders Dale
        orcid: null
      - name: Olav B. Smeland
        orcid: http://orcid.org/0000-0002-3761-5215
      - name: Ole Andreassen
        orcid: http://orcid.org/0000-0002-4461-3568
  comment:
    dislikes: 0
    thread: "8657234347"
    numReports: 0
    likes: 0
    id: "5465687068"
    createdAt: 2021-07-22T18:39:09
    author:
      username: berniemulvey
      about: ""
      name: Bernie Mulvey
      isPowerContributor: false
      profileUrl: https://disqus.com/by/berniemulvey/
      url: ""
      location: ""
      id: "368811423"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Did you check which genes are driving the "synapse organization"
      enrichment? The clustered protocadherin locus is GWAS significant in, I
      believe, all of these disorders. Several of those 20-some genes have
      ontology terms including "synapse organization" (which is true of these
      genes). However, the density and complex transcriptional regulation of
      these along with LD results in several PCDH genes being associated to
      variants by QTLs and so forth. Just sharing to be cautious, as this
      phenomenon has spoiled many a moment of ontologic excitement in my own
      work.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.07.16.21260608v1
  tweets:
    - created_at: Sun Jul 25 22:19:11 +0000 2021
      id: 1419422001182101500
      id_str: "1419422001182101504"
      text: >-
        üí¨ medRxiv comment on "Genome-wide association analys..."


        "Did you check which genes are driving the "synapse organ‚Ä¶ https://t.co/3ZLoTq4Bmt
      truncated: true
      entities:
        urls:
          - url: https://t.co/3ZLoTq4Bmt
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun Jul 25 22:19:11 +0000 2021
      id: 1419422002155114500
      id_str: "1419422002155114497"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/QdXewoXrgn
      truncated: false
      entities:
        urls:
          - url: https://t.co/QdXewoXrgn
      in_reply_to_status_id: 1419422001182101500
      in_reply_to_status_id_str: "1419422001182101504"
- preprint:
    id: "149831"
    doi: 10.1101/2021.07.07.21260122
    first_posted: 2021-07-12
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.07.21260122v1
    url: https://api.rxivist.org/v1/papers/149831
    title: Viral infection and Transmission in a large well-traced outbreak caused
      by the Delta SARS-CoV-2 variant
    category: epidemiology
    abstract: We report the first local transmission of the SARS-CoV-2 Delta variant
      in mainland China. All 167 infections could be traced back to the first
      index case. Daily sequential PCR testing of the quarantined subjects
      indicated that the viral loads of Delta infections, when they first become
      PCR+, were on average ~1000 times greater compared to A/B lineage
      infections during initial epidemic wave in China in early 2020, suggesting
      potentially faster viral replication and greater infectiousness of Delta
      during early infection. We performed high-quality sequencing on samples
      from 126 individuals. Reliable epidemiological data meant that, for 111
      transmission events, the donor and recipient cases were known. The
      estimated transmission bottleneck size was 1-3 virions with most minor
      intra-host single nucleotide variants (iSNVs) failing to transmit to the
      recipients. However, transmission heterogeneity of SARS-CoV-2 was also
      observed. The transmission of minor iSNVs resulted in at least 4 of the 30
      substitutions identified in the outbreak, highlighting the contribution of
      intra-host variants to population level viral diversity during rapid
      spread. Disease control activities, such as the frequency of population
      testing, quarantine during pre-symptomatic infection, and level of virus
      genomic surveillance should be adjusted in order to account for the
      increasing prevalence of the Delta variant worldwide.
    authors:
      - name: Baisheng Li
        orcid: null
      - name: Aiping Deng
        orcid: null
      - name: Kuibiao Li
        orcid: null
      - name: Yao Hu
        orcid: null
      - name: Zhencui Li
        orcid: null
      - name: Qianling Xiong
        orcid: null
      - name: Zhe Liu
        orcid: http://orcid.org/0000-0002-3592-3150
      - name: Qianfang Guo
        orcid: null
      - name: Lirong Zou
        orcid: null
      - name: Huan Zhang
        orcid: http://orcid.org/0000-0001-9366-2385
      - name: Meng Zhang
        orcid: http://orcid.org/0000-0002-9753-0635
      - name: Fangzhu Ouyang
        orcid: null
      - name: Juan Su
        orcid: null
      - name: Wenzhe Su
        orcid: null
      - name: Jing Xu
        orcid: http://orcid.org/0000-0003-3773-7973
      - name: Huifang Lin
        orcid: null
      - name: Jing Sun
        orcid: http://orcid.org/0000-0003-3741-0962
      - name: Jinju Peng
        orcid: null
      - name: Huimin Jiang
        orcid: null
      - name: Pingping Zhou
        orcid: null
      - name: Ting Hu
        orcid: http://orcid.org/0000-0001-6382-0602
      - name: Min Luo
        orcid: null
      - name: Yingtao Zhang
        orcid: null
      - name: Huanying Zheng
        orcid: null
      - name: Jianpeng Xiao
        orcid: null
      - name: Tao Liu
        orcid: http://orcid.org/0000-0002-8818-8313
      - name: Rongfei Che
        orcid: null
      - name: Hanri Zeng
        orcid: null
      - name: Zhonghua Zheng
        orcid: null
      - name: Yushi Huang
        orcid: null
      - name: Jianxiang Yu
        orcid: null
      - name: Lina Yi
        orcid: null
      - name: Jie Wu
        orcid: null
      - name: Jingdiao Chen
        orcid: null
      - name: Haojie Zhong
        orcid: null
      - name: Xiaoling Deng
        orcid: null
      - name: min Kang
        orcid: null
      - name: Oliver G. Pybus
        orcid: http://orcid.org/0000-0002-8797-2667
      - name: Matthew Hall
        orcid: http://orcid.org/0000-0002-5073-442X
      - name: Katrina A Lythgoe
        orcid: http://orcid.org/0000-0002-7089-7680
      - name: Yan Li
        orcid: http://orcid.org/0000-0003-3820-5960
      - name: Jun Yuan
        orcid: null
      - name: Jianfeng He
        orcid: null
      - name: Jing Lu
        orcid: http://orcid.org/0000-0002-5791-4749
  comment:
    dislikes: 0
    thread: "8644440599"
    numReports: 0
    likes: 0
    id: "5465648336"
    createdAt: 2021-07-22T18:07:27
    author:
      username: ken_jacobie
      about: ""
      name: Ken Jacobie
      isPowerContributor: false
      profileUrl: https://disqus.com/by/ken_jacobie/
      url: ""
      location: ""
      id: "236832084"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: What was the average age and INNATE IMMUNE SYSTEM STATUS of these
      167 person in this study? How many were CHEMOTHERAPY recipients etc...
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.07.07.21260122v1
  tweets:
    - created_at: Mon Jul 26 01:03:13 +0000 2021
      id: 1419463281828315100
      id_str: "1419463281828315145"
      text: >-
        üí¨ medRxiv comment on "Viral infection and Transmissi..."


        "What was the average age and INNATE IMMUNE SYSTEM STATUS‚Ä¶ https://t.co/u0LdJEai8f
      truncated: true
      entities:
        urls:
          - url: https://t.co/u0LdJEai8f
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 26 01:03:13 +0000 2021
      id: 1419463282713366500
      id_str: "1419463282713366529"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/v3X1joMTJY
      truncated: false
      entities:
        urls:
          - url: https://t.co/v3X1joMTJY
      in_reply_to_status_id: 1419463281828315100
      in_reply_to_status_id_str: "1419463281828315145"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8603406700"
    numReports: 0
    likes: 1
    id: "5465441224"
    createdAt: 2021-07-22T15:18:23
    author:
      username: hexa_gone
      about: ""
      name: hexa_gone
      isPowerContributor: false
      profileUrl: https://disqus.com/by/hexa_gone/
      url: ""
      location: ""
      id: "53930746"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: You said it.  previous infections provide very strong protection.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v3
  tweets:
    - created_at: Mon Jul 26 12:32:01 +0000 2021
      id: 1419636622476386300
      id_str: "1419636622476386319"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "You said it.  previous infections provide very strong pr‚Ä¶ https://t.co/jee3jENDQl
      truncated: true
      entities:
        urls:
          - url: https://t.co/jee3jENDQl
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 26 12:32:01 +0000 2021
      id: 1419636623319371800
      id_str: "1419636623319371781"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1419636622476386300
      in_reply_to_status_id_str: "1419636622476386319"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8603406700"
    numReports: 0
    likes: 1
    id: "5465439242"
    createdAt: 2021-07-22T15:16:42
    author:
      username: hexa_gone
      about: ""
      name: hexa_gone
      isPowerContributor: false
      profileUrl: https://disqus.com/by/hexa_gone/
      url: ""
      location: ""
      id: "53930746"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: strict mask enforcement offset by the unusually high viral load
      exposure. If strict mask enforcement was of any help, there wouldn't have
      been so many frontline medical staff who died.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v3
  tweets:
    - created_at: Mon Jul 26 14:22:31 +0000 2021
      id: 1419664431219454000
      id_str: "1419664431219453955"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "strict mask enforcement offset by the unusually high vir‚Ä¶ https://t.co/X7JPwWGxMC
      truncated: true
      entities:
        urls:
          - url: https://t.co/X7JPwWGxMC
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 26 14:22:31 +0000 2021
      id: 1419664432054030300
      id_str: "1419664432054030338"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1419664431219454000
      in_reply_to_status_id_str: "1419664431219453955"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8603406700"
    numReports: 0
    likes: 0
    id: "5469549393"
    createdAt: 2021-07-26T03:48:27
    author:
      username: MrGOrwell
      about: ""
      name: George Orwell
      isPowerContributor: false
      profileUrl: https://disqus.com/by/MrGOrwell/
      url: http://gutenberg.net.au/ebooks01/0100021.txt
      location: ""
      id: "36202421"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Carvallo study showed that PPE alone was ineffective at preventing
      PCR positive cases among HCW. 58% of HCW tested weekly over 2 months
      tested positive.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v3
  tweets:
    - created_at: Mon Jul 26 16:32:17 +0000 2021
      id: 1419697090448568300
      id_str: "1419697090448568325"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "Carvallo study showed that PPE alone was ineffective at‚Ä¶ https://t.co/IU1u0ezRKK
      truncated: true
      entities:
        urls:
          - url: https://t.co/IU1u0ezRKK
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 26 16:32:17 +0000 2021
      id: 1419697091509727200
      id_str: "1419697091509727233"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1419697090448568300
      in_reply_to_status_id_str: "1419697090448568325"
- preprint:
    id: "151060"
    doi: 10.1101/2021.07.21.453188
    first_posted: 2021-07-22
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.21.453188v1
    url: https://api.rxivist.org/v1/papers/151060
    title: Egg size variation in a long-lived polyandrous shorebird in the context
      of senescence and breeding phenology
    category: evolutionary-biology
    abstract: "Anisogamy is a central component of sex role evolution, however, the
      effect of female-female mating competition on egg size variation in
      polyandrous species is unclear. Moreover, egg size may also be shaped by
      age-dependent trade-offs between reproductive investments and somatic
      maintenance that are responsible for senescence. Here we investigate how
      mating behaviour and senescence are associated with egg size variation in
      female snowy plovers (Charadrius nivosus). Snowy plovers are long-lived
      shorebirds (longevity record: 20 years) that often produce several nests
      each year, with females either sequentially changing partners between
      breeding attempts or remaining monogamous between attempts. We examined
      how age, seasonality, body size, and mating behaviour relate to within-
      and between-female variation in egg volume using repeated measures
      collected over a 15-year period. We found no evidence of reproductive
      senescence in egg volume in snowy plover females. Rather, egg volume,
      polyandry, and re-nesting were strongly linked to breeding phenology:
      early breeding females had a higher likelihood of being polyandrous or
      replacing failed clutches, yet these individuals laid smaller eggs likely
      due to physiological limitations associated with the early season. Older
      individuals and local recruits secured the earliest breeding opportunities
      in the season suggesting that prior experience could give an edge in the
      female-female competition for mates. Larger females laid the largest eggs,
      as expected, but there was no relationship between body size and lay date
      - implying that size may not provide an advantage in female-female
      competition. Our findings highlight the existence of several direct and
      indirect constraints on female reproductive investment that likely shape
      individual variation in lifetime reproductive success. Future research
      investigating reproductive senescence of wild populations should consider
      mating system dynamics when examining variation in reproductive
      investment."
    authors:
      - name: Luke J Eberhart-Hertel
        orcid: http://orcid.org/0000-0001-7311-6088
      - name: Lourenco Falcao Rodrigues
        orcid: http://orcid.org/0000-0003-1371-649X
      - name: Johannes Krietsch
        orcid: http://orcid.org/0000-0002-8080-1734
      - name: Anne G Eberhart-Hertel
        orcid: http://orcid.org/0000-0001-7952-8243
      - name: Medardo Cruz-Lopez
        orcid: http://orcid.org/0000-0003-1737-9398
      - name: Karina Alejandra Vazquez-Rojas
        orcid: null
      - name: Erick Gonzalez-Medina
        orcid: http://orcid.org/0000-0002-9748-8641
      - name: Julia Schroeder
        orcid: http://orcid.org/0000-0002-4136-843X
      - name: Clemens Kuepper
        orcid: http://orcid.org/0000-0002-1507-8033
  comment:
    dislikes: 0
    thread: "8664302916"
    numReports: 0
    likes: 0
    id: "5469363443"
    createdAt: 2021-07-25T23:20:14
    author:
      username: lukeeberharthertel
      about: ""
      name: Luke Eberhart-Hertel
      isPowerContributor: false
      profileUrl: https://disqus.com/by/lukeeberharthertel/
      url: ""
      location: ""
      id: "372839211"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      This pre-print is a major revision of a previous pre-print found here:
      https://www.biorxiv.org/content/10.1101/2020.08.07.240150v1


      Please also see the comments related to the prior version for links to a pre-publication review of the work on Publons, and our open-access response to this review.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.07.21.453188v1
  tweets:
    - created_at: Mon Jul 26 18:29:29 +0000 2021
      id: 1419726584429359000
      id_str: "1419726584429359105"
      text: >-
        üí¨ bioRxiv comment on "Egg size variation in a long-l..."


        "This pre-print is a major revision of a previous pre-pri‚Ä¶ https://t.co/X2Tropmojp
      truncated: true
      entities:
        urls:
          - url: https://t.co/X2Tropmojp
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 26 18:29:29 +0000 2021
      id: 1419726585343750100
      id_str: "1419726585343750148"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/IZ2dBUEY3o
      truncated: false
      entities:
        urls:
          - url: https://t.co/IZ2dBUEY3o
      in_reply_to_status_id: 1419726584429359000
      in_reply_to_status_id_str: "1419726584429359105"
- preprint:
    id: 151530
    metric: 34
    title: Strong and opponent contributions of dorsomedial striatal pathways to
      behavior depends on cognitive demands and task strategy
    url: https://api.rxivist.org/v1/papers/151530
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.23.453573v1
    doi: 10.1101/2021.07.23.453573
    category: neuroscience
    first_posted: 2021-07-25
    abstract: A classic view of the striatum holds that activity in direct and
      indirect pathways oppositely modulates motor output. Whether this involves
      direct control of movement, or reflects a cognitive process underlying
      movement, has remained unresolved. Here we find that strong, opponent
      control of behavior by the two pathways of the dorsomedial striatum (DMS)
      depends on a task's cognitive demands. Furthermore, a latent state model
      (a hidden markov model with generalized linear model observations) reveals
      that - even within a single task - the contribution of the two pathways to
      behavior is state-dependent. Specifically, the two pathways have large
      contributions in one of two states associated with a strategy of evidence
      accumulation, compared to a state associated with a strategy of repeating
      previous choices. Thus, both the cognitive demands imposed by a task, as
      well as the strategy that mice pursue within a task, determine whether DMS
      pathways provide strong and opponent control of behavior.
    authors:
      - name: Scott Bolkan
      - name: Iris Stone
      - name: Lucas Pinto
      - name: Zoe Ashwood
      - name: Jorge Garcia
      - name: Alison Herman
      - name: Priyanka Singh
      - name: Akhil Bandi
      - name: Julia Cox
      - name: Christopher Zimmerman
      - name: Jounhong Cho
      - name: Ben Engelhard
      - name: Sue Koay
      - name: Jonathan Pillow
      - name: Ilana Witten
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Mon Jul 26 20:16:08 +0000 2021
      id: 1419753421389934600
      id_str: "1419753421389934592"
      text: >-
        üî• bioRxiv Neuroscience preprint by S. Bolkan et al:


        "Strong and opponent contributions of dorsomedial striatal pat‚Ä¶ https://t.co/WtccLx5ouO
      truncated: true
      entities:
        urls:
          - url: https://t.co/WtccLx5ouO
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "93916"
    doi: 10.1101/2020.08.07.240150
    first_posted: 2020-08-07
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.08.07.240150v1
    url: https://api.rxivist.org/v1/papers/93916
    title: Polyandry and senescence shape egg size variation in a precocial bird.
    category: evolutionary-biology
    abstract: >-
      Identifying age-dependent trade-offs between reproductive effort and
      survival in wild organisms is central for understanding the evolutionary
      mechanisms of senescence. According to the disposable soma theory,
      early-life energy investments in reproduction compromise late-life
      investments in somatic maintenance - leading to senescence. Once thought
      to only be detectable in captive populations, senescence has recently been
      documented by several longitudinal studies of wild organisms. However,
      some reproductive traits that are used to quantify senescence may also be
      shaped by other age-dependent processes such as mating tactics. For
      instance, polygamy, which is often positively associated with age, may
      lead to reduced gamete size due to trade-offs between gamete quantity and
      quality. Here we investigate how mating behaviour and senescence are
      associated with reproductive trade-offs of female snowy plovers
      (Charadrius nivosus). Snowy plovers are long-lived shorebirds (longevity
      record: 19 years) that produce several nests each year, with females
      either being polyandrous and sequentially changing partners between
      breeding attempts or remaining monogamous between attempts. We examined
      how age, seasonality, and mating tactics affect within-female variation in
      egg volume using repeated measures collected over a 14-year period. Our
      results provide clear evidence for senescence in snowy plover females
      starting at three years of age. Furthermore, females laid smaller eggs in
      years when they were polyandrous compared to years when they were
      monogamous, with early- and late-season clutches having the smallest eggs.
      We suggest that individual female reproductive performance is regulated by
      flexible mating tactics and age- and season-dependent effects. Our
      findings highlight the existence of multiple trade-offs for female
      reproductive investments that likely shape individual variation in
      lifetime reproductive success. We encourage future research investigating
      reproductive senescence of wild populations to incorporate age-dependent
      reproductive investments in light of mating system dynamics.


      ### Competing Interest Statement


      The authors have declared no competing interest.
    authors:
      - name: Lourenco Falcao Rodrigues
        orcid: http://orcid.org/0000-0003-1371-649X
      - name: Anne G Eberhart-Hertel
        orcid: http://orcid.org/0000-0001-7952-8243
      - name: Medardo Cruz-Lopez
        orcid: http://orcid.org/0000-0003-1737-9398
      - name: Erick Gonzalez-Medina
        orcid: http://orcid.org/0000-0002-9748-8641
      - name: Julia Schroeder
        orcid: http://orcid.org/0000-0002-4136-843X
      - name: Clemens Kuepper
        orcid: http://orcid.org/0000-0002-1507-8033
      - name: Luke J Eberhart-Hertel
        orcid: http://orcid.org/0000-0001-7311-6088
  comment:
    dislikes: 0
    thread: "8157071620"
    numReports: 0
    likes: 0
    id: "5469341877"
    createdAt: 2021-07-25T22:51:40
    author:
      username: lukeeberharthertel
      about: ""
      name: Luke Eberhart-Hertel
      isPowerContributor: false
      profileUrl: https://disqus.com/by/lukeeberharthertel/
      url: ""
      location: ""
      id: "372839211"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Thank you, Martin, for your constructive pre-pub review of our pre-print.


      Please see our response here: https://rpubs.com/leberhart/publons-response-9286190


      And our revised manuscript here: https://www.biorxiv.org/content/10.1101/2021.07.21.453188v1


      Note: there is currently no possibility on the Publons platform for authors to upload a response to reviews of their work, hence why we have made our response publicly accessible via the Rpubs link.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.08.07.240150v1
  tweets:
    - created_at: Mon Jul 26 20:21:03 +0000 2021
      id: 1419754658592141300
      id_str: "1419754658592141312"
      text: >-
        üí¨ bioRxiv comment on "Polyandry and senescence shape..."


        "Thank you, Martin, for your constructive pre-pub review‚Ä¶ https://t.co/OtXs2CJcuJ
      truncated: true
      entities:
        urls:
          - url: https://t.co/OtXs2CJcuJ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 26 20:21:03 +0000 2021
      id: 1419754659573649400
      id_str: "1419754659573649408"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/ZEDPtkjinr
      truncated: false
      entities:
        urls:
          - url: https://t.co/ZEDPtkjinr
      in_reply_to_status_id: 1419754658592141300
      in_reply_to_status_id_str: "1419754658592141312"
- preprint:
    id: "146991"
    doi: 10.1101/2021.06.22.21259318
    first_posted: 2021-06-22
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.22.21259318v1
    url: https://api.rxivist.org/v1/papers/146991
    title: "Efficacy of Proxalutamide in Hospitalized COVID-19 Patients: A
      Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Clinical
      Trial"
    category: infectious-diseases
    abstract: "Background: Severe acute respiratory syndrome coronavirus 2
      (SARS-CoV-2) infectivity is mediated by the androgen-promoted protease,
      transmembrane protease, serine 2 (TMPRSS2). Previously, we have shown that
      treatment with proxalutamide, a non-steroidal androgen receptor
      antagonist, accelerates viral clearance and clinical remission in
      outpatients with coronavirus disease 2019 (COVID-19) compared to placebo.
      The effects in hospitalized COVID-19 patients were unknown. Methods: Men
      and women hospitalized but not requiring mechanical ventilation were
      randomized (1:1 ratio) to receive 300 mg of proxalutamide per day or
      placebo for 14 days. The study was conducted at eight sites in the state
      of Amazonas, Brazil. The primary outcome measure was the clinical status
      (8-point ordinal scale) at 14-days post-randomization. The primary
      efficacy endpoint was the 14-day recovery ratio (alive hospital discharge
      [scores 1, 2]). Findings: A total of 645 patients were randomized (317
      received proxalutamide, 328 placebo) and underwent intention-to-treat
      analysis. The 14-day median ordinal scale score in the proxalutamide group
      was 1 (interquartile range [IQR]=1-2) versus 7 (IQR=2-8) for placebo,
      P<0.001. The 14-day recovery rate was 81.4% for proxalutamide and 35.7%
      for placebo (recovery ratio, 2.28; 95% CI 1.95-2.66 [P<0.001]). The 28-day
      all-cause mortality rate was 11.0% for proxalutamide versus 49.4% for
      placebo (hazard ratio, 0.16; 95% CI 0.11-0.24). The median
      post-randomization time to recovery was 5 days (IQR=3-8) for proxalutamide
      versus 10 days (IQR=6-15) for placebo. Interpretation: Hospitalized
      COVID-19 patients not requiring mechanical ventilation receiving
      proxalutamide had a 128% higher recovery rate than those treated with
      placebo. All-cause mortality was reduced by 77.7% over 28 days.
      (ClinicalTrials.gov number, NCT04728802)."
    authors:
      - name: Flavio A Cadegiani
        orcid: http://orcid.org/0000-0002-2699-4344
      - name: Daniel N Fonseca
        orcid: null
      - name: John McCoy
        orcid: http://orcid.org/0000-0003-1577-9910
      - name: Ricardo A. Zimerman
        orcid: null
      - name: Fatima N Mirza
        orcid: http://orcid.org/0000-0003-1299-6258
      - name: Michael N Correia
        orcid: null
      - name: Renan N Barros
        orcid: null
      - name: Dirce C Onety
        orcid: null
      - name: Karla Cristina P Israel
        orcid: null
      - name: Brenda G Almeida
        orcid: null
      - name: Emilyn O Guerreiro
        orcid: null
      - name: Jose Enrique M Medeiros
        orcid: null
      - name: Raquel N Nicolau
        orcid: null
      - name: Luiza FM Nicolau
        orcid: null
      - name: Rafael X Cunha
        orcid: null
      - name: Maria Fernanda R Barroco
        orcid: null
      - name: Patricia S da Silva
        orcid: null
      - name: Gabriel S. Ferreira
        orcid: http://orcid.org/0000-0003-1554-8346
      - name: Flavio Renan PC Alcantara
        orcid: null
      - name: Angelo M Ribeiro
        orcid: null
      - name: Felipe O de Almeida
        orcid: null
      - name: Adailson A de Souza
        orcid: null
      - name: Suzyane S do Rosario
        orcid: null
      - name: Raysa WS Paulain
        orcid: null
      - name: Alessandra Reis
        orcid: null
      - name: Marissa Li
        orcid: null
      - name: Claudia E Thompson
        orcid: null
      - name: Gerald J Nau
        orcid: null
      - name: Carlos Gustavo Wambier
        orcid: http://orcid.org/0000-0002-4636-4489
      - name: Andy Goren
        orcid: http://orcid.org/0000-0002-8190-2289
  comment:
    dislikes: 0
    thread: "8608446739"
    numReports: 0
    likes: 0
    id: "5469256879"
    createdAt: 2021-07-25T21:13:52
    author:
      username: drwambier
      about: ""
      name: drwambier
      isPowerContributor: false
      profileUrl: https://disqus.com/by/drwambier/
      url: ""
      location: ""
      id: "372636231"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "Dear Olavo Amaral, thank you for your question, and for the
      opportunity to clarify that even further. The 3 Manaus sites had
      randomized distribution throughout the trial, starting at 1:1, and only
      after bulk, blinded, randomized distribution to 2 sites with 50 treatment
      boxes of a single arm, the randomization in Manaus accumulated the other
      arm. At the last week of enrollment in Manaus, the randomization was
      greatly unbalanced. Bulk shipping caused bulk accumulation. Just to
      facilitate understanding to the readers... I'll give you an easy imaginary
      example: If you had a bag of Christmas M&M with same amount of green and
      red M&Ms. You start a blinded distribution at random. Then, a shipment has
      to be done of 50 M&M of the same color... at a 1:1 random chance: A Red vs
      Green coin toss is performed. Coin is tossed: Red.... someone unblinded
      who does not interact with the participants removes 50 red M&M from the
      bag, and ship it by airplane to a remote city of the Amazon. The bag now
      has more green (and investigators and patients don't know), and the
      blinded, random distribution continues. Then you do it again, at random,
      1:1 chance: it was red again... 50 reds again (randomly assigned by
      chance)... by the end of the bag, even though the chances of assigning
      green are higher, the distribution is still at random.**** As discussed in
      the manuscript, the uneven distribution between sites is likely a bias
      that favored the PLACEBO ARM, as hospitals with more structure (Manaus)
      ended up receiving more PLACEBO, by chance. For future trials with similar
      difficulties, we would advise investigators to attempt \"sequential\"
      distribution of boxes to remote sites (A-B-A-B-A-B-A). Bulk distribution
      of a single arm to remote sites was crucial to ensure the all patients
      took 14 days of the same arm, without confusion or sharing. We hope that
      the future studies with antiandrogens for covid19 don't have the same
      logistic and dispensing hurdles."
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.22.21259318v1
  tweets:
    - created_at: Mon Jul 26 22:20:09 +0000 2021
      id: 1419784634955665400
      id_str: "1419784634955665410"
      text: >-
        üí¨ medRxiv comment on "Efficacy of Proxalutamide in H..."


        "Dear Olavo Amaral, thank you for your question, and for‚Ä¶ https://t.co/t2oLPu8dUP
      truncated: true
      entities:
        urls:
          - url: https://t.co/t2oLPu8dUP
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon Jul 26 22:20:10 +0000 2021
      id: 1419784635857477600
      id_str: "1419784635857477640"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/0z3rHjK5bK
      truncated: false
      entities:
        urls:
          - url: https://t.co/0z3rHjK5bK
      in_reply_to_status_id: 1419784634955665400
      in_reply_to_status_id_str: "1419784634955665410"
- preprint:
    id: "144777"
    doi: 10.1101/2021.06.01.21258176
    first_posted: 2021-06-04
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.01.21258176v1
    url: https://api.rxivist.org/v1/papers/144777
    title: "Necessity of COVID-19 Vaccination in Previously Infected Individuals: A
      Retrospective Cohort Study"
    category: infectious-diseases
    abstract: "Background: There are good reasons to expect natural infection to
      provide protection against future infection with SARS-CoV-2. The purpose
      of this study was to evaluate the necessity of COVID-19 vaccination in
      persons previously infected with SARS-CoV-2. Methods: Employees of the
      Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination was started, were included. Any subject who tested
      positive for SARS-CoV-2 at least 42 days earlier was considered previously
      infected. One was considered vaccinated 14 days after receipt of the
      second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of
      SARS-CoV-2 infection over the next four months, among previously infected
      subjects who received the vaccine, was compared with those of previously
      infected subjects who remained unvaccinated, previously uninfected
      subjects who received the vaccine, and previously uninfected subjects who
      remained unvaccinated. Results: Among the 52238 included employees, 1220
      (47%) of 2579 previously infected subjects received the vaccine, compared
      with 29461 (59%) of 49659 not previously infected. The cumulative
      incidence of SARS-CoV-2 infection did not differ among previously infected
      unvaccinated subjects, previously infected subjects who were vaccinated,
      and previously uninfected subjects who were vaccinated, and was much lower
      than that of previously uninfected subjects who remained unvaccinated. Not
      one of the 1359 previously infected subjects who remained unvaccinated had
      a SARS-CoV-2 infection over the duration of the study. Conclusion:
      Individuals who have had SARS-CoV-2 infection are unlikely to benefit from
      COVID-19 vaccination, and vaccines can be safely prioritized to those who
      have not been infected before."
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Patrick C. Burke
        orcid: null
      - name: Amy S. Nowacki
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8574386276"
    numReports: 0
    likes: 0
    id: "5469224002"
    createdAt: 2021-07-25T20:41:51
    author:
      username: disqus_I9dKrNeeup
      about: ""
      name: IndependentDoc
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_I9dKrNeeup/
      url: ""
      location: ""
      id: "52788396"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: The reinfection rate using all "possible reinfections" was 0.4%
      with infection defined as positive test, not the original definition of
      COVID-19 which is illness symptoms plus positive test.  This is superior
      to the infection rates after two doses of mRNA vaccine, the current gold
      standard for vaccine effectiveness.  In a large multi-center prospective
      cohort study of previously infected UK NHS workers, prior infection was
      93% effective at preventing reinfection in a group much more exposed to
      infection risk than those participating in mRNA vaccine trials. This is
      science that is not being followed under current vaccination guidelines.
      https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00675-9/fulltext
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
  tweets:
    - created_at: Tue Jul 27 01:04:11 +0000 2021
      id: 1419825911789236200
      id_str: "1419825911789236235"
      text: >-
        üí¨ medRxiv comment on "Necessity of COVID-19 Vaccinat..."


        "The reinfection rate using all "possible reinfections" w‚Ä¶ https://t.co/61xW4W0HfJ
      truncated: true
      entities:
        urls:
          - url: https://t.co/61xW4W0HfJ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 27 01:04:11 +0000 2021
      id: 1419825912519041000
      id_str: "1419825912519041026"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/oTURmeVcNy
      truncated: false
      entities:
        urls:
          - url: https://t.co/oTURmeVcNy
      in_reply_to_status_id: 1419825911789236200
      in_reply_to_status_id_str: "1419825911789236235"
- preprint:
    id: "107398"
    doi: 10.1101/2020.03.10.20033761
    first_posted: 2020-03-13
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.03.10.20033761v1
    url: https://api.rxivist.org/v1/papers/107398
    title: Inferring the number of COVID-19 cases from recently reported deaths
    category: epidemiology
    abstract: We estimate the number of COVID-19 cases from newly reported deaths in
      a population without previous reports. Our results suggest that by the
      time a single death occurs, hundreds to thousands of cases are likely to
      be present in that population. This suggests containment via contact
      tracing will be challenging at this point, and other response strategies
      should be considered. Our approach is implemented in a publicly available,
      user-friendly, online tool.
    authors:
      - name: Thibaut Jombart
        orcid: http://orcid.org/0000-0003-2226-8692
      - name: Kevin van Zandvoort
        orcid: null
      - name: Timothy W Russell
        orcid: http://orcid.org/0000-0001-5610-6080
      - name: Christopher I Jarvis
        orcid: http://orcid.org/0000-0002-0812-2446
      - name: Amy Gimma
        orcid: http://orcid.org/0000-0003-2645-7212
      - name: Sam Abbott
        orcid: http://orcid.org/0000-0001-8057-8037
      - name: Samuel Clifford
        orcid: http://orcid.org/0000-0002-3774-3882
      - name: Sebastian Funk
        orcid: http://orcid.org/0000-0002-2842-3406
      - name: Hamish Gibbs
        orcid: http://orcid.org/0000-0003-4413-453X
      - name: Yang Liu
        orcid: http://orcid.org/0000-0003-4433-1066
      - name: Carl A.B. Pearson
        orcid: http://orcid.org/0000-0003-0701-7860
      - name: Nikos I Bosse
        orcid: null
      - name: Centre for the Mathematical Modelling of Infectious Diseases COVID-19
          Working Group
        orcid: null
      - name: Rosalind M Eggo
        orcid: http://orcid.org/0000-0002-0362-6717
      - name: Adam J Kucharski
        orcid: http://orcid.org/0000-0001-8814-9421
      - name: W. John Edmunds
        orcid: null
  comment:
    dislikes: 0
    thread: "7913207556"
    numReports: 0
    likes: 0
    id: "5470739007"
    createdAt: 2021-07-27T01:29:32
    author:
      username: vaskorbasak
      about: ""
      name: Vaskor Basak
      isPowerContributor: false
      profileUrl: https://disqus.com/by/vaskorbasak/
      url: ""
      location: ""
      id: "137163069"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Thank you very much for sharing this paper. I am interested to know
      what lag time was assumed between infections and deaths when calculating
      or inferring the CFR figures. Was it possible to use a distribution of
      variable lag times, based on real life data, for more sophisticated
      modelling? Also, has the lag time increased and/or CFR decreased as new
      medical interventions have slowed down the rapid onset of Covid-19 for
      severe cases requiring hospitalisation, since the beginning of the
      pandemic?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.03.10.20033761v1
  tweets:
    - created_at: Tue Jul 27 12:31:39 +0000 2021
      id: 1419998920479019000
      id_str: "1419998920479019020"
      text: >-
        üí¨ medRxiv comment on "Inferring the number of COVID-..."


        "Thank you very much for sharing this paper. I am interes‚Ä¶ https://t.co/4JMb7wdbMD
      truncated: true
      entities:
        urls:
          - url: https://t.co/4JMb7wdbMD
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 27 12:31:39 +0000 2021
      id: 1419998921477263400
      id_str: "1419998921477263361"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/3TtJqJ2x8c
      truncated: false
      entities:
        urls:
          - url: https://t.co/3TtJqJ2x8c
      in_reply_to_status_id: 1419998920479019000
      in_reply_to_status_id_str: "1419998920479019020"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 0
    id: "5470636570"
    createdAt: 2021-07-26T23:43:18
    author:
      username: rusbowden
      about: ""
      name: rusbowden
      isPowerContributor: false
      profileUrl: https://disqus.com/by/rusbowden/
      url: ""
      location: ""
      id: "10245173"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      We have a problem here, DaveGinOly, with you not sticking with the topic
      of mask-wearing and fretting about what may be some flaw in my
      understanding of something you feel to be an expert on -- and yet you cite
      nothing to back up anything you say. My "pull quote" says nothing about
      me, and my shortcomings, whatever they may be, have very little to do, in
      the grand scheme of things, with the pandemic. 


      The study started with the fact that mask wearing stopped the flu from spreading, and used known factors to plug into the simulation. It was not the reverse, that there was a simulation, based on a hypothetical model, to show how mask wearing might hypothetically work.


      It's saying, now that we know the effect of mask wearing on this past season's spread of the flu, we can attempt a simulation of previous years. It's like saying, if only our team's unsuccessful goalie blocked as many shots as some successful goalie, we would have won such-and-so more games and been champions. So let's get a better goalie for upcoming years.


      You are incorrect about the real world results. The study starts with real world results, and simulates what this could have meant for previous years.


      FYI, within the same state, and you choose the state, we know that mask wearing has helped cities get out of the "red". Double masking has been shown to prevent both the contraction and, when contracted, the severity of the virus. We also know which mask ought go on top when doing so. More mask research papers and discussions listed here: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1#comment-5398414471
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Tue Jul 27 14:17:41 +0000 2021
      id: 1420025603722555400
      id_str: "1420025603722555398"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "We have a problem here, DaveGinOly, with you not stickin‚Ä¶ https://t.co/94RIKPaG6Y
      truncated: true
      entities:
        urls:
          - url: https://t.co/94RIKPaG6Y
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 27 14:17:41 +0000 2021
      id: 1420025604670382000
      id_str: "1420025604670382090"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1420025603722555400
      in_reply_to_status_id_str: "1420025603722555398"
- preprint:
    id: "142062"
    doi: 10.1101/2021.05.14.21257248
    first_posted: 2021-05-17
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.14.21257248v1
    url: https://api.rxivist.org/v1/papers/142062
    title: Interim Report of a Phase 2 Randomized Trial of a Plant-Produced
      Virus-Like Particle Vaccine for Covid-19 in Healthy Adults Aged 18-64 and
      Older Adults Aged 65 and Older
    category: infectious-diseases
    abstract: The rapid spread of SARS-CoV-2 globally continues to impact humanity
      on a global scale with rising morbidity and mortality. Despite the
      development of multiple effective vaccines, new vaccines continue to be
      required to supply ongoing demand. We report Day 42 interim safety and
      immunogenicity data from a Phase 2, randomized, placebo-controlled trial
      in Adults aged 18+ immunized with a virus-like particle vaccine candidate
      produced in plants displaying SARS-CoV-2 spike glycoprotein (CoVLP)
      adjuvanted with AS03 (NCT04636697). This report focuses on presenting
      safety, tolerability and immunogenicity, as measured by neutralizing
      antibody (NAb) and cell mediated immunity (IFN-{gamma} and IL-4 ELISpot)
      responses, in Adults aged 18-64 (Adults) and Older Adults aged 65+ (Older
      Adults). CoVLP adjuvanted with AS03 was well-tolerated and adverse events
      (AE) were primarily mild or moderate and of transient duration. AEs in
      Older Adults were more limited than those observed in the Adult
      population. CoVLP with AS03 induced a significant humoral immune response
      in both age cohorts. CoVLP with AS03 induced a greater humoral response in
      Adults than Older Adults after a single dose but this effect was overcome
      with a second dose when both age cohorts responded with NAb titers that
      were ~10-fold higher than those in a panel of sera from patients
      recovering from COVID-19. A single dose of CoVLP with AS03 induced a
      significant IFN-{gamma} response in both age cohorts; a second dose
      significantly boosted IFN-{gamma} and IL-4 responses in both age cohorts.
      Adults generated a stronger IFN-{gamma} and IL-4 cellular response than
      did Older Adults after one or two doses of AS03-adjuvanted CoVLP. Safety
      and immunogenicity from Adults with comorbidities as well as final safety
      and immunogenicity responses after 12 months will be reported upon
      availability.
    authors:
      - name: Philipe Gobeil
        orcid: null
      - name: St√©phane Pillet
        orcid: null
      - name: Annie S√©guin
        orcid: null
      - name: Iohann Boulay
        orcid: null
      - name: Asif Mahmood
        orcid: null
      - name: Donald C Vinh
        orcid: null
      - name: Nathalie Charland
        orcid: null
      - name: Philippe Boutet
        orcid: null
      - name: Fran√ßois P Roman
        orcid: null
      - name: Robbert Van Der Most
        orcid: null
      - name: Maria de los Angeles Ceregido Perez
        orcid: null
      - name: Brian J Ward
        orcid: null
      - name: Nathalie Landry
        orcid: http://orcid.org/0000-0003-3500-0484
  comment:
    dislikes: 0
    thread: "8524534867"
    numReports: 0
    likes: 0
    id: "5470439013"
    createdAt: 2021-07-26T20:40:57
    author:
      username: Double_Up
      about: ""
      name: Double_Up
      isPowerContributor: false
      profileUrl: https://disqus.com/by/Double_Up/
      url: ""
      location: ""
      id: "23881310"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: So far, so good.  No infectious agents added to the SARS-2 shot,
      that's a plus, and if Phase 3 goes as well this Medicago-GSK shot may be
      safe enough for many I know to take, with so many possibly having SARS-2
      already but no way to prove it since tests are garbage and antibody tests
      are about 50% accurate at best.  Safety over hype.  People I work with
      cannot take any SARS-2 shots due to medical conditions they have but
      they're being treated like cattle, horrible.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.14.21257248v1
  tweets:
    - created_at: Tue Jul 27 16:32:12 +0000 2021
      id: 1420059456294031400
      id_str: "1420059456294031362"
      text: >-
        üí¨ medRxiv comment on "Interim Report of a Phase 2 Ra..."


        "So far, so good.  No infectious agents added to the SARS‚Ä¶ https://t.co/fXKpC2CoYw
      truncated: true
      entities:
        urls:
          - url: https://t.co/fXKpC2CoYw
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 27 16:32:12 +0000 2021
      id: 1420059457191612400
      id_str: "1420059457191612416"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/5wHaTwuGUe
      truncated: false
      entities:
        urls:
          - url: https://t.co/5wHaTwuGUe
      in_reply_to_status_id: 1420059456294031400
      in_reply_to_status_id_str: "1420059456294031362"
- preprint:
    id: "141140"
    doi: 10.1101/2021.05.06.21256615
    first_posted: 2021-05-08
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.06.21256615v1
    url: https://api.rxivist.org/v1/papers/141140
    title: "The evidence on transmission dynamics of COVID-19 from pre- and
      asymptomatic cases: protocol for a systematic review. (Version 2 modified
      on 6 July 2021)"
    category: infectious-diseases
    abstract: "Background The role of cases of SARS-CoV-2 who remain without
      symptoms throughout the active phase of the disease (asymptomatics) and
      those who have not developed symptoms yet when surveyed (pre-symptomatics)
      is at present unclear, despite the important role that they may play in
      infecting third parties. There is also a lack of clarity on the role of
      pauci-symptomatic persons with COVID-19 and the degree to which they may
      be associated with transmission compared to fully symptomatic persons.
      Methods We will search LitCovid, medRxiv, Google Scholar and the WHO
      Covid-19 database using Covid-19, SARS-CoV-2, transmission, and
      appropriate synonyms as search terms. We will also search the reference
      lists of included studies are searched for additional relevant studies. We
      will include studies of people exposed to SARS CoV-2 within 2-14 days
      (incubation time) of close contact or suspected community or institutional
      exposure to index asymptomatic infected individuals, as defined in each
      study with secondary case(s) infected. We will only include studies which
      provide microbiological proof of transmission outcome (culturable virus
      and /or genic sequencing). The inclusion of higher-quality evidence should
      overcome the methodological shortcomings of lower quality studies. We will
      assess quality of the chain of transmission evidence, microbiological
      proof and adequacy of follow up and symptom monitoring. Expected results
      We intend to present the evidence in three distinct packages: study
      description, methodological quality assessment and data extracted. We
      intend summarising the evidence and drawing conclusions"
    authors:
      - name: Tom Jefferson
        orcid: http://orcid.org/0000-0002-4778-2949
      - name: Annette Pluddemann
        orcid: http://orcid.org/0000-0003-2101-0390
      - name: Elisabeth Spencer
        orcid: null
      - name: Jon Brassey
        orcid: http://orcid.org/0000-0002-7812-6311
      - name: Cecilia Rosca
        orcid: http://orcid.org/0000-0003-2412-1942
      - name: IGHO ONAKPOYA
        orcid: null
      - name: David Evans
        orcid: null
      - name: John Conly
        orcid: null
      - name: Carl Heneghan
        orcid: http://orcid.org/0000-0002-1009-1992
  comment:
    dislikes: 0
    thread: "8651614699"
    numReports: 0
    likes: 0
    id: "5470213711"
    createdAt: 2021-07-26T17:44:49
    author:
      username: fortunisko
      about: ""
      name: Fortu Nisko
      isPowerContributor: false
      profileUrl: https://disqus.com/by/fortunisko/
      url: ""
      location: ""
      id: "360538392"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      From expected results.


      We intend to present the evidence in three distinct packages: study description, methodological quality assessment and data extracted. We intend on summarising the evidence and drawing conclusions as to the quality of the evidence.


      Fair enough. A ruthlessly non-politiccal assessment of the quality of scientific evidence will be the most significant portion of the research. Perhaps you might add to the discussion portion of your research paper the impact of basing policy on evidennce that does not meet the standard for policy-grade evidence. This is a very important discussion. Policy-makers seem to be ignorant of the standards necessary to draw conclusions that then can translate into sound policies for public health. They seem to have fallen into the trap of self-perpetuating policies that become untethered from an assessment of the quality of evidence.


      Wishing you luck and good fortune in your pursuit of a  worthy goal re quality of evidence.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.06.21256615v2
  tweets:
    - created_at: Tue Jul 27 18:28:21 +0000 2021
      id: 1420088686709026800
      id_str: "1420088686709026819"
      text: |-
        üí¨ medRxiv comment on "The evidence on transmission d..."

        "From expected results.

        We intend to present the evidenc‚Ä¶ https://t.co/A5iACL1xwU
      truncated: true
      entities:
        urls:
          - url: https://t.co/A5iACL1xwU
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 27 18:28:21 +0000 2021
      id: 1420088687694647300
      id_str: "1420088687694647301"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/sQsOpFz7pT
      truncated: false
      entities:
        urls:
          - url: https://t.co/sQsOpFz7pT
      in_reply_to_status_id: 1420088686709026800
      in_reply_to_status_id_str: "1420088686709026819"
- preprint:
    id: 143963
    metric: 16
    title: A connectomic study of a petascale fragment of human cerebral cortex
    url: https://api.rxivist.org/v1/papers/143963
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.29.446289v1
    doi: 10.1101/2021.05.29.446289
    category: neuroscience
    first_posted: 2021-05-30
    abstract: We acquired a rapidly preserved human surgical sample from the
      temporal lobe of the cerebral cortex. We stained a 1 mm3 volume with heavy
      metals, embedded it in resin, cut more than 5000 slices at ~30 nm and
      imaged these sections using a high-speed multibeam scanning electron
      microscope. We used computational methods to render the three-dimensional
      structure of 50,000 cells, hundreds of millions of neurites and 133.7
      million synaptic connections. The 1.4 petabyte electron microscopy volume,
      the segmented cells, cell parts, blood vessels, myelin, inhibitory and
      excitatory synapses, and 100 manually proofread cells are available to
      peruse online. Despite the incompleteness of the automated segmentation
      caused by split and merge errors, many interesting features were evident.
      Glia outnumbered neurons 2:1 and oligodendrocytes were the most common
      cell type in the volume. The E:I balance of neurons was 69:31%, similar to
      the ratio of excitatory versus inhibitory synapses in the volume, which
      was 63:37%. The E:I ratio of synapses was significantly higher on
      pyramidal neurons than inhibitory interneurons. We found that deep layer
      excitatory cell types can be classified into subsets, based on structural
      and connectivity differences, that chandelier interneurons not only
      innervate excitatory neuron initial segments as previously described, but
      also each others initial segments. Furthermore, among the thousands of
      weak connections established on each neuron, there exist rarer highly
      powerful axonal inputs that establish multi-synaptic contacts (up to ~20
      synapses) with target neurons. Our analysis indicates that these strong
      inputs are specific, and allow small numbers of axons to have an outsized
      role in the activity of some of their postsynaptic partners.
    authors:
      - name: Alexander Shapson-Coe
      - name: Michal Januszewski
      - name: Daniel R Berger
      - name: Art Pope
      - name: Yuelong Wu
      - name: Tim Blakely
      - name: Richard L. Schalek
      - name: Peter H Li
      - name: Shuohong Wang
      - name: Jeremy Maitlin-Shepard
      - name: Neha Karlupia
      - name: Sven Dorkenwald
      - name: Evelina Sjostedt
      - name: Laramie Leavitt
      - name: Dongil Lee
      - name: Luke Bailey
      - name: Angerica Fitzmaurice
      - name: Rohin Kar
      - name: Benjamin Field
      - name: Hank Wu
      - name: Julian Wagner-Carena
      - name: David Aley
      - name: Joanna Lau
      - name: Zudi Lin
      - name: Donglai Wei
      - name: Hanspeter Pfister
      - name: Adi Peleg
      - name: Viren Jain
      - name: Jeff W Lichtman
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Tue Jul 27 20:14:43 +0000 2021
      id: 1420115454069153800
      id_str: "1420115454069153796"
      text: >-
        üî• bioRxiv Neuroscience preprint by A. Shapson-Coe et al:


        "A connectomic study of a petascale fragment of human cer‚Ä¶ https://t.co/V8h7ea3V6k
      truncated: true
      entities:
        urls:
          - url: https://t.co/V8h7ea3V6k
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "141140"
    doi: 10.1101/2021.05.06.21256615
    first_posted: 2021-05-08
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.06.21256615v1
    url: https://api.rxivist.org/v1/papers/141140
    title: "The evidence on transmission dynamics of COVID-19 from pre- and
      asymptomatic cases: protocol for a systematic review. (Version 2 modified
      on 6 July 2021)"
    category: infectious-diseases
    abstract: "Background The role of cases of SARS-CoV-2 who remain without
      symptoms throughout the active phase of the disease (asymptomatics) and
      those who have not developed symptoms yet when surveyed (pre-symptomatics)
      is at present unclear, despite the important role that they may play in
      infecting third parties. There is also a lack of clarity on the role of
      pauci-symptomatic persons with COVID-19 and the degree to which they may
      be associated with transmission compared to fully symptomatic persons.
      Methods We will search LitCovid, medRxiv, Google Scholar and the WHO
      Covid-19 database using Covid-19, SARS-CoV-2, transmission, and
      appropriate synonyms as search terms. We will also search the reference
      lists of included studies are searched for additional relevant studies. We
      will include studies of people exposed to SARS CoV-2 within 2-14 days
      (incubation time) of close contact or suspected community or institutional
      exposure to index asymptomatic infected individuals, as defined in each
      study with secondary case(s) infected. We will only include studies which
      provide microbiological proof of transmission outcome (culturable virus
      and /or genic sequencing). The inclusion of higher-quality evidence should
      overcome the methodological shortcomings of lower quality studies. We will
      assess quality of the chain of transmission evidence, microbiological
      proof and adequacy of follow up and symptom monitoring. Expected results
      We intend to present the evidence in three distinct packages: study
      description, methodological quality assessment and data extracted. We
      intend summarising the evidence and drawing conclusions"
    authors:
      - name: Tom Jefferson
        orcid: http://orcid.org/0000-0002-4778-2949
      - name: Annette Pluddemann
        orcid: http://orcid.org/0000-0003-2101-0390
      - name: Elisabeth Spencer
        orcid: null
      - name: Jon Brassey
        orcid: http://orcid.org/0000-0002-7812-6311
      - name: Cecilia Rosca
        orcid: http://orcid.org/0000-0003-2412-1942
      - name: IGHO ONAKPOYA
        orcid: null
      - name: David Evans
        orcid: null
      - name: John Conly
        orcid: null
      - name: Carl Heneghan
        orcid: http://orcid.org/0000-0002-1009-1992
  comment:
    dislikes: 0
    thread: "8651614699"
    numReports: 0
    likes: 0
    id: "5470204691"
    createdAt: 2021-07-26T17:37:56
    author:
      username: fortunisko
      about: ""
      name: Fortu Nisko
      isPowerContributor: false
      profileUrl: https://disqus.com/by/fortunisko/
      url: ""
      location: ""
      id: "360538392"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      From methods.


      We will include only studies that provide proof of transmission outcome using culturable virus and /or genetic sequencing. The inclusion of this higher-quality evidence aims to overcome the methodological shortcomings of lower quality studies. We will assess the microbiologic or genetic sequencing evidence in an effort to inform the quality of the chain of transmission evidence and adequacy of follow up of sign and symptom monitoring.


      This is reasonable and, in my view, essential.


      Also, the malady for which the infection is the cause must be very well ldefined. It would be false to claim that a person was pre-symptomatic if they did not present the definitive symptoms arrayed in the Severe Acute Respiratory Syndrome. Lack of symptoms specific to this particular malady would exclude the individual from the chain of transmission. In effect, the research must be based on the SARS patient and then work back from that. NOT the other way around, which depends on speculations and non-specificity.


      Likelihood is that you will end up making a rather vague analysis on influenza-like illness the symptoms of which may be presented in the chain of transmission toward an endpoint where the patient suffered influenza-like respiratory distress. The challenge you face is distinguishing that sort of chain from the chain specific to SARS-COV-2; and that means facing the ambiguities that define a distinction, such as it may be, between SARS-COV-1 and influenza and between SARS-COV-1 AND SARS-COV-2. If patients fall into a category that incudes infuenza-like illness, then, that places a heavy limitation on your research. It is the same limitation that applies to most of the research regarding what was deemed, by mere assertion alone, a new or novel pathogen.


      This must be addressed.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.06.21256615v2
  tweets:
    - created_at: Tue Jul 27 20:18:08 +0000 2021
      id: 1420116312978821000
      id_str: "1420116312978821125"
      text: |-
        üí¨ medRxiv comment on "The evidence on transmission d..."

        "From methods.

        We will include only studies that provide‚Ä¶ https://t.co/Uw1EBVvhkk
      truncated: true
      entities:
        urls:
          - url: https://t.co/Uw1EBVvhkk
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 27 20:18:08 +0000 2021
      id: 1420116313880604700
      id_str: "1420116313880604673"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/sQsOpFz7pT
      truncated: false
      entities:
        urls:
          - url: https://t.co/sQsOpFz7pT
      in_reply_to_status_id: 1420116312978821000
      in_reply_to_status_id_str: "1420116312978821125"
- preprint:
    id: "139518"
    doi: 10.1101/2021.04.23.441192
    first_posted: 2021-04-26
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.23.441192v1
    url: https://api.rxivist.org/v1/papers/139518
    title: Development of an oral swab based microbiome test for the detection of
      feline dental disease
    category: genomics
    abstract: Variations in the microbial composition of the mouth (the oral
      microbiome) have known associations with dental and systemic disease.
      While this is relatively well understood in humans, research on this topic
      in companion animals, and in cats in particular, has been limited. In this
      study, we used oral microbiome data obtained from shotgun metagenomic
      sequencing of 38,000 cats (data gathered through a direct-to-consumer cat
      DNA testing platform) to reveal the staggering diversity of the feline
      oral microbiome, identifying 8,344 microbial species across the entire
      cohort. We used a subset of these data points (6,110 cats) to develop a
      feline dental health test able to assess whether a cat is at risk of
      having periodontal disease, tooth resorption and halitosis based on their
      oral microbiome. After filtering out classified microbial reads with low
      abundance, we were able to detect, on average, 606 microbes per oral
      microbiome sample, identifying not just bacteria, but also viruses, fungi,
      archaea and protozoa. Due to the shortage of available published research
      on the microbial signature of tooth resorption and halitosis in cats, we
      used our periodontal disease feline cohort (n=570) to validate our
      approach. We observed microbial compositional abundance trends consistent
      with previously reported findings from feline, canine and human studies on
      periodontal disease. We used compositional abundance-based statistical
      methods relying on pairwise log-ratio (PLR) transformation to identify
      microbes significantly correlated with each of the three dental conditions
      of interest. We identified a set of 27 microbes that are predictive for
      all three dental conditions, as well as microbes specifically predictive
      of periodontal disease, tooth resorption or halitosis. We used the
      compositional abundance profiles of predictive microbes to develop a risk
      score based model assessing the probability that a cat is suffering from
      each of the three dental conditions. The model had highest sensitivity for
      halitosis (72%) and highest specificity for tooth resorption (78%).
      Lastly, we observed relatively consistent dental disease risk profiles
      when we compared data from sample collection methods targeting the whole
      mouth versus those targeting the gum line specifically. In contrast,
      samples collected in triplicates from the same cats using a sampling
      method targeting the whole mouth showed more variation in the generated
      risk profiles. This was likely due to a failure to consistently collect
      sufficient sample material from areas of the mouth where microbes relevant
      to dental pathology would be found in highest amounts (i.e., the gum
      line). For this reason, we have modified the instructions of the test to
      emphasize the importance of targeting the gum line during sample
      collection. Regular at home or in clinic screening with the feline dental
      health test described in this study has the potential to facilitate early
      detection and prevention of dental disease.
    authors:
      - name: Damian Kao
        orcid: null
      - name: Julie Yang
        orcid: null
      - name: Sean Nisperos
        orcid: null
      - name: Norma Drew
        orcid: null
      - name: Polina Berezovskaya
        orcid: null
      - name: Kaushalya Kuruppu
        orcid: null
      - name: Yuliana Mihaylova
        orcid: null
  comment:
    dislikes: 0
    thread: "8493743300"
    numReports: 0
    likes: 0
    id: "5470690498"
    createdAt: 2021-07-27T00:40:11
    author:
      username: charleswarden
      about: I am a Bioinformatics Specialist at City of Hope, but comments represent
        my own opinions.
      name: Charles Warden
      isPowerContributor: false
      profileUrl: https://disqus.com/by/charleswarden/
      url: https://sites.google.com/site/cwarden45/about-me
      location: Monrovia, CA
      id: "84464988"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Hi,


      Thank you very much for posting this preprint.


      I can think of a number of questions, but I hope these are the most important:


      <b>1)</b> I noticed that you filter for samples with ‚Äú<i>>10,000 and <500,000 classified microbial reads</i>.‚Äù


      <b>Does this filter also apply to returning results to customers?</b>


      Based upon data / results I will mention in <b>2)</b>, I believe my cat‚Äôs samples may have had <a href="https://github.com/cwarden45/Bastu_Cat_Genome/blob/master/basepaws_Dental_Health_Test/HCWGS0003.23.HCWGS0003_Kraken2.kreport">~25% bacterial reads</a> (at least for the ~15% WGS sample).  For the earlier lcWGS samples (for ‚ÄúHealth + Breed‚Äù kits), I thought they were 2-4 million reads each.  If the Dental Health Test was similar, then I think my cat‚Äôs sample(s) would have had ‚Äú<i><500,000 classified microbial reads</i>‚Äù.  However, I am not sure if I am misunderstanding something?


      <b>2)</b> You can see the various measurements for my 1 cat here:


      <a href="https://github.com/cwarden45/Bastu_Cat_Genome/tree/master/basepaws_Dental_Health_Test">https://github.com/cwarden45/Bastu_Cat_Genome/tree/master/basepaws_Dental_Health_Test</a>


      My question is whether there is some figure in this preprint that I can use to compare the scores for my cat (or <b><i>any</i> customer can do for their cat</b>), compared to the density distributions cases and controls used for the risk estimation in this paper (for what I might call a training set)?


      I am also curious if those proportions say consistent among batches (and filtered samples or full samples, if they are all returned to customers).


      I think this might be similar to <b>Figure 3</b>, but I am not sure how to map the scores for my cat.


      <b>3)</b> Relative to the ordinary sample collection, is anything added to the liquid to limit or prevent<b> post-collection bacterial blooms</b>?


      If something was already added, is there any evidence that helps restrict / prevent bacterial growth from earlier tests?


      <b>4)</b> The Competing Interest Statement currently says ‚Äú<i>The authors have declared no competing interest</i>‚Äù.  However, because you are working for a company that offers a Dental Health Test based upon these results, I believe you need to declare a <b>competing interest</b>.  Is there something that I might be missing?


      Thanks again!


      Sincerely,

      Charles
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.04.23.441192v1
  tweets:
    - created_at: Tue Jul 27 22:19:34 +0000 2021
      id: 1420146874015748000
      id_str: "1420146874015748105"
      text: |-
        üí¨ bioRxiv comment on "Development of an oral swab ba..."

        "Hi,

        Thank you very much for posting this preprint.

        I c‚Ä¶ https://t.co/35SsiN6Wxe
      truncated: true
      entities:
        urls:
          - url: https://t.co/35SsiN6Wxe
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jul 27 22:19:34 +0000 2021
      id: 1420146874942697500
      id_str: "1420146874942697473"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/zyft4OhGvf
      truncated: false
      entities:
        urls:
          - url: https://t.co/zyft4OhGvf
      in_reply_to_status_id: 1420146874015748000
      in_reply_to_status_id_str: "1420146874015748105"
- preprint:
    id: "141140"
    doi: 10.1101/2021.05.06.21256615
    first_posted: 2021-05-08
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.06.21256615v1
    url: https://api.rxivist.org/v1/papers/141140
    title: "The evidence on transmission dynamics of COVID-19 from pre- and
      asymptomatic cases: protocol for a systematic review. (Version 2 modified
      on 6 July 2021)"
    category: infectious-diseases
    abstract: "Background The role of cases of SARS-CoV-2 who remain without
      symptoms throughout the active phase of the disease (asymptomatics) and
      those who have not developed symptoms yet when surveyed (pre-symptomatics)
      is at present unclear, despite the important role that they may play in
      infecting third parties. There is also a lack of clarity on the role of
      pauci-symptomatic persons with COVID-19 and the degree to which they may
      be associated with transmission compared to fully symptomatic persons.
      Methods We will search LitCovid, medRxiv, Google Scholar and the WHO
      Covid-19 database using Covid-19, SARS-CoV-2, transmission, and
      appropriate synonyms as search terms. We will also search the reference
      lists of included studies are searched for additional relevant studies. We
      will include studies of people exposed to SARS CoV-2 within 2-14 days
      (incubation time) of close contact or suspected community or institutional
      exposure to index asymptomatic infected individuals, as defined in each
      study with secondary case(s) infected. We will only include studies which
      provide microbiological proof of transmission outcome (culturable virus
      and /or genic sequencing). The inclusion of higher-quality evidence should
      overcome the methodological shortcomings of lower quality studies. We will
      assess quality of the chain of transmission evidence, microbiological
      proof and adequacy of follow up and symptom monitoring. Expected results
      We intend to present the evidence in three distinct packages: study
      description, methodological quality assessment and data extracted. We
      intend summarising the evidence and drawing conclusions"
    authors:
      - name: Tom Jefferson
        orcid: http://orcid.org/0000-0002-4778-2949
      - name: Annette Pluddemann
        orcid: http://orcid.org/0000-0003-2101-0390
      - name: Elisabeth Spencer
        orcid: null
      - name: Jon Brassey
        orcid: http://orcid.org/0000-0002-7812-6311
      - name: Cecilia Rosca
        orcid: http://orcid.org/0000-0003-2412-1942
      - name: IGHO ONAKPOYA
        orcid: null
      - name: David Evans
        orcid: null
      - name: John Conly
        orcid: null
      - name: Carl Heneghan
        orcid: http://orcid.org/0000-0002-1009-1992
  comment:
    dislikes: 0
    thread: "8651614699"
    numReports: 0
    likes: 0
    id: "5470191888"
    createdAt: 2021-07-26T17:27:59
    author:
      username: fortunisko
      about: ""
      name: Fortu Nisko
      isPowerContributor: false
      profileUrl: https://disqus.com/by/fortunisko/
      url: ""
      location: ""
      id: "360538392"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: The research should not use PCR or tests derived of PCR for
      assessing 1-Infection 2-infectiousness 3-illness. If the research depends
      on flawed data, at its root, then, the conclusions drawn will be no
      better. First establish what you are actually looking for - an intact
      viral particle that can be cultured. Further, establish that each supposed
      transmission be verified using such a method. And, de4fine the actual
      illness that is supposed to be directly associated with the pathogen you
      are looking for; that means a syndrome of acute severe respiratory
      distress.  Not a cough or a wheeze; not a fever; not a symptom that is
      applicable to many other potential causes. So make the causal relationship
      front and center. Specifically identify and test for the particular causal
      agent; specifically verify illness caused by that causal agent. Failing
      that, your research will be for nothing specific - not for a specific
      infection, not for a specific transmission, not for a specific malady.
      This should be noted in the strenghts/weakness portion of any research
      paper produced from your efforts.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.06.21256615v2
  tweets:
    - created_at: Wed Jul 28 01:06:32 +0000 2021
      id: 1420188892360286200
      id_str: "1420188892360286209"
      text: >-
        üí¨ medRxiv comment on "The evidence on transmission d..."


        "The research should not use PCR or tests derived of PCR‚Ä¶ https://t.co/98FR8PwXY2
      truncated: true
      entities:
        urls:
          - url: https://t.co/98FR8PwXY2
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 28 01:06:32 +0000 2021
      id: 1420188893140463600
      id_str: "1420188893140463619"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/sQsOpFz7pT
      truncated: false
      entities:
        urls:
          - url: https://t.co/sQsOpFz7pT
      in_reply_to_status_id: 1420188892360286200
      in_reply_to_status_id_str: "1420188892360286209"
- preprint:
    id: "143395"
    doi: 10.1101/2021.05.24.21257738
    first_posted: 2021-05-26
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.24.21257738v1
    url: https://api.rxivist.org/v1/papers/143395
    title: "Post-vaccination SARS-CoV-2 infection: risk factors and illness profile
      in a prospective, observational community-based case-control study"
    category: epidemiology
    abstract: "Background: Both BNT162b2 and ChAdOx1 vaccines show good efficacy in
      clinical trials and real-world data. However, some still contract
      SARS-CoV-2 post-vaccination. This study identifies risk factors associated
      with SARS-CoV-2 infection at least 14 days after first vaccination and
      describes characteristics of post-vaccination illness. Methods: Cases were
      UK adults reporting post-vaccination SARS-CoV-2 infection between 8th
      December 2020 and 1st May 2021, reporting on the COVID Symptom Study app.
      We assessed the associations of age, frailty, comorbidity, area-level
      deprivation and lifestyle factors with infection (vaccinated cases vs.
      negative-vaccinated controls); and vaccination with illness profile
      (vaccinated cases vs positive-unvaccinated controls). Findings:
      Post-vaccination infection risk was substantially higher in older adults
      with frailty (OR= 2.78, 95% CI [1.98-3.89], p-value<0.0001) and in
      individuals living in most deprived areas (OR vs. intermediate group=1.22,
      95%CI [1.04-1.43], p-value=0.01). Risk was lower in individuals with a
      healthier diet (OR=0.73, 95%CI [0.62-0.86], p-value<0.0001) and without
      obesity (OR=0.6, 95% CI [0.44-0.82], p-value=0.001). Vaccination was
      associated with reduced odds of hospitalisation (OR=0.36, 95%CI
      [0.28-0.46], p-value<0.0001), and high acute-symptom burden (OR=0.51,
      95%CI [0.42-0.61], p-value<0.0001). In the 60+ age group, risk of >28 days
      illness was lower following vaccination (OR=0.72 , 95%CI [0.51-1.00],
      p-value=0.05). Most symptoms were reported less in positive-vaccinated vs.
      positive-unvaccinated individuals, except sneezing, which was more common
      post-vaccination (OR=1.24, 95%CI [1.05-1.46], p-value=0.01).
      Interpretation: Our findings highlight reduced symptom burden and duration
      in those infected post-vaccination. Whilst reassuring, our data should
      prompt efforts to boost vaccine effectiveness in at-risk populations;
      moreover, targeted infection control measures will still be appropriate to
      minimise SARS-CoV-2 infection."
    authors:
      - name: Michela Antonelli
        orcid: http://orcid.org/0000-0002-3005-4523
      - name: Rose S. Penfold
        orcid: http://orcid.org/0000-0001-7023-7108
      - name: Jordi Merino
        orcid: http://orcid.org/0000-0001-8312-1438
      - name: Carole H. Sudre
        orcid: http://orcid.org/0000-0001-5753-428X
      - name: Erika Molteni
        orcid: http://orcid.org/0000-0001-7773-8140
      - name: Sarah Berry
        orcid: null
      - name: Liane S Canas
        orcid: null
      - name: Mark S Graham
        orcid: http://orcid.org/0000-0002-4170-1095
      - name: Kerstin Klaser
        orcid: http://orcid.org/0000-0002-5230-6939
      - name: Marc Modat
        orcid: http://orcid.org/0000-0002-5277-8530
      - name: Benjamin Murray
        orcid: http://orcid.org/0000-0002-2413-923X
      - name: Eric Kerfoot
        orcid: http://orcid.org/0000-0002-7255-6417
      - name: Liyuan Chen
        orcid: http://orcid.org/0000-0002-4099-4332
      - name: Jie Deng
        orcid: null
      - name: Marc F √ñsterdahl
        orcid: null
      - name: Nathan J Cheetham
        orcid: null
      - name: David Alden Drew
        orcid: null
      - name: Long Nguyen
        orcid: http://orcid.org/0000-0002-5436-4219
      - name: Joan Capdeila
        orcid: null
      - name: Christina Hu
        orcid: null
      - name: Somesh Selvachandran
        orcid: null
      - name: Lorenzo Polidori
        orcid: null
      - name: Anna May
        orcid: null
      - name: Jonathan Wolf
        orcid: http://orcid.org/0000-0002-0530-2257
      - name: Andrew T. Chan
        orcid: http://orcid.org/0000-0001-7284-6767
      - name: Alexander Hammers
        orcid: http://orcid.org/0000-0001-9530-4848
      - name: Emma Duncan
        orcid: null
      - name: Tim Spector
        orcid: http://orcid.org/0000-0002-9795-0365
      - name: Sebastien Ourselin
        orcid: http://orcid.org/0000-0002-5694-5340
      - name: Claire J. Steves
        orcid: http://orcid.org/0000-0002-4910-0489
  comment:
    dislikes: 0
    thread: "8555519904"
    numReports: 0
    likes: 0
    id: "5469738238"
    createdAt: 2021-07-26T10:03:20
    author:
      username: christophterasa
      about: ""
      name: Christoph Terasa
      isPowerContributor: false
      profileUrl: https://disqus.com/by/christophterasa/
      url: ""
      location: ""
      id: "67279553"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      In Table 2 on page 12, the heading on the rightmost column reads

      <blockquote>Control group of unvaccinated users testing <b><u>negative</u></b></blockquote>



      Shouldn't that be

      <blockquote>Control group of unvaccinated users testing <b><u>positive</u></b></blockquote>



      This is what I gathered from the text, and it makes more sense.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.24.21257738v2
  tweets:
    - created_at: Wed Jul 28 12:33:21 +0000 2021
      id: 1420361735408521200
      id_str: "1420361735408521226"
      text: >-
        üí¨ medRxiv comment on "Post-vaccination SARS-CoV-2 in..."


        "In Table 2 on page 12, the heading on the rightmost colu‚Ä¶ https://t.co/keMBW8C4Sj
      truncated: true
      entities:
        urls:
          - url: https://t.co/keMBW8C4Sj
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 28 12:33:21 +0000 2021
      id: 1420361736566153200
      id_str: "1420361736566153216"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jqzdMihvhU
      truncated: false
      entities:
        urls:
          - url: https://t.co/jqzdMihvhU
      in_reply_to_status_id: 1420361735408521200
      in_reply_to_status_id_str: "1420361735408521226"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8552957443"
    numReports: 0
    likes: 1
    id: "5471116292"
    createdAt: 2021-07-27T10:59:07
    author:
      username: JustinReilly
      about: ""
      name: JustinReilly
      isPowerContributor: false
      profileUrl: https://disqus.com/by/JustinReilly/
      url: ""
      location: ""
      id: "7480549"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      My comment submitted 7/27/2021:


      The following letter from Tess Lawrie et al. strongly rebuts this review by Roman et al. I highly recommend reading the letter as it is succinct and presents damning points:


      ‚ÄúWith misreporting of source data, highly selective study inclusion, ‚Äòcherry picking‚Äô of data within included studies, and conclusions that do not follow from the evidence, this article amounts to disinformation... We respectfully request investigation, and retraction of the article as it stands.‚Äù


      I join the letter‚Äôs signatories in calling for swift retraction. Thank you for your consideration.


      https://covid19criticalcare.com/wp-content/uploads/2021/07/RomanRebuttal_v7_EF_letterhead_ML-1.pdf
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v2
  tweets:
    - created_at: Wed Jul 28 14:17:33 +0000 2021
      id: 1420387959556255700
      id_str: "1420387959556255744"
      text: |-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."

        "My comment submitted 7/27/2021:

        The following letter fr‚Ä¶ https://t.co/g2I4qGhjCF
      truncated: true
      entities:
        urls:
          - url: https://t.co/g2I4qGhjCF
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 28 14:17:33 +0000 2021
      id: 1420387960457998300
      id_str: "1420387960457998340"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1420387959556255700
      in_reply_to_status_id_str: "1420387959556255744"
- preprint:
    id: "136808"
    doi: 10.1101/2021.04.06.438613
    first_posted: 2021-04-07
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.06.438613v1
    url: https://api.rxivist.org/v1/papers/136808
    title: Promoter-sequence determinants and structural basis of primer-dependent
      transcription initiation in Escherichia coli
    category: biochemistry
    abstract: Chemical modifications of RNA 5' ends enable "epitranscriptomic"
      regulation, influencing multiple aspects of RNA fate. In transcription
      initiation, a large inventory of substrates compete with nucleoside
      triphosphates (NTPs) for use as initiating entities, providing an ab
      initio mechanism for altering the RNA 5' end. In Escherichia coli cells,
      RNAs with a 5'-end hydroxyl are generated by use of dinucleotide RNAs as
      primers for transcription initiation, "primer-dependent initiation." Here
      we use massively systematic transcript end readout ("MASTER") to detect
      and quantify RNA 5' ends generated by primer-dependent initiation for ~410
      (~1,000,000) promoter sequences in E. coli. The results show
      primer-dependent initiation in E. coli involves any of the 16 possible
      dinucleotide primers and depends on promoter sequences in, upstream, and
      downstream of the primer binding site. The results yield a consensus
      sequence for primer dependent initiation, YTSS-2NTSS-1NTSSWTSS+1, where
      TSS is the transcription start site, NTSS-1NTSS is the primer binding
      site, Y is pyrimidine, and W is A or T. Biochemical and
      structure-determination studies show that the base pair
      (nontemplate-strand base:template-strand base) immediately upstream of the
      primer binding site (Y:RTSS-2, where R is purine) exerts its effect
      through the base on the DNA template strand (RTSS-2) through inter-chain
      base stacking with the RNA primer. Results from analysis of a large set of
      natural, chromosomally-encoded E. coli promoters support the conclusions
      from MASTER. Our findings provide a mechanistic and structural description
      of how TSS-region sequence hard-codes not only the TSS position, but also
      the potential for epitranscriptomic regulation through primer dependent
      transcription initiation.
    authors:
      - name: Kyle S. Skalenko
        orcid: http://orcid.org/0000-0002-1730-0398
      - name: Lingting Li
        orcid: null
      - name: Yuanchao Zhang
        orcid: http://orcid.org/0000-0001-9663-5841
      - name: Irina O Vvedenskaya
        orcid: null
      - name: Jared T. Winkelman
        orcid: null
      - name: Alexander Cope
        orcid: null
      - name: Deanne M. Taylor
        orcid: null
      - name: Premal Shah
        orcid: http://orcid.org/0000-0002-8424-4218
      - name: Richard H. Ebright
        orcid: http://orcid.org/0000-0001-8915-7140
      - name: Justin Block Kinney
        orcid: http://orcid.org/0000-0003-1897-3778
      - name: Yu Zhang
        orcid: http://orcid.org/0000-0001-7159-4561
      - name: Bryce E. Nickels
        orcid: http://orcid.org/0000-0001-7449-8831
  comment:
    dislikes: 0
    thread: "8468598524"
    numReports: 0
    likes: 0
    id: "5472804407"
    createdAt: 2021-07-28T15:43:12
    author:
      username: disqus_hAl8iT4xsy
      about: ""
      name: Alex Cope
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_hAl8iT4xsy/
      url: https://www.facebook.com/app_scoped_user_id/100000990664838/
      location: ""
      id: "47856765"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "Currently published at PNAS: https://doi.org/10.1073/pnas.2106388118"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.04.06.438613v1
  tweets:
    - created_at: Wed Jul 28 16:33:01 +0000 2021
      id: 1420422051182035000
      id_str: "1420422051182034948"
      text: |-
        üí¨ bioRxiv comment on "Promoter-sequence determinants..."

        "Currently published at PNAS: "

        https://t.co/vKXl6SbbnE
      truncated: false
      entities:
        urls:
          - url: https://t.co/vKXl6SbbnE
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 28 16:33:02 +0000 2021
      id: 1420422052016709600
      id_str: "1420422052016709633"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/Rx20xWMeiY
      truncated: false
      entities:
        urls:
          - url: https://t.co/Rx20xWMeiY
      in_reply_to_status_id: 1420422051182035000
      in_reply_to_status_id_str: "1420422051182034948"
- preprint:
    id: "150975"
    doi: 10.1101/2021.07.20.453145
    first_posted: 2021-07-21
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.20.453145v1
    url: https://api.rxivist.org/v1/papers/150975
    title: "Adolescent Development of Biological Rhythms: Estradiol Dependence and
      Effects of Combined Contraceptives"
    category: physiology
    abstract: "Purpose: Adolescence is a period of continuous development, including
      the maturation of endogenous rhythms across systems and timescales.
      Although these dynamic changes are well recognized, their continuous
      structure and hormonal dependence have not been systematically
      characterized. Given the well-established link between core body
      temperature (CBT) and reproductive hormones in adults, we hypothesized
      that high-resolution CBT can be applied to passively monitor pubertal
      development and disruption with high fidelity. Methods: To examine this
      possibility, we used signal processing to investigate the trajectory of
      CBT rhythms at the within-day (ultradian), daily (circadian), and
      ovulatory timescales, their dependence on estradiol, and the effects of
      hormonal contraceptives. Results: Puberty onset was marked by a rise in
      fecal estradiol (fE2), followed by an elevation in CBT and circadian
      power. This time period marked the commencement of 4-day rhythmicity in
      fE2, CBT, and ultradian power marking the onset of the estrous cycle. The
      rise in circadian amplitude was accelerated by E2 treatment, indicating a
      role for this hormone in rhythmic development. Contraceptive
      administration in later adolescence reduced CBT and circadian power and
      resulted in disruption to 4-day cycles that persisted after
      discontinuation. Conclusions: Our data reveal with precise temporal
      resolution how biological rhythms change across adolescence and
      demonstrate a role for E2 in the emergence and preservation of multiscale
      rhythmicity. These findings also demonstrate how hormones delivered
      exogenously in a non-rhythmic pattern can disrupt rhythmic development.
      These data lay the groundwork for a future in which temperature metrics
      provide an inexpensive, convenient method for monitoring pubertal
      maturation and support the development of hormone therapies that better
      mimic and support human chronobiology."
    authors:
      - name: Azure Dominique Grant
        orcid: http://orcid.org/0000-0003-2956-4267
      - name: Linda Wilbrecht
        orcid: http://orcid.org/0000-0003-3492-8141
      - name: Lance J Kriegsfeld
        orcid: http://orcid.org/0000-0002-6361-1496
  comment:
    dislikes: 0
    thread: "8662497505"
    numReports: 0
    likes: 0
    id: "5472711765"
    createdAt: 2021-07-28T14:33:17
    author:
      name: CircaReader
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Interesting paper with exciting results. There are certainly valuable
      implications from these findings.  After reading through, I had several
      comments that I thought I would share.  


      1. Add legend to figure 1 x axis, ‚ÄúDays‚Äù. Perhaps p-day would be useful.

      2. Is it standard to have text labels describing the results as seen in figure 2?

      3. What is the purpose of the colored arrows in figure 2?

      4. What is meant by ‚Äòsignificant trend‚Äô in figure 2/4? What test was used to determine this? Probably will need to clarify this statement
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.07.20.453145v1
  tweets:
    - created_at: Wed Jul 28 18:25:07 +0000 2021
      id: 1420450259281481700
      id_str: "1420450259281481728"
      text: >-
        üí¨ bioRxiv comment on "Adolescent Development of Biol..."


        "Interesting paper with exciting results. There are certa‚Ä¶ https://t.co/8RfAQ4y1hJ
      truncated: true
      entities:
        urls:
          - url: https://t.co/8RfAQ4y1hJ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 28 18:25:07 +0000 2021
      id: 1420450260338417700
      id_str: "1420450260338417665"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/l80y3Op07z
      truncated: false
      entities:
        urls:
          - url: https://t.co/l80y3Op07z
      in_reply_to_status_id: 1420450259281481700
      in_reply_to_status_id_str: "1420450259281481728"
- preprint:
    id: 132045
    metric: 47
    title: Tissue specific targeting of DNA nanodevices in a multicellular living
      organism
    url: https://api.rxivist.org/v1/papers/132045
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.03.05.434169v1
    doi: 10.1101/2021.03.05.434169
    category: biochemistry
    first_posted: 2021-03-06
    abstract: Nucleic acid nanodevices present great potential as agents for
      logic-based therapeutic intervention as well as in basic biology. Often,
      however, the disease targets that need corrective action are localized in
      specific organs and thus realizing the full potential of DNA nanodevices
      also requires ways to target them to specific cell-types in vivo. Here we
      show that by exploiting either endogenous or synthetic receptor-ligand
      interactions and by leveraging the biological barriers presented by the
      organism, we can target extraneously introduced DNA nanodevices to
      specific cell types in C. elegans, with sub-cellular precision. The
      amenability of DNA nanostructures to tissue-specific targeting in vivo
      significantly expands their utility in biomedical applications and
      discovery biology.
    authors:
      - name: Kasturi Chakraborty
      - name: Sunaina Surana
      - name: Simona Martin
      - name: Jihad Aburas
      - name: Sandrine Moutel
      - name: Franck Perez
      - name: Sandhya P Koushika
      - name: Paschalis Kratsios
      - name: Yamuna Krishnan
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Wed Jul 28 20:16:03 +0000 2021
      id: 1420478178146062300
      id_str: "1420478178146062337"
      text: >-
        üî• bioRxiv Biochemistry preprint by K. Chakraborty et al:


        "Tissue specific targeting of DNA nanodevices in a multic‚Ä¶ https://t.co/d4NDwWavMu
      truncated: true
      entities:
        urls:
          - url: https://t.co/d4NDwWavMu
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "149831"
    doi: 10.1101/2021.07.07.21260122
    first_posted: 2021-07-12
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.07.21260122v1
    url: https://api.rxivist.org/v1/papers/149831
    title: Viral infection and Transmission in a large well-traced outbreak caused
      by the Delta SARS-CoV-2 variant
    category: epidemiology
    abstract: We report the first local transmission of the SARS-CoV-2 Delta variant
      in mainland China. All 167 infections could be traced back to the first
      index case. Daily sequential PCR testing of the quarantined subjects
      indicated that the viral loads of Delta infections, when they first become
      PCR+, were on average ~1000 times greater compared to A/B lineage
      infections during initial epidemic wave in China in early 2020, suggesting
      potentially faster viral replication and greater infectiousness of Delta
      during early infection. We performed high-quality sequencing on samples
      from 126 individuals. Reliable epidemiological data meant that, for 111
      transmission events, the donor and recipient cases were known. The
      estimated transmission bottleneck size was 1-3 virions with most minor
      intra-host single nucleotide variants (iSNVs) failing to transmit to the
      recipients. However, transmission heterogeneity of SARS-CoV-2 was also
      observed. The transmission of minor iSNVs resulted in at least 4 of the 30
      substitutions identified in the outbreak, highlighting the contribution of
      intra-host variants to population level viral diversity during rapid
      spread. Disease control activities, such as the frequency of population
      testing, quarantine during pre-symptomatic infection, and level of virus
      genomic surveillance should be adjusted in order to account for the
      increasing prevalence of the Delta variant worldwide.
    authors:
      - name: Baisheng Li
        orcid: null
      - name: Aiping Deng
        orcid: null
      - name: Kuibiao Li
        orcid: null
      - name: Yao Hu
        orcid: null
      - name: Zhencui Li
        orcid: null
      - name: Qianling Xiong
        orcid: null
      - name: Zhe Liu
        orcid: http://orcid.org/0000-0002-3592-3150
      - name: Qianfang Guo
        orcid: null
      - name: Lirong Zou
        orcid: null
      - name: Huan Zhang
        orcid: http://orcid.org/0000-0001-9366-2385
      - name: Meng Zhang
        orcid: http://orcid.org/0000-0002-9753-0635
      - name: Fangzhu Ouyang
        orcid: null
      - name: Juan Su
        orcid: null
      - name: Wenzhe Su
        orcid: null
      - name: Jing Xu
        orcid: http://orcid.org/0000-0003-3773-7973
      - name: Huifang Lin
        orcid: null
      - name: Jing Sun
        orcid: http://orcid.org/0000-0003-3741-0962
      - name: Jinju Peng
        orcid: null
      - name: Huimin Jiang
        orcid: null
      - name: Pingping Zhou
        orcid: null
      - name: Ting Hu
        orcid: http://orcid.org/0000-0001-6382-0602
      - name: Min Luo
        orcid: null
      - name: Yingtao Zhang
        orcid: null
      - name: Huanying Zheng
        orcid: null
      - name: Jianpeng Xiao
        orcid: null
      - name: Tao Liu
        orcid: http://orcid.org/0000-0002-8818-8313
      - name: Rongfei Che
        orcid: null
      - name: Hanri Zeng
        orcid: null
      - name: Zhonghua Zheng
        orcid: null
      - name: Yushi Huang
        orcid: null
      - name: Jianxiang Yu
        orcid: null
      - name: Lina Yi
        orcid: null
      - name: Jie Wu
        orcid: null
      - name: Jingdiao Chen
        orcid: null
      - name: Haojie Zhong
        orcid: null
      - name: Xiaoling Deng
        orcid: null
      - name: min Kang
        orcid: null
      - name: Oliver G. Pybus
        orcid: http://orcid.org/0000-0002-8797-2667
      - name: Matthew Hall
        orcid: http://orcid.org/0000-0002-5073-442X
      - name: Katrina A Lythgoe
        orcid: http://orcid.org/0000-0002-7089-7680
      - name: Yan Li
        orcid: http://orcid.org/0000-0003-3820-5960
      - name: Jun Yuan
        orcid: null
      - name: Jianfeng He
        orcid: null
      - name: Jing Lu
        orcid: http://orcid.org/0000-0002-5791-4749
  comment:
    dislikes: 0
    thread: "8644440599"
    numReports: 0
    likes: 0
    id: "5472940751"
    createdAt: 2021-07-28T17:23:59
    author:
      username: disqus_TnC1GkfMS3
      about: ""
      name: John Pearson
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_TnC1GkfMS3/
      url: ""
      location: ""
      id: "52411695"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "FROM THE ARTICLE: We next evaluated viral load measurements at the
      time when SARS-CoV-2 was first detected by PCR in each subject."
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.07.07.21260122v1
  tweets:
    - created_at: Wed Jul 28 20:19:49 +0000 2021
      id: 1420479126453072000
      id_str: "1420479126453071875"
      text: >-
        üí¨ medRxiv comment on "Viral infection and Transmissi..."


        "FROM THE ARTICLE: We next evaluated viral load measureme‚Ä¶ https://t.co/xOOZW1441z
      truncated: true
      entities:
        urls:
          - url: https://t.co/xOOZW1441z
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 28 20:19:49 +0000 2021
      id: 1420479127149293600
      id_str: "1420479127149293568"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/v3X1joMTJY
      truncated: false
      entities:
        urls:
          - url: https://t.co/v3X1joMTJY
      in_reply_to_status_id: 1420479126453072000
      in_reply_to_status_id_str: "1420479126453071875"
- preprint:
    id: "151766"
    doi: 10.1101/2021.07.23.21260998
    first_posted: 2021-07-27
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.23.21260998v1
    url: https://api.rxivist.org/v1/papers/151766
    title: "Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A
      Population-Based Analysis"
    category: public-and-global-health
    abstract: Background There have been recent reports of myocarditis (including
      myocarditis, pericarditis or myopericarditis) as a side-effect of
      mRNA-based COVID-19 vaccines, particularly in young males. Less
      information is available regarding the risk of myocarditis from COVID-19
      infection itself. Such data would be helpful in developing a complete
      risk-benefit analysis for this population. Methods A de-identified,
      limited data set was created from the TriNetX Research Network,
      aggregating electronic health records from 48 mostly large U.S. Healthcare
      Organizations (HCOs). Inclusion criteria were a first COVID-19 diagnosis
      during the April 1, 2020 - March 31, 2021 time period, with an outpatient
      visit 1 month to 2 years before, and another 6 months to 2 years before
      that. Analysis was stratified by sex and age (12-17, 12-15, 16-19).
      Patients were excluded for any prior cardiovascular condition. Primary
      outcome was an encounter diagnosis of myocarditis within 90 days following
      the index date. Rates of COVID-19 cases and myocarditis not identified in
      the system were estimated and the results adjusted accordingly. Wilson
      score intervals were used for 95% confidence intervals due to the very low
      probability outcome. Results For the 12-17-year-old male cohort, 6/6,846
      (0.09%) patients developed myocarditis overall, with an adjusted rate per
      million of 876 cases (Wilson score interval 402 - 1,911). For the 12-15
      and 16-19 male age groups, the adjusted rates per million were 601 (257 -
      1,406) and 561 (240 - 1,313). For 12-17-year-old females, there were 3
      (0.04%) cases of myocarditis of 7,361 patients. The adjusted rate was 213
      (73 - 627) per million cases. For the 12-15- and 16-19-year-old female
      cohorts the adjusted rates per million cases were 235 (64 - 857) and 708
      (359 - 1,397). The outcomes occurred either within 5 days (40.0%) or from
      19-82 days (~60.0%). Conclusions Myocarditis (or pericarditis or
      myopericarditis) from primary COVID19 infection occurred at a rate as high
      as 450 per million in young males. Young males infected with the virus are
      up 6 times more likely to develop myocarditis as those who have received
      the vaccine.
    authors:
      - name: Mendel E Singer
        orcid: http://orcid.org/0000-0002-3331-3340
      - name: Ira B. Taub
        orcid: http://orcid.org/0000-0001-6031-0420
      - name: David C. Kaelber
        orcid: http://orcid.org/0000-0001-7855-9515
  comment:
    dislikes: 0
    thread: "8674814320"
    numReports: 0
    likes: 1
    id: "5471942076"
    createdAt: 2021-07-27T22:07:18
    author:
      username: disqus_6TsW9Jrcbg
      about: ""
      name: Caro__
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_6TsW9Jrcbg/
      url: ""
      location: ""
      id: "346153494"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Some remarks:

      - confidence intervals would be necessary when interpolating data from such small numbers

      - 90 days is a long period after a positive test for an acute event‚Ä¶

      - if you want to compare these numbers to vaccine-caused myo/pericarditis, you need to use the same method (same criteria and same codes) to determine these
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.07.23.21260998v1
  tweets:
    - created_at: Wed Jul 28 22:17:32 +0000 2021
      id: 1420508752118050800
      id_str: "1420508752118050821"
      text: |-
        üí¨ medRxiv comment on "Risk of Myocarditis from COVID..."

        "Some remarks:
        - confidence intervals would be necessary‚Ä¶ https://t.co/3JHTlOqBjl
      truncated: true
      entities:
        urls:
          - url: https://t.co/3JHTlOqBjl
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jul 28 22:17:33 +0000 2021
      id: 1420508753036599300
      id_str: "1420508753036599298"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/zKi1j2aTDY
      truncated: false
      entities:
        urls:
          - url: https://t.co/zKi1j2aTDY
      in_reply_to_status_id: 1420508752118050800
      in_reply_to_status_id_str: "1420508752118050821"
- preprint:
    id: "149748"
    doi: 10.1101/2021.07.10.451903
    first_posted: 2021-07-11
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.10.451903v1
    url: https://api.rxivist.org/v1/papers/149748
    title: Bacteria are everywhere, even in your COI marker gene data!
    category: bioinformatics
    abstract: The mitochondrial cytochrome C oxidase subunit I gene (COI) is
      commonly used in eDNA metabarcoding studies, especially for assessing
      metazoan diversity. Yet, a great number of COI operational taxonomic units
      or/and amplicon sequence variants are retrieved from such studies and
      referred to as "dark matter", and do not get a taxonomic assignment with a
      reference sequence. For a thorough investigation of this dark matter, we
      have developed the Dark mAtteR iNvestigator (DARN) software tool. A
      reference COI-oriented phylogenetic tree was built from 1,240 consensus
      sequences covering all the three domains of life, with more than 80% of
      those representing eukaryotic taxa. With respect to eukaryotes, consensus
      sequences at the family level were constructed from 183,330 retrieved from
      the Midori reference 2 database. Similarly, sequences from 559 bacterial
      genera and 41 archaeal were retrieved from the BOLD database. DARN makes
      use of the phylogenetic tree to investigate and quantify pre-processed
      sequences of amplicon samples to provide both a tabular and a graphical
      overview of phylogenetic assignments. To evaluate DARN, both environmental
      and bulk metabarcoding samples from different aquatic environments using
      various primer sets were analysed. We demonstrate that a large proportion
      of non-target prokaryotic organisms such as bacteria and archaea are also
      amplified in eDNA samples and we suggest bacterial COI sequences to be
      included in the reference databases used for the taxonomy assignment to
      allow for further analyses of dark matter. DARN source code is available
      on GitHub at https://github.com/hariszaf/darn and you may find it as a
      Docker at https://hub.docker.com/r/hariszaf/darn.
    authors:
      - name: Haris Zafeiropoulos
        orcid: http://orcid.org/0000-0002-4405-6802
      - name: Laura Gargan
        orcid: http://orcid.org/0000-0001-6034-4858
      - name: Sanni Hintikka
        orcid: http://orcid.org/0000-0001-6684-5194
      - name: Christina Pavloudi
        orcid: http://orcid.org/0000-0001-5106-6067
      - name: Jens Carlsson
        orcid: http://orcid.org/0000-0002-9262-5627
  comment:
    dislikes: 0
    thread: "8643312810"
    numReports: 0
    likes: 0
    id: "5473284469"
    createdAt: 2021-07-28T21:58:46
    author:
      username: charleswarden
      about: I am a Bioinformatics Specialist at City of Hope, but comments represent
        my own opinions.
      name: Charles Warden
      isPowerContributor: false
      profileUrl: https://disqus.com/by/charleswarden/
      url: https://sites.google.com/site/cwarden45/about-me
      location: Monrovia, CA
      id: "84464988"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Hi,


      Thank you very much positing this preprint.


      I apologize if I overlooked something, but is your strategy doing something to try and gauge whether the "dark matter" is related to the COI gene or is off-target sequence that may be contamination?


      As one example, I think there have been periods of time where top BLAST hits for PhiX sequence have said something else (because the lab didn't realize the PhiX spike-in could barcode hop into samples): https://www.biostars.org/p/376585/#435110


      Or, even if the PhiX sequences are already filtered, do you think DARN can help with things like this post-publication review thread:


      https://www.nature.com/articles/s41598-019-42455-9#article-comments


      In that second example, you can do things like filter for sequences present in at least 2 reads in at least 1 sample.  However, you can also see some troubleshooting that I think might be somewhat more similar <a href="https://github.com/cwarden45/PRJNA513845-eDNA_reanalysis/tree/master/metagenomics">here</a>, and I am wondering if you think DARN might help identify groups of samples with a higher fraction of sequences that might not be a good representation the original biological sample.


      Thank you again!  I think the topic is quite interesting and important.


      Sincerely,

      Charles
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.07.10.451903v1
  tweets:
    - created_at: Thu Jul 29 01:02:02 +0000 2021
      id: 1420550147998687200
      id_str: "1420550147998687236"
      text: |-
        üí¨ bioRxiv comment on "Bacteria are everywhere, even ..."

        "Hi,

        Thank you very much positing this preprint.

        I apol‚Ä¶ https://t.co/Z4st2DDdbq
      truncated: true
      entities:
        urls:
          - url: https://t.co/Z4st2DDdbq
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 29 01:02:02 +0000 2021
      id: 1420550148812386300
      id_str: "1420550148812386304"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/dcEHMj9egQ
      truncated: false
      entities:
        urls:
          - url: https://t.co/dcEHMj9egQ
      in_reply_to_status_id: 1420550147998687200
      in_reply_to_status_id_str: "1420550147998687236"
- preprint:
    id: "149252"
    doi: 10.1101/2021.07.05.21260050
    first_posted: 2021-07-07
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.05.21260050v1
    url: https://api.rxivist.org/v1/papers/149252
    title: Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in
      Ontario, Canada
    category: infectious-diseases
    abstract: "Background: The period from February to June 2021 was one during
      which initial wild-type SARS-CoV-2 strains were supplanted in Ontario,
      Canada, first by variants of concern (VOC) with the N501Y mutation
      (Alpha/B1.1.17, Beta/B.1.351 and Gamma/P.1 variants), and then by the
      Delta/B.1.617 variant. The increased transmissibility of these VOCs has
      been documented but data for increased virulence is limited. We used
      Ontario COVID-19 case data to evaluate the virulence of these VOCs
      compared to non-VOC SARS-CoV-2 infections, as measured by risk of
      hospitalization, intensive care unit (ICU) admission, and death. Methods:
      We created a retrospective cohort of people in Ontarios testing positive
      for SARS-CoV-2 and screened for VOCs, with dates of test report between
      February 7 and June 22, 2021 (n=211,197). We constructed mixed effects
      logistic regression models with hospitalization, ICU admission, and death
      as outcome variables. Models were adjusted for age, sex, time,
      comorbidities, and pregnancy status. Health units were included as random
      intercepts. Results: Compared to non-VOC SARS-CoV-2 strains, the adjusted
      elevation in risk associated with N501Y-positive variants was 59% (49-69%)
      for hospitalization; 105% (82-134%) for ICU admission; and 61% (40-87%)
      for death. Increases with Delta variant were more pronounced: 120%
      (93-153%) for hospitalization; 287% (198-399%) for ICU admission; and 137%
      (50-230%) for death. Interpretation: The progressive increase in
      transmissibility and virulence of SARS-CoV-2 VOCs will result in a
      significantly larger, and more deadly, pandemic than would have occurred
      in the absence of VOC emergence."
    authors:
      - name: David Fisman
        orcid: http://orcid.org/0000-0001-5009-6926
      - name: Ashleigh Tuite
        orcid: http://orcid.org/0000-0002-4373-9337
  comment:
    dislikes: 0
    thread: "8644668449"
    numReports: 0
    likes: 0
    id: "5472826361"
    createdAt: 2021-07-28T15:59:28
    author:
      username: jrghennemann
      about: ""
      name: J√∂rg Hennemann
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jrghennemann/
      url: ""
      location: ""
      id: "372856097"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Thank you or your contribution! I still do not understand, how this
      works. If vaccination is interfering the ration between deaths from Delta
      and all the other variants, what is the study based on? Hard numbers shown
      are just those in table 1. How can a "lower death rate" cause a "higher
      death risk"? This for me only makes sense, if the time between infection
      and death is much longer for Delta. But there are no data presented
      supporting this thesis. I`m really confused here, especially because the
      German press and also the first "experts" forecast the end of the world
      because of this study. You don't find their results unreasonable, but did
      you find a proof for the conclusion "Delta ist more dangerous" in the
      paper? I didn`t..
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.07.05.21260050v2
  tweets:
    - created_at: Thu Jul 29 12:31:54 +0000 2021
      id: 1420723759250501600
      id_str: "1420723759250501635"
      text: >-
        üí¨ medRxiv comment on "Progressive Increase in Virule..."


        "Thank you or your contribution! I still do not understan‚Ä¶ https://t.co/jBUkrBBx70
      truncated: true
      entities:
        urls:
          - url: https://t.co/jBUkrBBx70
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 29 12:31:54 +0000 2021
      id: 1420723760273920000
      id_str: "1420723760273920006"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/puR7zuoA1m
      truncated: false
      entities:
        urls:
          - url: https://t.co/puR7zuoA1m
      in_reply_to_status_id: 1420723759250501600
      in_reply_to_status_id_str: "1420723759250501635"
- preprint:
    id: "151604"
    doi: 10.1101/2021.07.23.21261030
    first_posted: 2021-07-26
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.23.21261030v1
    url: https://api.rxivist.org/v1/papers/151604
    title: "Breakthrough Symptomatic COVID-19 Infections Leading to Long Covid:
      Report from Long Covid Facebook Group Poll"
    category: epidemiology
    abstract: Vaccines have been shown to be extremely effective in preventing
      COVID-19 hospitalizations and deaths. However, a question remains whether
      vaccine breakthrough cases can still lead to Post-Acute Sequelae of
      SARS-CoV-2 (PASC), also known as Long Covid. To address this question, the
      Survivor Corps group, a grassroots COVID-19 organization focused on
      patient support and research, posted a poll to its 169,900 members that
      asked about breakthrough cases, Long Covid, and hospitalizations. 1,949
      people who self-report being fully vaccinated have responded to date.
      While robust data are needed in a larger, unbiased sample to extrapolate
      rates to the population, we analyzed the results of this public poll to
      determine what people were reporting regarding Long Covid after
      breakthrough infection and to prompt discussion of how breakthrough cases
      are measured. The poll was posted in the Survivor Corps Facebook group
      (~169,900 members). Of the 1,949 participants who responded to the poll,
      44 reported a symptomatic breakthrough case and 24 of those reported that
      the case led to symptoms of Long Covid. 1 of these 24 cases was reported
      to have led to hospitalization in addition to Long Covid.
    authors:
      - name: Daisy Massey
        orcid: http://orcid.org/0000-0002-9922-7808
      - name: Diana Berrent
        orcid: null
      - name: Harlan Krumholz
        orcid: http://orcid.org/0000-0003-2046-127X
  comment:
    dislikes: 0
    thread: "8672605173"
    numReports: 0
    likes: 0
    id: "5472799871"
    createdAt: 2021-07-28T15:39:52
    author:
      username: disqus_9R7Zqrbul4
      about: ""
      name: TS
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_9R7Zqrbul4/
      url: ""
      location: ""
      id: "372964515"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Agreed..  would have been nice if the authors took a little extra
      time in developing their methodology to obtain meaningful results instead
      of this rush job.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.07.23.21261030v1
  tweets:
    - created_at: Thu Jul 29 14:17:49 +0000 2021
      id: 1420750412416573400
      id_str: "1420750412416573456"
      text: >-
        üí¨ medRxiv comment on "Breakthrough Symptomatic COVID..."


        "Agreed..  would have been nice if the authors took a lit‚Ä¶ https://t.co/8g25UTQg4i
      truncated: true
      entities:
        urls:
          - url: https://t.co/8g25UTQg4i
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 29 14:17:49 +0000 2021
      id: 1420750413712687000
      id_str: "1420750413712687113"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/ybCOwnRou5
      truncated: false
      entities:
        urls:
          - url: https://t.co/ybCOwnRou5
      in_reply_to_status_id: 1420750412416573400
      in_reply_to_status_id_str: "1420750412416573456"
- preprint:
    id: "144845"
    doi: 10.1101/2021.06.02.21258231
    first_posted: 2021-06-05
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.02.21258231v1
    url: https://api.rxivist.org/v1/papers/144845
    title: Effectiveness of mRNA COVID-19 Vaccines among Employees in an American
      Healthcare System
    category: infectious-diseases
    abstract: Background. The mRNA SARS-CoV-2 vaccines have shown great promise in
      clinical trials. The purpose of this study was to evaluate the
      effectiveness of these vaccines under real-world conditions in the USA.
      Methods. Employees of the Cleveland Clinic Health System, previously not
      infected with SARS-CoV-2, and working in Ohio on Dec 16, 2020, the day
      COVID-19 vaccination began, were included. The cumulative incidence of
      SARS-CoV-2 infection, over the next 5 months, was compared among those who
      received the vaccine and those who did not, by modeling vaccination as a
      time-dependent covariate in Cox proportional hazards regression analyses
      adjusted for the slope of the epidemic curve as a continuous
      time-dependent covariate. Results. Of the 46866 included employees, 28223
      (60%) were vaccinated by the end of the study period. The cumulative
      incidence of SARS-CoV-2 infection was much higher among those not
      vaccinated than those vaccinated. Only 15 (0.7%) of the 2154 SARS-CoV-2
      infections during the study occurred among those vaccinated. After
      adjusting for the slope of the epidemic curve, age, and job type,
      vaccination was associated with a significantly reduced risk of SARS-CoV-2
      infection (HR 0.03, 95% C.I. 0.02 - 0.06, p < 0.001), corresponding to a
      vaccine effectiveness rate of 97.1% (95% CI 94.3 - 98.5). Vaccine
      effectiveness was 89.2% at 7 days and 95.0% at 14 days after the first
      vaccine dose. Conclusions. The mRNA SARS-CoV-2 vaccines are over 97%
      protective against COVID-19 in the working-age population, with
      substantial protection possibly apparent within a few days of the first
      dose.
    authors:
      - name: Nabin K. Shrestha
        orcid: http://orcid.org/0000-0001-6766-9874
      - name: Amy S. Nowacki
        orcid: null
      - name: Patrick C. Burke
        orcid: null
      - name: Paul Terpeluk
        orcid: null
      - name: Steven M. Gordon
        orcid: null
  comment:
    dislikes: 0
    thread: "8575541177"
    numReports: 0
    likes: 0
    id: "5472692941"
    createdAt: 2021-07-28T14:18:10
    author:
      username: disqus_o95zHIS3r8
      about: ""
      name: H.
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_o95zHIS3r8/
      url: ""
      location: ""
      id: "372961184"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: 5,372 were excluded from study due to infection how many had any
      vaccine?  795 not considered vaccinated how many had vaccine
      injection?  These are important questions.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.02.21258231v1
  tweets:
    - created_at: Thu Jul 29 16:37:18 +0000 2021
      id: 1420785516581212200
      id_str: "1420785516581212166"
      text: >-
        üí¨ medRxiv comment on "Effectiveness of mRNA COVID-19..."


        "5,372 were excluded from study due to infection how many‚Ä¶ https://t.co/ylYkB6YzmM
      truncated: true
      entities:
        urls:
          - url: https://t.co/ylYkB6YzmM
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 29 16:37:18 +0000 2021
      id: 1420785517466198000
      id_str: "1420785517466198016"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/hgU7PqRLRa
      truncated: false
      entities:
        urls:
          - url: https://t.co/hgU7PqRLRa
      in_reply_to_status_id: 1420785516581212200
      in_reply_to_status_id_str: "1420785516581212166"
- preprint:
    id: "144576"
    doi: 10.1101/2021.06.03.446862
    first_posted: 2021-06-03
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.06.03.446862v1
    url: https://api.rxivist.org/v1/papers/144576
    title: Unrestrained growth of correctly oriented microtubules instructs axonal
      microtubule orientation
    category: cell-biology
    abstract: In many eukaryotic cells, directed molecular transport occurs along
      microtubules. Within neuronal axons, transport over vast distances
      particularly relies on uniformly oriented microtubules, whose plus-ends
      point towards the distal axon tip (+end out). However, axonal microtubules
      initially have mixed orientations, and what breaks this orientation
      symmetry is poorly understood. Using live imaging, physical modeling and
      simulations, we found that +end out microtubules surpass a growth
      transition and undergo persistent long-term growth. In contrast,
      oppositely oriented microtubules remain short. We confirmed experimentally
      and in silico that the enhanced growth of +end out microtubules is
      critical for achieving uniform microtubule orientation. Our data suggest
      that the accelerated growth kinetics of correctly oriented microtubules
      instructs overall axonal microtubule orientation, thus enabling efficient
      long-range transport essential for neuronal functioning.
    authors:
      - name: Maximilian AH Jakobs
        orcid: http://orcid.org/0000-0002-0879-7937
      - name: Assaf Zemel
        orcid: null
      - name: Kristian Franze
        orcid: http://orcid.org/0000-0002-8425-7297
  comment:
    dislikes: 0
    thread: "8571415257"
    numReports: 0
    likes: 0
    id: "5473875496"
    createdAt: 2021-07-29T10:14:35
    author:
      username: disqus_VYxqCWKMak
      about: Working on molecular mechanisms of axon degeneration, in particular
        regulation by  NMNAT2 and SARM1
      name: Michael Coleman
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_VYxqCWKMak/
      url: https://colemanlab.brc.cam.ac.uk
      location: University of Cambridge
      id: "372971573"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      This is a really interesting article on a topic we tend to take for
      granted and then realise we (or at least I !) just hadn't thought about
      and certainly couldn't explain. Some mechanisms for microtubule polarity
      sorting in axons had been previously proposed but were recognised as being
      insufficient to fully explain the observations. Very nice original science
      with important implications for nervous system development, axon
      regeneration and neurodegenerative disease.



      <b>Summary of findings</b>



      Unlike dendrites, axons have microtubules that are almost all oriented with their growing (+) ends outwards. The mechanistic basis of this is not completely understood. Axonal microtubules are in a constant state of dynamic equilibrium, with their + ends growing but being subject to periodic ‚Äòcatastrophe‚Äô that shortens them, either by dying back from their previously growing + ends or by severing them to create two 'daughter' microtubules, each with the potential for new growth. Unlike in other cell types, axonal microtubules are not attached to the centrosome but form a tiling array along the axon composed of individual microtubules from a few microns to over 100 microns in length (see work of Peter Baas and colleagues). Some kind of relationship between this dynamic equilibrium and selection of polarity appears likely but it has been unclear what that might be.



      To understand the mechanism, Jakobs et al used live imaging of microtubules in Drosophila axons in culture, labelled with EB1-GFP, which marks the growing tip. They find that during early axon growth in culture, microtubules with their + ends oriented distally have a growth advantage over those in the opposite orientation, so that over time + end-out becomes the dominant orientation. 



      First, they show that each microtubule growth events is (on average) longer if the microtubule is further distal in a growing axon and if the microtubule is oriented + end out. The difference between + end out, and in, microtubules is more marked distally. 



      Then, they measure the shrinkage distances in these same orientations and locations using double labelling of EB1 and tubulin. They use a mathematical model to show that + end-out oriented microtubules near growing tips have essentially unbounded growth (since the average growth event is longer in distance than the average shrinkage event), while in other locations and orientations average microtubule length stabilises because of the larger contribution of shrinkage events. 




      Using two methods to disrupt microtubule polymerisation (nocodazole and increased osmolarity) they then confirmed the importance of this +/- growth difference in establishing unipolarity. They also hypothesised that microtubule growth promoting proteins locally synthesised at the axon tip, such as p150, would explain the longer growth cycles of +end out oriented microtubules there, and supported this hypothesis with p150 knockdown and dominant negative mutants. Again, removing the growth length differential also removed the orientation difference.



      Finally, they address the orientation imbalance in more proximal axon regions that is less easy to explain based on a p150 gradient. They propose a model in which dynein-mediated sliding of ‚Äì end out orientated microtubules towards the cell body, and templating of new microtubules, essentially matching existing orientation bias, could explain these differences. No additional data are presented for this part but it clearly forms a new hypothesis for further testing.



      <b>Implications</b>



      Axonal transport deficits are an important driver of axon loss and neurological deficits. For example, mutations in the anterograde motor protein KIF5A are associated with hereditary spastic paraplegia, Charcot-Marie Tooth disease and ALS, all disorders of long axon degeneration in which distal regions are affected first. Toxic blockade of axonal transport, for example in vincristine neuropathy, is also an important cause of axon damage. This article sheds light on the basic mechanisms that establish, and presumably also maintain effective, directional axonal transport. 



      Severe defects in this process of selection would be expected to result in failure of neuronal differentiation or axon growth. The likely phenotypic outcome of a severe defect would be embryonic lethality but partial defects could also occur and could therefore underlie disorders of axonal transport even if axons do initially form and carry out the process. Indeed, p150 mutations are associated with ALS. It would be really interesting to know how such mutations affect microtubule polarity and whether this underlies pathogenesis in these cases of ALS, or indeed in any other neurodegenerative disorders. It is challenging to address this in vivo, even in animal models, because of the requirement for live imaging of microtubule growth so I am not aware of any previous studies, but it is in principle an achievable aim now this mechanism has been identified.



      <b>Limitations</b>



      At present these findings are limited to Drosophila axons (seemingly dispersed starting from the entire CNS?) so it remains to be confirmed whether there are similar patterns in mammalian axons, and in different neuronal subtypes (e.g., CNS/PNS, motor/sensory, etc).



      <b>Minor suggestions for improvement</b>



      Just a presentational thing but in Fig 1E legend, would it be clearer to say ‚Äòblue, right to left downwards‚Äô than ‚Äòblue, left to right upwards‚Äô since these microtubule are in fact growing from right to left? Or probably the colour-coding explained in part D is already sufficient without this extra explanation? 



      A bit more introduction to what is templating and sliding would be helpful.



      It would be just marginally easier to follow without the switch in axon orientation between Figs 1-3 and Fig 4. But this is a minor point that perhaps just keeps our reversal learning sharp anyway!



      <b>Questions for the authors</b>



      Superficially, it could be imagined that the more stable an axonal microtubule the better, since they are so crucial for axonal transport. Yet, this is clearly not the case, otherwise the state of dynamic equilibrium would not have evolved. Does this new model for selection of orientation shed any light on what that advantage of the dynamic equilibrium is?



      Studies of shrinkage events are so far limited to shrinkage from the distal end. Is there any contribution also from severing and how could that be measured?



      If +end-out microtubules at the distal end have unbounded growth what eventually stops them? Something must do this in the end because otherwise a mature axon would be clogged with lots of microtubules extending right up to the distal tip. Is this one of the functions of severing?



      In Fig 3b and c, there seems to be not only a decrease in + end-out growth distances but an increase in the growth of ‚Äì end out microtubules. The same is true in Fig 3j and k when p150 is disrupted. Are these consistent observations and what could explain them? It would seem more likely that these interventions would disrupt microtubule growth regardless of orientation? 



      To what extent do you think similar mechanisms may operate in mature axons, or is this phenomenon limited to axon growth stages? At the very least it seems likely that they also recur during axon regeneratio but in this context it would be very interesting to know if there are CNS/PNS differences in vertebrates given the difference in axon regeneration.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.06.03.446862v1
  tweets:
    - created_at: Thu Jul 29 18:29:23 +0000 2021
      id: 1420813722315108400
      id_str: "1420813722315108356"
      text: >-
        üí¨ bioRxiv comment on "Unrestrained growth of correct..."


        "This is a really interesting article on a topic we tend‚Ä¶ https://t.co/qQiQR0gPUl
      truncated: true
      entities:
        urls:
          - url: https://t.co/qQiQR0gPUl
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 29 18:29:23 +0000 2021
      id: 1420813723216793600
      id_str: "1420813723216793604"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/2kNEHGyAC8
      truncated: false
      entities:
        urls:
          - url: https://t.co/2kNEHGyAC8
      in_reply_to_status_id: 1420813722315108400
      in_reply_to_status_id_str: "1420813722315108356"
- preprint:
    id: 151853
    metric: 21
    title: Disruption of the TCA cycle reveals an ATF4-dependent integration of
      redox and amino acid metabolism
    url: https://api.rxivist.org/v1/papers/151853
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.27.453996v1
    doi: 10.1101/2021.07.27.453996
    category: biochemistry
    first_posted: 2021-07-27
    abstract: The Tricarboxylic Acid Cycle (TCA) cycle is arguably the most critical
      metabolic cycle in physiology and exists as an essential interface
      coordinating cellular metabolism, bioenergetics, and redox homeostasis.
      Despite decades of research, a comprehensive investigation into the
      consequences of TCA cycle dysfunction remains elusive. Here, we targeted
      two TCA cycle enzymes, fumarate hydratase (FH) and succinate dehydrogenase
      (SDH), and combined metabolomics, transcriptomics, and proteomics analyses
      to fully appraise the consequences of TCA cycle inhibition (TCAi) in
      kidney epithelial cells. Our comparative approach shows that TCAi elicits
      a convergent rewiring of redox and amino acid metabolism dependent on the
      activation of ATF4 and the integrated stress response (ISR). Furthermore,
      we also uncover a divergent metabolic response, whereby acute FHi, but not
      SDHi, can maintain asparagine levels via reductive carboxylation and
      maintenance of cytosolic aspartate synthesis. Our work highlights an
      important interplay between the TCA cycle, redox biology and amino acid
      homeostasis.
    authors:
      - name: Dylan Gerard Ryan
      - name: Ming Yang
      - name: Hiran A Prag
      - name: Giovanny Rodriguez Blanco
      - name: Efterpi Nikitopoulou
      - name: Marc Segarra-Mondejar
      - name: Christopher A Powell
      - name: Tim Young
      - name: Nils Burger
      - name: Jan Lj Miljkovic
      - name: Michal Minczuk
      - name: Michael P Murphy
      - name: Alexander Von Kriegsheim
      - name: Christian Frezza
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Thu Jul 29 20:17:00 +0000 2021
      id: 1420840803988123600
      id_str: "1420840803988123656"
      text: >-
        üî• bioRxiv Biochemistry preprint by D. G. Ryan et al:


        "Disruption of the TCA cycle reveals an ATF4-dependent integr‚Ä¶ https://t.co/M29eXkOcsE
      truncated: true
      entities:
        urls:
          - url: https://t.co/M29eXkOcsE
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "107711"
    doi: 10.1101/2020.03.20.20037325
    first_posted: 2020-03-23
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.03.20.20037325v1
    url: https://api.rxivist.org/v1/papers/107711
    title: Predicting COVID-19 malignant progression with AI techniques
    category: infectious-diseases
    abstract: >-
      Background and purposeThe worldwide pandemic of coronavirus disease 2019
      (COVID-19) greatly challenges public medical systems. With limited medical
      resources, the treatment priority is determined by the severity of
      patients. However, many mild outpatients quickly deteriorate into
      severe/critical stage. It is crucial to early identify them and give
      timely treatment for optimizing treatment strategy and reducing mortality.
      This study aims to establish an AI model to predict mild patients with
      potential malignant progression.


      MethodsA total of 133 consecutively mild COVID-19 patients at admission who was hospitalized in Wuhan Pulmonary Hospital from January 3 to February 13, 2020, were selected in this retrospective IRB-approved study. All mild patients were categorized into groups with or without malignant progression. The clinical and laboratory data at admission, the first CT, and the follow-up CT at the severe/critical stage of the two groups were compared. Both multivariate logistic regression and deep learning-based methods were used to build the prediction models, with their area under ROC curves (AUC) compared.


      ResultsMultivariate logistic regression depicted 6 risk factors for malignant progression: age >55years (OR 5.334, 95%CI 1.8-15.803), comorbid with hypertension (OR 5.093, 95%CI 1.236-20.986), a decrease of albumin (OR 4.01, 95%CI 1.216-13.223), a decrease of lymphocyte (OR 3.459, 95%CI 1.067-11.209), the progressive consolidation from CT1 to CTsevere (OR 1.235, 95%CI 1.018-1.498), and elevated HCRP (OR 1.015, 95%CI 1.002-1.029); and one protective factor: the presence of fibrosis at CT1 (OR 0.656, 95%CI 0.473-0.91). By combining the clinical data and the temporal information of the CT data, our deep learning-based models achieved the best AUC of 0.954, which outperformed logistic regression (AUC: 0.893),


      ConclusionsOur deep learning-based methods can identify the mild patients who are easy to deteriorate into severe/critical cases efficiently and accurately, which undoubtedly helps to optimize the treatment strategy, reduce mortality, and relieve the medical pressure.
    authors:
      - name: Cong Fang
        orcid: null
      - name: Song Bai
        orcid: null
      - name: Qianlan Chen
        orcid: null
      - name: Yu Zhou
        orcid: http://orcid.org/0000-0002-2102-9377
      - name: Liming Xia
        orcid: null
      - name: Lixin Qin
        orcid: null
      - name: Shi Gong
        orcid: null
      - name: Xudong Xie
        orcid: null
      - name: Chunhua Zhou
        orcid: null
      - name: Dandan Tu
        orcid: null
      - name: Changzheng Zhang
        orcid: null
      - name: Xiaowu Liu
        orcid: null
      - name: Weiwei Chen
        orcid: null
      - name: Xiang Bai
        orcid: null
      - name: Philip H.S. Torr
        orcid: null
  comment:
    dislikes: 0
    thread: "8200620005"
    numReports: 0
    likes: 0
    id: "5473456849"
    createdAt: 2021-07-29T01:05:33
    author:
      username: lukezabotka
      about: ""
      name: Luke Zabotka
      isPowerContributor: false
      profileUrl: https://disqus.com/by/lukezabotka/
      url: ""
      location: ""
      id: "370352118"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "Article published: https://doi.org/10.1016/j.media.2021.102096"
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.03.20.20037325v3
  tweets:
    - created_at: Thu Jul 29 20:20:52 +0000 2021
      id: 1420841776827584500
      id_str: "1420841776827584522"
      text: |-
        üí¨ medRxiv comment on "Predicting COVID-19 malignant ..."

        "Article published: "

        https://t.co/IqhmufnCeE
      truncated: false
      entities:
        urls:
          - url: https://t.co/IqhmufnCeE
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 29 20:20:52 +0000 2021
      id: 1420841777662242800
      id_str: "1420841777662242819"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/Dp6U8rHowB
      truncated: false
      entities:
        urls:
          - url: https://t.co/Dp6U8rHowB
      in_reply_to_status_id: 1420841776827584500
      in_reply_to_status_id_str: "1420841776827584522"
- preprint:
    id: "151604"
    doi: 10.1101/2021.07.23.21261030
    first_posted: 2021-07-26
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.23.21261030v1
    url: https://api.rxivist.org/v1/papers/151604
    title: "Breakthrough Symptomatic COVID-19 Infections Leading to Long Covid:
      Report from Long Covid Facebook Group Poll"
    category: epidemiology
    abstract: Vaccines have been shown to be extremely effective in preventing
      COVID-19 hospitalizations and deaths. However, a question remains whether
      vaccine breakthrough cases can still lead to Post-Acute Sequelae of
      SARS-CoV-2 (PASC), also known as Long Covid. To address this question, the
      Survivor Corps group, a grassroots COVID-19 organization focused on
      patient support and research, posted a poll to its 169,900 members that
      asked about breakthrough cases, Long Covid, and hospitalizations. 1,949
      people who self-report being fully vaccinated have responded to date.
      While robust data are needed in a larger, unbiased sample to extrapolate
      rates to the population, we analyzed the results of this public poll to
      determine what people were reporting regarding Long Covid after
      breakthrough infection and to prompt discussion of how breakthrough cases
      are measured. The poll was posted in the Survivor Corps Facebook group
      (~169,900 members). Of the 1,949 participants who responded to the poll,
      44 reported a symptomatic breakthrough case and 24 of those reported that
      the case led to symptoms of Long Covid. 1 of these 24 cases was reported
      to have led to hospitalization in addition to Long Covid.
    authors:
      - name: Daisy Massey
        orcid: http://orcid.org/0000-0002-9922-7808
      - name: Diana Berrent
        orcid: null
      - name: Harlan Krumholz
        orcid: http://orcid.org/0000-0003-2046-127X
  comment:
    dislikes: 0
    thread: "8672605173"
    numReports: 0
    likes: 0
    id: "5474313521"
    createdAt: 2021-07-29T17:01:13
    author:
      username: disqus_ahb8GdlFBK
      about: ""
      name: Jodi Schneider
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_ahb8GdlFBK/
      url: ""
      location: ""
      id: "373017327"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: An Israeli study of healthcare workers published in NEJM says "Most
      breakthrough cases were mild or asymptomatic, although 19% had persistent
      symptoms (>6 weeks)." http://doi.org/10.1056/NEJMoa2109072
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.07.23.21261030v1
  tweets:
    - created_at: Thu Jul 29 22:20:56 +0000 2021
      id: 1420871995860955100
      id_str: "1420871995860955139"
      text: >-
        üí¨ medRxiv comment on "Breakthrough Symptomatic COVID..."


        "An Israeli study of healthcare workers published in NEJM‚Ä¶ https://t.co/QWAsp0th8E
      truncated: true
      entities:
        urls:
          - url: https://t.co/QWAsp0th8E
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jul 29 22:20:57 +0000 2021
      id: 1420871996812968000
      id_str: "1420871996812967938"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/ybCOwnzNCx
      truncated: false
      entities:
        urls:
          - url: https://t.co/ybCOwnzNCx
      in_reply_to_status_id: 1420871995860955100
      in_reply_to_status_id_str: "1420871995860955139"
- preprint:
    id: "151888"
    doi: 10.1101/2021.07.28.21261159
    first_posted: 2021-07-28
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.28.21261159v1
    url: https://api.rxivist.org/v1/papers/151888
    title: Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
    category: infectious-diseases
    abstract: "Background: BNT162b2 is a lipid nanoparticle-formulated,
      nucleoside-modified RNA vaccine encoding a prefusion-stabilized,
      membrane-anchored SARS-CoV-2 full-length spike protein. BNT162b2 is highly
      efficacious against COVID-19 and is currently authorized for emergency use
      or conditional approval worldwide. At the time of authorization, data
      beyond 2 months post-vaccination were unavailable. Methods: In an ongoing,
      placebo-controlled, observer-blinded, multinational, pivotal efficacy
      study, 44,165 [&ge;]16-year-old participants and 2,264 12-15-year-old
      participants were randomized to receive 2 doses, 21 days apart, of 30 g
      BNT162b2 or placebo. Study endpoints reported here are vaccine efficacy
      (VE) against laboratory-confirmed COVID-19 and safety data, both up to 6
      months post-vaccination. Results: BNT162b2 continued to be safe and well
      tolerated. Few participants had adverse events leading to study
      withdrawal. VE against COVID-19 was 91% (95% CI 89.0-93.2) through up to 6
      months of follow-up, among evaluable participants and irrespective of
      previous SARS-CoV-2 infection. VE of 86%-100% was seen across countries
      and in populations with diverse characteristics of age, sex,
      race/ethnicity, and COVID-19 risk factors in participants without evidence
      of previous SARS-CoV-2 infection. VE against severe disease was 97% % (95%
      CI 80.3-99.9). In South Africa, where the SARS-CoV-2 variant of concern,
      B.1.351 (beta), was predominant, 100% (95% CI 53.5, 100.0) VE was
      observed. Conclusion: With up to 6 months of follow-up and despite a
      gradually declining trend in vaccine efficacy, BNT162b2 had a favorable
      safety profile and was highly efficacious in preventing COVID-19.
      (ClinicalTrials.gov number, NCT04368728)"
    authors:
      - name: Stephen J. Thomas
        orcid: null
      - name: Edson D Moreira
        orcid: null
      - name: Nicholas Kitchin
        orcid: null
      - name: Judith Absalon
        orcid: http://orcid.org/0000-0002-1091-520X
      - name: Alejandra Gurtman
        orcid: null
      - name: Stephen Lockhart
        orcid: null
      - name: John L Perez
        orcid: null
      - name: Gonzalo P√©rez Marc
        orcid: null
      - name: Fernando P. Polack
        orcid: http://orcid.org/0000-0002-8432-9158
      - name: Cristiano Zerbini
        orcid: null
      - name: Ruth Bailey
        orcid: null
      - name: Kena A. Swanson
        orcid: null
      - name: Xia Xu
        orcid: null
      - name: Satrajit Roychoudhury
        orcid: null
      - name: Kenneth Koury
        orcid: null
      - name: Salim Bouguermouh
        orcid: null
      - name: Warren V. Kalina
        orcid: null
      - name: David Cooper
        orcid: null
      - name: Robert W Frenck
        orcid: null
      - name: Laura L. Hammitt
        orcid: http://orcid.org/0000-0001-6051-1484
      - name: √ñzlem T√ºreci
        orcid: null
      - name: Haylene Nell
        orcid: null
      - name: Axel Schaefer
        orcid: null
      - name: Serhat √únal
        orcid: null
      - name: Qi Yang
        orcid: http://orcid.org/0000-0003-4308-4382
      - name: Paul Liberator
        orcid: null
      - name: Dina B Tresnan
        orcid: null
      - name: Susan Mather
        orcid: null
      - name: Philip R. Dormitzer
        orcid: http://orcid.org/0000-0003-0671-6360
      - name: Uƒüur ≈ûahin
        orcid: null
      - name: William C. Gruber
        orcid: null
      - name: Kathrin U. Jansen
        orcid: null
      - name: C4591001 Clinical Trial Group
        orcid: null
  comment:
    dislikes: 0
    thread: "8677270016"
    numReports: 0
    likes: 1
    id: "5474205743"
    createdAt: 2021-07-29T15:40:59
    author:
      username: peter_p_v
      about: ""
      name: Peter P.V
      isPowerContributor: false
      profileUrl: https://disqus.com/by/peter_p_v/
      url: ""
      location: ""
      id: "373014078"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Every six month new vaccine will have to be developed. Is it possible?
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1
  tweets:
    - created_at: Fri Jul 30 01:05:43 +0000 2021
      id: 1420913460892868600
      id_str: "1420913460892868608"
      text: >-
        üí¨ medRxiv comment on "Six Month Safety and Efficacy ..."


        "Every six month new vaccine will have to be developed. I‚Ä¶ https://t.co/9yaIrUfG5F
      truncated: true
      entities:
        urls:
          - url: https://t.co/9yaIrUfG5F
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 30 01:05:43 +0000 2021
      id: 1420913461845012500
      id_str: "1420913461845012483"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/m0cKLPNLDg
      truncated: false
      entities:
        urls:
          - url: https://t.co/m0cKLPNLDg
      in_reply_to_status_id: 1420913460892868600
      in_reply_to_status_id_str: "1420913460892868608"
- preprint:
    id: "151888"
    doi: 10.1101/2021.07.28.21261159
    first_posted: 2021-07-28
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.07.28.21261159v1
    url: https://api.rxivist.org/v1/papers/151888
    title: Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
    category: infectious-diseases
    abstract: "Background: BNT162b2 is a lipid nanoparticle-formulated,
      nucleoside-modified RNA vaccine encoding a prefusion-stabilized,
      membrane-anchored SARS-CoV-2 full-length spike protein. BNT162b2 is highly
      efficacious against COVID-19 and is currently authorized for emergency use
      or conditional approval worldwide. At the time of authorization, data
      beyond 2 months post-vaccination were unavailable. Methods: In an ongoing,
      placebo-controlled, observer-blinded, multinational, pivotal efficacy
      study, 44,165 [&ge;]16-year-old participants and 2,264 12-15-year-old
      participants were randomized to receive 2 doses, 21 days apart, of 30 g
      BNT162b2 or placebo. Study endpoints reported here are vaccine efficacy
      (VE) against laboratory-confirmed COVID-19 and safety data, both up to 6
      months post-vaccination. Results: BNT162b2 continued to be safe and well
      tolerated. Few participants had adverse events leading to study
      withdrawal. VE against COVID-19 was 91% (95% CI 89.0-93.2) through up to 6
      months of follow-up, among evaluable participants and irrespective of
      previous SARS-CoV-2 infection. VE of 86%-100% was seen across countries
      and in populations with diverse characteristics of age, sex,
      race/ethnicity, and COVID-19 risk factors in participants without evidence
      of previous SARS-CoV-2 infection. VE against severe disease was 97% % (95%
      CI 80.3-99.9). In South Africa, where the SARS-CoV-2 variant of concern,
      B.1.351 (beta), was predominant, 100% (95% CI 53.5, 100.0) VE was
      observed. Conclusion: With up to 6 months of follow-up and despite a
      gradually declining trend in vaccine efficacy, BNT162b2 had a favorable
      safety profile and was highly efficacious in preventing COVID-19.
      (ClinicalTrials.gov number, NCT04368728)"
    authors:
      - name: Stephen J. Thomas
        orcid: null
      - name: Edson D Moreira
        orcid: null
      - name: Nicholas Kitchin
        orcid: null
      - name: Judith Absalon
        orcid: http://orcid.org/0000-0002-1091-520X
      - name: Alejandra Gurtman
        orcid: null
      - name: Stephen Lockhart
        orcid: null
      - name: John L Perez
        orcid: null
      - name: Gonzalo P√©rez Marc
        orcid: null
      - name: Fernando P. Polack
        orcid: http://orcid.org/0000-0002-8432-9158
      - name: Cristiano Zerbini
        orcid: null
      - name: Ruth Bailey
        orcid: null
      - name: Kena A. Swanson
        orcid: null
      - name: Xia Xu
        orcid: null
      - name: Satrajit Roychoudhury
        orcid: null
      - name: Kenneth Koury
        orcid: null
      - name: Salim Bouguermouh
        orcid: null
      - name: Warren V. Kalina
        orcid: null
      - name: David Cooper
        orcid: null
      - name: Robert W Frenck
        orcid: null
      - name: Laura L. Hammitt
        orcid: http://orcid.org/0000-0001-6051-1484
      - name: √ñzlem T√ºreci
        orcid: null
      - name: Haylene Nell
        orcid: null
      - name: Axel Schaefer
        orcid: null
      - name: Serhat √únal
        orcid: null
      - name: Qi Yang
        orcid: http://orcid.org/0000-0003-4308-4382
      - name: Paul Liberator
        orcid: null
      - name: Dina B Tresnan
        orcid: null
      - name: Susan Mather
        orcid: null
      - name: Philip R. Dormitzer
        orcid: http://orcid.org/0000-0003-0671-6360
      - name: Uƒüur ≈ûahin
        orcid: null
      - name: William C. Gruber
        orcid: null
      - name: Kathrin U. Jansen
        orcid: null
      - name: C4591001 Clinical Trial Group
        orcid: null
  comment:
    dislikes: 0
    thread: "8677270016"
    numReports: 0
    likes: 1
    id: "5474269194"
    createdAt: 2021-07-29T16:28:46
    author:
      username: disqus_enkiWv8Jnr
      about: ""
      name: aep
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_enkiWv8Jnr/
      url: ""
      location: ""
      id: "373015946"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: link to competing interest statement broken
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1
  tweets:
    - created_at: Fri Jul 30 12:32:48 +0000 2021
      id: 1421086371033329700
      id_str: "1421086371033329664"
      text: |-
        üí¨ medRxiv comment on "Six Month Safety and Efficacy ..."

        "link to competing interest statement broken"

        https://t.co/fnrzADpGfT
      truncated: false
      entities:
        urls:
          - url: https://t.co/fnrzADpGfT
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 30 12:32:48 +0000 2021
      id: 1421086371662471200
      id_str: "1421086371662471177"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/m0cKLPNLDg
      truncated: false
      entities:
        urls:
          - url: https://t.co/m0cKLPNLDg
      in_reply_to_status_id: 1421086371033329700
      in_reply_to_status_id_str: "1421086371033329664"
- preprint:
    id: "130004"
    doi: 10.1101/2021.02.26.21252096
    first_posted: 2021-03-08
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.02.26.21252096v1
    url: https://api.rxivist.org/v1/papers/130004
    title: "Self-reported real-world safety and reactogenicity of COVID-19 vaccines:
      An international vaccine-recipient survey."
    category: public-and-global-health
    abstract: "Background: The safety of COVID-19 vaccines has been demonstrated in
      selected populations in recent studies, but more data in specific groups
      is needed to inform vaccine choice and health policy. Objectives: An
      international, online survey was conducted to compare the safety,
      tolerability and reactogenicity of available COVID-19 vaccines in
      different recipient groups. Methods: This survey was launched in February
      2021, for 11 days. Recipients of a first COVID-19 vaccine dose [&ge;]7
      days prior to survey completion were eligible. The incidence and severity
      of vaccination side effects were assessed. Results: Survey was completed
      by 2,002 respondents, of whom 26.6% had prior COVID-19 infection (68.8%
      laboratory confirmed). Prior COVID-19 infection was associated with
      increased risk of any side effect (risk ratio 1.08, 95% confidence
      intervals [1.05-1.11]), fever (2.24 [1.86-2.70]), breathlessness (2.05
      [1.28-3.29]), flu-like illness (1.78 [1.51-2.10]), fatigue (1.34
      [1.20-1.49]) and local reactions (1.10 [1.06-1.15]). It was also
      associated with increased risk of severe side effects, leading to hospital
      care (1.56 [1.14-2.12]). While mRNA vaccines were associated with a higher
      incidence of any side effect (1.06 [1.01-1.11]) compared to viral
      vector-based vaccines, these were generally milder (p<0.001), mostly local
      reactions. Importantly, mRNA vaccine-recipients reported considerably
      lower incidence of systemic reactions (RR<0.6) including anaphylaxis,
      swelling, flu-like illness, breathlessness and fatigue, and of side
      effects requiring hospital care (0.42 [0.31-0.58]). Conclusion: For the
      first time, our study links prior COVID-19 illness with increased
      incidence of vaccination side effects and demonstrates that mRNA vaccines
      cause milder, less frequent systemic side effects, but more local
      reactions."
    authors:
      - name: Alexander G. Mathioudakis
        orcid: http://orcid.org/0000-0002-4675-9616
      - name: Murad Ghrew
        orcid: null
      - name: Andrew Ustianowski
        orcid: null
      - name: Shazaad Ahmad
        orcid: http://orcid.org/0000-0002-0400-8937
      - name: Ray Borrow
        orcid: http://orcid.org/0000-0002-0691-6568
      - name: Lida Pieretta Papavasileiou
        orcid: null
      - name: Dimitrios Petrakis
        orcid: null
      - name: Nawar Diar Bakerly
        orcid: http://orcid.org/0000-0003-2102-1997
  comment:
    dislikes: 0
    thread: "8428482931"
    numReports: 0
    likes: 0
    id: "5475006983"
    createdAt: 2021-07-30T02:26:52
    author:
      username: tobydelamo
      about: Schoolteacher and Supermom
      name: tobydelamo
      isPowerContributor: false
      profileUrl: https://disqus.com/by/tobydelamo/
      url: ""
      location: Seattle
      id: "116798296"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: Unfortunately, publishing this is going to increase vaccine
      hesitancy among those with prior covid illness. Not sure this is something
      that should have been studied...
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.02.26.21252096v1
  tweets:
    - created_at: Fri Jul 30 14:22:26 +0000 2021
      id: 1421113964906172400
      id_str: "1421113964906172418"
      text: >-
        üí¨ medRxiv comment on "Self-reported real-world safet..."


        "Unfortunately, publishing this is going to increase vacc‚Ä¶ https://t.co/2tboezNplK
      truncated: true
      entities:
        urls:
          - url: https://t.co/2tboezNplK
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 30 14:22:27 +0000 2021
      id: 1421113965954826200
      id_str: "1421113965954826246"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/iDH6QN3LFS
      truncated: false
      entities:
        urls:
          - url: https://t.co/iDH6QN3LFS
      in_reply_to_status_id: 1421113964906172400
      in_reply_to_status_id_str: "1421113964906172418"
- preprint:
    id: "149465"
    doi: 10.1101/2021.07.07.451145
    first_posted: 2021-07-09
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.07.451145v1
    url: https://api.rxivist.org/v1/papers/149465
    title: A geospatial mapping pipeline for ecologists
    category: ecology
    abstract: Geospatial modelling can give fundamental insights in the biogeography
      of life, providing key information about the living world in current and
      future climate scenarios. Emerging statistical and machine learning
      approaches can help us to generate new levels of predictive accuracy in
      exploring the spatial patterns in ecological and biophysical processes.
      Although these statistical models cannot necessarily represent the
      essential mechanistic insights that are needed to understand global
      biogeochemical processes under ever-changing environmental conditions,
      they can provide unparalleled predictive insights that can be useful for
      exploring the variation in biophysical processes across space. As such,
      these emerging tools can be a valuable approach to complement existing
      mechanistic approaches as we aim to understand the biogeography of Earth's
      ecosystems. Here, we present a comprehensive methodology that efficiently
      handles large datasets to produce global predictions. This mapping
      pipeline can be used to generate quantitative, spatially explicit
      predictions, with a particular emphasis on spatially-explicit insights
      into the evaluation of model uncertainties and inaccuracies.
    authors:
      - name: Johan van den Hoogen
        orcid: http://orcid.org/0000-0001-6624-8461
      - name: Niamh Robmann
        orcid: null
      - name: Devin Routh
        orcid: null
      - name: Thomas Lauber
        orcid: null
      - name: Nina van Tiel
        orcid: null
      - name: Olga Danylo
        orcid: null
      - name: Thomas W. Crowther
        orcid: http://orcid.org/0000-0001-5674-8913
  comment:
    dislikes: 0
    thread: "8638855821"
    numReports: 0
    likes: 0
    id: "5475317413"
    createdAt: 2021-07-30T11:03:02
    author:
      username: pedrochake
      about: ""
      name: pedro chake
      isPowerContributor: false
      profileUrl: https://disqus.com/by/pedrochake/
      url: ""
      location: ""
      id: "373059591"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: It is really worrying for science to see so many of these papers
      simply denying all what constitute good science. ALL good works are
      ignored, do the authors really think that they are the first doing mapping
      and ecological modelling?
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.07.07.451145v1
  tweets:
    - created_at: Fri Jul 30 16:31:22 +0000 2021
      id: 1421146409781366800
      id_str: "1421146409781366787"
      text: >-
        üí¨ bioRxiv comment on "A geospatial mapping pipeline ..."


        "It is really worrying for science to see so many of thes‚Ä¶ https://t.co/939yWqF6BC
      truncated: true
      entities:
        urls:
          - url: https://t.co/939yWqF6BC
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 30 16:31:22 +0000 2021
      id: 1421146410641207300
      id_str: "1421146410641207303"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/5WqN8O13q4
      truncated: false
      entities:
        urls:
          - url: https://t.co/5WqN8O13q4
      in_reply_to_status_id: 1421146409781366800
      in_reply_to_status_id_str: "1421146409781366787"
- preprint:
    id: "151960"
    doi: 10.1101/2021.07.28.453864
    first_posted: 2021-07-28
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.28.453864v1
    url: https://api.rxivist.org/v1/papers/151960
    title: The epithelial-specific ER stress sensor IRE1Œ≤ enables host-microbiota
      crosstalk to affect colon goblet cell development
    category: cell-biology
    abstract: Epithelial cells lining mucosal surfaces of the gastrointestinal and
      respiratory tracts uniquely express IRE1{beta} (Ern2), a paralogue of the
      most evolutionarily conserved endoplasmic reticulum stress sensor IRE1.
      How IRE1{beta} functions at the host-environment interface and why a
      second IRE1 paralogue evolved remain incompletely understood. Using
      conventionally raised and germ-free Ern2-/- mice, we found that IRE1{beta}
      was required for microbiota-induced goblet cell maturation and mucus
      barrier assembly in the colon. This occurred only after colonization of
      the alimentary tract with normal gut microflora, which induced IRE1{beta}
      expression. IRE1{beta} acted by splicing Xbp1 mRNA to expand ER function
      and prevent ER stress in goblet cells. Although IRE1 can also splice Xbp1
      mRNA, it did not act redundantly to IRE1{beta} in this context. By
      regulating assembly of the colon mucus layer, IRE1{beta} further shaped
      the composition of the gut microbiota. Mice lacking IRE1{beta} had a
      dysbiotic microbial community that failed to induce goblet cell
      development when transferred into germ-free wild type mice. These results
      show that IRE1{beta} evolved at mucosal surfaces to mediate crosstalk
      between gut microbes and the colonic epithelium required for normal
      homeostasis and host defense.
    authors:
      - name: Michael J. Grey
        orcid: http://orcid.org/0000-0001-7805-7398
      - name: Heidi De Luca
        orcid: null
      - name: Doyle V Ward
        orcid: null
      - name: Irini A. M. Kreulen
        orcid: null
      - name: Sage E. Foley
        orcid: null
      - name: Jay R Thiagarajah
        orcid: null
      - name: Beth A. McCormick
        orcid: null
      - name: Jerrold R Turner
        orcid: http://orcid.org/0000-0003-0627-9455
      - name: Wayne I Lencer
        orcid: http://orcid.org/0000-0001-7346-2730
  comment:
    dislikes: 0
    thread: "8678433824"
    numReports: 0
    likes: 0
    id: "5475282819"
    createdAt: 2021-07-30T10:11:56
    author:
      username: disqus_JNVBDeaHLu
      about: ""
      name: David Ron
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_JNVBDeaHLu/
      url: https://ron.cimr.cam.ac.uk
      location: University of Cambridge, United Kingdom
      id: "292386302"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      This study takes on the interesting question of mouse Ern2's role in
      goblet cell development and function, mucous layer integrity and the
      intestinal host-microbe interface.

      The emphasis, understandably, is on the mechanistic basis of the fitness-benefit arising from the duplication of the ancestral gene that gave rise to the two ERN paralogues: the broadly expressed ERN1 and mucous producing secretory epithelium-selective ERN2 of vertebrates.

      The finding that epithelial-selective depletion of mouse Xbp1, phenocopies the consequences of germline deletion of Ern2 is taken as evidence that Ern2 exerts at least some of its effects in goblet cells, via XBP1 - an effector common to the products of both ERN genes (IRE1a and IRE1b). This conclusion is plausible, but the data presented in figure 1A and 3A also suggests that the consequences of XBP1 depletion in terms of Alcian Blue positive cell number are 2X more severe than those of Ern2 deletion (~0.17 cells per crypt in wildtype, versus ~0.12 in the Ern2‚àÜ and ~0.06 in the XBP1‚àÜ). This may arise from XBP1 having a broad role in tissue development, with secondary consequences on goblet cells, but may also arise from a contribution of IRE1a (the product of the Ern1 gene) to XBP1 splicing in goblet cells - in other words reflecting functional redundancy between the two ERN isoforms in mucous producing cells. The latter possibility seems at odds with the emphasis in the abstracts on non-redundancy of the two isoforms, which suggests important qualitative differences between the two, whereas the two genes may in fact be pullin.g in the same direction, in so far as their effector functions are concerned.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.07.28.453864v1
  tweets:
    - created_at: Fri Jul 30 18:24:40 +0000 2021
      id: 1421174923825926100
      id_str: "1421174923825926147"
      text: >-
        üí¨ bioRxiv comment on "The epithelial-specific ER str..."


        "This study takes on the interesting question of mouse Er‚Ä¶ https://t.co/EzYLuUNDBz
      truncated: true
      entities:
        urls:
          - url: https://t.co/EzYLuUNDBz
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 30 18:24:40 +0000 2021
      id: 1421174924710973400
      id_str: "1421174924710973446"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/F7h2hElncP
      truncated: false
      entities:
        urls:
          - url: https://t.co/F7h2hElncP
      in_reply_to_status_id: 1421174923825926100
      in_reply_to_status_id_str: "1421174923825926147"
- preprint:
    id: 150837
    metric: 8
    title: Spontaneous emergence of multicellular heritability
    url: https://api.rxivist.org/v1/papers/150837
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.07.19.452990v1
    doi: 10.1101/2021.07.19.452990
    category: evolutionary-biology
    first_posted: 2021-07-20
    abstract: The Major Transitions in evolution include events and processes that
      result in the emergence of new levels of biological individuality. For
      collectives to undergo Darwinian evolution, their traits must be
      heritable, but the emergence of higher-level heritability is poorly
      understood and has long been considered a stumbling block for nascent
      evolutionary transitions. A change in the means by which genetic
      information is utilized and transmitted has been presumed necessary. Using
      analytical models, synthetic biology, and biologically-informed
      simulations, we explored the emergence of trait heritability during the
      evolution of multicellularity. Contrary to existing theory, we show that
      no additional layer of genetic regulation is necessary for traits of
      nascent multicellular organisms to become heritable; rather, heritability
      and the capacity to respond to natural selection on multicellular-level
      traits can arise ''for free.'' In fact, we find that a key emergent
      multicellular trait, organism size at reproduction, is usually more
      heritable than the underlying cell-level trait upon which it is based,
      given reasonable assumptions.
    authors:
      - name: Seyed Alireza Zamani-Dahaj
      - name: Anthony Burnetti
      - name: Thomas Day
      - name: william C Ratcliff
      - name: Peter J. Yunker
      - name: Matthew D Herron
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Fri Jul 30 20:16:05 +0000 2021
      id: 1421202963389841400
      id_str: "1421202963389841408"
      text: |-
        üî• bioRxiv Evolutionary-biology preprint by S. A. Zamani-Dahaj et al:

        "Spontaneous emergence of multicellular herit‚Ä¶ https://t.co/Ir8KorUPND
      truncated: true
      entities:
        urls:
          - url: https://t.co/Ir8KorUPND
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "144019"
    doi: 10.1101/2021.05.28.446065
    first_posted: 2021-05-30
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.28.446065v1
    url: https://api.rxivist.org/v1/papers/144019
    title: No evidence of human genome integration of SARS-CoV-2 found by long-read
      DNA sequencing
    category: genomics
    abstract: A recent study proposed severe acute respiratory syndrome coronavirus
      2 (SARS-CoV-2) hijacks the LINE-1 (L1) retrotransposition machinery to
      integrate into the DNA of infected cells. If confirmed, this finding could
      have significant clinical implications. Here, we applied deep (>50x)
      long-read Oxford Nanopore Technologies (ONT) sequencing to HEK293T cells
      infected with SARS-CoV-2, and did not find the virus integrated into the
      genome. By examining ONT data from separate HEK293T cultivars, we
      completely resolved 78 L1 insertions arising in vitro in the absence of L1
      overexpression systems. ONT sequencing applied to hepatitis B virus (HBV)
      positive liver cancer tissues located a single HBV insertion. These
      experiments demonstrate reliable resolution of retrotransposon and
      exogenous virus insertions via ONT sequencing. That we found no evidence
      of SARS-CoV-2 integration suggests such events are, at most, extremely
      rare in vivo, and therefore are unlikely to drive oncogenesis or explain
      post-recovery detection of the virus.
    authors:
      - name: Nathan Smits
        orcid: null
      - name: Jay Rasmussen
        orcid: null
      - name: Gabriela O. Bodea
        orcid: null
      - name: Alberto A Amarilla
        orcid: null
      - name: Patricia Gerdes
        orcid: null
      - name: Francisco J. Sanchez-Luque
        orcid: http://orcid.org/0000-0003-1138-6124
      - name: Prabha Ajjikuttira
        orcid: null
      - name: Naphak Modhiran
        orcid: null
      - name: Benjamin Liang
        orcid: null
      - name: Jamila Faivre
        orcid: null
      - name: Ira W Deveson
        orcid: http://orcid.org/0000-0003-3861-0472
      - name: Alexander A Khromykh
        orcid: http://orcid.org/0000-0001-6206-6935
      - name: Daniel Watterson
        orcid: null
      - name: Adam D Ewing
        orcid: http://orcid.org/0000-0002-4544-994X
      - name: Geoffrey J Faulkner
        orcid: http://orcid.org/0000-0001-5769-4494
  comment:
    dislikes: 0
    thread: "8666697743"
    numReports: 0
    likes: 0
    id: "5475794309"
    createdAt: 2021-07-30T18:01:48
    author:
      name: Andreas Martin Lisewski
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: >-
      Central to the authors‚Äô conclusions is their Fig. 3A (middle panel) which,
      however, is misleading: by including the y-axis origin (0) the authors
      unrealistically imply that they had an unlimited number n of ONT sequence
      reads. 

      While apparently they do not report this number for their own experiments, it can be estimated from their Table S1 (n ~ Yield/N50).



      It then follows that in Fig. 3A (middle) their data only gives a non-zero upper bound (< 1/n) for the ‚ÄúProportion of total ONT sequence (%)‚Äù, which here becomes about two orders of magnitude smaller than the levels reported by Zhang et al. (to which they directly compare).



      In summary, their main message then boils down to the following: without strong over-expression of L1 (as done in Zhang et al.), and without proper controls of other relevant virus/host factors, the fraction of candidate SARS-CoV-2 genomic integration events observed is about two orders of magnitude smaller than the one reported Zhang et al.



      This finding certainly does not invalidate (or ‚Äúcontradict") the important and far-reaching result reported by the Jaenisch group.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.05.28.446065v2
  tweets:
    - created_at: Fri Jul 30 20:19:49 +0000 2021
      id: 1421203903538946000
      id_str: "1421203903538946056"
      text: >-
        üí¨ bioRxiv comment on "No evidence of human genome in..."


        "Central to the authors‚Äô conclusions is their Fig. 3A (mi‚Ä¶ https://t.co/g8mrFI4u7Z
      truncated: true
      entities:
        urls:
          - url: https://t.co/g8mrFI4u7Z
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 30 20:19:50 +0000 2021
      id: 1421203904428134400
      id_str: "1421203904428134407"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/9PATjBrxnV
      truncated: false
      entities:
        urls:
          - url: https://t.co/9PATjBrxnV
      in_reply_to_status_id: 1421203903538946000
      in_reply_to_status_id_str: "1421203903538946056"
- preprint:
    id: "55658"
    doi: 10.1101/700237
    first_posted: 2019-07-14
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/700237v1
    url: https://api.rxivist.org/v1/papers/55658
    title: Can the microbiome influence host evolutionary trajectories?
    category: evolutionary-biology
    abstract: The microbiome shapes many traits in hosts, but we still do not
      understand how it influences host evolution. To impact host evolution, the
      microbiome must be heritable and have phenotypic effects on the host.
      However, the complex inheritance and context-dependence of the microbiome
      challenges traditional models of organismal evolution. Here, we take a
      multifaceted approach to identify conditions in which the microbiome
      influences host evolutionary trajectories. We explore quantitative genetic
      models to highlight how microbial inheritance and phenotypic effects can
      modulate host evolutionary responses to selection. We synthesize the
      literature across diverse taxa to find common scenarios of microbiome
      driven host evolution. First, hosts may leverage locally adapted microbes,
      increasing survivorship in stressful environments. Second, microbial
      variation may increase host phenotypic variation, enabling exploration of
      novel fitness landscapes. We further illustrate these effects by
      performing a meta-analysis of artificial selection in Drosophila, finding
      that bacterial diversity also frequently responds to host selection. We
      conclude by outlining key avenues of research and experimental procedures
      to improve our understanding of the complex interplay between hosts and
      microbiomes. By synthesizing perspectives through multiple conceptual and
      analytical approaches, we show how microbiomes can influence the
      evolutionary trajectories of hosts.
    authors:
      - name: Lucas P. Henry
        orcid: http://orcid.org/0000-0002-3130-4643
      - name: Marjolein Bruijning
        orcid: null
      - name: Simon K.G. Forsberg
        orcid: null
      - name: Julien F. Ayroles
        orcid: null
  comment:
    dislikes: 0
    thread: "7531999502"
    numReports: 0
    likes: 0
    id: "5474574647"
    createdAt: 2021-07-29T20:22:05
    author:
      username: umueller
      about: ""
      name: umueller
      isPowerContributor: false
      profileUrl: https://disqus.com/by/umueller/
      url: ""
      location: ""
      id: "4531288"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: "Box 1, left column, last paragraph: S is the selection
      differential, not the selection coefficient"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/700237v1
  tweets:
    - created_at: Fri Jul 30 22:19:27 +0000 2021
      id: 1421234009372307500
      id_str: "1421234009372307457"
      text: >-
        üí¨ bioRxiv comment on "Can the microbiome influence h..."


        "Box 1, left column, last paragraph: S is the selection d‚Ä¶ https://t.co/obUYfz4cNi
      truncated: true
      entities:
        urls:
          - url: https://t.co/obUYfz4cNi
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jul 30 22:19:27 +0000 2021
      id: 1421234010282504200
      id_str: "1421234010282504195"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/nxfIRx60Wr
      truncated: false
      entities:
        urls:
          - url: https://t.co/nxfIRx60Wr
      in_reply_to_status_id: 1421234009372307500
      in_reply_to_status_id_str: "1421234009372307457"
- preprint:
    id: "148434"
    doi: 10.1101/2021.06.28.21259039
    first_posted: 2021-07-02
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.28.21259039v1
    url: https://api.rxivist.org/v1/papers/148434
    title: COVID-19 vaccines and evidence-based medicine
    category: public-and-global-health
    abstract: OBJECTIVE To clarify efficacy, effectiveness, and harm of available
      vaccines for COVID-19, using measures in evidence-based medicine (EBM)
      that, in addition to relative risk reduction, consider absolute risk
      reduction and variations in baseline risks. DESIGN Systematic review of
      studies that have considered impacts of vaccines in relation to baseline
      risks. Calculation of risk reduction and harms from published data in two
      random controlled trials and one population-based implementation study.
      Analysis of risk reductions in geographical areas with varying baseline
      risks. Comparison of results concerning COVID-19 vaccine and selected
      prior vaccines. SETTING Random controlled trials of Pfizer and Moderna
      vaccines in multiple countries; population-based study using Pfizer
      vaccine in Israel. Counties with varying baseline risks in the United
      States; states with varying baseline risks in India. PARTICIPANTS 43,448
      and 30,420 subjects in the random controlled trials; 1,198,236 subjects in
      the population-based study. INTERVENTIONS Multi-site random controlled
      trials of vaccine efficacy; population-based administration of vaccine
      with determination of effectiveness by comparison of vaccinated and
      unvaccinated subjects. MAIN OUTCOME MEASURES Relative risk reduction
      (RRR), absolute risk reduction (ARR), number needed to be vaccinated to
      prevent one symptomatic infection (NNV), absolute risk of the intervention
      (ARI), and number needed to harm (NNH). RESULTS A systematic review of
      literature in medicine and public health showed very few reports regarding
      ARR, NNV, ARI, and NNH; use of these indicators to compare benefits versus
      harms; or analysis of these EBM indicators in the context of varying
      baseline risks. From data in the two random controlled trials and one
      population-based study, calculated ARR was approximately 1 percent (as
      compared to RRR of 50 to 95 percent), and NNV was in the range of 100 to
      500. In comparisons of ARR and NNV versus ARI and NNH, benefits and harms
      were not markedly different. From a sensitivity analysis of ARR and NNV in
      population groups with varying baseline risks, the effectiveness of
      vaccines as measured by ARR and NNV was substantially higher in regions
      with high as compared to low baseline risks. The ARR for COVID-19 vaccines
      was somewhat smaller and the NNV somewhat larger than achieved by some
      vaccines to prevent influenza and smallpox. CONCLUSION The efficacy and
      effectiveness of major COVID-19 vaccines, as measured by RRR, are
      impressive. As measured by ARR and NNV, which take into account variation
      in baseline risks, the effectiveness of the vaccines is substantially
      higher in areas with higher baseline risks. This finding can contribute to
      educational efforts, informed consent procedures, and policy making about
      priorities for vaccine distribution, especially under conditions of access
      barriers linked to poverty and inequality. WHAT IS ALREADY KNOWN ON THIS
      TOPIC Major COVID-19 vaccines so far have shown impressive efficacy in
      random controlled trials and effectiveness in population-based studies. To
      determine efficacy and effectiveness, these studies have used relative
      risk reduction (RRR), which shows the difference in event rate between
      those receiving and not receiving a vaccine. Reports of efficacy and
      effectiveness have not yet clarified other key indicators from
      evidence-based medicine (EBM) that consider variations baseline risks.
      Such indicators include measures of benefits such as absolute risk
      reduction (ARR) and number needed to be vaccinated (NNV), as well as
      measures of harm such as absolute risk of the intervention (ARI) and
      number needed to harm (NNH). WHAT THIS STUDY ADDS For COVID-19 vaccines,
      calculated ARR is somewhat lower and NNV somewhat higher than for certain
      prior vaccines such as those for influenza and smallpox. Indicators of
      harm for COVID-19 vaccines, as measured by ARI and NNH, appear to be in
      the same order of magnitude as indicators of benefit such as ARR and NNV.
      The effectiveness of COVID-19 vaccines, as measured by ARR and NNV, is
      substantially higher in geographical areas with high baseline risk,
      compared to areas with low baseline risk. These findings can assist in
      informed consent procedures, educational efforts, and priority setting in
      policies about distribution of vaccines, especially in the context of
      access barriers related to poverty and inequality.
    authors:
      - name: Andrew Larkin
        orcid: null
      - name: Howard Waitzkin
        orcid: http://orcid.org/0000-0001-5084-6117
  comment:
    dislikes: 0
    thread: "8626339152"
    numReports: 0
    likes: 0
    id: "5473832490"
    createdAt: 2021-07-29T08:59:44
    author:
      username: disqus_CDUZwoWjil
      about: ""
      name: Johannes
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_CDUZwoWjil/
      url: ""
      location: ""
      id: "159169073"
    isApproved: true
    isNewUserNeedsApproval: false
    raw_message: |-
      "We obtained the baseline risks for selected U.S. counties from the Johns
       Hopkins University dashboard and for selected states of India from the 
      New York Times dashboard"


      JHU has received well in excess of $100,000,000 from the BMGF.


      Is this a potential conflict of interest ?


      Many Thanks.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.28.21259039v1
  tweets:
    - created_at: Sat Jul 31 01:02:36 +0000 2021
      id: 1421275065136697300
      id_str: "1421275065136697345"
      text: >-
        üí¨ medRxiv comment on "COVID-19 vaccines and evidence..."


        ""We obtained the baseline risks for selected U.S. counti‚Ä¶ https://t.co/bWalIRrC7q
      truncated: true
      entities:
        urls:
          - url: https://t.co/bWalIRrC7q
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat Jul 31 01:02:36 +0000 2021
      id: 1421275066118123500
      id_str: "1421275066118123524"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/1boRqzyH8h
      truncated: false
      entities:
        urls:
          - url: https://t.co/1boRqzyH8h
      in_reply_to_status_id: 1421275065136697300
      in_reply_to_status_id_str: "1421275065136697345"
